PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Inglesby, TV				Inglesby, Thomas V.			Engineered H5N1: A Rare Time for Restraint in Science	ANNALS OF INTERNAL MEDICINE			English	Article								Two scientific teams have recently engineered the H5N1 virus to make it readily transmissible between ferrets. Given that ferrets are considered the most reliable animal surrogate for human influenza infection, the newly engineered H5N1 strain is probably transmissible between humans as well. The potential consequences of an engineered human-transmissible H5N1 strain are stunning. Although seasonal flu infects as much as 20% of the world's population-more than 1 billion persons-each year, only a small fraction of those with seasonal flu dies, most often the oldest, youngest, and sickest. If the newly engineered strain were to escape the laboratory (either by design or by accident) and spread as widely as seasonal flu with anywhere near the current confirmed H5N1 human case-fatality rate, it could endanger the lives of hundreds of millions of persons. The possible benefits of this work do not justify taking such risks. As clinicians, we have a stake in this issue with our responsibilities for the diagnosis and treatment of influenza. We embrace the principle of free and open exchange of scientific information, but we also believe in the principle of "first, do no harm." These 2 principles have come into a moment of rare conflict. It seems most reasonable and prudent to request that the involved scientific community and its institutions exercise restraint by restricting dissemination of the experimental results and discontinuing work on the engineered H5N1 strains. If a highly compelling case is made for continued work on this strain despite the risks, the work should be controlled and should merit the greatest scrutiny.	UPMC, Ctr Biosecur, Baltimore, MD 21202 USA		Inglesby, TV (corresponding author), UPMC, Ctr Biosecur, 621 E Pratt St,Suite 210, Baltimore, MD 21202 USA.	mjasen@upmc-biosecurity.org						[Anonymous], 2011, GUARDIAN        1231; MacKenzie D, 2011, NEW SCI         0926; WHO/GIP, 2003, CUM NUMB CONF HUM CA; World Health Organization, 2011, WHO CONC NEW H5N1 IN	4	5	6	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6					460	U120		10.7326/0003-4819-156-6-201203200-00387	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22282173				2022-12-28	WOS:000303150900018
J	Thuny, F; Grisoli, D; Collart, F; Habib, G; Raoult, D				Thuny, Franck; Grisoli, Dominique; Collart, Frederic; Habib, Gilbert; Raoult, Didier			Management of infective endocarditis: challenges and perspectives	LANCET			English	Review							NATIVE VALVE ENDOCARDITIS; STAPHYLOCOCCUS-AUREUS ENDOCARDITIS; SUBACUTE BACTERIAL-ENDOCARDITIS; CULTURE-NEGATIVE ENDOCARDITIS; ANTIMICROBIAL THERAPY; MOLECULAR DIAGNOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; INTERNATIONAL-COLLABORATION; SURGICAL-TREATMENT; 6-MONTH MORTALITY	Despite improvements in medical and surgical therapies, infective endocarditis is associated with poor prognosis and remains a therapeutic challenge. Many factors affect the outcome of this serious disease, including virulence of the microorganism, characteristics of the patients, presence of underlying disease, delays in diagnosis and treatment, surgical indications, and timing of surgery. We review the strengths and limitations of present therapeutic strategies and propose future directions for better management of endocarditis according to the most recent research. Novel perspectives on the management of endocarditis are emerging and off er hope for decreasing the rate of residual deaths by accelerating the process of diagnosis and risk stratification, reducing delays in starting antimicrobial therapy, rapid transfer of high-risk patients to specialised medico-surgical centres, development of new surgical methods, and close long-term follow-up.	[Thuny, Franck; Habib, Gilbert] Aix Marseille Univ, Dept Cardiol, Hop Timone, AP HM, F-13385 Marseille 05, France; [Grisoli, Dominique; Collart, Frederic] Aix Marseille Univ, Dept Chirurg, Hop Timone, AP HM, F-13385 Marseille 05, France; [Thuny, Franck; Raoult, Didier] Aix Marseille Univ, Unite Rech Malad Infect & Trop Emergentes, Fac Med, CNRS UMR 6236, F-13385 Marseille 05, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Raoult, D (corresponding author), Aix Marseille Univ, Unite Rech Malad Infect & Trop Emergentes, Fac Med, CNRS IRD UMR 6236, Blvd Jean Moulin, F-13385 Marseille 05, France.	didier.raoult@gmail.com	RAOULT, Didier/A-8434-2008; Thuny, Franck/ABC-7157-2020; Thuny, Franck/ABB-2408-2021; Thuny, Franck/GSD-2668-2022	RAOULT, Didier/0000-0002-0633-5974; Thuny, Franck/0000-0002-8727-7154; Thuny, Franck/0000-0002-8727-7154				ABRAMS B, 1979, ANN INTERN MED, V90, P789, DOI 10.7326/0003-4819-90-5-789; Aksoy O, 2007, CLIN INFECT DIS, V44, P364, DOI 10.1086/510583; Alexiou C, 2000, ANN THORAC SURG, V69, P1448, DOI 10.1016/S0003-4975(00)01139-5; ARANKI SF, 1994, CIRCULATION, V90, P175; Avierinos JF, 2007, ANN THORAC SURG, V84, P1935, DOI 10.1016/j.athoracsur.2007.06.050; Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564; Bannay A, 2011, EUR HEART J, V32, P2003, DOI 10.1093/eurheartj/ehp008; Benito N, 2009, ANN INTERN MED, V150, P586, DOI 10.7326/0003-4819-150-9-200905050-00004; Benoit M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008939; BERLIN JA, 1995, AM J CARDIOL, V76, P933, DOI 10.1016/S0002-9149(99)80264-1; Birmingham MC, 2003, CLIN INFECT DIS, V36, P159, DOI 10.1086/345744; Botelho-Nevers E, 2009, ARCH INTERN MED, V169, P1290, DOI 10.1001/archinternmed.2009.192; Branger S, 2003, J CLIN MICROBIOL, V41, P4435, DOI 10.1128/JCM.41.9.4435-4437.2003; Breitkopf C, 2005, CIRCULATION, V111, P1415, DOI 10.1161/01.CIR.0000158481.07569.8D; Cabell CH, 2005, AM HEART J, V150, P1092, DOI 10.1016/j.ahj.2005.03.057; Cabell CH, 2002, ARCH INTERN MED, V162, P90, DOI 10.1001/archinte.162.1.90; CANNADY PB, 1976, SOUTHERN MED J, V69, P1420; Casselman FP, 2003, CIRCULATION, V108, P48, DOI 10.1161/01.cir.0000087391.49121.ce; CATES JE, 1951, BMJ-BRIT MED J, V1, P653, DOI 10.1136/bmj.1.4708.653; Chambers JB, 2011, J ROY SOC MED, V104, P138, DOI 10.1258/jrsm.2011.100356; Chu VH, 2004, CIRCULATION, V109, P1745, DOI 10.1161/01.CIR.0000124719.61827.7F; Cooper HA, 2009, CIRCULATION, V120, P585, DOI 10.1161/CIRCULATIONAHA.108.834432; COPPENS L, 1983, ANTIMICROB AGENTS CH, V23, P36, DOI 10.1128/AAC.23.1.36; Daly CG, 2008, AUST DENT J, V53, P196, DOI 10.1111/j.1834-7819.2008.00049.x; David TE, 2007, J THORAC CARDIOV SUR, V133, P144, DOI 10.1016/j.jtcvs.2006.08.060; Delahaye F, 1999, J AM COLL CARDIOL, V33, P788, DOI 10.1016/S0735-1097(98)00624-X; Dickerman SA, 2007, AM HEART J, V154, P1086, DOI 10.1016/j.ahj.2007.07.023; DORMER AE, 1958, BRIT MED J, V1, P63, DOI 10.1136/bmj.1.5062.63; DREYFUS G, 1990, ANN THORAC SURG, V49, P706, DOI 10.1016/0003-4975(90)90007-S; dUdekem Y, 1997, EUR J CARDIO-THORAC, V11, P46, DOI 10.1016/S1010-7940(96)01020-2; Duval X, 2010, ANN INTERN MED, V152, P497, DOI 10.7326/0003-4819-152-8-201004200-00006; Evangelista A, 2004, HEART, V90, P614, DOI 10.1136/hrt.2003.029868; FANTIN B, 1992, ANTIMICROB AGENTS CH, V36, P907, DOI 10.1128/AAC.36.5.907; Fenollar F, 2007, INT J ANTIMICROB AG, V30, pS7, DOI 10.1016/j.ijantimicag.2007.06.024; Fenollar F, 2006, J INFECT DIS, V194, P1356, DOI 10.1086/508429; Fernandez-Hidalgo N, 2011, CLIN MICROBIOL INFEC, V17, P769, DOI 10.1111/j.1469-0691.2010.03314.x; Feuchtner GM, 2009, J AM COLL CARDIOL, V53, P436, DOI 10.1016/j.jacc.2008.01.077; Fournier PE, 2011, LANCET, V377, P1542, DOI 10.1016/S0140-6736(11)60021-4; Fournier PE, 2010, CLIN INFECT DIS, V51, P131, DOI 10.1086/653675; Fowler VG, 2006, NEW ENGL J MED, V355, P653, DOI 10.1056/NEJMoa053783; Fowler VG, 2005, JAMA-J AM MED ASSOC, V293, P3012, DOI 10.1001/jama.293.24.3012; Gaca JG, 2011, J THORAC CARDIOV SUR, V141, P98, DOI 10.1016/j.jtcvs.2010.09.016; Graham WH, 1973, BMJ-BRIT MED J, V2, P764; Habib G, 2009, EUR HEART J, V30, P2369, DOI 10.1093/eurheartj/ehp285; Hansalia S, 2009, ECHOCARDIOGR-J CARD, V26, P1264, DOI 10.1111/j.1540-8175.2009.01042.x; Hasbun R, 2003, JAMA-J AM MED ASSOC, V289, P1933, DOI 10.1001/jama.289.15.1933; Hoen B, 2005, EUR J CLIN MICROBIOL, V24, P12, DOI 10.1007/s10096-004-1266-6; Hoen B, 2002, JAMA-J AM MED ASSOC, V288, P75, DOI 10.1001/jama.288.1.75; HOGEVIK H, 1995, MEDICINE, V74, P324, DOI 10.1097/00005792-199511000-00003; Houpikian P, 2005, MEDICINE, V84, P162, DOI 10.1097/01.md.0000165658.82869.17; Iung B, 2004, J AM COLL CARDIOL, V43, P386, DOI 10.1016/j.jacc.2003.09.034; Kietselaer BLJH, 2007, EUR HEART J, V28, P948, DOI 10.1093/eurheartj/ehl322; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; Lalani T, 2010, CIRCULATION, V121, P1005, DOI 10.1161/CIRCULATIONAHA.109.864488; Lamas CC, 2003, HEART, V89, P258, DOI 10.1136/heart.89.3.258; Le T, 2003, CLIN INFECT DIS, V36, P615, DOI 10.1086/367661; Lepidi H, 2006, J INFECT DIS, V193, P1711, DOI 10.1086/504438; Letaief A, 2007, INT J INFECT DIS, V11, P430, DOI 10.1016/j.ijid.2006.10.006; Lichtman SS, 1943, ANN INTERN MED, V19, P787, DOI 10.7326/0003-4819-19-5-787; Liu YW, 2009, SCAND CARDIOVASC J, V43, P318, DOI 10.1080/14017430902737940; Lodise Thomas P., 2003, Clinical Infectious Diseases, V36, P1418, DOI 10.1086/375057; Loewe L, 1944, J AMER MED ASSOC, V124, P144, DOI 10.1001/jama.1944.02850030012003; Lopez J, 2011, HEART, V97, P1138, DOI 10.1136/hrt.2010.200295; MAINARDI JL, 1995, ANTIMICROB AGENTS CH, V39, P1984, DOI 10.1128/AAC.39.9.1984; Marcus R, 2011, INT J ANTIMICROB AG, V37, P491, DOI 10.1016/j.ijantimicag.2010.11.029; Millar B, 2001, SCAND J INFECT DIS, V33, P673, DOI 10.1080/00365540110026764; Millar BC, 2004, EUR J CLIN MICROBIOL, V23, P353, DOI 10.1007/s10096-004-1132-6; Modi P, 2008, EUR J CARDIO-THORAC, V34, P943, DOI 10.1016/j.ejcts.2008.07.057; Mourvillier B, 2004, INTENS CARE MED, V30, P2046, DOI 10.1007/s00134-004-2436-9; Muhlestein JB, 1999, J AM COLL CARDIOL, V33, P794; Murdoch DR, 2009, ARCH INTERN MED, V169, P463, DOI 10.1001/archinternmed.2008.603; Nkomo VT, 2007, HEART, V93, P1510, DOI 10.1136/hrt.2007.118810; Osler W, 1885, Br Med J, V1, P577; Pektok E, 2010, ANN THORAC SURG, V89, P1180, DOI 10.1016/j.athoracsur.2010.01.041; Ploux S, 2011, HEART RHYTHM, V8, P1478, DOI 10.1016/j.hrthm.2011.03.062; Raoult D, 2005, J CLIN MICROBIOL, V43, P5238, DOI 10.1128/JCM.43.10.5238-5242.2005; Ribera E, 1996, ANN INTERN MED, V125, P969, DOI 10.7326/0003-4819-125-12-199612150-00005; Richey R, 2008, BMJ-BRIT MED J, V336, P770, DOI 10.1136/bmj.39510.423148.AD; Rouzet F, 2008, CIRCULATION, V117, P781, DOI 10.1161/CIRCULATIONAHA.107.718114; Rovery C, 2005, J CLIN MICROBIOL, V43, P163, DOI 10.1128/JCM.43.1.163-167.2005; Ruttmann E, 2005, J THORAC CARDIOV SUR, V130, P765, DOI 10.1016/j.jtcvs.2005.03.016; San Roman JA, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.05.071; Shiue AB, 2010, AM J CARDIOL, V106, P1011, DOI 10.1016/j.amjcard.2010.05.034; SKEHAN JD, 1988, BRIT HEART J, V59, P62; Snygg-Martin U, 2008, CLIN INFECT DIS, V47, P23, DOI 10.1086/588663; Sy RW, 2011, EUR HEART J, V32, P2016, DOI 10.1093/eurheartj/ehp085; Sy RW, 2010, EUR HEART J, V31, P1890, DOI 10.1093/eurheartj/ehq110; Sy RW, 2009, CIRC-CARDIOVASC QUAL, V2, P469, DOI 10.1161/CIRCOUTCOMES.109.857938; Syed FF, 2007, PROG CARDIOVASC DIS, V50, P181, DOI 10.1016/j.pcad.2007.08.002; Tariq M, 2004, INT J INFECT DIS, V8, P163, DOI 10.1016/j.ijid.2004.02.001; Thuny F, 2005, CIRCULATION, V112, P69, DOI 10.1161/CIRCULATIONAHA.104.493155; Thuny F, 2010, HEART, V96, P892, DOI 10.1136/hrt.2008.151936; Thuny F, 2010, HEART, V96, P743, DOI 10.1136/hrt.2009.181594; Thuny F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009074; Thuny F, 2010, ARCH INTERN MED, V170, P211, DOI 10.1001/archinternmed.2009.486; Tleyjeh IM, 2007, CHEST, V132, P1025, DOI 10.1378/chest.06-2048; Tleyjeh IM, 2007, CIRCULATION, V115, P1721, DOI 10.1161/CIRCULATIONAHA.106.658831; Van Riet J, 2010, EUR J NUCL MED MOL I, V37, P1189, DOI 10.1007/s00259-010-1380-x; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1863, DOI 10.1001/archinte.152.9.1863; Vikram HR, 2003, JAMA-J AM MED ASSOC, V290, P3207, DOI 10.1001/jama.290.24.3207; Vind SH, 2010, J NUCL CARDIOL, V17, P516, DOI 10.1007/s12350-009-9174-x; WALLACE AG, 1965, CIRCULATION, V31, P450, DOI 10.1161/01.CIR.31.3.450; Wang A, 2005, AM HEART J, V150, P1086, DOI 10.1016/j.ahj.2005.01.023; WEINSTEIN AJ, 1973, JAMA-J AM MED ASSOC, V223, P1030, DOI 10.1001/jama.223.9.1030; Wilson W, 2007, J AM DENT ASSOC, V138, P739, DOI 10.1161/CIRCULATIONAHA.106.183095; Zegdi R, 2005, CIRCULATION, V111, P2532, DOI 10.1161/01.CIR.0000165122.08660.1A	106	274	292	4	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 10	2012	379	9819					965	975		10.1016/S0140-6736(11)60755-1	http://dx.doi.org/10.1016/S0140-6736(11)60755-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906NY	22317840				2022-12-28	WOS:000301353700037
J	Aaron, HJ; Frakt, AB				Aaron, Henry J.; Frakt, Austin B.			Why Now Is Not the Time for Premium Support	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Aaron, Henry J.] Brookings Inst, Washington, DC 20036 USA; [Frakt, Austin B.] Boston Univ, Sch Med, Dept Vet Affairs, VA Boston Healthcare Syst, Boston, MA 02118 USA; [Frakt, Austin B.] Boston Univ, Sch Publ Hlth, Boston, MA USA	Brookings Institution; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University	Aaron, HJ (corresponding author), Brookings Inst, Washington, DC 20036 USA.			Frakt, Austin/0000-0002-0795-5462				Abaluck J, 2011, AM ECON REV, V101, P1180, DOI 10.1257/aer.101.4.1180; [Anonymous], 1995, HLTH AFF MILLWOOD, V14, P8; Berenson RA, 2011, PRESERVING MEDICARE; Frakt A, 2011, HLTH EC         0419; Park E, 2011, LOWER THAN EXPECTED	5	9	9	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					877	879		10.1056/NEJMp1200448	http://dx.doi.org/10.1056/NEJMp1200448			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	904CY	22276779				2022-12-28	WOS:000301172500003
J	Sabbar, S; Nilles, EJ				Sabbar, Saweera; Nilles, Eric James			Deep Sulcus Sign	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sabbar, Saweera; Nilles, Eric James] Rashid Trauma Ctr, Dubai, U Arab Emirates		Sabbar, S (corresponding author), Rashid Trauma Ctr, Dubai, U Arab Emirates.	nillese@who.int	Nilles, Eric/ABA-4757-2021	Nilles, Eric/0000-0001-7044-5257					0	5	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					552	552		10.1056/NEJMicm1105315	http://dx.doi.org/10.1056/NEJMicm1105315			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GH	22316448				2022-12-28	WOS:000299991300011
J	Spence, D				Spence, Des			Continuity is never out of fashion	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 8	2012	344								e957	10.1136/bmj.e957	http://dx.doi.org/10.1136/bmj.e957			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IE	22318444				2022-12-28	WOS:000300279100013
J	Mack, JW; Cronin, A; Taback, N; Huskamp, HA; Keating, NL; Malin, JL; Earle, CC; Weeks, JC				Mack, Jennifer W.; Cronin, Angel; Taback, Nathan; Huskamp, Haiden A.; Keating, Nancy L.; Malin, Jennifer L.; Earle, Craig C.; Weeks, Jane C.			End-of-Life Care Discussions Among Patients With Advanced Cancer A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							METASTATIC COLORECTAL-CANCER; OUTCOMES RESEARCH; ILL PATIENTS; DEATH; SURVEILLANCE; SURVIVAL; PROGNOSTICATION; CHEMOTHERAPY; PREDICTORS; CARCINOMA	Background: National guidelines recommend that physicians discuss end-of-life (EOL) care planning with patients with cancer whose life expectancy is less than 1 year. Objective: To evaluate the incidence of EOL care discussions for patients with stage IV lung or colorectal cancer and where, when, and with whom these discussions take place. Design: Prospective cohort study of patients diagnosed with lung or colorectal cancer from 2003 to 2005. Setting: Participants lived in Northern California, Los Angeles County, North Carolina, Iowa, or Alabama or received care in 1 of 5 large HMOs or 1 of 15 Veterans Health Administration sites. Patients: 2155 patients with stage IV lung or colorectal cancer. Measurements: End-of-life care discussions reported in patient and surrogate interviews or documented in medical records through 15 months after diagnosis. Results: 73% of patients had EOL care discussions identified by at least 1 source. Among the 1470 patients who died during follow-up, 87% had EOL care discussions, compared with 41% of the 685 patients who were alive at the end of follow-up. Of the 1081 first EOL care discussions documented in records, 55% occurred in the hospital. Oncologists documented EOL care discussions with only 27% of their patients. Among 959 patients with documented EOL care discussions who died during follow-up, discussions took place a median of 33 days before death. Limitations: The depth and quality of EOL care discussions was not evaluated. Much of the information about discussions came from surrogates of patients who died before baseline interviews could be obtained. Conclusion: Although most patients with stage IV lung or colorectal cancer discuss EOL care planning with physicians before death, many discussions occur during acute hospital care, with providers other than oncologists, and late in the course of illness.	[Mack, Jennifer W.] Harvard Univ, Dana Farber Canc Inst, Childrens Hosp, Sch Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; Ontario Inst Canc Res, Toronto, ON, Canada	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates	Mack, JW (corresponding author), Harvard Univ, Dana Farber Canc Inst, Childrens Hosp, Sch Med, 450 Brookline Ave, Boston, MA 02215 USA.	jennifer_mack@dfci.harvard.edu	Keating, Nancy L/I-9968-2019	Keating, Nancy L/0000-0002-8274-4681; Taback, Nathan/0000-0001-9497-3951	National Cancer Institute (NCI) [U01 CA093344, U01 CA093332, U01 CA093324, U01 CA093348, U01 CA093329, U01 CA093339, U01 CA093326]; Department of Veterans Affairs [CRS 02-164]; American Cancer Society; National Palliative Care Research Center; NATIONAL CANCER INSTITUTE [U01CA093344, U01CA093332, K05CA166208, U01CA093329, U01CA093326, U01CA093339, U01CA093324] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Veterans Affairs(US Department of Veterans Affairs); American Cancer Society(American Cancer Society); National Palliative Care Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work of the CanCORS Consortium was supported by grants from the National Cancer Institute (NCI) to the Statistical Coordinating Center (U01 CA093344) and the NCI-supported Primary Data Collection and Research Centers (grant U01 CA093332 to the Dana-Farber Cancer Institute/Cancer Research Network, grant U01 CA093324 to Harvard Medical School/Northern California Cancer Center, grant U01 CA093348 to RAND/University of California, Los Angeles, grant U01 CA093329 to the University of Alabama at Birmingham, grant U01 CA093339 to the University of Iowa, grant U01 CA093326 to University of North Carolina) and by grant CRS 02-164 from the Department of Veterans Affairs to the Durham Veterans Affairs Medical Center. Dr. Mack was funded by an American Cancer Society Mentored Research Scholar Grant and by the National Palliative Care Research Center.	[Anonymous], STAND DEF FIN DISP C; Ayanian JZ, 2004, J CLIN ONCOL, V22, P2992, DOI 10.1200/JCO.2004.06.020; Blackstock AW, 2002, JNCI-J NATL CANCER I, V94, P284, DOI 10.1093/jnci/94.4.284; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Catalano P, 2012, MED CARE IN PRESS; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Earle CC, 2000, CHEST, V117, P1239, DOI 10.1378/chest.117.5.1239; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Jenkins V, 2011, J CLIN ONCOL, V29, P61, DOI 10.1200/JCO.2010.30.0814; Kato I, 2001, CANCER, V92, P2211, DOI 10.1002/1097-0142(20011015)92:8<2211::AID-CNCR1565>3.0.CO;2-W; Keating NL, 2010, J CLIN ONCOL, V28, P4364, DOI 10.1200/JCO.2009.26.8870; Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Lehmann L, 2007, J CLIN ONCOL, V25; Mack JW, 2010, J CLIN ONCOL, V28, P1203, DOI 10.1200/JCO.2009.25.4672; Malin JL, 2006, SUPPORT CARE CANCER, V14, P837, DOI 10.1007/s00520-005-0902-8; MIYAJI NT, 1993, SOC SCI MED, V36, P249, DOI 10.1016/0277-9536(93)90008-R; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; National Comprehensive Cancer Network, PRACT GUID ONC PALL; National Consensus Project for Quality Palliative Care, CLIN PRACT GUID QUAL; Prigerson H G, 1991, Home Health Care Serv Q, V12, P81; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Ruddick W, 1999, BIOETHICS, V13, P343, DOI 10.1111/1467-8519.00162; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; The AM, 2000, BRIT MED J, V321, P1376, DOI 10.1136/bmj.321.7273.1376; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863	32	276	278	2	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2012	156	3					204	U65		10.7326/0003-4819-156-3-201202070-00008	http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XD	22312140				2022-12-28	WOS:000299964200004
J	Junion, G; Spivakov, M; Girardot, C; Braun, M; Gustafson, EH; Birney, E; Furlong, EEM				Junion, Guillaume; Spivakov, Mikhail; Girardot, Charles; Braun, Martina; Gustafson, E. Hilary; Birney, Ewan; Furlong, Eileen E. M.			A Transcription Factor Collective Defines Cardiac Cell Fate and Reflects Lineage History	CELL			English	Article							HOLT-ORAM-SYNDROME; REGULATORY NETWORK; DROSOPHILA HEART; MUTUAL COFACTORS; FACTOR-BINDING; BOX GENES; MESODERM; ENHANCER; CARDIOGENESIS; TINMAN	Cell fate decisions are driven through the integration of inductive signals and tissue-specific transcription factors (TFs), although the details on how this information converges in cis remain unclear. Here, we demonstrate that the five genetic components essential for cardiac specification in Drosophila, including the effectors of Wg and Dpp signaling, act as a collective unit to cooperatively regulate heart enhancer activity, both in vivo and in vitro. Their combinatorial binding does not require any specific motif orientation or spacing, suggesting an alternative mode of enhancer function whereby cooperative activity occurs with extensive motif flexibility. A fraction of enhancers co-occupied by cardiogenic TFs had unexpected activity in the neighboring visceral mesoderm but could be rendered active in heart through single-site mutations. Given that cardiac and visceral cells are both derived from the dorsal mesoderm, this "dormant'' TF binding signature may represent a molecular footprint of these cells' developmental lineage.	[Junion, Guillaume; Spivakov, Mikhail; Girardot, Charles; Braun, Martina; Gustafson, E. Hilary; Furlong, Eileen E. M.] European Mol Biol Lab, Genome Biol Unit, D-69117 Heidelberg, Germany; [Spivakov, Mikhail; Birney, Ewan] European Bioinformat Inst EMBL EBI, Cambridge CB10 1SD, England	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Furlong, EEM (corresponding author), European Mol Biol Lab, Genome Biol Unit, D-69117 Heidelberg, Germany.	furlong@embl.de	Girardot, Charles/AAF-2417-2020; Junion, Guillaume/L-9129-2018; Junion, guillaume/AAA-2034-2019	Girardot, Charles/0000-0003-4301-3920; Junion, guillaume/0000-0003-0458-6021; Birney, Ewan/0000-0001-8314-8497; Gustafson, Eleanor Hilary/0000-0003-3978-8088; Furlong, Eileen/0000-0002-9544-8339; Spivakov, Mikhail/0000-0002-0383-3943	EMBL Genomics Core facility; Deutsche Forschungsgemeinschaft (DFG) [FU 750/1]; Human Frontier Science Program (HFSP); EMBO; EMBL EIPOD	EMBL Genomics Core facility; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Human Frontier Science Program (HFSP)(Human Frontier Science Program); EMBO(European Molecular Biology Organization (EMBO)); EMBL EIPOD	We are extremely grateful to M. Bienz, C.-H. Heldin, M. Frasch, and H. Jackle for antibodies. This work was technically supported by the EMBL Genomics Core facility, with specific thanks to Jos de Graaf for array hybridizations. We thank all members of the Furlong lab for discussions and comments on the manuscript, Stijn Van Dongen for help with assessing the robustness of clustering methods, and Thomas Sandmann for designing dsRNA probes. This work was supported by a Deutsche Forschungsgemeinschaft (DFG FU 750/1) grant and Human Frontier Science Program (HFSP) grant to E.E.M.F. and postdoctoral fellowships to G.J. from EMBO and to M.S. from the EMBL EIPOD program.	AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Blow MJ, 2010, NAT GENET, V42, P806, DOI 10.1038/ng.650; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brown CD, 2007, SCIENCE, V317, P1557, DOI 10.1126/science.1145893; Brown CO, 2004, J BIOL CHEM, V279, P10659, DOI 10.1074/jbc.M301648200; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; CAMPOSORTEGA JA, 1997, EMBRYONIC DEV DROSPH; Cheeseman P., 1996, ADV KNOWLEDGE DISCOV; Cherbas L, 2011, GENOME RES, V21, P301, DOI 10.1101/gr.112961.110; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Frasch M, 1999, SEMIN CELL DEV BIOL, V10, P61, DOI 10.1006/scdb.1998.0279; Gajewski K, 2001, DEV BIOL, V233, P425, DOI 10.1006/dbio.2001.0220; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; He AB, 2011, P NATL ACAD SCI USA, V108, P5632, DOI 10.1073/pnas.1016959108; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Jakobsen JS, 2007, GENE DEV, V21, P2448, DOI 10.1101/gad.437607; Ji HK, 2005, BIOINFORMATICS, V21, P3629, DOI 10.1093/bioinformatics/bti593; Kelly RG, 2002, TRENDS GENET, V18, P210, DOI 10.1016/S0168-9525(02)02642-2; Kulkarni MM, 2003, DEVELOPMENT, V130, P6569, DOI 10.1242/dev.00890; Lee HH, 2005, DEVELOPMENT, V132, P1429, DOI 10.1242/dev.01687; Lee HH, 2000, DEVELOPMENT, V127, P5497; LEE HH, 2006, DEV LARVAL VISCERAL; Liber D, 2010, CELL STEM CELL, V7, P114, DOI 10.1016/j.stem.2010.05.020; Lien CL, 1999, DEVELOPMENT, V126, P75; Liu YH, 2009, DEV CELL, V16, P280, DOI 10.1016/j.devcel.2009.01.006; Lockwood WK, 2002, MECH DEVELOP, V114, P13, DOI 10.1016/S0925-4773(02)00044-8; Molkentin JD, 2000, DEV BIOL, V217, P301, DOI 10.1006/dbio.1999.9544; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Olson EN, 2006, SCIENCE, V313, P1922, DOI 10.1126/science.1132292; Panne D, 2008, CURR OPIN STRUC BIOL, V18, P236, DOI 10.1016/j.sbi.2007.12.002; Pavesi G, 2004, NUCLEIC ACIDS RES, V32, pW199, DOI 10.1093/nar/gkh465; Perez-Pomares JM, 2009, INT J DEV BIOL, V53, P1427, DOI 10.1387/ijdb.072409jp; Reim I, 2005, DEVELOPMENT, V132, P4911, DOI 10.1242/dev.02077; Roider HG, 2007, BIOINFORMATICS, V23, P134, DOI 10.1093/bioinformatics/btl565; Sandmann T, 2006, NAT PROTOC, V1, P2839, DOI 10.1038/nprot.2006.383; Schlesinger J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001313; Senger K, 2004, MOL CELL, V13, P19, DOI 10.1016/S1097-2765(03)00500-8; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Sun GF, 2004, J CELL BIOCHEM, V92, P189, DOI 10.1002/jcb.20039; Swanson CI, 2010, DEV CELL, V18, P359, DOI 10.1016/j.devcel.2009.12.026; Takeuchi JK, 2009, NATURE, V459, P708, DOI 10.1038/nature08039; Thomas-Chollier M, 2008, NUCLEIC ACIDS RES, V36, pW119, DOI 10.1093/nar/gkn304; Walter K, 2008, BLOOD, V112, P1673, DOI 10.1182/blood-2008-02-142786; Wilczynski B, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.35; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Zaffran S, 2002, COLD SPRING HARB SYM, V67, P1, DOI 10.1101/sqb.2002.67.1; Zaffran S, 2002, CIRC RES, V91, P457, DOI 10.1161/01.RES.0000034152.74523.A8; Zaffran S, 2001, GENE DEV, V15, P2900; Zinzen RP, 2009, NATURE, V462, P65, DOI 10.1038/nature08531	55	186	186	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					473	486		10.1016/j.cell.2012.01.030	http://dx.doi.org/10.1016/j.cell.2012.01.030			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304916	Bronze			2022-12-28	WOS:000300225000016
J	Tennen, RI; Michishita-Kioi, E; Chua, KF				Tennen, Ruth I.; Michishita-Kioi, Eriko; Chua, Katrin F.			Finding a Target for Resveratrol	CELL			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; SIRTUINS; SIRT1	Despite resveratrol's well-documented health benefits, its mechanism of action remains controversial. In particular, the direct molecular target of resveratrol has been elusive. Park et al. now show that resveratrol directly inhibits cAMP-dependent phosphodiesterases, triggering a cascade of events that converge on the important energy-sensing metabolic regulators AMPK, SIRT1, and PGC-1 alpha.	[Tennen, Ruth I.; Chua, Katrin F.] Stanford Univ, Dept Med, Div Endocrinol Gerontol & Metab, Stanford, CA 94305 USA; [Tennen, Ruth I.; Chua, Katrin F.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA 94304 USA; [Michishita-Kioi, Eriko] Daiichi Sankyo Co Ltd, R&D Div, Shinagawa Ku, Tokyo 1408710, Japan	Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Daiichi Sankyo Company Limited	Chua, KF (corresponding author), Stanford Univ, Dept Med, Div Endocrinol Gerontol & Metab, Stanford, CA 94305 USA.	kfchua@stanford.edu						Baur JA, 2010, MECH AGEING DEV, V131, P261, DOI 10.1016/j.mad.2010.02.007; Canto C, 2010, CELL MOL LIFE SCI, V67, P3407, DOI 10.1007/s00018-010-0454-z; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Gerhart-Hines Z, 2011, MOL CELL, V44, P851, DOI 10.1016/j.molcel.2011.12.005; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Nakagawa T, 2011, J CELL SCI, V124, P833, DOI 10.1242/jcs.081067; Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482	11	83	104	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					387	389		10.1016/j.cell.2012.01.032	http://dx.doi.org/10.1016/j.cell.2012.01.032			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304906	Bronze			2022-12-28	WOS:000300225000005
J	Watson, J; Round, A; Hamilton, W				Watson, Jessica; Round, Alison; Hamilton, William			RATIONAL TESTING Raised inflammatory markers	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ERYTHROCYTE SEDIMENTATION-RATE; C-REACTIVE PROTEIN; LOWER RESPIRATORY-TRACT; GENERAL-PRACTICE; DIAGNOSTIC-ACCURACY; PRIMARY-CARE; INFECTIONS; PNEUMONIA; CHILDREN; ADULTS		[Hamilton, William] Peninsula Coll Med & Dent, Exeter EX2 4SG, Devon, England; [Watson, Jessica] Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England; [Round, Alison] Castle Pl Practice, Tiverton EX16 6NP, Devon, England	University of Exeter; University of Plymouth; University of Bristol	Hamilton, W (corresponding author), Peninsula Coll Med & Dent, Exeter EX2 4SG, Devon, England.	willie.hamilton@pcmd.ac.uk	Hamilton, Willie/G-8612-2014	Watson, Jessica/0000-0002-8177-6438; Hamilton, William/0000-0003-1611-1373	National Institute for Health Research [ACF-2008-25-003] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Bundy DG, 2007, JAMA-J AM MED ASSOC, V298, P438, DOI 10.1001/jama.298.4.438; Butalia S, 2008, JAMA-J AM MED ASSOC, V299, P806, DOI 10.1001/jama.299.7.806; Cals JWL, 2010, FAM PRACT, V27, P212, DOI 10.1093/fampra/cmp088; Cals JWL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1374; DahlerEriksen BS, 1997, SCAND J PRIM HEALTH, V15, P35, DOI 10.3109/02813439709043427; DINANT GJ, 1991, BRIT J GEN PRACT, V41, P365; DINANT GJ, 1992, FAM PRACT, V9, P28, DOI 10.1093/fampra/9.1.28; Erlinger TP, 2004, JAMA-J AM MED ASSOC, V291, P585, DOI 10.1001/jama.291.5.585; Falk G, 2009, FAM PRACT, V26, P10, DOI 10.1093/fampra/cmn095; FINCHER RME, 1986, ARCH INTERN MED, V146, P1581, DOI 10.1001/archinte.146.8.1581; Flood RG, 2008, PEDIATR INFECT DIS J, V27, P95, DOI 10.1097/INF.0b013e318157aced; FORD MJ, 1979, EUR J CLIN INVEST, V9, P191, DOI 10.1111/j.1365-2362.1979.tb00922.x; FROOM P, 1984, AM J CLIN PATHOL, V82, P198, DOI 10.1093/ajcp/82.2.198; GRONLIE M, 1991, Scandinavian Journal of Primary Health Care, V9, P97, DOI 10.3109/02813439109026591; Hassan Nada, 2011, BMJ, V342, pd3019, DOI 10.1136/bmj.d3019; Holm A, 2007, BRIT J GEN PRACT, V57, P555; Iversen OH, 1996, J INTERN MED, V240, P133, DOI 10.1046/j.1365-2796.1996.30195852000.x; Jakobsen KA, 2010, SCAND J PRIM HEALTH, V28, P229, DOI 10.3109/02813432.2010.506995; Johnson Heather L., 1999, Journal of Microbiology Immunology and Infection, V32, P73; Kesmarky G, 2008, CLIN HEMORHEOL MICRO, V39, P243, DOI 10.3233/CH-2008-1088; LluberasAcosta G, 1996, BRIT J CLIN PRACT, V50, P138; Monig H, 2002, FAM PRACT, V19, P436, DOI 10.1093/fampra/19.5.436; RAFNSSON V, 1979, ACTA MED SCAND, V206, P207; Sanders S, 2008, J PEDIATR, V153, P570, DOI 10.1016/j.jpeds.2008.04.023; Spangehl MJ, 1999, J BONE JOINT SURG AM, V81A, P672, DOI 10.2106/00004623-199905000-00008; THOMAS PD, 1987, CLIN RHEUMATOL, V6, P177, DOI 10.1007/BF02201020; THUE G, 1994, SCAND J CLIN LAB INV, V54, P291, DOI 10.3109/00365519409087525; Toriola AT, 2011, ANN ONCOL; Van den Bruel A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3082; van der Meer V, 2005, BRIT MED J, V331, P26, DOI 10.1136/bmj.38483.478183.EB; van Ravesteijn H, 2012, PATIENT EDUC COUNS, V86, P3, DOI 10.1016/j.pec.2011.02.003; Wiwanitkit Viroj, 2005, Infect Dis Obstet Gynecol, V13, P179, DOI 10.1080/10647440500068321; WYLER DJ, 1977, SOUTHERN MED J, V70, P1428, DOI 10.1097/00007611-197712000-00015	33	30	31	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2012	344								e454	10.1136/bmj.e454	http://dx.doi.org/10.1136/bmj.e454			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QT	22306478	Green Accepted, Green Submitted			2022-12-28	WOS:000300089000001
J	Cohen, JY; Haesler, S; Vong, L; Lowell, BB; Uchida, N				Cohen, Jeremiah Y.; Haesler, Sebastian; Vong, Linh; Lowell, Bradford B.; Uchida, Naoshige			Neuron-type-specific signals for reward and punishment in the ventral tegmental area	NATURE			English	Article							MIDBRAIN DOPAMINE NEURONS; GABAERGIC NEURONS; RAT; CHANNELRHODOPSIN-2; PREDICTION; ADDICTION; PROJECTIONS; MECHANISMS; RESPONSES; CORTEX	Dopamine has a central role in motivation and reward. Dopaminergic neurons in the ventral tegmental area (VTA) signal the discrepancy between expected and actual rewards (that is, reward prediction error)(1-3), but how they compute such signals is unknown. We recorded the activity of VTA neurons while mice associated different odour cues with appetitive and aversive outcomes. We found three types of neuron based on responses to odours and outcomes: approximately half of the neurons (type I, 52%) showed phasic excitation after reward-predicting odours and rewards in a manner consistent with reward prediction error coding; the other half of neurons showed persistent activity during the delay between odour and outcome that was modulated positively (type II, 31%) or negatively (type III, 18%) by the value of outcomes. Whereas the activity of type I neurons was sensitive to actual outcomes (that is, when the reward was delivered as expected compared to when it was unexpectedly omitted), the activity of type II and type III neurons was determined predominantly by reward-predicting odours. We 'tagged' dopaminergic and GABAergic neurons with the light-sensitive protein channelrhodopsin-2 and identified them based on their responses to optical stimulation while recording. All identified dopaminergic neurons were of type I and all GABAergic neurons were of type II. These results show that VTA GABAergic neurons signal expected reward, a key variable for dopaminergic neurons to calculate reward prediction error.	[Cohen, Jeremiah Y.; Haesler, Sebastian; Uchida, Naoshige] Harvard Univ, Dept Mol & Cellular Biol, Ctr Brain Sci, Cambridge, MA 02138 USA; [Vong, Linh; Lowell, Bradford B.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol, Boston, MA 02215 USA	Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Uchida, N (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Ctr Brain Sci, Cambridge, MA 02138 USA.	uchida@mcb.harvard.edu		Uchida, Naoshige/0000-0002-5755-9409; Haesler, Sebastian/0000-0003-4924-7381	Howard Hughes Medical Institute from the Helen Hay Whitney Foundation; Human Frontiers Science Program; Howard Hughes Medical Institute; Smith Family New Investigator Award; Alfred Sloan Foundation; Milton Fund;  [F32 DK078478];  [P30 DK046200];  [R01 DK075632];  [R01 DK089044];  [P30 DK057521]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK089044, P30DK057521, F32DK078478, R01DK075632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH095953] Funding Source: NIH RePORTER	Howard Hughes Medical Institute from the Helen Hay Whitney Foundation; Human Frontiers Science Program(Human Frontier Science Program); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Smith Family New Investigator Award; Alfred Sloan Foundation(Alfred P. Sloan Foundation); Milton Fund; ; ; ; ; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank M. Meister, V. N. Murthy, J. D. Schall and R. P. Heitz for comments, C. Dulac for sharing resources, C. I. Moore, J. Ritt and J. Siegle for advice about microdrives, K. Deisseroth for the AAV-FLEX-ChR2 construct, and E. Soucy and J. Greenwood for technical support. This work was supported by a Howard Hughes Medical Institute Fellowship from the Helen Hay Whitney Foundation (J.Y.C.); the Human Frontiers Science Program (S. H.); a Howard Hughes Medical Institute Collaborative Innovation Award, a Smith Family New Investigator Award, the Alfred Sloan Foundation, the Milton Fund (N. U.); F32 DK078478, P30 DK046200 (L. V.); and R01 DK075632, R01 DK089044, P30 DK046200, P30 DK057521 (B.B.L.).	Atasoy D, 2008, J NEUROSCI, V28, P7025, DOI 10.1523/JNEUROSCI.1954-08.2008; Backman CM, 2006, GENESIS, V44, P383, DOI 10.1002/dvg.20228; Bayer HM, 2005, NEURON, V47, P129, DOI 10.1016/j.neuron.2005.05.020; Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; Carr DB, 2000, J NEUROSCI, V20, P3864, DOI 10.1523/JNEUROSCI.20-10-03864.2000; Dobi A, 2010, J NEUROSCI, V30, P218, DOI 10.1523/JNEUROSCI.3884-09.2010; Fiorillo CD, 2008, NAT NEUROSCI, V11, P966, DOI 10.1038/nn.2159; Houk JC, 1995, MODELS INFORMATION P, P249; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009; Jhou TC, 2009, NEURON, V61, P786, DOI 10.1016/j.neuron.2009.02.001; JOHNSON SW, 1992, J NEUROSCI, V12, P483; Lammel S, 2008, NEURON, V57, P760, DOI 10.1016/j.neuron.2008.01.022; Lima SQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006099; Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017; Mansvelder HD, 2002, NEURON, V33, P905, DOI 10.1016/S0896-6273(02)00625-6; Margolis EB, 2006, J PHYSIOL-LONDON, V577, P907, DOI 10.1113/jphysiol.2006.117069; Matsumoto M, 2007, NATURE, V447, P1111, DOI 10.1038/nature05860; Matsumoto M, 2009, NATURE, V459, P837, DOI 10.1038/nature08028; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Nair-Roberts RG, 2008, NEUROSCIENCE, V152, P1024, DOI 10.1016/j.neuroscience.2008.01.046; Okada K, 2009, J NEUROSCI, V29, P4858, DOI 10.1523/JNEUROSCI.4415-08.2009; Omelchenko N, 2009, SYNAPSE, V63, P895, DOI 10.1002/syn.20668; Redish AD, 2004, SCIENCE, V306, P1944, DOI 10.1126/science.1102384; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; Schmitzer-Torbert N, 2004, J NEUROPHYSIOL, V91, P2259, DOI 10.1152/jn.00687.2003; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 2006, ANNU REV PSYCHOL, V57, P87, DOI 10.1146/annurev.psych.56.091103.070229; Steffensen SC, 1998, J NEUROSCI, V18, P8003; SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9; Szabo B, 2002, EUR J NEUROSCI, V15, P2057, DOI 10.1046/j.1460-9568.2002.02041.x; Takahashi YK, 2011, NAT NEUROSCI, V14, P1590, DOI 10.1038/nn.2957; Takikawa Y, 2004, J NEUROPHYSIOL, V92, P2520, DOI 10.1152/jn.00238.2004; Tan KR, 2010, NATURE, V463, P769, DOI 10.1038/nature08758; Thompson KG, 1996, J NEUROPHYSIOL, V76, P4040, DOI 10.1152/jn.1996.76.6.4040; Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878; Uchida N, 2003, NAT NEUROSCI, V6, P1224, DOI 10.1038/nn1142; Vong L, 2011, NEURON, V71, P142, DOI 10.1016/j.neuron.2011.05.028; Zhao SL, 2011, NAT METHODS, V8, P745, DOI 10.1038/nmeth.1668	38	773	782	0	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					85	U109		10.1038/nature10754	http://dx.doi.org/10.1038/nature10754			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22258508	Green Accepted			2022-12-28	WOS:000299726000040
J	Flegal, KM; Carroll, MD; Kit, BK; Ogden, CL				Flegal, Katherine M.; Carroll, Margaret D.; Kit, Brian K.; Ogden, Cynthia L.			Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OVERWEIGHT; HEALTH; AMERICANS; EPIDEMIC; FAT	Context Between 1980 and 1999, the prevalence of adult obesity (body mass index [BMI] >= 30) increased in the United States and the distribution of BMI changed. More recent data suggested a slowing or leveling off of these trends. Objective To estimate the prevalence of adult obesity from the 2009-2010 National Health and Nutrition Examination Survey (NHANES) and compare adult obesity and the distribution of BMI with data from 1999-2008. Design, Setting, and Participants NHANES includes measured heights and weights for 5926 adult men and women from a nationally representative sample of the civilian noninstitutionalized US population in 2009-2010 and for 22 847 men and women in 1999-2008. Main Outcome Measures The prevalence of obesity and mean BMI. Results In 2009-2010 the age-adjusted mean BMI was 28.7 (95% CI, 28.3-29.1) for men and also 28.7 (95% CI, 28.4-29.0) for women. Median BMI was 27.8 (inter-quartile range [IQR], 24.7-31.7) for men and 27.3 (IQR, 23.3-32.7) for women. The age-adjusted prevalence of obesity was 35.5% (95% CI, 31.9%-39.2%) among adult men and 35.8% (95% CI, 34.0%-37.7%) among adult women. Over the 12-year period from 1999 through 2010, obesity showed no significant increase among women overall (age-and race-adjusted annual change in odds ratio [AOR], 1.01; 95% CI, 1.00-1.03; P=.07), but increases were statistically significant for non-Hispanic black women (P=.04) and Mexican American women (P=.046). For men, there was a significant linear trend (AOR, 1.04; 95% CI, 1.02-1.06; P<.001) over the 12-year period. For both men and women, the most recent 2 years (2009-2010) did not differ significantly (P=.08 for men and P=.24 for women) from the previous 6 years (20032008). Trends in BMI were similar to obesity trends. Conclusion In 2009-2010, the prevalence of obesity was 35.5% among adult men and 35.8% among adult women, with no significant change compared with 2003-2008. JAMA. 2012;307(5):491-497 Published online January 17, 2012. doi:10.1001/jama.2012.39	[Flegal, Katherine M.; Carroll, Margaret D.; Kit, Brian K.; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Flegal, KM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4315, Hyattsville, MD 20782 USA.	kmf2@cdc.gov	Flegal, Katherine M/A-4608-2013					Aloia JF, 1999, OSTEOPOROSIS INT, V10, P114, DOI 10.1007/s001980050204; [Anonymous], 1994, Vital Health Stat 1, P1; Bellisari A, 2008, OBES REV, V9, P165, DOI 10.1111/j.1467-789X.2007.00392.x; Blakemore AIF, 2008, J CLIN ENDOCR METAB, V93, pS51, DOI 10.1210/jc.2008-1676; Braveman P, 2009, PREV CHRONIC DIS, V6; Casals-Casas C, 2008, INT J OBESITY, V32, pS53, DOI 10.1038/ijo.2008.207; Drewnowski A, 2005, AM J CLIN NUTR, V82, p265S, DOI 10.1093/ajcn/82.1.265S; Eriksson M, 2011, J INTERN MED, V269, P219, DOI 10.1111/j.1365-2796.2010.02312.x; Faeh D, 2010, SWISS MED WKLY, V140, DOI 10.4414/smw.2010.13090; Faeh D, 2010, OBESITY, V18, P644, DOI 10.1038/oby.2009.310; Ferndandez JR, 2003, AM J CLIN NUTR, V77, P71, DOI 10.1093/ajcn/77.1.71; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Flegal KM, 2009, AM J CLIN NUTR, V89, P500, DOI 10.3945/ajcn.2008.26847; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2000, INT J OBESITY, V24, P807, DOI 10.1038/sj.ijo.0801232; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Garcia-Alvarez A, 2007, PUBLIC HEALTH NUTR, V10, P1368, DOI 10.1017/S1368980007000973; Health Survey for England, 2009, HLTH SURV ENGL 2009; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010; Norberg M, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.5149; Pi-Sunyer FX, 1998, AM J CLIN NUTR, V68, P899; Rahman M, 2009, METABOLISM, V58, P1329, DOI 10.1016/j.metabol.2009.04.017; Rokholm B, 2010, OBES REV, V11, P835, DOI 10.1111/j.1467-789X.2010.00810.x; Ruesten A, 2011, PLOS ONE, V6, P27455, DOI DOI 10.1371/J0URNAL.P0NE.0027455; Shields Margot, 2011, NCHS Data Brief, P1; Stewart ST, 2009, NEW ENGL J MED, V361, P2252, DOI 10.1056/NEJMsa0900459; Swinburn BA, 2011, LANCET, V378, P804, DOI 10.1016/S0140-6736(11)60813-1; Wang YC, 2007, OBESITY, V15, P2855, DOI 10.1038/oby.2007.339; Wang YC, 2011, LANCET, V378, P815, DOI 10.1016/S0140-6736(11)60814-3; Wang YF, 2008, OBESITY, V16, P2323, DOI 10.1038/oby.2008.351; Zaninotto P, 2009, J EPIDEMIOL COMMUN H, V63, P140, DOI 10.1136/jech.2008.077305	33	3141	3196	7	390	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					491	497		10.1001/jama.2012.39	http://dx.doi.org/10.1001/jama.2012.39			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22253363	Bronze			2022-12-28	WOS:000299728000030
J	Goldenberg, AJ; Sharp, RR				Goldenberg, Aaron J.; Sharp, Richard R.			The Ethical Hazards and Programmatic Challenges of Genomic Newborn Screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Sharp, Richard R.] Cleveland Clin, Dept Bioeth, Ctr Eth Humanities & Spiritual Care, Cleveland, OH 44195 USA; [Sharp, Richard R.] Cleveland Clin, Genom Med Inst, Cleveland, OH 44195 USA; [Goldenberg, Aaron J.] Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH USA; [Goldenberg, Aaron J.; Sharp, Richard R.] Case Western Reserve Univ, Sch Med, Ctr Genet Res Eth & Law, Cleveland, OH USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Sharp, RR (corresponding author), Cleveland Clin, Dept Bioeth, Ctr Eth Humanities & Spiritual Care, 9500 Euclid Ave,JJ-60, Cleveland, OH 44195 USA.	sharpr3@ccf.org			NHGRI NIH HHS [R01 HG004500, R01HG004500, P50 HG003390, P50HG003390] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004500, P50HG003390] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		[Anonymous], 2008, CHANG MOR FOC NEWB S; Botkin JR, 2006, PEDIATRICS, V117, P1793, DOI 10.1542/peds.2005-2547; Clayton EW, 2010, J LAW MED ETHICS, V38, P697, DOI 10.1111/j.1748-720X.2010.00522.x; Grosse SD, 2006, PEDIATRICS, V117, P923, DOI 10.1542/peds.2005-0553; Lewis MH, 2011, PEDIATRICS, V127, P703, DOI 10.1542/peds.2010-1468; Newborn screening in the genomic era: setting a research agenda, NEWB SCREEN GEN ER S; Ormond KE, 2010, LANCET, V375, P1749, DOI 10.1016/S0140-6736(10)60599-5; Ross LF, 2010, KENNEDY INST ETHIC J, V20, P299; Sharp RR, 2011, GENET MED, V13, P191, DOI 10.1097/GIM.0b013e31820f603f; Tarini BA, 2006, PEDIATRICS, V118, P448, DOI 10.1542/peds.2005-2026	10	70	72	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					461	462		10.1001/jama.2012.68	http://dx.doi.org/10.1001/jama.2012.68			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22298675	Green Accepted			2022-12-28	WOS:000299728000024
J	Brohawn, SG; del Marmol, J; MacKinnon, R				Brohawn, Stephen G.; del Marmol, Josefina; MacKinnon, Roderick			Crystal Structure of the Human K2P TRAAK, a Lipid- and Mechano-Sensitive K+ Ion Channel	SCIENCE			English	Article							POLYUNSATURATED FATTY-ACIDS; DOMAIN POTASSIUM CHANNELS; ARACHIDONIC-ACID; TREK-1; PORE; RESOLUTION; TANDEM; LOCALIZATION; ACTIVATION; EXPRESSION	TRAAK channels, members of the two-pore domain K+ (potassium ion) channel family K2P, are expressed almost exclusively in the nervous system and control the resting membrane potential. Their gating is sensitive to polyunsaturated fatty acids, mechanical deformation of the membrane, and temperature changes. Physiologically, these channels appear to control the noxious input threshold for temperature and pressure sensitivity in dorsal root ganglia neurons. We present the crystal structure of human TRAAK at a resolution of 3.8 angstroms. The channel comprises two protomers, each containing two distinct pore domains, which create a two-fold symmetric K+ channel. The extracellular surface features a helical cap, 35 angstroms tall, that creates a bifurcated pore entryway and accounts for the insensitivity of two-pore domain K+ channels to inhibitory toxins. Two diagonally opposed gate-forming inner helices form membrane-interacting structures that may underlie this channel's sensitivity to chemical and mechanical properties of the cell membrane.	[MacKinnon, Roderick] Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10065 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10065 USA.	mackinn@mail.rockefeller.edu		del Marmol, Josefina/0000-0003-2715-0482; Brohawn, Stephen/0000-0001-6768-3406	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Alam A, 2009, NAT STRUCT MOL BIOL, V16, P30, DOI 10.1038/nsmb.1531; Bagriantsev SN, 2011, EMBO J, V30, P3594, DOI 10.1038/emboj.2011.230; Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Barel O, 2008, AM J HUM GENET, V83, P193, DOI 10.1016/j.ajhg.2008.07.010; Chemin J, 2005, EMBO J, V24, P44, DOI 10.1038/sj.emboj.7600494; Chemin J, 2005, J BIOL CHEM, V280, P4415, DOI 10.1074/jbc.M408246200; Cohen A, 2009, EUR BIOPHYS J BIOPHY, V39, P61, DOI 10.1007/s00249-009-0457-6; Cotten JF, 2006, ANESTH ANALG, V102, P779, DOI 10.1213/01.ane.0000194289.34345.63; Duprat F, 2000, MOL PHARMACOL, V57, P906; Enyedi P, 2010, PHYSIOL REV, V90, P559, DOI 10.1152/physrev.00029.2009; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Heurteaux C, 2006, NAT NEUROSCI, V9, P1134, DOI 10.1038/nn1749; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HODGKIN AL, 1947, J PHYSIOL-LONDON, V106, P341, DOI 10.1113/jphysiol.1947.sp004216; Honore E, 2002, EMBO J, V21, P2968, DOI 10.1093/emboj/cdf288; Kang D, 2005, J PHYSIOL-LONDON, V564, P103, DOI 10.1113/jphysiol.2004.081059; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim Y, 2001, PFLUG ARCH EUR J PHY, V442, P952, DOI 10.1007/s004240100626; Kim Y, 2001, PFLUG ARCH EUR J PHY, V442, P64, DOI 10.1007/s004240000496; Lafreniere RG, 2010, NAT MED, V16, P1157, DOI 10.1038/nm.2216; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 2000, FEBS LETT, V471, P137, DOI 10.1016/S0014-5793(00)01388-0; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Mathie A, 2010, J PHYSIOL-LONDON, V588, P3149, DOI 10.1113/jphysiol.2010.192344; Murbartian J, 2005, J BIOL CHEM, V280, P30175, DOI 10.1074/jbc.M503862200; Noel J, 2009, EMBO J, V28, P1308, DOI 10.1038/emboj.2009.57; OPSAHL LR, 1994, BIOPHYS J, V66, P75, DOI 10.1016/S0006-3495(94)80752-0; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Payandeh J, 2011, NATURE, V475, P353, DOI 10.1038/nature10238; Piechotta PL, 2011, EMBO J, V30, P3607, DOI 10.1038/emboj.2011.268; Sandoz G, 2006, EMBO J, V25, P5864, DOI 10.1038/sj.emboj.7601437; Tao X, 2009, SCIENCE, V326, P1668, DOI 10.1126/science.1180310; Ye S, 2010, NAT STRUCT MOL BIOL, V17, P1019, DOI 10.1038/nsmb.1865; ZHOU XL, 1995, FEBS LETT, V373, P170, DOI 10.1016/0014-5793(95)01035-D; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	42	284	295	4	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					436	441		10.1126/science.1213808	http://dx.doi.org/10.1126/science.1213808			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282805	Green Accepted			2022-12-28	WOS:000299466800041
J	Karan, S; Samitsu, S; Peng, XS; Kurashima, K; Ichinose, I				Karan, Santanu; Samitsu, Sadaki; Peng, Xinsheng; Kurashima, Keiji; Ichinose, Izumi			Ultrafast Viscous Permeation of Organic Solvents Through Diamond-Like Carbon Nanosheets	SCIENCE			English	Article							REVERSE-OSMOSIS MEMBRANES; PLASMA POLYMERIZATION; FILMS; NANOFILTRATION; PERFORMANCE; SEPARATION; EXCLUSION; TRANSPORT	Chemical, petrochemical, energy, and environment-related industries strongly require high-performance nanofiltration membranes applicable to organic solvents. To achieve high solvent permeability, filtration membranes must be as thin as possible, while retaining mechanical strength and solvent resistance. Here, we report on the preparation of ultrathin free-standing amorphous carbon membranes with Young's moduli of 90 to 170 gigapascals. The membranes can separate organic dyes at a rate three orders of magnitude greater than that of commercially available membranes. Permeation experiments revealed that the hard carbon layer has hydrophobic pores of similar to 1 nanometer, which allow the ultrafast viscous permeation of organic solvents through the membrane.	[Karan, Santanu; Samitsu, Sadaki; Peng, Xinsheng; Kurashima, Keiji; Ichinose, Izumi] Natl Inst Mat Sci, Polymer Mat Unit, Tsukuba, Ibaraki 3050044, Japan; [Ichinose, Izumi] Japan Sci & Technol Agcy JST, Chiyoda Ku, Tokyo 1020075, Japan	National Institute for Materials Science; Japan Science & Technology Agency (JST)	Ichinose, I (corresponding author), Natl Inst Mat Sci, Polymer Mat Unit, 1-1 Namiki, Tsukuba, Ibaraki 3050044, Japan.	ichinose.izumi@nims.go.jp	Karan, Santanu/I-2632-2015; Samitsu, Sadaki/H-2516-2011; Karan, Santanu/B-5166-2008; Peng, Xinsheng/A-1295-2009	Samitsu, Sadaki/0000-0002-4139-1656; Karan, Santanu/0000-0002-9140-9121	JST, CREST; Ministry of Education, Culture, Sports, Science and Technology, Japan [23350105]; Grants-in-Aid for Scientific Research [23350105] Funding Source: KAKEN	JST, CREST(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We gratefully acknowledge financial support from JST, CREST, and a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (no. 23350105). A part of this Report was used for a Japanese patent [application no. (2010) 180194].	Abbas GA, 2005, CARBON, V43, P303, DOI 10.1016/j.carbon.2004.09.016; AISENBERG S, 1971, J APPL PHYS, V42, P2953, DOI 10.1063/1.1660654; ANDERSON JL, 1974, BIOPHYS J, V14, P130, DOI 10.1016/S0006-3495(74)70005-4; Bondi A.A., 1968, PHYS PROPERTIES MOL; BUCK KB, 1970, BRIT POLYM SCI, V2, P238; Escobar IC, 2000, J MEMBRANE SCI, V175, P1, DOI 10.1016/S0376-7388(00)00398-7; Fornasiero F, 2008, P NATL ACAD SCI USA, V105, P17250, DOI 10.1073/pnas.0710437105; Froment G. F., 1979, CHEM REACTOR ANAL DE; HOLLAHAN JR, 1973, SCIENCE, V179, P500, DOI 10.1126/science.179.4072.500; Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298; HONEYBONE PJR, 1994, PHYS REV B, V50, P839, DOI 10.1103/PhysRevB.50.839; Ichinose I, 2004, J AM CHEM SOC, V126, P7162, DOI 10.1021/ja049141h; Ismail AF, 2011, CARBON-BASED MEMBRANES FOR SEPARATION PROCESSES, P1, DOI 10.1007/978-0-387-78991-0; Kiyono M, 2010, J MEMBRANE SCI, V359, P2, DOI 10.1016/j.memsci.2009.10.019; KOIDL P, 1990, MATER SCI FORUM, V52, P41, DOI [10.4028/www.scientific.net/MSF.52-53.41, DOI 10.4028/WWW.SCIENTIFIC.NET/MSF.52-53.41]; Li K, 2007, CERAMIC MEMBRANES SE; Othman R, 2010, J MEMBRANE SCI, V348, P287, DOI 10.1016/j.memsci.2009.11.012; PAN XD, 1990, VACUUM, V41, P1360, DOI 10.1016/0042-207X(90)93957-K; Robertson J, 2002, MAT SCI ENG R, V37, P129, DOI 10.1016/S0927-796X(02)00005-0; Shirakura A, 2006, THIN SOLID FILMS, V494, P84, DOI 10.1016/j.tsf.2005.08.366; Silva P, 2008, ADV MEM TECH APPL, P451, DOI DOI 10.1002/9780470276280.CH16; So SU, 2010, ORG PROCESS RES DEV, V14, P1313, DOI 10.1021/op1001403; Striemer CC, 2007, NATURE, V445, P749, DOI 10.1038/nature05532; Toh YHS, 2007, J MEMBRANE SCI, V301, P3, DOI 10.1016/j.memsci.2007.06.034; Van Krevelen D.W., 1990, PROPERTIES POLYM, Vthird; Vandezande P, 2008, CHEM SOC REV, V37, P365, DOI 10.1039/b610848m; WERNER M, 1993, DIAM RELAT MATER, V2, P939, DOI 10.1016/0925-9635(93)90254-Y; YASUDA H, 1973, J APPL POLYM SCI, V17, P201, DOI 10.1002/app.1973.070170116; Zhang QG, 2011, J MATER CHEM, V21, P1684, DOI 10.1039/c0jm03334k	29	272	300	26	466	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					444	447		10.1126/science.1212101	http://dx.doi.org/10.1126/science.1212101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282807				2022-12-28	WOS:000299466800043
J	Lopez, N; Graham, DJ; McGuire, R; Alliger, GE; Shao-Horn, Y; Cummins, CC; Nocera, DG				Lopez, Nazario; Graham, Daniel J.; McGuire, Robert, Jr.; Alliger, Glen E.; Shao-Horn, Yang; Cummins, Christopher C.; Nocera, Daniel G.			Reversible Reduction of Oxygen to Peroxide Facilitated by Molecular Recognition	SCIENCE			English	Article							ANION; OXIDATION; CRYPTAND	Generation of soluble sources of peroxide dianion (O-2(2-)) is a challenge in dioxygen chemistry. The oxidizing nature of this anion renders its stabilization in organic media difficult. This Report describes the chemically reversible reduction of oxygen (O-2) to cryptand-encapsulated O-2(2-). The dianion is stabilized by strong hydrogen bonds to N-H groups from the hexacarboxamide cryptand. Analogous stabilization of peroxide by hydrogen bonding has been invoked recently in crystalline saccharide and protein systems. The present peroxide adducts are stable at room temperature in dimethyl sulfoxide (DMSO) and N,N'-dimethylformamide (DMF). These adducts can be obtained in gram quantities from the cryptand-driven disproportionation reaction of potassium superoxide (KO2) at room temperature.	[Lopez, Nazario; Graham, Daniel J.; McGuire, Robert, Jr.; Alliger, Glen E.; Cummins, Christopher C.; Nocera, Daniel G.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Shao-Horn, Yang] MIT, Dept Mech Engn & Mat, Cambridge, MA 02139 USA; [Shao-Horn, Yang] MIT, Dept Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Nocera, DG (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ccummins@mit.edu; nocera@mit.edu	Cummins, Christopher/J-2961-2014	Cummins, Christopher/0000-0003-2568-3269; Lopez, Nazario/0000-0002-5949-5787	NSF-Centers for Chemical Innovation [CHE-0802907]; NSF [CHE-9808061, DBI-9729592]	NSF-Centers for Chemical Innovation; NSF(National Science Foundation (NSF))	This research was supported by the NSF-Centers for Chemical Innovation (CHE-0802907). Grants from the NSF also provided instrument support to the Department of Chemistry Instrument Facility at MIT (grants CHE-9808061 and DBI-9729592). D.J.G. thanks the NSF Graduate Research Fellowship Program for support. We thank Y. Surendranath for productive discussions and collecting mass spectrometry data, A. F. Cozzolino and P. Muller for structure refinement discussions, and F. A. Armstrong for helpful discussions. Complete crystallographic data were deposited in the Cambridge Crystallographic Database Centre (CCDC 831953 to 831955 and 831962).	Alliger GE, 2011, INORG CHEM, V50, P4107, DOI 10.1021/ic200143b; Alliger GE, 2010, INORG CHEM, V49, P3697, DOI 10.1021/ic100395a; Bard A. J., 2000, ELECTROCHEMICAL METH, P341; BARTLETT N, 1968, CHEM COMMUN, P1046, DOI 10.1039/c19680001046; Boal AK, 2010, SCIENCE, V329, P1526, DOI 10.1126/science.1190187; BUTLER A, 1994, CHEM REV, V94, P625, DOI 10.1021/cr00027a004; Desiraju GR, 1999, IUCR M CRYS, P11; GarciaViloca M, 1997, J AM CHEM SOC, V119, P1081, DOI 10.1021/ja962662n; GEORGE MV, 1975, CHEM REV, V75, P491, DOI 10.1021/cr60296a004; Girishkumar G, 2010, J PHYS CHEM LETT, V1, P2193, DOI 10.1021/jz1005384; GREHL M, 1995, ACTA CRYSTALLOGR C, V51, P1038, DOI 10.1107/S010827019401382X; JONES RD, 1979, CHEM REV, V79, P139, DOI 10.1021/cr60318a002; Kang SO, 2003, J AM CHEM SOC, V125, P10152, DOI 10.1021/ja034969+; Kang SO, 2010, J ORG CHEM, V75, P277, DOI 10.1021/jo901581w; Kato T, 2010, CHEM LETT, V39, P136, DOI 10.1246/cl.2010.136; MARICLE DL, 1965, ANAL CHEM, V37, P1562, DOI 10.1021/ac60231a027; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; Meunier B., 2000, METAL OXO METAL PERO; Meunier B., 2000, BIOMIMETIC OXIDATION; SAWYER DT, 1982, ANAL CHEM, V54, P1720, DOI 10.1021/ac00248a014; Sessler JL, 2006, MONOGR SUPRAMOL CHEM, P1, DOI 10.1039/9781847552471	21	71	72	5	217	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					450	453		10.1126/science.1212678	http://dx.doi.org/10.1126/science.1212678			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282808				2022-12-28	WOS:000299466800045
J	Drife, JO				Drife, James Owen			IN AND OUT OF HOSPITAL Saving Charlotte Bronte	BRITISH MEDICAL JOURNAL			English	Editorial Material												J.O.Drife@leeds.ac.uk							0	1	1	2	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 25	2012	344								e567	10.1136/bmj.e567	http://dx.doi.org/10.1136/bmj.e567			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885KV	22279091				2022-12-28	WOS:000299778800015
J	Aebischer, P				Aebischer, Patrick			The price of charity	NATURE			English	Editorial Material									Ecole Polytech Fed Lausanne, Lausanne, Switzerland	Ecole Polytechnique Federale de Lausanne	Aebischer, P (corresponding author), Ecole Polytech Fed Lausanne, Lausanne, Switzerland.	patrick.aebischer@epfl.ch	Aebischer, Patrick/E-1387-2013					Dorsey ER, 2010, JAMA-J AM MED ASSOC, V303, P137, DOI 10.1001/jama.2009.1987; Estermann T, 2011, FINANCIALLY SUSTAINA; Martin L, 2011, ALL TOGETHER NOW IMP	3	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2012	481	7381					260	260		10.1038/481260a	http://dx.doi.org/10.1038/481260a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	877VK	22258589	Bronze			2022-12-28	WOS:000299210600014
J	Maune, BM; Borselli, MG; Huang, B; Ladd, TD; Deelman, PW; Holabird, KS; Kiselev, AA; Alvarado-Rodriguez, I; Ross, RS; Schmitz, AE; Sokolich, M; Watson, CA; Gyure, MF; Hunter, AT				Maune, B. M.; Borselli, M. G.; Huang, B.; Ladd, T. D.; Deelman, P. W.; Holabird, K. S.; Kiselev, A. A.; Alvarado-Rodriguez, I.; Ross, R. S.; Schmitz, A. E.; Sokolich, M.; Watson, C. A.; Gyure, M. F.; Hunter, A. T.			Coherent singlet-triplet oscillations in a silicon-based double quantum dot	NATURE			English	Article							SPIN BLOCKADE	Silicon is more than the dominant material in the conventional microelectronics industry: it also has potential as a host material for emerging quantum information technologies. Standard fabrication techniques already allow the isolation of single electron spins in silicon transistor-like devices. Although this is also possible in other materials, silicon-based systems have the advantage of interacting more weakly with nuclear spins. Reducing such interactions is important for the control of spin quantum bits because nuclear fluctuations limit quantum phase coherence, as seen in recent experiments in GaAs-based quantum dots(1,2). Advances in reducing nuclear decoherence effects by means of complex control(3-5) still result in coherence times much shorter than those seen in experiments on large ensembles of impurity-bound electrons in bulk silicon crystals(6,7). Here we report coherent control of electron spins in two coupled quantum dots in an undoped Si/SiGe heterostructure and show that this system has a nuclei-induced dephasing time of 360 nanoseconds, which is an increase by nearly two orders of magnitude over similar measurements in GaAs-based quantum dots. The degree of phase coherence observed, combined with fast, gated electrical initialization, read-out and control, should motivate future development of silicon-based quantum information processors.	[Maune, B. M.; Borselli, M. G.; Huang, B.; Ladd, T. D.; Deelman, P. W.; Holabird, K. S.; Kiselev, A. A.; Alvarado-Rodriguez, I.; Ross, R. S.; Schmitz, A. E.; Sokolich, M.; Watson, C. A.; Gyure, M. F.; Hunter, A. T.] HRL Labs LLC, Malibu, CA 90265 USA	HRL Laboratories	Maune, BM (corresponding author), HRL Labs LLC, 3011 Malibu Canyon Rd, Malibu, CA 90265 USA.	bmmaune@hrl.com			United States Department of Defense	United States Department of Defense(United States Department of Defense)	We thank C. M. Marcus for discussions, J. R. Petta for assistance with measurement techniques and B. H. Fong for assistance with hyperfine calculations. Sponsored by United States Department of Defense. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressly or implied, of the United States Department of Defense or the US Government. Approved for public release, distribution unlimited.	Assali LVC, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.165301; Barthel C, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.266808; Bluhm H, 2011, NAT PHYS, V7, P109, DOI 10.1038/NPHYS1856; Borselli MG, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3623479; Borselli MG, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3569717; Coish WA, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.125337; DiVincenzo DP, 2000, NATURE, V408, P339, DOI 10.1038/35042541; Eriksson MA, 2004, QUANTUM INF PROCESS, V3, P133, DOI 10.1007/s11128-004-2224-z; Goswami S, 2007, NAT PHYS, V3, P41, DOI 10.1038/nphys475; HAYES RR, 2009, LIFETIME MEASUREMENT; Johnson AC, 2005, NATURE, V435, P925, DOI 10.1038/nature03815; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Koppens FHL, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.236802; Ladd TD, 2010, NATURE, V464, P45, DOI 10.1038/nature08812; Lai NS, 2011, SCI REP-UK, V1, DOI 10.1038/srep00110; Laird EA, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.056801; Liu HW, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.073310; Morello A, 2010, NATURE, V467, P687, DOI 10.1038/nature09392; Petta JR, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.067601; Petta JR, 2005, SCIENCE, V309, P2180, DOI 10.1126/science.1116955; Press D, 2010, NAT PHOTONICS, V4, P367, DOI 10.1038/NPHOTON.2010.83; Simmons CB, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.156804; Simmons S, 2011, NATURE, V470, P69, DOI 10.1038/nature09696; Tomita Y, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/1/015002; Tyryshkin A. M., 2011, NATURE MAT IN PRESS; West JR, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.230503; Xiao M, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3464324; Xiao M, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.096801	30	422	430	8	163	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2012	481	7381					344	347		10.1038/nature10707	http://dx.doi.org/10.1038/nature10707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258613				2022-12-28	WOS:000299210600038
J	Rice, SA; Haselkorn, R				Rice, Stuart A.; Haselkorn, Robert			Paul Mead Doty (1920-2011) OBITUARY	NATURE			English	Biographical-Item									[Rice, Stuart A.] Univ Chicago, Dept Chem, Chicago, IL 60637 USA; [Rice, Stuart A.] Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; [Haselkorn, Robert] Univ Chicago, Dept Chem, Chicago, IL 60637 USA; [Haselkorn, Robert] Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Rice, SA (corresponding author), Univ Chicago, Dept Chem, Chicago, IL 60637 USA.	rh01@uchicago.edu							0	1	1	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2012	481	7381					266	266		10.1038/481266a	http://dx.doi.org/10.1038/481266a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258598	Bronze			2022-12-28	WOS:000299210600021
J	Earley, A; Miskulin, D; Lamb, EJ; Levey, AS; Uhlig, K				Earley, Amy; Miskulin, Dana; Lamb, Edmund J.; Levey, Andrew S.; Uhlig, Katrin			Estimating Equations for Glomerular Filtration Rate in the Era of Creatinine Standardization A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							SERUM CYSTATIN-C; KIDNEY-FUNCTION; RENAL-DISEASE; COCKCROFT-GAULT; ESTIMATING GFR; MDRD; PERFORMANCE; VALIDATION; PREDICTION; CLEARANCE	Background: Clinical laboratories are increasingly reporting estimated glomerular filtration rate (GFR) by using serum creatinine assays traceable to a standard reference material. Purpose: To review the performance of GFR estimating equations to inform the selection of a single equation by laboratories and the interpretation of estimated GFR by clinicians. Data Sources: A systematic search of MEDLINE, without language restriction, between 1999 and 21 October 2011. Study Selection: Cross-sectional studies in adults that compared the performance of 2 or more creatinine-based GFR estimating equations with a reference GFR measurement. Eligible equations were derived or reexpressed and validated by using creatinine measurements traceable to the standard reference material. Data Extraction: Reviewers extracted data on study population characteristics, measured GFR, creatinine assay, and equation performance. Data Synthesis: Eligible studies compared the MDRD (Modification of Diet in Renal Disease) Study and CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations or modifications thereof. In 12 studies in North America, Europe, and Australia, the CKD-EPI equation performed better at higher GFRs (approximately > 60 mL/min per 1.73 m(2)) and the MDRD Study equation performed better at lower GFRs. In 5 of 8 studies in Asia and Africa, the equations were modified to improve their performance by adding a coefficient derived in the local population or removing a coefficient. Limitation: Methods of GFR measurement and study populations were heterogeneous. Conclusion: Neither the CKD-EPI nor the MDRD Study equation is optimal for all populations and GFR ranges. Using a single equation for reporting requires a tradeoff to optimize performance at either higher or lower GFR ranges. A general practice and public health perspective favors the CKD-EPI equation.	[Uhlig, Katrin] Tufts Med Ctr, Boston, MA 02111 USA; Kent & Canterbury Hosp, Canterbury, Kent, England	Tufts Medical Center; University of Kent	Uhlig, K (corresponding author), Tufts Med Ctr, 800 Washington St,Box 391, Boston, MA 02111 USA.	kuhlig@tuftsmedicalcenter.org			Kidney Disease: Improving Global Outcomes; KDIGO; National Kidney Foundation; National Institutes of Health	Kidney Disease: Improving Global Outcomes; KDIGO; National Kidney Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Primary Funding Source: Kidney Disease: Improving Global Outcomes.; Grant Support: By KDIGO.; Ms. Earley and Drs. Miskulin and Uhlig report the following: Grant (money to institution): National Kidney Foundation; Support for travel to meetings for the study or other purposes: National Kidney Foundation. Ms. Earley and Dr. Uhlig further report: Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like (money to institution): National Kidney Foundation. Dr. Miskulin further reports: Grant: National Kidney Foundation; Employment: Dialysis Clinic. Dr. Lamb: Support for travel to meetings for the study or other purposes: Kidney Disease: Improving Global Outcomes; Grants/grants pending (money to institution): National Institutes of Health. Dr. Levey: Support for travel to meetings for the study or other purposes (money to institution): National Kidney Foundation; Board membership (money to institution): National Kidney Foundation; Grants/grants pending (money to institution): National Kidney Foundation. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-2267.	BERGLUND F, 1975, J UROLOGY, V114, P802, DOI 10.1016/S0022-5347(17)67149-0; BJORNSSON TD, 1983, CLIN PHARMACOKINET, V8, P365, DOI 10.2165/00003088-198308040-00007; Blirup-Jensen S, 2008, SCAND J CLIN LAB INV, V68, P67, DOI 10.1080/00365510802150067; Cirillo M, 2010, AM J KIDNEY DIS, V56, P802, DOI 10.1053/j.ajkd.2010.07.002; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; Coresh J, 2006, CURR OPIN NEPHROL HY, V15, P276, DOI 10.1097/01.mnh.0000222695.84464.61; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Eriksen BO, 2010, KIDNEY INT, V78, P1305, DOI 10.1038/ki.2010.321; GATES GF, 1985, AM J KIDNEY DIS, V5, P199, DOI 10.1016/S0272-6386(85)80051-2; Grubb A, 2010, CLIN CHEM LAB MED, V48, P1619, DOI 10.1515/CCLM.2010.318; Horio M, 2010, AM J KIDNEY DIS, V56, P32, DOI 10.1053/j.ajkd.2010.02.344; HULL JH, 1981, CLIN PHARMACOL THER, V29, P516, DOI 10.1038/clpt.1981.72; Imai Enyu, 2007, Clin Exp Nephrol, V11, P41, DOI 10.1007/s10157-006-0453-4; Inker LA, 2011, AM J KIDNEY DIS, V58, P682, DOI 10.1053/j.ajkd.2011.05.019; JELLIFFE RW, 1973, ANN INTERN MED, V79, P604, DOI 10.7326/0003-4819-79-4-604; JELLIFFE RW, 1971, LANCET, V1, P975; Jones GRD, 2010, PATHOLOGY, V42, P487, DOI 10.3109/00313025.2010.494291; Jones GRD, 2009, PATHOLOGY, V41, P379, DOI 10.1080/00313020902884980; Kukla A, 2010, NEPHROL DIAL TRANSPL, V25, P1653, DOI 10.1093/ndt/gfp668; Kwong YT, 2010, AM J KIDNEY DIS, V56, P39, DOI 10.1053/j.ajkd.2010.02.347; Lane BR, 2010, J UROLOGY, V183, P896, DOI 10.1016/j.juro.2009.11.023; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Levey AS, 2000, J AM SOC NEPHROL, V11, p155A; Ma YC, 2006, J AM SOC NEPHROL, V17, P2937, DOI 10.1681/ASN.2006040368; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Matsushita K, 2010, AM J KIDNEY DIS, V55, P648, DOI 10.1053/j.ajkd.2009.12.016; MAWER GE, 1972, LANCET, V1, P12; Michels WM, 2010, CLIN J AM SOC NEPHRO, V5, P1003, DOI 10.2215/CJN.06870909; Miller WG, 2009, CLIN CHEM LAB MED, V47, P1017, DOI 10.1515/CCLM.2009.264; Murata K, 2011, CLIN J AM SOC NEPHRO, V6, P1963, DOI 10.2215/CJN.02300311; Myers GL, 2006, CLIN CHEM, V52, P5, DOI 10.1373/clinchem.2005.0525144; NANKIVELL BJ, 1995, TRANSPLANTATION, V59, P1683, DOI 10.1097/00007890-199506270-00007; Panteghini M, 2006, CLIN CHEM LAB MED, V44, P1287, DOI 10.1515/CCLM.2006.234; Poge U, 2011, NEPHROL DIAL TRANSPL, V26, P4104, DOI 10.1093/ndt/gfr183; Praditpornsilpa K, 2011, NEPHROL DIAL TRANSPL, V26, P2780, DOI 10.1093/ndt/gfq815; Redal-Baigorri B, 2011, DAN MED BULL, V58; Rule AD, 2004, ANN INTERN MED, V141, P929, DOI 10.7326/0003-4819-141-12-200412210-00009; Rule AD, 2009, AM J KIDNEY DIS, V53, P932, DOI 10.1053/j.ajkd.2009.02.011; Skali H, 2011, AM HEART J, V162, P548, DOI 10.1016/j.ahj.2011.06.006; Stevens LA, 2008, AM J KIDNEY DIS, V51, P395, DOI 10.1053/j.ajkd.2007.11.018; Stevens LA, 2006, NEW ENGL J MED, V354, P2473, DOI 10.1056/NEJMra054415; Stevens LA, 2011, KIDNEY INT, V79, P555, DOI 10.1038/ki.2010.462; Stevens LA, 2010, AM J KIDNEY DIS, V56, P486, DOI 10.1053/j.ajkd.2010.03.026; Stevens LA, 2009, J AM SOC NEPHROL, V20, P2305, DOI 10.1681/ASN.2009020171; Stevens LA, 2008, J NEPHROL, V21, P797; Tent H, 2010, CLIN J AM SOC NEPHRO, V5, P1960, DOI 10.2215/CJN.08761209; Teo BW, 2011, AM J KIDNEY DIS, V58, P56, DOI 10.1053/j.ajkd.2011.02.393; van Deventer HE, 2008, CLIN CHEM, V54, P1197, DOI 10.1373/clinchem.2007.099085; Vickery S, 2006, NEPHROL DIAL TRANSPL, V21, P2439, DOI 10.1093/ndt/gfl249; WALSER M, 1993, KIDNEY INT, V44, P1145, DOI 10.1038/ki.1993.361; White CA, 2010, CLIN CHEM, V56, P474, DOI 10.1373/clinchem.2009.135111; White SL, 2010, AM J KIDNEY DIS, V55, P660, DOI 10.1053/j.ajkd.2009.12.011; Yeo Y, 2010, NEPHRON CLIN PRACT, V114, pC108, DOI 10.1159/000254383; Zegers I.A.G., 2010, CERTIFICATION CYSTAT	57	343	356	0	38	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 5	2012	156	11					785	+		10.7326/0003-4819-156-11-201203200-00391	http://dx.doi.org/10.7326/0003-4819-156-11-201203200-00391			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	954ZK	22312131				2022-12-28	WOS:000304986500004
J	Copic, A; Latham, CF; Horlbeck, MA; D'Arcangelo, JG; Miller, EA				Copic, Alenka; Latham, Catherine F.; Horlbeck, Max A.; D'Arcangelo, Jennifer G.; Miller, Elizabeth A.			ER Cargo Properties Specify a Requirement for COPII Coat Rigidity Mediated by Sec13p	SCIENCE			English	Article							GPI-ANCHORED PROTEINS; PLASMA-MEMBRANE ATPASE; ENDOPLASMIC-RETICULUM; EDGE ELEMENT; VESICLE COAT; EXIT SITES; COMPLEX; YEAST; CURVATURE; TRANSPORT	Eukaryotic secretory proteins exit the endoplasmic reticulum (ER) via transport vesicles generated by the essential coat protein complex II (COPII) proteins. The outer coat complex, Sec13-Sec31, forms a scaffold that is thought to enforce curvature. By exploiting yeast bypass-of-sec-thirteen (bst) mutants, where Sec13p is dispensable, we probed the relationship between a compromised COPII coat and the cellular context in which it could still function. Genetic and biochemical analyses suggested that Sec13p was required to generate vesicles from membranes that contained asymmetrically distributed cargoes that were likely to confer opposing curvature. Thus, Sec13p may rigidify the COPII cage and increase its membrane-bending capacity; this function could be bypassed when a bst mutation renders the membrane more deformable.	[Copic, Alenka; Latham, Catherine F.; Horlbeck, Max A.; D'Arcangelo, Jennifer G.; Miller, Elizabeth A.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Miller, EA (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	em2282@columbia.edu		Copic, Alenka/0000-0003-0166-7731; Miller, Elizabeth/0000-0002-1033-8369	Columbia Research Initiatives in Science and Engineering; NIH [GM085089, GM078186]; Columbia Frontiers of Science fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085089, R01GM078186] Funding Source: NIH RePORTER	Columbia Research Initiatives in Science and Engineering; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Columbia Frontiers of Science fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. Goldberg, C. Boone, E. Snapp, and M. Lee for strains and reagents; T. Swayne, E. Bauer, R. Rothstein, J. Dittmar, and members of the Rothstein laboratory for technical assistance; and B. Antonny, J. Derganc, M. Lee, and F. Pincet for valuable discussions. This work was supported by a Columbia Research Initiatives in Science and Engineering award and NIH grants GM085089 and GM078186 to E. A. M. and by a Columbia Frontiers of Science fellowship to A. C. M. A. H. was an I. I. Rabi Science Scholar of Columbia University. Additional data described in the manuscript are presented in the supporting online material.	BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Bielli A, 2005, J CELL BIOL, V171, P919, DOI 10.1083/jcb.200509095; Brohawn SG, 2009, NAT STRUCT MOL BIOL, V16, P1173, DOI 10.1038/nsmb.1713; Copic A, 2009, GENETICS, V182, P757, DOI 10.1534/genetics.109.101105; Dancourt J, 2010, ANNU REV BIOCHEM, V79, P777, DOI 10.1146/annurev-biochem-061608-091319; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Fath S, 2007, CELL, V129, P1325, DOI 10.1016/j.cell.2007.05.036; Fujita M, 2008, BBA-GEN SUBJECTS, V1780, P410, DOI 10.1016/j.bbagen.2007.08.009; Fujita M, 2011, J CELL BIOL, V194, P61, DOI 10.1083/jcb.201012074; Fujita M, 2009, CELL, V139, P352, DOI 10.1016/j.cell.2009.08.040; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Miller EA, 2010, CURR OPIN CELL BIOL, V22, P447, DOI 10.1016/j.ceb.2010.04.003; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Saito K, 2009, CELL, V136, P891, DOI 10.1016/j.cell.2008.12.025; Schneiter R, 2004, BIOCHEM J, V381, P941, DOI 10.1042/BJ20040320; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; Stagg SM, 2008, CELL, V134, P474, DOI 10.1016/j.cell.2008.06.024; Stagg SM, 2006, NATURE, V439, P234, DOI 10.1038/nature04339; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Townley AK, 2008, J CELL SCI, V121, P3025, DOI 10.1242/jcs.031070; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Whittle JRR, 2010, J CELL BIOL, V190, P347, DOI 10.1083/jcb.201003092; Wilbur JD, 2010, DEV CELL, V18, P841, DOI 10.1016/j.devcel.2010.04.007; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	30	93	93	4	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 16	2012	335	6074					1359	1362		10.1126/science.1215909	http://dx.doi.org/10.1126/science.1215909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908ZM	22300850	Green Accepted			2022-12-28	WOS:000301531600050
J	Seo, MD; Velamakanni, S; Ishiyama, N; Stathopulos, PB; Rossi, AM; Khan, SA; Dale, P; Li, CM; Ames, JB; Ikura, M; Taylor, CW				Seo, Min-Duk; Velamakanni, Saroj; Ishiyama, Noboru; Stathopulos, Peter B.; Rossi, Ana M.; Khan, Samir A.; Dale, Philippa; Li, Congmin; Ames, James B.; Ikura, Mitsuhiko; Taylor, Colin W.			Structural and functional conservation of key domains in InsP(3) and ryanodine receptors	NATURE			English	Article							LIGAND-BINDING; CRYSTAL-STRUCTURES; CONFORMATIONAL-CHANGES; TRANSMEMBRANE DOMAINS; MOLECULAR-CLONING; INOSITOL; FORMS; PROBE	Inositol-1,4,5-trisphosphate receptors (InsP(3)Rs) and ryanodine receptors (RyRs) are tetrameric intracellular Ca2+ channels(1). In each of these receptor families, the pore, which is formed by carboxy-terminal transmembrane domains, is regulated by signals that are detected by large cytosolic structures. InsP(3)R gating is initiated by InsP(3) binding to the InsP(3)-binding core (IBC, residues 224-604 of InsP(3)R1)(2) and it requires the suppressor domain (SD, residues 1-223 of InsP(3)R1)(2-8). Here we present structures of the amino-terminal region (NT, residues 1-604) of rat InsP(3)R1 with (3.6 angstrom) and without (3.0 angstrom) InsP(3) bound. The arrangement of the three NT domains, SD, IBC-beta and IBC-alpha, identifies two discrete interfaces (alpha and beta) between the IBC and SD. Similar interfaces occur between equivalent domains (A, B and C) in RyR1 (ref. 9). The orientations of the three domains when docked into a tetrameric structure of InsP(3)R(10) and of the ABC domains docked into RyR(9) are remarkably similar. The importance of the alpha-interface for activation of InsP(3)R and RyR is confirmed by mutagenesis and, for RyR, by disease-causing mutations(9,11,12). Binding of InsP(3) causes partial closure of the clam-like IBC, disrupting the beta-interface and pulling the SD towards the IBC. This reorients an exposedSDloop ('hotspot' (HS) loop) that is essential for InsP(3)R activation(7). The loop is conserved in RyR and includes mutations that are associated with malignant hyperthermia and central core disease(9,11,12). The HS loop interacts with an adjacent NT, suggesting that activation re-arranges inter-subunit interactions. The A domain of RyR functionally replaced the SD in full-length InsP(3)R, and an InsP(3)R in which its C-terminal transmembrane region was replaced by that from RyR1 was gated by InsP(3) and blocked by ryanodine. Activation mechanisms are conserved between InsP(3)R and RyR. Allosteric modulation of two similar domain interfaces within an N-terminal subunit reorients the first domain (SD or A domain), allowing it, through interactions of the second domain of an adjacent subunit (IBC-beta or B domain), to gate the pore.	[Seo, Min-Duk; Ishiyama, Noboru; Stathopulos, Peter B.; Ikura, Mitsuhiko] Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 1L7, Canada; [Seo, Min-Duk; Ishiyama, Noboru; Stathopulos, Peter B.; Ikura, Mitsuhiko] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada; [Velamakanni, Saroj; Rossi, Ana M.; Khan, Samir A.; Dale, Philippa; Taylor, Colin W.] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; [Li, Congmin; Ames, James B.] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Cambridge; University of California System; University of California Davis	Ikura, M (corresponding author), Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 1L7, Canada.	mikura@uhnres.utoronto.ca; cwt1000@cam.ac.uk	; Taylor, Colin/G-2447-2010	Rossi, Ana Maria/0000-0001-8743-1089; Taylor, Colin/0000-0001-7771-1044; Ishiyama, Noboru/0000-0002-1426-6083; Stathopulos, Peter B./0000-0002-0536-6656; Ikura, Mitsuhiko/0000-0002-9524-1303	Heart and Stroke Foundation of Ontario [T-7181]; National Institutes of Health Research [EY012347, NS059969]; Wellcome Trust [085295]; Biotechnology and Biological Sciences Research Council [BB/H009736]; Medical Research Council [G0900049]; Canadian Institutes of Health Research; National Research Foundation of Korea [2009-352-E00006]; Biotechnology and Biological Sciences Research Council [BB/H009736/1] Funding Source: researchfish; BBSRC [BB/H009736/1] Funding Source: UKRI; MRC [G0900049] Funding Source: UKRI; NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059969] Funding Source: NIH RePORTER	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); National Institutes of Health Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome Trust); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Research Foundation of Korea(National Research Foundation of Korea); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank P. Allen and D. MacLennan for gifts of plasmids encoding RyR2 and RyR1, respectively. C.W.T. thanks T. Rahman and V. Konieczny for discussions. M.I. acknowledges K. Mikoshiba and T. Michikawa for long-standing support and discussions. This work was supported by grants from the Heart and Stroke Foundation of Ontario (T-7181) to M.I., National Institutes of Health Research (EY012347 and NS059969) to J.B.A., the Wellcome Trust (085295), the Biotechnology and Biological Sciences Research Council (BB/H009736) and the Medical Research Council (G0900049) to C.W.T. M.-D.S. is supported by postdoctoral fellowships from the Canadian Institutes of Health Research and the National Research Foundation of Korea (2009-352-E00006). A.M.R. is a fellow of Queens' College, Cambridge. M.I. holds a Canadian Research Chair in Cancer Structural Biology.	Amador FJ, 2009, P NATL ACAD SCI USA, V106, P11040, DOI 10.1073/pnas.0905186106; Anyatonwu G, 2009, J BIOL CHEM, V284, P8093, DOI 10.1074/jbc.M806932200; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Chan J, 2007, J MOL BIOL, V373, P1269, DOI 10.1016/j.jmb.2007.08.057; Chan J, 2010, J BIOL CHEM, V285, P36092, DOI 10.1074/jbc.M110.140160; CHU A, 1990, MOL PHARMACOL, V37, P735; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; George CH, 2004, MOL BIOL CELL, V15, P2627, DOI 10.1091/mbc.E03-09-0688; Hamada T, 2007, BIOCHEMISTRY-US, V46, P4272, DOI 10.1021/bi061557f; Iwai M, 2007, J BIOL CHEM, V282, P12755, DOI 10.1074/jbc.M609833200; Kenakin T., 1997, PHARMACOLOGIC ANAL D, Vsecond edition, P137, DOI DOI 10.1097/00007691-198803000-00029; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; Lin CC, 2011, NAT STRUCT MOL BIOL, V18, P1172, DOI 10.1038/nsmb.2112; Liu Z, 2010, J CELL SCI, V123, P1775, DOI 10.1242/jcs.064071; Lobo PA, 2009, STRUCTURE, V17, P1505, DOI 10.1016/j.str.2009.08.016; Ludtke SJ, 2011, STRUCTURE, V19, P1192, DOI 10.1016/j.str.2011.05.003; Mayer ML, 2006, NATURE, V440, P456, DOI 10.1038/nature04709; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OTSU K, 1990, J BIOL CHEM, V265, P13472; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Rossi AM, 2009, NAT CHEM BIOL, V5, P631, DOI 10.1038/nchembio.195; Samso M, 2009, PLOS BIOL, V7, P980, DOI 10.1371/journal.pbio.1000085; Schug ZT, 2006, J BIOL CHEM, V281, P24431, DOI 10.1074/jbc.M604190200; Serysheva II, 2010, CURR TOP MEMBR, V66, P171, DOI 10.1016/S1063-5823(10)66008-5; Sureshan KM, 2009, CHEM COMMUN, P1204, DOI 10.1039/b819328b; Tateishi H, 2009, CARDIOVASC RES, V81, P536, DOI 10.1093/cvr/cvn303; Taylor CW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004010; Tovey SC, 2006, NAT PROTOC, V1, P259, DOI 10.1038/nprot.2006.40; Tovey SC, 2010, J BIOL CHEM, V285, P12979, DOI 10.1074/jbc.M109.096016; Tung CC, 2010, NATURE, V468, P585, DOI 10.1038/nature09471; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; Wriggers W, 1999, J STRUCT BIOL, V125, P185, DOI 10.1006/jsbi.1998.4080; Yamazaki H, 2010, J BIOL CHEM, V285, P36081, DOI 10.1074/jbc.M110.140129; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	38	138	139	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 1	2012	483	7387					108	U159		10.1038/nature10751	http://dx.doi.org/10.1038/nature10751			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900HP	22286060	Green Submitted, Green Accepted			2022-12-28	WOS:000300877900055
J	Mackay, TFC; Richards, S; Stone, EA; Barbadilla, A; Ayroles, JF; Zhu, DH; Casillas, S; Han, Y; Magwire, MM; Cridland, JM; Richardson, MF; Anholt, RRH; Barron, M; Bess, C; Blankenburg, KP; Carbone, MA; Castellano, D; Chaboub, L; Duncan, L; Harris, Z; Javaid, M; Jayaseelan, JC; Jhangiani, SN; Jordan, KW; Lara, F; Lawrence, F; Lee, SL; Librado, P; Linheiro, RS; Lyman, RF; Mackey, AJ; Munidasa, M; Muzny, DM; Nazareth, L; Newsham, I; Perales, L; Pu, LL; Qu, C; Ramia, M; Reid, JG; Rollmann, SM; Rozas, J; Saada, N; Turlapati, L; Worley, KC; Wu, YQ; Yamamoto, A; Zhu, YM; Bergman, CM; Thornton, KR; Mittelman, D; Gibbs, RA				Mackay, Trudy F. C.; Richards, Stephen; Stone, Eric A.; Barbadilla, Antonio; Ayroles, Julien F.; Zhu, Dianhui; Casillas, Sonia; Han, Yi; Magwire, Michael M.; Cridland, Julie M.; Richardson, Mark F.; Anholt, Robert R. H.; Barron, Maite; Bess, Crystal; Blankenburg, Kerstin Petra; Carbone, Mary Anna; Castellano, David; Chaboub, Lesley; Duncan, Laura; Harris, Zeke; Javaid, Mehwish; Jayaseelan, Joy Christina; Jhangiani, Shalini N.; Jordan, Katherine W.; Lara, Fremiet; Lawrence, Faye; Lee, Sandra L.; Librado, Pablo; Linheiro, Raquel S.; Lyman, Richard F.; Mackey, Aaron J.; Munidasa, Mala; Muzny, Donna Marie; Nazareth, Lynne; Newsham, Irene; Perales, Lora; Pu, Ling-Ling; Qu, Carson; Ramia, Miquel; Reid, Jeffrey G.; Rollmann, Stephanie M.; Rozas, Julio; Saada, Nehad; Turlapati, Lavanya; Worley, Kim C.; Wu, Yuan-Qing; Yamamoto, Akihiko; Zhu, Yiming; Bergman, Casey M.; Thornton, Kevin R.; Mittelman, David; Gibbs, Richard A.			The Drosophila melanogaster Genetic Reference Panel	NATURE			English	Article							MCDONALD-KREITMAN TEST; SLIGHTLY DELETERIOUS MUTATIONS; ADAPTIVE PROTEIN EVOLUTION; QUANTITATIVE TRAITS; MOLECULAR EVOLUTION; DNA POLYMORPHISM; POPULATION-SIZE; RECOMBINATION; SELECTION; CHALLENGES	A major challenge of biology is understanding the relationship between molecular genetic variation and variation in quantitative traits, including fitness. This relationship determines our ability to predict phenotypes from genotypes and to understand how evolutionary forces shape variation within and between species. Previous efforts to dissect the genotype-phenotype map were based on incomplete genotypic information. Here, we describe the Drosophila melanogaster Genetic Reference Panel (DGRP), a community resource for analysis of population genomics and quantitative traits. The DGRP consists of fully sequenced inbred lines derived from a natural population. Population genomic analyses reveal reduced polymorphism in centromeric autosomal regions and the X chromosome, evidence for positive and negative selection, and rapid evolution of the X chromosome. Many variants in novel genes, most at low frequency, are associated with quantitative traits and explain a large fraction of the phenotypic variance. The DGRP facilitates genotype-phenotype mapping using the power of Drosophila genetics.	[Mackay, Trudy F. C.; Stone, Eric A.; Ayroles, Julien F.; Magwire, Michael M.; Carbone, Mary Anna; Duncan, Laura; Harris, Zeke; Jordan, Katherine W.; Lawrence, Faye; Lyman, Richard F.; Rollmann, Stephanie M.; Turlapati, Lavanya; Yamamoto, Akihiko] N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA; [Richards, Stephen; Zhu, Dianhui; Han, Yi; Bess, Crystal; Blankenburg, Kerstin Petra; Chaboub, Lesley; Javaid, Mehwish; Jayaseelan, Joy Christina; Jhangiani, Shalini N.; Lara, Fremiet; Lee, Sandra L.; Munidasa, Mala; Muzny, Donna Marie; Nazareth, Lynne; Newsham, Irene; Perales, Lora; Pu, Ling-Ling; Qu, Carson; Reid, Jeffrey G.; Saada, Nehad; Worley, Kim C.; Wu, Yuan-Qing; Zhu, Yiming; Gibbs, Richard A.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Barbadilla, Antonio; Casillas, Sonia; Barron, Maite; Castellano, David; Ramia, Miquel] Univ Autonoma Barcelona, Genom Bioinformat & Evolut Grp, Inst Biotecnol & Biomed IBB, Dept Genet & Microbiol, Bellaterra 08193, Spain; [Ayroles, Julien F.; Thornton, Kevin R.] Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; [Richardson, Mark F.; Linheiro, Raquel S.; Bergman, Casey M.] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; [Anholt, Robert R. H.] N Carolina State Univ, Dept Biol, Raleigh, NC 27695 USA; [Librado, Pablo; Rozas, Julio] Univ Barcelona, Fac Biol, Mol Evolutionary Genet Grp, Dept Genet, E-08028 Barcelona, Spain; [Mackey, Aaron J.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22908 USA; [Mittelman, David] Virginia Tech, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; [Mittelman, David] Virginia Tech, Dept Biol Sci, Blacksburg, VA 24061 USA	University of North Carolina; North Carolina State University; Baylor College of Medicine; Autonomous University of Barcelona; University of California System; University of California Irvine; University of Manchester; University of North Carolina; North Carolina State University; University of Barcelona; University of Virginia; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University	Mackay, TFC (corresponding author), N Carolina State Univ, Dept Genet, Box 7614, Raleigh, NC 27695 USA.	trudy_mackay@ncsu.edu	Casillas, Sònia/I-5442-2014; JAYASEELAN, JOY CHRISTINA/F-9824-2015; Stone, Eric/Q-7840-2016; Barbadilla, Antonio/A-6915-2017; Castellano, David/O-3582-2016; Rozas, Julio/A-1733-2009; Bergman, Casey/F-7854-2010; Anholt, Robert/S-5977-2019	Casillas, Sònia/0000-0001-8191-0062; JAYASEELAN, JOY CHRISTINA/0000-0002-7759-0139; Barbadilla, Antonio/0000-0002-0374-1475; Castellano, David/0000-0001-8778-6007; Rozas, Julio/0000-0002-6839-9148; Bergman, Casey/0000-0002-5462-9854; Chaboub, Lesley/0000-0002-2773-8027; Thornton, Kevin/0000-0003-0743-4445; Stone, Eric/0000-0002-2725-4209; Richardson, Mark/0000-0002-1650-0064; Worley, Kim/0000-0002-0282-1000; Librado, Pablo/0000-0001-5974-2189; Barron Aduriz, Maite Garazi/0000-0001-6146-6259; Linheiro, Raquel/0000-0003-2659-0910	National Institutes of Health [GM 45146, R01 GM 059469, MCI BFU 2009-09504, R01 GM 085183, NHGRI U54 HG003273]; NVIDIA Foundation; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059469, R01GM085183, R01GM045146] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NVIDIA Foundation; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health grant GM 45146 to T. F. C. M., E. A. S. and R. R. H. A.; R01 GM 059469 to R. R. H. A., MCI BFU 2009-09504 to A. B., R01 GM 085183 to K. R. T., NHGRI U54 HG003273 to R. A. G.; and an award through the NVIDIA Foundation's "Compute the Cure" programme to D.M.	Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Andolfatto P, 2001, GENETICS, V158, P657; Andolfatto P, 2005, NATURE, V437, P1149, DOI 10.1038/nature04107; Ayroles JF, 2009, NAT GENET, V41, P299, DOI 10.1038/ng.332; BEGUN DJ, 1993, NATURE, V365, P548, DOI 10.1038/365548a0; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427; Casillas S, 2007, MOL BIOL EVOL, V24, P2222, DOI 10.1093/molbev/msm150; CHARLESWORTH B, 1987, AM NAT, V130, P113, DOI 10.1086/284701; CHARLESWORTH B, 1993, GENETICS, V134, P1289; Charlesworth J, 2008, MOL BIOL EVOL, V25, P1007, DOI 10.1093/molbev/msn005; Clark AG, 2007, NATURE, V450, P203, DOI 10.1038/nature06341; DAVID JR, 1988, TRENDS GENET, V4, P106, DOI 10.1016/0168-9525(88)90098-4; Donnelly P, 2008, NATURE, V456, P728, DOI 10.1038/nature07631; Egea R, 2008, NUCLEIC ACIDS RES, V36, pW157, DOI 10.1093/nar/gkn337; Eyre-Walker A, 2002, GENETICS, V162, P2017; Eyre-Walker A, 2009, MOL BIOL EVOL, V26, P2097, DOI 10.1093/molbev/msp119; Falconer DS, 1996, INTRO QUANTITATIVE G; Fay JC, 2002, NATURE, V415, P1024, DOI 10.1038/4151024a; Flint J, 2009, GENOME RES, V19, P723, DOI 10.1101/gr.086660.108; Harbison ST, 2004, GENETICS, V166, P1807, DOI 10.1534/genetics.166.4.1807; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; JENKINS DL, 1995, P ROY SOC B-BIOL SCI, V261, P203, DOI 10.1098/rspb.1995.0137; Jukes T., 1969, MAMMALIAN PROTEIN ME, P21; Lynch M., 1998, GENETICS ANAL QUANTI; Mackay TFC, 2009, NAT REV GENET, V10, P565, DOI 10.1038/nrg2612; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Nei M., 1987, MOL EVOLUTIONARY GEN; Nielsen R, 2001, HEREDITY, V86, P641, DOI 10.1046/j.1365-2540.2001.00895.x; OHTA T, 1973, NATURE, V246, P96, DOI 10.1038/246096a0; Pospisilik JA, 2010, CELL, V140, P148, DOI 10.1016/j.cell.2009.12.027; Presgraves DC, 2005, CURR BIOL, V15, P1651, DOI 10.1016/j.cub.2005.07.065; Roy S, 2010, SCIENCE, V330, P1787, DOI 10.1126/science.1198374; Sackton TB, 2009, GENOME BIOL EVOL, V1, P449, DOI 10.1093/gbe/evp048; SAWYER SA, 1992, GENETICS, V132, P1161; Sella G, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000495; Sieberts SK, 2007, MAMM GENOME, V18, P389, DOI 10.1007/s00335-007-9040-6; Smith NGC, 2002, NATURE, V415, P1022, DOI 10.1038/4151022a; Stoletzki N, 2011, MOL BIOL EVOL, V28, P63, DOI 10.1093/molbev/msq249; TAJIMA F, 1989, GENETICS, V123, P585; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; Werren JH, 1997, ANNU REV ENTOMOL, V42, P587, DOI 10.1146/annurev.ento.42.1.587; Yamamoto A, 2008, P NATL ACAD SCI USA, V105, P12393, DOI 10.1073/pnas.0804889105	44	1001	1016	7	275	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2012	482	7384					173	178		10.1038/nature10811	http://dx.doi.org/10.1038/nature10811			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22318601	Green Accepted, Green Published, hybrid, Green Submitted			2022-12-28	WOS:000299994100029
J	Cooper, TF; O'Leary, RA; Lough, JM				Cooper, Timothy F.; O'Leary, Rebecca A.; Lough, Janice M.			Growth of Western Australian Corals in the Anthropocene	SCIENCE			English	Article							OCEAN ACIDIFICATION; CLIMATE-CHANGE; CARBON; CALCIFICATION; METABOLISM; PORITES; IMPACT; REEFS; CO2	Anthropogenic increases of atmospheric carbon dioxide lead to warmer sea surface temperatures and altered ocean chemistry. Experimental evidence suggests that coral calcification decreases as aragonite saturation drops but increases as temperatures rise toward thresholds optimal for coral growth. In situ studies have documented alarming recent declines in calcification rates on several tropical coral reef ecosystems. We show there is no widespread pattern of consistent decline in calcification rates of massive Porites during the 20th century on reefs spanning an 11 degrees latitudinal range in the southeast Indian Ocean off Western Australia. Increasing calcification rates on the high-latitude reefs contrast with the downward trajectory reported for corals on Australia's Great Barrier Reef and provide additional evidence that recent changes in coral calcification are responses to temperature rather than ocean acidification.	[Cooper, Timothy F.; O'Leary, Rebecca A.] Univ Western Australia, Australian Inst Marine Sci, Oceans Inst, Crawley 6009, Australia; [Lough, Janice M.] Australian Inst Marine Sci, Townsville, Qld 4810, Australia	Australian Institute of Marine Science; University of Western Australia; Australian Institute of Marine Science	Cooper, TF (corresponding author), Univ Western Australia, Australian Inst Marine Sci, Oceans Inst, Crawley 6009, Australia.	t.cooper@aims.gov.au	Lough, Janice M/L-1682-2013	Lough, Janice M/0000-0002-3789-1009	Australian Institute of Marine Science; BHP Billiton	Australian Institute of Marine Science; BHP Billiton	We thank N. Jeeves, K. Cook, T. Hyndes, P. Tinkler, G. Suosaari, M. Depczynski, and the crew of the RV Solander for support in collecting the cores; E. Matson for assistance in planning the sample collection, sample preparation, and undertaking the density measurements; and B. Radford for advice on the statistical analyses. An earlier version of the manuscript benefited from comments provided by A. Heyward and two anonymous reviewers. The coral calcification data used in this study has been archived in the AIMS Data Centre. This study was supported by the Australian Institute of Marine Science and BHP Billiton.	Buddemeier R.W., 1976, Oceanography and Marine Biology an Annual Review, V14, P183; Caldeira K, 2003, NATURE, V425, P365, DOI 10.1038/425365a; Cantin NE, 2010, SCIENCE, V329, P322, DOI 10.1126/science.1190182; Carilli JE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006324; CHALKER BE, 1990, CORAL REEFS, V9, P11, DOI 10.1007/BF00686717; Cooper TF, 2008, GLOBAL CHANGE BIOL, V14, P529, DOI 10.1111/j.1365-2486.2007.01520.x; De'ath G, 2009, SCIENCE, V323, P116, DOI 10.1126/science.1165283; Doney SC, 2009, ANNU REV MAR SCI, V1, P169, DOI 10.1146/annurev.marine.010908.163834; Eakin C. M., 2009, V205, P41; Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; Gattuso JP, 1998, ANNU REV ECOL SYST, V29, P405, DOI 10.1146/annurev.ecolsys.29.1.405; Guinotte JM, 2008, ANN NY ACAD SCI, V1134, P320, DOI 10.1196/annals.1439.013; Helmle KP, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1222; Hoegh-Guldberg O, 2007, SCIENCE, V318, P1737, DOI 10.1126/science.1152509; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; Kleypas JA, 1999, SCIENCE, V284, P118, DOI 10.1126/science.284.5411.118; Kleypas JA, 1999, AM ZOOL, V39, P146; Lough JM, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL034634; Lough JM, 2011, EARTH-SCI REV, V108, P170, DOI 10.1016/j.earscirev.2011.07.001; Lough JM, 2000, J EXP MAR BIOL ECOL, V245, P225, DOI 10.1016/S0022-0981(99)00168-9; Manzello DP, 2010, CORAL REEFS, V29, P749, DOI 10.1007/s00338-010-0623-4; Orr JC, 2005, NATURE, V437, P681, DOI 10.1038/nature04095; Pinheiro J, 2001, MIXED EFFECTS MODELS; Rayner NA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002670; Sabine CL, 2004, SCIENCE, V305, P367, DOI 10.1126/science.1097403; SMITH SV, 1981, LIMNOL OCEANOGR, V26, P612, DOI 10.4319/lo.1981.26.4.0612; Tanzil JTI, 2009, CORAL REEFS, V28, P519, DOI 10.1007/s00338-008-0457-5; Team RDCR, 2011, LANG ENV STAT COMP; Trenberth KE, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P235	29	109	113	6	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2012	335	6068					593	596		10.1126/science.1214570	http://dx.doi.org/10.1126/science.1214570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301320				2022-12-28	WOS:000299769200046
J	Cingoz, A; Yost, DC; Allison, TK; Ruehl, A; Fermann, ME; Hartl, I; Ye, J				Cingoez, Arman; Yost, Dylan C.; Allison, Thomas K.; Ruehl, Axel; Fermann, Martin E.; Hartl, Ingmar; Ye, Jun			Direct frequency comb spectroscopy in the extreme ultraviolet	NATURE			English	Article							HIGH-HARMONIC-GENERATION; SPECTRUM; PULSES; POWER	The development of the optical frequency comb(a spectrum consisting of a series of evenly spaced lines) has revolutionized metrology and precision spectroscopy owing to its ability to provide a precise and direct link between microwave and optical frequencies(1,2). A further advance in frequency comb technology is the generation of frequency combs in the extreme-ultraviolet spectral range by means of high-harmonic generation in a femtosecond enhancement cavity(3,4). Until now, combs produced by this method have lacked sufficient power for applications, a drawback that has also hampered efforts to observe phase coherence of the high-repetition-rate pulse train produced by high-harmonic generation, which is an extremely nonlinear process. Here we report the generation of extreme-ultraviolet frequency combs, reaching wavelengths of 40 nanometres, by coupling a high-power near-infrared frequency comb(5) to a robust femtosecond enhancement cavity. These combs are powerful enough for us to observe single-photon spectroscopy signals for both an argon transition at 82 nanometres and a neon transition at 63 nanometres, thus confirming the combs' coherence in the extreme ultraviolet. The absolute frequency of the argon transition has been determined by direct frequency comb spectroscopy. The resolved ten-megahertz linewidth of the transition, which is limited by the temperature of the argon atoms, is unprecedented in this spectral region and places a stringent upper limit on the linewidth of individual comb teeth. Owing to the lack of continuous-wave lasers, extreme-ultraviolet frequency combs are at present the only promising route to extending ultrahigh-precision spectroscopy to the spectral region below 100 nanometres. At such wavelengths there is a wide range of applications, including the spectroscopy of electronic transitions in molecules(6), experimental tests of bound-state and many-body quantum electrodynamics in singly ionized helium and neutral helium(7-9), the development of next-generation 'nuclear' clocks(10-12) and searches for variation of fundamental constants(13) using the enhanced sensitivity of highly charged ions(14).	[Cingoez, Arman; Yost, Dylan C.; Allison, Thomas K.; Ye, Jun] Natl Inst Stand & Technol, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; [Cingoez, Arman; Yost, Dylan C.; Allison, Thomas K.; Ye, Jun] Univ Colorado, Dept Phys, Boulder, CO 80309 USA; [Ruehl, Axel; Fermann, Martin E.; Hartl, Ingmar] IMRA Amer Inc, Ann Arbor, MI 48105 USA	National Institute of Standards & Technology (NIST) - USA; University of Colorado System; University of Colorado Boulder	Cingoz, A (corresponding author), Natl Inst Stand & Technol, Joint Inst Lab Astrophys, Boulder, CO 80309 USA.	acingoz@jila.colorado.edu; junye@jila.colorado.edu	Hartl, Ingmar/U-5997-2017; Ye, Jun/C-3312-2011	Hartl, Ingmar/0000-0001-7274-754X; Ye, Jun/0000-0003-0076-2112; Allison, Thomas/0000-0003-0289-8830	DARPA; AFOSR; NIST; NSF; Alexander von Humboldt Foundation (Germany)	DARPA(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); AFOSR(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); NIST(National Institute of Standards & Technology (NIST) - USA); NSF(National Science Foundation (NSF)); Alexander von Humboldt Foundation (Germany)(Alexander von Humboldt Foundation)	We thank J. L. Hall for the use of an iodine-stabilized laser, M. D. Swallows for the assistance with the hydrogen maser frequency transfer, and S. T. Cundiff and A. Foltynowicz for reading a draft of the manuscript. This research is funded by the DARPA, AFOSR, NIST and NSF. A. C. and T. K. A. are National Research Council postdoctoral fellows. A. R. acknowledges funding from the Alexander von Humboldt Foundation (Germany).	Allison TK, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.183903; Bellini M, 1998, PHYS REV LETT, V81, P297, DOI 10.1103/PhysRevLett.81.297; Berengut JC, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.210802; Campbell CJ, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.223001; Carlson DR, 2011, OPT LETT, V36, P2991, DOI 10.1364/OL.36.002991; Cundiff ST, 2003, REV MOD PHYS, V75, P325, DOI 10.1103/RevModPhys.75.325; ECKSTEIN JN, 1978, PHYS REV LETT, V40, P847, DOI 10.1103/PhysRevLett.40.847; Eidam T, 2010, OPT LETT, V35, P94, DOI 10.1364/OL.35.000094; Eyler EE, 2008, EUR PHYS J D, V48, P43, DOI 10.1140/epjd/e2007-00289-y; Gohle C, 2005, NATURE, V436, P234, DOI 10.1038/nature03851; Hartl I, 2007, OPT LETT, V32, P2870, DOI 10.1364/OL.32.002870; Herrmann M, 2009, PHYS REV A, V79, DOI 10.1103/PhysRevA.79.052505; Jones RJ, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.193201; Kandula DZ, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.063001; Krausz F, 2009, REV MOD PHYS, V81, P163, DOI 10.1103/RevModPhys.81.163; Lee J, 2011, OPT EXPRESS, V19, P23315, DOI 10.1364/OE.19.023315; Mairesse Y, 2003, SCIENCE, V302, P1540, DOI 10.1126/science.1090277; MERKT F, 1992, J CHEM PHYS, V96, P4149, DOI 10.1063/1.461870; MINNHAGEN L, 1973, J OPT SOC AM, V63, P1185, DOI 10.1364/JOSA.63.001185; Murphy MT, 2003, MON NOT R ASTRON SOC, V345, P609, DOI 10.1046/j.1365-8711.2003.06970.x; Ozawa A, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.253901; Peik E, 2003, EUROPHYS LETT, V61, P181, DOI 10.1209/epl/i2003-00210-x; Pinkert TJ, 2011, OPT LETT, V36, P2026, DOI 10.1364/OL.36.002026; Rellergert WG, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.200802; Ruehl A, 2010, OPT LETT, V35, P3015, DOI 10.1364/OL.35.003015; Schibli TR, 2008, NAT PHOTONICS, V2, P355, DOI 10.1038/nphoton.2008.79; Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a; Ye J, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.270801; Yost DC, 2008, OPT LETT, V33, P1099, DOI 10.1364/OL.33.001099; Yost DC, 2009, NAT PHYS, V5, P815, DOI 10.1038/NPHYS1398	30	320	334	6	188	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2012	482	7383					68	71		10.1038/nature10711	http://dx.doi.org/10.1038/nature10711			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22297971	Green Submitted			2022-12-28	WOS:000299726000036
J	Ludvigsson, J; Krisky, D; Casas, R; Battelino, T; Castano, L; Greening, J; Kordonouri, O; Otonkoski, T; Pozzilli, P; Robert, JJ; Veeze, HJ; Palmer, J				Ludvigsson, Johnny; Krisky, David; Casas, Rosaura; Battelino, Tadej; Castano, Luis; Greening, James; Kordonouri, Olga; Otonkoski, Timo; Pozzilli, Paolo; Robert, Jean-Jacques; Veeze, Henk J.; Palmer, Jerry			GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-CELL FUNCTION; DOUBLE-BLIND TRIAL; PROTEIN PEPTIDE DIAPEP277; LONG-TERM COMPLICATIONS; RECENT-ONSET; INSULIN-SECRETION; C-PEPTIDE; KETOACIDOSIS; CHILDREN; RECOMMENDATIONS	Background The 65-kD isoform of glutamic acid decarboxylase (GAD65) is a major autoantigen in type 1 diabetes. We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with recent-onset type 1 diabetes. Methods We studied 334 patients, 10 to 20 years of age, with type 1 diabetes, fasting C-peptide levels of more than 0.3 ng per milliliter (0.1 nmol per liter), and detectable serum GAD65 autoantibodies. Within 3 months after diagnosis, patients were randomly assigned to receive one of three study treatments: four doses of GAD-alum, two doses of GAD-alum followed by two doses of placebo, or four doses of placebo. The primary outcome was the change in the stimulated serum C-peptide level (after a mixed-meal tolerance test) between the baseline visit and the 15-month visit. Secondary outcomes included the glycated hemoglobin level, mean daily insulin dose, rate of hypoglycemia, and fasting and maximum stimulated C-peptide levels. Results The stimulated C-peptide level declined to a similar degree in all study groups, and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group (P=0.10). The use of GAD-alum as compared with placebo did not affect the insulin dose, glycated hemoglobin level, or hypoglycemia rate. Adverse events were infrequent and mild in the three groups, with no significant differences. Conclusions Treatment with GAD-alum did not significantly reduce the loss of stimulated C peptide or improve clinical outcomes over a 15-month period. (Funded by Diamyd Medical and the Swedish Child Diabetes Foundation; ClinicalTrials.gov number, NCT00723411.)	[Ludvigsson, Johnny] Linkoping Univ, Dept Clin & Expt Med, Div Pediat, S-58185 Linkoping, Sweden; [Krisky, David] Diamyd Med, Pittsburgh, PA USA; [Battelino, Tadej] Univ Med Ctr Univ Childrens Hosp, Fac Med, Ljubljana, Slovenia; [Castano, Luis] Hosp Cruces Univ Basque Country, Baracaldo, Bizkaia, Spain; [Greening, James] Leicester Royal Infirm, Dept Paediat, Leicester, Leics, England; [Kordonouri, Olga] Kinderkrankenhaus Bult, Diabet Ctr Children & Adolescents, Hannover, Germany; [Otonkoski, Timo] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Otonkoski, Timo] Helsinki Univ Cent Hosp, Helsinki, Finland; [Pozzilli, Paolo] Univ Campus Biomed, Rome, Italy; [Robert, Jean-Jacques] Univ Paris 05, Hop Necker Enfants Malades, Paris, France; [Veeze, Henk J.] Stichting Diabeter, Rotterdam, Netherlands; [Palmer, Jerry] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA; [Palmer, Jerry] Univ Washington, Seattle, WA 98195 USA	Linkoping University; Hospital Universitario Cruces; University of Leicester; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University Campus Bio-Medico - Rome Italy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Ludvigsson, J (corresponding author), Linkoping Univ, Dept Clin & Expt Med, Div Pediat, S-58185 Linkoping, Sweden.	johnny.ludvigsson@liu.se	Rica, Itxaso/E-7645-2012; Ludvigsson, Johnny/AAI-2051-2020; , Ivan/D-6804-2012	Ludvigsson, Johnny/0000-0003-1695-5234; , Ivan/0000-0002-3108-058X; Battelino, Tadej/0000-0002-0273-4732; Elding Larsson, Helena/0000-0003-3306-1742; Castano, Luis/0000-0003-0437-9401; Pozzilli, Paolo/0000-0001-5090-636X	Diamyd Medical; Swedish Child Diabetes Foundation (Barndiabetesfonden)	Diamyd Medical; Swedish Child Diabetes Foundation (Barndiabetesfonden)	Supported by Diamyd Medical and the Swedish Child Diabetes Foundation (Barndiabetesfonden).	AFOKE AO, 1993, SCAND J IMMUNOL, V37, P209, DOI 10.1111/j.1365-3083.1993.tb01758.x; Atkinson MA, 2001, LANCET, V358, P766; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; BOJESTIG M, 1994, NEW ENGL J MED, V330, P15, DOI 10.1056/NEJM199401063300103; Coutant R, 1998, DIABETOLOGIA, V41, P1040, DOI 10.1007/s001250051028; Diabet Control Complications Trial Res Grp, 1998, ANN INTERN MED, V128, P517, DOI 10.7326/0003-4819-128-7-199804010-00001; Diabetes Prevention Trial Type Stu, 2005, DIABETES CARE, V28, P1068; DUPRE J, 1988, DIABETES, V37, P1574; FEUTREN G, 1986, LANCET, V2, P119; Gottlieb PA, 2011, 71 SCI SESS AM DIAB; Greenbaum CJ, 2008, DIABETES CARE, V31, P1966, DOI 10.2337/dc07-2451; Herold KC, 2005, DIABETES, V54, P1763, DOI 10.2337/diabetes.54.6.1763; Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980; Komulainen J, 1996, ARCH DIS CHILD, V75, P410, DOI 10.1136/adc.75.5.410; Ludvigsson J, 2011, DIABETOLOGIA, V54, P634, DOI 10.1007/s00125-010-1988-1; Ludvigsson J, 2009, DIABETOLOGIA, V52, P175, DOI 10.1007/s00125-008-1211-9; Ludvigsson J, 2008, NEW ENGL J MED, V359, P1909, DOI 10.1056/NEJMoa0804328; Luppi P, 2011, PEDIATR DIABETES, V12, P276, DOI 10.1111/j.1399-5448.2010.00729.x; MADSBAD S, 1979, BRIT MED J, V2, P1257, DOI 10.1136/bmj.2.6200.1257; Mallinckrodt CH, 2008, DRUG INF J, V42, P303, DOI 10.1177/009286150804200402; Matthews JB, 2010, CLIN EXP IMMUNOL, V160, P176, DOI 10.1111/j.1365-2249.2010.04153.x; Nanto-Salonen K, 2008, LANCET, V372, P1746, DOI 10.1016/S0140-6736(08)61309-4; Nordwall M, 2008, DIABETES-METAB RES, V24, P472, DOI 10.1002/dmrr.871; Ostman J, 2000, DIABETIC MED, V17, P269, DOI 10.1046/j.1464-5491.2000.00265.x; Peakman M, 2010, DIABETES, V59, P2087, DOI 10.2337/db10-0630; Pescovitz MD, 2009, NEW ENGL J MED, V361, P2143, DOI 10.1056/NEJMoa0904452; Pundziute-Lycka A, 2002, DIABETOLOGIA, V45, P783, DOI 10.1007/s00125-002-0845-2; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; Schloot NC, 2007, DIABETES-METAB RES, V23, P276, DOI 10.1002/dmrr.707; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sherry N, 2011, LANCET, V378, P487, DOI 10.1016/S0140-6736(11)60931-8; Siddiqui O, 2009, J BIOPHARM STAT, V19, P227, DOI 10.1080/10543400802609797; Skyler JS, 2002, NEW ENGL J MED, V346, P1685; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; Steffes MW, 2003, DIABETES CARE, V26, P832, DOI 10.2337/diacare.26.3.832; Wherrett DK, 2011, LANCET, V378, P319, DOI 10.1016/S0140-6736(11)60895-7	36	216	229	0	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					433	442		10.1056/NEJMoa1107096	http://dx.doi.org/10.1056/NEJMoa1107096			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QX	22296077				2022-12-28	WOS:000299724400008
J	Stine, NW; Chokshi, DA				Stine, Nicholas W.; Chokshi, Dave A.			Opportunity in Austerity - A Common Agenda for Medicine and Public Health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Stine, Nicholas W.] Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Stine, NW (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.			Chokshi, Dave/0000-0001-7467-4591; Stine, Nicholas/0000-0001-8811-259X				[Anonymous], NAT HLTH EXP ACC TYP; Brandt AM, 2000, AM J PUBLIC HEALTH, V90, P707, DOI 10.2105/AJPH.90.5.707; Internal Revenue, 2011, INT REV B; McGinnis JM, 2002, HEALTH AFFAIR, V21, P78, DOI 10.1377/hlthaff.21.2.78	4	21	21	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					395	397		10.1056/NEJMp1112543	http://dx.doi.org/10.1056/NEJMp1112543			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	884QX	22296074				2022-12-28	WOS:000299724400004
J	Vinko, SM; Ciricosta, O; Cho, BI; Engelhorn, K; Chung, HK; Brown, CRD; Burian, T; Chalupsky, J; Falcone, RW; Graves, C; Hajkova, V; Higginbotham, A; Juha, L; Krzywinski, J; Lee, HJ; Messerschmidt, M; Murphy, CD; Ping, Y; Scherz, A; Schlotter, W; Toleikis, S; Turner, JJ; Vysin, L; Wang, T; Wu, B; Zastrau, U; Zhu, D; Lee, RW; Heimann, PA; Nagler, B; Wark, JS				Vinko, S. M.; Ciricosta, O.; Cho, B. I.; Engelhorn, K.; Chung, H-K; Brown, C. R. D.; Burian, T.; Chalupsky, J.; Falcone, R. W.; Graves, C.; Hajkova, V.; Higginbotham, A.; Juha, L.; Krzywinski, J.; Lee, H. J.; Messerschmidt, M.; Murphy, C. D.; Ping, Y.; Scherz, A.; Schlotter, W.; Toleikis, S.; Turner, J. J.; Vysin, L.; Wang, T.; Wu, B.; Zastrau, U.; Zhu, D.; Lee, R. W.; Heimann, P. A.; Nagler, B.; Wark, J. S.			Creation and diagnosis of a solid-density plasma with an X-ray free-electron laser	NATURE			English	Article							FLUORESCENCE YIELDS; TARGET; ALUMINUM; PULSES; AUGER; GAIN	Matter with a high energy density (>10(5) joules per cm(3)) is prevalent throughout the Universe, being present in all types of stars(1) and towards the centre of the giant planets(2,3); it is also relevant for inertial confinement fusion(4). Its thermodynamic and transport properties are challenging to measure, requiring the creation of sufficiently long-lived samples at homogeneous temperatures and densities(5,6). With the advent of the Linac Coherent Light Source (LCLS) X-ray laser(7), high-intensity radiation (>10(17) watts per cm(2), previously the domain of optical lasers) can be produced at X-ray wavelengths. The interaction of single atoms with such intense X-rays has recently been investigated(8). An understanding of the contrasting case of intense X-ray interaction with dense systems is important from a fundamental viewpoint and for applications. Here we report the experimental creation of a solid-density plasma at temperatures in excess of 10(6) kelvin on inertial-confinement time-scales using an X-ray free-electron laser. We discuss the pertinent physics of the intense X-ray-matter interactions, and illustrate the importance of electron-ion collisions. Detailed simulations of the interaction process conducted with a radiative-collisional code show good qualitative agreement with the experimental results. We obtain insights into the evolution of the charge state distribution of the system, the electron density and temperature, and the time-scales of collisional processes. Our results should inform future high-intensity X-ray experiments involving dense samples, such as X-ray diffractive imaging of biological systems, material science investigations, and the study of matter in extreme conditions.	[Vinko, S. M.; Ciricosta, O.; Higginbotham, A.; Murphy, C. D.; Wark, J. S.] Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England; [Cho, B. I.; Engelhorn, K.; Falcone, R. W.; Heimann, P. A.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; [Chung, H-K] IAEA, Nucl Data Sect, Atom & Mol Data Unit, A-1400 Vienna, Austria; [Brown, C. R. D.] AWE Aldermaston, Dept Plasma Phys, Reading RG7 4PR, Berks, England; [Burian, T.; Chalupsky, J.; Hajkova, V.; Juha, L.; Vysin, L.] Inst Phys ASCR, Prague 18221 8, Czech Republic; [Falcone, R. W.] Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; [Graves, C.; Krzywinski, J.; Lee, H. J.; Messerschmidt, M.; Scherz, A.; Schlotter, W.; Turner, J. J.; Wang, T.; Wu, B.; Zhu, D.; Lee, R. W.; Nagler, B.] SLAC Natl Accelerator Lab, Menlo Pk, CA 94025 USA; [Ping, Y.] Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; [Toleikis, S.] Deutsch Elektronensynchrotron DESY, D-22603 Hamburg, Germany; [Zastrau, U.] Univ Jena, IOQ, D-07743 Jena, Germany	University of Oxford; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; International Atomic Energy Agency; Czech Academy of Sciences; Institute of Physics of the Czech Academy of Sciences; University of California System; University of California Berkeley; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Friedrich Schiller University of Jena	Vinko, SM (corresponding author), Univ Oxford, Dept Phys, Clarendon Lab, Parks Rd, Oxford OX1 3PU, England.	sam.vinko@physics.ox.ac.uk	Cho, Byoung-ick I/A-6294-2011; Juha, Libor/H-2546-2014; Chalupský, Jaromír/H-2079-2014; Zhu, Diling/D-1302-2013; Vinko, Sam/I-4845-2013; Messerschmidt, Marc/Y-8929-2019; Hajkova, Vera/G-9391-2014; Burian, Tomas/H-3236-2014; Vyšín, Luděk/G-6885-2014; Messerschmidt, Marc/F-3796-2010	Chalupský, Jaromír/0000-0001-6930-1774; Vinko, Sam/0000-0003-1016-0975; Messerschmidt, Marc/0000-0002-8641-3302; Hajkova, Vera/0000-0002-0776-6012; Burian, Tomas/0000-0003-3982-9978; Messerschmidt, Marc/0000-0002-8641-3302; Vysin, Ludek/0000-0002-8549-0859; Juha, Libor/0000-0003-4189-8753; Ping, Yuan/0000-0002-4879-9072; Graves, Catherine/0000-0002-0907-583X; Wark, Justin/0000-0003-3055-3223; /0000-0001-5211-9933; Zastrau, Ulf/0000-0002-3575-4449	LCLS; Stanford University through the Stanford Institute for Materials Energy Sciences (SIMES); Lawrence Berkeley National Laboratory (LBNL); University of Hamburg through the BMBF [FSP 301]; Center for Free Electron Laser Science (CFEL); UK EPSRC [EP/F020449/1, EP/H035877/1, EP/G007187/1]; US DOE Basic Energy Science [DE-AC03-76SF00098]; SSAA [DE-FG52-06NA26212]; German Ministry for Education and Research (BMBF) [FSP 301];  [LC510];  [LC528];  [LA08024];  [ME10046];  [P108/11/1312];  [P205/11/0571];  [IAAX00100903];  [KAN300100702]; EPSRC [EP/H035877/1, EP/F020449/1, EP/G007187/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/H035877/1, EP/F020449/1, EP/G007187/1] Funding Source: researchfish	LCLS; Stanford University through the Stanford Institute for Materials Energy Sciences (SIMES); Lawrence Berkeley National Laboratory (LBNL); University of Hamburg through the BMBF; Center for Free Electron Laser Science (CFEL); UK EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); US DOE Basic Energy Science(United States Department of Energy (DOE)); SSAA; German Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); ; ; ; ; ; ; ; ; EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	Portions of this research were carried out on the SXR instrument at the LCLS, a division of SLAC National Accelerator Laboratory and an Office of Science user facility operated by Stanford University for the US Department of Energy. The SXR instrument and the Resonant Coherent Imaging (RCI) endstation are funded by a consortium whose membership includes the LCLS, Stanford University through the Stanford Institute for Materials Energy Sciences (SIMES), Lawrence Berkeley National Laboratory (LBNL), University of Hamburg through the BMBF priority programme FSP 301, and the Center for Free Electron Laser Science (CFEL). S. M. V., O.C. and J.S.W. thank the UK EPSRC for funding (EP/F020449/1 and EP/H035877/1). B. I. C., K. E., R. W. F. and P. A. H. acknowledge US DOE Basic Energy Science contract DE-AC03-76SF00098 and SSAA programme contract DE-FG52-06NA26212. T. B., J.C., L.J. and L. V. appreciate funding by grants LC510, LC528, LA08024, ME10046, P108/11/1312, P205/11/0571, IAAX00100903 and KAN300100702. U.Z. thanks the German Ministry for Education and Research (BMBF) for funding under FSP 301. C. D. M. was supported by UK EPSRC (EP/G007187/1). We also thank G. Gregori (Oxford University) for discussions.	BACK CA, 1992, PHYS REV A, V46, P3405, DOI 10.1103/PhysRevA.46.3405; BAILEY J, 1990, LASER PART BEAMS, V8, P555, DOI 10.1017/S0263034600008983; BAMBYNEK W, 1972, REV MOD PHYS, V44, P716, DOI 10.1103/RevModPhys.44.716; BONIFACIO R, 1994, PHYS REV LETT, V73, P70, DOI 10.1103/PhysRevLett.73.70; BURNETT NH, 1984, PHYS REV A, V29, P2294, DOI 10.1103/PhysRevA.29.2294; Chabrier G, 2009, PLASMA PHYS CONTR F, V51, DOI 10.1088/0741-3335/51/12/124014; Chalupsky J, 2010, OPT EXPRESS, V18, P27836, DOI 10.1364/OE.18.027836; CHEN MH, 1980, PHYS REV A, V21, P436, DOI 10.1103/PhysRevA.21.436; Chung H K, 2005, HIGH ENERGY DENSITY, V1, P3, DOI [10.1016/j.hedp.2005.07.001, DOI 10.1016/J.HEDP.2005.07.001]; Chung H. K., 2008, FLYCHK; Chung HK, 2007, HIGH ENERG DENS PHYS, V3, P57, DOI 10.1016/j.hedp.2007.02.001; Ciricosta O, 2011, HIGH ENERG DENS PHYS, V7, P111, DOI 10.1016/j.hedp.2011.02.003; Dusterer S, 2011, NEW J PHYS, V13, DOI 10.1088/1367-2630/13/9/093024; Gauthier JC, 1997, PHYS PLASMAS, V4, P1811, DOI 10.1063/1.872294; Helled R, 2011, ASTROPHYS J, V726, DOI 10.1088/0004-637X/726/1/15; LINDL J, 1995, PHYS PLASMAS, V2, P3933, DOI 10.1063/1.871025; Nagler B, 2009, NAT PHYS, V5, P693, DOI 10.1038/NPHYS1341; Remington BA, 2006, REV MOD PHYS, V78, P755, DOI 10.1103/RevModPhys.78.755; Rossall AK, 2010, J PHYS B-AT MOL OPT, V43, DOI 10.1088/0953-4075/43/15/155403; ROUSSE A, 1994, PHYS REV E, V50, P2200, DOI 10.1103/PhysRevE.50.2200; Saemann A, 1999, PHYS REV LETT, V82, P4843, DOI 10.1103/PhysRevLett.82.4843; Siwick BJ, 2003, SCIENCE, V302, P1382, DOI 10.1126/science.1090052; Sorokin A., 2010, REPORT PULSE ENERGY; STEWART JC, 1966, ASTROPHYS J, V144, P1203, DOI 10.1086/148714; Taylor R J, 1994, STARS THEIR STRUCTUR; Young L, 2010, NATURE, V466, P56, DOI 10.1038/nature09177	26	341	346	7	179	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					59	U75		10.1038/nature10746	http://dx.doi.org/10.1038/nature10746			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22278059				2022-12-28	WOS:000299726000034
J	Grandjean, P; Andersen, EW; Budtz-Jorgensen, E; Nielsen, F; Molbak, K; Weihe, P; Heilmann, C				Grandjean, Philippe; Andersen, Elisabeth Wreford; Budtz-Jorgensen, Esben; Nielsen, Flemming; Molbak, Kare; Weihe, Pal; Heilmann, Carsten			Serum Vaccine Antibody Concentrations in Children Exposed to Perfluorinated Compounds	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYFLUOROALKYL COMPOUNDS; PERFLUOROOCTANE SULFONATE; NATIONAL-HEALTH; MICE; ANTITOXIN; PATHWAYS; TOXIN	Context Perfluorinated compounds (PFCs) have emerged as important food contaminants. They cause immune suppression in a rodent model at serum concentrations similar to those occurring in the US population, but adverse health effects of PFC exposure are poorly understood. Objective To determine whether PFC exposure is associated with antibody response to childhood vaccinations. Design, Setting, and Participants Prospective study of a birth cohort from the National Hospital in the Faroe Islands. A total of 656 consecutive singleton births were recruited during 1999-2001, and 587 participated in follow-up through 2008. Main Outcome Measures Serum antibody concentrations against tetanus and diphtheria toxoids at ages 5 and 7 years. Results Similar to results of prior studies in the United States, the PFCs with the highest serum concentrations were perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA). Among PFCs in maternal pregnancy serum, PFOS showed the strongest negative correlations with antibody concentrations at age 5 years, for which a 2-fold greater concentration of exposure was associated with a difference of -39% (95% CI, -55% to -17%) in the diphtheria antibody concentration. PFCs in the child's serum at age 5 years showed uniformly negative associations with antibody levels, especially at age 7 years, except that the tetanus antibody level following PFOS exposure was not statistically significant. In a structural equation model, a 2-fold greater concentration of major PFCs in child serum was associated with a difference of -49% (95% CI, -67% to -23%) in the overall antibody concentration. A 2-fold increase in PFOS and PFOA concentrations at age 5 years was associated with odds ratios between 2.38 (95% CI, 0.89 to 6.35) and 4.20 (95% CI, 1.54 to 11.44) for falling below a clinically protective level of 0.1 IU/mL for tetanus and diphtheria antibodies at age 7 years. Conclusion Elevated exposures to PFCs were associated with reduced humoral immune response to routine childhood immunizations in children aged 5 and 7 years. JAMA. 2012;307(4):391-397	[Grandjean, Philippe] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02215 USA; [Grandjean, Philippe; Nielsen, Flemming] Univ So Denmark, Dept Environm Med, Odense, Denmark; [Andersen, Elisabeth Wreford; Budtz-Jorgensen, Esben] Univ Copenhagen, Dept Biostat, Copenhagen, Denmark; [Molbak, Kare] Statens Serum Inst, Dept Epidemiol, DK-2300 Copenhagen, Denmark; [Heilmann, Carsten] Natl Univ Hosp, Rigshosp, Pediat Clin, Copenhagen, Denmark	Harvard University; Harvard T.H. Chan School of Public Health; University of Southern Denmark; University of Copenhagen; Statens Serum Institut; Rigshospitalet; University of Copenhagen	Grandjean, P (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 401 Pk Dr,EOME 3E-110, Boston, MA 02215 USA.	pgrand@hsph.harvard.edu	Grandjean, Philippe/I-2962-2014	Grandjean, Philippe/0000-0003-4046-9658; Budtz-Jorgensen, Esben/0000-0002-5551-0724; Nielsen, Flemming/0000-0002-5657-405X; Molbak, Kare/0000-0002-3100-4990	National Institute of Environmental Health Sciences, NIH [ES012199]; US Environmental Protection Agency [R830758]; Danish Council for Strategic Research [09-063094]; Danish Environmental Protection Agency; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012199] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Environmental Protection Agency(United States Environmental Protection Agency); Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Environmental Protection Agency; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by the National Institute of Environmental Health Sciences, NIH (ES012199); the US Environmental Protection Agency (R830758); the Danish Council for Strategic Research (09-063094); and the Danish Environmental Protection Agency as part of the environmental support program DANCEA (Danish Cooperation for Environment in the Arctic).	Bollen K. A., 1989, J STAT ASS; Budtz-Jorgensen Esben, 2002, Environ Health, V1, P2, DOI 10.1186/1476-069X-1-2; Calafat AM, 2007, ENVIRON SCI TECHNOL, V41, P2237, DOI 10.1021/es062686m; Corsini E, 2011, TOXICOL APPL PHARM, V250, P108, DOI 10.1016/j.taap.2010.11.004; Dietert RR, 2008, J IMMUNOTOXICOL, V5, P401, DOI 10.1080/15476910802483324; European Food Safety Authority, 2008, EFSA J, V653, P1; Fair PA, 2011, J IMMUNOTOXICOL, V8, P17, DOI 10.3109/1547691X.2010.527868; Fang XM, 2009, TOXICOL SCI, V108, P367, DOI 10.1093/toxsci/kfp019; Fletcher T., STATUS REPORT PFOA I; Grandjean P, 1995, ENVIRON RES, V71, P29, DOI 10.1006/enrs.1995.1064; Grandjean P, 2001, NEUROTOXICOL TERATOL, V23, P305, DOI 10.1016/S0892-0362(01)00155-6; HASTIE T. J., 1990, MONOGRAPHS STAT APPL, V43; Haug LS, 2009, J CHROMATOGR A, V1216, P385, DOI 10.1016/j.chroma.2008.10.113; Heilmann C, 2006, PLOS MED, V3, P1352, DOI 10.1371/journal.pmed.0030311; Heilmann C, 2010, ENVIRON HEALTH PERSP, V118, P1434, DOI 10.1289/ehp.1001975; HENDRIKSEN CFM, 1988, J BIOL STAND, V16, P287, DOI 10.1016/0092-1157(88)90017-0; Kato K, 2009, ENVIRON SCI TECHNOL, V43, P2641, DOI 10.1021/es803156p; Keil DE, 2008, TOXICOL SCI, V103, P77, DOI 10.1093/toxsci/kfn015; MIYAMURA K, 1974, J BIOL STAND, V2, P189, DOI 10.1016/0092-1157(74)90015-8; Needham LL, 2011, ENVIRON SCI TECHNOL, V45, P1121, DOI 10.1021/es1019614; Olsen GW, 2007, ENVIRON HEALTH PERSP, V115, P1298, DOI 10.1289/ehp.10009; Peden-Adams MM, 2008, TOXICOL SCI, V104, P144, DOI 10.1093/toxsci/kfn059; Qazi MR, 2010, INT IMMUNOPHARMACOL, V10, P1420, DOI 10.1016/j.intimp.2010.08.009; Sanchez BN, 2005, J AM STAT ASSOC, V100, P1443, DOI 10.1198/016214505000001005; Skrondal A., 2004, GEN LATENT VARIABLE; Van Loveren H., 1999, Biomarkers, V4, P135, DOI 10.1080/135475099230949; Vestergren R, 2009, ENVIRON SCI TECHNOL, V43, P5565, DOI 10.1021/es900228k; Weihe P, 2008, ENVIRON SCI TECHNOL, V42, P6291, DOI 10.1021/es800695m	28	402	410	9	149	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2012	307	4					391	397		10.1001/jama.2011.2034	http://dx.doi.org/10.1001/jama.2011.2034			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EP	22274686	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000299464000025
J	Houk, AR; Jilkine, A; Mejean, CO; Boltyanskiy, R; Dufresne, ER; Angenent, SB; Altschuler, SJ; Wu, LF; Weiner, OD				Houk, Andrew R.; Jilkine, Alexandra; Mejean, Cecile O.; Boltyanskiy, Rostislav; Dufresne, Eric R.; Angenent, Sigurd B.; Altschuler, Steven J.; Wu, Lani F.; Weiner, Orion D.			Membrane Tension Maintains Cell Polarity by Confining Signals to the Leading Edge during Neutrophil Migration	CELL			English	Article							POSITIVE FEEDBACK; CORTICAL TENSION; MICROPIPETTE ASPIRATION; TETHER FORMATION; RAC ACTIVATION; CHEMOTAXIS; POLARIZATION; MYOSIN; DIFFUSION; GTPASE	Little is known about how neutrophils and other cells establish a single zone of actin assembly during migration. A widespread assumption is that the leading edge prevents formation of additional fronts by generating long-range diffusible inhibitors or by sequestering essential polarity components. We use morphological perturbations, cell-severing experiments, and computational simulations to show that diffusion-based mechanisms are not sufficient for long-range inhibition by the pseudopod. Instead, plasma membrane tension could serve as a long-range inhibitor in neutrophils. We find that membrane tension doubles during leading-edge protrusion, and increasing tension is sufficient for long-range inhibition of actin assembly and Rac activation. Furthermore, reducing membrane tension causes uniform actin assembly. We suggest that tension, rather than diffusible molecules generated or sequestered at the leading edge, is the dominant source of long-range inhibition that constrains the spread of the existing front and prevents the formation of secondary fronts.	[Houk, Andrew R.; Weiner, Orion D.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Houk, Andrew R.; Weiner, Orion D.] Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; [Jilkine, Alexandra; Altschuler, Steven J.; Wu, Lani F.] Univ Texas SW Med Ctr Dallas, Green Ctr Syst Biol, Dallas, TX 75390 USA; [Jilkine, Alexandra; Altschuler, Steven J.; Wu, Lani F.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Mejean, Cecile O.; Dufresne, Eric R.] Yale Univ, Dept Mech Engn & Mat Sci, New Haven, CT 06520 USA; [Boltyanskiy, Rostislav] Yale Univ, Dept Phys, New Haven, CT 06520 USA; [Angenent, Sigurd B.] Univ Wisconsin, Dept Math, Madison, WI 53706 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Yale University; Yale University; University of Wisconsin System; University of Wisconsin Madison	Weiner, OD (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.	orion.weiner@ucsf.edu	Weiner, Orion D/F-2576-2011; Dufresne, Eric R/A-7760-2009	Weiner, Orion D/0000-0002-1778-6543; Dufresne, Eric Robert/0000-0002-3091-5039	AHA; NSERC [DBI-0619674, U54 RR022232]; Welch Foundation [I-1644, R01 GM071794, I-1619]; Searle Scholars Award [GM084040];  [NSF-DMS0705431];  [GM081549]; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR022232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071794, R01GM081549, R01GM084040] Funding Source: NIH RePORTER	AHA(American Heart Association); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Welch Foundation(The Welch Foundation); Searle Scholars Award; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank our labs, Henry Bourne, John Clements, Robert Hochmuth, Dyche Mullins, and Michael Springer for helpful discussion and a critical reading of the manuscript. Support: AHA Predoctoral Fellowship (A.R.H.), NSERC Postdoctoral Fellowship (A.J.), DBI-0619674 (E.R.D.), U54 RR022232 (O.D.W., E.R.D.), NSF-DMS0705431 (S.B.A.), GM081549 and Welch Foundation I-1644 (L.F.W.), R01 GM071794 and Welch Foundation I-1619 (S.J.A.), and Searle Scholars Award and GM084040 (O.D.W.).	Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Altschuler SJ, 2008, NATURE, V454, P886, DOI 10.1038/nature07119; Barnhart EL, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001059; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Cai YF, 2010, J CELL SCI, V123, P413, DOI 10.1242/jcs.058297; Dai JW, 1999, BIOPHYS J, V77, P3363, DOI 10.1016/S0006-3495(99)77168-7; Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200; Fivaz M, 2008, CURR BIOL, V18, P44, DOI 10.1016/j.cub.2007.11.051; Garcia-Perez AI, 1999, ARCH BIOCHEM BIOPHYS, V362, P329, DOI 10.1006/abbi.1998.1051; Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; Hallett MB, 2007, TRENDS CELL BIOL, V17, P209, DOI 10.1016/j.tcb.2007.03.002; Herant M, 2005, J CELL SCI, V118, P1789, DOI 10.1242/jcs.02275; Hochmuth RM, 2000, J BIOMECH, V33, P15, DOI 10.1016/S0021-9290(99)00175-X; Inoue T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003068; Janetopoulos C, 2004, P NATL ACAD SCI USA, V101, P8951, DOI 10.1073/pnas.0402152101; Jilkine A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002271; Jilkine A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001121; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Keren K, 2008, NATURE, V453, P475, DOI 10.1038/nature06952; Keren K, 2011, EUR BIOPHYS J BIOPHY, V40, P1013, DOI 10.1007/s00249-011-0741-0; Kozlov MM, 2007, BIOPHYS J, V93, P3811, DOI 10.1529/biophysj.107.110411; Lee CY, 2011, J CELL SCI, V124, P1106, DOI 10.1242/jcs.078592; Lee S, 2010, MOL BIOL CELL, V21, P1810, DOI 10.1091/mbc.E10-01-0009; MALAWISTA SE, 1982, J CELL BIOL, V95, P960, DOI 10.1083/jcb.95.3.960; Mayer M, 2010, NATURE, V467, P617, DOI 10.1038/nature09376; Meili R, 2010, MOL BIOL CELL, V21, P405, DOI 10.1091/mbc.E09-08-0703; Meinhardt H, 1999, J CELL SCI, V112, P2867; Mori Y, 2008, BIOPHYS J, V94, P3684, DOI [10.1529/biophysj.107.120824, 10.1529/biophysj.107.120827]; Nakamura T, 2006, DEV CELL, V11, P495, DOI 10.1016/j.devcel.2006.08.002; Neilson MP, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000618; Otsuji M, 2007, PLOS COMPUT BIOL, V3, P1040, DOI 10.1371/journal.pcbi.0030108; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sasaki AT, 2004, J CELL BIOL, V167, P505, DOI 10.1083/jcb.200406177; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shao JY, 2002, J BIOMECH ENG-T ASME, V124, P388, DOI 10.1115/1.1486469; Sick S, 2006, SCIENCE, V314, P1447, DOI 10.1126/science.1130088; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Sun CX, 2004, BLOOD, V104, P3758, DOI 10.1182/blood-2004-03-0781; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wedlich-Soldner R, 2003, SCIENCE, V299, P1231, DOI 10.1126/science.1080944; Weiner OD, 2006, PLOS BIOL, V4, P186, DOI 10.1371/journal.pbio.0040038; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Weiner OD, 2007, PLOS BIOL, V5, P2053, DOI 10.1371/journal.pbio.0050221; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; Xiong YA, 2010, P NATL ACAD SCI USA, V107, P17079, DOI 10.1073/pnas.1011271107; Zhelev DV, 1996, CELL MOTIL CYTOSKEL, V35, P331	52	373	375	4	76	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					175	188		10.1016/j.cell.2011.10.050	http://dx.doi.org/10.1016/j.cell.2011.10.050			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265410	Green Accepted, Bronze			2022-12-28	WOS:000299540700023
J	Mukhopadhyay, S; Linstedt, AD				Mukhopadhyay, Somshuvra; Linstedt, Adam D.			Manganese Blocks Intracellular Trafficking of Shiga Toxin and Protects Against Shiga Toxicosis	SCIENCE			English	Article							RETROGRADE TRANSPORT; B-FRAGMENT; GOLGI; IDENTIFICATION; ENDOSOMES; CELLS; MICE	Infections with Shiga toxin (STx)-producing bacteria cause more than a million deaths each year and have no definitive treatment. To exert its cytotoxic effect, STx invades cells through retrograde membrane trafficking, escaping the lysosomal degradative pathway. We found that the widely available metal manganese (Mn2+) blocked endosome-to-Golgi trafficking of STx and caused its degradation in lysosomes. Mn2+ targeted the cycling Golgi protein GPP130, which STx bound in control cells during sorting into Golgi-directed endosomal tubules that bypass lysosomes. In tissue culture cells, treatment with Mn2+ yielded a protection factor of 3800 against STx-induced cell death. Furthermore, mice injected with nontoxic doses of Mn2+ were completely resistant to a lethal STx challenge. Thus, Mn2+ may represent a low-cost therapeutic agent for the treatment of STx infections.	[Mukhopadhyay, Somshuvra; Linstedt, Adam D.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Linstedt, AD (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.	linstedt@andrew.cmu.edu		Mukhopadhyay, Somshuvra/0000-0002-3420-7830	NIH [R01GM084111]; American Heart Association; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084111] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D. R. Smith, T. H. Lee, J. S. Minden, J. L. Brodsky, and M. A. Puthenveedu for advice; N. N. Urban and J. Dry-Henich for help with animal work; Y. Creeger for fluorescence-activated cell sorting; S. Truschel and B. Ballou for protein preparation; and J. Suhan for electron microscopy. Supported by NIH grant R01GM084111 to A. D. L. and an American Heart Association fellowship to S. M. A patent on the use of Mn<SUP>2+</SUP> to treat Shiga toxicosis is pending. The data reported in this paper are tabulated in the main text and in the supporting online material.	Aschner M, 2009, NEUROMOL MED, V11, P252, DOI 10.1007/s12017-009-8083-0; Bachert C, 2001, MOL BIOL CELL, V12, P3152, DOI 10.1091/mbc.12.10.3152; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; Fraser ME, 2004, J BIOL CHEM, V279, P27511, DOI 10.1074/jbc.M401939200; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Ishikawa S, 2003, INFECT IMMUN, V71, P3235, DOI 10.1128/IAI.71.6.3235-3239.2003; Johannes L, 1997, J BIOL CHEM, V272, P19554, DOI 10.1074/jbc.272.31.19554; Linstedt AD, 1997, MOL BIOL CELL, V8, P1073, DOI 10.1091/mbc.8.6.1073; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Mallard Frederic, 2003, Methods Mol Med, V73, P209; Mohawk KL, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/258185; Mohawk KL, 2010, MICROB PATHOGENESIS, V48, P131, DOI 10.1016/j.micpath.2010.01.003; Moreno JA, 2009, TOXICOL SCI, V112, P394, DOI 10.1093/toxsci/kfp220; Mukhopadhyay S, 2011, P NATL ACAD SCI USA, V108, P858, DOI 10.1073/pnas.1013642108; Mukhopadhyay S, 2010, MOL BIOL CELL, V21, P1282, DOI 10.1091/mbc.E09-11-0985; Natarajan R, 2004, MOL BIOL CELL, V15, P4798, DOI 10.1091/mbc.E04-05-0366; Ochoa T., 2006, OSKIS PAEDIAT PRINCI, P1116; Popoff V, 2007, J CELL SCI, V120, P2022, DOI 10.1242/jcs.003020; Puri S, 2002, TRAFFIC, V3, P641, DOI 10.1034/j.1600-0854.2002.30906.x; Saenz JB, 2007, INFECT IMMUN, V75, P4552, DOI 10.1128/IAI.00442-07; Sandvig K, 2005, GENE THER, V12, P865, DOI 10.1038/sj.gt.3302525; Shin IS, 2009, BMB REP, V42, P310, DOI 10.5483/BMBRep.2009.42.5.310; Stechmann B, 2010, CELL, V141, P231, DOI 10.1016/j.cell.2010.01.043; SUZUKI H, 1981, ENVIRON RES, V26, P521, DOI 10.1016/0013-9351(81)90227-9; TESH VL, 1993, INFECT IMMUN, V61, P3392, DOI 10.1128/IAI.61.8.3392-3402.1993; Wong CS, 2000, NEW ENGL J MED, V342, P1930, DOI 10.1056/NEJM200006293422601	26	89	105	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					332	335		10.1126/science.1215930	http://dx.doi.org/10.1126/science.1215930			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267811	Green Accepted			2022-12-28	WOS:000299273400046
J	Januel, JM; Chen, GM; Ruffieux, C; Quan, H; Douketis, JD; Crowther, MA; Colin, C; Ghali, WA; Burnand, B				Januel, Jean-Marie; Chen, Guanmin; Ruffieux, Christiane; Quan, Hude; Douketis, James D.; Crowther, Mark A.; Colin, Cyrille; Ghali, William A.; Burnand, Bernard		IMECCHI Grp	Symptomatic In-Hospital Deep Vein Thrombosis and Pulmonary Embolism Following Hip and Knee Arthroplasty Among Patients Receiving Recommended Prophylaxis A Systematic Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MOLECULAR-WEIGHT HEPARIN; FACTOR-XA INHIBITOR; VENOUS THROMBOEMBOLISM; DOUBLE-BLIND; DABIGATRAN ETEXILATE; REPLACEMENT SURGERY; ELECTIVE HIP; POSTOPERATIVE FONDAPARINUX; MECHANICAL PROPHYLAXIS; FOOT-PUMP	Context Symptomatic venous thromboembolism (VTE) after total or partial knee arthroplasty (TPKA) and after total or partial hip arthroplasty (TPHA) are proposed patient safety indicators, but its incidence prior to discharge is not defined. Objective To establish a literature-based estimate of symptomatic VTE event rates prior to hospital discharge in patients undergoing TPHA or TPKA. Data Sources Search of MEDLINE, EMBASE, and the Cochrane Library (1996 to 2011), supplemented by relevant articles. Study Selection Reports of incidence of symptomatic postoperative pulmonary embolism or deep vein thrombosis (DVT) before hospital discharge in patients who received VTE prophylaxis with either a low-molecular-weight heparin or a subcutaneous factor Xa inhibitor or oral direct inhibitor of factors Xa or IIa. Data Extraction and Synthesis Meta-analysis of randomized clinical trials and observational studies that reported rates of postoperative symptomatic VTE in patients who received recommended VTE prophylaxis after undergoing TPHA or TPKA. Data were independently extracted by 2 analysts, and pooled incidence rates of VTE, DVT, and pulmonary embolism were estimated using random-effects models. Results The analysis included 44 844 cases provided by 47 studies. The pooled rates of symptomatic postoperative VTE before hospital discharge were 1.09% (95% CI, 0.85%-1.33%) for patients undergoing TPKA and 0.53% (95% CI, 0.35%-0.70%) for those undergoing TPHA. The pooled rates of symptomatic DVT were 0.63% (95% CI, 0.47%-0.78%) for knee arthroplasty and 0.26% (95% CI, 0.14%-0.37%) for hip arthroplasty. The pooled rates for pulmonary embolism were 0.27% (95% CI, 0.16%-0.38%) for knee arthroplasty and 0.14% (95% CI, 0.07%-0.21%) for hip arthroplasty. There was significant heterogeneity for the pooled incidence rates of symptomatic postoperative VTE in TPKA studies but less heterogeneity for DVT and pulmonary embolism in TPKA studies and for VTE, DVT, and pulmonary embolism in TPHA studies. Conclusion Using current VTE prophylaxis, approximately 1 in 100 patients undergoing TPKA and approximately 1 in 200 patients undergoing TPHA develops symptomatic VTE prior to hospital discharge. JAMA. 2012;307(3):294-303	[Januel, Jean-Marie; Ruffieux, Christiane; Burnand, Bernard] Univ Lausanne Hosp, Inst Social & Prevent Med IUMSP, CH-1005 Lausanne, Switzerland; [Januel, Jean-Marie; Colin, Cyrille] Hosp Civils Lyon, Dept Med Informat Hlth Evaluat & Clin Res, Lyon, France; [Chen, Guanmin; Quan, Hude; Ghali, William A.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Ghali, William A.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Douketis, James D.; Crowther, Mark A.] St Josephs Hosp, Hamilton, ON, Canada; [Douketis, James D.; Crowther, Mark A.] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU Lyon; University of Calgary; University of Calgary; McGill University; McMaster University; McMaster University	Januel, JM (corresponding author), Univ Lausanne Hosp, Inst Social & Prevent Med IUMSP, Bugnon 17, CH-1005 Lausanne, Switzerland.	jean-marie.januel@chuv.ch	Douketis, James/AAO-5659-2021; Januel, Jean-Marie/P-9121-2015; Chen, Guanmin/AAN-4510-2020	Januel, Jean-Marie/0000-0001-5857-6553; Quan, Hude/0000-0002-7848-7256	Alberta Innovates Health Solutions, a government research funding agency in Alberta, Canada	Alberta Innovates Health Solutions, a government research funding agency in Alberta, Canada	Drs Ghali and Quan are funded as research scientists by Alberta Innovates Health Solutions, a government research funding agency in Alberta, Canada. This work has been conducted in the framework of the research agenda of IMECCHI (International Methodology Consortium for Coded Health Information), an international collaboration of health services researchers who aim to promote the methodological development and use of coded health information to promote quality of care and quality health policy decisions (http://www.imecchi.org/IMECCHI/).	Abad JI, 2007, ARCH ORTHOP TRAUM SU, V127, P665, DOI 10.1007/s00402-006-0239-x; American Academy of Orthopaedic Surgeons (AAOS), 2007, CLIN GUID PREV SYMPT; Aujesky DA, 2004, INT J QUAL HEALTH C, V16, P193, DOI 10.1093/intqhc/mzh039; Australia and New Zealand Working Party on the Management and Prevention of Venous Thromboembolism, 2007, PREV VEN THROMB BEST; Bauer KA, 2001, NEW ENGL J MED, V345, P1305, DOI 10.1056/NEJMoa011099; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bjornara BT, 2006, J BONE JOINT SURG BR, V88B, P386, DOI 10.1302/0301-620X.88B3.17207; Blanchard J, 1999, J BONE JOINT SURG BR, V81B, P654, DOI 10.1302/0301-620X.81B4.9464; Bruce J, 2001, Health Technol Assess, V5, P1; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; Colwell CW, 1999, J BONE JOINT SURG AM, V81A, P932, DOI 10.2106/00004623-199907000-00005; Colwell CW, 2003, J THROMB HAEMOST, V1, P2119, DOI 10.1046/j.1538-7836.2003.00368.x; Colwell CW, 2005, J BONE JOINT SURG AM, V87A, P2169, DOI 10.2106/JBJS.D.02184; Decousus H, 2010, ANN INTERN MED, V152, P218, DOI 10.7326/0003-4819-152-4-201002160-00006; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Douketis JD, 2002, ARCH INTERN MED, V162, P1465, DOI 10.1001/archinte.162.13.1465; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eikelboom JW, 2009, CHEST, V135, P513, DOI 10.1378/chest.08-2655; Eriksson BI, 2007, J THROMB HAEMOST, V5, P2178, DOI 10.1111/j.1538-7836.2007.02748.x; Eriksson BI, 2007, J THROMB HAEMOST, V5, P1660, DOI 10.1111/j.1538-7836.2007.02644.x; Eriksson BI, 2010, J THROMB HAEMOST, V8, P714, DOI 10.1111/j.1538-7836.2010.03748.x; Eriksson BI, 2009, J BONE JOINT SURG BR, V91B, P636, DOI 10.1302/0301-620X.91B5.21691; Eriksson BI, 2006, CIRCULATION, V114, P2374, DOI 10.1161/CIRCULATIONAHA.106.642074; Eriksson BI, 2011, THROMB HAEMOSTASIS, V105, P721, DOI 10.1160/TH10-10-0679; Eriksson BI, 2006, J THROMB HAEMOST, V4, P121, DOI 10.1111/j.1538-7836.2005.01657.x; Eriksson BI, 1997, NEW ENGL J MED, V337, P1329, DOI 10.1056/NEJM199711063371901; Eriksson BI, 2005, J THROMB HAEMOST, V3, P103, DOI 10.1111/j.1538-7836.2004.01100.x; Eriksson BI, 2004, J THROMB HAEMOST, V2, P1573, DOI 10.1111/j.1538-7836.2004.00890.x; Eriksson BI, 2003, THROMB HAEMOSTASIS, V89, P288; Francis CW, 2003, NEW ENGL J MED, V349, P1703, DOI 10.1056/NEJMoa035162; Fuji T, 2010, J ARTHROPLASTY, V25, P1267, DOI 10.1016/j.arth.2009.08.010; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Ginsberg JS, 2009, J ARTHROPLASTY, V24, P1, DOI 10.1016/j.arth.2008.01.132; Goodacre S, 2006, HEALTH TECHNOL ASSES, V10, P1; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hitos K, 2006, INT ANGIOL, V25, P343; Hull RD, 2000, ARCH INTERN MED, V160, P2199, DOI 10.1001/archinte.160.14.2199; Kakkar AK, 2008, LANCET, V372, P31, DOI 10.1016/S0140-6736(08)60880-6; Kalebo P, 1996, THROMB HAEMOSTASIS, V76, P893; Kerr J, 2010, THROMB HAEMOSTASIS, V103, P123, DOI 10.1160/TH09-07-0438; Kirwood BR, 2003, MED STAT, P180; Konstantinides S, 2008, NEW ENGL J MED, V359, P2804, DOI 10.1056/NEJMcp0804570; Lassen MR, 2007, J THROMB HAEMOST, V5, P2368, DOI 10.1111/j.1538-7836.2007.02764.x; Lassen MR, 2009, J THROMB HAEMOST, V7, P566, DOI 10.1111/j.1538-7836.2009.03301.x; Lassen MR, 2008, NEW ENGL J MED, V358, P2776, DOI 10.1056/NEJMoa076016; Lassen MR, 2008, J AM COLL CARDIOL, V51, P1498, DOI 10.1016/j.jacc.2008.03.007; Lassen MR, 2010, LANCET, V375, P807, DOI 10.1016/S0140-6736(09)62125-5; Lassen MR, 2009, NEW ENGL J MED, V361, P594, DOI 10.1056/NEJMoa0810773; Lassen MR, 1998, THROMB RES, V89, P281, DOI 10.1016/S0049-3848(98)00018-8; Lassen MR, 2002, LANCET, V359, P1715, DOI 10.1016/S0140-6736(02)08652-X; Leclerc JR, 1998, ARCH INTERN MED, V158, P873, DOI 10.1001/archinte.158.8.873; McManus RJ, 2011, BMJ; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Navarro-Quilis A, 2003, J THROMB HAEMOST, V1, P425, DOI 10.1046/j.1538-7836.2003.00142.x; Niazi Abid Ullah Khan, 2006, JPMA Journal of the Pakistan Medical Association, V56, P72; NICE, 2007, VAR SMOK CESS, P1; Nicolaides AN, 2006, INT ANGIOL, V25, P101; Pitto RP, 2004, J BONE JOINT SURG BR, V86B, P639, DOI 10.1302/0301-620X.86B5.14763; Planes A, 1999, THROMB HAEMOSTASIS, V81, P22; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Romano PS, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.2.154; Samama CM, 1997, BRIT J ANAESTH, V78, P660, DOI 10.1093/bja/78.6.660; Schellong SM, 2008, CURR OPIN PULM MED, V14, P374, DOI 10.1097/MCP.0b013e32830a4cb1; Scottish Intercollegiate Guidelines Network (SIGN), 2010, PREV MAN VEN THROMB; Societe Francaise d'Anesthesie et de Reanimation (SFAR), PREV MAL THROMB VEIN; Stein PD, 2008, AM J MED, V121, P565, DOI 10.1016/j.amjmed.2008.02.033; Tufano A, 2011, SEMIN THROMB HEMOST, V37, P252, DOI 10.1055/s-0031-1273089; Turpie AGG, 2005, J THROMB HAEMOST, V3, P2479, DOI 10.1111/j.1538-7836.2005.01602.x; Turpie AGG, 2002, LANCET, V359, P1721, DOI 10.1016/S0140-6736(02)08648-8; Turpie AGG, 2001, NEW ENGL J MED, V344, P619, DOI 10.1056/NEJM200103013440901; Turpie AGG, 2009, LANCET, V373, P1673, DOI 10.1016/S0140-6736(09)60734-0; Turpie AGG, 2009, THROMB HAEMOSTASIS, V101, P68, DOI 10.1160/TH08-07-0460; Warwick D, 1998, J BONE JOINT SURG AM, V80A, P1158, DOI 10.2106/00004623-199808000-00009; Weiner BJ, 2006, MED CARE RES REV, V63, P29, DOI 10.1177/1077558705283122; Weitz JI, 2010, THROMB HAEMOSTASIS, V104, P1150, DOI 10.1160/TH10-05-0273; White RH, 2002, CURR OPIN PULM MED, V8, P365, DOI 10.1097/01.MCP.0000020326.82739.3A; White RH, 1998, ARCH INTERN MED, V158, P1525, DOI 10.1001/archinte.158.14.1525; Windisch C, 2011, INT ORTHOP, V35, P995, DOI 10.1007/s00264-010-1091-8; Wolowacz SE, 2009, THROMB HAEMOSTASIS, V101, P77, DOI 10.1160/TH08-07-0493; Xing KH, 2008, THROMB RES, V123, P24, DOI 10.1016/j.thromres.2008.05.005; Yoo MC, 1997, INT ORTHOP, V21, P399	83	175	188	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2012	307	3					294	303		10.1001/jama.2011.2029	http://dx.doi.org/10.1001/jama.2011.2029			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877EY	22253396	Bronze			2022-12-28	WOS:000299161200025
J	Hooper, L				Hooper, L.			Review: Interventions to reduce or modify dietary fat reduce cardiovascular events	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ E Anglia, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Hooper, L (corresponding author), Univ E Anglia, Norwich NR4 7TJ, Norfolk, England.	l.hooper@uea.ac.uk	Hooper, Lee/D-2795-2009	Hooper, Lee/0000-0002-7904-3331					0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-5	10.7326/0003-4819-156-2-201201170-02005	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31YU	22250167				2022-12-28	WOS:000208919700006
J	Masset, E; Haddad, L; Cornelius, A; Isaza-Castro, J				Masset, Edoardo; Haddad, Lawrence; Cornelius, Alexander; Isaza-Castro, Jairo			Effectiveness of agricultural interventions that aim to improve nutritional status of children: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VEGETABLES; LESSONS	Objective To assess the effectiveness of agricultural interventions in improving the nutritional status of children in developing countries. Design Systematic review. Data sources Published and unpublished reports (after 1990) in English identified by searching 10 databases (Agris, Econlit, Eldis, IBSS, IDEAS, IFPRI, Jolis, PubMed, Web of Science, and World Bank), websites, previous systematic reviews, and reference lists and by contacting experts. Study selection Included studies assessed effects of agricultural interventions aiming at improving the nutritional status of children (bio-fortification, home gardens, small scale fisheries and aquaculture, dairy development, and animal husbandry and poultry development). Only studies that used a valid counterfactual analysis were included. Before/after studies and participants/non-participants comparisons affected by selection bias were excluded. Data analysis Results were analysed for four intermediate outcomes (programme participation, income, dietary diversity, and micronutrient intake) and one final outcome (prevalence of under-nutrition). Analysis was by summary tables of mean effects and by meta-analysis (for vitamin A absorption). Results The review included 23 studies, mostly evaluating home garden interventions. The studies reviewed did not report participation rates or the characteristics of participants in programmes. The interventions had a positive effect on the production of the agricultural goods promoted, but not on households' total income. The interventions were successful in promoting the consumption of food rich in protein and micronutrients, but the effect on the overall diet of poor people remains unclear. No evidence was found of an effect on the absorption of iron, but some evidence exists of a positive effect on absorption of vitamin A. Very little evidence was found of a positive effect on the prevalence of stunting, wasting, and underweight among children aged under 5. Conclusions The question posed by the review cannot be answered with any level of confidence. The data available show a poor effect of these interventions on nutritional status, but methodological weaknesses of the studies cast serious doubts on the validity of these results. More rigorous and better designed studies are needed, as well as the establishment of agreed quality standards to guide researchers in this important area.	[Masset, Edoardo; Haddad, Lawrence] Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England; [Isaza-Castro, Jairo] Univ Sussex, Brighton BN1 9RU, E Sussex, England	University of Sussex; University of Sussex	Masset, E (corresponding author), Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England.	e.masset@ids.ac.uk		Isaza Castro, Jairo Guillermo/0000-0001-5488-9608	Department for International Development (DFID)	Department for International Development (DFID)	This review was financially supported by the Department for International Development (DFID). We thank Imran Choudury (DFID), Max Gasteen (DFID), and Todd Benson of the International Food Policy Research Institute (IFPRI) for their guidance in the process of designing the protocol. We thank Jeff Brunton of the Institute of Education (IOE), University of London, for providing and supporting the use of the EPPI-Reviewer software. We thank Jeremy Lind and Christophe Bene of the Institute of Development Studies (IDS) for their help in refining the search of the pastoralist and fisheries literatures. Finally, we thank Anna Taylor (DFID), Tim Wheeler (DFID), Hugh Waddington of the International Initiative for Impact Evaluation (3ie), and particularly Todd Benson (IFPRI) for their comments on an earlier draft of the review. The views and the conclusions expressed in this review are those of the authors and do not necessarily reflect views of DFID or of the aforementioned people.	Aiga H, 2009, T ROY SOC TROP MED H, V103, P827, DOI 10.1016/j.trstmh.2009.03.028; Attig G. A., 1993, Food, Nutrition and Agriculture, P18; Berti PR, 2004, PUBLIC HEALTH NUTR, V7, P599, DOI 10.1079/PHN2003595; Borenstein M., 2009, INTRO METAANALYSIS; Bushamuka Victor N., 2005, Food and Nutrition Bulletin, V26, P17; de Pee S, 1998, AM J CLIN NUTR, V68, P1068, DOI 10.1093/ajcn/68.5.1068; Faber M, 2002, AM J CLIN NUTR, V76, P1048, DOI 10.1093/ajcn/76.5.1048; Greiner Ted, 1995, Food and Nutrition Bulletin, V16, P193; Gunaratna NS, 2010, FOOD POLICY, V35, P202, DOI 10.1016/j.foodpol.2009.11.003; Haddad Lawrence, 2000, Food and Nutrition Bulletin, V21, P367; Hoorweg J, 2000, ECOL FOOD NUTR, V39, P395, DOI 10.1080/03670244.2000.9991627; Jones Katharine M., 2005, Food and Nutrition Bulletin, V26, P198; Karawazuka N, 2010, 2106 WORLD FISH CTR; Kidala D, 2000, PUBLIC HEALTH NUTR, V3, P425, DOI 10.1017/S1368980000000495; Laurie SM, 2008, J SCI FOOD AGR, V88, P2093, DOI 10.1002/jsfa.3319; Leroy JL, 2007, J NUTR, V137, P2311, DOI 10.1093/jn/137.10.2311; Low JW, 2007, FOOD NUTR BULL, V28, pS258, DOI 10.1177/15648265070282S205; Makhotla L., 2004, Development Southern Africa, V21, P575, DOI 10.1080/0376835042000265496; Marsh R, 1997, FOOD SECURITY AND INNOVATIONS, P247; Masset E., 2011, SYSTEMATIC REV AGR I; Murshed-e-Jahan K, 2010, AQUAC RES, V41, P481, DOI 10.1111/j.1365-2109.2009.02337.x; Nielsen H, 2003, J NUTR, V133, p4027S, DOI 10.1093/jn/133.11.4027S; Olney DK, 2009, FOOD NUTR BULL, V30, P355, DOI 10.1177/156482650903000407; Roos N, 2003, J NUTR, V133, p4021S, DOI 10.1093/jn/133.11.4021S; Ruel M. T., 2001, CAN FOOD BASED STRAT; Schipani Steven, 2002, Food and Nutrition Bulletin, V23, P175; Schmidt M. I., 1995, Development Southern Africa, V12, P713, DOI 10.1080/03768359508439851; Smitasiri Suttilak, 1999, Food and Nutrition Bulletin, V20, P243; Smith LC, 2000, OVERCOMING CHILD MAL; Talukder A, 2010, HOMESTEAD FOOD PRODU; Vijayaraghavan K., 1997, Food and Nutrition Bulletin, V18, P337; World Bank, 2007, AGR NUTR PARTHW SYN	32	209	210	3	77	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	2012	344								d8222	10.1136/bmj.d8222	http://dx.doi.org/10.1136/bmj.d8222			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888YY	22251864	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000300041800013
J	Peters, J; Anzueto, A				Peters, Jay; Anzueto, Antonio			Azithromycin once daily for 1 year reduced acute COPD exacerbations	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Peters, Jay; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Peters, J (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.							Friedlander AL, 2010, CHEST, V138, P1202, DOI 10.1378/chest.10-0196; Global Initiative for Chronic Obstructive Lung Disease, GLOB STRAT DIAGN MAN	2	4	4	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-10	10.7326/0003-4819-156-2-201201170-02010	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V41QD	22250172				2022-12-28	WOS:000209559800001
J	Conwell, Y; Farley-Toombs, C				Conwell, Yeates; Farley-Toombs, Carole			Evidence supports the obvious: suicides need not happen	LANCET			English	Editorial Material									[Conwell, Yeates; Farley-Toombs, Carole] Univ Rochester, Med Ctr, Rochester, NY 14642 USA	University of Rochester	Conwell, Y (corresponding author), Univ Rochester, Med Ctr, Rochester, NY 14642 USA.	yeates_conwell@urmc.rochester.edu	Conwell, Yeates/C-9347-2011	Conwell, Yeates/0000-0001-8517-2132	NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH071604] Funding Source: NIH RePORTER; NIMH NIH HHS [R24 MH071604] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Coffey CE, 2007, JT COMM J QUAL PATIE, V33, P193, DOI 10.1016/S1553-7250(07)33022-5; *I MED, 2002, RED SUIC NAT IMP; Institute of Medicine (US) Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders, 2006, IMPR QUAL HLTH CAR M; Knox KL, 2004, AM J PUBLIC HEALTH, V94, P37, DOI 10.2105/AJPH.94.1.37; Knox KL, 2003, BMJ-BRIT MED J, V327, P1376, DOI 10.1136/bmj.327.7428.1376; Mrazek P., 1994, REDUCING RISKS MENTA; While D, 2012, LANCET, V379, P1005, DOI 10.1016/S0140-6736(11)61712-1	9	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 17	2012	379	9820					981	982		10.1016/S0140-6736(11)61917-X	http://dx.doi.org/10.1016/S0140-6736(11)61917-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22305765	Green Accepted			2022-12-28	WOS:000301712300009
J	Schietinger, A; Delrow, JJ; Basom, RS; Blattman, JN; Greenberg, PD				Schietinger, Andrea; Delrow, Jeffrey J.; Basom, Ryan S.; Blattman, Joseph N.; Greenberg, Philip D.			Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State	SCIENCE			English	Article							CHRONIC VIRAL-INFECTION; LYMPHOCYTE-PROLIFERATION; EFFECTOR FUNCTION; MECHANISMS; EXHAUSTION; ANTIGEN; ANERGY; EOMESODERMIN; AUTOANTIGEN; INDUCTION	Tolerant self-antigen-specific CD8 T cells fail to proliferate in response to antigen, thereby preventing autoimmune disease. By using an in vivo mouse model, we show that tolerant T cells proliferate and become functional under lymphopenic conditions, even in a tolerogenic environment. However, T cell rescue is only transient, with tolerance reimposed upon lymphorepletion even in the absence of tolerogen (self-antigen), challenging the prevailing paradigm that continuous antigen exposure is critical to maintain tolerance. Genome-wide messenger RNA and microRNA profiling revealed that tolerant T cells have a tolerance-specific gene profile that can be temporarily overridden under lymphopenic conditions but is inevitably reimposed, which suggests epigenetic regulation. These insights into the regulatory mechanisms that maintain or break self-tolerance may lead to new strategies for the treatment of cancer and autoimmunity.	[Schietinger, Andrea; Blattman, Joseph N.; Greenberg, Philip D.] Univ Washington UW, Dept Immunol, Seattle, WA 98195 USA; [Schietinger, Andrea; Blattman, Joseph N.; Greenberg, Philip D.] Fred Hutchinson Canc Res Ctr FHCRC, Program Immunol, Seattle, WA 98109 USA; [Delrow, Jeffrey J.; Basom, Ryan S.] FHCRC, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Greenberg, PD (corresponding author), Univ Washington UW, Dept Immunol, Seattle, WA 98195 USA.	pgreen@u.washington.edu			NIH [R01 CA033084, K01 CA117985, P30 CA015704-35]; Korea Research Institute of Bioscience and Biotechnology [FND 7008-08]; Pilot and Feasibility Project Award [P30 DK 56465]; Cancer Research Institute; NATIONAL CANCER INSTITUTE [R01CA033084, K01CA117985, P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056465] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Korea Research Institute of Bioscience and Biotechnology; Pilot and Feasibility Project Award; Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank S. Funk, C. Fowler, X. Tan, C. Chou, the other members of the Greenberg lab, and M. Philip for technical support and helpful discussion; the Abkowitz lab for providing the hemavet; M. Black from the UW Flow Cytometry Core Lab; J. Cao from the Immune Monitoring Shared Resource; and A. Dawson from the Genomics Shared Resource at the FHCRC. This work was supported by NIH grants R01 CA033084 (to P.D.G.), K01 CA117985 (to J.N.B.), and P30 CA015704-35 (to J.J.D. and R.S.B.); a grant FND 7008-08 from the Korea Research Institute of Bioscience and Biotechnology (to P.D.G.); and a Pilot and Feasibility Project Award (from P30 DK 56465 to B. Torok-Storb) (to A.S.). A.S. was supported by the Irvington Institute Fellowship Program of the Cancer Research Institute. All of the data reported in this paper are tabulated in the main text and in the supporting online material. The microarray data have been deposited in the Gene Expression Omnibus (GEO accession number GSE32025).	Baitsch L, 2011, J CLIN INVEST, V121, P2350, DOI 10.1172/JCI46102; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Cairns BR, 2009, NATURE, V461, P193, DOI 10.1038/nature08450; Choi S, 2007, SEMIN IMMUNOL, V19, P140, DOI 10.1016/j.smim.2007.02.005; Datta S, 2009, TRENDS IMMUNOL, V30, P430, DOI 10.1016/j.it.2009.06.002; Ebert PJR, 2009, NAT IMMUNOL, V10, P1162, DOI 10.1038/ni.1797; Grosso JF, 2007, J CLIN INVEST, V117, P3383, DOI 10.1172/JCI31184; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; JONES RJ, 1989, LANCET, V1, P754; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Morimoto J, 2007, J IMMUNOL, V178, P6849, DOI 10.4049/jimmunol.178.11.6849; Mueller DL, 2010, NAT IMMUNOL, V11, P21, DOI 10.1038/ni.1817; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Ohlen C, 2002, J EXP MED, V195, P1407, DOI 10.1084/jem.20011063; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; Quigley M, 2010, NAT MED, V16, P1147, DOI 10.1038/nm.2232; RAMSDELL F, 1992, SCIENCE, V257, P1130, DOI 10.1126/science.257.5073.1130; ROCHA B, 1993, J EXP MED, V177, P1517, DOI 10.1084/jem.177.5.1517; Safford M, 2005, NAT IMMUNOL, V6, P472, DOI 10.1038/ni1193; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; Teague RM, 2006, NAT MED, V12, P335, DOI 10.1038/nm1359; Teague RM, 2008, IMMUNITY, V28, P662, DOI 10.1016/j.immuni.2008.03.012; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Williams KA, 2007, SEMIN IMMUNOL, V19, P318, DOI 10.1016/j.smim.2007.10.004; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Yusuf I, 2003, TRENDS IMMUNOL, V24, P380, DOI 10.1016/S1471-4906(03)00141-8	31	124	127	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2012	335	6069					723	727		10.1126/science.1214277	http://dx.doi.org/10.1126/science.1214277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	889AY	22267581	Green Accepted			2022-12-28	WOS:000300047100054
J	McCartney, M				McCartney, Margaret			MEDICINE AND THE MEDIA Would you like your telomeres tested?	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Newswire PR, 2011, PR NEWSWIRE     1208	1	2	2	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 8	2012	344								e681	10.1136/bmj.e681	http://dx.doi.org/10.1136/bmj.e681			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IE	22318437				2022-12-28	WOS:000300279100004
J	Xu, XH; Coats, JK; Yang, CF; Wang, A; Ahmed, OM; Alvarado, M; Izumi, T; Shah, NM				Xu, Xiaohong; Coats, Jennifer K.; Yang, Cindy F.; Wang, Amy; Ahmed, Osama M.; Alvarado, Maricruz; Izumi, Tetsuro; Shah, Nirao M.			Modular Genetic Control of Sexually Dimorphic Behaviors	CELL			English	Article							ESTROGEN-RECEPTOR-ALPHA; VENTROMEDIAL HYPOTHALAMIC NUCLEUS; POSTERODORSAL MEDIAL AMYGDALA; NON-GENOMIC ACTIONS; MICE LACKING; MESSENGER-RNA; LORDOSIS BEHAVIOR; SEX-DIFFERENCES; RAT-BRAIN; TARGETED DISRUPTION	Sex hormones such as estrogen and testosterone are essential for sexually dimorphic behaviors in vertebrates. However, the hormone-activated molecular mechanisms that control the development and function of the underlying neural circuits remain poorly defined. We have identified numerous sexually dimorphic gene expression patterns in the adult mouse hypothalamus and amygdala. We find that adult sex hormones regulate these expression patterns in a sex-specific, regionally restricted manner, suggesting that these genes regulate sex typical behaviors. Indeed, we find that mice with targeted disruptions of each of four of these genes (Brs3, Cckar, Irs4, Sytl4) exhibit extremely specific deficits in sex specific behaviors, with single genes controlling the pattern or extent of male sexual behavior, male aggression, maternal behavior, or female sexual behavior. Taken together, our findings demonstrate that various components of sexually dimorphic behaviors are governed by separable genetic programs.	[Coats, Jennifer K.; Yang, Cindy F.; Ahmed, Osama M.; Shah, Nirao M.] Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94158 USA; [Xu, Xiaohong; Wang, Amy; Alvarado, Maricruz; Shah, Nirao M.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94158 USA; [Izumi, Tetsuro] Gunma Univ, Dept Mol Med, Maebashi, Gunma 3718512, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Gunma University	Shah, NM (corresponding author), Univ Calif San Francisco, Program Neurosci, MC 2722, San Francisco, CA 94158 USA.	nms@ucsf.edu		Ahmed, Osama/0000-0003-3539-3150; Yang, Cindy/0000-0001-6144-4658	NSF; Sandler postdoctoral fellowship; Genentech graduate fellowship; ARCS; Edward Mallinckrodt, Jr. Foundation; NARSAD; NIH [R01NS049488, DP1OD006425]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049488] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006425] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); Sandler postdoctoral fellowship; Genentech graduate fellowship; ARCS; Edward Mallinckrodt, Jr. Foundation; NARSAD(NARSAD); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank R. Axel, H. Baier, H. Bourne, and S. Lomvardas for comments on the manuscript; D. Anderson, C. Bargmann, D. Julius, H. Zoghbi, and Shahlab members for discussions; and A. Barczak, P. Nittler, and E. Tumer for help with microarrays. This work was supported by NSF graduate fellowship (O.M.A.); Sandler postdoctoral fellowship (X. X.); Genentech graduate fellowship (C.F.Y. and J.K.C.); ARCS award (J.K.C.); Edward Mallinckrodt, Jr. Foundation, NARSAD, and NIH (N.M.S.; R01NS049488, DP1OD006425).	AKESSON TR, 1987, NEUROENDOCRINOLOGY, V45, P257, DOI 10.1159/000124737; Allen E, 1923, J AMER MED ASSOC, V81, P819, DOI 10.1001/jama.1923.02650100027012; Arnold AP, 2003, ANN NY ACAD SCI, V1007, P176, DOI 10.1196/annals.1286.018; BABCOCK AM, 1988, PHYSIOL BEHAV, V43, P195, DOI 10.1016/0031-9384(88)90237-5; Balthazart J, 2010, EUR J NEUROSCI, V32, P2116, DOI 10.1111/j.1460-9568.2010.07518.x; Baum MJ, 2003, SCAND J PSYCHOL, V44, P213, DOI 10.1111/1467-9450.00338; BEEMAN EA, 1947, PHYSIOL ZOOL, V20, P373, DOI 10.1086/physzool.20.4.30151969; Bendesky A, 2011, NATURE, V472, P313, DOI 10.1038/nature09821; Berna MJ, 2007, CURR OPIN PHARMACOL, V7, P583, DOI 10.1016/j.coph.2007.09.011; Blaustein JD, 2008, ANNU REV PSYCHOL, V59, P93, DOI 10.1146/annurev.psych.59.103006.093556; BLOCH GJ, 1987, PHYSIOL BEHAV, V39, P217, DOI 10.1016/0031-9384(87)90012-6; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Cahill L, 2006, NAT REV NEUROSCI, V7, P477, DOI 10.1038/nrn1909; CANTERAS NS, 1995, J COMP NEUROL, V360, P213, DOI 10.1002/cne.903600203; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Clodfelter KH, 2006, MOL ENDOCRINOL, V20, P1333, DOI 10.1210/me.2005-0489; Cooke B, 1998, FRONT NEUROENDOCRIN, V19, P323, DOI 10.1006/frne.1998.0171; Cooke BM, 2006, NEUROSCIENCE, V138, P997, DOI 10.1016/j.neuroscience.2005.06.018; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; DESJARDINS C, 1973, SCIENCE, V182, P939, DOI 10.1126/science.182.4115.939; DEVRIES GJ, 1990, J NEUROENDOCRINOL, V2, P1, DOI 10.1111/j.1365-2826.1990.tb00385.x; Dewing P, 2003, MOL BRAIN RES, V118, P82, DOI 10.1016/S0169-328X(03)00339-5; Dickson BJ, 2008, SCIENCE, V322, P904, DOI 10.1126/science.1159276; DORNAN WA, 1989, PHYSIOL BEHAV, V45, P969, DOI 10.1016/0031-9384(89)90223-0; Dugger BN, 2008, NEUROENDOCRINOLOGY, V88, P17, DOI 10.1159/000119740; Dugger BN, 2007, HORM BEHAV, V51, P195, DOI 10.1016/j.yhbeh.2006.10.001; Dulac C, 2006, ANNU REV GENET, V40, P449, DOI 10.1146/annurev.genet.39.073003.093937; EMERY DE, 1976, PHYSIOL BEHAV, V17, P803, DOI 10.1016/0031-9384(76)90044-5; Enoch MA, 2009, NEUROPSYCHOPHARMACOL, V34, P1245, DOI 10.1038/npp.2008.171; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Foradori CD, 2008, FRONT NEUROENDOCRIN, V29, P169, DOI 10.1016/j.yfrne.2007.10.005; Gagnidze K, 2010, PROG BRAIN RES, V186, P97, DOI 10.1016/B978-0-444-53630-3.00007-5; Gammie SC, 2001, BRAIN RES, V898, P232, DOI 10.1016/S0006-8993(01)02189-8; GANDELMAN R, 1972, HORM BEHAV, V3, P23, DOI 10.1016/0018-506X(72)90003-7; Garcia LR, 2001, CELL, V107, P777, DOI 10.1016/S0092-8674(01)00600-6; Ghosh MG, 2000, CANCER RES, V60, P6367; Gomi H, 2005, J CELL BIOL, V171, P99, DOI 10.1083/jcb.200505179; Gregg C, 2010, SCIENCE, V329, P643, DOI 10.1126/science.1190830; GUILLAMON A, 1988, DEV BRAIN RES, V44, P281, DOI 10.1016/0165-3806(88)90226-X; Henderson LP, 2007, NEUROPHARMACOLOGY, V52, P1439, DOI 10.1016/j.neuropharm.2007.01.022; Hilke S, 2007, BRAIN RES, V1144, P70, DOI 10.1016/j.brainres.2007.01.107; Holland KL, 1997, PHYSIOL BEHAV, V62, P537, DOI 10.1016/S0031-9384(97)80331-9; Holmes MM, 2009, NEUROSCIENCE, V158, P1251, DOI 10.1016/j.neuroscience.2008.11.020; Insel TR, 2004, ANNU REV NEUROSCI, V27, P697, DOI 10.1146/annurev.neuro.27.070203.144148; Juntti SA, 2010, NEURON, V66, P260, DOI 10.1016/j.neuron.2010.03.024; Kagitani F, 1997, NUCLEIC ACIDS RES, V25, P3428, DOI 10.1093/nar/25.17.3428; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Kellendonk C, 2009, TRENDS NEUROSCI, V32, P347, DOI 10.1016/j.tins.2009.02.003; KOCH M, 1989, BRAIN RES, V489, P101, DOI 10.1016/0006-8993(89)90012-7; KONISHI M, 1989, NEURON, V3, P541, DOI 10.1016/0896-6273(89)90264-X; Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901; Kudwa AE, 2003, J NEUROENDOCRINOL, V15, P978, DOI 10.1046/j.1365-2826.2003.01089.x; Kudwa AE, 2006, NEUROSCIENCE, V138, P921, DOI 10.1016/j.neuroscience.2005.10.018; Ladenheim EE, 2008, ENDOCRINOLOGY, V149, P971, DOI 10.1210/en.2007-1319; LAUBER AH, 1991, ENDOCRINOLOGY, V129, P3180, DOI 10.1210/endo-129-6-3180; Lin DY, 2011, NATURE, V470, P221, DOI 10.1038/nature09736; Lishko PV, 2011, NATURE, V471, P387, DOI 10.1038/nature09767; Liu Y, 2011, NATURE, V472, P95, DOI 10.1038/nature09822; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Manoli DS, 2006, TRENDS NEUROSCI, V29, P444, DOI 10.1016/j.tins.2006.06.006; Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007; McDevitta MA, 2008, MOL CELL ENDOCRINOL, V290, P24, DOI 10.1016/j.mce.2008.04.003; MCGILL TE, 1964, SCIENCE, V145, P514, DOI 10.1126/science.145.3631.514; MENDELSON SD, 1984, PHARMACOL BIOCHEM BE, V21, P755, DOI 10.1016/S0091-3057(84)80015-5; Micevych P, 2009, FRONT NEUROENDOCRIN, V30, P315, DOI 10.1016/j.yfrne.2009.04.011; Miczek KA, 2001, BEHAV BRAIN RES, V125, P167, DOI 10.1016/S0166-4328(01)00298-4; Morris JA, 2004, NAT NEUROSCI, V7, P1034, DOI 10.1038/nn1325; Morris JA, 2008, BRAIN RES, V1190, P115, DOI 10.1016/j.brainres.2007.11.005; Morris JA, 2008, J COMP NEUROL, V506, P851, DOI 10.1002/cne.21536; Morrow EM, 2008, SCHIZOPHR RES, V106, P265, DOI 10.1016/j.schres.2008.08.021; Musatov S, 2006, P NATL ACAD SCI USA, V103, P10456, DOI 10.1073/pnas.0603045103; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; Nett ST, 1999, J NEUROPHYSIOL, V81, P192, DOI 10.1152/jn.1999.81.1.192; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; Ogawa S, 2000, P NATL ACAD SCI USA, V97, P14737, DOI 10.1073/pnas.250473597; ORO AE, 1988, NEUROENDOCRINOLOGY, V47, P225, DOI 10.1159/000124916; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Pirnik Z, 2010, PEPTIDES, V31, P139, DOI 10.1016/j.peptides.2009.09.035; Raskin K, 2009, J NEUROSCI, V29, P4461, DOI 10.1523/JNEUROSCI.0296-09.2009; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Ring JR, 1944, ENDOCRINOLOGY, V34, P269, DOI 10.1210/endo-34-4-269; Rinn JL, 2005, TRENDS GENET, V21, P298, DOI 10.1016/j.tig.2005.03.005; Rinn JL, 2004, DEV CELL, V6, P791, DOI 10.1016/j.devcel.2004.05.005; ROSELLI C E, 1987, Steroids, V50, P495, DOI 10.1016/0039-128X(87)90034-1; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; Scordalakes EM, 2003, BEHAV NEUROSCI, V117, P38, DOI 10.1037/0735-7044.117.1.38; Shah NM, 2004, NEURON, V43, P313, DOI 10.1016/j.neuron.2004.07.008; SHUGHRUE PJ, 1992, ENDOCRINOLOGY, V131, P381, DOI 10.1210/en.131.1.381; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; van der Zanden LFM, 2011, NAT GENET, V43, P48, DOI 10.1038/ng.721; van Nas A, 2009, ENDOCRINOLOGY, V150, P1235, DOI 10.1210/en.2008-0563; Vasudevan N, 2008, FRONT NEUROENDOCRIN, V29, P238, DOI 10.1016/j.yfrne.2007.08.003; Verdugo RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-58; VONSCHILCHER F, 1976, BEHAV BIOL, V17, P187, DOI 10.1016/S0091-6773(76)90444-2; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wersinger SR, 1997, HORM BEHAV, V32, P176, DOI 10.1006/hbeh.1997.1419; Wersinger SR, 2002, MOL PSYCHIATR, V7, P975, DOI 10.1038/sj.mp.4001195; Whited KL, 2006, AM J PHYSIOL-GASTR L, V291, pG156, DOI 10.1152/ajpgi.00569.2005; Wiesner BP, 1930, Q J EXP PHYSIOL, V20, P273, DOI 10.1113/expphysiol.1930.sp000505; Winslow JT, 2002, NEUROPEPTIDES, V36, P221, DOI 10.1054/npep.2002.0909; WINSLOW JT, 1993, NATURE, V365, P545, DOI 10.1038/365545a0; Wolfe CA, 2005, DEV BRAIN RES, V157, P34, DOI 10.1016/j.devbrainres.2005.03.001; Wu MV, 2011, CURR OPIN NEUROBIOL, V21, P116, DOI 10.1016/j.conb.2010.09.014; Wu MV, 2009, CELL, V139, P61, DOI 10.1016/j.cell.2009.07.036; Yang X, 2006, GENOME RES, V16, P995, DOI 10.1101/gr.5217506; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004; Zoghbi HY, 2010, NEURON, V68, P165, DOI 10.1016/j.neuron.2010.10.015	111	159	162	3	60	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					596	607		10.1016/j.cell.2011.12.018	http://dx.doi.org/10.1016/j.cell.2011.12.018			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304924	Green Accepted, Bronze			2022-12-28	WOS:000300225000025
J	Boyden, LM; Choi, M; Choate, KA; Nelson-Williams, CJ; Farhi, A; Toka, HR; Tikhonova, IR; Bjornson, R; Mane, SM; Colussi, G; Lebel, M; Gordon, RD; Semmekrot, BA; Poujol, A; Valimaki, MJ; De Ferrari, ME; Sanjad, SA; Gutkin, M; Karet, FE; Tucci, JR; Stockigt, JR; Keppler-Noreuil, KM; Porter, CC; Anand, SK; Whiteford, ML; Davis, ID; Dewar, SB; Bettinelli, A; Fadrowski, JJ; Belsha, CW; Hunley, TE; Nelson, RD; Trachtman, H; Cole, TRP; Pinsk, M; Bockenhauer, D; Shenoy, M; Vaidyanathan, P; Foreman, JW; Rasoulpour, M; Thameem, F; Al-Shahrouri, HZ; Radhakrishnan, J; Gharavi, AG; Goilav, B; Lifton, RP				Boyden, Lynn M.; Choi, Murim; Choate, Keith A.; Nelson-Williams, Carol J.; Farhi, Anita; Toka, Hakan R.; Tikhonova, Irina R.; Bjornson, Robert; Mane, Shrikant M.; Colussi, Giacomo; Lebel, Marcel; Gordon, Richard D.; Semmekrot, Ben A.; Poujol, Alain; Valimaki, Matti J.; De Ferrari, Maria E.; Sanjad, Sami A.; Gutkin, Michael; Karet, Fiona E.; Tucci, Joseph R.; Stockigt, Jim R.; Keppler-Noreuil, Kim M.; Porter, Craig C.; Anand, Sudhir K.; Whiteford, Margo L.; Davis, Ira D.; Dewar, Stephanie B.; Bettinelli, Alberto; Fadrowski, Jeffrey J.; Belsha, Craig W.; Hunley, Tracy E.; Nelson, Raoul D.; Trachtman, Howard; Cole, Trevor R. P.; Pinsk, Maury; Bockenhauer, Detlef; Shenoy, Mohan; Vaidyanathan, Priya; Foreman, John W.; Rasoulpour, Majid; Thameem, Farook; Al-Shahrouri, Hania Z.; Radhakrishnan, Jai; Gharavi, Ali G.; Goilav, Beatrice; Lifton, Richard P.			Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities	NATURE			English	Article							WNK KINASES; K+ CHANNEL; PROTEINS; SEQUENCE; GENE; UBIQUITINATION; COTRANSPORTER; TUBULE; ROMK	Hypertension affects one billion people and is a principal reversible risk factor for cardiovascular disease. Pseudohypoaldosteronism type II (PHAII), a rare Mendelian syndrome featuring hypertension, hyperkalaemia and metabolic acidosis, has revealed previously unrecognized physiology orchestrating the balance between renal salt reabsorption and K(+) and H(+) excretion(1). Here we used exome sequencing to identify mutations in kelch-like 3 (KLHL3) or cullin 3 (CUL3) in PHAII patients from 41 unrelated families. KLHL3 mutations are either recessive or dominant, whereas CUL3 mutations are dominant and predominantly de novo. CUL3 and BTB-domain-containing kelch proteins such as KLHL3 are components of cullin-RING E3 ligase complexes that ubiquitinate substrates bound to kelch propeller domains(2-8). Dominant KLHL3 mutations are clustered in short segments within the kelch propeller and BTB domains implicated in substrate(9) and cullin(5) binding, respectively. Diverse CUL3 mutations all result in skipping of exon 9, producing an in-frame deletion. Because dominant KLHL3 and CUL3 mutations both phenocopy recessive loss-of-function KLHL3 mutations, they may abrogate ubiquitination of KLHL3 substrates. Disease features are reversed by thiazide diuretics, which inhibit the Na-Cl cotransporter in the distal nephron of the kidney; KLHL3 and CUL3 are expressed in this location, suggesting a mechanistic link between KLHL3 and CUL3 mutations, increased Na-Cl reabsorption, and disease pathogenesis. These findings demonstrate the utility of exome sequencing in disease gene identification despite the combined complexities of locus heterogeneity, mixed models of transmission and frequent de novo mutation, and establish a fundamental role for KLHL3 and CUL3 in blood pressure, K(+) and pH homeostasis.	[Boyden, Lynn M.; Choi, Murim; Nelson-Williams, Carol J.; Farhi, Anita] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Boyden, Lynn M.; Choi, Murim; Nelson-Williams, Carol J.; Farhi, Anita] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; [Choate, Keith A.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Toka, Hakan R.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; [Tikhonova, Irina R.; Bjornson, Robert; Mane, Shrikant M.] Yale Univ, Yale Ctr Genome Anal, New Haven, CT 06510 USA; [Colussi, Giacomo; De Ferrari, Maria E.] Osped Niguarda Ca Granda, Nephrol Unit, I-20162 Milan, Italy; [Lebel, Marcel] Univ Laval, Dept Med, Ste Foy, PQ G1K 7P4, Canada; [Gordon, Richard D.] Univ Queensland, Sch Med, Endocrine Hypertens Res Ctr, Brisbane, Qld 4006, Australia; [Semmekrot, Ben A.] Canisius Wilhelmina Hosp, Dept Pediat, NL-6500 GS Nijmegen, Netherlands; [Poujol, Alain] Pays Aix Hosp, Dept Pediat, F-13616 Aix En Provence, France; [Valimaki, Matti J.] Univ Helsinki, Cent Hosp, Dept Med, Div Endocrinol, FIN-00290 Helsinki, Finland; [Sanjad, Sami A.] American Univ, Med Ctr, Dept Pediat & Adolescent Med, Beirut 11072020, Lebanon; [Gutkin, Michael] Univ Med & Dent New Jersey, Hypertens Res Ctr, Newark, NJ 07103 USA; [Karet, Fiona E.] Univ Cambridge, Dept Med Genet, Cambridge CB2 1TN, England; [Tucci, Joseph R.] Roger Williams Med Ctr, Div Endocrinol, Providence, RI 02908 USA; [Stockigt, Jim R.] Alfred Hosp, Dept Endocrinol & Diabet, Ewen Downie Metab Unit, Melbourne, Vic 3004, Australia; [Keppler-Noreuil, Kim M.] Univ Iowa, Childrens Hosp, Dept Pediat, Div Med Genet, Iowa City, IA 52242 USA; [Porter, Craig C.] Med Coll Wisconsin, Dept Pediat, Div Nephrol, Milwaukee, WI 53226 USA; [Anand, Sudhir K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA USA; [Whiteford, Margo L.] Royal Hosp Sick Children, Duncan Guthrie Inst Med Genet, Glasgow G3 8SJ, Lanark, Scotland; [Davis, Ira D.] Baxter Healthcare Corp, McGaw Pk, IL 60085 USA; [Dewar, Stephanie B.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Bettinelli, Alberto] Mandic Hosp, Div Pediat, I-23807 Merate, Italy; [Fadrowski, Jeffrey J.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD 21287 USA; [Belsha, Craig W.] St Louis Univ, Hlth Sci Ctr, Dept Pediat, Div Nephrol, St Louis, MO 63110 USA; [Hunley, Tracy E.] Vanderbilt Univ, Dept Pediat, Med Ctr, Div Nephrol, Nashville, TN 37232 USA; [Nelson, Raoul D.] Univ Utah, Dept Pediat, Div Nephrol, Salt Lake City, UT 84132 USA; [Trachtman, Howard] Cohen Childrens Med Ctr New York, Div Nephrol, New Hyde Pk, NY 11040 USA; [Cole, Trevor R. P.] Birmingham Womens Hosp, W Midlands Reg Genet Serv, Birmingham B15 2TG, W Midlands, England; [Pinsk, Maury] Univ Alberta, Dept Pediat, Div Nephrol, Edmonton, AB T6G 2M7, Canada; [Bockenhauer, Detlef] UCL, Inst Child Hlth, Renal Unit, London WC1N 1EH, England; [Shenoy, Mohan] Royal Manchester Childrens Hosp, Dept Nephrol, Manchester M27 4HA, Lancs, England; [Vaidyanathan, Priya] Childrens Natl Med Ctr, Dept Endocrinol, Washington, DC 20010 USA; [Foreman, John W.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Rasoulpour, Majid] Connecticut Childrens Med Ctr, Div Nephrol, Hartford, CT 06106 USA; [Thameem, Farook; Al-Shahrouri, Hania Z.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA; [Radhakrishnan, Jai; Gharavi, Ali G.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Goilav, Beatrice] Childrens Hosp Montefiore, Div Nephrol, Bronx, NY 10467 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University; Harvard University; Brigham & Women's Hospital; Yale University; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Laval University; University of Queensland; Canisius-Wilhelmina Hospital; University of Helsinki; Helsinki University Central Hospital; American University of Beirut; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Cambridge; Roger Williams Medical Center; Florey Institute of Neuroscience & Mental Health; University of Iowa; Medical College of Wisconsin; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Glasgow; Baxter International Inc; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; Saint Louis University; Vanderbilt University; Utah System of Higher Education; University of Utah; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Birmingham Women's Hospital; University of Alberta; University of London; University College London; Royal Manchester Children's Hospital; Children's National Health System; Duke University; Connecticut Children's Medical Center; University of Texas System; University of Texas Health San Antonio; Columbia University; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore	Lifton, RP (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.	richard.lifton@yale.edu	Toka, Hakan/AAQ-2162-2021; Choi, Murim/AAP-9120-2021; Goilav, Beatrice/AAF-8349-2021; Pinsk, Maury/L-5936-2019; Bockenhauer, Detlef/AAF-6495-2020; Trachtman, Howard/GSE-2340-2022; Colussi, Giacomo/AFV-2812-2022; Gordon, Richard D/K-2555-2012	Pinsk, Maury/0000-0001-7668-665X; Bockenhauer, Detlef/0000-0001-5878-941X; Colussi, Giacomo/0000-0001-6133-1899; hunley, tracy/0000-0002-8766-551X; Trachtman, Howard/0000-0001-7447-9489; Karet, Fiona/0000-0002-2457-2869; Goilav, Beatrice/0000-0002-5204-7965	Leducq Transatlantic Network on Hypertension; National Institutes of Health [P30-DK079310, UL1-RR024139]; Great Ormond Street Hospital Childrens Charity [V0901] Funding Source: researchfish; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024138, UL1RR024139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079310] Funding Source: NIH RePORTER	Leducq Transatlantic Network on Hypertension; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Great Ormond Street Hospital Childrens Charity; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the PHAII subjects, their families, and the health care professionals whose participation made this study possible; S. Umlauf and the staff of the Yale Center for Genome Analysis; J. Santosuosso; H. Tirrell and the staff of Beckman Coulter Genomics; V. Klump, Y. Lu, U. Scholl and J. Zhou for providing reagents; W. Hill for artistic assistance with Fig. 1d; and E. Boyden, S. Boyden, L. Cooley and M. Hochstrasser for helpful discussions. This work was supported in part by the Leducq Transatlantic Network on Hypertension and grants from the National Institutes of Health (P30-DK079310 and UL1-RR024139).	Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Bachmann S, 1999, ANAT EMBRYOL, V200, P447, DOI 10.1007/s004290050294; Choi M, 2011, SCIENCE, V331, P768, DOI 10.1126/science.1198785; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Hudson Andrew M., 2008, V48, P6, DOI 10.1007/978-0-387-09595-0_2; Kahle KT, 2008, ANNU REV PHYSIOL, V70, P329, DOI 10.1146/annurev.physiol.70.113006.100651; Kahle KT, 2003, NAT GENET, V35, P372, DOI 10.1038/ng1271; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Ko B, 2010, AM J PHYSIOL-RENAL, V299, pF300, DOI 10.1152/ajprenal.00441.2009; Lai F, 2000, GENOMICS, V66, P65, DOI 10.1006/geno.2000.6181; Lalioti MD, 2006, NAT GENET, V38, P1124, DOI 10.1038/ng1877; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Leviel F, 2010, J CLIN INVEST, V120, P1627, DOI 10.1172/JCI40145; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lo SC, 2006, EMBO J, V25, P3605, DOI 10.1038/sj.emboj.7601243; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ring AM, 2007, P NATL ACAD SCI USA, V104, P4020, DOI 10.1073/pnas.0611727104; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rozen S, 2000, Methods Mol Biol, V132, P365; Sarikas A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-220; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Stogios PJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r82; Tong KI, 2007, MOL CELL BIOL, V27, P7511, DOI 10.1128/MCB.00753-07; Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200; Wang YL, 2007, NUCLEIC ACIDS RES, V35, pD298, DOI 10.1093/nar/gkl952; Wang YL, 2000, TRENDS BIOCHEM SCI, V25, P300, DOI 10.1016/S0968-0004(00)01561-9; Welling PA, 2009, AM J PHYSIOL-RENAL, V297, pF849, DOI 10.1152/ajprenal.00181.2009; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443; Zhang MQ, 1998, HUM MOL GENET, V7, P919, DOI 10.1093/hmg/7.5.919; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zimmerman ES, 2010, CURR OPIN STRUC BIOL, V20, P714, DOI 10.1016/j.sbi.2010.08.010	39	419	435	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					98	U126		10.1038/nature10814	http://dx.doi.org/10.1038/nature10814			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22266938	Green Accepted			2022-12-28	WOS:000299726000043
J	Meyer, JR; Dobias, DT; Weitz, JS; Barrick, JE; Quick, RT; Lenski, RE				Meyer, Justin R.; Dobias, Devin T.; Weitz, Joshua S.; Barrick, Jeffrey E.; Quick, Ryan T.; Lenski, Richard E.			Repeatability and Contingency in the Evolution of a Key Innovation in Phage Lambda	SCIENCE			English	Article							BACTERIOPHAGE-LAMBDA; MEMBRANE-PROTEINS; RECEPTOR; ADAPTATION; MECHANISMS; MALTOPORIN; DYNAMICS; CONSISTS; BINDING; SURFACE	The processes responsible for the evolution of key innovations, whereby lineages acquire qualitatively new functions that expand their ecological opportunities, remain poorly understood. We examined how a virus, bacteriophage l, evolved to infect its host, Escherichia coli, through a novel pathway. Natural selection promoted the fixation of mutations in the virus's host-recognition protein, J, that improved fitness on the original receptor, LamB, and set the stage for other mutations that allowed infection through a new receptor, OmpF. These viral mutations arose after the host evolved reduced expression of LamB, whereas certain other host mutations prevented the phage from evolving the new function. This study shows the complex interplay between genomic processes and ecological conditions that favor the emergence of evolutionary innovations.	[Meyer, Justin R.; Lenski, Richard E.] Michigan State Univ, Dept Zool, E Lansing, MI 48824 USA; [Meyer, Justin R.; Barrick, Jeffrey E.; Lenski, Richard E.] Michigan State Univ, BEACON Ctr Study Evolut Act, E Lansing, MI 48824 USA; [Dobias, Devin T.] Washington Univ, Dept Biol, St Louis, MO 63130 USA; [Weitz, Joshua S.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; [Weitz, Joshua S.] Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA; [Barrick, Jeffrey E.] Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA; [Quick, Ryan T.; Lenski, Richard E.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Washington University (WUSTL); University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; University of Texas System; University of Texas Austin; Michigan State University	Meyer, JR (corresponding author), Michigan State Univ, Dept Zool, E Lansing, MI 48824 USA.	justin.raymond.meyer@gmail.com	Weitz, Joshua S/I-6696-2012; Barrick, Jeffrey/A-3046-2012	Weitz, Joshua S/0000-0002-3433-8312; Barrick, Jeffrey/0000-0003-0888-7358; Lenski, Richard/0000-0002-1064-8375	BEACON Center for the Study of Evolution in Action (NSF) [DBI-0939454]; Defense Advanced Research Projects Agency [HR0011-09-1-0055]; NIH [R00GM087550]; James S. McDonnell Foundation; Burroughs Wellcome Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R00GM087550] Funding Source: NIH RePORTER	BEACON Center for the Study of Evolution in Action (NSF); Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James S. McDonnell Foundation; Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the BEACON Center for the Study of Evolution in Action (NSF Cooperative Agreement DBI-0939454), the Defense Advanced Research Projects Agency (HR0011-09-1-0055 to R. E. L. and J.S.W.), and the NIH (R00GM087550 to J.E.B.). J.S.W. also acknowledges the support of the James S. McDonnell Foundation and the Burroughs Wellcome Fund. We thank N. Hajela and L. Zaman for help in the lab; D. Court for sharing phage cI26; the Michigan State University Research Technology Support Facility for help with genome sequencing; Z. Blount, T. Ferenci, C. Marx, L. Zaman, I. Wang, M. Kreitman, B. He, and J. Reinitz for discussions; and the anonymous reviewers for help revising. R. E. L. will make the evolved strains available to qualified recipients, subject to completion of a material transfer agreement that can be found at www.technologies.msu.edu/inventors/mta-cda/mta/mta-forms. The genome-sequence data for the phage and bacteria have been deposited in the National Center for Biotechnology Information, NIH, Sequence Read Archive (SRA043942). Other data and analysis scripts have been deposited at the Dryad Digital Repository (doi:10.5061/dryad.sh7rm2pt).	Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Berkane E, 2006, BIOCHEMISTRY-US, V45, P2708, DOI 10.1021/bi051800v; Blount ZD, 2008, P NATL ACAD SCI USA, V105, P7899, DOI 10.1073/pnas.0803151105; Bohannan BJM, 2000, ECOL LETT, V3, P362, DOI 10.1046/j.1461-0248.2000.00161.x; BRAUNBRETON C, 1978, MOL GEN GENET, V159, P143, DOI 10.1007/BF00270887; Cairns J, 2007, PHAGE ORIGINS MOL BI; Cooper VS, 2001, J BACTERIOL, V183, P2834, DOI 10.1128/JB.183.9.2834-2841.2001; Crozat E, 2011, J BACTERIOL, V193, P429, DOI 10.1128/JB.01341-10; Darwin C., 1877, ORIGIN SPECIES; Dennehy JJ, 2009, TRENDS MICROBIOL, V17, P450, DOI 10.1016/j.tim.2009.07.006; Dieckmann U., 2004, ADAPTIVE SPECIATION; Duffy S, 2007, EVOLUTION, V61, P2614, DOI 10.1111/j.1558-5646.2007.00226.x; Edwards RA, 2005, NAT REV MICROBIOL, V3, P504, DOI 10.1038/nrmicro1163; Elena SF, 2003, NAT REV GENET, V4, P457, DOI 10.1038/nrg1088; ERNI B, 1987, J BIOL CHEM, V262, P5238; Esquinas-Rychen M, 2001, J MOL MICROB BIOTECH, V3, P361; Ferris MT, 2007, GENETICS, V176, P1013, DOI 10.1534/genetics.106.064634; Fisher R.A., 1930, GENETICAL THEORY NAT; Flores CO, 2011, P NATL ACAD SCI USA, V108, pE288, DOI 10.1073/pnas.1101595108; Friedman DI, 2001, CURR OPIN MICROBIOL, V4, P201, DOI 10.1016/S1369-5274(00)00189-2; Gallet R, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-181; Gavrilets S., 2010, EXTENDED EVOLUTIONAR; Gould S. J., 1989, WONDERFUL LIFE; Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09; Grayson P, 2007, P NATL ACAD SCI USA, V104, P14652, DOI 10.1073/pnas.0703274104; Gurnev PA, 2006, J MOL BIOL, V359, P1447, DOI 10.1016/j.jmb.2006.04.034; Hall AR, 2011, AM NAT, V177, P44, DOI 10.1086/657441; Hendrix R. W, 1983, LAMBDA, VII; HENDRIX RW, 1992, SCIENCE, V258, P1145, DOI 10.1126/science.1439823; Holmes EC, 2009, ANNU REV ECOL EVOL S, V40, P353, DOI 10.1146/annurev.ecolsys.110308.120248; Katsura I., 1981, LAMBDA; Kefala G, 2010, PROTEIN SCI, V19, P1117, DOI 10.1002/pro.369; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Maynard ND, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001017; Mayr E., 1963, ANIMAL SPECIES EVOLU; Pepin KM, 2010, NAT REV MICROBIOL, V8, P802, DOI 10.1038/nrmicro2440; Pigliucci M, 2008, PHILOS SCI, V75, P887, DOI 10.1086/594532; SARIS PEJ, 1987, FEMS MICROBIOL LETT, V44, P371, DOI 10.1111/j.1574-6968.1987.tb02316.x; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Schneider D, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-18; Thompson J.N., 2005, INTERSPEC INTERACT; Thompson JD., 1994, COEVOLUTIONARY PROCE; Torsvik V, 2002, SCIENCE, V296, P1064, DOI 10.1126/science.1071698; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; Wang J, 2000, J BACTERIOL, V182, P508, DOI 10.1128/JB.182.2.508-512.2000; Woods RJ, 2011, SCIENCE, V331, P1433, DOI 10.1126/science.1198914; Wright S, 1931, GENETICS, V16, P0097	47	269	279	4	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					428	432		10.1126/science.1214449	http://dx.doi.org/10.1126/science.1214449			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282803	Green Accepted			2022-12-28	WOS:000299466800039
J	Miller, AN; Long, SB				Miller, Alexandria N.; Long, Stephen B.			Crystal Structure of the Human Two-Pore Domain Potassium Channel K2P1	SCIENCE			English	Article							BACKGROUND K+ CHANNELS; SELECTIVITY FILTER; ION-BINDING; ALPHA-HELIX; FATTY-ACIDS; PORE; TREK-1; TWIK-1; LEAK; CONDUCTION	Two-pore domain potassium (K+) channels (K2P channels) control the negative resting potential of eukaryotic cells and regulate cell excitability by conducting K+ ions across the plasma membrane. Here, we present the 3.4 angstrom resolution crystal structure of a human K2P channel, K2P1 (TWIK-1). Unlike other K+ channel structures, K2P1 is dimeric. An extracellular cap domain located above the selectivity filter forms an ion pathway in which K+ ions flow through side portals. Openings within the transmembrane region expose the pore to the lipid bilayer and are filled with electron density attributable to alkyl chains. An interfacial helix appears structurally poised to affect gating. The structure lays a foundation to further investigate how K2P channels are regulated by diverse stimuli.	[Miller, Alexandria N.; Long, Stephen B.] Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10065 USA; [Miller, Alexandria N.] Mem Sloan Kettering Canc Ctr, Louis Gerstner Jr Grad Sch Biomed Sci, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Long, SB (corresponding author), Mem Sloan Kettering Canc Ctr, Struct Biol Program, 1275 York Ave, New York, NY 10065 USA.	longs@mskcc.org		Miller, Alexandria N./0000-0003-3986-7923; Long, Stephen/0000-0002-8144-1398	Burroughs Wellcome Career Award in the Biomedical Sciences; Gerstner Young Investigator Award	Burroughs Wellcome Career Award in the Biomedical Sciences(Burroughs Wellcome Fund); Gerstner Young Investigator Award	We thank the staff of beamlines X25 and X29 (National Synchrotron Light Source, Brookhaven National Laboratory) for assistance at the synchrotron; C. D. Lima, N. P. Pavletich, Z. Lu, and members of the Long laboratory for helpful discussions; and N. P. Pavletich, M. B. Long, and J. P. Greenfield for comments on the manuscript. This work was supported in part by a Burroughs Wellcome Career Award in the Biomedical Sciences and by a Gerstner Young Investigator Award to S. B. L. Coordinates and structure factors have been deposited in the Protein Data Bank (PDB ID 3UKM).	AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; Ashmole I, 2009, J PHYSIOL-LONDON, V587, P4769, DOI 10.1113/jphysiol.2009.175430; Ben-Abu Y, 2009, NAT STRUCT MOL BIOL, V16, P71, DOI 10.1038/nsmb.1525; Chemin J, 2005, EMBO J, V24, P44, DOI 10.1038/sj.emboj.7600494; Chemin J, 2005, J BIOL CHEM, V280, P4415, DOI 10.1074/jbc.M408246200; Clarke CE, 2008, J BIOL CHEM, V283, P16985, DOI 10.1074/jbc.M801368200; Dedman A, 2009, EUR BIOPHYS J BIOPHY, V38, P293, DOI 10.1007/s00249-008-0318-8; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Enyedi P, 2010, PHYSIOL REV, V90, P559, DOI 10.1152/physrev.00029.2009; Feliciangeli S, 2007, CELL, V130, P563, DOI 10.1016/j.cell.2007.06.012; Feliciangeli S, 2010, J BIOL CHEM, V285, P4798, DOI 10.1074/jbc.M109.078535; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HODGKIN AL, 1947, J PHYSIOL-LONDON, V106, P341, DOI 10.1113/jphysiol.1947.sp004216; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; Honore E, 2002, EMBO J, V21, P2968, DOI 10.1093/emboj/cdf288; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kim Y, 2001, PFLUG ARCH EUR J PHY, V442, P64, DOI 10.1007/s004240000496; Kjeldsen K, 2010, EXP CLIN CARDIOL, V15, pE96; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; LOCKHART DJ, 1993, SCIENCE, V260, P198, DOI 10.1126/science.8469972; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Ma LQ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001726; MacKinnon R, 2004, ANGEW CHEM INT EDIT, V43, P4265, DOI 10.1002/anie.200400662; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Payandeh J, 2011, NATURE, V475, P353, DOI 10.1038/nature10238; Piechotta PL, 2011, EMBO J, V30, P3607, DOI 10.1038/emboj.2011.268; Plant LD, 2010, P NATL ACAD SCI USA, V107, P10743, DOI 10.1073/pnas.1004712107; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; Sandoz G, 2011, P NATL ACAD SCI USA, V108, P2605, DOI 10.1073/pnas.1015788108; Tao X, 2009, SCIENCE, V326, P1668, DOI 10.1126/science.1180310; Ye S, 2010, NAT STRUCT MOL BIOL, V17, P1019, DOI 10.1038/nsmb.1865; Zhou M, 2009, J NEUROSCI, V29, P8551, DOI 10.1523/JNEUROSCI.5784-08.2009; Zhou Y, 2004, BIOCHEMISTRY-US, V43, P4978, DOI 10.1021/bi049876z; Zhou YF, 2003, J MOL BIOL, V333, P965, DOI 10.1016/j.jmb.2003.09.022; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	45	213	219	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					432	436		10.1126/science.1213274	http://dx.doi.org/10.1126/science.1213274			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282804				2022-12-28	WOS:000299466800040
J	Paul, DR				Paul, Donald R.			Creating New Types of Carbon-Based Membranes	SCIENCE			English	Editorial Material							TRANSPORT; NANOTUBES		Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Paul, DR (corresponding author), Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA.	drp@che.utexas.edu						Baker R. W., 2004, MEMBRANE TECHNOLOGY, DOI DOI 10.1002/0470020393; Bird R. B., 2002, INTERPHASE TRANSPORT; Ismail AF, 2011, CARBON-BASED MEMBRANES FOR SEPARATION PROCESSES, P1, DOI 10.1007/978-0-387-78991-0; Karan S, 2012, SCIENCE, V335, P444, DOI 10.1126/science.1212101; Lerf A, 2006, J PHYS CHEM SOLIDS, V67, P1106, DOI 10.1016/j.jpcs.2006.01.031; Nair RR, 2012, SCIENCE, V335, P442, DOI 10.1126/science.1211694; NORTON FJ, 1953, J AM CERAM SOC, V36, P90, DOI 10.1111/j.1151-2916.1953.tb12843.x; OKADA T, 1991, J MEMBRANE SCI, V59, P133, DOI 10.1016/S0376-7388(00)81179-5; Qin XC, 2011, NANO LETT, V11, P2173, DOI 10.1021/nl200843g; Robertson J, 2002, MAT SCI ENG R, V37, P129, DOI 10.1016/S0927-796X(02)00005-0; SRINIVASAN R, 1994, J MEMBRANE SCI, V86, P67, DOI 10.1016/0376-7388(93)E0128-7; Striemer CC, 2007, NATURE, V445, P749, DOI 10.1038/nature05532; Thomas JA, 2008, NANO LETT, V8, P2788, DOI 10.1021/nl8013617; Yampolskii Y.P., 2006, MAT SCI MEMBRANES GA	14	108	131	2	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					413	414		10.1126/science.1216923	http://dx.doi.org/10.1126/science.1216923			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282798				2022-12-28	WOS:000299466800033
J	Poulsen, H; Nissen, P				Poulsen, Hanne; Nissen, Poul			The Inner Workings of a Dynamic Duo	SCIENCE			English	Editorial Material							CRYSTAL-STRUCTURE; POTASSIUM CHANNEL; SELECTIVITY; TWIK-1		[Poulsen, Hanne] Aarhus Univ, Ctr Membrane Pumps Cells & Dis Pumpkin, Danish Natl Res Fdn, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Mol Biol & Genet, DK-8000 Aarhus C, Denmark	Aarhus University; Danmarks Grundforskningsfond; Aarhus University	Poulsen, H (corresponding author), Aarhus Univ, Ctr Membrane Pumps Cells & Dis Pumpkin, Danish Natl Res Fdn, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	hp@mb.au.dk; pn@mb.au.dk	Nissen, Poul/D-5774-2014	Nissen, Poul/0000-0003-0948-6628				Bagriantsev SN, 2011, EMBO J, V30, P3594, DOI 10.1038/emboj.2011.230; Brohawn SG, 2012, SCIENCE, V335, P436, DOI 10.1126/science.1213808; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Franks NP, 2004, TRENDS PHARMACOL SCI, V25, P601, DOI 10.1016/j.tips.2004.09.003; HODGKIN AL, 1947, J PHYSIOL-LONDON, V106, P341, DOI 10.1113/jphysiol.1947.sp004216; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Ma LQ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001726; Miller AN, 2012, SCIENCE, V335, P432, DOI 10.1126/science.1213274; Payandeh J, 2011, NATURE, V475, P353, DOI 10.1038/nature10238; Piechotta PL, 2011, EMBO J, V30, P3607, DOI 10.1038/emboj.2011.268	10	5	5	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					416	417		10.1126/science.1217679	http://dx.doi.org/10.1126/science.1217679			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282800				2022-12-28	WOS:000299466800035
J	Schwartz, LM; Woloshin, S; Andrews, A; Stukel, TA				Schwartz, Lisa M.; Woloshin, Steven; Andrews, Alice; Stukel, Therese A.			Influence of medical journal press releases on the quality of associated newspaper coverage: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEWS MEDIA; SCIENTIFIC MEETINGS; INFORMATION; ABSTRACTS; ARTICLES	Objective To determine whether the quality of press releases issued by medical journals can influence the quality of associated newspaper stories. Design Retrospective cohort study of medical journal press releases and associated news stories. Setting We reviewed consecutive issues (going backwards from January 2009) of five major medical journals (Annals of Internal Medicine, BMJ, Journal of the National Cancer Institute, JAMA, and New England Journal of Medicine) to identify the first 100 original research articles with quantifiable outcomes and that had generated any newspaper coverage (unique stories >= 100 words long). We identified 759 associated newspaper stories using Lexis Nexis and Factiva searches, and 68 journal press releases using Eurekalert and journal website searches. Two independent research assistants assessed the quality of journal articles, press releases, and a stratified random sample of associated newspaper stories (n=343) by using a structured coding scheme for the presence of specific quality measures: basic study facts, quantification of the main result, harms, and limitations. Main outcome Proportion of newspaper stories with specific quality measures (adjusted for whether the quality measure was present in the journal article's abstract or editor note). Results We recorded a median of three newspaper stories per journal article (range 1-72). Of 343 stories analysed, 71% reported on articles for which medical journals had issued press releases. 9% of stories quantified the main result with absolute risks when this information was not in the press release, 53% did so when it was in the press release (relative risk 6.0, 95% confidence interval 2.3 to 15.4), and 20% when no press release was issued (2.2, 0.83 to 6.1). 133 (39%) stories reported on research describing beneficial interventions. 24% mentioned harms (or specifically declared no harms) when harms were not mentioned in the press release, 68% when mentioned in the press release (2.8, 1.1 to 7.4), and 36% when no press release was issued (1.5, 0.49 to 4.4). 256 (75%) stories reported on research with important limitations. 16% reported any limitations when limitations were not mentioned in the press release, 48% when mentioned in the press release (3.0, 1.5 to 6.2), and 21% if no press release was issued (1.3, 0.50 to 3.6). Conclusion High quality press releases issued by medical journals seem to make the quality of associated newspaper stories better, whereas low quality press releases might make them worse.	[Schwartz, Lisa M.; Woloshin, Steven] Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA; [Schwartz, Lisa M.; Woloshin, Steven; Andrews, Alice] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med & Media, Lebanon, NH USA; [Stukel, Therese A.] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Populat Hlth, Lebanon, NH USA; [Stukel, Therese A.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Stukel, Therese A.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada	VA Outcomes Group; Dartmouth College; Dartmouth College; University of Toronto; University of Toronto	Woloshin, S (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA.	steven.woloshin@dartmouth.edu		Stukel, Therese/0000-0002-2951-1360; Andrews, Alice/0000-0001-9972-1585	National Cancer Institute	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by a grant from the National Cancer Institute. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	Bartlett C, 2002, BRIT MED J, V325, P81, DOI 10.1136/bmj.325.7355.81; Bernal-Delgado E, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-14; Berwanger O, 2009, J CLIN EPIDEMIOL, V62, P387, DOI 10.1016/j.jclinepi.2008.05.013; BurrellesLuce, 2008, 2008 TOP NEWSP BLOGS; de Semir V, 1998, JAMA-J AM MED ASSOC, V280, P294, DOI 10.1001/jama.280.3.294; ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; Grilli R, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000389, DOI 10.1002/14651858.CD000389]; Hochman M, 2008, JAMA-J AM MED ASSOC, V300, P1544, DOI 10.1001/jama.300.13.1544; Kuriya B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002828; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; Pew Research Center for the People and the Press, 2011, INT GAINS TEL PUBL M; Schwartz LM, 2006, BMJ-BRIT MED J, V333, P1248, DOI 10.1136/bmj.38985.564317.7C; Schwartz LM, 2002, JAMA-J AM MED ASSOC, V287, P3136, DOI 10.1001/jama.287.23.3136; Schwartz LM, 2002, JAMA-J AM MED ASSOC, V287, P2859, DOI 10.1001/jama.287.21.2859; Schwitzer G, 2008, PLOS MED, V5, P700, DOI 10.1371/journal.pmed.0050095; Smith DE, 2005, MED J AUSTRALIA, V183, P190, DOI 10.5694/j.1326-5377.2005.tb06992.x; Stryker JE, 2002, PREV MED, V35, P519, DOI 10.1006/pmed.2002.1102; The Cochrane Collaboration, 2011, PREP SUMM FIND TABL; VANTRIGT AM, 1994, SOC SCI MED, V38, P637, DOI 10.1016/0277-9536(94)90261-5; WALTER SD, 1985, STAT MED, V4, P437, DOI 10.1002/sim.4780040405; Woloshin S, 2002, JAMA-J AM MED ASSOC, V287, P2856, DOI 10.1001/jama.287.21.2856; Woloshin S, 2006, MED J AUSTRALIA, V184, P576, DOI 10.5694/j.1326-5377.2006.tb00384.x; Woloshin S, 2009, ANN INTERN MED, V150, P613, DOI 10.7326/0003-4819-150-9-200905050-00007	24	81	81	0	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2012	344								d8164	10.1136/bmj.d8164	http://dx.doi.org/10.1136/bmj.d8164			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885LJ	22286507	Green Published, hybrid			2022-12-28	WOS:000299780200001
J	Ding, L; Saunders, TL; Enikolopov, G; Morrison, SJ				Ding, Lei; Saunders, Thomas L.; Enikolopov, Grigori; Morrison, Sean J.			Endothelial and perivascular cells maintain haematopoietic stem cells	NATURE			English	Article							PROGENITOR CELLS; SELF-RENEWAL; EXPRESSION; GENE; MICE; MAINTENANCE; DELETION; NICHES; TRANSPLANTATION; OSTEOBLASTS	Several cell types have been proposed to create niches for haematopoietic stem cells (HSCs). However, the expression patterns of HSC maintenance factors have not been systematically studied and no such factor has been conditionally deleted from any candidate niche cell. Thus, the cellular sources of these factors are undetermined. Stem cell factor (SCF; also known as KITL) is a key niche component that maintains HSCs. Here, using Scf(gfp) knock-in mice, we found that Scf was primarily expressed by perivascular cells throughout the bone marrow. HSC frequency and function were not affected when Scf was conditionally deleted from haematopoietic cells, osteoblasts, nestin-cre- or nestin-creER-expressing cells. However, HSCs were depleted from bone marrow when Scf was deleted from endothelial cells or leptin receptor (Lepr)-expressing perivascular stromal cells. Most HSCs were lost when Scf was deleted from both endothelial and Lepr-expressing perivascular cells. Thus, HSCs reside in a perivascular niche in which multiple cell types express factors that promote HSC maintenance.	[Ding, Lei; Morrison, Sean J.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Childrens Res Inst, Dept Pediat, Dallas, TX 75390 USA; [Saunders, Thomas L.] Univ Michigan, Ann Arbor, MI 48109 USA; [Enikolopov, Grigori] Cold Spring Harbor Lab, New York, NY 11724 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Michigan System; University of Michigan; Cold Spring Harbor Laboratory	Morrison, SJ (corresponding author), Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Childrens Res Inst, Dept Pediat, Dallas, TX 75390 USA.	Sean.Morrison@UTSouthwestern.edu	Morrison, Sean/ABD-5326-2021; Enikolopov, Grigori/P-5731-2019	Enikolopov, Grigori/0000-0001-8178-8917; Saunders, Thom/0000-0003-2015-101X; Morrison, Sean/0000-0003-1587-8329	Howard Hughes Medical Institute (HHMI); National Heart, Lung and Blood Institute [5R01HL097760]; Helen Hay Whitney Foundation; National Institute of Aging [R01AG040209]; NYSTEM; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG040209] Funding Source: NIH RePORTER	Howard Hughes Medical Institute (HHMI)(Howard Hughes Medical Institute); National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Helen Hay Whitney Foundation; National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NYSTEM; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the Howard Hughes Medical Institute (HHMI) and the National Heart, Lung and Blood Institute (5R01HL097760). L. D. was supported by a Helen Hay Whitney Foundation Fellowship and by the HHMI. G. E. was supported by the National Institute of Aging (R01AG040209) and NYSTEM. We thank M. White and D. Adams for flow cytometry, E. Hughes at the UM transgenic core for helping to generate Scf<SUP>gfp</SUP> and Scf<SUP>fl</SUP> mice, M. Purkey for technical assistance, J. Peyer and M. Lim for discussion, and C. Mountford, S. Grove and R. Coolon for managing the mouse colony. This work was initiated in the Life Sciences Institute at the University of Michigan then completed at Children's Research Institute at UT Southwestern.	Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Balordi F, 2007, J NEUROSCI, V27, P5936, DOI 10.1523/JNEUROSCI.1040-07.2007; Barker JE, 1997, EXP HEMATOL, V25, P542; BARKER JE, 1994, EXP HEMATOL, V22, P174; Blair HC, 1999, BIOCHEM BIOPH RES CO, V255, P778, DOI 10.1006/bbrc.1999.0260; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Butler JM, 2010, CELL STEM CELL, V6, P251, DOI 10.1016/j.stem.2010.02.001; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726; de Boer J, 2003, EUR J IMMUNOL, V33, P314, DOI 10.1002/immu.200310005; DeFalco J, 2001, SCIENCE, V291, P2608, DOI 10.1126/science.1056602; HEINRICH MC, 1993, BLOOD, V82, P771, DOI 10.1182/blood.V82.3.771.bloodjournal823771; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kiel MJ, 2008, NAT REV IMMUNOL, V8, P290, DOI 10.1038/nri2279; Kiel MJ, 2007, CELL STEM CELL, V1, P204, DOI 10.1016/j.stem.2007.06.001; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kim I, 2006, BLOOD, V108, P737, DOI 10.1182/blood-2005-10-4135; Kimura Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026918; Kobayashi H, 2010, NAT CELL BIOL, V12, P1046, DOI 10.1038/ncb2108; Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; WOLF NS, 1978, CELL TISSUE KINET, V11, P335, DOI 10.1111/j.1365-2184.1978.tb00806.x; Yamazaki S, 2011, CELL, V147, P1146, DOI 10.1016/j.cell.2011.09.053; Yoshihara H, 2007, CELL STEM CELL, V1, P685, DOI 10.1016/j.stem.2007.10.020	43	1225	1265	8	148	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2012	481	7382					457	U65		10.1038/nature10783	http://dx.doi.org/10.1038/nature10783			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881GY	22281595	Green Accepted			2022-12-28	WOS:000299471800030
J	Tuveson, DA; Neoptolemos, JP				Tuveson, David A.; Neoptolemos, John P.			Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches	CELL			English	Editorial Material							CELLS	Although metastasis is a major cause of morbidity and mortality in patients with pancreatic cancer, the requisite events are currently unknown. In this issue of Cell, Haeno et al. and Rhim et al. propose that metastasis occurs much earlier than previously anticipated, with clear implications for improving patient care.	[Tuveson, David A.] Canc Res UK Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England; [Tuveson, David A.] Cambridge Pancreat Canc Ctr, Cambridge CB2 0RE, England; [Tuveson, David A.] Lustgarten Fdn Pancreat Canc Lab Cold Spring Harb, Cold Spring Harbor, NY 11724 USA; [Neoptolemos, John P.] Natl Inst Hlth Res, Pancreas Biomed Res Unit, Liverpool L69 3GA, Merseyside, England; [Neoptolemos, John P.] Natl Inst Hlth Res, Liverpool Canc Ctr, Liverpool L69 3GA, Merseyside, England	Cancer Research UK; CRUK Cambridge Institute; University of Liverpool; University of Liverpool	Tuveson, DA (corresponding author), Canc Res UK Cambridge Res Inst, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England.	david.tuveson@cancer.org.uk; j.p.neoptolemos@liverpool.ac.uk	Neoptolemos, John/HGU-7742-2022	Neoptolemos, John/0000-0002-6201-7399	National Institute for Health Research [NF-SI-0510-10126] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mazur PK, 2012, GUT, V61, P1488, DOI 10.1136/gutjnl-2011-300756; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Qiu WL, 2011, ONCOTARGET, V2, P862; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Xu ZH, 2010, AM J PATHOL, V177, P2585, DOI 10.2353/ajpath.2010.090899; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	10	145	159	2	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					21	23		10.1016/j.cell.2011.12.021	http://dx.doi.org/10.1016/j.cell.2011.12.021			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265397	Bronze			2022-12-28	WOS:000299540700009
J	Tompkins, RG				Tompkins, Ronald G.			Survival of children with burn injuries	LANCET			English	Editorial Material							ASSOCIATION/SHRINERS-HOSPITALS; QUESTIONNAIRE		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Tompkins, RG (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.	rtompkins@partners.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700, U54GM062119] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM021700, U54 GM062119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULL JP, 1949, ANN SURG, V130, P160, DOI 10.1097/00000658-194908000-00002; Daltroy LH, 2000, J BURN CARE REHABIL, V21, P29, DOI 10.1097/00004630-200021010-00007; Herndon DN, 2004, LANCET, V363, P1895, DOI 10.1016/S0140-6736(04)16360-5; Kazis LE, 2002, J BURN CARE REHABIL, V23, P196, DOI 10.1097/00004630-200205000-00009; Kraft R, 2012, LANCET, V379, P1013, DOI 10.1016/S0140-6736(11)61345-7; Mathis D, 2011, NAT REV IMMUNOL, V11, P81, DOI 10.1038/nri2922; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; Sheridan RL, 2000, JAMA-J AM MED ASSOC, V283, P69, DOI 10.1001/jama.283.1.69; Sheridan Robert L., 2001, Pediatr Crit Care Med, V2, P223, DOI 10.1097/00130478-200107000-00006; Silver GM, 2007, J BURN CARE RES, V28, P222, DOI 10.1097/BCR.0B013E318031AA44; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354	11	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2012	379	9820					983	984		10.1016/S0140-6736(11)61626-7	http://dx.doi.org/10.1016/S0140-6736(11)61626-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22296811	Green Accepted			2022-12-28	WOS:000301712300010
J	Winikoff, B; Sheldon, WR				Winikoff, Beverly; Sheldon, Wendy R.			Abortion: what is the problem?	LANCET			English	Editorial Material									[Winikoff, Beverly; Sheldon, Wendy R.] Gynu Hlth Projects, New York, NY 10010 USA		Winikoff, B (corresponding author), Gynu Hlth Projects, New York, NY 10010 USA.	bwinikoff@gynuity.org						Ahman E, 2010, METHODOLOGIES ESTIMA, P13; Gomperts RJ, 2008, BJOG-INT J OBSTET GY, V115, P1171, DOI 10.1111/j.1471-0528.2008.01787.x; Raymond EG, OBSTET GYNE IN PRESS; Sedgh G, 2010, METHODOLOGIES ESTIMA, P23; Sedgh G, 2012, LANCET, V379, P625, DOI 10.1016/S0140-6736(11)61786-8; *UN, 1995, POP DEV PROGR ACT AD; World Health Organization, 1992, WHOMSM925; World Health Organization, 2013, UNS AB GLOB REG EST	8	9	9	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 18	2012	379	9816					594	596		10.1016/S0140-6736(12)60038-5	http://dx.doi.org/10.1016/S0140-6736(12)60038-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	897ES	22264434				2022-12-28	WOS:000300629000007
J	Meyer, R				Meyer, Ryan			Finding the true value of US climate science	NATURE			English	Editorial Material									Calif Ocean Sci Trust, Oakland, CA USA		Meyer, R (corresponding author), Calif Ocean Sci Trust, Oakland, CA USA.	ryan.meyer@calost.org		Meyer, Ryan/0000-0001-9696-7651					0	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2012	482	7384					133	133		10.1038/482133a	http://dx.doi.org/10.1038/482133a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	888HI	22318567	Bronze			2022-12-28	WOS:000299994100004
J	Rhee, EP; Scott, JA; Dighe, AS				Rhee, Eugene P.; Scott, James A.; Dighe, Anand S.			Case 4-2012: A 37-Year-Old Man with Muscle Pain, Weakness, and Weight Loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THYROTOXIC PERIODIC PARALYSIS; THYROID-HORMONE TREATMENT; HYPOKALEMIA; POTASSIUM; HYPERTHYROIDISM; DISORDERS; MUTATIONS		[Rhee, Eugene P.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA; [Scott, James A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Dighe, Anand S.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Rhee, Eugene P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Scott, James A.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Dighe, Anand S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Rhee, EP (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.		Dighe, Anand/AAP-9640-2020	Dighe, Anand/0000-0003-4130-0758				Ahlawat SK, 1999, POSTGRAD MED J, V75, P193, DOI 10.1136/pgmj.75.882.193; Araya P, 1996, MUSCLE NERVE, V19, P677; Baskerville JR, 2001, EMERG MED J, V18, P514, DOI 10.1136/emj.18.6.514; BERNING J, 1975, LANCET, V1, P110; Bulman DE, 1999, NEUROLOGY, V53, P1932, DOI 10.1212/WNL.53.9.1932; CHOPRA IJ, 1975, MED CLIN N AM, V59, P1109, DOI 10.1016/S0025-7125(16)31961-7; DESAIYAJNIK V, 1995, ENDOCRINOLOGY, V136, P629, DOI 10.1210/en.136.2.629; Eberlein M, 2007, CHEST, V131, P1248, DOI 10.1378/chest.06-1066; FARESE RV, 1991, NEW ENGL J MED, V325, P1223, DOI 10.1056/NEJM199110243251706; FATOURECHI V, 1971, MAYO CLIN PROC, V46, P682; Gennari FJ, 1998, NEW ENGL J MED, V339, P451, DOI 10.1056/NEJM199808133390707; Gordon D L, 1998, Endocr Pract, V4, P142; KAMEL KS, 1994, AM J KIDNEY DIS, V24, P597, DOI 10.1016/S0272-6386(12)80220-4; KONE BC, 2002, ACID BASE ELECT DISO, P381; Kung AWC, 2006, J CLIN ENDOCR METAB, V91, P2490, DOI 10.1210/jc.2006-0356; LIN MH, 1978, J BIOL CHEM, V253, P723; Lin SH, 2005, MAYO CLIN PROC, V80, P99, DOI 10.1016/S0025-6196(11)62965-0; Lin SH, 2004, ARCH INTERN MED, V164, P1561, DOI 10.1001/archinte.164.14.1561; Lin SH, 2001, QJM-MON J ASSOC PHYS, V94, P133, DOI 10.1093/qjmed/94.3.133; Lin SH, 2007, CURR MED CHEM, V14, P1551, DOI 10.2174/092986707780831050; Liu Zhao, 2006, Endocr Pract, V12, P427; Lu KC, 2004, AM J EMERG MED, V22, P544, DOI 10.1016/j.ajem.2004.09.016; MCCLEAVE DJ, 1978, AUST NZ J MED, V8, P180, DOI 10.1111/j.1445-5994.1978.tb04508.x; Orgiazzi J, 2000, ENDOCRIN METAB CLIN, V29, P339, DOI 10.1016/S0889-8529(05)70135-3; PTACEK LJ, 1994, CELL, V77, P863; Ryan DP, 2010, CELL, V140, P88, DOI 10.1016/j.cell.2009.12.024; SAEIAN K, 1988, ARCH INTERN MED, V148, P708, DOI 10.1001/archinte.148.3.708; SCHWARTZ WB, 1967, NEW ENGL J MED, V276, P383, DOI 10.1056/NEJM196702162760705; Tempark T, 2010, ENDOCRINE, V38, P328, DOI 10.1007/s12020-010-9393-6; Weiner ID, 1997, J AM SOC NEPHROL, V8, P1179; Young WF, 2007, NEW ENGL J MED, V356, P601, DOI 10.1056/NEJMcp065470; Zumo LA, 2002, J NATL MED ASSOC, V94, P383	32	20	26	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					553	560		10.1056/NEJMcpc1110051	http://dx.doi.org/10.1056/NEJMcpc1110051			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GH	22316449				2022-12-28	WOS:000299991300012
J	Suthana, N; Haneef, Z; Stern, J; Mukamel, R; Behnke, E; Knowlton, B; Fried, I				Suthana, Nanthia; Haneef, Zulfi; Stern, John; Mukamel, Roy; Behnke, Eric; Knowlton, Barbara; Fried, Itzhak			Memory Enhancement and Deep-Brain Stimulation of the Entorhinal Area	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ELECTRICAL-STIMULATION; HIPPOCAMPAL-THETA; GLOBUS-PALLIDUS; RECALL; NEUROGENESIS; RESET	BACKGROUND The medial temporal structures, including the hippocampus and the entorhinal cortex, are critical for the ability to transform daily experience into lasting memories. We tested the hypothesis that deep-brain stimulation of the hippocampus or entorhinal cortex alters memory performance. METHODS We implanted intracranial depth electrodes in seven subjects to identify seizure-onset zones for subsequent epilepsy surgery. The subjects completed a spatial learning task during which they learned destinations within virtual environments. During half the learning trials, focal electrical stimulation was given below the threshold that elicits an afterdischarge (i.e., a neuronal discharge that occurs after termination of the stimulus). RESULTS Entorhinal stimulation applied while the subjects learned locations of landmarks enhanced their subsequent memory of these locations: the subjects reached these landmarks more quickly and by shorter routes, as compared with locations learned without stimulation. Entorhinal stimulation also resulted in a resetting of the phase of the theta rhythm, as shown on the hippocampal electroencephalogram. Direct hippocampal stimulation was not effective. In this small series, no adverse events associated with the procedure were observed. CONCLUSIONS Stimulation of the entorhinal region enhanced memory of spatial information when applied during learning. (Funded by the National Institutes of Health and the Dana Foundation.)	[Suthana, Nanthia; Mukamel, Roy; Behnke, Eric; Fried, Itzhak] Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Suthana, Nanthia; Mukamel, Roy; Behnke, Eric; Fried, Itzhak] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA; [Haneef, Zulfi; Stern, John] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA; [Knowlton, Barbara] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Fried, Itzhak] Tel Aviv Univ, Funct Neurosurg Unit, Tel Aviv Med Ctr, IL-69978 Tel Aviv, Israel; [Fried, Itzhak] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Fried, I (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, 740 Westwood Plaza, Los Angeles, CA 90095 USA.	ifried@mednet.ucla.edu	Mukamel, Roy/AAV-2900-2021	Mukamel, Roy/0000-0001-9359-8950; Stern, John/0000-0002-3549-1642; Suthana, Nanthia/0000-0002-8796-3277	National Institutes of Health [5T32NS07449]; National Institute of Neurological Disorders and Stroke [NS033221]; Dana Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033221, T32NS007449] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Dana Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by grants from the National Institutes of Health (5T32NS07449), the National Institute of Neurological Disorders and Stroke (NS033221), and the Dana Foundation.	AGNEW WF, 1990, EPILEPSIA, V31, pS27, DOI 10.1111/j.1528-1157.1990.tb05845.x; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Boon P, 2007, EPILEPSIA, V48, P1551, DOI 10.1111/j.1528-1167.2007.01005.x; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Coleshill SG, 2004, J NEUROSCI, V24, P1612, DOI 10.1523/JNEUROSCI.4352-03.2004; Davis KD, 1997, NAT MED, V3, P671, DOI 10.1038/nm0697-671; Delis DC, 2000, CALIFORNIA VERBAL LE, DOI DOI 10.1016/j.schres.2003.09.011; Ehret A, 2001, J NEUROCHEM, V76, P555, DOI 10.1046/j.1471-4159.2001.00030.x; Ekstrom AD, 2003, NATURE, V425, P184, DOI 10.1038/nature01964; Ekstrom AD, 2006, HIPPOCAMPUS, V16, P101; Engel JJ, 1993, SURG TREATMENT EPILE, P743; Fernandez G, 1999, HIPPOCAMPUS, V9, P35, DOI 10.1002/(SICI)1098-1063(1999)9:1<35::AID-HIPO4>3.0.CO;2-Z; Fried I, 1999, J NEUROSURG, V91, P697, DOI 10.3171/jns.1999.91.4.0697; Fried I, 1993, STEREOTACTIC SURG RA, P149; FRISK V, 1990, NEUROPSYCHOLOGIA, V28, P121, DOI 10.1016/0028-3932(90)90095-6; GORDON B, 1990, ELECTROEN CLIN NEURO, V75, P371, DOI 10.1016/0013-4694(90)90082-U; HALGREN E, 1985, BRAIN COGNITION, V4, P287, DOI 10.1016/0278-2626(85)90022-3; HALGREN E, 1985, ELECTROEN CLIN NEURO, V61, P375, DOI 10.1016/0013-4694(85)91028-4; Hamani C, 2008, ANN NEUROL, V63, P119, DOI 10.1002/ana.21295; Hartley T, 2003, NEURON, V37, P877, DOI 10.1016/S0896-6273(03)00095-3; Hua M., 2005, WECHSLER MEMORY SCAL, V3; Jobst B, 2010, EPILEPSY RES, V89, P154, DOI 10.1016/j.eplepsyres.2009.08.017; Lacruz ME, 2010, NEUROSCIENCE, V170, P623, DOI 10.1016/j.neuroscience.2010.06.042; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Lezak M.D., 1995, NEUROPSYCHOLOGICAL A; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; McCartney H, 2004, HIPPOCAMPUS, V14, P684, DOI 10.1002/hipo.20019; Meyers J. E., 1995, REY COMPLEX FIGURE T; SMITH ML, 1989, NEUROPSYCHOLOGIA, V27, P71, DOI 10.1016/0028-3932(89)90091-2; Soriano-Mas C, 2005, BEHAV BRAIN RES, V160, P141, DOI 10.1016/j.bbr.2004.11.025; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Stone SSD, 2011, J NEUROSCI, V31, P13469, DOI 10.1523/JNEUROSCI.3100-11.2011; Suthana NA, 2009, J NEUROSCI, V29, P10512, DOI 10.1523/JNEUROSCI.0621-09.2009; Toda H, 2008, J NEUROSURG, V108, P132, DOI 10.3171/JNS/2008/108/01/0132; Vertes RP, 2005, HIPPOCAMPUS, V15, P923, DOI 10.1002/hipo.20118; Vidailhet M, 2005, NEW ENGL J MED, V352, P459, DOI 10.1056/NEJMoa042187; Vinogradova O S, 1996, Neurosci Behav Physiol, V26, P113, DOI 10.1007/BF02359414; Wechsler D, 1997, WECHSLER ADULT INTEL, VIII; Williams JM, 2003, HIPPOCAMPUS, V13, P109, DOI 10.1002/hipo.10082	40	286	300	4	70	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					502	510		10.1056/NEJMoa1107212	http://dx.doi.org/10.1056/NEJMoa1107212			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GH	22316444	Green Accepted			2022-12-28	WOS:000299991300006
J	Woolf, SH; Harris, R				Woolf, Steven H.; Harris, Russell			The Harms of Screening New Attention to an Old Concern	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Woolf, Steven H.] Virginia Commonwealth Univ, Dept Family Med, Richmond, VA 23298 USA; [Harris, Russell] Univ N Carolina, Sch Med, Chapel Hill, NC USA; [Harris, Russell] Univ N Carolina, Sch Publ Hlth, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA	Virginia Commonwealth University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Woolf, SH (corresponding author), Virginia Commonwealth Univ, West Hosp, Dept Family Med, 1200 E Broad St,POB 980251, Richmond, VA 23298 USA.	swoolf@vcu.edu						[Anonymous], 2009, Obstet Gynecol, V114, P1409, DOI 10.1097/AOG.0b013e3181c6f8a4; Bach PB, 2011, NEW ENGL J MED, V365, P2036, DOI 10.1056/NEJMc1110293; Brawley O, 2011, JAMA-J AM MED ASSOC, V306, P2495, DOI 10.1001/jama.2011.1800; Brawley OW., PROSTATE CANC SCREEN; Brownlee S., 2007, OVERTREATED WHY TOO; Jain M., 2011, WASHINGTON POST 1101, pE5; Schwartz LM, 2004, JAMA-J AM MED ASSOC, V291, P71, DOI 10.1001/jama.291.1.71	7	64	64	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					565	566		10.1001/jama.2012.100	http://dx.doi.org/10.1001/jama.2012.100			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318274				2022-12-28	WOS:000299992500017
J	Diekema, DS				Diekema, Douglas S.			Improving Childhood Vaccination Rates	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMMUNIZATION; CHILDREN		[Diekema, Douglas S.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Diekema, Douglas S.] Seattle Childrens Res Inst, Treuman Katz Ctr Pediat Bioeth, Seattle, WA USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital	Diekema, DS (corresponding author), Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA.			Diekema, Douglas/0000-0002-1703-5176				[Anonymous], 2011, MMWR MORB MORTAL WKL, V60, P700; [Anonymous], 2011, MMWR-MORBID MORTAL W, V60, P700; Diekema DS, 2005, PEDIATRICS, V115, P1428, DOI 10.1542/peds.2005-0316; Opel DJ, 2009, ARCH PEDIAT ADOL MED, V163, P432, DOI 10.1001/archpediatrics.2009.42; Washington State Department of Health, 2011, SCH CHILDC ASS DAT I	5	86	86	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					391	393		10.1056/NEJMp1113008	http://dx.doi.org/10.1056/NEJMp1113008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	884QX	22296072				2022-12-28	WOS:000299724400002
J	Fee, C; Burstin, H; Maselli, JH; Hsia, RY				Fee, Christopher; Burstin, Helen; Maselli, Judith H.; Hsia, Renee Y.			Association of Emergency Department Length of Stay With Safety-Net Status	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVING QUALITY; TIME; ANTIBIOTICS; ANALGESIA; VISITS; REFORM; IMPACT; PAIN	Context Performance measures, particularly pay for performance, may have unintended consequences for safety-net institutions caring for disproportionate shares of Medicaid or uninsured patients. Objective To describe emergency department (ED) compliance with proposed length-of-stay measures for admissions (8 hours or 480 minutes) and discharges, transfers, and observations (4 hours or 240 minutes) by safety-net status. Design, Setting, and Participants The 2008 National Hospital Ambulatory Medical Care Survey (NHAMCS) ED data were stratified by safety-net status (Centers for Disease Control and Prevention definition) and disposition (admission, discharge, observation, transfer). The 2008 NHAMCS is a national probability sample of 396 hospitals (90.2% unweighted response rate) and 34 134 patient records. Visits were excluded for patients younger than 18 years, missing length-of-stay data or dispositions of missing, other, left against medical advice, or dead on arrival. Median and 90th percentile ED lengths of stay were calculated for each disposition and admission/discharge sub-categories (critical care, psychiatric, routine) stratified by safety-net status. Multivariable analyses determined associations with length-of-stay measure compliance. Main Outcome Measures Emergency Department length-of-stay measure compliance by disposition and safety-net status. Results Of the 72.1% ED visits (N=24 719) included in the analysis, 42.3% were to safety-net EDs and 57.7% were to non-safety-net EDs. The median length of stay for safety-net was 269 minutes (interquartile range [IQR], 178-397 minutes) for admission vs 281 minutes (IQR, 178-401 minutes) for non-safety-net EDs; 156 minutes (IQR, 95-239 minutes) for discharge vs 148 minutes (IQR, 88-238 minutes); 355 minutes (IQR, 221-675 minutes) for observations vs 298 minutes (IQR, 195-440 minutes); and 235 minutes (IQR, 155-378 minutes) for transfers vs 239 minutes (IQR, 142-368 minutes). Safety-net status was not independently associated with compliance with ED length-of-stay measures; the odds ratio was 0.83 for admissions (95% CI, 0.52-1.34); 1.03 for discharges (95% CI, 0.83-1.27); 1.05 for observations (95% CI, 0.57-1.95), 1.30 for transfers (95% CI, 0.70-2.45]); or subcategories except for psychiatric discharges (1.67, [95% CI, 1.02-2.74]). Conclusion Compliance with proposed ED length-of-stay measures for admissions, discharges, transfers, and observations did not differ significantly between safety-net and non-safety-net hospitals. JAMA. 2012;307(5):476-482	[Fee, Christopher; Hsia, Renee Y.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA; [Maselli, Judith H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Burstin, Helen] Natl Qual Forum, Washington, DC USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Fee, C (corresponding author), Univ Calif San Francisco, Dept Emergency Med, 505 Parnassus Ave,POB 0208, San Francisco, CA 94143 USA.	christopher.fee@ucsf.edu			Google; NIH/NCRR/OD UCSF-CTSI [KL2 RR024130]; Robert Wood Johnson Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024130] Funding Source: NIH RePORTER	Google(Google Incorporated); NIH/NCRR/OD UCSF-CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The authors have completed and submitted the ICMJE form for Disclosure of Potential Conflicts of Interest. Dr Fee has reported that he received consultancy fees from Google and honoraria from the University of California, San Francisco Office of Continuing Medical Education for organizing and speaking at an annual CME course. Dr Burstin is a paid employee of the National Quality Forum. No other disclosures were reported.; This work was supported by grant KL2 RR024130 (Dr Hsia) from the NIH/NCRR/OD UCSF-CTSI and by the Robert Wood Johnson Foundation Physician Faculty Scholars Program (Dr Hsia).	Accreditation Council for Graduate Medical Education, EM MED GUID; [Anonymous], 2010, NAT HLTH HOSP NETW F; [Anonymous], 2009, NAT VOL CONS STAND E; Burt Catharine W, 2004, Vital Health Stat 13, P1; Carr BG, 2007, J TRAUMA, V63, P9, DOI 10.1097/TA.0b013e31805d8f6b; Centers for Disease Control and Prevention, NHAMCS EST PROC AMB; Centers for Disease Control and Prevention, 2010, NHAMCS SCOP SAMPL DE; Chang G, 2011, ANN EMERG MED, V58, P127, DOI 10.1016/j.annemergmed.2010.12.003; Fee C, 2007, ANN EMERG MED, V50, P501, DOI 10.1016/j.annemergmed.2007.08.003; Fee Christopher, 2007, Ann Emerg Med, V50, pe1, DOI 10.1016/j.annemergmed.2007.03.019; Graff L, 2002, ACAD EMERG MED, V9, P1091, DOI 10.1111/j.1553-2712.2002.tb01563.x; Healthcare Cost and Utilization Project, HEALTHC COST UT PROJ; Herring A, 2009, ACAD EMERG MED, V16, P609, DOI 10.1111/j.1553-2712.2009.00428.x; Kulstad EB, 2010, AM J EMERG MED, V28, P304, DOI 10.1016/j.ajem.2008.12.014; Mills AM, 2010, POSTGRAD MED, V122, P75, DOI 10.3810/pgm.2010.01.2101; Mills AM, 2009, ACAD EMERG MED, V16, P603, DOI 10.1111/j.1553-2712.2009.00441.x; Moskop JC, 2009, ANN EMERG MED, V53, P605, DOI 10.1016/j.annemergmed.2008.09.019; New Zealand Ministry of Health, EM DEP; Ontario Ministry of Health and Long-Term Care, ONT WAIT TIM EM ROOM; Pines JM, 2008, ACAD EMERG MED, V15, P825, DOI 10.1111/j.1553-2712.2008.00200.x; Pines JM, 2007, ANN EMERG MED, V50, P510, DOI 10.1016/j.annemergmed.2007.07.021; Pines JM, 2010, ACAD EMERG MED, V17, P834, DOI 10.1111/j.1553-2712.2010.00780.x; Pines JM, 2010, ACAD EMERG MED, V17, P276, DOI 10.1111/j.1553-2712.2009.00676.x; Pines JM, 2009, ACAD EMERG MED, V16, P617, DOI 10.1111/j.1553-2712.2009.00456.x; Pines JM, 2009, ACAD EMERG MED, V16, P403, DOI 10.1111/j.1553-2712.2009.00381.x; Sills MR, 2011, ANN EMERG MED, V57, P191, DOI 10.1016/j.annemergmed.2010.08.027; Smulowitz P, 2009, INTERN EMERG MED, V4, P501, DOI 10.1007/s11739-009-0313-9; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112; Wang CJ, 2009, NEW ENGL J MED, V361, P1821, DOI 10.1056/NEJMp0907656; Weber EJ, 2011, ANN EMERG MED, V57, P79, DOI 10.1016/j.annemergmed.2010.08.013	30	41	41	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					476	482		10.1001/jama.2012.41	http://dx.doi.org/10.1001/jama.2012.41			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22298679	Bronze, Green Accepted			2022-12-28	WOS:000299728000028
J	Boyce, N				Boyce, Niall			The art of medicine Shakespeare under water	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Boyce, N (corresponding author), The Lancet, London NW1 7BY, England.								0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 28	2012	379	9813					306	307		10.1016/S0140-6736(12)60133-0	http://dx.doi.org/10.1016/S0140-6736(12)60133-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	889BA	22292164				2022-12-28	WOS:000300047300024
J	Shetty, P				Shetty, Priya			Profile Ndola Prata: fighting for women's reproductive health	LANCET			English	Biographical-Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 28	2012	379	9813					305	305		10.1016/S0140-6736(12)60132-9	http://dx.doi.org/10.1016/S0140-6736(12)60132-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889BA	22284647	Bronze			2022-12-28	WOS:000300047300023
J	Dustin, ML; Meyer-Hermann, M				Dustin, Michael L.; Meyer-Hermann, Michael			Antigen Feast or Famine	SCIENCE			English	Editorial Material							PLASMA-CELL DIFFERENTIATION; MHC CLASS-II; B-LYMPHOCYTES; COMPARTMENTS		[Dustin, Michael L.] NYU, Sch Med, Skirball Inst Mol Med, New York, NY 10016 USA; [Meyer-Hermann, Michael] Helmholtz Ctr Infect Res, Dept Syst Immunol, Braunschweig, Germany; [Meyer-Hermann, Michael] Univ Technol, Bioctr Life Sci, Braunschweig, Germany	New York University; Helmholtz Association; Helmholtz-Center for Infection Research; Braunschweig University of Technology	Dustin, ML (corresponding author), NYU, Sch Med, Skirball Inst Mol Med, New York, NY 10016 USA.	michael.dustin@med.nyu.edu	Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Chaturvedi A, 2011, NAT IMMUNOL, V12, P1119, DOI 10.1038/ni.2116; Garin A, 2010, IMMUNITY, V33, P84, DOI 10.1016/j.immuni.2010.07.005; Gondre-Lewis TA, 2001, J IMMUNOL, V166, P6657, DOI 10.4049/jimmunol.166.11.6657; Meyer-Hermann ME, 2006, MATH MED BIOL, V23, P255, DOI 10.1093/imammb/dql012; Nutt SL, 2011, SEMIN IMMUNOL, V23, P341, DOI 10.1016/j.smim.2011.08.010; Omori SA, 2006, IMMUNITY, V25, P545, DOI 10.1016/j.immuni.2006.08.015; Pelletier N, 2010, NAT IMMUNOL, V11, P1110, DOI 10.1038/ni.1954; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Siemasko K, 1998, J IMMUNOL, V160, P5203; Thaunat O, 2012, SCIENCE, V335, P475, DOI 10.1126/science.1214100; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032; Yasuda T, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001592	14	12	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					408	409		10.1126/science.1218165	http://dx.doi.org/10.1126/science.1218165			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282794	Green Submitted			2022-12-28	WOS:000299466800029
J	McCartney, M				McCartney, Margaret			SOCIAL MEDIA How much of a social media profile can doctors have?	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020; Roundtree, Aimee/B-8838-2012	McCartney, Margaret/0000-0002-7238-6358				American Medical Association, 2011, PROF US SOC MED; [Anonymous], 2008, US TODAY        0811; [Anonymous], 2011, DAILY MAIL      0103; [Anonymous], NURSES BREASTS PROMP; [Anonymous], 2008, PRESS J         0906; [Anonymous], 2011, NURSING TIMES   1102; BMA, 2011, US SOC MED; GMC, YOUR FEEDB DO YOU TH; Reuters, 2011, GUARDIAN        1230; STV, 2011, STV             1207; 2008, DAILY MAIL      0228	11	21	21	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 23	2012	344								e440	10.1136/bmj.e440	http://dx.doi.org/10.1136/bmj.e440			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KB	22271528				2022-12-28	WOS:000299776800006
J	Antes, G; Clarke, M				Antes, Gerd; Clarke, Mike			Knowledge as a key resource for health challenges	LANCET			English	Editorial Material									[Antes, Gerd] Univ Freiburg, Inst Med Biometrie & Med Informat, German Cochrane Ctr, D-79110 Freiburg, Germany; [Clarke, Mike] Queens Univ Belfast, Inst Clin Sci, Belfast, Antrim, North Ireland	University of Freiburg; Queens University Belfast	Antes, G (corresponding author), Univ Freiburg, Inst Med Biometrie & Med Informat, German Cochrane Ctr, D-79110 Freiburg, Germany.	antes@cochrane.de			Medical Research Council [G0901530] Funding Source: Medline; MRC [G0901530] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], EVIDENCE AID JAPANES; Bastian H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000326; Chalmers I, 2009, LANCET, V374, P86, DOI 10.1016/S0140-6736(09)60329-9; Clark S, 2010, LANCET, V376, P10, DOI 10.1016/S0140-6736(10)61001-X; Clarke Mike, 2011, PLoS Curr, V3, pRRN1270, DOI 10.1371/currents.RRN1270; Clarke Mike, 2008, J Evid Based Med, V1, P9, DOI 10.1111/j.1756-5391.2008.00007.x; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; European Parliament, 2011, FOOD FROM FARM TO FO, P1; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; Pang T, 2006, LANCET, V367, P284, DOI 10.1016/S0140-6736(06)68050-1; Pang Tikki, 2009, J Evid Based Med, V2, P44, DOI 10.1111/j.1756-5391.2009.01016.x; RAYLEIGH, 1885, 54 M BRIT ASS ADV SC, P3	12	7	7	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 21	2012	379	9812					195	196		10.1016/S0140-6736(12)60084-1	http://dx.doi.org/10.1016/S0140-6736(12)60084-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879FW	22265619				2022-12-28	WOS:000299316100011
J	Bhattacharjee, S; Stahelin, RV; Speicher, KD; Speicher, DW; Haldar, K				Bhattacharjee, Souvik; Stahelin, Robert V.; Speicher, Kaye D.; Speicher, David W.; Haldar, Kasturi			Endoplasmic Reticulum PI(3)P Lipid Binding Targets Malaria Proteins to the Host Cell	CELL			English	Article							RED-BLOOD-CELLS; PLASMODIUM-FALCIPARUM; EFFECTOR PROTEINS; ERYTHROCYTE; PARASITES; VIRULENCE; SIGNAL; EXPORT; ORGANIZATION; MEMBRANE	Hundreds of effector proteins of the human malaria parasite Plasmodium falciparum constitute a "secretome" carrying a host-targeting (HT) signal, which predicts their export from the intracellular pathogen into the surrounding erythrocyte. Cleavage of the HT signal by a parasite endoplasmic reticulum (ER) protease, plasmepsin V, is the proposed export mechanism. Here, we show that the HT signal facilitates export by recognition of the lipid phosphatidylinositol-3-phosphate (PI(3)P) in the ER, prior to and independent of protease action. Secretome HT signals, including those of major virulence determinants, bind PI(3)P with nanomolar affinity and amino acid specificities displayed by HT-mediated export. PI(3)P-enriched regions are detected within the parasite's ER and colocalize with endogenous HT signal on ER precursors, which also display high-affinity binding to PI(3)P. A related pathogenic oomycete's HT signal export is dependent on PI(3)P binding, without cleavage by plasmepsin V. Thus, PI(3)P in the ER functions in mechanisms of secretion and pathogenesis.	[Bhattacharjee, Souvik; Haldar, Kasturi] Univ Notre Dame, Ctr Rare & Neglected Dis, Notre Dame, IN 46556 USA; [Bhattacharjee, Souvik; Haldar, Kasturi] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; [Stahelin, Robert V.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Stahelin, Robert V.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, South Bend, IN 46617 USA; [Speicher, Kaye D.; Speicher, David W.] Wistar Inst Anat & Biol, Ctr Syst & Computat Biol, Philadelphia, PA 19104 USA; [Speicher, Kaye D.; Speicher, David W.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA	University of Notre Dame; University of Notre Dame; University of Notre Dame; Indiana University System; Indiana University South Bend; The Wistar Institute; The Wistar Institute	Haldar, K (corresponding author), Univ Notre Dame, Ctr Rare & Neglected Dis, Notre Dame, IN 46556 USA.	khaldar@nd.edu	Haldar, Kasturi/C-6685-2014; Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NIH [HL069630, AI039071, HL078826, AI081077, HL038794, CA10815]; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038794, R01HL069630, P01HL078826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039071, R01AI081077] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project was conceived by K.H., R.V.S., and S.B., and the experiments were planned by K.H., R.V.S., S.B., D.W.S., and K.D.S. S.B., R.V.S., and K.D.S. conducted the experiments. K.H., R.V.S., and S.B. wrote the paper with input from all authors. We thank Yi Xue and Jordan L. Scott for excellent technical assistance, Andrew Osborne (University College of London) for helpful discussions, and Caroline Furtado Junqueira for help in figure representation. We would also like to thank Lennell Reynolds Jr., the Cell Imaging Facility at Northwestern University, and William Archer at the University of Notre Dame for help with electron microscopy. This work was partially supported by NIH grants HL069630, AI039071, HL078826 (K.H.); AI081077 (R.V.S.); HL038794 (D.W.S.) and CA10815 (Wistar Proteomics Core Facility).	Bhattacharjee Souvik, 2006, PLoS Pathogens, V2, DOI 10.1371/journal.ppat.0020050; Boddey JA, 2010, NATURE, V463, P627, DOI 10.1038/nature08728; Chang HH, 2008, MOL BIOCHEM PARASIT, V160, P107, DOI 10.1016/j.molbiopara.2008.04.011; Cooke BM, 2006, J CELL BIOL, V172, P899, DOI 10.1083/jcb.200509122; CRARY JL, 1992, MOL BIOCHEM PARASIT, V53, P185, DOI 10.1016/0166-6851(92)90020-K; de Koning-Ward TF, 2009, NATURE, V459, P945, DOI 10.1038/nature08104; Dou DL, 2008, PLANT CELL, V20, P1930, DOI 10.1105/tpc.107.056093; Duffy PE, 2003, CURR OPIN MICROBIOL, V6, P371, DOI 10.1016/S1369-5274(03)00090-0; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; ELMENDORF HG, 1993, PARASITOL TODAY, V9, P98, DOI 10.1016/0169-4758(93)90216-3; Goldberg DE, 2010, NAT REV MICROBIOL, V8, P617, DOI 10.1038/nrmicro2420; Haldar K, 2007, CURR OPIN HEMATOL, V14, P203, DOI 10.1097/MOH.0b013e3280f31b2d; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Kale SD, 2010, CELL, V142, P284, DOI 10.1016/j.cell.2010.06.008; Kutateladze TG, 2010, NAT CHEM BIOL, V6, P507, DOI [10.1038/NCHEMBIO.390, 10.1038/nchembio.390]; Kyes SA, 2007, EUKARYOT CELL, V6, P1511, DOI 10.1128/EC.00173-07; Lee SA, 2005, P NATL ACAD SCI USA, V102, P13052, DOI 10.1073/pnas.0503900102; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Lopez-Estrano C, 2003, P NATL ACAD SCI USA, V100, P12402, DOI 10.1073/pnas.2133080100; Maier AG, 2009, NAT REV MICROBIOL, V7, P341, DOI 10.1038/nrmicro2110; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Nguitragool W, 2011, CELL, V145, P665, DOI 10.1016/j.cell.2011.05.002; Osborne AR, 2010, MOL BIOCHEM PARASIT, V171, P25, DOI 10.1016/j.molbiopara.2010.01.003; Russo I, 2010, NATURE, V463, P632, DOI 10.1038/nature08726; Sargeant TJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-r12; Spielmann T, 2010, TRENDS PARASITOL, V26, P6, DOI 10.1016/j.pt.2009.10.001; Stace CL, 2006, BBA-MOL CELL BIOL L, V1761, P913, DOI 10.1016/j.bbalip.2006.03.006; Tawk L, 2010, EUKARYOT CELL, V9, P1519, DOI 10.1128/EC.00124-10; Vaid A, 2010, BLOOD, V115, P2500, DOI 10.1182/blood-2009-08-238972; van Ooij C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000084; Whisson SC, 2007, NATURE, V450, P115, DOI 10.1038/nature06203; Wiser MF, 1997, P NATL ACAD SCI USA, V94, P9108, DOI 10.1073/pnas.94.17.9108; World Health Organization, 2010, MALARIAREPORT	35	89	94	0	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 20	2012	148	1-2					201	212		10.1016/j.cell.2011.10.051	http://dx.doi.org/10.1016/j.cell.2011.10.051			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265412	Bronze, Green Accepted			2022-12-28	WOS:000299540700025
J	Rabeh, WM; Bossard, F; Xu, HJ; Okiyoneda, T; Bagdany, M; Mulvihill, CM; Du, K; di Bernardo, S; Liu, YH; Konermann, L; Roldan, A; Lukacs, GL				Rabeh, Wael M.; Bossard, Florian; Xu, Haijin; Okiyoneda, Tsukasa; Bagdany, Miklos; Mulvihill, Cory M.; Du, Kai; di Bernardo, Salvatore; Liu, Yuhong; Konermann, Lars; Roldan, Ariel; Lukacs, Gergely L.			Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore Delta F508 CFTR Folding and Function	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAIN; SMALL-MOLECULE CORRECTORS; TRAFFICKING DEFECT; IN-VITRO; MUTATION; IDENTIFICATION; STABILITY; CHAPERONE; DEGRADATION	The folding and misfolding mechanism of multidomain proteins remains poorly understood. Although thermodynamic instability of the first nucleotide-binding domain (NBD1) of Delta F508 CFTR (cystic fibrosis transmembrane conductance regulator) partly accounts for the mutant channel degradation in the endoplasmic reticulum and is considered as a drug target in cystic fibrosis, the link between NBD1 and CFTR misfolding remains unclear. Here, we show that Delta F508 destabilizes NBD1 both thermodynamically and kinetically, but correction of either defect alone is insufficient to restore Delta F508 CFTR biogenesis. Instead, both Delta F508-NBD1 energetic and the NBD1-MSD2 (membrane-spanning domain 2) interface stabilization are required for wild-type-like folding, processing, and transport function, suggesting a synergistic role of NBD1 energetics and topology in CFTR-coupled domain assembly. Identification of distinct structural deficiencies may explain the limited success of Delta F508 CFTR corrector molecules and suggests structure-based combination corrector therapies. These results may serve as a framework for understanding the mechanism of interface mutation in multidomain membrane proteins.	[Rabeh, Wael M.; Bossard, Florian; Xu, Haijin; Okiyoneda, Tsukasa; Bagdany, Miklos; Mulvihill, Cory M.; Du, Kai; di Bernardo, Salvatore; Roldan, Ariel; Lukacs, Gergely L.] McGill Univ, Dept Physiol, Montreal, PQ H3E 1Y6, Canada; [Rabeh, Wael M.; Lukacs, Gergely L.] McGill Univ, GRASP, Montreal, PQ H3E 1Y6, Canada; [Liu, Yuhong; Konermann, Lars] Univ Western Ontario, Dept Chem, London, ON N6A 5B7, Canada	McGill University; McGill University; Western University (University of Western Ontario)	Lukacs, GL (corresponding author), McGill Univ, Dept Physiol, Montreal, PQ H3E 1Y6, Canada.	gergely.lukacs@mcgill.ca	Rabeh, Wael/AAO-4647-2020	Rabeh, Wael/0000-0001-6071-8581; Okiyoneda, Tsukasa/0000-0002-5175-2224; Roldan, Ariel/0000-0002-8159-5450; Lukacs, Gergely/0000-0003-0900-0675	Cystic Fibrosis Foundation Therapeutics Inc; Cystic Fibrosis Canada; NIH-NIDDK [DK075302]; Canadian Institute of Health Research; Canadian Foundation for Innovation; GRASP; Canadian Cystic Fibrosis Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075302] Funding Source: NIH RePORTER	Cystic Fibrosis Foundation Therapeutics Inc; Cystic Fibrosis Canada; NIH-NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); GRASP; Canadian Cystic Fibrosis Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank H. Lewis, C. Lima, J.R. Riordan, J. Young, E. Buck, and the Cystic Fibrosis Foundation Therapeutics, Inc. for valuable reagents and feedbacks, J. Young and D. Thomas for providing access to the Chirascan and qPCR instruments, and N. Kartner, G. Veit, J. Szapor, D. Scicchitano, and F. Pianofor for helpful comments on the manuscript. We thank the Cystic Fibrosis Foundation Therapeutics Inc, Cystic Fibrosis Canada, NIH-NIDDK (grant number DK075302), Canadian Institute of Health Research, and the Canadian Foundation for Innovation for operating and infrastructure support. W.M.R. was partially supported by GRASP and a Canadian Cystic Fibrosis Foundation postdoctoral fellowship. L.K. and G.L.L. are holders of Canada Research Chairs.	Aleksandrov AA, 2010, J MOL BIOL, V401, P194, DOI 10.1016/j.jmb.2010.06.019; Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clancy JP, 2012, THORAX, V67, P12, DOI 10.1136/thoraxjnl-2011-200393; Cui LY, 2007, J MOL BIOL, V365, P981, DOI 10.1016/j.jmb.2006.10.086; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; Du K, 2009, MOL BIOL CELL, V20, P1903, DOI 10.1091/mbc.E08-09-0950; Feng LA, 2010, SCIENCE, V330, P635, DOI 10.1126/science.1195230; Fulop K, 2009, BIOCHEM BIOPH RES CO, V379, P706, DOI 10.1016/j.bbrc.2008.12.142; Grove DE, 2009, MOL BIOL CELL, V20, P4059, DOI 10.1091/mbc.E08-09-0929; Han JH, 2007, NAT REV MOL CELL BIO, V8, P319, DOI 10.1038/nrm2144; He LH, 2008, J BIOL CHEM, V283, P26383, DOI 10.1074/jbc.M803894200; He LH, 2010, FASEB J, V24, P3103, DOI 10.1096/fj.09-141788; Hoelen H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015458; Kalid O, 2010, J COMPUT AID MOL DES, V24, P971, DOI 10.1007/s10822-010-9390-0; Khushoo A, 2011, MOL CELL, V41, P682, DOI 10.1016/j.molcel.2011.02.027; Lewis HA, 2010, J MOL BIOL, V396, P406, DOI 10.1016/j.jmb.2009.11.051; Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200; Lo MC, 2004, ANAL BIOCHEM, V332, P153, DOI 10.1016/j.ab.2004.04.031; Loo TW, 2008, J BIOL CHEM, V283, P28190, DOI 10.1074/jbc.M805834200; Loo TW, 2010, BIOCHEMISTRY-US, V49, P6352, DOI 10.1021/bi100807h; Loo TW, 2009, BIOCHEMISTRY-US, V48, P9882, DOI 10.1021/bi9004842; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mornon JP, 2009, CELL MOL LIFE SCI, V66, P3469, DOI 10.1007/s00018-009-0133-0; Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Pissarra LS, 2008, CHEM BIOL, V15, P62, DOI 10.1016/j.chembiol.2007.11.012; Protasevich I, 2010, PROTEIN SCI, V19, P1917, DOI 10.1002/pro.479; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; Riordan JR, 2008, ANNU REV BIOCHEM, V77, P701, DOI 10.1146/annurev.biochem.75.103004.142532; Robert R, 2010, MOL PHARMACOL, V77, P922, DOI 10.1124/mol.109.062679; Rosser MFN, 2008, MOL BIOL CELL, V19, P4570, DOI 10.1091/mbc.E08-04-0357; Roy G, 2010, MOL BIOL CELL, V21, P597, DOI 10.1091/mbc.E09-05-0427; Sampson HM, 2011, CHEM BIOL, V18, P231, DOI 10.1016/j.chembiol.2010.11.016; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Senisterra GA, 2008, J BIOMOL SCREEN, V13, P337, DOI 10.1177/1087057108317825; Serohijos AWR, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000008; Serohijos AWR, 2008, P NATL ACAD SCI USA, V105, P3256, DOI 10.1073/pnas.0800254105; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Stratford FLL, 2007, BIOCHEM J, V401, P581, DOI 10.1042/BJ20060968; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; Teem JL, 1996, RECEPTOR CHANNEL, V4, P63; Thibodeau PH, 2010, J BIOL CHEM, V285, P35825, DOI 10.1074/jbc.M110.131623; Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Van Goor F, 2011, P NATL ACAD SCI USA, V108, P18843, DOI 10.1073/pnas.1105787108; Wang C, 2010, PROTEIN SCI, V19, P1932, DOI 10.1002/pro.480; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; Wang Y, 2007, J BIOL CHEM, V282, P33247, DOI 10.1074/jbc.C700175200; Wiseman RL, 2007, CELL, V131, P809, DOI 10.1016/j.cell.2007.10.025; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; Zhou RH, 2007, P NATL ACAD SCI USA, V104, P5824, DOI 10.1073/pnas.0701249104	57	221	227	0	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					150	163		10.1016/j.cell.2011.11.024	http://dx.doi.org/10.1016/j.cell.2011.11.024			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265408	Green Accepted, Bronze			2022-12-28	WOS:000299540700021
J	Vedral, V				Vedral, Vlatko			Moving Beyond Trust in Quantum Computing	SCIENCE			English	Editorial Material									Univ Oxford, Dept Atom & Laser Phys, Oxford OX1 3PU, England	University of Oxford	Vedral, V (corresponding author), Univ Oxford, Dept Atom & Laser Phys, Oxford OX1 3PU, England.	vlatko.vedral@gmail.com	Vedral, Vlatko/L-3270-2016; vedral, vlatko/P-1712-2014	Vedral, Vlatko/0000-0002-8588-2940; vedral, vlatko/0000-0003-4561-5124				Barz S, 2012, SCIENCE, V335, P303, DOI 10.1126/science.1214707; Broadbent A, 2009, ANN IEEE SYMP FOUND, P517, DOI 10.1109/FOCS.2009.36; Rivest R. L., 1978, FOUND SEC COMPUT, V4, P169; Walther P, 2005, NATURE, V434, P169, DOI 10.1038/nature03347	6	3	3	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					294	295		10.1126/science.1216922	http://dx.doi.org/10.1126/science.1216922			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267800				2022-12-28	WOS:000299273400033
J	Spence, D				Spence, Des			FROM THE FRONTLINE Bad medicine: medical nutrition	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						[Anonymous], NUTR SUPPORT ADULTS	1	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 18	2012	344								e451	10.1136/bmj.e451	http://dx.doi.org/10.1136/bmj.e451			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YZ	22257980				2022-12-28	WOS:000300041900007
J	Hakim, O; Resch, W; Yamane, A; Klein, I; Kieffer-Kwon, KR; Jankovic, M; Oliveira, T; Bothmer, A; Voss, TC; Ansarah-Sobrinho, C; Mathe, E; Liang, GQ; Cobell, J; Nakahashi, H; Robbiani, DF; Nussenzweig, A; Hager, GL; Nussenzweig, MC; Casellas, R				Hakim, Ofir; Resch, Wolfgang; Yamane, Arito; Klein, Isaac; Kieffer-Kwon, Kyong-Rim; Jankovic, Mila; Oliveira, Thiago; Bothmer, Anne; Voss, Ty C.; Ansarah-Sobrinho, Camilo; Mathe, Ewy; Liang, Genqing; Cobell, Jesse; Nakahashi, Hirotaka; Robbiani, Davide F.; Nussenzweig, Andre; Hager, Gordon L.; Nussenzweig, Michel C.; Casellas, Rafael			DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes	NATURE			English	Article							CLASS-SWITCH RECOMBINATION; SEQUENCING REVEALS; HUMAN GENOME; BREAKS; CELLS; AID; IDENTIFICATION; REARRANGEMENTS; ORGANIZATION; MECHANISMS	Recurrent chromosomal translocations underlie both haematopoietic and solid tumours. Their origin has been ascribed to selection of random rearrangements, targeted DNA damage, or frequent nuclear interactions between translocation partners; however, the relative contribution of each of these elements has not been measured directly or on a large scale. Here we examine the role of nuclear architecture and frequency of DNA damage in the genesis of chromosomal translocations by measuring these parameters simultaneously in cultured mouse B lymphocytes. In the absence of recurrent DNA damage, translocations between Igh or Myc and all other genes are directly related to their contact frequency. Conversely, translocations associated with recurrent site-directed DNA damage are proportional to the rate of DNA break formation, as measured by replication protein A accumulation at the site of damage. Thus, non-targeted rearrangements reflect nuclear organization whereas DNA break formation governs the location and frequency of recurrent translocations, including those driving B-cell malignancies.	[Klein, Isaac; Jankovic, Mila; Oliveira, Thiago; Bothmer, Anne; Robbiani, Davide F.; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA; [Hakim, Ofir; Voss, Ty C.; Hager, Gordon L.] NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; [Resch, Wolfgang; Yamane, Arito; Kieffer-Kwon, Kyong-Rim; Ansarah-Sobrinho, Camilo; Liang, Genqing; Cobell, Jesse; Nakahashi, Hirotaka; Casellas, Rafael] NCI, NIAMS, NIH, Bethesda, MD 20892 USA; [Oliveira, Thiago] Univ Sao Paulo, Med Sch Ribeirao Preto, Dept Genet, Natl Inst Sci & Technol Stem Cells & Cell Therapy, BR-14051140 Ribeirao Preto, SP, Brazil; [Oliveira, Thiago] Ctr Cell Based Therapy, BR-14051140 Ribeirao Preto, SP, Brazil; [Nussenzweig, Andre] NCI, Lab Genome Integr, NIH, Bethesda, MD 20892 USA; [Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA; [Casellas, Rafael] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Universidade de Sao Paulo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA.	nussen@rockefeller.edu; casellar@mail.nih.gov	Yamane, Arito/A-2959-2013; Oliveira, Thiago Y/ABF-5186-2020; Oliveira, Thiago Y/HGA-3848-2022; Mathe, Ewy/L-1616-2019; Robbiani, Davide F./AAF-7662-2019; Nussenzweig, Michel/AAE-7292-2019	Oliveira, Thiago Y/0000-0002-2654-0879; Oliveira, Thiago Y/0000-0002-2654-0879; Robbiani, Davide F./0000-0001-7379-3484; Mathe, Ewy/0000-0003-4491-8107; Resch, Wolfgang/0000-0001-7594-5963; Hakim, Ofir/0000-0003-0063-2721	Starr Foundation; NIH [AI037526]; NIAMS; NCI, NIH; NATIONAL CANCER INSTITUTE [ZIABC010283, ZIABC010027, ZIABC010959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037526, R37AI037526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041148] Funding Source: NIH RePORTER	Starr Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank members of the Casellas and Nussenzweig laboratories for discussions; G. Gutierrez from NIAMS genomics facility for technical assistance. This work was supported in part by a grant from the Starr Foundation to M.C.N., by NIH grant number AI037526 to M.C.N. and the Intramural Research Program of NIAMS and NCI, NIH. M.C.N. is an HHMI investigator. This study made use of the high-performance computational capabilities of the Biowulf Linux cluster at the NIH (http://biowulf.nih.gov), and the resources of NCI's High-Throughput Imaging Facility.	Bothmer A, 2010, J EXP MED, V207, P855, DOI 10.1084/jem.20100244; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Chakalova L, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000729; Chiarle R, 2011, CELL, V147, P107, DOI 10.1016/j.cell.2011.07.049; Cremer T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003889; Hakim O, 2011, GENOME RES, V21, P697, DOI 10.1101/gr.111153.110; Hakim O, 2010, CURR OPIN CELL BIOL, V22, P305, DOI 10.1016/j.ceb.2010.04.005; Klein IA, 2011, CELL, V147, P95, DOI 10.1016/j.cell.2011.07.048; Kuchen S, 2010, IMMUNITY, V32, P828, DOI 10.1016/j.immuni.2010.05.009; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Meaburn KJ, 2007, NATURE, V445, P379, DOI 10.1038/445379a; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Nussenzweig A, 2010, CELL, V141, P27, DOI 10.1016/j.cell.2010.03.016; Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192; Parada LA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-r44; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Robbiani DF, 2009, MOL CELL, V36, P631, DOI 10.1016/j.molcel.2009.11.007; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Simonis M, 2006, NAT GENET, V38, P1348, DOI 10.1038/ng1896; Tsai AG, 2008, CELL, V135, P1130, DOI 10.1016/j.cell.2008.10.035; Vuong BQ, 2009, NAT IMMUNOL, V10, P420, DOI 10.1038/ni.1708; Wang JH, 2009, NATURE, V460, P231, DOI 10.1038/nature08159; Yamane A, 2011, NAT IMMUNOL, V12, P62, DOI 10.1038/ni.1964; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zhang Y, 2010, ADV IMMUNOL, V106, P93, DOI 10.1016/S0065-2776(10)06004-9	28	158	164	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 5	2012	484	7392					69	+		10.1038/nature10909	http://dx.doi.org/10.1038/nature10909			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	919QN	22314321	Green Accepted			2022-12-28	WOS:000302343400035
J	Osrin, D; Hill, ZE				Osrin, David; Hill, Zelee Elizabeth			Chlorhexidine cord cleansing to reduce neonatal mortality	LANCET			English	Editorial Material							UMBILICAL-CORD		[Osrin, David; Hill, Zelee Elizabeth] UCL Inst Global Hlth, London WC1N 1EH, England	University of London; University College London	Osrin, D (corresponding author), UCL Inst Global Hlth, London WC1N 1EH, England.	d.osrin@ucl.ac.uk		Osrin, David/0000-0001-9691-9684	Wellcome Trust [091561] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bennett J, 1999, INT J EPIDEMIOL, V28, P1172, DOI 10.1093/ije/28.6.1172; Bhutta ZA, 2011, LANCET, V377, P403, DOI 10.1016/S0140-6736(10)62274-X; Darmstadt GL, 2008, J HEALTH POPUL NUTR, V26, P36; Darmstadt GL, 2009, INT J GYNECOL OBSTET, V107, pS89, DOI 10.1016/j.ijgo.2009.07.010; El Arifeen S, 2012, LANCET, V379, P1022, DOI 10.1016/S0140-6736(11)61848-5; Kesterton AJ, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-20; Lawn JE, 2009, BJOG-INT J OBSTET GY, V116, P49, DOI 10.1111/j.1471-0528.2009.02328.x; Mullany LC, 2006, LANCET, V367, P910, DOI 10.1016/S0140-6736(06)68381-5; Soofi S, 2012, LANCET, V379, P1029, DOI 10.1016/S0140-6736(11)61877-1; TRAVERSO HP, 1989, LANCET, V1, P486; *WHO, 2009, WHOFCHCAH0902 UNICEF; Zupan J, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/1465-1858.CD001057	12	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2012	379	9820					984	986		10.1016/S0140-6736(12)60114-7	http://dx.doi.org/10.1016/S0140-6736(12)60114-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JE	22322125	Green Accepted			2022-12-28	WOS:000301712300011
J	Lee, JH; Silhavy, JL; Lee, JE; Al-Gazali, L; Thomas, S; Davis, EE; Bielas, SL; Hill, KJ; Iannicelli, M; Brancati, F; Gabriel, SB; Russ, C; Logan, CV; Sharif, SM; Bennett, CP; Abe, M; Hildebrandt, F; Diplas, BH; Attie-Bitach, T; Katsanis, N; Rajab, A; Koul, R; Sztriha, L; Waters, ER; Ferro-Novick, S; Woods, CG; Johnson, CA; Valente, EM; Zaki, MS; Gleeson, JG				Lee, Jeong Ho; Silhavy, Jennifer L.; Lee, Ji Eun; Al-Gazali, Lihadh; Thomas, Sophie; Davis, Erica E.; Bielas, Stephanie L.; Hill, Kiley J.; Iannicelli, Miriam; Brancati, Francesco; Gabriel, Stacey B.; Russ, Carsten; Logan, Clare V.; Sharif, Saghira Malik; Bennett, Christopher P.; Abe, Masumi; Hildebrandt, Friedhelm; Diplas, Bill H.; Attie-Bitach, Tania; Katsanis, Nicholas; Rajab, Anna; Koul, Roshan; Sztriha, Laszlo; Waters, Elizabeth R.; Ferro-Novick, Susan; Woods, C. Geoffrey; Johnson, Colin A.; Valente, Enza Maria; Zaki, Maha S.; Gleeson, Joseph G.			Evolutionarily Assembled cis-Regulatory Module at a Human Ciliopathy Locus	SCIENCE			English	Article							GENE; MUTATIONS; JOUBERT; TRANSPORT; MEMBRANE; DISEASE; CILIUM; CELLS; HEAD	Neighboring genes are often coordinately expressed within cis-regulatory modules, but evidence that nonparalogous genes share functions in mammals is lacking. Here, we report that mutation of either TMEM138 or TMEM216 causes a phenotypically indistinguishable human ciliopathy, Joubert syndrome. Despite a lack of sequence homology, the genes are aligned in a head-to-tail configuration and joined by chromosomal rearrangement at the amphibian-to-reptile evolutionary transition. Expression of the two genes is mediated by a conserved regulatory element in the noncoding intergenic region. Coordinated expression is important for their interdependent cellular role in vesicular transport to primary cilia. Hence, during vertebrate evolution of genes involved in ciliogenesis, nonparalogous genes were arranged to a functional gene cluster with shared regulatory elements.	[Lee, Jeong Ho; Silhavy, Jennifer L.; Lee, Ji Eun; Bielas, Stephanie L.; Hill, Kiley J.; Gleeson, Joseph G.] Univ Calif San Diego, Dept Neurosci, Howard Hughes Med Inst, Neurogenet Lab, San Diego, CA 92103 USA; [Al-Gazali, Lihadh] United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Pediat, Al Ain, U Arab Emirates; [Thomas, Sophie; Attie-Bitach, Tania] Univ Paris 05, Hop Necker Enfants Malad, Dept Genet, INSERM,U781, Paris, France; [Davis, Erica E.; Katsanis, Nicholas] Duke Univ, Med Ctr, Ctr Human Dis Modeling, Durham, NC USA; [Katsanis, Nicholas] Duke Univ, Med Ctr, Dept Cell Biol & Pediat, Durham, NC USA; [Iannicelli, Miriam; Brancati, Francesco; Valente, Enza Maria] Ist Ricovero & Cura Carattere Sci Casa Sollievo S, Mendel Lab, San Giovanni Rotondo, Italy; [Gabriel, Stacey B.; Russ, Carsten] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA; [Abe, Masumi] Natl Inst Radiol Sci, Transcriptome Res Ctr, Chiba 260, Japan; [Hildebrandt, Friedhelm] Univ Michigan, Dept Pediat, HHMI, Ann Arbor, MI 48109 USA; [Diplas, Bill H.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA; [Rajab, Anna] Minist Hlth, Directorate Gen Hlth Affairs, Genet Unit, Muscat, Oman; [Koul, Roshan] Sultan Qaboos Univ Hosp, Coll Med & Hlth Sci, Dept Child Hlth Neurol, Muscat, Oman; [Sztriha, Laszlo] Univ Szeged, Dept Pediat, Div B, Szeged, Hungary; [Waters, Elizabeth R.] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; [Ferro-Novick, Susan] Univ Calif San Diego, HHMI, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Woods, C. Geoffrey] St James Univ Hosp, Leeds Inst Mol Med, Sect Ophthalmol & Neurosci, Leeds, W Yorkshire, England; [Zaki, Maha S.] Natl Res Ctr, Human Genet & Genome Res Div, Dept Clin Genet, Giza, Egypt	Howard Hughes Medical Institute; University of California System; University of California San Diego; United Arab Emirates University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Duke University; Duke University; IRCCS Casa Sollievo Della Sofferenza; Istituto CSS Mendel; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; National Institutes for Quantum Science & Technology; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Johns Hopkins University; Sultan Qaboos University; Szeged University; California State University System; San Diego State University; Howard Hughes Medical Institute; University of California System; University of California San Diego; Saint James's University Hospital; University of Leeds; Egyptian Knowledge Bank (EKB); National Research Centre (NRC)	Gleeson, JG (corresponding author), Univ Calif San Diego, Dept Neurosci, Howard Hughes Med Inst, Neurogenet Lab, San Diego, CA 92103 USA.	jogleeson@ucsd.edu	Lee, Jeong Ho/G-7361-2012; Valente, Enza Maria/G-2942-2017; Brancati, Francesco/AAC-3778-2022; Katsanis, Nicholas/E-1837-2012; Zaki, Maha S/B-9361-2013; ATTIE-BITACH, Tania/K-1453-2017; thomas, sophie/GVS-1279-2022; THOMAS, Sophie/F-4492-2017	Valente, Enza Maria/0000-0002-0600-6820; Brancati, Francesco/0000-0003-3624-2354; ATTIE-BITACH, Tania/0000-0002-1155-3626; THOMAS, Sophie/0000-0002-8569-3277; Johnson, Colin/0000-0002-2979-8234; Zaki, Maha/0000-0001-7840-0002; Abe, Masumi/0000-0003-1550-2006; Katsanis, Nicholas/0000-0002-2480-0171; Logan, Clare/0000-0003-4323-1602; Diplas, Bill/0000-0001-9248-7351; Davis, Erica/0000-0002-2412-8397; Bielas, Stephanie/0000-0003-0567-5632	Broad Sequencing Plaform; UCSD Neuroscience Core [P30NS047101]; American Philosophical Society; Italian Ministry of Health [RC2010]; Telethon Foundation Italy [GGP08145]; Pierfranco and Luisa Mariani Foundation; l'Agence National pour la Recherche [ANR-2010-BLAN-1122 01-Foetocilpath]; American Heart Association [09POST2250641]; Newlife Foundation for Disabled Children; Medical Research Council [G0700073]; Sir Jules Thorn Charitable Trust [09/JTA]; European Community [241955]; SYSCILIA; NIH [NS052455, NS04843, DK068306, DK090917, U54 HG003067, EY021872, HD042601, DK075972, DK072301]; Simons Foundation Autism Research Initiative; HHMI; MRC [G0700073] Funding Source: UKRI; The Sir Jules Thorn Charitable Trust [09JTA] Funding Source: researchfish; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042601] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY021872] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [RC4DK090917, R01DK075972, R01DK072301, R01DK068306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047101, R01NS048453, R01NS052455] Funding Source: NIH RePORTER	Broad Sequencing Plaform; UCSD Neuroscience Core; American Philosophical Society; Italian Ministry of Health(Ministry of Health, Italy); Telethon Foundation Italy(Fondazione Telethon); Pierfranco and Luisa Mariani Foundation; l'Agence National pour la Recherche(French National Research Agency (ANR)); American Heart Association(American Heart Association); Newlife Foundation for Disabled Children; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Sir Jules Thorn Charitable Trust; European Community(European Commission); SYSCILIA; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Simons Foundation Autism Research Initiative; HHMI(Howard Hughes Medical Institute); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); The Sir Jules Thorn Charitable Trust; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the patients and families for invaluable contributions; the Broad Sequencing Plaform, the UCSD Neuroscience Core (grant P30NS047101), and T. Meerloo at the UCSD ImmunoEM Core; M. G. Rosenfeld, B. Ren, P. Novick, K. Frazer, and S. Rifkin for discussion; and C. Janke (Centre de Recherche de Biochimie Macromoleculaire, Montpellier, France, GT335 antibody), T. Caspary (Emory Arl13b antibody), P. Aza-Blanc (Sanford-Burnham Institute, siRNAs), and D. Traver (UCSD) for ZF4 cells. This work was supported by the Daland Fellowship from the American Philosophical Society (J.H.L.), the Italian Ministry of Health (RC2010, Ricerca Finalizzata 2006), Telethon Foundation Italy (GGP08145, E.M.V.), the Pierfranco and Luisa Mariani Foundation (E.M.V.), l'Agence National pour la Recherche (grant ANR-2010-BLAN-1122 01-Foetocilpath, T.A.-B.), the American Heart Association (grant 09POST2250641, J.E.L.), Newlife Foundation for Disabled Children, the Medical Research Council (grant G0700073), the Sir Jules Thorn Charitable Trust (09/JTA, C.A.J.), European Community's Seventh Framework Programme FP7/2009 (241955), SYSCILIA (E.E.D., N.K., C.A.J.), Distinguished George W. Brumley Professorship (N.K.), the NIH (grants NS052455 and NS04843, J.G.G.; DK068306 and DK090917, F.H.; U54 HG003067, E.S. Lander; EY021872, E.E.D.; HD042601, DK075972, DK072301, N.K.), Simons Foundation Autism Research Initiative (J.G.G.), and HHMI (F.H., S.F.-N., J.G.G.).	Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Cai HQ, 2007, DEV CELL, V12, P671, DOI 10.1016/j.devcel.2007.04.005; Doherty D, 2009, SEMIN PEDIATR NEUROL, V16, P143, DOI 10.1016/j.spen.2009.06.002; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Jeziorska DM, 2009, SEMIN CELL DEV BIOL, V20, P856, DOI 10.1016/j.semcdb.2009.07.007; Keeler LC, 2003, AM J HUM GENET, V73, P656, DOI 10.1086/378206; Khanna H, 2009, NAT GENET, V41, P739, DOI 10.1038/ng.366; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; Manzanares M, 2000, NATURE, V408, P854, DOI 10.1038/35048570; Nachury MV, 2010, ANNU REV CELL DEV BI, V26, P59, DOI 10.1146/annurev.cellbio.042308.113337; PAPERMASTER DS, 1985, INVEST OPHTH VIS SCI, V26, P1386; Pathak N, 2007, MOL BIOL CELL, V18, P4353, DOI 10.1091/mbc.E07-06-0537; Ruiz-Perez VL, 2003, AM J HUM GENET, V72, P728, DOI 10.1086/368063; Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534; SOROKIN S, 1962, J CELL BIOL, V15, P363, DOI 10.1083/jcb.15.2.363; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Tobin JL, 2009, GENET MED, V11, P386, DOI 10.1097/GIM.0b013e3181a02882; Valente EM, 2003, AM J HUM GENET, V73, P663, DOI 10.1086/378241; Valente EM, 2010, NAT GENET, V42, P619, DOI 10.1038/ng.594	19	60	64	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2012	335	6071					966	969		10.1126/science.1213506	http://dx.doi.org/10.1126/science.1213506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ZQ	22282472	Green Accepted			2022-12-28	WOS:000300931800046
J	Paytan, A				Paytan, Adina			Mountains, Weathering, and Climate	SCIENCE			English	Editorial Material									Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Paytan, A (corresponding author), Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA.	apaytan@ucsc.edu						BERNER RA, 1983, AM J SCI, V283, P641, DOI 10.2475/ajs.283.7.641; Berner RA., 1997, TECTONIC UPLIFT CLIM, P353; Burton KW, 2006, J GEOCHEM EXPLOR, V88, P262, DOI 10.1016/j.gexplo.2005.08.052; DERRY LA, 1997, TECTONIC UPLIFT CLIM, P289; Filippelli GM, 1997, GEOLOGY, V25, P27, DOI 10.1130/0091-7613(1997)025<0027:IOTAMA>2.3.CO;2; Holland H. D., 2003, TREAT GEOCHEM, V6, P369; MILLIMAN JD, 1983, J GEOL, V91, P1, DOI 10.1086/628741; Misra S, 2012, SCIENCE, V335, P818, DOI 10.1126/science.1214697; Ravizza G. E., 2003, TREATISE GEOCHEM, V6, P551; van de Flierdt T, 2007, EARTH PLANET SC LETT, V259, P432, DOI 10.1016/j.epsl.2007.05.003; WALKER JCG, 1981, J GEOPHYS RES-OCEANS, V86, P9776, DOI 10.1029/JC086iC10p09776; West AJ, 2005, EARTH PLANET SC LETT, V235, P211, DOI 10.1016/j.epsl.2005.03.020; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	13	4	4	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	2012	335	6070					810	811		10.1126/science.1218342	http://dx.doi.org/10.1126/science.1218342			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893LC	22282474				2022-12-28	WOS:000300356400032
J	Dancey, JE; Bedard, PL; Onetto, N; Hudson, TJ				Dancey, Janet E.; Bedard, Philippe L.; Onetto, Nicole; Hudson, Thomas J.			The Genetic Basis for Cancer Treatment Decisions	CELL			English	Review							SOMATIC MUTATIONS; PRIMARY TUMORS; GENOME; KRAS; METASTASES; EVOLUTION; CARCINOMA; WORKFORCE; RECURRENT; ANTIBODY	Personalized cancer medicine is based on increased knowledge of the cancer mutation repertoire and availability of agents that target altered genes or pathways. Given advances in cancer genetics, technology, and therapeutics development, the timing is right to develop a clinical trial and research framework to move future clinical decisions from heuristic to evidence-based decisions. Although the challenges of integrating genomic testing into cancer treatment decision making are wide-ranging and complex, there is a scientific and ethical imperative to realize the benefits of personalized cancer medicine, given the overwhelming burden of cancer and the unprecedented opportunities for advancements in outcomes for patients.	[Dancey, Janet E.; Onetto, Nicole; Hudson, Thomas J.] Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada; [Dancey, Janet E.] Queens Univ, NCIC Clin Trials Grp, Kingston, ON K7L 3N6, Canada; [Bedard, Philippe L.] Univ Toronto, Princess Margaret Hosp, Div Med Oncol & Hematol, Univ Hlth Network, Toronto, ON M5S 1A1, Canada; [Bedard, Philippe L.] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada; [Hudson, Thomas J.] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada; [Hudson, Thomas J.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A1, Canada	Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; Queens University - Canada; Canadian Cancer Trials Group; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto	Hudson, TJ (corresponding author), Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada.	tom.hudson@oicr.on.ca		Bedard, Philippe/0000-0002-6771-2999	Ontario Institute for Cancer Research; Ontario Ministry of Economic Development and Innovation; Cancer Care Ontario; Birmingham Cancer Research Fund; Princess Margaret Hospital Foundation	Ontario Institute for Cancer Research; Ontario Ministry of Economic Development and Innovation; Cancer Care Ontario; Birmingham Cancer Research Fund; Princess Margaret Hospital Foundation	We thank our numerous clinical and research colleagues in Ontario who have been involved in the design and execution of a pilot study to assess genomic testing of actionable mutations in a multicenter clinical trial setting and, in particular, Dr. Lillian Siu at the University Health Network's Princess Margaret Hospital for critical advice during the preparation of this manuscript. J.E.D. and T.J.H. are supported by Investigator Awards from the Ontario Institute for Cancer Research and through generous support from the Ontario Ministry of Economic Development and Innovation. The authors also wish to thank Cancer Care Ontario, the Birmingham Cancer Research Fund, and the Princess Margaret Hospital Foundation for their support.	Agulnik M, 2007, J CLIN ONCOL, V25, P2184, DOI 10.1200/JCO.2006.07.6554; Bang YJ, 2010, LANCET, V376, P1302; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bookman MA, 2003, J CLIN ONCOL, V21, P283, DOI 10.1200/JCO.2003.10.104; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Chabner BA, 2011, NEW ENGL J MED, V364, P1087, DOI 10.1056/NEJMp1100548; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cooksey JA, 2005, GENET MED, V7, P439, DOI 10.1097/01.GIM.0000172416.35285.9F; Cooksey JA, 2006, GENET MED, V8, P603, DOI 10.1097/01.gim.0000242307.83900.77; Dias-Santagata D, 2010, EMBO MOL MED, V2, P146, DOI 10.1002/emmm.201000070; Eid J, 2009, SCIENCE, V323, P133, DOI 10.1126/science.1162986; EMEA Committee for Medicinal Products, 2008, EMEACHMPPGXWP1284352; *FDA, 2005, GUID IND PHARM DAT S; FDA (Food and Drug Administration), 2011, FDA APPR XALK COMP D; FDA (Food and Drug Administration), 2010, DRAFT GUID IND COD 2; Fleming GF, 2010, GYNECOL ONCOL, V116, P15, DOI 10.1016/j.ygyno.2009.09.025; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Fumagalli D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-101; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Jensen JD, 2011, CLIN CANCER RES, V17, P667, DOI 10.1158/1078-0432.CCR-10-1133; Jones SJM, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r82; Kalikaki A, 2008, BRIT J CANCER, V99, P923, DOI 10.1038/sj.bjc.6604629; Knijn N, 2011, BRIT J CANCER, V104, P1020, DOI 10.1038/bjc.2011.26; Korlach J, 2010, METHOD ENZYMOL, V472, P431, DOI 10.1016/S0076-6879(10)72001-2; Kozarewa I, 2011, METHODS MOL BIOL, V733, P279, DOI 10.1007/978-1-61779-089-8_20; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; MacConaill LE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007887; McGuire AL, 2008, NAT REV GENET, V9, P152, DOI 10.1038/nrg2302; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mousses S, 2008, Oncogene, V27 Suppl 2, pS58, DOI 10.1038/onc.2009.354; Natrajan R, 2011, EXPERT REV MOL DIAGN, V11, P425, DOI [10.1586/ERM.11.18, 10.1586/erm.11.18]; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Rothberg JM, 2011, NATURE, V475, P348, DOI 10.1038/nature10242; Santini D, 2008, ONCOLOGIST, V13, P1270, DOI 10.1634/theoncologist.2008-0181; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Toronto Int Data Release Workshop, 2009, NATURE, V461, P168, DOI 10.1038/461168a; Von Hoff DD, 2010, J CLIN ONCOL, V28, P4877, DOI 10.1200/JCO.2009.26.5983; Wang Y, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-8; Wong KM, 2011, ANNU REV GENOM HUM G, V12, P407, DOI 10.1146/annurev-genom-082509-141532; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	48	223	227	0	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					409	420		10.1016/j.cell.2012.01.014	http://dx.doi.org/10.1016/j.cell.2012.01.014			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304912	Bronze			2022-12-28	WOS:000300225000011
J	Majumdar, A; Cesario, WC; White-Grindley, E; Jiang, HQ; Ren, FZ; Khan, M; Li, LY; Choi, EML; Kannan, K; Guo, FL; Unruh, J; Slaughter, B; Si, K				Majumdar, Amitabha; Cesario, Wanda Colon; White-Grindley, Erica; Jiang, Huoqing; Ren, Fengzhen; Khan, Mohammed Repon''; Li, Liying; Choi, Edward Man-Lik; Kannan, Kasthuri; Guo, Fengli; Unruh, Jay; Slaughter, Brian; Si, Kausik			Critical Role of Amyloid-like Oligomers of Drosophila Orb2 in the Persistence of Memory	CELL			English	Article							CYTOPLASMIC POLYADENYLATION ELEMENT; LOCAL PROTEIN-SYNTHESIS; LONG-TERM-MEMORY; MESSENGER-RNA TRANSLATION; SYNAPTIC PLASTICITY; MUTANT DROSOPHILA; NEURONAL ISOFORM; APLYSIA CPEB; KINASE-II; FACILITATION	A long-standing question in the study of long-term memory is how a memory trace persists for years when the proteins that initiated the process turn over and disappear within days. Previously, we postulated that self-sustaining amyloidogenic oligomers of cytoplasmic polyadenylation elementbinding protein (CPEB) provide a mechanism for the maintenance of activity-dependent synaptic changes and, thus, the persistence of memory. Here, we found that the Drosophila CPEB Orb2 forms amyloid-like oligomers, and oligomers are enriched in the synaptic membrane fraction. Of the two protein isoforms of Orb2, the amyloid-like oligomer formation is dependent on the Orb2A form. A point mutation in the prion-like domain of Orb2A, which reduced amyloid-like oligomerization of Orb2, did not interfere with learning or memory persisting up to 24 hr. However the mutant flies failed to stabilize memory beyond 48 hr. These results support the idea that amyloid-like oligomers of neuronal CPEB are critical for the persistence of long-term memory.	[Majumdar, Amitabha; Cesario, Wanda Colon; White-Grindley, Erica; Jiang, Huoqing; Ren, Fengzhen; Khan, Mohammed Repon''; Li, Liying; Choi, Edward Man-Lik; Kannan, Kasthuri; Guo, Fengli; Unruh, Jay; Slaughter, Brian; Si, Kausik] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Khan, Mohammed Repon''; Li, Liying; Si, Kausik] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Kannan, Kasthuri] Penn State Univ, University Pk, PA 16802 USA	Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Si, K (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	ksi@stowers.org	Kannan, Kasthuri/A-5403-2013; Choi, Edward/AAQ-1502-2021	Choi, Edward/0000-0002-8148-120X; majumdar, amitabha/0000-0002-6594-0672; Unruh, Jay/0000-0003-3077-4990; Kannan, Kasthuri/0000-0002-8479-0657	NICHD; Searle Foundation; March of Dimes; Klingenstein Foundation; McKnight Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084947] Funding Source: NIH RePORTER	NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Searle Foundation; March of Dimes(March of Dimes); Klingenstein Foundation(Klingenstein Philanthropies); McKnight Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Gary Struhl, Paul Garrity, Gerry Rubin, Krystena Keleman, Douglas Armstrong, Greg Suh, Scott Wadell, Andre Fiala, and Troy Zars for the fly stocks and Patrick Verstreken for reagents for recombineering based tagging. We thank the TRiP at Harvard Medical School (NIH/NIGMS R01-GM084947) for providing transgenic RNAi fly stock. The monoclonal antibodies against CSP, Dlg, Synapsin, Syntaxin, and FasII were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA, USA. The antibodies against synaptotagmin, endophilin, and dPAK were kind gifts from Hugo Bellen and Nick Harden. We acknowledge Brian Sanderson, Eric Jessen, Kym Delventhal, and Kyle Weaver from the Stowers Institute Molecular Biology department for generating the mutant library. We thank Jenifer Krass in the Si lab for performing the blind analysis of the behavioral experiments. We are particularly thankful to Gunther Hollopeter and Dr. Rong Li of the Stowers Institute and Dr. Hiroshi Nishimune of KU Medical School for help in preparation of the manuscript. K.S. is supported by the Searle Foundation, the March of Dimes Basil O'Connor Starter Award, the Klingenstein Foundation, and the McKnight Foundation.	Alarcon JM, 2004, LEARN MEMORY, V11, P318, DOI 10.1101/lm.72704; Alberti S, 2009, CELL, V137, P146, DOI 10.1016/j.cell.2009.02.044; Aso Y, 2010, CURR BIOL, V20, P1445, DOI 10.1016/j.cub.2010.06.048; Atkins CM, 2004, J NEUROSCI, V24, P5193, DOI 10.1523/JNEUROSCI.0854-04.2004; Berry J, 2008, PROG BRAIN RES, V169, P293, DOI 10.1016/S0079-6123(07)00018-0; CHIN GJ, 1989, J NEUROSCI, V9, P38; Colomb J, 2009, GENES BRAIN BEHAV, V8, P407, DOI 10.1111/j.1601-183X.2009.00482.x; CRICK F, 1984, NATURE, V312, P101, DOI 10.1038/312101a0; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Fiumara F, 2010, CELL, V143, P1121, DOI 10.1016/j.cell.2010.11.042; Fowler DM, 2007, TRENDS BIOCHEM SCI, V32, P217, DOI 10.1016/j.tibs.2007.03.003; Hamada FN, 2008, NATURE, V454, P217, DOI 10.1038/nature07001; Hammer ND, 2007, P NATL ACAD SCI USA, V104, P12494, DOI 10.1073/pnas.0703310104; Heinrich SU, 2011, P NATL ACAD SCI USA, V108, P2999, DOI 10.1073/pnas.1019368108; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; Hou FJ, 2011, CELL, V146, P448, DOI 10.1016/j.cell.2011.06.041; Huang YS, 2006, EMBO J, V25, P4865, DOI 10.1038/sj.emboj.7601322; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Huang YS, 2003, GENE DEV, V17, P638, DOI 10.1101/gad.1053003; Iconomidou VA, 2008, CURR PROTEIN PEPT SC, V9, P291, DOI 10.2174/138920308784534041; Keleman K, 2007, NAT NEUROSCI, V10, P1587, DOI 10.1038/nn1996; Kim YC, 2007, J NEUROSCI, V27, P7640, DOI 10.1523/JNEUROSCI.1167-07.2007; Krashes MJ, 2008, J NEUROSCI, V28, P3103, DOI 10.1523/JNEUROSCI.5333-07.2008; Krashes MJ, 2009, CELL, V139, P416, DOI 10.1016/j.cell.2009.08.035; Kundel M, 2009, J NEUROSCI, V29, P13630, DOI 10.1523/JNEUROSCI.2910-08.2009; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; Mahr A, 2006, GENE EXPR PATTERNS, V6, P299, DOI 10.1016/j.modgep.2005.07.006; Maji SK, 2009, SCIENCE, V325, P328, DOI 10.1126/science.1173155; Martin KC, 2000, CURR OPIN NEUROBIOL, V10, P587, DOI 10.1016/S0959-4388(00)00128-8; Mastushita-Sakai T, 2010, P NATL ACAD SCI USA, V107, P11987, DOI 10.1073/pnas.1004433107; McBride SMJ, 1999, NEURON, V24, P967, DOI 10.1016/S0896-6273(00)81043-0; MCGUIRE SE, 2004, SCI STKE, pPL6; Miniaci MC, 2008, NEURON, V59, P1024, DOI 10.1016/j.neuron.2008.07.036; Nisimura T, 2005, J NEUROSCI, V25, P7507, DOI 10.1523/JNEUROSCI.1862-05.2005; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Saupe SJ, 2007, PRION, V1, P110, DOI 10.4161/pri.1.2.4666; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Si K, 2003, CELL, V115, P893, DOI 10.1016/S0092-8674(03)01021-3; Si K, 2010, CELL, V140, P421, DOI 10.1016/j.cell.2010.01.008; SIEGEL RW, 1979, P NATL ACAD SCI USA, V76, P3430, DOI 10.1073/pnas.76.7.3430; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Sutton MA, 2006, CELL, V127, P49, DOI 10.1016/j.cell.2006.09.014; TEMPEL BL, 1984, P NATL ACAD SCI-BIOL, V81, P3577, DOI 10.1073/pnas.81.11.3577; TEMPEL BL, 1983, P NATL ACAD SCI-BIOL, V80, P1482, DOI 10.1073/pnas.80.5.1482; Toyama BH, 2011, ANNU REV BIOCHEM, V80, P557, DOI 10.1146/annurev-biochem-090908-120656; Unoki S, 2005, EUR J NEUROSCI, V22, P1409, DOI 10.1111/j.1460-9568.2005.04318.x; Venkatesh T.R., 1980, Basic Life Sciences, V16, P313; Wells DG, 2001, J NEUROSCI, V21, P9541, DOI 10.1523/JNEUROSCI.21-24-09541.2001; Wickner RB, 2008, BIOESSAYS, V30, P955, DOI 10.1002/bies.20821; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Zearfoss NR, 2008, J NEUROSCI, V28, P8502, DOI 10.1523/JNEUROSCI.1756-08.2008	53	195	204	0	27	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					515	529		10.1016/j.cell.2012.01.004	http://dx.doi.org/10.1016/j.cell.2012.01.004			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22284910	Bronze			2022-12-28	WOS:000300225000019
J	Durkin, K; Coppieters, W; Drogemuller, C; Ahariz, N; Cambisano, N; Druet, T; Fasquelle, C; Haile, A; Horin, P; Huang, LS; Kamatani, Y; Karim, L; Lathrop, M; Moser, S; Oldenbroek, K; Rieder, S; Sartelet, A; Solkner, J; Stalhammar, H; Zelenika, D; Zhang, ZY; Leeb, T; Georges, M; Charlier, C				Durkin, Keith; Coppieters, Wouter; Droegemueller, Cord; Ahariz, Naima; Cambisano, Nadine; Druet, Tom; Fasquelle, Corinne; Haile, Aynalem; Horin, Petr; Huang, Lusheng; Kamatani, Yohichiro; Karim, Latifa; Lathrop, Mark; Moser, Simon; Oldenbroek, Kor; Rieder, Stefan; Sartelet, Arnaud; Soelkner, Johann; Stalhammar, Hans; Zelenika, Diana; Zhang, Zhiyan; Leeb, Tosso; Georges, Michel; Charlier, Carole			Serial translocation by means of circular intermediates underlies colour sidedness in cattle	NATURE			English	Article							GENE; PATTERN	Colour sidedness is a dominantly inherited phenotype of cattle characterized by the polarization of pigmented sectors on the flanks, snout and ear tips(1). It is also referred to as 'lineback' or 'witrik' (which means white back), as colour-sided animals typically display a white band along their spine. Colour sidedness is documented at least since the Middle Ages and is presently segregating in several cattle breeds around the globe, including in Belgian blue and brown Swiss(1,2). Here we report that colour sidedness is determined by a first allele on chromosome 29 (Cs-29), which results from the translocation of a 492-kilobase chromosome 6 segment encompassing KIT to chromosome 29, and a second allele on chromosome 6 (Cs-6), derived from the first by repatriation of fused 575-kilobase chromosome 6 and 29 sequences to the KIT locus. We provide evidence that both translocation events involved circular intermediates. This is the first example, to our knowledge, of a phenotype determined by homologous yet non-syntenic alleles that result from a novel copy-number-variant-generating mechanism.	[Durkin, Keith; Coppieters, Wouter; Ahariz, Naima; Cambisano, Nadine; Druet, Tom; Fasquelle, Corinne; Karim, Latifa; Sartelet, Arnaud; Zhang, Zhiyan; Georges, Michel; Charlier, Carole] Univ Liege B34, GIGA R, Unit Anim Genom, B-4000 Liege, Sart Tilman, Belgium; [Durkin, Keith; Coppieters, Wouter; Ahariz, Naima; Cambisano, Nadine; Druet, Tom; Fasquelle, Corinne; Karim, Latifa; Sartelet, Arnaud; Zhang, Zhiyan; Georges, Michel; Charlier, Carole] Univ Liege B34, Fac Vet Med, B-4000 Liege, Sart Tilman, Belgium; [Droegemueller, Cord; Leeb, Tosso] Univ Bern, Inst Genet, CH-3001 Bern, Switzerland; [Haile, Aynalem] ICARDA, Aleppo, Syria; [Horin, Petr] Univ Vet & Pharmaceut Sci Brno, Inst Genet, Brno 61242, Czech Republic; [Huang, Lusheng] Key Lab Anim Biotechnol Jiangxi Prov, Nanchang 330045, Jiangxi, Peoples R China; [Huang, Lusheng] Minist Agr China, Nanchang 330045, Jiangxi, Peoples R China; [Kamatani, Yohichiro; Lathrop, Mark; Zelenika, Diana] Ctr Etud Polymorphisme Humain, Fdn Jean Dausset, F-75012 Paris, France; [Kamatani, Yohichiro; Lathrop, Mark; Zelenika, Diana] CEA IC Ctr Natl Genotypage, F-91057 Evry, France; [Moser, Simon; Rieder, Stefan] Bern Univ Appl Sci, Swiss Coll Agr, CH-3052 Zollikofen, Switzerland; [Oldenbroek, Kor] Ctr Genet Resources Netherlands CGN, NL-6701 BH Wageningen, Netherlands; [Soelkner, Johann] Univ Nat Resources & Appl Life Sci, Div Livestock Sci, A-1180 Vienna, Austria; [Stalhammar, Hans] Viking Genet, S-53221 Ornsro, Skara, Sweden	University of Liege; University of Liege; University of Bern; CGIAR; International Center for Agricultural Research in the Dry Areas (ICARDA); University of Veterinary Sciences Brno; Ministry of Agriculture & Rural Affairs; Foundation Jean Dausset-CEPH; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Natural Resources & Life Sciences, Vienna	Georges, M (corresponding author), Univ Liege B34, GIGA R, Unit Anim Genom, 1 Ave Hop, B-4000 Liege, Sart Tilman, Belgium.	michel.georges@ulg.ac.be	Coppieters, Wouter/AAF-5030-2021; Leeb, Tosso/G-3187-2014; Horin, Petr/E-3907-2012; Kamatani, Yoichiro/N-5513-2015; Oldenbroek, Kor/AAE-6063-2019	Coppieters, Wouter/0000-0001-8109-7825; Leeb, Tosso/0000-0003-0553-4880; Druet, Tom/0000-0003-1637-1706; Durkin, Keith/0000-0001-7475-6618; Drogemuller, Cord/0000-0001-9773-522X; Solkner, Johann/0000-0002-1517-5829; Georges, Michel/0000-0003-4124-2375; Charlier, Carole/0000-0002-9694-094X	Walloon Direction General Operationnelle Agriculture, Resources Naturelles et Environnement [D31-1206, D31-1214]; Swiss National Science Foundation [31003A_133034]; GIGA-R	Walloon Direction General Operationnelle Agriculture, Resources Naturelles et Environnement; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); GIGA-R	This work was funded by the Walloon Direction General Operationnelle Agriculture, Resources Naturelles et Environnement (grants D31-1206 and D31-1214) and the Swiss National Science Foundation (grant 31003A_133034 to T. L.). We are grateful for the support of the GIGA-R Genomics platform, to P. Melvin, to G. Mekuriaw and staff of the Andassa livestock research center, Viking Genetics, Swissgenetics and the Schweizer Braunviehzuchtverband for their assistance in sample collection, to J. Vermeesch and B. Nowakowska for their assistance with array CGH.	Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Borneman AR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001287; Brooks SA, 2007, CYTOGENET GENOME RES, V119, P225, DOI 10.1159/000112065; Charlier C, 1996, MAMM GENOME, V7, P138, DOI 10.1007/s003359900034; Charlier C, 2008, NAT GENET, V40, P449, DOI 10.1038/ng.96; Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516; Drogemuller C, 2009, ANIM GENET, V40, P225, DOI 10.1111/j.1365-2052.2008.01826.x; Ge B, 2005, GENOME RES, V15, P1584, DOI 10.1101/gr.4023805; Graux C, 2009, LEUKEMIA, V23, P125, DOI 10.1038/leu.2008.278; Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu GE, 2010, GENOME RES, V20, P693, DOI 10.1101/gr.105403.110; Liu GE, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-571; Marklund S, 1998, GENOME RES, V8, P826, DOI 10.1101/gr.8.8.826; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Olson T, 1999, GENETICS OF CATTLE, P33; Porter V, 2002, MASONS WORLD DICT LI; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Selzer RR, 2005, GENE CHROMOSOME CANC, V44, P305, DOI 10.1002/gcc.20243; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907; Workman C, 2002, GENOME BIOL, V3; Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x	22	105	107	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2012	482	7383					81	U103		10.1038/nature10757	http://dx.doi.org/10.1038/nature10757			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22297974	Green Published			2022-12-28	WOS:000299726000039
J	Landon, BE				Landon, Bruce E.			Keeping Score under a Global Payment System	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ALTERNATIVE QUALITY CONTRACT; CARE		[Landon, Bruce E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Landon, BE (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.							Mechanic RE, 2011, HEALTH AFFAIR, V30, P1734, DOI 10.1377/hlthaff.2011.0264; Rittenhouse DR, 2009, NEW ENGL J MED, V361, P2301, DOI 10.1056/NEJMp0909327; Song Z, 2011, NEW ENGL J MED, V365, P909, DOI 10.1056/NEJMsa1101416	3	34	34	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					393	395		10.1056/NEJMp1112637	http://dx.doi.org/10.1056/NEJMp1112637			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	884QX	22296073				2022-12-28	WOS:000299724400003
J	Chu, H; Chung, WH				Chu, Hosuk; Chung, Won-Ho			Perilymph Fistula Test	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Chu, Hosuk; Chung, Won-Ho] Sungkyunkwan Univ, Seoul, South Korea	Sungkyunkwan University (SKKU)	Chu, H (corresponding author), Sungkyunkwan Univ, Seoul, South Korea.								0	4	4	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					E8	E8		10.1056/NEJMicm1010568	http://dx.doi.org/10.1056/NEJMicm1010568			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	881EQ	22276842				2022-12-28	WOS:000299464100008
J	Varmus, H; Harlow, E				Varmus, Harold; Harlow, Ed			Provocative questions in cancer research	NATURE			English	Editorial Material							MORTALITY; OBESITY					harold.varmus@nih.gov	Devdariani, Alexander/G-5334-2010	Devdariani, Alexander/0000-0002-0605-6705				Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603; [Anonymous], 2000, ROLE UN 21 CENTURY; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Committee on a Framework for Developing a New Taxonomy of Disease, 2011, PREC MED BUILD KNOWL; Guminski AD, 2002, LANCET ONCOL, V3, P312, DOI 10.1016/S1470-2045(02)00733-7; Hilbert D., 1902, B AM MATH SOC, V8, P437, DOI [DOI 10.1090/S0002-9904-1902-00923-3, 10.1090/S0002-9904-1902-00923-3]; McCormick F, 2011, J SURG ONCOL, V103, P464, DOI 10.1002/jso.21749; Renehan AG, 2010, EUR J CANCER, V46, P2581, DOI 10.1016/j.ejca.2010.07.052; Varmus H, 2003, SCIENCE, V302, P398, DOI 10.1126/science.1091769	9	23	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2012	481	7382					436	437		10.1038/481436a	http://dx.doi.org/10.1038/481436a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	881GY	22281578				2022-12-28	WOS:000299471800014
J	Morris, K				Morris, Kelly			Hazel Dockrell: ambassador for international health research	LANCET			English	Biographical-Item																		DOCKRELL H, PUBLICATION LIST	1	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 21	2012	379	9812					211	211		10.1016/S0140-6736(12)60090-7	http://dx.doi.org/10.1016/S0140-6736(12)60090-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	879FW	22265620				2022-12-28	WOS:000299316100023
J	Rhim, AD; Mirek, ET; Aiello, NM; Maitra, A; Bailey, JM; McAllister, F; Reichert, M; Beatty, GL; Rustgi, AK; Vonderheide, RH; Leach, SD; Stanger, BZ				Rhim, Andrew D.; Mirek, Emily T.; Aiello, Nicole M.; Maitra, Anirban; Bailey, Jennifer M.; McAllister, Florencia; Reichert, Maximilian; Beatty, Gregory L.; Rustgi, Anil K.; Vonderheide, Robert H.; Leach, Steven D.; Stanger, Ben Z.			EMT and Dissemination Precede Pancreatic Tumor Formation	CELL			English	Article							NATURAL-HISTORY; E-CADHERIN; CANCER; CELLS; INFLAMMATION; PROGRESSION; TRANSITIONS; EXPRESSION; INDUCTION; SELECTION	Metastasis is the leading cause of cancer-associated death but has been difficult to study because it involves a series of rare, stochastic events. To capture these events, we developed a sensitive method to tag and track pancreatic epithelial cells in a mouse model of pancreatic cancer. Tagged cells invaded and entered the bloodstream unexpectedly early, before frank malignancy could be detected by rigorous histologic analysis; this behavior was widely associated with epithelial-to-mesenchymal transition (EMT). Circulating pancreatic cells maintained a mesenchymal phenotype, exhibited stem cell properties, and seeded the liver. EMT and invasiveness were most abundant at inflammatory foci, and induction of pancreatitis increased the number of circulating pancreatic cells. Conversely, treatment with the immunosuppressive agent dexamethasone abolished dissemination. These results provide insight into the earliest events of cellular invasion in situ and suggest that inflammation enhances cancer progression in part by facilitating EMT and entry into the circulation.	[Rhim, Andrew D.; Mirek, Emily T.; Aiello, Nicole M.; Reichert, Maximilian; Rustgi, Anil K.; Stanger, Ben Z.] Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; [Stanger, Ben Z.] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [Rhim, Andrew D.; Mirek, Emily T.; Aiello, Nicole M.; Beatty, Gregory L.; Vonderheide, Robert H.; Stanger, Ben Z.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Rhim, Andrew D.; Mirek, Emily T.; Aiello, Nicole M.; Reichert, Maximilian; Beatty, Gregory L.; Rustgi, Anil K.; Vonderheide, Robert H.; Stanger, Ben Z.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Bailey, Jennifer M.; Leach, Steven D.] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Surg, Baltimore, MD 21231 USA; [Maitra, Anirban] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21231 USA; [McAllister, Florencia] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Oncol, Baltimore, MD 21231 USA; [McAllister, Florencia] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Clin Pharmacol, Baltimore, MD 21231 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Stanger, BZ (corresponding author), Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.	bstanger@exchange.upenn.edu	Reichert, Maximilian/GOH-1246-2022	Mirek, Emily/0000-0002-9683-8216; Beatty, Gregory/0000-0001-7165-5993; Bailey-Lundberg, Jennifer/0000-0002-4750-106X; Aiello, Nicole/0000-0003-1616-5785	NIH [DK088945, DK007066, CA134292, T32GM066691, CA138907, CA117969, DK083355, DK083111]; AGA/FDHN; National Pancreas Foundation; AACR; Pancreatic Cancer Action Network; Pennsylvania Department of Health; Pew Charitable Trusts; NATIONAL CANCER INSTITUTE [P01CA117969, K08CA138907, F32CA157044, P01CA134292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK088945, R01DK083355, P30DK019525, P30DK050306, T32DK007066, DP2DK083111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM066691] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AGA/FDHN; National Pancreas Foundation; AACR; Pancreatic Cancer Action Network; Pennsylvania Department of Health; Pew Charitable Trusts; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank I. Ben-Porath, L. Chodosh, A. Minn, A. Rustgi, M. C. Simon, and H. Zong for helpful discussions; M. Emmett, A. Pannikar, and M. Rovira for technical assistance; N. Bardeesy, R. DePinho, S. Konieczny, and D. Melton for mouse strains; and J. Habener and D. Melton for gifts of antibodies. We are grateful to R. Hruban for providing confirmation of histological impressions. This work was supported by the NIH (DK088945 and DK007066 to A. D. R., CA134292 to A. M. and S. D. L., T32GM066691 to F. M., CA138907 to G. L. B., CA117969, DK083355, and DK083111 to B.Z.S.), AGA/FDHN (A. D. R.), National Pancreas Foundation (A. D. R. and M. R.), AACR and Pancreatic Cancer Action Network (Pathway to Leadership Award to J. M. B. and Career Development Award to B.Z.S.), Pennsylvania Department of Health (R. H. V. and B.Z.S.), and the Pew Charitable Trusts (B.Z.S.). Experiments utilized the Molecular Pathology and Imaging, Molecular Biology, and Cell Culture core facilities within the NIH/Penn Center for Molecular Studies in Digestive and Liver Diseases (P30-DK050306), the Abramson Family Cancer Research Institute, and the Diabetes and Endocrine Research Center (P30-DK19525).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Greco FA, 2009, SEMIN ONCOL, V36, P6, DOI 10.1053/j.seminoncol.2008.10.007; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grover S, 2010, GASTROENTEROLOGY, V139, P1076, DOI 10.1053/j.gastro.2010.08.012; Gu GQ, 2003, MECH DEVELOP, V120, P35, DOI 10.1016/S0925-4773(02)00330-1; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Gupta PB, 2005, COLD SH Q B, V70, P291, DOI 10.1101/sqb.2005.70.033; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HELLMAN S, 1994, J CLIN ONCOL, V12, P2229, DOI 10.1200/JCO.1994.12.10.2229; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Ignatiadis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015624; Jimeno A, 2009, MOL CANCER THER, V8, P310, DOI 10.1158/1535-7163.MCT-08-0924; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Ledford H, 2011, NATURE, V472, P273, DOI 10.1038/472273a; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mohammad RM, 1998, PANCREAS, V16, P19, DOI 10.1097/00006676-199801000-00004; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Okimura A, 2009, MED MOL MORPHOL, V42, P222, DOI 10.1007/s00795-009-0462-y; Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375; Park JY, 2011, APPL IMMUNOHISTO M M, V19, P444, DOI 10.1097/PAI.0b013e318206d958; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Rovira M, 2010, P NATL ACAD SCI USA, V107, P75, DOI 10.1073/pnas.0912589107; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Sakorafas GH, 2003, DIGEST LIVER DIS, V35, P482, DOI 10.1016/S1590-8658(03)00221-4; Sivere JT, 2008, GASTROENTEROLOGY, V134, P544, DOI 10.1053/j.gastro.2007.11.003; Stairs DB, 2011, CANCER CELL, V19, P470, DOI 10.1016/j.ccr.2011.02.007; Stoecklein NH, 2008, CANCER CELL, V13, P441, DOI 10.1016/j.ccr.2008.04.005; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Wang F, 2007, CANCER RES, V67, P8486, DOI 10.1158/0008-5472.CAN-07-0498; Weinberg RA, 2008, CARCINOGENESIS, V29, P1092, DOI 10.1093/carcin/bgn104; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	47	1416	1466	7	288	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					349	361		10.1016/j.cell.2011.11.025	http://dx.doi.org/10.1016/j.cell.2011.11.025			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265420	Bronze, Green Accepted			2022-12-28	WOS:000299540700036
J	Su, F; Viros, A; Milagre, C; Trunzer, K; Bollag, G; Spleiss, O; Reis, JS; Kong, XJ; Koya, RC; Flaherty, KT; Chapman, PB; Kim, MJ; Hayward, R; Martin, M; Yang, H; Wang, QQ; Hilton, H; Hang, JS; Noe, J; Lambros, M; Geyer, F; Dhomen, N; Niculescu-Duvaz, I; Zambon, A; Niculescu-Duvaz, D; Preece, N; Robert, L; Otte, NJ; Mok, S; Kee, D; Ma, Y; Zhang, C; Habets, G; Burton, EA; Wong, B; Nguyen, H; Kockx, M; Andries, L; Lestini, B; Nolop, KB; Lee, RJ; Joe, AK; Troy, JL; Gonzalez, R; Hutson, TE; Puzanov, I; Chmielowski, B; Springer, CJ; McArthur, GA; Sosman, JA; Lo, RS; Ribas, A; Marais, R				Su, Fei; Viros, Amaya; Milagre, Carla; Trunzer, Kerstin; Bollag, Gideon; Spleiss, Olivia; Reis-Filho, Jorge S.; Kong, Xiangju; Koya, Richard C.; Flaherty, Keith T.; Chapman, Paul B.; Kim, Min Jung; Hayward, Robert; Martin, Matthew; Yang, Hong; Wang, Qiongqing; Hilton, Holly; Hang, Julie S.; Noe, Johannes; Lambros, Maryou; Geyer, Felipe; Dhomen, Nathalie; Niculescu-Duvaz, Ion; Zambon, Alfonso; Niculescu-Duvaz, Dan; Preece, Natasha; Robert, Lidia; Otte, Nicholas J.; Mok, Stephen; Kee, Damien; Ma, Yan; Zhang, Chao; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Hoa Nguyen; Kockx, Mark; Andries, Luc; Lestini, Brian; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Troy, James L.; Gonzalez, Rene; Hutson, Thomas E.; Puzanov, Igor; Chmielowski, Bartosz; Springer, Caroline J.; McArthur, Grant A.; Sosman, Jeffrey A.; Lo, Roger S.; Ribas, Antoni; Marais, Richard			RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATION; MELANOMA; KINASE; CARCINOGENESIS; PROLIFERATION; VEMURAFENIB; RESISTANCE; PLX4032; PATHWAY; LINES	BACKGROUND Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors. METHODS We performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib. An analysis of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed. RESULTS Among 21 tumor samples, 13 had RAS mutations (12 in HRAS). In a validation set of 14 samples, 8 had RAS mutations (4 in HRAS). Thus, 60% (21 of 35) of the specimens harbored RAS mutations, the most prevalent being HRAS Q61L. Increased proliferation of HRAS Q61L-mutant cell lines exposed to vemurafenib was associated with mitogen-activated protein kinase (MAPK)-pathway signaling and activation of ERK-mediated transcription. In a mouse model of HRAS Q61L-mediated skin carcinogenesis, the vemurafenib analogue PLX4720 was not an initiator or a promoter of carcinogenesis but accelerated growth of the lesions harboring HRAS mutations, and this growth was blocked by concomitant treatment with a MEK inhibitor. CONCLUSIONS Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib. The molecular mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions. (Funded by Hoffmann-La Roche and others; ClinicalTrials.gov numbers, NCT00405587, NCT00949702, NCT01001299, and NCT01006980.)	[Ribas, Antoni] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Med Ctr, Los Angeles, CA 90095 USA; [Su, Fei; Kim, Min Jung; Yang, Hong; Wang, Qiongqing; Hilton, Holly; Hang, Julie S.; Lestini, Brian; Lee, Richard J.; Joe, Andrew K.] Hoffmann La Roche, Nutley, NJ USA; [Viros, Amaya; Milagre, Carla; Reis-Filho, Jorge S.; Hayward, Robert; Martin, Matthew; Lambros, Maryou; Geyer, Felipe; Dhomen, Nathalie; Niculescu-Duvaz, Ion; Zambon, Alfonso; Niculescu-Duvaz, Dan; Preece, Natasha; Springer, Caroline J.; Marais, Richard] Inst Canc Res, London SW3 6JB, England; [Viros, Amaya] Univ Autonoma Barcelona, Hosp Vall dHebron, E-08193 Barcelona, Spain; [Trunzer, Kerstin; Spleiss, Olivia; Noe, Johannes] Hoffmann La Roche AG, Basel, Switzerland; [Bollag, Gideon; Ma, Yan; Zhang, Chao; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Hoa Nguyen; Nolop, Keith B.] Plexxikon, Berkeley, CA USA; [Kong, Xiangju; Koya, Richard C.; Robert, Lidia; Otte, Nicholas J.; Mok, Stephen; Chmielowski, Bartosz; Lo, Roger S.; Ribas, Antoni] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA; [Flaherty, Keith T.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Flaherty, Keith T.] Harvard Univ, Sch Med, Boston, MA USA; [Chapman, Paul B.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Kee, Damien; McArthur, Grant A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Kockx, Mark; Andries, Luc] HistoGeneX, Antwerp, Belgium; [Troy, James L.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Gonzalez, Rene] Univ Colorado, Ctr Canc, Aurora, CO USA; [Hutson, Thomas E.] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA; [Puzanov, Igor; Sosman, Jeffrey A.] Vanderbilt Univ, Nashville, TN USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Roche Holding; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Autonomous University of Barcelona; Roche Holding; Plexxikon; UCLA Jonsson Comprehensive Cancer Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Peter Maccallum Cancer Center; Medical College of Wisconsin; University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor University Medical Center; Vanderbilt University	Ribas, A (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Med Ctr, 11-934 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	aribas@mednet.ucla.edu; richard.marais@icr.ac.uk	Hutson, Thomas/AAS-9639-2020; Zambon, Alfonso/J-2529-2012; PUZANOV, IGOR/AAP-2966-2020; Zambon, Alfonso/AFC-3324-2022; gonzález, rene/W-2081-2019	Hutson, Thomas/0000-0002-4529-4212; Zambon, Alfonso/0000-0002-8074-2308; PUZANOV, IGOR/0000-0002-9803-3497; Zambon, Alfonso/0000-0002-8074-2308; , Matthew/0000-0002-8948-961X; Springer, Caroline/0000-0002-0650-4002; Dhomen, Nathalie/0000-0003-1961-2173; Viros, Amaya/0000-0001-5177-5015; Chmielowski, Bartosz/0000-0002-2374-3320; McArthur, Grant/0000-0001-8908-6071; Marais, Richard/0000-0001-7484-4183	Hoffmann-La Roche; Plexxikon; Seaver Institute; Louise Belley and Richard Schnarr Fund; Fred L. Hartley Family Foundation; Wesley Coyle Memorial Fund; Ruby Family Foundation; Albert Stroberg and Betsy Patterson Fund; Jonsson Cancer Center Foundation; Caltech-UCLA Joint Center for Translational Medicine; European Organisation for Research and Treatment of Cancer Melanoma Group, Cancer Research U.K. (CRUK) [C107/A10433, CRUK-A8274]; American Institute for Cancer Research [09-0773]; Institute of Cancer Research; Breakthrough Breast Cancer; NATIONAL CANCER INSTITUTE [K22CA151638, K24CA097588] Funding Source: NIH RePORTER; Cancer Research UK [11566, 19279] Funding Source: researchfish	Hoffmann-La Roche(Hoffmann-La Roche); Plexxikon; Seaver Institute; Louise Belley and Richard Schnarr Fund; Fred L. Hartley Family Foundation; Wesley Coyle Memorial Fund; Ruby Family Foundation; Albert Stroberg and Betsy Patterson Fund; Jonsson Cancer Center Foundation; Caltech-UCLA Joint Center for Translational Medicine; European Organisation for Research and Treatment of Cancer Melanoma Group, Cancer Research U.K. (CRUK); American Institute for Cancer Research; Institute of Cancer Research; Breakthrough Breast Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK)	Supported in part by Hoffmann-La Roche and Plexxikon (to Drs. Su, Trunzer, and Bollag); the Seaver Institute, the Louise Belley and Richard Schnarr Fund, the Fred L. Hartley Family Foundation, the Wesley Coyle Memorial Fund, the Ruby Family Foundation, the Albert Stroberg and Betsy Patterson Fund, the Jonsson Cancer Center Foundation, and the Caltech-UCLA Joint Center for Translational Medicine (to Drs. Lo and Ribas); the European Organisation for Research and Treatment of Cancer Melanoma Group, Cancer Research U.K. (CRUK) (C107/A10433 and CRUK-A8274), the American Institute for Cancer Research (09-0773), and the Institute of Cancer Research (to Dr. Marais); and Breakthrough Breast Cancer and the 2010 CRUK Future Leaders Prize in Cancer Research (to Dr. Reis-Filho).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Alam M, 2001, NEW ENGL J MED, V344, P975, DOI 10.1056/NEJM200103293441306; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; BURNS PA, 1991, ONCOGENE, V6, P1973; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Infante JR, 2011, J CLIN ONCOL, V29; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kefford R, 2010, J CLIN ONCOL S, V28, p611s; Koya RC, 2002, LEUKEMIA, V16, P1645, DOI 10.1038/sj.leu.2402582; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Niehr F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-76; Oberholzer PA, 2011, J CLIN ONCOL    1107; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Ribas A, 2011, J CLIN ONCOL, V29, P8509; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Uribe P, 2011, PATHOL RES PRACT, V207, P337, DOI 10.1016/j.prp.2011.03.002; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; White AC, 2011, P NATL ACAD SCI USA, V108, P7425, DOI 10.1073/pnas.1012670108; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646	34	796	808	2	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					207	215		10.1056/NEJMoa1105358	http://dx.doi.org/10.1056/NEJMoa1105358			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877RZ	22256804	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000299201400006
J	Klein, L				Klein, Liviu			Apixaban reduced stroke and systemic embolism compared with warfarin in atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Klein, L (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.							Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; del Zoppo GJ, 2011, NEW ENGL J MED, V365, P952, DOI 10.1056/NEJMe1107516; Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017	3	0	0	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-2	10.7326/0003-4819-156-2-201201170-02002	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02002			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31YU	22250164				2022-12-28	WOS:000208919700001
J	Sandhaus, RA				Sandhaus, Robert A.			Gene Therapy Meets Stem Cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sandhaus, Robert A.] Natl Jewish Hlth, Denver, CO USA; [Sandhaus, Robert A.] AlphaNet, Miami, FL USA	National Jewish Health	Sandhaus, RA (corresponding author), Natl Jewish Hlth, Denver, CO USA.							Yusa K, 2011, NATURE, V478, P391, DOI 10.1038/nature10424	1	8	8	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					567	569		10.1056/NEJMcibr1113400	http://dx.doi.org/10.1056/NEJMcibr1113400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888GH	22316453				2022-12-28	WOS:000299991300015
J	van de Water, W; Markopoulos, C; van de Velde, CJH; Seynaeve, C; Hasenburg, A; Rea, D; Putter, H; Nortier, JWR; de Craen, AJM; Hille, ETM; Bastiaannet, E; Hadji, P; Westendorp, RGJ; Liefers, GJ; Jones, SE				van de Water, Willemien; Markopoulos, Christos; van de Velde, Cornelis J. H.; Seynaeve, Caroline; Hasenburg, Annette; Rea, Daniel; Putter, Hein; Nortier, Johan W. R.; de Craen, Anton J. M.; Hille, Elysee T. M.; Bastiaannet, Esther; Hadji, Peyman; Westendorp, Rudi G. J.; Liefers, Gerrit-Jan; Jones, Stephen E.			Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor-Positive Breast Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPETING CAUSES; INTERNATIONAL-SOCIETY; DEATH; STAGE; OLDER; RECOMMENDATIONS; GUIDELINES; SURVIVAL; THERAPY	Context In addition to classic tumor-related prognostic factors, patient characteristics may be associated with breast cancer outcome. Objective To assess the association between age at diagnosis and breast cancer outcome in postmenopausal women with hormone receptor-positive breast cancer. Design, Setting, and Patients Study analysis of 9766 patients enrolled in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) randomized clinical trial between January 2001 and January 2006. Age at diagnosis was categorized as younger than 65 years (n=5349), 65 to 74 years (n=3060), and 75 years or older (n=1357). Main Outcome Measures Primary end point was disease-specific mortality; secondary end points were other-cause mortality and breast cancer relapse. Results During median follow-up of approximately 5.1 years, there were a total of 1043 deaths. Disease-specific mortality, as a proportion of all-cause mortality, decreased with categorical age group (78% [<65 years], 56% [65-74 years], and 36% [>= 75 years]; P<.001). In multivariable analyses, compared with patients younger than 65 years, disease-specific mortality increased with age for patients aged 65 to 74 years (hazard ratio [HR], 1.25; 95% CI, 1.01-1.54); and patients aged 75 years or older (HR, 1.63; 95% CI, 1.23-2.16) (P<.001). Similarly, breast cancer relapse increased with age for patients aged 65-74 years (HR, 1.07; 95% CI, 0.91-1.25 and patients aged 75 years or older (HR, 1.29; 95% CI, 1.05-1.60) (P=.06). Other-cause mortality increased with age in patients aged 65 to 74 years (HR, 2.66; 95% CI, 1.96-3.63) and patients aged 75 years or older (HR, 7.30; 95% CI, 5.29-10.07) (P<.001). Conclusion Among postmenopausal women with hormone receptor-positive breast cancer, increasing age was associated with a higher disease-specific mortality. JAMA. 2012;307(6):590-597	[van de Water, Willemien; van de Velde, Cornelis J. H.; Hille, Elysee T. M.; Bastiaannet, Esther; Liefers, Gerrit-Jan] Leiden Univ, Med Ctr, Dept Surg Oncol, NL-2300 RC Leiden, Netherlands; [van de Water, Willemien; de Craen, Anton J. M.; Bastiaannet, Esther; Westendorp, Rudi G. J.] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands; [Putter, Hein] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands; [Nortier, Johan W. R.] Leiden Univ, Med Ctr, Dept Med Oncol, NL-2300 RC Leiden, Netherlands; [Markopoulos, Christos] Univ Athens, Sch Med, Dept Surg, Breast Unit, GR-11527 Athens, Greece; [Seynaeve, Caroline] Erasmus MC, Daniel Den Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands; [Hasenburg, Annette] Univ Hosp Freiburg, Dept Obstet & Gynecol, Freiburg, Germany; [Rea, Daniel] Univ Birmingham, Dept Med Oncol, Birmingham, W Midlands, England; [Hadji, Peyman] Univ Marburg, Dept Gynecol, Marburg, Germany; [Jones, Stephen E.] US Oncol Res, Dept Med Oncol, The Woodlands, TX USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Athens Medical School; National & Kapodistrian University of Athens; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Freiburg; University of Birmingham; Philipps University Marburg; US Oncology Network	van de Velde, CJH (corresponding author), Leiden Univ, Med Ctr, Dept Surg Oncol, Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	c.j.h.van_de_velde@lumc.nl	Putter, Hein/C-2244-2018; Markopoulos, Christos/AAD-8501-2019; van de Velde, Cornelis/AAY-8360-2020	Putter, Hein/0000-0001-5395-1422; Markopoulos, Christos/0000-0002-5072-6390; 	Pfizer; AstraZeneca UK; Novartis; Dutch Cancer Society (KWF); USOncology Research	Pfizer(Pfizer); AstraZeneca UK(AstraZeneca); Novartis(Novartis); Dutch Cancer Society (KWF)(KWF Kankerbestrijding); USOncology Research	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Markopoulos reported receipt of an institutional grant from Pfizer; honoraria for lectures from Pfizer, AstraZeneca UK, and Novartis; and has institutional grants pending from AstraZeneca UK and Novartis. Dr van de Velde reported receipt of an institutional grant from Pfizer and reported membership on the European Cancer Organization board. Dr Hasenburg reported receipt of an institutional consulting fee from Pfizer; support for travel to study meetings from Pfizer, GlaxoSmithKline, Sanofi Pasteur, AstraZeneca, Medconcept, Amgen, and Merck Sharp & Dohme; fees for participation in review activities from Pfizer; and payment for lectures from Pfizer, GlaxoSmithKline, Sanofi Pasteur, AstraZeneca, Medconcept, Amgen, and Merck Sharp & Dohme. Dr Rea reported receipt of an institutional grant from Pfizer and support for travel to study meetings from Pfizer. Dr de Craen reported receipt of an institutional grant from the Dutch Cancer Society (KWF). Dr Hille reported receipt of an institutional grant from Pfizer and has institutional grants pending from Pfizer and the Dutch Cancer Society (KWF). Dr Hadji reported receipt of an institutional research grant and a lecture fee and support for traveling to TEAM Steering Committee Meetings from Pfizer. Dr Jones reported receipt of an institutional research grant from USOncology Research, support to travel to meetings from Pfizer, and being an adviser and member Pfizer USA's speaker's bureau. The other authors reported no potential conflict of interest.	Allemani C, 2010, EUR J CANCER, V46, P1528, DOI 10.1016/j.ejca.2010.02.016; [Anonymous], 2009, INT SOC GER ONC ANN; Bastiaannet E, 2010, BREAST CANCER RES TR, V124, P801, DOI 10.1007/s10549-010-0898-8; Braithwaite D, 2010, JNCI-J NATL CANCER I, V102, P1468, DOI 10.1093/jnci/djq344; Chapman JAW, 2008, JNCI-J NATL CANCER I, V100, P252, DOI 10.1093/jnci/djn014; de Wreede LC, 2010, COMPUT METH PROG BIO, V99, P261, DOI 10.1016/j.cmpb.2010.01.001; Diab SG, 2000, J NATL CANCER I, V92, P550, DOI 10.1093/jnci/92.7.550; Du XL, 2008, AM J CLIN ONCOL-CANC, V31, P105, DOI 10.1097/COC.0b013e318142c865; Durbecq V, 2010, MANAGEMENT OF BREAST CANCER IN OLDER WOMEN, P21, DOI 10.1007/978-1-84800-265-4_2; Eisinger F, 2007, INT J CANCER, V120, P1136, DOI 10.1002/ijc.22444; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fish EB, 1998, ANN SURG ONCOL, V5, P368, DOI 10.1007/BF02303502; Gennari R, 2004, CANCER-AM CANCER SOC, V101, P1302, DOI 10.1002/cncr.20535; Giordano SH, 2005, J CLIN ONCOL, V23, P783, DOI 10.1200/JCO.2005.04.175; Hanrahan EO, 2007, J CLIN ONCOL, V25, P4952, DOI 10.1200/JCO.2006.08.0499; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Latouche A, 2007, STAT MED, V26, P5370, DOI 10.1002/sim.3114; Lewis JH, 2003, J CLIN ONCOL, V21, P1383, DOI 10.1200/JCO.2003.08.010; Lichtman SM, 2007, EUR J CANCER, V43, P14, DOI 10.1016/j.ejca.2006.11.004; Mell LK, 2010, CANCER-AM CANCER SOC, V116, P5365, DOI 10.1002/cncr.25370; National Cancer Institute, CANC STAT FACT SHEET; Pallis AG, 2010, EUR J CANCER, V46, P1502, DOI 10.1016/j.ejca.2010.02.022; Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712; Schairer C, 2004, JNCI-J NATL CANCER I, V96, P1311, DOI 10.1093/jnci/djh253; van de Velde CJH, 2011, LANCET, V377, P321, DOI 10.1016/S0140-6736(10)62312-4; van de Water W, ONCOLOGIST, DOI [10.1634/theoncologist2011-0037, DOI 10.1634/THEONCOLOGIST2011-0037]; van Nes JGH, 2010, BRIT J SURG, V97, P671, DOI 10.1002/bjs.6962; White J, 2003, CANCER-AM CANCER SOC, V97, P893, DOI 10.1002/cncr.11141; Wildiers H, 2007, LANCET ONCOL, V8, P1101, DOI 10.1016/S1470-2045(07)70378-9; Yancik R, 2001, JAMA-J AM MED ASSOC, V285, P885, DOI 10.1001/jama.285.7.885; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936; Zulman DM, 2011, J GEN INTERN MED, V26, P783, DOI 10.1007/s11606-010-1629-x	32	146	148	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					590	597		10.1001/jama.2012.84	http://dx.doi.org/10.1001/jama.2012.84			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318280	Bronze			2022-12-28	WOS:000299992500023
J	Vesper, HW; Kuiper, HC; Mirel, LB; Johnson, CL; Pirkle, JL				Vesper, Hubert W.; Kuiper, Heather C.; Mirel, Lisa B.; Johnson, Clifford L.; Pirkle, James L.			Levels of Plasma trans-Fatty Acids in Non-Hispanic White Adults in the United States in 2000 and 2009	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Vesper, Hubert W.; Kuiper, Heather C.; Pirkle, James L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; [Mirel, Lisa B.; Johnson, Clifford L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Vesper, HW (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.	hvesper@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Centers for Disease Control and Prevention, NAT HLTH NUTR EX SUR; Gebauer SK, 2007, LIPIDS, V42, P787, DOI 10.1007/s11745-007-3095-8; Lagerstedt SA, 2001, MOL GENET METAB, V73, P38, DOI 10.1006/mgme.2001.3170; Mossoba MM, 2009, OFFICIAL METHODS DET, P20; Mozaffarian D, 2009, EUR J CLIN NUTR, V63, pS5, DOI 10.1038/sj.ejcn.1602973; [No title captured]	6	68	69	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					562	563		10.1001/jama.2012.112	http://dx.doi.org/10.1001/jama.2012.112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318273	Green Accepted, Bronze			2022-12-28	WOS:000299992500014
J	Detsky, AS; Gauthier, SR; Fuchs, VR				Detsky, Allan S.; Gauthier, Stephen R.; Fuchs, Victor R.			Specialization in Medicine How Much Is Appropriate?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYOCARDIAL-INFARCTION; UNITED-STATES; MORTALITY; OUTCOMES; CANADA; CARE		[Detsky, Allan S.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Detsky, Allan S.; Gauthier, Stephen R.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada; [Fuchs, Victor R.] Stanford Univ, Dept Econ, Stanford, CA 94305 USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Stanford University	Detsky, AS (corresponding author), 600 Univ Ave,Room 429, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca		Gauthier, Stephen/0000-0002-6133-3066				Baicker K, 2004, HEALTH AFFAIR, V23, pW4184, DOI 10.1377/hlthaff.W4.184; Kaul P, 2004, CIRCULATION, V110, P1754, DOI 10.1161/01.CIR.0000142671.06167.91; Levy MM, 2008, ANN INTERN MED, V148, P801, DOI 10.7326/0003-4819-148-11-200806030-00002; Lipscombe LL, 2005, ARCH INTERN MED, V165, P2090, DOI 10.1001/archinte.165.18.2090; OECD, 2011, OECD HLTH DAT HLTH C, DOI [10.1787/data-00541-en, DOI 10.1787/DATA-00541-EN]; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; 2005, AM FAM PHYS, V71, P2260	8	27	27	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					463	464		10.1001/jama.2012.44	http://dx.doi.org/10.1001/jama.2012.44			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22298676				2022-12-28	WOS:000299728000025
J	Pelletier, D; Hafler, DA				Pelletier, Daniel; Hafler, David A.			Fingolimod for Multiple Sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SPHINGOSINE 1-PHOSPHATE; ORAL FINGOLIMOD; INTRAMUSCULAR INTERFERON; NATURAL-HISTORY; T-CELLS; FTY720; SURVIVAL; PROLIFERATION; NATALIZUMAB	A 37-year-old man with multiple sclerosis was evaluated for consideration of oral immunotherapy. Six years earlier, he had reported acute monocular visual disturbance. The diagnosis of multiple sclerosis was subsequently confirmed by means of examination of cerebrospinal fluid, which revealed an increased IgG index and oligoclonal banding, and by abnormal results on magnetic resonance imaging (MRI). There was no family history of multiple sclerosis. Daily injections of glatiramer acetate were initiated at the time of diagnosis, but two consecutive annual brain MRI scans revealed substantial disease activity. He was then switched to interferon beta therapy, but this treatment was discontinued after the patient had two episodes of acute neurologic worsening. Monthly natalizumab therapy was then considered, but a test for JC virus antibodies was positive. Neurologic examination showed disk pallor and visual acuity of 20/40 in the right eye, partial internuclear ophthalmoplegia, wide-based gait, and posterior column deficits in both legs. The patient was referred to a specialist in multiple sclerosis for consideration of oral fingolimod therapy.	[Pelletier, Daniel] Yale Univ, Dept Neurol, Sch Med, Yale Multiple Sclerosis Ctr, New Haven, CT 06520 USA; Yale Univ, Dept Immunobiol, Sch Med, New Haven, CT 06520 USA	Yale University; Yale University	Pelletier, D (corresponding author), Yale Univ, Dept Neurol, Sch Med, Yale Multiple Sclerosis Ctr, 15 York St,LLCI 709,POB 208018, New Haven, CT 06520 USA.	daniel.pelletier@yale.edu			Synarc; Bayer; Biogen Idec; Genetech; Teva Neuroscience; EMD Serono; Novartis; Revalesio; Sanofi-Aventis; McKinsey; NKT Therapeutics; Pfizer	Synarc; Bayer(Bayer AG); Biogen Idec(Biogen); Genetech; Teva Neuroscience(Teva Pharmaceutical Industries); EMD Serono; Novartis(Novartis); Revalesio; Sanofi-Aventis(Sanofi-Aventis); McKinsey; NKT Therapeutics; Pfizer(Pfizer)	Dr. Pelletier reports receiving consulting fees from Synarc, Bayer, Biogen Idec, Genetech, Teva Neuroscience, EMD Serono, Novartis, and Revalesio and grant support from Biogen Idec; and Dr. Hafler, receiving consulting fees from Sanofi-Aventis, McKinsey, NKT Therapeutics, Novartis, Biogen Idec, Teva Neuroscience, and Pfizer and owning stock options in NKT Therapeutics. No other potential conflict of interest relevant to this article was reported.	[Anonymous], NCT00731692 CLINICAL; [Anonymous], 2010, GIL FING CAPS MED GU; Brinkmann V, 2001, TRANSPLANT P, V33, P530, DOI 10.1016/S0041-1345(00)02126-6; Brinkmann V, 2006, CURR OPIN PHARMACOL, V6, P244, DOI 10.1016/j.coph.2005.12.004; Bronnum-Hansen H, 2004, BRAIN, V127, P844, DOI 10.1093/brain/awh104; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Comi G, 2010, LANCET, V375, P1436; Comi G, 2010, MULT SCLER, V16, P197, DOI 10.1177/1352458509357065; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Compston A, 2006, MCALPINES MULTIPLE S, V4th; Conzett KB, 2011, ARCH DERMATOL, V147, P991, DOI 10.1001/archdermatol.2011.212; Edsall LC, 1997, J NEUROSCI, V17, P6952; Espinosa PS, 2011, MULT SCLER J, V17, P1387, DOI 10.1177/1352458511410344; FDA Drug Safety Communication, FDA DRUG SAF COMM SA; Gorelik L, 2010, ANN NEUROL, V68, P295, DOI 10.1002/ana.22128; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Hafler DA, 2005, IMMUNOL REV, V204, P208, DOI 10.1111/j.0105-2896.2005.00240.x; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Hartung HP, 2009, ANN NEUROL, V66, P429, DOI 10.1002/ana.21880; Hu YH, 2011, MOL CELL NEUROSCI, V48, P72, DOI 10.1016/j.mcn.2011.06.007; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Kappos L, 2006, NEUROLOGY, V67, P1242, DOI 10.1212/01.wnl.0000237641.33768.8d; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Kobelt G, 2006, NEUROLOGY, V66, P1696, DOI 10.1212/01.wnl.0000218309.01322.5c; Koyrakh L, 2005, AM J TRANSPLANT, V5, P529, DOI 10.1111/j.1600-6143.2005.00754.x; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Le Page E, 2011, MULT SCLER J, V17, P867, DOI 10.1177/1352458511398371; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mehling M, 2008, NEUROLOGY, V71, P1261, DOI 10.1212/01.wnl.0000327609.57688.ea; Mehling M, 2010, NEUROLOGY, V75, P403, DOI 10.1212/WNL.0b013e3181ebdd64; Miron VE, 2008, ANN NEUROL, V63, P61, DOI 10.1002/ana.21227; Miron VE, 2010, AM J PATHOL, V176, P2682, DOI 10.2353/ajpath.2010.091234; Pham THM, 2008, IMMUNITY, V28, P122, DOI 10.1016/j.immuni.2007.11.017; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; SADOVNICK AD, 1992, NEUROLOGY, V42, P991, DOI 10.1212/WNL.42.5.991; Schwab SR, 2007, NAT IMMUNOL, V8, P1295, DOI 10.1038/ni1545; Tremlett H, 2008, MULT SCLER J, V14, P314, DOI 10.1177/1352458507084264; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; Yamagata K, 2003, GLIA, V41, P199, DOI 10.1002/glia.10180; Zhou PJ, 2009, CLIN EXP IMMUNOL, V157, P40, DOI 10.1111/j.1365-2249.2009.03942.x	42	213	219	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					339	347		10.1056/NEJMct1101691	http://dx.doi.org/10.1056/NEJMct1101691			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EQ	22276823				2022-12-28	WOS:000299464100005
J	Emanuel, EJ; Pearson, SD				Emanuel, Ezekiel J.; Pearson, Steven D.			Physician Autonomy and Health Care Reform	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Emanuel, Ezekiel J.] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA; [Pearson, Steven D.] Massachusetts Gen Hosp, Inst Technol Assessment, Inst Clin & Econ Review, Boston, MA 02114 USA	University of Pennsylvania; Pennsylvania Medicine; Harvard University; Massachusetts General Hospital	Emanuel, EJ (corresponding author), Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, 122 Coll Hall, Philadelphia, PA 19104 USA.	zemanuel@upenn.edu						Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Berwick DM, 2011, NEW ENGL J MED, V365, P1753, DOI 10.1056/NEJMp1111671; Brook RH, 2011, JAMA-J AM MED ASSOC, V306, P2020, DOI 10.1001/jama.2011.1621; Buchbinder R, 2009, NEW ENGL J MED, V361, P557, DOI 10.1056/NEJMoa0900429; DWORKIN G, 1988, THEORY PRACTICE AUTO, pCH1; Milstein A, 2009, HEALTH AFFAIR, V28, P1317, DOI 10.1377/hlthaff.28.5.1317; Reinertsen JL, 2003, ANN INTERN MED, V138, P992, DOI 10.7326/0003-4819-138-12-200306170-00011; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; Thomson-Reuters, 2011 NAT PHYS SURV F	9	43	45	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2012	307	4					367	368		10.1001/jama.2012.19	http://dx.doi.org/10.1001/jama.2012.19			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EP	22274681				2022-12-28	WOS:000299464000020
J	Peters, M; Heijboer, H; Smiers, F; Giordano, PC				Peters, M.; Heijboer, H.; Smiers, F.; Giordano, P. C.			Diagnosis and management of thalassaemia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BETA-THALASSEMIA; IRON-CHELATION; CELL TRANSPLANTATION; SURVIVAL; DEFERASIROX; THERAPY; IMPROVEMENT		[Peters, M.; Heijboer, H.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Paediat Haematol, NL-1105 AZ Amsterdam, Netherlands; [Smiers, F.] Leiden Univ, Med Ctr, Haematol Oncol & Bone Marrow Transplant Unit, Dept Paediat, Leiden, Netherlands; [Giordano, P. C.] Leiden Univ, Med Ctr, Dept Human & Clin Genet, Haemoglobinopathies Lab, Leiden, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Peters, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Paediat Haematol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.peters@amc.uva.nl						Anderson LJ, 2001, EUR HEART J, V22, P2171, DOI 10.1053/euhj.2001.2822; Angelucci E, 2000, NEW ENGL J MED, V343, P327, DOI 10.1056/NEJM200008033430503; Borgna-Pignatti C, 2005, ANN NY ACAD SCI, V1054, P40, DOI 10.1196/annals.1345.006; Brittenham GM, 2011, NEW ENGL J MED, V364, P146, DOI 10.1056/NEJMct1004810; Cao A, 2002, INT J HEMATOL, V76, P105, DOI 10.1007/BF03165098; Cappellini M.-D., 2008, GUIDELINES CLIN MANA, V2nd; Cappellini MD, 2011, BLOOD, V118, P884, DOI 10.1182/blood-2010-11-316646; Castiella A, 2011, EUR RADIOL, V21, P137, DOI 10.1007/s00330-010-1899-z; Deugnier Y, 2011, GASTROENTEROLOGY, V141, P1202, DOI 10.1053/j.gastro.2011.06.065; Di Bartolomeo P, 2008, AM J HEMATOL, V83, P528, DOI 10.1002/ajh.21175; Flint J, 1998, BAILLIERE CLIN HAEM, V11, P1, DOI 10.1016/S0950-3536(98)80069-3; Galanello R, 2010, ANN NY ACAD SCI, V1202, P79, DOI 10.1111/j.1749-6632.2010.05591.x; Gardenghi S, 2007, BLOOD, V109, P5027, DOI 10.1182/blood-2006-09-048868; Giardine B, 2007, HUM MUTAT, V28, DOI 10.1002/humu.9479; Higgs DR, 2008, THALASSAEMIA SYNDROM, P133; Kirk P, 2009, CIRCULATION, V120, P1961, DOI 10.1161/CIRCULATIONAHA.109.874487; La Nasa G, 2005, ANN NY ACAD SCI, V1054, P186, DOI 10.1196/annals.1345.023; Lal A, 2011, NEW ENGL J MED, V364, P710, DOI 10.1056/NEJMoa1010174; Lorey F, 2001, BRIT J HAEMATOL, V115, P72, DOI 10.1046/j.1365-2141.2001.03080.x; Modell B, 2000, LANCET, V355, P2051, DOI 10.1016/S0140-6736(00)02357-6; Olivieri NF, 2010, HEMATOL ONCOL CLIN N, V24, P1055, DOI 10.1016/j.hoc.2010.08.008; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056/NEJM199504063321404; Pennell DJ, 2011, HAEMATOL-HEMATOL J, V96, P48, DOI 10.3324/haematol.2010.031468; Roberts D., 2007, COCHRANE DB SYST REV, V3; ROBERTS DJ, 2005, COCHRANE DB SYST REV, V4; Ryan K, 2010, BRIT J HAEMATOL, V149, P35, DOI 10.1111/j.1365-2141.2009.08054.x; Smiers FJ, 2010, PEDIATR CLIN N AM, V57, P181, DOI 10.1016/j.pcl.2010.01.003; Sodani P, 2010, BLOOD, V115, P1296, DOI 10.1182/blood-2009-05-218982; Taher AT, 2011, BRIT J HAEMATOL, V152, P512, DOI 10.1111/j.1365-2141.2010.08486.x; Taher AT, 2010, BLOOD, V115, P1886, DOI 10.1182/blood-2009-09-243154; Toumba Meropi, 2007, Pediatr Endocrinol Rev, V5, P642; Vichinsky Elliott P, 2009, Hematology Am Soc Hematol Educ Program, P35, DOI 10.1182/asheducation-2009.1.35; Vichinsky EP, 2005, PEDIATRICS, V116, pE818, DOI 10.1542/peds.2005-0843; Weatherall DJ, 1997, ANN TROP MED PARASIT, V91, P885, DOI 10.1080/00034989760653	35	24	25	1	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	2012	344								e228	10.1136/bmj.e228	http://dx.doi.org/10.1136/bmj.e228			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885KV	22277544				2022-12-28	WOS:000299778800012
J	Mentzer, A; Perry, M; Fitzgerald, N; Barrington, S; Siddiqui, A; Kulasegaram, R				Mentzer, Alex; Perry, Melissa; Fitzgerald, Naomi; Barrington, Sally; Siddiqui, Ata; Kulasegaram, Ranjababu			Is it all cerebral toxoplasmosis?	LANCET			English	Editorial Material							NERVOUS-SYSTEM LYMPHOMA		[Mentzer, Alex; Perry, Melissa; Fitzgerald, Naomi; Kulasegaram, Ranjababu] Guys & St Thomas NHS Fdn Trust, Dept GU HIV Med, London SE1 7EH, England; [Barrington, Sally] Guys & St Thomas NHS Fdn Trust, Dept Nucl Med, London SE1 7EH, England; [Siddiqui, Ata] Guys & St Thomas NHS Fdn Trust, Dept Radiol, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Mentzer, A (corresponding author), Guys & St Thomas NHS Fdn Trust, Dept GU HIV Med, Westminster Bridge Rd, London SE1 7EH, England.	alexmentzer@doctors.net.uk		Barrington, Sally/0000-0002-2516-5288; Mentzer, Alexander/0000-0002-4502-2209				[Anonymous], TIM TEST HIV EXP HEA; Gerstner ER, 2010, ARCH NEUROL-CHICAGO, V67, P291, DOI 10.1001/archneurol.2010.3; Norden AD, 2011, J NEURO-ONCOL, V101, P487, DOI 10.1007/s11060-010-0269-7; ODoherty MJ, 1997, J NUCL MED, V38, P1575; Sparano JA, 2007, CURR OPIN ONCOL, V19, P458, DOI 10.1097/CCO.0b013e3282c8c835	5	8	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 21	2012	379	9812					286	286		10.1016/S0140-6736(11)61579-1	http://dx.doi.org/10.1016/S0140-6736(11)61579-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879FW	22265631				2022-12-28	WOS:000299316100043
J	Li, Z; Tuteja, G; Schug, J; Kaestner, KH				Li, Zhaoyu; Tuteja, Geetu; Schug, Jonathan; Kaestner, Klaus H.			Foxa1 and Foxa2 Are Essential for Sexual Dimorphism in Liver Cancer	CELL			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; NUCLEAR FACTOR 3-GAMMA; TRANSCRIPTION FACTORS; GLUCOSE-HOMEOSTASIS; ANDROGEN RECEPTOR; IN-VIVO; HEPATOCYTE; ESTROGEN; GENES; MICE	Hepatocellular carcinoma (HCC) is sexually dimorphic in both rodents and humans, with significantly higher incidence in males, an effect that is dependent on sex hormones. The molecular mechanisms by which estrogens prevent and androgens promote liver cancer remain unclear. Here, we discover that sexually dimorphic HCC is completely reversed in Foxa1- and Foxa2-deficient mice after diethylnitrosamine-induced hepatocarcinogenesis. Coregulation of target genes by Foxa1/a2 and either the estrogen receptor (ER alpha) or the androgen receptor (AR) was increased during hepatocarcinogenesis in normal female or male mice, respectively, but was lost in Foxa1/2-deficient mice. Thus, both estrogen-dependent resistance to and androgen-mediated facilitation of HCC depend on Foxa1/2. Strikingly, single nucleotide polymorphisms at FOXA2 binding sites reduce binding of both FOXA2 and ER alpha to their targets in human liver and correlate with HCC development in women. Thus, Foxa factors and their targets are central for the sexual dimorphismof HCC.	[Kaestner, Klaus H.] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Perelman Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Kaestner, KH (corresponding author), Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	kaestner@mail.med.upenn.edu		Li, Zhaoyu/0000-0002-1136-2758	NIDDK [P01-DK049210]; NSREC; JDRF; University of Pennsylvania Diabetes and Endocrinology Center (DERC) [P30-DK19525]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049210, R01DK055342, P30DK019525] Funding Source: NIH RePORTER	NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NSREC; JDRF(Juvenile Diabetes Research Foundation); University of Pennsylvania Diabetes and Endocrinology Center (DERC); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs. Jeff Albrecht, Linda Greenbaum, and Snorri Thorgeirsson for valuable comments on the manuscript. We acknowledge Alan Fox, Olga Smirnova, Karrie Brondell, Amber Riblett, James LaRossa, and Reina Aoki for their excellent technical support. We also thank Dr. Erik Knudsen for sharing his hepatocarcinogenesis protocol. This study was supported by the NIDDK (P01-DK049210 to KHK). Z.L. was supported by NSREC and JDRF postdoctoral fellowship awards. We thank the University of Pennsylvania Diabetes and Endocrinology Center (DERC) for the use of the Functional Genomics Core (P30-DK19525).	Bochkis IM, 2008, NAT MED, V14, P828, DOI 10.1038/nm.1853; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Di Maio M, 2006, ANN NY ACAD SCI, V1089, P252, DOI 10.1196/annals.1386.007; Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gao N, 2009, DEV CELL, V16, P588, DOI 10.1016/j.devcel.2009.02.010; Gao N, 2008, GENE DEV, V22, P3435, DOI 10.1101/gad.1752608; Genazzani AR, 2007, HUM REPROD UPDATE, V13, P175, DOI 10.1093/humupd/dml042; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hollingsworth AB, 1998, BREAST CANCER RES TR, V47, P63, DOI 10.1023/A:1005872132373; Kaestner KH, 2005, CELL CYCLE, V4, P1146, DOI 10.4161/cc.4.9.2033; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; Kaestner KH, 2010, CURR OPIN GENET DEV, V20, P527, DOI 10.1016/j.gde.2010.06.005; Kalra M, 2008, WORLD J GASTROENTERO, V14, P5945, DOI 10.3748/wjg.14.5945; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Lawrence T, 2007, SCIENCE, V317, P51, DOI 10.1126/science.1146052; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Li ZY, 2009, J CLIN INVEST, V119, P1537, DOI 10.1172/JCI38201; Liu ZL, 2008, BIOCHEM BIOPH RES CO, V365, P729, DOI 10.1016/j.bbrc.2007.11.069; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Ma CL, 2008, GASTROENTEROLOGY, V135, P947, DOI 10.1053/j.gastro.2008.05.046; Ma WL, 2008, GASTROENTEROLOGY, V135, P1805; May R, 2009, STEM CELLS, V27, P2571, DOI 10.1002/stem.193; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Oliver JD, 2002, PHARMACOL TOXICOL, V91, P1, DOI 10.1034/j.1600-0773.2002.910101.x; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PAULSON DF, 1984, ANNU REV MED, V35, P341, DOI 10.1146/annurev.me.35.020184.002013; Qatanani M, 2005, CURR DRUG METAB, V6, P329, DOI 10.2174/1389200054633899; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rubins NE, 2005, MOL CELL BIOL, V25, P7069, DOI 10.1128/MCB.25.16.7069-7077.2005; Russel FGM, 2008, TRENDS PHARMACOL SCI, V29, P200, DOI 10.1016/j.tips.2008.01.006; Shen W, 2001, J BIOL CHEM, V276, P42812, DOI 10.1074/jbc.M106344200; Shimizu I, 1998, GUT, V42, P112, DOI 10.1136/gut.42.1.112; SMOLEV JK, 1977, J UROLOGY, V118, P216, DOI 10.1016/S0022-5347(17)57949-5; Stice JP, 2009, FUTUR CARDIOL, V5, P93, DOI 10.2217/14796678.5.1.93; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Thean LF, 2010, GENE CHROMOSOME CANC, V49, P99, DOI 10.1002/gcc.20724; TSUTSUI S, 1992, VIRCHOWS ARCH B, V62, P371, DOI 10.1007/BF02899706; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tuteja G, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp536; Vlaming MLH, 2006, J PHARMACOL EXP THER, V318, P319, DOI 10.1124/jpet.106.101774; Wu MH, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001143; Yager JD, 1996, ANNU REV PHARMACOL, V36, P203, DOI 10.1146/annurev.pa.36.040196.001223; Yamamoto R., 1991, INT J CANCER, V49, P83; Yu XP, 2005, ANN NY ACAD SCI, V1061, P77, DOI 10.1196/annals.1336.009; Zhang LP, 2005, CELL METAB, V2, P141, DOI 10.1016/j.cmet.2005.07.002; Zumoff B, 1998, P SOC EXP BIOL MED, V217, P30	51	257	266	2	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					72	83		10.1016/j.cell.2011.11.026	http://dx.doi.org/10.1016/j.cell.2011.11.026			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265403	Bronze, Green Accepted			2022-12-28	WOS:000299540700015
J	Macilwain, C				Macilwain, Colin			Funding in 2012: "Great Recession" Starts to Bite	CELL			English	Editorial Material								Biomedical research budgets are frozen or falling in developed countries. Can expansion in developing nations continue as economic contagion spreads?										Macilwain C, 2011, CELL, V144, P167, DOI 10.1016/j.cell.2011.01.002	1	2	2	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 20	2012	148	1-2					14	16		10.1016/j.cell.2012.01.005	http://dx.doi.org/10.1016/j.cell.2012.01.005			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265395	Bronze			2022-12-28	WOS:000299540700006
J	Klein, L				Klein, Liviu			Rivaroxaban reduced stroke and systemic embolism compared with warfarin in nonvalvular AF	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Klein, Liviu] Univ California San Francisco, San Francisco, CA USA	University of California System; University of California San Francisco	Klein, L (corresponding author), Univ California San Francisco, San Francisco, CA USA.								0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-3	10.7326/0003-4819-156-2-201201170-02003	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31YU	22250165				2022-12-28	WOS:000208919700002
J	Wilson, IH; Walker, IA				Wilson, Iain H.; Walker, Isabeau A.			BMJ WINTER APPEAL Lifebox: give a little, help a lot	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Wilson, Iain H.] Assoc Anaesthetists Great Britain & Ireland, London, England; [Walker, Isabeau A.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Wilson, IH (corresponding author), Assoc Anaesthetists Great Britain & Ireland, London, England.							Funk LM, 2010, LANCET, V376, P1055, DOI 10.1016/S0140-6736(10)60392-3; Walker IA, 2008, LANCET, V371, P968, DOI 10.1016/S0140-6736(08)60432-8; WHO, GUID SAF SURG 2009 S	3	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2012	344								e313	10.1136/bmj.e313	http://dx.doi.org/10.1136/bmj.e313			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YY	22251865				2022-12-28	WOS:000300041800011
J	Su, D; Hu, Q; Li, Q; Thompson, JR; Cui, GF; Fazly, A; Davies, BA; Botuyan, MV; Zhang, ZG; Mer, G				Su, Dan; Hu, Qi; Li, Qing; Thompson, James R.; Cui, Gaofeng; Fazly, Ahmed; Davies, Brian A.; Botuyan, Maria Victoria; Zhang, Zhiguo; Mer, Georges			Structural basis for recognition of H3K56-acetylated histone H3-H4 by the chaperone Rtt106	NATURE			English	Article							NUCLEOSOME CORE PARTICLE; MACROMOLECULAR STRUCTURES; LYSINE 56; ACETYLATION; DNA; CHROMATIN; H3; MODEL; SPECTROSCOPY; REFINEMENT	Dynamic variations in the structure of chromatin influence virtually all DNA-related processes in eukaryotes and are controlled in part by post-translational modifications of histones(1-3). One such modification, the acetylation of lysine 56 (H3K56ac) in the amino-terminal alpha-helix (alpha N) of histone H3, has been implicated in the regulation of nucleosome assembly during DNA replication and repair, and nucleosome disassembly during gene transcription(4-10). In Saccharomyces cerevisiae, the histone chaperone Rtt106 contributes to the deposition of newly synthesized H3K56ac-carrying H3-H4 complex on replicating DNA(5), but it is unclear how Rtt106 binds H3-H4 and specifically recognizes H3K56ac as there is no apparent acetylated lysine reader domain in Rtt106. Here, we show that two domains of Rtt106 are involved in a combinatorial recognition of H3-H4. An N-terminal domain homodimerizes and interacts with H3-H4 independently of acetylation while a double pleckstrin-homology (PH) domain binds the K56-containing region of H3. Affinity is markedly enhanced upon acetylation of K56, an effect that is probably due to increased conformational entropy of the aN helix of H3. Our data support a mode of interaction where the N-terminal homodimeric domain of Rtt106 intercalates between the two H3-H4 components of the (H3-H4)(2) tetramer while two double PH domains in the Rtt106 dimer interact with each of the two H3K56ac sites in (H3-H4)(2). We show that the Rtt106-(H3-H4)(2) interaction is important for gene silencing and the DNA damage response.	[Su, Dan; Hu, Qi; Li, Qing; Cui, Gaofeng; Fazly, Ahmed; Davies, Brian A.; Botuyan, Maria Victoria; Zhang, Zhiguo; Mer, Georges] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Thompson, James R.] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Zhang, ZG (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.	zhang.zhiguo@mayo.edu; mer.georges@mayo.edu	hu, qi/K-1462-2014; Cui, Gaofeng/A-1107-2013; su, dan/GYJ-1940-2022; Mer, Georges/AAT-4946-2021	Cui, Gaofeng/0000-0001-5267-9033; Mer, Georges/0000-0002-1900-1578; /0000-0003-3279-0425	US Department of Energy, Basic Energy Sciences, Office of Science [W-31-109-ENG-38]; National Institutes of Health; NATIONAL CANCER INSTITUTE [P50CA108961, R01CA132878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072719] Funding Source: NIH RePORTER	US Department of Energy, Basic Energy Sciences, Office of Science(United States Department of Energy (DOE)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to N. Juranic, S. Macura and T. Burghardt for experimental advice, Y. Kim for assistance with X-ray data collection, Z. Zhang for suggestions on chemical synthesis, and K. Luger and A. Hieb for advice on the preparation of histones. We acknowledge the use of synchrotron beamlines 19BM and 19ID of the Structural Biology Center at Argonne National Laboratory's APS, supported by the US Department of Energy, Basic Energy Sciences, Office of Science, under contract no. W-31-109-ENG-38. This work was funded in part by National Institutes of Health grants to Z.Z. and G.M.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Botuyan MVE, 2004, STRUCTURE, V12, P1137, DOI 10.1016/j.str.2004.06.002; Bowman A, 2010, NUCLEIC ACIDS RES, V38, P695, DOI 10.1093/nar/gkp1003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen CC, 2008, CELL, V134, P231, DOI 10.1016/j.cell.2008.06.035; Corpet A, 2009, TRENDS CELL BIOL, V19, P29, DOI 10.1016/j.tcb.2008.10.002; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Huang R, 2010, J AM CHEM SOC, V132, P9986, DOI 10.1021/ja103954u; Huang SB, 2005, P NATL ACAD SCI USA, V102, P13410, DOI 10.1073/pnas.0506176102; Huang SB, 2007, EMBO J, V26, P2274, DOI 10.1038/sj.emboj.7601670; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Li Q, 2008, CELL, V134, P244, DOI 10.1016/j.cell.2008.06.018; Liu YW, 2010, J BIOL CHEM, V285, P4251, DOI 10.1074/jbc.M109.055996; Luger K, 2006, CHROMOSOME RES, V14, P5, DOI 10.1007/s10577-005-1026-1; Luger K, 1999, METHOD ENZYMOL, V304, P3; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; VanDemark AP, 2006, MOL CELL, V22, P363, DOI 10.1016/j.molcel.2006.03.025; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Williams SK, 2008, P NATL ACAD SCI USA, V105, P9000, DOI 10.1073/pnas.0800057105; Xie W, 2009, MOL CELL, V33, P417, DOI 10.1016/j.molcel.2009.02.004; Yuan J, 2009, CELL CYCLE, V8, P1747, DOI 10.4161/cc.8.11.8620; Zhou H, 2006, BIOCHEMISTRY-US, V45, P2852, DOI 10.1021/bi0521083	38	82	84	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 1	2012	483	7387					104	U152		10.1038/nature10861	http://dx.doi.org/10.1038/nature10861			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900HP	22307274	Green Accepted			2022-12-28	WOS:000300877900054
J	Baselga, J; Bradbury, I; Eidtmann, H; Di Cosimo, S; de Azambuja, E; Aura, C; Gomez, H; Dinh, P; Fauria, K; Van Dooren, V; Aktan, G; Goldhirsch, A; Chang, TW; Horvath, Z; Coccia-Portugal, M; Domont, J; Tseng, LM; Kunz, G; Sohn, JH; Semiglazov, V; Lerzo, G; Palacova, M; Probachai, V; Pusztai, L; Untch, M; Gelber, RD; Piccart-Gebhart, M				Baselga, Jose; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Fauria, Karine; Van Dooren, Veerle; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horvath, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Kunz, Georg; Sohn, Joo Hyuk; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymyr; Pusztai, Lajos; Untch, Michael; Gelber, Richard D.; Piccart-Gebhart, Martine		NeoALTTO Study Team	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial	LANCET			English	Article							ADJUVANT CHEMOTHERAPY; INHIBITOR; PLUS; COMBINATION; APOPTOSIS; GW572016; SAFETY; WOMEN; ERBB2	Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy. Methods In this parallel groups, randomised, open-label, phase 3 study undertaken between Jan 5, 2008, and May 27, 2010, women from 23 countries with HER2-positive primary breast cancer with tumours greater than 2 cm in diameter were randomly assigned to oral lapatinib (1500 mg), intravenous trastuzumab (loading dose 4 mg/kg, subsequent doses 2 mg/kg), or lapatinib (1000 mg) plus trastuzumab. Treatment allocation was by stratified, permuted blocks randomisation, with four stratification factors. Anti-HER2 therapy alone was given for the first 6 weeks; weekly paclitaxel (80 mg/m(2)) was then added to the regimen for a further 12 weeks, before definitive surgery was undertaken. After surgery, patients received adjuvant chemotherapy followed by the same targeted therapy as in the neoadjuvant phase to 52 weeks. The primary endpoint was the rate of pathological complete response (pCR), analysed by intention to treat. This trial is registered with ClinicalTrials.gov, NCT00553358. Findings 154 patients received lapatinib, 149 trastuzumab, and 152 the combination. pCR rate was significantly higher in the group given lapatinib and trastuzumab (78 of 152 patients [51.3%; 95% CI 43.1-59.5]) than in the group given trastuzumab alone (44 of 149 patients [29.5%; 22.4-37.5]; difference 21.1%, 9.1-34.2, p=0.0001). We recorded no significant difference in pCR between the lapatinib (38 of 154 patients [24.7%, 18.1-32.3]) and the trastuzumab (difference -4.8%, -17.6 to 8.2, p=0.34) groups. No major cardiac dysfunctions occurred. Frequency of grade 3 diarrhoea was higher with lapatinib (36 patients [23.4%]) and lapatinib plus trastuzumab (32 [21.1%]) than with trastuzumab (three [2.0%]). Similarly, grade 3 liver-enzyme alterations were more frequent with lapatinib (27 [17.5%]) and lapatinib plus trastuzumab (15 [9.9%]) than with trastuzumab (11 [7.4%]). Interpretation Dual inhibition of HER2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting.	[Baselga, Jose] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Baselga, Jose; Di Cosimo, Serena; Fauria, Karine] SOLTI Breast Canc Res Grp, Barcelona, Spain; [Bradbury, Ian] Frontier Sci Scotland, Kincraig, Scotland; [Bradbury, Ian] Queens Univ Belfast, Belfast, Antrim, North Ireland; [Eidtmann, Holger] Univ Hosp Kiel, Kiel, Germany; [Di Cosimo, Serena] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain; [Aura, Claudia] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [de Azambuja, Evandro; Van Dooren, Veerle] Inst Jules Bordet, Breast European Adjuvant Study Team, B-1000 Brussels, Belgium; [Dinh, Phuong] Inst Jules Bordet, Breast Int Grp, B-1000 Brussels, Belgium; [Piccart-Gebhart, Martine] Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium; [Gomez, Henry] Inst Nacl Enfermedades Neoplas, Lima, Peru; [Aktan, Gursel] GlaxoSmithKline, Collegeville, PA USA; [Goldhirsch, Aron] European Inst Oncol, Milan, Italy; [Goldhirsch, Aron] St Anna Clin, Swiss Ctr Breast Hlth, Lugano, Switzerland; [Chang, Tsai-Wang] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan; [Horvath, Zsolt] Natl Inst Oncol, Budapest, Hungary; [Coccia-Portugal, Maria] Eastleigh Breast Care Ctr, Pretoria, South Africa; [Domont, Julien] Inst Gustave Roussy, Villejuif, France; [Tseng, Ling-Min] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Taipei 112, Taiwan; [Kunz, Georg] St Johannes Hosp, Dortmund, Germany; [Sohn, Joo Hyuk] Yonsei Univ, Coll Med, Seoul, South Korea; [Semiglazov, Vladimir] Petrov Res Inst Oncol, St Petersburg, Russia; [Lerzo, Guillermo] Invest Clin Ciudad Autonoma Buenos Aires, Buenos Aires, DF, Argentina; [Palacova, Marketa] Masarykuv Onkol Ustav, Brno, Czech Republic; [Probachai, Volodymyr] City Clin Hosp, Dnepropetrovsk, Ukraine; [Pusztai, Lajos] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Untch, Michael] Charite, Clin Gynaecol Gynaecol Oncol & Obstet, Breast Canc Ctr, D-13353 Berlin, Germany; [Gelber, Richard D.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Gelber, Richard D.] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; SOLTI Breast Cancer Research Group; Queens University Belfast; University of Kiel; Schleswig Holstein University Hospital; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Institut Jules Bordet; Breast International Group; Institut Jules Bordet; Institut Jules Bordet; Instituto Nacional de Enfermedades Neoplasicas; GlaxoSmithKline; IRCCS European Institute of Oncology (IEO); National Cheng Kung University; National Cheng Kung University Hospital; National Institute of Oncology Hungary; UNICANCER; Gustave Roussy; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; St. Johannes Hospital; Yonsei University; Yonsei University Health System; N.N. Petrov Research Institute of Oncology; Masaryk Memorial Cancer Institute; University of Texas System; UTMD Anderson Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Dana-Farber Cancer Institute; Frontier Science Foundation	Baselga, J (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Lawrence House 108, Boston, MA 02114 USA.	jbaselga@partners.org	Kwong, Ava/D-8005-2013; Pusztai, Lajos/AAB-2901-2019; Horvath, Zsolt/B-9524-2012; , Di Cosimo Serena/E-9418-2017; Ferro, Antonella/AAA-8241-2020	Kwong, Ava/0000-0002-6968-9489; Horvath, Zsolt/0000-0002-5376-7737; , Di Cosimo Serena/0000-0002-4666-8052; Ferro, Antonella/0000-0003-4109-6769; Hickish, Tamas/0000-0001-6770-7279; Ciruelos, Eva/0000-0002-2796-1042; Semiglazov, Vladimir/0000-0003-0077-9619; Sohn, Joohyuk/0000-0002-2303-2764; de Azambuja, Evandro/0000-0001-9501-4509; Llombart Cussac, Antonio/0000-0003-4515-8293; Gomez, Henry/0000-0003-2660-1843	GlaxoSmithKline; Roche; Novartis; Amgen; Abbott; AstraZeneca; Pfizer; Sanofi; Bristol-Myers Squibb; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); Roche(Roche Holding); Novartis(Novartis); Amgen(Amgen); Abbott(Abbott Laboratories); AstraZeneca(AstraZeneca); Pfizer(Pfizer); Sanofi; Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JB has received honoraria from Roche. IB's institution has received funding from GlaxoSmithKline and Roche. HE has been a speaker and received travel grants from GlaxoSmithKline. SDC has been a speaker for GlaxoSmithKline. EdA has served on an advisory board and received a travelling grant from GlaxoSmithKline, and has been a speaker for Roche. KF's institution has received travelling grants from GlaxoSmithKline. VVD's and T-WC's institutions have received research funding from GlaxoSmithKline. AG has received honoraria from GlaxoSmithKline and Roche. T-WC has been a speaker for GlaxoSmithKline, Roche, Novartis, and Amgen; and has received consultancy funding from GlaxoSmithKline, Roche, Abbott, AstraZeneca, Novartis, and Amgen. LP has received consultancy fees from Pfizer, Sanofi, and Bristol-Myers Squibb; and research grants from Bristol-Myers Squibb and AstraZeneca. RDG's institution has received research funding from GlaxoSmithKline and Roche. MP-G has received honoraria from GlaxoSmithKline and Roche, and her institution has received research funding from GlaxoSmithKline. GA is a salaried employee of GlaxoSmithKline and retains stock and stock options at the company. The other authors declare that they have no conflicts of interest.	Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Chang JCN, 2011, ASCO M S, V29, P505; Cox DR., 1970, ANAL BINARY DATA; Crown JP, 2007, J CLIN ONCOL, V25; Dang C, 2010, J CLIN ONCOL, V28, P2982, DOI 10.1200/JCO.2009.26.5900; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Fisher ER, 2002, CANCER-AM CANCER SOC, V95, P681, DOI 10.1002/cncr.10741; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Guarneri V, 2011, J CLIN ONCOL S, P507; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Holmes FA, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.506; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Mohsin SK, 2005, J CLIN ONCOL, V23, P2460, DOI 10.1200/JCO.2005.00.661; Moy B, 2009, J CLIN ONCOL, V27; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Untch M, 2011, CANC RES S2, V70, pP1; Untch M, 2012, LANCET ONCOL, V13, P135, DOI 10.1016/S1470-2045(11)70397-7; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Xia WL, 2005, ONCOGENE, V24, P6213, DOI 10.1038/sj.onc.1208774	30	942	987	4	118	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2012	379	9816					633	640		10.1016/S0140-6736(11)61847-3	http://dx.doi.org/10.1016/S0140-6736(11)61847-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897ES	22257673	Green Accepted			2022-12-28	WOS:000300629000034
J	Santolaya, ME; O'Ryan, ML; Valenzuela, MT; Prado, V; Vergara, R; Munoz, A; Toneatto, D; Grana, G; Wang, HJ; Clemens, R; Dull, PM				Elena Santolaya, Maria; O'Ryan, Miguel L.; Teresa Valenzuela, Maria; Prado, Valeria; Vergara, Rodrigo; Munoz, Alma; Toneatto, Daniela; Grana, Gabriela; Wang, Huajun; Clemens, Ralf; Dull, Peter M.		V72P10 Meningococcal B Adolescent	Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study	LANCET			English	Article							BINDING-PROTEIN; MENINGITIS; COVERAGE	Background Effective glycoconjugate vaccines against Neisseria meningitidis serogroups A, C, W-135, and Y have been developed, but serogroup B remains a major cause of severe invasive disease in infants and adolescents worldwide. We assessed immunogenicity and tolerability of a four-component vaccine (4CMenB) in adolescents. Methods We did a randomised, observer-blind, placebo-controlled, study at 12 sites in Santiago and Valparaiso, Chile. Adolescents aged 11-17 years received one, two, or three doses of 4CMenB at 1 month, 2 month, or 6 month intervals. Immunogenicity was assessed as serum bactericidal activity using human complement (hSBA) against three reference strains for individual vaccine antigens, and assessed by ELISA against the fourth strain. Local and systemic reactions were recorded 7 days after each vaccination, and adverse events were monitored throughout the study. Participants were initially randomised to five groups (3:3:3:3:1) during the primary phase to receive either one dose, two doses 1 or 2 months apart, or three doses of 4CMenB, or three doses of placebo, with an additional three groups generated for the booster phase. All subjects received at least one dose of 4CMenB. Geometric mean titres, proportions of participants with serum bactericidal antibody titres of 4 or more, and Clopper-Pearson 95% CIs were calculated. The study is registered with ClinicalTrials.gov, number NCT00661713. Findings Overall, 1631 adolescents (mean age 13.8 [SD 1.9] years) received at least one dose of 4CMenB. After two or three doses, 99-100% of recipients had hSBA titres of 4 or more against test strains, compared with 92-97% after one dose (p<0.0145) and 29-50% after placebo. At 6 months 91-100% of participants still had titres of 4 or more for each strain after two or three doses, but only 73-76% after one dose; seroresponse rates reached 99-100% for each strain after second or third doses at 6 months. Local and systemic reaction rates were similar after each 4CMenB injection and did not increase with subsequent doses, but remained higher than placebo. No vaccine-related serious adverse events were reported and no significant safety signals were identified. Interpretation On the basis of immunogenicity responses this study provides evidence for an adolescent 4CMenB vaccine schedule of two doses, 1-6 months apart, to provide protection against meningococcal B infection. The extent of this protection against meningococcus B variants circulating worldwide will be determined by national surveys.	[O'Ryan, Miguel L.; Prado, Valeria] Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Microbiol, Santiago, Chile; [Elena Santolaya, Maria] Univ Chile, Fac Med, Hosp Dr Luis Calvo Mackenna, Dept Pediat, Santiago, Chile; [Teresa Valenzuela, Maria] Univ Los Andes, Dept Salud Publ & Epidemiol, Santiago, Chile; [Vergara, Rodrigo] Univ Valparaiso, Escuela Med, Valparaiso, Chile; [Munoz, Alma] Ctr Vacunas Desarrollo, Santiago, Chile; [Toneatto, Daniela; Grana, Gabriela; Wang, Huajun; Clemens, Ralf; Dull, Peter M.] Novartis Vaccines & Diagnost, Siena, Italy	Universidad de Chile; Universidad de Chile; Universidad de los Andes - Chile; Universidad de Valparaiso; Novartis	O'Ryan, ML (corresponding author), Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Microbiol, Diagonal Paraguay 265,Piso 14,Of 1403, Santiago, Chile.	moryan@med.uchile.cl	O'Ryan, Miguel/H-3478-2013	O'Ryan, Miguel/0000-0002-7926-2163; Valenzuela, M Teresa/0000-0002-9433-6423; Clemens, Ralf/0000-0003-4685-4207	Novartis Vaccines and Diagnostics	Novartis Vaccines and Diagnostics	Funding Novartis Vaccines and Diagnostics.	Baxter R, 2011, PEDIATR INFECT DIS J, V30, pE41, DOI 10.1097/INF.0b013e3182054ab9; Beernink PT, 2009, J INFECT DIS, V199, P1360, DOI 10.1086/597806; Boisier P, 2007, CLIN INFECT DIS, V44, P657, DOI 10.1086/511646; Donnelly J, 2011, 11 EUR MEN DIS SOC E; Donnelly J, 2010, P NATL ACAD SCI USA, V107, P19490, DOI 10.1073/pnas.1013758107; European Union Invasive Bacterial Infections Surveillance Network, INV NEISS MEN EUR 20; Findlow J, 2010, CLIN INFECT DIS, V51, P1127, DOI 10.1086/656741; FINNE J, 1987, J IMMUNOL, V138, P4402; Frasch CE, 2009, VACCINE, V27, pB112, DOI 10.1016/j.vaccine.2009.04.065; Giuliani MM, 2006, P NATL ACAD SCI USA, V103, P10834, DOI 10.1073/pnas.0603940103; Giuliani MM, 2010, VACCINE, V28, P5023, DOI 10.1016/j.vaccine.2010.05.014; Granoff DM, 2010, CLIN INFECT DIS, V50, pS54, DOI 10.1086/648966; Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063; Jackson LA, 2009, CLIN INFECT DIS, V49, pE1, DOI 10.1086/599117; Jiang HQ, 2010, VACCINE, V28, P6086, DOI 10.1016/j.vaccine.2010.06.083; Kimura A, 2011, CLIN VACCINE IMMUNOL, V18, P483, DOI 10.1128/CVI.00304-10; McNicholas A, 2007, HUM VACCINES, V3, P196, DOI 10.4161/hv.3.5.4458; NEDELEC J, 1990, J NEUROIMMUNOL, V29, P49, DOI 10.1016/0165-5728(90)90146-E; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Racloz VN, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-175; Sadarangani M, 2010, LANCET INFECT DIS, V10, P112, DOI 10.1016/S1473-3099(09)70324-X; Serruto D, 2010, P NATL ACAD SCI USA, V107, P3770, DOI 10.1073/pnas.0915162107; Snape MD, 2010, PEDIATR INFECT DIS J, V29, pE71, DOI 10.1097/INF.0b013e3181f59f6d; Stephens DS, 2007, FEMS MICROBIOL REV, V31, P3, DOI 10.1111/j.1574-6976.2006.00051.x; Tan LKK, 2010, NEW ENGL J MED, V362, P1511, DOI 10.1056/NEJMra0906357; WYLE FA, 1972, J INFECT DIS, V126, P514, DOI 10.1093/infdis/126.5.514	26	182	186	0	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2012	379	9816					617	624		10.1016/S0140-6736(11)61713-3	http://dx.doi.org/10.1016/S0140-6736(11)61713-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897ES	22260988				2022-12-28	WOS:000300629000032
J	Tiemann, L; Gamez, G; Kumada, N; Muraki, K				Tiemann, L.; Gamez, G.; Kumada, N.; Muraki, K.			Unraveling the Spin Polarization of the v=5/2 Fractional Quantum Hall State	SCIENCE			English	Article							COMPOSITE FERMIONS; CHARGE; STATISTICS; FLUID	The fractional quantum Hall (FQH) effect at filling factor v = 5/2 has recently come under close scrutiny, as its ground state may possess quasi-particle excitations obeying nonabelian statistics, a property sought for topologically protected quantum operations. However, its microscopic origin remains unknown, and candidate model wave functions include those with undesirable abelian statistics. We report direct measurements of the electron spin polarization of the v = 5/2 FQH state using resistively detected nuclear magnetic resonance. We find the system to be fully polarized, which unambiguously rules out the most likely abelian contender and lends strong support for the v = 5/2 state being nonabelian. Our measurements reveal an intrinsically different nature of interaction in the first excited Landau level underlying the physics at v = 5/2.	[Tiemann, L.; Gamez, G.; Kumada, N.; Muraki, K.] NTT Corp, NTT Basic Res Labs, Atsugi, Kanagawa 2430198, Japan; [Tiemann, L.; Muraki, K.] Japan Sci & Technol Agcy JST, ERATO Nucl Spin Elect Project, Kawaguchi, Saitama 3320012, Japan	Nippon Telegraph & Telephone Corporation; Japan Science & Technology Agency (JST)	Tiemann, L (corresponding author), NTT Corp, NTT Basic Res Labs, 3-1 Morinosato Wakamiya, Atsugi, Kanagawa 2430198, Japan.	lars.tiemann@gmail.com; muraki.koji@lab.ntt.co.jp	Muraki, Koji/M-3468-2016; Kumada, Norio/V-9410-2019	Muraki, Koji/0000-0003-0289-5496; Kumada, Norio/0000-0001-7826-6894				Bid A, 2010, NATURE, V466, P585, DOI 10.1038/nature09277; Desrat W, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.256807; Dimov I, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.126804; Dolev M, 2008, NATURE, V452, P829, DOI [10.1038/nature06855, 10.1038/natureO6855]; Feiguin AE, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.115322; Freytag N, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.246804; Gamez G., 2011, V 5 2 FRACTIONAL QUA; GREITER M, 1992, NUCL PHYS B, V374, P567, DOI 10.1016/0550-3213(92)90401-V; HALDANE FDM, 1983, PHYS REV LETT, V51, P605, DOI 10.1103/PhysRevLett.51.605; HALPERIN BI, 1983, HELV PHYS ACTA, V56, P75; JAIN JK, 1989, PHYS REV LETT, V63, P199, DOI 10.1103/PhysRevLett.63.199; Kukushkin IV, 1999, PHYS REV LETT, V82, P3665, DOI 10.1103/PhysRevLett.82.3665; Kumada N, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.076805; Lee SS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.236807; Levin M, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.236806; MOORE G, 1991, NUCL PHYS B, V360, P362, DOI 10.1016/0550-3213(91)90407-O; Morf RH, 1998, PHYS REV LETT, V80, P1505, DOI 10.1103/PhysRevLett.80.1505; Nayak C, 1996, NUCL PHYS B, V479, P529, DOI 10.1016/0550-3213(96)00430-0; Nayak C, 2008, REV MOD PHYS, V80, P1083, DOI 10.1103/RevModPhys.80.1083; Read N, 2000, PHYS REV B, V61, P10267, DOI 10.1103/PhysRevB.61.10267; Rhone TD, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.196805; Scarola VW, 2000, NATURE, V406, P863, DOI 10.1038/35022524; Smet JH, 2002, NATURE, V415, P281, DOI 10.1038/415281a; Stern M, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.096801; Venkatachalam V, 2011, NATURE, V469, P185, DOI 10.1038/nature09680; WEN XG, 1991, PHYS REV LETT, V66, P802, DOI 10.1103/PhysRevLett.66.802; WILLETT R, 1987, PHYS REV LETT, V59, P1776, DOI 10.1103/PhysRevLett.59.1776; Willett RL, 2009, P NATL ACAD SCI USA, V106, P8853, DOI 10.1073/pnas.0812599106	31	128	128	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	2012	335	6070					828	831		10.1126/science.1216697	http://dx.doi.org/10.1126/science.1216697			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893LC	22282477	Green Submitted			2022-12-28	WOS:000300356400037
J	Mishra, GD; Kuh, D				Mishra, Gita D.; Kuh, Diana			Health symptoms during midlife in relation to menopausal transition: British prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							LATENT CLASS ANALYSIS; WOMENS HEALTH; VASOMOTOR SYMPTOMS; LIFE	Objective To characterise symptoms experienced by women during the transition into natural menopause, to classify women into distinct symptom profiles or trajectories, and to relate these profiles to sociodemographic factors and health behaviours. Design Nationally representative cohort study. Setting England, Scotland, and Wales. Participants 695 women followed-up since birth in 1946 and annually from age 47 to 54 who experienced natural menopause and reported on 20 common health symptoms. Main outcome measure Longitudinal profiles for reported bothersome symptoms. Results Of 20 individual symptoms, 18 formed into four stable symptom groups: psychological, somatic, vasomotor, and sexual discomfort. Using latent class analyses, all except the somatic group of symptoms showed a clear relation with the timing of menopause for some women. A small proportion of women (10%, n=63) had a severe psychological symptom profile that peaked at or in the year after menopause. For vasomotor symptoms, 14% of women (n=83) had the early severe profile that also peaked around early postmenopause and then declined noticeably; 11% (n=67) had the late severe profile of bothersome symptoms that increased rapidly in perimenopause and remained high for four years or more after menopause. Women were less likely to have a profile for severe vasomotor symptoms if they were from a non-manual social class (odds ratio 0.79, 95% confidence interval 0.57 to 1.01) or had degree level qualifications (0.37, 0.18 to 0.77). The 14% of women (n=85) who had the late severe profile for sexual discomfort showed a similar increase in symptoms until menopause, with symptoms persisting after menopause. Married women were more likely to have the late severe or late moderate profile than women of other marital status (2.40, 1.30 to 4.41). Four profiles each were identified for somatic symptoms (mild, moderate, severe, and very severe), although these did not vary by chronological age or age at menopause. Conclusion Profiles for psychological, vasomotor, and sexual discomfort symptoms relative to age at menopause could help health professionals to tailor their advice for women with natural menopause.	[Mishra, Gita D.; Kuh, Diana] Royal Free & Univ Coll Med Sch, MRC Unit Lifelong Hlth & Ageing, London WC1E 6BT, England; [Mishra, Gita D.] Univ Queensland, Sch Populat Hlth, Herston, Qld 4006, Australia	University of London; University College London; University of Queensland	Mishra, GD (corresponding author), Royal Free & Univ Coll Med Sch, MRC Unit Lifelong Hlth & Ageing, London WC1E 6BT, England.	g.mishra@sph.uq.edu.au	Kuh, Diana/L-6019-2014	Kuh, Diana/0000-0001-7386-2857	Medical Research Council; Australian National Health and Medical Research Council; Medical Research Council [MC_U123092725, MC_U123092720] Funding Source: researchfish; MRC [MC_U123092720, MC_U123092725] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The Medical Research Council provided funding for the National Survey of Health and Development and financial support for DK and GDM. GDM also received funding from the Australian National Health and Medical Research Council.	Berecki-Gisolf J, 2009, MENOPAUSE, V16, P1021, DOI 10.1097/gme.0b013e3181a8c49f; Col NF, 2009, MENOPAUSE, V16, P453, DOI 10.1097/gme.0b013e31818d414e; Cray L, 2010, MENOPAUSE, V17, P972, DOI 10.1097/gme.0b013e3181dd1f95; Croudace TJ, 2003, AM J EPIDEMIOL, V157, P834, DOI 10.1093/aje/kwg049; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Freeman EW, 2007, CLIMACTERIC, V10, P197, DOI 10.1080/13697130601181486; Gold EB, 2006, AM J PUBLIC HEALTH, V96, P1226, DOI 10.2105/AJPH.2005.066936; Greene JG, 1998, MATURITAS, V29, P25, DOI 10.1016/S0378-5122(98)00025-5; Hardy R, 2002, SOC SCI MED, V55, P1975, DOI 10.1016/S0277-9536(01)00326-4; HUNTER M, 1986, MATURITAS, V8, P217, DOI 10.1016/0378-5122(86)90029-0; Kuh Diana, 2003, J Br Menopause Soc, V9, P55, DOI 10.1258/136218003100322206; Kuh DL, 1997, BRIT J OBSTET GYNAEC, V104, P923, DOI 10.1111/j.1471-0528.1997.tb14352.x; Mishra G, 2006, MENOPAUSE, V13, P880, DOI 10.1097/01.gme.0000228090.21196.bf; Muthen B. O., 2002, BEHAVIORMETRIKA, V29, P81, DOI [DOI 10.2333/BHMK.29.81, 10.2333/bhmk.29.81]; Muthen LK, 2010, MPLUS STAT SOFTWARE; National Institutes of Health, 2005, NIH STAT OF THE SCI; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; SIMPSON ER, 1983, J STEROID BIOCHEM, V19, P707, DOI 10.1016/0022-4731(83)90239-X; Soules M R, 2001, Menopause, V8, P402, DOI 10.1097/00042192-200111000-00004; Thurston RC, 2009, AM J EPIDEMIOL, V170, P766, DOI 10.1093/aje/kwp203; Wadsworth MEJ, 2003, SOC SCI MED, V57, P2193, DOI 10.1016/S0277-9536(03)00083-2	21	84	86	1	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 8	2012	344								e402	10.1136/bmj.e402	http://dx.doi.org/10.1136/bmj.e402			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IE	22318435	Green Published, hybrid			2022-12-28	WOS:000300279100002
J	Shui, IM; Baggs, J; Patel, M; Parashar, UD; Rett, M; Belongia, EA; Hambidge, SJ; Glanz, JM; Klein, NP; Weintraub, E				Shui, Irene M.; Baggs, James; Patel, Manish; Parashar, Umesh D.; Rett, Melisa; Belongia, Edward A.; Hambidge, Simon J.; Glanz, Jason M.; Klein, Nicola P.; Weintraub, Eric			Risk of Intussusception Following Administration of a Pentavalent Rotavirus Vaccine in US Infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNIZATION PRACTICES ACIP; UNITED-STATES; ADVISORY-COMMITTEE; ADVERSE EVENTS; SAFETY; GASTROENTERITIS; CHILDREN; RECOMMENDATIONS; SURVEILLANCE; PREVENTION	Context Current rotavirus vaccines were not associated with intussusception in large prelicensure trials. However, recent postlicensure data from international settings suggest the possibility of a low-level elevated risk, primarily in the first week after the first vaccine dose. Objective To examine the risk of intussusception following pentavalent rotavirus vaccine (RV5) in US infants. Design, Setting, and Patients This cohort study included infants 4 to 34 weeks of age, enrolled in the Vaccine Safety Datalink (VSD) who received RV5 from May 2006-February 2010. We calculated standardized incidence ratios (SIRs), relative risks (RRs), and 95% confidence intervals for the association between intussusception and RV5 by comparing the rates of intussusception in infants who had received RV5 with the rates of intussusception in infants who received other recommended vaccines without concomitant RV5 during the concurrent period and with the expected number of intussusception visits based on background rates assessed prior to US licensure of the RV5 (2001-2005). Main Outcome Measure Intussusception occurring in the 1- to 7-day and 1- to 30-day risk windows following RV5 vaccination. Results During the study period, 786 725 total RV5 doses, which included 309 844 first doses, were administered. We did not observe a statistically significant increased risk of intussusception with RV5 for either comparison group following any dose in either the 1- to 7-day or 1- to 30-day risk window. For the 1- to 30-day window following all RV5 doses, we observed 21 cases of intussusception compared with 20.9 expected cases (SIR, 1.01; 95% CI, 0.62-1.54); following dose 1, we observed 7 cases compared with 5.7 expected cases (SIR, 1.23; 95% CI, 0.5-2.54). For the 1- to 7-day window following all RV5 doses, we observed 4 cases compared with 4.3 expected cases (SIR, 0.92; 95% CI, 0.25-2.36); for dose 1, we observed 1 case compared with 0.8 expected case (SIR, 1.21; 95% CI, 0.03-6.75). The upper 95% CI limit of the SIR (6.75) from the historical comparison translates to an upper limit for the attributable risk of 1 intussusception case per 65 287 RV5 dose-1 recipients. Conclusion Among US infants aged 4 to 34 weeks who received RV5, the risk of intussusception was not increased compared with infants who did not receive the rotavirus vaccine. JAMA. 2012;307(6):598-604	[Shui, Irene M.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Shui, Irene M.; Rett, Melisa] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02115 USA; [Shui, Irene M.; Rett, Melisa] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Baggs, James; Patel, Manish; Parashar, Umesh D.; Weintraub, Eric] Ctr Dis Control & Prevent, Atlanta, GA USA; [Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA; [Hambidge, Simon J.; Glanz, Jason M.] Kaiser Permanente Colorado, Inst Hlth Res, Colorado Springs, CO USA; [Hambidge, Simon J.] Denver Hlth, Community Hlth Serv, Denver, CO USA; [Hambidge, Simon J.; Glanz, Jason M.] Univ Colorado, Sch Publ Hlth, Dept Epidemiol, Denver, CO 80202 USA; [Klein, Nicola P.] No Calif Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Centers for Disease Control & Prevention - USA; Kaiser Permanente; Denver Health Medical Center; Colorado School of Public Health; University of Colorado System; University of Colorado Denver; Kaiser Permanente	Shui, IM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.	ishui@hsph.harvard.edu		Belongia, Edward/0000-0001-7478-0415; Hambidge, Simon/0000-0002-7535-0668; Baggs, James/0000-0003-0757-4683	Centers for Disease Control and Prevention (CDC); AHIP; MedImmune; Kaiser Colorado Institute for Health Research; Merck; GlaxoSmithKline; Pfizer; Sanofi Pasteur; Novartis; Vaccine Safety Datalink [200-2002-00732]	Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); AHIP; MedImmune(AstraZenecaMedimmune); Kaiser Colorado Institute for Health Research; Merck(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Sanofi Pasteur; Novartis(Novartis); Vaccine Safety Datalink	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Shui reports receiving institutional support from America's Health Insurance Plan (AHIP) for writing or reviewing a manuscript and for travel support. Dr Rett reports receiving institutional support for writing or reviewing a manuscript and travel support from AHIP. Dr Belongia reports receiving institutional grant support from the Centers for Disease Control and Prevention (CDC) and AHIP and pending research support from MedImmune. Dr Hambidge reports receiving institutional grant and travel support from Kaiser Colorado Institute for Health Research-funding for Vaccine Safety Datalink work from the CDC through a cooperative agreement with AHIP and pending institutional support from the CDC for several vaccine safety investigations under the umbrella of the Vaccine Safety Datalink. Dr Glanz reports receiving institutional grant support from the CDC. Dr Klein reports receiving institutional grant support from the CDC and research support for other projects from Merck, GlaxoSmithKline, Pfizer, Sanofi Pasteur, and Novartis. No other financial conflicts were reported.; This study was supported in part by the Vaccine Safety Datalink contract (200-2002-00732) with AHIP, funded by the CDC.	Baggs J, 2011, PEDIATRICS, V127, pS45, DOI 10.1542/peds.2010-1722H; Bartlett D. L., 2010, Morbidity and Mortality Weekly Report, V59, P521; Belongia EA, 2010, PEDIATR INFECT DIS J, V29, P1, DOI 10.1097/INF.0b013e3181af8605; Bines JE, 2004, VACCINE, V22, P569, DOI 10.1016/j.vaccine.2003.09.016; Bines JE, 2009, J INFECT DIS, V200, pS282, DOI 10.1086/605051; Buttery JP, 2011, VACCINE, V29, P3061, DOI 10.1016/j.vaccine.2011.01.088; Chang EJ, 2002, PEDIATR INFECT DIS J, V21, P97, DOI 10.1097/00006454-200202000-00003; Cortese M, 2010, ADV COMM IMM PRACT M; Cortese Margaret M., 2009, Morbidity and Mortality Weekly Report, V58, P1; Curns AT, 2010, J INFECT DIS, V201, P1617, DOI 10.1086/652403; Greenberg HB, 2011, NEW ENGL J MED, V364, P2354, DOI 10.1056/NEJMe1105302; Johnson B, 2010, J PEDIATR GASTR NUTR, V51, P458, DOI 10.1097/MPG.0b013e3181d3273f; Justice F, 2005, J PAEDIATR CHILD H, V41, P475, DOI 10.1111/j.1440-1754.2005.00686.x; Kramarz P, 2001, PEDIATR INFECT DIS J, V20, P410, DOI 10.1097/00006454-200104000-00008; Lieu TA, 2007, MED CARE, V45, pS89, DOI 10.1097/MLR.0b013e3180616c0a; Macias M, 45 ICAAC ANN M DEC 1; Moon SS, 2010, PEDIATR INFECT DIS J, V29, P919, DOI 10.1097/INF.0b013e3181e232ea; Mullooly J, 1999, AM J EPIDEMIOL, V149, P186; Mullooly JP, 2008, METHOD INFORM MED, V47, P328, DOI 10.3414/ME0500; Murphy TV, 2003, J INFECT DIS, V187, P1309, DOI 10.1086/374420; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Parashar Umesh D., 2006, Morbidity and Mortality Weekly Report, V55, P1; Patel M, 2009, J INFECT DIS, V200, pS39, DOI 10.1086/605035; Patel MM, 2011, NEW ENGL J MED, V364, P2283, DOI 10.1056/NEJMoa1012952; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; Shui IM, 2009, VACCINE, V27, P5307, DOI 10.1016/j.vaccine.2009.06.092; Simonsen L, 2001, LANCET, V358, P1224, DOI 10.1016/S0140-6736(01)06346-2; Steele AD, 2010, VACCINE, V28, P6542, DOI 10.1016/j.vaccine.2008.08.034; Tate JE, 2011, PEDIATR INFECT DIS J, V30, pS56, DOI 10.1097/INF.0b013e3181fefdc0; Tate JE, 2011, PEDIATR INFECT DIS J, V30, pS30, DOI 10.1097/INF.0b013e3181ffe3eb; Tate JE, 2009, PEDIATRICS, V124, P465, DOI 10.1542/peds.2008-3528; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664	32	96	103	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					598	604		10.1001/jama.2012.97	http://dx.doi.org/10.1001/jama.2012.97			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318281				2022-12-28	WOS:000299992500024
J	Ersche, KD; Jones, PS; Williams, GB; Turton, AJ; Robbins, TW; Bullmore, ET				Ersche, Karen D.; Jones, P. Simon; Williams, Guy B.; Turton, Abigail J.; Robbins, Trevor W.; Bullmore, Edward T.			Abnormal Brain Structure Implicated in Stimulant Drug Addiction	SCIENCE			English	Article							SUBSTANCE USE DISORDERS; BASAL GANGLIA; RESPONSE-INHIBITION; COCAINE DEPENDENCE; PREFRONTAL CORTEX; TEMPORAL-LOBE; IMPULSIVITY; MEMORY; REINFORCEMENT; SYSTEMS	Addiction to drugs is a major contemporary public health issue, characterized by maladaptive behavior to obtain and consume an increasing amount of drugs at the expense of the individual's health and social and personal life. We discovered abnormalities in fronto-striatal brain systems implicated in self-control in both stimulant-dependent individuals and their biological siblings who have no history of chronic drug abuse; these findings support the idea of an underlying neurocognitive endophenotype for stimulant drug addiction.	[Ersche, Karen D.; Jones, P. Simon; Williams, Guy B.; Turton, Abigail J.; Robbins, Trevor W.; Bullmore, Edward T.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England; [Ersche, Karen D.; Jones, P. Simon; Williams, Guy B.; Turton, Abigail J.; Robbins, Trevor W.; Bullmore, Edward T.] Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; [Ersche, Karen D.; Jones, P. Simon; Williams, Guy B.; Turton, Abigail J.; Robbins, Trevor W.; Bullmore, Edward T.] Univ Cambridge, Dept Psychiat, Cambridge CB2 3EB, England; [Williams, Guy B.] Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Bullmore, Edward T.] GlaxoSmithKline Inc, Clin Unit Cambridge, Addenbrookes Ctr Clin Invest, Cambridge CB2 2GG, England; [Bullmore, Edward T.] Natl Hlth Serv Trust, Cambridgeshire & Peterborough Fdn, Cambridge CB21 5EF, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; GlaxoSmithKline	Ersche, KD (corresponding author), Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England.	ke220@cam.ac.uk	Robbins, Trevor W/A-7551-2008; Bullmore, Ed/C-1706-2012	Bullmore, Ed/0000-0002-8955-8283; Robbins, Trevor/0000-0003-0642-5977; Williams, Guy/0000-0001-5223-6654	Wellcome Trust Clinical Research Facility at Addenbrooke's Hospital; Wolfson Brain Imaging Centre; U.K. Medical Research Council (MRC); MRC; Wellcome Trust; MRC [G0701497] Funding Source: UKRI; Medical Research Council [G0701497, G0001354, G1000183B, G0001354B] Funding Source: researchfish	Wellcome Trust Clinical Research Facility at Addenbrooke's Hospital(Wellcome Trust); Wolfson Brain Imaging Centre; U.K. Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank all volunteers for their participation in this study and the clinical study officers at the Mental Health Research Network for their dedicated support with volunteer recruitment. The authors are grateful to the staff at the Wellcome Trust Clinical Research Facility at Addenbrooke's Hospital and the Wolfson Brain Imaging Centre for their help and support throughout the study. This work was funded by the U.K. Medical Research Council (MRC) and conducted within the Behavioral and Clinical Neuroscience Institute at the University of Cambridge, which is jointly funded by the MRC and the Wellcome Trust. K. D. E., P.S.J., and A.J.T. are supported by a research grant of the MRC. T. W. R. and A.J.T. consult for Cambridge Cognition. E. T. B. is employed 50% by GlaxoSmithKline and 50% by the University of Cambridge. K. D. E., P.S.J., and G. B. W. declare that they have no conflicts of interest.	Aron AR, 2007, J NEUROSCI, V27, P3743, DOI 10.1523/JNEUROSCI.0519-07.2007; Belin D, 2009, BEHAV BRAIN RES, V199, P89, DOI 10.1016/j.bbr.2008.09.027; Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8; Casey BJ, 2010, J AM ACAD CHILD PSY, V49, P1189, DOI 10.1016/j.jaac.2010.08.017; Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073; Ersche KD, 2011, BRAIN, V134, P2013, DOI 10.1093/brain/awr138; Ersche KD, 2010, BIOL PSYCHIAT, V68, P770, DOI 10.1016/j.biopsych.2010.06.015; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; Graybiel AM, 1995, CURR OPIN NEUROBIOL, V5, P733, DOI 10.1016/0959-4388(95)80100-6; Hammers A, 2003, HUM BRAIN MAPP, V19, P224, DOI 10.1002/hbm.10123; Kroener S, 2010, NEUROPSYCHOPHARMACOL, V35, P2292, DOI 10.1038/npp.2010.107; Kwon JS, 2003, J NEUROL NEUROSUR PS, V74, P962, DOI 10.1136/jnnp.74.7.962; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; Li CSR, 2006, DRUG ALCOHOL DEPEN, V85, P205, DOI 10.1016/j.drugalcdep.2006.04.008; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; Madsen KS, 2010, NEUROPSYCHOLOGIA, V48, P854, DOI 10.1016/j.neuropsychologia.2009.11.001; Merikangas KR, 1998, ARCH GEN PSYCHIAT, V55, P973, DOI 10.1001/archpsyc.55.11.973; Nigg JT, 2006, J AM ACAD CHILD PSY, V45, P468, DOI 10.1097/01.chi.0000199028.76452.a9; Padmala S, 2010, NEUROPSYCHOLOGIA, V48, P558, DOI 10.1016/j.neuropsychologia.2009.10.017; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Tabibnia G, 2011, J NEUROSCI, V31, P4805, DOI 10.1523/JNEUROSCI.2859-10.2011; Tarter RE, 2003, AM J PSYCHIAT, V160, P1078, DOI 10.1176/appi.ajp.160.6.1078; Wright IC, 2002, NEUROIMAGE, V17, P256, DOI 10.1006/nimg.2002.1163; Yin HH, 2006, NAT REV NEUROSCI, V7, P464, DOI 10.1038/nrn1919	29	372	387	3	145	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2012	335	6068					601	604		10.1126/science.1214463	http://dx.doi.org/10.1126/science.1214463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301321				2022-12-28	WOS:000299769200048
J	Foltz, DR; Stukenberg, PT				Foltz, Daniel R.; Stukenberg, P. Todd			A New Histone at the Centromere?	CELL			English	Editorial Material							OUTER KINETOCHORE; CENP-A; COMPLEX; FOLD; DNA; FANCM	The centromere is a classic system to study epigenetic specification, and most research has focused on a specialized histone variant, CENP-A, that is required for kinetochore assembly. Now Nishino et al. reveal a new level of complexity for centromeric chromatin, by showing that the kinetochore complex CENP-T-W-S-X shares structural and functional properties with canonical histones.	[Foltz, Daniel R.; Stukenberg, P. Todd] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Stukenberg, PT (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	pts7h@virginia.edu		Stukenberg, Todd/0000-0002-6788-2111; Foltz, Daniel/0000-0001-7423-6188	NIGMS NIH HHS [R01 GM081576, T32 GM008136, R01 GM063045] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063045, R01GM081576, T32GM008136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 2009, J CELL BIOL, V186, P173, DOI 10.1083/jcb.200903100; Gascoigne KE, 2011, CELL, V145, P410, DOI 10.1016/j.cell.2011.03.031; Hori T, 2008, CELL, V135, P1039, DOI 10.1016/j.cell.2008.10.019; Jansen LET, 2007, J CELL BIOL, V176, P795, DOI 10.1083/jcb.200701066; Lavelle C, 2007, CELL CYCLE, V6, P2113, DOI 10.4161/cc.6.17.4631; Nishino T, 2012, CELL, V148, P487, DOI 10.1016/j.cell.2011.11.061; Prendergast L, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001082; Screpanti E, 2011, CURR BIOL, V21, P391, DOI 10.1016/j.cub.2010.12.039; Singh TR, 2010, MOL CELL, V37, P879, DOI 10.1016/j.molcel.2010.01.036; Yan ZJ, 2010, MOL CELL, V37, P865, DOI 10.1016/j.molcel.2010.01.039; Zeitlin SG, 2009, P NATL ACAD SCI USA, V106, P15762, DOI 10.1073/pnas.0908233106	11	3	3	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					394	396		10.1016/j.cell.2012.01.023	http://dx.doi.org/10.1016/j.cell.2012.01.023			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304909	Green Accepted, Bronze			2022-12-28	WOS:000300225000008
J	Tracey, KJ				Tracey, Kevin J.			Immune Cells Exploit a Neural Circuit to Enter the CNS	CELL			English	Editorial Material							T-CELLS	Multiple sclerosis (MS) is associated with the appearance of autoreactive T cells in the central nervous system. Using a mouse model of MS, Arima et al. now show that this attack begins at a specific spinal cord location. T cell entry into the CNS is regulated by a reflex neural circuit originating from leg muscle contractions.	Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY 11030 USA	Northwell Health	Tracey, KJ (corresponding author), Feinstein Inst Med Res, Lab Biomed Sci, 350 Community Dr, Manhasset, NY 11030 USA.	kjtracey@nshs.edu		Tracey, Kevin J/0000-0003-1884-6314	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057226] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057226] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arima Y, 2012, CELL, V148, P447, DOI 10.1016/j.cell.2012.01.022; Koopman FA, 2011, MOL MED, V17, P937, DOI 10.2119/molmed.2011.00065; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Tracey KJ, 2009, NAT REV IMMUNOL, V9, P418, DOI 10.1038/nri2566	5	24	26	1	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					392	394		10.1016/j.cell.2012.01.025	http://dx.doi.org/10.1016/j.cell.2012.01.025			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304908	Green Accepted, Bronze			2022-12-28	WOS:000300225000007
J	McCahill, LE; Single, RM; Bowles, EJA; Feigelson, HS; James, TA; Barney, T; Engel, JM; Onitilo, AA				McCahill, Laurence E.; Single, Richard M.; Bowles, Erin J. Aiello; Feigelson, Heather S.; James, Ted A.; Barney, Tom; Engel, Jessica M.; Onitilo, Adedayo A.			Variability in Reexcision Following Breast Conservation Surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARCINOMA IN-SITU; CONSERVING SURGERY; CANCER SURGERY; MARGIN STATUS; RE-EXCISION; POSITIVE MARGINS; SURGICAL MARGINS; THERAPY; QUALITY; WOMEN	Context Health care reform calls for increasing physician accountability and transparency of outcomes. Partial mastectomy is the most commonly performed procedure for invasive breast cancer and often requires reexcision. Variability in reexcision might be reflective of the quality of care. Objective To assess hospital and surgeon-specific variation in reexcision rates following partial mastectomy. Design, Setting, and Patients An observational study of breast surgery performed between 2003 and 2008 intended to evaluate variability in breast cancer surgical care outcomes and evaluate potential quality measures of breast cancer surgery. Women with invasive breast cancer undergoing partial mastectomy from 4 institutions were studied (1 university hospital [University of Vermont] and 3 large health plans [Kaiser Permanente Colorado, Group Health, and Marshfield Clinic]). Data were obtained from electronic medical records and chart abstraction of surgical, pathology, radiology, and outpatient records, including detailed surgical margin status. Logistic regression including surgeon-level random effects was used to identify predictors of reexcision. Main Outcome Measure Incidence of reexcision. Results A total of 2206 women with 2220 invasive breast cancers underwent partial mastectomy and 509 patients (22.9%; 95% CI, 21.2%-24.7%) underwent reexcision (454 patients [89.2%; 95% CI, 86.5%-91.9%] had 1 reexcision, 48 [9.4%; 95% CI, 6.9%-12.0%] had 2 reexcisions, and 7 [1.4%; 95% CI, 0.4%-2.4%] had 3 reexcisions). Among all patients undergoing initial partial mastectomy, total mastectomy was performed in 190 patients (8.5%; 95% CI, 7.2%-9.5%). Reexcision rates for margin status following initial surgery were 85.9% (95% CI, 82.0%-89.8%) for initial positive margins, 47.9% (95% CI, 42.0%-53.9%) for less than 1.0 mm margins, 20.2% (95% CI, 15.3%-25.0%) for 1.0 to 1.9 mm margins, and 6.3% (95% CI, 3.2%-9.3%) for 2.0 to 2.9 mm margins. For patients with negative margins, reexcision rates varied widely among surgeons (range, 0%-70%; P=.003) and institutions (range, 1.7%-20.9%; P<.001). Reexcision rates were not associated with surgeon procedure volume after adjusting for case mix (P=.92). Conclusion Substantial surgeon and institutional variation were observed in reexcision following partial mastectomy in women with invasive breast cancer. JAMA. 2012;307(5):467-475	[McCahill, Laurence E.] Michigan State Univ, Van Andel Res Inst, Richard J Lacks Canc Ctr, Grand Rapids, MI USA; [McCahill, Laurence E.] Michigan State Univ, Dept Surg, Grand Rapids, MI USA; [Single, Richard M.] Univ Vermont, Dept Math & Stat, Burlington, VT 05405 USA; [James, Ted A.] Univ Vermont, Dept Surg, Burlington, VT 05405 USA; [Bowles, Erin J. Aiello] Grp Hlth Res Inst, Seattle, WA USA; [Feigelson, Heather S.] Kaiser Permanente Colorado, Denver, CO USA; [Engel, Jessica M.] St Michaels Stevens Point & Marshfield Clin Res F, Marshfield Clin Canc Care, Marshfield, WI USA; [Onitilo, Adedayo A.] Weston Ctr, Marshfield Clin, Hematol Oncol Dept, Weston, ACT, Australia; [Onitilo, Adedayo A.] Marshfield Clin Res Fdn, Marshfield, WI USA	Michigan State University; Van Andel Institute; Michigan State University; University of Vermont; University of Vermont; Kaiser Permanente	McCahill, LE (corresponding author), St Marys Hlth Care, Richard J Lacks Canc Ctr, 250 Cherry St SE, Grand Rapids, MI 49503 USA.	mccahill@trinity-health.org			National Institutes of Health [1RC1CA145402-01]; NATIONAL CANCER INSTITUTE [RC1CA145402] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by grant 1RC1CA145402-01 from the American Recovery and Reinvestment Act of 2009 by the National Institutes of Health.	Azu M, 2010, ANN SURG ONCOL, V17, P558, DOI 10.1245/s10434-009-0765-1; Birkmeyer JD, 2004, J AM COLL SURGEONS, V198, P626, DOI 10.1016/j.jamcollsurg.2003.11.017; Blair SL, 2009, J AM COLL SURGEONS, V209, P608, DOI 10.1016/j.jamcollsurg.2009.07.026; Bowles EA, 2011, CLIN MED RES, V9, P144, DOI [10.3121/cmr.2011. 1020. ps2-03, DOI 10.3121/CMR.2011.1020.PS2-03]; Cellini C, 2004, ANN SURG ONCOL, V11, P915, DOI 10.1245/ASO.2004.12.037; Chan KC, 2001, CANCER, V91, P9, DOI 10.1002/1097-0142(20010101)91:1<9::AID-CNCR2>3.0.CO;2-E; Dick Andrew W, 2011, J Natl Cancer Inst, V103, P92, DOI 10.1093/jnci/djq499; Dillon MF, 2007, ANN SURG ONCOL, V14, P1618, DOI 10.1245/s10434-006-9246-y; El-Tamer MB, 2007, ANN SURG, V245, P665, DOI 10.1097/01.sla.0000245833.48399.9a; Hornbrook Mark C, 2005, J Natl Cancer Inst Monogr, P12; Houssami N, 2010, EUR J CANCER, V46, P3219, DOI 10.1016/j.ejca.2010.07.043; Katipamula R, 2009, J CLIN ONCOL, V27, P4082, DOI 10.1200/JCO.2008.19.4225; Kotwall C, 2007, AM SURGEON, V73, P337; Kunos C, 2006, BREAST J, V12, P28, DOI 10.1111/j.1075-122X.2006.00181.x; Larsen K, 2000, BIOMETRICS, V56, P909, DOI 10.1111/j.0006-341X.2000.00909.x; Lovrics PJ, 2010, CAN J SURG, V53, P305; McCahill LE, 2009, ARCH SURG-CHICAGO, V144, P455, DOI 10.1001/archsurg.2009.56; Menes TS, 2005, ANN SURG ONCOL, V12, P881, DOI 10.1245/ASO.2005.03.021; Morrow M, 2009, JAMA-J AM MED ASSOC, V302, P1551, DOI 10.1001/jama.2009.1450; Olsen MK, 2008, STAT MED, V27, P6055, DOI 10.1002/sim.3446; Papa MZ, 1999, J SURG ONCOL, V70, P167, DOI 10.1002/(SICI)1096-9098(199903)70:3<167::AID-JSO4>3.0.CO;2-7; Persing S, 2011, ANN SURG ONCOL, V18, P3061, DOI 10.1245/s10434-011-1916-8; Singletary SE, 2002, AM J SURG, V184, P383, DOI 10.1016/S0002-9610(02)01012-7; Spiegelhalter DJ, 2007, BAYESIAN APPROACHES; Taghian A, 2005, ANN SURG, V241, P629, DOI 10.1097/01.sla.0000157272.04803.1b; Waljee JF, 2008, ANN SURG ONCOL, V15, P1297, DOI 10.1245/s10434-007-9777-x; Weissman JS, 2011, NEW ENGL J MED, V364, P2276, DOI 10.1056/NEJMp1103069; Young OE, 2007, ANN ROY COLL SURG, V89, P118, DOI 10.1308/003588407X155473	28	363	370	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					467	475		10.1001/jama.2012.43	http://dx.doi.org/10.1001/jama.2012.43			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22298678	Bronze			2022-12-28	WOS:000299728000027
J	Ricklefs, RE; Renner, SS				Ricklefs, Robert E.; Renner, Susanne S.			Global Correlations in Tropical Tree Species Richness and Abundance Reject Neutrality	SCIENCE			English	Article							DIVERSITY; SPECIATION; DIVERSIFICATION; COEVOLUTION; EXTINCTION	Patterns of species richness and relative abundance at some scales cannot be distinguished from predictions of null models, including zero-sum neutral models of population change and random speciation-extinction models of evolutionary diversification. Both models predict that species richness or population abundance produced by independent iterations of the same processes in different regions should be uncorrelated. We find instead that the number of species and individuals in families of trees in forest plots are strongly correlated across Southeast Asia, Africa, and tropical America. These correlations imply that deterministic processes influenced by evolutionarily conservative family-level traits constrain the number of confamilial tree species and individuals that can be supported in regional species pools and local assemblages in humid tropical forests.	[Ricklefs, Robert E.] Univ Missouri, Dept Biol, St Louis, MO 63121 USA; [Renner, Susanne S.] Univ Munich, Dept Biol, D-80638 Munich, Germany	University of Missouri System; University of Missouri Saint Louis; University of Munich	Ricklefs, RE (corresponding author), Univ Missouri, Dept Biol, 8001 Nat Bridge Rd, St Louis, MO 63121 USA.	ricklefs@umsl.edu			Alexander von Humboldt Foundation; Curators of the University of Missouri	Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Curators of the University of Missouri	We are grateful to the principal investigators of the CTFS forest plots used in this analysis for the assembly and sharing of unique data on the structure and dynamics of tropical forests: R. Condit, S. Hubbell, R. Foster (Barro Colorado Island, Panama); S. Bunyavejchewin (Huai Kha Khaeng, Thailand); D. Thomas, D. Kenfack, G. Chuyong (Korup, Cameroon); M. Alvarez (La Planada, Colombia); S. Tan, L. H. Seng, S. Davies, T. Yamakura (Lambir, Malaysia); S. Noor, R. Kassim (Pasoh, Malaysia); and R. Valencia (Yasuni, Ecuador). The manuscript benefitted from the insightful and constructive comments of two reviewers. R. E. R. thanks the Alexander von Humboldt Foundation and the Curators of the University of Missouri for financial support. Original data are available at www.ctfs.si.edu.	Byng JW, 2016, BOT J LINN SOC, V181, P1, DOI 10.1111/boj.12385; Comita LS, 2010, SCIENCE, V329, P330, DOI 10.1126/science.1190772; CONDIT R, 1995, TRENDS ECOL EVOL, V10, P18, DOI 10.1016/S0169-5347(00)88955-7; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; Gaston KJ, 1998, PHILOS T R SOC B, V353, P219, DOI 10.1098/rstb.1998.0204; GENTRY AH, 1982, ANN MO BOT GARD, V69, P557, DOI 10.2307/2399084; Givnish TJ, 2010, TAXON, V59, P1326, DOI 10.1002/tax.595003; Givnish TJ, 1999, J ECOL, V87, P193, DOI 10.1046/j.1365-2745.1999.00333.x; HEY J, 1992, EVOLUTION, V46, P627, DOI [10.2307/2409633, 10.1111/j.1558-5646.1992.tb02071.x]; Hubbell Stephen P., 2001, V32, pi; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; Jaramillo C, 2006, SCIENCE, V311, P1893, DOI 10.1126/science.1121380; Kreft H, 2007, P NATL ACAD SCI USA, V104, P5925, DOI 10.1073/pnas.0608361104; LEIGH EG, 1981, J THEOR BIOL, V90, P213; Liu XB, 2012, ECOL LETT, V15, P111, DOI 10.1111/j.1461-0248.2011.01715.x; Mangan SA, 2010, NATURE, V466, P752, DOI 10.1038/nature09273; McGill BJ, 2005, P NATL ACAD SCI USA, V102, P16701, DOI 10.1073/pnas.0504225102; NEE S, 1992, P NATL ACAD SCI USA, V89, P8322, DOI 10.1073/pnas.89.17.8322; NEE S, 1994, PHILOS T ROY SOC B, V344, P305, DOI 10.1098/rstb.1994.0068; Nee S, 2006, ANNU REV ECOL EVOL S, V37, P1, DOI 10.1146/annurev.ecolsys.37.091305.110035; Pitman NCA, 2001, ECOLOGY, V82, P2101, DOI 10.1890/0012-9658(2001)082[2101:DADOTS]2.0.CO;2; Pitman NCA, 2002, ECOLOGY, V83, P3210, DOI 10.1890/0012-9658(2002)083[3210:ACOTSD]2.0.CO;2; Rabosky DL, 2009, ECOL LETT, V12, P735, DOI 10.1111/j.1461-0248.2009.01333.x; RICKLEFS RE, 1994, EVOLUTION, V48, P1619, DOI 10.1111/j.1558-5646.1994.tb02200.x; Ricklefs RE, 2006, ECOLOGY, V87, P1424, DOI 10.1890/0012-9658(2006)87[1424:TUNTOB]2.0.CO;2; Ricklefs RE, 2010, PHILOS T R SOC B, V365, P1139, DOI 10.1098/rstb.2009.0279; Ricklefs RE, 2010, P NATL ACAD SCI USA, V107, P1265, DOI 10.1073/pnas.0913626107; Ricklefs Robert E., 2009, P257; Ronsted N, 2005, P ROY SOC B-BIOL SCI, V272, P2593, DOI 10.1098/rspb.2005.3249; Terborgh J, 1996, ECOLOGY, V77, P561, DOI 10.2307/2265630; Wing SL, 2009, P NATL ACAD SCI USA, V106, P18627, DOI 10.1073/pnas.0905130106	31	79	80	1	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					464	467		10.1126/science.1215182	http://dx.doi.org/10.1126/science.1215182			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282811				2022-12-28	WOS:000299466800049
J	Gregori, G; Ravasio, A; Murphy, CD; Schaar, K; Baird, A; Bell, AR; Benuzzi-Mounaix, A; Bingham, R; Constantin, C; Drake, RP; Edwards, M; Everson, ET; Gregory, CD; Kuramitsu, Y; Lau, W; Mithen, J; Niemann, C; Park, HS; Remington, BA; Reville, B; Robinson, APL; Ryutov, DD; Sakawa, Y; Yang, S; Woolsey, NC; Koenig, M; Miniati, F				Gregori, G.; Ravasio, A.; Murphy, C. D.; Schaar, K.; Baird, A.; Bell, A. R.; Benuzzi-Mounaix, A.; Bingham, R.; Constantin, C.; Drake, R. P.; Edwards, M.; Everson, E. T.; Gregory, C. D.; Kuramitsu, Y.; Lau, W.; Mithen, J.; Niemann, C.; Park, H. -S.; Remington, B. A.; Reville, B.; Robinson, A. P. L.; Ryutov, D. D.; Sakawa, Y.; Yang, S.; Woolsey, N. C.; Koenig, M.; Miniati, F.			Generation of scaled protogalactic seed magnetic fields in laser-produced shock waves	NATURE			English	Article							EXPERIMENTAL ASTROPHYSICS; LABORATORY SIMULATIONS; TURBULENCE; MAGNETOHYDRODYNAMICS; GALAXIES; CRITERIA	The standard model for the origin of galactic magnetic fields is through the amplification of seed fields via dynamo or turbulent processes to the level consistent with present observations(1-3). Although other mechanisms may also operate(4,5), currents from misaligned pressure and temperature gradients (the Biermann battery process) inevitably accompany the formation of galaxies in the absence of a primordial field. Driven by geometrical asymmetries in shocks(6) associated with the collapse of protogalactic structures, the Biermann battery is believed to generate tiny seed fields to a level of about 10(-21) gauss (refs 7, 8). With the advent of high-power laser systems in the past two decades, a new area of research has opened in which, using simple scaling relations(9,10), astrophysical environments can effectively be reproduced in the laboratory(11,12). Here we report the results of an experiment that produced seed magnetic fields by the Biermann battery effect. We show that these results can be scaled to the intergalactic medium, where turbulence, acting on timescales of around 700 million years, can amplify the seed fields(13,14) sufficiently to affect galaxy evolution.	[Gregori, G.; Murphy, C. D.; Schaar, K.; Baird, A.; Bell, A. R.; Edwards, M.; Lau, W.; Mithen, J.; Reville, B.; Yang, S.] Univ Oxford, Dept Phys, Oxford OX1 3PU, England; [Gregori, G.; Bingham, R.; Robinson, A. P. L.] Rutherford Appleton Lab, Didcot OX11 0QX, Oxon, England; [Ravasio, A.; Benuzzi-Mounaix, A.; Koenig, M.] Univ Paris 06, Lab Utilisat Lasers Intenses, CNRS CEA, Ecole Polytech,UMR7605, F-91128 Palaiseau, France; [Bingham, R.] Univ Strathclyde, Dept Phys, Glasgow G4 0NG, Lanark, Scotland; [Constantin, C.; Everson, E. T.; Niemann, C.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA; [Drake, R. P.] Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48103 USA; [Gregory, C. D.; Woolsey, N. C.] Univ York, Dept Phys, York YO10 5DD, N Yorkshire, England; [Kuramitsu, Y.; Sakawa, Y.] Osaka Univ, Inst Laser Engn, Suita, Osaka 5650871, Japan; [Park, H. -S.; Remington, B. A.; Ryutov, D. D.] Lawrence Livermore Natl Lab, Livermore, CA 94551 USA; [Miniati, F.] ETH, Dept Phys, CH-8093 Zurich, Switzerland	University of Oxford; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; CEA; Institut Polytechnique de Paris; University of Strathclyde; University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; University of York - UK; Osaka University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Swiss Federal Institutes of Technology Domain; ETH Zurich	Gregori, G (corresponding author), Univ Oxford, Dept Phys, Parks Rd, Oxford OX1 3PU, England.	g.gregori1@physics.ox.ac.uk; fm@phys.ethz.ch	Reville, Brian/N-9330-2017; Bingham, Robert/N-2042-2019; Drake, R Paul/I-9218-2012; Reville, Brian/O-2595-2019; Sakawa, Youichi/J-5707-2016	Reville, Brian/0000-0002-3778-1432; Bingham, Robert/0000-0002-9843-7635; Drake, R Paul/0000-0002-5450-9844; Reville, Brian/0000-0002-3778-1432; Sakawa, Youichi/0000-0003-4165-1048; Woolsey, Nigel/0000-0002-2444-9027; Niemann, Christoph/0000-0001-5489-9144; Benuzzi Mounaix, Alessandra/0000-0001-6248-9479	European Research Council under the European Community; EU	European Research Council under the European Community(European Research Council (ERC)); EU(European Commission)	We thank the LULI technical team for their support during the experiments. The research leading to these results has received funding from the European Research Council under the European Community's Seventh Framework Programme. This work was also supported by the EU programme Laserlab-Europe. Partial support from the Science and Technology Facilities Council (the Central Laser Facility and the Centre for Fundamental Physics) and the Engineering and Physical Sciences Research Council of the United Kingdom is also acknowledged.	Bell AR, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.035003; Bernet ML, 2008, NATURE, V454, P302, DOI 10.1038/nature07105; Cho J, 2000, ASTROPHYS J, V538, P217, DOI 10.1086/309127; Everson ET, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3246785; Hansen JF, 2006, PHYS PLASMAS, V13, DOI 10.1063/1.2168157; Hansen JF, 2005, ASTROPHYS SPACE SCI, V298, P61, DOI 10.1007/s10509-005-3912-6; HAYES WD, 1957, J FLUID MECH, V2, P595, DOI 10.1017/S0022112057000403; Kulsrud RM, 1997, ASTROPHYS J, V480, P481, DOI 10.1086/303987; MacFarlane JJ, 2006, J QUANT SPECTROSC RA, V99, P381, DOI 10.1016/j.jqsrt.2005.05.031; Medvedev MV, 2007, ASTROPHYS SPACE SCI, V307, P245, DOI 10.1007/s10509-006-9288-4; Miniati F, 2000, ASTROPHYS J, V542, P608, DOI 10.1086/317027; Miniati F, 2011, ASTROPHYS J, V729, DOI 10.1088/0004-637X/729/1/73; Murphy EJ, 2009, ASTROPHYS J, V706, P482, DOI 10.1088/0004-637X/706/1/482; PARKER EN, 1955, ASTROPHYS J, V122, P293, DOI 10.1086/146087; Reich C, 2000, PHYS REV LETT, V84, P4846, DOI 10.1103/PhysRevLett.84.4846; Remington BA, 1999, SCIENCE, V284, P1488, DOI 10.1126/science.284.5419.1488; Remington BA, 2006, REV MOD PHYS, V78, P755, DOI 10.1103/RevModPhys.78.755; Ryu D, 2008, SCIENCE, V320, P909, DOI 10.1126/science.1154923; Ryutov D, 1999, ASTROPHYS J, V518, P821, DOI 10.1086/307293; Ryutov DD, 2000, ASTROPHYS J SUPPL S, V127, P465, DOI 10.1086/313320; Schlickeiser R, 2003, ASTROPHYS J, V599, pL57, DOI 10.1086/381246; Sur S, 2010, ASTROPHYS J LETT, V721, pL134, DOI 10.1088/2041-8205/721/2/L134; Xu H, 2008, ASTROPHYS J LETT, V688, pL57, DOI 10.1086/595617; Zeldovich Ya.B, 1966, PHYS SHOCK WAVES HIG, VI; Zweibel EG, 1997, NATURE, V385, P131, DOI 10.1038/385131a0	26	105	107	1	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2012	481	7382					480	483		10.1038/nature10747	http://dx.doi.org/10.1038/nature10747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881GY	22281596				2022-12-28	WOS:000299471800034
J	Taylor, KG				Taylor, Kenneth G.			PERSONAL VIEW There's no evidence that 25% of hospital patients would be better off cared for out of hospital	BRITISH MEDICAL JOURNAL			English	Editorial Material												kandgtaylor@blueyonder.co.uk						2011, BRIT MED J, V343; 2011, BRIT MED J, V343	2	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 25	2012	344								e587	10.1136/bmj.e587	http://dx.doi.org/10.1136/bmj.e587			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KV	22277545				2022-12-28	WOS:000299778800018
J	Barz, S; Kashefi, E; Broadbent, A; Fitzsimons, JF; Zeilinger, A; Walther, P				Barz, Stefanie; Kashefi, Elham; Broadbent, Anne; Fitzsimons, Joseph F.; Zeilinger, Anton; Walther, Philip			Demonstration of Blind Quantum Computing	SCIENCE			English	Article							MANIPULATION; COMPUTATION; ALGORITHMS; SPINS	Quantum computers, besides offering substantial computational speedups, are also expected to preserve the privacy of a computation. We present an experimental demonstration of blind quantum computing in which the input, computation, and output all remain unknown to the computer. We exploit the conceptual framework of measurement-based quantum computation that enables a client to delegate a computation to a quantum server. Various blind delegated computations, including one- and two-qubit gates and the Deutsch and Grover quantum algorithms, are demonstrated. The client only needs to be able to prepare and transmit individual photonic qubits. Our demonstration is crucial for unconditionally secure quantum cloud computing and might become a key ingredient for real-life applications, especially when considering the challenges of making powerful quantum computers widely available.	[Barz, Stefanie; Zeilinger, Anton; Walther, Philip] Univ Vienna, Fac Phys, Vienna Ctr Quantum Sci & Technol, A-1090 Vienna, Austria; [Barz, Stefanie; Zeilinger, Anton; Walther, Philip] Austrian Acad Sci, Inst Quantum Opt & Quantum Informat, A-1090 Vienna, Austria; [Kashefi, Elham] Univ Edinburgh, Sch Informat, Edinburgh EH8 9AB, Midlothian, Scotland; [Broadbent, Anne] Univ Waterloo, Inst Quantum Comp, Waterloo, ON N2L 3G1, Canada; [Broadbent, Anne] Univ Waterloo, Dept Combinator & Optimizat, Waterloo, ON N2L 3G1, Canada; [Fitzsimons, Joseph F.] Natl Univ Singapore, Ctr Quantum Technol, Singapore 117543, Singapore; [Fitzsimons, Joseph F.] Univ Coll Dublin, Sch Phys, Dublin 4, Ireland	University of Vienna; Austrian Academy of Sciences; University of Edinburgh; University of Waterloo; University of Waterloo; National University of Singapore; University College Dublin	Barz, S (corresponding author), Univ Vienna, Fac Phys, Vienna Ctr Quantum Sci & Technol, Boltzmanngasse 5, A-1090 Vienna, Austria.	stefanie.barz@univie.ac.at	Walther, Philip/O-2993-2019; Walther, Philip/D-6346-2018; Barz, Stefanie/M-7464-2014; Zeilinger, Anton/A-1170-2011	Walther, Philip/0000-0002-4964-817X; Walther, Philip/0000-0002-4964-817X; Fitzsimons, Joseph/0000-0002-7097-0294	European Commission, Q-ESSENCE [248095]; European Research Council [QIT4QAD]; John Templeton Foundation; Austrian Science Fund (FWF) [SFB-FOCUS, Y585-N20]; Engineering and Physical Sciences Research Council [EP/E059600/1]; Canada's Natural Sciences and Engineering Research Council; Institute for Quantum Computing; QuantumWorks; National Research Foundation; Ministry of Education, Singapore; Air Force Office of Scientific Research, Air Force Material Command, U.S. Air Force [FA8655-11-1-3004]; EPSRC [EP/E059600/1] Funding Source: UKRI; Austrian Science Fund (FWF) [Y 585] Funding Source: researchfish	European Commission, Q-ESSENCE(European Commission); European Research Council(European Research Council (ERC)European Commission); John Templeton Foundation; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Canada's Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Institute for Quantum Computing; QuantumWorks; National Research Foundation; Ministry of Education, Singapore(Ministry of Education, Singapore); Air Force Office of Scientific Research, Air Force Material Command, U.S. Air Force(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	The authors are grateful to C. Brukner, V. Danos, and R. Prevedel for discussions and to F. Cipcigan and J. Schmole for support. We acknowledge support from the European Commission, Q-ESSENCE (no. 248095); European Research Council senior grant (QIT4QAD); John Templeton Foundation; Austrian Science Fund (FWF): [SFB-FOCUS] and [Y585-N20]; Engineering and Physical Sciences Research Council; grant EP/E059600/1; Canada's Natural Sciences and Engineering Research Council; the Institute for Quantum Computing; QuantumWorks; the National Research Foundation and Ministry of Education, Singapore; and the Air Force Office of Scientific Research, Air Force Material Command, U.S. Air Force, under grant no. FA8655-11-1-3004. S. B. designed and performed the experiments, acquired the experimental data, carried out theoretical calculations and the data analysis, and wrote the manuscript. E. K., A. B., and J. F. contributed to the data analysis, carried out theoretical calculations, and wrote the manuscript. A.Z. supervised the project. P. W. contributed to the planning of the experiment, wrote the manuscript, and supervised the project. All authors discussed the results and commented on the manuscript.	Aharonov D., 2010, INNOVATIONS COMPUTER, P453; Arrighi P, 2006, INT J QUANTUM INF, V4, P883, DOI 10.1142/S0219749906002171; Berezovsky J, 2008, SCIENCE, V320, P349, DOI 10.1126/science.1154798; Bialczak RC, 2010, NAT PHYS, V6, P409, DOI 10.1038/NPHYS1639; Broadbent A, 2009, ANN IEEE SYMP FOUND, P517, DOI 10.1109/FOCS.2009.36; Childs AM, 2005, QUANTUM INF COMPUT, V5, P456; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; Danos V, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.052310; Danos V, 2007, J ACM, V54, DOI 10.1145/1219092.1219096; DEUTSCH D, 1992, P ROY SOC LOND A MAT, V439, P553, DOI 10.1098/rspa.1992.0167; DiCarlo L, 2009, NATURE, V460, P240, DOI 10.1038/nature08121; FEYNMAN RP, 1982, INT J THEOR PHYS, V21, P467, DOI 10.1007/BF02650179; Fushman I, 2008, SCIENCE, V320, P769, DOI 10.1126/science.1154643; Gentry C, 2009, ACM S THEORY COMPUT, P169, DOI 10.1145/1536414.1536440; Giovannetti V, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.230502; Gross D, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.052315; Grover L. K., 1996, Proceedings of the Twenty-Eighth Annual ACM Symposium on the Theory of Computing, P212, DOI 10.1145/237814.237866; Hanson R, 2008, NATURE, V453, P1043, DOI 10.1038/nature07129; Hayes B, 2008, COMMUN ACM, V51, P9, DOI 10.1145/1364782.1364789; Hedges MP, 2010, NATURE, V465, P1052, DOI 10.1038/nature09081; James DFV, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.052312; Kaltenbaek R, 2010, NAT PHYS, V6, P850, DOI [10.1038/NPHYS1777, 10.1038/nphys1777]; Kielpinski D, 2002, NATURE, V417, P709, DOI 10.1038/nature00784; Kiesel N, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.210502; Kim K, 2010, NATURE, V465, P590, DOI 10.1038/nature09071; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Lu CY, 2007, NAT PHYS, V3, P91, DOI 10.1038/nphys507; Magniez F, 2006, LECT NOTES COMPUT SC, V4051, P72, DOI 10.1007/11786986_8; Makhlin Y, 2001, REV MOD PHYS, V73, P357, DOI 10.1103/RevModPhys.73.357; McKague M, 2011, LECT NOTES COMPUT SC, V6519, P113, DOI 10.1007/978-3-642-18073-6_10; Monz T, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.130506; Neeley M, 2009, SCIENCE, V325, P722, DOI 10.1126/science.1173440; O'Brien JL, 2003, NATURE, V426, P264, DOI 10.1038/nature02054; Prevedel R, 2007, NATURE, V445, P65, DOI 10.1038/nature05346; Raussendorf R, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.022312; Rivest R. L., 1978, FOUND SEC COMPUT, V4, P169; Shor PW, 1997, SIAM J COMPUT, V26, P1484, DOI [10.1137/S0097539795293172, 10.1137/S0036144598347011]; Tame MS, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.140501; Tokunaga Y, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.210501; Vallone G, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.050302; Walther P, 2005, NATURE, V434, P169, DOI 10.1038/nature03347; Yamamoto T, 2003, NATURE, V425, P941, DOI 10.1038/nature02015	50	250	255	16	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					303	308		10.1126/science.1214707	http://dx.doi.org/10.1126/science.1214707			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267806	Green Submitted			2022-12-28	WOS:000299273400039
J	Katada, S; Imhof, A; Sassone-Corsi, P				Katada, Sayako; Imhof, Axel; Sassone-Corsi, Paolo			Connecting Threads: Epigenetics and Metabolism	CELL			English	Article							HISTONE ACETYLATION; CIRCADIAN CONTROL; PHOSPHORYLATION; COMPLEXES; GROWTH; GENE	Chromatin-modifying enzymes have long been proposed to be the authors of an epigenetic language, but the origin and meaning of the messages they write in chromatin are still mysterious. Recent studies suggesting that the effects of diet can be passed on epigenetically to offspring add weight to the idea that histones act as metabolic sensors, converting changes in metabolism into stable patterns of gene expression. The challenge will now be to understand how localized fluctuations in levels of metabolites control chromatin modifiers in space and time, translating a dynamic metabolic state into a histone map.	[Katada, Sayako; Imhof, Axel; Sassone-Corsi, Paolo] Univ Calif Irvine, Sch Med, Ctr Epigenet & Metab, Irvine, CA 92697 USA; [Imhof, Axel] Univ Munich, Adolf Butenandt Inst, Munich Ctr Integrated Prot Sci, D-80336 Munich, Germany	University of California System; University of California Irvine; University of Munich	Sassone-Corsi, P (corresponding author), Univ Calif Irvine, Sch Med, Ctr Epigenet & Metab, Irvine, CA 92697 USA.	psc@uci.edu	Imhof, Axel/AAU-5313-2021	Imhof, Axel/0000-0003-2993-8249; Katada, Sayako/0000-0002-0466-0466				Albaugh BN, 2011, CHEMBIOCHEM, V12, P290, DOI 10.1002/cbic.201000438; Bancaud A, 2009, EMBO J, V28, P3785, DOI 10.1038/emboj.2009.340; Barth TK, 2010, TRENDS BIOCHEM SCI, V35, P618, DOI 10.1016/j.tibs.2010.05.006; Borrelli E, 2008, NEURON, V60, P961, DOI 10.1016/j.neuron.2008.10.012; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Fujiki R, 2009, NATURE, V459, P455, DOI 10.1038/nature07954; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859; Katoh Y, 2011, MOL CELL, V41, P554, DOI 10.1016/j.molcel.2011.02.018; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Leibundgut M, 2008, CURR OPIN STRUC BIOL, V18, P714, DOI 10.1016/j.sbi.2008.09.008; Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Painter RC, 2005, REPROD TOXICOL, V20, P345, DOI 10.1016/j.reprotox.2005.04.005; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Sinclair DAR, 2009, P NATL ACAD SCI USA, V106, P13427, DOI 10.1073/pnas.0904638106; Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Turner BM, 2009, PHILOS T R SOC B, V364, P3403, DOI 10.1098/rstb.2009.0125; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	28	227	232	2	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					24	28		10.1016/j.cell.2012.01.001	http://dx.doi.org/10.1016/j.cell.2012.01.001			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265398	Bronze			2022-12-28	WOS:000299540700010
J	Kretzschmar, K; Watt, FM				Kretzschmar, Kai; Watt, Fiona M.			Lineage Tracing	CELL			English	Article							FOLLICLE STEM-CELLS; LABEL-RETAINING CELLS; HAIR FOLLICLE; ESTROGEN-RECEPTOR; MOUSE EPIDERMIS; CRE RECOMBINASE; SMALL-INTESTINE; NERVOUS-SYSTEM; REPORTER MOUSE; GENE-TRANSFER	Lineage tracing is the identification of all progeny of a single cell. Although its origins date back to developmental biology of invertebrates in the 19th century, lineage tracing is now an essential tool for studying stem cell properties in adult mammalian tissues. Lineage tracing provides a powerful means of understanding tissue development, homeostasis, and disease, especially when it is combined with experimental manipulation of signals regulating cell-fate decisions. Recently, the combination of inducible recombinases, multicolor reporter constructs, and live-cell imaging has provided unprecedented insights into stem cell biology. Here we discuss the different experimental strategies currently available for lineage tracing, their associated caveats, and new opportunities to integrate lineage tracing with the monitoring of intracellular signaling pathways.	[Kretzschmar, Kai; Watt, Fiona M.] Univ Cambridge, Wellcome Trust Ctr Stem Cell Res, Cambridge CB2 1QR, England; [Watt, Fiona M.] Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Cambridge CB2 0RE, England	University of Cambridge; Cancer Research UK; CRUK Cambridge Institute	Watt, FM (corresponding author), Univ Cambridge, Wellcome Trust Ctr Stem Cell Res, Tennis Court Rd, Cambridge CB2 1QR, England.	fiona.watt@cancer.org.uk	Kretzschmar, Kai/F-1174-2013; Watt, Fiona/AHB-0226-2022	Kretzschmar, Kai/0000-0002-4745-6684; Watt, Fiona/0000-0001-9151-5154	UK Medical Research Council (MRC); MRC; Wellcome Trust; Cancer Research UK; European Union; Cambridge University; Hutchison Whampoa	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Cancer Research UK(Cancer Research UK); European Union(European Commission); Cambridge University(University of Cambridge); Hutchison Whampoa	K.K. is the recipient of a PhD studentship from the UK Medical Research Council (MRC). F.M.W. gratefully acknowledges financial support from the MRC, Wellcome Trust, Cancer Research UK, and the European Union Framework 7 programme. We also gratefully acknowledge the support of Cambridge University and Hutchison Whampoa. We are grateful to Denny Cottle, Ryan Driskell, and the other members of the Watt group for their comments.	Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Arwert EN, 2010, P NATL ACAD SCI USA, V107, P19903, DOI 10.1073/pnas.1007404107; AXELROD D, 1979, BIOPHYS J, V26, P557, DOI 10.1016/S0006-3495(79)85271-6; BALAKIER H, 1982, DEV BIOL, V90, P352, DOI 10.1016/0012-1606(82)90384-0; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen MR, 2010, GENESIS, V48, P585, DOI 10.1002/dvg.20666; Choate KA, 2010, SCIENCE, V330, P94, DOI 10.1126/science.1192280; Clayton E, 2007, NATURE, V446, P185, DOI 10.1038/nature05574; Conklin E.G., 1905, J ACAD NAT SCI PHILA, V12, P1, DOI DOI 10.5962/BHL.TITLE.4801; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; Giangreco A, 2009, P NATL ACAD SCI USA, V106, P9286, DOI 10.1073/pnas.0900668106; Gilbert S.F., 2000, DEV BIOL; Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103; Grove EA, 2008, SCIENCE, V319, P288, DOI 10.1126/science.1153743; HARRISON DA, 1993, CURR BIOL, V3, P424, DOI 10.1016/0960-9822(93)90349-S; Hirrlinger J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004286; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; Horsley V, 2006, CELL, V126, P597, DOI 10.1016/j.cell.2006.06.048; Iglesias P, 2009, BIOSENS BIOELECTRON, V24, P3126, DOI 10.1016/j.bios.2009.04.013; Itasaki N, 1999, NAT CELL BIOL, V1, pE203, DOI 10.1038/70231; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Kemp R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh090; Kennedy MJ, 2010, NAT METHODS, V7, P973, DOI 10.1038/NMETH.1524; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; Kyrkanides S, 2003, MOL THER, V8, P790, DOI 10.1016/j.ymthe.2003.07.005; LEDOUARIN NM, 1980, NATURE, V286, P663, DOI 10.1038/286663a0; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; Li ER, 2005, FEBS LETT, V579, P6479, DOI 10.1016/j.febslet.2005.10.022; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Lo Celso C, 2008, STEM CELLS, V26, P1241, DOI 10.1634/stemcells.2007-0651; Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Magnusdottir E, 2007, P NATL ACAD SCI USA, V104, P14988, DOI 10.1073/pnas.0707323104; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; Mcdonald SAC, 2008, GASTROENTEROLOGY, V134, P500, DOI 10.1053/j.gastro.2007.11.035; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MINTZ B, 1965, SCIENCE, V148, P1233; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; Novelli MR, 1996, SCIENCE, V272, P1187, DOI 10.1126/science.272.5265.1187; Nowak JA, 2008, CELL STEM CELL, V3, P33, DOI 10.1016/j.stem.2008.05.009; Nystul T, 2007, CELL STEM CELL, V1, P277, DOI 10.1016/j.stem.2007.07.009; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Rieger MA, 2009, J CELL BIOCHEM, V108, P343, DOI 10.1002/jcb.22273; Rinkevich Y, 2011, NATURE, V476, P409, DOI 10.1038/nature10346; ROSENQUIST GC, 1981, DEV BIOL, V87, P201, DOI 10.1016/0012-1606(81)90143-3; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SCHMIDT GH, 1987, DEVELOPMENT, V100, P535; SERBEDZIJA GN, 1989, DEVELOPMENT, V106, P809; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Snippert HJ, 2011, NAT PROTOC, V6, P1221, DOI 10.1038/nprot.2011.365; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Steinberg MS, 2007, CURR OPIN GENET DEV, V17, P281, DOI 10.1016/j.gde.2007.05.002; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Sutherland K.D., 2011, CANCER CELL, V19, P754; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tsujita M, 1999, J NEUROSCI, V19, P10318; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Vogt Walther, 1929, Wilhelm Roux Arch Entwickl Mech Org, V120, P384, DOI 10.1007/BF02109667; Vooijs M, 2007, DEVELOPMENT, V134, P535, DOI 10.1242/dev.02733; Waddington CH, 1932, PHILOS T R SOC LON B, V221, P179, DOI 10.1098/rstb.1932.0003; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Watt FM, 2008, CURR OPIN CELL BIOL, V20, P171, DOI 10.1016/j.ceb.2008.01.010; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; WEISBLAT DA, 1978, SCIENCE, V202, P1295, DOI 10.1126/science.725606; Weissman Irving L., 2005, V265, P35; WINTON DJ, 1989, BRIT J CANCER, V60, P59, DOI 10.1038/bjc.1989.220; Yamamoto M, 2009, GENESIS, V47, P107, DOI 10.1002/dvg.20474; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031; Zong H, 2005, CELL, V121, P479, DOI 10.1016/j.cell.2005.02.012	101	435	453	2	74	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					33	45		10.1016/j.cell.2012.01.002	http://dx.doi.org/10.1016/j.cell.2012.01.002			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265400	Bronze			2022-12-28	WOS:000299540700012
J	Maher, CA; Wilson, RK				Maher, Christopher A.; Wilson, Richard K.			Chromothripsis and Human Disease: Piecing Together the Shattering Process	CELL			English	Review							MAMMALIAN-CELL FUSION; CANCER DEVELOPMENT; REARRANGEMENTS; MECHANISM; TELOMERES	The unprecedented resolution of high-throughput genomics has enabled the recent discovery of a phenomenon by which specific regions of the genome are shattered and then stitched together via a single devastating event, referred to as chromothripsis. Potential mechanisms governing this process are now emerging, with implications for our understanding of the role of genomic rearrangements in development and disease.	[Maher, Christopher A.; Wilson, Richard K.] Washington Univ, Sch Med, Genome Inst, St Louis, MO 63108 USA; [Maher, Christopher A.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63108 USA; [Maher, Christopher A.; Wilson, Richard K.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Maher, CA (corresponding author), Washington Univ, Sch Med, Genome Inst, St Louis, MO 63108 USA.	cmaher@dom.wustl.edu	Wilson, Richard K./AAF-4139-2019	Wilson, Richard K./0000-0002-1992-1358	NIH [R00CA149182-03]; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [R00CA149182] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	C.A.M. is funded by an NIH grant R00CA149182-03 and a Prostate Cancer Foundation Young Investigator Award.	Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hastings PJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000327; Kloosterman WP, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r103; Kloosterman WP, 2011, HUM MOL GENET, V20, P1916, DOI 10.1093/hmg/ddr073; Lee JA, 2007, CELL, V131, P1235, DOI 10.1016/j.cell.2007.11.037; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Liu PF, 2011, CELL, V146, P888, DOI 10.1016/j.cell.2011.07.042; Magrangeas F, 2011, BLOOD, V118, P675, DOI 10.1182/blood-2011-03-344069; McClintock B, 1941, GENETICS, V26, P234; Murnane JP, 2006, DNA REPAIR, V5, P1082, DOI 10.1016/j.dnarep.2006.05.030; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Pampalona J, 2010, MUTAT RES-FUND MOL M, V683, P16, DOI 10.1016/j.mrfmmm.2009.10.001; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; SPERLING K, 1974, CHROMOSOMA, V45, P121, DOI 10.1007/BF00362306; Stanulla M, 2001, HUM MOL GENET, V10, P2481, DOI 10.1093/hmg/10.22.2481; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Tsai AG, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-S1-S1; Tubio JMC, 2011, NATURE, V470, P476, DOI 10.1038/470476a	21	116	120	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 20	2012	148	1-2					29	32		10.1016/j.cell.2012.01.006	http://dx.doi.org/10.1016/j.cell.2012.01.006			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265399	Green Accepted, Bronze			2022-12-28	WOS:000299540700011
J	Kotton, DN; Muse, VV; Nishino, M				Kotton, Darrell N.; Muse, Victorine V.; Nishino, Michiya			Case 2-2012: A 63-Year-Old Woman with Dyspnea and Rapidly Progressive Respiratory Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KASABACH-MERRITT-SYNDROME; BREAST IMPLANTS; HALO SIGN; METASTATIC ANGIOSARCOMA; ASPERGILLOSIS; DIAGNOSIS; SILICONE; GALACTOMANNAN; DISEASES; CT		[Kotton, Darrell N.] Boston Med Ctr, Dept Med, Boston, MA 02218 USA; [Kotton, Darrell N.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Muse, Victorine V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Nishino, Michiya] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Muse, Victorine V.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Nishino, Michiya] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Boston Medical Center; Boston University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kotton, DN (corresponding author), Boston Med Ctr, Dept Med, Boston, MA 02218 USA.			Nishino, Michiya/0000-0003-4692-4981; Kotton, Darrell/0000-0002-9604-8476				Abraham JA, 2007, ANN SURG ONCOL, V14, P1953, DOI 10.1245/s10434-006-9335-y; Adem C, 2001, ARCH PATHOL LAB MED, V125, P1562; ARCOMANO MA, 1991, J NUCL MED, V32, P2278; Balzer BL, 2009, HUM PATHOL, V40, P1564, DOI 10.1016/j.humpath.2009.03.020; Bernathova M, 2006, BREAST, V15, P255, DOI 10.1016/j.breast.2005.04.015; Bocklage T, 2001, MODERN PATHOL, V14, P1216, DOI 10.1038/modpathol.3880463; Brinton LA, 1997, J NATL CANCER I, V89, P1341, DOI 10.1093/jnci/89.18.1341; CLARKSON P, 1962, Guys Hosp Rep, V111, P335; Iyoda Masayuki, 2005, Clin Exp Nephrol, V9, P252, DOI 10.1007/s10157-005-0366-7; Janowsky EC, 2000, NEW ENGL J MED, V342, P781, DOI 10.1056/NEJM200003163421105; JENNINGS TA, 1988, CANCER-AM CANCER SOC, V62, P2436, DOI 10.1002/1097-0142(19881201)62:11<2436::AID-CNCR2820621132>3.0.CO;2-J; Kariv R, 2000, MEDICINE, V79, P349, DOI 10.1097/00005792-200011000-00001; Kim Y, 1999, J COMPUT ASSIST TOMO, V23, P622, DOI 10.1097/00004728-199907000-00025; Kirkpatrick CJ, 2000, AM J PATHOL, V156, P1455, DOI 10.1016/S0002-9440(10)65014-6; Koo S, 2009, CLIN INFECT DIS, V49, P1650, DOI 10.1086/647942; KUHLMAN JE, 1985, RADIOLOGY, V157, P611, DOI 10.1148/radiology.157.3.3864189; Lechner MG, 2011, CANCER-AM CANCER SOC, V117, P1478, DOI 10.1002/cncr.25654; MAZZOCCHI A, 1993, TUMORI, V79, P137, DOI 10.1177/030089169307900212; Meersseman W, 2008, AM J RESP CRIT CARE, V177, P27, DOI 10.1164/rccm.200704-606OC; Moussa S. H. Y., 2002, Archives of Gynecology and Obstetrics, V267, P43, DOI 10.1007/s004040100224; NAKA N, 1995, CANCER, V75, P989, DOI 10.1002/1097-0142(19950215)75:4<989::AID-CNCR2820750414>3.0.CO;2-K; Okada F, 2007, INT J CANCER, V121, P2364, DOI 10.1002/ijc.23125; Parron M, 2008, ARCH BRONCONEUMOL, V44, P386, DOI 10.1016/S0300-2896(08)70453-8; Pfeiffer CD, 2006, CLIN INFECT DIS, V42, P1417, DOI 10.1086/503427; Pittet B, 2005, LANCET INFECT DIS, V5, P94, DOI 10.1016/S1473-3099(05)01281-8; Salmasi A, 2010, BREAST CARE, V5, P105, DOI 10.1159/000301599; Saunders ND, 2007, J THORAC CARDIOV SUR, V134, P1076, DOI 10.1016/j.jtcvs.2007.04.051; Takenaka Miki, 2009, Kurume Medical Journal, V56, P33; Urschel H C Jr, 2000, Chest Surg Clin N Am, V10, P393; Weiss S.W., 2008, ENZINGER WEISSS SOFT, P703; Weissferdt A, 2010, ANN DIAGN PATHOL, V14, P296, DOI 10.1016/j.anndiagpath.2010.03.001; Wright PK, 2006, J PLAST RECONSTR AES, V59, P1118, DOI 10.1016/j.bjps.2006.01.020	32	6	6	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					259	269		10.1056/NEJMcpc1109274	http://dx.doi.org/10.1056/NEJMcpc1109274			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877RZ	22256809				2022-12-28	WOS:000299201400013
J	Lim, LS				Lim, Lionel S.			Adding a panel manager to EMR reminders improved some preventive care processes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Lim, Lionel S.] Griffin Hosp, Derby, CT 06418 USA		Lim, LS (corresponding author), Griffin Hosp, Derby, CT 06418 USA.			Lim, Lionel/0000-0002-0730-8767				Chen EH, 2011, ARCH INTERN MED, V171, P1558, DOI 10.1001/archinternmed.2011.395; Dale J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006903.pub2; McBride CM, 1999, PATIENT EDUC COUNS, V37, P3, DOI 10.1016/S0738-3991(98)00098-6	3	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-12	10.7326/0003-4819-156-2-201201170-02012	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V41QD	22250174				2022-12-28	WOS:000209559800003
J	Pavia, AT				Pavia, Andrew T.			Laboratory Creation of a Highly Transmissible H5N1 Influenza Virus: Balancing Substantial Risks and Real Benefits	ANNALS OF INTERNAL MEDICINE			English	Article							RECEPTOR-BINDING; HUMAN INFECTION; HEMAGGLUTININ	Controversy erupted when influenza researchers announced that they had created an H5N1 influenza virus that was transmissible between ferrets. The controversy escalated when the National Science Advisory Board for Biosecurity (NSABB) recommended that the work be published but recommended significant voluntary redactions. The responses to the NSABB action and to the research itself have been polarized. A readily transmitted H5N1 virus could be extraordinarily lethal; therefore, the risk for accidental release is significant, and deliberate misuse of the data to create a biological weapon is possible. However, the knowledge gained by these and future experiments under appropriate safeguards is likely to allow critical understanding of influenza transmission and virulence. It would be irresponsible to adopt either extreme solution: to prevent and censor the research or to allow unlimited distribution without careful review by an independent group, such as the NSABB.	Univ Utah, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah	Pavia, AT (corresponding author), Univ Utah, 295 Chipeta Way, Salt Lake City, UT 84108 USA.	andy.pavia@hsc.utah.edu						Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279; [Anonymous], 2012, NY TIMES        0107; Baskin CR, 2009, P NATL ACAD SCI USA, V106, P3455, DOI 10.1073/pnas.0813234106; Belser JA, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001705; Belser JA, 2009, ADV VIRUS RES, V73, P55, DOI 10.1016/S0065-3527(09)73002-7; Enserink M, 2011, SCIENCE, V334, P1192, DOI 10.1126/science.334.6060.1192; Garcia-Sastre A, 2006, J INFECT DIS, V194, pS127, DOI 10.1086/507546; Grady D, 2011, NY TIMES        1220; Inglesby TV, 2011, BIOSECUR BIOTERROR; Jackson S, 2009, J VIROL, V83, P8131, DOI 10.1128/JVI.00534-09; Kash JC, 2006, NATURE, V443, P578, DOI 10.1038/nature05181; Maines TR, 2011, VIROLOGY, V413, P139, DOI 10.1016/j.virol.2011.02.015; Maines TR, 2006, P NATL ACAD SCI USA, V103, P12121, DOI 10.1073/pnas.0605134103; National Science Advisory Board for Biosecurity, 2007, PROP FRAM OVERS DUAL; National Science Advisory Board for Biosecurity, 2011, GUID ENH PERS REL ST; O'Toole T, 2009, BIOSECUR BIOTERROR, V7, P25, DOI 10.1089/bsp.2009.1001; Palese P, 2012, NATURE, V481, P115, DOI 10.1038/481115a; Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; Tumpey TM, 2007, SCIENCE, V315, P655, DOI 10.1126/science.1136212; Tumpey TM, 2009, ANNU REV MICROBIOL, V63, P79, DOI 10.1146/annurev.micro.091208.073359; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Uyeki TM, 2009, CLIN INFECT DIS, V49, P279, DOI 10.1086/600035; Van Hoeven N, 2009, P NATL ACAD SCI USA, V106, P3366, DOI 10.1073/pnas.0813172106; Vong S, 2009, J INFECT DIS, V199, P1744, DOI 10.1086/599208; WHO, 2012, CUM NUMB CONF HUM CA; Yen HL, 2009, P NATL ACAD SCI USA, V106, P286, DOI 10.1073/pnas.0811052106	27	3	3	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2012	156	6					463	U125		10.7326/0003-4819-156-6-201203200-00386	http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00386			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930PF	22282172				2022-12-28	WOS:000303150900019
J	Schwartz, SD; Hubschman, JP; Heilwell, G; Franco-Cardenas, V; Pan, CK; Ostrick, RM; Mickunas, E; Gay, R; Klimanskaya, I; Lanza, R				Schwartz, Steven D.; Hubschman, Jean-Pierre; Heilwell, Gad; Franco-Cardenas, Valentina; Pan, Carolyn K.; Ostrick, Rosaleen M.; Mickunas, Edmund; Gay, Roger; Klimanskaya, Irina; Lanza, Robert			Embryonic stem cell trials for macular degeneration: a preliminary report	LANCET			English	Article							RETINAL-PIGMENT EPITHELIUM; TRANSPLANTATION; TRANSLOCATION; MORPHOLOGY; RPE	Background It has been 13 years since the discovery of human embryonic stem cells (hESCs). Our report provides the first description of hESC-derived cells transplanted into human patients. Methods We started two prospective clinical studies to establish the safety and tolerability of subretinal transplantation of hESC-derived retinal pigment epithelium (RPE) in patients with Stargardt's macular dystrophy and dry age-related macular degeneration-the leading cause of blindness in the developed world. Preoperative and postoperative ophthalmic examinations included visual acuity, fluorescein angiography, optical coherence tomography, and visual field testing. These studies are registered with ClinicalTrials.gov, numbers NCT01345006 and NCT01344993. Findings Controlled hESC differentiation resulted in greater than 99% pure RPE. The cells displayed typical RPE behaviour and integrated into the host RPE layer forming mature quiescent monolayers after trans plantation in animals. The stage of differentiation substantially affected attachment and survival of the cells in vitro after clinical formulation. Lightly pigmented cells attached and spread in a substantially greater proportion (>90%) than more darkly pigmented cells after culture. After surgery, structural evidence confirmed cells had attached and continued to persist during our study. We did not identify signs of hyperproliferation, abnormal growth, or immune mediated transplant rejection in either patient during the first 4 months. Although there is little agreement between investigators on visual endpoints in patients with low vision, it is encouraging that during the observation period neither patient lost vision. Best corrected visual acuity improved from hand motions to 20/800 (and improved from 0 to 5 letters on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual acuity chart) in the study eye of the patient with Stargardt's macular dystrophy, and vision also seemed to improve in the patient with dry age-related macular degeneration (from 21 ETDRS letters to 28). Interpretation The hESC-derived RPE cells showed no signs of hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection after 4 months. The future therapeutic goal will be to treat patients earlier in the disease processes, potentially increasing the likelihood of photoreceptor and central visual rescue.	[Schwartz, Steven D.; Hubschman, Jean-Pierre; Heilwell, Gad; Franco-Cardenas, Valentina; Pan, Carolyn K.; Ostrick, Rosaleen M.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90095 USA; [Mickunas, Edmund; Gay, Roger; Klimanskaya, Irina; Lanza, Robert] Adv Cell Technol, Marlborough, MA 01752 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schwartz, SD (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90095 USA.	schwartz@jsei.ucla.edu; rlanza@advancedcell.com		Pan, Carolyn/0000-0002-1031-7488; Lanza, Robert/0000-0002-3047-3074; Hubschman, Jean-Pierre/0000-0002-8631-3467	Advanced Cell Technology	Advanced Cell Technology	Advanced Cell Technology.	Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183; ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273; Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118; Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3; Bull ND, 2011, STEM CELLS, V29, P1170, DOI 10.1002/stem.676; Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981; Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335; Drukker M, 2006, STEM CELLS, V24, P221, DOI 10.1634/stemcells.2005-0188; Fink DW, 2009, ESSENTIALS OF STEM CELL BIOLOGY, 2ND EDITION, P619, DOI 10.1016/B978-0-12-374729-7.00068-8; Gamm DM, 2008, STEM CELLS, V26, P3182, DOI 10.1634/stemcells.2008-0300; Hentze H, 2009, STEM CELL RES, V2, P198, DOI 10.1016/j.scr.2009.02.002; Kaplan H J, 1999, Chem Immunol, V73, P207; Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005; Klimanskaya I, 2005, LANCET, V365, P1636, DOI 10.1016/S0140-6736(05)66473-2; Klimanskaya I, 2006, NATURE, V444, P481, DOI 10.1038/nature05142; Lanza RP, 2002, NAT BIOTECHNOL, V20, P689, DOI 10.1038/nbt703; Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149; Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149; Lu F, 2007, MOL VIS, V13, P2066; Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189; MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029; Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622; Okamura RM, 2007, J NEUROIMMUNOL, V192, P134, DOI 10.1016/j.jneuroim.2007.09.030; SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127; Sparrrow JR, 2010, CURR MOL MED, V10, P802; Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tezel TH, 1998, EXP EYE RES, V66, P807, DOI 10.1006/exer.1998.0492; Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350	31	990	1075	12	318	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2012	379	9817					713	720		10.1016/S0140-6736(12)60028-2	http://dx.doi.org/10.1016/S0140-6736(12)60028-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899CU	22281388				2022-12-28	WOS:000300792600027
J	Stephens, DS				Stephens, David S.			Prevention of serogroup B meningococcal disease	LANCET			English	Editorial Material							VACCINES; EPIDEMIC		[Stephens, David S.] Emory Univ, Sch Med, Atlanta, GA 30322 USA; [Stephens, David S.] VA Med Ctr, Atlanta, GA 30033 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Stephens, DS (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30322 USA.	dstep01@emory.edu						Boccadifuoco G, 2011, MEN SEPT CHILDR AD C; Santolaya ME, 2012, LANCET, V379, P617, DOI 10.1016/S0140-6736(11)61713-3; Gasparini R, 2011, HUM VACCINES, V7, P170, DOI 10.4161/hv.7.2.13717; Lennon D, 2009, CLIN INFECT DIS, V49, P597, DOI 10.1086/603552; Maiden MCJ, 2008, J INFECT DIS, V197, P737, DOI 10.1086/527401; Mascioni A, 2009, J BIOL CHEM, V284, P8729, DOI 10.1074/jbc.M808831200; Miller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2; Stephens DS, 2011, LANCET INFECT DIS, V11, P421, DOI 10.1016/S1473-3099(11)70096-2	10	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2012	379	9816					592	594		10.1016/S0140-6736(11)61934-X	http://dx.doi.org/10.1016/S0140-6736(11)61934-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897ES	22260987				2022-12-28	WOS:000300629000006
J	Mirnezami, R; Nicholson, J; Darzi, A				Mirnezami, Reza; Nicholson, Jeremy; Darzi, Ara			Preparing for Precision Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH		[Mirnezami, Reza; Darzi, Ara] Univ London Imperial Coll Sci Technol & Med, Sect Biosurg & Surg Technol, Dept Surg & Canc, London, England; [Nicholson, Jeremy] Univ London Imperial Coll Sci Technol & Med, Sect Biomol Med, Dept Surg & Canc, London, England	Imperial College London; Imperial College London	Mirnezami, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Biosurg & Surg Technol, Dept Surg & Canc, London, England.		Nicholson, Jeremy K/B-3395-2012	Nicholson, Jeremy K/0000-0002-8123-8349				Committee on a Framework for Developing a New Taxonomy of Disease; National Research Council, 2011, PREC MED BUILD KNOWL; Katsanis SH, 2008, SCIENCE, V320, P53, DOI 10.1126/science.1156604; Mayor S, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6215; Scheuner MT, 2009, GENET MED, V11, P510, DOI 10.1097/GIM.0b013e3181a53331	4	442	470	3	138	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					489	491		10.1056/NEJMp1114866	http://dx.doi.org/10.1056/NEJMp1114866			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888GH	22256780				2022-12-28	WOS:000299991300004
J	Brueton, R				Brueton, Richard			PERSONAL VIEW Expatriate surgeons have helped advance orthopaedic care in Africa	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Free Hosp, London, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Brueton, R (corresponding author), Royal Free Hosp, London, England.	bruetons@ar2.net							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 8	2012	344								e938	10.1136/bmj.e938	http://dx.doi.org/10.1136/bmj.e938			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IE	22318443				2022-12-28	WOS:000300279100011
J	Hooton, TM; Roberts, PL; Stapleton, AE				Hooton, Thomas M.; Roberts, Pacita L.; Stapleton, Ann E.			Cefpodoxime vs Ciprofloxacin for Short-Course Treatment of Acute Uncomplicated Cystitis A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT-INFECTIONS; STAPHYLOCOCCUS-AUREUS; ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; ANTIMICROBIAL RESISTANCE; FLUOROQUINOLONE USE; WOMEN; THERAPY; PYELONEPHRITIS; GUIDELINES	Context Although fluoroquinolones remain the most reliable urinary antimicrobial, resistance rates have increased and effective fluoroquinolone-sparing antimicrobials are needed. Objective To determine whether cefpodoxime is noninferior to ciprofloxacin for treatment of acute cystitis. Design, Setting, and Patients Randomized, double-blind trial of 300 women aged 18 to 55 years with acute uncomplicated cystitis comparing ciprofloxacin (n=150) with cefpodoxime (n=150); patients were from a student health center in Seattle, Washington, and a referral center in Miami, Florida. The study was conducted from 2005 to 2009 and outcomes were assessed at 5 to 9 days and 28 to 30 days after completion of therapy. Intent-to-treat and per-protocol analyses were performed; 15 women in the ciprofloxacin group and 17 women in the cefpodoxime group were lost to follow-up. Interventions Patients were given 250 mg of ciprofloxacin orally twice daily for 3 days or 100 mg of cefpodoxime proxetil orally twice daily for 3 days. Main Outcome Measures Overall clinical cure (defined as not requiring antimicrobial treatment during follow-up) at the 30-day follow-up visit. Secondary outcomes were clinical and microbiological cure at the first follow-up visit and vaginal Escherichia coli colonization at each follow-up visit. The hypothesis that cefpodoxime would be noninferior to ciprofloxacin by a 10% margin (ie, for the difference in the primary outcome for ciprofloxacin minus cefpodoxime, the upper limit of the confidence interval would be <10%) was formulated prior to data collection. Results The overall clinical cure rate at the 30-day visit with the intent-to-treat approach in which patients lost to follow-up were considered as having clinical cure was 93%(139/150) for ciprofloxacin compared with 82%(123/150) for cefpodoxime (difference of 11%; 95% CI, 3%-18%); and for the intent-to-treat approach in which patients lost to follow-up were considered as having not responded to treatment, the clinical cure rate was 83% (124/150) for ciprofloxacin compared with 71% (106/150) for cefpodoxime (difference of 12%; 95% CI, 3%-21%). The microbiological cure rate was 96% (123/128) for ciprofloxacin compared with 81% (104/129) for cefpodoxime (difference of 15%; 95% CI, 8%-23%). At first follow-up, 16% of women in the ciprofloxacin group compared with 40% of women in the cefpodoxime group had vaginal E coli colonization. Conclusions Among women with uncomplicated cystitis, a 3-day regimen of cefpodoxime compared with ciprofloxacin did not meet criteria for noninferiority for achieving clinical cure. These findings, along with concerns about possible adverse ecological effects associated with other broad-spectrum beta-lactams, do not support the use of cefpodoxime as a first-line fluoroquinolone-sparing antimicrobial for acute uncomplicated cystitis.	[Hooton, Thomas M.] Univ Miami, Sch Med, Dept Med, Miami, FL USA; [Roberts, Pacita L.; Stapleton, Ann E.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	University of Miami; University of Washington; University of Washington Seattle	Hooton, TM (corresponding author), Clin Res Bldg,1120 NW 14th St,Ste 310G, Miami, FL 33136 USA.	thooton@med.miami.edu	Stapleton, Ann E/N-2428-2015; Hug, Balthasar L./G-1568-2010	Stapleton, Ann E/0000-0003-0130-8659; 	National Institute of Diabetes and Digestive and Kidney Diseases [P01 DK053369, SCOR P50 DK64540]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070906, R01DK062863, P50DK064540, P01DK053369, R01DK088830] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants P01 DK053369 and SCOR P50 DK64540 from the National Institute of Diabetes and Digestive and Kidney Diseases.	Charbonneau P, 2006, CLIN INFECT DIS, V42, P778, DOI 10.1086/500319; Chow S. C., 2003, SAMPLE SIZE CALCULAT; Clinical and Laboratory Standards Institute (CLSI), 2005, M100S15M1002005 CLSI; COUNTS GW, 1982, REV INFECT DIS, V4, P484; Goettsch W, 2000, J ANTIMICROB CHEMOTH, V46, P223, DOI 10.1093/jac/46.2.223; Gupta K, 2003, INFECT DIS CLIN N AM, V17, P243, DOI 10.1016/S0891-5520(03)00006-0; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Hooton Thomas M., 1996, P67; Hooton TM, 2005, JAMA-J AM MED ASSOC, V293, P949, DOI 10.1001/jama.293.8.949; Hooton TM, 2004, CLIN INFECT DIS, V39, P75, DOI 10.1086/422145; Huang ES, 2002, ARCH INTERN MED, V162, P41, DOI 10.1001/archinte.162.1.41; Iravani A, 1999, J ANTIMICROB CHEMOTH, V43, P67, DOI 10.1093/jac/43.suppl_1.67; Kallen AJ, 2006, ARCH INTERN MED, V166, P635, DOI 10.1001/archinte.166.6.635; Karlowsky JA, 2011, ANTIMICROB AGENTS CH, V55, P3169, DOI 10.1128/AAC.00066-11; Kavatha D, 2003, ANTIMICROB AGENTS CH, V47, P897, DOI 10.1128/AAC.47.3.897-900.2003; MacDougall C, 2005, CLIN INFECT DIS, V41, P435, DOI 10.1086/432056; Naber KG, 2004, INT J ANTIMICROB AG, V23, P596, DOI 10.1016/j.ijantimicag.2003.12.017; Nicolle LE, 2002, SCAND J INFECT DIS, V34, P487, DOI 10.1080/00365540110080728; Olson RP, 2009, ANTIMICROB AGENTS CH, V53, P1285, DOI 10.1128/AAC.01188-08; Pabich WL, 2003, J INFECT DIS, V188, P1054, DOI 10.1086/378203; Paterson DL, 2004, CLIN INFECT DIS, V38, pS341, DOI 10.1086/382690; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Richard GA, 2002, UROLOGY, V59, P334, DOI 10.1016/S0090-4295(01)01562-X; Rogues AM, 2007, INFECT CONT HOSP EP, V28, P1389, DOI 10.1086/523280; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427	25	42	43	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					583	589		10.1001/jama.2012.80	http://dx.doi.org/10.1001/jama.2012.80			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318279	Green Accepted, Bronze			2022-12-28	WOS:000299992500022
J	Czaja, AD; Johnson, CM; Yamaguchi, KE; Beard, BL				Czaja, Andrew D.; Johnson, Clark M.; Yamaguchi, Kosei E.; Beard, Brian L.			Comment on "Abiotic Pyrite Formation Produces a Large Fe Isotope Fractionation"	SCIENCE			English	Editorial Material							BLACK-SEA; IRON; SEDIMENTS; EARTH		[Czaja, Andrew D.; Johnson, Clark M.; Beard, Brian L.] Univ Wisconsin, Dept Geosci, Madison, WI 53706 USA; [Czaja, Andrew D.; Johnson, Clark M.; Yamaguchi, Kosei E.; Beard, Brian L.] NASA, Astrobiol Inst, Washington, DC USA; [Yamaguchi, Kosei E.] Toho Univ, Dept Chem, Funabashi, Chiba 2748510, Japan	University of Wisconsin System; University of Wisconsin Madison; National Aeronautics & Space Administration (NASA); Toho University	Czaja, AD (corresponding author), Univ Wisconsin, Dept Geosci, 1215 W Dayton St, Madison, WI 53706 USA.	aczaja@geology.wisc.edu	Yamaguchi, Kosei E/B-2882-2008; Guilbaud, Romain/R-1428-2017	Yamaguchi, Kosei E/0000-0001-8728-6918; Guilbaud, Romain/0000-0001-9701-9522				Anderson TF, 2004, AM J SCI, V304, P203, DOI 10.2475/ajs.304.3.203; Butler IB, 2005, EARTH PLANET SC LETT, V236, P430, DOI 10.1016/j.epsl.2005.05.022; Craddock PR, 2011, EARTH PLANET SC LETT, V303, P121, DOI 10.1016/j.epsl.2010.12.045; Czaja AD, 2010, EARTH PLANET SC LETT, V292, P170, DOI 10.1016/j.epsl.2010.01.032; Guilbaud R, 2011, SCIENCE, V332, P1548, DOI 10.1126/science.1202924; Guilbaud R, 2011, GEOCHIM COSMOCHIM AC, V75, P2721, DOI 10.1016/j.gca.2011.02.023; Guilbaud R, 2010, EARTH PLANET SC LETT, V300, P174, DOI 10.1016/j.epsl.2010.10.004; Heimann A, 2010, EARTH PLANET SC LETT, V294, P8, DOI 10.1016/j.epsl.2010.02.015; Hurtgen MT, 1999, AM J SCI, V299, P556, DOI 10.2475/ajs.299.7-9.556; Johnson CM, 2008, GEOCHIM COSMOCHIM AC, V72, P151, DOI 10.1016/j.gca.2007.10.013; Johnson CM, 2003, CONTRIB MINERAL PETR, V144, P523, DOI 10.1007/s00410-002-0418-x; Skulan JL, 2002, GEOCHIM COSMOCHIM AC, V66, P2995, DOI 10.1016/S0016-7037(02)00902-X; Taylor S.R., 1985, CONTINENTAL CRUST IT; Yamaguchi K., 2002, THESIS PENNSYLVANIA; Yamaguchi KE, 2005, CHEM GEOL, V218, P135, DOI 10.1016/j.chemgeo.2005.01.020	15	10	11	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2012	335	6068								10.1126/science.1211804	http://dx.doi.org/10.1126/science.1211804			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301304				2022-12-28	WOS:000299769200024
J	Volkow, ND; Baler, RD				Volkow, Nora D.; Baler, Ruben D.			To Stop or Not to Stop?	SCIENCE			English	Editorial Material							RECEPTOR AVAILABILITY; DOPAMINE-D-2 RECEPTORS; BRAIN STRUCTURE; METABOLISM; TEMPERAMENT		[Volkow, Nora D.; Baler, Ruben D.] NIDA, Rockville, MD 20857 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Volkow, ND (corresponding author), NIDA, 6001 Execut Blvd, Rockville, MD 20857 USA.	nvolkow@nida.nih.gov			Intramural NIH HHS [Z99 DA999999] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000550] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Ersche KD, 2012, SCIENCE, V335, P601, DOI 10.1126/science.1214463; Everitt BJ, 2008, PHILOS T R SOC B, V363, P3125, DOI 10.1098/rstb.2008.0089; Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0; Hakamata Y, 2006, NEUROSCI LETT, V396, P33, DOI 10.1016/j.neulet.2005.11.017; Lee B, 2009, J NEUROSCI, V29, P14734, DOI 10.1523/JNEUROSCI.3765-09.2009; Moffitt TE, 2011, P NATL ACAD SCI USA, V108, P2693, DOI 10.1073/pnas.1010076108; Peper JS, 2007, HUM BRAIN MAPP, V28, P464, DOI 10.1002/hbm.20398; Simon NW, 2011, J NEUROSCI, V31, P17460, DOI 10.1523/JNEUROSCI.3772-11.2011; Van Laere K, 2009, ARCH GEN PSYCHIAT, V66, P196, DOI 10.1001/archgenpsychiatry.2008.530; Volkow ND, 2011, MOL PSYCHIATR, V16, P818, DOI 10.1038/mp.2011.30; Volkow ND, 2000, CEREB CORTEX, V10, P318, DOI 10.1093/cercor/10.3.318; VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210; Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015; Volkow ND, 2007, J NEUROSCI, V27, P12700, DOI 10.1523/JNEUROSCI.3371-07.2007; Volkow ND, 2006, ARCH GEN PSYCHIAT, V63, P999, DOI 10.1001/archpsyc.63.9.999; Wills TA, 2001, DEV PSYCHOL, V37, P283, DOI 10.1037/0012-1649.37.3.283	17	26	27	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2012	335	6068					546	548		10.1126/science.1218170	http://dx.doi.org/10.1126/science.1218170			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301310	Green Accepted			2022-12-28	WOS:000299769200031
J	Berzin, TM; Greenberger, NJ; Levy, BD; Loscalzo, J				Berzin, Tyler M.; Greenberger, Norton J.; Levy, Bruce D.; Loscalzo, Joseph			Worth a Second Look	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRONKHITE-CANADA-SYNDROME; MANAGEMENT; ALOPECIA; CANCER		[Levy, Bruce D.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Levy, BD (corresponding author), Brigham & Womens Hosp, Dept Med, Harvard Inst Med Bldg,Ave Louis Pasteur HIM855, Boston, MA 02115 USA.	blevy@partners.org	Loscalzo, Joseph/ABD-8980-2021	Berzin, Tyler/0000-0002-4364-6210	Lighthouse Learning; TIMI (Thrombolysis in Myocardial Infarction) Study Group	Lighthouse Learning; TIMI (Thrombolysis in Myocardial Infarction) Study Group	Dr. Greenberger reports receiving consulting fees from Lighthouse Learning, a medical content company that is not supported by pharmaceutical grants, and from the TIMI (Thrombolysis in Myocardial Infarction) Study Group. No other potential conflict of interest relevant to this article was reported.	Allbritton J, 1998, CUTIS, V61, P229; CRONKHITE LW, 1955, NEW ENGL J MED, V252, P1011, DOI 10.1056/NEJM195506162522401; DANIEL ES, 1982, MEDICINE, V61, P293, DOI 10.1097/00005792-198209000-00002; Goo YS, 2001, ENDOSCOPY, V33, P385; JOHNSON GK, 1972, GASTROENTEROLOGY, V63, P140; KATAYAMA Y, 1985, AM J SURG PATHOL, V9, P65, DOI 10.1097/00000478-198501000-00011; Okamoto K, 2008, DIGESTION, V78, P82, DOI 10.1159/000165354; PEART AG, 1984, DIGEST DIS SCI, V29, P470, DOI 10.1007/BF01296227; Ward E, 2002, SOUTHERN MED J, V95, P272; Ward EM, 2003, EXPERT OPIN PHARMACO, V4, P385, DOI 10.1517/14656566.4.3.385; Yashiro M, 2004, DIGESTION, V69, P57, DOI 10.1159/000076560	11	7	9	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					464	469		10.1056/NEJMcps0907563	http://dx.doi.org/10.1056/NEJMcps0907563			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QX	22296081				2022-12-28	WOS:000299724400013
J	Beringue, V; Herzog, L; Jaumain, E; Reine, F; Sibille, P; Le Dur, A; Vilotte, JL; Laude, H				Beringue, Vincent; Herzog, Laetitia; Jaumain, Emilie; Reine, Fabienne; Sibille, Pierre; Le Dur, Annick; Vilotte, Jean-Luc; Laude, Hubert			Facilitated Cross-Species Transmission of Prions in Extraneural Tissue	SCIENCE			English	Article							TRANSGENIC MICE; VARIANT CJD; SCRAPIE AGENT; PROTEIN; STRAINS; DISEASE; BSE; PATHOGENESIS; PREVALENCE; PHENOTYPE	Prions are infectious pathogens essentially composed of PrPSc, an abnormally folded form of the host-encoded prion protein PrPC. Constrained steric interactions between PrPSc and PrPC are thought to provide prions with species specificity and to control cross-species transmission into other host populations, including humans. We compared the ability of brain and lymphoid tissues from ovine and human PrP transgenic mice to replicate foreign, inefficiently transmitted prions. Lymphoid tissue was consistently more permissive than the brain to prions such as those causing chronic wasting disease and bovine spongiform encephalopathy. Furthermore, when the transmission barrier was overcome through strain shifting in the brain, a distinct agent propagated in the spleen, which retained the ability to infect the original host. Thus, prion cross-species transmission efficacy can exhibit a marked tissue dependence.	[Beringue, Vincent; Herzog, Laetitia; Jaumain, Emilie; Reine, Fabienne; Sibille, Pierre; Le Dur, Annick; Laude, Hubert] INRA, UR892, F-78350 Jouy En Josas, France; [Vilotte, Jean-Luc] INRA, UMR1313, F-78350 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Beringue, V (corresponding author), INRA, UR892, Batiment 440, F-78350 Jouy En Josas, France.	vincent.beringue@jouy.inra.fr; hubert.laude@jouy.inra.fr	Vilotte, Jean-Luc/AAF-4688-2019	Sibille, Pierre/0000-0003-0225-6619	Alliance Biosecure Foundation; INRA-Transfert	Alliance Biosecure Foundation; INRA-Transfert	We thank the animal facility staff (Infectiologie Experimentale Rongeurs Poissons, Jouy-en-Josas, France) for excellent animal care; S. Mouillet-Richard, O. Andreoletti, and H. Rezaei for critical reading of the manuscript; R. Young (INRA-Jouy, France) and M. Farrow (University College London, UK) for English style editing; A. Groner (Commonwealth Serum Laboratories Behring, Marburg, Germany) for tg7 mice; and C. Laude for mouse drawings in graphics. This work was partly supported by the Alliance Biosecure Foundation and INRA-Transfert.	Aguzzi A, 2007, NAT REV MOL CELL BIO, V8, P552, DOI 10.1038/nrm2204; AHMED R, 1988, J EXP MED, V167, P1719, DOI 10.1084/jem.167.5.1719; Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Beringue V, 2008, EMERG INFECT DIS, V14, P1898, DOI 10.3201/eid1412.080941; Beringue V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001419; Beringue V, 2008, VET RES, V39, DOI 10.1051/vetres:2008024; Beringue V, 2007, J NEUROSCI, V27, P6965, DOI 10.1523/JNEUROSCI.0693-07.2007; Beringue V, 2006, PLOS PATHOG, V2, P956, DOI 10.1371/journal.ppat.0020112; Bishop MT, 2006, LANCET NEUROL, V5, P393, DOI 10.1016/S1474-4422(06)70413-6; Brown KL, 2009, J IMMUNOL, V183, P5199, DOI 10.4049/jimmunol.0802695; Capobianco R, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030031; Clewley JP, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1442; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; EPSTEIN LG, 1991, VIROLOGY, V180, P583, DOI 10.1016/0042-6822(91)90072-J; Frosh A, 2004, LANCET, V364, P1260, DOI 10.1016/S0140-6736(04)17143-2; Ghani AC, 2002, CR BIOL, V325, P37, DOI 10.1016/S1631-0691(02)01389-6; GIBBS CJ, 1973, SCIENCE, V182, P67, DOI 10.1126/science.182.4107.67; Heikenwalder M, 2005, SCIENCE, V307, P1107, DOI 10.1126/science.1106460; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Hilton DA, 2004, J PATHOL, V203, P733, DOI 10.1002/path.1580; KIMBERLIN RH, 1986, J GEN VIROL, V67, P255, DOI 10.1099/0022-1317-67-2-255; KIMBERLIN RH, 1988, CIBA F SYMP, V135, P37; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Le Dur A, 2005, P NATL ACAD SCI USA, V102, P16031, DOI 10.1073/pnas.0502296102; Li JL, 2010, SCIENCE, V327, P869, DOI 10.1126/science.1183218; Nonno R, 2006, PLOS PATHOG, V2, P112, DOI 10.1371/journal.ppat.0020012; Padilla D, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001319; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Scott MR, 1997, J VIROL, V71, P9032, DOI 10.1128/JVI.71.12.9032-9044.1997; Tamguney G, 2006, J VIROL, V80, P9104, DOI 10.1128/JVI.00098-06; Telling Glenn C., 2008, V459, P249, DOI 10.1007/978-1-59745-234-2_17; Tixador P, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000859; Wadsworth JDF, 2004, SCIENCE, V306, P1793, DOI 10.1126/science.1103932	34	98	99	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					472	475		10.1126/science.1215659	http://dx.doi.org/10.1126/science.1215659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282814				2022-12-28	WOS:000299466800052
J	Thompson, JN				Thompson, John N.			The Role of Coevolution	SCIENCE			English	Editorial Material							KEY INNOVATION; CONTINGENCY; POPULATION; EVOLUTION		Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Thompson, JN (corresponding author), Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA.	jnthomp@ucsc.edu						Blount ZD, 2008, P NATL ACAD SCI USA, V105, P7899, DOI 10.1073/pnas.0803151105; Brockhurst MA, 2003, ECOL LETT, V6, P975, DOI 10.1046/j.1461-0248.2003.00531.x; EHRLICH PR, 1964, EVOLUTION, V18, P586, DOI 10.2307/2406212; Meyer JR, 2012, SCIENCE, V335, P428, DOI 10.1126/science.1214449; Morran LT, 2011, SCIENCE, V333, P216, DOI 10.1126/science.1206360; Ricklefs RE, 2010, P NATL ACAD SCI USA, V107, P1265, DOI 10.1073/pnas.0913626107; Thompson J.N., 2005, INTERSPEC INTERACT; WRIGHT SEWALL, 1932, PROC SIXTH INTERNAT CONGR GENETICS ITHACA NEW YORK, V1, P356; Yoder JB, 2010, AM NAT, V176, P802, DOI 10.1086/657048	9	13	17	1	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					410	411		10.1126/science.1217807	http://dx.doi.org/10.1126/science.1217807			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	881FG	22282796				2022-12-28	WOS:000299466800031
J	Bear, HD; Tang, G; Rastogi, P; Geyer, CE; Robidoux, A; Atkins, JN; Baez-Diaz, L; Brufsky, AM; Mehta, RS; Fehrenbacher, L; Young, JA; Senecal, FM; Gaur, R; Margolese, RG; Adams, PT; Gross, HM; Costantino, JP; Swain, SM; Mamounas, EP; Wolmark, N				Bear, Harry D.; Tang, Gong; Rastogi, Priya; Geyer, Charles E., Jr.; Robidoux, Andre; Atkins, James N.; Baez-Diaz, Luis; Brufsky, Adam M.; Mehta, Rita S.; Fehrenbacher, Louis; Young, James A.; Senecal, Francis M.; Gaur, Rakesh; Margolese, Richard G.; Adams, Paul T.; Gross, Howard M.; Costantino, Joseph P.; Swain, Sandra M.; Mamounas, Eleftherios P.; Wolmark, Norman			Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL ADJUVANT BREAST; DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; PHASE-III; PREOPERATIVE CHEMOTHERAPY; DOCETAXEL; PACLITAXEL; THERAPY; TRIAL; WOMEN	BACKGROUND Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown to improve outcomes when added to taxanes in patients with metastatic breast cancer. The primary aims of this trial were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant chemotherapy with docetaxel, followed by doxorubicin plus cyclophosphamide, would increase the rates of pathological complete response in the breast in women with operable, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and whether adding bevacizumab to these chemotherapy regimens would increase the rates of pathological complete response. METHODS We randomly assigned 1206 patients to receive neoadjuvant therapy consisting of docetaxel (100 mg per square meter of body-surface area on day 1), docetaxel (75 mg per square meter on day 1) plus capecitabine (825 mg per square meter twice a day on days 1 to 14), or docetaxel (75 mg per square meter on day 1) plus gemcitabine (1000 mg per square meter on days 1 and 8) for four cycles, with all regimens followed by treatment with doxorubicin-cyclophosphamide for four cycles. Patients were also randomly assigned to receive or not to receive bevacizumab (15 mg per kilogram of body weight) for the first six cycles of chemotherapy. RESULTS The addition of capecitabine or gemcitabine to docetaxel therapy, as compared with docetaxel therapy alone, did not significantly increase the rate of pathological complete response (29.7% and 31.8%, respectively, vs. 32.7%; P = 0.69). Both capecitabine and gemcitabine were associated with increased toxic effects - specifically, the hand-foot syndrome, mucositis, and neutropenia. The addition of bevacizumab significantly increased the rate of pathological complete response (28.2% without bevacizumab vs. 34.5% with bevacizumab, P = 0.02). The effect of bevacizumab on the rate of pathological complete response was not the same in the hormone-receptor-positive and hormone-receptor-negative subgroups. The addition of bevacizumab increased the rates of hypertension, left ventricular systolic dysfunction, the hand-foot syndrome, and mucositis. CONCLUSIONS The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response, which was the primary end point of this study. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00408408.)	[Bear, Harry D.; Tang, Gong; Rastogi, Priya; Geyer, Charles E., Jr.; Robidoux, Andre; Atkins, James N.; Baez-Diaz, Luis; Brufsky, Adam M.; Mehta, Rita S.; Fehrenbacher, Louis; Young, James A.; Senecal, Francis M.; Gaur, Rakesh; Margolese, Richard G.; Adams, Paul T.; Gross, Howard M.; Costantino, Joseph P.; Swain, Sandra M.; Mamounas, Eleftherios P.; Wolmark, Norman] Natl Surg Adjuvant Breast & Bowel Project NSABP, Pittsburgh, PA USA; [Tang, Gong; Costantino, Joseph P.] Univ Pittsburgh, Grad Sch Publ Hlth, NSABP Biostat Ctr, Pittsburgh, PA USA; [Tang, Gong; Costantino, Joseph P.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Rastogi, Priya; Brufsky, Adam M.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15261 USA; [Wolmark, Norman] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; [Bear, Harry D.] Virginia Commonwealth Univ, Virginia Sch Med, Coll Med, Richmond, VA 23284 USA; [Bear, Harry D.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23284 USA; [Geyer, Charles E., Jr.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Robidoux, Andre] Ctr Hosp Univ Montreal, Montreal, PQ, Canada; [Margolese, Richard G.] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada; [Atkins, James N.] SE Canc Control Consortium Community Clin Oncol P, Goldsboro, NC USA; [Baez-Diaz, Luis] Minority Based CCOP, San Juan, PR USA; [Mehta, Rita S.] Univ Calif Irvine, Orange, CA USA; [Fehrenbacher, Louis] Kaiser Permanente Oncol Clin Trials, Vallejo, CA USA; [Young, James A.] Colorado Canc Res Program, Colorado Springs, CO USA; [Senecal, Francis M.] NW Med Specialties, Tacoma, WA USA; [Gaur, Rakesh] CCOP, Kansas City, MO USA; [Adams, Paul T.] Genesys Reg Med Ctr, Grand Blanc, MI USA; [Gross, Howard M.] CCOP, Dayton, OH USA; [Mamounas, Eleftherios P.] Aultman Hosp, Ctr Canc, Canton, OH USA; [Swain, Sandra M.] Medstar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Allegheny General Hospital; Virginia Commonwealth University; Virginia Commonwealth University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Universite de Montreal; McGill University; University of California System; University of California Irvine; Kaiser Permanente; MedStar Washington Hospital Center	Bear, HD (corresponding author), VCUHS, Div Surg Oncol, Box 980011, Richmond, VA 23298 USA.	hdbear@vcu.edu	Geyer, Charles/AGY-0119-2022; Brufsky, Adam/AAE-7470-2020	Geyer, Charles/0000-0002-2379-5702; , Gong/0000-0002-6247-4338; Swain, Sandra/0000-0002-1320-3830; Brufsky, Adam/0000-0001-8080-7960	National Cancer Institute [U10-CA-12027, U10-CA-69651, U10-CA-37377, U10-CA-69974, U10-CA-44066]; Department of Health and Human Services; Public Health Service; F. Hoffmann-La Roche; Genentech USA; Eli Lilly; NATIONAL CANCER INSTITUTE [U10CA069651, U10CA044066, P30CA062203, U10CA012027, U10CA037377, U10CA180844, U10CA069974] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Health and Human Services; Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); F. Hoffmann-La Roche(Hoffmann-La Roche); Genentech USA(Roche HoldingGenentech); Eli Lilly(Eli Lilly); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Cancer Institute (U10-CA-12027, U10-CA-69651, U10-CA-37377, U10-CA-69974, and U10-CA-44066), the Department of Health and Human Services, the Public Health Service, F. Hoffmann-La Roche, Genentech USA, and Eli Lilly.	Albain KS, 2008, J CLIN ONCOL, V26, P3950, DOI 10.1200/JCO.2007.11.9362; Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665; Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P32; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Gianni L, 2009, J CLIN ONCOL, V27, P2474, DOI 10.1200/JCO.2008.19.2567; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Hunt KK, 2009, ANN SURG, V250, P558, DOI 10.1097/SLA.0b013e3181b8fd5e; Joensuu H, 2010, CANC RES S2, V70, p84s; Mamounas EP, 2005, J CLIN ONCOL, V23, P2694, DOI 10.1200/JCO.2005.05.188; Mamounas EP, 2005, J CLIN ONCOL, V23, P3686, DOI 10.1200/JCO.2005.10.517; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; O'Shaughnessy J, 2002, J CLIN ONCOL, V20, P2812, DOI 10.1200/JCO.2002.09.002; O'Shaughnessy J, 2010, CANCER RES, V70, p85s; Poole CJ, 2008, J CLIN ONCOL S, V26, p8s; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Roche H, 2006, J CLIN ONCOL, V24, P5664, DOI 10.1200/JCO.2006.07.3916; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Verma N, 2011, J CLIN ONCOL, V29, P603, DOI 10.1200/JCO.2010.32.9060; von Minckwitz G, 2012, NEW ENGL J MED, V366, P299, DOI 10.1056/NEJMoa1111065	25	354	373	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					310	320		10.1056/NEJMoa1111097	http://dx.doi.org/10.1056/NEJMoa1111097			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EQ	22276821	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000299464100002
J	von Minckwitz, G; Eidtmann, H; Rezai, M; Fasching, PA; Tesch, H; Eggemann, H; Schrader, I; Kittel, K; Hanusch, C; Kreienberg, R; Solbach, C; Gerber, B; Jackisch, C; Kunz, G; Blohmer, JU; Huober, J; Hauschild, M; Fehm, T; Muller, BM; Denkert, C; Loibl, S; Nekljudova, V; Untch, M				von Minckwitz, Gunter; Eidtmann, Holger; Rezai, Mahdi; Fasching, Peter A.; Tesch, Hans; Eggemann, Holm; Schrader, Iris; Kittel, Kornelia; Hanusch, Claus; Kreienberg, Rolf; Solbach, Christine; Gerber, Bernd; Jackisch, Christian; Kunz, Georg; Blohmer, Jens-Uwe; Huober, Jens; Hauschild, Maik; Fehm, Tanja; Mueller, Berit Maria; Denkert, Carsten; Loibl, Sibylle; Nekljudova, Valentina; Untch, Michael		German Breast Grp; Arbeitsgemeinschaft Gynakologische	Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III; TRIAL; TRASTUZUMAB; DOCETAXEL; SURVIVAL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; THERAPY	Background Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. We evaluated the efficacy, measured according to the rate of pathological complete response (absence of invasive and intraductal disease in the breast and the axillary lymph nodes), and the safety of adding bevacizumab to neoadjuvant chemotherapy in patients with early-stage breast cancer. Methods We randomly assigned 1948 patients with a median tumor size of 40 mm on palpation to receive neoadjuvant epirubicin and cyclophosphamide followed by docetaxel, with or without concomitant bevacizumab. Patients with untreated HER2-negative breast cancer were eligible if they had large tumors, hormone-receptor-negative disease, or hormone-receptor-positive disease with palpable nodes or positive findings on sentinel-node biopsy, and no increased cardiovascular or bleeding risk. Results Overall, the rates of pathological complete response were 14.9% with epirubicin and cyclophosphamide followed by docetaxel and 18.4% with epirubicin and cyclophosphamide followed by docetaxel plus bevacizumab (odds ratio with addition of bevacizumab, 1.29; 95% confidence interval, 1.02 to 1.65; P = 0.04); the corresponding rates of pathological complete response were 27.9% and 39.3% among 663 patients with triple-negative tumors (P = 0.003) and 7.8% and 7.7% among 1262 patients with hormone-receptor-positive tumors (P = 1.00). Breast-conserving surgery was possible in 66.6% of the patients in both groups. The addition of bevacizumab, as compared with neoadjuvant therapy alone, was associated with a higher incidence of grade 3 or 4 toxic effects (febrile neutropenia, mucositis, the hand-foot syndrome, infection, and hypertension) but with a similar incidence of surgical complications. Conclusions The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response among patients with HER2-negative early-stage breast cancer. Efficacy was restricted primarily to patients with triple-negative tumors, in whom the pathological complete response is considered to be a reliable predictor of long-term outcome. (Funded by Sanofi-Aventis and Roche, Germany; ClinicalTrials.gov number, NCT00567554.)	[von Minckwitz, Gunter; Loibl, Sibylle; Nekljudova, Valentina] GBG Forsch, German Breast Grp, D-63263 Neu Isenburg, Germany; [Eidtmann, Holger] Univ Frauenklin, Kiel, Germany; [Rezai, Mahdi] Luisenkrankenhaus, Dusseldorf, Germany; [Fasching, Peter A.] Friedrich Alexander Univ Erlangen Nuremberg, Comprehens Canc Ctr Erlangen Nuremberg, Univ Hosp Erlangen, Dept Gynecol & Obstet, Erlangen, Germany; [Tesch, Hans] Onkol Bethanien, Frankfurt, Germany; [Eggemann, Holm] Univ Frauenklin, Magdeburg, Germany; [Schrader, Iris] Henrietten Stiftung, Hannover, Germany; [Kittel, Kornelia] Onkol Praxis, Berlin, Germany; [Blohmer, Jens-Uwe] St Gertrauden Hosp, Berlin, Germany; [Mueller, Berit Maria; Denkert, Carsten] Charite, Inst Pathol, Berlin, Germany; [Hanusch, Claus] Klinikum Roten Kreuz, Munich, Germany; [Kreienberg, Rolf] Univ Frauenklin, Ulm, Germany; [Solbach, Christine] Univ Frauenklin, Frankfurt, Germany; [Gerber, Bernd] Univ Frauenklin, Rostock, Germany; [Jackisch, Christian] Stadt Kliniken, Offenbach, Germany; [Kunz, Georg] St Johannes Hosp, Dortmund, Germany; [Hauschild, Maik] Frauenklin, Rheinfelden, Germany; [Fehm, Tanja] Univ Frauenklin, Tubingen, Germany; [Untch, Michael] HELIOS Klin, Berlin, Germany; [Huober, Jens] Kantonsspital, St Gallen, Switzerland	German Breast Group; University of Kiel; Schleswig Holstein University Hospital; University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ulm University; University of Rostock; Sana Klinikum Offenbach; St. Johannes Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helios Kliniken; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	von Minckwitz, G (corresponding author), GBG Forsch, German Breast Grp, Martin Behaim Str 12, D-63263 Neu Isenburg, Germany.	gunter.vonminckwitz@germanbreastgroup.de	Denkert, Carsten/AHE-2675-2022; Fasching, Peter A/ABH-9912-2020	Fasching, Peter A/0000-0003-4885-8471; Blohmer, Jens-Uwe/0000-0002-7969-250X; Fehm, Tanja/0000-0002-4926-0108; Denkert, Carsten/0000-0002-2249-0982	Sanofi-Aventis; Roche, Germany; Roche; Novartis; Pfizer; Amgen; Celgene; Eisai; Bristol-Myers Squibb; GlaxoSmithKline	Sanofi-Aventis(Sanofi-Aventis); Roche, Germany(Roche Holding); Roche(Roche Holding); Novartis(Novartis); Pfizer(Pfizer); Amgen(Amgen); Celgene(Bristol-Myers SquibbCelgene Corporation); Eisai(Eisai Co Ltd); Bristol-Myers Squibb(Bristol-Myers Squibb); GlaxoSmithKline(GlaxoSmithKline)	Supported by grants from Sanofi-Aventis and Roche, Germany.; Dr. von Minckwitz reports receiving research grants, consulting fees, and lecture (including speakers' bureau) fees from Roche and Sanofi-Aventis; Dr. Eidtmann, receiving payment for board membership and reimbursement for travel expenses from Roche; Dr. Fasching, receiving grant support from Novartis and lecture fees from Pfizer, Roche, and Novartis; Dr. Tesch, receiving consulting fees from Amgen, Roche, Novartis, Celgene, and Eisai; Dr. Kreienberg, receiving payment for board membership from AstraZeneca and consulting fees from Novartis and Pfizer; Dr. Jackisch, receiving reimbursement for travel expenses from Roche and Amgen; Dr. Huober, receiving consulting fees from Amgen, Roche, Bristol-Myers Squibb, and Sanofi-Aventis, grant support from GlaxoSmithKline, and lecture (including speakers' bureau) fees from Sanofi-Aventis and Roche; Dr. Denkert, holding stock options in Sividon Diagnostics; and Dr. Loibl, receiving grant support, lecture (including speakers' bureau) fees, and reimbursement for travel expenses from Roche. No other potential conflict of interest relevant to this article was reported.	America Joint Committee on Cancer, 2010, AJCC CANC STAG MAN; Bear HD, 2012, NEW ENGL J MED, V366, P310, DOI 10.1056/NEJMoa1111097; Bear HD, 2011, J CLIN ONCOL S, V29, P1005; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P32; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Golshan M, 2011, ANN SURG ONCOL, V18, P733, DOI 10.1245/s10434-010-1366-8; Huober J, 2010, BREAST CANCER RES TR, V124, P133, DOI 10.1007/s10549-010-1103-9; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Miles D, 2011, J CLIN ONCOL, V29, P83, DOI 10.1200/JCO.2010.30.2794; Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457; Miller K, 2009, J CLIN ONCOL S, V27, p488s; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Pocock S. J., 1975, BIOMETRICS, V31, P102; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Untch M, 2011, J CLIN ONCOL, V29, P3351, DOI 10.1200/JCO.2010.31.4930; Untch M, 2010, J CLIN ONCOL, V28, P2024, DOI 10.1200/JCO.2009.23.8451; von Minckwitz G, 2005, J CLIN ONCOL, V23, P2676, DOI 10.1200/JCO.2005.05.078; von Minckwitz G, 2011, ANN ONCOL, V22, P301, DOI 10.1093/annonc/mdq350; von Minckwitz G, J CLIN ONCO IN PRESS; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P542, DOI 10.1093/jnci/djn085; von Minckwitz G, 2011, BREAST CANCER RES TR, V125, P145, DOI 10.1007/s10549-010-1228-x	24	389	393	3	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					299	309		10.1056/NEJMoa1111065	http://dx.doi.org/10.1056/NEJMoa1111065			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EQ	22276820	Bronze			2022-12-28	WOS:000299464100001
J	Hatcher, S; Arroll, B				Hatcher, Simon; Arroll, Bruce			THERAPEUTICS Newer antidepressants for the treatment of depression in adults	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							2ND-GENERATION ANTIDEPRESSANTS; METAANALYSIS; OUTCOMES; SEVERITY; BENEFITS; DISORDER; ANXIETY; HARMS; RISK; CARE		[Hatcher, Simon] Univ Auckland, Dept Psychol Med, Auckland 1, New Zealand	University of Auckland	Hatcher, S (corresponding author), Univ Auckland, Dept Psychol Med, Private Bag 92019, Auckland 1, New Zealand.	s.hatcher@auckland.ac.nz						Andrade C, 2010, J CLIN PSYCHIAT, V71, P1565, DOI 10.4088/JCP.09r05786blu; [Anonymous], 2008, Drug Ther Bull, V46, P29, DOI 10.1136/dtb.2008.03.0009; Arroll B, 2003, BMJ-BRIT MED J, V327, P1144, DOI 10.1136/bmj.327.7424.1144; Arroll B, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007954; Arroll B, 2009, J PRIM HEALTH CARE, V1, P26, DOI 10.1071/HC09026; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Cameron IM, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X583209; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; Connolly KR, 2011, DRUGS, V71, P43, DOI 10.2165/11587620-000000000-00000; Coupland C, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4551; Eyding D, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4737; Fountoulakis KN, 2011, INT J NEUROPSYCHOPH, V14, P405, DOI 10.1017/S1461145710000957; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Gartlehner G, 2011, ANN INTERN MED, V155, P772, DOI 10.7326/0003-4819-155-11-201112060-00009; Gartlehner G, 2008, DRUG SAFETY, V31, P851, DOI 10.2165/00002018-200831100-00004; Gentile S, 2011, J AFFECT DISORDERS, V128, P1, DOI 10.1016/j.jad.2010.02.125; Gilbody S, 2006, ARCH INTERN MED, V166, P2314, DOI 10.1001/archinte.166.21.2314; Hawton K, 2010, BRIT J PSYCHIAT, V196, P354, DOI 10.1192/bjp.bp.109.070219; Hetrick SE, 2010, CURR OPIN PSYCHIATR, V23, P53, DOI 10.1097/YCO.0b013e328334bc92; Horder J, 2010, J PSYCHOPHARMACOL; Kendrick T, 2009, HLTH TECHNOL ASSESS, V13; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Lam RW, 2009, J AFFECT DISORDERS, V117, pS26, DOI 10.1016/j.jad.2009.06.041; Mark TL, 2011, AM J GERIAT PSYCHIAT, V19, P211, DOI 10.1097/JGP.0b013e3181f1803d; Moore M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3999; National Institute for Health and Clinical Excellence, 2009, TREATM MAN DEPR AD U; National Institute for Health and Clinical Excellence, 2007, ANT POSTN MENT HLTH; Nease DE, 2003, J FAM PRACTICE, V52, P118; Nutt DJ, 2009, J PSYCHOPHARMACOL, V23, P343, DOI 10.1177/0269881109105498; Pagura J, 2011, J CLIN PSYCHIAT, V72, P494, DOI 10.4088/JCP.09m05776blu; Reid S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1468; Taylor MJ, 2006, ARCH GEN PSYCHIAT, V63, P1217, DOI 10.1001/archpsyc.63.11.1217; Wu P, 2007, PSYCHIAT SERV, V58, P349, DOI 10.1176/appi.ps.58.3.349	33	9	9	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 19	2012	344								d8300	10.1136/bmj.d8300	http://dx.doi.org/10.1136/bmj.d8300			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888ZA	22262785				2022-12-28	WOS:000300042000007
J	Vegetti, S; Lagattuta, DJ; McKean, JP; Auger, MW; Fassnacht, CD; Koopmans, LVE				Vegetti, S.; Lagattuta, D. J.; McKean, J. P.; Auger, M. W.; Fassnacht, C. D.; Koopmans, L. V. E.			Gravitational detection of a low-mass dark satellite galaxy at cosmological distance	NATURE			English	Article							MILKY-WAY; MATTER SUBSTRUCTURE; LENSES; HALOES; STATISTICS; SUBHALOES; B1938+666; EVOLUTION; SCALE	The mass function of dwarf satellite galaxies that are observed around Local Group galaxies differs substantially from simulations(1-5) based on cold dark matter: the simulations predict many more dwarf galaxies than are seen. The Local Group, however, may be anomalous in this regard(6,7). A massive dark satellite in an early-type lens galaxy at a redshift of 0.222 was recently found(8) using a method based on gravitational lensing(9,10), suggesting that the mass fraction contained in substructure could be higher than is predicted from simulations. The lack of very low-mass detections, however, prohibited any constraint on their mass function. Here we report the presence of a (1.9 +/- 0.1) x 10(8)M(circle dot) dark satellite galaxy in the Einstein ring system JVAS B1938+666 (ref. 11) at a redshift of 0.881, where M(circle dot) denotes the solar mass. This satellite galaxy has a mass similar to that of the Sagittarius(12) galaxy, which is a satellite of the Milky Way. We determine the logarithmic slope of the mass function for substructure beyond the local Universe to be 1.1(-0.4)(+0.6), with an average mass fraction of 3.3(-1.8)(+3.6) per cent, by combining data on both of these recently discovered galaxies. Our results are consistent with the predictions from cold dark matter simulations(13-15) at the 95 per cent confidence level, and therefore agree with the view that galaxies formed hierarchically in a Universe composed of cold dark matter.	[Vegetti, S.] MIT, Kavli Inst Astrophys & Space Res, Cambridge, MA 02139 USA; [Lagattuta, D. J.; Fassnacht, C. D.] Univ Calif Davis, Dept Phys, Davis, CA 95616 USA; [McKean, J. P.] ASTRON, NL-7991 PD Dwingeloo, Netherlands; [Auger, M. W.] Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; [Koopmans, L. V. E.] Univ Groningen, Kapteyn Astron Inst, NL-9700 AV Groningen, Netherlands	Massachusetts Institute of Technology (MIT); University of California System; University of California Davis; University of California System; University of California Santa Barbara; University of Groningen	Vegetti, S (corresponding author), MIT, Kavli Inst Astrophys & Space Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	svegetti@space.mit.edu		Fassnacht, Christopher/0000-0002-4030-5461	Massachusetts Institute of Technology; NWO-VIDI; National Science Foundation; STFC [ST/J001538/1] Funding Source: UKRI; Science and Technology Facilities Council [ST/J001538/1, ST/H00243X/1] Funding Source: researchfish	Massachusetts Institute of Technology; NWO-VIDI(Netherlands Organization for Scientific Research (NWO)); National Science Foundation(National Science Foundation (NSF)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	Our results are based on observations made with the W. M. Keck Observatory and the Hubble Space Telescope. S. V. is supported by a Pappalardo Fellowship at the Massachusetts Institute of Technology, L. V. E. K. is supported (in part) through an NWO-VIDI program subsidy, and D.J.L. and C. D. F. acknowledge support from the National Science Foundation. The authors are grateful to P. Marshall for comments and feedback.	Boylan-Kolchin M, 2011, MON NOT R ASTRON SOC, V415, pL40, DOI 10.1111/j.1745-3933.2011.01074.x; Boylan-Kolchin M, 2010, MON NOT R ASTRON SOC, V406, P896, DOI 10.1111/j.1365-2966.2010.16774.x; Busha M. T., ASTROPHYS J UNPUB; Dalal N, 2002, ASTROPHYS J, V572, P25, DOI 10.1086/340303; Diemand J, 2007, ASTROPHYS J, V667, P859, DOI 10.1086/520573; Diemand J, 2007, ASTROPHYS J, V657, P262, DOI 10.1086/510736; Gilmore G, 2007, ASTROPHYS J, V663, P948, DOI 10.1086/518025; KAUFFMANN G, 1993, MON NOT R ASTRON SOC, V264, P201, DOI 10.1093/mnras/264.1.201; Keeton CR, 2003, ASTROPHYS J, V598, P138, DOI 10.1086/378934; King LJ, 1998, MON NOT R ASTRON SOC, V295, pL41, DOI 10.1046/j.1365-8711.1998.295241.x; Klypin A, 1999, ASTROPHYS J, V522, P82, DOI 10.1086/307643; Koopmans LVE, 2005, MON NOT R ASTRON SOC, V363, P1136, DOI 10.1111/j.1365-2966.2005.09523.x; Kravtsov A, 2010, ADV ASTRON, V2010, DOI 10.1155/2010/281913; Mao SD, 1998, MON NOT R ASTRON SOC, V295, P587, DOI 10.1046/j.1365-8711.1998.01319.x; Mateo M, 1998, ANNU REV ASTRON ASTR, V36, P435, DOI 10.1146/annurev.astro.36.1.435; Metcalf RB, 2002, ASTROPHYS J, V567, pL5, DOI 10.1086/339798; Moore B, 1999, ASTROPHYS J, V524, pL19, DOI 10.1086/312287; Riechers DA, 2011, ASTROPHYS J, V730, DOI 10.1088/0004-637X/730/2/108; Springel V, 2008, MON NOT R ASTRON SOC, V391, P1685, DOI 10.1111/j.1365-2966.2008.14066.x; Strigari LE, 2007, ASTROPHYS J, V669, P676, DOI 10.1086/521914; Tonry JL, 2000, ASTRON J, V119, P1078, DOI 10.1086/301273; Vegetti S, 2010, MON NOT R ASTRON SOC, V408, P1969, DOI 10.1111/j.1365-2966.2010.16865.x; Vegetti S, 2009, MON NOT R ASTRON SOC, V392, P945, DOI 10.1111/j.1365-2966.2008.14005.x; Vegetti S, 2009, MON NOT R ASTRON SOC, V400, P1583, DOI 10.1111/j.1365-2966.2009.15559.x; Walker MG, 2007, ASTROPHYS J, V667, pL53, DOI 10.1086/521998; Xu DD, 2009, MON NOT R ASTRON SOC, V398, P1235, DOI 10.1111/j.1365-2966.2009.15230.x	28	223	224	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2012	481	7381					341	343		10.1038/nature10669	http://dx.doi.org/10.1038/nature10669			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258612	Green Submitted			2022-12-28	WOS:000299210600037
J	Lanzavecchia, A; Sallusto, F				Lanzavecchia, Antonio; Sallusto, Federica			Ralph M. Steinman 1943-2011 Obituary	CELL			English	Biographical-Item									[Lanzavecchia, Antonio; Sallusto, Federica] Biomed Res Inst, CH-6500 Bellinzona, Switzerland	Universita della Svizzera Italiana	Lanzavecchia, A (corresponding author), Biomed Res Inst, CH-6500 Bellinzona, Switzerland.	lanzavecchia@irb.unisi.ch; federica.sallusto@irb.unisi.ch						STEINMAN RM, PUBLICATION LIST	1	9	9	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 9	2011	147	6					1216	1217		10.1016/j.cell.2011.11.040	http://dx.doi.org/10.1016/j.cell.2011.11.040			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	863FL	22263224	Bronze			2022-12-28	WOS:000298148100008
J	Liu, JJ; Horst, R; Katritch, V; Stevens, RC; Wuthrich, K				Liu, Jeffrey J.; Horst, Reto; Katritch, Vsevolod; Stevens, Raymond C.; Wuethrich, Kurt			Biased Signaling Pathways in beta(2)-Adrenergic Receptor Characterized by F-19-NMR	SCIENCE			English	Article							PROTEIN-COUPLING DOMAIN; ADRENERGIC-RECEPTOR; CRYSTAL-STRUCTURE; TRANSMEMBRANE RECEPTORS; CONFORMATIONAL-CHANGES; NMR-SPECTROSCOPY; PARTIAL AGONISTS; LIGAND-BINDING; BETA(2); ACTIVATION	Extracellular ligand binding to G protein-coupled receptors (GPCRs) modulates G protein and beta-arrestin signaling by changing the conformational states of the cytoplasmic region of the receptor. Using site-specific F-19-NMR (fluorine-19 nuclear magnetic resonance) labels in the beta(2)-adrenergic receptor (beta(2)AR) in complexes with various ligands, we observed that the cytoplasmic ends of helices VI and VII adopt two major conformational states. Changes in the NMR signals reveal that agonist binding primarily shifts the equilibrium toward the G protein-specific active state of helix VI. In contrast, beta-arrestin-biased ligands predominantly impact the conformational states of helix VII. The selective effects of different ligands on the conformational equilibria involving helices VI and VII provide insights into the long-range structural plasticity of beta(2)AR in partial and biased agonist signaling.	[Liu, Jeffrey J.; Horst, Reto; Katritch, Vsevolod; Stevens, Raymond C.; Wuethrich, Kurt] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Wuethrich, Kurt] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Stevens, RC (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stevens@scripps.edu; wuthrich@scripps.edu	Katritch, Vsevolod/Y-2721-2019; Stevens, Raymond/K-7272-2015; Horst, Reto/AAY-9812-2020; Katritch, Vsevolod/Q-8357-2016	Stevens, Raymond/0000-0002-4522-8725; Katritch, Vsevolod/0000-0003-3883-4505; Wuthrich, Kurt/0000-0001-8739-6965	NIH Roadmap Initiative [P50 GM073197]; PSI [U54 GM094618]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM094618, P50GM073197] Funding Source: NIH RePORTER	NIH Roadmap Initiative(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PSI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by NIH Roadmap Initiative grant P50 GM073197 for technology development and purchase of the <SUP>19</SUP>F-NMR probe, and by PSI: Biology grant U54 GM094618 for GPCR biology studies. The authors thank J. Velasquez for help on molecular biology; C. Cornillez-Ty, T. Trinh, and K. Allin for help on baculovirus expression; J. Gatchalian for ligand-binding assays; P. Stanczak for assistance with the paramagnetic titration experiment; V. Cherezov for helpful discussions; I. Wilson for careful review and scientific feedback on the manuscript; K. Kadyshevskaya for assistance with figure preparation; and A. Walker for assistance with manuscript preparation. R.C.S. is a founder and member of the board of directors of Receptos, a GPCR structure-based drug discovery company.	Baker JG, 2010, BRIT J PHARMACOL, V160, P1048, DOI 10.1111/j.1476-5381.2010.00754.x; Bokoch MP, 2010, NATURE, V463, P108, DOI 10.1038/nature08650; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Danielson MA, 1996, ANNU REV BIOPH BIOM, V25, P163, DOI 10.1146/annurev.bb.25.060196.001115; de Graaf C, 2008, J MED CHEM, V51, P4978, DOI 10.1021/jm800710x; Deupi X, 2011, CURR OPIN STRUC BIOL, V21, P541, DOI 10.1016/j.sbi.2011.06.002; Drake MT, 2008, J BIOL CHEM, V283, P5669, DOI 10.1074/jbc.M708118200; Evanics F, 2007, BBA-GEN SUBJECTS, V1770, P221, DOI 10.1016/j.bbagen.2006.10.017; FALKE JJ, 1992, BIOPHYS J, V62, P82, DOI 10.1016/S0006-3495(92)81787-3; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Granier S, 2007, J BIOL CHEM, V282, P13895, DOI 10.1074/jbc.M611904200; Hanson MA, 2008, STRUCTURE, V16, P897, DOI 10.1016/j.str.2008.05.001; Hilty C, 2004, CHEMBIOCHEM, V5, P467, DOI 10.1002/cbic.200300815; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Jaakola VP, 2010, J BIOL CHEM, V285, P13032, DOI 10.1074/jbc.M109.096974; Kahsai AW, 2011, NAT CHEM BIOL, V7, P692, DOI [10.1038/NCHEMBIO.634, 10.1038/nchembio.634]; Katritch V, 2009, J MOL RECOGNIT, V22, P307, DOI 10.1002/jmr.949; Klein-Seetharaman J, 1999, P NATL ACAD SCI USA, V96, P13744, DOI 10.1073/pnas.96.24.13744; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Nobles KN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001707; Nygaard R, 2009, TRENDS PHARMACOL SCI, V30, P249, DOI 10.1016/j.tips.2009.02.006; Rajagopal K, 2005, J CLIN INVEST, V115, P2971, DOI 10.1172/JCI26950; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648; Rosenbaum DM, 2011, NATURE, V469, P236, DOI 10.1038/nature09665; Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330; Shenoy SK, 2011, TRENDS PHARMACOL SCI, V32, P521, DOI 10.1016/j.tips.2011.05.002; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Wacker D, 2010, J AM CHEM SOC, V132, P11443, DOI 10.1021/ja105108q; Westfield GH, 2011, P NATL ACAD SCI USA, V108, P16086, DOI 10.1073/pnas.1113645108; Wisler JW, 2007, P NATL ACAD SCI USA, V104, P16657, DOI 10.1073/pnas.0707936104; Xu F, 2011, SCIENCE, V332, P322, DOI 10.1126/science.1202793; Yao XJ, 2009, P NATL ACAD SCI USA, V106, P9501, DOI 10.1073/pnas.0811437106; Yao XJ, 2006, NAT CHEM BIOL, V2, P417, DOI 10.1038/nchembio801	40	501	507	5	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 2	2012	335	6072					1106	1110		10.1126/science.1215802	http://dx.doi.org/10.1126/science.1215802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ZL	22267580	Green Accepted			2022-12-28	WOS:000300931100049
J	Black, RE; El Arifeen, S				Black, Robert E.; El Arifeen, Shams			Community-based treatment of severe childhood pneumonia	LANCET			English	Editorial Material							DEVELOPING-COUNTRIES; ORAL AMOXICILLIN; CASE-MANAGEMENT; CHILDREN; TRIAL; PAKISTAN		[Black, Robert E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [El Arifeen, Shams] Int Ctr Diarrhoeal Dis Res Bangladesh ICDDR B, Ctr Child & Adolescent Hlth, Dhaka, Bangladesh	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; International Centre for Diarrhoeal Disease Research (ICDDR)	Black, RE (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	rblack@jhsph.edu		Black, Robert/0000-0001-9926-7984; Arifeen, Shams/0000-0002-5372-5932				Bari A, 2011, LANCET, V378, P1796, DOI 10.1016/S0140-6736(11)61140-9; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; Chowdhury EK, 2008, LANCET, V372, P822, DOI 10.1016/S0140-6736(08)61166-6; GAVI Alliance, VACC GOAL IND; Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9; Marsh DR, 2008, B WORLD HEALTH ORGAN, V86, P381, DOI 10.2471/BLT.07.048462; Roth DE, 2010, INT J EPIDEMIOL, V39, P795, DOI 10.1093/ije/dyp391; Soofi S, 2012, LANCET, V379, P729, DOI 10.1016/S0140-6736(11)61714-5; Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X; [WHO UNICEF], 2008, IMCI CHART BOOKL STA; WHO, 2012, REC MAN COM IN PRESS	13	3	3	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 25	2012	379	9817					692	694		10.1016/S0140-6736(11)61843-6	http://dx.doi.org/10.1016/S0140-6736(11)61843-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	899CU	22285052				2022-12-28	WOS:000300792600007
J	Weil, A				Weil, Alan			The Value of Federalism in Defining Essential Health Benefits	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Natl Acad State Hlth Policy, Washington, DC USA		Weil, A (corresponding author), Natl Acad State Hlth Policy, Washington, DC USA.							Center for Consumer Information and Insurance Oversight Department of Health and Human Services, 2011, ESS HLTH BEN B; Institute of Medicine, 2012, ESS HLTH BEN BAL COV, DOI 10. 17226/13234; Mello MM, 2001, HEALTH AFFAIR, V20, P101, DOI 10.1377/hlthaff.20.5.101	3	10	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2012	366	8					679	681		10.1056/NEJMp1200693	http://dx.doi.org/10.1056/NEJMp1200693			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	896FS	22316423				2022-12-28	WOS:000300551500003
J	Luo, WY; Sehgal, A				Luo, Wenyu; Sehgal, Amita			Regulation of Circadian Behavioral Output via a MicroRNA-JAK/STAT Circuit	CELL			English	Article							DROSOPHILA-MELANOGASTER; MOLECULAR OSCILLATIONS; SYNAPTIC TRANSMISSION; TARGET PREDICTIONS; CLOCK; EXPRESSION; KINASE; GENE; RECEPTOR; RHYTHMS	Although molecular components of the circadian clock are known, mechanisms that transmit signals from the clock and produce rhythmic behavior are poorly understood. We find that the microRNA miR-279 regulates the JAK/STAT pathway to drive rest: activity rhythms in Drosophila. Overexpression of microRNA miR-279 or miR-279 deletion attenuates rest: activity rhythms. Oscillations of the clock protein PERIOD are normal in pacemaker neurons lacking miR-279, suggesting that miR-279 acts downstream of the clock. We identify the JAK/STAT ligand, Upd, as a target of miR-279 and show that knockdown of Upd rescues the behavioral phenotype of miR-279 mutants. Manipulations of the JAK/STAT pathway also disrupt circadian rhythms. In addition, central clock neurons project in the vicinity of Upd-expressing neurons, providing a possible physical connection by which the central clock could regulate JAK/STAT signaling to control rest: activity rhythms.	[Luo, Wenyu; Sehgal, Amita] Univ Penn, Sch Med, Cell & Mol Biol Program, Philadelphia, PA 19104 USA; [Sehgal, Amita] Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Sehgal, A (corresponding author), Univ Penn, Sch Med, Cell & Mol Biol Program, Philadelphia, PA 19104 USA.	amita@mail.med.upenn.edu			NIH [1-R560NS-048471, 2R01NS04847]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035703, R37NS048471, R56NS048471, R01NS048471] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are very grateful to Zhaohai Yang and Zhifeng Yue for generating the NE95-11-24 fly line. We thank L. Zipursky, B. Edgar, D. Bilder, S. Hou, G. Baeg, T. Cline, W. Odenwald, I. Rebay, J. Blau, and M. Rosbash for providing miR-279, JAK/STAT, and other fly stocks; S. Hou, D. Harrison, P. Taghert, and P. Hardin for STAT92E, UPD, HOP, PDFR, and CLK antibodies; E. Izaurralde and K. Basler for pAc5.1-F. Luc and pUASTattB vectors; X. Zheng and D. Chen for developing PER antibodies; W. Joiner, A. Crocker, and S. Kumar for outcrossing some mutants and GAL4 lines; and other members of the laboratory for useful discussions. The work was supported by NIH grants 1-R560NS-048471 and 2R01NS04847. A.S. is an Investigator in the HHMI.	Allada R, 2010, ANNU REV PHYSIOL, V72, P605, DOI 10.1146/annurev-physiol-021909-135815; Arbouzova NI, 2006, DEVELOPMENT, V133, P2605, DOI 10.1242/dev.02411; Asher G, 2011, CELL METAB, V13, P125, DOI 10.1016/j.cmet.2011.01.006; Baines RA, 2001, J NEUROSCI, V21, P1523, DOI 10.1523/JNEUROSCI.21-05-01523.2001; Banerjee S, 2010, CANCER RES, V70, P1356, DOI 10.1158/0008-5472.CAN-09-2178; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Cayirlioglu P, 2008, SCIENCE, V319, P1256, DOI 10.1126/science.1149483; Cheng HYM, 2007, NEURON, V54, P813, DOI 10.1016/j.neuron.2007.05.017; ESKIN A, 1979, FED PROC, V38, P2570; Ghiglione C, 2002, DEVELOPMENT, V129, P5437, DOI 10.1242/dev.00116; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Hamada FN, 2008, NATURE, V454, P217, DOI 10.1038/nature07001; Harmer SL, 2009, ANNU REV PLANT BIOL, V60, P357, DOI 10.1146/annurev.arplant.043008.092054; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Helfrich-Forster C, 2000, J NEUROSCI, V20, P3339, DOI 10.1523/JNEUROSCI.20-09-03339.2000; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Hyun S, 2005, NEURON, V48, P267, DOI 10.1016/j.neuron.2005.08.025; Kadener S, 2009, GENE DEV, V23, P2179, DOI 10.1101/gad.1819509; Kaneko M, 1997, J NEUROSCI, V17, P6745; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; Kojima S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011264; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1999, DEV BIOL, V213, P432, DOI 10.1006/dbio.1999.9390; McGuire S. E., 2004, SCI STKE, V2004, pp16, DOI DOI 10.1125/STKE.2202004P16; Nicolai LJJ, 2010, P NATL ACAD SCI USA, V107, P20553, DOI 10.1073/pnas.1010198107; Nitabach MN, 2008, CURR BIOL, V18, pR84, DOI 10.1016/j.cub.2007.11.061; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; Ren DJ, 2001, SCIENCE, V294, P2372, DOI 10.1126/science.1065635; Ruby JG, 2007, GENOME RES, V17, P1850, DOI 10.1101/gr.6597907; Sathyanarayanan S, 2004, CELL, V116, P603, DOI 10.1016/S0092-8674(04)00128-X; Shafer OT, 2006, J COMP NEUROL, V498, P180, DOI 10.1002/cne.21021; Shi LH, 2009, J BIOL CHEM, V284, P25791, DOI 10.1074/jbc.M109.033993; Vitalini MW, 2006, J BIOL RHYTHM, V21, P432, DOI 10.1177/0748730406294396; Williams JA, 2001, SCIENCE, V293, P2251, DOI 10.1126/science.1063097; Yang M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-83; Yang ZH, 2001, NEURON, V29, P453, DOI 10.1016/S0896-6273(01)00218-5; Yoon WH, 2011, NAT CELL BIOL, V13, P1062, DOI 10.1038/ncb2316; Zheng XZ, 2008, GENETICS, V178, P1147, DOI 10.1534/genetics.107.088658; Zheng X, 2007, P NATL ACAD SCI USA, V104, P15899, DOI 10.1073/pnas.0701599104	45	102	110	1	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 17	2012	148	4					765	779		10.1016/j.cell.2011.12.024	http://dx.doi.org/10.1016/j.cell.2011.12.024			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	897DH	22305007	Bronze, Green Accepted			2022-12-28	WOS:000300622400017
J	Fouchier, RAM; Herfst, S; Osterhaus, ADME				Fouchier, Ron A. M.; Herfst, Sander; Osterhaus, Albert D. M. E.			Restricted Data on Influenza H5N1 Virus Transmission	SCIENCE			English	Editorial Material							MODEL		[Fouchier, Ron A. M.; Herfst, Sander; Osterhaus, Albert D. M. E.] Erasmus MC, Dept Virol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Fouchier, RAM (corresponding author), Erasmus MC, Dept Virol, Rotterdam, Netherlands.	r.fouchier@eras-musmc.nl	Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869; Herfst, Sander/0000-0001-9866-8903; Osterhaus, Albert/0000-0002-6074-1172				Chen LM, 2012, VIROLOGY, V422, P105, DOI 10.1016/j.virol.2011.10.006; Cline TD, 2011, J VIROL, V85, P12262, DOI 10.1128/JVI.05582-11; D. H. H. S. Pandemic Infl uenza Plan, 2005, D H H S PANDEMIC INF; Domenech J., 2009, SCI TECH PARIS, V28, P293; Food and Agricultural Organization, 2011, H5N1 HPAI GLOB OV AP; Gao YW, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000709; Maines TR, 2006, P NATL ACAD SCI USA, V103, P12121, DOI 10.1073/pnas.0605134103; NSABB, 2007, PROP FRAM; Sorrell EM, 2011, CURR OPIN VIROL, V1, P635, DOI 10.1016/j.coviro.2011.07.003; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Yen HL, 2007, J VIROL, V81, P6890, DOI 10.1128/JVI.00170-07	11	34	39	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2012	335	6069					662	663		10.1126/science.1218376	http://dx.doi.org/10.1126/science.1218376			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	889AY	22267582				2022-12-28	WOS:000300047100035
J	Kadowaki, T; Ueki, K; Yamauchi, T; Kubota, N				Kadowaki, Takashi; Ueki, Kohjiro; Yamauchi, Toshimasa; Kubota, Naoto			SnapShot: Insulin Signaling Pathways	CELL			English	Editorial Material							INSIGHTS; KINASE		[Kadowaki, Takashi; Ueki, Kohjiro; Yamauchi, Toshimasa; Kubota, Naoto] Univ Tokyo, Grad Sch Med, Dept Diabet & Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Diabet & Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan.		Kubota, Naoto/N-7892-2015					Cohen P, 2006, NAT REV MOL CELL BIO, V7, P867, DOI 10.1038/nrm2043; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lin HV, 2011, CELL METAB, V14, P9, DOI 10.1016/j.cmet.2011.06.003; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705	10	32	32	1	24	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					624	U258	624.e1	10.1016/j.cell.2012.01.034	http://dx.doi.org/10.1016/j.cell.2012.01.034			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304926	Bronze			2022-12-28	WOS:000300225000028
J	Laan, L; Pavin, N; Husson, J; Romet-Lemonne, G; van Duijn, M; Lopez, MP; Vale, RD; Julicher, F; Reck-Peterson, SL; Dogterom, M				Laan, Liedewij; Pavin, Nenad; Husson, Julien; Romet-Lemonne, Guillaume; van Duijn, Martijn; Lopez, Magdalena Preciado; Vale, Ronald D.; Juelicher, Frank; Reck-Peterson, Samara L.; Dogterom, Marileen			Cortical Dynein Controls Microtubule Dynamics to Generate Pulling Forces that Position Microtubule Asters	CELL			English	Article							CELL CORTEX; CAENORHABDITIS-ELEGANS; FISSION YEAST; CYTOPLASMIC DYNEIN; MICROFABRICATED CHAMBERS; C-ELEGANS; SPINDLE; MOTOR; DEPOLYMERIZATION; PROCESSIVITY	Dynein at the cortex contributes to microtubule-based positioning processes such as spindle positioning during embryonic cell division and centrosome positioning during fibroblast migration. To investigate how cortical dynein interacts with microtubule ends to generate force and how this functional association impacts positioning, we have reconstituted the 'cortical' interaction between dynein and dynamic microtubule ends in an in vitro system using microfabricated barriers. We show that barrier-attached dynein captures microtubule ends, inhibits growth, and triggers microtubule catastrophes, thereby controlling microtubule length. The subsequent interaction with shrinking microtubule ends generates pulling forces up to several pN. By combining experiments in microchambers with a theoretical description of aster mechanics, we show that dynein-mediated pulling forces lead to the reliable centering of microtubule asters in simple confining geometries. Our results demonstrate the intrinsic ability of cortical microtubule-dynein interactions to regulate microtubule dynamics and drive positioning processes in living cells.	[Laan, Liedewij; Husson, Julien; Romet-Lemonne, Guillaume; van Duijn, Martijn; Lopez, Magdalena Preciado; Dogterom, Marileen] FOM Inst AMOLF, NL-1098 XG Amsterdam, Netherlands; [Pavin, Nenad; Juelicher, Frank] Max Planck Inst Phys Complex Syst MPI PKS, Dresden, Germany; [Pavin, Nenad] Univ Zagreb, Fac Sci, Dept Phys, Zagreb 10002, Croatia; [Vale, Ronald D.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA; [Vale, Ronald D.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Reck-Peterson, Samara L.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Laan, Liedewij; Vale, Ronald D.; Reck-Peterson, Samara L.; Dogterom, Marileen] Marine Biol Lab, Physiol Course, Woods Hole, MA 02543 USA	AMOLF; Max Planck Society; University of Zagreb; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Marine Biological Laboratory - Woods Hole	Dogterom, M (corresponding author), FOM Inst AMOLF, Sci Pk 104, NL-1098 XG Amsterdam, Netherlands.	dogterom@amolf.nl	Husson, Julien/B-8466-2018; Julicher, Frank/B-1828-2009; Pavin, Nenad/N-6376-2013	Husson, Julien/0000-0002-8230-1469; Julicher, Frank/0000-0003-4731-9185; Pavin, Nenad/0000-0002-4313-1081; Reck-Peterson, Samara/0000-0002-1553-465X; Romet-Lemonne, Guillaume/0000-0002-4938-1065; Laan, Liedewij/0000-0002-7138-9004; van Duijn, Martijn/0000-0002-6654-994X; Preciado Lopez, Magdalena/0000-0003-4929-3310	European network Active BIOMICS; HFSP; Stichting voor Fundamenteel Onderzoek der Materie (FOM); Nederlandse organisatie voor Wetenschappelijk Onderzoek (NWO); Volkswagen Stiftung; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R13GM085967] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD004268] Funding Source: NIH RePORTER	European network Active BIOMICS; HFSP(Human Frontier Science Program); Stichting voor Fundamenteel Onderzoek der Materie (FOM)(FOM (The Netherlands)); Nederlandse organisatie voor Wetenschappelijk Onderzoek (NWO)(Netherlands Organization for Scientific Research (NWO)); Volkswagen Stiftung(Volkswagen); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This collaborative project benefited greatly from interactions during the Physiology Course at the MBL, Woods Hole. All experiments were performed by L.L., together with J.H. (optical trap) and M.P.L. (supplemental gliding assays), based on chamber functionalization technology developed by G.R.L. and M.v.D., under supervision of M.D.R.V. and S.R.P. provided materials and expertise on dynein. Theory was developed by N.P. and L.L., under supervision of F.J. We thank M. Footer for providing us with axonemes; C. Celati for help with the centrosome purifications; E.L. Munteanu and J.W.J. Kerssemakers for developing the optical trap set-up, C. Retif, H. Bar, and M. Seynen for technical support, and S. Kryazhimskiy for help with statistical analysis. We thank S. Tans, I. Tolic-Norrelykke, and H. Bakker for critical reading of previous versions of the manuscript. N.P. acknowledges support by the Volkswagen Stiftung. M.D. greatfully acknowledges financial support from the European network Active BIOMICS, and from HFSP. This work is part of the research program of the "Stichting voor Fundamenteel Onderzoek der Materie (FOM),'' which is financially supported by the "Nederlandse organisatie voor Wetenschappelijk Onderzoek (NWO).''	Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Akiyoshi B, 2010, NATURE, V468, P576, DOI 10.1038/nature09594; Burakov A, 2003, J CELL BIOL, V162, P963, DOI 10.1083/jcb.200305082; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Chang F, 1996, CELL, V84, P191, DOI 10.1016/S0092-8674(00)80973-3; Cho C, 2008, J BIOL CHEM, V283, P25839, DOI 10.1074/jbc.M802951200; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Dogterom M, 1998, PHYS REV LETT, V81, P485, DOI 10.1103/PhysRevLett.81.485; Dogterom M, 2005, CURR OPIN CELL BIOL, V17, P67, DOI 10.1016/j.ceb.2004.12.011; Dogterom M, 1997, SCIENCE, V278, P856, DOI 10.1126/science.278.5339.856; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Faivre-Moskalenko C, 2002, P NATL ACAD SCI USA, V99, P16788, DOI 10.1073/pnas.252407099; Franck AD, 2007, NAT CELL BIOL, V9, P832, DOI 10.1038/ncb1609; Gennerich A, 2007, CELL, V131, P952, DOI 10.1016/j.cell.2007.10.016; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Grishchuk EL, 2005, NATURE, V438, P384, DOI 10.1038/nature04132; Grissom PM, 2009, MOL BIOL CELL, V20, P963, DOI 10.1091/mbc.E08-09-0979; Gusnowski EM, 2011, J CELL BIOL, V194, P377, DOI 10.1083/jcb.201103128; HAMAGUCHI MS, 1986, DEV GROWTH DIFFER, V28, P143, DOI 10.1111/j.1440-169x.1986.00143.x; Holy TE, 1997, P NATL ACAD SCI USA, V94, P6228, DOI 10.1073/pnas.94.12.6228; Howard J, 2006, PHYS BIOL, V3, P54, DOI 10.1088/1478-3975/3/1/006; Janson ME, 2003, J CELL BIOL, V161, P1029, DOI 10.1083/jcb.200301147; Kerssemakers JWJ, 2006, NATURE, V442, P709, DOI 10.1038/nature04928; Kimura K, 2011, P NATL ACAD SCI USA, V108, P137, DOI 10.1073/pnas.1013275108; Komarova Y, 2009, J CELL BIOL, V184, P691, DOI 10.1083/jcb.200807179; Koonce MP, 1999, EMBO J, V18, P6786, DOI 10.1093/emboj/18.23.6786; Kozlowski C, 2007, CELL, V129, P499, DOI 10.1016/j.cell.2007.03.027; Laan L, 2008, P NATL ACAD SCI USA, V105, P8920, DOI 10.1073/pnas.0710311105; Laan L, 2010, METHOD CELL BIOL, V95, P617, DOI 10.1016/S0091-679X(10)95031-0; Labbe JC, 2003, CURR BIOL, V13, P707, DOI 10.1016/S0960-9822(03)00251-3; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; McIntosh JR, 2010, J CELL SCI, V123, P3425, DOI 10.1242/jcs.067611; Minc N, 2009, CURR BIOL, V19, P83, DOI 10.1016/j.cub.2008.12.008; Nguyen-Ngoc T, 2007, NAT CELL BIOL, V9, P1294, DOI 10.1038/ncb1649; O'Rourke SM, 2010, NAT CELL BIOL, V12, P1235, DOI 10.1038/ncb2128; Oguchi Y, 2011, NAT CELL BIOL, V13, P846, DOI 10.1038/ncb2256; Picone R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000542; Powers AF, 2009, CELL, V136, P865, DOI 10.1016/j.cell.2008.12.045; Reck-Peterson SL, 2006, CELL, V126, P335, DOI 10.1016/j.cell.2006.05.046; Romet-Lemonne G, 2005, NANO LETT, V5, P2350, DOI 10.1021/nl0507111; Sage D, 2005, IEEE T IMAGE PROCESS, V14, P1372, DOI 10.1109/TIP.2005.852787; Savoian MS, 2000, NAT CELL BIOL, V2, P948, DOI 10.1038/35046605; Schmoranzer J, 2003, J CELL SCI, V116, P4513, DOI 10.1242/jcs.00748; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Vallee RB, 2006, CELL CYCLE, V5, P2447, DOI 10.4161/cc.5.21.3395; Varma D, 2008, J CELL BIOL, V182, P1045, DOI 10.1083/jcb.200710106; Vogel SK, 2009, PLOS BIOL, V7, P918, DOI 10.1371/journal.pbio.1000087; Wuhr M, 2009, CELL CYCLE, V8, P1115; Yamamoto A, 2001, MOL BIOL CELL, V12, P3933, DOI 10.1091/mbc.12.12.3933; Zhu J, 2010, MOL BIOL CELL, V21, P4418, DOI 10.1091/mbc.E10-07-0627	53	264	265	0	75	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					502	514		10.1016/j.cell.2012.01.007	http://dx.doi.org/10.1016/j.cell.2012.01.007			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304918	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000300225000018
J	Tauris, TM				Tauris, Thomas M.			Spin-Down of Radio Millisecond Pulsars at Genesis	SCIENCE			English	Article							X-RAY BINARIES; LOW-MASS; ACCRETION; EVOLUTION; RADIATION; STARS	Millisecond pulsars are old neutron stars that have been spun up to high rotational frequencies via accretion of mass from a binary companion star. An important issue for understanding the physics of the early spin evolution of millisecond pulsars is the impact of the expanding magnetosphere during the terminal stages of the mass-transfer process. Here, I report binary stellar evolution calculations that show that the braking torque acting on a neutron star, when the companion star decouples from its Roche lobe, is able to dissipate >50% of the rotational energy of the pulsar. This effect may explain the apparent difference in observed spin distributions between x-ray and radio millisecond pulsars and help account for the noticeable age discrepancy with their young white dwarf companions.	[Tauris, Thomas M.] Univ Bonn, Argelander Inst Astron, Hugel 71, D-53121 Bonn, Germany; [Tauris, Thomas M.] Max Planck Inst Radioastron, D-53121 Bonn, Germany	University of Bonn; Max Planck Society	Tauris, TM (corresponding author), Univ Bonn, Argelander Inst Astron, Hugel 71, D-53121 Bonn, Germany.	tauris@astro.uni-bonn.de		Tauris, Thomas/0000-0002-3865-7265	University of Bonn [EXC 1076]	University of Bonn	I gratefully thank N. Langer and M. Kramer for discussions and funding and without whom these results would not be possible and R. Eatough for helpful comments on the SOM. This work was partly supported by the Cluster of Excellence proposal EXC 1076, "The nature of forces and matter," at the University of Bonn. Radio pulsar data has been obtained from the ATNF Pulsar Catalogue (www.atnf.csiro.au/research/pulsar/psrcat/).	Alberts F, 1996, NATURE, V380, P676, DOI 10.1038/380676a0; ALPAR MA, 1982, NATURE, V300, P728, DOI 10.1038/300728a0; Archibald AM, 2009, SCIENCE, V324, P1411, DOI 10.1126/science.1172740; BHATTACHARYA D, 1991, PHYS REP, V203, P1, DOI 10.1016/0370-1573(91)90064-S; Bildsten L, 1998, ASTROPHYS J, V501, pL89, DOI 10.1086/311440; Burderi L, 2001, ASTROPHYS J, V560, pL71, DOI 10.1086/324220; Chakrabarty D, 2003, NATURE, V424, P42, DOI 10.1038/nature01732; D'Angelo CR, 2010, MON NOT R ASTRON SOC, V406, P1208, DOI 10.1111/j.1365-2966.2010.16749.x; Frank J., 2002, ACCRETION POWER ASTR, V3rd; GHOSH P, 1992, NATO ADV SCI I C-MAT, V377, P487; Hessels JWT, 2008, AIP CONF PROC, V1068, P130; Hessels JWT, 2006, SCIENCE, V311, P1901, DOI 10.1126/science.1123430; ILLARIONOV AF, 1975, ASTRON ASTROPHYS, V39, P185; Lamb F., 2005, BINARY RADIO PULSARS, V328, P299; LAMB FK, 1973, ASTROPHYS J, V184, P271, DOI 10.1086/152325; LORIMER DR, 1995, NATURE, V376, P393; Nelson LA, 2004, ASTROPHYS J, V616, P1124, DOI 10.1086/421698; Papitto A, 2011, ASTRON ASTROPHYS, V535, DOI 10.1051/0004-6361/201117995; Patruno A, 2010, ASTROPHYS J, V722, P909, DOI 10.1088/0004-637X/722/1/909; Podsiadlowski P, 2002, ASTROPHYS J, V565, P1107, DOI 10.1086/324686; RAPPAPORT S, 1995, MON NOT R ASTRON SOC, V273, P731, DOI 10.1093/mnras/273.3.731; RUDERMAN M, 1989, ASTROPHYS J, V343, P292, DOI 10.1086/167704; RUDERMAN M, 1989, ASTROPHYS J, V336, P507, DOI 10.1086/167029; Shapiro S.L., 1983, BLACK HOLES WHITE DW; SHKLOVSKII IS, 1970, SOV ASTRON, V13, P734; Tauris TM, 1999, ASTRON ASTROPHYS, V350, P928; van Kerkwijk M. H., 2005, ASP C SER, V328, P357; Wang YM, 1997, ASTROPHYS J, V475, pL135, DOI 10.1086/310481; WEBBINK RF, 1983, ASTROPHYS J, V270, P678, DOI 10.1086/161159; Wijnands R, 1998, NATURE, V394, P344, DOI 10.1038/28557	33	64	66	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2012	335	6068					561	563		10.1126/science.1216355	http://dx.doi.org/10.1126/science.1216355			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301314	Green Submitted			2022-12-28	WOS:000299769200037
J	Chalisey, A; Shah, S; Karim, M				Chalisey, Anil; Shah, Shahzad; Karim, Mahzuz			Acute dyspnoea-not always above the diaphragm	LANCET			English	Editorial Material							HEPATIC HYDROTHORAX; PATHOPHYSIOLOGY		[Chalisey, Anil; Shah, Shahzad; Karim, Mahzuz] Norfolk & Norwich Univ Hosp, Dept Renal Med, Norwich NR4 7UY, Norfolk, England	Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Karim, M (corresponding author), Norfolk & Norwich Univ Hosp, Dept Renal Med, Colney Lane, Norwich NR4 7UY, Norfolk, England.	mkarim@doctors.org.uk	Karim, Mahzuz/H-3138-2019					Kiafar C, 2008, ANN HEPATOL, V7, P313, DOI 10.1016/S1665-2681(19)31831-9; Leblanc M, 2001, SEMIN DIALYSIS, V14, P50, DOI 10.1046/j.1525-139x.2001.00014.x; Losanoff JE, 2010, J THORAC CARDIOV SUR, V139, pE127, DOI 10.1016/j.jtcvs.2009.05.035; Roussos A, 2007, J GASTROEN HEPATOL, V22, P1388, DOI 10.1111/j.1440-1746.2007.05069.x	4	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 28	2012	379	9813					384	384		10.1016/S0140-6736(11)61652-8	http://dx.doi.org/10.1016/S0140-6736(11)61652-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889BA	22284658				2022-12-28	WOS:000300047300045
J	Rohringer, N; Ryan, D; London, RA; Purvis, M; Albert, F; Dunn, J; Bozek, JD; Bostedt, C; Graf, A; Hill, R; Hau-Riege, SP; Rocca, JJ				Rohringer, Nina; Ryan, Duncan; London, Richard A.; Purvis, Michael; Albert, Felicie; Dunn, James; Bozek, John D.; Bostedt, Christoph; Graf, Alexander; Hill, Randal; Hau-Riege, Stefan P.; Rocca, Jorge J.			Atomic inner-shell X-ray laser at 1.46 nanometres pumped by an X-ray free-electron laser	NATURE			English	Article							RADIATION; OPERATION; AMPLIFIER	Since the invention of the laser more than 50 years ago, scientists have striven to achieve amplification on atomic transitions of increasingly shorter wavelength(1-7). The introduction of X-ray free-electron lasers(8-10) makes it possible to pump new atomic X-ray lasers(11-13) with ultrashort pulse duration, extreme spectral brightness and full temporal coherence. Here we describe the implementation of an X-ray laser in the kiloelectronvolt energy regime, based on atomic population inversion and driven by rapid K-shell photo-ionization using pulses from an X-ray free-electron laser. We established a population inversion of the K alpha transition in singly ionized neon(14) at 1.46 nanometres (corresponding to a photon energy of 849 electronvolts) in an elongated plasma column created by irradiation of a gas medium. We observed strong amplified spontaneous emission from the end of the excited plasma. This resulted in femtosecond-duration, high-intensity X-ray pulses of much shorter wavelength and greater brilliance than achieved with previous atomic X-ray lasers. Moreover, this scheme provides greatly increased wavelength stability, monochromaticity and improved temporal coherence by comparison with present-day X-ray free-electron lasers. The atomic X-ray lasers realized here may be useful for high-resolution spectroscopy and nonlinear X-ray studies.	[Ryan, Duncan; Purvis, Michael; Rocca, Jorge J.] Colorado State Univ, Ft Collins, CO 80523 USA; [Ryan, Duncan; Purvis, Michael; Rocca, Jorge J.] NSF Engn Res Ctr Extreme Ultraviolet Sci & Techno, Ft Collins, CO 80523 USA; [Bozek, John D.; Bostedt, Christoph] SLAC Natl Accelerator Lab, LCLS, Menlo Pk, CA 94025 USA; [Rohringer, Nina; London, Richard A.; Albert, Felicie; Dunn, James; Graf, Alexander; Hill, Randal; Hau-Riege, Stefan P.] Lawrence Livermore Natl Lab, Livermore, CA 94551 USA	Colorado State University; National Science Foundation (NSF); Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Rohringer, N (corresponding author), DESY, Max Planck Adv Study Grp, Ctr Free Electron Laser Sci, Notkestr 85, D-22607 Hamburg, Germany.	nina.rohringer@asg.mpg.de	Bozek, John D/E-9260-2010; Rohringer, Nina/N-3238-2014; Albert, Felicie/G-2645-2013; Rohringer, Nina/B-8030-2012; Rohringer, Nina/AAI-9477-2020	Bozek, John D/0000-0001-7486-7238; Rohringer, Nina/0000-0001-7905-3567; Rohringer, Nina/0000-0001-7905-3567; Ryan, Duncan/0000-0001-7702-8499	US Department of Energy by Lawrence Livermore National Laboratory (LLNL) [DE-AC52-07NA27344]; LLNL's LDRD [09-LW-044]; US Department of Energy Basic Energy Sciences AMOS	US Department of Energy by Lawrence Livermore National Laboratory (LLNL)(United States Department of Energy (DOE)); LLNL's LDRD; US Department of Energy Basic Energy Sciences AMOS	This work was performed under the auspices of the US Department of Energy by Lawrence Livermore National Laboratory (LLNL; DE-AC52-07NA27344) and was supported by LLNL's LDRD programme, 09-LW-044. Portions of this research were carried out at the Linac Coherent Light Source, a national user facility operated by Stanford University on behalf of the US Department of Energy, Office of Basic Energy Sciences. J.J.R., M. P. and D. R. were supported by the US Department of Energy Basic Energy Sciences AMOS Program. We thank M. J. Pivovaroff and K. A. van Bibber for their encouragement and support for this project; R. W. Lee, T. Ditmire, L. Young, R. Falcone and S. Le Pape for discussions of the experimental design; J.-C. Castagna, C.-M. Tsai, S. Schorb, M. L. Swiggers and M. Messerschmidt for their assistance with the experiment; M. J. Bogan for the loan of the X-ray CCD camera and A. Barty for the design of Fig. 1. We also acknowledge support of the LCLS software engineers for the control and data acquisition. We are indebted to the LCLS operating team for their support during beam time in achieving the necessary pulse energies for this experiment.	Ackermann W, 2007, NAT PHOTONICS, V1, P336, DOI 10.1038/nphoton.2007.76; AXELROD TS, 1976, PHYS REV A, V13, P376, DOI 10.1103/PhysRevA.13.376; Daido H, 2002, REP PROG PHYS, V65, P1513, DOI 10.1088/0034-4885/65/10/204; Doumy G, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.083002; DUGUAY MA, 1967, APPL PHYS LETT, V10, P350, DOI 10.1063/1.1728208; EDER DC, 1994, PHYS PLASMAS, V1, P1744, DOI 10.1063/1.870936; Elton R., 1990, XRAY LASERS; Emma P, 2010, NAT PHOTONICS, V4, P641, DOI [10.1038/NPHOTON.2010.176, 10.1038/nphoton.2010.176]; HOPF FA, 1975, PHYS REV A, V12, P2534, DOI 10.1103/PhysRevA.12.2534; Kanter EP, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.233001; KAPTEYN HC, 1986, PHYS REV LETT, V57, P2939, DOI 10.1103/PhysRevLett.57.2939; KAPTEYN HC, 1992, APPL OPTICS, V31, P4931, DOI 10.1364/AO.31.004931; Lan K, 2004, LASER PART BEAMS, V22, P261, DOI 10.1017/S0263034604223084; MATTHEWS DL, 1985, PHYS REV LETT, V54, P110, DOI 10.1103/PhysRevLett.54.110; Mukamel S, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.235110; Pile D, 2011, NAT PHOTONICS, V5, P456, DOI 10.1038/nphoton.2011.178; Rocca JJ, 1999, REV SCI INSTRUM, V70, P3799, DOI 10.1063/1.1150041; Rohringer N, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.033416; Rohringer N, 2009, PHYS REV A, V80, DOI 10.1103/PhysRevA.80.013809; Rus B, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.063806; Schweigert IV, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.012504; SILFVAST WT, 1983, OPT LETT, V8, P551, DOI 10.1364/OL.8.000551; STROBEL GL, 1993, P SOC PHOTO-OPT INS, V1860, P157, DOI 10.1117/12.147574; SUCKEWER S, 1985, PHYS REV LETT, V55, P1753, DOI 10.1103/PhysRevLett.55.1753; Suckewer S, 2009, LASER PHYS LETT, V6, P411, DOI 10.1002/lapl.200910023; Sun YP, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.013812; Tanaka S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.043001; Vartanyants IA, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.144801; Young L, 2010, NATURE, V466, P56, DOI 10.1038/nature09177; Zhao J, 2008, OPT EXPRESS, V16, P3546, DOI 10.1364/OE.16.003546	30	254	256	7	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2012	481	7382					488	491		10.1038/nature10721	http://dx.doi.org/10.1038/nature10721			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881GY	22281598				2022-12-28	WOS:000299471800036
J	Schrijver, CJ; Brown, JC; Battams, K; Saint-Hilaire, P; Liu, W; Hudson, H; Pesnell, WD				Schrijver, C. J.; Brown, J. C.; Battams, K.; Saint-Hilaire, P.; Liu, W.; Hudson, H.; Pesnell, W. D.			Destruction of Sun-Grazing Comet C/2011 N3 (SOHO) Within the Low Solar Corona	SCIENCE			English	Article								Observations of comets in Sun-grazing orbits that survive solar insolation long enough to penetrate into the Sun's inner corona provide information on the solar atmosphere and magnetic field as well as on the makeup of the comet. On 6 July 2011, the Solar Dynamics Observatory (SDO) observed the demise of comet C/2011 N3 (SOHO) within the low solar corona in five wavelength bands in the extreme ultraviolet (EUV). The comet penetrated to within 0.146 solar radius (similar to 100,000 kilometers) of the solar surface before its EUV signal disappeared. Before that, material released into the coma-at first seen in absorption-formed a variable EUV-bright tail. During the final 10 minutes of observation by SDO's Atmospheric Imaging Assembly, similar to 6 x 10(8) to 6 x 10(10) grams of total mass was lost (corresponding to an effective nucleus diameter of similar to 10 to 50 meters), as estimated from the tail's deceleration due to interaction with the surrounding coronal material; the EUV absorption by the comet and the brightness of the tail suggest that the mass was at the high end of this range. These observations provide evidence that the nucleus had broken up into a family of fragments, resulting in accelerated sublimation in the Sun's intense radiation field.	[Schrijver, C. J.; Liu, W.] Lockheed Martin Adv Technol Ctr, Palo Alto, CA 94304 USA; [Brown, J. C.; Hudson, H.] Univ Glasgow, Sch Phys & Astron, Glasgow G12 8QQ, Lanark, Scotland; [Battams, K.] USN, Res Lab, Washington, DC 20375 USA; [Saint-Hilaire, P.; Hudson, H.] Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; [Liu, W.] Stanford Univ, WW Hansen Expt Phys Lab, Stanford, CA 94305 USA; [Pesnell, W. D.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	Lockheed Martin; University of Glasgow; United States Department of Defense; United States Navy; Naval Research Laboratory; University of California System; University of California Berkeley; Stanford University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Schrijver, CJ (corresponding author), Lockheed Martin Adv Technol Ctr, 3251 Hanover St, Palo Alto, CA 94304 USA.	schrijver@lmsal.com	Pesnell, William D/D-1062-2012	Pesnell, William D/0000-0002-8306-2500; Schrijver, Carolus/0000-0002-6010-8182; Battams, Karl/0000-0002-8692-6925	NASA SDO/AIA [NNG04EA00C]; Science and Technology Facilities Council [ST/I001808/1] Funding Source: researchfish; STFC [ST/I001808/1] Funding Source: UKRI	NASA SDO/AIA; Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	Supported by NASA SDO/AIA contract NNG04EA00C to Lockheed Martin's Solar and Astrophysics Laboratory. The SDO/AIA data can be accessed at http://aia.lmsal.com; the STEREO/SECCHI data can be accessed at http://stereo-ssc.nascom.nasa.gov/data/ins_data/secchi. We thank the four reviewers and the editor for their help in improving the manuscript.	Boerner P, 2012, SOL PHYS, V275, P41, DOI 10.1007/s11207-011-9804-8; Brueckner GE, 1995, SOL PHYS, V162, P357, DOI 10.1007/BF00733434; Cravens TE, 2002, SCIENCE, V296, P1042, DOI 10.1126/science.1070001; GUHATHAKURTA M, 1993, ASTROPHYS J, V414, pL145, DOI 10.1086/187017; Howard RA, 2008, SPACE SCI REV, V136, P67, DOI 10.1007/s11214-008-9341-4; Iseli M, 2002, ICARUS, V155, P350, DOI 10.1006/icar.2001.6722; Knight MM, 2010, ASTRON J, V139, P926, DOI 10.1088/0004-6256/139/3/926; LEMEN JR, 2011, SOL PHYS, DOI DOI 10.1007/S11207-011-9776-8; Lisse CM, 2004, SPACE SCI S, P631; Schrijver CJ, 2003, SOL PHYS, V212, P165, DOI 10.1023/A:1022908504100	10	27	27	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					324	328		10.1126/science.1211688	http://dx.doi.org/10.1126/science.1211688			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267810	Green Published			2022-12-28	WOS:000299273400044
J	Gourlay, ML; Fine, JP; Preisser, JS; May, RC; Li, CX; Lui, LY; Ransohoff, DF; Cauley, JA; Ensrud, KE				Gourlay, Margaret L.; Fine, Jason P.; Preisser, John S.; May, Ryan C.; Li, Chenxi; Lui, Li-Yung; Ransohoff, David F.; Cauley, Jane A.; Ensrud, Kristine E.		Study Osteoporotic Fractures Res	Bone-Density Testing Interval and Transition to Osteoporosis in Older Women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REPLACEMENT THERAPY; CANCER; FRACTURES; INFERENCE; ADULT	BACKGROUND Although bone mineral density (BMD) testing to screen for osteoporosis (BMD T score, -2.50 or lower) is recommended for women 65 years of age or older, there are few data to guide decisions about the interval between BMD tests. METHODS We studied 4957 women, 67 years of age or older, with normal BMD (T score at the femoral neck and total hip, -1.00 or higher) or osteopenia (T score, -1.01 to -2.49) and with no history of hip or clinical vertebral fracture or of treatment for osteoporosis, followed prospectively for up to 15 years. The BMD testing interval was defined as the estimated time for 10% of women to make the transition to osteoporosis before having a hip or clinical vertebral fracture, with adjustment for estrogen use and clinical risk factors. Transitions from normal BMD and from three subgroups of osteopenia (mild, moderate, and advanced) were analyzed with the use of parametric cumulative incidence models. Incident hip and clinical vertebral fractures and initiation of treatment with bisphosphonates, calcitonin, or raloxifene were treated as competing risks. RESULTS The estimated BMD testing interval was 16.8 years (95% confidence interval [CI], 11.5 to 24.6) for women with normal BMD, 17.3 years (95% CI, 13.9 to 21.5) for women with mild osteopenia, 4.7 years (95% CI, 4.2 to 5.2) for women with moderate osteopenia, and 1.1 years (95% CI, 1.0 to 1.3) for women with advanced osteopenia. CONCLUSIONS Our data indicate that osteoporosis would develop in less than 10% of older, postmenopausal women during rescreening intervals of approximately 15 years for women with normal bone density or mild osteopenia, 5 years for women with moderate osteopenia, and 1 year for women with advanced osteopenia. (Funded by the National Institutes of Health.)	[Gourlay, Margaret L.] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27599 USA; [Fine, Jason P.; Preisser, John S.; May, Ryan C.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA; [Ransohoff, David F.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; [Li, Chenxi] Univ N Carolina, N Carolina Translat & Clin Sci Inst, Chapel Hill, NC 27599 USA; [Lui, Li-Yung] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA; [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA; [Ensrud, Kristine E.] Minneapolis Vet Affairs Hlth Care Syst, Dept Med, Minneapolis, MN USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; California Pacific Medical Center; California Pacific Medical Center Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Gourlay, ML (corresponding author), Univ N Carolina, Dept Family Med, Aycock Bldg,Manning Dr, Chapel Hill, NC 27599 USA.	margaret_gourlay@med.unc.edu	Li, Chenxi/D-1004-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036	National Institutes of Health [K23RR024685, AG05407, AR35582, AG05394, AR35584, AR35583, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, 2 R01 AG027574-22A1]; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR024685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582, R01AR035584, R01AR035583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027576, R01AG027574, R01AG005394, R01AG005407] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by a grant (K23RR024685) from the National Institutes of Health. The Study of Osteoporotic Fractures is supported by grants (AG05407, AR35582, AG05394, AR35584, AR35583, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, and 2 R01 AG027574-22A1) from the National Institutes of Health.	American College of Obstetricians and Gynecologists, 2008, ACOG PRACT B; [Anonymous], 2010, CLIN GUID PREV TREAT; Bonnick SL, 2010, MENOPAUSE, V17, P25, DOI [10.1097/gme.0b013e3181c617e6, 10.1097/gme.0b013e3181e617e6]; Calonge N, 2011, ANN INTERN MED, V154, P356, DOI 10.7326/0003-4819-154-5-201103010-00307; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; Esserman L, 2009, JAMA-J AM MED ASSOC, V302, P1685, DOI 10.1001/jama.2009.1498; Fine J P, 2001, Biostatistics, V2, P85, DOI 10.1093/biostatistics/2.1.85; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Frost SA, 2009, J BONE MINER RES, V24, P1800, DOI [10.1359/JBMR.090514, 10.1359/jbmr.090514]; Greendale GA, 2002, ARCH INTERN MED, V162, P665, DOI 10.1001/archinte.162.6.665; Hillier TA, 2007, ARCH INTERN MED, V167, P155, DOI 10.1001/archinte.167.2.155; Hodgson Stephen F, 2003, Endocr Pract, V9, P544; Hudgens M, 2011, U N CAROLINA CHAPPEL; Jeong JH, 2006, J R STAT SOC C-APPL, V55, P187, DOI 10.1111/j.1467-9876.2006.00532.x; Jeong JH, 2007, BIOSTATISTICS, V8, P184, DOI 10.1093/biostatistics/kxj040; Kanis JA, 2009, BONE, V44, P734, DOI 10.1016/j.bone.2009.01.373; Klein J. P., 2003, SURVIVAL ANAL TECHNI; Lee M, 2011, STAT MED, V30, P3221, DOI 10.1002/sim.4349; Lewiecki EM, 2008, BONE, V43, P1115, DOI 10.1016/j.bone.2008.08.106; Lim LS, 2009, AM J PREV MED, V36, P366, DOI 10.1016/j.amepre.2009.01.013; Lindsey JC, 1999, STAT MED, V18, P890, DOI 10.1002/(SICI)1097-0258(19990415)18:7<890::AID-SIM90>3.0.CO;2-7; Looker AC, 2010, J BONE MINER RES, V25, P64, DOI 10.1359/jbmr.090706; Partridge AH, 2009, NEW ENGL J MED, V361, P2499, DOI 10.1056/NEJMp0911288; Peng L, 2007, BIOMETRIKA, V94, P735, DOI 10.1093/biomet/asm059; SAS Institute, 2008, SAS STAT 9 2 US GUID; Sawaya GF, 2009, NEW ENGL J MED, V361, P2503, DOI 10.1056/NEJMp0911380; Schwartz LM, 2004, JAMA-J AM MED ASSOC, V291, P71, DOI 10.1001/jama.291.1.71	28	165	170	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					225	233		10.1056/NEJMoa1107142	http://dx.doi.org/10.1056/NEJMoa1107142			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877RZ	22256806	Green Published, Green Accepted			2022-12-28	WOS:000299201400008
J	Karsenty, G; Ferron, M				Karsenty, Gerard; Ferron, Mathieu			The contribution of bone to whole-organism physiology	NATURE			English	Review							TRYPTOPHAN-HYDROXYLASE INHIBITORS; SYMPATHETIC-NERVOUS-SYSTEM; RECEPTOR-RELATED PROTEIN-5; TYROSINE-PHOSPHATASE 1B; ENERGY-METABOLISM; BODY-WEIGHT; INVOLUTIONAL OSTEOPOROSIS; POSTMENOPAUSAL WOMEN; SEROTONIN SYNTHESIS; GLUCOSE-METABOLISM	The mouse genetic revolution has shown repeatedly that most organs have more functions than expected. This has led to the realization that, in addition to a molecular and cellular approach, there is a need for a whole-organism study of physiology. The skeleton is an example of how a whole-organism approach to physiology can broaden the functions of a given organ, reveal connections of this organ with others such as the brain, pancreas and gut, and shed new light on the pathogenesis of degenerative diseases affecting multiple organs.	[Karsenty, Gerard; Ferron, Mathieu] Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Karsenty, G (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA.	gk2172@columbia.edu	Ferron, Mathieu/M-7794-2013	Karsenty, Gerard/0000-0002-9253-7627	National Institutes of Health; Canadian Diabetes Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD065439] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Diabetes Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank T. Clemens, P. Ducy, M. Gershon, M. Kassem, S. Kousteni and members of the Karsenty laboratory for comments on the manuscript. We apologize to our colleagues whose work is not directly discussed and/or cited in this article because of space constraints. G. K. is supported by the National Institutes of Health, and M. F. by the Canadian Diabetes Association.	Baldock PA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008415; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Bartell SM, 2011, J BONE MINER RES, V26, P1710, DOI 10.1002/jbmr.406; Bernard C., 1865, INTRO ETUDE MED EXPT; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bjornholm M, 2007, J CLIN INVEST, V117, P1354, DOI 10.1172/JCI30688; Bliziotes M, 2010, J CLIN ENDOCR METAB, V95, P4124, DOI 10.1210/jc.2010-0861; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Bonnet N, 2007, BONE, V40, P1209, DOI 10.1016/j.bone.2007.01.006; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Cannon W.B., 1932, WISDOM BODY; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen SK, 2010, CELL, V141, P775, DOI 10.1016/j.cell.2010.03.055; Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405; Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388; Delibegovic M, 2007, MOL CELL BIOL, V27, P7727, DOI 10.1128/MCB.00959-07; Delibegovic M, 2009, DIABETES, V58, P590, DOI 10.2337/db08-0913; Dhillon H, 2006, NEURON, V49, P191, DOI 10.1016/j.neuron.2005.12.021; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Elefteriou F, 2004, P NATL ACAD SCI USA, V101, P3258, DOI 10.1073/pnas.0308744101; Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010; Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105; Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Frost M, 2011, J BONE MINER RES, V26, P1721, DOI 10.1002/jbmr.376; Frost M, 2010, J BONE MINER RES, V25, P673, DOI 10.1002/jbmr.44; Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002; Gibson WT, 2004, J CLIN ENDOCR METAB, V89, P4821, DOI 10.1210/jc.2004-0376; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; GURNEY CW, 1960, JAMA-J AM MED ASSOC, V173, P1828, DOI 10.1001/jama.1960.73020340003013; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; Hay E, 2005, J BIOL CHEM, V280, P13616, DOI 10.1074/jbc.M411999200; Hinoi E, 2008, J CELL BIOL, V183, P1235, DOI 10.1083/jcb.200809113; Hori M, 2011, ENDOCRINOLOGY, V152, P4, DOI 10.1210/en.2010-0800; Inose H, 2011, J BONE MINER RES, V26, P2002, DOI 10.1002/jbmr.439; Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kaye W, 1998, BIOL PSYCHIAT, V44, P825, DOI 10.1016/S0006-3223(98)00195-4; Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428-09; Lam DD, 2011, CELL METAB, V13, P584, DOI 10.1016/j.cmet.2011.03.016; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Legroux-Gerot I, 2005, JOINT BONE SPINE, V72, P489, DOI 10.1016/j.jbspin.2004.07.011; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu QY, 2008, J PHARMACOL EXP THER, V325, P47, DOI 10.1124/jpet.107.132670; MANN JJ, 1992, ARCH GEN PSYCHIAT, V49, P442; MERLE B, 1990, BONE MINER, V11, P237, DOI 10.1016/0169-6009(90)90062-K; Miheller P, 2010, WORLD J GASTROENTERO, V16, P5536, DOI 10.3748/wjg.v16.i44.5536; Misra M, 2011, NEUROENDOCRINOLOGY, V93, P65, DOI 10.1159/000323771; Modder UI, 2010, J BONE MINER RES, V25, P415, DOI 10.1359/jbmr.090721; MONOD J, 1961, COLD SPRING HARB SYM, V26, P389, DOI 10.1101/SQB.1961.026.01.048; Motyl KJ, 2010, ARCH BIOCHEM BIOPHYS, V503, P2, DOI 10.1016/j.abb.2010.07.030; Oury F, 2011, CELL, V144, P796, DOI 10.1016/j.cell.2011.02.004; Oury F, 2010, GENE DEV, V24, P2330, DOI 10.1101/gad.1977210; Pi M, 2005, J BIOL CHEM, V280, P40201, DOI 10.1074/jbc.M505186200; Pogoda P, 2006, J BONE MINER RES, V21, P1591, DOI 10.1359/JBMR.060709; Pollock NK, 2011, J CLIN ENDOCR METAB, V96, pE1092, DOI 10.1210/jc.2010-2731; POSER JW, 1979, J BIOL CHEM, V254, P431; RAISZ LG, 1963, NATURE, V197, P1015, DOI 10.1038/1971015a0; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Rodriguez-Bores L, 2007, WORLD J GASTROENTERO, V13, P6156, DOI 10.3748/wjg.v13.i46.6156; Saarinen A, 2010, CLIN ENDOCRINOL, V72, P481, DOI 10.1111/j.1365-2265.2009.03680.x; Sato S, 2007, NAT MED, V13, P1234, DOI 10.1038/nm1640; Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963; Shi Y, 2008, P NATL ACAD SCI USA, V105, P20529, DOI 10.1073/pnas.0808701106; Shi ZC, 2008, J MED CHEM, V51, P3684, DOI 10.1021/jm800338j; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Vilaca T., 2011, ENDOCR REV, V32, pP3; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Warden SJ, 2010, BONE, V46, P985, DOI 10.1016/j.bone.2009.12.031; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yadav VK, 2011, J EXP MED, V208, P41, DOI 10.1084/jem.20101940; Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098; Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051; Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	90	340	356	1	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					314	320		10.1038/nature10763	http://dx.doi.org/10.1038/nature10763			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258610	Green Accepted			2022-12-28	WOS:000299210600033
J	Strowig, T; Henao-Mejia, J; Elinav, E; Flavell, R				Strowig, Till; Henao-Mejia, Jorge; Elinav, Eran; Flavell, Richard			Inflammasomes in health and disease	NATURE			English	Review							SPECK-LIKE PROTEIN; INTERLEUKIN-1-BETA CONVERTING ENZYME; CASPASE RECRUITMENT DOMAIN; TYPE-2 DIABETES-MELLITUS; NF-KAPPA-B; NALP3 INFLAMMASOME; NLRP3 INFLAMMASOME; INSULIN-RESISTANCE; CELL-DEATH; INTESTINAL INFLAMMATION	Inflammasomes are a group of protein complexes built around several proteins, including NLRP3, NLRC4, AIM2 and NLRP6. Recognition of a diverse range of microbial, stress and damage signals by inflammasomes results in direct activation of caspase-1, which subsequently induces secretion of potent pro-inflammatory cytokines and a form of cell death called pyroptosis. Inflammasome-mediated processes are important during microbial infections and also in regulating both metabolic processes and mucosal immune responses. We review the functions of the different inflammasome complexes and discuss how aberrations in them are implicated in the pathogenesis of human diseases.	[Strowig, Till; Henao-Mejia, Jorge; Elinav, Eran; Flavell, Richard] Yale Univ, Dept Immunobiol, New Haven, CT 06520 USA; [Flavell, Richard] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Yale University; Howard Hughes Medical Institute	Flavell, R (corresponding author), Yale Univ, Dept Immunobiol, New Haven, CT 06520 USA.	richard.flavell@yale.edu	Elinav, Eran/ABE-8881-2020	Elinav, Eran/0000-0002-5775-2110; Strowig, Till/0000-0003-0185-1459	Leukemia and Lymphoma Society; Cancer Research Institute; United States-Israel Educational Foundation; Israel Foundation	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Cancer Research Institute; United States-Israel Educational Foundation; Israel Foundation	We thank S. Eisenbarth, M. de Zoete, C. Thaiss, P. Licona-Limon, V. Nagy and A. Rongvaux for critically reading the manuscript, and F. Manzo for help with its submission. We apologize to those whose work was not cited owing to space constraints. T. S. and J.H.M. are supported by postdoctoral fellowships from the Leukemia and Lymphoma Society. E. E. is supported by the Cancer Research Institute (2010-2012) and the United States-Israel Educational Foundation (2009), and is the recipient of the Claire and Emmanuel G. Rosenblatt award from the American Physicians for Medicine in Israel Foundation. R. F. is an Investigator of the Howard Hughes Medical Institute.	Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Bauer C, 2010, GUT, V59, P1192, DOI 10.1136/gut.2009.197822; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724; Broz P, 2010, CELL HOST MICROBE, V8, P471, DOI 10.1016/j.chom.2010.11.007; Broz P, 2010, J EXP MED, V207, P1745, DOI 10.1084/jem.20100257; Bryan NB, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-23; Bryan NB, 2009, J IMMUNOL, V182, P3173, DOI 10.4049/jimmunol.0802367; Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chen GY, 2011, J IMMUNOL, V186, P7187, DOI 10.4049/jimmunol.1100412; Chi HH, 2004, CIRCULATION, V110, P1678, DOI 10.1161/01.CIR.0000142085.39015.31; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Denoble AE, 2011, P NATL ACAD SCI USA, V108, P2088, DOI 10.1073/pnas.1012743108; Dinarello CA, 2010, CURR OPIN ENDOCRINOL, V17, P314, DOI 10.1097/MED.0b013e32833bf6dc; Dinarello CA, 2010, EUR J IMMUNOL, V40, P599, DOI 10.1002/eji.201040319; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Elinav E, 2011, IMMUNITY, V34, P665, DOI 10.1016/j.immuni.2011.05.007; Ellebedy AH, 2011, P NATL ACAD SCI USA, V108, P2927, DOI 10.1073/pnas.1012455108; Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032; Fernandes-Alnemri T, 2010, NAT IMMUNOL, V11, P385, DOI 10.1038/ni.1859; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Feve B, 2009, NAT REV ENDOCRINOL, V5, P305, DOI 10.1038/nrendo.2009.62; Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306; Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549; Gregory SM, 2011, SCIENCE, V331, P330, DOI 10.1126/science.1199478; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Guarda G, 2009, NATURE, V460, P269, DOI 10.1038/nature08100; Hirota SA, 2011, INFLAMM BOWEL DIS, V17, P1359, DOI 10.1002/ibd.21478; Hoffman HM, 2010, CURR ALLERGY ASTHM R, V10, P229, DOI 10.1007/s11882-010-0109-z; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Hornung V, 2010, EUR J IMMUNOL, V40, P620, DOI 10.1002/eji.200940185; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Hsu LC, 2008, P NATL ACAD SCI USA, V105, P7803, DOI 10.1073/pnas.0802726105; Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108; Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861; Isoda K, 2006, J ATHEROSCLER THROMB, V13, P21, DOI 10.5551/jat.13.21; Jin MS, 2008, IMMUNITY, V29, P182, DOI 10.1016/j.immuni.2008.07.007; Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040; Kerur N, 2011, CELL HOST MICROBE, V9, P363, DOI 10.1016/j.chom.2011.04.008; Kofoed EM, 2011, NATURE, V477, P592, DOI 10.1038/nature10394; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Kuroda E, 2011, IMMUNITY, V34, P514, DOI 10.1016/j.immuni.2011.03.019; Lamkanfi M, 2007, J IMMUNOL, V178, P8022, DOI 10.4049/jimmunol.178.12.8022; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Lightfield KL, 2008, NAT IMMUNOL, V9, P1171, DOI 10.1038/ni.1646; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Menu P, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.18; Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960; Miao EA, 2010, P NATL ACAD SCI USA, V107, P3076, DOI 10.1073/pnas.0913087107; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Netea MG, 2006, NAT MED, V12, P650, DOI 10.1038/nm1415; Normand S, 2011, P NATL ACAD SCI USA, V108, P9601, DOI 10.1073/pnas.1100981108; Pazar B, 2011, J IMMUNOL, V186, P2495, DOI 10.4049/jimmunol.1001284; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891; Sander LE, 2011, NATURE, V474, P385, DOI 10.1038/nature10072; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Seino S, 2001, DIABETOLOGIA, V44, P906, DOI 10.1007/s001250100531; Siegmund B, 2001, P NATL ACAD SCI USA, V98, P13249, DOI 10.1073/pnas.231473998; Stasakova J, 2005, J GEN VIROL, V86, P185, DOI 10.1099/vir.0.80422-0; Stehlik C, 2007, J IMMUNOL, V179, P7993, DOI 10.4049/jimmunol.179.12.7993; Stienstra R, 2010, CELL METAB, V12, P593, DOI 10.1016/j.cmet.2010.11.011; Sutterwala FS, 2007, J EXP MED, V204, P3235, DOI 10.1084/jem.20071239; Taxman DJ, 2010, CELL HOST MICROBE, V8, P7, DOI 10.1016/j.chom.2010.06.005; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	100	1549	1639	19	517	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					278	286		10.1038/nature10759	http://dx.doi.org/10.1038/nature10759			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258606				2022-12-28	WOS:000299210600029
J	Kawaoka, Y				Kawaoka, Yoshihiro			Flu transmission work is urgent	NATURE			English	Editorial Material									[Kawaoka, Yoshihiro] Univ Tokyo, Tokyo 1138654, Japan; [Kawaoka, Yoshihiro] Univ Wisconsin Madison, Madison, WI 53706 USA	University of Tokyo; University of Wisconsin System; University of Wisconsin Madison	Kawaoka, Y (corresponding author), Univ Tokyo, Tokyo 1138654, Japan.	kawaokay@svm.vetmed.wisc.edu							0	44	44	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2012	482	7384					155	155		10.1038/nature10884	http://dx.doi.org/10.1038/nature10884			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	888HI	22278057	Bronze			2022-12-28	WOS:000299994100013
J	Carnes, M				Carnes, Molly			What Would Patsy Mink Think?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PREJUDICE; CLIMATE; WOMEN; GAP		[Carnes, Molly] Univ Wisconsin Madison, Dept Med, Madison, WI 53706 USA; [Carnes, Molly] Univ Wisconsin Madison, Dept Psychiat, Madison, WI 53706 USA; [Carnes, Molly] Univ Wisconsin Madison, Dept Ind & Syst Engn, Madison, WI USA; [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Carnes, M (corresponding author), Univ Wisconsin Madison, Dept Med, Madison, WI 53706 USA.	mlcarnes@wisc.edu						DEVINE PG, 1989, J PERS SOC PSYCHOL, V56, P5, DOI 10.1037/0022-3514.56.5.680; Eagly AH, 2002, PSYCHOL REV, V109, P573, DOI 10.1037//0033-295X.109.3.573; Foster SW, 2000, ACAD MED, V75, P653, DOI 10.1097/00001888-200006000-00019; Isaac C, 2011, ACAD MED, V86, P59, DOI 10.1097/ACM.0b013e318200561d; Ley TJ, 2008, SCIENCE, V322, P1472, DOI 10.1126/science.1165878; Lind DS, 2002, J SURG RES, V105, P31, DOI 10.1006/jsre.2002.6442; Lo Sasso AT, 2011, HEALTH AFFAIR, V30, P193, DOI 10.1377/hlthaff.2010.0597; Pohlhaus JR, 2011, ACAD MED, V86, P759, DOI 10.1097/ACM.0b013e31821836ff; Shollen SL, 2009, ACAD MED, V84, P87, DOI 10.1097/ACM.0b013e3181900edf; Women in U.S, WOMEN US ACAD MED ST; Wright AL, 2003, ACAD MED, V78, P500, DOI 10.1097/00001888-200305000-00015	11	5	5	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					571	572		10.1001/jama.2012.79	http://dx.doi.org/10.1001/jama.2012.79			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888GT	22318277				2022-12-28	WOS:000299992500020
J	Wilhite, AW; Fong, EA				Wilhite, Allen W.; Fong, Eric A.			Coercive Citation in Academic Publishing	SCIENCE			English	Editorial Material									[Wilhite, Allen W.; Fong, Eric A.] Univ Alabama, Coll Business Adm, Huntsville, AL 35899 USA	University of Alabama System; University of Alabama Huntsville	Wilhite, AW (corresponding author), Univ Alabama, Coll Business Adm, Huntsville, AL 35899 USA.	wilhitea@uah.edu		Wilhite, Allen/0000-0002-0787-1314				[Anonymous], 2005, NATURE, V435, P1003, DOI 10.1038/4351003a; APA, 2010, PUBL MAN APA; Lawrence PA, 2003, NATURE, V422, P259, DOI 10.1038/422259a; Monastersky R., 2005, CHRON HIGHER ED 1014; Romano NC, 2009, COMMUN ASSOC INF SYS, V25, P41; Seglen P. O., 1997, BRIT MED J, V314, P497, DOI DOI 10.1136/BMJ.314.7079.497; Smith R, 1997, BRIT MED J, V314, P461	7	251	256	1	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2012	335	6068					542	543		10.1126/science.1212540	http://dx.doi.org/10.1126/science.1212540			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	885HI	22301307				2022-12-28	WOS:000299769200028
J	Lustig, RH; Schmidt, LA; Brindis, CD				Lustig, Robert H.; Schmidt, Laura A.; Brindis, Claire D.			The toxic truth about sugar	NATURE			English	Editorial Material							FRUCTOSE		[Lustig, Robert H.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Lustig, Robert H.] Univ Calif San Francisco, Ctr Obes Assessment Study & Treatment, San Francisco, CA 94143 USA; [Schmidt, Laura A.; Brindis, Claire D.] Univ Calif San Francisco, Clin & Translat Sci Inst, San Francisco, CA 94118 USA; [Schmidt, Laura A.; Brindis, Claire D.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lustig, RH (corresponding author), Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.	rlustig@peds.ucsf.edu	Lustig, Robert/O-9380-2019; Fernandez-Revelles, Andres B/A-4391-2012	Lustig, Robert/0000-0001-6983-2639; Fernandez-Revelles, Andres B/0000-0002-8089-650X; Brindis, Claire/0000-0002-2284-3936				Babor TF, 2003, ALCOHOL NO ORDINARY; Engelhard C.L., 2009, REDUCING OBESITY POL; Finkelstein EA, 2003, HEALTH AFFAIR, V22, pW219; Garber Andrea K, 2011, Curr Drug Abuse Rev, V4, P146; Joint WHO/FAO Expert Consultation, 2003, WHO TECHN REP SER; Lustig RH, 2010, J AM DIET ASSOC, V110, P1307, DOI 10.1016/j.jada.2010.06.008; Room R, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2364; Sturm R, 2010, HEALTH AFFAIR, V29, P1052, DOI 10.1377/hlthaff.2009.0061; Tappy L, 2010, NUTRITION, V26, P1044, DOI 10.1016/j.nut.2010.02.014; Vio F., 2007, FOOD POLICY DEV COUN	10	487	501	4	242	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					27	29		10.1038/482027a	http://dx.doi.org/10.1038/482027a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22297952	Bronze			2022-12-28	WOS:000299726000014
J	Palmert, MR; Dunkel, L				Palmert, Mark R.; Dunkel, Leo			Delayed Puberty	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GONADOTROPIN-RELEASING-HORMONE; GENOME-WIDE ASSOCIATION; FOLLICLE-STIMULATING-HORMONE; IDIOPATHIC SHORT STATURE; BODY-MASS INDEX; CONSTITUTIONAL DELAY; HYPOGONADOTROPIC HYPOGONADISM; TESTOSTERONE TREATMENT; AROMATASE INHIBITOR; PREDICTIVE FACTORS	A 14-year-old boy with an unremarkable medical history presents because of lack of pubertal development. He has always been relatively short, but his growth velocity is slowing as compared with that of his peers. His height is 146 cm 957.5 in., <3rd percentile for age), and his weight is 37 kg 982 lb, 3rd percentile). His father, who is 168 cm (66.1 in.) tall, continued to grow until his second year in college; his mother is 153 cm (60.2 in.) tall and began menstruating at the age of 14.0 years. The patient's target height on the basis of the parental heights is 167 cm (65.8 in.). The physical examination reveals Tanner stage 1 pubic hair and prepubertal-sized testes. How should the boy be evaluated and treated?	[Palmert, Mark R.] Hosp Sick Children, Div Endocrinol, Toronto, ON M5G 1X8, Canada; [Palmert, Mark R.] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Palmert, Mark R.] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Dunkel, Leo] Queen Mary Univ London, Barts London Sch Med & Dent, William Harvey Res Inst, Ctr Endocrinol, London EC1M 6BQ, England	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of London; Queen Mary University London	Palmert, MR (corresponding author), Hosp Sick Children, Div Endocrinol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mark.palmert@sickkids.ca; l.dunkel@qmul.ac.uk			Novo Nordisk; Japan Chemical Research Pharmaceuticals; Sandoz of the European Society of Pediatric Endocrinology; Grand Rounds lecture at McGill University; Eli Lilly; Pfizer	Novo Nordisk(Novo Nordisk); Japan Chemical Research Pharmaceuticals; Sandoz of the European Society of Pediatric Endocrinology; Grand Rounds lecture at McGill University; Eli Lilly(Eli Lilly); Pfizer(Pfizer)	Dr. Palmert reports receiving funding as a member of the Hvidore Study of Childhood Diabetes, which is supported by Novo Nordisk; payment for lectures at the 2011 Japanese Endocrine Society Meeting and the 2011 Asahikawa Winter Conference on Molecular Medicine with support from Japan Chemical Research Pharmaceuticals; and payment for participating in a symposium sponsored by Sandoz at the 2011 Annual Meeting of the European Society of Pediatric Endocrinology, as well as for a Grand Rounds lecture at McGill University sponsored by Eli Lilly. Dr. Dunkel reports receiving lecture fees from Pfizer and payment for participating in a symposium sponsored by Sandoz at the 2011 Annual Meeting of the European Society of Pediatric Endocrinology. No other potential conflict of interest relevant to this article was reported.	Aksglaede L, 2009, PEDIATRICS, V123, pE932, DOI 10.1542/peds.2008-2491; ALBANESE A, 1995, J PEDIATR-US, V126, P545, DOI 10.1016/S0022-3476(95)70347-0; Bianco SDC, 2009, NAT REV ENDOCRINOL, V5, P569, DOI 10.1038/nrendo.2009.177; BIRO FM, 1995, J PEDIATR-US, V127, P100, DOI 10.1016/S0022-3476(95)70265-2; COUNTS DR, 1987, J CLIN ENDOCR METAB, V64, P1174, DOI 10.1210/jcem-64-6-1174; Coutant R, 2010, J CLIN ENDOCR METAB, V95, P5225, DOI 10.1210/jc.2010-1535; Elks CE, 2010, NAT GENET, V42, P1077, DOI 10.1038/ng.714; Gajdos ZKZ, 2010, MOL CELL ENDOCRINOL, V324, P21, DOI 10.1016/j.mce.2010.01.038; Gajdos ZKZ, 2008, J CLIN ENDOCR METAB, V93, P4290, DOI 10.1210/jc.2008-0981; Gianetti E, 2010, J CLIN ENDOCR METAB, V95, P2857, DOI 10.1210/jc.2009-2320; Gilsanz V, 2011, J PEDIATR-US, V158, P52, DOI 10.1016/j.jpeds.2010.06.054; Grinspon RP, 2010, J CLIN ENDOCR METAB, V95, P2811, DOI 10.1210/jc.2009-2732; Han JC, 2006, J CLIN ENDOCR METAB, V91, P2081, DOI 10.1210/jc.2005-2762; He CY, 2009, NAT GENET, V41, P724, DOI 10.1038/ng.385; Hero M, 2005, J CLIN ENDOCR METAB, V90, P6396, DOI 10.1210/jc.2005-1392; Hero M, 2010, J BONE MINER RES, V25, P1536, DOI 10.1002/jbmr.56; Lee JM, 2010, ARCH PEDIAT ADOL MED, V164, P139, DOI 10.1001/archpediatrics.2009.258; Liu PY, 2009, J CLIN ENDOCR METAB, V94, P801, DOI 10.1210/jc.2008-1648; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; Nathan BM, 2006, J PEDIATR ENDOCR MET, V19, P971; Ong KK, 2009, NAT GENET, V41, P729, DOI 10.1038/ng.382; Perry JRB, 2009, NAT GENET, V41, P648, DOI 10.1038/ng.386; Pitteloud N, 2002, J CLIN ENDOCR METAB, V87, P152, DOI 10.1210/jc.87.1.152; Pitteloud N, 2002, J CLIN ENDOCR METAB, V87, P4128, DOI 10.1210/jc.2002-020518; Raivio T, 2007, NEW ENGL J MED, V357, P863, DOI 10.1056/NEJMoa066494; Resende EAMR, 2007, J CLIN ENDOCR METAB, V92, P1424, DOI 10.1210/jc.2006-1569; RICHMAN RA, 1988, NEW ENGL J MED, V319, P1563, DOI 10.1056/NEJM198812153192402; ROSENFELD RG, 1982, PEDIATRICS, V69, P681; Sedlmeyer IL, 2002, J CLIN ENDOCR METAB, V87, P5581, DOI 10.1210/jc.2002-020862; Sedlmeyer IL, 2002, J CLIN ENDOCR METAB, V87, P1613, DOI 10.1210/jc.87.4.1613; Segal TY, 2009, J CLIN ENDOCR METAB, V94, P780, DOI 10.1210/jc.2008-0302; Shulman DI, 2008, PEDIATRICS, V121, pE975, DOI 10.1542/peds.2007-2081; SOLIMAN AT, 1995, METABOLISM, V44, P1013, DOI 10.1016/0026-0495(95)90098-5; Sorensen K, 2010, J CLIN ENDOCR METAB, V95, P263, DOI 10.1210/jc.2009-1478; Sulem P, 2009, NAT GENET, V41, P734, DOI 10.1038/ng.383; Sun SMS, 2002, PEDIATRICS, V110, P911, DOI 10.1542/peds.110.5.911; Susman EJ, 2010, ARCH PEDIAT ADOL MED, V164, P166, DOI 10.1001/archpediatrics.2009.261; Tommiska J, 2010, J CLIN ENDOCR METAB, V95, P3063, DOI 10.1210/jc.2009-2344; Vaaralahti K, 2011, FERTIL STERIL, V95, P2756, DOI 10.1016/j.fertnstert.2010.12.059; Warne DW, 2009, FERTIL STERIL, V92, P594, DOI 10.1016/j.fertnstert.2008.07.1720; Wehkalampi K, 2008, J CLIN ENDOCR METAB, V93, P723, DOI 10.1210/jc.2007-1786; Wickman S, 2001, J CLIN ENDOCR METAB, V86, P4887, DOI 10.1210/jc.86.10.4887; Wickman S, 2001, LANCET, V357, P1743, DOI 10.1016/S0140-6736(00)04895-9; Wilson DA, 2010, J PEDIATR-US, V156, P308, DOI 10.1016/j.jpeds.2009.08.038; Wit CM, 2002, J CLIN ENDOCR METAB, V87, P604; WU FCW, 1993, J CLIN ENDOCR METAB, V76, P26, DOI 10.1210/jc.76.1.26; Wu TJ, 2002, PEDIATRICS, V110, P752, DOI 10.1542/peds.110.4.752	48	203	213	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					443	453		10.1056/NEJMcp1109290	http://dx.doi.org/10.1056/NEJMcp1109290			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QX	22296078				2022-12-28	WOS:000299724400009
J	Cheneau, M; Barmettler, P; Poletti, D; Endres, M; Schauss, P; Fukuhara, T; Gross, C; Bloch, I; Kollath, C; Kuhr, S				Cheneau, Marc; Barmettler, Peter; Poletti, Dario; Endres, Manuel; Schauss, Peter; Fukuhara, Takeshi; Gross, Christian; Bloch, Immanuel; Kollath, Corinna; Kuhr, Stefan			Light-cone-like spreading of correlations in a quantum many-body system	NATURE			English	Article							MATRIX RENORMALIZATION-GROUP; LIEB-ROBINSON BOUNDS; DYNAMICS; ATOMS	In relativistic quantum field theory, information propagation is bounded by the speed of light. No such limit exists in the non-relativistic case, although in real physical systems, short-range interactions may be expected to restrict the propagation of information to finite velocities. The question of how fast correlations can spread in quantum many-body systems has been long studied(1). The existence of a maximal velocity, known as the Lieb-Robinson bound, has been shown theoretically to exist in several interacting many-body systems (for example, spins on a lattice(2-5))-such systems can be regarded as exhibiting an effective light cone that bounds the propagation speed of correlations. The existence of such a 'speed of light' has profound implications for condensed matter physics and quantum information, but has not been observed experimentally. Here we report the time-resolved detection of propagating correlations in an interacting quantum many-body system. By quenching a one-dimensional quantum gas in an optical lattice, we reveal how quasiparticle pairs transport correlations with a finite velocity across the system, resulting in an effective light cone for the quantum dynamics. Our results open perspectives for understanding the relaxation of closed quantum systems far from equilibrium(6), and for engineering the efficient quantum channels necessary for fast quantum computations(7).	[Cheneau, Marc; Endres, Manuel; Schauss, Peter; Fukuhara, Takeshi; Gross, Christian; Bloch, Immanuel; Kuhr, Stefan] Max Planck Inst Quantum Opt, D-85748 Garching, Germany; [Barmettler, Peter; Poletti, Dario; Kollath, Corinna] Univ Geneva, Dept Phys Theor, CH-1211 Geneva, Switzerland; [Bloch, Immanuel] Univ Munich, D-80799 Munich, Germany; [Kollath, Corinna] Ecole Polytech, CNRS, Ctr Phys Theor, F-91128 Palaiseau, France; [Kuhr, Stefan] Univ Strathclyde, SUPA, Glasgow G4 0NG, Lanark, Scotland	Max Planck Society; University of Geneva; University of Munich; Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris; University of Strathclyde	Cheneau, M (corresponding author), Max Planck Inst Quantum Opt, D-85748 Garching, Germany.	marc.cheneau@mpq.mpg	Gross, Christian/P-5475-2014; Cheneau, Marc/O-9312-2014; Fukuhara, Takeshi/A-6254-2014; Bloch, Immanuel/N-9169-2019; Barmettler, Peter/K-2912-2012; Kuhr, Stefan/F-7296-2011; Schauss, Peter/AAV-1298-2020; Bloch, Immanuel/G-3174-2010; Kuhr, Stefan/ABC-8654-2020; Poletti, Dario/A-3028-2009	Gross, Christian/0000-0003-2292-5234; Cheneau, Marc/0000-0001-7261-566X; Fukuhara, Takeshi/0000-0002-6702-9882; Barmettler, Peter/0000-0003-0431-6726; Kuhr, Stefan/0000-0001-8386-5357; Schauss, Peter/0000-0002-8505-5195; Bloch, Immanuel/0000-0002-0679-4759; Kuhr, Stefan/0000-0001-8386-5357; Poletti, Dario/0000-0001-5626-0176	MPG; DFG; EU; JSPS; 'Triangle de la physique'; ANR; SNSF; Fondation Ernst et Lucie Schmidheiny	MPG(Max Planck Society); DFG(German Research Foundation (DFG)); EU(European Commission); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); 'Triangle de la physique'; ANR(French National Research Agency (ANR)); SNSF(Swiss National Science Foundation (SNSF)); Fondation Ernst et Lucie Schmidheiny	We thank C. Weitenberg and J. F. Sherson for their contribution to the design and construction of the apparatus. We also thank D. Baeriswyl, T. Giamarchi, V. Gritsev and S. Huber for discussions. C. K. acknowledges previous collaboration on a related subject with A. Lauchli. We acknowledge funding by MPG, DFG, EU (NAMEQUAM, AQUTE, Marie Curie Fellowship to M. C.), JSPS (Postdoctoral Fellowship for Research Abroad to T. F.), 'Triangle de la physique', ANR (FAMOUS) and SNSF (under division II and MaNEP). Financial support for the computer cluster on which the calculations were performed was provided by the Fondation Ernst et Lucie Schmidheiny.	Bakr WS, 2009, NATURE, V462, P74, DOI 10.1038/nature08482; Bloch I, 2008, REV MOD PHYS, V80, P885, DOI 10.1103/RevModPhys.80.885; Bose S, 2007, CONTEMP PHYS, V48, P13, DOI 10.1080/00107510701342313; Bravyi S, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.050401; Cramer M, 2008, CRM SER, V8, P51; Daley AJ, 2004, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2004/04/P04005; Eisert J, 2010, REV MOD PHYS, V82, P277, DOI 10.1103/RevModPhys.82.277; Eisert J, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.240501; Endres M, 2011, SCIENCE, V334, P200, DOI [10.1126/science.1209284, 10.1126/science.1210268]; FISHER MPA, 1989, PHYS REV B, V40, P546, DOI 10.1063/1.38820; Hastings MB, 2006, COMMUN MATH PHYS, V265, P781, DOI 10.1007/s00220-006-0030-4; Hastings MB, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.104431; KIBBLE TWB, 1976, J PHYS A-MATH GEN, V9, P1387, DOI 10.1088/0305-4470/9/8/029; Kollath C, 2005, PHYS REV A, V71, DOI 10.1103/PhysRevA.71.053606; Kuhner TD, 2000, PHYS REV B, V61, P12474, DOI 10.1103/PhysRevB.61.12474; Lauchli AM, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/05/P05018; LIEB EH, 1972, COMMUN MATH PHYS, V28, P251, DOI 10.1007/BF01645779; Nachtergaele B., 2011, MUCH ADO SOMETHING W; Nachtergaele B, 2006, J STAT PHYS, V124, P1, DOI 10.1007/s10955-006-9143-6; Nachtergaele B, 2006, COMMUN MATH PHYS, V265, P119, DOI 10.1007/s00220-006-1556-1; Nachtergaele B, 2009, COMMUN MATH PHYS, V286, P1073, DOI 10.1007/s00220-008-0630-2; Polkovnikov A, 2011, REV MOD PHYS, V83, P863, DOI 10.1103/RevModPhys.83.863; Schollwock U, 2011, ANN PHYS-NEW YORK, V326, P96, DOI 10.1016/j.aop.2010.09.012; Sherson JF, 2010, NATURE, V467, P68, DOI 10.1038/nature09378; Vidal G, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.070201; White SR, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.076401; ZUREK WH, 1985, NATURE, V317, P505, DOI 10.1038/317505a0	30	562	564	3	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2012	481	7382					484	487		10.1038/nature10748	http://dx.doi.org/10.1038/nature10748			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881GY	22281597	Green Accepted, Green Submitted			2022-12-28	WOS:000299471800035
J	Bevans, M; Sternberg, EM				Bevans, Margaret; Sternberg, Esther M.			Caregiving Burden, Stress, and Health Effects Among Family Caregivers of Adult Cancer Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STEM-CELL TRANSPLANTATION; SWEAT PATCHES; WOMEN; DYSREGULATION; EXPERIENCE; CORTISOL; RISK; PATHOPHYSIOLOGY; PLASMA; CARE	Unlike professional caregivers such as physicians and nurses, informal caregivers, typically family members or friends, provide care to individuals with a variety of conditions including advanced age, dementia, and cancer. This experience is commonly perceived as a chronic stressor, and caregivers often experience negative psychological, behavioral, and physiological effects on their daily lives and health. In this report, we describe the experience of a 53-year-old woman who is the sole caregiver for her husband, who has acute myelogenous leukemia and was undergoing allogeneic hematopoietic stem cell transplantation. During his intense and unpredictable course, the caregiver's burden is complex and complicated by multiple competing priorities. Because caregivers are often faced with multiple concurrent stressful events and extended, unrelenting stress, they may experience negative health effects, mediated in part by immune and autonomic dysregulation. Physicians and their interdisciplinary teams are presented daily with individuals providing such care and have opportunity to intervene. This report describes a case that exemplifies caregiving burden and discusses the importance of identifying caregivers at risk of negative health outcomes and intervening to attenuate the stress associated with the caregiving experience. JAMA. 2012;307(4):398-403	[Bevans, Margaret] NIMH, Neuroendocrine Immunol & Behav Sect, NIH, Ctr Clin, Bethesda, MD 20892 USA; [Bevans, Margaret] US PHS, Nursing & Patient Care Serv, Hlth Clin Ctr, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Mental Health (NIMH); United States Public Health Service	Bevans, M (corresponding author), NIMH, Neuroendocrine Immunol & Behav Sect, NIH, Ctr Clin, 10 Ctr Dr,Room 2B13,MSC 1151, Bethesda, MD 20892 USA.	mbevans@cc.nih.gov			NIH Clinical Center; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002585] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL001144, ZIACL001150, ZIACL001154] Funding Source: NIH RePORTER	NIH Clinical Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); CLINICAL CENTER	The authors would like to acknowledge the family featured in the case study and for providing permission to publish their story. We also thank Leslie Wehrlen, RN, BSN, OCN; Alyson Ross, RN, MS; Stephen Klagholz, BS, Gwenyth Wallen, RN, PhD; and Clare Hastings, RN, PhD, FAAN, at the NIH Clinical Center for their support of this program of research and help with the manuscript, none of whom received compensation beyond their regular salaries.	American Medical Association, CAR SELF ASS QUEST; American MedicalAssociation, 2008, HEALTH LIF STEPS QUE; [Anonymous], PATIENT REPORTED OUT; Armaiz-Pena GN, 2009, BRAIN BEHAV IMMUN, V23, P10, DOI 10.1016/j.bbi.2008.06.007; Beattie S, 2011, PSYCHO-ONCOLOGY, V20, P1137, DOI 10.1002/pon.1962; Bevans M, 2011, PSYCHO-ONCOLOGY, V20, P615, DOI 10.1002/pon.1906; Bevans MF, 2008, SUPPORT CARE CANCER, V16, P1243, DOI 10.1007/s00520-008-0420-6; Bishop MM, 2007, J CLIN ONCOL, V25, P1403, DOI 10.1200/JCO.2006.07.5705; Bjorntorp P, 2000, INT J OBESITY, V24, pS80, DOI 10.1038/sj.ijo.0801285; Cizza G, 2008, BIOL PSYCHIAT, V64, P907, DOI 10.1016/j.biopsych.2008.05.035; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101; Epstein-Lubow G, 2010, J AM GERIATR SOC, V58, P387, DOI 10.1111/j.1532-5415.2009.02701.x; Fletcher BAS, 2008, ONCOL NURS FORUM, V35, P187, DOI 10.1188/08.ONF.E23-E44; Foster LW, 2004, J PSYCHOSOC ONCOL, V22, P1, DOI 10.1300/J077v22n02_01; Frey P, 2002, BONE MARROW TRANSPL, V30, P741, DOI 10.1038/sj.bmt.1703676; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Gouin JP, 2008, NEUROIMMUNOMODULAT, V15, P251, DOI 10.1159/000156468; Grant Marcia, 2005, Oncol Nurs Forum, V32, pE1, DOI 10.1188/05.ONF.E1-E8; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; Hodges LJ, 2005, SOC SCI MED, V60, P1, DOI 10.1016/j.socscimed.2004.04.018; Jacobs TL, 2011, PSYCHONEUROENDOCRINO, V36, P664, DOI 10.1016/j.psyneuen.2010.09.010; Juster RP, 2010, NEUROSCI BIOBEHAV R, V35, P2, DOI 10.1016/j.neubiorev.2009.10.002; Kim Y, 2008, J AGING HEALTH, V20, P483, DOI 10.1177/0898264308317533; Kim Y, 2007, PSYCHOSOM MED, V69, P283, DOI 10.1097/PSY.0b013e3180417cf4; Kurtz ME, 2004, MED SCI MONITOR, V10, pCR447; Lederbogen F, 2010, EUR J ENDOCRINOL, V163, P443, DOI 10.1530/EJE-10-0491; Lee S, 2003, AM J PREV MED, V24, P113, DOI 10.1016/S0749-3797(02)00582-2; Lucini D, 2008, EUR J CANCER, V44, P2437, DOI 10.1016/j.ejca.2008.08.006; Marques-Deak A, 2006, J IMMUNOL METHODS, V315, P99, DOI 10.1016/j.jim.2006.07.011; Nader N, 2010, TRENDS ENDOCRIN MET, V21, P277, DOI 10.1016/j.tem.2009.12.011; National Alliance for Caregiving and AARP, CAR US 2009; National Comprehensive Cancer Network, 2011, DISTR MAN CLIN RES N; Nijm J, 2009, ANN MED, V41, P224, DOI 10.1080/07853890802508934; Northouse LL, 2010, CA-CANCER J CLIN, V60, P317, DOI 10.3322/caac.20081; Pace TWW, 2007, BRAIN BEHAV IMMUN, V21, P9, DOI 10.1016/j.bbi.2006.08.009; Palos GR, 2011, CANCER-AM CANCER SOC, V117, P1070, DOI 10.1002/cncr.25695; Pasquini M, 2011, CURRENT USE OUTCOME; Phillips TM, 2001, J BIOCHEM BIOPH METH, V49, P253, DOI 10.1016/S0165-022X(01)00202-0; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Roepke SK, 2011, J HEALTH PSYCHOL, V16, P58, DOI 10.1177/1359105310369188; Rohleder N, 2009, J CLIN ONCOL, V27, P2909, DOI 10.1200/JCO.2008.18.7435; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Sherwood PR, 2008, PSYCHO-ONCOLOGY, V17, P986, DOI 10.1002/pon.1314; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; Stenberg U, 2010, PSYCHO-ONCOLOGY, V19, P1013, DOI 10.1002/pon.1670; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Steudte S, 2011, PSYCHIAT RES, V186, P310, DOI 10.1016/j.psychres.2010.09.002; Strahler J, 2010, PSYCHOPHYSIOLOGY, V47, P587, DOI 10.1111/j.1469-8986.2009.00957.x; Thayer JF, 2010, BRAIN BEHAV IMMUN, V24, P1223, DOI 10.1016/j.bbi.2010.07.247; Williams LA, 2007, ONCOL NURS FORUM, V34, P379, DOI 10.1188/07.ONF.379-387	52	344	354	8	95	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2012	307	4					398	403		10.1001/jama.2012.29	http://dx.doi.org/10.1001/jama.2012.29			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	881EP	22274687	Green Accepted			2022-12-28	WOS:000299464000026
J	Choi, YK; Moody, IS; Sims, PC; Hunt, SR; Corso, BL; Perez, I; Weiss, GA; Collins, PG				Choi, Yongki; Moody, Issa S.; Sims, Patrick C.; Hunt, Steven R.; Corso, Brad L.; Perez, Israel; Weiss, Gregory A.; Collins, Philip G.			Single-Molecule Lysozyme Dynamics Monitored by an Electronic Circuit	SCIENCE			English	Article							T4 LYSOZYME; CARBON NANOTUBES; ELECTRICAL DETECTION; DOMAIN MOTIONS; PROTEIN; FUNCTIONALIZATION; ENZYMES; DNA; TRANSISTORS; KINETICS	Tethering a single lysozyme molecule to a carbon nanotube field-effect transistor produced a stable, high-bandwidth transducer for protein motion. Electronic monitoring during 10-minute periods extended well beyond the limitations of fluorescence techniques to uncover dynamic disorder within a single molecule and establish lysozyme as a processive enzyme. On average, 100 chemical bonds are processively hydrolyzed, at 15-hertz rates, before lysozyme returns to its nonproductive, 330-hertz hinge motion. Statistical analysis differentiated single-step hinge closure from enzyme opening, which requires two steps. Seven independent time scales governing lysozyme's activity were observed. The pH dependence of lysozyme activity arises not from changes to its processive kinetics but rather from increasing time spent in either nonproductive rapid motions or an inactive, closed conformation.	[Moody, Issa S.; Weiss, Gregory A.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; [Choi, Yongki; Collins, Philip G.] Univ Calif Irvine, Inst Surface & Interface Sci, Irvine, CA 92697 USA; [Choi, Yongki; Sims, Patrick C.; Hunt, Steven R.; Corso, Brad L.; Perez, Israel; Collins, Philip G.] Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA; [Weiss, Gregory A.] Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Weiss, GA (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	gweiss@uci.edu; collinsp@uci.edu	Weiss, Gregory/AEN-4604-2022		National Cancer Institute of the NIH [R01 CA133592-01, T32CA009054]; NSF [DMR-0801271, ECCS-0802077]; NSF (Center for Chemical Innovation on Chemistry at the Space-Time Limit) [CHE-0802913]; NATIONAL CANCER INSTITUTE [R01CA133592, T32CA009054] Funding Source: NIH RePORTER	National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NSF(National Science Foundation (NSF)); NSF (Center for Chemical Innovation on Chemistry at the Space-Time Limit); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was sponsored by the National Cancer Institute of the NIH (R01 CA133592-01 and T32CA009054) and NSF (DMR-0801271, ECCS-0802077, and the Center for Chemical Innovation on Chemistry at the Space-Time Limit CHE-0802913).	ARNOLD GE, 1994, J BIOMOL STRUCT DYN, V12, P457, DOI 10.1080/07391102.1994.10508751; Artyukhin AB, 2004, LANGMUIR, V20, P1442, DOI 10.1021/la035699b; Besteman K, 2003, NANO LETT, V3, P727, DOI 10.1021/nl034139u; Bhabha G, 2011, SCIENCE, V332, P234, DOI 10.1126/science.1198542; BROOKS B, 1985, P NATL ACAD SCI USA, V82, P4995, DOI 10.1073/pnas.82.15.4995; Chen RJ, 2004, J AM CHEM SOC, V126, P1563, DOI 10.1021/ja038702m; Chen RJ, 2003, P NATL ACAD SCI USA, V100, P4984, DOI 10.1073/pnas.0837064100; Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b; Chen Y, 2003, J PHYS CHEM B, V107, P7947, DOI 10.1021/jp022406z; Claridge SA, 2011, ACS NANO, V5, P693, DOI 10.1021/nn103298x; Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; de Groot BL, 1998, PROTEINS, V31, P116, DOI 10.1002/(SICI)1097-0134(19980501)31:2<116::AID-PROT2>3.0.CO;2-K; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; Goldsmith BR, 2008, NANO LETT, V8, P189, DOI 10.1021/nl0724079; Goldsmith BR, 2007, SCIENCE, V315, P77, DOI 10.1126/science.1135303; Gruner G, 2006, ANAL BIOANAL CHEM, V384, P322, DOI 10.1007/s00216-005-3400-4; Heller I, 2008, NANO LETT, V8, P591, DOI 10.1021/nl072996i; Heredia KL, 2005, J AM CHEM SOC, V127, P16955, DOI 10.1021/ja054482w; Hu DH, 2004, BIOPHYS J, V87, P656, DOI 10.1529/biophysj.104.042101; Huang S, 2010, NAT NANOTECHNOL, V5, P868, DOI [10.1038/nnano.2010.213, 10.1038/NNANO.2010.213]; Hunt SR, 2011, NANO LETT, V11, P1055, DOI 10.1021/nl103935r; JENSEN HB, 1972, EUR J BIOCHEM, V28, P116, DOI 10.1111/j.1432-1033.1972.tb01891.x; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Li C, 2005, J AM CHEM SOC, V127, P12484, DOI 10.1021/ja053761g; Lu HP, 2004, CURR PHARM BIOTECHNO, V5, P261, DOI 10.2174/1389201043376887; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; Meroueh SO, 2006, P NATL ACAD SCI USA, V103, P4404, DOI 10.1073/pnas.0510182103; Min W, 2005, ACCOUNTS CHEM RES, V38, P923, DOI 10.1021/ar040133f; Park SJ, 2002, SCIENCE, V295, P1503, DOI 10.1126/science.1067003; Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101; Patolsky F, 2006, SCIENCE, V313, P1100, DOI 10.1126/science.1128640; Patolsky F, 2006, ANAL CHEM, V78, P4260, DOI 10.1021/ac069419j; Perello DJ, 2009, J APPL PHYS, V105, DOI 10.1063/1.3151916; Prisbrey L, 2010, J PHYS CHEM B, V114, P3330, DOI 10.1021/jp910946v; Rosenblatt S, 2002, NANO LETT, V2, P869, DOI 10.1021/nl025639a; Roy R, 2008, NAT METHODS, V5, P507, DOI 10.1038/NMETH.1208; Schedin F, 2007, NAT MATER, V6, P652, DOI 10.1038/nmat1967; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Sorgenfrei S, 2011, NANO LETT, V11, P3739, DOI 10.1021/nl201781q; Sorgenfrei S, 2011, NAT NANOTECHNOL, V6, P125, DOI 10.1038/nnano.2010.275; Star A, 2004, ORG LETT, V6, P2089, DOI 10.1021/ol0495826; Star A, 2003, NANO LETT, V3, P459, DOI 10.1021/nl0340172; Stern E, 2007, NANO LETT, V7, P3405, DOI 10.1021/nl071792z; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; TSUGITA A, 1968, J BIOL CHEM, V243, P391; Tsutsui M, 2011, SCI REP-UK, V1, DOI 10.1038/srep00046; Wang YM, 2010, J PHYS CHEM B, V114, P6669, DOI 10.1021/jp1004506; Xiao Y, 2003, SCIENCE, V299, P1877, DOI 10.1126/science.1080664; Xie SN, 2001, SINGLE MOL, V2, P229, DOI 10.1002/1438-5171(200112)2:4<229::AID-SIMO229>3.0.CO;2-9; Xu WL, 2009, J PHYS CHEM C, V113, P2393, DOI 10.1021/jp808240c; Zhang T, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/33/332001; Zhao YL, 2008, ADV MATER, V20, P1910, DOI 10.1002/adma.200702804	56	178	188	4	225	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					319	324		10.1126/science.1214824	http://dx.doi.org/10.1126/science.1214824			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267809	Green Accepted, Green Published			2022-12-28	WOS:000299273400043
J	McCartney, M				McCartney, Margaret			MEDICINE AND THE MEDIA Show us the evidence for telehealth	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Cleland JGF, 2005, J AM COLL CARDIOL, V45, P1654, DOI 10.1016/j.jacc.2005.01.050; Department of Health, 2011, WHOS SYST DEM PROGR; Goodwin N, ARE WHOLE SYSTEM DEM; Guardian Professional, GUARDIAN PROFESSIONA; Inglis SC, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub2; InPharm, INPHARM; McLean S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007717.pub2; Polisena J, 2010, J TELEMED TELECARE, V16, P120, DOI 10.1258/jtt.2009.090812	8	14	14	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	2012	344								e469	10.1136/bmj.e469	http://dx.doi.org/10.1136/bmj.e469			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YZ	22257981				2022-12-28	WOS:000300041900009
J	Adams, ST; Leveson, SH				Adams, Simon T.; Leveson, Stephen H.			Clinical prediction rules	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ARTIFICIAL NEURAL-NETWORKS; C-SPINE RULE; STATISTICS NOTES; LOGISTIC-REGRESSION; CLASSIFICATION; NOMOGRAMS; MODELS; IMPACT; SCORE		[Adams, Simon T.; Leveson, Stephen H.] York Hosp, Hull York Med Sch, Learning & Res Ctr, York YO31 8HE, N Yorkshire, England	University of Hull; University of York - UK	Adams, ST (corresponding author), York Hosp, Hull York Med Sch, Learning & Res Ctr, York YO31 8HE, N Yorkshire, England.	rpbgt@hotmail.com						ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; ALTMAN DG, 1994, BRIT MED J, V309, P188, DOI 10.1136/bmj.309.6948.188; ALVARADO A, 1986, ANN EMERG MED, V15, P557, DOI 10.1016/S0196-0644(86)80993-3; Austin PC, 2010, J CLIN EPIDEMIOL, V63, P1145, DOI 10.1016/j.jclinepi.2009.12.004; Ayer T, 2010, RADIOGRAPHICS, V30, P13, DOI 10.1148/rg.301095057; Bandiera G, 2003, ANN EMERG MED, V42, P395, DOI 10.1016/S0196-0644(03)00422-0; Bellazzi R, 2008, INT J MED INFORM, V77, P81, DOI 10.1016/j.ijmedinf.2006.11.006; Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468; Bland JM, 2002, BRIT MED J, V324, P606, DOI 10.1136/bmj.324.7337.606; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; Chun FKH, 2007, BJU INT, V99, P794, DOI 10.1111/j.1464-410X.2006.06694.x; Collins JA, 2005, HUM REPROD, V20, P2932, DOI 10.1093/humrep/dei131; Cookson J, 2010, CLIN MED, V10, P141, DOI 10.7861/clinmedicine.10-2-141; Doerfler R., 2009, UMAP J, V30, P457; Eastham JA, 1999, UROLOGY, V54, P709, DOI 10.1016/S0090-4295(99)00213-7; Gandara E, 2010, CLIN CHEST MED, V31, P629, DOI 10.1016/j.ccm.2010.07.002; Gardner W, 1996, J CONSULT CLIN PSYCH, V64, P602, DOI 10.1037/0022-006X.64.3.602; Grobman WA, 2006, AM J OBSTET GYNECOL, V194, P888, DOI 10.1016/j.ajog.2005.09.002; Hermundstad AM, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002063; Hong WD, 2011, CLINICS, V66, P119, DOI 10.1590/S1807-59322011000100021; KLEINMUNTZ B, 1990, PSYCHOL BULL, V107, P296, DOI 10.1037/0033-2909.107.3.296; LAM KK, 1983, BRIT J DIS CHEST, V77, P390, DOI 10.1016/S0007-0971(83)80076-X; Liao L, 2003, J AM COLL CARDIOL, V42, P851, DOI 10.1016/S0735-1097(03)00836-2; MARCHESE MC, 1992, PERCEPT MOTOR SKILL, V75, P583; Neuro AI., 2007, INTELLIGENT SYSTEMS; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; SIGGAARDANDERSE.O, 1963, SCAND J CLIN LAB INV, V15, P211, DOI 10.3109/00365516309079734; Stiell IG, 2003, NEW ENGL J MED, V349, P2510, DOI 10.1056/NEJMoa031375; Taylor SL, 2005, AM J SURG, V189, P219, DOI 10.1016/j.amjsurg.2004.11.010; Toll DB, 2008, J CLIN EPIDEMIOL, V61, P1085, DOI 10.1016/j.jclinepi.2008.04.008; Tsai CL, 2010, AM J EMERG MED, V28, P803, DOI 10.1016/j.ajem.2009.04.009; Tu JV, 1996, J CLIN EPIDEMIOL, V49, P1225, DOI 10.1016/S0895-4356(96)00002-9; Verma S, 1997, AM J ROENTGENOL, V169, P825, DOI 10.2214/ajr.169.3.9275906; Westreich D, 2010, J CLIN EPIDEMIOL, V63, P826, DOI 10.1016/j.jclinepi.2009.11.020; Yealy DM, 2003, NEW ENGL J MED, V349, P2553, DOI 10.1056/NEJMe038184	38	149	150	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	2012	344								d8312	10.1136/bmj.d8312	http://dx.doi.org/10.1136/bmj.d8312			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888YP	22250218	Bronze			2022-12-28	WOS:000300040900011
J	Kraft, R; Herndon, DN; Al-Mousawi, AM; Williams, FN; Finnerty, CC; Jeschke, MG				Kraft, Robert; Herndon, David N.; Al-Mousawi, Ahmed M.; Williams, Felicia N.; Finnerty, Celeste C.; Jeschke, Marc G.			Burn size and survival probability in paediatric patients in modern burn care: a prospective observational cohort study	LANCET			English	Article							MORTALITY; CHILDREN; SEPSIS; AGE	Background Patient survival after severe burn injury is largely determined by burn size. Modern developments in burn care have greatly improved survival and outcomes. However, no large analysis of outcomes in paediatric burn patients with present treatment regimens exists. This study was designed to identify the burn size associated with significant increases in morbidity and mortality in paediatric patients. Methods We undertook a single-centre prospective observational cohort study using clinical data for paediatric patients with burns of at least 30% of their total body surface area (TBSA). Patients were stratified by burn size in 10% increments, ranging from 30% to 100% TBSA, with a secondary assignment made according to the outcome of a receiver operating characteristic (ROC) analysis. Statistical analysis was done with Student's t test, chi(2) test, logistic regression, and ROC analysis, as appropriate, with significance set at p<0.05. Findings 952 severely burned paediatric patients were admitted to the centre between 1998 and 2008. All groups were comparable in age (mean 7.3 [SD 5.3] years, ranging from 6.1 [5.1] years in the 30-39% TBSA group to 9.6 [5.4] years in the 90-100% TBSA group) and sex distribution (628 [66%] boys, ranging from 59% [73/123] in the 60-69% TBSA group to 82% [42/51] in the 90-100% TBSA group). 123 (13%) patients died (increasing from 3% [five of 180] in the 30-39% TBSA group to 55% [28/51] in the 90-100% TBSA group; p<0.0001), 154 (16%) developed multiorgan failure (increasing from 6% [ten] in the 30-39% TBSA group to 45% [23] in the 90-100% TBSA group; p<0.0001), and 89 (9%) had sepsis (increasing from 2% [three] in the 30-39% TBSA group to 26% [13] in the 90-100% TBSA group; p<0.0001). Burn size of 62% TBSA was a crucial threshold for mortality (odds ratio 10.07, 95% CI 5.56-18.22, p<0.0001). Interpretation We established that, in a modern paediatric burn care setting, a burn size of roughly 60% TBSA is a crucial threshold for postburn morbidity and mortality. On the basis of these findings, we recommend that paediatric patients with greater than 60% TBSA burns be immediately transferred to a specialised burn centre. Furthermore, at the burn centre, patients should be treated with increased vigilance and improved therapies, in view of the increased risk of poor outcome associated with this burn size.	[Jeschke, Marc G.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Dept Surg,Div Plast Surg,Ross Tilley Burn Ctr, Toronto, ON M4N 3M5, Canada; [Kraft, Robert; Herndon, David N.; Al-Mousawi, Ahmed M.; Williams, Felicia N.; Finnerty, Celeste C.; Jeschke, Marc G.] Univ Texas Med Branch, Shriners Hosp Children, Galveston, TX 77550 USA; [Finnerty, Celeste C.] Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77550 USA; [Finnerty, Celeste C.] Univ Texas Med Branch, Sealy Ctr Mol Med, Galveston, TX 77550 USA; [Herndon, David N.; Al-Mousawi, Ahmed M.; Williams, Felicia N.; Finnerty, Celeste C.; Jeschke, Marc G.] Univ Texas Med Branch, Dept Surg, Galveston, TX 77550 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Jeschke, MG (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Dept Surg,Div Plast Surg,Ross Tilley Burn Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	dherndon@utmb.edu; marc.jeschke@sunnybrook.ca	Herndon, David/AAC-3354-2020		Shriners Hospitals for Children [8660, 8740, 84080, 8760, 9145]; US National Institutes of Health [R01-GM56687, R01-GM087285-01, KL2RR029875, UL1RR029876, T32-GM008256, P50-GM60338]; US National Institute on Disability and Rehabilitation Research [H133A020102, H133A070026]; Institute for Translational Sciences; CFI [25407]; Physicians' Services Incorporated Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000071] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR029875, UL1RR029876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056687, R01GM087285, P50GM060338, T32GM008256] Funding Source: NIH RePORTER	Shriners Hospitals for Children; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Institute on Disability and Rehabilitation Research; Institute for Translational Sciences; CFI(Canada Foundation for Innovation); Physicians' Services Incorporated Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank all the individuals who participated in this study; all the research staff; Eileen Figueroa and Steven Schuenke from the Department of Surgery, University of Texas Medical Branch, and Alisha Goldberg from the Institute for Translational Sciences, University of Texas Medical Branch, for their assistance in manuscript preparation; and Ronald P Mlcak, Deb Benjamin, Wesley Benjamin, Kathryn Epperson, Joanna Huddleston, Mary Kelly, Xuyang Liang, Maria Magno, Liz Montemayor, Marc Nicolai, Sylvia Ojeda, Maricela Pantoja, Cathy Reed, Lisa Magliolo Richardson, Lucille Robles, Siara Tinney, Judith A Underbrink, Pam Stevens, Mario M Celis, Holly Goode, Erick M Henry, and Maria E Cantu for their assistance in obtaining the study measurements. This work is supported by grants from Shriners Hospitals for Children (8660, 8740, 84080, 8760, and 9145), US National Institutes of Health (R01-GM56687, R01-GM087285-01, KL2RR029875, UL1RR029876, T32-GM008256, and P50-GM60338), US National Institute on Disability and Rehabilitation Research (H133A020102, H133A070026), Institute for Translational Sciences, CFI Leaders Opportunity Fund (project number 25407), and Physicians' Services Incorporated Foundation.	BONE RC, 1992, CHEST, V101, P1481, DOI 10.1378/chest.101.6.1481; BULL JP, 1949, ANN SURG, V130, P160, DOI 10.1097/00000658-194908000-00002; Cairns BA, 2008, J TRAUMA, V64, P1069, DOI 10.1097/TA.0b013e318166b7d9; Cox RA, 2007, PULM PHARMACOL THER, V20, P172, DOI 10.1016/j.pupt.2006.03.013; Cree MG, 2008, J BURN CARE RES, V29, P585, DOI 10.1097/BCR.0b013e31817db88f; Cree MG, 2009, BURNS, V35, P63, DOI 10.1016/j.burns.2008.04.010; Desai M H, 1988, J Burn Care Rehabil, V9, P637, DOI 10.1097/00004630-198811000-00014; DONG YL, 1993, J TRAUMA, V35, P340, DOI 10.1097/00005373-199309000-00002; DONG YL, 1993, J SURG RES, V54, P480, DOI 10.1006/jsre.1993.1074; Gibran NS, 2006, J BURN CARE RES, V27, P437, DOI 10.1097/01.BCR.0000226084.26680.56; Hart DW, 2001, ANN SURG, V233, P827, DOI 10.1097/00000658-200106000-00013; Jeschke MG, 2008, ANN SURG, V248, P387, DOI 10.1097/SLA.0b013e3181856241; Jeschke MG, 2008, PEDIATRICS, V121, P497, DOI 10.1542/peds.2007-1363; Jeschke MG, 2007, SHOCK, V28, P172, DOI 10.1097/shk.0b013e318047b9e2; Katakura T, 2004, J IMMUNOL, V172, P1407, DOI 10.4049/jimmunol.172.3.1407; KLEIN GL, 1995, BONE, V17, P455, DOI 10.1016/8756-3282(95)00279-1; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; Leffler M, 2007, J SURG RES, V143, P398, DOI 10.1016/j.jss.2007.01.030; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; McEntire S J, 2006, Pediatr Rehabil, V9, P57, DOI 10.1080/13638490500074576; Mlcak RP, 2006, ANN SURG, V244, P121, DOI 10.1097/01.sla.0000217678.78472.d3; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; Schinkel S, 2005, EUR J MED RES, V10, P76; Spies M, 2002, AM J PHYSIOL-GASTR L, V283, pG703, DOI 10.1152/ajpgi.00149.2001; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Wolf SE, 1997, ANN SURG, V225, P554, DOI 10.1097/00000658-199705000-00012; XIA ZF, 1992, J TRAUMA, V32, P245; ZAWACKI BE, 1979, ANN SURG, V189, P1, DOI 10.1097/00000658-197901000-00001	28	117	122	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2012	379	9820					1013	1021		10.1016/S0140-6736(11)61345-7	http://dx.doi.org/10.1016/S0140-6736(11)61345-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JE	22296810	Green Accepted			2022-12-28	WOS:000301712300029
J	Degner, JF; Pai, AA; Pique-Regi, R; Veyrieras, JB; Gaffney, DJ; Pickrell, JK; De Leon, S; Michelini, K; Lewellen, N; Crawford, GE; Stephens, M; Gilad, Y; Pritchard, JK				Degner, Jacob F.; Pai, Athma A.; Pique-Regi, Roger; Veyrieras, Jean-Baptiste; Gaffney, Daniel J.; Pickrell, Joseph K.; De Leon, Sherryl; Michelini, Katelyn; Lewellen, Noah; Crawford, Gregory E.; Stephens, Matthew; Gilad, Yoav; Pritchard, Jonathan K.			DNase I sensitivity QTLs are a major determinant of human expression variation	NATURE			English	Article							HUMAN GENE-EXPRESSION; TRANSCRIPTION FACTOR-BINDING; GENOME-WIDE ASSOCIATION; OPEN CHROMATIN; MAP; YEAST	The mapping of expression quantitative trait loci (eQTLs) has emerged as an important tool for linking genetic variation to changes in gene regulation(1-5). However, it remains difficult to identify the causal variants underlying eQTLs, and little is known about the regulatory mechanisms by which they act. Here we show that genetic variants that modify chromatin accessibility and transcription factor binding are a major mechanism through which genetic variation leads to gene expression differences among humans. We used DNase I sequencing to measure chromatin accessibility in 70 Yoruba lymphoblastoid cell lines, for which genome-wide genotypes and estimates of gene expression levels are also available(6-8). We obtained a total of 2.7 billion uniquely mapped DNase I-sequencing (DNase-seq) reads, which allowed us to produce genome-widemaps of chromatin accessibility for each individual. We identified 8,902 locations at which the DNase-seq read depth correlated significantly with genotype at a nearby single nucleotide polymorphism or insertion/deletion (false discovery rate = 10%). We call such variants 'DNase I sensitivity quantitative trait loci' (dsQTLs). We found that dsQTLs are strongly enriched within inferred transcription factor binding sites and are frequently associated with allele-specific changes in transcription factor binding. A substantial fraction (16%) of dsQTLs are also associated with variation in the expression levels of nearby genes (that is, these loci are also classified as eQTLs). Conversely, we estimate that as many as 55% of eQTL single nucleotide polymorphisms are also dsQTLs. Our observations indicate that dsQTLs are highly abundant in the human genome and are likely to be important contributors to phenotypic variation.	[Degner, Jacob F.; Pai, Athma A.; Pique-Regi, Roger; Veyrieras, Jean-Baptiste; Gaffney, Daniel J.; Pickrell, Joseph K.; Stephens, Matthew; Gilad, Yoav; Pritchard, Jonathan K.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Degner, Jacob F.] Univ Chicago, Comm Genet Genom & Syst Biol, Chicago, IL 60637 USA; [Veyrieras, Jean-Baptiste] BioMiningLabs, F-69001 Lyon, France; [Gaffney, Daniel J.; De Leon, Sherryl; Michelini, Katelyn; Lewellen, Noah; Pritchard, Jonathan K.] Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; [Crawford, Gregory E.] Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA; [Crawford, Gregory E.] Duke Univ, Div Med Genet, Dept Pediat, Sch Med, Durham, NC 27708 USA; [Stephens, Matthew] Univ Chicago, Dept Stat, Chicago, IL 60637 USA	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; Duke University; Duke University; University of Chicago	Pritchard, JK (corresponding author), Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.	gilad@uchicago.edu; pritch@uchicago.edu	Pique-Regi, Roger/A-4110-2009	Pique-Regi, Roger/0000-0002-1262-2275; Pai, Athma/0000-0002-7995-9948	National Institutes of Health [HG006123, MH084703, MH090951]; Howard Hughes Medical Institute; Chicago Fellows Program; American Heart Association; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG006123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH090951, R01MH084703] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Chicago Fellows Program; American Heart Association(American Heart Association); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank members of the Pritchard, Przeworski, Stephens and Gilad laboratories for many helpful comments or discussions, and the ENCODE Project for publicly available ChIP-seq data. This work was supported by grants from the National Institutes of Health to Y.G. (HG006123) and J.K.P. (MH084703 and MH090951), by the Howard Hughes Medical Institute, by the Chicago Fellows Program (to R. P. R.), by the American Heart Association (to A. A. P.), and by the NIH Genetics and Regulation Training grant (A.A.P. and J.F.D.).	Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10; Boyle AP, 2008, CELL, V132, P311, DOI 10.1016/j.cell.2007.12.014; Boyle AP, 2011, GENOME RES, V21, P456, DOI 10.1101/gr.112656.110; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Cheung VG, 2005, NATURE, V437, P1365, DOI 10.1038/nature04244; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Gaulton KJ, 2010, NAT GENET, V42, P255, DOI 10.1038/ng.530; Guan YT, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000279; Hesselberth JR, 2009, NAT METHODS, V6, P283, DOI [10.1038/NMETH.1313, 10.1038/nmeth.1313]; Kasowski M, 2010, SCIENCE, V328, P232, DOI 10.1126/science.1183621; McDaniell R, 2010, SCIENCE, V328, P235, DOI 10.1126/science.1184655; Mirny LA, 2010, P NATL ACAD SCI USA, V107, P22534, DOI 10.1073/pnas.0913805107; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Nica AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000895; Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888; Pickrell JK, 2010, NATURE, V464, P768, DOI 10.1038/nature08872; Pique-Regi R, 2011, GENOME RES, V21, P447, DOI 10.1101/gr.112623.110; Raveh-Sadka T, 2009, GENOME RES, V19, P1480, DOI 10.1101/gr.088260.108; Song Lingyun, 2010, Cold Spring Harb Protoc, V2010, DOI 10.1101/pdb.prot5384; Storey JD, 2004, J R STAT SOC B, V66, P187, DOI 10.1111/j.1467-9868.2004.00439.x; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Veyrieras JB, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000214; Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730; Wasson T, 2009, GENOME RES, V19, P2101, DOI 10.1101/gr.093450.109; Zheng W, 2010, NATURE, V464, P1187, DOI 10.1038/nature08934	30	419	425	4	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2012	482	7385					390	394		10.1038/nature10808	http://dx.doi.org/10.1038/nature10808			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	892LG	22307276	Green Accepted			2022-12-28	WOS:000300287100044
J	Reed, MD; DiCarlo, L; Nigg, SE; Sun, L; Frunzio, L; Girvin, SM; Schoelkopf, RJ				Reed, M. D.; DiCarlo, L.; Nigg, S. E.; Sun, L.; Frunzio, L.; Girvin, S. M.; Schoelkopf, R. J.			Realization of three-qubit quantum error correction with superconducting circuits	NATURE			English	Article							ALGORITHMS; COMPUTER; QUBITS	Quantum computers could be used to solve certain problems exponentially faster than classical computers, but are challenging to build because of their increased susceptibility to errors. However, it is possible to detect and correct errors without destroying coherence, by using quantum error correcting codes(1). The simplest of these are three-quantum-bit (three-qubit) codes, which map a one-qubit state to an entangled three-qubit state; they can correct any single phase-flip or bit-flip error on one of the three qubits, depending on the code used(2). Here we demonstrate such phase-and bit-flip error correcting codes in a superconducting circuit. We encode a quantum state(3,4), induce errors on the qubits and decode the error syndrome-a quantum state indicating which error has occurred-by reversing the encoding process. This syndrome is then used as the input to a three-qubit gate that corrects the primary qubit if it was flipped. As the code can recover from a single error on any qubit, the fidelity of this process should decrease only quadratically with error probability. We implement the correcting three-qubit gate (known as a conditional-conditional NOT, or Toffoli, gate) in 63 nanoseconds, using an interaction with the third excited state of a single qubit. We find 85 +/- 1 per cent fidelity to the expected classical action of this gate, and 78 +/- 1 per cent fidelity to the ideal quantum process matrix. Using this gate, we perform a single pass of both quantum bit- and phase-flip error correction and demonstrate the predicted first-order insensitivity to errors. Concatenation of these two codes in a nine-qubit device would correct arbitrary single-qubit errors. In combination with recent advances in superconducting qubit coherence times(5,6), this could lead to scalable quantum technology.	[Reed, M. D.; Nigg, S. E.; Sun, L.; Frunzio, L.; Girvin, S. M.; Schoelkopf, R. J.] Yale Univ, Dept Phys & Appl Phys, New Haven, CT 06520 USA; [DiCarlo, L.] Delft Univ Technol, Kavli Inst Nanosci, NL-2628 CJ Delft, Netherlands	Yale University; Delft University of Technology	Reed, MD (corresponding author), Yale Univ, Dept Phys & Appl Phys, New Haven, CT 06520 USA.	matthew.reed@yale.edu; robert.schoelkopf@yale.edu	Schoelkopf, Robert J/J-8178-2012; Frunzio, Luigi/O-1573-2019; DiCarlo, Leonardo/F-8714-2010	Frunzio, Luigi/0000-0002-0272-5481; Sun, Luyan/0000-0003-4419-5674	LPS/NSA under ARO [W911NF-09-1-0514]; NSF [DMR-0653377, DMR-1004406]; CNR-Istituto di Cibernetica, Pozzuoli, Italy; Swiss NSF; Dutch NWO	LPS/NSA under ARO; NSF(National Science Foundation (NSF)); CNR-Istituto di Cibernetica, Pozzuoli, Italy; Swiss NSF(Swiss National Science Foundation (SNSF)); Dutch NWO(Netherlands Organization for Scientific Research (NWO))	We thank G. Kirchmair, M. Mirrahimi, I. Chuang and M. Devoret for discussions. We acknowledge support from LPS/NSA under ARO contract no. W911NF-09-1-0514 and from the NSF under grants no. DMR-0653377 and no. DMR-1004406. Additional support was provided by CNR-Istituto di Cibernetica, Pozzuoli, Italy (L. F.), the Swiss NSF (S.E.N.) and the Dutch NWO (L.D.C.).	Boulant N, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.130501; Chiaverini J, 2004, NATURE, V432, P602, DOI 10.1038/nature03074; Cory DG, 1998, PHYS REV LETT, V81, P2152, DOI 10.1103/PhysRevLett.81.2152; DiCarlo L, 2010, NATURE, V467, P574, DOI 10.1038/nature09416; DiCarlo L, 2009, NATURE, V460, P240, DOI 10.1038/nature08121; Fedorov A, 2012, NATURE, V481, P170, DOI 10.1038/nature10713; Kim Z, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.120501; Knill E, 2001, PHYS REV LETT, V86, P5811, DOI 10.1103/PhysRevLett.86.5811; Lanyon BP, 2009, NAT PHYS, V5, P134, DOI 10.1038/NPHYS1150; Majer J, 2007, NATURE, V449, P443, DOI 10.1038/nature06184; Mariantoni M, 2011, SCIENCE, V334, P61, DOI 10.1126/science.1208517; Monz T, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.040501; Neeley M, 2010, NATURE, V467, P570, DOI 10.1038/nature09418; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Paik H, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.240501; Reed MD, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.173601; Schindler P, 2011, SCIENCE, V332, P1059, DOI 10.1126/science.1203329; Schreier JA, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.180502; SHOR PW, 1995, PHYS REV A, V52, pR2493, DOI 10.1103/PhysRevA.52.R2493; Shor PW, 1997, SIAM J COMPUT, V26, P1484, DOI [10.1137/S0097539795293172, 10.1137/S0036144598347011]; Strauch FW, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.167005; Tornberg L, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.214528; Wallraff A, 2004, NATURE, V431, P162, DOI 10.1038/nature02851	27	408	415	7	109	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2012	482	7385					382	385		10.1038/nature10786	http://dx.doi.org/10.1038/nature10786			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	892LG	22297844	Green Submitted			2022-12-28	WOS:000300287100042
J	Gillison, ML; Broutian, T; Pickard, RKL; Tong, ZY; Xiao, WH; Kahle, L; Graubard, BI; Chaturvedi, AK				Gillison, Maura L.; Broutian, Tatevik; Pickard, Robert K. L.; Tong, Zhen-you; Xiao, Weihong; Kahle, Lisa; Graubard, Barry I.; Chaturvedi, Anil K.			Prevalence of Oral HPV Infection in the United States, 2009-2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-PAPILLOMAVIRUS TYPES; NUTRITION EXAMINATION SURVEY; SQUAMOUS-CELL CARCINOMAS; NATIONAL-HEALTH; HEAD; VACCINE; RISK; PERSISTENCE; FEMALES; TOBACCO	Context Human papillomavirus (HPV) infection is the principal cause of a distinct form of oropharyngeal squamous cell carcinoma that is increasing in incidence among men in the United States. However, little is known about the epidemiology of oral HPV infection. Objective To determine the prevalence of oral HPV infection in the United States. Design, Setting, and Participants A cross-sectional study was conducted as part of the National Health and Nutrition Examination Survey (NHANES) 2009-2010, a statistically representative sample of the civilian noninstitutionalized US population. Men and women aged 14 to 69 years examined at mobile examination centers were eligible. Participants (N=5579) provided a 30-second oral rinse and gargle with mouthwash. For detection of HPV types, DNA purified from oral exfoliated cells was evaluated by polymerase chain reaction and type-specific hybridization. Demographic and behavioral data were obtained by standardized interview. Statistical analyses used NHANES sample weights to provide weighted prevalence estimates for the US population. Main Outcome Measures Prevalence of oral HPV infection. Results The prevalence of oral HPV infection among men and women aged 14 to 69 years was 6.9% (95% CI, 5.7%-8.3%) and of HPV type 16 was 1.0% (95% CI, 0.7%-1.3%). Oral HPV infection followed a bimodal pattern with respect to age, with peak prevalence among individuals aged 30 to 34 years (7.3%; 95% CI, 4.6%-11.4%) and 60 to 64 years (11.4%; 95% CI, 8.5%-15.1%). Men had a significantly higher prevalence than women for any oral HPV infection (10.1% [95% CI, 8.3%-12.3%] vs 3.6% [95% CI, 2.6%-5.0%], P < .001; unadjusted prevalence ratio [PR], 2.80 [95% CI, 2.02-3.88]). Infection was less common among those without vs those with a history of any type of sexual contact (0.9% [95% CI, 0.4%-1.8%] vs 7.5% [95% CI, 6.1%-9.1%], P < .001; PR, 8.69 [95% CI, 3.91-19.31]) and increased with number of sexual partners (P < .001 for trend) and cigarettes smoked per day (P < .001 for trend). Associations with age, sex, number of sexual partners, and current number of cigarettes smoked per day were independently associated with oral HPV infection in multivariable models. Conclusion Among men and women aged 14 to 69 years in the United States, the overall prevalence of oral HPV infection was 6.9%, and the prevalence was higher among men than among women. JAMA. 2012;307(7):693-703 Published online January 26, 2012. doi:10.1001/jama.2012.101	[Gillison, Maura L.; Broutian, Tatevik; Pickard, Robert K. L.; Tong, Zhen-you; Xiao, Weihong] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Kahle, Lisa] Informat Management Serv Inc, Silver Spring, MD USA; [Graubard, Barry I.; Chaturvedi, Anil K.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Information Management Services, Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gillison, ML (corresponding author), Ohio State Univ, Ctr Comprehens Canc, 420 W 12th Ave, Columbus, OH 43210 USA.	maura.gillison@osumc.edu	Chaturvedi, Anil/J-2024-2015	Chaturvedi, Anil/0000-0003-2696-8899	Merck; Ohio State University Comprehensive Cancer Center; John and Nina Cassils; National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIACP010213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023175] Funding Source: NIH RePORTER	Merck(Merck & Company); Ohio State University Comprehensive Cancer Center; John and Nina Cassils; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Gillison is the principal investigator of the unrestricted grant from Merck in support of this study and has been a consultant to Merck and GlaxoSmithKline. No other disclosures were reported.; This study was supported by the Ohio State University Comprehensive Cancer Center, Merck, John and Nina Cassils, and the Intramural Research Program of the National Cancer Institute.	[Anonymous], 2009 2010 DAT DOC CO; Applebaum KM, 2007, JNCI-J NATL CANCER I, V99, P1801, DOI 10.1093/jnci/djm233; Arnson Y, 2010, J AUTOIMMUN, V34, pJ258, DOI 10.1016/j.jaut.2009.12.003; Bottalico D, 2011, J INFECT DIS, V204, P787, DOI 10.1093/infdis/jir383; Broutian TR, 2011, J CLIN VIROL, V50, P270, DOI 10.1016/j.jcv.2010.12.005; Castellsague Xavier, 2003, J Natl Cancer Inst Monogr, P20; Castle PE, 2005, J INFECT DIS, V191, P1808, DOI 10.1086/428779; Rodriguez AC, 2010, JNCI-J NATL CANCER I, V102, P315, DOI 10.1093/jnci/djq001; Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; Dunne EF, 2007, JAMA-J AM MED ASSOC, V297, P813, DOI 10.1001/jama.297.8.813; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Finer LB, 2007, PUBLIC HEALTH REP, V122, P73, DOI 10.1177/003335490712200110; Garcia-Pineres AJ, 2006, CANCER RES, V66, P11070, DOI 10.1158/0008-5472.CAN-06-2034; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537; Gravitt PE, 2011, J CLIN INVEST, V121, P4593, DOI 10.1172/JCI57149; Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357; Hariri S, 2011, J INFECT DIS, V204, P566, DOI 10.1093/infdis/jir341; Hernandez BY, 2008, EMERG INFECT DIS, V14, P888, DOI 10.3201/eid1406.070616; Hong AM, 2010, VACCINE, V28, P3269, DOI 10.1016/j.vaccine.2010.02.098; Korn E, 1998, SURV METHODOL, V24, P193; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Markowitz LE, 2009, J INFECT DIS, V200, P1059, DOI 10.1086/604729; Marks M, 2009, J VIROL METHODS, V156, P152, DOI 10.1016/j.jviromet.2008.10.013; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339; Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971; Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4; *RES TRIANGL I, 2008, SUDAAN LANG MAN REL; Safaeian M, 2010, JNCI-J NATL CANCER I, V102, P1653, DOI 10.1093/jnci/djq384; Schwartz SM, 1998, JNCI-J NATL CANCER I, V90, P1626, DOI 10.1093/jnci/90.21.1626; Smith EM, 2010, CANCER CAUSE CONTROL, V21, P1369, DOI 10.1007/s10552-010-9564-z; Smith JS, 2008, J ADOLESCENT HEALTH, V43, pS5, DOI 10.1016/j.jadohealth.2008.07.009; Wang SS, 2004, BRIT J CANCER, V91, P1269, DOI 10.1038/sj.bjc.6602088; Wiley DJ, 2006, CANCER EPIDEM BIOMAR, V15, P915, DOI 10.1158/1055-9965.EPI-05-0963	39	709	720	2	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	2012	307	7					693	703		10.1001/jama.2012.101	http://dx.doi.org/10.1001/jama.2012.101			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	892HY	22282321	Green Accepted, Bronze			2022-12-28	WOS:000300278500026
J	Kato, A; Obara, K; Igarashi, T; Tsuruoka, H; Nakagawa, S; Hirata, N				Kato, Aitaro; Obara, Kazushige; Igarashi, Toshihiro; Tsuruoka, Hiroshi; Nakagawa, Shigeki; Hirata, Naoshi			Propagation of Slow Slip Leading Up to the 2011 M-w 9.0 Tohoku-Oki Earthquake	SCIENCE			English	Article							PACIFIC COAST; FAULT SLIP; REPEATING EARTHQUAKES; FORESHOCK SEQUENCES; DYNAMIC PROPAGATION; JAPAN TRENCH; NUCLEATION; RUPTURE; AFTERSHOCKS; INTERFACE	Many large earthquakes are preceded by one or more foreshocks, but it is unclear how these foreshocks relate to the nucleation process of the mainshock. On the basis of an earthquake catalog created using a waveform correlation technique, we identified two distinct sequences of foreshocks migrating at rates of 2 to 10 kilometers per day along the trench axis toward the epicenter of the 2011 moment magnitude (M-w) 9.0 Tohoku-Oki earthquake in Japan. The time history of quasi-static slip along the plate interface, based on small repeating earthquakes that were part of the migrating seismicity, suggests that two sequences involved slow-slip transients propagating toward the initial rupture point. The second sequence, which involved large slip rates, may have caused substantial stress loading, prompting the unstable dynamic rupture of the mainshock.	[Kato, Aitaro; Obara, Kazushige; Igarashi, Toshihiro; Tsuruoka, Hiroshi; Nakagawa, Shigeki; Hirata, Naoshi] Univ Tokyo, Earthquake Res Inst, Tokyo 113, Japan	University of Tokyo	Kato, A (corresponding author), Univ Tokyo, Earthquake Res Inst, 7-3-1 Hongo, Tokyo 113, Japan.	akato@eri.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [24740302] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank M. Nakatani for helpful comments and suggestions and the National Research Institute for Earth Science and Disaster Prevention, Tohoku Univ., and JMA for allowing us to use waveform data from their permanent stations. JMA provided us with an earthquake catalog. This study was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan, under its Observation and Research Program for Prediction of Earthquakes and Volcanic Eruptions.	Abercrombie RE, 1996, NATURE, V381, P303, DOI 10.1038/381303a0; Ando R, 2011, EARTH PLANETS SPACE, V63, P767, DOI 10.5047/eps.2011.05.016; Aso N, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL046935; Bouchon M, 2011, SCIENCE, V331, P877, DOI 10.1126/science.1197341; Chen T, 2009, J GEOPHYS RES-SOL EA, V114, DOI 10.1029/2008JB005749; DIETERICH JH, 1979, J GEOPHYS RES, V84, P2161, DOI 10.1029/JB084iB05p02161; Dodge DA, 1996, J GEOPHYS RES-SOL EA, V101, P22371, DOI 10.1029/96JB02269; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; ELLSWORTH WL, 1995, SCIENCE, V268, P851, DOI 10.1126/science.268.5212.851; Heki K, 1997, NATURE, V386, P595, DOI 10.1038/386595a0; Hirose F, 2011, EARTH PLANETS SPACE, V63, P513, DOI 10.5047/eps.2011.05.019; Houston H, 2011, NAT GEOSCI, V4, P404, DOI [10.1038/ngeo1157, 10.1038/NGEO1157]; Ide S, 2011, SCIENCE, V332, P1426, DOI 10.1126/science.1207020; Igarashi T, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL044609; Kato N, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL048565; Lapusta N, 2000, J GEOPHYS RES-SOL EA, V105, P23765, DOI 10.1029/2000JB900250; Matsuzawa T, 2004, EARTH PLANETS SPACE, V56, P803, DOI 10.1186/BF03353087; McGuire JJ, 2005, NATURE, V434, P457, DOI 10.1038/nature03377; Miyazaki S, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019410; Miyazaki S, 2011, EARTH PLANETS SPACE, V63, P637, DOI 10.5047/eps.2011.07.001; Mori J, 1996, GEOPHYS RES LETT, V23, P2437, DOI 10.1029/96GL02491; Nadeau RM, 1998, B SEISMOL SOC AM, V88, P790; Nakajima J, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026773; Obara K, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2008JB006048; OHNAKA M, 1992, TECTONOPHYSICS, V211, P149, DOI 10.1016/0040-1951(92)90057-D; Ohnaka M, 1999, J GEOPHYS RES-SOL EA, V104, P817, DOI 10.1029/1998JB900007; Peng ZG, 2005, GEOPHYS J INT, V160, P1027, DOI 10.1111/j.1365-246X.2005.02569.x; Peng ZG, 2009, NAT GEOSCI, V2, P877, DOI 10.1038/ngeo697; Shelly DR, 2007, NATURE, V446, P305, DOI 10.1038/nature05666; SHIBAZAKI B, 1992, GEOPHYS RES LETT, V19, P1189, DOI 10.1029/92GL01072; Suito H, 2011, EARTH PLANETS SPACE, V63, P615, DOI 10.5047/eps.2011.06.053; Uchida N, 2009, GONDWANA RES, V16, P527, DOI 10.1016/j.gr.2009.04.002; Yagi Y, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018189	33	454	469	4	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2012	335	6069					705	708		10.1126/science.1215141	http://dx.doi.org/10.1126/science.1215141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	889AY	22267578				2022-12-28	WOS:000300047100049
J	Deary, IJ; Yang, J; Davies, G; Harris, SE; Tenesa, A; Liewald, D; Luciano, M; Lopez, LM; Gow, AJ; Corley, J; Redmond, P; Fox, HC; Rowe, SJ; Haggarty, P; McNeill, G; Goddard, ME; Porteous, DJ; Whalley, LJ; Starr, JM; Visscher, PM				Deary, Ian J.; Yang, Jian; Davies, Gail; Harris, Sarah E.; Tenesa, Albert; Liewald, David; Luciano, Michelle; Lopez, Lorna M.; Gow, Alan J.; Corley, Janie; Redmond, Paul; Fox, Helen C.; Rowe, Suzanne J.; Haggarty, Paul; McNeill, Geraldine; Goddard, Michael E.; Porteous, David J.; Whalley, Lawrence J.; Starr, John M.; Visscher, Peter M.			Genetic contributions to stability and change in intelligence from childhood to old age	NATURE			English	Article							COMMON SNPS EXPLAIN; LATER LIFE; COGNITIVE DECLINE; LARGE PROPORTION; HUMAN HEIGHT; HERITABILITY; ABILITIES; VARIANCE; MODELS	Understanding the determinants of healthy mental ageing is a priority for society today(1,2). So far, we know that intelligence differences show high stability from childhood to old age(3,4) and there are estimates of the genetic contribution to intelligence at different ages(5,6). However, attempts to discover whether genetic causes contribute to differences in cognitive ageing have been relatively uninformative(7-10). Here we provide an estimate of the genetic and environmental contributions to stability and change in intelligence across most of the human lifetime. We used genome-wide single nucleotide polymorphism (SNP) data from 1,940 unrelated individuals whose intelligence was measured in childhood (age 11 years) and again in old age (age 65, 70 or 79 years)(11,12). We use a statistical method that allows genetic (co)variance to be estimated from SNP data on unrelated individuals(13-17). We estimate that causal genetic variants in linkage disequilibrium with common SNPs account for 0.24 of the variation in cognitive ability change from childhood to old age. Using bivariate analysis, we estimate a genetic correlation between intelligence at age 11 years and in old age of 0.62. These estimates, derived from rarely available data on lifetime cognitive measures, warrant the search for genetic causes of cognitive stability and change.	[Deary, Ian J.; Davies, Gail; Liewald, David; Luciano, Michelle; Lopez, Lorna M.; Gow, Alan J.; Corley, Janie; Redmond, Paul] Univ Edinburgh, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland; [Deary, Ian J.; Davies, Gail; Harris, Sarah E.; Liewald, David; Luciano, Michelle; Lopez, Lorna M.; Gow, Alan J.; Porteous, David J.; Starr, John M.; Visscher, Peter M.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh EH8 9JZ, Midlothian, Scotland; [Yang, Jian; Visscher, Peter M.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [Harris, Sarah E.; Tenesa, Albert; Porteous, David J.] Western Gen Hosp, Inst Genet & Mol Med, Med Genet Sect, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; [Tenesa, Albert; Rowe, Suzanne J.] Univ Edinburgh, Sch Vet Studies, Roslin Inst, Edinburgh EH25 9RG, Midlothian, Scotland; [McNeill, Geraldine; Whalley, Lawrence J.] Inst Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland; [Redmond, Paul] Univ Aberdeen, Rowett Inst Nutr & Hlth, Nutr & Epigenet Grp, Aberdeen AB21 9SB, Scotland; [Goddard, Michael E.] Australia & Victorian Dept Primary Ind, Bundoora, Vic 3083, Australia; [Goddard, Michael E.] Univ Melbourne, Dept Food & Agr Syst, Parkville, Vic 3011, Australia; [Starr, John M.] Univ Edinburgh, Alzheimer Scotland Dementia Res Ctr, Edinburgh EH8 9JZ, Midlothian, Scotland; [Visscher, Peter M.] Univ Queensland, Diamantina Inst, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; [Visscher, Peter M.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia	University of Edinburgh; University of Edinburgh; QIMR Berghofer Medical Research Institute; University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Aberdeen; University of Aberdeen; University of Melbourne; University of Edinburgh; University of Queensland; University of Queensland	Deary, IJ (corresponding author), Univ Edinburgh, Dept Psychol, 7 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.	i.deary@ed.ac.uk; peter.visscher@uq.edu.au	Porteous, David/AAA-3446-2021; Lopez, Lorna M/F-7265-2010; Rowe, Suzanne/HGF-1418-2022; Gow, Alan J/A-6070-2009; whalley, lawrence j/E-9019-2011; Luciano, Michelle/F-7277-2010; Porteous, David J/C-7289-2013; Deary, Ian J/C-6297-2009; Haggarty, Paul/C-1696-2009; Visscher, Peter/ABB-6151-2020; Yang, Jian/A-5852-2010; Lopez, Lorna/AAR-4912-2020	Porteous, David/0000-0003-1249-6106; Rowe, Suzanne/0000-0001-8727-5960; Gow, Alan J/0000-0002-3320-4531; Luciano, Michelle/0000-0003-0935-7682; Porteous, David J/0000-0003-1249-6106; Deary, Ian J/0000-0002-1733-263X; Visscher, Peter/0000-0002-2143-8760; Yang, Jian/0000-0003-2001-2474; Lopez, Lorna/0000-0002-0241-9783; McNeill, Geraldine/0000-0003-0373-650X; Goddard, Michael/0000-0001-9917-7946; Tenesa, Albert/0000-0003-4884-4475	Australian Research Council; National Health and Medical Research Council; BBSRC; EPSRC; ESRC; MRC; BBSRC [BB/F019394/1] Funding Source: UKRI; MRC [G0700704] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F019394/1] Funding Source: researchfish; Medical Research Council [G0700704B, G0700704] Funding Source: researchfish; Chief Scientist Office [CZB/4/505, ETM/55] Funding Source: researchfish	Australian Research Council(Australian Research Council); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Chief Scientist Office	We thank the cohort participants who contributed to these studies. Genotyping of the ABC1936, LBC1921 and LBC1936 cohorts and the analyses conducted here were supported by the UK's Biotechnology and Biological Sciences Research Council (BBSRC). Phenotype collection in the LBC1921 was supported by the BBSRC, The Royal Society and The Chief Scientist Office of the Scottish Government. Phenotype collection in the LBC1936 was supported by Research Into Ageing (continues as part of Age UK's The Disconnected Mind project). Phenotype collection in the ABC1936 was supported by the BBSRC, the Wellcome Trust and the Alzheimer's Research Trust. The Australian-based researchers acknowledge support from the Australian Research Council and the National Health and Medical Research Council. M. L. is a Royal Society of Edinburgh/Lloyds TSB Foundation for Scotland Personal Research Fellow. The work was undertaken in The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (G0700704/84698), for which funding from the BBSRC, EPSRC, ESRC and MRC is gratefully acknowledged.	Brayne C, 2007, NAT REV NEUROSCI, V8, P233, DOI 10.1038/nrn2091; Calvin CM, 2011, INT J EPIDEMIOL, V40, P626, DOI 10.1093/ije/dyq190; Davies G, 2011, MOL PSYCHIATR, V16, P996, DOI 10.1038/mp.2011.85; Deary IJ, 2012, ANNU REV PSYCHOL, V63, P453, DOI 10.1146/annurev-psych-120710-100353; Deary IJ, 2010, NAT REV NEUROSCI, V11, P201, DOI 10.1038/nrn2793; Deary IJ, 2009, BRIT MED BULL, V92, P135, DOI 10.1093/bmb/ldp033; Deary IJ, 2009, HUM GENET, V126, P215, DOI 10.1007/s00439-009-0655-4; Deary Ian J, 2007, BMC Geriatr, V7, P28, DOI 10.1186/1471-2318-7-28; Deary IJ, 2004, J PERS SOC PSYCHOL, V86, P130, DOI 10.1037/0022-3514.86.1.130; Deary IJ, 2000, INTELLIGENCE, V28, P49, DOI 10.1016/S0160-2896(99)00031-8; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; Finkel D, 2009, DEV PSYCHOL, V45, P820, DOI 10.1037/a0015332; Gilmour AR, 1995, BIOMETRICS, V51, P1440, DOI 10.2307/2533274; Gow AJ, 2011, PSYCHOL AGING, V26, P232, DOI 10.1037/a0021072; Harris SE, 2011, TRENDS COGN SCI, V15, P388, DOI 10.1016/j.tics.2011.07.004; Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803; Lee SH, 2011, AM J HUM GENET, V88, P294, DOI 10.1016/j.ajhg.2011.02.002; Lee T, 2010, BRAIN RES REV, V64, P1, DOI 10.1016/j.brainresrev.2010.02.001; Mcgue M, 2007, TWIN RES HUM GENET, V10, P255, DOI 10.1375/twin.10.2.255; Plassman BL, 2010, ANN INTERN MED, V153, P182, DOI 10.7326/0003-4819-153-3-201008030-00258; Powell JE, 2010, NAT REV GENET, V11, P800, DOI 10.1038/nrg2865; Reynolds CA, 2005, DEV PSYCHOL, V41, P3, DOI 10.1037/0012-1649.41.1.3; Tucker-Drob EM, 2011, NEUROPSYCHOLOGY, V25, P368, DOI 10.1037/a0022348; Visscher PM, 2010, TWIN RES HUM GENET, V13, P517, DOI 10.1375/twin.13.6.517; Yang J, 2011, NAT GENET, V43, P519, DOI 10.1038/ng.823; Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608	27	173	175	3	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2012	482	7384					212	215		10.1038/nature10781	http://dx.doi.org/10.1038/nature10781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	888HI	22258510	Green Accepted			2022-12-28	WOS:000299994100037
J	Murray, CJL; Rosenfeld, LC; Lim, SS; Andrews, KG; Foreman, KJ; Haring, D; Fullman, N; Naghavi, M; Lozano, R; Lopez, AD				Murray, Christopher J. L.; Rosenfeld, Lisa C.; Lim, Stephen S.; Andrews, Kathryn G.; Foreman, Kyle J.; Haring, Diana; Fullman, Nancy; Naghavi, Mohsen; Lozano, Rafael; Lopez, Alan D.			Global malaria mortality between 1980 and 2010: a systematic analysis	LANCET			English	Article							PLASMODIUM-FALCIPARUM MALARIA; DIAGNOSTIC GOLD STANDARDS; VERBAL AUTOPSY; CHILD-MORTALITY; NATIONAL CAUSES; 187 COUNTRIES; VALIDATION; AFRICA; HEALTH; PROGRESS	Background During the past decade, renewed global and national efforts to combat malaria have led to ambitious goals. We aimed to provide an accurate assessment of the levels and time trends in malaria mortality to aid assessment of progress towards these goals and the focusing of future efforts. Methods We systematically collected all available data for malaria mortality for the period 1980-2010, correcting for misclassification bias. We developed a range of predictive models, including ensemble models, to estimate malaria mortality with uncertainty by age, sex, country, and year. We used key predictors of malaria mortality such as Plasmodium falciparum parasite prevalence, first-line antimalarial drug resistance, and vector control. We used out-of-sample predictive validity to select the final model. Findings Global malaria deaths increased from 995 000 (95% uncertainty interval 711 000-1 412 000) in 1980 to a peak of 1 817 000 (1 430 000-2 366 000) in 2004, decreasing to 1 238 000 (929 000-1 685 000) in 2010. In Africa, malaria deaths increased from 493 000 (290 000-747 000) in 1980 to 1 613 000 (1 243 000-2 145 000) in 2004, decreasing by about 30% to 1 133 000 (848 000-1 591 000) in 2010. Outside of Africa, malaria deaths have steadily decreased from 502 000 (322 000-833 000) in 1980 to 104 000 (45 000-191 000) in 2010. We estimated more deaths in individuals aged 5 years or older than has been estimated in previous studies: 435 000 (307 000-658 000) deaths in Africa and 89 000 (33 000-177 000) deaths outside of Africa in 2010. Interpretation Our findings show that the malaria mortality burden is larger than previously estimated, especially in adults. There has been a rapid decrease in malaria mortality in Africa because of the scaling up of control activities supported by international donors. Donor support, however, needs to be increased if malaria elimination and eradication and broader health and development goals are to be met.	[Murray, Christopher J. L.; Rosenfeld, Lisa C.; Lim, Stephen S.; Andrews, Kathryn G.; Foreman, Kyle J.; Haring, Diana; Fullman, Nancy; Naghavi, Mohsen; Lozano, Rafael] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA; [Lopez, Alan D.] Univ Queensland, Sch Populat Hlth, Herston, Qld, Australia	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Queensland	Murray, CJL (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA.	cjlm@u.washington.edu	Lozano, Rafael/T-5352-2018; Lim, Stephen S/B-4055-2012; Lopez, Alan/AAA-2734-2022; Lopez, Alan D/F-1487-2010	Lozano, Rafael/0000-0002-7356-8823; Lopez, Alan D/0000-0001-5818-6512	Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation)	The Bill & Melinda Gates Foundation.	Abu-Raddad LJ, 2006, SCIENCE, V314, P1603, DOI 10.1126/science.1132338; [Anonymous], 2011, LANCET, V378, P1896, DOI 10.1016/S0140-6736(11)61826-6; [Anonymous], GLOB REP ANT EFF DRU; [Anonymous], FIN GLOB HLTH 2010 D; Barat LM, 2006, AM J TROP MED HYG, V74, P12, DOI 10.4269/ajtmh.2006.74.12; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Dhingra N, 2010, LANCET, V376, P1768, DOI 10.1016/S0140-6736(10)60831-8; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6; Flaxman AD, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-29; Flaxman AD, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000328; Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1; Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2; Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; HANDCOCK MS, 1994, J AM STAT ASSOC, V89, P368, DOI 10.2307/2290832; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0; Hay SI, 2010, LANCET, V376, P1716, DOI 10.1016/S0140-6736(10)61084-7; Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000290; Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; James SL, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-31; KNOTTERS M, 1995, GEODERMA, V67, P227, DOI 10.1016/0016-7061(95)00011-C; Korenromp E, MALARIA INCIDENCE ES; Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1; Landagan OZ, 2007, STAT PROBABIL LETT, V77, P401, DOI 10.1016/j.spl.2006.08.006; Leach-Kemon K, 2012, HEALTH AFFAIR, V31, P228, DOI 10.1377/hlthaff.2011.1154; Lengeler C, 1999, COCHRANE DATABASE SY, P1; Lim SS, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001091; Lozano R, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-32; Lysenko A.J., 1968, MEDICINSKAJA GEOGRAF, P25; Murray CJL, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-30; Murray CJL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000262; Murray CJ, GLOBAL BURDEN DIS CO; Naghavi M, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-9; Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9; Rajaratnam JK, 2010, LANCET, V375, P1704, DOI 10.1016/S0140-6736(10)60517-X; Ravishankar N, 2009, LANCET, V373, P2113, DOI 10.1016/S0140-6736(09)60881-3; Reyburn H, 2005, JAMA-J AM MED ASSOC, V293, P1461, DOI 10.1001/jama.293.12.1461; Ringwald P, 2005, SUSCEPTIBILITY PLASM; Rowe AK, 2006, INT J EPIDEMIOL, V35, P691, DOI 10.1093/ije/dyl027; Shah NK, 2011, LANCET, V377, P991, DOI 10.1016/S0140-6736(11)60378-4; Snow RW, 2004, AM J TROP MED HYG, V71, P16, DOI 10.4269/ajtmh.2004.71.16; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; STURCHLER D, 1989, PARASITOL TODAY, V5, P39, DOI 10.1016/0169-4758(89)90188-9; Tatem AJ, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-4; Trape JF, 2011, LANCET INFECT DIS, V11, P925, DOI 10.1016/S1473-3099(11)70194-3; Trape JF, 2002, TRENDS PARASITOL, V18, P224, DOI 10.1016/S1471-4922(02)02249-3; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; Trigg PI, 1998, B WORLD HEALTH ORGAN, V76, P11; United Nations News Service Section, 2011, UN ENV STRESS MAL DE; WHO, 2010, WORLD MALARIA REPORT 2010, P1; *WHO, WORLD MAL REP 2005; WHO, 2011, WORLD MAL SIT 1994; WHO, WORLD MAL REP 2011; *WHO, WORLD HLTH REP 1999; *WHO, GLOB BURD DIS GBD 20; *WHO, WORLD MAL REP 2009; World Health Organization, 2004, GLOB BURD DIS 2004 U; WORLDHEALTH ORGANIZATION (WHO), 2008, WORLD MAL REP 2008	60	1025	1059	2	260	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2012	379	9814					413	431		10.1016/S0140-6736(12)60034-8	http://dx.doi.org/10.1016/S0140-6736(12)60034-8			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891AF	22305225				2022-12-28	WOS:000300187800032
J	Iverson, V; Morris, RM; Frazar, CD; Berthiaume, CT; Morales, RL; Armbrust, EV				Iverson, Vaughn; Morris, Robert M.; Frazar, Christian D.; Berthiaume, Chris T.; Morales, Rhonda L.; Armbrust, E. Virginia			Untangling Genomes from Metagenomes: Revealing an Uncultured Class of Marine Euryarchaeota	SCIENCE			English	Article							BACTERIA; ARCHAEA; SEA; ASSEMBLAGES; METABOLISM; SEQUENCE	Ecosystems are shaped by complex communities of mostly unculturable microbes. Metagenomes provide a fragmented view of such communities, but the ecosystem functions of major groups of organisms remain mysterious. To better characterize members of these communities, we developed methods to reconstruct genomes directly from mate-paired short-read metagenomes. We closed a genome representing the as-yet uncultured marine group II Euryarchaeota, assembled de novo from 1.7% of a metagenome sequenced from surface seawater. The genome describes a motile, photo-heterotrophic cell focused on degradation of protein and lipids and clarifies the origin of proteorhodopsin. It also demonstrates that high-coverage mate-paired sequence can overcome assembly difficulties caused by interstrain variation in complex microbial communities, enabling inference of ecosystem functions for uncultured members.	[Iverson, Vaughn; Morris, Robert M.; Frazar, Christian D.; Berthiaume, Chris T.; Morales, Rhonda L.; Armbrust, E. Virginia] Univ Washington, Sch Oceanog, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Armbrust, EV (corresponding author), Univ Washington, Sch Oceanog, Box 357940, Seattle, WA 98195 USA.	armbrust@uw.edu	Morris, Robert/C-5188-2012		Gordon and Betty Moore Foundation; NSF [OCE-0723866]	Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); NSF(National Science Foundation (NSF))	We thank D. Kingsbury and T. Hunkapiller for helpful conversations about experimental design; W. Martens-Habbena, D. Stahl, and J. Baross for reviewing draft protein annotations; Q. Wang for providing the RDP classifier training set data; D. Schruth for technical support; and A. Ingalls and J. Baross for valuable comments on the draft manuscript. We are grateful to Life Technologies, Incorporated, for SOLiD sequencing of the October 2008 sample. This study was supported by a Gordon and Betty Moore Foundation Marine Microbiology Investigator Award and NSF grant OCE-0723866. Sequences reported in this study have been deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive under accession no. SRA047968 and in GenBank under accession nos. JF965490 to JF965492 and JN591771 to JN592031. The Whole Genome Shotgun project has been deposited at DNA Data Bank of Japan/European Molecular Biology Laboratory/GenBank under the accession AHCG00000000. The version described in this paper is the first version, AHCG01000000. Information regarding the custom software developed for use in this research is available at http://armbrustlab.ocean.washington.edu/software.	Azam F, 2007, NAT REV MICROBIOL, V5, P782, DOI 10.1038/nrmicro1747; Beja O, 2004, CURR OPIN BIOTECH, V15, P187, DOI 10.1016/j.copbio.2004.03.005; Beja O, 2000, ENVIRON MICROBIOL, V2, P516, DOI 10.1046/j.1462-2920.2000.00133.x; DeLong EF, 2006, SCIENCE, V311, P496, DOI 10.1126/science.1120250; Falkowski PG, 2008, SCIENCE, V320, P1034, DOI 10.1126/science.1153213; Frigaard NU, 2006, NATURE, V439, P847, DOI 10.1038/nature04435; Galand PE, 2010, LIMNOL OCEANOGR, V55, P2117, DOI 10.4319/lo.2010.55.5.2117; Ghai R, 2010, ISME J, V4, P1154, DOI 10.1038/ismej.2010.44; Herfort L, 2007, FEMS MICROBIOL ECOL, V62, P242, DOI 10.1111/j.1574-6941.2007.00397.x; Hess M, 2011, SCIENCE, V331, P463, DOI 10.1126/science.1200387; Karl DM, 2007, NAT REV MICROBIOL, V5, P759, DOI 10.1038/nrmicro1749; Koga Y, 2007, MICROBIOL MOL BIOL R, V71, P97, DOI 10.1128/MMBR.00033-06; Mardis ER, 2008, TRENDS GENET, V24, P133, DOI 10.1016/j.tig.2007.12.007; Martin-Cuadrado AB, 2008, ISME J, V2, P865, DOI 10.1038/ismej.2008.40; Moreira D, 2004, ENVIRON MICROBIOL, V6, P959, DOI 10.1111/j.1462-2920.2004.00644.x; Pernthaler A, 2002, APPL ENVIRON MICROB, V68, P661, DOI 10.1128/AEM.68.2.661-667.2002; Petrovskaya LE, 2010, FEBS LETT, V584, P4193, DOI 10.1016/j.febslet.2010.09.005; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Rappe MS, 2003, ANNU REV MICROBIOL, V57, P369, DOI 10.1146/annurev.micro.57.030502.090759; Reysenbach AL, 2008, GEOBIOLOGY, V6, P331, DOI 10.1111/j.1472-4669.2008.00152.x; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; Rusch DB, 2007, PLOS BIOL, V5, P398, DOI 10.1371/journal.pbio.0050077; Rusch DB, 2010, P NATL ACAD SCI USA, V107, P16184, DOI 10.1073/pnas.1009513107; STALEY JT, 1985, ANNU REV MICROBIOL, V39, P321, DOI 10.1146/annurev.mi.39.100185.001541; Stepanauskas R, 2007, P NATL ACAD SCI USA, V104, P9052, DOI 10.1073/pnas.0700496104; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Walsh DA, 2009, SCIENCE, V326, P578, DOI 10.1126/science.1175309; Walter JM, 2007, P NATL ACAD SCI USA, V104, P2408, DOI 10.1073/pnas.0611035104; Yooseph S, 2007, PLOS BIOL, V5, P432, DOI 10.1371/journal.pbio.0050016	29	329	339	5	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2012	335	6068					587	590		10.1126/science.1212665	http://dx.doi.org/10.1126/science.1212665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301318				2022-12-28	WOS:000299769200044
J	Bowman, D				Bowman, David			Bring elephants to Australia?	NATURE			English	Editorial Material							FIRE		Univ Tasmania, Sch Plant Sci, Hobart, Tas 7001, Australia	University of Tasmania	Bowman, D (corresponding author), Univ Tasmania, Sch Plant Sci, Private Bag 55, Hobart, Tas 7001, Australia.	david.bowman@utas.edu.au	Bowman, David M.J.S./A-2930-2011	Bowman, David M.J.S./0000-0001-8075-124X				Bond WJ, 2005, TRENDS ECOL EVOL, V20, P387, DOI 10.1016/j.tree.2005.04.025; Burgess CP, 2009, MED J AUSTRALIA, V190, P567, DOI 10.5694/j.1326-5377.2009.tb02566.x; Donlan J, 2005, NATURE, V436, P913, DOI 10.1038/436913a; Finlayson C. M., 1997, Wetlands Ecology and Management, V5, P19, DOI 10.1023/A:1008271219441; Flannery T, 1994, FUTURE EATERS ECOLOG; Johnson C, 2006, AUSTR MAMMAL EXTINCT; Johnson CN, 2007, P R SOC B, V274, P341, DOI 10.1098/rspb.2006.3711; Low T., 1999, FERAL FUTURE UNTOLD; Setterfield SA, 2010, DIVERS DISTRIB, V16, P854, DOI 10.1111/j.1472-4642.2010.00688.x; Williams RJ, 2006, AUSTRAL ECOL, V31, P925, DOI 10.1111/j.1442-9993.2006.01655.x	10	40	43	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					30	30		10.1038/482030a	http://dx.doi.org/10.1038/482030a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22297953	Bronze			2022-12-28	WOS:000299726000015
J	Murray, J; King, D				Murray, James; King, David			Oil's tipping point has passed	NATURE			English	Editorial Material									[Murray, James] Univ Washington, Sch Oceanog, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Murray, J (corresponding author), Univ Washington, Sch Oceanog, Seattle, WA 98195 USA.	jmurray@u.washington.edu	, James Murray/HCI-3547-2022	Murray, James/0000-0002-8577-7964				[Anonymous], 2011, REP DIAL OIL SANDS C; [Anonymous], 2011, ANN EN OUTL 2011 US; [Anonymous], 2007, FIND CRIT NUMB WHAT; Energy Watch Group, 2007, EWG SER, V3/2007; Hamilton JD, 2009, BROOKINGS PAP ECO AC, P215; Hirsch R.L., 2005, PEAKING WORLD OIL PR; Hirsch R.L., 2010, IMPENDING WORLD ENER; Hughes D, 2011, WILL NATURAL GAS FUE; International Energy Agency, 2008, WORLD EN OUTL 2008; National Research Council, 2007, COAL MIN PROC COAL R; Owen NA, 2010, ENERG POLICY, V38, P4743, DOI 10.1016/j.enpol.2010.02.026; Rutledge D, 2011, INT J COAL GEOL, V85, P23, DOI 10.1016/j.coal.2010.10.012; World Energy Council, 2010, 2010 SURV EN RES	13	257	259	1	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2012	481	7382					433	435		10.1038/481433a	http://dx.doi.org/10.1038/481433a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	881GY	22281577	Bronze			2022-12-28	WOS:000299471800013
J	Saeed, H; Massarweh, S				Saeed, Hayder; Massarweh, Suleiman			Hypertrophic Pulmonary Osteoarthropathy and Tripe Palms	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Saeed, Hayder; Massarweh, Suleiman] Univ Kentucky, Lexington, KY 40506 USA	University of Kentucky	Saeed, H (corresponding author), Univ Kentucky, Lexington, KY 40506 USA.	massarweh@uky.edu	Massarweh, Suleiman/O-1332-2013	Saeed, Hayder/0000-0001-5295-6088					0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					360	360		10.1056/NEJMicm1110862	http://dx.doi.org/10.1056/NEJMicm1110862			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	881EQ	22276825				2022-12-28	WOS:000299464100007
J	Dohrenwend, A				Dohrenwend, Anne			Of What Am I Afraid?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									McLaren Reg Med Ctr, Dept Internal Med Residency Program, Flint, MI USA	Michigan State University; Michigan State University College of Human Medicine	Dohrenwend, A (corresponding author), McLaren Reg Med Ctr, Dept Internal Med Residency Program, Flint, MI USA.	anned@mclaren.org							0	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2012	307	4					371	372		10.1001/jama.2012.1	http://dx.doi.org/10.1001/jama.2012.1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EP	22274683				2022-12-28	WOS:000299464000022
J	Artaxo, P				Artaxo, Paulo			Break down boundaries in climate research	NATURE			English	Editorial Material									Univ Sao Paulo, BR-05508 Sao Paulo, Brazil	Universidade de Sao Paulo	Artaxo, P (corresponding author), Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.	artaxo@if.usp.br	Artaxo, Paulo/E-8874-2010	Artaxo, Paulo/0000-0001-7754-3036					0	10	11	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2012	481	7381					239	239		10.1038/481239a	http://dx.doi.org/10.1038/481239a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	877VK	22258570				2022-12-28	WOS:000299210600004
J	Alibhai, SMH; Yun, LS; Cheung, AM; Paszat, L				Alibhai, Shabbir M. H.; Yun, Lingsong; Cheung, Angela M.; Paszat, Lawrence			Screening for Osteoporosis in Men Receiving Androgen Deprivation Therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PROSTATE-CANCER		[Alibhai, Shabbir M. H.] Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Cheung, Angela M.] Univ Hlth Network, Osteoporosis Program, Toronto, ON, Canada; [Yun, Lingsong; Paszat, Lawrence] Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Alibhai, SMH (corresponding author), Univ Hlth Network, Dept Med, Toronto, ON, Canada.	shabbir.alibhai@uhn.on.ca		Cheung, Angela M./0000-0001-8332-0744; Alibhai, Shabbir/0000-0001-7815-6046	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Alibhai SMH, 2009, J CLIN ONCOL, V27, P3452, DOI 10.1200/JCO.2008.20.0923; Duncan Graeme G, 2006, Can J Urol, V13, P2962; Ito K, 2010, ANN INTERN MED, V152, P621, DOI 10.7326/0003-4819-152-10-201005180-00002; Shahinian VB, 2005, CANCER-AM CANCER SOC, V103, P1615, DOI 10.1002/cncr.20955; Sharifi N, 2005, JAMA-J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238; Yee EFT, 2007, J GEN INTERN MED, V22, P1305, DOI 10.1007/s11606-007-0291-4	6	38	38	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2012	307	3					255	256		10.1001/jama.2011.2022	http://dx.doi.org/10.1001/jama.2011.2022			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877EY	22253389				2022-12-28	WOS:000299161200017
J	Kolbe, JJ; Leal, M; Schoener, TW; Spiller, DA; Losos, JB				Kolbe, Jason J.; Leal, Manuel; Schoener, Thomas W.; Spiller, David A.; Losos, Jonathan B.			Founder Effects Persist Despite Adaptive Differentiation: A Field Experiment with Lizards	SCIENCE			English	Article							EVOLUTION; DYNAMICS; ROLES	The extent to which random processes such as founder events contribute to evolutionary divergence is a long-standing controversy in evolutionary biology. To determine the respective contributions of founder effects and natural selection, we conducted an experiment in which brown anole (Anolis sagrei) lizard populations were established on seven small islands in the Bahamas, from male-female pairs randomly drawn from the same large-island source. These founding events generated significant among-island genetic and morphological differences that persisted throughout the course of the experiment despite all populations adapting in the predicted direction-shorter hindlimbs-in response to the narrower vegetation on the small islands. Thus, using a replicated experiment in nature, we showed that both founder effects and natural selection jointly determine trait values in these populations.	[Kolbe, Jason J.; Losos, Jonathan B.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; [Kolbe, Jason J.; Losos, Jonathan B.] Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA; [Leal, Manuel] Duke Univ, Dept Biol, Durham, NC 27708 USA; [Schoener, Thomas W.; Spiller, David A.] Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA; [Schoener, Thomas W.; Spiller, David A.] Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA	Harvard University; Harvard University; Duke University; University of California System; University of California Davis; University of California System; University of California Davis	Kolbe, JJ (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, 26 Oxford St, Cambridge, MA 02138 USA.	jjkolbe@gmail.com	Leal, Manuel/A-7220-2010		National Geographic Society [8704-09]; NSF [DEB-0444763, DEB-0949415]; Duke University	National Geographic Society(National Geographic Society); NSF(National Science Foundation (NSF)); Duke University	We thank B. Pinder, J. Piovia-Scott, D. Steinberg, Y. Stuart, C. Thornber, and C. White for assistance; the National Geographic Society (grant 8704-09), NSF (grants DEB-0444763 and DEB-0949415), and Duke University for funding; and the Bahamas Ministry of Agriculture and the Bahamas Environment, Science & Technology Commission of the Ministry of the Environment for permission to conduct this research. This material was based on work supported by NSF while one of the authors (D.A.S.) was working at NSF. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of NSF.	Aguin-Pombo D., 2009, ENCY ISLANDS, P582; Barton N. H., 1998, P102; BARTON NH, 1984, ANNU REV ECOL SYST, V15, P133, DOI 10.1146/annurev.es.15.110184.001025; Berry R. J., 1998, P35; Carson H. L., 1971, STADLER S, V3, P51; CHAKRABORTY R, 1977, EVOLUTION, V31, P347, DOI 10.1111/j.1558-5646.1977.tb01017.x; Clegg SM, 2002, EVOLUTION, V56, P2090; Coyne JA, 1997, EVOLUTION, V51, P643, DOI [10.2307/2411143, 10.1111/j.1558-5646.1997.tb03650.x]; Endler J.A., 1986, Monographs in Population Biology, pviii; Grant PR, 2002, P NATL ACAD SCI USA, V99, P7818, DOI 10.1073/pnas.132260299; Grant PR, 2001, GENETICA, V112, P359, DOI 10.1023/A:1013363032724; Grant PR, 1998, EVOLUTION ISLANDS; Kilpatrick C.W., 1981, P28; Kinnison MT, 2007, FUNCT ECOL, V21, P444, DOI 10.1111/j.1365-2435.2007.01278.x; Losos JB, 2009, ORGANISM ENVIRON, V10, P1; Losos JB, 2000, EVOLUTION, V54, P301, DOI 10.1111/j.0014-3820.2000.tb00032.x; Mayr E., 1954, EVOLUTION PROCESS, P157; Mayr E., 1963, ANIMAL SPECIES EVOLU; NEI M, 1975, EVOLUTION, V29, P1, DOI 10.2307/2407137; Price T, 2007, SPECIATION BIRDS; Reznick David, 2004, P101, DOI 10.1017/CBO9780511542022.009; Reznick DN, 2001, GENETICA, V112, P183, DOI 10.1023/A:1013352109042; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Schoener TW, 2002, ECOL MONOGR, V72, P383, DOI 10.1890/0012-9615(2002)072[0383:POACAL]2.0.CO;2; Schoener TW, 2001, SCIENCE, V294, P1525, DOI 10.1126/science.1064396; Simoes P, 2008, EVOLUTION, V62, P1817, DOI 10.1111/j.1558-5646.2008.00423.x; Spiller DA, 2007, ECOLOGY, V88, P37, DOI 10.1890/0012-9658(2007)88[37:AOIFDF]2.0.CO;2; Tarr CL, 1998, MOL ECOL, V7, P719, DOI 10.1046/j.1365-294x.1998.00385.x; TEMPLETON AR, 1980, GENETICS, V94, P1011; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610	30	96	99	3	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 2	2012	335	6072					1086	1089		10.1126/science.1209566	http://dx.doi.org/10.1126/science.1209566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ZL	22300849				2022-12-28	WOS:000300931100043
J	Delamothe, T				Delamothe, Tony			ON THE CONTRARY Migrant healthcare: public health versus politics	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												tdelamothe@bmj.com						George A, 2011, IMPACT MIGRATION CON; Goldin I, 2011, EXCEPTIONAL PEOPLE M	2	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 8	2012	344								e924	10.1136/bmj.e924	http://dx.doi.org/10.1136/bmj.e924			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IE	22318441				2022-12-28	WOS:000300279100009
J	Kazanjian, P				Kazanjian, Powel			Lifelong Curiosity: Frederick Novy and the Rat Virus	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Frederick Novy (1864-1957) was a U. S. physician, medical researcher, and influential microbiologist of the early 20th century who devised culture techniques to visualize anaerobic bacteria, parasites, and spirochetes. In 1909 he began to investigate the cause of unexplained deaths in his laboratory rats, which he hypothesized were due to an "ultramicroscopic organism" or "filterable virus." But in 1918, the test tubes he had been using for these experiments vanished from his laboratory. His dream of finding a virus as the likely cause of the mysterious deaths of his rats apparently was lost. Novy retired in 1935. Thirty-three years later, in 1951, a box containing the test tubes was discovered by chance during clean-up in preparation for a laboratory move. Novy's curiosity had not waned with time. Notified of the find, and 16 years into his retirement, he returned to his laboratory at the age of 88 to continue the experiments that he had begun more than 40 years earlier. He completed his investigations in 1953 and published his findings that a virus was indeed the unidentified organism that had swiftly killed his laboratory rats in 1909.	Univ Michigan, Taubman Ctr 3119, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kazanjian, P (corresponding author), Univ Michigan, Taubman Ctr 3119, 1500 E Med Ctr Dr,SPC 5378, Ann Arbor, MI 48109 USA.	pkazanji@umich.edu						[Anonymous], 1953, SAN FRANCISCO C 0125; [Anonymous], 1953, TIME            0202; [Anonymous], 1953, NY TIMES        0125, P18; [Anonymous], 1953, NEW YORK HERALD 0125; [Anonymous], 1953, DETROIT TIMES   0125, P7; [Anonymous], 1953, MICHIGAN ALUMNU 0314, P285; [Anonymous], 1953, CLEARWATER SUN  0125, P14; [Anonymous], 1953, SUNDAY STAR A, P16; [Anonymous], 1953, TOLEDO BLADE    0125; [Anonymous], 1953, WASHINGTON POST 0125, P4; [Anonymous], 1953, SAN DIEGO UNION 0125; [Anonymous], 1953, ANN ARBOR NEWS  1210, P4; Beijerinck M., 1899, CENT BAKTERIOL PARAS, V5, P27; Broeck CT., 1935, COMMUNICATION   0312; COLE GA, 1970, AM J EPIDEMIOL, V91, P339, DOI 10.1093/oxfordjournals.aje.a121144; De Kruif P., 1962, SWEEPING WIND, V7, P83; Furstenburg AC, 1958, PHAROS, P31; GOOD R, 1950, Med Bull (Ann Arbor), V16, P257; GOULD SE, 1958, AM J CLIN PATHOL, V29, P297, DOI 10.1093/ajcp/29.4.297; JORDAN RT, 1953, J INFECT DIS, V93, P124, DOI 10.1093/infdis/93.2.124; Lewis S., 1925, ARROWSMITH; LONG E R, 1958, Trans Stud Coll Physicians Phila, V26, P34; NATHANSON N, 1970, AM J EPIDEMIOL, V91, P328, DOI 10.1093/oxfordjournals.aje.a121143; NOVY FG, 1953, J INFECT DIS, V93, P111, DOI 10.1093/infdis/93.2.111; Novy FG., 1910, REPRINTS MICHIGAN AC, V12, P17; Novy FG., 1911, T CLIN SOC U MICHIGA, V2, P182; Novy FG., 1904, INDIANA MED J, V22, P303; Novy FG., 1914, T CLIN SOC, V5, P74; Novy FG., 1911, PHYS SURG, V33, P243; Novy FG., 1904, PHARM ERA, V31, P207; Novy FG., 1911, T CLIN SOC U MICHIGA, V2, P179; Novy FG, 1906, T ASSOC AM PHYSICIAN, V21, P456; Novy Frederick G., 1890, NOVY PAPERS U MICHIG; Novy Frederick G., 1918, NOVY PAPERS U MICHIG; Novy Frederick G., 1909, NOVY PAPERS U MICHIG; Novy Frederick G., 1911, NOVY PAPERS U MICHIG; Novy Frederick G., 1910, NOVY PAPERS U UNPUB; NUNGESTER W J, 1957, J Bacteriol, V74, P545; NUNGESTER W J, 1953, Med Bull (Ann Arbor), V19, P55; Schorer Mark, 1961, S LEWIS AM LIFE	40	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2012	156	3					234	U100		10.7326/0003-4819-156-3-201202070-00013	http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XD	22312143				2022-12-28	WOS:000299964200008
J	Cohen, PA				Cohen, Pieter A.			Assessing Supplement Safety - The FDA's Controversial Proposal	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Cohen, Pieter A.] Cambridge Hlth Alliance, Somerville, MA USA; [Cohen, Pieter A.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Cambridge Health Alliance; Harvard University; Harvard Medical School	Cohen, PA (corresponding author), Cambridge Hlth Alliance, Somerville, MA USA.							Carpenter D, 2010, PRINC STUD AM POLIT, P1; Food and Drug Administration, ENF REP JAN 26 2011; Food and Drug Administration, 2011, GUID IND DI IN PRESS; Institute of Medicine, 2004, DIET SUPPL FRAM EV S, P141	4	54	54	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					389	391		10.1056/NEJMp1113325	http://dx.doi.org/10.1056/NEJMp1113325			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	884QX	22276780	Green Published, Bronze			2022-12-28	WOS:000299724400001
J	Agrawal, S; Budetti, P				Agrawal, Shantanu; Budetti, Peter			Physician Medical Identity Theft	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Ctr Program Integr, Ctr Medicare Serv, Baltimore, MD USA; Ctr Program Integr, Ctr Medicaid Serv, Baltimore, MD USA	Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services	Agrawal, S (corresponding author), CMS Ctr Program Integr, 7500 Secur Blvd,Mail Stop AR-18-50, Baltimore, MD 21244 USA.	shantanu.agrawal1@cms.hhs.gov						Conn Joseph, 2006, Mod Healthc, V36, P26; Federal Trade Commission, 2007, 2006 ID THEFT SURV R; Federal Trade Commission, 2010, CONS SENT NETW DAT B; Fiegl C., NEW CMS PROGRAM ASSI; Mancilla Desla, 2009, Perspect Health Inf Manag, V6, p1e; Office of Inspector General U. S. Department of Health and Human Services, MED ID THEFT FRAUD I; Solow Brian K, 2010, Physician Exec, V36, P30; Sullivan KM, 2009, AM J LAW MED, V35, P647, DOI 10.1177/009885880903500406	8	6	6	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					459	460		10.1001/jama.2012.78	http://dx.doi.org/10.1001/jama.2012.78			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22298674				2022-12-28	WOS:000299728000023
J	Gong, P				Gong, Peng			Cultural history holds back Chinese research	NATURE			English	Editorial Material									[Gong, Peng] Tsinghua Univ, Ctr Earth Syst Sci, Beijing, Peoples R China; [Gong, Peng] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA	Tsinghua University; University of California System; University of California Berkeley	Gong, P (corresponding author), Tsinghua Univ, Ctr Earth Syst Sci, Beijing, Peoples R China.	penggong@berkeley.edu							0	6	7	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2012	481	7382					411	411		10.1038/481411a	http://dx.doi.org/10.1038/481411a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	881GY	22281557	Bronze			2022-12-28	WOS:000299471800004
J	Gostin, LO; Garcia, KK				Gostin, Lawrence O.; Garcia, Kelli K.			Affordable Care Act Litigation The Supreme Court and the Future of Health Care Reform	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gostin, Lawrence O.; Garcia, Kelli K.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				DeNavas-Walt C., 2009, INCOME POVERTY HLTH; Elhauge E, 2012, NEW ENGL J MED, V366, DOI 10.1056/NEJMp1113618; Holan G, COST UNCOMPENSATED C; National Health Law Program O'Neill Institute for National and Global Health Law, NAT HLTH LAW PROGR	4	9	9	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2012	307	4					369	370		10.1001/jama.2012.16	http://dx.doi.org/10.1001/jama.2012.16			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EP	22274682				2022-12-28	WOS:000299464000021
J	Tourtier, JP; Cottez, S				Tourtier, Jean-Pierre; Cottez, Sophie			Pulmonary Cement Embolism after Vertebroplasty	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Tourtier, Jean-Pierre; Cottez, Sophie] Mil Hosp Val de Grace, Paris, France	Val-de-Grace Hospital	Tourtier, JP (corresponding author), Mil Hosp Val de Grace, Paris, France.								0	14	15	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					258	258		10.1056/NEJMicm1010341	http://dx.doi.org/10.1056/NEJMicm1010341			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877RZ	22256808				2022-12-28	WOS:000299201400012
J	Landon, BE				Landon, Bruce E.			Use of Quality Indicators in Patient Care A Senior Primary Care Physician Trying to Take Good Care of His Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH INFORMATION-TECHNOLOGY; OECD COUNTRIES; MEDICAL HOME; STRUCTURAL CAPABILITIES; PERFORMANCE; IMPROVE; PAY; MANAGEMENT; MASSACHUSETTS; GUIDELINES	Dr A is a senior primary care physician who recently moved from a small private practice to a larger group-model practice. He believes he was able to provide higher-quality and more individualized care for his patients in his small practice. As Dr A has discovered, quality measurement and improvement activities in primary care have evolved from a focus on an individual patient in an examination room to a systems approach that incorporates population management. Although many frustrations remain with physicians' ability to measure and influence the quality of care received by populations of patients, quality measures and monitoring have improved and should continue to improve. However, the perspective of patients and experienced physicians like Dr A also should be incorporated into quality measurement and management systems. Dr A clearly has the welfare of his patients at heart, and his experience and perspective could help improve his organization's systems of care and identify resources to deliver the best care. JAMA. 2012;307(9):956-964 www.jama.com	[Landon, Bruce E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Landon, BE (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	Landon@hcp.med.harvard.edu						Agency for Healthcare Research and Quality, 2009, NAT HEALTHC QUAL REP; *AM AC FAM PHYS AM, 2007, JOINT PRINC PAT CTR; Anderson GF, 2008, HEALTH AFFAIR, V27, P1718, DOI 10.1377/hlthaff.27.6.1718; Anderson GF, 2007, HEALTH AFFAIR, V26, P1481, DOI 10.1377/hlthaff.26.5.1481; Anderson GF, 2000, HEALTH AFFAIR, V19, P150, DOI 10.1377/hlthaff.19.3.150; [Anonymous], 2010, MIRROR MIRROR WALL P; Audet AMJ, 2005, HEALTH AFFAIR, V24, P843, DOI 10.1377/hlthaff.24.3.843; Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; Berenson RA, 2010, J GEN INTERN MED, V25, P619, DOI 10.1007/s11606-010-1290-4; Blank L, 2003, ANN INTERN MED, V138, P839, DOI 10.7326/0003-4819-138-10-200305200-00012; Buntin MB, 2011, HEALTH AFFAIR, V30, P464, DOI 10.1377/hlthaff.2011.0178; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Campbell S, 2007, NEW ENGL J MED, V357, P181, DOI 10.1056/NEJMsr065990; Campbell SM, 2009, NEW ENGL J MED, V361, P368, DOI 10.1056/NEJMsa0807651; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Center for Medicare & Medicaid Services, NAT HLTH EXP ACC 200; Center for Medicare & Medicaid Services, PHYS QUAL REP IN; Center for Studying Health System Change, 1997, COMM TRACK STUD PHYS; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Chernew ME, 2011, HEALTH AFFAIR, V30, P51, DOI 10.1377/hlthaff.2010.0980; Chin MH, 2004, DIABETES CARE, V27, P2, DOI 10.2337/diacare.27.1.2; Damberg CL, 2010, AM J MANAG CARE, V16, P601; Davidoff F, 2008, ANN INTERN MED, V149, P670, DOI 10.7326/0003-4819-149-9-200811040-00009; Davis K, 2007, MIRROR MIRROR WALL I; Friedberg MW, 2011, J GEN INTERN MED, V26, P498, DOI 10.1007/s11606-010-1597-1; Friedberg MW, 2009, ANN INTERN MED, V151, P456, DOI 10.7326/0003-4819-151-7-200910060-00006; Friedberg MW, 2009, J GEN INTERN MED, V24, P162, DOI 10.1007/s11606-008-0856-x; Greene RA, 2004, AM J MANAG CARE, V10, P670; Hayward RA, 2007, AM J MANAG CARE, V13, P126; Hibbard JH, 2005, HEALTH AFFAIR, V24, P1150, DOI 10.1377/hlthaff.24.4.1150; Isaac T, 2009, ARCH INTERN MED, V169, P305, DOI 10.1001/archinternmed.2008.551; Jamtvedt G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub2; Kupersmith J, 2007, HEALTH AFFAIR, V26, pW156, DOI 10.1377/hlthaff.26.2.w156; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Landon BE, 2008, AM J MANAG CARE, V14, P377; Landon BE, 2007, NEW ENGL J MED, V356, P921, DOI 10.1056/NEJMsa062860; Landon BE, 2010, HEALTH AFFAIR, V29, P827, DOI 10.1377/hlthaff.2010.0016; McClellan MB, 2002, TECHNOLOGICAL CHANGE; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Merritt Hawkins, 2011 SURV FIN YEAR M; National Committee for Quality Assurance, 2010, STAT HLTH CAR QUAL R; Poon EG, 2003, J BIOMED INFORM, V36, P80, DOI 10.1016/S1532-0464(03)00061-3; Poon EG, 2010, MED CARE, V48, P203, DOI 10.1097/MLR.0b013e3181c16203; Reid RJ, 2010, HEALTH AFFAIR, V29, P835, DOI 10.1377/hlthaff.2010.0158; Rittenhouse DR, 2010, MED CARE RES REV, V67, P301, DOI 10.1177/1077558709353324; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Rosenthal MB, 2008, NEW ENGL J MED, V359, P1197, DOI 10.1056/NEJMp0804658; Shah NR, 2006, J AM MED INFORM ASSN, V13, P5, DOI 10.1197/jamia.M1868; Shekelle PG, 2002, QUAL SAF HEALTH CARE, V11, P6, DOI 10.1136/qhc.11.1.6; Simon SR, 2005, AM J MED, V118, P521, DOI 10.1016/j.amjmed.2004.12.023; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; Topel R, 2003, MEASURING GAINS MED; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Weiss KB, 2000, CHEST, V118, p53S, DOI 10.1378/chest.118.2_suppl.53S; Werner RM, 2009, JAMA-J AM MED ASSOC, V301, P1375, DOI 10.1001/jama.2009.423	56	11	11	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					956	964		10.1001/jama.2012.119	http://dx.doi.org/10.1001/jama.2012.119			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	904CU	22298564				2022-12-28	WOS:000301172100024
J	Mitchell, RN; Kilian, TM; Evans, DAD				Mitchell, Ross N.; Kilian, Taylor M.; Evans, David A. D.			Supercontinent cycles and the calculation of absolute palaeolongitude in deep time	NATURE			English	Article							TRUE POLAR WANDER; RODINIA; CORE; TECTONICS; GONDWANA; ROTATION	Traditional models of the supercontinent cycle predict that the next supercontinent-'Amasia'-will form either where Pangaea rifted (the 'introversion'(1) model) or on the opposite side of the world (the 'extroversion'(2-4) models). Here, by contrast, we develop an 'orthoversion'(5) model whereby a succeeding supercontinent forms 90 degrees away, within the great circle of subduction encircling its relict predecessor. A supercontinent aggregates over a mantle downwelling but then influences global-scale mantle convection to create an upwelling under the landmass(6). We calculate the minimum moment of inertia about which oscillatory true polar wander occurs owing to the prolate shape of the non-hydrostatic Earth(5,7). By fitting great circles to each supercontinent's true polar wander legacy, we determine that the arc distances between successive supercontinent centres (the axes of the respective minimum moments of inertia) are 88 degrees for Nuna to Rodinia and 87 degrees for Rodinia to Pangaea-as predicted by the orthoversion model. Supercontinent centres can be located back into Precambrian time, providing fixed points for the calculation of absolute palaeolongitude over billion-year timescales. Palaeogeographic reconstructions additionally constrained in palaeolongitude will provide increasingly accurate estimates of ancient plate motions and palaeobiogeographic affinities.	[Mitchell, Ross N.; Kilian, Taylor M.; Evans, David A. D.] Yale Univ, New Haven, CT 06511 USA	Yale University	Mitchell, RN (corresponding author), Yale Univ, 210 Whitney Ave, New Haven, CT 06511 USA.	ross.mitchell@yale.edu		Kilian, Taylor/0000-0001-7859-293X; Evans, David/0000-0001-8952-5273	NSF; Division Of Earth Sciences [1114432] Funding Source: National Science Foundation	NSF(National Science Foundation (NSF)); Division Of Earth Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	We are grateful for discussions with J. Besse, W. Bleeker, M. Brandon, I. Rose and L. Tauxe, editorial suggestions from P. Hoffman and B. Skinner, and reviews from B. Steinberger and R. Van der Voo. R.N.M. was funded by an NSF Graduate Research Fellowship.	Becker TW, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000168; Burke K, 2008, EARTH PLANET SC LETT, V265, P49, DOI 10.1016/j.epsl.2007.09.042; CAPUTO MV, 1985, GEOL SOC AM BULL, V96, P1020, DOI 10.1130/0016-7606(1985)96<1020:MOGCAG>2.0.CO;2; CELALSENGOR AM, 1979, NATURE, V279, P590, DOI 10.1038/279590a0; Cogne JP, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000227; Collins WJ, 2003, EARTH PLANET SC LETT, V205, P225, DOI 10.1016/S0012-821X(02)01043-9; Deschamps F, 2011, NAT GEOSCI, V4, P879, DOI [10.1038/NGEO1295, 10.1038/ngeo1295]; Evans DAD, 2003, TECTONOPHYSICS, V362, P303, DOI 10.1016/S0040-1951(02)000642-X; Evans DAD, 2011, GEOLOGY, V39, P443, DOI 10.1130/G31654.1; Evans DAD, 2009, GEOL SOC SPEC PUBL, V327, P371, DOI 10.1144/SP327.16; Evans DAD, 2010, NATURE, V466, P326, DOI 10.1038/466326a; FORSYTH D, 1975, GEOPHYS J ROY ASTR S, V43, P163, DOI 10.1111/j.1365-246X.1975.tb00631.x; Garnero EJ, 2007, GEOL SOC AM SPEC PAP, V430, P79, DOI 10.1130/2007.2430(05); GOLD T, 1955, NATURE, V175, P526, DOI 10.1038/175526a0; Gonnermann HM, 2009, NATURE, V459, P560, DOI 10.1038/nature08018; HARTNADY CJH, 1991, NATURE, V352, P476, DOI 10.1038/352476d0; Hatton CJ, 1997, S AFR J GEOL, V100, P301; Hoffman PF., 1997, EARTH STRUCTURE INTR, P459; KIRSCHVINK JL, 1980, GEOPHYS J ROY ASTR S, V62, P699, DOI 10.1111/j.1365-246X.1980.tb02601.x; Li XH, 2004, PRECAMBRIAN RES, V132, P405, DOI 10.1016/j.precamres.2004.03.008; Li ZX, 2008, PRECAMBRIAN RES, V160, P179, DOI 10.1016/j.precamres.2007.04.021; Li ZX, 2011, GEOLOGY, V39, P39, DOI 10.1130/G31461.1; Li ZX, 2009, PHYS EARTH PLANET IN, V176, P143, DOI 10.1016/j.pepi.2009.05.004; Macdonald FA, 2010, SCIENCE, V327, P1241, DOI 10.1126/science.1183325; Maloof AC, 2006, GEOL SOC AM BULL, V118, P1099, DOI 10.1130/B25892.1; Mardia K.V., 1977, APPL STAT, V26, P238, DOI DOI 10.2307/2346963; McCausland PJA, 2011, PRECAMBRIAN RES, V187, P58, DOI 10.1016/j.precamres.2011.02.004; MCFADDEN PL, 1990, GEOPHYS J INT, V103, P163, DOI 10.1111/j.1365-246X.1990.tb01761.x; Mitchell RN, 2010, GEOLOGY, V38, P755, DOI 10.1130/G30910.1; Murphy JB, 2009, GONDWANA RES, V15, P408, DOI 10.1016/j.gr.2008.09.005; NANCE RD, 1988, SCI AM, V259, P72, DOI 10.1038/scientificamerican0788-72; Pavoni N, 2008, SWISS J GEOSCI, V101, P629, DOI 10.1007/s00015-008-1284-y; Schmidt PW, 2010, GEOPHYS J INT, V182, P711, DOI 10.1111/j.1365-246X.2010.04652.x; Steinberger B, 2008, NATURE, V452, P620, DOI 10.1038/nature06824; Swanson-Hysell NL, 2009, NAT GEOSCI, V2, P713, DOI 10.1038/NGEO622; Torsvik TH, 2002, GEOPHYS J INT, V151, P771, DOI 10.1046/j.1365-246X.2002.01799.x; Torsvik TH, 2008, REV GEOPHYS, V46, DOI 10.1029/2007RG000227; Torsvik TH, 2010, NATURE, V466, P352, DOI 10.1038/nature09216; VANDERVOO R, 1994, EARTH PLANET SC LETT, V122, P239, DOI 10.1016/0012-821X(94)90063-9; Veevers JJ, 1997, J GEOL, V105, P225, DOI 10.1086/515914; Zhong SJ, 2007, EARTH PLANET SC LETT, V261, P551, DOI 10.1016/j.epsl.2007.07.049	41	100	114	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					208	U96		10.1038/nature10800	http://dx.doi.org/10.1038/nature10800			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22318605				2022-12-28	WOS:000299994100036
J	Earn, DJD; He, DH; Loeb, MB; Fonseca, K; Lee, BE; Dushoff, J				Earn, David J. D.; He, Daihai; Loeb, Mark B.; Fonseca, Kevin; Lee, Bonita E.; Dushoff, Jonathan			Effects of School Closure on Incidence of Pandemic Influenza in Alberta, Canada	ANNALS OF INTERNAL MEDICINE			English	Article							ABSOLUTE-HUMIDITY; H1N1; TRANSMISSION; INFECTION; TIME; INTERVENTION; VACCINATION; STRATEGIES; EVOLUTION; INFERENCE	Background: Control of pandemic influenza by social-distancing measures, such as school closures, is a controversial aspect of pandemic planning. However, investigations of the extent to which these measures actually affect the progression of a pandemic have been limited. Objective: To examine correlations between the incidence of pandemic H1N1 (pH1N1) influenza in Alberta, Canada, in 2009 and school closures or weather changes, and to estimate the effects of school closures and weather changes on pH1N1 transmission. Design: Mathematical transmission models were fit to data that compared the pattern of confirmed pH1N1 cases with the school calendar and weather patterns. Setting: Alberta, Canada, from 19 April 2009 to 2 January 2010. Data Sources: 2009 virologic test results, 2006 census data, 2009 daily temperature and humidity data, and 2009 school calendars. Measurements: Age-specific daily counts of positive results for pH1N1 from the complete database of 35 510 specimens submitted to the Alberta Provincial Laboratory for Public Health for virologic testing from 19 April 2009 to 2 January 2010. Results: The ending and restarting of school terms had a major effect in attenuating the first wave and starting the second wave of pandemic influenza cases. Mathematical models suggested that school closure reduced transmission among school-age children by more than 50% and that this was a key factor in interrupting transmission. The models also indicated that seasonal changes in weather had a significant effect on the temporal pattern of the epidemic. Limitations: Data probably represent a small sample of all viral infections. The mathematical models make simplifying assumptions in order to make simulations and analysis feasible. Conclusion: Analysis of data from unrestricted virologic testing during an influenza pandemic provides compelling evidence that closing schools can have dramatic effects on transmission of pandemic influenza. School closure seems to be an effective strategy for slowing the spread of pandemic influenza in countries with social contact networks similar to those in Canada.	[Earn, David J. D.] McMaster Univ, Dept Math & Stat, Hamilton, ON L8S 4K1, Canada; Univ Calgary, Calgary, AB, Canada; Edmonton Clin Hlth Acad, Edmonton, AB, Canada	McMaster University; University of Calgary	Earn, DJD (corresponding author), McMaster Univ, Dept Math & Stat, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	earn@math.mcmaster.ca; daihai@math.mcmaster.ca	He, Daihai/AAT-8735-2021; He, Daihai/A-9347-2008	Earn, David/0000-0002-7562-1341; He, Daihai/0000-0003-3253-654X	Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Public Health Agency of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Public Health Agency of Canada	Grant Support: By the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Public Health Agency of Canada.	Aiello AE, 2010, AM J INFECT CONTROL, V38, P251, DOI 10.1016/j.ajic.2009.12.007; Aiello AE, 2010, J INFECT DIS, V201, P491, DOI 10.1086/650396; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Alberta Health Services, 2009, RESTR INFL RESP VIR; ANDERSON R M, 1991; Basta NE, 2009, AM J EPIDEMIOL, V170, P679, DOI 10.1093/aje/kwp237; Bootsma MCJ, 2007, P NATL ACAD SCI USA, V104, P7588, DOI 10.1073/pnas.0611071104; Breto C, 2009, ANN APPL STAT, V3, P319, DOI 10.1214/08-AOAS201; Burnham K.P., 2002, MODEL SELECTION MULT, VSecond edition; Campbell G.S., 1998, INTRO ENV BIOPHYSICS, Vsecond, DOI [10.1007/978-1-4612-1626-1, DOI 10.1007/978-1-4612-1626-1]; Cauchemez S, 2008, NATURE, V452, P750, DOI 10.1038/nature06732; Cauchemez S, 2009, LANCET INFECT DIS, V9, P473, DOI 10.1016/S1473-3099(09)70176-8; Doucet A., 2001, SEQUENTIAL MONTE CAR; Dushoff J, 2004, P NATL ACAD SCI USA, V101, P16915, DOI 10.1073/pnas.0407293101; Earn DJD, 2002, TRENDS ECOL EVOL, V17, P334, DOI 10.1016/S0169-5347(02)02502-8; Earn DJD, 2009, MATH BIOL, V14, P151; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062; Ghani AC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004383; GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3; Government of Alberta, 2006, 2006 CENS AN ALB PRO; Hatchett RJ, 2007, P NATL ACAD SCI USA, V104, P7582, DOI 10.1073/pnas.0610941104; He DH, 2011, THEOR ECOL-NETH, V4, P283, DOI 10.1007/s12080-011-0123-3; He DH, 2010, J R SOC INTERFACE, V7, P271, DOI 10.1098/rsif.2009.0151; Ionides EL, 2006, P NATL ACAD SCI USA, V103, P18438, DOI 10.1073/pnas.0603181103; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Katriel G, 2011, J R SOC INTERFACE, V8, P856, DOI 10.1098/rsif.2010.0515; King AA, 2008, NATURE, V454, P877, DOI 10.1038/nature07084; Lee BE, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-277; Lipsitch M, 2009, NEW ENGL J MED, V361, P112, DOI 10.1056/NEJMp0904380; Loeb M, 2010, JAMA-J AM MED ASSOC, V303, P943, DOI 10.1001/jama.2010.250; LONDON WP, 1973, AM J EPIDEMIOL, V98, P453, DOI 10.1093/oxfordjournals.aje.a121575; Lowen AC, 2007, PLOS PATHOG, V3, P1470, DOI 10.1371/journal.ppat.0030151; Ma JL, 2006, MATH BIOSCI ENG, V3, P161; Miller E, 2010, LANCET, V375, P1100, DOI 10.1016/S0140-6736(09)62126-7; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; Mukhi SN, 2010, ONLINE J PUBLIC HLTH, P2; Ontario Ministry of Health and Long-Term Care, 2009, GUID MAN PAT INFL LI; Oxford JS, 2000, REV MED VIROL, V10, P119, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;119::AID-RMV272&gt;3.0.CO;2-O; Pourbohloul B, 2009, INFLUENZA OTHER RESP, V3, P215, DOI 10.1111/j.1750-2659.2009.00100.x; Pulinets SA, 2006, ANN GEOPHYS-GERMANY, V24, P835, DOI 10.5194/angeo-24-835-2006; Shaman Jeffrey, 2009, PLoS Curr, V2, pRRN1138, DOI 10.1371/currents.RRN1138; Shaman J, 2009, P NATL ACAD SCI USA, V106, P3243, DOI 10.1073/pnas.0806852106; Shoji M, 2011, TOHOKU J EXP MED, V224, P251, DOI 10.1620/tjem.224.251; Svensson A, 2007, MATH BIOSCI, V208, P300, DOI 10.1016/j.mbs.2006.10.010; Tuite AR, 2010, CAN MED ASSOC J, V182, P128, DOI 10.1503/cmaj.091807; World Health Organization, 2010, PAND H1N1 2010 UPD 1; World Health Organization, PAND H1N1 2009 UPD 7; Wu JT, 2010, EMERG INFECT DIS, V16, P538, DOI 10.3201/eid1603.091216; Yang Y, 2009, SCIENCE, V326, P729, DOI 10.1126/science.1177373	50	130	130	6	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2012	156	3					173	U32		10.7326/0003-4819-156-3-201202070-00005	http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XD	22312137				2022-12-28	WOS:000299964200001
J	Goundry, B; Bell, L; Langtree, M; Moorthy, A				Goundry, Beth; Bell, Laura; Langtree, Matthew; Moorthy, Arumugam			Diagnosis and management of Raynaud's phenomenon	BRITISH MEDICAL JOURNAL			English	Review							PLACEBO-CONTROLLED TRIAL; SYSTEMIC-SCLEROSIS; DOUBLE-BLIND; PHENOMENON SECONDARY; ILOPROST THERAPY; GINKGO-BILOBA; SCLERODERMA; EFFICACY; NITROGLYCERIN; PATHOGENESIS		[Goundry, Beth; Bell, Laura; Langtree, Matthew; Moorthy, Arumugam] Univ Hosp Leicester NHS Trust, Dept Rheumatol, Leicester LE1 5WW, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester	Moorthy, A (corresponding author), Univ Hosp Leicester NHS Trust, Dept Rheumatol, Leicester LE1 5WW, Leics, England.	moorthyarumugam@hotmail.com						Anderson ME, 2002, RHEUMATOLOGY, V41, P324, DOI 10.1093/rheumatology/41.3.324; [Anonymous], 2000, COCHRANE DATABASE SY; Avouac J, 2011, ANN RHEUM DIS, V70, P630, DOI 10.1136/ard.2010.134304; Bakst R, 2008, J AM ACAD DERMATOL, V59, P633, DOI 10.1016/j.jaad.2008.06.004; Belch J, 2008, ARTHRITIS RHEUM, V58, pS622; Choi WS, 2009, CLIN RHEUMATOL, V28, P553, DOI 10.1007/s10067-008-1084-9; Chung L, 2009, ARTHRITIS RHEUM-US, V60, P870, DOI 10.1002/art.24351; Dziadzio M, 1999, ARTHRITIS RHEUM-US, V42, P2646, DOI 10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T; Fraenkel Liana, 2002, Curr Rheumatol Rep, V4, P123, DOI 10.1007/s11926-002-0007-z; Gliddon AE, 2007, ARTHRITIS RHEUM, V56, P3837, DOI 10.1002/art.22965; Health & Safety Executive, CONTR VIBR WORK REG; Herrick AL, 2005, RHEUMATOLOGY, V44, P587, DOI 10.1093/rheumatology/keh552; Herrick AL, 2011, ARTHRITIS RHEUM-US, V63, P775, DOI 10.1002/art.30195; Herrick AL, 2010, ARTHRITIS RHEUM-US, V62, P2595, DOI 10.1002/art.27543; Kawald A, 2008, J RHEUMATOL, V35, P1830; Koenig M, 2008, ARTHRITIS RHEUM-US, V58, P3902, DOI 10.1002/art.24038; Kowal-Bielecka O, 2009, ANN RHEUM DIS, V68, P620, DOI 10.1136/ard.2008.096677; Malenfant D, 2009, RHEUMATOLOGY, V48, P791, DOI 10.1093/rheumatology/kep039; Milio G, 2006, RHEUMATOLOGY, V45, P999, DOI 10.1093/rheumatology/kel038; Muir AH, 2002, VASC MED, V7, P265, DOI 10.1191/1358863x02vm455oa; Palmer KT, 2000, OCCUP ENVIRON MED, V57, P448, DOI 10.1136/oem.57.7.448; Reynaud's and Scleroderma Association, DIG ULC; Reynaud's and Scleroderma Association, COP RAYN; RIERA G, 1993, J RHEUMATOL, V20, P66; Rosato E, 2009, CLIN RHEUMATOL, V28, P1379, DOI 10.1007/s10067-009-1251-7; Sambo P, 2001, J RHEUMATOL, V28, P2257; Schiopu E, 2009, J RHEUMATOL, V36, P2264, DOI 10.3899/jrheum.090270; Scorza R, 2001, CLIN EXP RHEUMATOL, V19, P503; Shenoy PD, 2010, RHEUMATOLOGY, V49, P2420, DOI 10.1093/rheumatology/keq291; Suter LG, 2007, AM J MED, V120, P264, DOI 10.1016/j.amjmed.2006.06.007; Thompson AE, 2005, RHEUMATOLOGY, V44, P145, DOI 10.1093/rheumatology/keh390; Wigley FM, 2002, NEW ENGL J MED, V347, P1001, DOI 10.1056/NEJMcp013013; WOLLERSHEIM H, 1986, CLIN PHARMACOL THER, V40, P219, DOI 10.1038/clpt.1986.166	33	47	50	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	2012	344								e289	10.1136/bmj.e289	http://dx.doi.org/10.1136/bmj.e289			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	892ID	22315243				2022-12-28	WOS:000300279000002
J	Dutchak, PA; Katafuchi, T; Bookout, AL; Choi, JH; Yu, RT; Mangelsdorf, DJ; Kliewer, SA				Dutchak, Paul A.; Katafuchi, Takeshi; Bookout, Angie L.; Choi, Jang Hyun; Yu, Ruth T.; Mangelsdorf, David J.; Kliewer, Steven A.			Fibroblast Growth Factor-21 Regulates PPAR gamma Activity and the Antidiabetic Actions of Thiazolidinediones	CELL			English	Article							ACTIVATED-RECEPTOR-GAMMA; INCREASES ENERGY-EXPENDITURE; BETA-KLOTHO; INSULIN SENSITIVITY; METABOLIC-ACTIVITY; 3T3 FIBROBLASTS; C/EBP-ALPHA; EXPRESSION; OBESITY; FIBROBLAST-GROWTH-FACTOR-21	Fibroblast growth factor-21 (FGF21) is a circulating hepatokine that beneficially affects carbohydrate and lipid metabolism. Here, we report that FGF21 is also an inducible, fed-state autocrine factor in adipose tissue that functions in a feed-forward loop to regulate the activity of peroxisome proliferator-activated receptor gamma (PPAR gamma), a master transcriptional regulator of adipogenesis. FGF21 knockout (KO) mice display defects in PPARg signaling including decreased body fat and attenuation of PPAR gamma-dependent gene expression. Moreover, FGF21-KO mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight gain and edema side effects of the PPAR gamma agonist rosiglitazone. This loss of function in FGF21-KO mice is coincident with a marked increase in the sumoylation of PPAR gamma, which reduces its transcriptional activity. Adding back FGF21 prevents sumoylation and restores PPAR gamma activity. Collectively, these results reveal FGF21 as a key mediator of the physiologic and pharmacologic actions of PPAR gamma.	[Katafuchi, Takeshi; Bookout, Angie L.; Mangelsdorf, David J.; Kliewer, Steven A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Dutchak, Paul A.; Kliewer, Steven A.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; [Bookout, Angie L.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Hypothalam Res, Dallas, TX 75390 USA; [Mangelsdorf, David J.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; [Choi, Jang Hyun] Harvard Univ, Sch Med, Div Metab & Chron Dis, Dept Canc Biol,Dana Farber Canc Inst, Boston, MA 02115 USA; [Choi, Jang Hyun] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Yu, Ruth T.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Salk Institute	Mangelsdorf, DJ (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.	davo.mango@utsouthwestern.edu; steven.kliewer@utsouthwestern.edu	Choi, Jang Hyun/B-3055-2012	Yu, Ruth/0000-0002-9527-9627; Mangelsdorf, David/0000-0002-4355-0796	Howard Hughes Medical Institute; NIH [RL1GM084436, R56DK089600, U19DK62434, GM007062]; Robert A. Welch Foundation [I-1275, I-1558]; Leona M. and Harry B. Helmsley Charitable Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK089600, R01DK067158, U19DK062434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, RL1GM084436] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); Leona M. and Harry B. Helmsley Charitable Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs. Regina Goetz and Moosa Mohammadi for recombinant FGF21 protein, Dr. James Richardson for histopathology expertise, and members of the D.J.M./S.A.K. laboratory for discussion. This research was supported by the Howard Hughes Medical Institute (to D.J.M.), NIH Grants RL1GM084436 and R56DK089600 (to D.J.M. and S.A.K.), U19DK62434 (to D.J.M.), and GM007062 (to A.L.B.), the Robert A. Welch Foundation (I-1275 to D.J.M. and I-1558 to S.A.K.), and the Leona M. and Harry B. Helmsley Charitable Trust (to R.T.Y.).	Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Arner P, 2008, FEBS LETT, V582, P1725, DOI 10.1016/j.febslet.2008.04.038; Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Badman MK, 2009, ENDOCRINOLOGY, V150, P4931, DOI 10.1210/en.2009-0532; Berglund ED, 2009, ENDOCRINOLOGY, V150, P4084, DOI 10.1210/en.2009-0221; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291; Christodoulides C, 2009, J CLIN ENDOCR METAB, V94, P3594, DOI 10.1210/jc.2009-0111; Coskun T, 2008, ENDOCRINOLOGY, V149, P6018, DOI 10.1210/en.2008-0816; Dushay J, 2010, GASTROENTEROLOGY, V139, P456, DOI 10.1053/j.gastro.2010.04.054; Fisher FM, 2010, DIABETES, V59, P2781, DOI 10.2337/db10-0193; Floyd ZE, 2004, OBES RES, V12, P921, DOI 10.1038/oby.2004.112; Guan YF, 2005, NAT MED, V11, P861, DOI 10.1038/nm1278; Hondares E, 2010, CELL METAB, V11, P206, DOI 10.1016/j.cmet.2010.02.001; Hotta Y, 2009, ENDOCRINOLOGY, V150, P4625, DOI 10.1210/en.2009-0119; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Inagaki T, 2008, CELL METAB, V8, P77, DOI 10.1016/j.cmet.2008.05.006; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Johnson CL, 2009, GASTROENTEROLOGY, V137, P1795, DOI 10.1053/j.gastro.2009.07.064; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kharitonenkov A, 2007, ENDOCRINOLOGY, V148, P774, DOI 10.1210/en.2006-1168; Kurosu H, 2007, J BIOL CHEM, V282, P26687, DOI 10.1074/jbc.M704165200; Lefterova MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008; Li K, 2009, EUR J ENDOCRINOL, V161, P391, DOI 10.1530/EJE-09-0335; Li XF, 2009, FEBS LETT, V583, P3230, DOI 10.1016/j.febslet.2009.09.012; Lundasen T, 2007, BIOCHEM BIOPH RES CO, V360, P437, DOI 10.1016/j.bbrc.2007.06.068; Mai K, 2009, DIABETES, V58, P1532, DOI 10.2337/db08-1775; Moyers JS, 2007, J CELL PHYSIOL, V210, P1, DOI 10.1002/jcp.20847; Muise ES, 2008, MOL PHARMACOL, V74, P403, DOI 10.1124/mol.108.044826; Ogawa Y, 2007, P NATL ACAD SCI USA, V104, P7432, DOI 10.1073/pnas.0701600104; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Potthoff MJ, 2009, P NATL ACAD SCI USA, V106, P10853, DOI 10.1073/pnas.0904187106; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Sarruf DA, 2010, DIABETES, V59, P1817, DOI 10.2337/db09-1878; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Suzuki M, 2008, MOL ENDOCRINOL, V22, P1006, DOI 10.1210/me.2007-0313; Tacer KF, 2010, MOL ENDOCRINOL, V24, P2050, DOI 10.1210/me.2010-0142; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Wang H, 2008, MOL CELL BIOL, V28, P188, DOI 10.1128/MCB.00992-07; Wente W, 2006, DIABETES, V55, P2470, DOI 10.2337/db05-1435; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Xu J, 2009, DIABETES, V58, P250, DOI 10.2337/db08-0392; Yamashita D, 2004, GENES CELLS, V9, P1017, DOI 10.1111/j.1365-2443.2004.00786.x; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang H, 2005, P NATL ACAD SCI USA, V102, P9406, DOI 10.1073/pnas.0501744102; Zhang X, 2008, DIABETES, V57, P1246, DOI 10.2337/db07-1476	56	409	432	2	74	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					556	567		10.1016/j.cell.2011.11.062	http://dx.doi.org/10.1016/j.cell.2011.11.062			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304921	Green Accepted, Bronze			2022-12-28	WOS:000300225000022
J	Ogden, CL; Carroll, MD; Kit, BK; Flegal, KM				Ogden, Cynthia L.; Carroll, Margaret D.; Kit, Brian K.; Flegal, Katherine M.			Prevalence of Obesity and Trends in Body Mass Index Among US Children and Adolescents, 1999-2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD OVERWEIGHT; RISK-FACTORS; ADIPOSITY; BMI	Context The prevalence of childhood obesity increased in the 1980s and 1990s but there were no significant changes in prevalence between 1999-2000 and 2007-2008 in the United States. Objectives To present the most recent estimates of obesity prevalence in US children and adolescents for 2009-2010 and to investigate trends in obesity prevalence and body mass index (BMI) among children and adolescents between 1999-2000 and 2009-2010. Design, Setting, and Participants Cross-sectional analyses of a representative sample (N=4111) of the US child and adolescent population (birth through 19 years of age) with measured heights and weights from the National Health and Nutrition Examination Survey 2009-2010. Main Outcome Measures Prevalence of high weight-for-recumbent length (>= 95th percentile on the growth charts) among infants and toddlers from birth to 2 years of age and obesity (BMI >= 95th percentile of the BMI-for-age growth charts) among children and adolescents aged 2 through 19 years. Analyses of trends in obesity by sex and race/ethnicity, and analyses of trends in BMI within sex-specific age groups for 6 survey periods (1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008, and 2009-2010) over 12 years. Results In 2009-2010, 9.7% (95% CI, 7.6%-12.3%) of infants and toddlers had a high weight-for-recumbent length and 16.9% (95% CI, 15.4%-18.4%) of children and adolescents from 2 through 19 years of age were obese. There was no difference in obesity prevalence among males (P=.62) or females (P=.65) between 2007-2008 and 2009-2010. However, trend analyses over a 12-year period indicated a significant increase in obesity prevalence between 1999-2000 and 20092010 in males aged 2 through 19 years (odds ratio, 1.05; 95% CI, 1.01-1.10) but not in females (odds ratio, 1.02; 95% CI, 0.98-1.07) per 2-year survey cycle. There was a significant increase in BMI among adolescent males aged 12 through 19 years (P=.04) but not among any other age group or among females. Conclusion In 2009-2010, the prevalence of obesity in children and adolescents was 16.9%; this was not changed compared with 2007-2008. JAMA. 2012;307(5):483-490 Published online January 17, 2012. doi:10.1001/jama.2012.40	[Ogden, Cynthia L.; Carroll, Margaret D.; Kit, Brian K.; Flegal, Katherine M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Ogden, CL (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4414, Hyattsville, MD 20782 USA.	cogden@cdc.gov	Flegal, Katherine M/A-4608-2013		Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Aeberli I, 2010, PUBLIC HEALTH NUTR, V13, P806, DOI 10.1017/S1368980009991558; Centers for Disease Control and Prevention, NAT HLTH NUTR EX SUR; Centers for Disease Control and Prevention, STAT PROGR; Ekblom OB, 2004, SCAND J PUBLIC HEALT, V32, P257, DOI 10.1080/1403494031009498; Flegal KM, 2010, AM J CLIN NUTR, V91, P1020, DOI 10.3945/ajcn.2009.28589; Flegal KM, 2000, INT J OBESITY, V24, P807, DOI 10.1038/sj.ijo.0801232; Freedman DS, 2007, J PEDIATR-US, V150, P12, DOI 10.1016/j.jpeds.2006.08.042; Freedman DS, 2009, AM J CLIN NUTR, V90, P210, DOI 10.3945/ajcn.2009.27525; Freedman DS, 2005, INT J OBESITY, V29, P1, DOI 10.1038/sj.ijo.0802735; Freedman DS, 2007, J PEDIAT, V150, pe2; Grummer-Strawn Laurence M., 2010, Morbidity and Mortality Weekly Report, V59, P1; Guo, 2002, VITAL HLTH STAT, V11, DOI DOI 10.1016/J.BBRC.2015.06.114; Kalies H, 2002, INT J OBESITY, V26, P1211, DOI 10.1038/sj.ijo.0802013; Kouda K, 2010, J EPIDEMIOL, V20, P212, DOI 10.2188/jea.JE20090079; Kromeyer-Hauschild K, 2007, EUR J CLIN NUTR, V61, P404, DOI 10.1038/sj.ejcn.1602533; McCrindle BW, 2010, J PEDIATR-US, V157, P837, DOI 10.1016/j.jpeds.2010.05.014; Melgen C, 2008, METABOLISM, V57, P934, DOI 10.1016/j.metabol.2008.02.008; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Ogden Cynthia L, 2010, Natl Health Stat Report, P1; Ogden CL, 2011, SPRINGER SER EPIDEMI, P69, DOI 10.1007/978-1-4419-6039-9_5; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Olds TS, 2010, INT J OBESITY, V34, P57, DOI 10.1038/ijo.2009.211; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Salanave B, 2009, INT J PEDIATR OBES, V4, P66, DOI 10.1080/17477160902811207; Sekhobo JP, 2010, PUBLIC HEALTH REP, V125, P218, DOI 10.1177/003335491012500210; Sharma A. J., 2009, Morbidity and Mortality Weekly Report, V58, P769; Sherry B, 2007, ARCH PEDIAT ADOL MED, V161, P1154, DOI 10.1001/archpedi.161.12.1154; Singh AS, 2008, OBES REV, V9, P474, DOI 10.1111/j.1467-789X.2008.00475.x; Sjoberg A, 2008, ACTA PAEDIATR, V97, P118, DOI 10.1111/j.1651-2227.2007.00613.x; Skinner C.J., 1989, ANAL COMPLEX SURVEYS; Wang YF, 2008, OBESITY, V16, P2323, DOI 10.1038/oby.2008.351; Wolters KM, 1982, INTRO VARIANCE ESTIM	32	3440	3511	13	290	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					483	490		10.1001/jama.2012.40	http://dx.doi.org/10.1001/jama.2012.40			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22253364	Green Accepted, Bronze			2022-12-28	WOS:000299728000029
J	Sokol, DK				Sokol, Daniel K.			ETHICS MAN Matters of life and death and quality of life	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, London, England	Imperial College London	Sokol, DK (corresponding author), Univ London Imperial Coll Sci Technol & Med, London, England.	daniel.sokol@talk21.com						Mortimer J, 1997, 3 RUMPOLE OMNIBUS; SAINT-EXUPERY A., 1999, LE PETIT PRINCE	2	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2012	344								e775	10.1136/bmj.e775	http://dx.doi.org/10.1136/bmj.e775			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889QJ	22298096				2022-12-28	WOS:000300088000017
J	Anderson, R; Hollingsworth, TD; Truscott, J; Brooker, S				Anderson, Roy; Hollingsworth, T. Deirdre; Truscott, James; Brooker, Simon			Optimisation of mass chemotherapy to control soil-transmitted helminth infection	LANCET			English	Editorial Material									[Anderson, Roy; Hollingsworth, T. Deirdre; Truscott, James] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England; [Brooker, Simon] London Sch Hyg & Trop Med, London WC1, England; [Brooker, Simon] Wellcome Trust Res Programme, Kenya Med Res Inst, Nairobi, Kenya	Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Kenya Medical Research Institute	Anderson, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England.	roy.anderson@imperial.ac.uk	Hollingsworth, Deirdre/D-2421-2009	Hollingsworth, Deirdre/0000-0001-5962-4238; Anderson, Roy/0000-0002-9528-3175	Wellcome Trust [092654, 098045] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; ANDERSON RM, 1985, PARASITOLOGY, V90, P629, DOI 10.1017/S0031182000052288; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Department for International Development, 2012, UK PROT 140 MILL NEG; Hotez PJ, 2009, LANCET, V373, P1570, DOI 10.1016/S0140-6736(09)60233-6; Miguel E, 2004, ECONOMETRICA, V72, P159, DOI 10.1111/j.1468-0262.2004.00481.x; Pullan RL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000958; Savioli L, 1999, MONITORING HELMINTH; WHO, 2010, WORKING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES: FIRST WHO REPORT ON NEGLECTED TROPICAL DISEASES, P1	9	39	39	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2012	379	9813					289	290		10.1016/S0140-6736(12)60120-2	http://dx.doi.org/10.1016/S0140-6736(12)60120-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889BA	22284644				2022-12-28	WOS:000300047300010
J	Melendez, E; Goldstein, AM; Sagar, P; Badizadegan, K				Melendez, Elliot; Goldstein, Allan M.; Sagar, Pallavi; Badizadegan, Kamran			A Newborn Boy with Vomiting, Diarrhea, and Abdominal Distention Hirschsprung's disease with enterocolitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTOPERATIVE ENTEROCOLITIS; CALRETININ IMMUNOHISTOCHEMISTRY; RISK-FACTORS; 1ST STOOL; DIAGNOSIS; BIOPSIES; CHILDREN; INFANTS		[Melendez, Elliot] Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; [Melendez, Elliot] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Goldstein, Allan M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Sagar, Pallavi] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Badizadegan, Kamran] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Melendez, Elliot] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Goldstein, Allan M.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Sagar, Pallavi] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Badizadegan, Kamran] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Melendez, E (corresponding author), Childrens Hosp, Dept Pediat, Boston, MA 02115 USA.							Bachur RG, 2001, PEDIATRICS, V108, P311, DOI 10.1542/peds.108.2.311; Baker MD, 1999, ARCH PEDIAT ADOL MED, V153, P508; BILL AH, 1962, AM J SURG, V103, P70, DOI 10.1016/0002-9610(62)90016-8; Ceneviva G, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.2.e19; CLARK DA, 1977, PEDIATRICS, V60, P457; ELHALABY EA, 1995, J PEDIATR SURG, V30, P76, DOI 10.1016/0022-3468(95)90615-0; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Guinard-Samuel V, 2009, MODERN PATHOL, V22, P1379, DOI 10.1038/modpathol.2009.110; Hackam DJ, 1998, J PEDIATR SURG, V33, P830, DOI 10.1016/S0022-3468(98)90652-2; Haricharan RN, 2008, J PEDIATR SURG, V43, P1115, DOI 10.1016/j.jpedsurg.2008.02.039; Kapur RR, 2009, PEDIATR DEVEL PATHOL, V12, P6, DOI 10.2350/08-02-0424.1; MARTY TL, 1995, J PEDIATR SURG, V30, P652, DOI 10.1016/0022-3468(95)90681-9; Menezes M, 2006, PEDIATR SURG INT, V22, P316, DOI 10.1007/s00383-006-1639-2; Monforte-Munoz H, 1998, ARCH PATHOL LAB MED, V122, P721; Morabito A, 2006, PEDIATR SURG INT, V22, P179, DOI 10.1007/s00383-005-1617-0; Ostlie DJ, 2003, J PEDIATR SURG, V38, P1039, DOI 10.1016/S0022-3468(03)00187-8; Pastor AC, 2009, J PEDIATR SURG, V44, P251, DOI 10.1016/j.jpedsurg.2008.10.052; Polley, 1986, PEDIATR SURG INT, V1, P80, DOI 10.1007/BF00166865; Prato AP, 2008, J PEDIATR SURG, V43, P612, DOI 10.1016/j.jpedsurg.2007.10.007; Qualman SJ, 1999, PEDIATR DEVEL PATHOL, V2, P588, DOI 10.1007/s100249900167; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Ruttenstock E, 2010, PEDIATR SURG INT, V26, P1101, DOI 10.1007/s00383-010-2695-1; SHERRY SN, 1955, J PEDIATR-US, V46, P158, DOI 10.1016/S0022-3476(55)80205-3; Suita S, 2005, J PEDIATR SURG, V40, P197, DOI 10.1016/j.jpedsurg.2004.09.052; SWENSON O, 1973, J PEDIATR SURG, V8, P587, DOI 10.1016/0022-3468(73)90395-3; Wu XJ, 2009, J PEDIATR SURG, V44, P1401, DOI 10.1016/j.jpedsurg.2008.11.004	26	7	9	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					361	372		10.1056/NEJMcpc1103562	http://dx.doi.org/10.1056/NEJMcpc1103562			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EQ	22276826				2022-12-28	WOS:000299464100009
J	Spence, D				Spence, Des			FROM THE FRONTLINE Transforming translation	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						2011, BRIT MED J, V343, DOI DOI 10.1136/BMJ.D721	1	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 25	2012	344								e596	10.1136/bmj.e596	http://dx.doi.org/10.1136/bmj.e596			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KV	22279092				2022-12-28	WOS:000299778800020
J	Davidson, EA; de Araujo, AC; Artaxo, P; Balch, JK; Brown, IF; Bustamante, MMC; Coe, MT; DeFries, RS; Keller, M; Longo, M; Munger, JW; Schroeder, W; Soares, BS; Souza, CM; Wofsy, SC				Davidson, Eric A.; de Araujo, Alessandro C.; Artaxo, Paulo; Balch, Jennifer K.; Brown, I. Foster; Bustamante, Mercedes M. C.; Coe, Michael T.; DeFries, Ruth S.; Keller, Michael; Longo, Marcos; Munger, J. William; Schroeder, Wilfrid; Soares-Filho, Britaldo S.; Souza, Carlos M., Jr.; Wofsy, Steven C.			The Amazon basin in transition	NATURE			English	Review							ABOVEGROUND LIVE BIOMASS; CLIMATE-CHANGE; LAND-COVER; EXPERIMENTAL DROUGHT; BRAZILIAN AMAZON; FOREST SOILS; CARBON; FIRE; SCALE; DYNAMICS	Agricultural expansion and climate variability have become important agents of disturbance in the Amazon basin. Recent studies have demonstrated considerable resilience of Amazonian forests to moderate annual drought, but they also show that interactions between deforestation, fire and drought potentially lead to losses of carbon storage and changes in regional precipitation patterns and river discharge. Although the basin-wide impacts of land use and drought may not yet surpass the magnitude of natural variability of hydrologic and biogeochemical cycles, there are some signs of a transition to a disturbance-dominated regime. These signs include changing energy and water cycles in the southern and eastern portions of the Amazon basin.	[Davidson, Eric A.; Balch, Jennifer K.; Brown, I. Foster; Coe, Michael T.] Woods Hole Res Ctr, Falmouth, MA 02540 USA; [de Araujo, Alessandro C.] Embrapa Amazonia Oriental, BR-66095100 Belem, Para, Brazil; [de Araujo, Alessandro C.] Large Scale Biosphere Atmosphere Expt Amazonia LB, INPA, BR-69060001 Manaus, Amazonas, Brazil; [Artaxo, Paulo] Univ Sao Paulo, Inst Fis, BR-05508090 Sao Paulo, Brazil; [Balch, Jennifer K.] Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA; [Brown, I. Foster] Univ Fed Acre, BR-69915900 Rio Branco, AC, Brazil; [Bustamante, Mercedes M. C.] Univ Brasilia, Inst Ciencias Biol, Dept Ecol, BR-70910900 Brasilia, DF, Brazil; [DeFries, Ruth S.] Columbia Univ, Dept Ecol Evolut & Environm Biol, New York, NY 10027 USA; [Keller, Michael] US Forest Serv, USDA, Int Inst Trop Forestry, San Juan, PR 00926 USA; [Keller, Michael] Embrapa Monitoramento Satelite, Campinas, SP, Brazil; [Longo, Marcos; Munger, J. William] Harvard Univ, Sch Engn & Appl Sci, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; [Schroeder, Wilfrid] Univ Maryland, Earth Syst Sci Interdisciplinary Ctr, College Pk, MD 20740 USA; [Soares-Filho, Britaldo S.] Univ Fed Minas Gerais, Ctr Sensoriamento Remoto, BR-31270900 Belo Horizonte, MG, Brazil; [Souza, Carlos M., Jr.] Imazon, Ctr Geotecnol Imazon, BR-66060160 Belem, Para, Brazil	Woods Hole Research Center; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Institute Nacional de Pesquisas da Amazonia; Universidade de Sao Paulo; National Center for Ecological Analysis & Synthesis; Universidade Federal do Acre (UFAC); Universidade de Brasilia; Columbia University; United States Department of Agriculture (USDA); United States Forest Service; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Harvard University; University System of Maryland; University of Maryland College Park; Universidade Federal de Minas Gerais	Davidson, EA (corresponding author), Woods Hole Res Ctr, 149 Woods Hole Rd, Falmouth, MA 02540 USA.	edavidson@whrc.org	Artaxo, Paulo/E-8874-2010; Bustamante, Mercedes/AAQ-7231-2020; Brown, Irving Foster/J-3766-2014; Davidson, Eric A/K-4984-2013; Keller, Michael/A-8976-2012; Souza, CARLOS/AAK-8207-2021; Munger, J William/H-4502-2013; Schroeder, Wilfrid/F-6738-2010; Longo, Marcos/F-5033-2014; Bustamante, Mercedes MC/H-7597-2015; Bustamante, Mercedes/GQZ-8625-2022	Artaxo, Paulo/0000-0001-7754-3036; Bustamante, Mercedes/0000-0003-1008-452X; Brown, Irving Foster/0000-0003-1877-0866; Davidson, Eric A/0000-0002-8525-8697; Keller, Michael/0000-0002-0253-3359; Souza, CARLOS/0000-0002-0205-6134; Munger, J William/0000-0002-1042-8452; Longo, Marcos/0000-0001-5062-6245; Bustamante, Mercedes MC/0000-0003-1008-452X; Coe, Michael/0000-0002-7470-0697	Brazilian Ministry of Science and Technology (MCT); National Institute for Space Research (INPE); National Institute of Amazonian Research (INPA); NASA [NNX08AF63A, NNX11AF20G]	Brazilian Ministry of Science and Technology (MCT); National Institute for Space Research (INPE); National Institute of Amazonian Research (INPA); NASA(National Aeronautics & Space Administration (NASA))	We thank the Brazilian Ministry of Science and Technology (MCT), the National Institute for Space Research (INPE) and the National Institute of Amazonian Research (INPA) for designing, leading and managing the LBA project. We also thank D. Wickland (NASA) for more than a decade of leadership and support for the LBA-Eco project component of LBA. We thank the LBA-Eco team members who contributed to discussions on an early draft of this manuscript at a workshop in Foz do Iguacu in August 2010, and S. Saleska for comments on the manuscript. We thank P. Lefebvre and W. Kingerlee for assistance with figure and manuscript preparation. Development of this manuscript was supported by NASA grants NNX08AF63A and NNX11AF20G.	Alencar AAC, 2004, ECOL APPL, V14, pS139; Alencar A, 2006, EARTH INTERACT, V10; Andreae MO, 2004, SCIENCE, V303, P1337, DOI 10.1126/science.1092779; Aragao LEOC, 2010, SCIENCE, V328, P1275, DOI 10.1126/science.1186925; Arima EY, 2005, ANN ASSOC AM GEOGR, V95, P525, DOI 10.1111/j.1467-8306.2005.00473.x; Artaxo P, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000666; Asner GP, 2005, SCIENCE, V310, P480, DOI 10.1126/science.1118051; Asner GP, 2004, GLOBAL CHANGE BIOL, V10, P844, DOI 10.1111/j.1529-8817.2003.00766.x; Asner GP, 2006, P NATL ACAD SCI USA, V103, P12947, DOI 10.1073/pnas.0604093103; Avissar R, 1998, J ATMOS SCI, V55, P2666, DOI 10.1175/1520-0469(1998)055<2666:AEOTSA>2.0.CO;2; Balch JK, 2008, GLOBAL CHANGE BIOL, V14, P2276, DOI 10.1111/j.1365-2486.2008.01655.x; Balch JK, 2011, FOREST ECOL MANAG, V261, P68, DOI 10.1016/j.foreco.2010.09.029; Barlow Jos, 2006, P225; Bevan SL, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD011112; Brando PM, 2008, PHILOS T R SOC B, V363, P1839, DOI 10.1098/rstb.2007.0031; Brando PM, 2010, P NATL ACAD SCI USA, V107, P14685, DOI 10.1073/pnas.0908741107; Brondizio E. S., 2009, INAMAZONIA GLOBAL CH, P117; Bustamante M. M. C, CLIM CHANGE UNPUB; Butt N, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD015174; Cerri CEP, 2004, GLOBAL CHANGE BIOL, V10, P815, DOI 10.1111/j.1365-2486.2004.00759.x; Chambers JQ, 2009, ECOL LETT, V12, pE22, DOI 10.1111/j.1461-0248.2009.01398.x; Coe MT, 2011, BIOGEOCHEMISTRY, V105, P119, DOI 10.1007/s10533-011-9582-2; Coe MT, 2008, HYDROL PROCESS, V22, P2542, DOI 10.1002/hyp.6850; Coe MT, 2009, J HYDROL, V369, P165, DOI 10.1016/j.jhydrol.2009.02.043; Coe MT, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000740; Costa MH, 2003, J HYDROL, V283, P206, DOI 10.1016/S0022-1694(03)00267-1; Costa MH, 1999, J GEOPHYS RES-ATMOS, V104, P14189, DOI 10.1029/1998JD200126; D'Amelio MTS, 2009, ATMOS CHEM PHYS, V9, P8785, DOI 10.5194/acp-9-8785-2009; da Rocha HR, 2009, J GEOPHYS RES-BIOGEO, V114, DOI 10.1029/2007JG000640; Da Silva RR, 2008, J CLIMATE, V21, P1153, DOI 10.1175/2007JCLI1304.1; Davidson EA, 2004, GLOBAL CHANGE BIOL, V10, P519, DOI 10.1111/j.1529-8817.2003.00779.x; Davidson EA, 2008, GLOBAL CHANGE BIOL, V14, P998, DOI 10.1111/j.1365-2486.2008.01542.x; Davidson EA, 2007, NATURE, V447, P995, DOI 10.1038/nature05900; Davidson EA, 2010, J GEOPHYS RES-BIOGEO, V115, DOI [10.1029/20091G001202, 10.1029/2009JG001202]; de Almeida AS, 2010, EARTH INTERACT, V14, DOI 10.1175/2009EI290.1; do Carmo JB, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025436; Espirito-Santo FDB, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043146; Eva HD, 2004, GLOBAL CHANGE BIOL, V10, P731, DOI 10.1111/j.1529-8817.2003.00774.x; Fearnside PM, 2009, FOREST ECOL MANAG, V258, P1968, DOI 10.1016/j.foreco.2009.07.042; Fisher JI, 2008, ECOL LETT, V11, P554, DOI 10.1111/j.1461-0248.2008.01169.x; Fisher RA, 2006, PLANT CELL ENVIRON, V29, P151, DOI 10.1111/j.1365-3040.2005.01407.x; Gatti LV, 2010, TELLUS B, V62, P581, DOI 10.1111/j.1600-0889.2010.00484.x; Gloor M, 2009, GLOBAL CHANGE BIOL, V15, P2418, DOI 10.1111/j.1365-2486.2009.01891.x; Grace J, 2006, J BIOGEOGR, V33, P387, DOI 10.1111/j.1365-2699.2005.01448.x; Gurney KR, 2011, TELLUS B, V63, P328, DOI 10.1111/j.1600-0889.2011.00534.x; Holscher D, 1997, J HYDROL, V193, P293, DOI 10.1016/S0022-1694(96)03145-9; Houghton R. A., 2009, INAMAZONIA GLOBAL CH, P409; Huete AR, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025583; Instituto Nacional de Pesquisas Espaciais & National Institute for Space Research, 2011, PROJ PROD MON FLORST; Johnson MS, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL034619; Knox R, 2011, J CLIMATE, V24, P2368, DOI 10.1175/2010JCL13815.1; Leite NK, 2011, BIOGEOCHEMISTRY, V105, P37, DOI 10.1007/s10533-010-9568-5; Lewis SL, 2011, SCIENCE, V331, P554, DOI 10.1126/science.1200807; Lloyd J, 2009, ECOL LETT, V12, pE19, DOI 10.1111/j.1461-0248.2009.01326.x; da Costa ACL, 2010, NEW PHYTOL, V187, P579, DOI 10.1111/j.1469-8137.2010.03309.x; Longo KM, 1999, J GEOPHYS RES-ATMOS, V104, P12113, DOI 10.1029/1999JD900044; Luizao FJ, 2009, GEOPHYS MONOGR SER, V186, P311, DOI 10.1029/2008GM000742; Malhi Y, 2006, GLOBAL CHANGE BIOL, V12, P1107, DOI 10.1111/j.1365-2486.2006.01120.x; Malhi Y, 2009, P NATL ACAD SCI USA, V106, P20610, DOI 10.1073/pnas.0804619106; Marengo JA, 2008, PHILOS T R SOC B, V363, P1773, DOI 10.1098/rstb.2007.0015; Marengo JA, 2004, THEOR APPL CLIMATOL, V78, P79, DOI 10.1007/S00704-004-0045-8; Marengo JA, 2007, TROPICAL RAINFOREST, P236; Melack JM, 2004, GLOBAL CHANGE BIOL, V10, P530, DOI 10.1111/j.1365-2486.2004.00763.x; Melack JM, 2009, GEOPHYS MONOGR SER, V186, P525, DOI 10.1029/2008GM000721; Miller JB, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL029213; Miller SD, 2011, P NATL ACAD SCI USA, V108, P19431, DOI 10.1073/pnas.1105068108; Morton DC, 2005, EARTH INTERACT, V9; Morton DC, 2006, P NATL ACAD SCI USA, V103, P14637, DOI 10.1073/pnas.0606377103; Neeff T, 2006, ECOSYSTEMS, V9, P609, DOI 10.1007/s10021-006-0001-9; Neill C, 2000, ADV SOIL SCI-SER, P197; Nemani RR, 2003, SCIENCE, V300, P1560, DOI 10.1126/science.1082750; Nepstad D., 2004, Global Change Biology, V10, P704, DOI 10.1111/j.1529-8817.2003.00772.x; Nepstad D, 2001, FOREST ECOL MANAG, V154, P395, DOI 10.1016/S0378-1127(01)00511-4; Nepstad DC, 2008, PHILOS T R SOC B, V363, P1737, DOI 10.1098/rstb.2007.0036; Nepstad DC, 2007, ECOLOGY, V88, P2259, DOI 10.1890/06-1046.1; NEPSTAD DC, 1994, NATURE, V372, P666, DOI 10.1038/372666a0; Nobre CA, 2009, CURR OPIN ENV SUST, V1, P28, DOI 10.1016/j.cosust.2009.07.003; Oliveira PHF, 2007, TELLUS B, V59, P338, DOI [10.1111/j.1600-0889.2007.00270.x, 10.1111/J.1600-0889.2007.00270.x]; Oliveira RS, 2005, FUNCT ECOL, V19, P574, DOI 10.1111/j.1365-2435.2005.01003.x; Pan YD, 2011, SCIENCE, V333, P988, DOI 10.1126/science.1201609; Phillips OL, 2010, NEW PHYTOL, V187, P631, DOI 10.1111/j.1469-8137.2010.03359.x; Phillips OL, 2009, SCIENCE, V323, P1344, DOI 10.1126/science.1164033; Quesada CA, 2010, BIOGEOSCIENCES, V7, P1515, DOI 10.5194/bg-7-1515-2010; Rammig A, 2010, NEW PHYTOL, V187, P694, DOI 10.1111/j.1469-8137.2010.03318.x; Ray D, 2005, ECOL APPL, V15, P1664, DOI 10.1890/05-0404; Richey JE, 2002, NATURE, V416, P617, DOI 10.1038/416617a; Saatchi SS, 2007, GLOBAL CHANGE BIOL, V13, P816, DOI 10.1111/j.1365-2486.2007.01323.x; SALATI E, 1984, SCIENCE, V225, P129, DOI 10.1126/science.225.4658.129; Saleska SR, 2003, SCIENCE, V302, P1554, DOI 10.1126/science.1091165; Sano E.E., 2007, MAPEAMENTO COBERTURA; Santos AJB, 2004, GLOBAL CHANGE BIOL, V10, P877, DOI 10.1111/j.1529-8817.2003.00777.x; Silvestrini RA, 2011, ECOL APPL, V21, P1573, DOI 10.1890/10-0827.1; Soares BS, 2006, NATURE, V440, P520, DOI 10.1038/nature04389; Soares B, 2010, P NATL ACAD SCI USA, V107, P10821, DOI 10.1073/pnas.0913048107; Telles EDC, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2002GB001953; ter Steege H, 2006, NATURE, V443, P444, DOI 10.1038/nature05134; Vieira ICG, 2003, REMOTE SENS ENVIRON, V87, P470, DOI 10.1016/j.rse.2002.09.002; Williams E, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000380; Xu LL, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006458; Zarin DJ, 2005, FRONT ECOL ENVIRON, V3, P365, DOI 10.2307/3868585	100	726	743	16	571	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					321	328		10.1038/nature10717	http://dx.doi.org/10.1038/nature10717			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258611				2022-12-28	WOS:000299210600034
J	Greaves, M; Maley, CC				Greaves, Mel; Maley, Carlo C.			Clonal evolution in cancer	NATURE			English	Review							STEM-CELLS; BARRETTS-ESOPHAGUS; SOMATIC MUTATIONS; IN-SITU; LEUKEMIA; PROGRESSION; SELECTION; HETEROGENEITY; DIVERSITY; METASTASIS	Cancers evolve by a reiterative process of clonal expansion, genetic diversification and clonal selection within the adaptive landscapes of tissue ecosystems. The dynamics are complex, with highly variable patterns of genetic diversity and resulting clonal architecture. Therapeutic intervention may destroy cancer clones and erode their habitats, but it can also inadvertently provide a potent selective pressure for the expansion of resistant variants. The inherently Darwinian character of cancer is the primary reason for this therapeutic failure, but it may also hold the key to more effective control.	[Greaves, Mel] Inst Canc Res, Div Mol Pathol, Sutton SM2 5NG, Surrey, England; [Maley, Carlo C.] Univ Calif San Francisco, Dept Surg, Helen Diller Family Comprehens Canc Ctr, Ctr Evolut & Canc, San Francisco, CA 94115 USA	University of London; Institute of Cancer Research - UK; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Greaves, M (corresponding author), Inst Canc Res, Div Mol Pathol, Brookes Lawley Bldg,15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	mel.greaves@icr.ac.uk		Greaves, Melvyn/0000-0002-7239-1384	Leukaemia & Lymphoma Research UK; Kay Kendall Leukaemia Fund; American Cancer Society [117209-RSG-09-163-01-CNE]; NIH [P01 CA91955, U54 CA143803, R01 CA149566, R01 CA140657]; NATIONAL CANCER INSTITUTE [U54CA143803, R01CA140657, P01CA091955, R01CA149566] Funding Source: NIH RePORTER	Leukaemia & Lymphoma Research UK; Kay Kendall Leukaemia Fund; American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The research of M. G. is supported by Leukaemia & Lymphoma Research UK and The Kay Kendall Leukaemia Fund. The research of C. M. is supported by Research Scholar Grant #117209-RSG-09-163-01-CNE from the American Cancer Society and NIH grants P01 CA91955, U54 CA143803, R01 CA149566 and R01 CA140657. The authors thank C. Cooper and J. Clark for the use of the image in Fig. 4.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Akala OO, 2008, NATURE, V453, P228, DOI 10.1038/nature06869; Aktipis CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026100; Allred DC, 2008, CLIN CANCER RES, V14, P370, DOI 10.1158/1078-0432.CCR-07-1127; Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020; Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Bateman CM, 2010, BLOOD, V115, P3553, DOI 10.1182/blood-2009-10-251413; Beerenwinkel N, 2007, PLOS COMPUT BIOL, V3, P2239, DOI 10.1371/journal.pcbi.0030225; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Campbell PJ, 2008, P NATL ACAD SCI USA, V105, P13081, DOI 10.1073/pnas.0801523105; Chen J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017933; Chin L, 2011, NAT MED, V17, P297, DOI 10.1038/nm.2323; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clappier E, 2011, J EXP MED, V208, P653, DOI 10.1084/jem.20110105; Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843; de Visser JAGM, 2006, GENETICS, V172, P2093, DOI 10.1534/genetics.105.052373; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Durinck S, 2011, CANCER DISCOV, V1, P137, DOI 10.1158/2159-8290.CD-11-0028; Duy C, 2011, NATURE, V473, P384, DOI 10.1038/nature09883; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255; Gatenby RA, 2009, CANCER RES, V69, P4894, DOI 10.1158/0008-5472.CAN-08-3658; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Goff D, 2010, CELL STEM CELL, V6, P296, DOI 10.1016/j.stem.2010.03.008; Gonzalez-Garcia I, 2002, P NATL ACAD SCI USA, V99, P13085, DOI 10.1073/pnas.202139299; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Grant P. R., 2008, WHY SPECIES MULTIPLY; Greaves M., 2000, CANC EVOLUTIONARY LE; Greaves M, 2011, NAT MED, V17, P1046, DOI 10.1038/nm.2458; Greaves M, 2010, SEMIN CANCER BIOL, V20, P65, DOI 10.1016/j.semcancer.2010.03.002; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Greenman C, 2006, GENETICS, V173, P2187, DOI 10.1534/genetics.105.044677; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Isoda T, 2009, P NATL ACAD SCI USA, V106, P17882, DOI 10.1073/pnas.0904658106; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; Leedham SJ, 2008, GUT, V57, P1041, DOI 10.1136/gut.2007.143339; Loeb LA, 2011, NAT REV CANCER, V11, P450, DOI 10.1038/nrc3063; MALAISE EP, 1973, EUR J CANCER, V9, P305, DOI 10.1016/0014-2964(73)90099-6; Maley CC, 2004, CANCER RES, V64, P3414, DOI 10.1158/0008-5472.CAN-03-3249; Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768; Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Merlo LMF, 2010, CANCER PREV RES, V3, P1388, DOI 10.1158/1940-6207.CAPR-10-0108; Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Olivier M, 2011, CURR OPIN ONCOL, V23, P88, DOI 10.1097/CCO.0b013e3283412dfa; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; Park SY, 2010, J CLIN INVEST, V120, P636, DOI 10.1172/JCI40724; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Pepper JW, 2009, EVOL APPL, V2, P62, DOI 10.1111/j.1752-4571.2008.00063.x; Piccirillo SGM, 2009, ONCOGENE, V28, P1807, DOI 10.1038/onc.2009.27; Pienta KJ, 2008, TRANSL ONCOL, V1, P158, DOI 10.1593/tlo.08178; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Reid BJ, 2010, NAT REV CANCER, V10, P87, DOI 10.1038/nrc2773; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; Sawyers CL, 2009, NAT MED, V15, P1158, DOI 10.1038/nm1009-1158; Schwartz M, 2006, CANCER LETT, V232, P13, DOI 10.1016/j.canlet.2005.07.039; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Siegmund KD, 2009, P NATL ACAD SCI USA, V106, P4828, DOI 10.1073/pnas.0810276106; Solit D, 2010, NATURE, V468, P902, DOI 10.1038/468902a; Sprouffske K, 2011, CANCER PREV RES, V4, P1135, DOI 10.1158/1940-6207.CAPR-10-0374; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Tao Y, 2011, P NATL ACAD SCI USA, V108, P12042, DOI 10.1073/pnas.1108715108; Tsai AG, 2008, CELL, V135, P1130, DOI 10.1016/j.cell.2008.10.035; Tsao JL, 1999, AM J PATHOL, V154, P1815, DOI 10.1016/S0002-9440(10)65437-5; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Varley KE, 2009, NUCLEIC ACIDS RES, V37, P4603, DOI 10.1093/nar/gkp457; Wargo AR, 2007, P NATL ACAD SCI USA, V104, P19914, DOI 10.1073/pnas.0707766104; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Welsh JS, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2010-0301; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Youn A, 2011, BIOINFORMATICS, V27, P175, DOI 10.1093/bioinformatics/btq630; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011	100	1866	1920	9	438	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					306	313		10.1038/nature10762	http://dx.doi.org/10.1038/nature10762			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258609	Green Accepted			2022-12-28	WOS:000299210600032
J	Moynihan, R				Moynihan, Ray			SUSTAINABLE HEALTHCARE The greening of medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Newcastle, Callaghan, NSW 2308, Australia	University of Newcastle	Moynihan, R (corresponding author), Univ Newcastle, Callaghan, NSW 2308, Australia.	Ray.Moynihan@newcastle.edu.au	Moynihan, Ray/ABC-3010-2020					Challacombe B., 2008, BMJ-BRIT MED J, V336, P1173; Charlesworth A, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6520; Connor A, 2011, CLIN MED, V11, P242, DOI 10.7861/clinmedicine.11-3-242; Health Care Without Harm, 2011, GLOBAL GREEN HLTH HO; NHS Sustainable Development Unit, 2009, SAV CARB IMPR HLTH U; NHS Sustainable Development Unit, 2010, SAV CARB IMPR HLTH U; Pencheon D, 2009, J HEALTH SERV RES PO, V14, P2, DOI 10.1258/jhsrp.2008.008147; Raffle AE, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4596; Sneyd JR, 2010, ANAESTHESIA, V65, P435, DOI 10.1111/j.1365-2044.2010.06332.x; *STOCKH COUNT COUN, 2009, ENV CLASS PHARM; Stockholm Environment Institute ARUP NHS Sustainable Development Unit, 2010, CO2E RED POT NHS ENG; Stockholm Environment Institute NHS Sustainable Development Unit, 2009, NHS SUST DEV UN NHS; Zander A, 2011, J PUBLIC HEALTH-UK, V33, P272, DOI 10.1093/pubmed/fdq048	13	7	7	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	2012	344								d8360	10.1136/bmj.d8360	http://dx.doi.org/10.1136/bmj.d8360			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888YP	22250219				2022-12-28	WOS:000300040900009
J	Cooper, DS; Biondi, B				Cooper, David S.; Biondi, Bernadette			Subclinical thyroid disease	LANCET			English	Article							CORONARY-HEART-DISEASE; ALL-CAUSE MORTALITY; CARDIOVASCULAR RISK-FACTORS; INTIMA-MEDIA THICKNESS; LOW SERUM THYROTROPIN; BONE-MINERAL DENSITY; L-THYROXINE THERAPY; 5-YEAR FOLLOW-UP; QUALITY-OF-LIFE; DOUBLE-BLIND	Subclinical thyroid diseases-subclinical hyperthyroidism and subclinical hypothyroidism-are common clinical entities that encompass mild degrees of thyroid dysfunction. The clinical significance of mild thyroid overactivity and underactivity is uncertain, which has led to controversy over the appropriateness of diagnostic testing and possible treatment. In this Seminar, we discuss the definition, epidemiology, differential diagnoses, risks of progression to overt thyroid disease, potential effects on various health outcomes, and management of subclinical hyperthyroidism and subclinical hypothyroidism. Treatment recommendations are based on the degree to which thyroid-stimulating hormone concentrations have deviated from normal and underlying comorbidities. Large-scale randomised trials are urgently needed to inform how to best care for individuals with subclinical thyroid disease.	[Cooper, David S.] Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, Baltimore, MD 21287 USA; [Biondi, Bernadette] Univ Naples Federico II, Dept Clin & Mol Endocrinol & Oncol, Naples, Italy	Johns Hopkins University; University of Naples Federico II	Cooper, DS (corresponding author), Johns Hopkins Univ, Sch Med, Div Endocrinol & Metab, 1830 E Monument St,Suite 333, Baltimore, MD 21287 USA.	dscooper@jhmi.edu	Biondi, Bernadette/AAH-7664-2020	Biondi, Bernadette/0000-0001-8360-4464				Abalovich M, 2002, THYROID, V12, P63, DOI 10.1089/105072502753451986; Abalovich M, 2007, J CLIN ENDOCR METAB, V92, pS1, DOI 10.1210/jc.2007-0141; Abraham-Nordling M, 2008, EUR J ENDOCRINOL, V158, P823, DOI 10.1530/EJE-07-0877; Abu-Helalah M, 2010, J MED SCREEN, V17, P164, DOI 10.1258/jms.2010.010057; Allan WC, 2000, J MED SCREEN, V7, P127, DOI 10.1136/jms.7.3.127; American Academy of Family Physicians, THYR; Andersen S, 2002, J CLIN ENDOCR METAB, V87, P1068, DOI 10.1210/jc.87.3.1068; Anderson L, 2010, AM J ROENTGENOL, V195, P216, DOI 10.2214/AJR.09.3680; [Anonymous], 2006, STEDMANS MED DICT; Atzmon G, 2009, J CLIN ENDOCR METAB, V94, P4768, DOI 10.1210/jc.2009-0808; Auer J, 2001, AM HEART J, V142, P838, DOI 10.1067/mhj.2001.119370; Bahn RS, 2011, THYROID, V21, P593, DOI 10.1089/thy.2010.0417; Bakker SJL, 2001, J CLIN ENDOCR METAB, V86, P1206, DOI 10.1210/jc.86.3.1206; Bauer DC, 2001, ANN INTERN MED, V134, P561, DOI 10.7326/0003-4819-134-7-200104030-00009; Belin RM, 2004, J CLIN ENDOCR METAB, V89, P6077, DOI 10.1210/jc.2004-0431; Benhadi N, 2009, EUR J ENDOCRINOL, V160, P985, DOI 10.1530/EJE-08-0953; Berg AO, 2004, ANN INTERN MED, V140, P125, DOI 10.7326/0003-4819-140-2-200401200-00014; Biondi B, 2000, J CLIN ENDOCR METAB, V85, P4701, DOI 10.1210/jc.85.12.4701; Biondi B, THYROID; Biondi B, 2008, ENDOCR REV, V29, P76, DOI 10.1210/er.2006-0043; Biondi B, 2007, THYROID, V17, P625, DOI 10.1089/thy.2007.0158; Biondi B, 2010, J CLIN ENDOCR METAB, V95, P3614, DOI 10.1210/jc.2010-1245; Boekholdt SM, 2010, CLIN ENDOCRINOL, V72, P404, DOI 10.1111/j.1365-2265.2009.03640.x; Brennan MD, 2006, THYROID, V16, P375, DOI 10.1089/thy.2006.16.375; Brenta G, 2003, AM J CARDIOL, V91, P1327, DOI 10.1016/S0002-9149(03)00322-9; Buscemi S, 2007, J ENDOCRINOL INVEST, V30, P230, DOI 10.1007/BF03347430; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Cappola AR, 2006, JAMA-J AM MED ASSOC, V295, P1033, DOI 10.1001/jama.295.9.1033; Cappola AR, 2003, J CLIN ENDOCR METAB, V88, P2438, DOI 10.1210/jc.2003-030398; Caraccio N, 2002, J CLIN ENDOCR METAB, V87, P1533, DOI 10.1210/jc.87.4.1533; Casey BM, 2006, OBSTET GYNECOL, V107, P337, DOI 10.1097/01.AOG.0000197991.64246.9a; Committee on Patient Safety and Quality Improvement, 2007, Obstet Gynecol, V110, P959; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; Danese ND, 2000, J CLIN ENDOCR METAB, V85, P2993, DOI 10.1210/jcem.85.9.6841; de Jong FJ, 2006, J CLIN ENDOCR METAB, V91, P2569, DOI 10.1210/jc.2006-0449; de Jongh RT, 2011, EUR J ENDOCRINOL, V165, P545, DOI 10.1530/EJE-11-0430; Diez JJ, 2005, J CLIN ENDOCR METAB, V90, P4124, DOI 10.1210/jc.2005-0375; Diez JJ, 2004, J CLIN ENDOCR METAB, V89, P4890, DOI 10.1210/jc.2003-032061; Diez JJ, 2003, GERONTOLOGY, V49, P316, DOI 10.1159/000071713; Diez JJ, 2009, AM J MED SCI, V337, P225, DOI 10.1097/MAJ.0b013e318187e16d; Dobert N, 2003, ACTA MED AUST, V30, P130; Dorr M, 2008, EUR J ENDOCRINOL, V159, P145, DOI 10.1530/EJE-08-0140; Dorr M, 2010, CLIN ENDOCRINOL, V73, P821, DOI 10.1111/j.1365-2265.2010.03882.x; Dorr M, 2006, J CLIN ENDOCR METAB, V91, P530, DOI 10.1210/jc.2005-1786; Erem C, 2006, CLIN ENDOCRINOL, V64, P323, DOI 10.1111/j.1365-2265.2006.02464.x; Faber J, 1998, CLIN ENDOCRINOL, V48, P285; Faber J, 2001, EUR J ENDOCRINOL, V145, P391, DOI 10.1530/eje.0.1450391; FIGGE J, 1994, AM J MED, V96, P229, DOI 10.1016/0002-9343(94)90147-3; Flynn RW, 2010, J CLIN ENDOCR METAB, V95, P186, DOI 10.1210/jc.2009-1625; FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365-2265.1993.tb02403.x; Franchini M, 2011, CLIN APPL THROMB-HEM, V17, P387, DOI 10.1177/1076029610364521; Gammage MD, 2007, ARCH INTERN MED, V167, P928, DOI 10.1001/archinte.167.9.928; Glenn GC, 1996, ARCH PATHOL LAB MED, V120, P929; GLINOER D, 1993, J ENDOCRINOL INVEST, V16, P881, DOI 10.1007/BF03348950; Grabe HJ, 2005, ACTA PSYCHIAT SCAND, V112, P286, DOI 10.1111/j.1600-0447.2005.00586.x; Grimnes G, 2008, THYROID, V18, P1147, DOI 10.1089/thy.2008.0158; Gussekloo J, 2004, JAMA-J AM MED ASSOC, V292, P2591, DOI 10.1001/jama.292.21.2591; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Haentjens P, 2008, EUR J ENDOCRINOL, V159, P329, DOI 10.1530/EJE-08-0110; Hansen PS, 2004, J CLIN ENDOCR METAB, V89, P1181, DOI 10.1210/jc.2003-031641; Helfand M, 1998, ANN INTERN MED, V129, P141, DOI 10.7326/0003-4819-129-2-199807150-00020; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Iervasi G, 2007, ARCH INTERN MED, V167, P1526, DOI 10.1001/archinte.167.14.1526; Jaeschke R, 1996, J GEN INTERN MED, V11, P744, DOI 10.1007/BF02598988; Jordan N, 2003, J CLIN ENDOCR METAB, V88, P1002, DOI 10.1210/jc.2002-021301; Jorde R, 2006, J CLIN ENDOCR METAB, V91, P145, DOI 10.1210/jc.2005-1775; Kalmijn S, 2000, CLIN ENDOCRINOL, V53, P733, DOI 10.1046/j.1365-2265.2000.01146.x; Klein I, 2007, CIRCULATION, V116, P1725, DOI 10.1161/CIRCULATIONAHA.106.678326; Knudsen N, 2005, J CLIN ENDOCR METAB, V90, P4019, DOI 10.1210/jc.2004-2225; Kong WM, 2002, AM J MED, V112, P348, DOI 10.1016/S0002-9343(02)01022-7; Krassas GE, 2010, ENDOCR REV, V31, P702, DOI 10.1210/er.2009-0041; Ladenson PW, 2000, ARCH INTERN MED, V160, P1573, DOI 10.1001/archinte.160.11.1573; Laurberg P, 1998, J CLIN ENDOCR METAB, V83, P765, DOI 10.1210/jc.83.3.765; Laurberg P, 2010, BEST PRACT RES CL EN, V24, P13, DOI 10.1016/j.beem.2009.08.013; Lee JS, 2010, ARCH INTERN MED, V170, P1876, DOI 10.1001/archinternmed.2010.424; LEUNG AS, 1993, OBSTET GYNECOL, V81, P349; Li YS, 2008, J CLIN ENDOCR METAB, V93, P1751, DOI 10.1210/jc.2007-2368; Lindeman RD, 1999, J AM GERIATR SOC, V47, P703, DOI 10.1111/j.1532-5415.1999.tb01593.x; Liu D, 2010, J HUM HYPERTENS, V24, P134, DOI 10.1038/jhh.2009.44; Lorenz MW, 2010, EUR HEART J, V31, P2041, DOI 10.1093/eurheartj/ehq189; Luboshitzky R, 2002, THYROID, V12, P421, DOI 10.1089/105072502760043512; Maratou E, 2009, EUR J ENDOCRINOL, V160, P785, DOI 10.1530/EJE-08-0797; MARIOTTI S, 1993, J CLIN ENDOCR METAB, V77, P1130, DOI 10.1210/jc.77.5.1130; Mazziotti G, 2005, J BONE MINER RES, V20, P480, DOI 10.1359/JBMR.041126; McDermott MT, 2001, J CLIN ENDOCR METAB, V86, P4585, DOI 10.1210/jc.86.10.4585; McQuade C, 2011, THYROID, V21, P837, DOI 10.1089/thy.2010.0298; Meier C, 2001, J CLIN ENDOCR METAB, V86, P4860, DOI 10.1210/jc.86.10.4860; Meyerovitch J, 2007, ARCH INTERN MED, V167, P1533, DOI 10.1001/archinte.167.14.1533; Monzani F, 2001, J CLIN ENDOCR METAB, V86, P1110, DOI 10.1210/jc.86.3.1110; Monzani F, 2004, J CLIN ENDOCR METAB, V89, P2099, DOI 10.1210/jc.2003-031669; MUDDE AH, 1994, CLIN ENDOCRINOL, V41, P421, DOI 10.1111/j.1365-2265.1994.tb02571.x; MULLER B, 1995, NEW ENGL J MED, V333, P964, DOI 10.1056/NEJM199510123331503; Negro R, 2006, J CLIN ENDOCR METAB, V91, P2587, DOI 10.1210/jc.2005-1603; Negro R, 2010, J CLIN ENDOCR METAB, V95, P1699, DOI 10.1210/jc.2009-2009; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; Ochs N, 2008, ANN INTERN MED, V148, P832, DOI 10.7326/0003-4819-148-11-200806030-00225; Owen PJD, 2007, THYROID, V17, P519, DOI 10.1089/thy.2007.0051; Parle J, 2010, J CLIN ENDOCR METAB, V95, P3623, DOI 10.1210/jc.2009-2571; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; Pearce EN, 2010, THYROID, V20, P369, DOI 10.1089/thy.2009.0272; Petretta M, 2001, EUR J ENDOCRINOL, V145, P691, DOI 10.1530/eje.0.1450691; Psaltopoulou T, 2007, EUR J INTERN MED, V18, P423, DOI 10.1016/j.ejim.2006.12.010; Razvi S, 2007, J CLIN ENDOCR METAB, V92, P1715, DOI 10.1210/jc.2006-1869; Razvi S, 2010, J CLIN ENDOCR METAB, V95, P1734, DOI 10.1210/jc.2009-1749; Roberts LM, 2006, ANN INTERN MED, V145, P573, DOI 10.7326/0003-4819-145-8-200610170-00006; Rodondi N, 2005, ARCH INTERN MED, V165, P2460, DOI 10.1001/archinte.165.21.2460; Rodondi N, 2008, J AM COLL CARDIOL, V52, P1152, DOI 10.1016/j.jacc.2008.07.009; Rodondi N, 2010, JAMA-J AM MED ASSOC, V304, P1365, DOI 10.1001/jama.2010.1361; Rosario PW, 2008, CLIN ENDOCRINOL, V68, P491, DOI 10.1111/j.1365-2265.2007.03030.x; Rosario PW, 2010, CLIN ENDOCRINOL, V72, P685, DOI 10.1111/j.1365-2265.2009.03696.x; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; Schouten BJ, 2011, CLIN ENDOCRINOL, V74, P257, DOI 10.1111/j.1365-2265.2010.03908.x; Sgarbi JA, 2003, J CLIN ENDOCR METAB, V88, P1672, DOI 10.1210/jc.2002-021046; Sgarbi JA, 2010, EUR J ENDOCRINOL, V162, P569, DOI 10.1530/EJE-09-0845; Simonsick EM, 2009, ARCH INTERN MED, V169, P2011, DOI 10.1001/archinternmed.2009.392; Singh S, 2008, INT J CARDIOL, V125, P41, DOI 10.1016/j.ijcard.2007.02.027; Somwaru LL, 2009, J CLIN ENDOCR METAB, V94, P1342, DOI 10.1210/jc.2008-1696; Stagnaro-Green A, 2011, THYROID, V21, P1081, DOI 10.1089/thy.2011.0087; Stone MB, 2003, MEDICARE COVERAGE RO; Surks MI, 2007, J CLIN ENDOCR METAB, V92, P4575, DOI 10.1210/jc.2007-1499; Surks MI, 2010, J CLIN ENDOCR METAB, V95, P496, DOI 10.1210/jc.2009-1845; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; Taddei S, 2003, J CLIN ENDOCR METAB, V88, P3731, DOI 10.1210/jc.2003-030039; Tan ZS, 2008, ARCH INTERN MED, V168, P1514, DOI 10.1001/archinte.168.14.1514; Tauchmanova L, 2004, MATURITAS, V48, P299, DOI 10.1016/j.maturitas.2004.02.017; Teng WP, 2006, NEW ENGL J MED, V354, P2783, DOI 10.1056/NEJMoa054022; The Association of Clinical Biochemistry British Thyroid Association British Thyroid Foundation, 2006, UK GUID US THYR FUNC; Tribulova N, 2010, VASC PHARMACOL, V52, P102, DOI 10.1016/j.vph.2009.10.001; Vadiveloo T, 2011, J CLIN ENDOCR METAB, V96, P59; Vaidya B, 2007, J CLIN ENDOCR METAB, V92, P203, DOI 10.1210/jc.2006-1748; van der Cammen TJM, 2003, J AM GERIATR SOC, V51, P884, DOI 10.1046/j.1365-2389.2003.51278.x; van Osch LADM, 2004, NEUROLOGY, V62, P1967, DOI 10.1212/01.WNL.0000128134.84230.9F; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vanderpump MPJ, 1996, BMJ-BRIT MED J, V313, P539; Vestergaard P, 2003, THYROID, V13, P585, DOI 10.1089/105072503322238854; Volzke H, 2007, J CLIN ENDOCR METAB, V92, P2421, DOI 10.1210/jc.2007-0179; Volzke H, 2004, J CLIN ENDOCR METAB, V89, P2145, DOI 10.1210/jc.2003-031028; Walsh JP, 2010, J CLIN ENDOCR METAB, V95, P1095, DOI 10.1210/jc.2009-1977; Walsh JP, 2005, ARCH INTERN MED, V165, P2467, DOI 10.1001/archinte.165.21.2467; Wartofsky L, 2005, J CLIN ENDOCR METAB, V90, P5483, DOI 10.1210/jc.2005-0455; Williams GR, 2009, NAT CLIN PRACT ENDOC, V5, P10, DOI 10.1038/ncpendmet1004; Yavuz H. A., 2000, Journal of Endocrinological Investigation, V23, P38; Yazici M, 2004, INT J CARDIOL, V95, P135, DOI 10.1016/j.ijcard.2003.05.015; Yonem O, 2002, ENDOCR J, V49, P307, DOI 10.1507/endocrj.49.307; Zaidi Mone, 2009, Curr Osteoporos Rep, V7, P47	145	547	582	4	111	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 24	2012	379	9821					1142	1154		10.1016/S0140-6736(11)60276-6	http://dx.doi.org/10.1016/S0140-6736(11)60276-6			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916VR	22273398				2022-12-28	WOS:000302131800036
J	Ruger, JP				Ruger, Jennifer Prah			Fair Enough? Inviting Inequities in State Health Benefits	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ruger, Jennifer Prah] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA; [Ruger, Jennifer Prah] Yale Univ, Sch Med, New Haven, CT USA; [Ruger, Jennifer Prah] Yale Univ, Grad Sch Arts & Sci, New Haven, CT USA; [Ruger, Jennifer Prah] Yale Univ, Sch Law, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Ruger, JP (corresponding author), Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA.							*AG HEALTHC RES QU, 2004, AHRQ PUBL; [Anonymous], 2011, ESS HLTH BEN B; Freedman KB, 2000, J BONE JOINT SURG AM, V82A, P1063, DOI 10.2106/00004623-200008000-00001; Kaiser Family Foundation, MED BEN ONL DAT; Ruger JenniferPrah., 2009, HLTH SOCIAL JUSTICE	5	9	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	2012	366	8					681	683		10.1056/NEJMp1200751	http://dx.doi.org/10.1056/NEJMp1200751			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	896FS	22316422				2022-12-28	WOS:000300551500004
J	Gnant, M; Steger, GG				Gnant, Michael; Steger, Guenther G.			Dual inhibition of HER2 in breast cancer treatment	LANCET			English	Editorial Material							TRASTUZUMAB; CHEMOTHERAPY		[Gnant, Michael] Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, A-1090 Vienna, Austria; Med Univ Vienna, Dept Med Oncol, Ctr Comprehens Canc, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Gnant, M (corresponding author), Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, A-1090 Vienna, Austria.	michael.gnant@meduniwien.ac.at	Gnant, Michael/AAN-7054-2020	Gnant, Michael/0000-0003-1002-2118				Alba E, 2011, CANCER RES, V71, DOI 10.1158/0008-5472.SABCS11-P007-04; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Bozovic I, 2011, BREAST INT GROUP DEC; Garnock-Jones KP, 2010, DRUGS, V70, P215, DOI 10.2165/11203700-000000000-00000; Gianni L, 2011, CANCER RES, V71, DOI 10.1158/0008-5472.SABCS11-55-1; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Gnant M, 2009, LANCET, V374, P2029, DOI 10.1016/S0140-6736(09)62097-3; Guarneri V, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.507; Hall PS, 2011, PHARMACOECONOMICS, V29, P415, DOI 10.2165/11588340-000000000-00000; Holmes FA, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.506; Joensuu H, 2009, J CLIN ONCOL, V27, P5685, DOI 10.1200/JCO.2008.21.4577; Steger GG, 2007, J CLIN ONCOL, V25, P2012, DOI 10.1200/JCO.2006.09.1777; Untch M, 2012, LANCET ONCOL, V13, P135, DOI 10.1016/S1470-2045(11)70397-7	15	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2012	379	9816					596	598		10.1016/S0140-6736(12)60068-3	http://dx.doi.org/10.1016/S0140-6736(12)60068-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897ES	22257672				2022-12-28	WOS:000300629000008
J	Josefowicz, SZ; Niec, RE; Kim, HY; Treuting, P; Chinen, T; Zheng, Y; Umetsu, DT; Rudensky, AY				Josefowicz, Steven Z.; Niec, Rachel E.; Kim, Hye Young; Treuting, Piper; Chinen, Takatoshi; Zheng, Ye; Umetsu, Dale T.; Rudensky, Alexander Y.			Extrathymically generated regulatory T cells control mucosal T(H)2 inflammation	NATURE			English	Article							TRANSCRIPTION FACTOR FOXP3; IN-VIVO; BOWEL-DISEASE; INDUCTION; RESPONSES; LINEAGE; FATE; GENE; MICE; HOMEOSTASIS	A balance between pro- and anti-inflammatory mechanisms at mucosal interfaces, which are sites of constitutive exposure to microbes and non-microbial foreign substances, allows for efficient protection against pathogens yet prevents adverse inflammatory responses associated with allergy, asthma and intestinal inflammation(1). Regulatory T (T-reg) cells prevent systemic and tissue-specific autoimmunity and inflammatory lesions at mucosal interfaces. These cells are generated in the thymus (tT(reg) cells) and in the periphery (induced (i)T-reg cells), and their dual origin implies a division of labour between tT(reg) and iT(reg) cells in immune homeostasis. Here we show that a highly selective blockage in differentiation of iT(reg) cells in mice did not lead to unprovoked multi-organ autoimmunity, exacerbation of induced tissue-specific autoimmune pathology, or increased pro-inflammatory responses of T helper 1 (T(H)1) and T(H)17 cells. However, mice deficient in iT(reg) cells spontaneously developed pronounced T(H)2-type pathologies at mucosal sites-in the gastrointestinal tract and lungs-with hallmarks of allergic inflammation and asthma. Furthermore, iT(reg)-cell deficiency altered gut microbial communities. These results suggest that whereas T-reg cells generated in the thymus appear sufficient for control of systemic and tissue-specific autoimmunity, extrathymic differentiation of T-reg cells affects commensal microbiota composition and serves a distinct, essential function in restraint of allergic-type inflammation at mucosal interfaces.	[Josefowicz, Steven Z.; Niec, Rachel E.; Chinen, Takatoshi; Rudensky, Alexander Y.] Howard Hughes Med Inst, New York, NY 10021 USA; [Josefowicz, Steven Z.; Niec, Rachel E.; Chinen, Takatoshi; Rudensky, Alexander Y.] Sloan Kettering Inst, Program Immunol, New York, NY 10021 USA; [Josefowicz, Steven Z.] Rockefeller Univ, Lab Chromatin Biol & Epigenet, New York, NY 10065 USA; [Kim, Hye Young; Umetsu, Dale T.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; [Treuting, Piper] Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA; [Chinen, Takatoshi] Keio Univ, Dept Microbiol & Immunol, Sch Med, Tokyo 1608582, Japan; [Zheng, Ye] Salk Inst Biol Studies, Nomis Fdn Labs Immunobiol & Microbial Pathogenesi, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Washington; University of Washington Seattle; Keio University; Salk Institute	Rudensky, AY (corresponding author), Howard Hughes Med Inst, New York, NY 10021 USA.	rudenska@mskcc.org	Treuting, Piper M./AAB-2721-2019; Zheng, Ye/G-4866-2015; Kim, Hye Young/AAF-7609-2020	Treuting, Piper M./0000-0002-1812-1519; Zheng, Ye/0000-0001-5012-4309; Kim, Hye Young/0000-0001-5978-512X; Niec, Rachel/0000-0002-8525-3693; josefowicz, steven/0000-0001-7453-779X	NIH MSTP [GM07739]; NINDS [1F31NS073203-01]; Department of Microbiology and Immunology, Keio University School of Medicine; NIH [R37 AI034206]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS073203] Funding Source: NIH RePORTER	NIH MSTP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Department of Microbiology and Immunology, Keio University School of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank T. Tedder for depleting CD20 antibody, R. Tudor for assistance interpreting lung pathology, P. DeRoos for assistance with Ig ELISA assays, B. Johnson for immunohistochemical expertise, Y. Chen for assistance with airway measurements, and E. Pamer, L. Lipuma, A. Gobourne and R. Khanin for help with analysis of intestinal microbiota. This work was supported by NIH MSTP grant GM07739 and NINDS grant 1F31NS073203-01 (R.E.N.), Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from Department of Microbiology and Immunology, Keio University School of Medicine (T. C.) and NIH grant R37 AI034206 (A. Y. R.). A. Y. R is an investigator with the Howard Hughes Medical Institute.	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Bautista JL, 2009, NAT IMMUNOL, V10, P610, DOI 10.1038/ni.1739; Burich A, 2001, AM J PHYSIOL-GASTR L, V281, pG764, DOI 10.1152/ajpgi.2001.281.3.G764; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Gottschalk RA, 2010, J EXP MED, V207, P1701, DOI 10.1084/jem.20091999; Hill JA, 2008, IMMUNITY, V29, P758, DOI 10.1016/j.immuni.2008.09.018; Hori S, 2011, TRENDS IMMUNOL, V32, P295, DOI 10.1016/j.it.2011.04.004; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Komatsu N, 2009, P NATL ACAD SCI USA, V106, P1903, DOI 10.1073/pnas.0811556106; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Leung MWL, 2009, J EXP MED, V206, P2121, DOI 10.1084/jem.20091033; Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607; MAGURRAN A. E., 2004, MEASURING BIOLOGICAL; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Moran AE, 2011, J EXP MED, V208, P1279, DOI 10.1084/jem.20110308; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Nolting J, 2009, J EXP MED, V206, P2131, DOI 10.1084/jem.20090639; Nossa CW, 2010, WORLD J GASTROENTERO, V16, P4135, DOI 10.3748/wjg.v16.i33.4135; Ouyang WM, 2010, IMMUNITY, V32, P642, DOI 10.1016/j.immuni.2010.04.012; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Stromnes IM, 2006, NAT PROTOC, V1, P1810, DOI 10.1038/nprot.2006.285; Tian L, 2011, BLOOD, V118, P1845, DOI 10.1182/blood-2011-04-346056; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Ubeda C, 2010, J CLIN INVEST, V120, P4332, DOI 10.1172/JCI43918; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wang YQ, 2011, IMMUNITY, V35, P337, DOI 10.1016/j.immuni.2011.08.012; Wohlfert EA, 2011, J CLIN INVEST, V121, P4503, DOI 10.1172/JCI57456; Xu LL, 2010, IMMUNITY, V33, P313, DOI 10.1016/j.immuni.2010.09.001; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	39	588	610	1	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2012	482	7385					395	U1510		10.1038/nature10772	http://dx.doi.org/10.1038/nature10772			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	892LG	22318520	Green Accepted			2022-12-28	WOS:000300287100045
J	Kim, TW; Michniewicz, M; Bergmann, DC; Wang, ZY				Kim, Tae-Wuk; Michniewicz, Marta; Bergmann, Dominique C.; Wang, Zhi-Yong			Brassinosteroid regulates stomatal development by GSK3-mediated inhibition of a MAPK pathway	NATURE			English	Article							RECEPTOR KINASE BRI1; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTORS; GSK3-LIKE KINASES; PLANT-GROWTH; ARABIDOPSIS; BZR1; DIFFERENTIATION; INTEGRATION; PERCEPTION	Plants must coordinate the regulation of biochemistry and anatomy to optimize photosynthesis and water-use efficiency. The formation of stomata, epidermal pores that facilitate gas exchange, is highly coordinated with other aspects of photosynthetic development. The signalling pathways controlling stomata development are not fully understood(1,2), although mitogen-activated protein kinase (MAPK) signalling is known to have key roles. Here we demonstrate in Arabidopsis that brassinosteroid regulates stomatal development by activating the MAPK kinase kinase (MAPKKK) YDA (also known as YODA). Genetic analyses indicate that receptor kinase-mediated brassinosteroid signalling inhibits stomatal development through the glycogen synthase kinase 3 (GSK3)-like kinase BIN2, and BIN2 acts upstream of YDA but downstream of the ERECTA family of receptor kinases. Complementary in vitro and in vivo assays show that BIN2 phosphorylates YDA to inhibit YDA phosphorylation of its substrate MKK4, and that activities of downstream MAPKs are reduced in brassinosteroid-deficient mutants but increased by treatment with either brassinosteroid or GSK3-kinase inhibitor. Our results indicate that brassinosteroid inhibits stomatal development by alleviating GSK3-mediated inhibition of this MAPK module, providing two key links; that of a plant MAPKKK to its upstream regulators and of brassinosteroid to a specific developmental output.	[Kim, Tae-Wuk; Wang, Zhi-Yong] Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; [Kim, Tae-Wuk] Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea; [Michniewicz, Marta; Bergmann, Dominique C.] Stanford Univ, Dept Biol, Stanford, CA 94305 USA	Carnegie Institution for Science; Hanyang University; Stanford University	Wang, ZY (corresponding author), Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA.	zywang24@stanford.edu	Wang, Zhi-Yong/E-3810-2012	Wang, Zhi-Yong/0000-0003-4602-3390; Bergmann, Dominique/0000-0003-0873-3543	National Institutes of Health [R01GM066258]; US Department of Energy [DE-FG02-08ER15973]; Herman Frasch Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086632, R01GM066258] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Energy(United States Department of Energy (DOE)); Herman Frasch Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K. Torii for providing seeds of the er erl1 erl2 triple mutant and scrm-D mutant, J.-M. Zhou for providing the HOPAI1 transgenic line and J. Li for providing the bin2-3 bil1 bil2 triple mutant. Research was primarily supported by a grant from the National Institutes of Health (R01GM066258), and partially supported by the US Department of Energy (DE-FG02-08ER15973) and the Herman Frasch Foundation. D. C. B. is an investigator of the Howard Hughes Medical Institute.	Bergmann DC, 2004, SCIENCE, V304, P1494, DOI 10.1126/science.1096014; Bergmann DC, 2007, ANNU REV PLANT BIOL, V58, P163, DOI 10.1146/annurev.arplant.58.032806.104023; Chinchilla D, 2007, NATURE, V448, P497, DOI 10.1038/nature05999; De Rybel B, 2009, CHEM BIOL, V16, P594, DOI 10.1016/j.chembiol.2009.04.008; Dong JA, 2010, CURR TOP DEV BIOL, V91, P267, DOI 10.1016/S0070-2153(10)91009-0; Earley KW, 2006, PLANT J, V45, P616, DOI 10.1111/j.1365-313X.2005.02617.x; He JX, 2002, P NATL ACAD SCI USA, V99, P10185, DOI 10.1073/pnas.152342599; Hothorn M, 2011, NATURE, V474, P467, DOI 10.1038/nature10153; Kanaoka MM, 2008, PLANT CELL, V20, P1775, DOI 10.1105/tpc.108.060848; Kang CY, 2009, PLANT CELL, V21, P2624, DOI 10.1105/tpc.109.069765; Kim TW, 2010, ANNU REV PLANT BIOL, V61, P681, DOI 10.1146/annurev.arplant.043008.092057; Kim TW, 2009, NAT CELL BIOL, V11, P1254, DOI 10.1038/ncb1970; Kinoshita T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227; Lampard GR, 2008, SCIENCE, V322, P1113, DOI 10.1126/science.1162263; Li JM, 2002, SCIENCE, V295, P1299; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; Luo XM, 2010, DEV CELL, V19, P872, DOI 10.1016/j.devcel.2010.10.023; Rowe MH, 2010, CURR OPIN PLANT BIOL, V13, P548, DOI 10.1016/j.pbi.2010.06.002; Rozhon W, 2010, PLANT J, V62, P215, DOI 10.1111/j.1365-313X.2010.04145.x; Saibo NJM, 2003, PLANT J, V33, P989, DOI 10.1046/j.1365-313X.2003.01684.x; She J, 2011, NATURE, V474, P472, DOI 10.1038/nature10178; Shpak ED, 2005, SCIENCE, V309, P290, DOI 10.1126/science.1109710; Sun Y, 2010, DEV CELL, V19, P765, DOI 10.1016/j.devcel.2010.10.010; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Tang WQ, 2008, SCIENCE, V321, P557, DOI 10.1126/science.1156973; Tang WQ, 2011, NAT CELL BIOL, V13, P124, DOI 10.1038/ncb2151; Thummel CS, 2002, GENE DEV, V16, P3113, DOI 10.1101/gad.1042102; Wang HC, 2007, PLANT CELL, V19, P63, DOI 10.1105/tpc.106.048298; Wang ZY, 2002, DEV CELL, V2, P505, DOI 10.1016/S1534-5807(02)00153-3; Wrzaczek M, 2007, J BIOL CHEM, V282, P5249, DOI 10.1074/jbc.M610135200; Yan ZY, 2009, PLANT PHYSIOL, V150, P710, DOI 10.1104/pp.109.138099; Zhang J, 2007, CELL HOST MICROBE, V1, P175, DOI 10.1016/j.chom.2007.03.006; Zhang SQ, 1997, PLANT CELL, V9, P809, DOI 10.1105/tpc.9.5.809	33	349	382	17	187	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2012	482	7385					419	U1526		10.1038/nature10794	http://dx.doi.org/10.1038/nature10794			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	892LG	22307275	Green Accepted			2022-12-28	WOS:000300287100050
J	Garand, E; Kamrath, MZ; Jordan, PA; Wolk, AB; Leavitt, CM; McCoy, AB; Miller, SJ; Johnson, MA				Garand, Etienne; Kamrath, Michael Z.; Jordan, Peter A.; Wolk, Arron B.; Leavitt, Christopher M.; McCoy, Anne B.; Miller, Scott J.; Johnson, Mark A.			Determination of Noncovalent Docking by Infrared Spectroscopy of Cold Gas-Phase Complexes	SCIENCE			English	Article							VIBRATIONAL SPECTROSCOPY; ASYMMETRIC CATALYSIS; PHOTODISSOCIATION; ACID; CONFORMATION; CHEMISTRY; PEPTIDES; SPECTRA	Multidentate, noncovalent interactions between small molecules and biopolymer fragments are central to processes ranging from drug action to selective catalysis. We present a versatile and sensitive spectroscopic probe of functional groups engaged in hydrogen bonding in such contexts. This involves measurement of the frequency changes in specific covalent bonds upon complex formation, information drawn from otherwise transient complexes that have been extracted from solution and conformationally frozen near 10 kelvin in gas-phase clusters. Resonances closely associated with individual oscillators are easily identified through site-specific isotopic labeling, as demonstrated by application of the method to an archetypal system involving a synthetic tripeptide known to bind biaryl substrates through tailored hydrogen bonding to catalyze their asymmetric bromination. With such data, calculations readily converge on the plausible operative structures in otherwise computationally prohibitive, high-dimensionality landscapes.	[Garand, Etienne; Kamrath, Michael Z.; Jordan, Peter A.; Wolk, Arron B.; Leavitt, Christopher M.; Miller, Scott J.; Johnson, Mark A.] Yale Univ, Sterling Chem Lab, New Haven, CT 06520 USA; [McCoy, Anne B.] Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	Yale University; University System of Ohio; Ohio State University	Johnson, MA (corresponding author), Yale Univ, Sterling Chem Lab, POB 208107, New Haven, CT 06520 USA.	mark.johnson@yale.edu	Wolk, Arron/G-8968-2013; Miller, Scott/N-7761-2017	Wolk, Arron/0000-0002-5269-7319; Miller, Scott/0000-0001-7817-1318; Garand, Etienne/0000-0001-5062-5453	Air Force Office of Scientific Research [FA-9550-09-1-0139]; U.S. NSF [CHE-091199, CHE-0848242]; NIH [R01-GM068649]; Yale University Faculty of Arts and Sciences High Performance Computing facility; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068649, R37GM068649] Funding Source: NIH RePORTER	Air Force Office of Scientific Research(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); U.S. NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yale University Faculty of Arts and Sciences High Performance Computing facility; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	M.A.J. thanks the Air Force Office of Scientific Research under grant FA-9550-09-1-0139. We also thank the U.S. NSF under grants CHE-091199 (M.A.J.) and CHE-0848242 (A. B. M.). S.J.M thanks the NIH under grant R01-GM068649. This work was supported in part by the Yale University Faculty of Arts and Sciences High Performance Computing facility (and staff).	Bajorath F, 2002, NAT REV DRUG DISCOV, V1, P882, DOI 10.1038/nrd941; Bakker JM, 2003, J CHEM PHYS, V119, P11180, DOI 10.1063/1.1622657; Bleicher KH, 2003, NAT REV DRUG DISCOV, V2, P369, DOI 10.1038/nrd1086; Doyle AG, 2007, CHEM REV, V107, P5713, DOI 10.1021/cr068373r; Dunbar RC, 2010, INT J MASS SPECTROM, V297, P107, DOI 10.1016/j.ijms.2010.07.001; Elliott BM, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2966002; GARDNER RR, 1995, J AM CHEM SOC, V117, P3280, DOI 10.1021/ja00116a036; Goebbert DJ, 2009, J PHYS CHEM A, V113, P5874, DOI 10.1021/jp809390x; Gustafson JL, 2011, ANGEW CHEM INT EDIT, V50, P5125, DOI 10.1002/anie.201101147; Gustafson JL, 2010, SCIENCE, V328, P1251, DOI 10.1126/science.1188403; Ham S, 2003, J CHEM PHYS, V119, P1451, DOI 10.1063/1.1581855; HARIS PI, 1992, BIOCHEMISTRY-US, V31, P6279, DOI 10.1021/bi00142a016; Hunter EPL, 1998, J PHYS CHEM REF DATA, V27, P413, DOI 10.1063/1.556018; Inokuchi Y, 2003, J PHYS CHEM A, V107, P11319, DOI 10.1021/jp030475n; Jeffrey G.A., 2012, HYDROGEN BONDING BIO; Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361; Kamrath MZ, 2011, J AM CHEM SOC, V133, P6440, DOI 10.1021/ja200849g; Kamrath MZ, 2011, INT J MASS SPECTROM, V300, P91, DOI 10.1016/j.ijms.2010.10.021; Knowles RR, 2010, P NATL ACAD SCI USA, V107, P20678, DOI 10.1073/pnas.1006402107; Lee HM, 2010, PHYS CHEM CHEM PHYS, V12, P6278, DOI 10.1039/b925551f; Lehn JM, 2002, P NATL ACAD SCI USA, V99, P4763, DOI 10.1073/pnas.072065599; OKUMURA M, 1986, J CHEM PHYS, V85, P2328, DOI 10.1063/1.451079; Perrin CL, 1997, ANNU REV PHYS CHEM, V48, P511, DOI 10.1146/annurev.physchem.48.1.511; Prins LJ, 2001, ANGEW CHEM INT EDIT, V40, P2382, DOI 10.1002/1521-3773(20010702)40:13<2382::AID-ANIE2382>3.0.CO;2-G; RAO CP, 1980, BIOCHEMISTRY-US, V19, P425, DOI 10.1021/bi00544a004; Rizzo TR, 2009, INT REV PHYS CHEM, V28, P481, DOI 10.1080/01442350903069931; Semrouni D, 2010, J AM SOC MASS SPECTR, V21, P728, DOI 10.1016/j.jasms.2010.01.029; Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197; SONAR S, 1994, NAT STRUCT BIOL, V1, P512, DOI 10.1038/nsb0894-512; Stearns JA, 2007, J AM CHEM SOC, V129, P11814, DOI 10.1021/ja0736010; Stearns JA, 2009, PHYS CHEM CHEM PHYS, V11, P125, DOI 10.1039/b814143f; Stepanian SG, 1996, VIB SPECTROSC, V11, P123, DOI 10.1016/0924-2031(95)00068-2; TADESSE L, 1991, J AM CHEM SOC, V113, P7036, DOI 10.1021/ja00018a052; Taylor MS, 2006, ANGEW CHEM INT EDIT, V45, P1520, DOI 10.1002/anie.200503132; Wang L, 2011, J AM CHEM SOC, V133, P16062, DOI 10.1021/ja204035k; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C	36	109	109	0	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2012	335	6069					694	698		10.1126/science.1214948	http://dx.doi.org/10.1126/science.1214948			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	889AY	22267579	Green Accepted			2022-12-28	WOS:000300047100046
J	Chen, GB; Bradford, WD; Seidel, CW; Li, R				Chen, Guangbo; Bradford, William D.; Seidel, Chris W.; Li, Rong			Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PHENOTYPIC VARIATION; BUDDING YEAST; KINETOCHORE; CHAPERONE	Aneuploidy-the state of having uneven numbers of chromosomes-is a hallmark of cancer(1) and a feature identified in yeast from diverse habitats(2-5). Recent studies have shown that aneuploidy is a form of large-effect mutation that is able to confer adaptive phenotypes under diverse stress conditions(2,6). Here we investigate whether pleiotropic stress could induce aneuploidy in budding yeast (Saccharomyces cerevisae). We show that whereas diverse stress conditions can induce an increase in chromosome instability, proteotoxic stress, caused by transient Hsp90 (also known as Hsp82 or Hsc82) inhibition or heat shock, markedly increased chromosome instability to produce a cell population with high karyotype diversity. The induced chromosome instability is linked to an evolutionarily conserved role for the Hsp90 chaperone complex in kinetochore assembly(7,8). Continued growth in the presence of an Hsp90 inhibitor resulted in the emergence of drug-resistant colonies with chromosome XV gain. This drug-resistance phenotype is a quantitative trait involving copy number increases of at least two genes located on chromosome XV. Shortterm exposure to Hsp90 stress potentiated fast adaptation to unrelated cytotoxic compounds by means of different aneuploid chromosome stoichiometries. These findings demonstrate that aneuploidy is a form of stress-inducible mutation in eukaryotes, capable of fuelling rapid phenotypic evolution and drug resistance, and reveal a new role for Hsp90 in regulating the emergence of adaptive traits under stress.	[Chen, Guangbo; Bradford, William D.; Seidel, Chris W.; Li, Rong] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Chen, Guangbo; Li, Rong] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center	Li, R (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	rli@stowers.org			National Institutes of Health [RO1GM059964]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059964] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank N. Pavelka, B. Rubinstein and H. Li for help with data analysis, J. Zhu, B. Fleharty and J. Haug for experimental assistance, S. Lindquist for helpful discussions, and T. Potapova and B. Slaughter for comments on the manuscript. Chromosome fragment strains and Chr XV disomy are gifts from F. Spencer and A. Amon, respectively. This work was supported by National Institutes of Health grant RO1GM059964 to R.L.	Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; Borneman AR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001287; Davies AE, 2010, J CELL BIOL, V189, P261, DOI 10.1083/jcb.200910036; Gardner RD, 2001, GENETICS, V157, P1493; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Infante JJ, 2003, GENETICS, V165, P1745; Jarosz DF, 2010, SCIENCE, V330, P1820, DOI 10.1126/science.1195487; Kvitek DJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000223; McClellan AJ, 2007, CELL, V131, P121, DOI 10.1016/j.cell.2007.07.036; Niikura Y, 2006, ONCOGENE, V25, P4133, DOI 10.1038/sj.onc.1209461; Pavelka N, 2010, CURR OPIN CELL BIOL, V22, P809, DOI 10.1016/j.ceb.2010.06.003; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Rosenberg SM, 2001, NAT REV GENET, V2, P504, DOI 10.1038/35080556; Selmecki A, 2008, MOL MICROBIOL, V68, P624, DOI 10.1111/j.1365-2958.2008.06176.x; Selmecki A, 2010, EUKARYOT CELL, V9, P991, DOI 10.1128/EC.00060-10; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Specchia V, 2010, NATURE, V463, P662, DOI 10.1038/nature08739; SPENCER F, 1990, GENETICS, V124, P237; Stemmann O, 2002, P NATL ACAD SCI USA, V99, P8585, DOI 10.1073/pnas.082223899; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210	21	171	173	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2012	482	7384					246	250		10.1038/nature10795	http://dx.doi.org/10.1038/nature10795			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22286062	Green Accepted			2022-12-28	WOS:000299994100044
J	Israel, MA; Yuan, SH; Bardy, C; Reyna, SM; Mu, YL; Herrera, C; Hefferan, MP; Van Gorp, S; Nazor, KL; Boscolo, FS; Carson, CT; Laurent, LC; Marsala, M; Gage, FH; Remes, AM; Koo, EH; Goldstein, LSB				Israel, Mason A.; Yuan, Shauna H.; Bardy, Cedric; Reyna, Sol M.; Mu, Yangling; Herrera, Cheryl; Hefferan, Michael P.; Van Gorp, Sebastiaan; Nazor, Kristopher L.; Boscolo, Francesca S.; Carson, Christian T.; Laurent, Louise C.; Marsala, Martin; Gage, Fred H.; Remes, Anne M.; Koo, Edward H.; Goldstein, Lawrence S. B.			Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells	NATURE			English	Article							AMYLOID BETA-PROTEIN; MICROTUBULE-BINDING; SENILE PLAQUES; DOWN-SYNDROME; MOUSE MODEL; TAU; APP; PHOSPHORYLATION; FIBROBLASTS; DYSFUNCTION	Our understanding of Alzheimer's disease pathogenesis is currently limited by difficulties in obtaining live neurons from patients and the inability to model the sporadic form of the disease. It may be possible to overcome these challenges by reprogramming primary cells from patients into induced pluripotent stem cells (iPSCs). Here we reprogrammed primary fibroblasts from two patients with familial Alzheimer's disease, both caused by a duplication of the amyloid-beta precursor protein gene(1) (APP; termed APP(Dp)), two with sporadic Alzheimer's disease (termed sAD1, sAD2) and two non-demented control individuals into iPSC lines. Neurons from differentiated cultures were purified with fluorescence-activated cell sorting and characterized. Purified cultures contained more than 90% neurons, clustered with fetal brain messenger RNA samples by microarray criteria, and could form functional synaptic contacts. Virtually all cells exhibited normal electrophysiological activity. Relative to controls, iPSC-derived, purified neurons from the two APP(Dp) patients and patient sAD2 exhibited significantly higher levels of the pathological markers amyloid-beta(1-40), phospho-tau(Thr 231) and active glycogen synthase kinase-3 beta (aGSK-3 beta). Neurons from APP(Dp) and sAD2 patients also accumulated large RAB5-positive early endosomes compared to controls. Treatment of purified neurons with beta-secretase inhibitors, but not gamma-secretase inhibitors, caused significant reductions in phospho-Tau(Thr 231) and aGSK-3 beta levels. These results suggest a direct relationship between APP proteolytic processing, but not amyloid-beta, in GSK-3 beta activation and tau phosphorylation in human neurons. Additionally, we observed that neurons with the genome of one sAD patient exhibited the phenotypes seen in familial Alzheimer's disease samples. More generally, we demonstrate that iPSC technology can be used to observe phenotypes relevant to Alzheimer's disease, even though it can take decades for overt disease to manifest in patients.	[Israel, Mason A.; Yuan, Shauna H.; Reyna, Sol M.; Herrera, Cheryl; Goldstein, Lawrence S. B.] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; [Israel, Mason A.; Yuan, Shauna H.; Reyna, Sol M.; Herrera, Cheryl; Goldstein, Lawrence S. B.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Israel, Mason A.; Reyna, Sol M.] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Yuan, Shauna H.; Koo, Edward H.; Goldstein, Lawrence S. B.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Bardy, Cedric; Mu, Yangling; Gage, Fred H.] Salk Inst Biol Studies, La Jolla, CA 92037 USA; [Hefferan, Michael P.; Marsala, Martin] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Van Gorp, Sebastiaan] Maastricht Univ, Med Ctr, Dept Anesthesiol, NL-6202 AZ Maastricht, Netherlands; [Nazor, Kristopher L.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA; [Boscolo, Francesca S.; Laurent, Louise C.] Univ Calif San Diego, Dept Reprod Med, La Jolla, CA 92093 USA; [Carson, Christian T.] BD Biosci, La Jolla, CA 92037 USA; [Marsala, Martin] Slovak Acad Sci, Inst Neurobiol, SK-04001 Kosice, Slovakia; [Remes, Anne M.] Univ Oulu, Neurol & Clin Res Ctr, Dept Clin Med, FIN-90015 Oulu, Finland	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute; University of California System; University of California San Diego; Maastricht University; Scripps Research Institute; University of California System; University of California San Diego; Slovak Academy of Sciences; University of Oulu	Goldstein, LSB (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	lgoldstein@ucsd.edu	Bardy, Cedric/F-1182-2019	Bardy, Cedric/0000-0001-8321-0852; Laurent, Louise/0000-0002-2095-7534; Israel, Mason/0000-0003-0867-0626; Yuan, Shauna/0000-0003-4058-4146; van Gorp, Sebastiaan/0000-0003-3820-7536	University of California, San Diego (UCSD) Alzheimer's Disease Research Center [AGO 5131]; UCSD [P30 NS047101]; California Institute of Regenerative Medicine (CIRM) [TR1-01250, CL1-00502, RM1-01717]; FP7 Marie Curie IOF; Weatherstone Foundation; National Institutes of Health [K12 HD001259]; Hartwell Foundation; Lookout Fund; McDonnell Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD001259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047101, RC1NS068705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005131] Funding Source: NIH RePORTER	University of California, San Diego (UCSD) Alzheimer's Disease Research Center; UCSD; California Institute of Regenerative Medicine (CIRM)(California Institute for Regenerative Medicine); FP7 Marie Curie IOF; Weatherstone Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hartwell Foundation; Lookout Fund; McDonnell Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank D. Galasko, M. Sundsmo, J. Rivera, J. Fontaine, C. Gigliotti and B. Yu at the University of California, San Diego (UCSD) Alzheimer's Disease Research Center for patient samples and data (grant AGO 5131); S. Dowdy and N. Yoshioka for viral vectors; B. Balderas at BD Biosciences for antibodies; C. Santucci and S. Nguyen for teratoma assay assistance; the UCSD Neuroscience Microscopy Shared Facility (grant P30 NS047101); and Planned Parenthood of the Pacific Southwest for fetal brain specimens. Funding was from California Institute of Regenerative Medicine (CIRM) comprehensive grants (M. M., F. H. G., L. S. B. G.), CIRM predoctoral fellowship (M. A. I.), FP7 Marie Curie IOF (C. B.), Weatherstone Foundation fellowship (K. L. N.), National Institutes of Health K12 HD001259, the Hartwell Foundation (L. C. L., F. S. B.), the Lookout Fund and the McDonnell Foundation (F. H. G.). L. S. B. G. is an investigator with the Howard Hughes Medical Institute. Some experiments were conducted in J. F. Loring's laboratory (The Scripps Research Institute) with support from grants TR1-01250, CL1-00502, RM1-01717 (CIRM) and a gift from the Esther O'Keefe Foundation.	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Buerger K, 2002, NEUROLOGY, V59, P627, DOI 10.1212/WNL.59.4.627; Buerger K, 2006, BRAIN, V129, P3035, DOI 10.1093/brain/awl269; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; Cao XW, 2008, GENE DEV, V22, P3320, DOI 10.1101/gad.1726608; Cataldo A, 2001, ANN NEUROL, V50, P661, DOI 10.1002/ana.1254.abs; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677; Emre N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012148; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gasparini L, 1998, FASEB J, V12, P17, DOI 10.1096/fasebj.12.1.17; Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168; Ha NN, 2011, CELL STEM CELL, V8, P267, DOI 10.1016/j.stem.2011.01.013; HAMOS JE, 1989, NEUROLOGY, V39, P355, DOI 10.1212/WNL.39.3.355; Jiang Y, 2010, P NATL ACAD SCI USA, V107, P1630, DOI 10.1073/pnas.0908953107; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Nixon RA, 2005, NEUROBIOL AGING, V26, P373, DOI 10.1016/j.neurobiolaging.2004.09.018; Park IH, 2008, NAT PROTOC, V3, P1180, DOI 10.1038/nprot.2008.92; Qiang L, 2011, CELL, V146, P359, DOI 10.1016/j.cell.2011.07.007; Qin S, 2004, ACTA NEUROPATHOL, V107, P209, DOI 10.1007/s00401-003-0800-4; Reddy BVVG, 2011, DEVELOPMENT, V138, P5201, DOI 10.1242/dev.069385; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Rovelet-Lecrux A, 2007, J NEUROL NEUROSUR PS, V78, P1158, DOI 10.1136/jnnp.2006.113514; Salehi A, 2006, NEURON, V51, P29, DOI 10.1016/j.neuron.2006.05.022; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takashima A., 2001, CURRENT PROTOCOLS CE, V12; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Urbach A, 2010, CELL STEM CELL, V6, P407, DOI 10.1016/j.stem.2010.04.005; Yuan SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017540	36	803	856	15	382	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					216	U107		10.1038/nature10821	http://dx.doi.org/10.1038/nature10821			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22278060	Green Accepted, Green Submitted			2022-12-28	WOS:000299994100038
J	MacFadden, DR; Crystal, E; Krahn, AD; Mangat, I; Healey, JS; Dorian, P; Birnie, D; Simpson, CS; Khaykin, Y; Pinter, A; Nanthakumar, K; Calzavara, AJ; Austin, PC; Tu, JV; Lee, DS				MacFadden, Derek R.; Crystal, Eugene; Krahn, Andrew D.; Mangat, Iqwal; Healey, Jeffrey S.; Dorian, Paul; Birnie, David; Simpson, Christopher S.; Khaykin, Yaariv; Pinter, Arnold; Nanthakumar, Kumaraswamy; Calzavara, Andrew J.; Austin, Peter C.; Tu, Jack V.; Lee, Douglas S.			Sex Differences in Implantable Cardioverter-Defibrillator Outcomes: Findings From a Prospective Defibrillator Database	ANNALS OF INTERNAL MEDICINE			English	Article							SUDDEN CARDIAC DEATH; PRIMARY PREVENTION; GENDER-DIFFERENCES; WOMEN; MORTALITY; SURVIVAL; REGISTRY; DISEASE; ARREST; IMPACT	Background: Sex differences in the use and outcomes of implantable cardioverter-defibrillators (ICDs) have not been fully studied. Objective: To examine potential sex differences in ICD implantation and device outcomes. Design: Health payer-mandated, prospective study of patients referred for ICD implantation, with comprehensive, longitudinal follow-up for complications, deaths, and device outcomes. Setting: 18 ICD implantation and follow-up centers in Ontario, Canada. Patients: 6021 patients (4733 men) referred for ICD implantation from February 2007 to July 2010. Measurements: Multivariate-adjusted ICD implantation rate, complications up to day 45, multivariate-adjusted complications, device outcomes (including appropriate shocks and therapies), and deaths occurring during 1-year follow-up. Results: Rates of ICD implantation were similar in men and women (relative risk, 0.99 [95% CI, 0.97 to 1.02]; P = 0.60). However, women were significantly more likely to experience major complications by 45 days (odds ratio, 1.78 [CI, 1.24 to 2.58]; P = 0.002) and 1 year (hazard ratio [HR], 1.91 [CI, 1.48 to 2.47]; P < 0.001) after implantation. Occurrence of any major or minor complication was also increased in women at both 45-day follow-up (odds ratio, 1.50 [CI, 1.12 to 2.00]; P = 0.006) and 1-year follow-up (HR, 1.55 [CI, 1.25 to 1.93]; P < 0.001). After implantation, women were less likely than men to receive appropriate ICD shock (HR, 0.69 [CI, 0.51 to 0.93]; P = 0.015) or appropriate therapy via shock or antitachycardia pacing (HR, 0.73 [CI, 0.59 to 0.90]; P = 0.003). Total mortality among defibrillator recipients did not differ between men and women (HR, 1.00 [CI, 0.64 to 1.55]; P = 0.99). Limitation: The differential effects of sex on prereferral events were not examined. Conclusion: Although ICD implantation rates were similar after referral to an electrophysiologist, women who underwent ICD implantation had greater risks for complications and were less likely to experience appropriate ICD-delivered therapies than men.	[Lee, Douglas S.] Inst Clin Evaluat Sci, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada; Univ Western Ontario, London, ON, Canada; McMaster Univ, Hamilton, ON, Canada; Univ Ottawa, Ottawa, ON, Canada; Queens Univ, Kingston, ON, Canada; Southlake Reg Hlth Ctr, Newmarket, ON, Canada	University of Toronto; University of Toronto; Western University (University of Western Ontario); McMaster University; University of Ottawa; Queens University - Canada; Southlake Regional Health Centre	Lee, DS (corresponding author), Inst Clin Evaluat Sci, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	dlee@ices.on.ca	, Nanthakumar/AAA-9943-2020	Lee, Douglas/0000-0001-7078-745X; Austin, Peter/0000-0003-3337-233X; Tu, Jack/0000-0003-0111-722X	Canadian Institutes of Health Research [MOP 111150]; Ontario Ministry of Health and Long-Term Care	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario)	Grant Support: By an operating grant from the Canadian Institutes of Health Research (MOP 111150) and the Ontario Ministry of Health and Long-Term Care.	Airaksinen KEJ, 1998, J AM COLL CARDIOL, V31, P301, DOI 10.1016/S0735-1097(97)00489-0; Albert CM, 2008, AM HEART J, V156, P367, DOI 10.1016/j.ahj.2008.02.026; Albert CM, 2003, CIRCULATION, V107, P2096, DOI 10.1161/01.CIR.0000065223.21530.11; Albert CM, 1996, CIRCULATION, V93, P1170, DOI 10.1161/01.CIR.93.6.1170; Anderson KP, 2009, CIRCULATION, V119, P1069, DOI 10.1161/CIRCULATIONAHA.108.841452; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Birnie DH, 2007, CAN MED ASSOC J, V177, P41, DOI 10.1503/cmaj.060730; Chen HA, 2007, PACE, V30, P390, DOI 10.1111/j.1540-8159.2007.00680.x; Chugh SS, 2009, J AM COLL CARDIOL, V54, P2006, DOI 10.1016/j.jacc.2009.07.038; CUPPLES LA, 1992, CIRCULATION, V85, P11; Curtis LH, 2007, JAMA-J AM MED ASSOC, V298, P1517, DOI 10.1001/jama.298.13.1517; Daugherty SL, 2009, AM HEART J, V158, P224, DOI 10.1016/j.ahj.2009.05.018; El-Chami MF, 2007, HEART RHYTHM, V4, P1420, DOI 10.1016/j.hrthm.2007.07.024; Ghanbari H, 2009, ARCH INTERN MED, V169, P1500, DOI 10.1001/archinternmed.2009.255; Guru V, 2006, CIRCULATION, V113, P507, DOI 10.1161/CIRCULATIONAHA.105.576652; Henyan NN, 2006, J INTERN MED, V260, P467, DOI 10.1111/j.1365-2796.2006.01713.x; Hernandez AF, 2007, JAMA-J AM MED ASSOC, V298, P1525, DOI 10.1001/jama.298.13.1525; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Humphries KH, 2007, J AM COLL CARDIOL, V49, P1552, DOI 10.1016/j.jacc.2006.08.068; Jacobs AK, 2003, CIRCULATION, V107, P375, DOI 10.1161/01.CIR.0000048895.18974.6B; Jacobs AK, 2002, J AM COLL CARDIOL, V39, P1608, DOI 10.1016/S0735-1097(02)01835-1; Kannel WB, 1998, AM HEART J, V136, P205, DOI 10.1053/hj.1998.v136.90226; Lampert R, 2004, J AM COLL CARDIOL, V43, P2293, DOI 10.1016/j.jacc.2004.03.031; Larsen JA, 1998, J CARDIOVASC ELECTR, V9, P655, DOI 10.1111/j.1540-8167.1998.tb00950.x; Lee DS, 2008, HEART RHYTHM, V5, P1250, DOI 10.1016/j.hrthm.2008.05.015; Lee DS, 2007, J AM COLL CARDIOL, V49, P2408, DOI 10.1016/j.jacc.2007.02.058; Lee DS, 2010, J AM COLL CARDIOL, V55, P774, DOI 10.1016/j.jacc.2009.11.029; Lee DS, 2009, CIRC-HEART FAIL, V2, P616, DOI 10.1161/CIRCHEARTFAILURE.109.869743; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; MacFadden DR, 2009, HEART RHYTHM, V6, P1289, DOI 10.1016/j.hrthm.2009.05.017; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Peterson PN, 2009, CIRCULATION, V119, P1078, DOI 10.1161/CIRCULATIONAHA.108.793463; Rosner B., 1999, FUNDAMENTALS BIOSTAT; Russo AM, 2008, J CARDIOVASC ELECTR, V19, P720, DOI 10.1111/j.1540-8167.2008.01129.x; Russo AM, 2009, J CARDIOVASC ELECTR, V20, P973, DOI 10.1111/j.1540-8167.2009.01489.x; Tu JV, 2004, NEW ENGL J MED, V350, P1414, DOI 10.1056/NEJMsa031697; Udell JA, 2007, INT J TECHNOL ASSESS, V23, P354, DOI 10.1017/S0266462307070389; Wathen MS, 2004, CIRCULATION, V110, P2591, DOI 10.1161/01.CIR.0000145610.64014.E4; Yancy CW, 2009, AM HEART J, V157, P754, DOI 10.1016/j.ahj.2008.12.016; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	41	94	94	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2012	156	3					195	+		10.7326/0003-4819-156-3-201202070-00007	http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XD	22312139				2022-12-28	WOS:000299964200003
J	Arima, Y; Harada, M; Kamimura, D; Park, JH; Kawano, F; Yull, FE; Kawamoto, T; Iwakura, Y; Betz, UAK; Marquez, G; Blackwell, TS; Ohira, Y; Hirano, T; Murakami, M				Arima, Yasunobu; Harada, Masaya; Kamimura, Daisuke; Park, Jin-Haeng; Kawano, Fuminori; Yull, Fiona E.; Kawamoto, Tadafumi; Iwakura, Yoichiro; Betz, Ulrich A. K.; Marquez, Gabriel; Blackwell, Timothy S.; Ohira, Yoshinobu; Hirano, Toshio; Murakami, Masaaki			Regional Neural Activation Defines a Gateway for Autoreactive T Cells to Cross the Blood-Brain Barrier	CELL			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE ENCEPHALOMYELITIS; ADOPTIVE TRANSFER; SPLEEN-CELLS; IN-VITRO; IMMUNE; PROLIFERATION; INTERLEUKIN-6; SYSTEM; MICE	Although it is believed that neural activation can affect immune responses, very little is known about the neuroimmune interactions involved, especially the regulators of immune traffic across the blood-brain barrier which occurs in neuroimmune diseases such as multiple sclerosis (MS). Using a mouse model of MS, experimental autoimmune encephalomyelitis, we show that autoreactive T cells access the central nervous system via the fifth lumbar spinal cord. This location is defined by IL-6 amplifier-dependent upregulation of the chemokine CCL20 in associated dorsal blood vessels, which in turn depends on gravity-induced activation of sensory neurons by the soleus muscle in the leg. Impairing soleus muscle contraction by tail suspension is sufficient to reduce localized chemokine expression and block entry of pathogenic T cells at the fifth lumbar cord, suggesting that regional neuroimmune interactions may offer therapeutic targets for a variety of neurological diseases.	[Arima, Yasunobu; Harada, Masaya; Kamimura, Daisuke; Park, Jin-Haeng; Hirano, Toshio; Murakami, Masaaki] Osaka Univ, Lab Dev Immunol, JST CREST, Grad Sch Frontier Biosci,Grad Sch Med, Suita, Osaka 5650871, Japan; [Arima, Yasunobu; Harada, Masaya; Kamimura, Daisuke; Park, Jin-Haeng; Hirano, Toshio; Murakami, Masaaki] Osaka Univ, WPI Immunol Frontier Res Ctr, Suita, Osaka 5650871, Japan; [Kawano, Fuminori; Ohira, Yoshinobu] Osaka Univ, Dept Hlth & Sports Sci, Grad Sch Med, Osaka 5600043, Japan; [Yull, Fiona E.; Blackwell, Timothy S.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Blackwell, Timothy S.] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; [Kawamoto, Tadafumi] Tsurumi Univ, Dept Dent Med, Radioisotope Res Inst, Yokohama, Kanagawa 2308501, Japan; [Iwakura, Yoichiro] Univ Tokyo, Ctr Expt Med & Syst Biol, Inst Med Sci, Tokyo 1088639, Japan; [Betz, Ulrich A. K.] Portfolio Dev Merck Serono, Merck KGaA, D-64293 Darmstadt, Germany; [Marquez, Gabriel] Natl Ctr Biotechnol CNB CSIC, Madrid 28049, Spain; [Hirano, Toshio] RIKEN Res Ctr Allergy & Immunol, Lab Cytokine Signaling, Yokohama, Kanagawa 2300045, Japan	Osaka University; Osaka University; Osaka University; Vanderbilt University; Vanderbilt University; Tsurumi University; University of Tokyo; Merck KGaA; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); RIKEN	Murakami, M (corresponding author), Osaka Univ, Lab Dev Immunol, JST CREST, Grad Sch Frontier Biosci,Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	murakami@molonc.med.osaka-u.ac.jp	Iwakura, Yoichiro/E-5457-2011	Iwakura, Yoichiro/0000-0002-9934-5775; Harada, Masaya/0000-0002-1318-3542; Kamimura, Daisuke/0000-0003-1022-4430; , Masaaki/0000-0001-7159-7279	KAKENHI; JST-CREST; Osaka Foundation for the Promotion of Clinical Immunology; Grants-in-Aid for Scientific Research [10J05573] Funding Source: KAKEN	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); JST-CREST(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); Osaka Foundation for the Promotion of Clinical Immunology; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr. M. Kopf (Max-Planck-Institute of Immunobiology, Germany) for the IL-6-deficient mice, Dr. G. Karsenty (Baylor College of Medicine, Houston, TX) for the type I collagen-Cre mice, and Dr. S. Akira (Osaka University, Osaka, Japan) for the STAT3<SUP>flox/flox</SUP> mice. We appreciate the excellent technical assistances provided by Dr. J-J. Jiang, Ms. A. Okuyama, and Ms. N. Kumai, and thank Ms. R. Masuda for her excellent secretarial work. We thank Dr. M. Yagi and Dr. P. Karagiannis (Osaka University) for carefully reading the manuscript. We are grateful to Dr. Fujio Murakami (Osaka University) for important discussions and advice for how to do the neural experiments and thank Dr. M. Miyasaka (Osaka University) for important discussions about blood vessels for lymphocyte migration. We are also grateful to Dr. Y. Nakatsuji and Dr. M. Kinoshita (Osaka University) for important discussions about MS patients and thank Dr. Y. Okuyama and Dr. H. Ogura (Osaka University) for important discussions and carefully reading this manuscript. We thank Dr. Y. Oke (Osaka University) for important discussions about the tail suspension experiment. We thank Jihye Lee for her help in preparing the Graphical Abstract. This work was supported by KAKENHI (Y.A., M.H., T.H., and M.M.), the JST-CREST program (T.H. and M.M.), and the Osaka Foundation for the Promotion of Clinical Immunology (M.M.).	Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; BROSNAN CF, 1985, P NATL ACAD SCI USA, V82, P5915, DOI 10.1073/pnas.82.17.5915; Canu MH, 2009, EXP NEUROL, V218, P98, DOI 10.1016/j.expneurol.2009.04.009; De-Doncker L, 2005, J EXP BIOL, V208, P4585, DOI 10.1242/jeb.01931; Dimitrijevic M, 2007, EUR J PHARMACOL, V577, P170, DOI 10.1016/j.ejphar.2007.08.021; Felten DL, 2000, PROG BRAIN RES, V122, P381; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Hirano T, 2010, P JPN ACAD B-PHYS, V86, P717, DOI 10.2183/pjab.86.717; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Kaufman MP, 2002, CLIN AUTON RES, V12, P429, DOI 10.1007/s10286-002-0059-1; Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123; Kawano F, 2007, AM J PHYSIOL-CELL PH, V293, pC35, DOI 10.1152/ajpcell.00297.2006; Kawano F, 2002, NEUROSCIENCE, V114, P1133, DOI 10.1016/S0306-4522(02)00304-4; Longhurst JC, 2010, J ACUPUNCT MERIDIAN, V3, P67, DOI 10.1016/S2005-2901(10)60014-3; MATSUMOTO Y, 1988, AM J PATHOL, V133, P306; McGavern DB, 2011, NAT REV IMMUNOL, V11, P318, DOI 10.1038/nri2971; Murakami M, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00022; Murakami M, 2011, J EXP MED, V208, P103, DOI 10.1084/jem.20100900; Nakao R, 2009, MOL CELL BIOL, V29, P4798, DOI 10.1128/MCB.01347-08; Nance DM, 2007, BRAIN BEHAV IMMUN, V21, P736, DOI 10.1016/j.bbi.2007.03.008; Nishihara M, 2007, INT IMMUNOL, V19, P695, DOI 10.1093/intimm/dxm045; Ogura H, 2008, IMMUNITY, V29, P628, DOI 10.1016/j.immuni.2008.07.018; Ohira M, 2002, JPN J PHYSIOL, V52, P235, DOI 10.2170/jjphysiol.52.235; Ohira Y., 2004, J GRAVIT PHYSL, V11, pP127; PANITCH HS, 1980, CELL IMMUNOL, V56, P163, DOI 10.1016/0008-8749(80)90091-X; Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Sadikot Ruxana T., 2008, V477, P383, DOI 10.1007/978-1-60327-517-0_29; Salinas S, 2010, NAT REV MICROBIOL, V8, P645, DOI 10.1038/nrmicro2395; Sawa Y, 2009, IMMUNITY, V30, P447, DOI 10.1016/j.immuni.2009.01.007; Smith SA, 2006, EXP PHYSIOL, V91, P89, DOI 10.1113/expphysiol.2005.032367; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Takeda K, 1998, J IMMUNOL, V161, P4652; Thayer JF, 2010, BRAIN BEHAV IMMUN, V24, P1223, DOI 10.1016/j.bbi.2010.07.247; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Ueda N, 2006, INT IMMUNOL, V18, P1397, DOI 10.1093/intimm/dxl073; Varona R, 2001, J CLIN INVEST, V107, pR37, DOI 10.1172/JCI11297; Watkins LR, 1999, P NATL ACAD SCI USA, V96, P7710, DOI 10.1073/pnas.96.14.7710; Wilson EH, 2010, J CLIN INVEST, V120, P1368, DOI 10.1172/JCI41911; Xie WR, 2010, PAIN, V151, P447, DOI 10.1016/j.pain.2010.08.006	40	216	221	3	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					447	457		10.1016/j.cell.2012.01.022	http://dx.doi.org/10.1016/j.cell.2012.01.022			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304915	Bronze			2022-12-28	WOS:000300225000014
J	Swinnen, J; Squicciarini, P				Swinnen, Johan; Squicciarini, Pasquamaria			Mixed Messages on Prices and Food Security	SCIENCE			English	Editorial Material							COUNTRIES		[Swinnen, Johan; Squicciarini, Pasquamaria] Katholieke Univ Leuven, Ctr Inst & Econ Performance LICOS, Louvain, Belgium; [Swinnen, Johan; Squicciarini, Pasquamaria] Katholieke Univ Leuven, Dept Econ, Louvain, Belgium; [Swinnen, Johan] Stanford Univ, Ctr Food Secur & Environm, Palo Alto, CA 94304 USA	KU Leuven; KU Leuven; Stanford University	Squicciarini, P (corresponding author), Katholieke Univ Leuven, Ctr Inst & Econ Performance LICOS, Louvain, Belgium.	mara.squicciarini@econ.kuleuven.be	Swinnen, Johan/AAC-1736-2021	Swinnen, Johan/0000-0002-8650-1978				Anderson K., 2007, AGR TRADE REFORM DOH; Andreoni J, 2003, AM ECON REV, V93, P792, DOI 10.1257/000282803322157098; Banerjee A., 2011, POOR EC RADICAL RETH; Baumeister R.F., 2001, REV GEN PSYCHOL, V5, P323, DOI [10.1037//1089-2680.5.4.323, DOI 10.1037//1089-2680.5.4.323, https://doi.org/10.1037/1089-2680.5.4.323, DOI 10.1037/1089-2680.5.4.323]; Bouet A., 2010, 00994 IFPRI; Bureau J. C., 2006, World Trade Review, V5, P225, DOI 10.1017/S147474560600276X; Christiaensen Luc., 2007, EARTH AGR POVERTY RE; Cline W.R., 2004, TRADE POLICY GLOBAL; FAO, 2008, FAOHLC08INF1; FAO, HIGH FOOD PRIC SUPP; Food and Agriculture Organization (FAO), 2010, STATE FOOD INSECURIT; Hawkins V., 2002, JOURNALISM STUD, P225, DOI [10.1080/14616700220129991, DOI 10.1080/14616700220129991]; Headey D., 2011, 01087 IFPRI; Hertel T. W., 2006, POVERTY WTO; Hertel TW, 2007, ECON POLICY, P289; Hertel Thomas W., 2005, J INT TRADE ECON DEV, V14, P377, DOI DOI 10.1080/09638190500372404; Ivanic M., 2008, WORKING PAPER SERIES; Jakobsen PV, 2000, J PEACE RES, V37, P131, DOI 10.1177/0022343300037002001; Marks L. A., 2003, Journal of Agribusiness, V21, P1; MARSHALL LL, 1981, SOC BEHAV PERSONAL, V9, P223, DOI 10.2224/sbp.1981.9.2.223; McCluskey J. J., 2004, American Journal of Agricultural Economics, V86, P1230, DOI 10.1111/j.0002-9092.2004.00670.x; McCluskey J. J., 2010, OXFORD HDB GOVT BUSI, P643; Naylor RL, 2010, POPUL DEV REV, V36, P693, DOI 10.1111/j.1728-4457.2010.00354.x; OXFAM International, AGR CAMP GLOB FOOD P; OXFAM International, 2005, INT CEL GET DUMP WSF; Panagariya A, 2005, WORLD ECON, V28, P1277, DOI 10.1111/j.1467-9701.2005.00734.x; ROSEACKERMAN S, 1982, Q J ECON, V97, P193, DOI 10.2307/1880754; Sarris A., 2010, FOOD SECURITY AFRICA; SWINNEN J., 2011, FOOD SECURITY TRANSI; Swinnen JFM, 2006, WORLD ECON, V29, P637, DOI 10.1111/j.1467-9701.2006.00804.x; Swinnen J, 2011, DEV POLICY REV, V29, P667, DOI 10.1111/j.1467-7679.2011.00552.x; Verpoorten M., 2012, 303 LICOS; World Bank, 2008, FOOD PRIC SURG COULD; World Bank, 2003, REACH RUR POOR; World Bank, 2009, IMPL AGR DEV WORLD B	35	93	95	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					405	406		10.1126/science.1210806	http://dx.doi.org/10.1126/science.1210806			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	881FG	22282793				2022-12-28	WOS:000299466800028
J	Andrews, NC				Andrews, Nancy C.			Closing the Iron Gate	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEPCIDIN; ANEMIA; OVERLOAD		Duke Univ, Sch Med, Durham, NC 27706 USA	Duke University	Andrews, NC (corresponding author), Duke Univ, Sch Med, Durham, NC 27706 USA.			Andrews, Nancy/0000-0003-0243-4462	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK089705, R01DK066373] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK066373, R01 DK089705] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Finberg KE, 2008, NAT GENET, V40, P569, DOI 10.1038/ng.130; Gardenghi S, 2010, J CLIN INVEST, V120, P4466, DOI 10.1172/JCI41717; Nicolas G, 2003, NAT GENET, V34, P97, DOI 10.1038/ng1150; Preza GC, 2011, J CLIN INVEST   1101; Roy CN, 2005, CURR OPIN HEMATOL, V12, P107, DOI 10.1097/00062752-200503000-00001	5	19	19	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					376	377		10.1056/NEJMcibr1112780	http://dx.doi.org/10.1056/NEJMcibr1112780			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	881EQ	22276828				2022-12-28	WOS:000299464100011
J	Haeno, H; Gonen, M; Davis, MB; Herman, JM; Iacobuzio-Donahue, CA; Michor, F				Haeno, Hiroshi; Gonen, Mithat; Davis, Meghan B.; Herman, Joseph M.; Iacobuzio-Donahue, Christine A.; Michor, Franziska			Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies	CELL			English	Article							PROGRESSION; CARCINOMA; SURVIVAL; DORMANCY; CHEMOTHERAPY; GEMCITABINE; INSTABILITY; RESECTION; DYNAMICS; PATTERNS	Pancreatic cancer is a leading cause of cancer-related death, largely due to metastatic dissemination. We investigated pancreatic cancer progression by utilizing a mathematical framework of metastasis formation together with comprehensive data of 228 patients, 101 of whom had autopsies. We found that pancreatic cancer growth is initially exponential. After estimating the rates of pancreatic cancer growth and dissemination, we determined that patients likely harbor metastases at diagnosis and predicted the number and size distribution of metastases as well as patient survival. These findings were validated in an independent database. Finally, we analyzed the effects of different treatment modalities, finding that therapies that efficiently reduce the growth rate of cells earlier in the course of treatment appear to be superior to upfront tumor resection. These predictions can be validated in the clinic. Our interdisciplinary approach provides insights into the dynamics of pancreatic cancer metastasis and identifies optimum therapeutic interventions.	[Davis, Meghan B.; Herman, Joseph M.; Iacobuzio-Donahue, Christine A.] Johns Hopkins Univ Hosp, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21231 USA; [Iacobuzio-Donahue, Christine A.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21231 USA; [Iacobuzio-Donahue, Christine A.] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21231 USA; [Iacobuzio-Donahue, Christine A.] Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21231 USA; [Herman, Joseph M.] Johns Hopkins Univ Hosp, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA; [Haeno, Hiroshi; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Haeno, Hiroshi; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Gonen, Mithat] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Memorial Sloan Kettering Cancer Center	Iacobuzio-Donahue, CA (corresponding author), Johns Hopkins Univ Hosp, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21231 USA.	ciacobu@jhmi.edu; michor@jimmy.harvard.edu	Iacobuzio-Donahue, Christine/ABF-1295-2020; Gonen, Mithat/E-4826-2012	Iacobuzio-Donahue, Christine/0000-0002-4672-3023; Gonen, Mithat/0000-0001-8683-8477	National Institutes of Health [CA106610, CA62924]; Sol Goldman Pancreatic Cancer Research Center; Michael Rolfe Pancreatic Cancer Foundation; George Rubis Endowment for Pancreatic Cancer Research; Joseph C. Monastra Foundation for Pancreatic Cancer Research; Alfredo Scatena Memorial Fund; National Cancer Institute's Physical Sciences-Oncology Center [U54CA143798]; NATIONAL CANCER INSTITUTE [P50CA062924, R01CA140599, K08CA106610, U54CA143798] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sol Goldman Pancreatic Cancer Research Center; Michael Rolfe Pancreatic Cancer Foundation; George Rubis Endowment for Pancreatic Cancer Research; Joseph C. Monastra Foundation for Pancreatic Cancer Research; Alfredo Scatena Memorial Fund; National Cancer Institute's Physical Sciences-Oncology Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors would like to thank the Michor lab and Georg Lubeck for helpful comments. This work was supported by National Institutes of Health grants CA106610 and CA62924 (C.A.I.-D.), Pilot Funding from the Sol Goldman Pancreatic Cancer Research Center, the Michael Rolfe Pancreatic Cancer Foundation, the George Rubis Endowment for Pancreatic Cancer Research, the Joseph C. Monastra Foundation for Pancreatic Cancer Research, and The Alfredo Scatena Memorial Fund. Furthermore, we would like to acknowledge support from the National Cancer Institute's Physical Sciences-Oncology Center, U54CA143798 (H. H., M. G., and F. M.).	AMIKURA K, 1995, INT J PANCREATOL, V17, P139; Andasari V, 2011, J MATH BIOL, V63, P141, DOI 10.1007/s00285-010-0369-1; Artinyan A, 2011, CANCER-AM CANCER SOC, V117, P2044, DOI 10.1002/cncr.25763; Arvold ND, 2011, INT J RADIAT ONCOL, V80, P1383, DOI 10.1016/j.ijrobp.2010.04.058; Ayoub JP, 1998, J CLIN ONCOL, V16, P2105, DOI 10.1200/JCO.1998.16.6.2105; Cameron MD, 2000, CANCER RES, V60, P2541; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Chauviere AH, 2010, CURR BREAST CANCER R, V2, P121, DOI 10.1007/s12609-010-0020-6; Desai S, 2009, INT J RADIAT ONCOL, V75, P1450, DOI 10.1016/j.ijrobp.2009.01.023; Dingli D, 2007, CANCER BIOL THER, V6, P383, DOI 10.4161/cbt.6.3.3720; Embuscado EE, 2005, CANCER BIOL THER, V4, P548, DOI 10.4161/cbt.4.5.1663; Haeno H, 2010, J THEOR BIOL, V263, P30, DOI 10.1016/j.jtbi.2009.11.005; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hsu CC, 2010, ANN SURG ONCOL, V17, P981, DOI 10.1245/s10434-009-0743-7; Iacobuzio-Donahue CA, 2012, GUT, V61, P1085, DOI 10.1136/gut.2010.236026; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Jadhav S, 2007, CURR PHARM DESIGN, V13, P1511, DOI 10.2174/138161207780765909; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Katz MHG, 2009, ANN SURG ONCOL, V16, P836, DOI 10.1245/s10434-008-0295-2; Klein CA, 2006, CELL CYCLE, V5, P1788, DOI 10.4161/cc.5.16.3097; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Michor F, 2006, J THEOR BIOL, V240, P521, DOI 10.1016/j.jtbi.2005.10.021; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Neuhaus P., 2008, J CLIN ONCOL S, V26, p214s; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Quaranta V, 2008, SEMIN CANCER BIOL, V18, P338, DOI 10.1016/j.semcancer.2008.03.018; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sato N, 2006, J HEPATO-BILIARY-PAN, V13, P286, DOI 10.1007/s00534-005-1057-1; Schellenberg D, 2011, INT J RADIAT ONCOL, V81, P181, DOI 10.1016/j.ijrobp.2010.05.006; SESHADRI R, 1987, CANCER RES, V47, P407; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sherratt J A, 2001, Methods Mol Med, V57, P309, DOI 10.1385/1-59259-136-1:309; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Valastyan S, 2009, GENE DEV, V23, P2592, DOI 10.1101/gad.1832709; van Heek NT, 2002, AM J PATHOL, V161, P1541, DOI 10.1016/S0002-9440(10)64432-X; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	48	303	316	1	48	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					362	375		10.1016/j.cell.2011.11.060	http://dx.doi.org/10.1016/j.cell.2011.11.060			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265421	Bronze, Green Accepted			2022-12-28	WOS:000299540700037
J	Appleby, J				Appleby, John			DATA BRIEFING Reducing greenhouse gas emissions: on target?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London W1G 0AN, England		Appleby, J (corresponding author), Kings Fund, London W1G 0AN, England.	j.appleby@kingsfund.org.uk						NHS Sustainable Development Unit, 2008, SAV CARB IMPR HLTH N; NHS Sustainable Development Unit, 2011, SAV CARB IMPR HLTH U; NHS Sustainable Development Unit, SUST NHS HL IN PRESS; UN Statistics Division, 2011, ENV IND GREENH GAS E	4	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 18	2012	344								e376	10.1136/bmj.e376	http://dx.doi.org/10.1136/bmj.e376			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YZ	22258106				2022-12-28	WOS:000300041900011
J	McKee, M				McKee, Martin			PERSONAL VIEW Does anyone understand the government's plan for the NHS?	BRITISH MEDICAL JOURNAL			English	Editorial Material									London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	McKee, M (corresponding author), London Sch Hyg & Trop Med, London WC1, England.	martin.mckee@lshtm.ac.uk	McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683				2011, BRIT MED J, V342, pD566; 2008, HLTH AFFAIRS, V27, P58	2	12	12	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2012	344								e399	10.1136/bmj.e399	http://dx.doi.org/10.1136/bmj.e399			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YY	22252040	Green Submitted			2022-12-28	WOS:000300041800010
J	Rhee, HS; Pugh, BF				Rhee, Ho Sung; Pugh, B. Franklin			Genome-wide structure and organization of eukaryotic pre-initiation complexes	NATURE			English	Article							RNA-POLYMERASE-II; START SITE SELECTION; PHOTO-CROSS-LINKING; IN-VIVO; TRANSCRIPTION INITIATION; SACCHAROMYCES-CEREVISIAE; PERVASIVE TRANSCRIPTION; BIDIRECTIONAL PROMOTERS; PREINITIATION COMPLEX; GENE-REGULATION	Transcription and regulation of genes originate from transcription pre-initiation complexes (PICs). Their structural and positional organization across eukaryotic genomes is unknown. Here we applied lambda exonuclease to chromatin immunoprecipitates (termed ChIP-exo) to examine the precise location of 6,045 PICs in Saccharomyces. PICs, including RNA polymerase II and protein complexes TFIIA, TFIIB, TFIID (or TBP), TFIIE, TFIIF, TFIIH and TFIIK were positioned within promoters and excluded from coding regions. Exonuclease patterns were in agreement with crystallographic models of the PIC, and were sufficiently precise to identify TATA-like elements at so-called TATA-less promoters. These PICs and their transcription start sites were positionally constrained at TFIID-engaged downstream +1 nucleosomes. At TATA-box-containing promoters, which are depleted of TFIID, a 11 nucleosome was positioned to be in competition with the PIC, which may allow greater latitude in start-site selection. Our genomic localization of messenger RNA and non-coding RNA PICs reveals that two PICs, in inverted orientation, may occupy the flanking borders of nucleosome-free regions. Their unambiguous detection may help distinguish bona fide genes from transcriptional noise.	[Rhee, Ho Sung; Pugh, B. Franklin] Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pugh, BF (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, University Pk, PA 16802 USA.	bfp2@psu.edu			National Institutes of Health [GM059055]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059055] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank I. Albert and Y. Li for bioinformatic support, and members of the Pugh laboratory and the Penn State Center for Eukaryotic Gene Regulation for valuable discussions. Sequencing was performed at the Penn State Genomics Core Facility. This work was supported by National Institutes of Health grant GM059055.	Ahn SH, 2009, EMBO J, V28, P205, DOI 10.1038/emboj.2008.280; Albert I, 2008, BIOINFORMATICS, V24, P1305, DOI 10.1093/bioinformatics/btn119; Ansari A, 2005, GENE DEV, V19, P2969, DOI 10.1101/gad.1362305; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chen HT, 2004, CELL, V119, P169, DOI 10.1016/j.cell.2004.09.028; David L, 2006, P NATL ACAD SCI USA, V103, P5320, DOI 10.1073/pnas.0601091103; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Faitar SL, 2001, MOL CELL BIOL, V21, P4427, DOI 10.1128/MCB.21.14.4427-4440.2001; Flom G, 2005, CURR GENET, V47, P368, DOI 10.1007/s00294-005-0580-6; Forget D, 2004, MOL CELL BIOL, V24, P1122, DOI 10.1128/MCB.24.3.1122-1131.2004; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Gerstein MB, 2007, GENOME RES, V17, P669, DOI 10.1101/gr.6339607; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; Granovskaia MV, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r24; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Jacquier A, 2009, NAT REV GENET, V10, P833, DOI 10.1038/nrg2683; Jiang CZ, 2009, NAT REV GENET, V10, P161, DOI 10.1038/nrg2522; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Koerber RT, 2009, MOL CELL, V35, P889, DOI 10.1016/j.molcel.2009.09.011; Kostrewa D, 2009, NATURE, V462, P323, DOI 10.1038/nature08548; Kuehner JN, 2006, J BIOL CHEM, V281, P14119, DOI 10.1074/jbc.M601937200; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; Liu X, 2010, SCIENCE, V327, P206, DOI 10.1126/science.1182015; Matangkasombut O, 2000, GENE DEV, V14, P951; Mayer A, 2010, NAT STRUCT MOL BIOL, V17, P1272, DOI 10.1038/nsmb.1903; Mohibullah N, 2008, GENE DEV, V22, P2994, DOI 10.1101/gad.1724408; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pal M, 2005, MOL CELL, V19, P101, DOI 10.1016/j.molcel.2005.05.024; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; Rhee HS, 2011, CELL, V147, P1408, DOI 10.1016/j.cell.2011.11.013; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Singh BN, 2007, MOL CELL, V27, P806, DOI 10.1016/j.molcel.2007.07.013; Sugihara F, 2011, NUCLEIC ACIDS RES, V39, P59, DOI 10.1093/nar/gkq741; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; Tirosh I, 2008, GENOME RES, V18, P1084, DOI 10.1101/gr.076059.108; van Dijk EL, 2011, NATURE, V475, P114, DOI 10.1038/nature10118; Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016; Wei W, 2011, TRENDS GENET, V27, P267, DOI 10.1016/j.tig.2011.04.002; Xu ZY, 2009, NATURE, V457, P1033, DOI 10.1038/nature07728; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	50	347	352	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 15	2012	483	7389					295	301		10.1038/nature10799	http://dx.doi.org/10.1038/nature10799			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	908HP	22258509	Green Accepted			2022-12-28	WOS:000301481800041
J	Osterholm, MT; Henderson, DA				Osterholm, Michael T.; Henderson, Donald A.			Life Sciences at a Crossroads: Respiratory Transmissible H5N1	SCIENCE			English	Editorial Material							INFLUENZA; VACCINE; VIRUS		Univ Minnesota, Sch Med, Ctr Infect Dis Res, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Div Environm Hlth Sci, Minneapolis, MN 55455 USA; Univ Pittsburgh, UPMC, Ctr Biosecur, Pittsburgh, PA 15213 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh		mto@umn.edu						[Anonymous], 2011, APPR CONTR PREV EL H; [Anonymous], 2007, WHO GEN TECH REP; CDC, 2010, PERC VIS INFL LIK IL; CDC, 2009, H1N1 INFL VACC DOS A; Food and Agricultural Organization of the United Nations (FAO, 2011, STAMP OUT H5N1 AV IN; Khan K, 2009, NEW ENGL J MED, V361, P212, DOI 10.1056/NEJMc0904559; MURRAY R, 1961, AM REV RESPIR DIS, V83, P160; MURRAY R, 1969, B WORLD HEALTH ORGAN, V41, P495; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X	9	22	23	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	2012	335	6070					801	802		10.1126/science.1218612	http://dx.doi.org/10.1126/science.1218612			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	893LC	22267584				2022-12-28	WOS:000300356400026
J	Leung, CT; Brugge, JS				Leung, Cheuk T.; Brugge, Joan S.			Outgrowth of single oncogene-expressing cells from suppressive epithelial environments	NATURE			English	Article							IN-VIVO; BREAST-CANCER; EXTRUSION; MORPHOGENESIS; APOPTOSIS; MIGRATION; ACINI	Tumorigenesis is a clonal evolution process that is initiated from single cells within otherwise histologically normal tissue(1). It is unclear how single, sporadic mutant cells that have sustained oncogenic alterations evolve within a tightly regulated tissue environment. Here we investigated the effects of inducing oncogene expression in single cells in organotypic mammary acini as a model to elucidate the processes by which oncogenic alterations initiate clonal progression from organized epithelial environments. Sporadic cells induced to overexpress oncogenes that specifically perturb cell-cycle checkpoints (for example, E7 from human papilloma virus 16, and cyclin D1), deregulate Myc transcription or activate AKT signalling remained quiescent within growth-arrested acini. By contrast, single cells that overexpress ERBB2 initiated a cellular cascade involving cell translocation from the epithelial layer, as well as luminal outgrowth that is characteristic of neoplastic progression in early-stage epithelial tumours. In addition, ERBB2-mediated cell translocation to the lumen was found to depend on extracellular-regulated kinase and matrix metalloproteinase activities, and genetic alterations that perturb local cell-matrix adhesion drove cell translocation. We also provide evidence that luminal cell translocation may drive clonal selection by promoting either the death or the expansion of quiescent oncogene-expressing cells, depending on whether the pre-existing alterations allow anchorage-independent survival and growth. Our data show that the initial outgrowth of single oncogene-expressing cells from organized epithelial structures is a highly regulated process, and we propose that a cell translocation mechanism allows sporadic mutant cells to evade suppressive micro-environments and elicits clonal selection for survival and proliferative expansion outside the native niches of these cells.	[Leung, Cheuk T.; Brugge, Joan S.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Brugge, JS (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	Joan_Brugge@hms.harvard.edu		Leung, Cheuk/0000-0002-5838-5535	National Cancer Institute [CA080111]; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA105134, P01CA080111] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank S. Valastyan, T. Muranen and W. Lee for critical reading of the manuscript. We thank the members of the Brugge laboratory for comments and discussion, the Nikon Imaging Center at Harvard Medical School for providing imaging equipment and software, and the laboratory of G. Danuser for imaging software support. This work was supported by a grant from the National Cancer Institute (CA080111, to J.S.B.) and an American Cancer Society postdoctoral fellowship (C.T.L.).	Aman A, 2010, DEV BIOL, V341, P20, DOI 10.1016/j.ydbio.2009.11.014; Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; Bullen TF, 2006, LAB INVEST, V86, P1052, DOI 10.1038/labinvest.3700464; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; Gibson MC, 2005, SCIENCE, V307, P1785, DOI 10.1126/science.1104751; Gunawardane RN, 2005, CANCER RES, V65, P11572, DOI 10.1158/0008-5472.CAN-05-1196; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; Hogan C, 2009, NAT CELL BIOL, V11, P460, DOI 10.1038/ncb1853; Holst CR, 2003, CANCER RES, V63, P1596; ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kajita M, 2010, J CELL SCI, V123, P171, DOI 10.1242/jcs.057976; Li XH, 2010, GENE DEV, V24, P933, DOI 10.1101/gad.1901510; Lincoln DW, 2005, FRONT BIOSCI-LANDMRK, V10, P506, DOI 10.2741/1546; Marshall TW, 2011, MOL BIOL CELL, V22, P3962, DOI 10.1091/mbc.E11-05-0469; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Pearson GW, 2007, J CELL BIOL, V179, P1555, DOI 10.1083/jcb.200706099; Rosenblatt J, 2001, CURR BIOL, V11, P1847, DOI 10.1016/S0960-9822(01)00587-5; Shen J, 2005, SCIENCE, V307, P1789, DOI 10.1126/science.1104784; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231	26	168	172	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2012	482	7385					410	U160		10.1038/nature10826	http://dx.doi.org/10.1038/nature10826			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	892LG	22318515	Green Accepted			2022-12-28	WOS:000300287100048
J	McColl, K				McColl, Karen			PR AND LOBBYING Wendell Potter: Pulling the curtains back on spin	BRITISH MEDICAL JOURNAL			English	Editorial Material												karenmccoll@gmail.com						Alliance for Lobbying Transparency, 2012, PROP STAT REG HAS LO; Bureau of Investigative Journalism, VID BELL POTT EX FIL; Cabinet Office, 2012, INTR STAT REG LOBB; Chartered Institute of Public Relations, 2011, CIPR SOC MED CIPRSM; Newman M, 2011, INDEPENDENT     1206; Potter W., 2010, DEADLY SPIN INSURANC	6	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	2012	344								e833	10.1136/bmj.e833	http://dx.doi.org/10.1136/bmj.e833			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892ID	22315248				2022-12-28	WOS:000300279000006
J	Arumugam, D; Atherton, JJ; Martin, PT				Arumugam, Deepak; Atherton, John J.; Martin, Paul T.			A lethal injection?	LANCET			English	Editorial Material							BRUGADA-SYNDROME		[Arumugam, Deepak] Royal Jubilee Hosp, Dept Cardiol, Victoria, BC V8R 1J8, Canada; [Atherton, John J.; Martin, Paul T.] Royal Brisbane & Womens Hosp, Dept Cardiol, Brisbane, Qld, Australia; [Atherton, John J.; Martin, Paul T.] Univ Queensland, Sch Med, Brisbane, Qld, Australia	Royal Brisbane & Women's Hospital; University of Queensland	Arumugam, D (corresponding author), Royal Jubilee Hosp, Dept Cardiol, 1952 Bay St, Victoria, BC V8R 1J8, Canada.	deepak_mugsy@yahoo.com.au	Atherton, John J/B-9994-2011; Martin, Paul T/B-7318-2016	Atherton, John J/0000-0003-2271-578X; Martin, Paul T/0000-0002-5151-2394; Martin, Paul/0000-0002-0674-6191				Antzelevitch C, 2005, HEART RHYTHM, V2, P429, DOI 10.1016/jhrthm.2005.01.005; GREEN RL, 1974, NEW ENGL J MED, V291, P223, DOI 10.1056/NEJM197408012910503; HIGGINS GA, 1952, NEW ENGL J MED, V247, P644, DOI 10.1056/NEJM195210232471706; PETSAS AA, 1973, CHEST, V64, P66, DOI 10.1378/chest.64.1.66; Postema PG, 2009, HEART RHYTHM, V6, P1335, DOI 10.1016/j.hrthm.2009.07.002	5	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 4	2012	379	9814					492	492		10.1016/S0140-6736(11)61711-X	http://dx.doi.org/10.1016/S0140-6736(11)61711-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891AF	22305227				2022-12-28	WOS:000300187800039
J	Fletcher, T				Fletcher, Thomas			Born to be wild?	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Fletcher, T (corresponding author), The Lancet, London NW1 7BY, England.	t.m.fletcher@hotmail.co.uk						Barnes JC, 2011, CRIMINOLOGY, V49, P923, DOI 10.1111/j.1745-9125.2011.00243.x; Moffitt TE, 2005, PSYCHOL BULL, V131, P533, DOI 10.1037/0033-2909.131.4.533; Moran P, 2012, LANCET, V379, P236, DOI 10.1016/S0140-6736(11)61141-0; Rhee SH, 2002, PSYCHOL BULL, V128, P490, DOI 10.1037//0033-2909.128.3.490; Viding E, 2008, PHILOS T R SOC B, V363, P2519, DOI 10.1098/rstb.2008.0037; World Health Organization, 2002, WORLD REPORT VIOLENC	6	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2012	379	9814					395	395		10.1016/S0140-6736(12)60167-6	http://dx.doi.org/10.1016/S0140-6736(12)60167-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	891AF	22305213				2022-12-28	WOS:000300187800014
J	Qiang, L; Accili, D				Qiang, Li; Accili, Domenico			FGF21 and the Second Coming of PPAR gamma	CELL			English	Editorial Material							ACTIVATED-RECEPTOR-GAMMA; FIBROBLAST-GROWTH-FACTOR-21; STATES; GENES; ALPHA	Peptide hormone fibroblast growth factor-21 (FGF21) has insulin-mimetic properties. Dutchak et al. now suggest that FGF21 also acts in an autocrine fashion in adipocytes and is required to mediate effects of the PPAR gamma agonist class of antidiabetic drugs. Does this new property improve FGF21's fledgling clinical prospects or endorse a clinical resuscitation of PPAR gamma agonists?	[Qiang, Li; Accili, Domenico] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Qiang, Li; Accili, Domenico] Columbia Univ Coll Phys & Surg, Berrie Diabet Ctr, New York, NY 10032 USA	Columbia University; Columbia University	Accili, D (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA.	da230@columbia.edu	Qiang, Li/C-9560-2012	Qiang, Li/0000-0001-8322-1797	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL087123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058282, R37DK058282, P30DK063608, R01DK057539, R01DK064819] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL087123] Funding Source: Medline; NIDDK NIH HHS [P30 DK063608, R01 DK057539, R01 DK064819, R01 DK058282, P30 DK063608-01, R37 DK058282] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291; Dutchak PA, 2012, CELL, V148, P556, DOI 10.1016/j.cell.2011.11.062; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Muise ES, 2008, MOL PHARMACOL, V74, P403, DOI 10.1124/mol.108.044826; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; Wang H, 2008, MOL CELL BIOL, V28, P188, DOI 10.1128/MCB.00992-07; Wente W, 2006, DIABETES, V55, P2470, DOI 10.2337/db05-1435	9	17	20	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					397	398		10.1016/j.cell.2012.01.020	http://dx.doi.org/10.1016/j.cell.2012.01.020			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304910	Bronze, Green Accepted			2022-12-28	WOS:000300225000009
J	DeVore, NM; Scott, EE				DeVore, Natasha M.; Scott, Emily E.			Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001	NATURE			English	Article							COMBINED 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY; REMAINS HORMONE DRIVEN; FUNCTIONAL-CHARACTERIZATION; MACROMOLECULAR STRUCTURES; 17,20-LYASE ACTIVITY; CRYSTAL-STRUCTURES; BINDING DOMAIN; HUMAN P450C17; CYP17; INHIBITORS	Cytochrome P450 17A1 (also known as CYP17A1 and cytochrome P450c17) catalyses the biosynthesis of androgens in humans(1). As prostate cancer cells proliferate in response to androgen steroids(2,3), CYP17A1 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic castration-resistant prostate cancer(4), but drug development has been hampered by lack of information regarding the structure of CYP17A1. Here we report X-ray crystal structures of CYP17A1, which were obtained in the presence of either abiraterone, a first-in-class steroidal inhibitor recently approved by the US Food and Drug Administration for late-stage prostate cancer(5), or TOK-001, an inhibitor that is currently undergoing clinical trials(4,6). Both of these inhibitors bind the haem iron, forming a 60 degrees angle above the haem plane and packing against the central I helix with the 3 beta-OH interacting with aspargine 202 in the F helix. Notably, this binding mode differs substantially from those that are predicted by homology models and from steroids in other cytochrome P450 enzymes with known structures, and some features of this binding mode are more similar to steroid receptors. Whereas the overall structure of CYP17A1 provides a rationale for understanding many mutations that are found in patients with steroidogenic diseases, the active site reveals multiple steric and hydrogen bonding features that will facilitate a better understanding of the enzyme's dual hydroxylase and lyase catalytic capabilities and assist in rational drug design. Specifically, structure-based design is expected to aid development of inhibitors that bind only CYP17A1 and solely inhibit its androgen-generating lyase activity to improve treatment of prostate and other hormone-responsive cancers.	[DeVore, Natasha M.; Scott, Emily E.] Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA	University of Kansas	Scott, EE (corresponding author), Univ Kansas, Dept Med Chem, 1251 Wescoe Hall Dr, Lawrence, KS 66045 USA.	eescott@ku.edu		DeVore, Natasha/0000-0003-0772-8929	US Department of Energy Office of Biological and Environmental Research; US National Institutes of Health (NIH), National Center for Research Resources; National Institute of General Medical Sciences; NIH through the KU COBRE Center for Protein Structure and Function [NIH RR17708];  [GM076343]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708, P30RR030926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM076343, R01GM076343] Funding Source: NIH RePORTER	US Department of Energy Office of Biological and Environmental Research(United States Department of Energy (DOE)); US National Institutes of Health (NIH), National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH through the KU COBRE Center for Protein Structure and Function; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	X-ray data were collected at the Stanford Synchrotron Radiation Lightsource (SSRL). The SSRL Structural Molecular Biology Program is supported by the US Department of Energy Office of Biological and Environmental Research and by the US National Institutes of Health (NIH), National Center for Research Resources, Biomedical Technology Program and the National Institute of General Medical Sciences. We thank C.-J. Liu and the University of Kansas (KU) Center of Biomedical Research Excellence (COBRE) Center for Cancer Experimental Therapeutics for synthesizing abiraterone (NIH RR030926), M. R. Waterman for the full-length CYP17A1 construct, J. Wang for assistance with the Fe(IV)=O construct used in docking and A. Skinner and J. Aube for manuscript suggestions. This research was funded by the NIH through the KU COBRE Center for Protein Structure and Function (NIH RR17708) and GM076343.	Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Attard G, 2009, CANCER RES, V69, P4937, DOI 10.1158/0008-5472.CAN-08-4531; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Auchus RJ, 1998, TRENDS ENDOCRIN MET, V9, P47, DOI 10.1016/S1043-2760(98)00016-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blason-Lauber A, 2000, J CLIN ENDOCR METAB, V85, P1226; Brodie A, 2009, UROL ONCOL-SEMIN ORI, V27, P53, DOI 10.1016/j.urolonc.2008.07.036; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; De Jesus-Tran KP, 2006, PROTEIN SCI, V15, P987, DOI 10.1110/ps.051905906; DeLano W.L, PYMOL MOL GRAPHICS S; DeVore NM, 2009, DRUG METAB DISPOS, V37, P1319, DOI 10.1124/dmd.109.026765; Dhir V, 2009, J CLIN ENDOCR METAB, V94, P3058, DOI 10.1210/jc.2009-0172; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ergun-Longmire B, 2006, J CLIN ENDOCR METAB, V91, P4179, DOI 10.1210/jc.2006-0469; Ghosh D, 2009, NATURE, V457, P219, DOI 10.1038/nature07614; Gupta MK, 2001, J CLIN ENDOCR METAB, V86, P4416, DOI 10.1210/jc.86.9.4416; Haider SM, 2010, J MOL BIOL, V400, P1078, DOI 10.1016/j.jmb.2010.05.069; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang PX, 2010, ANNU REV PHYSIOL, V72, P247, DOI 10.1146/annurev-physiol-021909-135917; Hutschenreuter TU, 2004, J ENZYM INHIB MED CH, V19, P17, DOI 10.1080/14756360310001640913; IMAI T, 1993, J BIOL CHEM, V268, P19681; Jagusch C, 2008, BIOORGAN MED CHEM, V16, P1992, DOI 10.1016/j.bmc.2007.10.094; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Katsumata N, 2010, METABOLISM, V59, P275, DOI 10.1016/j.metabol.2009.07.024; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee-Robichaud P, 2004, J STEROID BIOCHEM, V92, P119, DOI 10.1016/j.jsbmb.2004.07.005; Leslie A. G., 1998, MOSFLM 6 0; Long F, 2008, ACTA CRYSTALLOGR D, V64, P125, DOI 10.1107/S0907444907050172; Mast N, 2008, P NATL ACAD SCI USA, V105, P9546, DOI 10.1073/pnas.0803717105; Mast N, 2011, J BIOL CHEM, V286, P5607, DOI 10.1074/jbc.M110.188433; Miller WL, 2011, ENDOCR REV, V32, P81, DOI 10.1210/er.2010-0013; Molina A, 2011, J UROLOGY, V185, P787, DOI 10.1016/j.juro.2010.10.042; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Pechurskaya TA, 2008, BIOCHEMISTRY-MOSCOW+, V73, P806, DOI 10.1134/S0006297908070092; Rosa S, 2010, HORM RES PAEDIAT, V73, P198, DOI 10.1159/000284362; Sahakitrungruang T, 2009, J CLIN ENDOCR METAB, V94, P3089, DOI 10.1210/jc.2009-0645; SHEN AL, 1989, J BIOL CHEM, V264, P7584; Swart AC, 2010, J STEROID BIOCHEM, V119, P112, DOI 10.1016/j.jsbmb.2009.12.014; Tiosano D, 2008, EUR J ENDOCRINOL, V158, P385, DOI 10.1530/EJE-07-0712; Vasaitis T, 2008, MOL CANCER THER, V7, P2348, DOI 10.1158/1535-7163.MCT-08-0230; Vasaitis TS, 2011, J STEROID BIOCHEM, V125, P23, DOI 10.1016/j.jsbmb.2010.11.005; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P449, DOI 10.1016/j.coph.2008.06.004	43	218	226	1	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2012	482	7383					116	U149		10.1038/nature10743	http://dx.doi.org/10.1038/nature10743			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22266943	Green Accepted			2022-12-28	WOS:000299726000047
J	Morris, PD; Trevest, KJ; Butt, AY; Grech, ED				Morris, P. D.; Trevest, K. J.; Butt, A. Y.; Grech, E. D.			PICTURE QUIZ A 43 year old woman with a 40 year history of exertional chest pain	BRITISH MEDICAL JOURNAL			English	Editorial Material							CORONARY-ARTERY; SINUS		[Morris, P. D.; Trevest, K. J.; Grech, E. D.] No Gen Hosp, Chesterman Unit, Sheffield S5 7AU, S Yorkshire, England; [Butt, A. Y.] Chesterfield Royal Hosp, Chesterfield, Derby, England	Northern General Hospital	Morris, PD (corresponding author), No Gen Hosp, Chesterman Unit, Sheffield S5 7AU, S Yorkshire, England.	paulmorris@doctors.org.uk	Morris, Paul D/J-7583-2012	Morris, Paul/0000-0002-3965-121X				Basso C, 2000, J AM COLL CARDIOL, V35, P1493, DOI 10.1016/S0735-1097(00)00566-0; Cheitlin MD, 2008, J AM COLL CARDIOL, V51, P2065, DOI 10.1016/j.jacc.2008.02.048; Gersony WM, 2007, J AM COLL CARDIOL, V50, P2083, DOI 10.1016/j.jacc.2007.08.023; Leschka S, 2005, EUR HEART J, V26, P1482, DOI 10.1093/eurheartj/ehi261; Stangl V, 2008, EUR HEART J, V29, P707, DOI 10.1093/eurheartj/ehn047	5	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 2	2012	344								e628	10.1136/bmj.e628	http://dx.doi.org/10.1136/bmj.e628			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QO	22302833				2022-12-28	WOS:000300088500004
J	Ibrahim, MS				Ibrahim, Mohammed Shafiq			PERSONAL VIEW A revolution in an Egyptian hospital	BRITISH MEDICAL JOURNAL			English	Editorial Material									Manshiet El Bakry Gen Hosp, Cairo, Egypt		Ibrahim, MS (corresponding author), Manshiet El Bakry Gen Hosp, Cairo, Egypt.	solymr82@yahoo.com							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2012	344								e576	10.1136/bmj.e576	http://dx.doi.org/10.1136/bmj.e576			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889QJ	22298093				2022-12-28	WOS:000300088000009
J	Patel, K				Patel, Kinesh			STARTING OUT Are we prepared to sacrifice good feeling for pensions?	BRITISH MEDICAL JOURNAL			English	Editorial Material																		2012, BRIT MED J, V344, DOI DOI 10.1136/BMJ.E613	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2012	344								e699	10.1136/bmj.e699	http://dx.doi.org/10.1136/bmj.e699			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889QJ	22298094				2022-12-28	WOS:000300088000012
J	Palmer, DJ; Sullivan, T; Gold, MS; Prescott, SL; Heddle, R; Gibson, RA; Makrides, M				Palmer, D. J.; Sullivan, T.; Gold, M. S.; Prescott, S. L.; Heddle, R.; Gibson, R. A.; Makrides, M.			Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FISH-OIL SUPPLEMENTATION; DIETARY-FAT; FOLLOW-UP; DISEASE; ASTHMA; PREVALENCE; RISK; DHA	Objective To determine whether dietary n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation of pregnant women with a fetus at high risk of allergic disease reduces immunoglobulin E associated eczema or food allergy at 1 year of age. Design Follow-up of infants at high hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO) randomised controlled trial. Setting Adelaide, South Australia. Participants 706 infants at high hereditary risk of developing allergic disease whose mothers were participating in the DOMInO trial. Interventions The intervention group (n=368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n=338) received matched vegetable oil capsules without n-3 LCPUFA. Main outcome measure Immunoglobulin E associated allergic disease (eczema or food allergy with sensitisation) at 1 year of age. Results No differences were seen in the overall percentage of infants with immunoglobulin E associated allergic disease between the n-3 LCPUFA and control groups (32/368 (9%) v 43/338 (13%); unadjusted relative risk 0.68, 95% confidence interval 0.43 to 1.05, P=0.08; adjusted relative risk 0.70, 0.45 to 1.09, P=0.12), although the percentage of infants diagnosed as having atopic eczema (that is, eczema with associated sensitisation) was lower in the n-3 LCPUFA group (26/368 (7%) v 39/338 (12%); unadjusted relative risk 0.61, 0.38 to 0.98, P=0.04; adjusted relative risk 0.64, 0.40 to 1.02, P=0.06). Fewer infants were sensitised to egg in the n-3 LCPUFA group (34/368 (9%) v 52/338 (15%); unadjusted relative risk 0.61, 0.40 to 0.91, P=0.02; adjusted relative risk 0.62, 0.41 to 0.93, P=0.02), but no difference between groups in immunoglobulin E associated food allergy was seen. Conclusion n-3 LCPUFA supplementation in pregnancy did not reduce the overall incidence of immunoglobulin E associated allergies in the first year of life, although atopic eczema and egg sensitisation were lower. Longer term follow-up is needed to determine if supplementation has an effect on respiratory allergic diseases and aeroallergen sensitisation in childhood.	[Palmer, D. J.; Makrides, M.] Womens & Childrens Hlth Res Inst, Adelaide, SA 5006, Australia; [Sullivan, T.] Univ Adelaide, Data Management & Anal Ctr, Adelaide, SA 5005, Australia; [Gold, M. S.; Makrides, M.] Univ Adelaide, Sch Paediat & Reprod Hlth, Adelaide, SA 5006, Australia; [Prescott, S. L.] Princess Margaret Hosp Children, Perth, WA 6008, Australia; [Heddle, R.] Royal Adelaide Hosp, SA Pathol, Adelaide, SA 5005, Australia; [Gibson, R. A.] Univ Adelaide, Sch Agr Food & Wine, Glen Osmond, SA 5064, Australia	Womens & Childrens Hospital Australia; University of Adelaide; University of Adelaide; University of Western Australia; Royal Adelaide Hospital; SA Pathology; University of Adelaide	Makrides, M (corresponding author), Womens & Childrens Hlth Res Inst, 72 King William Rd, Adelaide, SA 5006, Australia.	maria.makrides@health.sa.gov.au	Prescott, Susan/H-5665-2014; Makrides, Maria/B-6392-2014; Palmer, Debra J/L-8554-2013; Palmer, Debra/AAH-6160-2019; Gibson, Robert Alan/E-7546-2012	Makrides, Maria/0000-0003-3832-541X; Palmer, Debra J/0000-0003-2498-8343; Gibson, Robert Alan/0000-0002-8750-525X; Sullivan, Thomas/0000-0002-6930-5406	Australian National Health and Medical Research Council [399389]; Australian Egg Corporation Limited; Australian Egg Corporation; NHMRC; Commonwealth Serum Laboratories; Vaxine; GlaxoSmithKline; Healthed	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Egg Corporation Limited(Australian Eggs); Australian Egg Corporation(Australian Eggs); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Commonwealth Serum Laboratories; Vaxine; GlaxoSmithKline(GlaxoSmithKline); Healthed	The study was supported by grants from the Australian National Health and Medical Research Council (ID 399389) and Australian Egg Corporation Limited. Treatment and placebo capsules were donated by Efamol, UK.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: all authors had support from the National Health and Medical Research Council (NHMRC) of Australia and the Australian Egg Corporation for the submitted work; MSG has received honorariums from Nutricia; SLP has received grants from the NHMRC and honorariums from the Nestle Nutrition Institute and Fonterra and has been paid for lectures by the World Allergy Association and the American Academy of Asthma, Allergy and Immunology; RH has been paid for expert testimony from Analysis Plus and Rodika Research Services and has received grants from Commonwealth Serum Laboratories, Vaxine, GlaxoSmithKline, and Healthed; RAG has received grants from the NHMRC and honorariums from Fonterra; MM has received grants from the NHMRC and honorariums from Fonterra, Nestle Nutrition Institute, and Nutricia.	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Brenna JT, 2009, ANN NUTR METAB, V55, P97, DOI 10.1159/000228998; Calder PC, 2002, BRIT J NUTR, V87, pS31, DOI 10.1079/BJN2001455; Caughey GE, 1996, AM J CLIN NUTR, V63, P116, DOI 10.1093/ajcn/63.1.116; CHAN A, 2008, PREGNANCY OUTCOME S; Chan A, 2007, PREGNANCY OUTCOME S; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Furuhjelm C, 2009, ACTA PAEDIATR, V98, P1461, DOI 10.1111/j.1651-2227.2009.01355.x; Gottrand F, 2008, J NUTR, V138, p1807S, DOI 10.1093/jn/138.9.1807S; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; James MJ, 2000, AM J CLIN NUTR, V71, p343S, DOI 10.1093/ajcn/71.1.343s; Kemp AS, 1999, J PAEDIATR CHILD H, V35, P229, DOI 10.1046/j.1440-1754.1999.00343.x; Koletzko B, 2007, BRIT J NUTR, V98, P873, DOI 10.1017/S0007114507764747; Krauss-Etschmann S, 2008, J ALLERGY CLIN IMMUN, V121, P464, DOI 10.1016/j.jaci.2007.09.018; Makrides M, 2010, JAMA-J AM MED ASSOC, V304, P1675, DOI 10.1001/jama.2010.1507; Mantzioris E, 2000, AM J CLIN NUTR, V72, P42; Meyer BJ, 2003, LIPIDS, V38, P391, DOI 10.1007/s11745-003-1074-0; Olsen SF, 2008, AM J CLIN NUTR, V88, P167, DOI 10.1093/ajcn/88.1.167; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Prescott SL, 2004, CURR OPIN CLIN NUTR, V7, P123, DOI 10.1097/00075197-200403000-00004; Robertson CF, 2004, MED J AUSTRALIA, V180, P273, DOI 10.5694/j.1326-5377.2004.tb05924.x; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Smuts CM, 2003, LIPIDS, V38, P407, DOI 10.1007/s11745-003-1076-y; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x	29	144	150	0	38	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	2012	344								e184	10.1136/bmj.e184	http://dx.doi.org/10.1136/bmj.e184			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QD	22294737	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000300087400002
J	Collinge, J				Collinge, John			The Risk of Prion Zoonoses	SCIENCE			English	Editorial Material							CREUTZFELDT-JAKOB-DISEASE; BLOOD; ASSAY; REPLICATION; INFECTION; PROTEIN; HUMANS		UCL Inst Neurol, MRC Prion Unit, London WC1N 3BG, England	University of London; University College London	Collinge, J (corresponding author), UCL Inst Neurol, MRC Prion Unit, London WC1N 3BG, England.	j.collinge@prion.ucl.ac.uk			Medical Research Council [MC_U123192748] Funding Source: Medline; MRC [MC_U123192748] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 2008, SEAC POSITION STATEM; Beringue V, 2012, SCIENCE, V335, P472, DOI 10.1126/science.1215659; BERNOULLI C, 1977, LANCET, V1, P478; Brown P, 2000, NEUROLOGY, V55, P1075, DOI 10.1212/WNL.55.8.1075; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; Collinge J, 2006, LANCET, V367, P2068, DOI 10.1016/S0140-6736(06)68930-7; Edgeworth JA, 2011, LANCET, V377, P487, DOI 10.1016/S0140-6736(10)62308-2; FRASER H, 1992, PRION DIS HUMANS ANI, pCH22; Gregori L, 2011, LANCET, V377, P444, DOI 10.1016/S0140-6736(11)60057-3; Health Protection Report, 2011, HLTH PROT REP HLTH P; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Hilton DA, 2004, J PATHOL, V203, P733, DOI 10.1002/path.1580; LI JL, 2010, P NATL ACAD SCI USA, V327, P869, DOI DOI 10.1126/SCIENCE.1183218; Lloyd S, 2011, TOP CURR CHEM, V305, P1, DOI 10.1007/128_2011_157; Peden A, 2010, HAEMOPHILIA, V16, P296, DOI 10.1111/j.1365-2516.2009.02181.x; Race R, 2001, J VIROL, V75, P10106, DOI 10.1128/JVI.75.21.10106-10112.2001; Thackray AM, 2003, J VIROL, V77, P7991, DOI 10.1128/JVI.77.14.7991-7998.2003; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Wroe SJ, 2006, LANCET, V368, P2061, DOI 10.1016/S0140-6736(06)69835-8	21	18	18	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					411	413		10.1126/science.1218167	http://dx.doi.org/10.1126/science.1218167			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282797				2022-12-28	WOS:000299466800032
J	Kramer, DB; Buxton, AE; Zimetbaum, PJ				Kramer, Daniel B.; Buxton, Alfred E.; Zimetbaum, Peter J.			Time for a Change - A New Approach to ICD Replacement	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kramer, Daniel B.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kramer, DB (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.							Curtis AB, 2009, CIRCULATION, V120, P921, DOI 10.1161/CIRCULATIONAHA.109.890335; Epstein AE, 2008, CIRCULATION, V117, pE350, DOI 10.1161/CIRCUALTIONAHA.108.189742; Hammill SC, 2009, HEART RHYTHM, V6, P1397, DOI 10.1016/j.hrthm.2009.07.015; Kramer DB, 2010, HEART RHYTHM, V7, P1537, DOI 10.1016/j.hrthm.2010.07.018; Lampert R, 2010, HEART RHYTHM, V7, P1008, DOI 10.1016/j.hrthm.2010.04.033; Poole JE, 2010, CIRCULATION, V122, P1553, DOI 10.1161/CIRCULATIONAHA.110.976076	6	68	68	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					291	293		10.1056/NEJMp1111467	http://dx.doi.org/10.1056/NEJMp1111467			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	881EQ	22276818				2022-12-28	WOS:000299464100013
J	Bandosz, P; O'Flaherty, M; Drygas, W; Rutkowski, M; Koziarek, J; Wyrzykowski, B; Bennett, K; Zdrojewski, T; Capewell, S				Bandosz, Piotr; O'Flaherty, Martin; Drygas, Wojciech; Rutkowski, Marcin; Koziarek, Jacek; Wyrzykowski, Bogdan; Bennett, Kathleen; Zdrojewski, Tomasz; Capewell, Simon			Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; TRENDS; RATES; SENSITIVITY; DECREASE; CARE	Objectives To examine how much of the observed rapid decrease in mortality from coronary heart disease in Poland after the political, social, and economic transformation in the early 1990s could be explained by the use of medical and surgical treatments and how much by changes in cardiovascular risk factors. Design A modelling study. Setting Sources of data included controlled trials and meta-analyses, national surveys, and official statistics. Participants Population of adults aged 25-74 in Poland in 1991-2005. Main outcome measures Number of deaths prevented or postponed in 2005 attributable to specific treatments for coronary heart disease and changes in risk factors. A previously validated epidemiological model for coronary heart disease was used to combine and analyse data on the uptake and effectiveness of specific cardiac treatments and changes in risk factors. The observed fall in deaths from coronary heart disease from 1991 to 2005 was then partitioned among specific treatments and risk factor changes. Results From 1991 to 2005, the death rate from coronary heart disease in Poland halved, resulting in 26 200 fewer coronary deaths in 2005 in people aged 25-74. About 37% (minimum estimate 13%, maximum estimate 77%) of this decrease was attributable to treatments, including treatments for heart failure (12%), initial treatments for acute coronary syndrome (9%), secondary prevention treatments after myocardial infarction or revascularisation (7%), chronic angina treatments (3%), and other treatments (6%). About 54% of the fall was attributed to changes in risk factors (minimum estimate 41%, maximum estimate 65%), mainly reductions in total cholesterol concentration (39%) and an increase in leisuretime physical activity (10%); however, these were partially offset by increases in body mass index (-4%) and prevalence of diabetes (-2%). Blood pressure fell in women, explaining about 29% of their decrease in mortality, but rose in men generating a negative influence (-8%). About 15% of the observed decrease in mortality was attributable to reduced smoking in men but was negligible in women. Conclusions Over half of the recent fall in mortality from coronary heart disease in Poland can be attributed to reductions in major risk factors and about one third to evidence based medical treatments.	[Bandosz, Piotr; Rutkowski, Marcin; Wyrzykowski, Bogdan; Zdrojewski, Tomasz] Med Univ Gdansk, Dept Hypertens & Diabetol, PL-80211 Gdansk, Poland; [O'Flaherty, Martin; Capewell, Simon] Univ Liverpool, Div Publ Hlth, Liverpool L69 3GB, Merseyside, England; [Drygas, Wojciech; Koziarek, Jacek] Inst Cardiol, CVD Prevent & Hlth Promot, Dept Epidemiol, PL-04635 Warsaw, Poland; [Bennett, Kathleen] St James Hosp, Trinity Ctr Hlth Sci, Dept Pharmacol & Therapeut, Dublin 8, Ireland	Fahrenheit Universities; Medical University Gdansk; University of Liverpool; Institute of Cardiology - Poland; Trinity College Dublin	Zdrojewski, T (corresponding author), Med Univ Gdansk, Dept Hypertens & Diabetol, Ul Debinki 7, PL-80211 Gdansk, Poland.	tz@gumed.edu.pl	Zdrojewski, Tomasz/AAA-8875-2020; Bandosz, Piotr/E-4964-2017; Drygas, Wojciech/GLR-9863-2022	Zdrojewski, Tomasz/0000-0001-6015-8561; O'Flaherty, Martin/0000-0001-8944-4131; Bennett, Kathleen/0000-0002-2861-7665	Polish Ministry of Health; European Commission PHEA; UK Medical Research Council [91367]; MRC [G0900847] Funding Source: UKRI; Medical Research Council [G0900847] Funding Source: researchfish	Polish Ministry of Health; European Commission PHEA; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by the Polish Ministry of Health, the European Commission PHEA, and the UK Medical Research Council (grant No 91367).	Aspelund T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013957; BEAGLEHOLE R, 1986, BMJ-BRIT MED J, V292, P33, DOI 10.1136/bmj.292.6512.33; Bjorck L, 2009, EUR HEART J, V30, P1046, DOI 10.1093/eurheartj/ehn554; Bots M L, 1996, J Cardiovasc Risk, V3, P271, DOI 10.1097/00043798-199606000-00002; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Broda Grazyna, 2005, Kardiol Pol, V63, pS601; Capewell S, 1999, HEART, V81, P380, DOI 10.1136/hrt.81.4.380; Capewell S, 2000, CIRCULATION, V102, P1511, DOI 10.1161/01.CIR.102.13.1511; Capewell S, 2011, LANCET, V378, P752, DOI 10.1016/S0140-6736(10)62302-1; Drygas W, 2009, PUBLIC HEALTH, V123, P592, DOI 10.1016/j.puhe.2009.08.004; Drygas W., 2005, KARDIOL POL, V63, P636; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Gierlotka M, 2005, KARDIOL POL, V62, P13; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Jasinski B, 2010, KARDIOL POL, V68, P520; Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; Laatikainen T, 2005, AM J EPIDEMIOL, V162, P764, DOI 10.1093/aje/kwi274; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; Men T, 2003, BRIT MED J, V327, P964, DOI 10.1136/bmj.327.7421.964; Nichol MB, 1999, ANN PHARMACOTHER, V33, P531, DOI 10.1345/aph.18233; Palmieri L, 2010, AM J PUBLIC HEALTH, V100, P684, DOI 10.2105/AJPH.2008.147173; Polonski L, 2007, KARDIOL POL, V65, P861; Rywik S, 1985, Przegl Lek, V42, P299; Stelmach Wlodzimierz, 2004, Int J Occup Med Environ Health, V17, P393; Unal B, 2004, CIRCULATION, V109, P1101, DOI 10.1161/01.CIR.0000118498.35499.B2; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; Wijeysundera HC, 2010, JAMA-J AM MED ASSOC, V303, P1841, DOI 10.1001/jama.2010.580; Wojtyniak B., 2008, SYTUACJA ZDROWOTNA L; World Bank, 2011, OP DAT; World Health Organization Department of Health Statistics and Informatics, 2010, WHO MORT DAT; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zatonski W., 2008, CLOSING HLTH GAP EUR; Zatonski WA, 2005, BMJ-BRIT MED J, V331, P187, DOI 10.1136/bmj.331.7510.187; Zatonski WA, 1998, BMJ-BRIT MED J, V316, P1047; Zatonski W, 2008, EUR J EPIDEMIOL, V23, P3, DOI 10.1007/s10654-007-9195-1; Zdrojewski T, 2004, J HUM HYPERTENS, V18, P557, DOI 10.1038/sj.jhh.1001739; Zdrojewski Tomasz, 2004, Kardiol Pol, V61, P546; Zembala Marian, 2006, Kardiol Pol, V64, P445	40	111	112	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	2012	344								d8136	10.1136/bmj.d8136	http://dx.doi.org/10.1136/bmj.d8136			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KV	22279114	Green Published, hybrid			2022-12-28	WOS:000299778800010
J	Emborg, HD; Krause, TG; Hviid, A; Simonsen, J; Molbak, K				Emborg, Hanne-Dorthe; Krause, Tyra Grove; Hviid, Anders; Simonsen, Jacob; Molbak, Kare			Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTION; STRAIN	Objective To determine the effectiveness of an adjuvanted monovalent vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases. Design Historical cohort study. Setting Mandatory national reporting systems, 2 November 2009 to 31 January 2010, Denmark. Participants 388 069 people under 65 years of age with a diagnosis in the past five years of at least one underlying disease expected to increase the risk of severe illness after influenza. Main outcome measures Laboratory confirmed H1N1 infection and influenza related hospital admission with laboratory confirmed H1N1 infection. Estimates of vaccine effectiveness were adjusted for age and underlying disease. Results The effectiveness of pandemic vaccine against confirmed H1N1 infection 14 days after one dose of vaccine was 49% (95% confidence interval 10% to 71%). The effectiveness of vaccine against admission to hospital for confirmed H1N1 infection was 44% (-19% to 73%). Conclusions The adjuvanted monovalent vaccine against pandemic influenza A/H1N1 was offered late in the 2009-10 influenza season. Among chronically ill people, this vaccine offered protection against laboratory confirmed H1N1 infection but only offered non-significant protection against influenza related hospital admissions confirmed as H1N1 infection. This finding is of public health relevance because the population of chronically ill people is a major target group for pandemic vaccinations and because of the delayed availability of pandemic vaccines in a forthcoming pandemic.	[Emborg, Hanne-Dorthe; Krause, Tyra Grove; Hviid, Anders; Simonsen, Jacob; Molbak, Kare] Statens Serum Inst, Div Epidemiol, DK-2300 Copenhagen, Denmark	Statens Serum Institut	Emborg, HD (corresponding author), Statens Serum Inst, Div Epidemiol, DK-2300 Copenhagen, Denmark.	hde@ssi.dk	Emborg, Hanne-Dorthe/GRS-8769-2022; Hviid, Anders/AAH-4319-2020	Hviid, Anders/0000-0002-7509-9127; Molbak, Kare/0000-0002-3100-4990; Simonsen, Jacob/0000-0002-8700-4826	European Vaccine Manufacture through EpiConcept	European Vaccine Manufacture through EpiConcept	This study was supported by European Vaccine Manufacture through a grant managed by EpiConcept. The funding source did not influence or participate in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; writing the manuscript; or the decision to submit the article for publication. The researchers were independent of the funder.	Andersen TF, 1999, DAN MED BULL, V46, P263; Andrews N, 2011, J INFECT DIS, V203, P32, DOI 10.1093/infdis/jiq014; Chan M., 2009, WORLD NOW START 2009; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; ECDC, 2011, PROT CAS CONTR STUD; Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062; Gubbels S, 2010, EURO SURVEILL, V15; Hak E, 2002, J EPIDEMIOL COMMUN H, V56, P951, DOI 10.1136/jech.56.12.951; Hardelid P, 2011, EURO SURVEILL, V16; Harder K.M., 2011, EURO SURVEILL, V16; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Johansen K, 2009, EUROSURVEILLANCE, V14, P12; Kelly HA, 2011, VACCINE, V29, P6419, DOI 10.1016/j.vaccine.2011.03.055; Ortqvist A, 2011, CLIN INFECT DIS, V52, P1203, DOI 10.1093/cid/cir182; Pedersen CB, 2006, DAN MED BULL, V53, P441; Puig-Barbera J, 2010, VACCINE, V28, P7460, DOI 10.1016/j.vaccine.2010.09.042; Simpson CR, 2010, HEALTH TECHNOL ASSES, V14, P323, DOI 10.3310/hta14340-05; Skowronski DM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000258; Valenciano M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000388; Wichmann O, 2010, EUROSURVEILLANCE, V15, P2; World Health Organization, 2011, INT CLASS DIS ICD	21	23	23	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	2012	344								d7901	10.1136/bmj.d7901	http://dx.doi.org/10.1136/bmj.d7901			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885KV	22277542	hybrid			2022-12-28	WOS:000299778800002
J	Guallar-Castillon, P; Rodriguez-Artalejo, F; Lopez-Garcia, E; Leon-Munoz, LM; Amiano, P; Ardanaz, E; Arriola, L; Barricarte, A; Buckland, G; Chirlaque, MD; Dorronsoro, M; Huerta, JM; Larranaga, N; Marin, P; Martinez, C; Molina, E; Navarro, C; Quiros, JR; Rodriguez, L; Sanchez, MJ; Gonzalez, CA; Moreno-Iribas, C				Guallar-Castillon, Pilar; Rodriguez-Artalejo, Fernando; Lopez-Garcia, Esther; Leon-Munoz, Luz M.; Amiano, Pilar; Ardanaz, Eva; Arriola, Larraitz; Barricarte, Aurelio; Buckland, Genevieve; Chirlaque, Maria-Dolores; Dorronsoro, Miren; Huerta, Jose-Maria; Larranaga, Nerea; Marin, Pilar; Martinez, Carmen; Molina, Esther; Navarro, Carmen; Ramon Quiros, J.; Rodriguez, Laudina; Jose Sanchez, Maria; Gonzalez, Carlos A.; Moreno-Iribas, Conchi			Consumption of fried foods and risk of coronary heart disease: Spanish cohort of the European Prospective Investigation into Cancer and Nutrition study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; ENDOTHELIAL FUNCTION; DIETARY PATTERNS; FATTY-ACIDS; MEAL RICH; OLIVE OIL; SPAIN; FISH; EPIDEMIOLOGY; HYPERTENSION	Objective To assess the association between consumption of fried foods and risk of coronary heart disease. Design Prospective cohort study. Setting Spanish cohort of the European Prospective Investigation into Cancer and Nutrition. Participants 40 757 adults aged 29-69 and free of coronary heart disease at baseline (1992-6), followed up until 2004. Main outcome measures Coronary heart disease events and vital status identified by record linkage with hospital discharge registers, population based registers of myocardial infarction, and mortality registers. Results During a median follow-up of 11 years, 606 coronary heart disease events and 1135 deaths from all causes occurred. Compared with being in the first (lowest) quarter of fried food consumption, the multivariate hazard ratio of coronary heart disease in the second quarter was 1.15 (95% confidence interval 0.91 to 1.45), in the third quarter was 1.07 (0.83 to 1.38), and in the fourth quarter was 1.08 (0.82 to 1.43; P for trend 0.74). The results did not vary between those who used olive oil for frying and those who used sunflower oil. Likewise, no association was observed between fried food consumption and all cause mortality: multivariate hazard ratio for the highest versus the lowest quarter of fried food consumption was 0.93 (95% confidence interval 0.77 to 1.14; P for trend 0.98). Conclusion In Spain, a Mediterranean country where olive or sunflower oil is used for frying, the consumption of fried foods was not associated with coronary heart disease or with all cause mortality.	[Guallar-Castillon, Pilar; Rodriguez-Artalejo, Fernando; Lopez-Garcia, Esther; Leon-Munoz, Luz M.] Autonomous Univ Madrid, Sch Med, Dept Prevent Med & Publ Hlth, Madrid 28029, Spain; [Guallar-Castillon, Pilar; Rodriguez-Artalejo, Fernando; Lopez-Garcia, Esther; Leon-Munoz, Luz M.; Amiano, Pilar; Ardanaz, Eva; Arriola, Larraitz; Barricarte, Aurelio; Chirlaque, Maria-Dolores; Dorronsoro, Miren; Huerta, Jose-Maria; Larranaga, Nerea; Marin, Pilar; Martinez, Carmen; Molina, Esther; Navarro, Carmen; Jose Sanchez, Maria; Moreno-Iribas, Conchi] CIBER Epidemiol & Salud Publ, Madrid, Spain; [Amiano, Pilar; Arriola, Larraitz; Dorronsoro, Miren; Larranaga, Nerea] Basque Govt, Inst Invest IIS BioDonostia, Publ Hlth Div Gipuzkoa, Donostia San Sebastian, Spain; [Ardanaz, Eva; Barricarte, Aurelio; Marin, Pilar; Moreno-Iribas, Conchi] Publ Hlth Inst Navarra, Pamplona, Spain; [Moreno-Iribas, Conchi] Autonomous Univ Barcelona, Dept Obstet & Gynecol, Dept Pediat, Barcelona, Spain; [Buckland, Genevieve; Gonzalez, Carlos A.] Hosp Llobregat, Catalan Inst Oncol, Canc Epidemiol Res Programme, Unit Nutr Environm & Canc, Barcelona, Spain; [Chirlaque, Maria-Dolores; Huerta, Jose-Maria; Navarro, Carmen] Murcia Reg Hlth Council, Dept Epidemiol, Murcia, Spain; [Navarro, Carmen] Univ Murcia, Dept Publ Hlth & Prevent Med, E-30001 Murcia, Spain; [Martinez, Carmen; Molina, Esther; Jose Sanchez, Maria] Andalusian Sch Publ Hlth, Granada, Spain; [Ramon Quiros, J.; Rodriguez, Laudina] Publ Hlth & Hlth Planning Directorate, Oviedo, Asturias, Spain	Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Basque Government; Public Health Institute of Navarra; Autonomous University of Barcelona; Catalan Institute of Oncology; Murcia Regional Health Council; University of Murcia; Escuela Andaluza de Salud Publica	Guallar-Castillon, P (corresponding author), Autonomous Univ Madrid, Sch Med, Dept Prevent Med & Publ Hlth, Madrid 28029, Spain.	mpilar.guallar@uam.es	Guallar-Castillon, Pilar/F-1533-2016; González, Carlos A A/O-4651-2014; Huerta, José María/N-8654-2015; Lopez-Garcia, Esther/A-8894-2019; Sánchez, Maria-José/D-1087-2011; León-Muñoz, Luz M/H-8275-2017	Guallar-Castillon, Pilar/0000-0003-4759-6713; González, Carlos A A/0000-0003-2822-9715; Huerta, José María/0000-0002-9637-3869; Sánchez, Maria-José/0000-0003-4817-0757; Leon-Munoz, Luz Maria/0000-0001-5447-5907; Larranaga, Nerea/0000-0002-9993-9880; Arriola, Larraitz/0000-0001-8487-7181; Buckland, Genevieve/0000-0003-2060-6598; Molina-Montes, Esther/0000-0002-0428-2426; Navarro, Carmen/0000-0001-8896-7483	FIS [PI04-0257, PI06-0366, PI04-2342, PI04-1822, PI04-1821, PI04-2188, PI08-0166]; RETIC of the Instituto de Salud Carlos III [RD06/0020]; Spanish regional government of Andalusia; Spanish regional government of Asturias; Spanish regional government of Basque Country; Spanish regional government of Murcia; Spanish regional government of Navarra; Catalan Institute of Oncology; Ministry of Education	FIS(Instituto de Salud Carlos III); RETIC of the Instituto de Salud Carlos III(Instituto de Salud Carlos III); Spanish regional government of Andalusia; Spanish regional government of Asturias(Principality of Asturias); Spanish regional government of Basque Country; Spanish regional government of Murcia; Spanish regional government of Navarra; Catalan Institute of Oncology; Ministry of Education	This study was funded by research grants from FIS (PI04-0257, PI06-0366, PI04-2342, PI04-1822, PI04-1821, PI04-2188, and PI08-0166); RETIC (RD06/0020) of the Instituto de Salud Carlos III; and funds from the Spanish regional governments of Andalusia, Asturias, Basque Country, Murcia, and Navarra, and the Catalan Institute of Oncology. EL-G has a Ramon y Cajal contract from the Ministry of Education. Authors of this report, and not the funding agencies, are responsible for its content. The funder did not have any role in the study design; collection, analysis, and interpretation of the data; the writing of the report; and the decision to submit the article for publication.	[Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS91; [Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS110; [Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS100; Ansorena D, 2010, J FOOD SCI, V75, pH62, DOI 10.1111/j.1750-3841.2009.01472.x; Astrup A, 2011, AM J CLIN NUTR, V93, P684, DOI 10.3945/ajcn.110.004622; Bach-Faig A, 2011, PUBLIC HEALTH NUTR, V14, P622, DOI 10.1017/S1368980010002752; Bingham S, 2004, NAT REV CANCER, V4, P206, DOI 10.1038/nrc1298; Boskou G, 2006, EUR J LIPID SCI TECH, V108, P109, DOI 10.1002/ejlt.200500236; Burke BS, 1947, J AM DIET ASSOC, V23, P104; Casal S, 2010, FOOD CHEM TOXICOL, V48, P2972, DOI 10.1016/j.fct.2010.07.036; Danesh J, 2007, EUR J EPIDEMIOL, V22, P129, DOI 10.1007/s10654-006-9096-8; Donfrancesco C, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-53; Drewnowski A, 2010, FAT DETECTION TASTE; Echarte M, 2001, J FOOD PROTECT, V64, P1062, DOI 10.4315/0362-028X-64.7.1062; Fillion L, 1998, INT J FOOD SCI NUTR, V49, P157, DOI 10.3109/09637489809089395; Gallina-Toschi T, 2005, J SEP SCI, V28, P859, DOI 10.1002/jssc.200500044; Guallar-Castillon P, 2007, AM J CLIN NUTR, V86, P198, DOI 10.1093/ajcn/86.1.198; Haftenberger M, 2002, PUBLIC HEALTH NUTR, V5, P1163, DOI 10.1079/PHN2002397; He K, 2008, AM J CLIN NUTR, V88, P1111, DOI 10.1093/ajcn/88.4.1111; He K, 2009, AM J CARDIOL, V103, P1238, DOI 10.1016/j.amjcard.2009.01.016; Huerta JM, 2009, REV ESP CARDIOL, V62, P143, DOI 10.1016/S0300-8932(09)70156-3; Iqbal R, 2008, CIRCULATION, V118, P1929, DOI 10.1161/CIRCULATIONAHA.107.738716; Kabagambe EK, 2003, EUR J CLIN NUTR, V57, P1447, DOI 10.1038/sj.ejcn.1601709; LITIN L, 1993, NEW ENGL J MED, V329, P1969, DOI 10.1056/NEJM199312233292620; Luepker RV, 2003, CIRCULATION, V108, P2543, DOI 10.1161/01.CIR.0000100560.46946.EA; Majumder K, 2009, J AGR FOOD CHEM, V57, P471, DOI 10.1021/jf8028557; Mozaffarian D, 2003, CIRCULATION, V107, P1372, DOI 10.1161/01.CIR.0000055315.79177.16; Nielsen SJ, 2002, OBES RES, V10, P370, DOI 10.1038/oby.2002.51; Pokorn Jan, 2003, Forum Nutr, V56, P348; Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394; Riboli E, 1997, INT J EPIDEMIOL, V26, pS6, DOI 10.1093/ije/26.suppl_1.S6; Samra R.A., 2010, FAT DETECTION TASTE; SANCHEZMUNIZ FJ, 1994, Z ERNAHRUNGSWISS, V33, P16, DOI 10.1007/BF01610575; Sayon-Orea C, 2011, NUTR METAB CARDIOVAS; Slimani N, 1991, EUROPEAN PROSPECTIVE; Soriguer F, 2003, AM J CLIN NUTR, V78, P1092, DOI 10.1093/ajcn/78.6.1092; Sutherland WHF, 1999, ARTERIOSCL THROM VAS, V19, P1340, DOI 10.1161/01.ATV.19.5.1340; Tormo MJ, 2000, J EPIDEMIOL COMMUN H, V54, P221, DOI 10.1136/jech.54.3.221; Varela-Moreiras G, 2010, EUR J CLIN NUTR, V64, pS37, DOI 10.1038/ejcn.2010.208; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Williams MJA, 1999, J AM COLL CARDIOL, V33, P1050, DOI 10.1016/S0735-1097(98)00681-0; Williams MJA, 2001, NUTR METAB CARDIOVAS, V11, P147	42	58	58	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2012	344								e363	10.1136/bmj.e363	http://dx.doi.org/10.1136/bmj.e363			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885KP	22275385	Green Published, hybrid			2022-12-28	WOS:000299778200002
J	Freed-Pastor, WA; Mizuno, H; Zhao, X; Langerod, A; Moon, SH; Rodriguez-Barrueco, R; Barsotti, A; Chicas, A; Li, WC; Polotskaia, A; Bissell, MJ; Osborne, TF; Tian, B; Lowe, SW; Silva, JM; Borresen-Dale, AL; Levine, AJ; Bargonetti, J; Prives, C				Freed-Pastor, William A.; Mizuno, Hideaki; Zhao, Xi; Langerod, Anita; Moon, Sung-Hwan; Rodriguez-Barrueco, Ruth; Barsotti, Anthony; Chicas, Agustin; Li, Wencheng; Polotskaia, Alla; Bissell, Mina J.; Osborne, Timothy F.; Tian, Bin; Lowe, Scott W.; Silva, Jose M.; Borresen-Dale, Anne-Lise; Levine, Arnold J.; Bargonetti, Jill; Prives, Carol			Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway	CELL			English	Article							COA REDUCTASE INHIBITORS; HYDROPHOBIC AMINO-ACIDS; LI-FRAUMENI-SYNDROME; BREAST-CANCER; GENE-EXPRESSION; TERMINAL DOMAIN; GAIN; CELL; CHOLESTEROL; APOPTOSIS	p53 is a frequent target for mutation in human tumors, and mutant p53 proteins can actively contribute to tumorigenesis. We employed a three-dimensional culture model in which nonmalignant breast epithelial cells form spheroids reminiscent of acinar structures found in vivo, whereas breast cancer cells display highly disorganized morphology. We found that mutant p53 depletion is sufficient to phenotypically revert breast cancer cells to a more acinar-like morphology. Genome-wide expression analysis identified the mevalonate pathway as significantly upregulated by mutant p53. Statins and sterol biosynthesis intermediates reveal that this pathway is both necessary and sufficient for the phenotypic effects of mutant p53 on breast tissue architecture. Mutant p53 associates with sterol gene promoters at least partly via SREBP transcription factors. Finally, p53 mutation correlates with highly expressed sterol biosynthesis genes in human breast tumors. These findings implicate the mevalonate pathway as a therapeutic target for tumors bearing mutations in p53.	[Freed-Pastor, William A.; Moon, Sung-Hwan; Barsotti, Anthony; Prives, Carol] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Mizuno, Hideaki; Levine, Arnold J.] Simons Ctr Syst Biol, Inst Adv Study, Princeton, NJ 08540 USA; [Mizuno, Hideaki] Chugai Pharmaceut Co Ltd, Discovery Sci & Technol Dept, Kamakura, Kanagawa 2478530, Japan; [Zhao, Xi; Langerod, Anita; Borresen-Dale, Anne-Lise] Oslo Univ Hosp Radiumhosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway; [Zhao, Xi; Borresen-Dale, Anne-Lise] Univ Oslo, Fac Med, Inst Clin Med, N-0450 Oslo, Norway; [Silva, Jose M.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Rodriguez-Barrueco, Ruth; Silva, Jose M.] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Chicas, Agustin; Lowe, Scott W.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Li, Wencheng; Tian, Bin; Bargonetti, Jill] UMDNJ New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 08854 USA; [Polotskaia, Alla] CUNY, Grad Ctr, Biochem Program, New York, NY 10065 USA; [Polotskaia, Alla] CUNY, Grad Ctr, Biol Program, New York, NY 10065 USA; [Polotskaia, Alla] CUNY Hunter Coll, Dept Biol Sci, New York, NY 10065 USA; [Bissell, Mina J.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; [Osborne, Timothy F.] Sanford Burnham Med Res Inst, Metabol Signaling & Dis Program, Orlando, FL 32827 USA	Columbia University; Institute for Advanced Study - USA; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Oslo; University of Oslo; Columbia University; Columbia University; Cold Spring Harbor Laboratory; Rutgers State University New Brunswick; Rutgers State University Medical Center; City University of New York (CUNY) System; City University of New York (CUNY) System; City University of New York (CUNY) System; Hunter College (CUNY); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Sanford Burnham Prebys Medical Discovery Institute	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	clp3@columbia.edu	Rodriguez-Barrueco, Ruth/F-6810-2010; Mizuno, Hideaki/A-4702-2012; Mizuno, Hideaki/AAC-6161-2021; Li, Wencheng/J-7675-2012	Rodriguez-Barrueco, Ruth/0000-0003-4925-8865; Mizuno, Hideaki/0000-0002-7246-2576; Mizuno, Hideaki/0000-0002-7246-2576; Tian, Bin/0000-0001-8903-8256; Bargonetti, Jill/0000-0003-2692-0991; FREED-PASTOR, WILLIAM/0000-0002-7377-2111	Breast Cancer Research Foundation;  [CA87497];  [CA77742]; NATIONAL CANCER INSTITUTE [R37CA064786, P30CA008748, R01CA077742, P01CA087497] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Prives laboratory members, Masha Poyurovsky in particular, for helpful discussions. Ella Freulich provided invaluable technical assistance. We would like to thank Carlos Cordon Cardo, Josep Maria Domingo-Domenech and Dennis Bonal for advice and help with xenograft models. This work was supported by CA87497, CA77742 and The Breast Cancer Research Foundation.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Ahern TP, 2011, JNCI-J NATL CANCER I, V103, P1461, DOI 10.1093/jnci/djr291; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Barsotti AM, 2009, ONCOGENE, V28, P4295, DOI 10.1038/onc.2009.282; Beckerman R, 2009, GENE DEV, V23, P1364, DOI 10.1101/gad.1795709; Bissell MJ, 2005, COLD SH Q B, V70, P343, DOI 10.1101/sqb.2005.70.013; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Blais L, 2000, ARCH INTERN MED, V160, P2363, DOI 10.1001/archinte.160.15.2363; Bossi G, 2008, CELL CYCLE, V7, P1870, DOI 10.4161/cc.7.12.6161; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Browning DRL, 2007, INT J CANCER, V120, P833, DOI 10.1002/ijc.22366; BUCHWALD H, 1992, LANCET, V339, P1154, DOI 10.1016/0140-6736(92)90744-N; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Cauley JA, 2003, J WOMENS HEALTH, V12, P749, DOI 10.1089/154099903322447710; Clendening JW, 2010, P NATL ACAD SCI USA, V107, P15051, DOI 10.1073/pnas.0910258107; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Garwood ER, 2010, BREAST CANCER RES TR, V119, P137, DOI 10.1007/s10549-009-0507-x; Ghosh-Choudhury N, 2010, CELL SIGNAL, V22, P749, DOI 10.1016/j.cellsig.2009.12.010; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Kamisuki S, 2009, CHEM BIOL, V16, P882, DOI 10.1016/j.chembiol.2009.07.007; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kidera Yasuhiro, 2010, J Exp Clin Cancer Res, V29, P127, DOI 10.1186/1756-9966-29-127; Kim E, 2009, BIOCHEM PHARMACOL, V77, P11, DOI 10.1016/j.bcp.2008.08.030; Koyuturk M, 2007, CANCER LETT, V250, P220, DOI 10.1016/j.canlet.2006.10.009; Kubatka P, 2011, Klin Onkol, V24, P41; Kumar AS, 2008, CANCER EPIDEM BIOMAR, V17, P1028, DOI 10.1158/1055-9965.EPI-07-0726; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Larsson O, 1996, CRIT REV ONCOL HEMAT, V22, P197, DOI 10.1016/1040-8428(96)00193-X; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LIN JY, 1995, ONCOGENE, V10, P2387; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Mo HB, 2004, EXP BIOL MED, V229, P567, DOI 10.1177/153537020422900701; Mori S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006772; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Peart MJ, 2006, CANCER CELL, V10, P173, DOI 10.1016/j.ccr.2006.08.014; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Reed BD, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000133; Sato R, 2010, ARCH BIOCHEM BIOPHYS, V501, P177, DOI 10.1016/j.abb.2010.06.004; Shibata MA, 2004, CARCINOGENESIS, V25, P1887, DOI 10.1093/carcin/bgh201; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Ugawa T, 2000, BRIT J PHARMACOL, V131, P63, DOI 10.1038/sj.bjp.0703545; Vasudevan A, 1999, J MED CHEM, V42, P1333, DOI 10.1021/jm9900873; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Yan WS, 2010, J BIOL CHEM, V285, P14229, DOI 10.1074/jbc.M109.097253; Zhang YH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.214585	57	596	616	2	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					244	258		10.1016/j.cell.2011.12.017	http://dx.doi.org/10.1016/j.cell.2011.12.017			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265415	Green Accepted, Bronze			2022-12-28	WOS:000299540700028
J	Knott, SRV; Peace, JM; Ostrow, AZ; Gan, Y; Rex, AE; Viggiani, CJ; Tavare, S; Aparicio, OM				Knott, Simon R. V.; Peace, Jared M.; Ostrow, A. Zachary; Gan, Yan; Rex, Alexandra E.; Viggiani, Christopher J.; Tavare, Simon; Aparicio, Oscar M.			Forkhead Transcription Factors Establish Origin Timing and Long-Range Clustering in S. cerevisiae	CELL			English	Article							EUKARYOTIC REPLICATION ORIGINS; CHROMOSOMAL DNA-REPLICATION; CELL-CYCLE; HISTONE DEACETYLASE; GENE-EXPRESSION; GENOME-WIDE; FHA DOMAIN; CHROMATIN; INITIATION; ACTIVATION	The replication of eukaryotic chromosomes is organized temporally and spatially within the nucleus through epigenetic regulation of replication origin function. The characteristic initiation timing of specific origins is thought to reflect their chromatin environment or sub-nuclear positioning, however the mechanism remains obscure. Here we show that the yeast Forkhead transcription factors, Fkh1 and Fkh2, are global determinants of replication origin timing. Forkhead regulation of origin timing is independent of local levels or changes of transcription. Instead, we show that Fkh1 and Fkh2 are required for the clustering of early origins and their association with the key initiation factor Cdc45 in G1 phase, suggesting that Fkh1 and Fkh2 selectively recruit origins to emergent replication factories. Fkh1 and Fkh2 bind Fkh-activated origins, and interact physically with ORC, providing a plausible mechanism to cluster origins. These findings add a new dimension to our understanding of the epigenetic basis for differential origin regulation and its connection to chromosomal domain organization.	[Knott, Simon R. V.; Peace, Jared M.; Ostrow, A. Zachary; Gan, Yan; Rex, Alexandra E.; Viggiani, Christopher J.; Tavare, Simon; Aparicio, Oscar M.] Univ So Calif, Mol & Computat Biol Program, Los Angeles, CA 90089 USA; [Tavare, Simon] Univ Cambridge, Dept Oncol, Cambridge CB2 1TN, England	University of Southern California; University of Cambridge	Aparicio, OM (corresponding author), Univ So Calif, Mol & Computat Biol Program, Los Angeles, CA 90089 USA.	oaparici@usc.edu		Aparicio, Oscar/0000-0002-5591-0277	USC Epigenome Center; Whittier Foundation; NIH [5R01-GM065494, 3R01-GM065494-S1, P50-HG02790]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG002790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065494] Funding Source: NIH RePORTER	USC Epigenome Center; Whittier Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank: J. Aparicio, M. Arbeitman, C. Fox, and M. Michael for critical evaluation of the manuscript; M. Arbeitman for sharing equipment; S.P. Bell for purified ORC and antibody; L. Chen for valuable insight; J. Dalton for help with microscopy; C. Fox for plasmids, strains, antibody, and helpful discussion; R. Kalhor for the 4C protocol and invaluable advice; U. Keich for helpful discussion; and M. Hampsey, D. Kowalski and R. Young for strains. This work was funded by a pilot grant from the USC Epigenome Center sponsored by the Whittier Foundation (to O.M.A), NIH grants 5R01-GM065494 and 3R01-GM065494-S1 (to O.M.A.), and P50-HG02790 (to S.R.V.K. and S.T.).	Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Aparicio JG, 2004, MOL CELL BIOL, V24, P4769, DOI 10.1128/MCB.24.11.4769-4780.2004; Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Boros J, 2003, NUCLEIC ACIDS RES, V31, P2279, DOI 10.1093/nar/gkg347; Cadoret JC, 2008, P NATL ACAD SCI USA, V105, P15837, DOI 10.1073/pnas.0805208105; Chang VK, 2004, MOL CELL BIOL, V24, P6514, DOI 10.1128/MCB.24.14.6514-6524.2004; Chen YH, 2009, BIOINFORMATICS, V25, P2514, DOI 10.1093/bioinformatics/btp486; Danis E, 2004, NAT CELL BIOL, V6, P721, DOI 10.1038/ncb1149; Darieva Z, 2003, CURR BIOL, V13, P1740, DOI 10.1016/j.cub.2003.08.053; Darieva Z, 2010, MOL CELL, V38, P29, DOI 10.1016/j.molcel.2010.02.030; DILLER JD, 1994, TRENDS BIOCHEM SCI, V19, P320, DOI 10.1016/0968-0004(94)90070-1; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; Duan Z, 2010, NATURE, V465, P363, DOI 10.1038/nature08973; Eaton ML, 2011, GENOME RES, V21, P164, DOI 10.1101/gr.116038.110; Eaton ML, 2010, GENE DEV, V24, P748, DOI 10.1101/gad.1913210; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; Flanagan JF, 1999, NUCLEIC ACIDS RES, V27, P2022, DOI 10.1093/nar/27.9.2022; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5; Gondor A, 2009, NAT REV GENET, V10, P269, DOI 10.1038/nrg2555; Goren A, 2008, GENE DEV, V22, P1319, DOI 10.1101/gad.468308; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Heun P, 2001, J CELL BIOL, V152, P385, DOI 10.1083/jcb.152.2.385; Hiratani L, 2009, CURR OPIN GENET DEV, V19, P142, DOI 10.1016/j.gde.2009.02.002; Hollenhorst PC, 2001, GENE DEV, V15, P2445, DOI 10.1101/gad.906201; Hu FF, 2008, GENETICS, V179, P863, DOI 10.1534/genetics.108.086611; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin QW, 1998, J CELL BIOL, V141, P21, DOI 10.1083/jcb.141.1.21; Karnani N, 2010, MOL BIOL CELL, V21, P393, DOI 10.1091/mbc.E09-08-0707; Keich U, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-372; Kitamura E, 2006, CELL, V125, P1297, DOI 10.1016/j.cell.2006.04.041; Knott SRV, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-305; Knott SRV, 2009, EPIGENETICS-US, V4, P262; Knott SRV, 2009, GENE DEV, V23, P1077, DOI 10.1101/gad.1784309; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Kumar R, 2000, CURR BIOL, V10, P896, DOI 10.1016/S0960-9822(00)00618-7; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; MacAlpine D, 2005, CHROMOSOME RES, V13, P309, DOI 10.1007/s10577-005-1508-1; MacAlpine HK, 2010, GENOME RES, V20, P201, DOI 10.1101/gr.097873.109; MacIsaac KD, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-113; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Mechali M, 2010, NAT REV MOL CELL BIO, V11, P728, DOI 10.1038/nrm2976; Meister P, 2007, EMBO J, V26, P1315, DOI 10.1038/sj.emboj.7601538; Miotto B, 2007, M S-MED SCI, V23, P735, DOI 10.1051/medsci/20072389735; Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028; Morozov AV, 2007, P NATL ACAD SCI USA, V104, P7068, DOI 10.1073/pnas.0701356104; Murakami H, 2010, CELL CYCLE, V9, P3233, DOI 10.4161/cc.9.16.12599; Pappas DL, 2004, GENE DEV, V18, P769, DOI 10.1101/gad.1173204; Parkhomchuk D, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp596; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; Pic-Taylor A, 2004, MOL CELL BIOL, V24, P10036, DOI 10.1128/MCB.24.22.10036-10046.2004; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; Reynolds D, 2003, GENE DEV, V17, P1789, DOI 10.1101/gad.1074103; Ryba T, 2010, GENOME RES, V20, P761, DOI 10.1101/gr.099655.109; Sequeira-Mendes J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000446; Sporbert A, 2002, MOL CELL, V10, P1355, DOI 10.1016/S1097-2765(02)00729-3; Stevenson JB, 1999, GENE DEV, V13, P146, DOI 10.1101/gad.13.2.146; Sun KM, 2002, GENE DEV, V16, P2085, DOI 10.1101/gad.994902; Unnikrishnan A, 2010, NAT STRUCT MOL BIOL, V17, P430, DOI 10.1038/nsmb.1780; Viggiani C.J., 2010, COLD SPRING HARB PRO; Viggiani CJ, 2006, YEAST, V23, P1045, DOI 10.1002/yea.1406; Viggiani Christopher J., 2009, V521, P255, DOI [10.1007/978-1-60327-815-7_14, 10.1007/978-1-60327-817-5_14]; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Weber JM, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-100; Weinreich M, 2004, BBA-GENE STRUCT EXPR, V1677, P142, DOI 10.1016/j.bbaexp.2003.11.015	69	135	136	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					99	111		10.1016/j.cell.2011.12.012	http://dx.doi.org/10.1016/j.cell.2011.12.012			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265405	Green Accepted, Bronze			2022-12-28	WOS:000299540700017
J	Nobile, CJ; Fox, EP; Nett, JE; Sorrells, TR; Mitrovich, QM; Hernday, AD; Tuch, BB; Andes, DR; Johnson, AD				Nobile, Clarissa J.; Fox, Emily P.; Nett, Jeniel E.; Sorrells, Trevor R.; Mitrovich, Quinn M.; Hernday, Aaron D.; Tuch, Brian B.; Andes, David R.; Johnson, Alexander D.			A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans	CELL			English	Article							DENTURE STOMATITIS; BACILLUS-SUBTILIS; YEAST; REGULATORS; GENOME; GENES; MODEL; SPECIFICITY; INFECTIONS; ANNOTATION	A biofilm is an organized, resilient group of microbes in which individual cells acquire properties, such as drug resistance, that are distinct from those observed in suspension cultures. Here, we describe and analyze the transcriptional network controlling biofilm formation in the pathogenic yeast Candida albicans, whose biofilms are a major source of medical device-associated infections. We have combined genetic screens, genome-wide approaches, and two in vivo animal models to describe a master circuit controlling biofilm formation, composed of six transcription regulators that form a tightly woven network with similar to 1,000 target genes. Evolutionary analysis indicates that the biofilm network has rapidly evolved: genes in the biofilm circuit are significantly weighted toward genes that arose relatively recently with ancient genes being underrepresented. This circuit provides a framework for understanding many aspects of biofilm formation by C. albicans in a mammalian host. It also provides insights into how complex cell behaviors can arise from the evolution of transcription circuits.	[Nobile, Clarissa J.; Fox, Emily P.; Sorrells, Trevor R.; Mitrovich, Quinn M.; Hernday, Aaron D.; Tuch, Brian B.; Johnson, Alexander D.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94102 USA; [Fox, Emily P.; Sorrells, Trevor R.] Univ Calif San Francisco, Dept Biochem & Biophys, Tetrad Program, San Francisco, CA 94102 USA; [Nett, Jeniel E.; Andes, David R.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison	Nobile, CJ (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94102 USA.	clarissa.nobile@ucsf.edu	Andes, David/ABE-8033-2020; Nobile, Clarissa/C-2407-2015	Nobile, Clarissa/0000-0003-0799-6499; Sorrells, Trevor/0000-0002-3527-8622; Fox, Emily/0000-0002-8411-7622; Andes, David/0000-0002-7927-9950	NIH [R01AI073289, R01AI049187, R01AI083311, T32AI060537, F32AI088822]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073289, R01AI049187, R01AI083311, F32AI088822, T32AI060537] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Oliver Homann for developing MochiView, Christopher Baker and Isabel Nocedal for help with evolutionary analysis, Francisco De La Vega for making possible the RNAseq analysis, Chiraj Dalal for computational advice, Lauren Booth for comments on the manuscript, and Sudarsi Desta, Jeanselle Dea, and Jorge Mendoza for technical assistance. We are grateful for the advice of Kurt Thorn in the acquisition of the CSLM images at the Nikon Imaging Center at UCSF. This study was supported by NIH grants R01AI073289 (D.R.A.) and R01AI049187 and R01AI083311 (A.D.J.). C.J.N. was supported by NIH fellowships T32AI060537 and F32AI088822. The content is the responsibility of the authors and does not necessarily represent the views of the NIH.	Alabadi D, 2001, SCIENCE, V293, P880, DOI 10.1126/science.1061320; Andes D, 2004, INFECT IMMUN, V72, P6023, DOI 10.1128/IAI.72.10.6023-6031.2004; Askew C, 2011, MOL MICROBIOL, V79, P940, DOI 10.1111/j.1365-2958.2010.07504.x; Baillie GS, 1999, J MED MICROBIOL, V48, P671, DOI 10.1099/00222615-48-7-671; Borneman AR, 2006, GENE DEV, V20, P435, DOI 10.1101/gad.1389306; Bruno VM, 2010, GENOME RES, V20, P1451, DOI 10.1101/gr.109553.110; Chandra J, 2001, J BACTERIOL, V183, P5385, DOI 10.1128/JB.183.18.5385-5394.2001; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; de Hoon MJL, 2010, CURR BIOL, V20, pR735, DOI 10.1016/j.cub.2010.06.031; Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002; Douglas LJ, 2003, TRENDS MICROBIOL, V11, P30, DOI 10.1016/S0966-842X(02)00002-1; Fernandez A, 2011, NATURE, V474, P502, DOI 10.1038/nature09992; Hamoen LW, 2003, MICROBIOL-SGM, V149, P9, DOI 10.1099/mic.0.26003-0; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; HAWSER SP, 1994, INFECT IMMUN, V62, P915, DOI 10.1128/IAI.62.3.915-921.1994; Hepworth SR, 1998, MOL CELL BIOL, V18, P5750, DOI 10.1128/MCB.18.10.5750; Homann OR, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-49; Homann OR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000783; Kojic EM, 2004, CLIN MICROBIOL REV, V17, P255, DOI 10.1128/CMR.17.2.255-267.2004; Kolter R, 2006, NATURE, V441, P300, DOI 10.1038/441300a; Lavoie H, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000329; Lin ZG, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-581; Locke JCW, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100018; Long M, 2003, NAT REV GENET, V4, P865, DOI 10.1038/nrg1204; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Mitrovich QM, 2010, SCIENCE, V330, P838, DOI 10.1126/science.1194554; Muller D, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000279; Nett J, 2006, CURR OPIN MICROBIOL, V9, P340, DOI 10.1016/j.mib.2006.06.007; Nett JE, 2010, INFECT IMMUN, V78, P3650, DOI 10.1128/IAI.00480-10; Ni L, 2009, GENE DEV, V23, P1351, DOI 10.1101/gad.1781909; Nobile CJ, 2005, CURR BIOL, V15, P1150, DOI 10.1016/j.cub.2005.05.047; Nobile CJ, 2008, CURR BIOL, V18, P1017, DOI 10.1016/j.cub.2008.06.034; Nobile CJ, 2006, EUKARYOT CELL, V5, P1604, DOI 10.1128/EC.00194-06; Nobile CJ, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000133; Ramage G, 2004, ORAL SURG ORAL MED O, V98, P53, DOI 10.1016/j.tripleo.2003.04.002; Ramage G, 2002, FEMS MICROBIOL LETT, V214, P95, DOI 10.1111/j.1574-6968.2002.tb11330.x; Sahni N, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000363; Schinabeck MK, 2004, ANTIMICROB AGENTS CH, V48, P1727, DOI 10.1128/AAC.48.5.1727-1732.2004; Sellam A, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-7-r71; Sellam A, 2009, EUKARYOT CELL, V8, P1174, DOI 10.1128/EC.00074-09; Suel GM, 2006, NATURE, V440, P545, DOI 10.1038/nature04588; Sugino RP, 2012, MOL BIOL EVOL, V29, P71, DOI 10.1093/molbev/msr118; Tuch BB, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001070; Uppuluri P, 2010, EUKARYOT CELL, V9, P1531, DOI 10.1128/EC.00111-10; Uppuluri P, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000828; Wapinski I, 2007, NATURE, V449, P54, DOI 10.1038/nature06107; Webb BC, 1998, AUST DENT J, V43, P160, DOI 10.1111/j.1834-7819.1998.tb00157.x; Wilson J, 1998, BRIT DENT J, V185, P380, DOI 10.1038/sj.bdj.4809821; Wilson NK, 2010, CELL STEM CELL, V7, P532, DOI 10.1016/j.stem.2010.07.016; Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032; Zhu C, 2009, GENOME RES, V19, P556, DOI 10.1101/gr.090233.108	52	461	520	4	72	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 20	2012	148	1-2					126	138		10.1016/j.cell.2011.10.048	http://dx.doi.org/10.1016/j.cell.2011.10.048			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265407	Bronze, Green Accepted			2022-12-28	WOS:000299540700019
J	Rocheteau, P; Gayraud-Morel, B; Siegl-Cachedenier, I; Blasco, MA; Tajbakhsh, S				Rocheteau, Pierre; Gayraud-Morel, Barbara; Siegl-Cachedenier, Irene; Blasco, Maria A.; Tajbakhsh, Shahragim			A Subpopulation of Adult Skeletal Muscle Stem Cells Retains All Template DNA Strands after Cell Division	CELL			English	Article							SATELLITE CELLS; SELF-RENEWAL; SELECTIVE SEGREGATION; DISTINCT; PAX7; HETEROGENEITY; EXPRESSION; SPECIFICATION; PROGENITORS; QUIESCENT	Satellite cells are adult skeletal muscle stem cells that are quiescent and constitute a poorly defined heterogeneous population. Using transgenic Tg:Pax7-nGFP mice, we show that Pax7-nGFP(Hi) cells are less primed for commitment and have a lower metabolic status and delayed first mitosis compared to Pax7-nGFP(Lo) cells. Pax7-nGFP(Hi) can give rise to Pax7-nGFP(Lo) cells after serial transplantations. Proliferating Pax7-nGFP(Hi) cells exhibit lower metabolic activity, and the majority performs asymmetric DNA segregation during cell division, wherein daughter cells retaining template DNA strands express stem cell markers. Using chromosome orientation-fluorescence in situ hybridization, we demonstrate that all chromatids segregate asymmetrically, whereas Pax7-nGFP(Lo) cells perform random DNA segregation. Therefore, quiescent Pax7-nGFP(Hi) cells represent a reversible dormant stem cell state, and during muscle regeneration, Pax7-nGFP(Hi) cells generate distinct daughter cell fates by asymmetrically segregating template DNA strands to the stem cell. These findings provide major insights into the biology of stem cells that segregate DNA asymmetrically.	[Rocheteau, Pierre; Gayraud-Morel, Barbara; Tajbakhsh, Shahragim] CNRS, Dept Dev Biol, Inst Pasteur Stem Cells & Dev, URA 2578, F-75015 Paris, France; [Siegl-Cachedenier, Irene; Blasco, Maria A.] Spanish Natl Canc Ctr CNIO, Mol Oncol Programme, Telomeres & Telomerase Grp, Madrid 28029, Spain	Centre National de la Recherche Scientifique (CNRS); Centro Nacional de Investigaciones Oncologicas (CNIO)	Tajbakhsh, S (corresponding author), CNRS, Dept Dev Biol, Inst Pasteur Stem Cells & Dev, URA 2578, 25 Rue Dr Roux, F-75015 Paris, France.	shaht@pasteur.fr	Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X; Gayraud-Morel, Barbara/0000-0002-1168-8504	Conseil de la Region Ile-de-France; MICINN; European Union (EU); European Research Council (ERC); Lilly Foundation; Korber European Research Award; Institut Pasteur; Association Recherche contre le Cancer; Association Francaise contre le Myopathies; Centre national de la recherche scientifique; Agence Nationale de la Recherche [ANR-06-BLAN-0039]; Optistem; Fondation pour la Recherche Medicale	Conseil de la Region Ile-de-France(Region Ile-de-France); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); European Union (EU)(CGIAREuropean Commission); European Research Council (ERC)(European Research Council (ERC)European Commission); Lilly Foundation; Korber European Research Award; Institut Pasteur(European Commission); Association Recherche contre le Cancer; Association Francaise contre le Myopathies(Association Francaise contre les Myopathies); Centre national de la recherche scientifique(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Optistem; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	For cytometry we thank M. Nguyen, P.-H. Commere, N. Aulner (PFC, Institut Pasteur, Paris), A. Henry (IMRB, UFR de Medecine, Creteil), and funding by the Conseil de la Region Ile-de-France (SESAME 2007, Imagole; given to S. Shorte). We thank also members of the lab for critical comments. M.A.B. is funded by grants from the MICINN, the European Union, the European Research Council (ERC), The Lilly Foundation, and the Korber European Research Award. S.T. acknowledges support from the Institut Pasteur, Association Recherche contre le Cancer, Association Francaise contre le Myopathies, Centre national de la recherche scientifique, Agence Nationale de la Recherche (ANR-06-BLAN-0039), EU Framework 7 projects EuroSysStem, Optistem, and the Fondation pour la Recherche Medicale.	Armakolas A, 2006, SCIENCE, V311, P1146, DOI 10.1126/science.1120519; Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bailey SM, 1996, MUTAGENESIS, V11, P139, DOI 10.1093/mutage/11.2.139; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; Biressi S, 2007, DEV BIOL, V308, P281, DOI 10.1016/j.ydbio.2007.06.006; Bowman GR, 2008, CELL, V134, P945, DOI 10.1016/j.cell.2008.07.015; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cairns J, 2006, GENETICS, V174, P1069, DOI 10.1534/genetics.104.66886; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Conboy MJ, 2007, PLOS BIOL, V5, P1120, DOI 10.1371/journal.pbio.0050102; Cortes F, 2003, DNA REPAIR, V2, P719, DOI 10.1016/S1568-7864(03)00044-2; Deprimo SE, 1996, TRANSGENIC RES, V5, P459, DOI 10.1007/BF01980211; Escobar M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1260; Falconer E, 2010, NATURE, V463, P93, DOI 10.1038/nature08644; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Garstka HL, 2003, NUCLEIC ACIDS RES, V31, P5039, DOI 10.1093/nar/gkg717; Gayraud-Morel B, 2007, DEV BIOL, V312, P13, DOI 10.1016/j.ydbio.2007.08.059; Gayraud-Morel B, 2012, J CELL SCI, V125, P1738, DOI 10.1242/jcs.097006; Hall JK, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001081; Jory A, 2009, STEM CELLS, V27, P2769, DOI 10.1002/stem.220; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; Kitamoto T, 2010, STEM CELLS, V28, P2205, DOI 10.1002/stem.547; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; Kuang S, 2006, J CELL BIOL, V172, P103, DOI 10.1083/jcb.200508001; Kuang S, 2008, TRENDS MOL MED, V14, P82, DOI 10.1016/j.molmed.2007.12.004; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Lansdorp PM, 2007, CELL, V129, P1244, DOI 10.1016/j.cell.2007.06.017; Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Macara IG, 2008, CELL, V135, P801, DOI 10.1016/j.cell.2008.11.006; Mitchell PO, 2005, DEV BIOL, V283, P240, DOI 10.1016/j.ydbio.2005.04.016; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Morel BG, 2009, REGEN MED, V4, P293, DOI 10.2217/17460751.4.2.293; Moyes CD, 1998, J EXP BIOL, V201, P299; Neumuller RA, 2009, GENE DEV, V23, P2675, DOI 10.1101/gad.1850809; Oustanina S, 2004, EMBO J, V23, P3430, DOI 10.1038/sj.emboj.7600346; Potten CS, 2002, J CELL SCI, V115, P2381; Quyn AJ, 2010, CELL STEM CELL, V6, P175, DOI 10.1016/j.stem.2009.12.007; Rando TA, 2007, CELL, V129, P1239, DOI 10.1016/j.cell.2007.06.019; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384; Sambasivan R, 2011, DEVELOPMENT, V138, P3647, DOI 10.1242/dev.067587; Sambasivan R, 2009, DEV CELL, V16, P810, DOI 10.1016/j.devcel.2009.05.008; Schepers AG, 2011, EMBO J, V30, P1104, DOI 10.1038/emboj.2011.26; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Shinin V, 2006, NAT CELL BIOL, V8, P677, DOI 10.1038/ncb1425; Tajbakhsh S, 2009, J INTERN MED, V266, P372, DOI 10.1111/j.1365-2796.2009.02158.x; Tajbakhsh S, 2009, NAT REV MOL CELL BIO, V10, P804, DOI 10.1038/nrm2784; Tajbakhsh S, 2008, CURR OPIN CELL BIOL, V20, P716, DOI 10.1016/j.ceb.2008.10.004; White MA, 2008, NATURE, V455, P1248, DOI 10.1038/nature07282; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Zammit PS, 2006, J HISTOCHEM CYTOCHEM, V54, P1177, DOI 10.1369/jhc.6R6995.2006; Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007	55	302	316	2	57	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					112	125		10.1016/j.cell.2011.11.049	http://dx.doi.org/10.1016/j.cell.2011.11.049			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265406	Bronze			2022-12-28	WOS:000299540700018
J	Schaechter, M				Schaechter, Moselio			RETROSPECTIVE Lynn Margulis (1938-2011)	SCIENCE			English	Biographical-Item									San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University	Schaechter, M (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.	mschaech@sunstroke.sdsu.edu						MARGULIS L, PUBLICATION LIST	1	5	5	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2012	335	6066					302	302		10.1126/science.1218027	http://dx.doi.org/10.1126/science.1218027			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267805				2022-12-28	WOS:000299273400038
J	Krimsky, S				Krimsky, Sheldon			The art of medicine The short life of a race drug	LANCET			English	Editorial Material							BLACK PATIENTS; HEART-FAILURE; BIDIL		[Krimsky, Sheldon] Tufts Univ, Tufts Sch Med, Dept Urban & Environm Policy & Planning & Publ Hl, Medford, MA 02155 USA; [Krimsky, Sheldon] Tufts Univ, Tufts Sch Med, Dept Family Med, Medford, MA 02155 USA	Tufts University; Tufts University	Krimsky, S (corresponding author), Tufts Univ, Tufts Sch Med, Dept Urban & Environm Policy & Planning & Publ Hl, Medford, MA 02155 USA.	sheldon.krimsky@tufts.edu						Bibbins-Domingo K, 2007, ANN INTERN MED, V146, P52, DOI 10.7326/0003-4819-146-1-200701020-00009; Bloche MG, 2004, NEW ENGL J MED, V351, P2035, DOI 10.1056/NEJMp048271; Duster T, 2007, LANCET, V369, P702, DOI 10.1016/S0140-6736(07)60320-1; Frank D, 2010, J GEN INTERN MED, V25, P384, DOI 10.1007/s11606-009-1190-7; Kahn J, 2004, YALE J HLTH POLICY L, V4, P41; Kahn J., 2011, RACE GENETIC REVOLUT; Krimsky Sheldon, 2011, RACE GENETIC REVOLUT, P95; Seguin B, 2008, PHARMACOGENOMICS J, V8, P169, DOI 10.1038/sj.tpj.6500489; Temple R, 2007, ANN INTERN MED, V146, P57, DOI 10.7326/0003-4819-146-1-200701020-00010	9	9	9	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 14	2012	379	9811					114	115		10.1016/S0140-6736(12)60052-X	http://dx.doi.org/10.1016/S0140-6736(12)60052-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879GM	22256352	Bronze			2022-12-28	WOS:000299317700022
J	Varghese, GM; Trowbridge, P; Doherty, T				Varghese, George M.; Trowbridge, Paul; Doherty, Tom			Investigating and managing pyrexia of unknown origin in adults	BRITISH MEDICAL JOURNAL			English	Review							STRUCTURED DIAGNOSTIC PROTOCOL; PROSPECTIVE MULTICENTER; FEVER; SCINTIGRAPHY; PET/CT; YIELD; FUO		[Varghese, George M.] Christian Med Coll & Hosp, Dept Med & Infect Dis, Vellore, India; [Trowbridge, Paul] Brown Univ, Rhode Island Hosp, Dept Intern Med, Providence, RI USA; [Doherty, Tom] Hosp Trop Dis, London, England	Christian Medical College & Hospital (CMCH) Vellore; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	Varghese, GM (corresponding author), Christian Med Coll & Hosp, Dept Med & Infect Dis, Vellore, India.	georgemvarghese@hotmail.com	Varghese, George/AAQ-8219-2021; Trowbridge, Paul/AAH-8542-2020	Varghese, George M/0000-0002-4040-5649				Armstrong WS, 1999, CLIN INFECT DIS, V28, P341, DOI 10.1086/515138; Arnow PM, 1997, LANCET, V350, P575, DOI 10.1016/S0140-6736(97)07061-X; Balink H, 2009, CLIN NUCL MED, V34, P862, DOI 10.1097/RLU.0b013e3181becfb1; Bleeker-Rovers CP, 2007, EUR J NUCL MED MOL I, V34, P694, DOI 10.1007/s00259-006-0295-z; Bleeker-Rovers CP, 2007, MEDICINE, V86, P26, DOI 10.1097/md.0b013e31802fe858; Bleeker-Rovers CP, 2009, SEMIN NUCL MED, V39, P81, DOI 10.1053/j.semnuclmed.2008.10.002; de Kleijn EMH, 1997, MEDICINE, V76, P392, DOI 10.1097/00005792-199711000-00002; de Kleijn EMHA, 1997, MEDICINE, V76, P401, DOI 10.1097/00005792-199711000-00003; Durack D T, 1991, Curr Clin Top Infect Dis, V11, P35; Efstathiou SP, 2010, EUR J INTERN MED, V21, P137, DOI 10.1016/j.ejim.2009.11.006; ERBEL R, 1988, EUR HEART J, V9, P43; Ferda J, 2010, EUR J RADIOL, V73, P518, DOI 10.1016/j.ejrad.2008.12.014; Hot A, 2009, ARCH INTERN MED, V169, P2018, DOI 10.1001/archinternmed.2009.401; IIKUNI Y, 1994, INTERNAL MED, V33, P67, DOI 10.2169/internalmedicine.33.67; Keidar Z, 2008, J NUCL MED, V49, P1980, DOI 10.2967/jnumed.108.054692; Kejariwal D, 2001, J Postgrad Med, V47, P104; Kjaer A, 2002, J NUCL MED, V43, P140; Knockaert DC, 1996, ARCH INTERN MED, V156, P618, DOI 10.1001/archinte.156.6.618; KNOCKAERT DC, 1994, CLIN INFECT DIS, V18, P601, DOI 10.1093/clinids/18.4.601; Knockaert DC, 2003, J INTERN MED, V253, P263, DOI 10.1046/j.1365-2796.2003.01120.x; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; PETERSDORF RG, 1992, ARCH INTERN MED, V152, P21, DOI 10.1001/archinte.152.1.21; Saltoglu N, 2004, J INFECTION, V48, P81, DOI 10.1016/j.jinf.2003.08.006; Vanderschueren S, 2003, AM J MED, V115, P572, DOI 10.1016/S0002-9343(03)00376-0; Vanderschueren S, 2003, ARCH INTERN MED, V163, P1033, DOI 10.1001/archinte.163.9.1033; Zheng MH, 2008, TROP DOCT, V38, P221, DOI 10.1258/td.2007.070293	26	29	33	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 15	2010	341								c5470	10.1136/bmj.c5470	http://dx.doi.org/10.1136/bmj.c5470			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	668FH	22312655				2022-12-28	WOS:000283253500004
J	Morin, CM; Benca, R				Morin, Charles M.; Benca, Ruth			Chronic insomnia	LANCET			English	Article							COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; GENERALIZED ANXIETY DISORDER; MAJOR DEPRESSIVE DISORDER; CLINICAL EFFECTIVENESS TRIAL; SELF-HELP TREATMENT; DOXEPIN 1 MG; OLDER-ADULTS; DOUBLE-BLIND; PERSISTENT INSOMNIA	Insomnia is a prevalent complaint in clinical practice that can present independently or comorbidly with another medical or psychiatric disorder. In either case, it might need treatment of its own. Of the different therapeutic options available, benzodiazepine-receptor agonists (BzRAs) and cognitive-behavioural therapy (CBT) are supported by the best empirical evidence. BzRAs are readily available and effective in the short-term management of insomnia, but evidence of long-term efficacy is scarce and most hypnotic drugs are associated with potential adverse effects. CBT is an effective alternative for chronic insomnia. Although more time consuming than drug management, CBT produces sleep improvements that are sustained over time, and this therapy is accepted by patients. Although CBT is not readily available in most clinical settings, access and delivery can be made easier through use of innovative methods such as telephone consultations, group therapy, and self-help approaches. Combined CBT and drug treatment can optimise outcomes, although evidence to guide clinical practice on the best way to integrate these approaches is scarce.	[Morin, Charles M.] Univ Laval, Ecole Psychol, Quebec City, PQ G1V 0A6, Canada; [Benca, Ruth] Univ Wisconsin, Madison, WI USA	Laval University; University of Wisconsin System; University of Wisconsin Madison	Morin, CM (corresponding author), Univ Laval, Ecole Psychol, Pavillon FAS, Quebec City, PQ G1V 0A6, Canada.	cmorin@psy.ulaval.ca	Morin, Charles M./A-4700-2008	Morin, Charles M./0000-0002-8649-8895	Organon; Merck; Sanofi-Aventis; Canadian Institutes of Health Research [MT-42504]; National Institute of Mental Health [MH-079188]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH079188] Funding Source: NIH RePORTER	Organon; Merck(Merck & Company); Sanofi-Aventis(Sanofi-Aventis); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	CMM has served as a consultant for Eli-Lilly, Merck, and Sanofi-Aventis and has received research grants from Organon, Merck, and Sanofi-Aventis. RB has served as a consultant for Merck and Sanofi-Aventis.; Preparation of this Seminar was supported partly by grants from the Canadian Institutes of Health Research (MT-42504) and the National Institute of Mental Health (MH-079188).	Aikens JE, 2005, J AM BOARD FAM PRACT, V18, P257, DOI 10.3122/jabfm.18.4.257; Altena E, 2010, BIOL PSYCHIAT, V67, P182, DOI 10.1016/j.biopsych.2009.08.003; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS; American Psychiatric Association, 2010, DSM 5 DEV SLEEP WAK; Ancoli-Israel S, 2010, SLEEP, V33, P225, DOI 10.1093/sleep/33.2.225; Avidan AY, 2005, J AM GERIATR SOC, V53, P955, DOI 10.1111/j.1532-5415.2005.53304.x; Bastien Celyne H, 2004, Behav Sleep Med, V2, P50, DOI 10.1207/s15402010bsm0201_5; Bastien CH, 2004, J CONSULT CLIN PSYCH, V72, P653, DOI 10.1037/0022-006X.72.4.653; Beaulieu-Bonneau S, 2007, SLEEP, V30, P1739, DOI 10.1093/sleep/30.12.1739; Belleville G, 2007, J CONSULT CLIN PSYCH, V75, P325, DOI 10.1037/0022-006X.75.2.325; Benca RM, 2005, PSYCHIAT SERV, V56, P332, DOI 10.1176/appi.ps.56.3.332; BENCA RM, 1992, ARCH GEN PSYCHIAT, V49, P651; Benke D, 2009, NEUROPHARMACOLOGY, V56, P174, DOI 10.1016/j.neuropharm.2008.06.013; Bonnet MH, 2010, SLEEP MED REV, V14, P9, DOI 10.1016/j.smrv.2009.05.002; Brassington GS, 2000, J AM GERIATR SOC, V48, P1234, DOI 10.1111/j.1532-5415.2000.tb02596.x; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; Buscemi N, 2005, J GEN INTERN MED, V20, P1151, DOI 10.1111/j.1525-1497.2005.0243.x; Buscemi N, 2007, J GEN INTERN MED, V22, P1335, DOI 10.1007/s11606-007-0251-z; Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473; Buysse DJ, 2007, SLEEP MED, V8, P198, DOI 10.1016/j.sleep.2006.10.006; Chang PP, 1997, AM J EPIDEMIOL, V146, P105; Chesson A, 2000, SLEEP, V23, P237; Cohrs S, 2008, CNS DRUGS, V22, P939, DOI 10.2165/00023210-200822110-00004; Crofford LJ, 2005, ARTHRITIS RHEUM-US, V52, P1264, DOI 10.1002/art.20983; Currie SR, 2004, ADDICTION, V99, P1121, DOI 10.1111/j.1360-0443.2004.00835.x; Currie SR, 2000, J CONSULT CLIN PSYCH, V68, P407, DOI 10.1037//0022-006X.68.3.407; Daley M, 2009, SLEEP MED, V10, P427, DOI 10.1016/j.sleep.2008.04.005; Daley M, 2009, SLEEP, V32, P55; Deuschle M, 2010, SLEEP, V33, P343, DOI 10.1093/sleep/33.3.343; Dew MA, 2003, PSYCHOSOM MED, V65, P63, DOI 10.1097/01.PSY.0000039756.23250.7C; Edinger JD, 2005, ARCH INTERN MED, V165, P2527, DOI 10.1001/archinte.165.21.2527; Edinger JD, 2004, SLEEP, V27, P1567, DOI 10.1093/sleep/27.8.1567; Edinger JD, 2008, OVERCOMING INSOMNIA; Espie CA, 2008, J CLIN ONCOL, V26, P4651, DOI 10.1200/JCO.2007.13.9006; Espie CA, 2007, SLEEP, V30, P574, DOI 10.1093/sleep/30.5.574; Espie CA, 2009, SLEEP, V32, P1549, DOI 10.1093/sleep/32.12.1549; Fava M, 2006, BIOL PSYCHIAT, V59, P1052, DOI 10.1016/j.biopsych.2006.01.016; Fava M, 2009, J CLIN PSYCHOPHARM, V29, P222, DOI 10.1097/JCP.0b013e3181a390ba; Ferguson SA, 2010, EXPERT REV NEUROTHER, V10, P305, DOI 10.1586/ERN.10.1; Fortier-Brochu E, 2012, SLEEP MED REV, V16, P83, DOI 10.1016/j.smrv.2011.03.008; Hauri PJ, 1997, SLEEP, V20, P1111, DOI 10.1093/sleep/20.12.1111; Hening W.A., 2009, RESTLESS LEGS SYNDRO; Hindmarch I, 2001, HUM PSYCHOPHARM CLIN, V16, P159, DOI 10.1002/hup.282.abs; HOHAGEN F, 1993, EUR ARCH PSY CLIN N, V242, P329, DOI 10.1007/BF02190245; Holbrook AM, 2000, CAN MED ASSOC J, V162, P225; Hoque R, 2009, J CLIN SLEEP MED, V5, P471; Irwin MR, 2006, HEALTH PSYCHOL, V25, P3, DOI 10.1037/0278-6133.25.1.3; Fernandez-San-Martin MI, 2010, SLEEP MED, V11, P505, DOI 10.1016/j.sleep.2009.12.009; Jacobs GD, 2004, ARCH INTERN MED, V164, P1888, DOI 10.1001/archinte.164.17.1888; Jansson-Frojmark M, 2008, J PSYCHOSOM RES, V64, P443, DOI 10.1016/j.jpsychores.2007.10.016; KALES A, 1991, CLIN PHARMACOL THER, V49, P468, DOI 10.1038/clpt.1991.55; Krystal AD, 2003, SLEEP, V26, P793, DOI 10.1093/sleep/26.7.793; Krystal AD, 2008, SLEEP, V31, P79, DOI 10.1093/sleep/31.1.79; Krystal AD, 2009, SLEEP MED REV, V13, P265, DOI 10.1016/j.smrv.2008.08.001; Lanfranchi PA, 2009, SLEEP, V32, P760, DOI 10.1093/sleep/32.6.760; Lichstein KL, 2000, PSYCHOL AGING, V15, P232, DOI 10.1037/0882-7974.15.2.232; Littner M, 2003, SLEEP, V26, P754, DOI 10.1093/sleep/26.6.754; Luyster FS, 2010, J CLIN SLEEP MED, V6, P196; Manber R, 2008, SLEEP, V31, P489, DOI 10.1093/sleep/31.4.489; Mayer G, 2009, SLEEP, V32, P351, DOI 10.1093/sleep/32.3.351; Mayers AG, 2005, HUM PSYCHOPHARM CLIN, V20, P533, DOI 10.1002/hup.726; MCCLUSKY HY, 1991, AM J PSYCHIAT, V148, P121; McCurry SM, 2007, PSYCHOL AGING, V22, P18, DOI 10.1037/0882-7974.22.1.18; MENDELSON WB, 1992, J CLIN PSYCHIAT, V53, P4; MILBY JB, 1993, AM J PSYCHIAT, V150, P1259; Mimeault V, 1999, J CONSULT CLIN PSYCH, V67, P511, DOI 10.1037/0022-006X.67.4.511; Montgomery SA, 2009, INT CLIN PSYCHOPHARM, V24, P214, DOI 10.1097/YIC.0b013e32832dceb9; Morgan K, 2003, BRIT J GEN PRACT, V53, P923; Morgenthaler T, 2006, SLEEP, V29, P1415; Morin CM, 2006, SLEEP, V29, P1398, DOI 10.1093/sleep/29.11.1398; Morin CM, 2009, JAMA-J AM MED ASSOC, V301, P2005, DOI 10.1001/jama.2009.682; Morin CM, 2009, ARCH INTERN MED, V169, P447, DOI 10.1001/archinternmed.2008.610; Morin CM, 2006, SLEEP MED, V7, P123, DOI 10.1016/j.sleep.2005.08.008; Morin CM, 2004, AM J PSYCHIAT, V161, P332, DOI 10.1176/appi.ajp.161.2.332; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Morin CM, 2002, BEHAV RES THER, V40, P741, DOI 10.1016/S0005-7967(01)00055-9; Morin CM, 1999, SLEEP, V22, P1134, DOI 10.1093/sleep/22.8.1134; Morin CM, 2003, INSOMNIA CLIN GUIDE; Morphy H, 2007, SLEEP, V30, P274; MURTAGH DRR, 1995, J CONSULT CLIN PSYCH, V63, P79, DOI 10.1037/0022-006X.63.1.79; National Institutes of Health, 2005, Sleep, V28, P1049; Nierenberg AA, 2010, PSYCHOL MED, V40, P41, DOI 10.1017/S0033291709006011; Nierenberg AA, 1999, J CLIN PSYCHIAT, V60, P221, DOI 10.4088/JCP.v60n0403; Nofzinger EA, 2004, AM J PSYCHIAT, V161, P2126, DOI 10.1176/appi.ajp.161.11.2126; Nowell PD, 1997, JAMA-J AM MED ASSOC, V278, P2170; Ohayon MM, 2009, SLEEP MED, V10, P952, DOI 10.1016/j.sleep.2009.07.008; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Pallesen S, 2003, BEHAV RES THER, V41, P31, DOI 10.1016/S0005-7967(01)00122-X; Pearson NJ, 2006, ARCH INTERN MED, V166, P1775, DOI 10.1001/archinte.166.16.1775; Perlis ML, 1997, J AFFECT DISORDERS, V42, P209, DOI 10.1016/S0165-0327(96)01411-5; Perlis ML, 2001, SLEEP, V24, P110, DOI 10.1093/sleep/24.1.110; Pollack M, 2008, ARCH GEN PSYCHIAT, V65, P551, DOI 10.1001/archpsyc.65.5.551; Richardson GS, 2008, J CLIN SLEEP MED, V4, P456; Richardson GS, 2002, J CLIN PSYCHOPHARM, V22, P511, DOI 10.1097/00004714-200210000-00012; Riemann D, 2007, SLEEP, V30, P955, DOI 10.1093/sleep/30.8.955; Riemann D, 2010, SLEEP MED REV, V14, P19, DOI 10.1016/j.smrv.2009.04.002; Ritterband LM, 2009, ARCH GEN PSYCHIAT, V66, P692, DOI 10.1001/archgenpsychiatry.2009.66; Roehrs TA, 2009, DRUGS, V69, P5, DOI 10.2165/11531260-000000000-00000; Roth T, 2007, SLEEP, V30, P1555, DOI 10.1093/sleep/30.11.1555; Roth T, 2006, SLEEP, V29, P335, DOI 10.1093/sleep/29.3.335; Roth T, 2006, BIOL PSYCHIAT, V60, P1364, DOI 10.1016/j.biopsych.2006.05.039; Russell IJ, 2009, SLEEP MED, V10, P604, DOI 10.1016/j.sleep.2009.01.009; Rybarczyk B, 2005, J CONSULT CLIN PSYCH, V73, P1164, DOI 10.1037/0022-006X.73.6.1164; Sack RL, 2007, SLEEP, V30, P1460, DOI 10.1093/sleep/30.11.1460; Sateia MJ, 2000, SLEEP, V23, P243; Savard J, 2005, J CLIN ONCOL, V23, P6083, DOI 10.1200/JCO.2005.09.548; Savard J, 2011, PSYCHO-ONCOLOGY, V20, P1013, DOI 10.1002/pon.1818; Scharf M, 2008, J CLIN PSYCHIAT, V69, P1557, DOI 10.4088/JCP.v69n1005; Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487; Shekleton JA, 2010, SLEEP MED REV, V14, P47, DOI 10.1016/j.smrv.2009.06.001; Simon GE, 1997, AM J PSYCHIAT, V154, P1417; Sivertsen B, 2006, JAMA-J AM MED ASSOC, V295, P2851, DOI 10.1001/jama.295.24.2851; Sivertsen B, 2006, AM J EPIDEMIOL, V163, P1018, DOI 10.1093/aje/kwj145; Smith MT, 2005, CLIN PSYCHOL REV, V25, P559, DOI 10.1016/j.cpr.2005.04.004; Smith MT, 2004, SLEEP MED REV, V8, P119, DOI 10.1016/S1087-0792(03)00044-3; Smith MT, 2002, AM J PSYCHIAT, V159, P5, DOI 10.1176/appi.ajp.159.1.5; Soeffing JP, 2008, SLEEP MED, V9, P165, DOI 10.1016/j.sleep.2007.02.009; Spielman AJ., 1991, VARIED NATURE INSOMN, P1, DOI DOI 10.1007/978-1-4757-9586-8_1; Suka M, 2003, J OCCUP HEALTH, V45, P344, DOI 10.1539/joh.45.344; Taylor DJ, 2007, BEHAV THER, V38, P49, DOI 10.1016/j.beth.2006.04.002; Vallieres A, 2005, J SLEEP RES, V14, P447, DOI 10.1111/j.1365-2869.2005.00480.x; Vallieres A, 2005, BEHAV RES THER, V43, P1611, DOI 10.1016/j.brat.2004.11.011; van Straten A, 2009, SLEEP MED REV, V13, P61, DOI 10.1016/j.smrv.2008.04.006; Vgontzas AN, 2010, SLEEP, V33, P1159, DOI 10.1093/sleep/33.9.1159; Vincent N, 2001, SLEEP, V24, P411, DOI 10.1093/sleep/24.4.411; Walsh JK, 2006, J CLIN SLEEP MED, V2, P35; Walsh JK, 2006, SLEEP MED, V7, P155, DOI 10.1016/j.sleep.2005.05.004; Walsh JK., 2009, J CLIN SLEEP MED, V5(2, pS27, DOI [10.5664/jcsm.5.2S.S27, DOI 10.5664/JCSM.5.2S.S27]; Wang PS, 2001, J AM GERIATR SOC, V49, P1685, DOI 10.1111/j.1532-5415.2001.49280.x; Wiegand MH, 2008, DRUGS, V68, P2411, DOI 10.2165/0003495-200868170-00001; Wilson S, 2005, DRUGS, V65, P927, DOI 10.2165/00003495-200565070-00003; Wine JN, 2009, ANN PHARMACOTHER, V43, P707, DOI 10.1345/aph.1L320; Zammit G, 2009, DRUG SAFETY, V32, P735, DOI 10.2165/11312920-000000000-00000; Zammit GK, 2006, J CLIN SLEEP MED, V2, P417	136	471	510	15	135	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 24	2012	379	9821					1129	1141		10.1016/S0140-6736(11)60750-2	http://dx.doi.org/10.1016/S0140-6736(11)60750-2			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916VR	22265700				2022-12-28	WOS:000302131800035
J	Parker, C				Parker, Chris			What (if anything) to do about low-risk prostate cancer	LANCET			English	Editorial Material									Royal Marsden Natl Hlth Serv Fdn Trust, Acad Urol Unit, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust	Parker, C (corresponding author), Royal Marsden Natl Hlth Serv Fdn Trust, Acad Urol Unit, Sutton SM2 5PT, Surrey, England.	chris.parker@rmh.nhs.uk			Cancer Research UK [10588] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127; Dickinson L, 2011, EUR UROL, V59, P477, DOI 10.1016/j.eururo.2010.12.009; Fleshner NE, 2012, LANCET, V379, P1103, DOI 10.1016/S0140-6736(11)61619-X; Merrill RM, 1997, CANCER EPIDEM BIOMAR, V6, P763; Parker C, 2004, LANCET ONCOL, V5, P101, DOI 10.1016/S1470-2045(04)01384-1; Roobol MJ, 2010, EUR UROL, V57, P79, DOI 10.1016/j.eururo.2009.08.025; Theoret MR, 2011, NEW ENGL J MED, V365, P97, DOI 10.1056/NEJMp1106783; Wilt TJ, 2011, AM UR ASS ANN M WASH	8	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 24	2012	379	9821					1078	1080		10.1016/S0140-6736(12)60066-X	http://dx.doi.org/10.1016/S0140-6736(12)60066-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916VR	22277569				2022-12-28	WOS:000302131800008
J	Clark, CE; Taylor, RS; Shore, AC; Ukoumunne, OC; Campbell, JL				Clark, Christopher E.; Taylor, Rod S.; Shore, Angela C.; Ukoumunne, Obioha C.; Campbell, John L.			Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis	LANCET			English	Article							PERIPHERAL ARTERIAL-DISEASE; ANKLE-BRACHIAL INDEX; CORONARY-SUBCLAVIAN STEAL; INTERMITTENT CLAUDICATION; CARDIOVASCULAR EVENTS; GENERAL-PRACTICE; ENDOVASCULAR THERAPY; PREVALENCE; STENOSIS; RISK	Background Differences in systolic blood pressure (SBP) of 10 mm Hg or more or 15 mm Hg or more between arms have been associated with peripheral vascular disease and attributed to subclavian stenosis. We investigated whether an association exists between this difference and central or peripheral vascular disease, and mortality. Methods We searched Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane, and Medline In Process databases for studies published before July, 2011, showing differences in SBP between arms, with data for subclavian stenosis, peripheral vascular disease, cerebrovascular disease, cardiovascular disease, or survival. We used random effects meta-analysis to combine estimates of the association between differences in SBP between arms and each outcome. Findings We identified 28 eligible studies for review, 20 of which were included in our meta-analyses. In five invasive studies using angiography, mean difference in SBP between arms was 36.9 mm Hg (95% CI 35.4-38.4) for proven subclavian stenosis (>50% occlusion), and a difference of 10 mm Hg or more was strongly associated with subclavian stenosis (risk ratio [RR] 8.8, 95% CI 3.6-21.2). In non-invasive studies, pooled findings showed that a difference of 15 mm Hg or more was associated with peripheral vascular disease (nine cohorts; RR 2.5, 95% CI 1.6-3.8; sensitivity 15%, 9-23; specificity 96%, 94-98); pre-existing cerebrovascular disease (five cohorts; RR 1.6, 1.1-2.4; sensitivity 8%, 2-26; specificity 93%, 86-97); and increased cardio vascular mortality (four cohorts; hazard ratio [HR] 1.7, 95% CI 1.1-2.5) and all-cause mortality (HR 1.6, 1.1-2.3). A difference of 10 mm Hg or higher was associated with peripheral vascular disease (five studies; RR 2.4, 1.5-3.9; sensitivity 32%, 23-41; specificity 91%, 86-94). Interpretation A difference in SBP of 10 mm Hg or more, or of 15 mm Hg or more, between arms might help to identify patients who need further vascular assessment. A difference of 15 mm Hg or more could be a useful indicator of risk of vascular disease and death.	[Clark, Christopher E.; Taylor, Rod S.; Campbell, John L.] Univ Exeter, Primary Care Res Grp, Inst Hlth Serv Res, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England; [Shore, Angela C.] Univ Exeter, Peninsula NIHR Clin Res Facil, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England; [Shore, Angela C.] Univ Exeter, Inst Biomed & Clin Sci, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England; [Ukoumunne, Obioha C.] Univ Exeter, Peninsula Collaborat Leadership Appl Hlth Res & C, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England	University of Exeter; University of Plymouth; University of Exeter; University of Plymouth; University of Exeter; University of Plymouth; University of Exeter; University of Plymouth	Clark, CE (corresponding author), Univ Exeter, Primary Care Res Grp, Inst Hlth Serv Res, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England.	christopher.clark@pms.ac.uk	Taylor, Rod/R-9581-2019; Franzeck, Fabian C/B-5055-2011; Campbell, John/A-5792-2011	Taylor, Rod/0000-0002-3043-6011; Campbell, John/0000-0002-6752-3493; Shore, Angela/0000-0003-3039-308X	Royal College of General Practitioners; South West GP Trust; Peninsula Collaboration for Leadership in Applied Health Research and Care; Scientific Foundation Board of the Royal College of General Practitioners [SFB-2009-06]; Peninsula College of Medicine and Dentistry; University of Exeter; University of Plymouth; National Health Service South West; National Institute for Health Research	Royal College of General Practitioners; South West GP Trust; Peninsula Collaboration for Leadership in Applied Health Research and Care; Scientific Foundation Board of the Royal College of General Practitioners; Peninsula College of Medicine and Dentistry; University of Exeter; University of Plymouth; National Health Service South West; National Institute for Health Research(National Institute for Health Research (NIHR))	Royal College of General Practitioners, South West GP Trust, and Peninsula Collaboration for Leadership in Applied Health Research and Care.; We thank Joy Choules and the staff of Exeter Medical Library for their assistance in obtaining the full text papers for this Article; Victor Aboyans (Centre hospitalier universitaire Limoges) for responding to author enquiries; and Chris Hyde and Willie Hamilton (Peninsual College of Medicine and Dentistry) for constructive comments. This research was funded by the Scientific Foundation Board of the Royal College of General Practitioners (grant No SFB-2009-06) and the South West GP Trust. CEC and OCU are supported by The Peninsula Collaboration for Leadership in Applied Health Research and Care, a collaboration between the Peninsula College of Medicine and Dentistry, University of Exeter, University of Plymouth, and National Health Service South West, funded by the National Institute for Health Research. The University of Exeter is the research sponsor for this study. The views and opinions expressed in this report are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.	Aboyans V, 2007, J AM COLL CARDIOL, V49, P1540, DOI 10.1016/j.jacc.2006.09.055; Aboyans V, 2010, ATHEROSCLEROSIS, V211, P266, DOI 10.1016/j.atherosclerosis.2010.01.013; Agarwal R, 2008, HYPERTENSION, V51, P657, DOI 10.1161/HYPERTENSIONAHA.107.104943; Akers JA-IR., 2009, SYSTEMATIC REV CRDS; Anekwe L, 2007, INTERARM DIFF ERENCE; Aung PP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000123.pub2; Baribeau Y, 2002, CIRCULATION, V106, pI11, DOI 10.1161/01.cir.0000032894.55215.32; CALLIGARO KD, 1990, J VASC SURG, V11, P832, DOI 10.1067/mva.1990.17471; Campbell NC, 2007, BRIT J GEN PRACT, V57, P311; Clark CE, 2007, J HUM HYPERTENS, V21, P633, DOI 10.1038/sj.jhh.1002209; Clark CE, 2006, J HUM HYPERTENS, V20, P923, DOI 10.1038/sj.jhh.1002093; Clark CE, 2002, FAM PRACT, V19, P439, DOI 10.1093/fampra/19.5.439; Clark CE, 2001, BRIT MED J, V323, P399, DOI 10.1136/bmj.323.7309.399; Clark CE, 2009, DIABETIC MED S1, V26, P128; Clark CE, 2010, DIABETIC MED, V27, P44; Clark CE, 2007, FAM PRACT, V24, P420, DOI 10.1093/fampra/cmm035; Clark CE, 2009, BRIT J GEN PRACT, V59, P428, DOI 10.3399/bjgp09X420752; CONI N, 1992, BRIT J GEN PRACT, V42, P149; Costa SM, 2007, ANGIOLOGY, V58, P242, DOI 10.1177/0003319707300371; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; Cui R, 2006, ATHEROSCLEROSIS, V184, P420, DOI 10.1016/j.atherosclerosis.2005.05.005; Department of Health, 2008, PUTT PREV 1 VASC CHE; Dieter RS, 2004, ANGIOLOGY, V55, P625, DOI 10.1177/00033197040550i603; Donnelly R, 2000, BRIT MED J, V320, P698, DOI 10.1136/bmj.320.7236.698; Donnelly R, 2002, EUR J VASC ENDOVASC, V23, P100, DOI 10.1053/ejvs.2001.1544; English JL, 2001, CATHETER CARDIO INTE, V54, P8, DOI 10.1002/ccd.1230; Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197; Fowkes FGR, 2010, JAMA-J AM MED ASSOC, V303, P841, DOI 10.1001/jama.2010.221; FRANK SM, 1991, ANESTHESIOLOGY, V75, P457, DOI 10.1097/00000542-199109000-00013; Gutierrez GR, 2001, ANGIOLOGY, V52, P189, DOI 10.1177/000331970105200305; Harbord RM, 2007, BIOSTATISTICS, V8, P239, DOI 10.1093/biostatistics/kxl004; Harbord RM, 2009, STATA J, V9, P211, DOI 10.1177/1536867X0900900203; He Tie-chun, 2002, Chinese Journal of Biomedical Engineering, V21, P182; Heneghan C, 2007, BRIT J GEN PRACT, V57, P948, DOI 10.3399/096016407782604965; Higgins J.P.T., 2021, COCHRANE HDB SYSTEMA, DOI [DOI 10.1002/9781119536604, 10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; HUGHSON WG, 1978, BRIT MED J, V1, P1379, DOI 10.1136/bmj.1.6124.1379; Igarashi Yuko, 2007, J Cardiol, V50, P281; Karagiannis A, 2005, ANGIOLOGY, V56, P565, DOI 10.1177/000331970505600507; Kawamura T, 2008, ARQ BRAS CARDIOL, V90, P322, DOI 10.1590/S0066-782X2008000500003; KIEKARA O, 1985, ACTA CHIR SCAND, V151, P437; Kimura A, 2004, J HYPERTENS, V22, P2277, DOI 10.1097/00004872-200412000-00009; Lane D, 2002, J HYPERTENS, V20, P1089, DOI 10.1097/00004872-200206000-00019; LAWSON JD, 1979, SOUTHERN MED J, V72, P1369, DOI 10.1097/00007611-197911000-00006; Lobato EB, 2001, J CARDIOTHOR VASC AN, V15, P689, DOI 10.1053/jcan.2001.28309; MAGAARD F, 1976, SCAND J THORAC CARD, V10, P85, DOI 10.3109/14017437609167774; Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]; Matsumura K, 2002, JPN J INTERVENT CARD, V17, P382; Mendelson Gad, 2004, Cardiol Rev, V12, P276, DOI 10.1097/01.crd.0000127858.46493.da; Moll F., 1983, BRUIT, V8, P18; National Institute for Health and Clinical Excellence, 2011, HYPERT CLIN MAN PRI; Orme S, 1999, AGE AGEING, V28, P537, DOI 10.1093/ageing/28.6.537; Osborn LA, 2002, CATHETER CARDIO INTE, V56, P162, DOI 10.1002/ccd.10198; Parati G, 2010, J HUM HYPERTENS, V24, P779, DOI 10.1038/jhh.2010.54; Parker E, 2009, BRIT J GEN PRACT, V59, P206, DOI 10.3399/bjgp09X395012; RAY SA, 1994, BRIT J SURG, V81, P188, DOI 10.1002/bjs.1800810208; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Shadman R, 2004, J AM COLL CARDIOL, V44, P618, DOI 10.1016/j.jacc.2004.04.044; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; SUMNER DS, 1986, J VASC SURG, V3, P560, DOI 10.1067/mva.1986.avs0030560b; Tan TY, 2002, J NEUROIMAGING, V12, P131, DOI 10.1111/j.1552-6569.2002.tb00109.x; University of Leicester, 2008, HDB VASC RISK ASS RI; Verberk WJ, 2011, AM J HYPERTENS, V24, P1201, DOI 10.1038/ajh.2011.125; WALKER PM, 1985, J VASC SURG, V2, P154, DOI 10.1067/mva.1985.avs0020154; Wang KQ, 2010, CHINESE MED J-PEKING, V123, P45, DOI 10.3760/cma.j.issn.0366-6999.2010.01.008; Westerband A, 2003, J VASC SURG, V38, P699, DOI 10.1016/S0741-5214(03)00728-6; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zheng ZJ, 1997, ATHEROSCLEROSIS, V131, P115, DOI 10.1016/S0021-9150(97)06089-9	68	236	273	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 10	2012	379	9819					905	914		10.1016/S0140-6736(11)61710-8	http://dx.doi.org/10.1016/S0140-6736(11)61710-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906NY	22293369				2022-12-28	WOS:000301353700030
J	Antos, JR				Antos, Joseph R.			The Wyden-Ryan Proposal - A Foundation for Realistic Medicare Reform	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Amer Enterprise Inst Publ Policy Res, Washington, DC USA	American Enterprise Institute for Public Policy Research	Antos, JR (corresponding author), Amer Enterprise Inst Publ Policy Res, Washington, DC USA.							[Anonymous], 2011, 2011 ANN REP BOARDS; Debt Reduction Task Force of the Bipartisan Policy Center, 2010, REST AM FUT REV EC C; House Committee on the Budget, PATH PROSP REST AM P; Suderman P, 2011, P RYANS MEDICARE COM; Wyden R., 2011, GUARANTEED CHOICES S	5	9	9	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					879	881		10.1056/NEJMp1200446	http://dx.doi.org/10.1056/NEJMp1200446			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	904CY	22276781				2022-12-28	WOS:000301172500004
J	Britnell, L; Gorbachev, RV; Jalil, R; Belle, BD; Schedin, F; Mishchenko, A; Georgiou, T; Katsnelson, MI; Eaves, L; Morozov, SV; Peres, NMR; Leist, J; Geim, AK; Novoselov, KS; Ponomarenko, LA				Britnell, L.; Gorbachev, R. V.; Jalil, R.; Belle, B. D.; Schedin, F.; Mishchenko, A.; Georgiou, T.; Katsnelson, M. I.; Eaves, L.; Morozov, S. V.; Peres, N. M. R.; Leist, J.; Geim, A. K.; Novoselov, K. S.; Ponomarenko, L. A.			Field-Effect Tunneling Transistor Based on Vertical Graphene Heterostructures	SCIENCE			English	Article							HEXAGONAL BORON-NITRIDE; HIGH-FREQUENCY; ELECTRONICS; TRANSPORT; DEVICES; CARBON; STATE; GATE	An obstacle to the use of graphene as an alternative to silicon electronics has been the absence of an energy gap between its conduction and valence bands, which makes it difficult to achieve low power dissipation in the OFF state. We report a bipolar field-effect transistor that exploits the low density of states in graphene and its one-atomic-layer thickness. Our prototype devices are graphene heterostructures with atomically thin boron nitride or molybdenum disulfide acting as a vertical transport barrier. They exhibit room-temperature switching ratios of approximate to 50 and approximate to 10,000, respectively. Such devices have potential for high-frequency operation and large-scale integration.	[Britnell, L.; Mishchenko, A.; Georgiou, T.; Geim, A. K.; Novoselov, K. S.; Ponomarenko, L. A.] Univ Manchester, Sch Phys & Astron, Manchester M13 9PL, Lancs, England; [Gorbachev, R. V.; Jalil, R.; Belle, B. D.; Schedin, F.; Geim, A. K.] Univ Manchester, Manchester Ctr Mesosci & Nanotechnol, Manchester M13 9PL, Lancs, England; [Katsnelson, M. I.] Radboud Univ Nijmegen, Inst Mol & Mat, NL-6525 AJ Nijmegen, Netherlands; [Eaves, L.] Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England; [Morozov, S. V.] Russian Acad Sci, Inst Microelect Technol, Chernogolovka 142432, Russia; [Peres, N. M. R.] Univ Minho, Dept Fis, P-4710057 Braga, Portugal; [Peres, N. M. R.] Natl Univ Singapore, Graphene Res Ctr, Singapore 117542, Singapore; [Peres, N. M. R.] Natl Univ Singapore, Dept Phys, Singapore 117542, Singapore; [Leist, J.] Moment Performance Mat, Strongsville, OH 44070 USA	University of Manchester; University of Manchester; Radboud University Nijmegen; University of Nottingham; Russian Academy of Sciences; Universidade do Minho; National University of Singapore; National University of Singapore	Geim, AK (corresponding author), Univ Manchester, Sch Phys & Astron, Manchester M13 9PL, Lancs, England.	geim@manchester.ac.uk; kostya@manchester.ac.uk; leonid.ponomarenko@manchester.ac.uk	Geim, Andre K/J-7888-2012; Mishchenko, Artem/C-7561-2011; Gorbachev, Roman/I-2512-2013; Morozov, Sergey V/H-3171-2014; Ponomarenko, Leonid/AAF-1731-2021; Novoselov, Kostya S/G-9581-2014; Katsnelson, Mikhail I./D-4359-2012; Jalil, Rashid/Z-2262-2019	Geim, Andre K/0000-0003-2861-8331; Mishchenko, Artem/0000-0002-0427-5664; Gorbachev, Roman/0000-0003-3604-5617; Morozov, Sergey V/0000-0003-3075-7787; Novoselov, Kostya S/0000-0003-4972-5371; Jalil, Rashid/0000-0002-8347-9955; Eaves, Laurence/0000-0002-5334-0987; Peres, Nuno/0000-0002-7928-8005; hai yan, he/0000-0003-0366-6185	European Research Council; European Commision; Engineering and Physical Research Council (UK); Royal Society; U.S. Office of Naval Research; U.S. Air Force Office of Scientific Research; Korber Foundation; Swiss National Science Foundation; EPSRC [EP/K005014/1, EP/G035954/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/K005014/1, EP/G035954/1] Funding Source: researchfish	European Research Council(European Research Council (ERC)European Commission); European Commision; Engineering and Physical Research Council (UK)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Royal Society(Royal Society of London); U.S. Office of Naval Research(Office of Naval Research); U.S. Air Force Office of Scientific Research(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); Korber Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by the European Research Council, European Commision FP7, Engineering and Physical Research Council (UK), the Royal Society, U.S. Office of Naval Research, U.S. Air Force Office of Scientific Research, and the Korber Foundation. A.M. acknowledges support from the Swiss National Science Foundation.	Avouris P, 2007, NAT NANOTECHNOL, V2, P605, DOI 10.1038/nnano.2007.300; Castro EV, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.216802; Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109; Dean CR, 2010, NAT NANOTECHNOL, V5, P722, DOI 10.1038/nnano.2010.172; Elias DC, 2009, SCIENCE, V323, P610, DOI 10.1126/science.1167130; Geim AK, 2009, SCIENCE, V324, P1530, DOI 10.1126/science.1158877; Gorbachev RV, 2011, SMALL, V7, P465, DOI 10.1002/smll.201001628; Han MY, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.206805; Han SJ, 2011, NANO LETT, V11, P3690, DOI 10.1021/nl2016637; HEIBLUM M, 1990, IBM J RES DEV, V34, P530, DOI 10.1147/rd.344.0530; Kharche N, 2011, NANO LETT, V11, P5274, DOI 10.1021/nl202725w; Liao L, 2010, NATURE, V467, P305, DOI 10.1038/nature09405; Lin YM, 2011, SCIENCE, V332, P1294, DOI 10.1126/science.1204428; LURYI S, 1988, APPL PHYS LETT, V52, P501, DOI 10.1063/1.99649; Mayorov AS, 2011, NANO LETT, V11, P2396, DOI 10.1021/nl200758b; Novoselov KS, 2005, P NATL ACAD SCI USA, V102, P10451, DOI 10.1073/pnas.0502848102; Oostinga JB, 2008, NAT MATER, V7, P151, DOI 10.1038/nmat2082; Ponomarenko LA, 2011, NAT PHYS, V7, P958, DOI [10.1038/nphys2114, 10.1038/NPHYS2114]; Ponomarenko LA, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.136801; Schwierz F, 2010, NAT NANOTECHNOL, V5, P487, DOI [10.1038/NNANO.2010.89, 10.1038/nnano.2010.89]; Sciambi A, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.085301; Simmons JA, 1998, J APPL PHYS, V84, P5626, DOI 10.1063/1.368610; SIMMONS JG, 1963, J APPL PHYS, V34, P1793, DOI 10.1063/1.1702682; Stampfer C, 2011, FRONT PHYS-BEIJING, V6, P271, DOI 10.1007/s11467-011-0182-3; Wolf E.L., 1985, PRINCIPLES ELECT TUN; Wu YQ, 2011, NATURE, V472, P74, DOI 10.1038/nature09979; XU YN, 1991, PHYS REV B, V44, P7787, DOI 10.1103/PhysRevB.44.7787; Xue JM, 2011, NAT MATER, V10, P282, DOI 10.1038/NMAT2968; Zaslavsky A, 2003, APPL PHYS LETT, V83, P1653, DOI 10.1063/1.1600832	29	2010	2056	62	2284	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2012	335	6071					947	950		10.1126/science.1218461	http://dx.doi.org/10.1126/science.1218461			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ZQ	22300848	Green Submitted, Green Published			2022-12-28	WOS:000300931800040
J	Munoz, J; Kuriakose, P				Munoz, Javier; Kuriakose, Philip			Rash in an Immunocompromised Patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SWEETS-SYNDROME		[Munoz, Javier; Kuriakose, Philip] Henry Ford Hosp, Div Hematol Oncol, Dept Hematol & Oncol, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Munoz, J (corresponding author), Henry Ford Hosp, Div Hematol Oncol, Dept Hematol & Oncol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	javier.munoz@me.com	Hug, Balthasar L./G-1568-2010					Alencar C, 2009, AM J HEMATOL, V84, P688, DOI 10.1002/ajh.21510; Cohen PR, 2003, INT J DERMATOL, V42, P761, DOI 10.1046/j.1365-4362.2003.01891.x; Conesa V, 1998, AM J HEMATOL, V57, P179, DOI 10.1002/(SICI)1096-8652(199802)57:2<179::AID-AJH15>3.0.CO;2-7; National Comprehensive Cancer Network, SUPP CAR PAT APL; Rosenbeck L, 2011, NEW ENGL J MED, V364, pE5, DOI 10.1056/NEJMicm1006530; Sanz MA, 2009, BLOOD, V113, P1875, DOI 10.1182/blood-2008-04-150250	6	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					612	613		10.1001/jama.2012.96	http://dx.doi.org/10.1001/jama.2012.96			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318283				2022-12-28	WOS:000299992500026
J	Bonanomi, D; Chivatakarn, O; Bai, G; Abdesselem, H; Lettieri, K; Marquardt, T; Pierchala, BA; Pfaff, SL				Bonanomi, Dario; Chivatakarn, Onanong; Bai, Ge; Abdesselem, Houari; Lettieri, Karen; Marquardt, Till; Pierchala, Brian A.; Pfaff, Samuel L.			Ret Is a Multifunctional Coreceptor that Integrates Diffusible- and Contact-Axon Guidance Signals	CELL			English	Article							LIMB MOTOR AXONS; NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; TYROSINE KINASE; LIPID RAFTS; NEURAL DEVELOPMENT; NEURONAL SURVIVAL; GDNF FAMILY; RECEPTOR; LIGANDS	Growing axons encounter multiple guidance cues, but it is unclear how separate signals are resolved and integrated into coherent instructions for growth cone navigation. We report that glycosylphosphati-dylinositol (GPI)-anchored ephrin-As function as "reverse'' signaling receptors for motor axons when contacted by transmembrane EphAs present in the dorsal limb. Ephrin-A receptors are thought to depend on transmembrane coreceptors for transmitting signals intracellularly. We show that the receptor tyrosine kinase Ret is required for motor axon attraction mediated by ephrin-A reverse signaling. Ret also mediates GPI-anchored GFR alpha 1 signaling in response to GDNF, a diffusible chemoattractant in the limb, indicating that Ret is a multifunctional coreceptor for guidance molecules. Axons respond synergistically to coactivation by GDNF and EphA ligands, and these cooperative interactions are gated by GFR alpha 1 levels. Our studies uncover a hierarchical GPI-receptor signaling network that is constructed from combinatorial components and integrated through Ret using ligand coincidence detection.	[Bonanomi, Dario; Chivatakarn, Onanong; Bai, Ge; Lettieri, Karen; Pfaff, Samuel L.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; [Bonanomi, Dario; Chivatakarn, Onanong; Bai, Ge; Lettieri, Karen; Pfaff, Samuel L.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; [Abdesselem, Houari; Pierchala, Brian A.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; [Marquardt, Till] European Neurosci Inst Gottingen, Dev Neurobiol Lab, D-37077 Gottingen, Germany	Howard Hughes Medical Institute; Salk Institute; Salk Institute; University of Michigan System; University of Michigan	Pfaff, SL (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.	pfaff@salk.edu	Bonanomi, Dario/K-3450-2016; Bai, Ge/K-2608-2014	Bonanomi, Dario/0000-0003-4517-1244; 	HHMI; NINDS [NS054172, NS031249]; Salk pioneer fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054172, P01NS031249] Funding Source: NIH RePORTER	HHMI(Howard Hughes Medical Institute); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Salk pioneer fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Laura Franco for technical assistance; Christopher Hinckley for help with two-photon imaging; Shane Andrews for help with microscopy; Shawn Driscoll for help with data analysis; Arnon Rosenthal and Buffer Fennie for Gfra1 mice; Bennett Novitch for Olig2::Cre mice; Kuo-Fen Lee for p75 mice; Martin Goulding and Andrew Boyd for EphA4 mice; Frank Costantini for Ret mice; Tsung-Chang Sung, Zhijiang Chen, Kuo-Fen Lee, Yoo-shick Lim, and Dennis O'Leary for ephrin-A2/5 and p75 plasmids and helpful discussion. D.B. was supported by HHMI, O.C. by an NINDS fellowship, G.B. by HHMI and a Salk pioneer fellowship, and S.L.P. is an investigator with HHMI. This research was supported by NINDS grants NS054172 and NS031249 and HHMI.	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Bai G, 2011, CELL, V144, P106, DOI 10.1016/j.cell.2010.11.053; Bonanomi D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001735; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Damon DH, 2010, AUTON NEUROSCI-BASIC, V158, P65, DOI 10.1016/j.autneu.2010.06.004; Dessaud E, 2007, NATURE, V450, P717, DOI 10.1038/nature06347; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Dottori M, 1998, P NATL ACAD SCI USA, V95, P13248, DOI 10.1073/pnas.95.22.13248; Dudanova I, 2011, NEURON, V71, P1, DOI 10.1016/j.neuron.2011.06.030; Dudanova I, 2010, CURR BIOL, V20, P2150, DOI 10.1016/j.cub.2010.11.021; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Eberhart J, 2002, DEV BIOL, V247, P89, DOI 10.1006/dbio.2002.0695; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gallarda BW, 2008, SCIENCE, V320, P233, DOI 10.1126/science.1153758; Gould TW, 2008, J NEUROSCI, V28, P2131, DOI 10.1523/JNEUROSCI.5185-07.2008; Haase G, 2002, NEURON, V35, P893, DOI 10.1016/S0896-6273(02)00864-4; Helmbacher F, 2000, DEVELOPMENT, V127, P3313; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; Iwamasa H, 1999, DEV GROWTH DIFFER, V41, P685; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; Kao TJ, 2011, NEURON, V71, P76, DOI 10.1016/j.neuron.2011.05.031; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Knoll B, 2001, DEVELOPMENT, V128, P895; Konstantinova I, 2007, CELL, V129, P359, DOI 10.1016/j.cell.2007.02.044; Kramer ER, 2006, NEURON, V50, P35, DOI 10.1016/j.neuron.2006.02.020; Kretz A, 2006, BRAIN RES, V1090, P1, DOI 10.1016/j.brainres.2006.01.131; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Landmesser LT, 2001, INT J DEV NEUROSCI, V19, P175, DOI 10.1016/S0736-5748(00)00090-3; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lee SK, 2004, DEVELOPMENT, V131, P3295, DOI 10.1242/dev.01179; Lim YS, 2008, NEURON, V59, P746, DOI 10.1016/j.neuron.2008.07.032; Luria V, 2008, NEURON, V60, P1039, DOI 10.1016/j.neuron.2008.11.011; Marler KJM, 2008, J NEUROSCI, V28, P12700, DOI 10.1523/JNEUROSCI.1915-08.2008; Marquardt T, 2005, CELL, V121, P127, DOI 10.1016/j.cell.2005.01.020; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pierchala BA, 2006, J NEUROSCI, V26, P2777, DOI 10.1523/JNEUROSCI.3420-05.2006; Rashid T, 2005, NEURON, V47, P57, DOI 10.1016/j.neuron.2005.05.030; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Yam PT, 2009, NEURON, V62, P349, DOI 10.1016/j.neuron.2009.03.022	47	94	94	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					568	582		10.1016/j.cell.2012.01.024	http://dx.doi.org/10.1016/j.cell.2012.01.024			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304922	Green Accepted, Bronze			2022-12-28	WOS:000300225000023
J	Norman, C				Norman, Colin			2011 International Science & Engineering Visualization Challenge	SCIENCE			English	Editorial Material																			0	3	3	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2012	335	6068					525	535		10.1126/science.335.6068.525	http://dx.doi.org/10.1126/science.335.6068.525			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	885HI	22301294				2022-12-28	WOS:000299769200016
J	Verhagen, E; Deleglise, S; Weis, S; Schliesser, A; Kippenberg, TJ				Verhagen, E.; Deleglise, S.; Weis, S.; Schliesser, A.; Kippenberg, T. J.			Quantum-coherent coupling of a mechanical oscillator to an optical cavity mode	NATURE			English	Article							GROUND-STATE; OPTOMECHANICS; RESONATOR	Optical laser fields have been widely used to achieve quantum control over the motional and internal degrees of freedom of atoms and ions(1,2), molecules and atomic gases. A route to controlling the quantum states of macroscopic mechanical oscillators in a similar fashion is to exploit the parametric coupling between optical and mechanical degrees of freedom through radiation pressure in suitably engineered optical cavities(3-6). If the optomechanical coupling is 'quantum coherent'-that is, if the coherent coupling rate exceeds both the optical and the mechanical decoherence rate-quantum states are transferred from the optical field to the mechanical oscillator and vice versa. This transfer allows control of the mechanical oscillator state using the wide range of available quantum optical techniques. So far, however, quantum-coherent coupling of micromechanical oscillators has only been achieved using microwave fields at millikelvin temperatures(7,8). Optical experiments have not attained this regime owing to the large mechanical decoherence rates(9) and the difficulty of overcoming optical dissipation(10). Here we achieve quantum-coherent coupling between optical photons and a micromechanical oscillator. Simultaneously, coupling to the cold photon bath cools the mechanical oscillator to an average occupancy of 1.7 +/- 0.1 motional quanta. Excitation with weak classical light pulses reveals the exchange of energy between the optical light field and the micromechanical oscillator in the time domain at the level of less than one quantum on average. This optomechanical system establishes an efficient quantum interface between mechanical oscillators and optical photons, which can provide decoherence-free transport of quantum states through optical fibres. Our results offer a route towards the use of mechanical oscillators as quantum transducers or in microwave-to-optical quantum links(11-15).	[Verhagen, E.; Deleglise, S.; Weis, S.; Schliesser, A.; Kippenberg, T. J.] Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland; [Weis, S.; Schliesser, A.; Kippenberg, T. J.] Max Planck Inst Quantum Opt, D-85748 Garching, Germany	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Max Planck Society	Kippenberg, TJ (corresponding author), Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland.	tobias.kippenberg@epfl.ch	Verhagen, Ewold/J-9419-2013; Kippenberg, T. J./B-3133-2013; Deléglise, Samuel X/B-1599-2015; Schliesser, Albert/C-5619-2014	Kippenberg, T. J./0000-0002-3408-886X; Deléglise, Samuel X/0000-0002-8680-5170; Schliesser, Albert/0000-0003-4317-5030	ERC; DARPA/MTO ORCHID through the AFOSR; NCCR Quantum Science and Technology; Swiss National Science Foundation; Netherlands Organization for Scientific Research (NWO); Marie Curie Cofund Action; Marie Curie Individual Fellowship	ERC(European Research Council (ERC)European Commission); DARPA/MTO ORCHID through the AFOSR; NCCR Quantum Science and Technology; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Marie Curie Cofund Action; Marie Curie Individual Fellowship(European Commission)	We acknowledge R. Riviere for early contributions to this project and E. Gavartin and I. Vazquez Garcia for assistance in the early microfabrication phase. This work was supported by an ERC Starting Grant (SiMP), the DARPA/MTO ORCHID program through a grant from the AFOSR, the NCCR Quantum Science and Technology and the Swiss National Science Foundation. E. V. acknowledges a Rubicon Grant from the Netherlands Organization for Scientific Research (NWO), co-financed by a Marie Curie Cofund Action. S. D. is supported by a Marie Curie Individual Fellowship.	Akram U, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/8/083030; Anetsberger G, 2008, NAT PHOTONICS, V2, P627, DOI 10.1038/nphoton.2008.199; Arcizet O, 2009, PHYS REV A, V80, DOI 10.1103/PhysRevA.80.021803; Braginsky V. B., 1977, MEASUREMENT WEAK FOR; Chan J, 2011, NATURE, V478, P89, DOI 10.1038/nature10461; Clerk AA, 2010, REV MOD PHYS, V82, P1155, DOI 10.1103/RevModPhys.82.1155; Dobrindt JM, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.263602; Favero I, 2009, NAT PHOTONICS, V3, P201, DOI 10.1038/NPHOTON.2009.42; Groblacher S, 2009, NATURE, V460, P724, DOI 10.1038/nature08171; Khalili F, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.070403; Kimble HJ, 1998, PHYS SCRIPTA, VT76, P127, DOI 10.1238/Physica.Topical.076a00127; Kippenberg TJ, 2008, SCIENCE, V321, P1172, DOI 10.1126/science.1156032; Kippenberg TJ, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.033901; Lee KH, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.123604; Lvovsky AI, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.050402; Marquardt F, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.093902; O'Connell AD, 2010, NATURE, V464, P697, DOI 10.1038/nature08967; Regal CA, 2011, J PHYS CONF SER, V264, DOI 10.1088/1742-6596/264/1/012025; Riviere R, 2011, PHYS REV A, V83, DOI 10.1103/PhysRevA.83.063835; Romero-Isart O, 2011, PHYS REV A, V83, DOI 10.1103/PhysRevA.83.013803; Schliesser A, 2008, NAT PHYS, V4, P415, DOI 10.1038/nphys939; Schwab KC, 2005, PHYS TODAY, V58, P36, DOI 10.1063/1.2012461; Stannigel K, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.220501; Teufel JD, 2011, NATURE, V475, P359, DOI 10.1038/nature10261; Teufel JD, 2011, NATURE, V471, P204, DOI 10.1038/nature09898; Tian L, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.053806; Weis S, 2010, SCIENCE, V330, P1520, DOI 10.1126/science.1195596; Wilson-Rae I, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.093901; Zhang J, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.013808	30	639	644	10	288	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					63	67		10.1038/nature10787	http://dx.doi.org/10.1038/nature10787			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22297970	Green Submitted			2022-12-28	WOS:000299726000035
J	Appleby, J				Appleby, John			DATA BRIEFING English NHS hospital activity: doing less (with less or the same)?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London W1G 0AN, England		Appleby, J (corresponding author), Kings Fund, London W1G 0AN, England.	j.appleby@kingsfund.org.uk						Department of Health, 2012, COMM BAS TIM SER; Department of Health, ENGL RTT TIM SER; Department of Health, HIST TIM SER	3	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2012	344								e733	10.1136/bmj.e733	http://dx.doi.org/10.1136/bmj.e733			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889QJ	22297795				2022-12-28	WOS:000300088000013
J	Lansley, A				Lansley, Andrew			HEALTH AND SOCIAL CARE BILL Why legislation is necessary for my health reforms	BRITISH MEDICAL JOURNAL			English	Editorial Material									State Hlth, London, England		Lansley, A (corresponding author), State Hlth, London, England.							2012, BRIT MED J, V344, DOI DOI 10.1136/BMJ.E399; 2011, BRIT MED J, V343, DOI DOI 10.1136/BMJ.D8031	2	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2012	344								e789	10.1136/bmj.e789	http://dx.doi.org/10.1136/bmj.e789			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889QJ	22298097				2022-12-28	WOS:000300088000020
J	Cupples, ME; Hart, PM; Johnston, A; Jackson, AJ				Cupples, M. E.; Hart, P. M.; Johnston, A.; Jackson, A. J.			Improving healthcare access for people with visual impairment and blindness	BRITISH MEDICAL JOURNAL			English	Review							LOW-VISION		[Cupples, M. E.] Queens Univ, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland; [Hart, P. M.; Jackson, A. J.] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland; [Johnston, A.] Royal Natl Inst Blind, Belfast, Antrim, North Ireland; [Jackson, A. J.] Australian Coll Optometry, Melbourne, Vic, Australia	Queens University Belfast	Cupples, ME (corresponding author), Queens Univ, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland.	m.cupples@qub.ac.uk	Jackson, Jonathan/ABH-1264-2021	Jackson, Jonathan/0000-0003-4675-0272; Cupples, Margaret/0000-0002-4248-9700	Centre of Excellence for Public Health (Northern Ireland), a UKCRC Public Health Research Centre of Excellence; British Heart Foundation; Cancer Research UK; Economic and Social Research Council; Medical Research Council; Research and Development Office for the Northern Ireland Health and Social Services; Wellcome Trust, under the UK Clinical Research Collaboration; ESRC [ES/G007438/1] Funding Source: UKRI; Economic and Social Research Council [ES/G007438/1] Funding Source: researchfish	Centre of Excellence for Public Health (Northern Ireland), a UKCRC Public Health Research Centre of Excellence; British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Research and Development Office for the Northern Ireland Health and Social Services; Wellcome Trust, under the UK Clinical Research Collaboration(Wellcome Trust); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	AJ is employed by RNIB. MEC is partly funded by the Centre of Excellence for Public Health (Northern Ireland), a UKCRC Public Health Research Centre of Excellence. We thank the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, Research and Development Office for the Northern Ireland Health and Social Services, and the Wellcome Trust, under the auspices of the UK Clinical Research Collaboration for funding.	Bosanquet N, EVIDENCE BASE SUPPOR; Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823; Gilmour G, 2009, CAN J OPHTHALMOL, V44, P49, DOI 10.3129/i08-169; Ivers RQ, 1998, J AM GERIATR SOC, V46, P58; Lin MY, 2004, J AM GERIATR SOC, V52, P1996, DOI 10.1111/j.1532-5415.2004.52554.x; O'Day BL, 2004, AM J MED QUAL, V19, P193, DOI 10.1177/106286060401900503; Pearce E, 2011, BRIT J OPHTHALMOL, V95, P105, DOI 10.1136/bjo.2009.175703; Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x; Royal National Institute for the Blind, KEY INF STAT; Sibley E, INCLUSIVE HLTH SERVI; Silverstone B., 2000, VISION LOSS AGING SO; Thurston M, 2010, BRIT J VISUAL IMPA, V28, P90, DOI 10.1177/0264619609359304; van den Broek EGC, 2006, J INTELL DISABIL RES, V50, P470, DOI 10.1111/j.1365-2788.2006.00804.x; Waern M, 2002, BMJ-BRIT MED J, V324, P1355, DOI 10.1136/bmj.324.7350.1355; World Health Organization, 2011, VIS IMP BLINDN, P282	15	34	35	1	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JAN 30	2012	344								e542	10.1136/bmj.e542	http://dx.doi.org/10.1136/bmj.e542			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889QD	22290101	Green Submitted			2022-12-28	WOS:000300087400005
J	Schwank, G; Yang, SF; Restrepo, S; Basler, K				Schwank, Gerald; Yang, Schu-Fee; Restrepo, Simon; Basler, Konrad			Comment on "Dynamics of Dpp Signaling and Proliferation Control"	SCIENCE			English	Editorial Material							GROWTH-REGULATION; DROSOPHILA; BRINKER; GENE; GRADIENT; TARGET; MAD		[Schwank, Gerald; Yang, Schu-Fee; Restrepo, Simon; Basler, Konrad] Univ Zurich, Inst Mol Life Sci, Zurich, Switzerland	University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Mol Life Sci, Zurich, Switzerland.	basler@imls.uzh.ch	Schwank, Gerald/A-8586-2018; Schwank, Gerald/AAE-6640-2020	Schwank, Gerald/0000-0003-0767-2953; Schwank, Gerald/0000-0003-0767-2953; Restrepo, Simon/0000-0001-6965-8052; Basler, Konrad/0000-0003-3534-1529				Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Eivers E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006543; Hamaratoglu F, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001182; Hudson JB, 1998, DEVELOPMENT, V125, P1407; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Martin FA, 2004, DEVELOPMENT, V131, P4921, DOI 10.1242/dev.01385; Marty T, 2000, NAT CELL BIOL, V2, P745, DOI 10.1038/35036383; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Ninov N, 2010, CURR BIOL, V20, P513, DOI 10.1016/j.cub.2010.01.063; Schwank G, 2011, PLOS BIOL, V9, DOI [10.1371/journal.pbio.100111, 10.1371/journal.pbio.1001111]; Schwank G, 2011, DEV CELL, V20, P123, DOI 10.1016/j.devcel.2010.11.007; Schwank G, 2008, DEVELOPMENT, V135, P4003, DOI 10.1242/dev.025635; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Wartlick O, 2011, SCIENCE, V331, P1154, DOI 10.1126/science.1200037	15	37	37	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067								10.1126/science.1210997	http://dx.doi.org/10.1126/science.1210997			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282789				2022-12-28	WOS:000299466800024
J	Heath, I				Heath, Iona			LIFE AND DEATH The NHS gift economy is in peril	BRITISH MEDICAL JOURNAL			English	Editorial Material												iona.heath22@yahoo.co.uk						2011, TRIALS, V12, P249, DOI DOI 10.1186/1745-6215-12-249	1	1	1	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 25	2012	344								e590	10.1136/bmj.e590	http://dx.doi.org/10.1136/bmj.e590			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KV	22277546				2022-12-28	WOS:000299778800019
J	McCartney, M				McCartney, Margaret			MEDICINE AND THE MEDIA NHS pensions: all the rage	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				[Anonymous], BBC; [Anonymous], CARING COUNTRY THEMS; BMA, 2012, BMA PENS SURV 2012; Borland S, GP PENSION 140000 YE; Grice A, ANGER LANSLEY ACCUSE; Jaques H, 2012, BMJ CAREERS     0120, V20; Odone C, DOCTORS MUST ACCEPT; Portobello Clinic, PORT CLIN PRIC LIST; Scurr M, IM DISGUSTED MY GREE; Take the medicine: the doctors' union has been infected by Bob Crow syndrome, 2012, TIMES           0120, V2	10	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 25	2012	344								e613	10.1136/bmj.e613	http://dx.doi.org/10.1136/bmj.e613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KV	22277547				2022-12-28	WOS:000299778800022
J	Anderson, BL				Anderson, Barton L.			Bird-Brained Illusionists	SCIENCE			English	Editorial Material									Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia	University of Sydney	Anderson, BL (corresponding author), Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia.	barta@psych.usyd.edu.au		Anderson, Barton/0000-0003-0313-4285				Anderson BL, 2011, CURR BIOL, V21, P492, DOI 10.1016/j.cub.2011.02.011; BORGIA G, 1995, AM SCI, V83, P542; Endler JA, 2010, CURR BIOL, V20, P1679, DOI 10.1016/j.cub.2010.08.033; Kelley LA, 2012, SCIENCE, V335, P335, DOI 10.1126/science.1212443	4	3	4	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2012	335	6066					292	293		10.1126/science.1217451	http://dx.doi.org/10.1126/science.1217451			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	878RE	22267798				2022-12-28	WOS:000299273400031
J	Cui-Wang, TT; Hanus, C; Cui, T; Helton, T; Bourne, J; Watson, D; Harris, KM; Ehlers, MD				Cui-Wang, Tingting; Hanus, Cyril; Cui, Tao; Helton, Thomas; Bourne, Jennifer; Watson, Deborah; Harris, Kristen M.; Ehlers, Michael D.			Local Zones of Endoplasmic Reticulum Complexity Confine Cargo in Neuronal Dendrites	CELL			English	Article							PYRAMIDAL NEURONS; AMPA RECEPTORS; MEMBRANE; PROTEIN; SPINES; MICROTUBULES; MORPHOGENESIS; ORGANIZATION; PLASTICITY; MACHINERY	Following synthesis, integral membrane proteins dwell in the endoplasmic reticulum (ER) for variable periods that are typically rate limiting for plasma membrane delivery. In neurons, the ER extends for hundreds of microns as an anastomosing network throughout highly branched dendrites. However, little is known about the mobility, spatial scales, or dynamic regulation of cargo in the dendritic ER. Here, we show that membrane proteins, including AMPA-type glutamate receptors, rapidly diffuse within the continuous network of dendritic ER but are confined by increased ER complexity at dendritic branch points and near dendritic spines. The spatial range of receptor mobility is rapidly restricted by type I mGluR signaling through a mechanism involving protein kinase C (PKC) and the ER protein CLIMP63. Moreover, local zones of ER complexity compartmentalize ER export and correspond to sites of new dendritic branches. Thus, local control of ER complexity spatially scales secretory trafficking within elaborate dendritic arbors.	[Cui-Wang, Tingting; Hanus, Cyril; Ehlers, Michael D.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; [Cui, Tao] CALTECH, Dept Elect Engn, Pasadena, CA 91125 USA; [Helton, Thomas; Ehlers, Michael D.] Pfizer Global Res & Dev, Neurosci Res Unit, Groton, CT 06340 USA; [Bourne, Jennifer; Watson, Deborah; Harris, Kristen M.] Univ Texas Austin, Ctr Learning & Memory, Dept Neurobiol, Austin, TX 78705 USA	Duke University; California Institute of Technology; Pfizer; University of Texas System; University of Texas Austin	Ehlers, MD (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.	michael.ehlers@pfizer.com	HANUS, Cyril/C-2200-2017	HANUS, Cyril/0000-0002-4012-6092; Harris, Kristen/0000-0002-1943-4744; Bourne, Jennifer/0000-0001-5501-0351; Wang, Tingting/0000-0001-5114-6737	NIH [NS039402, MH064748, MH086339, NS021184, EB002170]; Howard Hughes Medical Institute; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064748, R01MH095980, R01MH086339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021184, R01NS047574, R01NS039402, R37NS021184, R01NS074644, R23NS021184] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Ben Arenkiel, Ian Davison, Juliet Hernandez, Matt Kennedy, Tom Newpher, and Rui Peixoto for critical reading of the manuscript. We thank Larry Lindsey and Cam Robinson for help with EM data processing. We thank Irina Lebedeva and Marguerita Klein for technical assistance. We thank Zeiss USA for use of their structured illumination microcopy system. Work in the laboratory of M. D. E. was supported by NIH grants NS039402, MH064748, and MH086339, and the Howard Hughes Medical Institute. Work in the laboratory of K. M. H. is supported by NIH grants NS021184 and EB002170.	Aridor M, 2004, J NEUROSCI, V24, P3770, DOI 10.1523/JNEUROSCI.4775-03.2004; Cooney JR, 2002, J NEUROSCI, V22, P2215, DOI 10.1523/JNEUROSCI.22-06-02215.2002; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Ehlers MD, 2007, NEURON, V54, P447, DOI 10.1016/j.neuron.2007.04.010; Farah CA, 2005, J BIOL CHEM, V280, P9439, DOI 10.1074/jbc.M412304200; Farhan H, 2008, EMBO J, V27, P2043, DOI 10.1038/emboj.2008.136; Fiala JC, 2001, J AM MED INFORM ASSN, V8, P1; Fukatsu K, 2004, J BIOL CHEM, V279, P48976, DOI 10.1074/jbc.M408364200; Gardiol A, 1999, J NEUROSCI, V19, P168, DOI 10.1523/JNEUROSCI.19-01-00168.1999; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Grooms SY, 2006, J NEUROSCI, V26, P8339, DOI 10.1523/JNEUROSCI.0472-06.2006; Hanus C, 2008, TRAFFIC, V9, P1437, DOI 10.1111/j.1600-0854.2008.00775.x; Herpers B, 2004, MOL BIOL CELL, V15, P5306, DOI 10.1091/mbc.E04-05-0398; Horton AC, 2005, NEURON, V48, P757, DOI 10.1016/j.neuron.2005.11.005; Horton AC, 2003, J NEUROSCI, V23, P6188; Kennedy MJ, 2006, ANNU REV NEUROSCI, V29, P325, DOI 10.1146/annurev.neuro.29.051605.112808; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; Losonczy A, 2008, NATURE, V452, P436, DOI 10.1038/nature06725; Mameli M, 2007, SCIENCE, V317, P530, DOI 10.1126/science.1142365; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Newpher TM, 2008, NEURON, V58, P472, DOI 10.1016/j.neuron.2008.04.030; Nicholson DA, 2006, NEURON, V50, P431, DOI 10.1016/j.neuron.2006.03.022; Penn AC, 2008, EMBO J, V27, P3056, DOI 10.1038/emboj.2008.222; Sampo B, 2003, NEURON, V37, P611, DOI 10.1016/S0896-6273(03)00058-8; Santamaria F, 2006, NEURON, V52, P635, DOI 10.1016/j.neuron.2006.10.025; Schermelleh L, 2010, J CELL BIOL, V190, P165, DOI 10.1083/jcb.201002018; SCHWEIZER A, 1993, J CELL SCI, V104, P671; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; Sprague BL, 2005, TRENDS CELL BIOL, V15, P84, DOI 10.1016/j.tcb.2004.12.001; Spruston N, 2008, NAT REV NEUROSCI, V9, P206, DOI 10.1038/nrn2286; Sutton MA, 2006, CELL, V125, P785, DOI 10.1016/j.cell.2006.03.040; TERASAKI M, 1994, P NATL ACAD SCI USA, V91, P7510, DOI 10.1073/pnas.91.16.7510; Vedrenne C, 2006, TRAFFIC, V7, P639, DOI 10.1111/j.1600-0854.2006.00419.x; Vedrenne C, 2005, MOL BIOL CELL, V16, P1928, DOI 10.1091/mbc.E04-07-0554; Ye B, 2007, CELL, V130, P717, DOI 10.1016/j.cell.2007.06.032	35	135	140	1	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 20	2012	148	1-2					309	321		10.1016/j.cell.2011.11.056	http://dx.doi.org/10.1016/j.cell.2011.11.056			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265418	Green Accepted, Bronze			2022-12-28	WOS:000299540700033
J	Lu, HP				Lu, H. Peter			Enzymes in Coherent Motion	SCIENCE			English	Editorial Material							SINGLE-MOLECULE; CONFORMATIONAL DYNAMICS; T4 LYSOZYME; FORCE		[Lu, H. Peter] Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA; [Lu, H. Peter] Bowling Green State Univ, Ctr Photochem Sci, Bowling Green, OH 43403 USA	Bowling Green State University; Bowling Green State University	Lu, HP (corresponding author), Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA.	hplu@bgsu.edu			NIGMS NIH HHS [R01 GM098089, R01 GM084402] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098089, R01GM084402] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen Y, 2003, J PHYS CHEM B, V107, P7947, DOI 10.1021/jp022406z; Choi YK, 2012, SCIENCE, V335, P319, DOI 10.1126/science.1214824; GRASLUND A, 2009, SINGL MOL SPECTR CHE; Gumpp H, 2009, NANO LETT, V9, P3290, DOI 10.1021/nl9015705; He YF, 2011, J AM CHEM SOC, V133, P14389, DOI 10.1021/ja204644y; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; Lerch HP, 2005, P NATL ACAD SCI USA, V102, P10807, DOI 10.1073/pnas.0504995102; Lomholt MA, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.168302; Lu HP, 2005, ACCOUNTS CHEM RES, V38, P557, DOI 10.1021/ar0401451; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Min W, 2005, ACCOUNTS CHEM RES, V38, P923, DOI 10.1021/ar040133f; Miyashita O, 2003, P NATL ACAD SCI USA, V100, P12570, DOI 10.1073/pnas.2135471100; Wang YM, 2010, J PHYS CHEM B, V114, P6669, DOI 10.1021/jp1004506; Wiita AP, 2007, NATURE, V450, P124, DOI 10.1038/nature06231	14	7	7	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2012	335	6066					300	301		10.1126/science.1217170	http://dx.doi.org/10.1126/science.1217170			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267804	Green Accepted			2022-12-28	WOS:000299273400037
J	Narni-Mancinelli, E; Jaeger, BN; Bernat, C; Fenis, A; Kung, S; De Gassart, A; Mahmood, S; Gut, M; Heath, SC; Estelle, J; Bertosio, E; Vely, F; Gastinel, LN; Beutler, B; Malissen, B; Malissen, M; Gut, IG; Vivier, E; Ugolini, S				Narni-Mancinelli, Emilie; Jaeger, Baptiste N.; Bernat, Claire; Fenis, Aurore; Kung, Sam; De Gassart, Aude; Mahmood, Sajid; Gut, Marta; Heath, Simon C.; Estelle, Jordi; Bertosio, Elodie; Vely, Frederic; Gastinel, Louis N.; Beutler, Bruce; Malissen, Bernard; Malissen, Marie; Gut, Ivo G.; Vivier, Eric; Ugolini, Sophie			Tuning of Natural Killer Cell Reactivity by NKp46 and Helios Calibrates T Cell Responses	SCIENCE			English	Article							MOUSE NK CELLS; IN-VIVO; INHIBITORY RECEPTORS; ACTIVATION RECEPTOR; SELF-TOLERANCE; EXPRESSION; EDUCATION; RECOGNITION; IMMUNITY; ABSENCE	Natural killer (NK) cells are lymphocytes involved in antimicrobial and antitumoral immune responses. Using N-ethyl-N-nitrosourea mutagenesis in mice, we identified a mutant with increased resistance to viral infections because of the presence of hyperresponsive NK cells. Whole-genome sequencing and functional analysis revealed a loss-of-function mutation in the Ncr1 gene encoding the activating receptor NKp46. The down-regulation of NK cell activity by NKp46 was associated with the silencing of the Helios transcription factor in NK cells. NKp46 was critical for the subsequent development of antiviral and antibacterial T cell responses, which suggests that the regulation of NK cell function by NKp46 allows for the optimal development of adaptive immune responses. NKp46 blockade enhanced NK cell reactivity in vivo, which could enable the design of immunostimulation strategies in humans.	[Narni-Mancinelli, Emilie; Jaeger, Baptiste N.; Bernat, Claire; Fenis, Aurore; De Gassart, Aude; Bertosio, Elodie; Vely, Frederic; Malissen, Bernard; Malissen, Marie; Vivier, Eric; Ugolini, Sophie] Aix Marseille Univ, Ctr Immunol Marseille Luminy, F-13288 Marseille, France; [Narni-Mancinelli, Emilie; Jaeger, Baptiste N.; Bernat, Claire; Fenis, Aurore; De Gassart, Aude; Bertosio, Elodie; Vely, Frederic; Malissen, Bernard; Malissen, Marie; Vivier, Eric; Ugolini, Sophie] INSERM, U1104, F-13288 Marseille, France; [Narni-Mancinelli, Emilie; Jaeger, Baptiste N.; Bernat, Claire; Fenis, Aurore; De Gassart, Aude; Bertosio, Elodie; Vely, Frederic; Malissen, Bernard; Malissen, Marie; Vivier, Eric; Ugolini, Sophie] CNRS, UMR7280, F-13288 Marseille, France; [Kung, Sam; Mahmood, Sajid] Univ Manitoba, Dept Immunol, Apotex Ctr, Winnipeg, MB R3E 0T5, Canada; [Gut, Marta; Heath, Simon C.; Estelle, Jordi; Gut, Ivo G.] CNAG, Barcelona 08028, Spain; [Gastinel, Louis N.] Univ Limoges, Univ Hosp Limoges, INSERM, U850, F-87060 Limoges, France; [Beutler, Bruce] Univ Texas SW Med Ctr Dallas, Ctr Genet Host Def, Dallas, TX 75390 USA; [Vely, Frederic; Vivier, Eric] Hop Conception, Assistance Publ Hop Marseille, F-13385 Marseille, France; [Ugolini, Sophie] Ctr Lutte Canc, Inst Paoli Calmettes, F-13273 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Aix-Marseille Universite; University of Manitoba; CHU Limoges; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Limoges; University of Texas System; University of Texas Southwestern Medical Center Dallas; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UNICANCER; Institut Paoli-Calmette (IPC)	Vivier, E (corresponding author), Aix Marseille Univ, Ctr Immunol Marseille Luminy, Campus Luminy,Case 906, F-13288 Marseille, France.	vivier@ciml.univ-mrs.fr; ugolini@ciml.univ-mrs.fr	Heath, Simon C/J-4138-2012; Vivier, Eric/F-8939-2010; Narni-Mancinelli, Emilie/X-1888-2018; Vély, Frédéric/HHM-3894-2022; Estellé, Jordi/A-7976-2008; Gut, Ivo/ABF-3188-2020; Malissen, Bernard/AAK-4659-2020	Heath, Simon C/0000-0002-9550-0897; Vivier, Eric/0000-0001-7022-8287; Narni-Mancinelli, Emilie/0000-0002-7001-1026; Estellé, Jordi/0000-0002-6241-1732; Gut, Ivo/0000-0001-7219-632X; De Gassart, Aude/0000-0002-0574-344X; Ugolini, Sophie/0000-0003-4041-0103; Malissen, Bernard/0000-0003-1340-9342; Malissen, Marie/0000-0003-2331-1445; Jaeger, Baptiste N./0000-0001-8728-797X; Vely, Frederic/0000-0002-1682-0949	European Research Council; Functional Genomics in Mutant Mouse Models as Tools to Investigate the Complexity of Human Immunological Disease (MUGEN); Network of Excellence and Mechanisms; European Union; University of Manitoba; Natural Sciences and Engineering Research Council; Agence Nationale de la Recherche; Equipe labellisee "La Ligue"; Ligue Nationale contre le Cancer; Agence pour la Recherche sur le Cancer; Axa research fund; INSERM; CNRS; Aix-Marseille University	European Research Council(European Research Council (ERC)European Commission); Functional Genomics in Mutant Mouse Models as Tools to Investigate the Complexity of Human Immunological Disease (MUGEN); Network of Excellence and Mechanisms; European Union(European Commission); University of Manitoba; Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Equipe labellisee "La Ligue"; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Agence pour la Recherche sur le Cancer; Axa research fund(AXA Research Fund); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); Aix-Marseille University	We thank J. Ewbank, M. Blery, J.-C. Andrau and P. Kruse for advice; D. Dilg for bioinformatics analysis; M. Dalod for MCMV reagents; M. C. Carroll for H1N1; G. Lauvau for Lm-OVA; M. Roger for mice handling; and the Centre d'Immunologie de Marseille-Luminy (CIML) mouse house and cytometry core facilities. This work was supported by an European Research Council advanced grant (E. V. and S. U.); Functional Genomics in Mutant Mouse Models as Tools to Investigate the Complexity of Human Immunological Disease (MUGEN), Network of Excellence and Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices (MASTERSWITCH), Integrating Project from European Union (B. M. and M. M.); University of Manitoba Dean of Medicine Strategic Fund and Natural Sciences and Engineering Research Council (S. K.); Agence Nationale de la Recherche (E. V. and S. U.); Equipe labellisee "La Ligue," Ligue Nationale contre le Cancer (E. V. and S. U.); Agence pour la Recherche sur le Cancer (E.M.N.); Axa research fund (B.N.J.); and institutional grants from INSERM, CNRS, and Aix-Marseille University to the CIML. E. V. is a cofounder of and shareholder in Innate-Pharma. E.N.M., E. V., and S. U. designed, analyzed the experiments, and wrote the paper; C. B. identified Noe mouse during ENU screen; E.N.M. and A. F. performed and analyzed the experiments; S. K. and S. M. provided lentiviral vectors and protocols to transduce NK cells; A. D. G. generated Helios-expressing vectors; B.N.J., F. V., M. G., I. G. G., J.E., and S. C. H. performed the sequencing and the bioinformatics analysis; L.N.G. generated the model for NKp46<SUP>W32R</SUP>; M. M. and B. M. initiated and conducted the early phases of the ENU screen; and B. B. and E. B. helped in the ENU screen. The data reported in this paper are tabulated in the main paper and in the Supporting Online Material. Microarray data have been deposited at the National Center for Biotechnology Information GEO repository under accession no. GSE13229 and have been reported elsewhere (13). Ensembl accession number for Ikzf2 is ENSMUST00000027146. Material Transfer Agreements are required for use of the following reagents: Noe mice, NKp46-specific mAb, NKp46<SUP>iCre/iCre</SUP> mice, Helios short hairpin RNA, and control lentiviral vectors. The invention (U. S. Patent Application 61/499,485; NKp46-mediated NK cell tuning; E.N.M., S. U., and E. V.) relates to compounds that inhibit NKp46.	Andrews DM, 2010, J EXP MED, V207, P1333, DOI 10.1084/jem.20091193; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Brodin P, 2009, BLOOD, V113, P2434, DOI 10.1182/blood-2008-05-156836; Brown MG, 2001, SCIENCE, V292, P934, DOI 10.1126/science.1060042; Cagnano E, 2008, J INVEST DERMATOL, V128, P972, DOI 10.1038/sj.jid.5701111; Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179; Dovat S, 2005, J IMMUNOL, V175, P3508, DOI 10.4049/jimmunol.175.6.3508; Fernandez NC, 2005, BLOOD, V105, P4416, DOI 10.1182/blood-2004-08-3156; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Gur C, 2010, NAT IMMUNOL, V11, P121, DOI 10.1038/ni.1834; Halfteck GG, 2009, J IMMUNOL, V182, P2221, DOI 10.4049/jimmunol.0801878; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Lee SH, 2007, TRENDS IMMUNOL, V28, P252, DOI 10.1016/j.it.2007.04.001; Lee SH, 2009, J EXP MED, V206, P2235, DOI 10.1084/jem.20082387; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Narni-Mancinelli E, 2011, P NATL ACAD SCI USA, V108, P18324, DOI 10.1073/pnas.1112064108; Oppenheim DE, 2005, NAT IMMUNOL, V6, P928, DOI 10.1038/ni1239; Orr MT, 2010, CELL, V142, P847, DOI 10.1016/j.cell.2010.08.031; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Raulet DH, 2006, NAT REV IMMUNOL, V6, P520, DOI 10.1038/nri1863; Raulet DH, 2004, NAT IMMUNOL, V5, P996, DOI 10.1038/ni1114; Soderquest K, 2011, J IMMUNOL, V186, P3304, DOI 10.4049/jimmunol.1004122; Sun JC, 2008, J EXP MED, V205, P1819, DOI 10.1084/jem.20072448; Tripathy SK, 2008, J EXP MED, V205, P1829, DOI 10.1084/jem.20072446; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Waggoner SN, 2012, NATURE, V481, P394, DOI 10.1038/nature10624; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; Yokoyama WM, 2006, IMMUNITY, V24, P249, DOI 10.1016/j.immuni.2006.03.006; Zafirova B, 2009, IMMUNITY, V31, P270, DOI 10.1016/j.immuni.2009.06.017	32	151	156	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					344	348		10.1126/science.1215621	http://dx.doi.org/10.1126/science.1215621			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267813				2022-12-28	WOS:000299273400050
J	Rando, TA; Chang, HY				Rando, Thomas A.; Chang, Howard Y.			Aging, Rejuvenation, and Epigenetic Reprogramming: Resetting the Aging Clock	CELL			English	Review							EXTENDS LIFE-SPAN; STEM-CELLS; GENE-EXPRESSION; CALORIE RESTRICTION; GENOMIC INSTABILITY; HEMATOPOIETIC STEM; DNA METHYLATION; NONCODING RNA; SOMATIC-CELLS; PLURIPOTENCY	The underlying cause of aging remains one of the central mysteries of biology. Recent studies in several different systems suggest that not only may the rate of aging be modified by environmental and genetic factors, but also that the aging clock can be reversed, restoring characteristics of youthfulness to aged cells and tissues. This Review focuses on the emerging biology of rejuvenation through the lens of epigenetic reprogramming. By defining youthfulness and senescence as epigenetic states, a framework for asking new questions about the aging process emerges.	[Rando, Thomas A.; Chang, Howard Y.] Stanford Univ, Sch Med, Glenn Labs Biol Aging, Stanford, CA 94305 USA; [Rando, Thomas A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Chang, Howard Y.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Chang, Howard Y.] Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; [Rando, Thomas A.] VA Palo Alto Hlth Care Syst, RR&D Ctr Excellence, Palo Alto, CA 94304 USA; [Rando, Thomas A.] VA Palo Alto Hlth Care Syst, Neurol Serv, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Rando, TA (corresponding author), Stanford Univ, Sch Med, Glenn Labs Biol Aging, Stanford, CA 94305 USA.	rando@stanford.edu; howchang@stanford.edu		Rando, Thomas/0000-0001-5843-8564	Glenn Foundation for Medical Research; NIH [P01 AG036695, R37 AG23806]; Ellison Medical Foundation; NATIONAL INSTITUTE ON AGING [P01AG036695, R37AG023806, R01AG023806] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD000392] Funding Source: NIH RePORTER	Glenn Foundation for Medical Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the Glenn Foundation for Medical Research and from the NIH (P01 AG036695, R37 AG23806, and an NIH Director's Pioneer Award) to T.A.R. and by a grant to H.Y.C. from the Ellison Medical Foundation. H.Y.C. is an Early Career Scientist of the Howard Hughes Medical Institute. The authors would like to thank Dr. Ami Okada and Jamie Brett for useful comments on the manuscript.	Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; Agarwal S, 2010, NATURE, V464, P292, DOI 10.1038/nature08792; Agger K., 2009, GENE DEV, V23, P1171; Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Bahar R, 2006, NATURE, V441, P1011, DOI 10.1038/nature04844; Barradas M., 2009, GENE DEV, V23, P1177; Batista LFZ, 2011, NATURE, V474, P399, DOI 10.1038/nature10084; Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; Bunster E, 1933, ANAT REC, V57, P339, DOI 10.1002/ar.1090570404; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Campisi J, 2009, J GERONTOL A-BIOL, V64, P175, DOI 10.1093/gerona/gln065; CANO RJ, 1995, SCIENCE, V268, P1060, DOI 10.1126/science.7538699; Carlson ME, 2008, NATURE, V454, P528, DOI 10.1038/nature07034; Charville GW, 2011, PHILOS T R SOC B, V366, P85, DOI 10.1098/rstb.2010.0279; Chen C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000559; Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Dang WW, 2009, NATURE, V459, P802, DOI 10.1038/nature08085; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; Dhawan S, 2009, GENE DEV, V23, P906, DOI 10.1101/gad.1742609; Dodd IB, 2007, CELL, V129, P813, DOI 10.1016/j.cell.2007.02.053; Donohoe ME, 2009, NATURE, V460, P128, DOI 10.1038/nature08098; Douglas PM, 2010, J CELL BIOL, V190, P719, DOI 10.1083/jcb.201005144; Feng SH, 2010, SCIENCE, V330, P622, DOI 10.1126/science.1190614; Fielenbach N, 2008, GENE DEV, V22, P2149, DOI 10.1101/gad.1701508; FINERTY JC, 1952, PHYSIOL REV, V32, P277, DOI 10.1152/physrev.1952.32.3.277; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241; Girton JR, 2008, ADV GENET, V61, P1, DOI 10.1016/S0065-2660(07)00001-6; Greer EL, 2011, NATURE, V479, P365, DOI 10.1038/nature10572; Greer EL, 2010, NATURE, V466, P383, DOI 10.1038/nature09195; Guarente L, 2007, COLD SPRING HARB SYM, V72, P483, DOI 10.1101/sqb.2007.72.024; GURDON JB, 1962, DEV BIOL, V4, P256, DOI 10.1016/0012-1606(62)90043-X; Haigis MC, 2010, MOL CELL, V40, P333, DOI 10.1016/j.molcel.2010.10.002; Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hayflick L, 2007, ANN NY ACAD SCI, V1100, P1, DOI 10.1196/annals.1395.001; Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235; Hung T, 2010, RNA BIOL, V7, P582, DOI 10.4161/rna.7.5.13216; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603; Jones DL, 2011, NAT CELL BIOL, V13, P506, DOI 10.1038/ncb0511-506; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kauffman AL, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000372; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027; Kirkwood TBL, 2010, ANN NY ACAD SCI, V1204, P21, DOI 10.1111/j.1749-6632.2010.05520.x; Koga H, 2011, AGEING RES REV, V10, P205, DOI 10.1016/j.arr.2010.02.001; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Krizhanovsky V, 2009, NATURE, V460, P1085, DOI 10.1038/4601085a; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lee JH, 2009, HUM MOL GENET, V18, P2567, DOI 10.1093/hmg/ddp188; Lee JH, 2009, HUM MOL GENET, V18, P835, DOI 10.1093/hmg/ddn409; Lee N, 2005, NATURE, V438, P234, DOI 10.1038/nature04120; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Liu L, 2011, J CELL BIOL, V193, P257, DOI 10.1083/jcb.201010131; Loh KM, 2010, CELL STEM CELL, V7, P137, DOI 10.1016/j.stem.2010.07.005; Luo SJ, 2010, CELL, V143, P299, DOI 10.1016/j.cell.2010.09.013; Maegawa S, 2010, GENOME RES, V20, P332, DOI 10.1101/gr.096826.109; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Marion RM, 2010, CURR OPIN GENET DEV, V20, P190, DOI 10.1016/j.gde.2010.01.005; Martin GM, 2009, AGING CELL, V8, P761, DOI 10.1111/j.1474-9726.2009.00515.x; MCCAY CM, 1957, GERONTOLOGY, V1, P7, DOI 10.1159/000210677; Meissner A, 2010, NAT BIOTECHNOL, V28, P1079, DOI 10.1038/nbt.1684; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Murgatroyd C, 2010, AGING-US, V2, P107; Navarro P, 2008, SCIENCE, V321, P1693, DOI 10.1126/science.1160952; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Oberdoerffer P, 2007, NAT REV MOL CELL BIO, V8, P692, DOI 10.1038/nrm2238; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Ouyang ZQ, 2010, CELL STEM CELL, V7, P649, DOI 10.1016/j.stem.2010.11.018; Piccolo FM, 2011, PHILOS T R SOC B, V366, P2260, DOI 10.1098/rstb.2011.0004; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Rando OJ, 2007, CELL, V128, P655, DOI 10.1016/j.cell.2007.01.023; Rando OJ, 2009, ANNU REV BIOCHEM, V78, P245, DOI 10.1146/annurev.biochem.78.071107.134639; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rossant J, 2001, STEM CELLS, V19, P477, DOI 10.1634/stemcells.19-6-477; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sallon S, 2008, SCIENCE, V320, P1464, DOI 10.1126/science.1153600; Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683; Seviour EG, 2010, AGING-US, V2, P900, DOI 10.18632/aging.100248; Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Stadtfeld M, 2010, GENE DEV, V24, P2239, DOI 10.1101/gad.1963910; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TAUCHI H, 1977, MECH AGEING DEV, V6, P333, DOI 10.1016/0047-6374(77)90034-3; Tennen RI, 2011, TRENDS BIOCHEM SCI, V36, P39, DOI 10.1016/j.tibs.2010.07.009; Terranova R, 2006, J CELL SCI, V119, P2065, DOI 10.1242/jcs.02945; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016; Vaquero A, 2009, GENE DEV, V23, P1849, DOI 10.1101/gad.1807009; Vastenhouw NL, 2010, NATURE, V464, P922, DOI 10.1038/nature08866; Vijg J, 2005, ANN NY ACAD SCI, V1055, P35, DOI 10.1196/annals.1323.007; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Vreeland RH, 2000, NATURE, V407, P897, DOI 10.1038/35038060; Wang MC, 2008, SCIENCE, V322, P957, DOI 10.1126/science.1162011; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032; Zeng XM, 2007, STEM CELL REV, V3, P270, DOI 10.1007/s12015-007-9005-x	113	338	360	1	124	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					46	57		10.1016/j.cell.2012.01.003	http://dx.doi.org/10.1016/j.cell.2012.01.003			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265401	Bronze, Green Accepted			2022-12-28	WOS:000299540700013
J	Takahashi, N; Kitamura, K; Matsuo, N; Mayford, M; Kano, M; Matsuki, N; Ikegaya, Y				Takahashi, Naoya; Kitamura, Kazuo; Matsuo, Naoki; Mayford, Mark; Kano, Masanobu; Matsuki, Norio; Ikegaya, Yuji			Locally Synchronized Synaptic Inputs	SCIENCE			English	Article							CA1 PYRAMIDAL NEURONS; LONG-TERM POTENTIATION; CORTICAL-NEURONS; IN-VIVO; DENDRITES; SPIKES; RECORDINGS; SPINES	Synaptic inputs on dendrites are nonlinearly converted to action potential outputs, yet the spatiotemporal patterns of dendritic activation remain to be elucidated at single-synapse resolution. In rodents, we optically imaged synaptic activities from hundreds of dendritic spines in hippocampal and neocortical pyramidal neurons ex vivo and in vivo. Adjacent spines were frequently synchronized in spontaneously active networks, thereby forming dendritic foci that received locally convergent inputs from presynaptic cell assemblies. This precise subcellular geometry manifested itself during N-methyl-D-aspartate receptor-dependent circuit remodeling. Thus, clustered synaptic plasticity is innately programmed to compartmentalize correlated inputs along dendrites and may reify nonlinear synaptic integration.	[Takahashi, Naoya; Matsuki, Norio; Ikegaya, Yuji] Univ Tokyo, Lab Chem Pharmacol, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo, Japan; [Kitamura, Kazuo; Kano, Masanobu] Univ Tokyo, Dept Neurophysiol, Grad Sch Med, Bunkyo Ku, Tokyo, Japan; [Kitamura, Kazuo; Matsuo, Naoki; Ikegaya, Yuji] Japan Sci & Technol Agcy, Kawaguchi, Saitama, Japan; [Matsuo, Naoki] Kyoto Univ, HAKUBI Ctr, Sakyo Ku, Kyoto, Japan; [Mayford, Mark] Scripps Res Inst, Dept Cell Biol, La Jolla, CA USA	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Kyoto University; Scripps Research Institute	Ikegaya, Y (corresponding author), Univ Tokyo, Lab Chem Pharmacol, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo, Japan.	ikegaya@mol.f.u-tokyo.ac.jp	Matsuo, Naoki/B-9929-2008; Kitamura, Kazuo/F-3379-2013	Matsuo, Naoki/0000-0003-0988-4706; Kitamura, Kazuo/0000-0002-8956-4122; Takahashi, Naoya/0000-0002-6008-4627; Kano, Masanobu/0000-0002-0725-3292; Ikegaya, Yuji/0000-0003-2260-8191; Mayford, Mark/0000-0002-9001-5024	Ministry of Education, Culture, Sports, Science and Technology of Japan [21220006, 22115003, 23115504, 23800019]; Strategic Research Program for Brain Sciences; Funding Program for Next Generation World-Leading Researchers [LS023]; Grants-in-Aid for Scientific Research [22650083, 22680031] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Strategic Research Program for Brain Sciences(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Funding Program for Next Generation World-Leading Researchers(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors are grateful to K. Morita (University of Tokyo) for his comments on the manuscript. This work was partly supported by Grants-in-Aid for Science Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (nos. 21220006, 22115003, 23115504, and 23800019); the Strategic Research Program for Brain Sciences (development of biomarker candidates for social behavior); and by the Funding Program for Next Generation World-Leading Researchers (grant LS023).	Branco T, 2010, SCIENCE, V329, P1671, DOI 10.1126/science.1189664; Chen XW, 2011, NATURE, V475, P501, DOI 10.1038/nature10193; DeBello WM, 2008, TRENDS NEUROSCI, V31, P577, DOI 10.1016/j.tins.2008.08.006; Gasparini S, 2004, J NEUROSCI, V24, P11046, DOI 10.1523/JNEUROSCI.2520-04.2004; Golding NL, 1998, NEURON, V21, P1189, DOI 10.1016/S0896-6273(00)80635-2; Govindarajan A, 2011, NEURON, V69, P132, DOI 10.1016/j.neuron.2010.12.008; Harvey CD, 2008, SCIENCE, V321, P136, DOI 10.1126/science.1159675; Harvey CD, 2007, NATURE, V450, P1195, DOI 10.1038/nature06416; Hausser M, 2003, CURR OPIN NEUROBIOL, V13, P372, DOI 10.1016/S0959-4388(03)00075-8; Ikegaya Y, 2004, SCIENCE, V304, P559, DOI 10.1126/science.1093173; Kitamura K, 2008, NAT METHODS, V5, P61, DOI 10.1038/NMETH1150; Kleindienst T, 2011, NEURON, V72, P1012, DOI 10.1016/j.neuron.2011.10.015; Larkum ME, 1999, NATURE, V398, P338, DOI 10.1038/18686; Lee AK, 2002, NEURON, V36, P1183, DOI 10.1016/S0896-6273(02)01096-6; London M, 2005, ANNU REV NEUROSCI, V28, P503, DOI 10.1146/annurev.neuro.28.061604.135703; Losonczy A, 2006, NEURON, V50, P291, DOI 10.1016/j.neuron.2006.03.016; Losonczy A, 2008, NATURE, V452, P436, DOI 10.1038/nature06725; Makino H, 2011, NEURON, V72, P1001, DOI 10.1016/j.neuron.2011.09.036; Matsuo N, 2008, SCIENCE, V319, P1104, DOI 10.1126/science.1149967; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Montgomery JM, 2001, NEURON, V29, P691, DOI 10.1016/S0896-6273(01)00244-6; Sasaki T, 2011, SCIENCE, V331, P599, DOI 10.1126/science.1197598; Schiller J, 2000, NATURE, V404, P285, DOI 10.1038/35005094; Schiller J, 1997, J PHYSIOL-LONDON, V505, P605, DOI 10.1111/j.1469-7793.1997.605ba.x; Takahashi N, 2010, P NATL ACAD SCI USA, V107, P10244, DOI 10.1073/pnas.0914594107; Varga Z, 2011, P NATL ACAD SCI USA, V108, P15420, DOI 10.1073/pnas.1112355108	26	201	207	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2012	335	6066					353	356		10.1126/science.1210362	http://dx.doi.org/10.1126/science.1210362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267814				2022-12-28	WOS:000299273400052
J	Hopkins, R; Rausher, MD				Hopkins, Robin; Rausher, Mark D.			Pollinator-Mediated Selection on Flower Color Allele Drives Reinforcement	SCIENCE			English	Article							REPRODUCTIVE CHARACTER DISPLACEMENT; PREMATING ISOLATION; PHLOX-DRUMMONDII; SEXUAL SELECTION; EVOLUTION; SPECIATION; HYBRIDIZATION; PREFERENCES; ADAPTATION; CONSTANCY	Reinforcement is the process by which reduced hybrid fitness generates selection favoring the evolution of stronger prezygotic reproductive barriers between emerging species. Using common-garden field experiments, we quantified the strength of reinforcing selection in nature by demonstrating strong selection favoring an allele conferring increased pigment intensity in the plant Phlox drummondii in areas of sympatry with the closely related species Phlox cuspidata. Incomplete hybrid sterility between the two species generates selection for traits that decrease interspecies hybridization. In contrast, selection on this locus is undetectable in the absence of P. cuspidata. We demonstrate that reinforcing selection is generated by nonrandom pollinator movement, in which pollinators move less frequently between intensely pigmented P. drummondii and P. cuspidata than between lightly pigmented P. drummondii and P. cuspidata.	[Hopkins, Robin; Rausher, Mark D.] Duke Univ, Dept Biol, Durham, NC 27708 USA	Duke University	Hopkins, R (corresponding author), Duke Univ, Dept Biol, Box 90338, Durham, NC 27708 USA.	robin.hopkins@duke.edu			University of Texas Stengl Research Station; NSF [0841521]	University of Texas Stengl Research Station; NSF(National Science Foundation (NSF))	We thank M. Kirkpatrick, S. Otto, M. Whitlock, D. Des Marais, and members of the Rausher and Kirkpatrick laboratory group for advice on this manuscript and S. Scarpino for statistical consultation. We thank the University of Texas Stengl Research Station for field experiment support. This work was supported by NSF grant 0841521 to M.D.R. and a NSF Doctoral Dissertation Improvement Grant to R.H. and M.D.R. R.H. was supported by the NSF Graduate Research Fellowship Program. All data presented here are available in the supporting material.	Albert AYK, 2004, EVOLUTION, V58, P1099; Bradshaw HD, 2003, NATURE, V426, P176, DOI 10.1038/nature02106; BUTLIN R, 1987, TRENDS ECOL EVOL, V2, P8, DOI 10.1016/0169-5347(87)90193-5; CAISSE M, 1978, HEREDITY, V40, P371, DOI 10.1038/hdy.1978.44; Campbell DR, 1997, AM NAT, V149, P295, DOI 10.1086/285991; Chittka L, 1999, NATURWISSENSCHAFTEN, V86, P361, DOI 10.1007/s001140050636; Dobzhansky T., 1937; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; Hoballah ME, 2007, PLANT CELL, V19, P779, DOI 10.1105/tpc.106.048694; Hopkins R, 2012, EVOLUTION, V66, P469, DOI 10.1111/j.1558-5646.2011.01452.x; Hopkins R, 2011, NATURE, V469, P411, DOI 10.1038/nature09641; HOWARD DJ, 1993, HYBRID ZONES AND THE EVOLUTIONARY PROCESS, P46; Kirkpatrick M, 2002, AM NAT, V159, pS22, DOI 10.1086/338370; Kirkpatrick M, 2000, P ROY SOC B-BIOL SCI, V267, P1649, DOI 10.1098/rspb.2000.1191; Kirkpatrick M, 1999, GENETICS, V151, P865; LEVIN DA, 1967, AM J BOT, V54, P1122, DOI 10.2307/2440537; LEVIN DA, 1985, EVOLUTION, V39, P1275, DOI 10.1111/j.1558-5646.1985.tb05693.x; LIOU LW, 1994, EVOLUTION, V48, P1451, DOI 10.1111/j.1558-5646.1994.tb02187.x; Nosil P, 2003, P ROY SOC B-BIOL SCI, V270, P1911, DOI 10.1098/rspb.2003.2457; Ortiz-Barrientos D, 2009, ANN NY ACAD SCI, V1168, P156, DOI 10.1111/j.1749-6632.2009.04919.x; RAUSHER MD, 1978, SCIENCE, V200, P1071, DOI 10.1126/science.200.4345.1071; Ruane LG, 2008, EVOL ECOL, V22, P229, DOI 10.1007/s10682-007-9174-8; Servedio MR, 2003, ANNU REV ECOL EVOL S, V34, P339, DOI 10.1146/annurev.ecolsys.34.011802.132412; Servedio MR, 2000, EVOLUTION, V54, P21, DOI 10.1111/j.0014-3820.2000.tb00003.x; Servedio MR, 2004, EVOLUTION, V58, P913, DOI 10.1111/j.0014-3820.2004.tb00425.x; Servedio MR, 2001, EVOLUTION, V55, P1909, DOI 10.1111/j.0014-3820.2001.tb01309.x; Wallace AR, 1889, DARWINISM; WASER NM, 1986, AM NAT, V127, P593, DOI 10.1086/284507	28	174	177	26	481	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 2	2012	335	6072					1090	1092		10.1126/science.1215198	http://dx.doi.org/10.1126/science.1215198			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ZL	22300852				2022-12-28	WOS:000300931100044
J	Soofi, S; Ahmed, S; Fox, MP; MacLeod, WB; Thea, DM; Qazi, SA; Bhutta, ZA				Soofi, Sajid; Ahmed, Sheraz; Fox, Matthew P.; MacLeod, William B.; Thea, Donald M.; Qazi, Shamim A.; Bhutta, Zulfiqar A.			Effectiveness of community case management of severe pneumonia with oral amoxicillin in children aged 2-59 months in Matiari district, rural Pakistan: a cluster-randomised controlled trial	LANCET			English	Article							CHILDHOOD PNEUMONIA; PENICILLIN; MORTALITY; EQUIVALENCY; COUNTRIES; CARE	Background Pneumonia is a leading global cause of morbidity and mortality in children younger than 5 years. In Pakistan, the proportion of deaths due to pneumonia is higher in rural areas than it is in urban areas, with a substantial proportion of individuals dying at home because referral for care is problematic in such areas. We aimed to establish whether community case identification and management of severe pneumonia by oral antibiotics delivered through community health workers has the potential to reduce the number of infants dying at home. Methods We did a cluster-randomised controlled trial in Matiari district of rural Sindh, Pakistan. Public-sector lady health workers (LHWs) undertook community case management of WHO-defined severe pneumonia. The children in intervention clusters with suspected pneumonia were screened by LHWs and those diagnosed with severe pneumonia were prescribed oral amoxicillin syrup (90 mg/kg per day in two doses) for 5 days at home. Children in control clusters were given one dose of oral co-trimoxazole and were referred to their nearest health facility for admission and intravenous antibiotics, as per government policy. In both groups, follow-up visits at home were done at days 2, 3, 6, and 14 by LHW. The primary outcome was treatment failure by day 6 after enrolment. We matched and randomly allocated 18 clusters (union councils, the smallest administrative unit of the district) to either intervention and control using a computer-generated randomisation scheme. Analyses were done per-protocol. This trial is registered with ClinicalTrials.gov, number NCT01192789. Findings 2341 children in intervention clusters and 2069 children in control clusters participated in the study, enrolled between Feb 13, 2008, and March 15, 2010. We recorded 187 (8%) treatment failures by day 6 in the intervention group and 273 (13%) in the control group. After adjusting for clustering, the risk difference for treatment failure was -5.2% (95% CI -13.7% to 3.3%). We recorded three deaths, two by day 6 and one between days 7 and 14. We recorded no serious adverse events. Interpretation Public sector LHWs in Pakistan were able to satisfactorily diagnose and treat severe pneumonia at home in rural Pakistan. This strategy might effectively reach children with pneumonia in settings where referral is difficult, and it could be a key component of community detection and management strategies for childhood pneumonia.	[Soofi, Sajid; Ahmed, Sheraz; Bhutta, Zulfiqar A.] Aga Khan Univ, Div Women & Child Hlth, Karachi 74800, Pakistan; [Fox, Matthew P.; MacLeod, William B.; Thea, Donald M.; Bhutta, Zulfiqar A.] Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Boston, MA USA; [Qazi, Shamim A.] WHO, Dept Child & Adolescent Hlth, CH-1211 Geneva, Switzerland	Aga Khan University; Boston University; World Health Organization	Bhutta, ZA (corresponding author), Aga Khan Univ, Div Women & Child Hlth, Stadium Rd, Karachi 74800, Pakistan.	zulfiqar.bhutta@aku.edu	ahmed, sheraz/AAA-1100-2021; Fox, Matthew/K-2004-2019	ahmed, sheraz/0000-0003-2336-3165; MacLeod, William/0000-0001-8003-8874; Fox, Matthew/0000-0001-9887-0634; Thea, Donald/0000-0002-6933-1030	US Agency for International Development; USAID through the John Snow Incorporation [RA528942BAJ]; USAID through the Boston University, USA [RA528942BAJ]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI083097] Funding Source: NIH RePORTER	US Agency for International Development(United States Agency for International Development (USAID)); USAID through the John Snow Incorporation; USAID through the Boston University, USA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	US Agency for International Development through grants to John Snow Incorporation and Boston University, USA.; The content of this report is not necessarily the views or policies of WHO or US Agency for International Development (USAID), nor does mention of trade names, commercial projects, or organisations imply endorsement by the US Government. The content is the sole responsibility of the authors and does not necessarily represent the official views or policies of NIAID, WHO, or USAID. The study was funded by grants from USAID (RA528942BAJ) through the John Snow Incorporation and Boston University, USA. We thank the LHW National Programme for Family Planning and Primary Care for their exceptional support and all the staff of the study for their hard work and support. We would also like to thank Hasan Murad Shah for the excellent support	Addo-Yobo E, 2004, LANCET, V364, P1141, DOI 10.1016/S0140-6736(04)17100-6; Addo-Yobo E, 2011, TROP MED INT HEALTH, V16, P995, DOI 10.1111/j.1365-3156.2011.02787.x; [Anonymous], 2005, HDB INT MAN CHILDH I; Atkinson M, 2007, THORAX, V62, P1102, DOI 10.1136/thx.2006.074906; Bari A, 2011, LANCET, V378, P1796, DOI 10.1016/S0140-6736(11)61140-9; Bhutta Z.A., 2010, GLOB HLTH WORKFORCE, V1, P61; Bhutta ZA, 2007, PAKISTAN DEMOGRAPHIC, P89; Bhutta ZA, 2011, LANCET, V377, P403, DOI 10.1016/S0140-6736(10)62274-X; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Chowdhury EK, 2008, LANCET, V372, P822, DOI 10.1016/S0140-6736(08)61166-6; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9; Hussain H, 2008, HEALTH POLICY PLANN, V23, P438, DOI 10.1093/heapol/czn033; Larson BA, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-314; Nizami SQ, 1996, SOC SCI MED, V42, P1133, DOI 10.1016/0277-9536(95)00386-X; Oxford Policy Management, 2009, HLTH START PROGRAM E; Oxford Policy Management Group, LAD HLTH WORK PROGR; Rojas MX, 2006, COCHRANE DB SYST REV, V2; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; Schellenberg JA, 2003, LANCET, V361, P561, DOI 10.1016/S0140-6736(03)12515-9; Siddiqi S, 2001, HEALTH POLICY PLANN, V16, P193, DOI 10.1093/heapol/16.2.193; Theodoratou E, 2010, INT J EPIDEMIOL, V39, P155, DOI 10.1093/ije/dyq032; Tsarouhas N, 1998, PEDIATR EMERG CARE, V14, P338; UNICEF, 2007, UNICEF STAT REV; UNICEF W. H. O, 2006, PNEUM FORG KILL CHIL; USAID, 2009, GLOB RES ACT COOP AG; World Health Organization, 2007, HLTH SYST PROF PAK R; World Health Organization UNICEF, 2004, JOINT STAT MAN PNEUM; World Health Organization (WHO), 2005, POCK BOOK HOSP CAR C; Yeboah-Antwi K, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000340	31	68	69	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 25	2012	379	9817					729	737		10.1016/S0140-6736(11)61714-5	http://dx.doi.org/10.1016/S0140-6736(11)61714-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	899CU	22285055				2022-12-28	WOS:000300792600029
J	Reicks, M; Redden, JP; Mann, T; Mykerezi, E; Vickers, Z				Reicks, Marla; Redden, Joseph P.; Mann, Traci; Mykerezi, Elton; Vickers, Zata			Photographs in Lunch Tray Compartments and Vegetable Consumption Among Children in Elementary School Cafeterias	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Reicks, Marla; Vickers, Zata] Univ Minnesota, Dept Food Sci & Nutr, Minneapolis, MN 55455 USA; [Redden, Joseph P.] Univ Minnesota, Dept Mkt, Minneapolis, MN 55455 USA; [Mann, Traci] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA; [Mykerezi, Elton] Univ Minnesota, Dept Appl Econ, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Reicks, M (corresponding author), Univ Minnesota, Dept Food Sci & Nutr, Minneapolis, MN 55455 USA.	mann@umn.edu		Mykerezi, Elton/0000-0002-8131-1163				Blanchette L, 2005, J HUM NUTR DIET, V18, P431, DOI 10.1111/j.1365-277X.2005.00648.x; CIALDINI RB, 1990, J PERS SOC PSYCHOL, V58, P1015, DOI 10.1037/0022-3514.58.6.1015; Condon EM, 2009, J AM DIET ASSOC, V109, pS67, DOI 10.1016/j.jada.2008.10.062; Just DR, SMARTER LUNCHROOMS U; USDA, 2010, DIET GUID AM, DOI DOI 10.HTTP://WWW.CNPP.USDA.G0V/PUBLICATI0NS/DIETARYGUIDELINES/2010/P0LICYD0C/P0LICYD0C.PDF	5	32	32	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2012	307	8					784	785		10.1001/jama.2012.170	http://dx.doi.org/10.1001/jama.2012.170			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	896FQ	22302602	Bronze			2022-12-28	WOS:000300551300016
J	Balafoutas, L; Sutter, M				Balafoutas, Loukas; Sutter, Matthias			Affirmative Action Policies Promote Women and Do Not Harm Efficiency in the Laboratory	SCIENCE			English	Article							GENDER-DIFFERENCES; COMPETITION; GAP	Gender differences in choosing to enter competitions are one source of unequal labor market outcomes concerning wages and promotions. Given that studying the effects of policy interventions to support women is difficult with field data because of measurement problems and potential lack of control, we evaluated, in a set of controlled laboratory experiments, four interventions: quotas, where one of two winners of a competition must be female; two variants of preferential treatment, where a fixed increment is added to women's performance; and repetition of the competition, where a second competition takes place if no woman is among the winners. Compared with no intervention, all interventions encourage women to enter competitions more often, and performance is at least equally good, both during and after the competition.	[Balafoutas, Loukas; Sutter, Matthias] Univ Innsbruck, Dept Publ Finance, A-6020 Innsbruck, Austria; [Sutter, Matthias] Univ Gothenburg, Dept Econ, Gothenburg, Sweden	University of Innsbruck; University of Gothenburg	Sutter, M (corresponding author), Univ Innsbruck, Dept Publ Finance, A-6020 Innsbruck, Austria.	matthias.sutter@uibk.ac.at	Balafoutas, Loukas/Q-6025-2018; Sutter, Matthias/R-2018-2018	Balafoutas, Loukas/0000-0002-3477-5096; Sutter, Matthias/0000-0002-6143-8706	Austrian Science Foundation (FWF) [P22772]; D. Swarovski & Co. Forderfonds of the University of Innsbruck; Austrian Science Fund (FWF) [P 22772] Funding Source: researchfish	Austrian Science Foundation (FWF)(Austrian Science Fund (FWF)); D. Swarovski & Co. Forderfonds of the University of Innsbruck; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Financial support from the Austrian Science Foundation (FWF Project P22772) and the D. Swarovski & Co. Forderfonds of the University of Innsbruck is gratefully acknowledged. We thank G. Charness, N. Feltovich, U. Gneezy, M. Kocher, P. Kuhn, and P. Rey-Biel, as well as seminar participants at the University of Arizona at Tucson, the University of California at Santa Barbara, and the University of Athens and participants at the Economic Science Association meetings in Innsbruck and Melbourne, the Markets, Organization and Votes in Economics meeting in Barcelona, and the Behavioral and Experimental Economics Symposium in Maastricht, for valuable comments.	Altonji J.G., 1999, HDB LABOR EC, V3, P3143; Bartling B, 2009, AM ECON REV, V99, P93, DOI 10.1257/aer.99.2.93; Bertrand M, 2001, IND LABOR RELAT REV, V55, P3, DOI 10.2307/2696183; Blau F. D., 2010, EC WOMEN MEN WORK; Brandts J, 2006, AM ECON REV, V96, P669, DOI 10.1257/aer.96.3.669; Charness G, 2007, J ECON THEORY, V136, P417, DOI 10.1016/j.jet.2006.09.006; Croson R, 2009, J ECON LIT, V47, P448, DOI 10.1257/jel.47.2.448; Falk A, 2009, SCIENCE, V326, P535, DOI 10.1126/science.1168244; Fryer RG, 2005, J ECON PERSPECT, V19, P147, DOI 10.1257/089533005774357888; Gneezy U, 2004, AM ECON REV, V94, P377, DOI 10.1257/0002828041301821; Gneezy U, 2003, Q J ECON, V118, P1049, DOI 10.1162/00335530360698496; Gneezy U, 2009, ECONOMETRICA, V77, P1637, DOI 10.3982/ECTA6690; Goldin C, 2000, AM ECON REV, V90, P715, DOI 10.1257/aer.90.4.715; Gupta N. Datta, 2012, EC INQ; Niederle M., 2011, COSTLY IS DIVERSITY; Niederle M, 2010, J ECON PERSPECT, V24, P129, DOI 10.1257/jep.24.2.129; Weber A, 2010, AM ECON REV, V100, P358, DOI 10.1257/aer.100.2.358; Weichselbaumer D, 2007, ECON POLICY, P235; Wozniak D., 2010, MENSTRUAL CYCLE PERF	19	124	124	3	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2012	335	6068					579	582		10.1126/science.1211180	http://dx.doi.org/10.1126/science.1211180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	885HI	22301317				2022-12-28	WOS:000299769200042
J	Diabira, S; Morandi, X				Diabira, Sylma; Morandi, Xavier			Post-Traumatic Herniated Cervical Disk	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Diabira, Sylma; Morandi, Xavier] Pontchaillou Hosp, Rennes, France	CHU Rennes	Diabira, S (corresponding author), Pontchaillou Hosp, Rennes, France.	sylma.diabira@chu-rennes.fr	MORANDI, Xavier/ABC-5851-2020	MORANDI, Xavier/0000-0002-8031-7221					0	2	2	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					462	462		10.1056/NEJMicm1111194	http://dx.doi.org/10.1056/NEJMicm1111194			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	884QX	22296080				2022-12-28	WOS:000299724400011
J	Berry, JD; Dyer, A; Cai, X; Garside, DB; Ning, HY; Thomas, A; Greenland, P; Van Horn, L; Tracy, RP; Lloyd-Jones, DM				Berry, Jarett D.; Dyer, Alan; Cai, Xuan; Garside, Daniel B.; Ning, Hongyan; Thomas, Avis; Greenland, Philip; Van Horn, Linda; Tracy, Russell P.; Lloyd-Jones, Donald M.			Lifetime Risks of Cardiovascular Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; ASSOCIATION DETECTION PROJECT; NUTRITION EXAMINATION SURVEY; ALL-CAUSE MORTALITY; BLOOD-PRESSURE; FACTOR BURDEN; TRENDS; BLACK; MEN; ATHEROSCLEROSIS	Background The lifetime risks of cardiovascular disease have not been reported across the age spectrum in black adults and white adults. Methods We conducted a meta-analysis at the individual level using data from 18 cohort studies involving a total of 257,384 black men and women and white men and women whose risk factors for cardiovascular disease were measured at the ages of 45, 55, 65, and 75 years. Blood pressure, cholesterol level, smoking status, and diabetes status were used to stratify participants according to risk factors into five mutually exclusive categories. The remaining lifetime risks of cardiovascular events were estimated for participants in each category at each age, with death free of cardiovascular disease treated as a competing event. Results We observed marked differences in the lifetime risks of cardiovascular disease across risk-factor strata. Among participants who were 55 years of age, those with an optimal risk-factor profile (total cholesterol level, <180 mg per deciliter [4.7 mmol per liter]; blood pressure, <120 mm Hg systolic and 80 mm Hg diastolic; nonsmoking status; and nondiabetic status) had substantially lower risks of death from cardiovascular disease through the age of 80 years than participants with two or more major risk factors (4.7% vs. 29.6% among men, 6.4% vs. 20.5% among women). Those with an optimal risk-factor profile also had lower lifetime risks of fatal coronary heart disease or nonfatal myocardial infarction (3.6% vs. 37.5% among men, <1% vs. 18.3% among women) and fatal or nonfatal stroke (2.3% vs. 8.3% among men, 5.3% vs. 10.7% among women). Similar trends within risk-factor strata were observed among blacks and whites and across diverse birth cohorts. Conclusions Differences in risk-factor burden translate into marked differences in the lifetime risk of cardiovascular disease, and these differences are consistent across race and birth cohorts. (Funded by the National Heart, Lung, and Blood Institute.)	[Dyer, Alan; Cai, Xuan; Garside, Daniel B.; Ning, Hongyan; Greenland, Philip; Van Horn, Linda; Lloyd-Jones, Donald M.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Berry, Jarett D.] Univ Texas SW Med Ctr Dallas, Dept Med, Div Cardiol, Dallas, TX 75390 USA; [Greenland, Philip; Lloyd-Jones, Donald M.] Northwestern Univ, Feinberg Sch Med, Bluhm Cardiovasc Inst, Dept Med, Chicago, IL 60611 USA; [Thomas, Avis] Univ Minnesota, Sch Publ Hlth, Div Biostat, Coordinating Ctr Biometr Res, Minneapolis, MN 55455 USA; [Tracy, Russell P.] Univ Vermont, Coll Med, Burlington, VT 05405 USA	Northwestern University; Feinberg School of Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas; Northwestern University; Feinberg School of Medicine; University of Minnesota System; University of Minnesota Twin Cities; University of Vermont	Lloyd-Jones, DM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA.	dlj@northwestern.edu	Hippisley-Cox, Julia/AAY-2788-2020; Greenland, Philip/ABD-5528-2021; Burtscher, Martin/M-7015-2019; Lloyd-Jones, Donald M/C-5899-2009	Hippisley-Cox, Julia/0000-0002-2479-7283; Lloyd-Jones, Donald/0000-0003-0847-6110	National Heart, Lung, and Blood Institute (NHLBI) [R01-HL-43232, R01-HL68140, R21 HL085375, K23 HL092229, N01-HC-85079, N01-HC-85086, 35129, 15103, 55222, 75150, 45133, U01 HL080295]; UT Southwestern Medical Center; American Heart Association [10BG1A4280091]; National Institute of Neurological Disorders and Stroke; Women's Health Initiative [N01-WH-22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, 44221]; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085082, N01HC085085, N01HC075150, N01HC085083, N01HC085086, N01HC085081, N01HC055222, N01HC045133, N01HC035129, N01HC085084, N01HC085080, N01HC085079, N01HC015103] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043232, U01HL080295, R21HL085375, R01HL068140, K23HL092229] Funding Source: NIH RePORTER; WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH [N01WH042114, N01WH032119, N01WH042118, N01WH042113, N01WH032115, N01WH032111, N01WH032113, N01WH042115, N01WH032122, N01WH042111, N01WH042125, N01WH042116, N01WH032106, N01WH042129, N01WH042108, N01WH032112, N01WH042120, N01WH032102, N01WH042112, N01WH042107, N01WH042122, N01WH032101, N01WH042132, N01WH042109, N01WH042119, N01WH032105, N01WH042121, N01WH042117, N01WH042131, N01WH042110, N01WH032108, N01WH032100, N01WH042123, N01WH032118, N01WH042126, N01WH032109, N01WH042130, N01WH022110, N01WH042124] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); UT Southwestern Medical Center; American Heart Association(American Heart Association); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Women's Health Initiative; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by grants from the NHLBI (R01-HL-43232 and R01-HL68140) to the Multiple Risk Factor Intervention Trial; grants from the NHLBI to Dr. Lloyd-Jones (R21 HL085375) and Dr. Berry (K23 HL092229); funding from the Dedman Family Scholar in Clinical Care endowment at UT Southwestern Medical Center to Dr. Berry; and a grant from the American Heart Association (10BG1A4280091) to Dr. Berry.; The Atherosclerosis Risk in Communities Study, Framingham Heart Study, Framingham Offspring Study, Honolulu Heart Program, and Puerto Rico Heart Health Program are conducted and supported by the NHLBI in collaboration with the study investigators. The following were also supported by the NHLBI: the Cardiovascular Health Study (CHS) (contracts N01-HC-85079 through N01-HC-85086, 35129, 15103, 55222, 75150, and 45133 and grant U01 HL080295), with additional contributions from the National Institute of Neurological Disorders and Stroke, and the Women's Health Initiative (contracts N01-WH-22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221). A full list of principal CHS investigators and institutions can be found at www.chs-nhlbi.org/pi.htm, and a full listing of WHI investigators can be found at www.whiscience.org/publications/WHI_investigators_shortlist.pdf.; Funded by the National Heart, Lung, and Blood Institute	Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Beiser A, 2000, STAT MED, V19, P1495, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1495::AID-SIM441>3.0.CO;2-E; Berry JD, 2009, CIRCULATION, V119, P382, DOI 10.1161/CIRCULATIONAHA.108.800235; CARMAN WJ, 1994, CIRCULATION, V89, P703, DOI 10.1161/01.CIR.89.2.703; Carnethon MR, 2006, ARCH INTERN MED, V166, P1196, DOI 10.1001/archinte.166.11.1196; Cohen B B, 1987, Vital Health Stat 1, P1; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DELGADO JL, 1990, AM J PUBLIC HEALTH, V80, P6, DOI 10.2105/AJPH.80.Suppl.6; DYER AR, 1980, AM J EPIDEMIOL, V112, P736, DOI 10.1093/oxfordjournals.aje.a113046; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Ford ES, 2009, CIRCULATION, V120, P1181, DOI 10.1161/CIRCULATIONAHA.108.835728; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; GARCIAPALMIERI MR, 1970, CIRCULATION, V42, P541, DOI 10.1161/01.CIR.42.3.541; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; Gregg EW, 2005, JAMA-J AM MED ASSOC, V294, P182; Gregg EW, 2005, JAMA-J AM MED ASSOC, V293, P1868, DOI 10.1001/jama.293.15.1868; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Gupta S, 2010, JACC-CARDIOVASC IMAG, V3, P605, DOI 10.1016/j.jcmg.2010.03.005; Haan MN, 1996, ANN EPIDEMIOL, V6, P348, DOI 10.1016/S1047-2797(96)00054-3; HARRISON HH, 1986, CONTROL CLIN TRIALS, V7, pS91; Hozawa A, 2007, ARCH INTERN MED, V167, P573, DOI 10.1001/archinte.167.6.573; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; Lloyd-Jones DM, 2006, CIRCULATION, V113, P791, DOI 10.1161/CIRCULATIONAHA.105.548206; Lloyd-Jones DM, 2002, CIRCULATION, V106, P3068, DOI 10.1161/01.CIR.0000039105.49749.6F; Lloyd-Jones DM, 1999, LANCET, V353, P89, DOI 10.1016/S0140-6736(98)10279-9; Lloyd-Jones DM, 2007, AM J CARDIOL, V99, P535, DOI 10.1016/j.amjcard.2006.09.099; Lloyd-Lones DM, 2003, ARCH INTERN MED, V163, P1966, DOI 10.1001/archinte.163.16.1966; Loria CM, 1999, VITAL HLTH STAT SERI; Markides KS, 1996, ANN EPIDEMIOL, V6, P386, DOI 10.1016/S1047-2797(96)00061-0; Marma AK, 2010, CIRC-CARDIOVASC QUAL, V3, P8, DOI 10.1161/CIRCOUTCOMES.109.869727; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; Nelson KM, 2010, DIABETES CARE, V33, P2360, DOI 10.2337/dc10-0846; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; STAMLER J, 1975, J CHRON DIS, V28, P527, DOI 10.1016/0021-9681(75)90060-0; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; Thomas AJ, 2005, AM J PUBLIC HEALTH, V95, P1417, DOI 10.2105/AJPH.2004.048165; Wijeysundera HC, 2010, JAMA-J AM MED ASSOC, V303, P1841, DOI 10.1001/jama.2010.580; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6	43	612	633	4	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					321	329		10.1056/NEJMoa1012848	http://dx.doi.org/10.1056/NEJMoa1012848			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EQ	22276822	Green Accepted, Bronze			2022-12-28	WOS:000299464100003
J	Grayburn, PA				Grayburn, Paul A.			Interpreting the Coronary-Artery Calcium Score	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ATHEROSCLEROSIS; DISEASE		Baylor Univ, Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX USA	Baylor University; Baylor University Medical Center	Grayburn, PA (corresponding author), Baylor Univ, Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX USA.							Bonow RO, 2009, NEW ENGL J MED, V361, P990, DOI 10.1056/NEJMcp0902177; Polonsky TS, 2010, JAMA-J AM MED ASSOC, V303, P1610, DOI 10.1001/jama.2010.461; Rozanski A, 2011, J AM COLL CARDIOL, V57, P1622, DOI 10.1016/j.jacc.2011.01.019; Stone GW, 2011, NEW ENGL J MED, V364, P226, DOI 10.1056/NEJMoa1002358; Villines TC, 2011, J AM COLL CARDIOL, V58, P2533, DOI 10.1016/j.jacc.2011.10.851	5	14	16	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					294	296		10.1056/NEJMp1110647	http://dx.doi.org/10.1056/NEJMp1110647			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	881EQ	22276819				2022-12-28	WOS:000299464100014
J	Pizzo, PA; Clark, NM				Pizzo, Philip A.; Clark, Noreen M.			Alleviating Suffering 101-Pain Relief in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Pizzo, Philip A.] Stanford Univ, Off Dean, Sch Med, Stanford, CA 94305 USA; [Clark, Noreen M.] Univ Michigan, Ctr Managing Chron Dis, Ann Arbor, MI 48109 USA	Stanford University; University of Michigan System; University of Michigan	Pizzo, PA (corresponding author), Stanford Univ, Off Dean, Sch Med, Stanford, CA 94305 USA.							Institute of Medicine, 2011, REL PAIN AM BLU TRAN	1	142	144	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					197	199		10.1056/NEJMp1109084	http://dx.doi.org/10.1056/NEJMp1109084			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	877RZ	22256802				2022-12-28	WOS:000299201400002
J	Russell, JK; Porritt, LA; Lavallee, Y; Dingwell, DB				Russell, James K.; Porritt, Lucy A.; Lavallee, Yan; Dingwell, Donald B.			Kimberlite ascent by assimilation-fuelled buoyancy	NATURE			English	Article							SYSTEM CAO-MGO-AL2O3-SIO2-CO2; SLAVE CRATON; CONSTRAINTS; MAGMA; DISSOLUTION; LHERZOLITE; PERIDOTITE; XENOLITHS; PETROLOGY; CARBONATE	Kimberlite magmas have the deepest origin of all terrestrial magmas and are exclusively associated with cratons(1-3). During ascent, they travel through about 150 kilometres of cratonic mantle lithosphere and entrain seemingly prohibitive loads (more than 25 per cent by volume) of mantle-derived xenoliths and xenocrysts (including diamond)(4,5). Kimberlite magmas also reputedly have higher ascent rates(6-9) than other xenolith-bearing magmas(10,11). Exsolution of dissolved volatiles (carbon dioxide and water) is thought to be essential to provide sufficient buoyancy for the rapid ascent of these dense, crystal-rich magmas. The cause and nature of such exsolution, however, remains elusive and is rarely specified(6,9). Here we use a series of high-temperature experiments to demonstrate a mechanism for the spontaneous, efficient and continuous production of this volatile phase. This mechanism requires parental melts of kimberlite to originate as carbonatite-like melts. In transit through the mantle lithosphere, these silica-undersaturated melts assimilate mantle minerals, especially orthopyroxene, driving the melt to more silicic compositions, and causing a marked drop in carbon dioxide solubility. The solubility drop manifests itself immediately in a continuous and vigorous exsolution of a fluid phase, thereby reducing magma density, increasing buoyancy, and driving the rapid and accelerating ascent of the increasingly kimberlitic magma. Our model provides an explanation for continuous ascent of magmas laden with high volumes of dense mantle cargo, an explanation for the chemical diversity of kimberlite, and a connection between kimberlites and cratons.	[Russell, James K.; Porritt, Lucy A.] Univ British Columbia, Volcanol & Petrol Lab, Vancouver, BC V6T 1Z4, Canada; [Lavallee, Yan; Dingwell, Donald B.] Univ Munich, Dept Earth & Environm Sci, D-80333 Munich, Germany	University of British Columbia; University of Munich	Russell, JK (corresponding author), Univ British Columbia, Volcanol & Petrol Lab, Vancouver, BC V6T 1Z4, Canada.	krussell@eos.ubc.ca	Russell, James Kelly/AAC-6210-2019; Russell, James K/E-5311-2017; Lavallee, Yan/AAC-5259-2020; Dingwell, Donald B/A-4724-2011	Russell, James Kelly/0000-0002-2062-3155; Russell, James K/0000-0002-2062-3155; Dingwell, Donald B/0000-0002-3332-789X	Natural Sciences and Engineering Research Council; Marie Curie outbound fellowship; ERC	Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Marie Curie outbound fellowship; ERC(European Research Council (ERC)European Commission)	We acknowledge the laboratory support of W. Ertel-Ingritsch and S. Laumann at Ludwig Maximilian University. Funding for this research is from the Natural Sciences and Engineering Research Council (J.K.R.), a Marie Curie outbound fellowship (L. A. P.) and an ERC Advanced Researcher Grant (D. B. D.). The original manuscript benefitted from review by S. Sparks.	Anderson O. L., 1979, KIMBERLITES DIATREME, P344; Boyd F.R., 1973, LESOTHO KIMBERLITES, P254; BOYD FR, 1989, EARTH PLANET SC LETT, V96, P15, DOI 10.1016/0012-821X(89)90120-9; Brett RC, 2009, LITHOS, V112, P201, DOI 10.1016/j.lithos.2009.04.030; Brooker RA, 2011, B VOLCANOL, V73, P959, DOI 10.1007/s00445-011-0523-7; Canil D, 1999, EARTH PLANET SC LETT, V167, P227, DOI 10.1016/S0012-821X(99)00019-9; Canil D, 2008, LITHOS, V105, P111, DOI 10.1016/j.lithos.2008.02.011; Dalton JA, 1998, CONTRIB MINERAL PETR, V131, P123, DOI 10.1007/s004100050383; Dalton JA, 1998, J PETROL, V39, P1953, DOI 10.1093/petrology/39.11.1953; DAWSON JB, 1994, CONTRIB MINERAL PETR, V116, P473, DOI 10.1007/BF00310913; Dobson DP, 1996, EARTH PLANET SC LETT, V143, P207, DOI 10.1016/0012-821X(96)00139-2; Edwards BR, 1998, GEOLOGY, V26, P1103, DOI 10.1130/0091-7613(1998)026<1103:TSOMPN>2.3.CO;2; Ferguson J., 1973, LESOTHO KIMBERLITES, P207; HRMA P, 1985, J AM CERAM SOC, V68, P337, DOI 10.1111/j.1151-2916.1985.tb15236.x; Kavanagh JL, 2009, EARTH PLANET SC LETT, V286, P404, DOI 10.1016/j.epsl.2009.07.011; Keppler H, 2003, AM MINERAL, V88, P1822, DOI 10.2138/am-2003-11-1224; Kjarsgaard B.A., 2007, SPECIAL PUBLICATION, V5, P245; Kopylova MG, 1999, J PETROL, V40, P79, DOI 10.1093/petrology/40.1.79; Kopylova MG, 2000, EARTH PLANET SC LETT, V181, P71, DOI 10.1016/S0012-821X(00)00187-4; Lensky NG, 2006, EARTH PLANET SC LETT, V245, P278, DOI 10.1016/j.epsl.2005.11.064; Luth RW, 2009, CONTRIB MINERAL PETR, V158, P283, DOI 10.1007/s00410-009-0383-8; MCDONOUGH WF, 1990, EARTH PLANET SC LETT, V101, P1, DOI 10.1016/0012-821X(90)90119-I; Mitchell R.H., 1973, LITHOS, V6, P65; Mitchell R. H., 1986, KIMBERLITES MINERALO; Mitchell RH, 2008, J VOLCANOL GEOTH RES, V174, P1, DOI 10.1016/j.jvolgeores.2007.12.024; NIXON PH, 1995, J GEOCHEM EXPLOR, V53, P41, DOI 10.1016/0375-6742(94)00034-9; Patterson M, 2009, LITHOS, V112, P191, DOI 10.1016/j.lithos.2009.06.004; Price SE, 2000, J PETROL, V41, P789, DOI 10.1093/petrology/41.6.789; Shaw CSJ, 1999, CONTRIB MINERAL PETR, V135, P114, DOI 10.1007/s004100050501; Sparks RSJ, 2007, NATURE, V450, pE21, DOI 10.1038/nature06435; Sparks RSJ, 2006, J VOLCANOL GEOTH RES, V155, P18, DOI 10.1016/j.jvolgeores.2006.02.010; Sparks RSJ, 2009, LITHOS, V112, P429, DOI 10.1016/j.lithos.2009.05.032; SPARKS RSJ, 1977, EARTH PLANET SC LETT, V35, P234, DOI 10.1016/0012-821X(77)90126-1; SPERA FJ, 1984, CONTRIB MINERAL PETR, V88, P217, DOI 10.1007/BF00380167; Wilson L, 2007, NATURE, V447, P53, DOI 10.1038/nature05692; WYLLIE PJ, 1975, GEOLOGY, V3, P621, DOI 10.1130/0091-7613(1975)3<621:PKACEI>2.0.CO;2	36	201	214	1	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					352	U133		10.1038/nature10740	http://dx.doi.org/10.1038/nature10740			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258614				2022-12-28	WOS:000299210600040
J	Decramer, M; Janssens, W; Miravitlles, M				Decramer, Marc; Janssens, Wim; Miravitlles, Marc			Chronic obstructive pulmonary disease	LANCET			English	Article							INHALED ANTICHOLINERGIC BRONCHODILATOR; ACUTE EXACERBATIONS; LUNG-FUNCTION; VITAMIN-D; GLOBAL BURDEN; AIR-FLOW; SALMETEROL/FLUTICASONE PROPIONATE; FUNCTIONAL IMPAIRMENT; CARDIOVASCULAR EVENTS; RHINOVIRUS INFECTION	Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. The main cause is smoking tobacco, but other factors have been identified. Several pathobiological processes interact on a complex background of genetic determinants, lung growth, and environmental stimuli. The disease is further aggravated by exacerbations, particularly in patients with severe disease, up to 78% of which are due to bacterial infections, viral infections, or both. Comorbidities include ischaemic heart disease, diabetes, and lung cancer. Bronchodilators constitute the mainstay of treatment: beta(2) agonists and long-acting anticholinergic agents are frequently used (the former often with inhaled corticosteroids). Besides improving symptoms, these treatments are also thought to lead to some degree of disease modification. Future research should be directed towards the development of agents that notably affect the course of disease.	[Decramer, Marc; Janssens, Wim] Univ Louvain, Univ Hosp, Div Resp, B-3000 Louvain, Belgium; [Miravitlles, Marc] Hosp Clin Barcelona, Fundacio Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Decramer, M (corresponding author), Univ Louvain, Univ Hosp, Div Resp, Herestr 49, B-3000 Louvain, Belgium.	marc.decramer@uzleuven.be	Miravitlles, Marc/AAH-5284-2019	Miravitlles, Marc/0000-0002-9850-9520; Janssens, Wim/0000-0003-1830-2982	Boehringer-Pfizer; GlaxoSmithKline; AstraZeneca; Dompe; Novartis; Nycomed; UCB; Chiesi; Bayer Schering; Talecris; Almirall	Boehringer-Pfizer(Boehringer IngelheimPfizer); GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Dompe; Novartis(Novartis); Nycomed; UCB(UCB Pharma SA); Chiesi(Chiesi Pharmaceuticals Inc); Bayer Schering(Bayer AG); Talecris; Almirall(Almirall)	MD has received speaker fees from Boehringer-Pfizer, GlaxoSmithKline, and AstraZeneca, consulting fees from Boehringer-Pfizer, GlaxoSmithKline, AstraZeneca, Dompe, Novartis, and Nycomed, and grant support from AstraZeneca, GlaxoSmithKline, UCB, and Chiesi. WJ received consulting fees from AstraZeneca, Boehringer-Pfizer, and Novartis. MM has received speaker fees from Boehringer-Pfizer, AstraZeneca, Bayer Schering, Talecris, and Novartis, consulting fees from Boehringer-Pfizer, GlaxoSmithKline, AstraZeneca, Bayer Schering, Dompe, Almirall, Novartis, and Nycomed, and grant support from Talecris.	Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Allegra L, 2005, RESP MED, V99, P742, DOI 10.1016/j.rmed.2004.10.020; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Anthonisen NR, 2005, ANN INTERN MED, V142, P233, DOI 10.7326/0003-4819-142-4-200502150-00005; Barcelo B, 2008, EUR RESPIR J, V31, P555, DOI 10.1183/09031936.00010407; Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Barr RG, 2003, BMJ-BRIT MED J, V327, P643, DOI 10.1136/bmj.327.7416.643; Beeh KM, 2009, ADV THER, V26, P691, DOI 10.1007/s12325-009-0044-3; Booth FW, 2000, J APPL PHYSIOL, V88, P774, DOI 10.1152/jappl.2000.88.2.774; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Bozinovski S, 2008, AM J RESP CRIT CARE, V177, P269, DOI 10.1164/rccm.200705-678OC; Bracke Ken R., 2007, Inflammation & Allergy Drug Targets, V6, P75; Broekhuizen R, 2006, THORAX, V61, P17, DOI 10.1136/thx.2005.041996; Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4; Burgel PR, 2010, EUR RESPIR J, V36, P531, DOI 10.1183/09031936.00175109; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Casas A, 2006, EUR RESPIR J, V28, P123, DOI 10.1183/09031936.06.00063205; Celli B, 2010, CHEST, V137, P20, DOI 10.1378/chest.09-0011; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Chishimba L, 2010, THORAX, V65, P456, DOI 10.1136/thx.2009.128793; Cosio MG, 2009, NEW ENGL J MED, V360, P2445, DOI 10.1056/NEJMra0804752; Crim C, 2009, EUR RESPIR J, V34, P641, DOI 10.1183/09031936.00193908; Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009; Daniels JMA, 2010, CHEST, V138, P1108, DOI 10.1378/chest.09-2927; Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2; Decramer M, 2010, EUR RESPIR REV, V19, P134, DOI 10.1183/09059180.00003610; Decramer M, 2008, COPD, V5, P235, DOI 10.1080/15412550802237531; Decramer Marc, 2006, COPD, V3, P163, DOI 10.1080/15412550600830263; Decramer M, 2010, THORAX, V65, P837, DOI 10.1136/thx.2009.133355; Decramer M, 2009, LANCET, V374, P1171, DOI 10.1016/S0140-6736(09)61298-8; Demedts IK, 2007, AM J RESP CRIT CARE, V175, P998, DOI 10.1164/rccm.200608-1113OC; Di Stefano A, 2009, CLIN EXP IMMUNOL, V157, P316, DOI 10.1111/j.1365-2249.2009.03965.x; Doll H, 2005, PHARMACOECONOMICS, V23, P345, DOI 10.2165/00019053-200523040-00005; Drummond MB, 2008, JAMA-J AM MED ASSOC, V300, P2407, DOI 10.1001/jama.2008.717; Dusser D, 2006, EUR RESPIR J, V27, P547, DOI 10.1183/09031936.06.00062705; Edwards R, 2004, BRIT MED J, V328, P217, DOI 10.1136/bmj.328.7433.217; Eisner MD, 2010, AM J RESP CRIT CARE, V182, P693, DOI 10.1164/rccm.200811-1757ST; Ernst P, 2007, AM J RESP CRIT CARE, V176, P162, DOI 10.1164/rccm.200611-1630OC; Ewig S, 2000, CRIT CARE MED, V28, P692, DOI 10.1097/00003246-200003000-00015; Fabbri LM, 2008, EUR RESPIR J, V31, P204, DOI 10.1183/09031936.00114307; Fabbri LM, 2007, LANCET, V370, P797, DOI 10.1016/S0140-6736(07)61383-X; Fabbri LM, 2009, LANCET, V374, P695, DOI 10.1016/S0140-6736(09)61252-6; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Gershon AS, 2010, ARCH INTERN MED, V170, P560, DOI 10.1001/archinternmed.2010.17; Giangreco A, 2009, P NATL ACAD SCI USA, V106, P9286, DOI 10.1073/pnas.0900668106; Global Initiative for Chronic Obstructive Lung Disease, GLOB STRAT DIAGN MAN; Gooptu B, 2009, EUR RESPIR J, V34, P475, DOI 10.1183/09031936.00096508; Halbert RJ, 2006, EUR RESPIR J, V28, P523, DOI 10.1183/09031936.06.00124605; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Heath GW, 2009, AM J LIFESTYLE MED, V3, p27S, DOI 10.1177/1559827609334504; Hodge S, 2008, AM J RESP CRIT CARE, V178, P139, DOI 10.1164/rccm.200711-1666OC; Hogg James C, 2009, Proc Am Thorac Soc, V6, P668, DOI 10.1513/pats.200907-079DP; Hogg JC, 2009, ANNU REV PATHOL-MECH, V4, P435, DOI 10.1146/annurev.pathol.4.110807.092145; Hoogendoorn Martine, 2010, Int J Chron Obstruct Pulmon Dis, V5, P435, DOI 10.2147/COPD.S13826; Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006; Hurst JR, 2006, AM J RESP CRIT CARE, V174, P867, DOI 10.1164/rccm.200604-506OC; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Hurst JR, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-40; Hvidsten SC, 2010, CLIN RESPIR J, V4, P13, DOI 10.1111/j.1752-699X.2009.00137.x; Ito K, 2009, CHEST, V135, P173, DOI 10.1378/chest.08-1419; Janssens W, 2010, THORAX, V65, P215, DOI 10.1136/thx.2009.120659; Janssens W, 2009, AM J RESP CRIT CARE, V179, P630, DOI 10.1164/rccm.200810-1576PP; Jemal A, 2005, JAMA-J AM MED ASSOC, V294, P1255, DOI 10.1001/jama.294.10.1255; Jenkins CR, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-59; Kesten Steven, 2009, Int J Chron Obstruct Pulmon Dis, V4, P397; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; Lambrechts D, 2010, AM J RESP CRIT CARE, V181, P486, DOI 10.1164/rccm.200909-1364OC; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Lehouck A, 2012, ANN INTERN MED, V156, P105, DOI 10.7326/0003-4819-156-2-201201170-00004; MacNee William, 2009, Proc Am Thorac Soc, V6, P527, DOI 10.1513/pats.200905-027DS; Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC; Mancini GBJ, 2006, J AM COLL CARDIOL, V47, P2554, DOI 10.1016/j.jacc.2006.04.039; Mannino DM, 2008, EUR RESPIR J, V32, P962, DOI 10.1183/09031936.00012408; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Marin A, 2010, EUR RESPIR J, V35, P295, DOI 10.1183/09031936.00126808; McCrory DC, 2003, COCHRANE DB SYST REV, V4; McManus TE, 2008, RESP MED, V102, P1575, DOI 10.1016/j.rmed.2008.06.006; Menezes AMB, 2005, LANCET, V366, P1875, DOI 10.1016/S0140-6736(05)67632-5; Michele TM, 2010, NEW ENGL J MED, V363, P1097, DOI 10.1056/NEJMp1008502; Miravitlles M, 1999, CHEST, V116, P40, DOI 10.1378/chest.116.1.40; Miravitlles M, 2009, THORAX, V64, P863, DOI 10.1136/thx.2009.115725; Miravitlles M, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-58; Monso E, 2003, EPIDEMIOL INFECT, V131, P799, DOI 10.1017/S0950268803008872; MONSO E, 1995, AM J RESP CRIT CARE, V152, P1316, DOI 10.1164/ajrccm.152.4.7551388; Montero M, 2009, INFECTION, V37, P16, DOI 10.1007/s15010-008-8125-9; Moody A, 2004, THORAX, V59, P1; Mora S, 2007, CIRCULATION, V116, P2110, DOI 10.1161/CIRCULATIONAHA.107.729939; Murphy TF, 2008, AM J RESP CRIT CARE, V177, P853, DOI 10.1164/rccm.200709-1413OC; Nannini LJ, 2007, COCHRANE DB SYST REV, V4; Niewoehner DE, 2005, ANN INTERN MED, V143, P317, DOI 10.7326/0003-4819-143-5-200509060-00007; O'Donnell Denis E, 2006, Proc Am Thorac Soc, V3, P180, DOI 10.1513/pats.200508-093DO; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Opitz B, 2010, AM J RESP CRIT CARE, V181, P1294, DOI 10.1164/rccm.200909-1427SO; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Pitta F, 2005, AM J RESP CRIT CARE, V171, P972, DOI 10.1164/rccm.200407-855OC; Poole P, 2010, COCHRANE DB SYST REV, V2; Quint JK, 2010, CHEST, V137, P812, DOI 10.1378/chest.09-1541; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Ram FS., 2004, COCHRANE DB SYST REV, V3, DOI [DOI 10.1002/14651858.CD004104.PUB3, 10.1002/14651858.cd004104.pub3]; RAM FS, 2006, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD004403.PUB2; Ray NC, 2009, EXPERT OPIN THER PAT, V19, P1, DOI 10.1517/13543770802630331; Rennard Stephen I, 2006, Proc Am Thorac Soc, V3, P703, DOI 10.1513/pats.200605-121SF; Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418; Rutten FH, 2010, ARCH INTERN MED, V170, P880, DOI 10.1001/archinternmed.2010.112; Seemungal TAR, 2008, AM J RESP CRIT CARE, V178, P1139, DOI 10.1164/rccm.200801-145OC; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Sethi S, 2008, NEW ENGL J MED, V359, P2355, DOI 10.1056/NEJMra0800353; Sethi S, 2008, AM J RESP CRIT CARE, V177, P491, DOI 10.1164/rccm.200708-1234OC; Sethi S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-10; Silverman Edwin K, 2009, Proc Am Thorac Soc, V6, P539, DOI 10.1513/pats.200904-021DS; Sin DD, 2006, EUR RESPIR J, V28, P1245, DOI 10.1183/09031936.00133805; Sin DD, 2009, LANCET, V374, P712, DOI 10.1016/S0140-6736(09)61250-2; Sinden NJ, 2010, THORAX, V65, P930, DOI 10.1136/thx.2009.130260; Singh D, 2010, J CLIN PHARMACOL, V50, P94, DOI 10.1177/0091270009347873; Singh S, 2009, ARCH INTERN MED, V169, P219, DOI 10.1001/archinternmed.2008.550; Singh S, 2008, JAMA-J AM MED ASSOC, V300, P1439, DOI 10.1001/jama.300.12.1439; Soler N, 2007, THORAX, V62, P29, DOI 10.1136/thx.2005.056374; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Soriano JB, 2010, EUR RESPIR J, V36, P758, DOI 10.1183/09031936.00138409; Stockley RA, 2000, CHEST, V117, P1638, DOI 10.1378/chest.117.6.1638; Stolz D, 2007, CHEST, V131, P9, DOI 10.1378/chest.06-1500; Suissa S, 2010, RESPIRATION, V80, P3, DOI 10.1159/000315387; Sullivan AK, 2005, AM J RESP CRIT CARE, V172, P590, DOI 10.1164/rccm.200410-1332OC; Svanes C, 2010, THORAX, V65, P14, DOI 10.1136/thx.2008.112136; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; Tashkin DP, 2010, EXPERT OPIN PHARMACO, V11, P2077, DOI 10.1517/14656566.2010.499358; Taylor AE, 2010, EUR RESPIR J, V35, P1039, DOI 10.1183/09031936.00036709; Troosters T, 2005, AM J RESP CRIT CARE, V172, P19, DOI 10.1164/rccm.200408-1109SO; Troosters T, 2010, EUR RESPIR J, V36, P65, DOI 10.1183/09031936.00127809; Tsuji T, 2004, AM J RESP CELL MOL, V31, P643, DOI 10.1165/rcmb.2003-0290OC; Tsuji T, 2006, AM J RESP CRIT CARE, V174, P886, DOI 10.1164/rccm.200509-1374OC; Tuder Rubin M, 2006, Proc Am Thorac Soc, V3, P673, DOI 10.1513/pats.200605-124SF; van der Strate BWA, 2006, AM J RESP CRIT CARE, V173, P751, DOI 10.1164/rccm.200504-594OC; van Gestel YRBM, 2008, AM J CARDIOL, V102, P192, DOI 10.1016/j.amjcard.2008.03.038; Vollmer WM, 2009, EUR RESPIR J, V34, P588, DOI 10.1183/09031936.00164608; Walters JA, 2009, COCHRANE DB SYST REV, V1; Wedzicha JA, 2008, AM J RESP CRIT CARE, V177, P19, DOI 10.1164/rccm.200707-973OC; Weiss ST, 2010, NAT GENET, V42, P14, DOI 10.1038/ng0110-14; Wilk JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000429; Wilkinson TMA, 2003, AM J RESP CRIT CARE, V167, P1090, DOI 10.1164/rccm.200210-1179OC; World Health Organization, WORLD HLTH STAT 2008; Yanbaeva DG, 2007, CHEST, V131, P1557, DOI 10.1378/chest.06-2179; Zheng JP, 2008, LANCET, V371, P2013, DOI 10.1016/S0140-6736(08)60869-7	155	703	742	16	222	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 7	2012	379	9823					1341	1351		10.1016/S0140-6736(11)60968-9	http://dx.doi.org/10.1016/S0140-6736(11)60968-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922FB	22314182	Green Published, Bronze			2022-12-28	WOS:000302531100032
J	Kraemer, JD; Gostin, LO				Kraemer, John D.; Gostin, Lawrence O.			The Limits of Government Regulation of Science	SCIENCE			English	Editorial Material									[Kraemer, John D.; Gostin, Lawrence O.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA; [Kraemer, John D.] Georgetown Univ, Dept Hlth Syst Adm, Sch Nursing & Hlth Studies, Washington, DC 20057 USA	Georgetown University; Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				[Anonymous], 2010, CONTROLLED UNCLASSIF; [Anonymous], 2004, COMMUNICATION   0402; [Anonymous], 2009, 13526 NAT SEC INF; [Anonymous], 2005, COMMUNICATION   0527; Broad W., 2011, NY TIMES, pA1; Chamberlain A., 2004, SCI SECURITY POST 9; Chin TJ, 2008, NEW YORK U LAW REV, V83, P1883; Fitzpatrick J. P., 2011, GUIDANCE REGARDING C; Goldenson D. G., 2001, BOSTON COLL ENV AFF, V29, P311; IEEE, OFAC BACKGR; National Research Council, 2004, BIOT RES AG TERR; Office of Management and Budget, 110A OFF MAN BUDG; Steffan M., 2011, WASHINGTON POST 1013	13	9	9	5	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 2	2012	335	6072					1047	1049		10.1126/science.1219215	http://dx.doi.org/10.1126/science.1219215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	900ZL	22267583	Green Submitted			2022-12-28	WOS:000300931100028
J	Prahallad, A; Sun, C; Huang, SD; Di Nicolantonio, F; Salazar, R; Zecchin, D; Beijersbergen, RL; Bardelli, A; Bernards, R				Prahallad, Anirudh; Sun, Chong; Huang, Sidong; Di Nicolantonio, Federica; Salazar, Ramon; Zecchin, Davide; Beijersbergen, Roderick L.; Bardelli, Alberto; Bernards, Rene			Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR	NATURE			English	Article							METASTATIC COLORECTAL-CANCER; PAPILLARY THYROID-CARCINOMA; BRAF MUTATIONS; PANITUMUMAB; CETUXIMAB; MELANOMA; TARGET; KRAS	Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma(1). However, colon cancer patients harbouring the same BRAF (V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug(2-4). To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF (V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF (V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers(2,3,5)), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.	[Prahallad, Anirudh; Sun, Chong; Huang, Sidong; Beijersbergen, Roderick L.; Bernards, Rene] Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; [Prahallad, Anirudh; Sun, Chong; Huang, Sidong; Beijersbergen, Roderick L.; Bernards, Rene] Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands; [Di Nicolantonio, Federica; Zecchin, Davide; Bardelli, Alberto] Univ Turin, Lab Mol Genet, Inst Canc Res & Treatment, Sch Med, I-10060 Turin, Italy; [Di Nicolantonio, Federica; Bardelli, Alberto] FIRC IFOM Inst Mol Oncol, I-20100 Milan, Italy; [Salazar, Ramon] IDIBELL, Inst Catala Oncol LHospitalet de Llobregat, Lhospitalet Barcelona 08907, Spain	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Turin; IFOM - FIRC Institute of Molecular Oncology; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Di Nicolantonio, Federica/A-2503-2011; Sun, Chong/AAB-4859-2021; Toon, Christopher W/G-3610-2012; BARDELLI, Alberto/J-9721-2018	Di Nicolantonio, Federica/0000-0001-9618-2010; Sun, Chong/0000-0001-9008-2158; BARDELLI, Alberto/0000-0003-1647-5070; Bernards, Rene/0000-0001-8677-3423; Huang, Sidong/0000-0002-2838-4726; Beijersbergen, Roderick/0000-0003-0116-4130	EU [259015]; European Research Council; Netherlands Organisation for Scientific Research (NWO); Dutch Cancer Society; Netherlands Genomics Initiative (NGI); Associazione Italiana per la Ricerca sul Cancro (AIRC) [9970]; Italian Ministry of University and Research; Italian Ministry of Health, Regione Piemonte; Fondazione Piemontese per la Ricerca sul Cancro	EU(European Commission); European Research Council(European Research Council (ERC)European Commission); Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Genomics Initiative (NGI); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Health, Regione Piemonte; Fondazione Piemontese per la Ricerca sul Cancro	We thank P. Kumar, V. Gambino and W. Grernrum for assistance with experiments. We are grateful to C. Pochet for support. Major financial support for this work was provided by the EU Seventh Framework Programme, grant agreement 259015 (to A.B. and R.B.). Additional funding was provided by a European Research Council grant to R.B.; The Cancer Systems Biology Center grant by the Netherlands Organisation for Scientific Research (NWO); The Dutch Cancer Society; The Netherlands Genomics Initiative (NGI); The Associazione Italiana per la Ricerca sul Cancro (AIRC), 2010 Special Program Molecular Clinical Oncology 5x1000, project 9970; AIRC Investigator Grant (to A.B.); Italian Ministry of University and Research; Italian Ministry of Health, Regione Piemonte (to A.B. and F.D.N.); Intramural Grant, 5xmille 2008; and Fondazione Piemontese per la Ricerca sul Cancro (to A.B. and F.D.N.).	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Boone B, 2011, J CUTAN PATHOL, V38, P492, DOI 10.1111/j.1600-0560.2011.01673.x; Brummelkamp TR, 2006, NAT CHEM BIOL, V2, P202, DOI 10.1038/nchembio774; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kimura ET, 2003, CANCER RES, V63, P1454; Kopetz S., 2010, J CLIN ONCOL, V28; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Richman SD, 2009, J CLIN ONCOL, V27, P5931, DOI 10.1200/JCO.2009.22.4295; Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160; Trovisco V, 2004, J PATHOL, V202, P247, DOI 10.1002/path.1511; Wang RN, 2007, CELL, V128, P1119, DOI 10.1016/j.cell.2006.11.053; Wang ZQ, 2002, J BIOL CHEM, V277, P19470, DOI 10.1074/jbc.M201097200	22	1372	1410	4	209	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 1	2012	483	7387					100	U146		10.1038/nature10868	http://dx.doi.org/10.1038/nature10868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900HP	22281684	Green Submitted			2022-12-28	WOS:000300877900053
J	Kato, HE; Zhang, F; Yizhar, O; Ramakrishnan, C; Nishizawa, T; Hirata, K; Ito, J; Aita, Y; Tsukazaki, T; Hayashi, S; Hegemann, P; Maturana, AD; Ishitani, R; Deisseroth, K; Nureki, O				Kato, Hideaki E.; Zhang, Feng; Yizhar, Ofer; Ramakrishnan, Charu; Nishizawa, Tomohiro; Hirata, Kunio; Ito, Jumpei; Aita, Yusuke; Tsukazaki, Tomoya; Hayashi, Shigehiko; Hegemann, Peter; Maturana, Andres D.; Ishitani, Ryuichiro; Deisseroth, Karl; Nureki, Osamu			Crystal structure of the channelrhodopsin light-gated cation channel	NATURE			English	Article							OPTICAL CONTROL; PROTEIN; ACTIVATION; BACTERIORHODOPSIN; PHOTOCYCLE; PREDICTION; MEMBRANE	Channelrhodopsins (ChRs) are light-gated cation channels derived from algae that have shown experimental utility in optogenetics; for example, neurons expressing ChRs can be optically controlled with high temporal precision within systems as complex as freely moving mammals. Although ChRs have been broadly applied to neuroscience research, little is known about the molecular mechanisms by which these unusual and powerful proteins operate. Here we present the crystal structure of a ChR (a C1C2 chimaera between ChR1 and ChR2 from Chlamydomonas reinhardtii) at 2.3 angstrom resolution. The structure reveals the essential molecular architecture of ChRs, including the retinal-binding pocket and cation conduction pathway. This integration of structural and electrophysiological analyses provides insight into the molecular basis for the remarkable function of ChRs, and paves the way for the precise and principled design of ChR variants with novel properties.	[Kato, Hideaki E.; Nishizawa, Tomohiro; Tsukazaki, Tomoya; Ishitani, Ryuichiro; Nureki, Osamu] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130032, Japan; [Zhang, Feng; Yizhar, Ofer; Ramakrishnan, Charu; Deisseroth, Karl] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Zhang, Feng; Yizhar, Ofer; Ramakrishnan, Charu; Deisseroth, Karl] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Hirata, Kunio] RIKEN SPring 8 Ctr, Mikazuki, Hyogo 6795148, Japan; [Ito, Jumpei; Aita, Yusuke; Maturana, Andres D.] Nagaoka Univ Technol, Dept Bioengn, Niigata 9402188, Japan; [Hayashi, Shigehiko] Kyoto Univ, Grad Sch Sci, Dept Chem, Kyoto 6068502, Japan; [Hegemann, Peter] Humboldt Univ, Inst Biol, D-10115 Berlin, Germany	University of Tokyo; Stanford University; Howard Hughes Medical Institute; Stanford University; RIKEN; Nagaoka University of Technology; Kyoto University; Humboldt University of Berlin	Nureki, O (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 2-11-16 Yayoi, Tokyo 1130032, Japan.	deissero@stanford.edu; nureki@biochem.s.u-tokyo.ac.jp	NUREKI, OSAMU/G-4960-2014; Tsukazaki, Tomoya/N-2299-2019; Kato, Hideaki/AAQ-4323-2020; Macrae, Rhiannon/AAX-1536-2020; YIZHAR, OFER/AAV-8497-2021	Tsukazaki, Tomoya/0000-0002-6386-723X; Kato, Hideaki/0000-0002-1941-5535; Ramakrishnan, Charu/0000-0002-3474-6332; Yizhar, Ofer/0000-0003-4228-1448; Ito, Jumpei/0000-0001-5149-9962	Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT); McKnight Foundation; Gatsby Charitable Foundation; Keck Foundation; Snyder Foundation; Woo Foundation; Yu Foundation; National Institutes of Health; Defense Advanced Research Project Agency (DARPA)	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); McKnight Foundation; Gatsby Charitable Foundation; Keck Foundation(W.M. Keck Foundation); Snyder Foundation; Woo Foundation; Yu Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defense Advanced Research Project Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA))	We thank Y. Tanaka, T. Higuchi, M. Hattori and H. Nishimasu for useful discussions; T. Hino for technical support; and the beamline staff members at BL32XU of SPring-8 (Hyogo, Japan) and at X06SA of the Swiss Light Source (Villigen, Switzerland) for technical help during data collection. This work was supported by the Japan Society for the Promotion of Science (JSPS) through its "Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST program)" to O.N., by a grant for the National Project on Protein Structural and Functional Analyses from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to O.N., and by a Grant-in-Aid for Scientific Research (S) from MEXT to O.N. F.Z. is supported by the McKnight Foundation. K. D. is supported by the Gatsby Charitable Foundation and the Keck, Snyder, Woo, and Yu Foundations, as well as by the National Institutes of Health, and the Defense Advanced Research Project Agency Reorganization and Plasticity to Accelerate Injury Recovery (DARPA REPAIR) program.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Bamann C, 2008, J MOL BIOL, V375, P686, DOI 10.1016/j.jmb.2007.10.072; Bamann C, 2010, BIOCHEMISTRY-US, V49, P267, DOI 10.1021/bi901634p; Bas DC, 2008, PROTEINS, V73, P765, DOI 10.1002/prot.22102; Berndt A, 2011, P NATL ACAD SCI USA, V108, P7595, DOI 10.1073/pnas.1017210108; Berndt A, 2009, NAT NEUROSCI, V12, P229, DOI 10.1038/nn.2247; Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026; Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fenno L, 2011, ANNU REV NEUROSCI, V34, P389, DOI 10.1146/annurev-neuro-061010-113817; Gunaydin LA, 2010, NAT NEUROSCI, V13, P387, DOI 10.1038/nn.2495; Hirata K, 2010, AIP CONF PROC, V1234, P901, DOI 10.1063/1.3463362; Ishizuka T, 2006, NEUROSCI RES, V54, P85, DOI 10.1016/j.neures.2005.10.009; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kawate T, 2006, STRUCTURE, V14, P673, DOI 10.1016/j.str.2006.01.013; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Kleinlogel S, 2011, NAT NEUROSCI, V14, P513, DOI 10.1038/nn.2776; Lanyi JK, 2006, BBA-BIOENERGETICS, V1757, P1012, DOI 10.1016/j.bbabio.2005.11.003; Lasogga L, 2010, J PHYS CHEM A, V114, P2179, DOI 10.1021/jp904132f; Li X, 2005, P NATL ACAD SCI USA, V102, P17816, DOI 10.1073/pnas.0509030102; Lin JY, 2009, BIOPHYS J, V96, P1803, DOI 10.1016/j.bpj.2008.11.034; Matsui Y, 2002, J MOL BIOL, V324, P469, DOI 10.1016/S0022-2836(02)01110-5; MATSUNOYAGI A, 1977, BIOCHEM BIOPH RES CO, V78, P237, DOI 10.1016/0006-291X(77)91245-1; Mittelmeier TM, 2011, J CELL BIOL, V193, P741, DOI 10.1083/jcb.201009131; Muller M, 2011, J MOL BIOL, V414, P86, DOI 10.1016/j.jmb.2011.09.049; Nack M, 2010, PHOTOCH PHOTOBIO SCI, V9, P194, DOI 10.1039/b9pp00157c; Nagel G, 2002, SCIENCE, V296, P2395, DOI 10.1126/science.1072068; Nagel G, 2005, CURR BIOL, V15, P2279, DOI 10.1016/j.cub.2005.11.032; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; Petrek M, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-316; Plazzo A. P., 2011, J BIOL CHEM; Radu I, 2009, J AM CHEM SOC, V131, P7313, DOI 10.1021/ja8084274; Ritter E, 2008, J BIOL CHEM, V283, P35033, DOI 10.1074/jbc.M806353200; Ruffert K, 2011, BIOCHEM BIOPH RES CO, V410, P737, DOI 10.1016/j.bbrc.2011.06.024; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Stenkamp RE, 2008, ACTA CRYSTALLOGR D, V64, P902, DOI 10.1107/S0907444908017162; Sugiyama Y, 2009, PHOTOCH PHOTOBIO SCI, V8, P328, DOI 10.1039/b815762f; Tsunoda SP, 2009, PHOTOCHEM PHOTOBIOL, V85, P564, DOI 10.1111/j.1751-1097.2008.00519.x; Wang HX, 2009, J BIOL CHEM, V284, P5685, DOI 10.1074/jbc.M807632200; Wen L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012893; Yizhar O, 2011, NATURE, V477, P171, DOI 10.1038/nature10360; Yizhar O, 2011, NEURON, V71, P9, DOI 10.1016/j.neuron.2011.06.004; Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936	45	356	374	3	196	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 16	2012	482	7385					369	U115		10.1038/nature10870	http://dx.doi.org/10.1038/nature10870			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	892LG	22266941	Green Accepted			2022-12-28	WOS:000300287100039
J	Rohlsberger, R; Wille, HC; Schlage, K; Sahoo, B				Roehlsberger, Ralf; Wille, Hans-Christian; Schlage, Kai; Sahoo, Balaram			Electromagnetically induced transparency with resonant nuclei in a cavity	NATURE			English	Article							POPULATION-INVERSION; LASER OSCILLATION; ATOMIC GAS; OPTICS	The manipulation of light-matter interactions by quantum control of atomic levels has had a profound impact on optical sciences. Such manipulation has many applications, including nonlinear optics at the few-photon level(1-3), slow light(4,5), lasing without inversion(6-8) and optical quantum information processing(9,10). The critical underlying technique is electromagnetically induced transparency, in which quantum interference between transitions in multilevel atoms(11-15) renders an opaque medium transparent near an atomic resonance. With the advent of high-brilliance, accelerator-driven light sources such as storage rings or X-ray lasers, it has become attractive to extend the techniques of optical quantum control to the X-ray regime(16,17). Here we demonstrate electromagnetically induced transparency in the regime of hard X-rays, using the 14.4-kiloelectronvolt nuclear resonance of the Mossbauer isotope iron-57 (a two-level system). We exploit cooperative emission from ensembles of the nuclei, which are embedded in a low-finesse cavity and excited by synchrotron radiation. The spatial modulation of the photonic density of states in a cavity mode leads to the coexistence of superradiant and subradiant states of nuclei, respectively located at an antinode and a node of the cavity field. This scheme causes the nuclei to behave as effective three-level systems, with two degenerate levels in the excited state (one of which can be considered metastable). The radiative coupling of the nuclear ensembles by the cavity field establishes the atomic coherence necessary for the cancellation of resonant absorption. Because this technique does not require atomic systems with a metastable level, electromagnetically induced transparency and its applications can be transferred to the regime of nuclear resonances, establishing the field of nuclear quantum optics.	[Roehlsberger, Ralf; Wille, Hans-Christian; Schlage, Kai; Sahoo, Balaram] Deutsches Elektronen Synchrotron, D-22607 Hamburg, Germany	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Rohlsberger, R (corresponding author), Deutsches Elektronen Synchrotron, Notkestr 85, D-22607 Hamburg, Germany.	ralf.roehlsberger@desy.de	Wille, Hans-Christian/C-3881-2013; Röhlsberger, Ralf/J-4173-2013; Sahoo, Balaram/E-4828-2011	Röhlsberger, Ralf/0000-0001-6005-5183; Sahoo, Balaram/0000-0002-2050-4746; Wille, Hans-Christian/0000-0003-0851-3831				Anisimov PM, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.163604; AUTLER SH, 1955, PHYS REV, V100, P703, DOI 10.1103/PhysRev.100.703; BOLLER KJ, 1991, PHYS REV LETT, V66, P2593, DOI 10.1103/PhysRevLett.66.2593; Buth C, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.253001; Callens R, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.104423; Coussement R, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.107601; FANO U, 1961, PHYS REV, V124, P1866, DOI 10.1103/PhysRev.124.1866; Fleischhauer M, 2005, REV MOD PHYS, V77, P633, DOI 10.1103/RevModPhys.77.633; Gheysen S, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.155443; Gheysen S, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/48/485214; Glover TE, 2010, NAT PHYS, V6, P69, DOI 10.1038/NPHYS1430; HANSCH T, 1969, Z PHYS, V226, P293, DOI 10.1007/BF01392091; Harris SE, 1999, PHYS REV LETT, V82, P4611, DOI 10.1103/PhysRevLett.82.4611; HARRIS SE, 1990, PHYS REV LETT, V64, P1107, DOI 10.1103/PhysRevLett.64.1107; Hau LV, 1999, NATURE, V397, P594, DOI 10.1038/17561; Kash MM, 1999, PHYS REV LETT, V82, P5229, DOI 10.1103/PhysRevLett.82.5229; KOCHAROVSKAYA OA, 1988, JETP LETT+, V48, P630; Liu C, 2001, NATURE, V409, P490, DOI 10.1038/35054017; Lukin MD, 2003, REV MOD PHYS, V75, P457, DOI 10.1103/RevModPhys.75.457; Lukin MD, 2001, NATURE, V413, P273, DOI 10.1038/35095000; Padmabandu GG, 1996, PHYS REV LETT, V76, P2053, DOI 10.1103/PhysRevLett.76.2053; Rohlsberger R, 2010, J MOD OPTIC, V57, P1979, DOI 10.1080/09500340.2010.506248; Rohlsberger R, 2010, SCIENCE, V328, P1248, DOI 10.1126/science.1187770; Rohlsberger R, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.235412; Rohlsberger R, 2004, SPRINGER TRAC MOD PH, V208, P1; Schmidt H, 1996, OPT LETT, V21, P1936, DOI 10.1364/OL.21.001936; SCULLY MO, 1994, SCIENCE, V263, P337, DOI 10.1126/science.263.5145.337; Tanji-Suzuki H, 2011, SCIENCE, V333, P1266, DOI 10.1126/science.1208066; ZIBROV AS, 1995, PHYS REV LETT, V75, P1499, DOI 10.1103/PhysRevLett.75.1499	29	147	148	2	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					199	203		10.1038/nature10741	http://dx.doi.org/10.1038/nature10741			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22318603				2022-12-28	WOS:000299994100034
J	Semenza, GL				Semenza, Gregg L.			Hypoxia-Inducible Factors in Physiology and Medicine	CELL			English	Review							FACTOR-I; GENE-THERAPY; ANGIOGENIC CELLS; BINDING-SITES; KEY REGULATOR; DNA-BINDING; STEM-CELLS; HIF-1-ALPHA; EXPRESSION; MICE	Oxygen homeostasis represents an organizing principle for understanding metazoan evolution, development, physiology, and pathobiology. The hypoxia-inducible factors (HIFs) are transcriptional activators that function as master regulators of oxygen homeostasis in all metazoan species. Rapid progress is being made in elucidating homeostatic roles of HIFs in many physiological systems, determining pathological consequences of HIF dysregulation in chronic diseases, and investigating potential targeting of HIFs for therapeutic purposes.	[Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Pediat,McKusick Nathans Inst, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Med,McKusick Nathans Inst Gen, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Oncol,McKusick Nathans Inst G, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Radiat Oncol,McKusick Nathans, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Radiat Oncol,McKusick Nathans, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Biol Chem,McKusick Nathans In, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn,Dept Pediat,McKusick Nathans Inst, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu			National Institutes of Health [HHS-N268201000032C, P01-HL65608, U54-CA143868]; American Cancer Society; Japan Science and Technology Agency; NATIONAL CANCER INSTITUTE [U54CA143868] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	G.L.S. is the C. Michael Armstrong Professor at Johns Hopkins University School of Medicine and is supported by grants from the National Institutes of Health (HHS-N268201000032C, P01-HL65608, U54-CA143868), American Cancer Society, and Japan Science and Technology Agency. The author is grateful to Larissa Shimoda, Rena Feinman, Peter Campochiaro, Robert Cole, Chi Dang, Joseph Garcia, John Gearhart, Frank Gonzalez, Jun Liu, Mark Nicolls, Fan Pan, Akhilesh Pandey, Jon Resar, Mikhail Sitkovsky, Sara Sukumar, Denis Wirtz, John Harmon, Josef Prchal, and Nanduri Prabhakar for the opportunity to collaborate with them on studies that are described in this Review.	Beall CM, 2010, P NATL ACAD SCI USA, V107, P11459, DOI 10.1073/pnas.1002443107; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Bernhardt WM, 2009, P NATL ACAD SCI USA, V106, P21276, DOI 10.1073/pnas.0903978106; Bonnet S, 2006, CIRCULATION, V113, P2630, DOI 10.1161/CIRCULATIONAHA.105.609008; Bosch-Marce M, 2007, CIRC RES, V101, P1310, DOI 10.1161/CIRCRESAHA.107.153346; Botusan IR, 2008, P NATL ACAD SCI USA, V105, P19426, DOI 10.1073/pnas.0805230105; Brem H, 2007, EXP GERONTOL, V42, P523, DOI 10.1016/j.exger.2006.11.018; Brusselmans K, 2003, J CLIN INVEST, V111, P1519, DOI 10.1172/JCI200315496; Cai Z, 2008, CARDIOVASC RES, V77, P463, DOI 10.1093/cvr/cvm035; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Creager MA, 2011, CIRCULATION, V124, P1765, DOI 10.1161/CIRCULATIONAHA.110.009407; Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Dunwoodie SL, 2009, DEV CELL, V17, P755, DOI 10.1016/j.devcel.2009.11.008; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Eckle T, 2008, CIRCULATION, V118, P166, DOI 10.1161/CIRCULATIONAHA.107.758516; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Eubank TD, 2011, BLOOD, V117, P323, DOI 10.1182/blood-2010-01-261792; Feinman R, 2010, AM J PHYSIOL-GASTR L, V299, pG833, DOI 10.1152/ajpgi.00065.2010; Formenti F, 2010, P NATL ACAD SCI USA, V107, P12722, DOI 10.1073/pnas.1002339107; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hirota S.A., 2010, GASTROENTEROLOGY, V139, pe3; Hirota SA, 2010, GASTROENTEROLOGY, V139, P259, DOI 10.1053/j.gastro.2010.03.045; Hlatky MA, 2007, AM HEART J, V154, P1035, DOI 10.1016/j.ahj.2007.07.042; Huang LE, 2007, J MOL MED, V85, P139, DOI 10.1007/s00109-006-0133-6; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Jiang X, 2011, J CLIN INVEST, V121, P2336, DOI 10.1172/JCI46192; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lane N, 2010, NATURE, V467, P929, DOI 10.1038/nature09486; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Liu LX, 2008, J CELL PHYSIOL, V217, P319, DOI 10.1002/jcp.21503; Liu YV, 2007, J BIOL CHEM, V282, P37064, DOI 10.1074/jbc.M705015200; Loenarz C, 2011, EMBO REP, V12, P63, DOI 10.1038/embor.2010.170; Loinard C, 2009, CIRCULATION, V120, P50, DOI 10.1161/CIRCULATIONAHA.108.813303; Luckraz H, 2004, J HEART LUNG TRANSPL, V23, P527, DOI 10.1016/j.healun.2003.07.003; Lukashev D, 2007, CANCER METAST REV, V26, P273, DOI 10.1007/s10555-007-9054-2; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Mace KA, 2007, WOUND REPAIR REGEN, V15, P636, DOI 10.1111/j.1524-475X.2007.00278.x; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Mehta R, 2009, SCIENCE, V324, P1196, DOI 10.1126/science.1173507; Moeller BJ, 2007, CANCER METAST REV, V26, P241, DOI 10.1007/s10555-007-9056-0; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Nanduri J, 2009, P NATL ACAD SCI USA, V106, P1199, DOI 10.1073/pnas.0811018106; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Peng YJ, 2006, J PHYSIOL-LONDON, V577, P705, DOI 10.1113/jphysiol.2006.114033; Peng YJ, 2011, P NATL ACAD SCI USA, V108, P3065, DOI 10.1073/pnas.1100064108; Resar JR, 2005, CHEST, V128, P787, DOI 10.1378/chest.128.2.787; Rey S, 2011, BLOOD, V117, P4988, DOI 10.1182/blood-2010-11-321190; Rey S, 2009, P NATL ACAD SCI USA, V106, P20399, DOI 10.1073/pnas.0911921106; Sarkar K, 2012, CARDIOVASC RES, V93, P162, DOI 10.1093/cvr/cvr282; Sarkar K, 2009, P NATL ACAD SCI USA, V106, P18769, DOI 10.1073/pnas.0910561106; Schipani E, 2001, GENE DEV, V15, P2865; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Shimoda LA, 2011, AM J RESP CRIT CARE, V183, P152, DOI 10.1164/rccm.201009-1393PP; Simonson TS, 2010, SCIENCE, V329, P72, DOI 10.1126/science.1189406; Smith TG, 2006, PLOS MED, V3, P1178, DOI 10.1371/journal.pmed.0030290; Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010; Swietach P, 2007, CANCER METAST REV, V26, P299, DOI 10.1007/s10555-007-9064-0; Takeda N, 2010, GENE DEV, V24, P491, DOI 10.1101/gad.1881410; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Thangarajah H, 2009, P NATL ACAD SCI USA, V106, P13505, DOI 10.1073/pnas.0906670106; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wilkes DS, 2011, J CLIN INVEST, V121, P2155, DOI 10.1172/JCI58329; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Yi X, 2010, SCIENCE, V329, P75, DOI 10.1126/science.1190371; Yoon D, 2011, AM J PHYSIOL-CELL PH, V300, pC1215, DOI 10.1152/ajpcell.00044.2011; Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664; Yu AY, 1998, AM J PHYSIOL-LUNG C, V275, pL818, DOI 10.1152/ajplung.1998.275.4.L818; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912; Yuan GX, 2011, J CELL PHYSIOL, V226, P2925, DOI 10.1002/jcp.22640; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang XJ, 2011, J MOL MED, V89, P985, DOI 10.1007/s00109-011-0754-2; Zhang XJ, 2010, WOUND REPAIR REGEN, V18, P193, DOI 10.1111/j.1524-475X.2010.00570.x; Zinkernagel AS, 2007, J MOL MED, V85, P1339, DOI 10.1007/s00109-007-0282-2	102	1937	2032	34	474	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					399	408		10.1016/j.cell.2012.01.021	http://dx.doi.org/10.1016/j.cell.2012.01.021			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304911	Bronze, Green Accepted			2022-12-28	WOS:000300225000010
J	Cranford, SW; Tarakanova, A; Pugno, NM; Buehler, MJ				Cranford, Steven W.; Tarakanova, Anna; Pugno, Nicola M.; Buehler, Markus J.			Nonlinear material behaviour of spider silk yields robust webs	NATURE			English	Article							NATURALLY COMPLIANT STRUCTURES; MECHANICAL-PROPERTIES; DRAGLINE SILK; BIOMATERIAL; TOUGHNESS; STRENGTH; DESIGN; NANOSTRUCTURE; PERFORMANCE; ORIENTATION	Natural materials are renowned for exquisite designs that optimize function, as illustrated by the elasticity of blood vessels, the toughness of bone and the protection offered by nacre(1-5). Particularly intriguing are spider silks, with studies having explored properties ranging from their protein sequence(6) to the geometry of a web(7). This material system(8), highly adapted to meet a spider's many needs, has superior mechanical properties(9-15). In spite of much research into the molecular design underpinning the outstanding performance of silk fibres(1,6,10,13,16,17), and into the mechanical characteristics of web-like structures(18-21), it remains unknown how the mechanical characteristics of spider silk contribute to the integrity and performance of a spider web. Here we report web deformation experiments and simulations that identify the nonlinear response of silk threads to stress-involving softening at a yield point and substantial stiffening at large strain until failure-as being crucial to localize load-induced deformation and resulting in mechanically robust spider webs. Control simulations confirmed that a nonlinear stress response results in superior resistance to structural defects in the web compared to linear elastic or elastic-plastic (softening) material behaviour. We also show that under distributed loads, such as those exerted by wind, the stiff behaviour of silk under small deformation, before the yield point, is essential in maintaining the web's structural integrity. The superior performance of silk in webs is therefore not due merely to its exceptional ultimate strength and strain, but arises from the nonlinear response of silk threads to strain and their geometrical arrangement in a web.	[Cranford, Steven W.; Tarakanova, Anna; Buehler, Markus J.] MIT, Dept Civil & Environm Engn, LAMM, Cambridge, MA 02139 USA; [Cranford, Steven W.; Tarakanova, Anna; Buehler, Markus J.] MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; [Tarakanova, Anna] Cornell Univ, Dept Appl & Engn Phys, Ithaca, NY 14853 USA; [Pugno, Nicola M.] Politecn Torino, Dept Struct Engn & Geotech, Lab Bioinspired Nanomech Giuseppe Maria Pugno, I-10129 Turin, Italy; [Buehler, Markus J.] MIT, Ctr Computat Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Cornell University; Polytechnic University of Turin; Massachusetts Institute of Technology (MIT)	Buehler, MJ (corresponding author), MIT, Dept Civil & Environm Engn, LAMM, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	mbuehler@mit.edu	Cranford, Steve W./H-4260-2012; Buehler, Markus J./C-4580-2008; Pugno, Nicola/C-2289-2014	Buehler, Markus J./0000-0002-4173-9659; 	Office of Naval Research [N000141010562]; Army Research Office [W911NF-09-1-0541, W911NF-10-1-0127]; MIT-Italy (MITOR); Robert A. Brown Presidential Fellowship; METREGEN; European Research Council, under the European Union [279985]	Office of Naval Research(Office of Naval Research); Army Research Office; MIT-Italy (MITOR); Robert A. Brown Presidential Fellowship; METREGEN; European Research Council, under the European Union(European Research Council (ERC))	This work was supported primarily by the Office of Naval Research (N000141010562) with additional support from the National Science Foundation (MRSEC DMR-0819762, the NSF-REU programme, as well as CMMI-0642545) and the Army Research Office (W911NF-09-1-0541 and W911NF-10-1-0127). Support from the MIT-Italy programme (MITOR) and a Robert A. Brown Presidential Fellowship is gratefully acknowledged. N.M.P. is supported by the METREGEN grant (2009-2012) "Metrology on a cellular and macromolecular scale for regenerative medicine". An Ideas Starting Grant 2011 BIHSNAM on "Bio-inspired hierarchical super nanomaterials" was awarded to N.M.P. from the European Research Council, under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC grant (agreement number 279985). All simulations have been carried out at MIT's Laboratory for Atomistic and Molecular Mechanics (LAMM). We acknowledge assistance from S. and E. Buehler in taking photographs of the spider web.	Agnarsson I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011234; Aizenberg J, 2005, SCIENCE, V309, P275, DOI 10.1126/science.1112255; Alam MS, 2007, MECH MATER, V39, P145, DOI 10.1016/j.mechmat.2006.04.005; Alam MS, 2005, INT J DAMAGE MECH, V14, P365, DOI 10.1177/1056789505054313; Aoyanagi Y, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.038102; Buehler MJ, 2006, NATURE, V439, P307, DOI 10.1038/nature04408; Du N, 2006, BIOPHYS J, V91, P4528, DOI 10.1529/biophysj.106.089144; Foelix R., 2011, BIOL SPIDERS; Gao HJ, 2003, P NATL ACAD SCI USA, V100, P5597, DOI 10.1073/pnas.0631609100; Gosline JM, 1999, J EXP BIOL, V202, P3295; Kamat S, 2000, NATURE, V405, P1036, DOI 10.1038/35016535; Keten S, 2010, J R SOC INTERFACE, V7, P1709, DOI 10.1098/rsif.2010.0149; Keten S, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3385388; Keten S, 2010, NAT MATER, V9, P359, DOI [10.1038/nmat2704, 10.1038/NMAT2704]; Ko FK, 2004, BIOMACROMOLECULES, V5, P780, DOI 10.1021/bm0345099; Ko KK, 2002, MATER RES SOC SYMP P, V702, P17; Lefevre T, 2007, BIOPHYS J, V92, P2885, DOI 10.1529/biophysj.106.100339; Nova A, 2010, NANO LETT, V10, P2626, DOI 10.1021/nl101341w; Omenetto FG, 2010, SCIENCE, V329, P528, DOI 10.1126/science.1188936; Pugno NM, 2004, PHILOS MAG, V84, P2829, DOI 10.1080/14786430412331280382; Rammensee S, 2008, P NATL ACAD SCI USA, V105, P6590, DOI 10.1073/pnas.0709246105; Shao ZZ, 2002, NATURE, V418, P741, DOI 10.1038/418741a; Swanson BO, 2007, J EXP ZOOL PART A, V307A, P654, DOI 10.1002/jez.420; Swanson BO, 2009, INTEGR COMP BIOL, V49, P21, DOI 10.1093/icb/icp013; TERMONIA Y, 1994, MACROMOLECULES, V27, P7378, DOI 10.1021/ma00103a018; van Beek JD, 2002, P NATL ACAD SCI USA, V99, P10266, DOI 10.1073/pnas.152162299; Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013; Vollrath F, 1999, INT J BIOL MACROMOL, V24, P81, DOI 10.1016/S0141-8130(98)00076-2; VOLLRATH F, 1992, SCI AM, V266, P70, DOI 10.1038/scientificamerican0392-70; Vollrath F, 1996, P ROY SOC B-BIOL SCI, V263, P147, DOI 10.1098/rspb.1996.0023; VOLLRATH F, 1985, NATURWISSENSCHAFTEN, V72, P666, DOI 10.1007/BF00497445; Vollrath F, 2007, ANNU REV ECOL EVOL S, V38, P819, DOI 10.1146/annurev.ecolsys.37.091305.110221; Vollrath F, 2010, NATURE, V466, P319, DOI 10.1038/466319a	33	309	319	30	499	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					72	U91		10.1038/nature10739	http://dx.doi.org/10.1038/nature10739			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22297972	Green Accepted, Green Submitted			2022-12-28	WOS:000299726000037
J	Thaunat, O; Granja, AG; Barral, P; Filby, A; Montaner, B; Collinson, L; Martinez-Martin, N; Harwood, NE; Bruckbauer, A; Batista, FD				Thaunat, Olivier; Granja, Aitor G.; Barral, Patricia; Filby, Andrew; Montaner, Beatriz; Collinson, Lucy; Martinez-Martin, Nuria; Harwood, Naomi E.; Bruckbauer, Andreas; Batista, Facundo D.			Asymmetric Segregation of Polarized Antigen on B Cell Division Shapes Presentation Capacity	SCIENCE			English	Article							LYMPH-NODE; CLASS-II; SUBCAPSULAR SINUS; GERMINAL-CENTERS; DENDRITIC CELLS; LYMPHOCYTES; ENDOSOMES; COMPLEXES; SELECTION; REVEALS	During the activation of humoral immune responses, B cells acquire antigen for subsequent presentation to cognate T cells. Here we show that after mouse B cells accumulate antigen, it is maintained in a polarized distribution for extended periods in vivo. Using high-throughput imaging flow cytometry, we observed that this polarization is preserved during B cell division, promoting asymmetric antigen segregation among progeny. Antigen inheritance correlates with the ability of progeny to activate T cells: Daughter cells receiving larger antigen stores exhibit a prolonged capacity to present antigen, which renders them more effective in competing for T cell help. The generation of progeny with differential capacities for antigen presentation may have implications for somatic hypermutation and class switching during affinity maturation and as B cells commit to effector cell fates.	[Thaunat, Olivier; Granja, Aitor G.; Barral, Patricia; Montaner, Beatriz; Martinez-Martin, Nuria; Harwood, Naomi E.; Bruckbauer, Andreas; Batista, Facundo D.] Canc Res UK, Lymphocyte Interact Lab, London Res Inst, London WC2A 3LY, England; [Filby, Andrew] Canc Res UK, Flow Cytometry Lab, London Res Inst, London WC2A 3LY, England; [Collinson, Lucy] Canc Res UK, Electron Microscopy Lab, London Res Inst, London WC2A 3LY, England	Cancer Research UK; Cancer Research UK; Cancer Research UK	Batista, FD (corresponding author), Canc Res UK, Lymphocyte Interact Lab, London Res Inst, 44 Lincolns Inn Fields, London WC2A 3LY, England.	facundo.batista@cancer.org.uk	Granja, Aitor/K-8102-2014; Martinez-Martin, Nuria/A-9160-2017; Bruckbauer, Andreas/A-9598-2008; Thaunat, Olivier/M-2423-2014	Martinez-Martin, Nuria/0000-0003-2309-8920; Bruckbauer, Andreas/0000-0003-1419-9674; Montaner, Beatriz/0000-0001-9877-7317; Thaunat, Olivier/0000-0002-3648-8963; Barral, Patricia/0000-0003-4324-8973; Collinson, Lucy/0000-0003-0260-613X	Cancer Research UK; Royal Society; Societe Francaise de Transplantation; Societe Francaise de Nephrologie; Fondation pour la Recherche Medicale; Cancer Research UK [15691] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Royal Society(Royal Society of London); Societe Francaise de Transplantation; Societe Francaise de Nephrologie; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Cancer Research UK(Cancer Research UK)	We thank D. Davies, Biomedical Research Council, Guy's and St Thomas' National Health Service Foundation Trust, and King's College London for assistance with flow cytometry and H. Armer for technical assistance with electron microscopy. We also thank the members of the Lymphocyte Interaction Laboratory for critical reading of the manuscript. This work was funded by Cancer Research UK. F. D. B. also receives support from the Royal Society Wolfson Merit Award, and O.T. receives financial support from Societe Francaise de Transplantation, Societe Francaise de Nephrologie, and Fondation pour la Recherche Medicale. The authors declare that they have no competing financial interests.	Allen CDC, 2007, SCIENCE, V315, P528, DOI 10.1126/science.1136736; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Batista FD, 2000, EMBO J, V19, P513, DOI 10.1093/emboj/19.4.513; Batista FD, 1998, IMMUNITY, V8, P751, DOI 10.1016/S1074-7613(00)80580-4; Bergeland T, 2001, CURR BIOL, V11, P644, DOI 10.1016/S0960-9822(01)00177-4; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Carrasco YR, 2007, IMMUNITY, V27, P160, DOI 10.1016/j.immuni.2007.06.007; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Chaturvedi A, 2008, IMMUNITY, V28, P799, DOI 10.1016/j.immuni.2008.03.019; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; Hauser AE, 2007, IMMUNITY, V26, P655, DOI 10.1016/j.immuni.2007.04.008; Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Okada T, 2005, PLOS BIOL, V3, P1047, DOI 10.1371/journal.pbio.0030150; Phan TG, 2007, NAT IMMUNOL, V8, P992, DOI 10.1038/ni1494; Qi H, 2008, NATURE, V455, P764, DOI 10.1038/nature07345; Qi H, 2006, SCIENCE, V312, P1672, DOI 10.1126/science.1125703; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; Schwickert TA, 2007, NATURE, V446, P83, DOI 10.1038/nature05573; Siemasko K, 1998, J IMMUNOL, V160, P5203; Singhvi A, 2009, TRENDS CELL BIOL, V19, P1, DOI 10.1016/j.tcb.2008.10.004; Suzuki K, 2009, J EXP MED, V206, P1485, DOI 10.1084/jem.20090209; Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032; Zhong GM, 1997, P NATL ACAD SCI USA, V94, P13856, DOI 10.1073/pnas.94.25.13856	30	105	109	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					475	479		10.1126/science.1214100	http://dx.doi.org/10.1126/science.1214100			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282815				2022-12-28	WOS:000299466800053
J	Bolton, KL; Chenevix-Trench, G; Goh, C; Sadetzki, S; Ramus, SJ; Karlan, BY; Lambrechts, D; Despierre, E; Barrowdale, D; McGuffog, L; Healey, S; Easton, DF; Sinilnikova, O; Benitez, J; Garcia, MJ; Neuhausen, S; Gail, MH; Hartge, P; Peock, S; Frost, D; Evans, G; Eeles, R; Godwin, AK; Daly, MB; Kwong, A; Ma, ESK; Lazaro, C; Blanco, I; Montagna, M; D'Andrea, E; Nicoletto, MO; Johnatty, SE; Kruger, S; Jensen, A; Hogdall, E; Goode, EL; Fridley, BL; Loud, JT; Greene, MH; Mai, PL; Chetrit, A; Lubin, F; Hirsh-Yechezkel, G; Glendon, G; Andrulis, IL; Toland, AE; Senter, L; Gore, ME; Gourley, C; Michie, CO; Song, HL; Tyrer, J; Whittemore, AS; McGuire, V; Sieh, W; Kristoffersson, U; Olsson, H; Borg, A; Levine, DA; Steele, L; Beattie, MS; Chan, S; Nussbaum, RL; Moysich, KB; Gross, J; Cass, I; Walsh, C; Li, AJ; Leuchter, R; Gordon, O; Garcia-Closas, M; Gayther, SA; Chanock, SJ; Antoniou, AC; Pharoah, PDP				Bolton, Kelly L.; Chenevix-Trench, Georgia; Goh, Cindy; Sadetzki, Siegal; Ramus, Susan J.; Karlan, Beth Y.; Lambrechts, Diether; Despierre, Evelyn; Barrowdale, Daniel; McGuffog, Lesley; Healey, Sue; Easton, Douglas F.; Sinilnikova, Olga; Benitez, Javier; Garcia, Maria J.; Neuhausen, Susan; Gail, Mitchell H.; Hartge, Patricia; Peock, Susan; Frost, Debra; Evans, Gareth; Eeles, Rosalind; Godwin, Andrew K.; Daly, Mary B.; Kwong, Ava; Ma, Edmond S. K.; Lazaro, Conxi; Blanco, Ignacio; Montagna, Marco; D'Andrea, Emma; Nicoletto, Maria Ornella; Johnatty, Sharon E.; Krueger, Susanne; Jensen, Allan; Hogdall, Estrid; Goode, Ellen L.; Fridley, Brooke L.; Loud, Jennifer T.; Greene, Mark H.; Mai, Phuong L.; Chetrit, Angela; Lubin, Flora; Hirsh-Yechezkel, Galit; Glendon, Gord; Andrulis, Irene L.; Toland, Amanda E.; Senter, Leigha; Gore, Martin E.; Gourley, Charlie; Michie, Caroline O.; Song, Honglin; Tyrer, Jonathan; Whittemore, Alice S.; McGuire, Valerie; Sieh, Weiva; Kristoffersson, Ulf; Olsson, Hakan; Borg, Ake; Levine, Douglas A.; Steele, Linda; Beattie, Mary S.; Chan, Salina; Nussbaum, Robert L.; Moysich, Kirsten B.; Gross, Jenny; Cass, Ilana; Walsh, Christine; Li, Andrew J.; Leuchter, Ronald; Gordon, Ora; Garcia-Closas, Montserrat; Gayther, Simon A.; Chanock, Stephen J.; Antoniou, Antonis C.; Pharoah, Paul D. P.		EMBRACE; KConFab Investigators; Canc Genome Atlas Res Network	Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; PROGESTERONE-RECEPTOR; LOW-GRADE; NONSENSE; RISK; CARCINOMAS; POLYMERASE; CONSORTIUM; PATHOLOGY; FEATURES	Context Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2-related EOC was associated with an improved prognosis, but the effect of BRCA1 remains unclear. Objective To characterize the survival of BRCA carriers with EOC compared with noncarriers and to determine whether BRCA1 and BRCA2 carriers show similar survival patterns. Design, Setting, and Participants A pooled analysis of 26 observational studies on the survival of women with ovarian cancer, which included data from 1213 EOC cases with pathogenic germline mutations in BRCA1 (n=909) or BRCA2 (n=304) and from 2666 noncarriers recruited and followed up at variable times between 1987 and 2010 (the median year of diagnosis was 1998). Main Outcome Measure Five-year overall mortality. Results The 5-year overall survival was 36% (95% CI, 34%-38%) for noncarriers, 44% (95% CI, 40%-48%) for BRCA1 carriers, and 52% (95% CI, 46%-58%) for BRCA2 carriers. After adjusting for study and year of diagnosis, BRCA1 and BRCA2 mutation carriers showed a more favorable survival than noncarriers (for BRCA1: hazard ratio [HR], 0.78; 95% CI, 0.68-0.89; P<.001; and for BRCA2: HR, 0.61; 95% CI, 0.50-0.76; P<.001). These survival differences remained after additional adjustment for stage, grade, histology, and age at diagnosis (for BRCA1: HR, 0.73; 95% CI, 0.64-0.84; P<.001; and for BRCA2: HR, 0.49; 95% CI, 0.39-0.61; P<.001). The BRCA1 HR estimate was significantly different from the HR estimated in the adjusted model (P for heterogeneity=.003). Conclusion Among patients with invasive EOC, having a germline mutation in BRCA1 or BRCA2 was associated with improved 5-year overall survival. BRCA2 carriers had the best prognosis. JAMA. 2012;307(4):382-390	[Song, Honglin; Tyrer, Jonathan; Pharoah, Paul D. P.] Univ Cambridge, Strangeways Res Lab, Dept Oncol, Canc Res United Kingdom, Cambridge CB1 8RN, England; [Song, Honglin; Tyrer, Jonathan; Pharoah, Paul D. P.] Univ Cambridge, Strangeways Res Lab, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England; [Bolton, Kelly L.; Gail, Mitchell H.; Hartge, Patricia; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Bolton, Kelly L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Chenevix-Trench, Georgia; Healey, Sue; Johnatty, Sharon E.] Univ Queensland, Royal Brisbane Hosp, Queensland Inst Med Res, Herston, Qld, Australia; [Goh, Cindy] Addenbrookes Hosp, Cambridge, England; [Sadetzki, Siegal; Chetrit, Angela; Lubin, Flora; Hirsh-Yechezkel, Galit] Chaim Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Tel Hashomer, Israel; [Sadetzki, Siegal] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Ramus, Susan J.; Gayther, Simon A.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Karlan, Beth Y.; Gross, Jenny; Cass, Ilana; Walsh, Christine; Li, Andrew J.; Leuchter, Ronald; Gordon, Ora] Cedars Sinai Med Ctr, Womens Canc Program, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Lambrechts, Diether] Univ Leuven, VIB Vesalius Res Ctr, Louvain, Belgium; [Despierre, Evelyn] Univ Leuven, Univ Hosp Leuven, Dept Obstet & Gynaecol, Louvain, Belgium; [Barrowdale, Daniel; McGuffog, Lesley; Easton, Douglas F.; Peock, Susan; Frost, Debra; Antoniou, Antonis C.] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Cambridge, England; [Sinilnikova, Olga] Hosp Civils Lyon, Ctr Leon Berard, Unit Genet Predisposit Common Canc, Lyon, France; [Sinilnikova, Olga] Univ Lyon 1, INSERM, CNRS, Canc Res Ctr Lyon,U0152,UMR5286, F-69365 Lyon, France; [Garcia, Maria J.] Human Genet Grp, Madrid, Spain; [Benitez, Javier] Spanish Natl Canc Res Ctr, Human Canc Genet Program, Madrid, Spain; [Benitez, Javier] Spanish Natl Canc Res Ctr, Genotyping Unit, Madrid, Spain; [Benitez, Javier; Garcia, Maria J.] CIBERER, Madrid, Spain; [Neuhausen, Susan; Steele, Linda] Beckman Res Inst City Hope, Dept Populat Sci, Duarte, CA USA; [Evans, Gareth] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, England; [Eeles, Rosalind] Inst Canc Res, Oncogenet Team, Sutton, Surrey, England; [Eeles, Rosalind] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England; [Godwin, Andrew K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, MO USA; [Daly, Mary B.] Fox Chase Canc Ctr, Dept Clin Genet, Philadelphia, PA 19111 USA; [Kwong, Ava; Ma, Edmond S. K.] Hong Kong Sanat & Hosp, Canc Genet Ctr, Hong Kong Hereditary Breast Canc Family Registry, Hong Kong, Hong Kong, Peoples R China; [Ma, Edmond S. K.] Hong Kong Sanat & Hosp, Div Mol Pathol, Hong Kong, Hong Kong, Peoples R China; [Kwong, Ava] Univ Hong Kong, Queen Mary Hosp, Div Breast Surg, Hong Kong, Hong Kong, Peoples R China; [Lazaro, Conxi; Blanco, Ignacio] LHospitalet, Catalan Inst Oncol, Hereditary Canc Program, Barcelona, Spain; [Montagna, Marco] Ist Oncol Veneto IRCCS, Immunol & Mol Oncol Unit, Padua, Italy; [Nicoletto, Maria Ornella] Ist Oncol Veneto IRCCS, Med Oncol Unit 1, Padua, Italy; [D'Andrea, Emma] Ist Oncol Veneto IOV IRCCS, Dept Oncol & Surg Sci, Padua, Italy; [Krueger, Susanne; Jensen, Allan; Hogdall, Estrid] Univ Copenhagen, Rigshosp, Dept Virus Hormones & Canc, Danish Canc Soc, DK-2100 Copenhagen, Denmark; [Krueger, Susanne; Jensen, Allan; Hogdall, Estrid] Univ Copenhagen, Rigshosp, Dept Gynecol, DK-2100 Copenhagen, Denmark; [Goode, Ellen L.; Fridley, Brooke L.] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA; [Loud, Jennifer T.; Greene, Mark H.; Mai, Phuong L.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA; [Glendon, Gord; Andrulis, Irene L.] Canc Care Ontario, Ontario Canc Genet Network, Toronto, ON, Canada; [Andrulis, Irene L.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Toland, Amanda E.] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med & Mol Virol, Columbus, OH 43210 USA; [Toland, Amanda E.] Ohio State Univ, Comprehens Canc Ctr, Dept Immunol, Columbus, OH 43210 USA; [Toland, Amanda E.] Ohio State Univ, Comprehens Canc Ctr, Dept Med Genet, Columbus, OH 43210 USA; [Senter, Leigha] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Clin Canc Genet Program, Columbus, OH 43210 USA; [Gore, Martin E.] Royal Marsden Hosp, Gynecol Oncol Unit, London SW3 6JJ, England; [Gourley, Charlie; Michie, Caroline O.] Univ Edinburgh, Canc Res Ctr, Inst Genet & Mol Med, Western Gen Hosp, Edinburgh, Midlothian, Scotland; [Whittemore, Alice S.; McGuire, Valerie; Sieh, Weiva] Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA; [Olsson, Hakan; Borg, Ake] Lund Univ, Dept Oncol, Lund, Sweden; [Kristoffersson, Ulf] Univ & Reg Lab Skane, Dept Clin Genet, Lund, Sweden; [Levine, Douglas A.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; [Beattie, Mary S.; Chan, Salina; Nussbaum, Robert L.] Univ Calif San Francisco, Canc Risk Program, San Francisco, CA 94143 USA; [Beattie, Mary S.; Nussbaum, Robert L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Moysich, Kirsten B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA; [Garcia-Closas, Montserrat] Breakthrough Breast Canc Res Ctr, London, England; [Garcia-Closas, Montserrat] Inst Canc Res, Epidemiol Sect, London SW3 6JB, England; [Garcia-Closas, Montserrat] Inst Canc Res, Genet Sect, London SW3 6JB, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; University of Southern California; Cedars Sinai Medical Center; Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; University Hospital Leuven; University of Cambridge; CHU Lyon; UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; City of Hope; Beckman Research Institute of City of Hope; University of Manchester; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of Kansas; Fox Chase Cancer Center; University of Hong Kong; Catalan Institute of Oncology; IRCCS Istituto Oncologico Veneto (IOV); IRCCS Istituto Oncologico Veneto (IOV); IRCCS Istituto Oncologico Veneto (IOV); Danish Cancer Society; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Care Ontario; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Royal Marsden NHS Foundation Trust; University of Edinburgh; Stanford University; Lund University; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Roswell Park Cancer Institute; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Pharoah, PDP (corresponding author), Univ Cambridge, Strangeways Res Lab, Dept Oncol, Canc Res United Kingdom, Worts Causeway, Cambridge CB1 8RN, England.	paul.pharoah@srl.cam.ac.uk	montagna, marco/E-2225-2012; Kwong, Ava/D-8005-2013; Blanco, Ignacio/AAN-5426-2021; Saunders, Christobel M/H-5779-2014; Ramus, Susan/AAG-8352-2019; Garcia-Closas, Montserrat/F-3871-2015; D'Andrea, Emma/B-4374-2013; Whittemore, Alice S/F-9925-2014; GARCIA, CONXI LAZARO/Q-2410-2016; García, María J/G-1361-2016; Andrulis, Irene L./E-7267-2013; Verdrengh, Evelien/H-4571-2012; Fridley, Brooke L/D-8315-2015; Lester, Jenny/B-5933-2012; Pharoah, Paul/V-6658-2019; Toland, Amanda Ewart/E-4202-2011; Blanco, Ignacio/D-2565-2013; Chenevix-Trench, Georgia/AAV-2014-2020; Evans, D Gareth/AAB-4308-2022; Lambrechts, Diether/AAJ-3167-2020; Ma, Shiu Kwan Edmond/AAZ-7637-2021; Garcia-Closas, Montserrat/AAZ-6930-2021; Johnatty, Sharon E/R-8890-2016	montagna, marco/0000-0002-4929-2150; Kwong, Ava/0000-0002-6968-9489; Blanco, Ignacio/0000-0002-7414-7481; Saunders, Christobel M/0000-0003-2281-9829; Ramus, Susan/0000-0003-0005-7798; Garcia-Closas, Montserrat/0000-0003-1033-2650; GARCIA, CONXI LAZARO/0000-0002-7198-5906; García, María J/0000-0002-2236-9912; Fridley, Brooke L/0000-0001-7739-7956; Pharoah, Paul/0000-0001-8494-732X; Blanco, Ignacio/0000-0002-7414-7481; Chenevix-Trench, Georgia/0000-0002-1878-2587; Evans, D Gareth/0000-0002-8482-5784; Lambrechts, Diether/0000-0002-3429-302X; Ma, Shiu Kwan Edmond/0000-0002-1259-2205; Garcia-Closas, Montserrat/0000-0003-1033-2650; Johnatty, Sharon E/0000-0002-7888-1966; Hogdall, Estrid/0000-0003-4689-5658; Jensen, Allan/0000-0001-8124-4880; Thorne, Heather/0000-0003-3610-2511; Olsson, Hakan/0000-0002-8794-9635; Bolton, Kelly/0000-0001-6584-3357; Barrowdale, Daniel/0000-0003-1661-3939; Levine, Douglas/0000-0003-1038-8232; Kjaer, Susanne/0000-0002-8347-1398; Eeles, Rosalind/0000-0002-3698-6241	TetraLogic; Pfizer; Merck; Millennium; Roche; Schering-Plough; Merck Sharpe Dohme; Chugia; GlaxoSmithKline; PharmaMar; AstraZeneca; Cyclacel; Complete Genomics Inc.; Cancer Research UK [C490/A10119, C490/A10124, C1287/A10118, C1287/A11990, C5047/A8385]; Edinburgh Experimental Cancer Medicine Center [223175, HEALTH-F2-2009-223175]; European Community; Fondo de Investigacion Sanitaria [PS09/01094, PI081120]; Fundacion Mutua Madrilena [AP-8101-2010]; National Cancer Institute; DCEG from the Melville Trust for the Care and Cure of Cancer; National Institutes of Health; Nationaal Kankerplan-Actie 29' of Belgium; NHMRC of Australia; National Breast Cancer Foundation of Australia; Cancer Australia [628333]; Queensland Cancer Fund; Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia; Cancer Foundation of Western Australia; Scottish Funding Council; Scottish Chief Scientist's Office; Manchester NIHR Biomedical Research Center; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Mermaid 1 project; Danish Cancer Society; Ministero dell'Istruzione, dell'Universita e della Ricerca; Ministero della Salute [RFPS 2006-5-341353, ACC2/R6.9]; Israeli Cancer Association; Helen Diller Family Comprehensive Cancer Center at University of California San Francisco; Avon Foundation; Hong Kong Hereditary Breast Cancer Family Registry; Dr Ellen Li Charitable Foundation; National Cancer Institute [NO2-CP-11019-50, N02-CP-65504]; Westat, Inc, Rockville, MD; Asociacion Espanola Contra el Cancer; Carlos III Health Institute; Catalan Health Institute [ISCIIIRETIC RD06/0020/1051, PI10/01422, PI10/31488, 2009SGR290]; Autonomous Government of Catalonia; American Cancer Society [SIOP-06-258-06-COUN]; Instituto de Salud Carlos III;  [CA 74415];  [CA 61126-03];  [R01-CA 61107];  [R01-CA 122443];  [P50 CA 136393];  [P01 CA 130818];  [2P50 CA 058207]; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP011019] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA061107, K07CA143047, P50CA058207, R01CA122443, P01CA130818, R01CA061126, R01CA074415, P50CA136393] Funding Source: NIH RePORTER; Cancer Research UK [10118, 11174, 11022, 15007] Funding Source: researchfish; Chief Scientist Office [SCD/11] Funding Source: researchfish; The Francis Crick Institute [10119, 10124] Funding Source: researchfish	TetraLogic; Pfizer(Pfizer); Merck(Merck & Company); Millennium(Takeda Pharmaceutical Company Ltd); Roche(Roche Holding); Schering-Plough(Merck & CompanySchering Plough Corporation); Merck Sharpe Dohme(Merck & Company); Chugia; GlaxoSmithKline(GlaxoSmithKline); PharmaMar; AstraZeneca(AstraZeneca); Cyclacel(Cyclacel Pharmaceuticals Inc.); Complete Genomics Inc.; Cancer Research UK(Cancer Research UK); Edinburgh Experimental Cancer Medicine Center; European Community(European Commission); Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DCEG from the Melville Trust for the Care and Cure of Cancer; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nationaal Kankerplan-Actie 29' of Belgium; NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation of Australia; Cancer Australia; Queensland Cancer Fund; Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia(Cancer Council New South Wales); Cancer Foundation of Western Australia(Cancer Council Western Australia); Scottish Funding Council; Scottish Chief Scientist's Office; Manchester NIHR Biomedical Research Center; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Mermaid 1 project; Danish Cancer Society(Danish Cancer Society); Ministero dell'Istruzione, dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Ministero della Salute(Ministry of Health, Italy); Israeli Cancer Association; Helen Diller Family Comprehensive Cancer Center at University of California San Francisco; Avon Foundation; Hong Kong Hereditary Breast Cancer Family Registry; Dr Ellen Li Charitable Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Westat, Inc, Rockville, MD; Asociacion Espanola Contra el Cancer; Carlos III Health Institute(Instituto de Salud Carlos III); Catalan Health Institute; Autonomous Government of Catalonia(Generalitat de Catalunya); American Cancer Society(American Cancer Society); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); ; ; ; ; ; ; ; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK); Chief Scientist Office; The Francis Crick Institute	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Easton reported serving on the board of Genome Canada SIAC. Dr Godwin reported receiving consultancy fees from TetraLogic and Pfizer and grants from Merck, TetraLogic, and Millennium. Dr Gourley reported receiving consultancy fees from Roche, Schering-Plough, Merck Sharpe Dohme, Chugia, GlaxoSmithKline, and PharmaMar; receiving grants from AstraZeneca, GlaxoSmithKline, and Cyclacel; serving as a board member for Roche, Schering-Plough, and Chugai; receiving payment for lectures and educational presentations from Chugai and Merck Sharpe Dohme; and receiving compensation for travel expenses from Schering-Plough, Chugai, PharmaMar, Roche, and Boehringer Ingelheim. Dr Olsson reported receiving payment for lectures from NovoNordisk. Dr Nussbaum reported serving on the board and receiving consultancy fees and stock from Complete Genomics Inc. No other authors reported any disclosures.; This work was supported by grants C490/A10119, C490/A10124, C1287/A10118, C1287/A11990, C5047/A8385 from Cancer Research UK; grants 223175, HEALTH-F2-2009-223175 from the Edinburgh Experimental Cancer Medicine Center, the European Community's Seventh Framework Program; grants PS09/01094 and PI081120 from the Fondo de Investigacion Sanitaria; grant AP-8101-2010 from the Fundacion Mutua Madrilena; grants CA 74415, CA 61126-03, R01-CA 61107, R01-CA 122443, P50 CA 136393, P01 CA 130818, 2P50 CA 058207, and the Intramural Research Program of the National Cancer Institute, DCEG from the Melville Trust for the Care and Cure of Cancer, National Institutes of Health; the Nationaal Kankerplan-Actie 29' of Belgium; the NHMRC of Australia; the National Breast Cancer Foundation of Australia, Cancer Australia (628333); the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia; the Cancer Foundation of Western Australia; the Scottish Funding Council; the Scottish Chief Scientist's Office; the Manchester NIHR Biomedical Research Center; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Mermaid 1 project; the Danish Cancer Society; Ministero dell'Istruzione, dell'Universita e della Ricerca and Ministero della Salute ("Progetto Tumori Femminili" and RFPS 2006-5-341353, ACC2/R6.9"); the Israeli Cancer Association; the Helen Diller Family Comprehensive Cancer Center at University of California San Francisco; the Avon Foundation; The Hong Kong Hereditary Breast Cancer Family Registry and the Dr Ellen Li Charitable Foundation; and service grants NO2-CP-11019-50 and N02-CP-65504 (with Westat, Inc, Rockville, MD) through the National Cancer Institute; Asociacion Espanola Contra el Cancer, Spanish Health Research Fund; Carlos III Health Institute; and grants ISCIIIRETIC RD06/0020/1051, PI10/01422, PI10/31488, and 2009SGR290 from the Catalan Health Institute and Autonomous Government of Catalonia. Dr Karlan is supported by funding (grant SIOP-06-258-06-COUN) from the American Cancer Society, Clinical Research Professorship. Dr Garcia is the recipient of a Miguel Servet contract from the Instituto de Salud Carlos III. Dr Antoniou is a Cancer Research UK Senior Cancer Research Fellow.	Antoniou AC, 2007, AM J HUM GENET, V81, P1186, DOI 10.1086/522611; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Boyd J, 2000, JAMA-J AM MED ASSOC, V283, P2260, DOI 10.1001/jama.283.17.2260; Brookmeyer R, 2005, ENCY BIOSTATISTICS; Buisson M, 2006, HUM MUTAT, V27, P1024, DOI 10.1002/humu.20384; Buller RE, 2002, CLIN CANCER RES, V8, P1196; Cass I, 2003, CANCER, V97, P2187, DOI 10.1002/cncr.11310; Chenevix-Trench G, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1670; Chetrit A, 2008, J CLIN ONCOL, V26, P20, DOI 10.1200/JCO.2007.11.6905; Chiang JW, 2006, GYNECOL ONCOL, V101, P403, DOI 10.1016/j.ygyno.2005.10.034; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Foulkes WD, 2006, FAM CANCER, V5, P135, DOI 10.1007/s10689-005-2832-5; Gourley C, 2010, J CLIN ONCOL, V28, P2505, DOI 10.1200/JCO.2009.25.1082; Hennessy BTJ, 2010, J CLIN ONCOL, V28, P3570, DOI 10.1200/JCO.2009.27.2997; Keiding N, 2005, ENCY BIOSTATISTICS; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Lakhani SR, 2004, CLIN CANCER RES, V10, P2473, DOI 10.1158/1078-0432.CCR-1029-3; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Mazoyer S, 1998, AM J HUM GENET, V62, P713, DOI 10.1086/301768; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Moslehi R, 2000, AM J HUM GENET, V66, P1259, DOI 10.1086/302853; O'Donovan PJ, 2010, CARCINOGENESIS, V31, P961, DOI 10.1093/carcin/bgq069; Pal T, 2005, CANCER-AM CANCER SOC, V104, P2807, DOI 10.1002/cncr.21536; Pearce CL, 2008, BRIT J CANCER, V98, P282, DOI 10.1038/sj.bjc.6604170; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Pharoah PDP, 1999, CANCER RES, V59, P868; Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Soegaard M, 2008, CLIN CANCER RES, V14, P3761, DOI 10.1158/1078-0432.CCR-07-4806; Szabo C, 2000, HUM MUTAT, V16, P123, DOI 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y; Tan DSP, 2008, J CLIN ONCOL, V26, P5530, DOI 10.1200/JCO.2008.16.1703; Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456; Zhang SY, 2011, GYNECOL ONCOL, V121, P353, DOI 10.1016/j.ygyno.2011.01.020	37	421	435	3	56	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2012	307	4					382	390		10.1001/jama.2012.20	http://dx.doi.org/10.1001/jama.2012.20			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EP	22274685	Green Accepted, Bronze			2022-12-28	WOS:000299464000024
J	Jolly, K; Ingram, L; Khan, KS; Deeks, JJ; Freemantle, N; MacArthur, C				Jolly, Kate; Ingram, Lucy; Khan, Khalid S.; Deeks, Jonathan J.; Freemantle, Nick; MacArthur, Christine			Systematic review of peer support for breastfeeding continuation: metaregression analysis of the effect of setting, intensity, and timing	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; LOW-INCOME; COUNSELORS; PROMOTION; DURATION; INTERVENTION; BANGLADESH; EFFICACY; INFANTS; MOTHERS	Objective To examine the effect of setting, intensity, and timing of peer support on breast feeding. Design Systematic review and metaregression analysis of randomised controlled trials. Data sources Cochrane Library, Medline, CINAHL, the National Research Register, and British Nursing Index were searched from inception or from 1980 to 2011. Review methods Study selection, data abstraction, and quality assessment were carried out independently and in duplicate. Risk ratios and 95% confidence intervals were calculated for individual studies and pooled. Effects were estimated for studies grouped according to setting (high income countries, low or middle income countries, and the United Kingdom), intensity (<5 and >= 5 planned contacts), and timing of peer support (postnatal period with or without antenatal care), and analysed using metaregression for any and exclusive breast feeding at last study follow-up. Results Peer support interventions had a significantly greater effect on any breast feeding in low or middle income countries (P<0.001), reducing the risk of not breast feeding at all by 30% (relative risk 0.70, 95% confidence interval 0.60 to 0.82) compared with a reduction of 7% (0.93, 0.87 to 1.00) in high income countries. Similarly, the risk of non-exclusive breast feeding decreased significantly more in low or middle income countries than in high income countries: 37% (0.63, 0.52 to 0.78) compared with 10% (0.90, 0.85 to 0.97); P=0.01. No significant effect on breast feeding was observed in UK based studies. Peer support had a greater effect on any breastfeeding rates when given at higher intensity (P=0.02) and only delivered in the postnatal period (P<0.001), although no differences were observed of its effect on exclusive breastfeeding rates by intensity or timing. Conclusion Although peer support interventions increase breastfeeding continuation in low or middle income countries, especially exclusive breast feeding, this does not seem to apply in high income countries, particularly the United Kingdom, where breastfeeding support is part of routine postnatal healthcare. Peer support of low intensity does not seem to be effective. Policy relating to provision of peer support should be based on more specific evidence on setting and any new peer services in high income countries need to undergo concurrent evaluation.	[Jolly, Kate; Ingram, Lucy; Deeks, Jonathan J.; MacArthur, Christine] Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Birmingham B15 2TT, W Midlands, England; [Khan, Khalid S.] Barts & London Queen Marys Sch Med & Dent, London, England; [Freemantle, Nick] UCL, Dept Primary Care & Populat Hlth, London, England	University of Birmingham; University of London; Queen Mary University London; University of London; University College London	Jolly, K (corresponding author), Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Birmingham B15 2TT, W Midlands, England.	C.B.Jolly@bham.ac.uk	Deeks, Jon/AAV-5745-2020; MacArthur, Christine/ABA-8601-2021; Khan, Khalid S/AAT-8824-2020; Jolly, Kate/AAA-1341-2019	Deeks, Jon/0000-0002-8850-1971; MacArthur, Christine/0000-0003-0434-2158; Khan, Khalid S/0000-0001-5084-7312; Jolly, Kate/0000-0002-6224-2115; Freemantle, Nick/0000-0001-5807-5740	National Institute for Health Research	National Institute for Health Research(National Institute for Health Research (NIHR))	KJ, CM, and LI are part funded by the National Institute for Health Research through the Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme. The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health Research, the Department of Health, University of Birmingham, University College London, or the CLAHRC-BBC steering group.	Agrasada GV, 2005, ACTA PAEDIATR, V94, P1109, DOI 10.1080/08035250510025752; Anderson AK, 2005, ARCH PEDIAT ADOL MED, V159, P836, DOI 10.1001/archpedi.159.9.836; Arifeen S, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e67; Arifeen SE, 2009, LANCET, V374, P393, DOI 10.1016/S0140-6736(09)60828-X; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Bick DE, 1998, MIDWIFERY, V14, P242, DOI 10.1016/S0266-6138(98)90096-1; Bolling K, 2007, INFANT FEEDING SURVE; Britton C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001141.pub3; Chapman DJ, 2004, ARCH PEDIAT ADOL MED, V158, P897, DOI 10.1001/archpedi.158.9.897; Coutinho SB, 2005, LANCET, V366, P1094, DOI 10.1016/S0140-6736(05)67421-1; Deeks J, 2006, COCHRANE HDB SYSTEMA; Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188; Dennis CL, 2003, INT J NURS STUD, V40, P321, DOI 10.1016/S0020-7489(02)00092-5; Dennis CL, 2002, CAN MED ASSOC J, V166, P21; Di Meglio G, 2010, BREASTFEED MED, V5, P41, DOI 10.1089/bfm.2009.0016; Graffy J, 2004, BRIT MED J, V328, P26, DOI 10.1136/bmj.328.7430.26; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hoddinott P, 2011, MATERN CHILD NUTR, V7, P221, DOI 10.1111/j.1740-8709.2011.00336.x; Hopkinson J, 2009, J HUM LACT, V25, P287, DOI 10.1177/0890334409335482; Jakobsen MS, 1999, ACTA PAEDIATR, V88, P741, DOI 10.1080/08035259950169026; Jolly K, 2011, MIDWIFERY; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Leite AJM, 2005, ACTA PAEDIATR, V94, P741, DOI 10.1080/08035250410023854; Lewin S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004015.pub3; McInnes RJ, 2000, J PUBLIC HEALTH MED, V22, P138, DOI 10.1093/pubmed/22.2.138; Merewood A, 2006, ARCH PEDIAT ADOL MED, V160, P681, DOI 10.1001/archpedi.160.7.681; MONGEON M, 1995, CAN J PUBLIC HEALTH, V86, P124; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; Muirhead PE, 2006, BRIT J GEN PRACT, V56, P191; NIfHaC, 2009, IMPR HLTH NUTR PREG; The World Bank, 2011, COUNTR LEND GROUPS; Tylleskar T, 2011, LANCET, V378, P420, DOI 10.1016/S0140-6736(11)60738-1; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; Watt RG, 2009, J EPIDEMIOL COMMUN H, V63, P156, DOI 10.1136/jech.2008.077115; World Health Organization, 2001, OPT DUR EXCL BREASTF; World Health Organization, 2001, INF YOUNG CHILDR FEE; World Health Organization, 1991, INN DECL PROT PROM S	40	98	103	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	2012	344								d8287	10.1136/bmj.d8287	http://dx.doi.org/10.1136/bmj.d8287			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KV	22277543	hybrid, Green Accepted, Green Submitted			2022-12-28	WOS:000299778800011
J	Lisse, CM				Lisse, Carey M.			The Final Flight of a Sun-Diving Comet	SCIENCE			English	Editorial Material									Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA	Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Lisse, CM (corresponding author), Johns Hopkins Univ, Appl Phys Lab, Johns Hopkins Rd, Laurel, MD 20723 USA.	carey.lisse@jhuapl.edu	Lisse, Carey M/B-7772-2016	Lisse, Carey M/0000-0002-9548-1526				Knight MM, 2010, ASTRON J, V139, P926, DOI 10.1088/0004-6256/139/3/926; Lisse C. M., 2010, B AM ASTRON SOC, V42, P965; MARSDEN BG, 1989, ASTRON J, V98, P2306, DOI 10.1086/115301; Reach WT, 2009, ICARUS, V203, P571, DOI 10.1016/j.icarus.2009.05.027; Schrijver CJ, 2012, SCIENCE, V335, P324, DOI 10.1126/science.1211688; Sekanina Z, 2004, ASTROPHYS J, V607, P620, DOI 10.1086/383466; Wada K, 2009, ASTROPHYS J, V702, P1490, DOI 10.1088/0004-637X/702/2/1490; Weaver H. A., 2006, BAAS, V38, P490; Weaver HA, 2001, SCIENCE, V292, P1329, DOI 10.1126/science.1058606; Zsom A, 2010, ASTRON ASTROPHYS, V513, DOI 10.1051/0004-6361/200912976	10	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2012	335	6066					296	297		10.1126/science.1217168	http://dx.doi.org/10.1126/science.1217168			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267801				2022-12-28	WOS:000299273400034
J	Feng, S; Ekong, UD; Lobritto, SJ; Demetris, AJ; Roberts, JP; Rosenthal, P; Alonso, EM; Philogene, MC; Ikle, D; Poole, KM; Bridges, ND; Turka, LA; Tchao, NK				Feng, Sandy; Ekong, Udeme D.; Lobritto, Steven J.; Demetris, Anthony J.; Roberts, John P.; Rosenthal, Philip; Alonso, Estella M.; Philogene, Mary C.; Ikle, David; Poole, Katharine M.; Bridges, Nancy D.; Turka, Laurence A.; Tchao, Nadia K.			Complete Immunosuppression Withdrawal and Subsequent Allograft Function Among Pediatric Recipients of Parental Living Donor Liver Transplants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORGAN-TRANSPLANTATION; OPERATIONAL TOLERANCE; REJECTION; ANTIBODY; CELL; CHIMERISM	Context Although life-saving, liver transplantation burdens children with lifelong immunosuppression and substantial potential for morbidity and mortality. Objective To establish the feasibility of immunosuppression withdrawal in pediatric living donor liver transplant recipients. Design, Setting, and Patients Prospective, multicenter, open-label, single-group pilot trial conducted in 20 stable pediatric recipients (11 male; 55%) of parental living donor liver transplants for diseases other than viral hepatitis or an autoimmune disease who underwent immunosuppression withdrawal. Their median age was 6.9 months (interquartile range [IQR], 5.5-9.1 months) at transplant and 8 years 6 months (IQR, 6 years 5 months to 10 years 9 months) at study enrollment. Additional entry requirements included stable allograft function while taking a single immunosuppressive drug and no evidence of acute or chronic rejection or significant fibrosis on liver biopsy. Gradual immunosuppression withdrawal over a minimum of 36 weeks was instituted at 1 of 3 transplant centers between June 5, 2006, and November 18, 2009. Recipients were followed up for a median of 32.9 months (IQR, 1.0-49.9 months). Main Outcome Measures The primary end point was the proportion of operationally tolerant patients, defined as patients who remained off immunosuppression therapy for at least 1 year with normal graft function. Secondary clinical end points included the durability of operational tolerance, and the incidence, timing, severity, and reversibility of rejection. Results Of 20 pediatric patients, 12 (60%; 95% CI, 36.1%-80.9%) met the primary end point, maintaining normal allograft function for a median of 35.7 months (IQR, 28.1-39.7 months) after discontinuing immunosuppression therapy. Follow-up biopsies obtained more than 2 years after completing withdrawal showed no significant change compared with baseline biopsies. Eight patients did not meet the primary end point secondary to an exclusion criteria violation (n=1), acute rejection (n=2), or indeterminate rejection (n=5). Seven patients were treated with increased or reinitiation of immunosuppression therapy; all returned to baseline allograft function. Patients with operational tolerance compared with patients without operational tolerance initiated immunosuppression withdrawal later after transplantation (median of 100.6 months [IQR, 71.8-123.5] vs 73.0 months [IQR, 57.6-74.9], respectively; P=.03), had less portal inflammation (91.7% [95% CI, 61.5%-99.8%] vs 42.9% [95% CI, 9.9%-81.6%] with no inflammation; P=.04), and had lower total C4d scores on the screening liver biopsy (median of 6.1 [IQR, 5.1-9.3] vs 12.5 [IQR, 9.3-16.8]; P=.03). Conclusion In this pilot study, 60% of pediatric recipients of parental living donor liver transplants remained off immunosuppression therapy for at least 1 year with normal graft function and stable allograft histology. JAMA. 2012;307(3):283-293	[Feng, Sandy; Roberts, John P.; Rosenthal, Philip] Univ Calif San Francisco, Dept Surg, Div Transplantat, San Francisco, CA 94113 USA; [Rosenthal, Philip] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94113 USA; [Tchao, Nadia K.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94113 USA; [Ekong, Udeme D.; Alonso, Estella M.] Childrens Mem Hosp, Dept Pediat, Chicago, IL 60614 USA; [Ekong, Udeme D.; Alonso, Estella M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Lobritto, Steven J.] Columbia Univ, Dept Pediat, Morgan Stanley Childrens Hosp, Med Ctr, New York, NY 10027 USA; [Lobritto, Steven J.] Columbia Univ, Dept Surg, Morgan Stanley Childrens Hosp, Med Ctr, New York, NY 10027 USA; [Demetris, Anthony J.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Philogene, Mary C.; Turka, Laurence A.; Tchao, Nadia K.] Immune Tolerance Network, Bethesda, MD USA; [Turka, Laurence A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA; [Ikle, David; Poole, Katharine M.] Rho, Chapel Hill, NC USA; [Bridges, Nancy D.] NIAID, Div Allergy Immunol & Transplantat, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Columbia University; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; Columbia University; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Immune Tolerance Network; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Rho; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Feng, S (corresponding author), Univ Calif San Francisco, Dept Surg, Div Transplantat, 505 Parnasus Ave,POB 0780, San Francisco, CA 94113 USA.	sandy.feng@ucsfmedctr.org	Ekong, Udeme D./Y-1473-2019; Ikle, David/AAK-7541-2020	Ekong, Udeme D./0000-0002-3312-112X; Ikle, David/0000-0003-0091-5246	Novartis/DCL Laboratory; Bristol-Myers Squibb; National Institutes of Health/National Center for Research Resources [UL1 RR024131]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER	Novartis/DCL Laboratory; Bristol-Myers Squibb(Bristol-Myers Squibb); National Institutes of Health/National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Demetris reported that he has received fees as a consultant for pathology services related to clinical trials of immunosuppression drugs in adult de novo liver transplant recipients from Novartis/DCL Laboratory and Bristol-Myers Squibb; and is a co-inventor of Omnyx Digital Pathology Solution, a joint venture between the University of Pittsburgh Medical Center and General Electric to create a complete digital pathology solution. Dr Turka reported that he owns stock in and has a family member employed by Novartis. No other disclosures were reported.; The Immune Tolerance Network, an international clinical research consortium founded by the National Institutes of Health, funded the study. This study also was supported by grant UL1 RR024131 from the National Institutes of Health/National Center for Research Resources awarded to the University of California, San Francisco, Clinical & Translational Science Institute.	Assy N, 2007, TRANSPLANTATION, V83, P1571, DOI 10.1097/01.tp.0000266678.32250.76; Bellamy COC, 2007, HISTOPATHOLOGY, V50, P739, DOI 10.1111/j.1365-2559.2007.02677.x; BRAY RA, 1989, TRANSPLANTATION, V48, P834, DOI 10.1097/00007890-198911000-00022; Colvin RB, 2010, AM J TRANSPLANT, V10, P1509, DOI 10.1111/j.1600-6143.2010.03172.x; Del Compare ME, 2004, PEDIATR TRANSPLANT, V8, P496, DOI 10.1111/j.1399-3046.2004.00192.x; Demetris A, 2000, Hepatology, V31, P792; Demetris AJ, 2009, TRANSPL INT, V22, P120, DOI 10.1111/j.1432-2277.2008.00765.x; Devlin J, 1998, HEPATOLOGY, V27, P926, DOI 10.1002/hep.510270406; Eason JD, 2005, TRANSPLANTATION, V79, P1157, DOI 10.1097/01.TP.0000162084.46555.10; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fredericks EM, 2007, AM J TRANSPLANT, V7, P1974, DOI 10.1111/j.1600-6143.2007.01878.x; Isse K, 2012, AM J TRANSPLANT, V12, P27, DOI 10.1111/j.1600-6143.2011.03797.x; Koshiba T, 2007, TRANSPL IMMUNOL, V17, P94, DOI 10.1016/j.trim.2006.10.004; Long E, 2009, TRANSPLANTATION, V88, P1050, DOI 10.1097/TP.0b013e3181bb7913; Marteius T, 2009, TRANSPL IMMUNOL, V21, P244, DOI 10.1016/j.trim.2009.06.004; Martinez-Llordella M, 2007, AM J TRANSPLANT, V7, P309, DOI 10.1111/j.1600-6143.2006.01621.x; Mazariegos GV, 2007, TRANSPL IMMUNOL, V17, P114, DOI 10.1016/j.trim.2006.09.033; Mazariegos GV, 1997, TRANSPLANTATION, V63, P243, DOI 10.1097/00007890-199701270-00012; Pons JA, 2003, TRANSPLANTATION, V75, P1045, DOI 10.1097/01.TP.0000058472.71775.7D; RAMOS HC, 1995, TRANSPLANTATION, V59, P212, DOI 10.1097/00007890-199501270-00010; SANDBORN WJ, 1994, HEPATOLOGY, V19, P925; STARZL TE, 1993, HEPATOLOGY, V17, P1127; Takatsuki M, 2001, TRANSPLANTATION, V72, P449, DOI 10.1097/00007890-200108150-00016; Tisone G, 2006, J HEPATOL, V44, P702, DOI 10.1016/j.jhep.2005.11.047; Traum AZ, 2008, PEDIATRICS, V121, P1258, DOI 10.1542/peds.2008-0783; Troxell ML, 2006, ARCH PATHOL LAB MED, V130, P1489; Tryphonopoulos P, 2005, AM J TRANSPLANT, V5, P608, DOI 10.1111/j.1600-6143.2004.00743.x; Vaidya S, 2008, TRANSPLANTATION, V85, P1046, DOI 10.1097/TP.0b013e318168fdb5; Wong T, 1998, HEPATOLOGY, V28, P443, DOI 10.1002/hep.510280223; 1997, HEPATOLOGY, V25, P658	30	241	257	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2012	307	3					283	293		10.1001/jama.2011.2014	http://dx.doi.org/10.1001/jama.2011.2014			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877EY	22253395	Bronze			2022-12-28	WOS:000299161200024
J	Saklayen, MG				Saklayen, Mohammad G.			The RenalGuard system reduced kidney injury more than a control system in high-risk patients	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									VA Med Ctr, Dayton, OH USA; Wright State Univ, Dayton, OH USA	Wright State University Dayton	Saklayen, MG (corresponding author), VA Med Ctr, Dayton, OH USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-9	10.7326/0003-4819-156-2-201201170-02009	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31YU	22250171				2022-12-28	WOS:000208919700010
J	Smith, R; Lunt, N; Hanefeld, J				Smith, Richard; Lunt, Neil; Hanefeld, Johanna			The implications of PIP are more than just cosmetic	LANCET			English	Editorial Material							TOURISM		[Smith, Richard] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London WC1H 9SH, England; [Lunt, Neil] Univ York, Dept Social Policy & Social Work, York YO10 5DD, N Yorkshire, England; [Hanefeld, Johanna] Univ Edinburgh, Sch Social & Polit Sci, Edinburgh, Midlothian, Scotland	University of London; London School of Hygiene & Tropical Medicine; University of York - UK; University of Edinburgh	Smith, R (corresponding author), London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London WC1H 9SH, England.	richard.smith@lshtm.ac.uk		Smith, Richard/0000-0003-3837-6559				Cox S, 2012, BBC NEWS HLTH   0120; Department of Health, 2012, DEP HLTH STAT BREAST; Horton R, 2012, LANCET, V379, P204, DOI 10.1016/S0140-6736(12)60070-1; Lunt Neil, 2010, Open Med Inform J, V4, P1, DOI 10.2174/1874431101004010001; McKelvey A, 2009, BJOG-INT J OBSTET GY, V116, P1520, DOI 10.1111/j.1471-0528.2009.02294.x; Miyagi K, 2012, J PLAST RECONSTR AES, V65, P22, DOI 10.1016/j.bjps.2011.07.027; Office for National Statistics, 2011, INT PASS SURV 2011; Smith R, 2011, HEALTH POLICY, V103, P276, DOI 10.1016/j.healthpol.2011.06.009; Smith RD, 2009, LANCET, V373, P768, DOI 10.1016/S0140-6736(08)61780-8; UK National Health Service (NHS), 2012, PIP BREAST IMPL LAT; WHO, GLOB AL RESP SIL IMP	11	12	12	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 31	2012	379	9822					1180	1181		10.1016/S0140-6736(12)60166-4	http://dx.doi.org/10.1016/S0140-6736(12)60166-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	918DV	22305764				2022-12-28	WOS:000302230400012
J	Matsushita, H; Vesely, MD; Koboldt, DC; Rickert, CG; Uppaluri, R; Magrini, VJ; Arthur, CD; White, JM; Chen, YS; Shea, LK; Hundal, J; Wendl, MC; Demeter, R; Wylie, T; Allison, JP; Smyth, MJ; Old, LJ; Mardis, ER; Schreiber, RD				Matsushita, Hirokazu; Vesely, Matthew D.; Koboldt, Daniel C.; Rickert, Charles G.; Uppaluri, Ravindra; Magrini, Vincent J.; Arthur, Cora D.; White, J. Michael; Chen, Yee-Shiuan; Shea, Lauren K.; Hundal, Jasreet; Wendl, Michael C.; Demeter, Ryan; Wylie, Todd; Allison, James P.; Smyth, Mark J.; Old, Lloyd J.; Mardis, Elaine R.; Schreiber, Robert D.			Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting	NATURE			English	Article							ADAPTIVE IMMUNITY; TUMOR ESCAPE; IFN-GAMMA; GENOME; BREAST; GENE; RESOLUTION; MUTATIONS; RESPONSES; MELANOMA	Cancer immunoediting, the process by which the immune system controls tumour outgrowth and shapes tumour immunogenicity, is comprised of three phases: elimination, equilibrium and escape(1-5). Although many immune components that participate in this process are known, its underlying mechanisms remain poorly defined. A central tenet of cancer immunoediting is that T-cell recognition of tumour antigens drives the immunological destruction or sculpting of a developing cancer. However, our current understanding of tumour antigens comes largely from analyses of cancers that develop in immunocompetent hosts and thus may have already been edited. Little is known about the antigens expressed in nascent tumour cells, whether they are sufficient to induce protective antitumour immune responses or whether their expression is modulated by the immune system. Here, using massively parallel sequencing, we characterize expressed mutations in highly immunogenic methylcholanthrene-induced sarcomas derived from immunodeficient Rag2(-/-) mice that phenotypically resemble nascent primary tumour cells(1,3,5). Using class I prediction algorithms, we identify mutant spectrin-beta 2 as a potential rejection antigen of the d42m1 sarcoma and validate this prediction by conventional antigen expression cloning and detection. We also demonstrate that cancer immunoediting of d42m1 occurs via a T-cell-dependent immunoselection process that promotes outgrowth of pre-existing tumour cell clones lacking highly antigenic mutant spectrin-beta 2 and other potential strong antigens. These results demonstrate that the strong immunogenicity of an unedited tumour can be ascribed to expression of highly antigenic mutant proteins and show that outgrowth of tumour cells that lack these strong antigens via a T-cell-dependent immunoselection process represents one mechanism of cancer immunoediting.	[Matsushita, Hirokazu; Vesely, Matthew D.; Rickert, Charles G.; Arthur, Cora D.; White, J. Michael; Chen, Yee-Shiuan; Shea, Lauren K.; Schreiber, Robert D.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA; [Koboldt, Daniel C.; Magrini, Vincent J.; Hundal, Jasreet; Wendl, Michael C.; Demeter, Ryan; Wylie, Todd; Mardis, Elaine R.] Washington Univ, Sch Med, Genome Inst, St Louis, MO 63110 USA; [Uppaluri, Ravindra] Washington Univ, Sch Med, Dept Otolaryngol, St Louis, MO 63110 USA; [Magrini, Vincent J.; Wendl, Michael C.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Allison, James P.] Mem Sloan Kettering Canc Ctr, Dept Immunol, Ludwig Ctr Canc Immunotherapy, New York, NY 10021 USA; [Allison, James P.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; [Smyth, Mark J.] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia; [Smyth, Mark J.] Univ Melbourne, Dept Pathol, Parkville, Vic 2010, Australia; [Old, Lloyd J.] Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York Branch, New York, NY 10021 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center	Schreiber, RD (corresponding author), Washington Univ, Dept Pathol & Immunol, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	schreiber@immunology.wustl.edu	Schreiber, Robert/Q-7550-2019; Wendl, Michael C/A-2741-2008; uppaluri, ravi/AAU-2132-2020; Schreiber, Robert D/A-1276-2013; Magrini, Vincent/AAT-5830-2020; Mardis, Elaine/W-2202-2019; Smyth, Mark J/H-8709-2014; Vesely, Matthew/AFM-2324-2022; Vesely, Matthew/AAM-6813-2020	Schreiber, Robert D/0000-0001-6311-0432; Magrini, Vincent/0000-0002-2019-4872; Smyth, Mark J/0000-0001-7098-7240; Vesely, Matthew/0000-0001-9363-945X; Schreiber, Robert/0000-0003-1590-2341; White, James Michael/0000-0001-5110-6567; Allison, James/0000-0001-8980-5697	National Cancer Institute; Ludwig Institute for Cancer Research; Cancer Research Institute; WWWW Foundation; National Human Genome Research Institute; Howard Hughes Medical Institute; Ludwig Center for Cancer Immunotherapy; National Health and Medical Research Council of Australia (NHMRC); Association for International Cancer Research; NATIONAL CANCER INSTITUTE [U01CA141541, R01CA043059] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ludwig Institute for Cancer Research; Cancer Research Institute; WWWW Foundation; National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Ludwig Center for Cancer Immunotherapy; National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Association for International Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to J. Archambault for expert technical assistance, T. H. Hansen (Washington University) for providing MHC class I antibodies, S. Horvath and P. M. Allen (Washington University) for synthesizing MHC class I peptides, the National Institutes of Health (NIH) Tetramer Core Facility for producing MHC class I tetramers, and T. S. Stappenbeck (Washington University) for technical help in recovering frozen tumour samples. We also thank E. Unanue, P. M. Allen and J. Bui for criticisms and comments, all members of the Schreiber laboratory for discussions, and the many members of The Genome Institute at Washington University School of Medicine, especially L. Ding for her insights into our analytical approaches. This work was supported by grants to R. D. S. from the National Cancer Institute, the Ludwig Institute for Cancer Research, the Cancer Research Institute, and the WWWW Foundation; and to E. R. M. from the National Human Genome Research Institute. M. D. V. is supported by a pre-doctoral fellowship from the Cancer Research Institute. J. P. A. is supported by the Howard Hughes Medical Institute and the Ludwig Center for Cancer Immunotherapy; M. J. S. by the National Health and Medical Research Council of Australia (NH&MRC) and from the Association for International Cancer Research; and L.J.O. by the Ludwig Institute for Cancer Research and the Cancer Research Institute.	Boon T, 2006, ANNU REV IMMUNOL, V24, P175, DOI 10.1146/annurev.immunol.24.021605.090733; CHEN AC, 1989, P NATL ACAD SCI USA, V86, P1608, DOI 10.1073/pnas.86.5.1608; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; FELSENSTEIN, 1989, CLADISTICS, V5, P164; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Koboldt DC, 2009, BIOINFORMATICS, V25, P2283, DOI 10.1093/bioinformatics/btp373; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; OLD LJ, 1964, ANNU REV MED, V15, P167, DOI 10.1146/annurev.me.15.020164.001123; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; PREHN RT, 1957, J NATL CANCER I, V18, P769; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Ranganath S, 1998, J IMMUNOL, V161, P3822; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Segal NH, 2008, CANCER RES, V68, P889, DOI 10.1158/0008-5472.CAN-07-3095; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Totoki Y, 2011, NAT GENET, V43, P464, DOI 10.1038/ng.804; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Yewdell JW, 2006, IMMUNITY, V25, P533, DOI 10.1016/j.immuni.2006.09.005	36	834	883	4	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2012	482	7385					400	U149		10.1038/nature10755	http://dx.doi.org/10.1038/nature10755			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	892LG	22318521	Green Accepted			2022-12-28	WOS:000300287100046
J	McNally, BA; Somasundaram, A; Yamashita, M; Prakriya, M				McNally, Beth A.; Somasundaram, Agila; Yamashita, Megumi; Prakriya, Murali			Gated regulation of CRAC channel ion selectivity by STIM1	NATURE			English	Article							CA2+-DEPENDENT INACTIVATION; ORAI1; PORE; PERMEATION; SUBUNIT	Two defining functional features of ion channels are ion selectivity and channel gating. Ion selectivity is generally considered an immutable property of the open channel structure, whereas gating involves transitions between open and closed channel states, typically without changes in ion selectivity(1). In store-operated Ca2+ release-activated Ca2+ (CRAC) channels, the molecular mechanism of channel gating by the CRAC channel activator, stromal interaction molecule 1 (STIM1), remains unknown. CRAC channels are distinguished by a very high Ca2+ selectivity and are instrumental in generating sustained intracellular calcium concentration elevations that are necessary for gene expression and effector function in many eukaryotic cells(2). Here we probe the central features of the STIM1 gating mechanism in the human CRAC channel protein, ORAI1, and identify V102, a residue located in the extracellular region of the pore, as a candidate for the channel gate. Mutations at V102 produce constitutively active CRAC channels that are open even in the absence of STIM1. Unexpectedly, although STIM1-free V102 mutant channels are not Ca2+-selective, their Ca2+ selectivity is dose-dependently boosted by interactions with STIM1. Similar enhancement of Ca2+ selectivity is also seen in wild-type ORAI1 channels by increasing the number of STIM1 activation domains that are directly tethered to ORAI1 channels, or by increasing the relative expression of full-length STIM1. Thus, exquisite Ca2+ selectivity is not an intrinsic property of CRAC channels but rather a tuneable feature that is bestowed on otherwise non-selective ORAI1 channels by STIM1. Our results demonstrate that STIM1-mediated gating of CRAC channels occurs through an unusual mechanism in which permeation and gating are closely coupled.	[McNally, Beth A.; Somasundaram, Agila; Yamashita, Megumi; Prakriya, Murali] Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Sch Med, Chicago, IL 60611 USA	Northwestern University	Prakriya, M (corresponding author), Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Sch Med, 303 E Chicago Ave,Ward 8-296, Chicago, IL 60611 USA.	m-prakriya@northwestern.edu		Prakriya, Murali/0000-0003-0781-4480; Yamashita, Megumi/0000-0003-0196-0428	NIH [NS057499]; American Heart Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS057499, R01NS057499] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank C. Lingle, R. Lewis, K. Swartz, J. Sack, A. Gross, L. Tirado-Lee and T. Hornell for discussions and comments on the manuscript. This work was supported by NIH grant NS057499 to M. P. An American Heart Association predoctoral fellowship supported A.S.	Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Derler I, 2009, J BIOL CHEM, V284, P24933, DOI 10.1074/jbc.C109.024083; Doyle DA, 2004, TRENDS NEUROSCI, V27, P298, DOI 10.1016/j.tins.2004.04.004; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Hogan PG, 2010, ANNU REV IMMUNOL, V28, P491, DOI 10.1146/annurev.immunol.021908.132550; Hoover PJ, 2011, P NATL ACAD SCI USA, V108, P13299, DOI 10.1073/pnas.1101664108; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Li ZZ, 2011, CELL RES, V21, P305, DOI 10.1038/cr.2010.131; Madl J, 2010, J BIOL CHEM, V285, P41135, DOI 10.1074/jbc.M110.177881; McNally BA, 2009, P NATL ACAD SCI USA, V106, P22516, DOI 10.1073/pnas.0909574106; Mignen O, 2008, J PHYSIOL-LONDON, V586, P419, DOI 10.1113/jphysiol.2007.147249; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Mullins FM, 2009, P NATL ACAD SCI USA, V106, P15495, DOI 10.1073/pnas.0906781106; Navarro-Borelly L, 2008, J PHYSIOL-LONDON, V586, P5383, DOI 10.1113/jphysiol.2008.162503; Olcese R, 2007, J GEN PHYSIOL, V129, P457, DOI 10.1085/jgp.200709814; Peinelt C, 2008, J PHYSIOL-LONDON, V586, P3061, DOI 10.1113/jphysiol.2008.151365; Penna A, 2008, NATURE, V456, P116, DOI 10.1038/nature07338; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Prakriya M, 2006, J GEN PHYSIOL, V128, P373, DOI 10.1085/jgp.200609588; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P4538, DOI 10.1021/bi00412a047; Schindl R, 2008, J BIOL CHEM, V283, P20261, DOI 10.1074/jbc.M803101200; Scrimgeour N, 2009, J PHYSIOL-LONDON, V587, P2903, DOI 10.1113/jphysiol.2009.170662; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Yamashita M, 2007, J GEN PHYSIOL, V130, P525, DOI 10.1085/jgp.200709872; Yamashita M, 2011, J BIOL CHEM, V286, P9429, DOI 10.1074/jbc.M110.189035; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SYL, 2008, J BIOL CHEM, V283, P17662, DOI 10.1074/jbc.M801536200; Zhou YB, 2010, P NATL ACAD SCI USA, V107, P4896, DOI 10.1073/pnas.1001169107	30	171	173	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					241	U136		10.1038/nature10752	http://dx.doi.org/10.1038/nature10752			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22278058	Green Accepted			2022-12-28	WOS:000299994100043
J	Stone, JH; Zen, Y; Deshpande, V				Stone, John H.; Zen, Yoh; Deshpande, Vikram			MECHANISMS OF DISEASE IgG4-Related Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							REGULATORY T-CELLS; SERUM IGG4 LEVELS; AUTOIMMUNE PANCREATITIS; SYSTEMIC-DISEASE; IMMUNOGLOBULIN G4; MIKULICZS-DISEASE; TUBULOINTERSTITIAL NEPHRITIS; MULTIFOCAL FIBROSCLEROSIS; RETROPERITONEAL FIBROSIS; MEMBRANOUS NEPHROPATHY		[Stone, John H.] Massachusetts Gen Hosp, Rheumatol Unit, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Stone, John H.; Deshpande, Vikram] Harvard Univ, Sch Med, Boston, MA USA; [Zen, Yoh] Kings Coll Hosp London, Inst Liver Studies, London, England	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Stone, JH (corresponding author), Massachusetts Gen Hosp, Rheumatol Unit, Dept Med, Div Rheumatol Allergy & Immunol, 55 Fruit St,Yawkey 2C, Boston, MA 02114 USA.	jhstone@partners.org	Kumar, Shaji K/A-9853-2008	Kumar, Shaji K/0000-0001-5392-9284				Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Akahane C, 2002, INTERNAL MED, V41, P749, DOI 10.2169/internalmedicine.41.749; Akitake R, 2010, GUT, V59, P542, DOI 10.1136/gut.2009.200972; [Anonymous], REPORTS GRANT INTRAC; Aparisi L, 2005, GUT, V54, P703, DOI 10.1136/gut.2004.047142; Asada M, 2006, PANCREAS, V33, P20, DOI 10.1097/01.mpa.0000226881.48204.fd; AUCOUTURIER P, 1984, J IMMUNOL METHODS, V74, P151, DOI 10.1016/0022-1759(84)90376-4; Beck LH, 2010, KIDNEY INT, V77, P765, DOI 10.1038/ki.2010.34; Bjornsson E, 2008, CURR OPIN GASTROEN, V24, P389, DOI 10.1097/MOG.0b013e3282f6a7c5; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Chang MC, 2007, CLIN CHEM, V53, P1700, DOI 10.1373/clinchem.2007.085951; Chari ST, 2007, J GASTROENTEROL, V42, P39, DOI 10.1007/s00535-007-2046-8; Chari ST, 2010, PANCREAS, V39, P549, DOI 10.1097/MPA.0b013e3181e4d9e5; Cheuk W, 2008, AM J SURG PATHOL, V32, P671, DOI 10.1097/PAS.0b013e318157c068; COMINGS DE, 1967, ANN INTERN MED, V66, P884, DOI 10.7326/0003-4819-66-5-884; Cornell LD, 2007, AM J SURG PATHOL, V31, P1586, DOI 10.1097/PAS.0b013e318059b87c; Dahlgren M, 2010, ARTHRIT CARE RES, V62, P1312, DOI 10.1002/acr.20215; Debiec H, 2011, NEW ENGL J MED, V365, P477; Debiec H, 2011, NEW ENGL J MED, V364, P2101, DOI 10.1056/NEJMoa1013792; deBoer BA, 1997, INFECT IMMUN, V65, P1122, DOI 10.1128/IAI.65.3.1122-1125.1997; Deshpande V, 2006, AM J SURG PATHOL, V30, P1537, DOI 10.1097/01.pas.0000213331.09864.2c; Deshpande V, 2011, AM J SURG PATHOL, V35, P26, DOI 10.1097/PAS.0b013e3182027717; Detlefsen S, 2008, AM J SURG PATHOL, V32, P986, DOI 10.1097/PAS.0b013e31815d2583; Detlefsen S, 2010, HISTOPATHOLOGY, V57, P825, DOI 10.1111/j.1365-2559.2010.03717.x; Dhall D, 2010, HUM PATHOL, V41, P643, DOI 10.1016/j.humpath.2009.10.019; Ferrari S, 2009, J THROMB HAEMOST, V7, P1703, DOI 10.1111/j.1538-7836.2009.03568.x; Frulloni L, 2009, NEW ENGL J MED, V361, P2135, DOI 10.1056/NEJMoa0903068; Ghazale A, 2008, GASTROENTEROLOGY, V134, P706, DOI 10.1053/j.gastro.2007.12.009; Ghazale A, 2007, AM J GASTROENTEROL, V102, P1646, DOI 10.1111/j.1572-0241.2007.01264.x; Guarneri F, 2005, J CELL MOL MED, V9, P741, DOI 10.1111/j.1582-4934.2005.tb00506.x; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Inoue D, 2011, RADIOLOGY, V261, P625, DOI 10.1148/radiol.11102250; Kamisawa T, 2003, J GASTROENTEROL, V38, P982, DOI 10.1007/s00535-003-1175-y; Kamisawa T, 2009, GUT, V58, P1504, DOI 10.1136/gut.2008.172908; Kamisawa T, 2006, J GASTROENTEROL, V41, P613, DOI 10.1007/s00535-006-1862-6; Kamisawa T, 2010, NAT REV GASTRO HEPAT, V7, P401, DOI 10.1038/nrgastro.2010.81; Kamisawa T, 2010, J GASTROENTEROL, V45, P471, DOI 10.1007/s00535-010-0221-9; Kamisawa T, 2009, EUR J GASTROEN HEPAT, V21, P1136, DOI 10.1097/MEG.0b013e3283297417; Kanari H, 2010, INT ARCH ALLERGY IMM, V152, P47, DOI 10.1159/000312125; Kasashima S, 2008, AM J SURG PATHOL, V32, P197, DOI 10.1097/PAS.0b013e3181342f0d; Kawa S, 2002, GASTROENTEROLOGY, V122, P1264, DOI 10.1053/gast.2002.33022; Kawa S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001637; Kawa S, 2010, J GASTROENTEROL, V45, P355, DOI 10.1007/s00535-009-0197-5; Khosroshahi A, 2012, MEDICINE, V91, P57, DOI 10.1097/MD.0b013e3182431ef6; Khosroshahi A, 2011, CURR OPIN RHEUMATOL, V23, P72, DOI 10.1097/BOR.0b013e328341a229; Khosroshahi A, 2010, ARTHRITIS RHEUM-US, V62, P1755, DOI 10.1002/art.27435; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Kudo-Tanaka E, 2009, MOD RHEUMATOL, V19, P691, DOI 10.1007/s10165-009-0214-9; Levy MJ, 2006, ENDOSCOPY, V38, pS30, DOI 10.1055/s-2006-946648; Lohr JM, 2010, AM J GASTROENTEROL, V105, P2060, DOI 10.1038/ajg.2010.141; Miyake K, 2008, MOD RHEUMATOL, V18, P86, DOI 10.1007/s10165-007-0010-3; Miyoshi H, 2008, PANCREAS, V36, P133, DOI 10.1097/MPA.0b013e3181577553; Nirula A, 2011, CURR OPIN RHEUMATOL, V23, P119, DOI 10.1097/BOR.0b013e3283412fd4; Nishimori I, 2007, J GASTROENTEROL, V42, P6, DOI 10.1007/s00535-007-2043-y; Nishino T, 2006, INTERNAL MED, V45, P497, DOI 10.2169/internalmedicine.45.1565; Pace C, 2010, J ORAL MAXIL SURG, V68, P2591, DOI 10.1016/j.joms.2009.07.073; Park DH, 2008, GASTROENTEROLOGY, V134, P440, DOI 10.1053/j.gastro.2007.11.023; Raina A, 2009, AM J GASTROENTEROL, V104, P2295, DOI 10.1038/ajg.2009.325; Raissian Y, 2011, J AM SOC NEPHROL, V22, P1343, DOI 10.1681/ASN.2011010062; Rispens T, 2011, J AM CHEM SOC, V133, P10302, DOI 10.1021/ja203638y; Rispens T, 2009, J IMMUNOL, V182, P4275, DOI 10.4049/jimmunol.0804338; ROCK B, 1989, NEW ENGL J MED, V320, P1463, DOI 10.1056/NEJM198906013202206; Saeki T, 2006, INTERNAL MED, V45, P163, DOI 10.2169/internalmedicine.45.1431; Sah RP, 2011, CURR OPIN RHEUMATOL, V23, P108, DOI 10.1097/BOR.0b013e3283413469; Sah RP, 2010, CLIN GASTROENTEROL H, V8, P91, DOI 10.1016/j.cgh.2009.09.024; Sahani DV, 2004, RADIOLOGY, V233, P345, DOI 10.1148/radiol.2332031436; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Sato Y, 2010, J CLIN PATHOL, V63, P1084, DOI 10.1136/jcp.2010.082958; Schuurman J, 2001, MOL IMMUNOL, V38, P1, DOI 10.1016/S0161-5890(01)00050-5; Shimosegawa T, 2009, J GASTROENTEROL, V44, P503, DOI 10.1007/s00535-009-0054-6; Stone JH, 2010, ARTHRIT CARE RES, V62, P316, DOI 10.1002/acr.20095; Stone JH, 2009, ARTHRITIS RHEUM-US, V60, P3139, DOI 10.1002/art.24798; Strehl JD, 2011, J CLIN PATHOL, V64, P237, DOI 10.1136/jcp.2010.085613; Takahashi N, 2007, RADIOLOGY, V242, P791, DOI 10.1148/radiol.2423060003; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; Tsubata Y, 2010, INTERNAL MED, V49, P1593, DOI 10.2169/internalmedicine.49.3787; Umemura T, 2006, GUT, V55, P1367, DOI 10.1136/gut.2006.095059; Umemura T, 2008, AM J GASTROENTEROL, V103, P588, DOI 10.1111/j.1572-0241.2007.01750.x; Umemura T, 2007, HEPATOLOGY, V46, P463, DOI 10.1002/hep.21700; Warren SJP, 2003, J INVEST DERMATOL, V120, P104, DOI 10.1046/j.1523-1747.2003.12017.x; Wood N, 2004, CELL IMMUNOL, V231, P133, DOI 10.1016/j.cellimm.2005.01.001; Yadav D, 2003, CLIN GASTROENTEROL H, V1, P129, DOI 10.1053/cgh.2003.50016; Yamamoto M, 2005, RHEUMATOLOGY, V44, P227, DOI 10.1093/rheumatology/keh447; Yamamoto M, 2010, RHEUMATOL INT, V30, P565, DOI 10.1007/s00296-009-1030-4; Zen Y, 2007, HEPATOLOGY, V45, P1538, DOI 10.1002/hep.21697; Zen Y, 2010, AM J SURG PATHOL, V34, P1812, DOI 10.1097/PAS.0b013e3181f7266b; Zen Y, 2009, AM J SURG PATHOL, V33, P1886, DOI 10.1097/PAS.0b013e3181bd535b; Zen Y, 2009, AM J SURG PATHOL, V33, P1833, DOI 10.1097/PAS.0b013e3181b72882	89	1699	1817	7	171	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					539	551		10.1056/NEJMra1104650	http://dx.doi.org/10.1056/NEJMra1104650			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GH	22316447				2022-12-28	WOS:000299991300010
J	Ferner, R				Ferner, Robin			DRUG TALES AND OTHER STORIES Interactions	BRITISH MEDICAL JOURNAL			English	Editorial Material									Birmingham City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England		Ferner, R (corresponding author), Birmingham City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	R.E.Ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				2003, ARCH INTERN MED, V163, P2625; 2009, AM J MED, V122, P290, DOI DOI 10.1016/J.AMJMED.2008.09.038	2	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 8	2012	344								e865	10.1136/bmj.e865	http://dx.doi.org/10.1136/bmj.e865			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	892IE	22318440				2022-12-28	WOS:000300279100008
J	Qaseem, A; Humphrey, LL; Sweet, DE; Starkey, M; Shekelle, P				Qaseem, Amir; Humphrey, Linda L.; Sweet, Donna E.; Starkey, Melissa; Shekelle, Paul		Clinical Guidelines Comm Amer Coll	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							DIPEPTIDYL PEPTIDASE-4 INHIBITOR; FIXED-DOSE COMBINATION; RANDOMIZED CONTROLLED-TRIAL; IMPROVED GLYCEMIC CONTROL; SULFONYLUREA PLUS METFORMIN; CONGESTIVE-HEART-FAILURE; ALL-CAUSE MORTALITY; DOUBLE-BLIND; RETROSPECTIVE COHORT; INSULIN SENSITIVITY	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medications. Methods: This guideline is based on a systematic evidence review evaluating literature published on this topic from 1966 through April 2010 that was identified by using MEDLINE (updated through December 2010), EMBASE, and the Cochrane Central Register of Controlled Trials. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included all-cause mortality, cardiovascular morbidity and mortality, cerebrovascular morbidity, neuropathy, nephropathy, and retinopathy. This guideline grades the evidence and recommendations by using the American College of Physicians clinical practice guidelines grading system. Recommendation 1: ACP recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 diabetes when lifestyle modifications, including diet, exercise, and weight loss, have failed to adequately improve hyperglycemia (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians prescribe monotherapy with metformin for initial pharmacologic therapy to treat most patients with type 2 diabetes (Grade: strong recommendation; high-quality evidence). Recommendation 3: ACP recommends that clinicians add a second agent to metformin to treat patients with persistent hyperglycemia when lifestyle modifications and monotherapy with metformin fail to control hyperglycemia (Grade: strong recommendation; high-quality evidence).	[Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Univ Kansas, Sch Med, Wichita, KS 67214 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA	American College of Physicians; Oregon Health & Science University; University of Kansas; University of Kansas Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	aqaseem@acponline.org		Starkey, Melissa/0000-0002-5818-0265	ACP	ACP	Financial support for the development of this guideline comes exclusively from the ACP operating budget.	*AG HEALTHC RES QU, 2007, GUID COND COMP EFF R; Agarwal R, 2005, KIDNEY INT, V68, P285, DOI 10.1111/j.1523-1755.2005.00416.x; Alexander GC, 2008, ARCH INTERN MED, V168, P2088, DOI 10.1001/archinte.168.19.2088; Amador-Licona N, 2000, ARCH MED RES, V31, P571, DOI 10.1016/S0188-4409(00)00241-1; Asche CV, 2008, DRUG AGING, V25, P611, DOI 10.2165/00002512-200825070-00006; Aschner P, 2010, DIABETES OBES METAB, V12, P252, DOI 10.1111/j.1463-1326.2009.01187.x; Azoulay L, 2010, PHARMACOEPIDEM DR S, V19, P335, DOI 10.1002/pds.1834; Bailey CJ, 2005, CLIN THER, V27, P1548, DOI 10.1016/j.clinthera.2005.10.012; Bakris GL, 2006, J HYPERTENS, V24, P2047, DOI 10.1097/01.hjh.0000244955.39491.88; Bennett WL, 2011, ANN INTERN MED, V154, P602, DOI 10.7326/0003-4819-154-9-201105030-00336; Bennett WL, 2011, ORAL DIABETES MED AD; Blonde L, 2002, DIABETES OBES METAB, V4, P368, DOI 10.1046/j.1463-1326.2002.00229.x; Bolen S., 2007, COMP EFFECTIVENESS S; Bolen S, 2007, ANN INTERN MED, V147, P386, DOI 10.7326/0003-4819-147-6-200709180-00178; CAMPBELL IW, 1994, DIABETES METAB, V20, P394; Centers for Disease Control and Prevention, 2011, NAT DIAB FACT SHEET; Charbonnel B, 2006, DIABETES CARE, V29, P2638, DOI 10.2337/dc06-0706; Charpentier G, 2001, DIABETIC MED, V18, P828, DOI 10.1046/j.1464-5491.2001.00582.x; Chien Hsin-Hsi, 2007, J Chin Med Assoc, V70, P473, DOI 10.1016/S1726-4901(08)70044-3; Comaschi M, 2008, NUTR METAB CARDIOVAS, V18, P373, DOI 10.1016/j.numecd.2007.04.003; Comaschi M, 2007, DIABETES TECHNOL THE, V9, P387, DOI 10.1089/dia.2006.0023; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; DeFronzo RA, 2010, DIABETES CARE, V33, P951, DOI [10.2337/dc09-1521, 10.2337/dc10-0646]; Derosa G, 2005, CLIN THER, V27, P1383, DOI 10.1016/j.clinthera.2005.09.003; Derosa G, 2004, DIABETES NUTR METAB, V17, P143; Derosa G, 2006, DIABETES OBES METAB, V8, P197, DOI 10.1111/j.1463-1326.2005.00480.x; Derosa G, 2003, DIABETES RES CLIN PR, V60, P161, DOI 10.1016/S0168-8227(03)00057-3; Derosa G, 2010, DIABETES TECHNOL THE, V12, P233, DOI 10.1089/dia.2009.0141; Dormuth CR, 2009, ARCH INTERN MED, V169, P1395, DOI 10.1001/archinternmed.2009.214; Einhorn D, 2000, CLIN THER, V22, P1395, DOI 10.1016/S0149-2918(00)83039-8; Erdem G, 2008, DIABETES RES CLIN PR, V82, P214, DOI 10.1016/j.diabres.2008.07.021; Eurich DT, 2005, DIABETES CARE, V28, P2345, DOI 10.2337/diacare.28.10.2345; Evans JMM, 2006, DIABETOLOGIA, V49, P930, DOI 10.1007/s00125-006-0176-9; Feinglos M, 2005, DIABETES RES CLIN PR, V68, P167, DOI 10.1016/j.diabres.2004.09.002; Fisman EZ, 1999, CARDIOLOGY, V91, P195, DOI 10.1159/000006909; Fisman EZ, 2001, CLIN CARDIOL, V24, P151, DOI 10.1002/clc.4960240210; Fonseca V, 2000, JAMA-J AM MED ASSOC, V283, P1695, DOI 10.1001/jama.283.13.1695; Garber A, 2006, DIABETES OBES METAB, V8, P156, DOI 10.1111/j.1463-1326.2005.00570.x; Garber AJ, 2003, J CLIN ENDOCR METAB, V88, P3598, DOI 10.1210/jc.2002-021225; Garber AJ, 2002, DIABETES OBES METAB, V4, P201, DOI 10.1046/j.1463-1326.2002.00211.x; Garber A, 2009, LANCET, V373, P473, DOI 10.1016/S0140-6736(08)61246-5; GlaxoSmithKline, 2011, AVANDIA PACK INS; Goldberg RB, 2005, DIABETES CARE, V28, P1547, DOI 10.2337/diacare.28.7.1547; Goldstein BJ, 2007, DIABETES CARE, V30, P1979, DOI 10.2337/dc07-0627; Goldstein BJ, 2003, CLIN THER, V25, P890, DOI 10.1016/S0149-2918(03)80112-1; Gomez-Perez FJ, 2002, DIABETES-METAB RES, V18, P127, DOI 10.1002/dmrr.264; Gulliford M, 2004, DIABETES-METAB RES, V20, P239, DOI 10.1002/dmrr.457; Gupta AK, 2009, DIABETES OBES METAB, V11, P330, DOI 10.1111/j.1463-1326.2008.00965.x; Hallsten K, 2004, DIABETIC MED, V21, P1280, DOI 10.1111/j.1464-5491.2004.01332.x; Hallsten K, 2002, DIABETES, V51, P3479, DOI 10.2337/diabetes.51.12.3479; Hamann A, 2008, EXP CLIN ENDOCR DIAB, V116, P6, DOI 10.1055/s-2007-984441; Hanefeld M, 2004, DIABETES CARE, V27, P141, DOI 10.2337/diacare.27.1.141; Hanefeld M, 2007, NUTR METAB CARDIOVAS, V17, P13, DOI 10.1016/j.numecd.2005.12.003; HERMANN LS, 1991, DIABETES METAB, V17, P201; HERMANN LS, 1994, DIABETES CARE, V17, P1100, DOI 10.2337/diacare.17.10.1100; HERMANN LS, 1991, DIABETES METAB, V17, P174; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Home PD, 2007, DIABETIC MED, V24, P626, DOI 10.1111/j.1464-5491.2007.02160.x; Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3; Horton ES, 2000, DIABETES CARE, V23, P1660, DOI 10.2337/diacare.23.11.1660; Horton ES, 2004, CURR MED RES OPIN, V20, P883, DOI 10.1185/030079903125003881; Hsiao FY, 2009, DRUG SAFETY, V32, P675, DOI 10.2165/00002018-200932080-00006; Iliadis F, 2007, IN VIVO, V21, P1107; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jadzinsky M, 2009, DIABETES OBES METAB, V11, P611, DOI 10.1111/j.1463-1326.2009.01056.x; Jain R, 2006, PHARMACOTHERAPY, V26, P1388, DOI 10.1592/phco.26.10.1388; Jibran R, 2006, PAK J MED SCI, V22, P385; Johnson JA, 2005, DIABETIC MED, V22, P497, DOI 10.1111/j.1464-5491.2005.01448.x; Johnson JA, 2002, DIABETES CARE, V25, P2244, DOI 10.2337/diacare.25.12.2244; Jonker JT, 2010, J CLIN ENDOCR METAB, V95, P456, DOI 10.1210/jc.2009-1441; Jovanovic L, 2004, DIABETES RES CLIN PR, V63, P127, DOI 10.1016/j.diabres.2003.09.004; Kahler KH, 2007, DIABETES CARE, V30, P1689, DOI 10.2337/dc06-2272; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Kahn SE, 2008, DIABETES CARE, V31, P845, DOI 10.2337/dc07-2270; Kaku K, 2009, CURR MED RES OPIN, V25, P1111, DOI 10.1185/03007990902820816 ; Karter AJ, 2005, DIABETIC MED, V22, P986, DOI 10.1111/j.1464-5491.2005.01704.x; Kato T, 2009, EXP CLIN ENDOCR DIAB, V117, P593, DOI 10.1055/s-0029-1202792; Khan MA, 2002, DIABETES CARE, V25, P708, DOI 10.2337/diacare.25.4.708; Kiyici S, 2009, DIABETES RES CLIN PR, V86, P44, DOI 10.1016/j.diabres.2009.07.004; Landgraf R, 1999, EUR J CLIN PHARMACOL, V55, P165, DOI 10.1007/s002280050613; Lawrence JM, 2004, DIABETES CARE, V27, P41, DOI 10.2337/diacare.27.1.41; Lund SS, 2007, DIABETES OBES METAB, V9, P394, DOI 10.1111/j.1463-1326.2007.00713.x; Madsbad S, 2004, DIABETES CARE, V27, P1335, DOI 10.2337/diacare.27.6.1335; Madsbad S, 2001, DIABETIC MED, V18, P395, DOI 10.1046/j.1464-5491.2001.00490.x; Mafauzy M, 2002, DIABETES RES CLIN PR, V58, P45, DOI 10.1016/S0168-8227(02)00104-3; Marbury T, 1999, DIABETES RES CLIN PR, V43, P155, DOI 10.1016/S0168-8227(99)00002-9; Marre A, 2002, DIABETES OBES METAB, V4, P177, DOI 10.1046/j.1463-1326.2002.00196.x; Marre M, 2002, DIABETIC MED, V19, P673, DOI 10.1046/j.1464-5491.2002.00774.x; Maru S, 2005, DIABETES CARE, V28, P20, DOI 10.2337/diacare.28.1.20; McAfee AT, 2007, PHARMACOEPIDEM DR S, V16, P711, DOI 10.1002/pds.1443; McAlister FA, 2008, EUR J HEART FAIL, V10, P703, DOI 10.1016/j.ejheart.2008.05.013; Moses R, 1999, DIABETES CARE, V22, P119, DOI 10.2337/diacare.22.1.119; Nakamura T, 2006, DIABETES-METAB RES, V22, P385, DOI 10.1002/dmrr.633; Natali A, 2004, DIABETES CARE, V27, P1349, DOI 10.2337/diacare.27.6.1349; National Diabetes Information Clearinghouse (NDIC), 2008, NIH PUBL; Nauck MA, 2007, DIABETES OBES METAB, V9, P194, DOI 10.1111/j.1463-1326.2006.00704.x; Nauck M, 2009, DIABETES CARE, V32, P84, DOI 10.2337/dc08-1355; Pantalone KM, 2009, ACTA DIABETOL, V46, P145, DOI 10.1007/s00592-008-0090-3; Pavo I, 2003, J CLIN ENDOCR METAB, V88, P1637, DOI 10.1210/jc.2002-021786; Perez A, 2009, CURR MED RES OPIN, V25, P2915, DOI 10.1185/03007990903350011; Pfutzner A, 2005, J AM COLL CARDIOL, V45, P1925, DOI 10.1016/j.jacc.2005.03.041; Pratley RE, 2010, LANCET, V375, P1447, DOI 10.1016/S0140-6736(10)60307-8; Qaseem A, 2010, ANN INTERN MED, V153, P194, DOI 10.7326/0003-4819-153-3-201008030-00010; Qaseern A, 2007, ANN INTERN MED, V147, P417, DOI 10.7326/0003-4819-147-6-200709180-00012; Ramachandran A, 2004, J Assoc Physicians India, V52, P459; Raskin P, 2004, DIABETIC MED, V21, P329, DOI 10.1111/j.1464-5491.2004.01143.x; Rosak C, 2006, INT J CLIN PRACT, V60, P1040, DOI 10.1111/j.1742-1241.2006.01092.x; Rosenstock J, 2006, DIABETES OBES METAB, V8, P650, DOI 10.1111/j.1463-1326.2006.00659.x; Schernthaner G, 2004, J CLIN ENDOCR METAB, V89, P6068, DOI 10.1210/jc.2003-030861; Schwarz SL, 2008, DIABETES OBES METAB, V10, P652, DOI 10.1111/j.1463-1326.2007.00792.x; Scott R, 2008, DIABETES OBES METAB, V10, P959, DOI 10.1111/j.1463-1326.2007.00839.x; Scott R, 2007, INT J CLIN PRACT, V61, P171, DOI 10.1111/j.1742-1241.2006.01246.x; Seck T, 2010, INT J CLIN PRACT, V64, P562, DOI 10.1111/j.1742-1241.2010.02353.x; Seino Y, 2010, CURR MED RES OPIN, V26, P1013, DOI 10.1185/03007991003672551; Seufert J, 2008, DIABETES RES CLIN PR, V79, P453, DOI 10.1016/j.diabres.2007.11.014; Simpson SH, 2006, CAN MED ASSOC J, V174, P169, DOI 10.1503/cmaj.050748; Stewart MW, 2006, DIABETIC MED, V23, P1069, DOI 10.1111/j.1464-5491.2006.01942.x; Sutton MS, 2002, DIABETES CARE, V25, P2058, DOI 10.2337/diacare.25.11.2058; Takeda Pharmaceutical America, 2011, ACTOS PACK INS; Tan MH, 2004, DIABETIC MED, V21, P859, DOI 10.1111/j.1464-5491.2004.01258.x; Teramoto T, 2007, J ATHEROSCLER THROMB, V14, P86, DOI 10.5551/jat.14.86; Tolman KG, 2009, DRUG SAFETY, V32, P787, DOI 10.2165/11316510-000000000-00000; Tosi F, 2003, METABOLISM, V52, P862, DOI 10.1016/S0026-0495(03)00101-X; Tzoulaki I, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4731; Umpierrez G, 2006, CURR MED RES OPIN, V22, P751, DOI 10.1185/030079906X104786; Vakkilainen J, 2002, DIABETES-METAB RES, V18, P484, DOI 10.1002/dmrr.324; van der Meer RW, 2009, CIRCULATION, V119, P2069, DOI 10.1161/CIRCULATIONAHA.108.803916; Vijay SK, 2009, ACTA DIABETOL, V46, P27, DOI 10.1007/s00592-008-0054-7; Virtanen KA, 2003, DIABETES, V52, P283, DOI 10.2337/diabetes.52.2.283; Weissman P, 2005, CURR MED RES OPIN, V21, P2029, DOI 10.1185/030079905X74844; Williams-Herman D, 2009, CURR MED RES OPIN, V25, P569, DOI 10.1185/03007990802705679 ; Wolffenbuttel BHR, 1999, DIABETES CARE, V22, P463, DOI 10.2337/diacare.22.3.463; WOLFFENBUTTEL BHR, 1993, EUR J CLIN PHARMACOL, V45, P113, DOI 10.1007/BF00315490; Yamanouchi T, 2005, DIABETIC MED, V22, P980, DOI 10.1111/j.1464-5491.2005.01656.x	134	187	193	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2012	156	3					218	U92		10.7326/0003-4819-156-3-201202070-00011	http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00011			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XD	22312141				2022-12-28	WOS:000299964200006
J	Pollock, AM; Price, D; Roderick, P; Treuherz, T; McCoy, D; McKee, M; Reynolds, L				Pollock, Allyson M.; Price, David; Roderick, Peter; Treuherz, Tim; McCoy, David; McKee, Martin; Reynolds, Lucy			How the Health and Social Care Bill 2011 would end entitlement to comprehensive health care in England	LANCET			English	Editorial Material									[Pollock, Allyson M.; Price, David] Univ London, Ctr Primary Care & Publ Hlth, London E1 4NS, England; [McCoy, David] Inner N W London Primary Care Trusts, London, England; [McKee, Martin; Reynolds, Lucy] London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1, England	University of London; University of London; London School of Hygiene & Tropical Medicine	Pollock, AM (corresponding author), Univ London, Ctr Primary Care & Publ Hlth, London E1 4NS, England.	a.pollock@qmul.ac.uk	Mckee, Martin/E-6673-2018; Reynolds, Dr L/CAG-7830-2022; McKee, Marc D/E-2187-2011	Mckee, Martin/0000-0002-0121-9683; McKee, Marc D/0000-0001-8349-965X; pollock, allyson/0000-0002-7388-3110				38 Degrees, NHS EXP LEG ADV; House of Lords Select Committee on the Constitution, 2011, 197 HL SEL COMM CONS; House of Lords Select Committee on the Constitution, 2011, 240 HL SEL COMM CONS; NHS Future Forum, 2011, SUMM REP PROP CHANG; Pollock AM, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1695; Pollock AM, 2011, HLTH SOCIAL CARE BIL; Starfield B, 2009, J EPIDEMIOL COMMUN H, V63, P265, DOI 10.1136/jech.2008.084822	7	26	26	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2012	379	9814					387	389		10.1016/S0140-6736(12)60119-6	http://dx.doi.org/10.1016/S0140-6736(12)60119-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	891AF	22284434				2022-12-28	WOS:000300187800010
J	Landau, S				Landau, Stanley			Insulin-Induced Lipohypertrophy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Diabet & Endocrinol, Johannesburg, South Africa		Landau, S (corresponding author), Ctr Diabet & Endocrinol, Johannesburg, South Africa.	stan@cdecentr.co.za							0	4	4	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					E9	E9		10.1056/NEJMicm1101527	http://dx.doi.org/10.1056/NEJMicm1101527			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QX	22296094				2022-12-28	WOS:000299724400012
J	Kunimoto, K; Yamazaki, Y; Nishida, T; Shinohara, K; Ishikawa, H; Hasegawa, T; Okanoue, T; Hamada, H; Noda, T; Tamura, A; Tsukita, S; Tsukita, S				Kunimoto, Koshi; Yamazaki, Yuji; Nishida, Tomoki; Shinohara, Kyosuke; Ishikawa, Hiroaki; Hasegawa, Toshiaki; Okanoue, Takeshi; Hamada, Hiroshi; Noda, Tetsuo; Tamura, Atsushi; Tsukita, Shoichiro; Tsukita, Sachiko			Coordinated Ciliary Beating Requires Odf2-Mediated Polarization of Basal Bodies via Basal Feet	CELL			English	Article							PLANAR CELL POLARITY; EPITHELIAL-CELLS; MOTHER CENTRIOLES; MOTILE CILIA; BODY; CILIOGENESIS; MICROTUBULE; ORIENTATION; CENTROSOME; MOUSE	Coordinated beating of cilia in the trachea generates a directional flow of mucus required to clear the airways. Each cilium originates from a barrel-shaped basal body, from the side of which protrudes a structure known as the basal foot. We generated mice in which exons 6 and 7 of Odf2, encoding a basal body and centrosome-associated protein Odf2/cenexin, are disrupted. Although Odf2(Delta Ex6,7/Delta Ex6,7) mice form cilia, ciliary beating is uncoordinated, and the mice display a coughing/sneezing phenotype. Whereas residual expression of the C-terminal region of Odf2 in these mice is sufficient for ciliogenesis, the resulting basal bodies lack basal feet. Loss of basal feet in ciliated epithelia disrupted the polarized organization of apical microtubule lattice without affecting planar cell polarity. The requirement for Odf2 in basal foot formation, therefore, reveals a crucial role of this structure in the polarized alignment of basal bodies and coordinated ciliary beating.	[Kunimoto, Koshi; Yamazaki, Yuji; Tamura, Atsushi; Tsukita, Sachiko] Osaka Univ, Grad Sch Frontier Biosci, Biol Sci Lab, Suita, Osaka 5650871, Japan; [Kunimoto, Koshi; Yamazaki, Yuji; Tamura, Atsushi; Tsukita, Sachiko] Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; [Nishida, Tomoki; Hasegawa, Toshiaki] Osaka Univ, Res Ctr Ultra High Voltage Electron Microscopy, Osaka 5670047, Japan; [Shinohara, Kyosuke; Hamada, Hiroshi] Osaka Univ, Grad Sch Frontier Biosci, Dev Genet Grp, Suita, Osaka 5650871, Japan; [Shinohara, Kyosuke; Hamada, Hiroshi] Japan Sci & Technology Corp JST, CREST, Suita, Osaka 5650871, Japan; [Ishikawa, Hiroaki] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Okanoue, Takeshi] Saiseikai Suita Hosp, Dept Hepatol, Osaka 5640013, Japan; [Noda, Tetsuo] Canc Inst Japanese Fdn Canc Res, Dept Cell Biol, Tokyo 1358550, Japan; [Tsukita, Shoichiro] Kyoto Univ, Dept Cell Biol, Fac Med, Kyoto 6068315, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST); University of California System; University of California San Francisco; Japanese Foundation for Cancer Research; Kyoto University	Tsukita, S (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Biol Sci Lab, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	atsukita@biosci.med.osaka-u.ac.jp; atsukita@biosci.med.osaka-u.ac.jp	Shinohara, Kyosuke/AAU-2471-2020; Hamada, Hiroshi/N-6374-2015; Noda, Tetsuo/B-1667-2016; Shinohara, Kyosuke/I-1470-2016	Shinohara, Kyosuke/0000-0002-6350-1684; Hamada, Hiroshi/0000-0002-7196-5948; 	Ministry of Education, Culture, Sports, Science, and Technology of Japan; Grants-in-Aid for Scientific Research [23590334] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Y. Fujiyoshi, S. Kitajiri, T. Stearns, A. Wynshaw-Boris, and our laboratory members for discussion. We thank D. Sipp for critical reading of this manuscript. We thank Shu Lin Low, S. Watanabe, and R. Tokumasu for limited experimental collaboration. We thank M. Uji and A. Hagiwara for the excellent technical assistance. We also thank Y. Ohta, H. Mori, A. Takaoka, S. Yoshiba, K. Takaoka, I. Tateya, H. Shiratori, M. Inagaki, A. Inoko, and M. Ibi for technical advice. This work was supported in part by Grants-in-Aid for Creative Scientific Research (to Sachiko Tsukita) and Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. This work is dedicated to Shoichiro Tsukita, who contributed the initial planning of this study and passed away in 2005. Research planning and supervision were by Sachiko Tsukita and K.K. All experiments were conducted by K.K. in collaboration with H.I. (instruction in construction of targeting vector), Y.Y. (western blotting and RT-PCR), K.S./H.H. (live imaging), T. Nishida/T.H. (UHVEMT), A.T./T. Noda (generation of knockout mice), and H.I. and Y.Y. (transfection of F9 cells). Discussion was by K.K., Y.Y., K.S., T. Nishida, H.H., H.I., T.O., A.T, T. Noda, and Sachiko Tsukita. Discussion and manuscript writing were mainly by Sachiko Tsukita, K.K., and Y.Y.	Afzelius B A, 1979, Int Rev Exp Pathol, V19, P1; ANDERSON RG, 1972, J CELL BIOL, V54, P246, DOI 10.1083/jcb.54.2.246; Badano JL, 2006, ANNU REV GENOM HUM G, V7, P125, DOI 10.1146/annurev.genom.7.080505.115610; BOISVIEUXULRICH E, 1985, BIOL CELL, V55, P147, DOI 10.1111/j.1768-322X.1985.tb00417.x; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brohmann H, 1997, J BIOL CHEM, V272, P10327, DOI 10.1074/jbc.272.15.10327; GIBBONS IR, 1961, J BIOPHYS BIOCHEM CY, V11, P179, DOI 10.1083/jcb.11.1.179; GORDON RE, 1982, CELL MOTIL CYTOSKEL, V2, P385, DOI 10.1002/cm.970020407; Gray RS, 2009, NAT CELL BIOL, V11, P1225, DOI 10.1038/ncb1966; Guirao B, 2007, BIOPHYS J, V92, P1900, DOI 10.1529/biophysj.106.084897; Guirao B, 2010, NAT CELL BIOL, V12, P341, DOI 10.1038/ncb2040; Hagiwara H, 2000, HISTOCHEM J, V32, P669, DOI 10.1023/A:1004163315822; HARD R, 1983, TISSUE CELL, V15, P227, DOI 10.1016/0040-8166(83)90019-8; Heydeck W, 2009, DEV DYNAM, V238, P3035, DOI 10.1002/dvdy.22130; ISHIKAWA H, 1969, J CELL BIOL, V43, P312; Ishikawa H, 2005, NAT CELL BIOL, V7, P517, DOI 10.1038/ncb1251; Jones C, 2008, NAT GENET, V40, P69, DOI 10.1038/ng.2007.54; Kunimoto K, 2009, J CELL PHYSIOL, V220, P621, DOI 10.1002/jcp.21798; LANGE BMH, 1995, J CELL BIOL, V130, P919, DOI 10.1083/jcb.130.4.919; Luders J, 2007, NAT REV MOL CELL BIO, V8, P161, DOI 10.1038/nrm2100; Marshall WF, 2008, CURR OPIN CELL BIOL, V20, P48, DOI 10.1016/j.ceb.2007.11.009; Marshall WF, 2010, NAT CELL BIOL, V12, P314, DOI 10.1038/ncb0410-314; McNeill H, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003376; Mitchell B, 2007, NATURE, V447, P97, DOI 10.1038/nature05771; Morillas HN, 2007, RESPIRATION, V74, P252, DOI 10.1159/000101783; Nakagawa Y, 2001, MOL BIOL CELL, V12, P1687, DOI 10.1091/mbc.12.6.1687; OKO R, 1988, BIOL REPROD, V39, P673, DOI 10.1095/biolreprod39.3.673; Park TJ, 2008, NAT GENET, V40, P871, DOI 10.1038/ng.104; Park TJ, 2006, NAT GENET, V38, P303, DOI 10.1038/ng1753; REED W, 1984, J CELL SCI, V68, P1; Schweizer S, 2009, CELL TISSUE RES, V338, P295, DOI 10.1007/s00441-009-0861-3; Seeley ES, 2010, J CELL SCI, V123, P511, DOI 10.1242/jcs.061093; Sloboda RD, 2007, J CELL BIOL, V179, P575, DOI 10.1083/jcb.200709039; SOROKIN SP, 1968, J CELL SCI, V3, P207; Soung NK, 2006, MOL CELL BIOL, V26, P8316, DOI 10.1128/MCB.00671-06; Soung NK, 2009, DEV CELL, V16, P539, DOI 10.1016/j.devcel.2009.02.004; STERNBERG N, 1981, J MOL BIOL, V150, P487, DOI 10.1016/0022-2836(81)90376-4; Tarnasky H, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-67; Vladar EK, 2008, TRENDS CELL BIOL, V18, P517, DOI 10.1016/j.tcb.2008.08.004; Vladar EK, 2007, J CELL BIOL, V178, P31, DOI 10.1083/jcb.200703064; Voronina VA, 2009, J CELL BIOL, V185, P225, DOI 10.1083/jcb.200809144; Wallingford JB, 2010, CURR OPIN CELL BIOL, V22, P597, DOI 10.1016/j.ceb.2010.07.011; Zallen JA, 2007, CELL, V129, P1051, DOI 10.1016/j.cell.2007.05.050; Zariwala MA, 2007, ANNU REV PHYSIOL, V69, P423, DOI 10.1146/annurev.physiol.69.040705.141301	44	134	138	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 20	2012	148	1-2					189	200		10.1016/j.cell.2011.10.052	http://dx.doi.org/10.1016/j.cell.2011.10.052			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265411	Bronze			2022-12-28	WOS:000299540700024
J	Wang, ZG; Jiang, H; Chen, S; Du, FH; Wang, XD				Wang, Zhigao; Jiang, Hui; Chen, She; Du, Fenghe; Wang, Xiaodong			The Mitochondrial Phosphatase PGAM5 Functions at the Convergence Point of Multiple Necrotic Death Pathways	CELL			English	Article							DEPENDENT PROTEIN-KINASE; INTERACTING PROTEIN; CELL-DEATH; UBIQUITIN LIGASE; DRP1; INHIBITION; FISSION; PHOSPHORYLATION; DIVISION; NECROSIS	The programmed necrosis induced by TNF-alpha requires the activities of the receptor-interacting serine-threonine kinases RIP1 and RIP3 and their interaction with the mixed lineage kinase domain-like protein MLKL. We report the identification of RIP1- and RIP3-containing protein complexes that form specifically in response to necrosis induction. One component of these complexes is the mitochondrial protein phosphatase PGAM5, which presents as two splice variants, PGAM5L (long form) and PGAM5S (short form). Knockdown of either form attenuated necrosis induced by TNF-a as well as reactive oxygen species (ROS) and calcium ionophore, whereas knockdown of RIP3 and MLKL blocked only TNF-alpha-mediated necrosis. Upon necrosis induction, PGAM5S recruited the mitochondrial fission factor Drp1 and activated its GTPase activity by dephosphorylating the serine 637 site of Drp1. Drp1 activation caused mitochondrial fragmentation, an early and obligatory step for necrosis execution. These data defined PGAM5 as the convergent point for multiple necrosis pathways.	[Wang, Zhigao; Jiang, Hui; Du, Fenghe; Wang, Xiaodong] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Jiang, Hui; Chen, She; Wang, Xiaodong] Natl Inst Biol Sci, Beijing 102206, Peoples R China	University of Texas System; University of Texas Southwestern Medical Center Dallas; National Institute of Biological Sciences, Beijing	Wang, XD (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	wangxiaodong@nibs.ac.cn	Wang, Zhigao/ABE-9411-2021	Wang, Zhigao/0000-0002-6544-4302; Jiang, Hui/0000-0002-0277-9711; Wang, Xiaodong/0000-0001-9885-356X	Howard Hughes Medical Institute; Chinese Ministry of Science and Technology [2008AA022318, 2010CB835400]; NATIONAL CANCER INSTITUTE [P30CA142543] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Drs. Steve McKnight, Joe Goldstein, and Mike Brown for support and encouragement; Dr. Ayako Suzuki for help with the 2D electrophoresis; Drs. Lai Wang, Agata Rybarska, and Gregory Kunkel for critical reading of the manuscript. This work was supported by the Howard Hughes Medical Institute and the National High Technology Projects 863 (2008AA022318) and 973 (2010CB835400) from Chinese Ministry of Science and Technology.	Breckenridge DG, 2008, MOL CELL, V31, P586, DOI 10.1016/j.molcel.2008.07.015; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Cho DH, 2009, SCIENCE, V324, P102, DOI 10.1126/science.1171091; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Imai Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001229; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Lo SC, 2008, EXP CELL RES, V314, P1789, DOI 10.1016/j.yexcr.2008.02.014; Lo SC, 2006, J BIOL CHEM, V281, P37893, DOI 10.1074/jbc.M606539200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Otera H, 2011, J BIOCHEM, V149, P241, DOI 10.1093/jb/mvr002; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Takeda K, 2009, P NATL ACAD SCI USA, V106, P12301, DOI 10.1073/pnas.0901823106; Temkin V, 2006, MOL CELL BIOL, V26, P2215, DOI 10.1128/MCB.26.6.2215-2225.2006; Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107; Upton JW, 2010, CELL HOST MICROBE, V7, P302, DOI 10.1016/j.chom.2010.03.006; Vanlangenakker N, 2008, CURR MOL MED, V8, P207, DOI 10.2174/156652408784221306; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	34	633	678	10	169	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					228	243		10.1016/j.cell.2011.11.030	http://dx.doi.org/10.1016/j.cell.2011.11.030			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265414	Bronze			2022-12-28	WOS:000299540700027
J	Lok, AS; Gardiner, DF; Lawitz, E; Martorell, C; Everson, GT; Ghalib, R; Reindollar, R; Rustgi, V; McPhee, F; Wind-Rotolo, M; Persson, A; Zhu, K; Dimitrova, DI; Eley, T; Guo, T; Grasela, DM; Pasquinelli, C				Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio			Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMBINATION THERAPY; VIRUS-INFECTION; PEGINTERFERON ALPHA-2A; RANDOMIZED-TRIAL; TREATMENT-NAIVE; PLUS RIBAVIRIN; LIVER FIBROSIS; NS3 INHIBITOR; HCV INFECTION; BMS-650032	BACKGROUND Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen. METHODS This open-label, phase 2a study included an exploratory cohort of 21 patients with chronic HCV genotype 1 infection who had not had a response to previous therapy (i.e., had not had >= 2 log(10) decline in HCV RNA after >= 12 weeks of treatment with peginterferon and ribavirin). We randomly assigned patients to receive the NS5A replication complex inhibitor daclatasvir (60 mg once daily) and the NS3 protease inhibitor asunaprevir (600 mg twice daily) alone (group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 weeks. The primary end point was the percentage of patients with a sustained virologic response 12 weeks after the end of the treatment period. RESULTS A total of 4 patients in group A (36%; 2 of 9 with HCV genotype 1a and 2 of 2 with genotype 1b) had a sustained virologic response at 12 weeks after treatment and also at 24 weeks after treatment.. Six patients (all with HCV genotype 1a) had viral breakthrough while receiving therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had a viral response at the end of treatment but had a relapse after the treatment period. All 10 patients in group B had a sustained virologic response at 12 weeks after treatment, and 9 had a sustained virologic response at 24 weeks after treatment. Diarrhea was the most common adverse event in both groups. Six patients had transient elevations of alanine aminotransferase levels to more than 3 times the upper limit of the normal range. CONCLUSIONS This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virologic response can be achieved with two direct-acting antiviral agents only. In addition, a high rate of sustained virologic response was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01012895.)	[Lok, Anna S.] Univ Michigan, Med Ctr, Taubman Ctr 3912, Dept Internal Med,Div Gastroenterol,SPC 5362, Ann Arbor, MI 48109 USA; [Gardiner, David F.; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Grasela, Dennis M.; Pasquinelli, Claudio] Bristol Myers Squibb Co, Res & Dev, Hopewell, NJ USA; [Lawitz, Eric] Alamo Med Res, San Antonio, TX USA; [Martorell, Claudia] Res Inst, Springfield, MA USA; [Everson, Gregory T.] Univ Colorado Denver, Aurora, CO USA; [Ghalib, Reem] Texas Clin Res Inst, Arlington, TX USA; [Reindollar, Robert] Carolinas Ctr Liver Dis, Statesville, NC USA; [Rustgi, Vinod] Metropolitan Res, Fairfax, VA USA	University of Michigan System; University of Michigan; Bristol-Myers Squibb; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Lok, AS (corresponding author), Univ Michigan, Med Ctr, Taubman Ctr 3912, Dept Internal Med,Div Gastroenterol,SPC 5362, Ann Arbor, MI 48109 USA.	aslok@med.umich.edu		Yang, Shuman/0000-0002-9638-0890	Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck-Schering-Plough; Roche; Achillion Pharmaceuticals; Anadys Pharmaceuticals; Pharmasset; Merck; Vertex Pharmaceuticals; Biolex; GlobeImmune; Idera Pharmaceuticals; Inhibitex; Medtronic; Novartis; Santaris Pharma; Scynexis; Tibotec; ZymoGenetics; Genentech; ViiV Healthcare; Kowa; Roche-Genentech; Conatus Pharmaceuticals; Human Genome Sciences-Novartis; Pfizer; Duke Clinical Research; Johnson Johnson; ViroChem; Medical Research Council [G9817803B] Funding Source: researchfish	Abbott(Abbott Laboratories); Bristol-Myers Squibb(Bristol-Myers Squibb); Gilead Sciences(Gilead Sciences); GlaxoSmithKline(GlaxoSmithKline); Merck-Schering-Plough(Merck & CompanySchering Plough Corporation); Roche(Roche Holding); Achillion Pharmaceuticals; Anadys Pharmaceuticals; Pharmasset; Merck(Merck & Company); Vertex Pharmaceuticals(Vertex Pharmaceuticals); Biolex; GlobeImmune; Idera Pharmaceuticals; Inhibitex; Medtronic(Medtronic); Novartis(Novartis); Santaris Pharma; Scynexis; Tibotec; ZymoGenetics; Genentech(Roche HoldingGenentech); ViiV Healthcare; Kowa; Roche-Genentech(Roche HoldingGenentech); Conatus Pharmaceuticals; Human Genome Sciences-Novartis; Pfizer(Pfizer); Duke Clinical Research; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); ViroChem; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Dr. Lok reports receiving consulting fees from Abbott, Bristol-Myers Squibb, and Gilead Sciences and grant support from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck-Schering-Plough, and Roche; Dr. Gardiner, being an employee of and owning stock in Bristol-Myers Squibb; Dr. Lawitz, receiving consulting fees from Abbott, Achillion Pharmaceuticals, Anadys Pharmaceuticals, and Pharmasset, lecture fees from Merck and Vertex Pharmaceuticals, and grant support from Abbott, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Idera Pharmaceuticals, Inhibitex, Medtronic, Merck, Novartis, Pharmasset, Roche, Santaris Pharma, Scynexis, Tibotec, Vertex Pharmaceuticals, and ZymoGenetics (now part of Bristol-Myers Squibb); Dr. Martorell, receiving lecture fees from Bristol-Myers Squibb, Genentech (now Roche-Genentech), Gilead Sciences, Merck, Tibotec, and ViiV Healthcare and grant support from Abbott, Bristol-Myers Squibb, Gilead Sciences, Kowa, Novartis, and ViiV Healthcare; Dr. Everson, receiving consulting fees from Abbott, Roche-Genentech, and Vertex Pharmaceuticals, serving on a data and safety monitoring board for Merck, receiving grant support from Abbott, Bristol-Myers Squibb, Conatus Pharmaceuticals, Gilead Sciences, GlobeImmune, Human Genome Sciences-Novartis, Merck-Schering-Plough, Pfizer, Roche-Genentech, Tibotec, and Vertex Pharmaceuticals, owning a patent in conjunction with the University of Colorado for tests of liver function, and owning HepQuant, which develops these tests (but for which he has received no income or payment to date); Dr Ghalib, receiving grant support from Abbott, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Bristol-Myers Squibb, Duke Clinical Research, Roche-Genentech, Gilead Sciences, Johnson & Johnson, Medtronic, Merck, Novartis, Roche, Merck-Schering-Plough, Tibotec, Vertex Pharmaceuticals, ViroChem, and ZymoGenetics (Bristol-Myers Squibb); Dr. Rustgi, receiving consulting fees from Merck, Novartis, and Tibotec and lecture fees from Roche-Genentech, Gilead, and Merck; Drs. McPhee, Zhu, and Dimitrova, being employees of Bristol-Myers Squibb; and Drs. Wind-Rotolo, Persson, Eley, Guo, Grasela, and Pasquinelli, being employees of Bristol-Myers Squibb and owning stock in Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported.	[Anonymous], GLOBAL ALERT RESPONS; [Anonymous], ABCS HEPATITIS; Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004; Bifano M, 2010, HEPATOLOGY, V52, p719A; Bronowicki JP, 2011, J HEPATOL, V54, pS472, DOI 10.1016/S0168-8278(11)61197-5; Chayama K, 2011, HEPATOLOGY      1010; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Gane EJ, 2010, LANCET, V376, P1467, DOI 10.1016/S0140-6736(10)61384-0; Gao M, 2010, NATURE, V465, P96, DOI 10.1038/nature08960; Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309; Ghany MG, 2011, HEPATOLOGY, V54, P1433, DOI 10.1002/hep.24641; Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; McHutchison JG, 2009, NEW ENGL J MED, V361, P1027; McHutchison JG, 2009, NEW ENGL J MED, V361, P580, DOI 10.1056/NEJMoa0808010; McPhee F, 2010, J HEPATOL, V52, pS296, DOI 10.1016/S0168-8278(10)60763-5; Nettles RE, 2011, HEPATOLOGY, V54, P1956, DOI 10.1002/hep.24609; Pasquinelli C, 2009, HEPATOLOGY, V50, p411A; Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013; Poynard T, 2003, HEPATOLOGY, V38, P481, DOI 10.1053/jhep.2003.50319; Poynard T, 2002, J VIRAL HEPATITIS, V9, P128, DOI 10.1046/j.1365-2893.2002.00341.x; Rumi MG, 2010, GASTROENTEROLOGY, V138, P108, DOI [10.1053/j.gastro.2009.08.071, 10.1053/j.gastro.2010.04.037]; Schiff E, 2008, J HEPATOL, V48, pS46, DOI 10.1016/S0168-8278(08)60106-3; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086; Zeuzem S, 2010, HEPATOLOGY, V52, p876A; Zeuzem S, 2010, HEPATOLOGY, V52, p400A	27	489	510	0	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					216	224		10.1056/NEJMoa1104430	http://dx.doi.org/10.1056/NEJMoa1104430			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877RZ	22256805	Bronze			2022-12-28	WOS:000299201400007
J	Black, ME				Black, Mary E.			THE BIGGER PICTURE Whose health and safety?	BRITISH MEDICAL JOURNAL			English	Editorial Material												drmaryblack@gmail.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 18	2012	344								e392	10.1136/bmj.e392	http://dx.doi.org/10.1136/bmj.e392			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YZ	22257978				2022-12-28	WOS:000300041900005
J	Prutsky, G; Domecq, JP; Tsapas, A				Prutsky, Gabriela; Domecq, Juan Pablo; Tsapas, Apostolos			Insulin secretagogues were associated with increased mortality compared with metformin in type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Prutsky, Gabriela; Domecq, Juan Pablo; Tsapas, Apostolos] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN 55905 USA	Mayo Clinic	Prutsky, G (corresponding author), Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN 55905 USA.		Tsapas, Apostolos/P-5593-2019	Tsapas, Apostolos/0000-0003-0221-4072				Bennett WL, 2011, ANN INTERN MED, V154, P602, DOI 10.7326/0003-4819-154-9-201105030-00336; Boussageon R, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4169	2	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-7	10.7326/0003-4819-156-2-201201170-02007	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31YU	22250169				2022-12-28	WOS:000208919700008
J	Fleshner, NE; Lucia, MS; Egerdie, B; Aaron, L; Eure, G; Nandy, I; Black, L; Rittmaster, RS				Fleshner, Neil E.; Lucia, M. Scott; Egerdie, Blair; Aaron, Lorne; Eure, Gregg; Nandy, Indrani; Black, Libby; Rittmaster, Roger S.			Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial	LANCET			English	Article							EXPECTANT MANAGEMENT; ACTIVE SURVEILLANCE; HIGH-GRADE; MEN; ANTIGEN; RISK; FINASTERIDE; PREVENTION; INHIBITOR; CARCINOMA	Background We aimed to investigate the safety and efficacy of dutasteride, a 5 alpha-reductase inhibitor, on prostate cancer progression in men with low-risk disease who chose to be followed up with active surveillance. Methods In our 3 year, randomised, double-blind, placebo-controlled study, undertaken at 65 academic medical centres or outpatient clinics in North America, we enrolled men aged 48-82 years who had low-volume, Gleason score 5-6 prostate cancer and had chosen to be followed up with active surveillance. We randomly allocated participants in a one-to-one ratio, stratified by site and in block sizes of four, to receive once-daily dutasteride 0.5 mg or matching placebo. Participants were followed up for 3 years, with 12-core prostate biopsy samples obtained after 18 months and 3 years. The primary endpoint was time to prostate cancer progression, defined as the number of days between the start of study treatment and the earlier of either pathological progression (in patients with >= 1 biopsy assessment after baseline) or therapeutic progression (start of medical therapy). This trial is registered with ClinicalTrials.gov, number NCT00363311. Findings Between Aug 10, 2006, and March 26, 2007, we randomly allocated 302 participants, of whom 289 (96%) had at least one biopsy procedure after baseline and were included in the primary analysis. By 3 years, 54 (38%) of 144 men in the dutasteride group and 70 (48%) of 145 controls had prostate cancer progression (pathological or therapeutic; hazard ratio 0.62, 95% CI 0.43-0.89; p=0.009). Incidence of adverse events was much the same between treatment groups. 35 (24%) men in the dutasteride group and 23 (15%) controls had sexual adverse events or breast enlargement or tenderness. Eight (5%) men in the dutasteride group and seven (5%) controls had cardiovascular adverse events, but there were no prostate cancer-related deaths or instances of metastatic disease. Interpretation Dutasteride could provide a beneficial adjunct to active surveillance for men with low-risk prostate cancer.	[Fleshner, Neil E.] Univ Toronto, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; [Lucia, M. Scott] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA; [Egerdie, Blair] Urol Associates Urol Med Res, Kitchener, ON, Canada; [Aaron, Lorne] Urol S Shore Res, Quebec City, PQ, Canada; [Eure, Gregg] Univ Virginia, Eastern Virginia Med Sch, Dept Urol, Norfolk, VA USA; [Nandy, Indrani; Black, Libby; Rittmaster, Roger S.] GlaxoSmithKline, Res Triangle Pk, NC USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Colorado System; University of Colorado Anschutz Medical Campus; Eastern Virginia Medical School; University of Virginia; GlaxoSmithKline	Fleshner, NE (corresponding author), Univ Toronto, Princess Margaret Hosp, 3rd Floor,Room 130,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	neil.fleshner@utoronto.ca			GlaxoSmithKline; Bioniche; Dendreon; ECOG; Pfizer; Sanofi-Aventis; Southwest Oncology Group	GlaxoSmithKline(GlaxoSmithKline); Bioniche; Dendreon; ECOG; Pfizer(Pfizer); Sanofi-Aventis(Sanofi-Aventis); Southwest Oncology Group	NEF has served as a consultant, adviser, and speaker for GlaxoSmithKline, has served as a speaker for Novartis, and receives royalties from BioAdvantex. MSL reported consultancy for GlaxoSmithKline and his institution has received fee-for-service payments from GlaxoSmithKline for processing and interpreting biopsy samples from the reduction by dutasteride of clinical progression events in expectant management (REDEEM) study. BE has served as an advisory board participant and speaker for GlaxoSmithKline. LA has received travel support and payment for preparation of educational presentations from GlaxoSmithKline and his institution has received study funding and medication from GlaxoSmithKline. GE has served as a consultant or adviser for American Medical Systems, Thermatrx/AMS, and the American College of Surgeons; has served as an investigator for American Medical Systems, Astellas, Ferring, GlaxoSmithKline, GTx, Lilly, Ortho Urology, and Spectrum Pharmaceuticals; has participated in scientific studies or trials sponsored by Bioniche, Dendreon, ECOG, Pfizer, Sanofi-Aventis, the Southwest Oncology Group; and has participated as a meeting participant or lecturer for American Medical Systems, Astellas, Ferring, GlaxoSmithKline, Indevus, and Lilly. Indrani Nandy, LKB and RSR are employees of GlaxoSmithKline with equity ownership or stock.	American Cancer Society, 2008, CANC FACTS FIG; Andriole GL, 2011, J UROLOGY, V185, P126, DOI 10.1016/j.juro.2010.09.011; Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127; Barocas DA, 2008, J UROLOGY, V180, P1330, DOI 10.1016/j.juro.2008.06.019; Carter HB, 2007, J UROLOGY, V178, P2359, DOI 10.1016/j.juro.2007.08.039; Chan JM, 2011, CANCER CAUSE CONTROL, V22, P141, DOI 10.1007/s10552-010-9684-5; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Etzioni R, 2002, J NATL CANCER I, V94, P981; Finelli A, 2011, EUR UROL, V59, P509, DOI 10.1016/j.eururo.2010.12.018; Fleshner N, 2007, CONTEMP CLIN TRIALS, V28, P763, DOI 10.1016/j.cct.2007.05.006; Fleshner N, 2007, CANCER-AM CANCER SOC, V110, P1889, DOI 10.1002/cncr.23009; Frattaroli J, 2008, UROLOGY, V72, P1319, DOI 10.1016/j.urology.2008.04.050; Gleave M, 2006, PROSTATE, V66, P1674, DOI 10.1002/pros.20499; Howlader N., 2021, SEER CANC STAT REV, P1975; Klotz L, 2010, J CLIN ONCOL, V28, P126, DOI 10.1200/JCO.2009.24.2180; Lu-Yao GL, 2009, JAMA-J AM MED ASSOC, V302, P1202, DOI 10.1001/jama.2009.1348; McLeod DG, 2006, BJU INT, V97, P247, DOI 10.1111/j.1464-410X.2005.06051.x; National Comprehensive Cancer Network (NCCN), 2010, CLIN PRACT GUID ONC; Pinsky P, 2008, CANCER PREV RES, V1, P182, DOI 10.1158/1940-6207.CAPR-07-0007; Roehrborn CG, 2002, UROLOGY, V60, P434, DOI 10.1016/S0090-4295(02)01905-2; Roehrborn CG, 2011, EUR UROL, V59, P244, DOI 10.1016/j.eururo.2010.10.040; Roth AJ, 2003, CANCER, V97, P2910, DOI 10.1002/cncr.11386; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Shao YH, 2010, ARCH INTERN MED, V170, P1256, DOI 10.1001/archinternmed.2010.221; Somerville MC, 2009, CRC BIOSTAT SERIES, P387; Stratton MS, 2010, CANCER PREV RES, V3, P1035, DOI 10.1158/1940-6207.CAPR-09-0143; Thompson IM, 2006, J NATL CANCER I, V98, P1128, DOI 10.1093/jnci/djj307; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Warlick C, 2006, JNCI-J NATL CANCER I, V98, P355, DOI 10.1093/jnci/djj072; White RWD, 2010, NUTR CANCER, V62, P1036, DOI 10.1080/01635581.2010.492085	30	142	144	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 24	2012	379	9821					1103	1111		10.1016/S0140-6736(11)61619-X	http://dx.doi.org/10.1016/S0140-6736(11)61619-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916VR	22277570				2022-12-28	WOS:000302131800032
J	El Arifeen, S; Mullany, LC; Shah, R; Mannan, I; Rahman, SM; Talukder, MRR; Begum, N; Al-Kabir, A; Darmstadt, GL; Santosham, M; Black, RE; Baqui, AH				El Arifeen, Shams; Mullany, Luke C.; Shah, Rasheduzzaman; Mannan, Ishtiaq; Rahman, Syed M.; Talukder, M. Radwanur R.; Begum, Nazma; Al-Kabir, Ahmed; Darmstadt, Gary L.; Santosham, Mathuram; Black, Robert E.; Baqui, Abdullah H.			The effect of cord cleansing with chlorhexidine on neonatal mortality in rural Bangladesh: a community-based, cluster-randomised trial	LANCET			English	Article							NEWBORN UMBILICAL-CORD; SYLHET DISTRICT; SOUTHERN NEPAL; RISK-FACTORS; INFECTION; HEALTH; OMPHALITIS; IMPACT; CARE	Background Up to half of neonatal deaths in high mortality settings are due to infections, many of which can originate through the freshly cut umbilical cord stump. We aimed to assess the effectiveness of two cord-cleansing regimens with the promotion of dry cord care in the prevention of neonatal mortality. Design We did a community-based, parallel cluster-randomised trial in Sylhet, Bangladesh. We divided the study area into 133 clusters, which were randomly assigned to one of the two chlorhexidine cleansing regimens (single cleansing as soon as possible after birth; daily cleansing for 7 days after birth) or promotion of dry cord care. Randomisation was done by use of a computer-generated sequence, stratified by cluster-specific participation in a previous trial. All livebirths were eligible; those visited within 7 days by a local female village health worker trained to deliver the cord care intervention were enrolled. We did not mask study workers and participants to the study interventions. Our primary outcome was neonatal mortality (within 28 days of birth) per 1000 livebirths, which we analysed on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00434408. Results Between June, 2007, and September, 2009, we enrolled 29 760 newborn babies (10 329, 9423, and 10 008 in the multiple-cleansing, single-cleansing, and dry cord care groups, respectively). Neonatal mortality was lower in the single-cleansing group (22.5 per 1000 livebirths) than it was in the dry cord care group (28.3 per 1000 livebirths; relative risk [RR] 0.80 [95% CI] 0.65-0.98). Neonatal mortality in the multiple-cleansing group (26.6 per 1000 livebirths) was not statistically significantly lower than it was in the dry cord care group (RR 0.94 [0.78-1.14]). Compared with the dry cord care group, we recorded a statistically significant reduction in the occurrence of severe cord infection (redness with pus) in the multiple-cleansing group (risk per 1000 livebirths=4.2 vs risk per 1000 livebirths=1.2; RR 0.35 [0.15-0.81]) but not in the single-cleansing group (risk per 1000 livebirths=3.3; RR 0.77 [0.40-1.48]). Interpretation Chlorhexidine cleansing of a neonate's umbilical cord can save lives, but further studies are needed to establish the best frequency with which to deliver the intervention.	[Mullany, Luke C.; Shah, Rasheduzzaman; Mannan, Ishtiaq; Begum, Nazma; Santosham, Mathuram; Black, Robert E.; Baqui, Abdullah H.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [El Arifeen, Shams; Rahman, Syed M.; Talukder, M. Radwanur R.; Baqui, Abdullah H.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; [Mannan, Ishtiaq] Save Children USA, Bangladesh Field Off, Dhaka, Bangladesh; [Darmstadt, Gary L.] Bill & Melinda Gates Fdn, Global Hlth Program, Family Hlth Div, Seattle, WA USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; International Centre for Diarrhoeal Disease Research (ICDDR); Save the Children; Bill & Melinda Gates Foundation	Baqui, AH (corresponding author), Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St,Suite E8138, Baltimore, MD 21205 USA.	abaqui@jhsph.edu	Shah, Rashed/Q-4965-2019; Shah, Mohammad/K-9146-2013; Rahman, Syed Moshfiqur/AAH-9000-2019; Darmstadt, Gary/AAU-7488-2020	Shah, Rashed/0000-0001-9488-5134; Rahman, Syed Moshfiqur/0000-0002-9441-0590; Arifeen, Shams/0000-0002-5372-5932; Talukder, Mohammad Radwanur Rahman/0000-0002-8343-9777; Black, Robert/0000-0001-9926-7984; Darmstadt, Gary/0000-0002-7522-5824	United States Agency for International Development (USAID) [GHS-A-00-03-00019-00, GHS-A-00-09-00004-00]; Bill & Melinda Gates Foundation [131]; Johns Hopkins Bloomberg School of Public Health	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)); Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Johns Hopkins Bloomberg School of Public Health(Johns Hopkins University)	This research was funded by the United States Agency for International Development (USAID), through cooperative agreements (GHS-A-00-03-00019-00, GHS-A-00-09-00004-00) with the Johns Hopkins Bloomberg School of Public Health and by the Saving Newborn Lives program of Save the Children (USA) through a grant from the Bill & Melinda Gates Foundation (number 131). Projahnmo was comprised of the ICDDR,B; the Bangladesh Government's Ministry of Health and Family Welfare; Bangladeshi non-governmental organisations, including Shimantik, Save the Children (USA), Dhaka Shishu Hospital, and the Institute of Child and Mother Health; and the Johns Hopkins Bloomberg School of Public Health. We thank the many individuals in Sylhet district who gave their time generously and the field and data management staff of Projahnmo who worked tirelessly. We thank the members of the Projahnmo Technical Review Committee, the Bangladesh Ministry of Health and Family Welfare colleagues at the sub-district, district, and central levels, and the members of the Shimantik Executive Committee for their valuable help and advice. We also acknowledge the crucial innovative inputs of Projahnmo study group members.	Alam MA, 2008, J PERINATOL, V28, pS61, DOI 10.1038/jp.2008.164; Baqui AH, 2006, B WORLD HEALTH ORGAN, V84, P706, DOI 10.2471/BLT.05.026443; Baqui AH, 2008, LANCET, V371, P1936, DOI 10.1016/S0140-6736(08)60835-1; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Hayes RJ, 2009, INTERD STAT, P3; Huber P., 1967, P 5 BERK S MATH STAT; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; McClure EM, 2007, INT J GYNECOL OBSTET, V97, P89, DOI 10.1016/j.ijgo.2007.01.014; Mullany LC, 2006, LANCET, V367, P910, DOI 10.1016/S0140-6736(06)68381-5; Mullany LC, 2003, PEDIATR INFECT DIS J, V22, P996, DOI 10.1097/01.inf.0000095429.97172.48; Mullany LC, 2007, AM J EPIDEMIOL, V165, P203, DOI 10.1093/aje/kwj356; Mullany LC, 2006, PEDIATR INFECT DIS J, V25, P665, DOI 10.1097/01.inf.0000223489.02791.70; Mullany LC, 2012, PEDIATR INFECT DIS J, V31, P444, DOI 10.1097/INF.0b013e3182468ff0; Mullany LC, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-67; Mullany LC, 2009, PEDIATR INFECT DIS J, V28, P503, DOI 10.1097/INF.0b013e3181950910; Mullany LC, 2009, PEDIATR INFECT DIS J, V28, P17, DOI 10.1097/INF.0b013e318181fb4c; Shah R, 2010, J HEALTH POPUL NUTR, V28, P610; SHORTLAN.WR, 1968, J CLIN PATHOL, V21, P422, DOI 10.1136/jcp.21.4.422; Soofi S, 2012, LANCET, V379, P1029, DOI 10.1016/S0140-6736(11)61877-1; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; *WHO, 1998, CAR UMB CORD; World Health Organization [WHO], 1998, WHORHTMSM984; Zupan J, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/1465-1858.CD001057	24	127	127	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2012	379	9820					1022	1028		10.1016/S0140-6736(11)61848-5	http://dx.doi.org/10.1016/S0140-6736(11)61848-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JE	22322124				2022-12-28	WOS:000301712300030
J	Marin-Burgin, A; Mongiat, LA; Pardi, MB; Schinder, AF				Marin-Burgin, Antonia; Mongiat, Lucas A.; Belen Pardi, M.; Schinder, Alejandro F.			Unique Processing During a Period of High Excitation/Inhibition Balance in Adult-Born Neurons	SCIENCE			English	Article							ENHANCED SYNAPTIC PLASTICITY; GENERATED GRANULE CELLS; DENTATE GYRUS; PATTERN SEPARATION; HIPPOCAMPAL NEUROGENESIS; INHIBITION; MEMORY; INTEGRATION; BRAIN; RAT	The adult dentate gyrus generates new granule cells (GCs) that develop over several weeks and integrate into the preexisting network. Although adult hippocampal neurogenesis has been implicated in learning and memory, the specific role of new GCs remains unclear. We examined whether immature adult-born neurons contribute to information encoding. By combining calcium imaging and electrophysiology in acute slices, we found that weak afferent activity recruits few mature GCs while activating a substantial proportion of the immature neurons. These different activation thresholds are dictated by an enhanced excitation/inhibition balance transiently expressed in immature GCs. Immature GCs exhibit low input specificity that switches with time toward a highly specific responsiveness. Therefore, activity patterns entering the dentate gyrus can undergo differential decoding by a heterogeneous population of GCs originated at different times.	[Marin-Burgin, Antonia; Mongiat, Lucas A.; Belen Pardi, M.; Schinder, Alejandro F.] Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim Buenos Aires, Inst Leloir, Lab Plasticidad Neuronal, RA-1405 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute	Schinder, AF (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim Buenos Aires, Inst Leloir, Lab Plasticidad Neuronal, Ave Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.	aschinder@leloir.org.ar	Mongiat, Lucas/GXG-5680-2022; Marin-Burgin, Antonia/V-6602-2019	Mongiat, Lucas/0000-0003-2643-8062; Marin-Burgin, Antonia/0000-0003-0684-9796; Schinder, Alejandro/0000-0003-4863-8348	CONICET; National Institutes of Health [FIRCA R03TW008607-01]; Howard Hughes Medical Institute [55005963]; Agencia Nacional de Promocion Cientifica y Tecnologica [PICT2008, PICT2010]; FOGARTY INTERNATIONAL CENTER [R03TW008607] Funding Source: NIH RePORTER	CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Agencia Nacional de Promocion Cientifica y Tecnologica(ANPCyT); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	We thank M. Veggetti for technical assistance, S. Ge for the channelrhodopsin-2 viral construct, and B. Aimone, Y. Li, F. Gage, and M. Scanziani for insightful discussions. A.M.B., L.A.M., and A.F.S. are investigators of the National Research Council (CONICET). M.B.P. was supported by a CONICET fellowship. This work was supported by the Guggenheim Fellowship and by grants from the National Institutes of Health (FIRCA R03TW008607-01), the Howard Hughes Medical Institute (grant 55005963), and the Agencia Nacional de Promocion Cientifica y Tecnologica PICT2008 to A.F.S. and PICT2010 to A.M.B. and A.F.S.	Aimone JB, 2006, NAT NEUROSCI, V9, P723, DOI 10.1038/nn1707; Aimone JB, 2011, NEURON, V70, P589, DOI 10.1016/j.neuron.2011.05.010; Aimone JB, 2009, NEURON, V61, P187, DOI 10.1016/j.neuron.2008.11.026; Becker S, 2007, TRENDS COGN SCI, V11, P70, DOI 10.1016/j.tics.2006.10.013; BUZSAKI G, 1981, BRAIN RES, V230, P346, DOI 10.1016/0006-8993(81)90413-3; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Ewell LA, 2010, J NEUROSCI, V30, P12597, DOI 10.1523/JNEUROSCI.1854-10.2010; Ge SY, 2008, J PHYSIOL-LONDON, V586, P3759, DOI 10.1113/jphysiol.2008.155655; Ge SY, 2007, NEURON, V54, P559, DOI 10.1016/j.neuron.2007.05.002; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Jessberger S, 2003, EUR J NEUROSCI, V18, P2707, DOI 10.1111/j.1460-9568.2003.02986.x; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Lacefield CO, 2012, HIPPOCAMPUS, V22, P106, DOI 10.1002/hipo.20860; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Markwardt SJ, 2009, J NEUROSCI, V29, P15063, DOI 10.1523/JNEUROSCI.2727-09.2009; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mongiat LA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005320; Poo C, 2009, NEURON, V62, P850, DOI 10.1016/j.neuron.2009.05.022; Pouille F, 2009, NAT NEUROSCI, V12, P1577, DOI 10.1038/nn.2441; Priebe NJ, 2008, NEURON, V57, P482, DOI 10.1016/j.neuron.2008.02.005; Ramirez-Amaya V, 2006, J NEUROSCI, V26, P12237, DOI 10.1523/JNEUROSCI.2195-06.2006; Sahay A, 2011, NEURON, V70, P582, DOI 10.1016/j.neuron.2011.05.012; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; Tashiro A, 2007, J NEUROSCI, V27, P3252, DOI 10.1523/JNEUROSCI.4941-06.2007; Treves A, 2008, NEUROSCIENCE, V154, P1155, DOI 10.1016/j.neuroscience.2008.04.073; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wang S, 2000, J NEUROBIOL, V42, P248, DOI 10.1002/(SICI)1097-4695(20000205)42:2<248::AID-NEU8>3.3.CO;2-A	32	249	254	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 9	2012	335	6073					1238	1242		10.1126/science.1214956	http://dx.doi.org/10.1126/science.1214956			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904VB	22282476	Green Accepted			2022-12-28	WOS:000301225100049
J	Baker, M				Baker, Monya			THE CHANGES THAT COUNT	NATURE			English	Editorial Material							SELECTION											Cooper GM, 2011, NAT REV GENET, V12, P628, DOI 10.1038/nrg3046; Dowell RD, 2010, SCIENCE, V328, P469, DOI 10.1126/science.1189015; Ehrenreich IM, 2010, NATURE, V464, P1039, DOI 10.1038/nature08923; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Fowler DM, 2010, NAT METHODS, V7, P741, DOI 10.1038/nmeth.1492; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hicks S, 2011, HUM MUTAT, V32, P661, DOI 10.1002/humu.21490; Hietpas RT, 2011, P NATL ACAD SCI USA, V108, P7896, DOI 10.1073/pnas.1016024108; Lappalainen T, 2011, AM J HUM GENET, V89, P459, DOI 10.1016/j.ajhg.2011.08.004; Lin MF, 2011, GENOME RES, V21, P1916, DOI 10.1101/gr.108753.110; Lindblad-Toh K, 2011, NATURE, V478, P476, DOI 10.1038/nature10530; Parts L, 2011, GENOME RES, V21, P1131, DOI 10.1101/gr.116731.110; Rope AF, 2011, AM J HUM GENET, V89, P28, DOI 10.1016/j.ajhg.2011.05.017; Yandell M, 2011, GENOME RES, V21, P1529, DOI 10.1101/gr.123158.111	14	14	14	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					257	262		10.1038/482257a	http://dx.doi.org/10.1038/482257a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	888HI	22318607				2022-12-28	WOS:000299994100046
J	Henao-Mejia, J; Elinav, E; Jin, CC; Hao, LM; Mehal, WZ; Strowig, T; Thaiss, CA; Kau, AL; Eisenbarth, SC; Jurczak, MJ; Camporez, JP; Shulman, GI; Gordon, JI; Hoffman, HM; Flavell, RA				Henao-Mejia, Jorge; Elinav, Eran; Jin, Chengcheng; Hao, Liming; Mehal, Wajahat Z.; Strowig, Till; Thaiss, Christoph A.; Kau, Andrew L.; Eisenbarth, Stephanie C.; Jurczak, Michael J.; Camporez, Joao-Paulo; Shulman, Gerald I.; Gordon, Jeffrey I.; Hoffman, Hal M.; Flavell, Richard A.			Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity	NATURE			English	Article							NONALCOHOLIC FATTY LIVER; NLRP3 INFLAMMASOME; ANIMAL-MODELS; STEATOHEPATITIS; ACTIVATION; MECHANISM; CIRRHOSIS	Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease in the Western world. Twenty per cent of NAFLD individuals develop chronic hepatic inflammation (non-alcoholic steatohepatitis, NASH) associated with cirrhosis, portal hypertension and hepatocellular carcinoma, yet the causes of progression from NAFLD to NASH remain obscure. Here, we show that the NLRP6 and NLRP3 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression, as well as multiple aspects of metabolic syndrome via modulation of the gut microbiota. Different mouse models reveal that inflammasome-deficiency-associated changes in the configuration of the gut microbiota are associated with exacerbated hepatic steatosis and inflammation through influx of TLR4 and TLR9 agonists into the portal circulation, leading to enhanced hepatic tumour-necrosis factor (TNF)-alpha expression that drives NASH progression. Furthermore, co-housing of inflammasome-deficient mice with wild-type mice results in exacerbation of hepatic steatosis and obesity. Thus, altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.	[Henao-Mejia, Jorge; Elinav, Eran; Jin, Chengcheng; Strowig, Till; Thaiss, Christoph A.; Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Jin, Chengcheng] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; [Hao, Liming] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Mehal, Wajahat Z.; Jurczak, Michael J.; Camporez, Joao-Paulo; Shulman, Gerald I.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; [Kau, Andrew L.; Gordon, Jeffrey I.] Washington Univ, Sch Med, Ctr Genome Sci & Syst Biol, St Louis, MO 63108 USA; [Kau, Andrew L.] Washington Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63108 USA; [Eisenbarth, Stephanie C.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA; [Shulman, Gerald I.; Flavell, Richard A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Hoffman, Hal M.] Univ Calif San Diego, Dept Pediat, Rady Childrens Hosp San Diego, La Jolla, CA 92093 USA	Yale University; Yale University; Yale University; Yale University; Washington University (WUSTL); Washington University (WUSTL); Yale University; Howard Hughes Medical Institute; Rady Childrens Hospital San Diego; University of California System; University of California San Diego	Flavell, RA (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, 333 Cedar St, New Haven, CT 06520 USA.	richard.flavell@yale.edu	Kau, Andrew/AGX-9881-2022; Shulman, Gerald I./P-7176-2019; Camporez, Joao Paulo G/B-9122-2015; Elinav, Eran/ABE-8881-2020	Shulman, Gerald I./0000-0003-1529-5668; Elinav, Eran/0000-0002-5775-2110; Kau, Andrew/0000-0002-9386-3766; Eisenbarth, Stephanie/0000-0002-1244-208X; Jurczak, Michael/0000-0002-6335-6915; Camporez, Joao Paulo/0000-0003-3486-4301; Strowig, Till/0000-0003-0185-1459; Jin, Chengcheng/0000-0001-9207-3191	Cancer Research Institute; Israel-US educational foundation; American Physicians for Medicine in Israel Foundation; Leukemia and Lymphoma Society; VA Merit award; Howard Hughes Medical Institute; United States-Israel binational Foundation; Crohn's and Colitis Foundation of America;  [T32HL007974];  [K08A1085038];  [R01DK076674-01];  [R01 DK-40936];  [R24 DK-085638];  [P30 DK-45735];  [U24 DK-059635]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R24DK085638, U24DK059635, R01DK076674, R01DK040936] Funding Source: NIH RePORTER	Cancer Research Institute; Israel-US educational foundation(US-Israel Binational Science Foundation); American Physicians for Medicine in Israel Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); VA Merit award(US Department of Veterans Affairs); Howard Hughes Medical Institute(Howard Hughes Medical Institute); United States-Israel binational Foundation(US-Israel Binational Science Foundation); Crohn's and Colitis Foundation of America; ; ; ; ; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank E. Eynon, J. Alderman, A. Williams, F. Manzo and H. Elinav for technical assistance and discussions; M. Graham and C. Rahner for performing electron microscopy; D. R. Peaper for assistance in microbiological culture procedures; R. Sherwin for helpful advice; X. Fan for technical assistance; Yale Diabetes Endocrinology Research Center and Mouse Metabolic Phenotyping Center for assistance with the metabolic analysis. E. E. is supported by the Cancer Research Institute (2010-2012) and by a supplementary grant from the Israel-US educational foundation (2009) and is a recipient of the Claire and Emmanuel G. Rosenblatt award from the American Physicians for Medicine in Israel Foundation (2010-2011). J. H. M. and T. S. are supported by Leukemia and Lymphoma Society Postdoctoral Fellowships. S. C. E. is supported by T32HL007974 and K08A1085038. W.Z.M. is supported by R01DK076674-01 and the VA Merit award. This work was supported in part by the Howard Hughes Medical Institute (G. I. S., R. A. F.), the United States-Israel binational Foundation grant (E. E. and R. A. F.), the Crohn's and Colitis Foundation of America (A. K. and J. I. G.) and R01 DK-40936, R24 DK-085638, P30 DK-45735 and U24 DK-059635 The authors report no conflict of interest.	Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Almeida J, 2006, WORLD J GASTROENTERO, V12, P1493, DOI 10.3748/wjg.v12.i10.1493; Bajaj J. S., 2011, AJP GASTROINTESTINAL, V302, P168; BROOME U, 1990, GUT, V31, P468, DOI 10.1136/gut.31.4.468; Brydges SD, 2009, IMMUNITY, V30, P875, DOI 10.1016/j.immuni.2009.05.005; Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Charlton M, 2008, HEPATOLOGY, V47, P1431, DOI 10.1002/hep.22246; Crespo J, 2001, HEPATOLOGY, V34, P1158, DOI 10.1053/jhep.2001.29628; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; Diehl AM, 2005, HEPATOL RES, V33, P138, DOI 10.1016/j.hepres.2005.09.022; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Guebre-Xabier M, 2000, HEPATOLOGY, V31, P633, DOI 10.1002/hep.510310313; Guo X, 2011, MUCOSAL IMMUNOL, V4, P294, DOI 10.1038/mi.2010.76; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hjelkrem M C, 2008, Minerva Med, V99, P583; Ikejima K, 2005, HEPATOL RES, V33, P151, DOI 10.1016/j.hepres.2005.09.024; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Li ZP, 2003, HEPATOLOGY, V37, P343, DOI 10.1053/jhep.2003.50048; LUDWIG J, 1980, MAYO CLIN PROC, V55, P434; Makiura N, 2008, ORAL MICROBIOL IMMUN, V23, P348, DOI 10.1111/j.1399-302X.2007.00426.x; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935; Miura K, 2010, GASTROENTEROLOGY, V139, P323, DOI 10.1053/j.gastro.2010.03.052; Netea MG, 2006, NAT MED, V12, P650, DOI 10.1038/nm1415; PROPST A, 1995, GASTROENTEROLOGY, V108, P1607, DOI 10.1016/0016-5085(95)90724-6; Rivera CA, 2007, J HEPATOL, V47, P571, DOI 10.1016/j.jhep.2007.04.019; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Sheth SG, 1997, ANN INTERN MED, V126, P137, DOI 10.7326/0003-4819-126-2-199701150-00008; Shimada M, 2002, J HEPATOL, V37, P154, DOI 10.1016/S0168-8278(02)00099-5; Stienstra R, 2011, P NATL ACAD SCI USA, V108, P15324, DOI 10.1073/pnas.1100255108; Sutterwala FS, 2007, J LEUKOCYTE BIOL, V82, P259, DOI 10.1189/jlb.1206755; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279; Varela-Rey M, 2009, INT J BIOCHEM CELL B, V41, P969, DOI 10.1016/j.biocel.2008.10.027; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	41	1580	1694	29	696	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					179	U67		10.1038/nature10809	http://dx.doi.org/10.1038/nature10809			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22297845	Green Accepted			2022-12-28	WOS:000299994100030
J	Cease, AJ; Elser, JJ; Ford, CF; Hao, SG; Kang, L; Harrison, JF				Cease, Arianne J.; Elser, James J.; Ford, Colleen F.; Hao, Shuguang; Kang, Le; Harrison, Jon F.			Heavy Livestock Grazing Promotes Locust Outbreaks by Lowering Plant Nitrogen Content	SCIENCE			English	Article							INSECT HERBIVORE; GRASSLAND ECOSYSTEMS; FOOD SELECTION; LIFE-SPAN; CHINA; GEOMETRY; GRASSHOPPERS; REPRODUCTION; DEGRADATION; LIMITATION	Current paradigms generally assume that increased plant nitrogen (N) should enhance herbivore performance by relieving protein limitation, increasing herbivorous insect populations. We show, in contrast to this scenario, that host plant N enrichment and high-protein artificial diets decreased the size and viability of Oedaleus asiaticus, a dominant locust of north Asian grasslands. This locust preferred plants with low N content and artificial diets with low protein and high carbohydrate content. Plant N content was lowest and locust abundance highest in heavily livestock-grazed fields where soils were N-depleted, likely due to enhanced erosion. These results suggest that heavy livestock grazing and consequent steppe degradation in the Eurasian grassland promote outbreaks of this locust by reducing plant protein content.	[Cease, Arianne J.; Elser, James J.; Ford, Colleen F.; Harrison, Jon F.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; [Hao, Shuguang; Kang, Le] Chinese Acad Sci, Inst Zool, State Key Lab Integrated Pest Management, Beijing, Peoples R China	Arizona State University; Arizona State University-Tempe; Chinese Academy of Sciences; Institute of Zoology, CAS	Cease, AJ (corresponding author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.	arianne.cease@asu.edu; james.elser@asu.edu; lkang@ioz.ac.cn; jon.harrison@asu.edu	Elser, James/A-7082-2008; Elser, James J/AAL-6199-2020; Kang, Le/ABD-1116-2022; Cease, Arianne/F-9954-2014	Elser, James/0000-0002-1460-2155; Elser, James J/0000-0002-1460-2155; Kang, Le/0000-0003-4262-2329; Cease, Arianne/0000-0002-4778-0775	National Science Foundation (EAPSI, DDEP) [DEB-0925017, EAR-0746352]; Sigma Xi; Marley-Webb Foundation; Johnston Foundation; P.E.O.; Chinese Research Grants of Public Welfare Fund for Agriculture [200903021]; Foundation of Chinese Academy of Sciences [Kscx2-yw-z-1021]	National Science Foundation (EAPSI, DDEP); Sigma Xi; Marley-Webb Foundation; Johnston Foundation; P.E.O.; Chinese Research Grants of Public Welfare Fund for Agriculture; Foundation of Chinese Academy of Sciences(Chinese Academy of Sciences)	The authors thank F. Jin, D. Niren, D. Flynn, Y. Kong, Z. Fan, J. Esman, Q. Chen, and G. Zhang for field and laboratory assistance; M. Quinlan, D. Denardo, J. VandenBrooks, C. Klok, S. Behmer, and J. Sabo for helpful discussion of experimental design; J. Wu for funding and scientific support; and M. McCrackin, F. Clissold, and three anonymous reviewers for valuable comments on the manuscript. This work was supported by the National Science Foundation (EAPSI, DDEP to A. J. C., DEB-0925017 to J. J. E., and EAR-0746352 to J. F. H.), Sigma Xi, Achievement Rewards for College Scientists (Marley-Webb and Johnston Foundations), P.E.O. Scholar Award to A. J. C., the Chinese Research Grants of Public Welfare Fund for Agriculture (Project 200903021), and the Foundation of Chinese Academy of Sciences (Project Kscx2-yw-z-1021). A. J. C. designed and performed experiments, analyzed data, and wrote the paper. J. J. E. and J. F. H. designed experiments and wrote the paper. C. F. F. and S. H. designed and performed experiments. L. K. gave scientific support and guidance. Data used in the analyses are available in the Supporting Online Material.	Behmer ST, 2008, P NATL ACAD SCI USA, V105, P1977, DOI 10.1073/pnas.0711870105; Behmer ST, 2009, ANNU REV ENTOMOL, V54, P165, DOI 10.1146/annurev.ento.54.110807.090537; BERNAYS EA, 1983, NITROGEN ECOLOGICAL, P321; Berner D, 2005, OIKOS, V111, P525, DOI 10.1111/j.1600-0706.2005.14144.x; Branson DH, 2006, BIOSCIENCE, V56, P743, DOI 10.1641/0006-3568(2006)56[743:SMOIHI]2.0.CO;2; Cease AJ, 2010, J INSECT PHYSIOL, V56, P926, DOI 10.1016/j.jinsphys.2010.05.020; Chen Z., 2000, TYPICAL STEPPE ECOSY; Clissold FJ, 2006, J ANIM ECOL, V75, P1000, DOI 10.1111/j.1365-2656.2006.01122.x; Clissold FJ, 2009, ECOLOGY, V90, P3393, DOI 10.1890/09-0130.1; Elser JJ, 2007, ECOL LETT, V10, P1135, DOI 10.1111/j.1461-0248.2007.01113.x; Flynn D. F. B., 2011, THESIS COLUMBIA U NE; Galloway JN, 2004, BIOGEOCHEMISTRY, V70, P153, DOI 10.1007/s10533-004-0370-0; Han JG, 2008, RANGELAND J, V30, P233, DOI 10.1071/RJ08009; [IFA IFDC FAO], 2006, FERT US CROP; Joern A, 1997, OECOLOGIA, V112, P201, DOI 10.1007/s004420050301; Kang L., 1995, INSECT SCI, V2, P265; Kang L, 2007, PHILOS T R SOC B, V362, P997, DOI 10.1098/rstb.2007.2029; Lee KP, 2008, P NATL ACAD SCI USA, V105, P2498, DOI 10.1073/pnas.0710787105; MATTSON WJ, 1980, ANNU REV ECOL SYST, V11, P119, DOI 10.1146/annurev.es.11.110180.001003; Raubenheimer D, 2006, ANIM BEHAV, V71, P1253, DOI 10.1016/j.anbehav.2005.07.024; Raubenheimer D, 2003, J EXP BIOL, V206, P1669, DOI 10.1242/jeb.00336; Raubenheimer D, 1999, ENTOMOL EXP APPL, V91, P67, DOI 10.1023/A:1003682921131; RAUBENHEIMER D, 1993, ANIM BEHAV, V45, P953, DOI 10.1006/anbe.1993.1114; SIMPSON SJ, 1993, PHILOS T R SOC B, V342, P381, DOI 10.1098/rstb.1993.0166; Simpson SJ, 2009, AGING-US, V1, P875, DOI 10.18632/aging.100098; Song Huaiming, 2011, P IEEE INT C COMM KY, P1, DOI [DOI 10.1145/2063384.2063407, 10.1145/2063384.2063407]; Tong C, 2004, J ARID ENVIRON, V59, P133, DOI 10.1016/j.jaridenv.2004.01.004; White T. C. R., 1993, INADEQUATE ENV NITRO; Wu J., 2002, B ECOL SOC AM, V83, P189, DOI DOI 10.1890/0012-9623(2002)083; Wu L, 2008, J ENVIRON QUAL, V37, P663, DOI 10.2134/jeq2007.0196	30	146	183	16	274	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					467	469		10.1126/science.1214433	http://dx.doi.org/10.1126/science.1214433			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282812				2022-12-28	WOS:000299466800050
J	He, CC; Bassik, MC; Moresi, V; Sun, K; Wei, YJ; Zou, ZJ; An, ZY; Loh, J; Fisher, J; Sun, QH; Korsmeyer, S; Packer, M; May, HI; Hill, JA; Virgin, HW; Gilpin, C; Xiao, GH; Bassel-Duby, R; Scherer, PE; Levine, B				He, Congcong; Bassik, Michael C.; Moresi, Viviana; Sun, Kai; Wei, Yongjie; Zou, Zhongju; An, Zhenyi; Loh, Joy; Fisher, Jill; Sun, Qihua; Korsmeyer, Stanley; Packer, Milton; May, Herman I.; Hill, Joseph A.; Virgin, Herbert W.; Gilpin, Christopher; Xiao, Guanghua; Bassel-Duby, Rhonda; Scherer, Philipp E.; Levine, Beth			Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis	NATURE			English	Article							CAUSES INSULIN-RESISTANCE; MICE; BECLIN-1; MOUSE; GENE; DIET; PHOSPHORYLATION; TUMORIGENESIS; SENSITIVITY; DISRUPTION	Exercise has beneficial effects on human health, including protection against metabolic disorders such as diabetes(1). However, the cellular mechanisms underlying these effects are incompletely understood. The lysosomal degradation pathway, autophagy, is an intracellular recycling system that functions during basal conditions in organelle and protein quality control(2). During stress, increased levels of autophagy permit cells to adapt to changing nutritional and energy demands through protein catabolism(3). Moreover, in animal models, autophagy protects against diseases such as cancer, neurodegenerative disorders, infections, inflammatory diseases, ageing and insulin resistance(4-6). Here we show that acute exercise induces autophagy in skeletal and cardiac muscle of fed mice. To investigate the role of exercise-mediated autophagy in vivo, we generated mutant mice that show normal levels of basal autophagy but are deficient in stimulus (exercise- or starvation)-induced autophagy. These mice (termed BCL2 AAA mice) contain knock-in mutations in BCL2 phosphorylation sites (Thr69Ala, Ser70Ala and Ser84Ala) that prevent stimulus-induced disruption of the BCL2-beclin-1 complex and autophagy activation. BCL2 AAA mice show decreased endurance and altered glucose metabolism during acute exercise, as well as impaired chronic exercise-mediated protection against high-fat-diet-induced glucose intolerance. Thus, exercise induces autophagy, BCL2 is a crucial regulator of exercise- (and starvation)-induced autophagy in vivo, and autophagy induction may contribute to the beneficial metabolic effects of exercise.	[He, Congcong; Wei, Yongjie; Zou, Zhongju; An, Zhenyi; Sun, Qihua; Levine, Beth] Univ Texas SW Med Ctr Dallas, Ctr Autophagy Res, Dallas, TX 75390 USA; [He, Congcong; Sun, Kai; Wei, Yongjie; Zou, Zhongju; An, Zhenyi; Sun, Qihua; May, Herman I.; Hill, Joseph A.; Scherer, Philipp E.; Levine, Beth] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [He, Congcong; Wei, Yongjie; Zou, Zhongju; Levine, Beth] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; [Bassik, Michael C.; Fisher, Jill; Korsmeyer, Stanley] Dana Farber Canc Inst, Boston, MA 02115 USA; [Moresi, Viviana; Bassel-Duby, Rhonda] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; [Sun, Kai; Scherer, Philipp E.] Univ Texas SW Med Ctr Dallas, Touchstone Diabet Ctr, Dallas, TX 75390 USA; [Loh, Joy; Virgin, Herbert W.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO USA; [Packer, Milton; Xiao, Guanghua] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Gilpin, Christopher] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Levine, Beth] Univ Texas SW Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Levine, B (corresponding author), Univ Texas SW Med Ctr Dallas, Ctr Autophagy Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	beth.levine@utsouthwestern.edu	Scherer, Philipp E/K-7819-2012; Fernandez-Revelles, Andres B/A-4391-2012; Moresi, Viviana/N-7977-2013; May, Herman I/S-6782-2018; May, Herman I/M-8645-2019; An, Zhenyi/H-9061-2016	Scherer, Philipp E/0000-0003-0680-3392; Fernandez-Revelles, Andres B/0000-0002-8089-650X; May, Herman I/0000-0002-9264-2320; May, Herman I/0000-0002-9264-2320; Moresi, viviana/0000-0003-1912-0339; Virgin, Herbert/0000-0001-8580-7628; Sun, Kai/0000-0002-4778-4549	National Institutes of Health [RO1 CA109618, ROI HL080244, ROI HL090842, ROI AI084887, RCI DK086629, RO1 CA112023, 1PO1 DK0887761]; NATIONAL CANCER INSTITUTE [R01CA112023, P30CA142543, R01CA109618] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758, RC1DK086629, P01DK088761] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the UT Southwestern Mouse Metabolic Phenotyping Core and E. Berglund for assistance with metabolic measurements, J. Shelton for assistance with muscle stains, N. Mizushima for critical reagents, and B. D. Levine for expert advice. This work was supported by National Institutes of Health grants RO1 CA109618 (B. L.), ROI HL080244 (J. A. H.), ROI HL090842 (J. A. H.), ROI AI084887 (H. W. V.), RCI DK086629 (P. E. S.), RO1 CA112023 (P. E. S.) and 1PO1 DK0887761 (P.E.S.).	Almind K, 2007, P NATL ACAD SCI USA, V104, P2366, DOI 10.1073/pnas.0610416104; Asterholm IW, 2010, AM J PATHOL, V176, P1364, DOI 10.2353/ajpath.2010.090647; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Berglund ED, 2009, ENDOCRINOLOGY, V150, P4084, DOI 10.1210/en.2009-0221; Butchbach MER, 2007, NEUROBIOL DIS, V27, P207, DOI 10.1016/j.nbd.2007.04.009; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Ebato C, 2008, CELL METAB, V8, P325, DOI 10.1016/j.cmet.2008.08.009; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Handschin C, 2008, NATURE, V454, P463, DOI 10.1038/nature07206; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001; Kuma A, 2010, SEMIN CELL DEV BIOL, V21, P683, DOI 10.1016/j.semcdb.2010.03.002; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Malik SA, 2011, ONCOGENE, V30, P3918, DOI 10.1038/onc.2011.104; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823; Moresi V, 2010, CELL, V143, P35, DOI 10.1016/j.cell.2010.09.004; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ryder JW, 2001, ACTA PHYSIOL SCAND, V171, P249, DOI 10.1046/j.1365-201x.2001.00827.x; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Sheehan D. C., 1980, THEORY PRACTICE HIST, P162; Shetty S, 2009, TRENDS PHARMACOL SCI, V30, P234, DOI 10.1016/j.tips.2009.02.004; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Yang L, 2010, CELL METAB, V11, P467, DOI 10.1016/j.cmet.2010.04.005; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	32	791	847	14	231	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2012	481	7382					511	U126		10.1038/nature10758	http://dx.doi.org/10.1038/nature10758			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881GY	22258505	Green Accepted, Green Published			2022-12-28	WOS:000299471800041
J	Gillman, MW; Daniels, SR				Gillman, Matthew W.; Daniels, Stephen R.			Is Universal Pediatric Lipid Screening Justified?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILDHOOD; CHILDREN; RISK		[Gillman, Matthew W.] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Dept Populat Med,Obes Prevent Program, Boston, MA 02215 USA; [Gillman, Matthew W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02215 USA; [Daniels, Stephen R.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus	Gillman, MW (corresponding author), Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Dept Populat Med,Obes Prevent Program, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	matthew_gillman@hms.harvard.edu			NHLBI NIH HHS [K24 HL 068041, K24 HL068041] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL068041] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 2007, PEDIATRICS, V120, pe215; [Anonymous], INTEGRATED GUIDELINE; Daniels SR, 2008, PEDIATRICS, V122, P198, DOI 10.1542/peds.2008-1349; GILLMAN MW, 1993, J PEDIATR-US, V122, P837, DOI 10.1016/S0022-3476(09)90005-1; GILLMAN MW, 1993, AM J DIS CHILD, V147, P393, DOI 10.1001/archpedi.1993.02160280043015; Lloyd-Lones DM, 2003, ARCH INTERN MED, V163, P1966, DOI 10.1001/archinte.163.16.1966; Ritchie SK, 2010, PEDIATRICS, V126, P260, DOI 10.1542/peds.2009-2546; Wald NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018742; Wang YC, 2011, J PEDIATR-US, V158, P257, DOI 10.1016/j.jpeds.2010.07.058; Wang YC, 2011, J PEDIAT, V158, pe1	10	50	50	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2012	307	3					259	260		10.1001/jama.2011.2012	http://dx.doi.org/10.1001/jama.2011.2012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877EY	22253390	Green Accepted			2022-12-28	WOS:000299161200019
J	Malhi, GS; Berk, M				Malhi, Gin S.; Berk, Michael			Is the safety of lithium no longer in the balance?	LANCET			English	Editorial Material							DISORDER		[Malhi, Gin S.] Royal N Shore Hosp, CADE Clin, Dept Psychiat, Sydney, NSW 2065, Australia; [Malhi, Gin S.] Univ Sydney, Discipline Psychiat, Sydney Med Sch, Sydney, NSW 2006, Australia; [Malhi, Gin S.] No Sydney Cent Coast Area Hlth Serv, Sydney, NSW, Australia; [Berk, Michael] Deakin Univ, Sch Med, Geelong, Vic 3217, Australia; [Berk, Michael] Univ Melbourne, Orygen Youth Hlth Res Ctr, Ctr Youth Mental Hlth, Parkville, Vic 3052, Australia; [Berk, Michael] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia; [Berk, Michael] Swanston Ctr, Barwon Hlth & Geelong Clin, Geelong, Vic, Australia; [Berk, Michael] Mental Hlth Res Inst Victoria, Parkville, Vic, Australia	Royal North Shore Hospital; University of Sydney; University of Sydney; Deakin University; Orygen, The National Centre of Excellence in Youth Mental Health; University of Melbourne; University of Melbourne	Malhi, GS (corresponding author), Royal N Shore Hosp, CADE Clin, Dept Psychiat, Sydney, NSW 2065, Australia.	gin.malhi@sydney.edu.au	Berk, Michael/M-3585-2019; Malhi, Gin/Z-2418-2019; Berk, Michael/M-7891-2013	Berk, Michael/0000-0002-5554-6946; Berk, Michael/0000-0002-5554-6946; Malhi, Gin/0000-0002-4524-9091				Berk M, 1996, CLIN NEUROPHARMACOL, V19, P48, DOI 10.1097/00002826-199619010-00002; COPPEN A, 1983, J AFFECT DISORDERS, V5, P353, DOI 10.1016/0165-0327(83)90026-5; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Correll CU, 2011, EUR ARCH PSY CLIN N, V261, P417, DOI 10.1007/s00406-010-0177-z; Geddes JR, 2010, LANCET, V375, P385, DOI 10.1016/S0140-6736(09)61828-6; Malhi GS, 2011, BIPOLAR DISORD, V13, P219, DOI 10.1111/j.1399-5618.2011.00918.x; Malhi GS, 2011, CNS DRUGS, V25, P289, DOI 10.2165/11586970-000000000-00000; Malhi GS, 2009, AUST NZ J PSYCHIAT, V43, P1093; McKnight RF, 2012, LANCET, V379, P721, DOI 10.1016/S0140-6736(11)61516-X; Newcomer JW, 2005, CNS DRUGS, V19, P1; Ng F, 2009, BIPOLAR DISORD, V11, P559, DOI 10.1111/j.1399-5618.2009.00737.x; Severus WE, 2010, EUR PSYCHIAT, V25, P443, DOI 10.1016/j.eurpsy.2009.10.009; Severus WE, 2009, J AFFECT DISORDERS, V115, P466, DOI 10.1016/j.jad.2008.10.009; Tredget J, 2010, J AFFECT DISORDERS, V126, P436, DOI 10.1016/j.jad.2010.04.018; VESTERGAARD P, 1988, ACTA PSYCHIAT SCAND, V78, P434, DOI 10.1111/j.1600-0447.1988.tb06363.x	15	25	26	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2012	379	9817					690	692		10.1016/S0140-6736(11)61703-0	http://dx.doi.org/10.1016/S0140-6736(11)61703-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899CU	22265701				2022-12-28	WOS:000300792600006
J	Gill, JS; Tonelli, M				Gill, John S.; Tonelli, Marcello			Penny Wise, Pound Foolish? Coverage Limits on Immunosuppression after Kidney Transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Gill, John S.] Univ British Columbia, Div Nephrol, Vancouver, BC V5Z 1M9, Canada; [Tonelli, Marcello] Univ Alberta, Div Nephrol, Edmonton, AB, Canada; [Gill, John S.; Tonelli, Marcello] Interdisciplinary Chron Dis Collaborat, Calgary, AB, Canada	University of British Columbia; University of Alberta	Gill, JS (corresponding author), Univ British Columbia, Div Nephrol, Vancouver, BC V5Z 1M9, Canada.		Tonelli, Marcello/B-3028-2009	Tonelli, Marcello/0000-0002-0846-3187				Becker BN, 2010, CLIN J AM SOC NEPHRO, V5, P744, DOI 10.2215/CJN.02610310; Evans RW, 2010, CLIN J AM SOC NEPHRO, V5, P2323, DOI 10.2215/CJN.04220510; Kasiske BL, 2000, JAMA-J AM MED ASSOC, V283, P2445, DOI 10.1001/jama.283.18.2445; Page Timothy F, 2009, Expert Rev Pharmacoecon Outcomes Res, V9, P435, DOI 10.1586/erp.09.52; Woodward R S, 2008, Am J Transplant, V8, P2636, DOI 10.1111/j.1600-6143.2008.02422.x	5	57	58	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2012	366	7					586	589		10.1056/NEJMp1114394	http://dx.doi.org/10.1056/NEJMp1114394			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IL	22296029				2022-12-28	WOS:000300279800003
J	Hino, T; Arakawa, T; Iwanari, H; Yurugi-Kobayashi, T; Ikeda-Suno, C; Nakada-Nakura, Y; Kusano-Arai, O; Weyand, S; Shimamura, T; Nomura, N; Cameron, AD; Kobayashi, T; Hamakubo, T; Iwata, S; Murata, T				Hino, Tomoya; Arakawa, Takatoshi; Iwanari, Hiroko; Yurugi-Kobayashi, Takami; Ikeda-Suno, Chiyo; Nakada-Nakura, Yoshiko; Kusano-Arai, Osamu; Weyand, Simone; Shimamura, Tatsuro; Nomura, Norimichi; Cameron, Alexander D.; Kobayashi, Takuya; Hamakubo, Takao; Iwata, So; Murata, Takeshi			G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody	NATURE			English	Article							ADENOSINE A(2A) RECEPTOR; CRYSTAL-STRUCTURE; COMPLEX; GPCR; VALIDATION; EXPRESSION; RHODOPSIN; MODELS	G-protein-coupled receptors are the largest class of cell-surface receptors, and these membrane proteins exist in equilibrium between inactive and active states(1-13). Conformational changes induced by extracellular ligands binding to G-protein-coupled receptors result in a cellular response through the activation of G proteins. The A(2A) adenosine receptor (A(2A)AR) is responsible for regulating blood flow to the cardiac muscle and is important in the regulation of glutamate and dopamine release in the brain(14). Here we report the raising of a mouse monoclonal antibody against human A(2A)AR that prevents agonist but not antagonist binding to the extracellular ligand-binding pocket, and describe the structure of A(2A)AR in complex with the antibody Fab fragment (Fab2838). This structure reveals that Fab2838 recognizes the intracellular surface of A(2A)AR and that its complementarity-determining region, CDR-H3, penetrates into the receptor. CDR-H3 is located in a similar position to the G-protein carboxy-terminal fragment in the active opsin structure(1) and to CDR-3 of the nanobody in the active beta(2)-adrenergic receptor structure(2), but locks A(2A)AR in an inactive conformation. These results suggest a new strategy to modulate the activity of G-protein-coupled receptors.	[Hino, Tomoya; Arakawa, Takatoshi; Yurugi-Kobayashi, Takami; Ikeda-Suno, Chiyo; Weyand, Simone; Shimamura, Tatsuro; Nomura, Norimichi; Cameron, Alexander D.; Kobayashi, Takuya; Iwata, So; Murata, Takeshi] Japan Sci & Technol Agcy, Iwata Human Receptor Crystallog Project, ERATO, Sakyo Ku, Kyoto 6068501, Japan; [Hino, Tomoya; Arakawa, Takatoshi; Yurugi-Kobayashi, Takami; Ikeda-Suno, Chiyo; Shimamura, Tatsuro; Nomura, Norimichi; Kobayashi, Takuya; Iwata, So; Murata, Takeshi] Kyoto Univ, Dept Cell Biol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan; [Iwanari, Hiroko; Nakada-Nakura, Yoshiko; Kusano-Arai, Osamu; Hamakubo, Takao] Univ Tokyo, Dept Mol Biol & Med, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan; [Nakada-Nakura, Yoshiko] Perseus Proteom Inc, Meguro Ku, Tokyo 1530041, Japan; [Kusano-Arai, Osamu] Inst Immunol Co Ltd, Bunkyo Ku, Tokyo 1120004, Japan; [Weyand, Simone; Cameron, Alexander D.; Iwata, So] Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, Membrane Prot Crystallog Grp, London SW7 2AZ, England; [Weyand, Simone; Cameron, Alexander D.; Iwata, So] Diamond Light Source, Membrane Prot Lab, Didcot OX11 0DE, Oxon, England; [Weyand, Simone; Cameron, Alexander D.; Iwata, So] Rutherford Appleton Lab, Didcot OX11 0FA, Oxon, England; [Kobayashi, Takuya] Kyoto Univ, Fac Med, Japan Sci & Technol Agcy, Kyoto 6068501, Japan; [Iwata, So; Murata, Takeshi] RIKEN, Syst & Struct Biol Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; [Murata, Takeshi] Chiba Univ, Grad Sch Sci, Dept Chem, Chiba 2638522, Japan	Japan Science & Technology Agency (JST); Kyoto University; University of Tokyo; Imperial College London; Diamond Light Source; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; Japan Science & Technology Agency (JST); Kyoto University; RIKEN; Chiba University	Iwata, S (corresponding author), Japan Sci & Technol Agcy, Iwata Human Receptor Crystallog Project, ERATO, Sakyo Ku, Yoshidakonoe Cho, Kyoto 6068501, Japan.	so_iwata@mac.com; t.murata@faculty.chiba-u.jp	Cameron, Alexander/L-7288-2013; Arakawa, Takatoshi/K-9739-2013; Murata, Takeshi/J-6181-2017	Arakawa, Takatoshi/0000-0001-6496-5440; Murata, Takeshi/0000-0002-5748-4670; Cameron, Alexander/0000-0001-8776-3518	Japan Science and Technology Agency; MEXT, Japan; Development of New Functional Antibody Technologies (New Energy and Industrial Technology Development Organization, Japan); Biotechnology and Biological Sciences Research Council [BB/G023425/1]; Wellcome Trust at the Diamond Light Source, UK [062164/Z/00/Z]; BBSRC [BB/G023425/1] Funding Source: UKRI; Grants-in-Aid for Scientific Research [23370049, 22570114, 20221010] Funding Source: KAKEN	Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Development of New Functional Antibody Technologies (New Energy and Industrial Technology Development Organization, Japan); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust at the Diamond Light Source, UK; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the ERATO Human Receptor Crystallography Project of the Japan Science and Technology Agency (S. I.), by the Targeted Proteins Research Program of MEXT, Japan (S. I.), and by Development of New Functional Antibody Technologies (New Energy and Industrial Technology Development Organization, Japan) (T. Hamakubo). It was also partly funded by the Biotechnology and Biological Sciences Research Council (BB/G023425/1) (S. I.). The work was partly performed in the Membrane Protein Laboratory funded by the Wellcome Trust (grant 062164/Z/00/Z) (S. I.) at the Diamond Light Source, UK. Data were collected at Diamond Light Source beamline I24 with the assistance of G. Evans, R. Owen, D. Axford and J. Aishima.	Afonine PV, 2005, ACTA CRYSTALLOGR D, V61, P850, DOI 10.1107/S0907444905007894; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410; Chung KY, 2011, NATURE, V477, P611, DOI 10.1038/nature10488; DeLano W.L, PYMOL MOL GRAPHICS S; Dore AS, 2011, STRUCTURE, V19, P1283, DOI 10.1016/j.str.2011.06.014; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fredholm BB, 2005, ANNU REV PHARMACOL, V45, P385, DOI 10.1146/annurev.pharmtox.45.120403.095731; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Lebon G, 2011, NATURE, V474, P521, DOI 10.1038/nature10136; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Muller CE, 2011, BBA-BIOMEMBRANES, V1808, P1290, DOI 10.1016/j.bbamem.2010.12.017; Murakami M, 2008, NATURE, V453, P363, DOI 10.1038/nature06925; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648; Rosenbaum DM, 2011, NATURE, V469, P236, DOI 10.1038/nature09665; Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330; Shimamura T, 2008, J BIOL CHEM, V283, P17753, DOI 10.1074/jbc.C800040200; Shimamura T, 2011, NATURE, V475, P65, DOI 10.1038/nature10236; Warne T, 2003, BBA-BIOMEMBRANES, V1610, P133, DOI 10.1016/S0005-2736(02)00716-2; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Warne T, 2011, NATURE, V469, P241, DOI 10.1038/nature09746; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; Xu F, 2011, SCIENCE, V332, P322, DOI 10.1126/science.1202793; Yang ZR, 2005, BIOINFORMATICS, V21, P3369, DOI 10.1093/bioinformatics/bti534; Yao XJ, 2009, P NATL ACAD SCI USA, V106, P9501, DOI 10.1073/pnas.0811437106; Yurugi-Kobayashi T, 2009, BIOCHEM BIOPH RES CO, V380, P271, DOI 10.1016/j.bbrc.2009.01.053	35	227	242	1	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					237	U130		10.1038/nature10750	http://dx.doi.org/10.1038/nature10750			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22286059	Green Accepted			2022-12-28	WOS:000299994100042
J	Itzkovitz, S; Blat, IC; Jacks, T; Clevers, H; van Oudenaarden, A				Itzkovitz, Shalev; Blat, Irene C.; Jacks, Tyler; Clevers, Hans; van Oudenaarden, Alexander			Optimality in the Development of Intestinal Crypts	CELL			English	Article							DUODENAL PROGENITOR POPULATION; HEMATOPOIETIC STEM-CELLS; MOUSE SMALL-INTESTINE; PANETH CELLS; CANCER; DIFFERENTIATION; EPITHELIUM; LGR5; NEURONOGENESIS; PROLIFERATION	Intestinal crypts in mammals are comprised of long-lived stem cells and shorter-lived progenies. These two populations are maintained in specific proportions during adult life. Here, we investigate the design principles governing the dynamics of these proportions during crypt morphogenesis. Using optimal control theory, we show that a proliferation strategy known as a "bang-bang" control minimizes the time to obtain a mature crypt. This strategy consists of a surge of symmetric stem cell divisions, establishing the entire stem cell pool first, followed by a sharp transition to strictly asymmetric stem cell divisions, producing nonstem cells with a delay. We validate these predictions using lineage tracing and single-molecule fluorescence in situ hybridization of intestinal crypts in infant mice, uncovering small crypts that are entirely composed of Lgr5-labeled stem cells, which become a minority as crypts continue to grow. Our approach can be used to uncover similar design principles in other developmental systems.	[Itzkovitz, Shalev; van Oudenaarden, Alexander] MIT, Dept Phys, Cambridge, MA 02139 USA; [Blat, Irene C.; Jacks, Tyler; van Oudenaarden, Alexander] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Itzkovitz, Shalev; Blat, Irene C.; Jacks, Tyler; van Oudenaarden, Alexander] MIT, Dept Biol, Cambridge, MA 02139 USA; [Jacks, Tyler] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Clevers, Hans; van Oudenaarden, Alexander] Royal Netherlands Acad Arts & Sci, Hubrecht Inst KNAW, NL-3584 CT Utrecht, Netherlands; [Clevers, Hans; van Oudenaarden, Alexander] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center	van Oudenaarden, A (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	avano@mit.edu	van Oudenaarden, Alexander/AAA-1705-2019		NIH/NCI Physical Sciences Oncology Center at MIT [U54CA143874]; NIH [1DP1OD003936]; National Cancer Institute [P30-CA14051]; International Human Frontiers Science Program Organization; Machiah Foundation; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [U54CA143874, P30CA014051, DP1CA174420] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD003936] Funding Source: NIH RePORTER	NIH/NCI Physical Sciences Oncology Center at MIT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); International Human Frontiers Science Program Organization(Human Frontier Science Program); Machiah Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Uri Alon for suggesting the optimality problem. We thank Johan van Es for help with the lineage tracing experiments. We also thank George Oster, Hyun Youk, Stefan Semrau and Sandy Klemm for valuable discussions. This work was supported by the NIH/NCI Physical Sciences Oncology Center at MIT (U54CA143874) and a NIH Pioneer award (1DP1OD003936) to A.v.O. and in part by Cancer Center Support (core) grant P30-CA14051 from the National Cancer Institute. T.J. is a Howard Hughes Investigator and a Daniel K. Ludwig Scholar. S.I. acknowledges support from the International Human Frontiers Science Program Organization and the Machiah Foundation. I.B. acknowledges support from the Howard Hughes Medical Institute Gilliam fellowship.	ALNAFUSSI AI, 1982, VIRCHOWS ARCH B, V40, P51, DOI 10.1007/BF02932850; Alon U., 2006, INTRO SYSTEMS BIOL D; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; BJERKNES M, 1981, AM J ANAT, V160, P65, DOI 10.1002/aja.1001600106; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Brizova H, 2010, VIRCHOWS ARCH, V456, P671, DOI 10.1007/s00428-010-0922-8; Buske P, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001045; CAMERON IL, 1963, J CELL BIOL, V18, P31, DOI 10.1083/jcb.18.1.31; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Clayton E, 2007, NATURE, V446, P185, DOI 10.1038/nature05574; Frank SA, 2003, GENETICS, V163, P1527; GREY RD, 1968, DEV BIOL, V18, P501, DOI 10.1016/0012-1606(68)90054-7; Itzkovitz S, 2012, NAT CELL BIOL, V14, P106, DOI 10.1038/ncb2384; Kimble J, 2007, ANNU REV CELL DEV BI, V23, P405, DOI 10.1146/annurev.cellbio.23.090506.123326; Kirk D. E, 2004, OPTIMAL CONTROL THEO; Klein AM, 2010, CELL STEM CELL, V7, P214, DOI 10.1016/j.stem.2010.05.017; Komarova NL, 2008, J R SOC INTERFACE, V5, P105, DOI 10.1098/rsif.2007.1054; Koo D, 1977, ELEMENTS OPTIMIZATIO; Lander AD, 2009, PLOS BIOL, V7, P84, DOI 10.1371/journal.pbio.1000015; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Lopez-Garcia C, 2010, SCIENCE, V330, P822, DOI 10.1126/science.1196236; MACEVICZ S, 1976, BEHAV ECOL SOCIOBIOL, V1, P265, DOI 10.1007/BF00300068; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Michor F, 2003, J THEOR BIOL, V225, P377, DOI 10.1016/S0022-5193(03)00267-4; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; Nowakowski Richard S, 2002, Results Probl Cell Differ, V39, P1; PERELSON AS, 1976, J MATH BIOL, V3, P325, DOI 10.1007/BF00275065; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; QUASTLER H, 1959, EXP CELL RES, V17, P420, DOI 10.1016/0014-4827(59)90063-1; Raj A, 2008, NAT METHODS, V5, P877, DOI 10.1038/NMETH.1253; Raj A, 2010, NATURE, V463, P913, DOI 10.1038/nature08781; Reeves GT, 2009, PLOS BIOL, V7, P32, DOI 10.1371/journal.pbio.1000021; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Schepers AG, 2011, EMBO J, V30, P1104, DOI 10.1038/emboj.2011.26; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; Slack JMW, 2000, SCIENCE, V287, P1431, DOI 10.1126/science.287.5457.1431; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; THRASHER JD, 1966, J EXP ZOOL, V161, P9, DOI 10.1002/jez.1401610103; THRASHER JD, 1965, J EXP ZOOL, V159, P39, DOI 10.1002/jez.1401590105; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998	45	112	113	1	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					608	619		10.1016/j.cell.2011.12.025	http://dx.doi.org/10.1016/j.cell.2011.12.025			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304925	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000300225000026
J	Nishino, T; Takeuchi, K; Gascoigne, KE; Suzuki, A; Hori, T; Oyama, T; Morikawa, K; Cheeseman, IM; Fukagawa, T				Nishino, Tatsuya; Takeuchi, Kozo; Gascoigne, Karen E.; Suzuki, Aussie; Hori, Tetsuya; Oyama, Takuji; Morikawa, Kosuke; Cheeseman, Iain M.; Fukagawa, Tatsuo			CENP-T-W-S-X Forms a Unique Centromeric Chromatin Structure with a Histone-like Fold	CELL			English	Article							CRYSTAL-STRUCTURE; DNA; NUCLEOSOME; COMPLEX; CORE	The multiprotein kinetochore complex must assemble at a specific site on each chromosome to achieve accurate chromosome segregation. Defining the nature of the DNA-protein interactions that specify the position of the kinetochore and provide a scaffold for kinetochore formation remain key goals. Here, we demonstrate that the centromeric histone-fold-containing CENP-T-W and CENP-S-X complexes coassemble to form a stable CENP-T-W-S-X heterotetramer. High-resolution structural analysis of the individual complexes and the heterotetramer reveals similarity to other histone fold-containing complexes including canonical histones within a nucleosome. The CENP-T-W-S-X heterotetramer binds to and supercoils DNA. Mutants designed to compromise heterotetramerization or the DNA-protein contacts around the heterotetramer strongly reduce the DNA binding and supercoiling activities in vitro and compromise kinetochore assembly in vivo. These data suggest that the CENP-T-W-S-X complex forms a unique nucleosome-like structure to generate contacts with DNA, extending the "histone code'' beyond canonical nucleosome proteins.	[Nishino, Tatsuya; Takeuchi, Kozo; Suzuki, Aussie; Hori, Tetsuya; Fukagawa, Tatsuo] Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan; [Nishino, Tatsuya; Takeuchi, Kozo; Suzuki, Aussie; Hori, Tetsuya; Fukagawa, Tatsuo] Grad Univ Adv Studies SOKENDAI, Mishima, Shizuoka 4118540, Japan; [Gascoigne, Karen E.; Cheeseman, Iain M.] Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Gascoigne, Karen E.; Cheeseman, Iain M.] Nine Cambridge Ctr, Dept Biol, MIT, Cambridge, MA 02142 USA; [Oyama, Takuji; Morikawa, Kosuke] Osaka Univ, Takara Bio Endowed Div, Dept Biomol Recognit, Inst Prot Res, Suita, Osaka 5650874, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Osaka University	Fukagawa, T (corresponding author), Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan.	tfukagaw@lab.nig.ac.jp	Fukagawa, Tatsuo/AAK-3922-2021; Suzuki, Aussie/ABF-4170-2021	Suzuki, Aussie/0000-0001-7390-5116; Takeuchi, Kozo/0000-0003-2531-9264; Oyama, Takuji/0000-0002-3411-7608; nishino, tatsuya/0000-0001-8017-8762; Cheeseman, Iain/0000-0002-3829-5612	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Cabinet Office, Government of Japan; Searle Scholars Program; NIH/National Institute of General Medical Sciences [GM088313]; The International Human Frontier Science Program Organization; MEXT; EMBO; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088313] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23121530, 22570008] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Cabinet Office, Government of Japan; Searle Scholars Program; NIH/National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); The International Human Frontier Science Program Organization(Human Frontier Science Program); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); EMBO(European Molecular Biology Organization (EMBO)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors are grateful to M. Takahashi, K. Suzuki, K. Nakaguchi, and K. Kita for technical assistance; C. Davey for the generous gift of the pUC57-601-145 plasmid; and H. Kurumizaka for the advice on histone experiments. The synchrotron radiation experiments were performed at the BL38B1 and BL44XU of SPring-8 with the approval of the Japan Synchrotron Radiation Research Institute (JASRI) (Proposal No. 2010B1059, 2010B1060, and 2011A1211). This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan and the Cabinet Office, Government of Japan through its "Funding Program for Next Generation World-Leading Researchers'' to TF and grants from the Searle Scholars Program and the NIH/National Institute of General Medical Sciences (GM088313) to IMC. TN is supported by The International Human Frontier Science Program Organization grant and by Grants-in-Aid for Scientific Research from MEXT. KEG is supported by an EMBO long-term fellowship.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Amano M, 2009, J CELL BIOL, V186, P173, DOI 10.1083/jcb.200903100; Barnhart MC, 2011, J CELL BIOL, V194, P229, DOI 10.1083/jcb.201012017; Black B, 2011, CELL, V144, P471, DOI 10.1016/j.cell.2011.02.002; Burley SK, 1997, CURR OPIN STRUC BIOL, V7, P94, DOI 10.1016/S0959-440X(97)80012-7; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Gascoigne KE, 2011, CELL, V145, P410, DOI 10.1016/j.cell.2011.03.031; Guse A, 2011, NATURE, V477, P354, DOI 10.1038/nature10379; Hartlepp KF, 2005, MOL CELL BIOL, V25, P9886, DOI 10.1128/MCB.25.22.9886-9896.2005; Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366; Hori T, 2008, CELL, V135, P1039, DOI 10.1016/j.cell.2008.10.019; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Okada M, 2006, NAT CELL BIOL, V8, P446, DOI 10.1038/ncb1396; Perpelescu M, 2011, CHROMOSOMA, V120, P425, DOI 10.1007/s00412-011-0330-0; Prendergast L, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001082; Ribeiro SA, 2010, P NATL ACAD SCI USA, V107, P10484, DOI 10.1073/pnas.1002325107; Santaguida S, 2009, EMBO J, V28, P2511, DOI 10.1038/emboj.2009.173; Singh TR, 2010, MOL CELL, V37, P879, DOI 10.1016/j.molcel.2010.01.036; Suzuki A, 2011, J CELL BIOL, V193, P125, DOI 10.1083/jcb.201012050; Tachiwana H, 2011, NATURE, V476, P232, DOI 10.1038/nature10258; Van Hooser AA, 2001, J CELL SCI, V114, P3529; Vasudevan D, 2010, J MOL BIOL, V403, P1, DOI 10.1016/j.jmb.2010.08.039; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yan ZJ, 2010, MOL CELL, V37, P865, DOI 10.1016/j.molcel.2010.01.039	28	179	189	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					487	501		10.1016/j.cell.2011.11.061	http://dx.doi.org/10.1016/j.cell.2011.11.061			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304917	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000300225000017
J	Silvain, J; Beygui, F; Barthelemy, O; Pollack, C; Cohen, M; Zeymer, U; Huber, K; Goldstein, P; Cayla, G; Collet, JP; Vicaut, E; Montalescot, G				Silvain, Johanne; Beygui, Farzin; Barthelemy, Olivier; Pollack, Charles, Jr.; Cohen, Marc; Zeymer, Uwe; Huber, Kurt; Goldstein, Patrick; Cayla, Guillaume; Collet, Jean-Philippe; Vicaut, Eric; Montalescot, Gilles			Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELEVATION MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; UNSTABLE ANGINA-PECTORIS; EARLY INVASIVE STRATEGY; HIGH-RISK PATIENTS; INTRAVENOUS ENOXAPARIN; RANDOMIZED-TRIAL; UNSELECTED PATIENTS; SUBCUTANEOUS ENOXAPARIN; IIB/IIIA INHIBITORS	Objective To determine the efficacy and safety of enoxaparin compared with unfractionated heparin during percutaneous coronary intervention. Design Systematic review and meta-analysis. Data sources Medline and Cochrane database of systematic reviews, January 1996 to May 2011. Study selection Randomised and non-randomised studies comparing enoxaparin with unfractionated heparin during percutaneous coronary intervention and reporting on both mortality (efficacy end point) and major bleeding (safety end point) outcomes. Data extraction Sample size, characteristics, and outcomes, extracted independently and analysed. Data synthesis 23 trials representing 30 966 patients were identified, including 10 243 patients (33.1%) undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction, 8750 (28.2%) undergoing secondary percutaneous coronary intervention after fibrinolysis, and 11 973 (38.7%) with non-ST elevation acute coronary syndrome or stable patients scheduled for percutaneous coronary intervention. A total of 13 943 patients (45.0%) received enoxaparin and 17 023 (55.0%) unfractionated heparin. Enoxaparin was associated with significant reductions in death (relative risk 0.66, 95% confidence interval 0.57 to 0.76; P<0.001), the composite of death or myocardial infarction (0.68, 0.57 to 0.81; P<0.001), and complications of myocardial infarction (0.75, 0.6 to 0.85; P<0.001), and a reduction in incidence of major bleeding (0.80, 0.68 to 0.95; P=0.009). In patients who underwent primary percutaneous coronary intervention, the reduction in death (0.52, 0.42 to 0.64; P<0.001) was particularly significant and associated with a reduction in major bleeding (0.72, 0.56 to 0.93; P=0.01). Conclusion Enoxaparin seems to be superior to unfractionated heparin in reducing mortality and bleeding outcomes during percutaneous coronary intervention and particularly in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction.	[Silvain, Johanne; Beygui, Farzin; Barthelemy, Olivier; Collet, Jean-Philippe; Montalescot, Gilles] CHU Pitie Salpetriere, Inst Cardiol, Bur 2 236, F-75013 Paris, France; [Pollack, Charles, Jr.] Univ Penn, Penn Hosp, Dept Emergency Med, Philadelphia, PA 19104 USA; [Cohen, Marc] Newark Beth Israel Med Ctr, Div Cardiol, Newark, NJ USA; [Zeymer, Uwe] Herzzentrum Klinikum Ludwigshafen, Med Klin B, Ludwigshafen, Germany; [Huber, Kurt] Wilhelminen Hosp, Dept Internal Med Cardiol & Emergency Med, Vienna, Austria; [Goldstein, Patrick] CHRU Lille, SAMU, Lille, France; [Cayla, Guillaume] Ctr Hosp Caremeau, Dept Cardiol, Nimes, France; [Vicaut, Eric] Lariboisiere Hosp, Unite Rech Clin, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Pennsylvania; Pennsylvania Medicine; Newark Beth Israel Medical Center; Wilhelminenspital; Universite de Lille - ISITE; CHU Lille; Universite de Montpellier; CHU de Nimes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Montalescot, G (corresponding author), CHU Pitie Salpetriere, Inst Cardiol, Bur 2 236, 47 Blvd Hop, F-75013 Paris, France.	gilles.montalescot@psl.aphp.fr	SILVAIN, Johanne/C-7521-2016	SILVAIN, Johanne/0000-0002-1901-2808	la Federation Francaise de Cardiologie; Abbott Vascular; AstraZeneca; CLS Behring; Daiichi Sankyo; Eli Lilly; Biotronik; Iroko Cardio; Sanofi-Aventis; Bristol-Myers Squibb; Merck; Guerbet Medical; Medtronic; Boston Scientific; Cordis; Stago; Fondation de France; INSERM; Societe Francaise de Cardiologie; Medicines Company; Bayer; BMS; Boehringer Ingelheim; Pfizer; Schering-Plough; ITC Edison; Cardiovascular Research Foundation; Cleveland Clinic Research Foundation; Duke Institute; Europa; Lead-up; Institut de Cardiologie de Montreal; Menarini; Nanospheres; Novartis; Portola; TIMI study group; Abbott; Amgen; Servier	la Federation Francaise de Cardiologie; Abbott Vascular(Abbott Laboratories); AstraZeneca(AstraZeneca); CLS Behring; Daiichi Sankyo(Daiichi Sankyo Company Limited); Eli Lilly(Eli Lilly); Biotronik; Iroko Cardio; Sanofi-Aventis(Sanofi-Aventis); Bristol-Myers Squibb(Bristol-Myers Squibb); Merck(Merck & Company); Guerbet Medical; Medtronic(Medtronic); Boston Scientific(Boston Scientific); Cordis; Stago; Fondation de France(Fondation de France); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Societe Francaise de Cardiologie; Medicines Company; Bayer(Bayer AG); BMS(Bristol-Myers Squibb); Boehringer Ingelheim(Boehringer Ingelheim); Pfizer(Pfizer); Schering-Plough(Merck & CompanySchering Plough Corporation); ITC Edison; Cardiovascular Research Foundation; Cleveland Clinic Research Foundation; Duke Institute; Europa; Lead-up; Institut de Cardiologie de Montreal; Menarini(Menarini Group); Nanospheres; Novartis(Novartis); Portola; TIMI study group; Abbott(Abbott Laboratories); Amgen(Amgen); Servier(Servier)	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; the following financial relationships or activities: GC has received a research grant from la Federation Francaise de Cardiologie; consultant fees from Abbott Vascular, AstraZeneca, CLS Behring, Daiichi Sankyo, Eli Lilly; lecture fees from Abbott Vascular, AstraZeneca, Biotronik, CLS Behring, Daiichi Sankyo, Eli Lilly, and Iroko Cardio. MC has received grant support and speaker honorariums from Sanofi-Aventis, Bristol-Myers Squibb, and Merck. J-PC has received research grants from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Guerbet Medical, Medtronic, Boston Scientific, Cordis, Stago, Fondation de France, INSERM, Federation Francaise de Cardiologie, and Societe Francaise de Cardiologie; consulting fees from Sanofi-Aventis, Eli Lilly, and Bristol-Myers Squibb; and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, and AstraZeneca. PG has received consulting or board fees and lecture fees from AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Eli-Lilly, Sanofi-Aventis, and The Medicines Company. KH has received lecture fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Pfizer, Sanofi-Aventis, Schering-Plough, and The Medicines Company. GM has received support from Abbott Vascular, Boston Scientific, Cordis, Eli Lilly, Federation Francaise de Cardiologie, Fondation de France, Guerbet Medical, INSERM, ITC Edison, Medtronic, Pfizer, Sanofi-Aventis, Societe Francaise de Cardiologie, and Stago; consulting or board fees and lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cardiovascular Research Foundation, Cleveland Clinic Research Foundation, Daiichi-Sankyo, Duke Institute, Eli Lilly, Europa, Lead-up, GlaxoSmithKline, Institut de Cardiologie de Montreal, Menarini, Nanospheres, Novartis, Pfizer, Portola, Sanofi-Aventis, The Medicines Company, and TIMI study group. CP has received research grants from Sanofi-Aventis and GlaxoSmithKline, and consulting fees from Sanofi-Aventis, and BristolMyersSquibb. JS has received research grants from Sanofi-Aventis, Daiichi-Sankyo, Eli Lilly, Brahms, INSERM, Federation Francaise de Cardiologie, and Societe Francaise de Cardiologie; consulting fees from Daiichi-Sankyo and Eli Lilly; and speaker honorariums from AstraZeneca, Daiichi Sankyo, Eli Lilly, Iroko Cardio, and Servier. EV has received consulting fees and lecture fees from Abbott, Amgen, Eli Lilly, Pfizer, Sanofi-Aventis, and Servier. UZ has received research grants and speaker honorariums from BMS, Eli Lilly, and Sanofi-Aventis; and consulting and lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Portola, and The Medicines Company; no other relationships or activities that could appear to have influenced the submitted work.	Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; Bertel O, 2010, EUROINTERVENTION, V6, P407, DOI 10.4244/EIJV6I3A67; Bhatt DL, 2003, J AM COLL CARDIOL, V41, P20, DOI 10.1016/S0735-1097(02)02631-1; Blazing MA, 2004, JAMA-J AM MED ASSOC, V292, P55, DOI 10.1001/jama.292.1.55; Brener SJ, 2004, CIRCULATION, V110, P994, DOI 10.1161/01.CIR.0000139868.53594.24; Brieger D, 2011, CATHETER CARDIO INTE, V77, P182, DOI 10.1002/ccd.22674; Choussat R, 2002, J AM COLL CARDIOL, V40, P1943, DOI 10.1016/S0735-1097(02)02531-7; Clarke M, 2003, HDB SYSTEMATIC REV I; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Cohen M, 2002, AM HEART J, V144, P470, DOI 10.1067/mhj.2002.126115; Collet JP, 2004, AM HEART J, V147, P655, DOI 10.1016/j.ahj.2003.10.019; Cucherat M, 1997, COMPUT METH PROG BIO, V53, P187, DOI 10.1016/S0169-2607(97)00016-3; Danchin N, 2007, ACC SCI SESS MAR 24; De Luca G, 2009, THROMB HAEMOSTASIS, V102, P428, DOI 10.1160/TH09-05-0287; Diez JG, 2009, TEX HEART I J, V36, P98; Doll JA, 2009, J INTERV CARDIOL, V22, P453, DOI 10.1111/j.1540-8183.2009.00494.x; DROZD J, 2001, KARDIOL POL, V55, P520; Dubois CL, 2003, J AM COLL CARDIOL, V42, P1178, DOI 10.1016/S0735-1097(03)00917-3; Dudek A, 2000, J AM COLL CARDIOL, V35, p91A; Dudek D, 2000, AM J CARDIOL, V86, p15I; Dumaine R, 2007, ARCH INTERN MED, V167, P2423, DOI 10.1001/archinte.167.22.2423; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Ferguson JJ, 2004, JAMA-J AM MED ASSOC, V292, P45; Galeote G, 2002, REV ESP CARDIOL, V55, P1261, DOI 10.1016/S0300-8932(02)76798-5; Galeote G, 2009, MED INTENSIVA, V33, P1, DOI 10.1016/S0210-5691(09)70300-6; Gibson CM, 2007, J AM COLL CARDIOL, V49, P2238, DOI 10.1016/j.jacc.2007.01.093; Gibson CM, 2006, J AM COLL CARDIOL, V47, P2364, DOI 10.1016/j.jacc.2005.12.077; Goodman S, 2005, AM HEART J, V149, pS73, DOI 10.1016/j.ahj.2005.02.022; Jolly SS, 2011, LANCET, V377, P1409, DOI 10.1016/S0140-6736(11)60404-2; Karsch KR, 1996, J AM COLL CARDIOL, V28, P1437, DOI 10.1016/S0735-1097(96)00343-9; Kastrati A, 2008, NEW ENGL J MED, V359, P688, DOI 10.1056/NEJMoa0802944; Khoobiar S, 2008, J THROMB THROMBOLYS, V26, P85, DOI 10.1007/s11239-008-0258-2; Li YJ, 2010, AM HEART J, V159, P684, DOI 10.1016/j.ahj.2009.12.041; Lincoff AM, 2003, JAMA-J AM MED ASSOC, V289, P853, DOI 10.1001/jama.289.7.853; Madan M, 2005, AM J CARDIOL, V95, P1295, DOI 10.1016/j.amjcard.2005.01.071; Mehta SR, 2008, CIRCULATION, V118, P2038, DOI 10.1161/CIRCULATIONAHA.108.789479; Mehta SR, 2007, J AM COLL CARDIOL, V50, P1742, DOI 10.1016/j.jacc.2007.07.042; Mehta SR, 2005, CIRCULATION, V111, P1390, DOI 10.1161/01.CIR.0000158485.70761.67; Montalescot G, 2004, CIRCULATION, V110, P392, DOI 10.1161/01.CIR.0000136830.65073.C7; Montalescot G, 2003, AM J CARDIOL, V91, P925, DOI 10.1016/S0002-9149(03)00105-X; Montalescot G, 2008, EUR HEART J, V29, P462, DOI 10.1093/eurheartj/ehn008; Montalescot G, 2011, LANCET, V378, P693, DOI 10.1016/S0140-6736(11)60876-3; Montalescot G, 2006, NEW ENGL J MED, V355, P1006, DOI 10.1056/NEJMoa052711; Montalescot G, 2010, JACC-CARDIOVASC INTE, V3, P203, DOI 10.1016/j.jcin.2009.11.012; Montalescot G, 2009, JACC-CARDIOVASC INTE, V2, P1083, DOI 10.1016/j.jcin.2009.08.016; Natarajan MK, 2006, AM HEART J, V151, DOI 10.1016/j.ahj.2005.06.020; Navarese EP, 2011, J THROMB HAEMOST, V9, P1902, DOI 10.1111/j.1538-7836.2011.04445.x; Rabah MM, 1999, AM J CARDIOL, V84, P1391, DOI 10.1016/S0002-9149(99)00582-2; Rao SV, 2007, EUR HEART J, V28, P1193, DOI 10.1093/eurheartj/ehm019; Romagnoli E, 2011, 23 ANN TRANSC CARD T; Sabatine MS, 2005, CIRCULATION, V112, P3846, DOI 10.1161/CIRCULATIONAHA.105.595397; Sanchez-Pena P, 2005, BRIT J CLIN PHARMACO, V60, P364, DOI 10.1111/j.1365-2125.2005.02452.x; Schulz S, 2010, EUR HEART J, V31, P2482, DOI 10.1093/eurheartj/ehq330; Schulz S, 2010, EUR HEART J, V31, P582, DOI 10.1093/eurheartj/ehq008; Silvain J, 2010, EUR HEART J, V31, P2816, DOI 10.1093/eurheartj/ehq209; Silvain J, 2010, J AM COLL CARDIOL, V55, P617, DOI 10.1016/j.jacc.2009.08.077; Smith SC, 2006, CIRCULATION, V113, pE166, DOI 10.1161/CIRCULATIONAHA.106.173220; Steg PG, 2010, JAMA-J AM MED ASSOC, V304, P1339, DOI 10.1001/jama.2010.1320; Stone GW, 2008, NEW ENGL J MED, V358, P2218, DOI 10.1056/NEJMoa0708191; Stone GW, 2006, NEW ENGL J MED, V355, P2203, DOI 10.1056/NEJMoa062437; White HD, 2006, AM HEART J, V152, P1042, DOI 10.1016/j.ahj.2006.08.002; Wijns W, 2010, EUR HEART J, V31, P2501, DOI 10.1093/eurheartj/ehq277; Xiao ZH, 1998, CIRCULATION, V97, P251, DOI 10.1161/01.CIR.97.3.251; Yusuf S, 2006, JAMA-J AM MED ASSOC, V295, P1519; Zeymer U, 2008, THROMB HAEMOSTASIS, V99, P150, DOI 10.1160/TH07-07-0449; Zeymer U, 2006, AM J CARDIOL, V98, P19, DOI 10.1016/j.amjcard.2006.01.047; Zeymer U, 2009, EUROINTERVENTION, V4, P524, DOI 10.4244/EIJV4I4A88; 허성호, 2006, Korean Circulation Journal, V36, P573	68	124	132	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2012	344								e553	10.1136/bmj.e553	http://dx.doi.org/10.1136/bmj.e553			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QT	22306479	hybrid, Green Published			2022-12-28	WOS:000300089000002
J	Tobin, DM; Roca, FJ; Oh, SF; McFarland, R; Vickery, TW; Ray, JP; Ko, DC; Zou, YX; Bang, ND; Chau, TTH; Vary, JC; Hawn, TR; Dunstan, SJ; Farrar, JJ; Thwaites, GE; King, MC; Serhan, CN; Ramakrishnan, L				Tobin, David M.; Roca, Francisco J.; Oh, Sungwhan F.; McFarland, Ross; Vickery, Thad W.; Ray, John P.; Ko, Dennis C.; Zou, Yuxia; Bang, Nguyen D.; Chau, Tran T. H.; Vary, Jay C.; Hawn, Thomas R.; Dunstan, Sarah J.; Farrar, Jeremy J.; Thwaites, Guy E.; King, Mary-Claire; Serhan, Charles N.; Ramakrishnan, Lalita			Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections	CELL			English	Article							TUBERCULOUS MENINGITIS; MACROPHAGE DEATH; LIPID MEDIATORS; TNF-ALPHA; CELLS; NECROSIS; ASPIRIN; HIV; LEUKOTRIENE-B4; BIOSYNTHESIS	Susceptibility to tuberculosis is historically ascribed to an inadequate immune response that fails to control infecting mycobacteria. In zebrafish, we find that susceptibility to Mycobacterium marinum can result from either inadequate or excessive acute inflammation. Modulation of the leukotriene A(4) hydrolase (LTA4H) locus, which controls the balance of pro- and anti-inflammatory eicosanoids, reveals two distinct molecular routes to mycobacterial susceptibility converging on dysregulated TNF levels: inadequate inflammation causedby excess lipoxins and hyperinflammation driven by excess leukotriene B-4. We identify therapies that specifically target each of these extremes. In humans, we identify a single nucleotide polymorphism in the LTA4H promoter that regulates its transcriptional activity. In tuberculous meningitis, the polymorphism is associated with inflammatory cell recruitment, patient survival and response to adjunctive anti-inflammatory therapy. Together, our findings suggest that host-directed therapies tailored to patient LTA4H genotypes may counter detrimental effects of either extreme of inflammation.	[Tobin, David M.; Roca, Francisco J.; McFarland, Ross; Ray, John P.; Ko, Dennis C.; Ramakrishnan, Lalita] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; [Tobin, David M.; Zou, Yuxia] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; [Oh, Sungwhan F.; Vickery, Thad W.; Serhan, Charles N.] Harvard Univ, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med,Sch Med, Boston, MA 02115 USA; [Bang, Nguyen D.] Pham Ngoc Thach Hosp TB & Lung Dis, Ho Chi Minh City, Vietnam; [Vary, Jay C.; Hawn, Thomas R.; King, Mary-Claire; Ramakrishnan, Lalita] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Dunstan, Sarah J.; Farrar, Jeremy J.] Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam; [Dunstan, Sarah J.; Farrar, Jeremy J.] Univ Oxford, Ctr Trop Med, Nuffield Dept Clin Med, Oxford OX3 7LJ, England; [Thwaites, Guy E.] Kings Coll London, Ctr Clin Infect & Diagnost Res, St Thomas Hosp, London SE1 9RT, England; [King, Mary-Claire] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; [Ramakrishnan, Lalita] Univ Washington, Dept Immunol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Duke University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Washington; University of Washington Seattle; University of Oxford; University of Oxford; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Ramakrishnan, L (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.	lalitar@uw.edu	Farrar, Jeremy J./HGA-7610-2022; Ray, John/F-3187-2015; Dunstan, Sarah/AAO-9597-2020; Thwaites, Guy E/R-4993-2019	Ray, John/0000-0001-7294-4260; Thwaites, Guy E/0000-0002-2858-2087; King, Mary-Claire/0000-0001-9426-1743; Vary, James/0000-0001-5390-5426; Dunstan, Sarah/0000-0001-7873-933X; Farrar, Jeremy/0000-0002-2700-623X; Tobin, David/0000-0003-3465-5518; Ramakrishnan, Lalita/0000-0003-0692-5533	NIH; American Cancer Society; Mallinckrodt Scholar Award; educational ministry of Spain; NWRCE for Biodefense and Emerging Infectious Diseases Research; Burroughs Wellcome Fund; Wellcome Trust; American Skin Association; Dermatology Foundation; Chinese Academy of Sciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054503, R37AI054503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [DP1MH099901] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD008614] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Mallinckrodt Scholar Award; educational ministry of Spain; NWRCE for Biodefense and Emerging Infectious Diseases Research; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Wellcome Trust(Wellcome TrustEuropean Commission); American Skin Association; Dermatology Foundation; Chinese Academy of Sciences(Chinese Academy of Sciences); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Rachel Brem for advice and providing the HapMap genotypes; Amy Weinmann for advice and help with macrophage transfections; Victor Mulero for recombinant zebrafish TNF; Marcel Wolbers for help with statistical analysis of the TB meningitis cohort; Glenna Peterson and Tiffany Pecor for technical support; James Cameron for fish facility management; Paul Edelstein and John Szumowski for discussion; Paul Edelstein for advice on statistics; and Paul Edelstein, Brendan Cormack and Kevin Urdahl for manuscript review. Funded by grants from the NIH (L.R., C.N.S.), an American Cancer Society postdoctoral fellowship and a Mallinckrodt Scholar Award (D.M.T.), a postdoctoral fellowship from the educational ministry of Spain (F.J.R.), the NWRCE for Biodefense and Emerging Infectious Diseases Research (L.R. and D.C.K.), the Burroughs Wellcome Fund (L.R. and T.R.H.), the Wellcome Trust, UK (G.T., J.F., S.D., T.T.H.C. and N.D.B.), the American Skin Association, the Dermatology Foundation, and an NIH postdoctoral fellowship grant (J.C.V.), and the Chinese Academy of Sciences (Y.Z.). M.C.K. is an American Cancer Society Professor. D.M.T. is a recipient of the NIH Director's New Innovator Award and L.R. is a recipient of the NIH Director's Pioneer Award.	Agarwal N, 2009, NATURE, V460, P98, DOI 10.1038/nature08123; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Ariel A, 2003, J IMMUNOL, V170, P6266, DOI 10.4049/jimmunol.170.12.6266; Auerbach BJ, 1996, J BIOL CHEM, V271, P1329, DOI 10.1074/jbc.271.3.1329; Bafica A, 2005, J CLIN INVEST, V115, P1601, DOI 10.1172/JCI23949; Behr M, 2010, CELL, V140, P615, DOI 10.1016/j.cell.2010.02.030; CHAMBERS ST, 1984, LANCET, V2, P181; Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Clay H, 2008, IMMUNITY, V29, P283, DOI 10.1016/j.immuni.2008.06.011; Curtis J, 2011, TUBERCULOSIS, V91, P22, DOI 10.1016/j.tube.2010.11.001; Desvignes L, 2009, IMMUNITY, V31, P974, DOI 10.1016/j.immuni.2009.10.007; Divangahi M, 2010, NAT IMMUNOL, V11, P751, DOI 10.1038/ni.1904; Donald PR, 2004, NEW ENGL J MED, V351, P1719, DOI 10.1056/NEJMp048227; Fortin A, 2007, ANNU REV GENOM HUM G, V8, P163, DOI 10.1146/annurev.genom.8.080706.092315; GOLDMAN G, 1993, SURGERY, V113, P297; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Hawkey CR, 2005, CLIN INFECT DIS, V40, P1368, DOI 10.1086/429317; Kahawita IP, 2008, T ROY SOC TROP MED H, V102, P329, DOI 10.1016/j.trstmh.2008.01.004; Kwan CK, 2011, CLIN MICROBIOL REV, V24, P351, DOI 10.1128/CMR.00042-10; Lawn S.D., 2011, TUBERCULOSIS LANCET; MARKMAN M, 1981, NEW ENGL J MED, V305, P167; Mayanja-Kizza H, 2005, J INFECT DIS, V191, P856, DOI 10.1086/427995; Mayosi B.M., 2002, COCHRANE DB SYST REV, V4), DOI [10.1002/14651858.CD000526, DOI 10.1002/14651858.CD000526]; Misra UK, 2010, J NEUROL SCI, V293, P12, DOI 10.1016/j.jns.2010.03.025; Morris T, 2009, J IMMUNOL, V183, P2089, DOI 10.4049/jimmunol.0900477; MUTHUSWAMY P, 1995, CHEST, V107, P1621, DOI 10.1378/chest.107.6.1621; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; Prasad K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002244.pub3; Roca FJ, 2008, J IMMUNOL, V181, P5071, DOI 10.4049/jimmunol.181.7.5071; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schoeman J.F., 2011, J CHILD NEUROLOGY; Schoeman JF, 1997, PEDIATRICS, V99, P226, DOI 10.1542/peds.99.2.226; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; Serhan CN., 2010, FUNDAMENTALS INFLAMM, DOI 10.1017/CBO9781139195737; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573; Tobin DM, 2008, CELL MICROBIOL, V10, P1027, DOI 10.1111/j.1462-5822.2008.01133.x; Tobin DM, 2010, CELL, V140, P717, DOI 10.1016/j.cell.2010.02.013; Vandenabeele P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115re4; Volkman HE, 2010, SCIENCE, V327, P466, DOI 10.1126/science.1179663; Wallis RS, 2005, CLIN INFECT DIS, V41, P201, DOI 10.1086/430914	44	391	401	3	52	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					434	446		10.1016/j.cell.2011.12.023	http://dx.doi.org/10.1016/j.cell.2011.12.023			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304914	Green Accepted, Bronze			2022-12-28	WOS:000300225000013
J	Engel, P; Goepfert, A; Stanger, FV; Harms, A; Schmidt, A; Schirmer, T; Dehio, C				Engel, Philipp; Goepfert, Arnaud; Stanger, Frederic V.; Harms, Alexander; Schmidt, Alexander; Schirmer, Tilman; Dehio, Christoph			Adenylylation control by intra- or intermolecular active-site obstruction in Fic proteins	NATURE			English	Article							BARTONELLA-HENSELAE; AMPYLATION; FILAMENTATION; BINDING; GTPASES; DOC; AMP	Fic proteins that are defined by the ubiquitous FIC (filamentation induced by cyclic AMP) domain are known to catalyse adenylylation (also called AMPylation); that is, the transfer of AMP onto a target protein. In mammalian cells, adenylylation of small GTPases through Fic proteins injected by pathogenic bacteria can cause collapse of the actin cytoskeleton and cell death(1,2). It is unknown how this potentially deleterious adenylylation activity is regulated in the widespread Fic proteins that are found in all domains of life and that are thought to have critical roles in intrinsic signalling processes. Here we show that FIC-domain-mediated adenylylation is controlled by a conserved mechanism of ATP-binding-site obstruction that involves an inhibitory alpha-helix (alpha(inh)) with a conserved (S/T)XXXE(G/N) motif, and that in this mechanism the invariable glutamate competes with ATP gamma-phosphate binding. Consistent with this, FIC-domain-mediated growth arrest of bacteria by the VbhT toxin of Bartonella schoen-buchensis is intermolecularly repressed by the VbhA antitoxin through tight binding of its alpha(inh) to the FIC domain of VbhT, as shown by structure and function analysis. Furthermore, structural comparisons with other bacterial Fic proteins, such as Fic of Neisseria meningitidis and of Shewanella oneidensis, show that alpha(inh) frequently constitutes an amino-terminal or carboxy-terminal extension to the FIC domain, respectively, partially obstructing the ATP binding site in an intramolecular manner. After mutation of the inhibitory motif in various Fic proteins, including the human homologue FICD (also known as HYPE), adenylylation activity is considerably boosted, consistent with the anticipated relief of inhibition. Structural homology modelling of all annotated Fic proteins indicates that inhibition by alpha(inh) is universal and conserved through evolution, as the inhibitory motif is present in similar to 90% of all putatively adenylylation-active FIC domains, including examples from all domains of life and from viruses. Future studies should reveal how intrinsic or extrinsic factors modulate adenylylation activity by weakening the interaction of alpha(inh) with the FIC active site.	[Goepfert, Arnaud; Stanger, Frederic V.; Schirmer, Tilman; Dehio, Christoph] Univ Basel, Biozentrum, Core Program Struct Biol & Biophys, CH-4056 Basel, Switzerland; [Schmidt, Alexander] Univ Basel, Biozentrum, Prote Core Facil, CH-4056 Basel, Switzerland	University of Basel; University of Basel	Dehio, C (corresponding author), Univ Basel, Biozentrum, Core Program Struct Biol & Biophys, CH-4056 Basel, Switzerland.	Tilman.Schirmer@unibas.ch; Christoph.Dehio@unibas.ch	Dehio, Christoph/R-8277-2016; Harms, Alexander/J-5710-2019; Dehio, Christoph/AAD-5572-2019; Engel, Philipp/N-1788-2015	Dehio, Christoph/0000-0001-7288-1052; Harms, Alexander/0000-0003-2106-1286; Dehio, Christoph/0000-0001-7288-1052; Engel, Philipp/0000-0002-4678-6200; Stanger, Frederic/0000-0002-9847-5084	Swiss National Science Foundation [3100-061777, 3100-138414]; SystemsX.ch Swiss Initiative for Systems Biology [51RT 0_126008 (InfectX)]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); SystemsX.ch Swiss Initiative for Systems Biology	We thank T. Glatter for mass spectrometry analysis of samples at the Core Proteomics facility. We thank the staff of beamline X06SA of the Swiss Light Source for assistance with data acquisition. We are grateful to G. Pluschke for providing the genomic DNA of Neisseria meningitidis, the ASU Biodesign Institute for providing the plasmid enclosing the Shewanella oneidensis Fic protein and S. Mattoo and J. Dixon for providing the pET-GSTX plasmids enclosing HYPE and HYPE(H295A). We also thank D. Bumann and A. Boehm for providing plasmid pC10E and E. coli strain AB472, respectively. This work was supported by grants 3100-061777 and 3100-138414 from the Swiss National Science Foundation (to C. D. and T. S., respectively), and grant 51RT 0_126008 (InfectX) in the frame of the SystemsX.ch Swiss Initiative for Systems Biology (to C.D.).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Das D, 2009, PROTEINS, V75, P264, DOI 10.1002/prot.22338; Dehio C, 1997, J BACTERIOL, V179, P538, DOI 10.1128/jb.179.2.538-540.1997; Dehio C, 2001, INT J SYST EVOL MICR, V51, P1557, DOI 10.1099/00207713-51-4-1557; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engel P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001296; Engelberg-Kulka H, 2006, PLOS GENET, V2, P1518, DOI 10.1371/journal.pgen.0020135; Garcia-Pino A, 2008, J BIOL CHEM, V283, P30821, DOI 10.1074/jbc.M805654200; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kinch LN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005818; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Luong P, 2010, J BIOL CHEM, V285, P20155, DOI 10.1074/jbc.M110.114884; Mattoo S, 2011, J BIOL CHEM, V286, P32834, DOI 10.1074/jbc.M111.227603; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mukherjee S, 2011, NATURE, V477, P103, DOI 10.1038/nature10335; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Palanivelu DV, 2011, PROTEIN SCI, V20, P492, DOI 10.1002/pro.581; Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490; Rhomberg TA, 2009, CELL MICROBIOL, V11, P927, DOI 10.1111/j.1462-5822.2009.01302.x; Roy CR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.262pe14; Schmidt A, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.37; Schulein R, 2005, P NATL ACAD SCI USA, V102, P856, DOI 10.1073/pnas.0406796102; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Smith Susan J M, 2002, Methods Mol Biol, V189, P13; Soding J, 2005, NUCLEIC ACIDS RES, V33, pW244, DOI 10.1093/nar/gki408; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; UTSUMI R, 1982, J BACTERIOL, V151, P807, DOI 10.1128/JB.151.2.807-812.1982; Worby CA, 2009, MOL CELL, V34, P93, DOI 10.1016/j.molcel.2009.03.008; Xiao JY, 2010, NAT STRUCT MOL BIOL, V17, P1004, DOI 10.1038/nsmb.1867; Yarbrough ML, 2009, SCIENCE, V323, P269, DOI 10.1126/science.1166382; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110	32	110	118	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2012	482	7383					107	U138		10.1038/nature10729	http://dx.doi.org/10.1038/nature10729			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22266942				2022-12-28	WOS:000299726000045
J	Bornens, M				Bornens, Michel			The Centrosome in Cells and Organisms	SCIENCE			English	Review							CENTRIOLE; ORGANIZATION; POLARIZATION; CILIOGENESIS; INHERITANCE; COMPONENTS; MIGRATION; CLEAVAGE; SYMMETRY; DIVISION	The centrosome acts as the main microtubule-nucleating organelle in animal cells and plays a critical role in mitotic spindle orientation and in genome stability. Yet, despite its central role in cell biology, the centrosome is not present in all multicellular organisms or in all cells of a given organism. The main outcome of centrosome reproduction is the transmission of polarity to daughter cells and, in most animal species, the sperm-donated centrosome defines embryo polarity. Here I will discuss the role of the centrosome in cell polarity, resulting from its ability to position the nucleus at the cell center, and discuss how centrosome innovation might have been critical during metazoan evolution.	Inst Curie, Ctr Natl Rech Sci, UMR144, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Bornens, M (corresponding author), Inst Curie, Ctr Natl Rech Sci, UMR144, 26 Rue Ulm, F-75248 Paris 05, France.	mbornens@curie.fr			CNRS; Institut Curie	CNRS(Centre National de la Recherche Scientifique (CNRS)); Institut Curie	I thank J. Sillibourne, R. M. Rios, and two reviewers for critical reading of the manuscript, and M. Thery for providing some of the figures. This work is funded by both CNRS and Institut Curie. M. B. is acting as the chief scientific officer for "CYTOO Cell Architects," Grenoble, France.	Azimzadeh J, 2012, SCIENCE, V335, P461, DOI 10.1126/science.1214457; Azimzadeh J, 2010, CURR BIOL, V20, pR816, DOI 10.1016/j.cub.2010.08.010; Bahmanyar S, 2008, GENE DEV, V22, P91, DOI 10.1101/gad.1596308; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bornens M, 2007, ADV EXP MED BIOL, V607, P119; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI DOI 10.1515/9781400858712; Carvalho-Santos Z, 2011, J CELL BIOL, V194, P165, DOI 10.1083/jcb.201011152; Fink J, 2011, NAT CELL BIOL, V13, P771, DOI 10.1038/ncb2269; Fuentealba LC, 2008, P NATL ACAD SCI USA, V105, P7732, DOI 10.1073/pnas.0803027105; Gogendeau D, 2010, SEMIN CELL DEV BIOL, V21, P163, DOI 10.1016/j.semcdb.2009.07.001; Gonzalez C, 2008, CURR OPIN CELL BIOL, V20, P694, DOI 10.1016/j.ceb.2008.10.003; HAMAGUCHI MS, 1986, DEV GROWTH DIFFER, V28, P143, DOI 10.1111/j.1440-169x.1986.00143.x; Hurtado L, 2011, J CELL BIOL, V193, P917, DOI 10.1083/jcb.201011014; Kim J, 2010, NATURE, V464, P1048, DOI 10.1038/nature08895; Kimura K, 2011, P NATL ACAD SCI USA, V108, P137, DOI 10.1073/pnas.1013275108; King N, 2004, DEV CELL, V7, P313, DOI 10.1016/j.devcel.2004.08.010; Kitagawa D, 2011, CELL, V144, P364, DOI 10.1016/j.cell.2011.01.008; Kobayashi T, 2011, J CELL BIOL, V193, P435, DOI 10.1083/jcb.201101005; Lambert JD, 2002, NATURE, V420, P682, DOI 10.1038/nature01241; MALLER J, 1976, EXP CELL RES, V99, P285, DOI 10.1016/0014-4827(76)90585-1; Mardin BR, 2010, NAT CELL BIOL, V12, P1166, DOI 10.1038/ncb2120; Megraw TL, 2011, TRENDS CELL BIOL, V21, P470, DOI 10.1016/j.tcb.2011.04.007; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; Minc N, 2011, CELL, V144, P414, DOI 10.1016/j.cell.2011.01.016; MOUDJOU M, 1989, J CELL SCI, V94, P237; Newmark PA, 2002, NAT REV GENET, V3, P210, DOI 10.1038/nrg759; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Pitaval A, 2010, J CELL BIOL, V191, P303, DOI 10.1083/jcb.201004003; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; SZOLLOSI A, 1986, EUR J CELL BIOL, V40, P100; Thery M., UNPUB; Thery M, 2006, P NATL ACAD SCI USA, V103, P19771, DOI 10.1073/pnas.0609267103; Tournier F, 2001, METHOD CELL BIOL, V67, P213; van Breugel M, 2011, SCIENCE, V331, P1196, DOI 10.1126/science.1199325; Wang XQ, 2009, NATURE, V461, P947, DOI 10.1038/nature08435; Wuhr M, 2010, CURR BIOL, V20, P2040, DOI 10.1016/j.cub.2010.10.024; Zhu J, 2010, MOL BIOL CELL, V21, P4418, DOI 10.1091/mbc.E10-07-0627; Zonies S, 2010, DEVELOPMENT, V137, P1669, DOI 10.1242/dev.045823	41	308	316	3	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					422	426		10.1126/science.1209037	http://dx.doi.org/10.1126/science.1209037			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282802				2022-12-28	WOS:000299466800037
J	Tenaillon, O; Rodriguez-Verdugo, A; Gaut, RL; McDonald, P; Bennett, AF; Long, AD; Gaut, BS				Tenaillon, Olivier; Rodriguez-Verdugo, Alejandra; Gaut, Rebecca L.; McDonald, Pamela; Bennett, Albert F.; Long, Anthony D.; Gaut, Brandon S.			The Molecular Diversity of Adaptive Convergence	SCIENCE			English	Article							LONG-TERM EXPERIMENT; ESCHERICHIA-COLI; EXPERIMENTAL EVOLUTION; BENEFICIAL MUTATIONS; ADAPTATION; SELECTION; TEMPERATURE; EPISTASIS	To estimate the number and diversity of beneficial mutations, we experimentally evolved 115 populations of Escherichia coli to 42.2 degrees C for 2000 generations and sequenced one genome from each population. We identified 1331 total mutations, affecting more than 600 different sites. Few mutations were shared among replicates, but a strong pattern of convergence emerged at the level of genes, operons, and functional complexes. Our experiment uncovered a set of primary functional targets of high temperature, but we estimate that many other beneficial mutations could contribute to similar adaptive outcomes. We inferred the pervasive presence of epistasis among beneficial mutations, which shaped adaptive trajectories into at least two distinct pathways involving mutations either in the RNA polymerase complex or the termination factor rho.	[Tenaillon, Olivier; Rodriguez-Verdugo, Alejandra; Gaut, Rebecca L.; McDonald, Pamela; Bennett, Albert F.; Long, Anthony D.; Gaut, Brandon S.] Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; [Tenaillon, Olivier] INSERM, UMR S 722, F-75018 Paris, France; [Tenaillon, Olivier] Univ Paris Diderot, UMR S 722, F-75018 Paris, France	University of California System; University of California Irvine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Tenaillon, O (corresponding author), Univ Calif Irvine, Dept Ecol & Evolutionary Biol, 321 Steinhaus Hall, Irvine, CA 92697 USA.	olivier.tenaillon@inserm.fr; bgaut@uci.edu	Tenaillon, Olivier/L-9857-2017	Tenaillon, Olivier/0000-0002-3796-1601; Long, Tony/0000-0002-5007-8514	NSF [DEB-0748903]; Agence Nationale de la Recherche [ANR-08-GENM-023-001]	NSF(National Science Foundation (NSF)); Agence Nationale de la Recherche(French National Research Agency (ANR))	We thank L. Chao, C. Herman, and D. Schneider for discussion. This work was supported by NSF grant DEB-0748903 to A. F. B., A. D. L., and B. S. G. and by Agence Nationale de la Recherche, Programme Genomique, grant ANR-08-GENM-023-001 to O.T. Raw sequence data are available for download at http://wfitch.bio.uci.edu/similar to tdlong/Coli_EE_RawData.tgz.	Barrick JE, 2009, NATURE, V461, P1243, DOI 10.1038/nature08480; BENNETT AF, 1992, EVOLUTION, V46, P16, DOI 10.1111/j.1558-5646.1992.tb01981.x; BENNETT AF, 1990, NATURE, V346, P79, DOI 10.1038/346079a0; Burke MK, 2010, NATURE, V467, P587, DOI 10.1038/nature09352; CHAO L, 1983, NATURE, V303, P633, DOI 10.1038/303633a0; Chou HH, 2011, SCIENCE, V332, P1190, DOI 10.1126/science.1203799; Christin PA, 2010, TRENDS GENET, V26, P400, DOI 10.1016/j.tig.2010.06.005; Conrad TM, 2010, P NATL ACAD SCI USA, V107, P20500, DOI 10.1073/pnas.0911253107; Jeong H, 2009, J MOL BIOL, V394, P644, DOI 10.1016/j.jmb.2009.09.052; Khan AI, 2011, SCIENCE, V332, P1193, DOI 10.1126/science.1203801; Kishimoto T, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001164; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LEWONTIN RC, 1964, GENETICS, V49, P49; Poon A, 2005, GENETICS, V170, P1323, DOI 10.1534/genetics.104.037259; Read KLQ, 1998, AM STAT, V52, P175, DOI 10.2307/2685477; Riehle MM, 2001, P NATL ACAD SCI USA, V98, P525, DOI 10.1073/pnas.021448998; Rokyta DR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002075; Silander OK, 2007, PLOS BIOL, V5, P922, DOI 10.1371/journal.pbio.0050094; Teotonio H, 2009, NAT GENET, V41, P251, DOI 10.1038/ng.289; Weinreich DM, 2006, SCIENCE, V312, P111, DOI 10.1126/science.1123539; Woods R, 2006, P NATL ACAD SCI USA, V103, P9107, DOI 10.1073/pnas.0602917103	21	464	477	2	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					457	461		10.1126/science.1212986	http://dx.doi.org/10.1126/science.1212986			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282810				2022-12-28	WOS:000299466800047
J	Apicella, CL; Marlowe, FW; Fowler, JH; Christakis, NA				Apicella, Coren L.; Marlowe, Frank W.; Fowler, James H.; Christakis, Nicholas A.			Social networks and cooperation in hunter-gatherers	NATURE			English	Article							HUMAN ALTRUISM; EVOLUTION; RECIPROCITY; SOCIETIES; BEHAVIOR; MODELS	Social networks show striking structural regularities(1,2), and both theory and evidence suggest that networks may have facilitated the development of large-scale cooperation in humans(3-7). Here, we characterize the social networks of the Hadza, a population of hunter-gatherers in Tanzania(8). We show that Hadza networks have important properties also seen in modernized social networks, including a skewed degree distribution, degree assortativity, transitivity, reciprocity, geographic decay and homophily. We demonstrate that Hadza camps exhibit high between-group and low within-group variation in public goods game donations. Network ties are also more likely between people who give the same amount, and the similarity in cooperative behaviour extends up to two degrees of separation. Social distance appears to be as important as genetic relatedness and physical proximity in explaining assortativity in cooperation. Our results suggest that certain elements of social network structure may have been present at an early point in human history. Also, early humans may have formed ties with both kin and non-kin, based in part on their tendency to cooperate. Social networks may thus have contributed to the emergence of cooperation.	[Apicella, Coren L.; Christakis, Nicholas A.] Harvard Univ, Inst Quantitat Social Sci, Cambridge, MA 02138 USA; [Apicella, Coren L.; Christakis, Nicholas A.] Harvard Univ, Dept Hlth Care Policy, Sch Med, Boston, MA 02115 USA; [Marlowe, Frank W.] Univ Cambridge, Dept Anthropol, Cambridge CB2 3DZ, England; [Fowler, James H.] Univ Calif San Diego, Div Med Genet, San Diego, CA 92093 USA; [Fowler, James H.] Univ Calif San Diego, Dept Polit Sci, San Diego, CA 92093 USA; [Christakis, Nicholas A.] Harvard Univ, Dept Sociol, Cambridge, MA 02138 USA; [Christakis, Nicholas A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School; University of Cambridge; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Harvard University; Harvard Medical School	Christakis, NA (corresponding author), Harvard Univ, Inst Quantitat Social Sci, Cambridge, MA 02138 USA.	christakis@hcp.med.harvard.edu	Marlowe, Frank/G-9752-2012; Fowler, James H/C-2750-2008	Fowler, James H/0000-0001-7795-1638; Apicella, Coren/0000-0002-9661-6998	National Institute on Aging [P01-AG031093]; Science of Generosity Initiative of the University of Notre Dame; John Templeton Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG031093] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Science of Generosity Initiative of the University of Notre Dame; John Templeton Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grant P01-AG031093 from the National Institute on Aging and by the Science of Generosity Initiative of the University of Notre Dame (supported by the John Templeton Foundation). We are grateful for comments from S. Bowles, D. Eisenberg, F. Fu, H. Gintis, J. Henrich, P. Hooper, D. Hruschka, M. Nowak, D. Rand, P. Richerson and C. Tarnita. We thank A. Mabulla, I. Mabulla, M. Peterson, C. Bauchner and L. Meneades for help with data collection and preparation. We are grateful to D. Stafford and A. Hughes for sharing data regarding two villages in Honduras, as used in the Supplementary Information.	[Anonymous], 1995, P BRIT ACAD; Badham J, 2010, THEOR POPUL BIOL, V77, P71, DOI 10.1016/j.tpb.2009.11.003; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Berbesque JC, 2009, EVOL PSYCHOL-US, V7, P601, DOI 10.1177/147470490900700409; Bowles S, 2004, THEOR POPUL BIOL, V65, P17, DOI 10.1016/j.tpb.2003.07.001; Bowles S, 2006, SCIENCE, V314, P1569, DOI 10.1126/science.1134829; BOYD R, 1989, SOC NETWORKS, V11, P213, DOI 10.1016/0378-8733(89)90003-8; BOYD R, 1988, J THEOR BIOL, V132, P337, DOI 10.1016/S0022-5193(88)80219-4; Brent LJN, 2011, AM J PRIMATOL, V73, P720, DOI 10.1002/ajp.20949; CAMPBELL KE, 1991, SOC NETWORKS, V13, P203, DOI 10.1016/0378-8733(91)90006-F; Cole T, 2004, PERS RELATIONSHIP, V11, P135, DOI 10.1111/j.1475-6811.2004.00075.x; DAVIS JA, 1970, AM SOCIOL REV, V35, P843, DOI 10.2307/2093295; ESHEL I, 1982, P NATL ACAD SCI-BIOL, V79, P1331, DOI 10.1073/pnas.79.4.1331; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Fowler JH, 2011, P NATL ACAD SCI USA, V108, P1993, DOI 10.1073/pnas.1011687108; Fowler JH, 2010, P NATL ACAD SCI USA, V107, P5334, DOI 10.1073/pnas.0913149107; Fowler JH, 2009, P NATL ACAD SCI USA, V106, P1720, DOI 10.1073/pnas.0806746106; Gurven M, 2002, J ANTHROPOL RES, V58, P93, DOI 10.1086/jar.58.1.3631070; Hamilton MJ, 2007, P ROY SOC B-BIOL SCI, V274, P2195, DOI 10.1098/rspb.2007.0564; Hawkes K, 2001, EVOL HUM BEHAV, V22, P113, DOI 10.1016/S1090-5138(00)00066-0; Henrich J, 2001, AM ECON REV, V91, P73, DOI 10.1257/aer.91.2.73; Hill KR, 2011, SCIENCE, V331, P1286, DOI 10.1126/science.1199071; Hruschka D. J., 2010, FRIENDSHIP DEV ECOLO; Kaplan H.S., 2005, MORAL SENTIMENTS MAT, P75; KREBS D, 1975, J PERS SOC PSYCHOL, V32, P1134, DOI 10.1037/0022-3514.32.6.1134; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Marlowe F., 2010, HADZA HUNTER GATHERE, DOI DOI 10.1152/physiol.00027.2018; Nowak MA, 2006, SCIENCE, V314, P1560, DOI 10.1126/science.1133755; Nowak MA, 2010, NATURE, V466, P1057, DOI 10.1038/nature09205; Ohtsuki H, 2006, NATURE, V441, P502, DOI 10.1038/nature04605; Onnela JP, 2007, P NATL ACAD SCI USA, V104, P7332, DOI 10.1073/pnas.0610245104; Onnela JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016939; Rand D., 2011, P NATL ACAD SCI US, V108; Schildcrout JS, 2005, BIOSTATISTICS, V6, P633, DOI 10.1093/biostatistics/kxi033; Smith E.A., 1988, HUNTERS GATHERERS, VI, P222; Smith EA, 2010, CURR ANTHROPOL, V51, P19, DOI 10.1086/648530; Whitehead H, 2008, ANAL ANIMAL SOC QUAN, DOI 10.7208/chicago/9780226895246.001.0001	37	404	417	3	302	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2012	481	7382					497	U109		10.1038/nature10736	http://dx.doi.org/10.1038/nature10736			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	881GY	22281599	Green Submitted, Green Accepted			2022-12-28	WOS:000299471800038
J	Man, XY; Zheng, M				Man, Xiao-Yong; Zheng, Min			Papules, Plaques, and Nodules in an Immunocompromised Patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRICHOPHYTON-TONSURANS; MAJOCCHIS GRANULOMA; TINEA INCOGNITO		[Man, Xiao-Yong; Zheng, Min] Zhejiang Univ, Dept Dermatol, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China	Zhejiang University	Zheng, M (corresponding author), Zhejiang Univ, Dept Dermatol, Affiliated Hosp 2, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	minz@zju.edu.cn						Cornely OA, 2007, NEW ENGL J MED, V356, P348, DOI 10.1056/NEJMoa061094; Elgart ML, 1996, DERMATOL CLIN, V14, P51, DOI 10.1016/S0733-8635(05)70324-7; Hadacek BM, 1999, BRIT J DERMATOL, V140, P762; Liao YH, 1999, BRIT J DERMATOL, V140, P1194; RADENTZ WH, 1993, ARCH DERMATOL, V129, P1189; Romero FA, 2011, TRANSPL INFECT DIS, V13, P424, DOI 10.1111/j.1399-3062.2010.00596.x; Sanchez-Castellanos ME, 2007, MYCOSES, V50, P85, DOI 10.1111/j.1439-0507.2006.01321.x; Tan E, 2002, ARCH DERMATOL, V138, P118; Tateishi Y, 2004, ARCH DERMATOL, V140, P624, DOI 10.1001/archderm.140.5.624; WILSON JW, 1954, AMA ARCH DERM SYPH, V69, P258, DOI 10.1001/archderm.1954.01540150002002	10	0	3	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2012	307	4					404	405		10.1001/jama.2012.18	http://dx.doi.org/10.1001/jama.2012.18			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EP	22274688				2022-12-28	WOS:000299464000027
J	Shuttleworth, S				Shuttleworth, Sally			Victorian visions of child development	LANCET			English	Editorial Material									Univ Oxford, St Annes Coll, Oxford OX2 6HS, England	University of Oxford	Shuttleworth, S (corresponding author), Univ Oxford, St Annes Coll, Oxford OX2 6HS, England.	sally.shuttleworth@st-annes.ox.ac.uk							0	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 21	2012	379	9812					212	213		10.1016/S0140-6736(12)60091-9	http://dx.doi.org/10.1016/S0140-6736(12)60091-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879FW	22272394				2022-12-28	WOS:000299316100024
J	Rausch, T; Jones, DTW; Zapatka, M; Stutz, AM; Zichner, T; Weischenfeldt, J; Jager, N; Remke, M; Shih, D; Northcott, PA; Pfaff, E; Tica, J; Wang, Q; Massimi, L; Witt, H; Bender, S; Pleier, S; Cin, H; Hawkins, C; Beck, C; von Deimling, A; Hans, V; Brors, B; Eils, R; Scheurlen, W; Blake, J; Benes, V; Kulozik, AE; Witt, O; Martin, D; Zhang, C; Porat, R; Merino, DM; Wasserman, J; Jabado, N; Fontebasso, A; Bullinger, L; Rucker, FG; Dohner, K; Dohner, H; Koster, J; Molenaar, JJ; Versteeg, R; Kool, M; Tabori, U; Malkin, D; Korshunov, A; Taylor, MD; Lichter, P; Pfister, SM; Korbel, JO				Rausch, Tobias; Jones, David T. W.; Zapatka, Marc; Stuetz, Adrian M.; Zichner, Thomas; Weischenfeldt, Joachim; Jaeger, Natalie; Remke, Marc; Shih, David; Northcott, Paul A.; Pfaff, Elke; Tica, Jelena; Wang, Qi; Massimi, Luca; Witt, Hendrik; Bender, Sebastian; Pleier, Sabrina; Cin, Huriye; Hawkins, Cynthia; Beck, Christian; von Deimling, Andreas; Hans, Volkmar; Brors, Benedikt; Eils, Roland; Scheurlen, Wolfram; Blake, Jonathon; Benes, Vladimir; Kulozik, Andreas E.; Witt, Olaf; Martin, Dianna; Zhang, Cindy; Porat, Rinnat; Merino, Diana M.; Wasserman, Jonathan; Jabado, Nada; Fontebasso, Adam; Bullinger, Lars; Ruecker, Frank G.; Doehner, Konstanze; Doehner, Hartmut; Koster, Jan; Molenaar, Jan J.; Versteeg, Rogier; Kool, Marcel; Tabori, Uri; Malkin, David; Korshunov, Andrey; Taylor, Michael D.; Lichter, Peter; Pfister, Stefan M.; Korbel, Jan O.			Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; TELOMERE LENGTH; BREAST-CANCER; GENE; EXPRESSION; SIGNATURES; MECHANISM; RADIATION; CARRIERS; SUBTYPES	Genomic rearrangements are thought to occur progressively during tumor development. Recent findings, however, suggest an alternative mechanism, involving massive chromosome rearrangements in a one-step catastrophic event termed chromothripsis. We report the whole-genome sequencing-based analysis of a Sonic-Hedgehog medulloblastoma (SHH-MB) brain tumor from a patient with a germline TP53 mutation (Li-Fraumeni syndrome), uncovering massive, complex chromosome rearrangements. Integrating TP53 status with microarray and deep sequencing-based DNA rearrangement data in additional patients reveals a striking association between TP53 mutation and chromothripsis in SHH-MBs. Analysis of additional tumor entities substantiates a link between TP53 mutation and chromothripsis, and indicates a context-specific role for p53 in catastrophic DNA rearrangements. Among these, we observed a strong association between somatic TP53 mutations and chromothripsis in acutemyeloid leukemia. These findings connect p53 status and chromothripsis in specific tumor types, providing a genetic basis for understanding particularly aggressive subtypes of cancer.	[Jones, David T. W.; Zapatka, Marc; Remke, Marc; Pfaff, Elke; Witt, Hendrik; Bender, Sebastian; Pleier, Sabrina; Cin, Huriye; Kool, Marcel; Lichter, Peter; Pfister, Stefan M.] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol, Div Mol Genet, D-69120 Heidelberg, Germany; [Rausch, Tobias; Stuetz, Adrian M.; Zichner, Thomas; Weischenfeldt, Joachim; Tica, Jelena; Blake, Jonathon; Benes, Vladimir] EMBL, D-69117 Heidelberg, Germany; [Jaeger, Natalie; Brors, Benedikt; Eils, Roland] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol, Div Theoret Bioinformat, D-69120 Heidelberg, Germany; [Remke, Marc; Wang, Qi; Witt, Hendrik; Bender, Sebastian; Pleier, Sabrina; Beck, Christian; Kulozik, Andreas E.; Witt, Olaf; Pfister, Stefan M.] Univ Heidelberg Hosp, Dept Pediat Oncol Hematol & Immunol, D-69120 Heidelberg, Germany; [Shih, David; Northcott, Paul A.; Hawkins, Cynthia; Tabori, Uri; Taylor, Michael D.] Univ Toronto, Hosp Sick Children Res Inst, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1L7, Canada; [Massimi, Luca] Univ Cattolica Sacro Cuore, Sch Med, I-00168 Rome, Italy; [Hawkins, Cynthia] Hosp Sick Children, Dept Pathol, Toronto, ON M5G 1L7, Canada; [von Deimling, Andreas; Korshunov, Andrey] Heidelberg Univ, Dept Neuropathol, D-69120 Heidelberg, Germany; [von Deimling, Andreas; Korshunov, Andrey] DKFZ, Clin Cooperat Unit Neuropathol, D-69120 Heidelberg, Germany; [Hans, Volkmar] Evangel Krankenhaus, Inst Neuropathol, D-33617 Bielefeld, Germany; [Scheurlen, Wolfram] Childrens Hosp, Cnopfsche Kinderklin, Nurnberg, Germany; [Martin, Dianna; Zhang, Cindy; Porat, Rinnat; Merino, Diana M.; Wasserman, Jonathan; Tabori, Uri; Malkin, David] Univ Toronto, Hosp Sick Children, Dept Pediat, Genet & Genome Biol Program, Toronto, ON M5G 1X8, Canada; [Martin, Dianna; Zhang, Cindy; Porat, Rinnat; Merino, Diana M.; Wasserman, Jonathan; Tabori, Uri; Malkin, David] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada; [Jabado, Nada; Fontebasso, Adam] McGill Univ, Ctr Hlth, Montreal, PQ H3H 2R9, Canada; [Bullinger, Lars; Ruecker, Frank G.; Doehner, Konstanze; Doehner, Hartmut] Univ Ulm, Dept Internal Med 3, D-89081 Ulm, Germany; [Koster, Jan; Molenaar, Jan J.; Versteeg, Rogier] Amsterdam Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Taylor, Michael D.] Univ Toronto, Hosp Sick Children, Div Neurosurg, Toronto, ON M5G 1X8, Canada; [Korbel, Jan O.] European Bioinformat Inst, Cambridge CB10 1SD, England	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; Ulm University; University of Amsterdam; Academic Medical Center Amsterdam; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); European Molecular Biology Laboratory (EMBL)	Lichter, P (corresponding author), German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol, Div Mol Genet, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	peter.lichter@dkfz-heidelberg.de; s.pfister@dkfz-heidelberg.de; jan.korbel@embl-heidelberg.de	Rausch, Tobias/H-6511-2019; Jones, David TW/G-9588-2013; Döhner, Hartmut/C-8933-2016; Northcott, Paul A/N-4022-2018; Versteeg, Rogier/AAQ-1765-2020; Kulozik, Andreas/AAO-2432-2020; Jabado, Nada/AAN-4026-2020; Bullinger, Lars/AAL-7965-2020; Koster, Jan/C-5934-2008; von Deimling, Andreas/F-7774-2013; Brors, Benedikt/E-5620-2013; Zapatka, Marc/G-9896-2013; Malkin, David/AAW-8715-2021; Pfister, Stefan M/F-6860-2013; Shih, David J H/H-3186-2011; Korbel, Jan O/G-6470-2012; Wasserman, JD/AAF-8145-2019; Hawkins, Cynthia/M-2571-2019; Jones, David T. W./Z-1963-2019; Witt, Hendrik/L-7810-2015; Kool, Marcel/H-2541-2013; Wasserman, Jonathan D/M-4298-2013; Shih, David J. H./AAE-8726-2019; Weischenfeldt, Joachim/O-3681-2015; Eils, Roland/B-6121-2009	Rausch, Tobias/0000-0001-5773-5620; Jones, David TW/0000-0002-2036-5141; Döhner, Hartmut/0000-0003-2116-5536; Northcott, Paul A/0000-0002-1220-5252; Koster, Jan/0000-0002-0890-7585; von Deimling, Andreas/0000-0002-5863-540X; Brors, Benedikt/0000-0001-5940-3101; Zapatka, Marc/0000-0001-8287-5967; Pfister, Stefan M/0000-0002-5447-5322; Shih, David J H/0000-0002-9802-4937; Korbel, Jan O/0000-0002-2798-3794; Wasserman, JD/0000-0001-7088-8146; Wasserman, Jonathan D/0000-0001-7088-8146; Shih, David J. H./0000-0002-9802-4937; Weischenfeldt, Joachim/0000-0002-3917-5524; Eils, Roland/0000-0002-0034-4036; Taylor, Michael/0000-0001-7009-3466; Stuetz, Adrian/0000-0001-7650-3470; Bullinger, Lars/0000-0002-5890-5510; Benes, Vladimir/0000-0002-0352-2547; Versteeg, Rogier/0000-0001-7172-0388; Zichner, Thomas/0000-0001-9848-7598; Korshunov, Andrey/0000-0002-5257-3623; Wang, Qi/0000-0002-6420-1720; Remke, Marc/0000-0002-9404-9993; Jaeger, Natalie/0000-0002-9589-7580; Tabori, Uri/0000-0002-5019-2683; Tica, Jelena/0000-0001-9036-4083	German Cancer Aid [109252]; BMBF [01GS0871]; European Commission [Health-F2-2010-260791]; NIH [R01CA148699b]; Pediatric Brain Tumor Foundation; Canadian Institutes for Health Research [MOP-97834]; German Research Foundation [BU 1339/3-1, KO 4037/1-1]; NATIONAL CANCER INSTITUTE [R01CA148699] Funding Source: NIH RePORTER	German Cancer Aid(Deutsche Krebshilfe); BMBF(Federal Ministry of Education & Research (BMBF)); European Commission(European CommissionEuropean Commission Joint Research Centre); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pediatric Brain Tumor Foundation; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); German Research Foundation(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bettina Haase, David Ibbertsen, and Dinko Pavlinic from the EMBL GeneCore sequencing team for excellent support; and Matthias Hentze and Lars Steinmetz for valuable comments on earlier versions of the manuscript. High-performance computing facilities at EMBL and DKFZ supported the study technically. The project was supported by grants from the German Cancer Aid (109252) and the BMBF (ICGC "PedBrain" Tumor Project; to P.L., S.M.P., A.K., R.E., B.B., O.W., and J.O.K.; and 01GS0871; to L.B., K.D., and H.D.), the European Commission (Health-F2-2010-260791, to J.O.K.), the NIH (R01CA148699b) and the Pediatric Brain Tumor Foundation (to M.D.T.), the Canadian Institutes for Health Research (MOP-97834, to D.M.), and the German Research Foundation (BU 1339/3-1, to L.B., and KO 4037/1-1, to J.O.K.).	Abyzov A, 2011, GENOME RES, V21, P974, DOI 10.1101/gr.114876.110; Buhren J, 2000, J NEUROPATH EXP NEUR, V59, P229; Buonamici S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001599; Chiang DY, 2009, NAT METHODS, V6, P99, DOI [10.1038/nmeth.1276, 10.1038/NMETH.1276]; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Dahm-Daphi J, 2005, ONCOGENE, V24, P1663, DOI 10.1038/sj.onc.1208396; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Haferlach C, 2008, LEUKEMIA, V22, P1539, DOI 10.1038/leu.2008.143; Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593; Hastings PJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000327; Howarth KD, 2011, GENOME RES, V21, P525, DOI 10.1101/gr.114116.110; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Ishida Y, 2010, CARCINOGENESIS, V31, P1694, DOI 10.1093/carcin/bgq145; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kloosterman WP, 2011, HUM MOL GENET, V20, P1916, DOI 10.1093/hmg/ddr073; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504; Lam HYK, 2010, NAT BIOTECHNOL, V28, P47, DOI 10.1038/nbt.1600; Lee JA, 2007, CELL, V131, P1235, DOI 10.1016/j.cell.2007.11.037; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Meyerson M, 2011, CELL, V144, P9, DOI 10.1016/j.cell.2010.12.025; Mills RE, 2011, NATURE, V470, P59, DOI 10.1038/nature09708; Mrozek K, 2008, SEMIN ONCOL, V35, P365, DOI 10.1053/j.seminoncol.2008.04.007; Northcott PA, 2011, ACTA NEUROPATHOL, V122, P231, DOI 10.1007/s00401-011-0846-7; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Parkin B, 2010, BLOOD, V116, P4958, DOI 10.1182/blood-2010-01-266999; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pfaff E, 2010, J CLIN ONCOL, V28, P5188, DOI 10.1200/JCO.2010.31.1670; Pfister S, 2009, J CLIN ONCOL, V27, P1627, DOI 10.1200/JCO.2008.17.9432; Remke M, 2011, J CLIN ONCOL, V29, P3852, DOI 10.1200/JCO.2011.36.2798; Rieber J, 2009, GENE CHROMOSOME CANC, V48, P558, DOI 10.1002/gcc.20665; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Storlazzi CT, 2010, GENOME RES, V20, P1198, DOI 10.1101/gr.106252.110; Tabori U, 2007, CANCER RES, V67, P1415, DOI 10.1158/0008-5472.CAN-06-3682; Taylor MD, 2000, NEUROSURGERY, V47, P888, DOI 10.1097/00006123-200010000-00020; Thanasoula M, 2010, CURR BIOL, V20, P521, DOI 10.1016/j.cub.2010.01.046; Trkova M, 2007, CANCER, V110, P694, DOI 10.1002/cncr.22834; Tusell L, 2010, BIOCHEM SOC T, V38, P1698, DOI 10.1042/BST0381698; Villani A, 2011, LANCET ONCOL, V12, P559, DOI 10.1016/S1470-2045(11)70119-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waszak SM, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000988; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394	53	578	594	1	87	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					59	71		10.1016/j.cell.2011.12.013	http://dx.doi.org/10.1016/j.cell.2011.12.013			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265402	Green Accepted, Bronze			2022-12-28	WOS:000299540700014
J	Mitchell, AD; Studdert, DM				Mitchell, Andrew D.; Studdert, David M.			Plain Packaging of Tobacco Products in Australia A Novel Regulation Faces Legal Challenge	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Mitchell, Andrew D.; Studdert, David M.] Univ Melbourne, Melbourne Law Sch, Parkville, Vic 3052, Australia	University of Melbourne	Studdert, DM (corresponding author), Univ Melbourne, Melbourne Law Sch, 207 Bouverie St, Parkville, Vic 3052, Australia.	d.studdert@unimelb.edu.au	Mitchell, Andrew D/AAO-3714-2021; Studdert, David/AAF-3116-2021	Mitchell, Andrew D/0000-0001-8399-8563; Studdert, David/0000-0003-0585-5537				[Anonymous], PAR CONV PROT IND PR; [Anonymous], ROL MED PROM RED TOB; [Anonymous], WORLD TRAD ORG MIN C; Gervais D, ANAL COMPATIBILITY C; Kerr C, 2011, AUSTRALIAN      1114; [No title captured]	6	25	25	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2012	307	3					261	262		10.1001/jama.2011.2009	http://dx.doi.org/10.1001/jama.2011.2009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877EY	22253391				2022-12-28	WOS:000299161200020
J	Macchiaiolo, M; Gagliardi, MG; Toscano, A; Guccione, P; Bartuli, A				Macchiaiolo, Marina; Gagliardi, Maria Giulia; Toscano, Alessandra; Guccione, Paolo; Bartuli, Andrea			Homozygous familial hypercholesterolaemia	LANCET			English	Editorial Material									[Macchiaiolo, Marina] Bambino Gesu Children Hosp, Dept Paediat, Rare Dis Unit, I-00165 Rome, Italy; [Gagliardi, Maria Giulia; Toscano, Alessandra; Guccione, Paolo] Bambino Gesu Children Hosp, Dept Cardiol & Cardiac Surg, I-00165 Rome, Italy	IRCCS Bambino Gesu; IRCCS Bambino Gesu	Macchiaiolo, M (corresponding author), Bambino Gesu Children Hosp, Dept Paediat, Rare Dis Unit, Piazza St Onofrio 5, I-00165 Rome, Italy.	marina.macchiaiolo@opbg.net	macchiaiolo, marina/HGU-2371-2022; Toscano, Alessandra/AAA-8633-2020; Guccione, Paolo/AAB-1874-2020	Toscano, Alessandra/0000-0002-9833-4513; Gagliardi, Maria Giulia/0000-0001-6646-2361					0	32	32	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 7	2012	379	9823					1330	1330		10.1016/S0140-6736(11)61476-1	http://dx.doi.org/10.1016/S0140-6736(11)61476-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922FB	22285056				2022-12-28	WOS:000302531100030
J	Perez, DR				Perez, Daniel R.			H5N1 Debates: Hung Up on the Wrong Questions	SCIENCE			English	Editorial Material							INFLUENZA-VIRUS; RECEPTOR SPECIFICITY; TRANSMISSION; HEMAGGLUTININ; POLYMERASE		Univ Maryland, Dept Vet Med, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Perez, DR (corresponding author), Univ Maryland, Dept Vet Med, College Pk, MD 20742 USA.	dperez1@umd.edu	Perez, Daniel R./D-5044-2016	Perez, Daniel R./0000-0002-6569-5689	NIAID NIH HHS [HHSN266200700010C, U01 AI070469] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI070469] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abelin A, 2011, VACCINE, V29, P1135, DOI 10.1016/j.vaccine.2010.11.042; Agricultural Research Service, 2002, USDA SEC POL PROC BI; [Anonymous], 2011, PBS NEWSHOUR    1222; Baxby D, 1996, FEMS IMMUNOL MED MIC, V16, P1; Gao YW, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000709; Maines TR, 2006, P NATL ACAD SCI USA, V103, P12121, DOI 10.1073/pnas.0605134103; Maines TR, 2009, SCIENCE, V325, P484, DOI 10.1126/science.1177238; Matrosovich M, 2009, REV SCI TECH OIE, V28, P203, DOI 10.20506/rst.28.1.1870; Matrosovich MN, 2001, VIROLOGY, V281, P156, DOI 10.1006/viro.2000.0799; Schrauwen EJA, 2011, EMERG INFECT DIS, V17, P200, DOI 10.3201/eid1702.101268; Sorrell EM, 2009, P NATL ACAD SCI USA, V106, P7565, DOI 10.1073/pnas.0900877106; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; Taubenberger JK, 2010, CELL HOST MICROBE, V7, P440, DOI 10.1016/j.chom.2010.05.009; Tumpey TM, 2007, SCIENCE, V315, P655, DOI 10.1126/science.1136212; Van Hoeven N, 2009, P NATL ACAD SCI USA, V106, P3366, DOI 10.1073/pnas.0813172106; Van Kerkhove MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014582; Watanabe Y, 2012, TRENDS MICROBIOL, V20, P11, DOI 10.1016/j.tim.2011.10.003; WHO Media Centre, 2011, WHO MEDIA CTR   1230	18	13	13	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	2012	335	6070					799	801		10.1126/science.1219066	http://dx.doi.org/10.1126/science.1219066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	893LC	22267585	Green Accepted			2022-12-28	WOS:000300356400025
J	Moore, W				Moore, Wendy			PAST CARING Extreme measures: the history of breast cancer surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												wendymoore@ntlworld.com						Austoker J, 1985, Soc Soc Hist Med Bull (Lond), V37, P100; HEISTER L, 1748, GEN SYSTEM SURG; Leopold E., 1999, DARKER RIBBON BREAST; OLSON JS, 2002, BATHSHEBAS BREAST WO	4	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 8	2012	344								e834	10.1136/bmj.e834	http://dx.doi.org/10.1136/bmj.e834			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IE	22318439				2022-12-28	WOS:000300279100006
J	Lau, E; Kluger, H; Varsano, T; Lee, K; Scheffler, I; Rimm, DL; Ideker, T; Ronai, ZA				Lau, Eric; Kluger, Harriet; Varsano, Tal; Lee, KiYoung; Scheffler, Immo; Rimm, David L.; Ideker, Trey; Ronai, Ze'ev A.			PKC epsilon Promotes Oncogenic Functions of ATF2 in the Nucleus while Blocking Its Apoptotic Function at Mitochondria	CELL			English	Article							ACTIVATING TRANSCRIPTION FACTOR-2; DOUBLE-EDGED-SWORD; KINASE-C-EPSILON; GENE-EXPRESSION; SUBCELLULAR-LOCALIZATION; MELANOMA-CELLS; HEXOKINASE-II; CYTOCHROME-C; CANCER; SURVIVAL	The transcription factor ATF2 elicits oncogenic activities in melanoma and tumor suppressor activities in nonmalignant skin cancer. Here, we identify that ATF2 tumor suppressor function is determined by its ability to localize at the mitochondria, where it alters membrane permeability following genotoxic stress. The ability of ATF2 to reach the mitochondria is determined by PKC epsilon, which directs ATF2 nuclear localization. Genotoxic stress attenuates PKC epsilon effect on ATF2; enables ATF2 nuclear export and localization at the mitochondria, where it perturbs the HK1-VDAC1 complex; increases mitochondrial permeability; and promotes apoptosis. Significantly, high levels of PKC epsilon, as seen in melanoma cells, block ATF2 nuclear export and function at the mitochondria, thereby attenuating apoptosis following exposure to genotoxic stress. In melanoma tumor samples, high PKC epsilon levels associate with poor prognosis. Overall, our findings provide the framework for understanding how subcellular localization enables ATF2 oncogenic or tumor suppressor functions.	[Lau, Eric; Varsano, Tal; Ronai, Ze'ev A.] Sanford Burnham Med Res Inst, Signal Transduct Program, La Jolla, CA 92037 USA; [Kluger, Harriet; Rimm, David L.] Yale Univ, Dept Pathol, New Haven, CT 06520 USA; [Lee, KiYoung; Ideker, Trey] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Lee, KiYoung; Ideker, Trey] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; [Scheffler, Immo] Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; [Lee, KiYoung] Ajou Univ, Sch Med, Dept Biomed Informat, Suwon 443749, South Korea	Sanford Burnham Prebys Medical Discovery Institute; Yale University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Ajou University	Ronai, ZA (corresponding author), Sanford Burnham Med Res Inst, Signal Transduct Program, La Jolla, CA 92037 USA.	ronai@sbmri.org		Ideker, Trey/0000-0002-1708-8454; Rimm, David/0000-0001-5820-4397; RONAI, ZEEV/0000-0002-3859-0400	ACS; Illinois Division; NCI [117090-PF-09-112-01-GMC, 5-T32-CA121949, CA099961, CA051995]; NATIONAL CANCER INSTITUTE [T32CA121949, R01CA099961, R29CA051995, R01CA051995] Funding Source: NIH RePORTER	ACS(American Cancer Society); Illinois Division; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Meenhard Herlyn and John Clifford for melanoma and SCC cell lines, Jorge Moscat and Maria Diaz-Meco for PKC reagents, members of the Salvesen lab, Robbin Newlin and Yoav Altman for technical assistance, and Colin Goding for helpful comments on the manuscript. We also thank Ronai laboratory members, Meifan Chen, Hyungsoo Kim, Ersheng Kuang, Marzia Scortegagna, and Meera Shah for technical advice and assistance and Gustavo Gutierrez for bacterial ATF2 proteins. Support from ACS Postdoctoral Fellowship, Illinois Division and NCI T32 training grant (117090-PF-09-112-01-GMC and 5-T32-CA121949 to E.L.) and NCI grants (CA099961 and CA051995 to Z.A.R.) are gratefully acknowledged. D.L.R. is a consultant for and stockholder in HistoRx, the exclusive licensee of the Yale-owned AQUA technology used in this work.	Abu-Hamad S, 2009, J CELL SCI, V122, P1906, DOI 10.1242/jcs.040188; Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037; Barrett LE, 2006, P NATL ACAD SCI USA, V103, P5155, DOI 10.1073/pnas.0510477103; Berger AJ, 2003, CANCER RES, V63, P8103; Bhoumik A, 2005, MOL CELL, V18, P577, DOI 10.1016/j.molcel.2005.04.015; Bhoumik A, 2002, J CLIN INVEST, V110, P643, DOI 10.1172/JCI200216081; Bhoumik A, 2004, P NATL ACAD SCI USA, V101, P4222, DOI 10.1073/pnas.0400195101; Bhoumik A, 2008, P NATL ACAD SCI USA, V105, P1674, DOI 10.1073/pnas.0706057105; Carvalho ACP, 2004, CELL DEATH DIFFER, V11, P1265, DOI 10.1038/sj.cdd.4401508; Deng XH, 2008, CANCER RES, V68, P9663, DOI 10.1158/0008-5472.CAN-08-2229; Fu XA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002009; Gillespie S, 2005, MOL CANCER THER, V4, P668, DOI 10.1158/1535-7163.MCT-04-0332; Gonelli A, 2009, MINI-REV MED CHEM, V9, P498, DOI 10.2174/138955709787847967; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; King MA, 2007, CYTOM PART A, V71A, P668, DOI 10.1002/cyto.a.20428; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025; Lee J, 2005, J BIOL CHEM, V280, P40398, DOI 10.1074/jbc.C500140200; Li Shuangwei, 2010, Genes Cancer, V1, P316; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Maekawa T, 2008, ONCOGENE, V27, P1045, DOI 10.1038/sj.onc.1210727; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moin SM, 2007, J BIOL CHEM, V282, P21124, DOI 10.1074/jbc.M701696200; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Sand JM, 2010, J INVEST DERMATOL, V130, P270, DOI 10.1038/jid.2009.212; Shah M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001258; Shoshan-Barmatz V, 2010, BBA-BIOENERGETICS, V1797, P1281, DOI 10.1016/j.bbabio.2010.03.003; Shulga N, 2009, CELL CYCLE, V8, P3355, DOI 10.4161/cc.8.20.9853; Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344; Yamasaki T, 2009, J BIOL CHEM, V284, P8567, DOI 10.1074/jbc.M808719200; Yu M, 2008, J INVEST DERMATOL, V128, P1797, DOI 10.1038/sj.jid.5701243; Zalk R, 2005, BIOCHEM J, V386, P73, DOI 10.1042/BJ20041356	39	58	64	1	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					543	555		10.1016/j.cell.2012.01.016	http://dx.doi.org/10.1016/j.cell.2012.01.016			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304920	Green Accepted, Bronze			2022-12-28	WOS:000300225000021
J	Park, SJ; Ahmad, F; Philp, A; Baar, K; Williams, T; Luo, HB; Ke, HM; Rehmann, H; Taussig, R; Brown, AL; Kim, MK; Beaven, MA; Burgin, AB; Manganiello, V; Chung, JH				Park, Sung-Jun; Ahmad, Faiyaz; Philp, Andrew; Baar, Keith; Williams, Tishan; Luo, Haibin; Ke, Hengming; Rehmann, Holger; Taussig, Ronald; Brown, Alexandra L.; Kim, Myung K.; Beaven, Michael A.; Burgin, Alex B.; Manganiello, Vincent; Chung, Jay H.			Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases	CELL			English	Article							ACTIVATED PROTEIN-KINASE; SMALL-MOLECULE ACTIVATORS; LIFE-SPAN; PHOSPHOLIPASE-C; CYCLIC-AMP; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL-FUNCTION; CALORIE RESTRICTION; SIGNALING PATHWAY; CARDIAC MYOCYTES	Resveratrol, a polyphenol in red wine, has been reported as a calorie restriction mimetic with potential antiaging and antidiabetogenic properties. It is widely consumed as a nutritional supplement, but its mechanism of action remains a mystery. Here, we report that the metabolic effects of resveratrol result from competitive inhibition of cAMP-degrading phosphodiesterases, leading to elevated cAMP levels. The resulting activation of Epac1, a cAMP effector protein, increases intracellular Ca2+ levels and activates the CamKK beta-AMPK pathway via phospholipase C and the ryanodine receptor Ca2+-release channel. As a consequence, resveratrol increases NAD(+) and the activity of Sirt1. Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice. Therefore, administration of PDE4 inhibitors may also protect against and ameliorate the symptoms of metabolic diseases associated with aging.	[Park, Sung-Jun; Brown, Alexandra L.; Kim, Myung K.; Chung, Jay H.] NHLBI, Lab Obes & Aging Res, Genet & Dev Biol Ctr, NIH, Bethesda, MD 20892 USA; [Ahmad, Faiyaz; Manganiello, Vincent] NHLBI, Cardiovasc Pulm Branch, NIH, Bethesda, MD 20892 USA; [Beaven, Michael A.] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; [Philp, Andrew; Baar, Keith] Univ Calif Davis, Funct Mol Biol Lab, Davis, CA 95616 USA; [Williams, Tishan; Ke, Hengming] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Luo, Haibin] Sun Yat Sen Univ, Sch Pharmaceut Sci, Struct Biol Lab, Guangzhou 510006, Guangdong, Peoples R China; [Rehmann, Holger] Univ Med Ctr, Dept Mol Canc Res, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; [Rehmann, Holger] Univ Med Ctr, Canc Genom Ctr, NL-3584 CG Utrecht, Netherlands; [Taussig, Ronald] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Burgin, Alex B.] Emerald BioStruct, Bainbridge Isl, WA 98110 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Davis; University of North Carolina; University of North Carolina Chapel Hill; Sun Yat Sen University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Chung, JH (corresponding author), NHLBI, Lab Obes & Aging Res, Genet & Dev Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.	chungj@nhlbi.nih.gov	Khan, Faiyaz Ahmad/AAW-7944-2021	Philp, Andrew/0000-0003-3860-4136; Baar, Keith/0000-0001-9337-6186	National Heart Lung and Blood Institute, National Institutes of Health; Netherlands Organization for Scientific Research (NWO); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002540, ZIAHL006118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059791] Funding Source: NIH RePORTER	National Heart Lung and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Intramural Research Program, National Heart Lung and Blood Institute, National Institutes of Health. We thank Andrew Marks for the Ryr2 phosphoantibody; Dr. Yan Tang for sharing data regarding inhibition of PDE3 by resveratrol; Marije Rensen-De Leeuw and Yan Tang for technical assistance; Shutong Yang and Dalton Saunders for animal management; and Alexandra Brown for manuscript review and comments. H.R. is supported by the Netherlands Organization for Scientific Research (NWO).	Ahmad F, 2009, BIOCHEM J, V424, P399, DOI 10.1042/BJ20090842; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Beher D, 2009, CHEM BIOL DRUG DES, V74, P619, DOI 10.1111/j.1747-0285.2009.00901.x; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Brasnyo P, 2011, BRIT J NUTR, V106, P383, DOI 10.1017/S0007114511000316; Burgin AB, 2010, NAT BIOTECHNOL, V28, P63, DOI 10.1038/nbt.1598; Campos-Toimil M, 2007, EUR J PHARMACOL, V577, P91, DOI 10.1016/j.ejphar.2007.08.003; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Crowell JA, 2004, TOXICOL SCI, V82, P614, DOI 10.1093/toxsci/kfh263; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Donmez G, 2010, CELL, V142, P320, DOI 10.1016/j.cell.2010.06.020; El-Mowafy AM, 2003, CARCINOGENESIS, V24, P869, DOI 10.1093/carcin/bgg015; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Gevrey JC, 2002, J BIOL CHEM, V277, P22407, DOI 10.1074/jbc.M201624200; Gruber J, 2007, ANN NY ACAD SCI, V1100, P530, DOI 10.1196/annals.1395.059; Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; MANGANIELLO V, 1973, J BIOL CHEM, V248, P7164; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Oestreich EA, 2007, J BIOL CHEM, V282, P5488, DOI 10.1074/jbc.M608495200; Oestreich EA, 2009, J BIOL CHEM, V284, P1514, DOI 10.1074/jbc.M806994200; Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682; Park CE, 2007, EXP MOL MED, V39, P222, DOI 10.1038/emm.2007.25; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Pereira L, 2007, J PHYSIOL-LONDON, V583, P685, DOI 10.1113/jphysiol.2007.133066; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rondinone CM, 2000, J BIOL CHEM, V275, P10093, DOI 10.1074/jbc.275.14.10093; Sareen D, 2007, MOL PHARMACOL, V72, P1466, DOI 10.1124/mol.107.039040; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; SELAWRY H, 1973, BIOCHEM BIOPH RES CO, V51, P198, DOI 10.1016/0006-291X(73)90528-7; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Suchankova G, 2009, BIOCHEM BIOPH RES CO, V378, P836, DOI 10.1016/j.bbrc.2008.11.130; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Vingtdeux V, 2010, J BIOL CHEM, V285, P9100, DOI 10.1074/jbc.M109.060061; Viswanathan M, 2005, DEV CELL, V9, P605, DOI 10.1016/j.devcel.2005.09.017; Wehrens XHT, 2004, CIRC RES, V94, pE61, DOI 10.1161/01.RES.0000125626.33738.E2; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Yang L, 2008, EXP NEUROL, V211, P311, DOI 10.1016/j.expneurol.2007.02.010	67	996	1053	27	345	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					421	433		10.1016/j.cell.2012.01.017	http://dx.doi.org/10.1016/j.cell.2012.01.017			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304913	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000300225000012
J	Crasta, K; Ganem, NJ; Dagher, R; Lantermann, AB; Ivanova, EV; Pan, YF; Nezi, L; Protopopov, A; Chowdhury, D; Pellman, D				Crasta, Karen; Ganem, Neil J.; Dagher, Regina; Lantermann, Alexandra B.; Ivanova, Elena V.; Pan, Yunfeng; Nezi, Luigi; Protopopov, Alexei; Chowdhury, Dipanjan; Pellman, David			DNA breaks and chromosome pulverization from errors in mitosis	NATURE			English	Article							KINETOCHORE-MICROTUBULE ATTACHMENT; TUMOR-SUPPRESSOR; NUCLEAR-PORE; CANCER-CELLS; REPLICATION; INSTABILITY; ANEUPLOIDY; DAMAGE; TUMORIGENESIS; COMPLEX	The involvement of whole-chromosome aneuploidy in tumorigenesis is the subject of debate, in large part because of the lack of insight into underlying mechanisms. Here we identify a mechanism by which errors in mitotic chromosome segregation generate DNA breaks via the formation of structures called micronuclei. Whole-chromosome-containing micronuclei form when mitotic errors produce lagging chromosomes. We tracked the fate of newly generated micronuclei and found that they undergo defective and asynchronous DNA replication, resulting in DNA damage and often extensive fragmentation of the chromosome in the micronucleus. Micronuclei can persist in cells over several generations but the chromosome in the micronucleus can also be distributed to daughter nuclei. Thus, chromosome segregation errors potentially lead to mutations and chromosome rearrangements that can integrate into the genome. Pulverization of chromosomes in micronuclei may also be one explanation for 'chromothripsis' in cancer and developmental disorders, where isolated chromosomes or chromosome arms undergo massive local DNA breakage and rearrangement.	[Crasta, Karen; Ganem, Neil J.; Dagher, Regina; Lantermann, Alexandra B.; Nezi, Luigi; Pellman, David] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Crasta, Karen; Ganem, Neil J.; Dagher, Regina; Pellman, David] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Crasta, Karen; Ganem, Neil J.; Dagher, Regina; Pellman, David] Howard Hughes Med Inst, Boston, MA 02115 USA; [Ivanova, Elena V.; Protopopov, Alexei] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA; [Pan, Yunfeng; Chowdhury, Dipanjan] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Pellman, D (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02115 USA.	david_pellman@dfci.harvard.edu	Crasta, Karen C/F-8752-2015; Nezi, Luigi/AAB-1957-2019	Nezi, Luigi/0000-0002-4670-7656; Crasta, Karen/0000-0001-9849-6080; Ivanova, Elena/0000-0002-5069-4974; Ganem, Neil/0000-0003-0269-6585	Howard Hughes Medical Institute; NIH [GM083299, 1R01CA142698-01]; NATIONAL CANCER INSTITUTE [R01CA142698, R00CA154531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083299] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. D'Andrea, M. E. McLaughlin, T. A. Rapoport, J. Walters and Pellman laboratory members for discussions and/or comments on the manuscript; L. Cameron for advice and help on microscopy; H. Li for irradiation of cells; M. Nitta and M. Hennessy for preliminary experiments; and V. Larionov, B. Stillman, J. Ellenberg, I. Mattaj, A. Miyawaki and T. Kuroda for reagents. D. P. was supported by the Howard Hughes Medical Institute and the NIH (GM083299); K. C. was a fellow of A*STAR Singapore; N.J.G. was a fellow of the Leukemia and Lymphoma Society; Y.P. and D. C. were funded by the NIH (1R01CA142698-01).	Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; Baker DJ, 2009, CANCER CELL, V16, P475, DOI 10.1016/j.ccr.2009.10.023; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Cimini D, 2008, BBA-REV CANCER, V1786, P32, DOI 10.1016/j.bbcan.2008.05.003; Dalton WB, 2007, CANCER RES, V67, P11487, DOI 10.1158/0008-5472.CAN-07-5162; DeLuca JG, 2002, J CELL BIOL, V159, P549, DOI 10.1083/jcb.200208159; DePamphilis M. L., 2011, GENOME DUPLICATION; Dimitrova DS, 2002, J CELL SCI, V115, P51; Dultz E, 2008, J CELL BIOL, V180, P857, DOI 10.1083/jcb.200707026; Franz C, 2007, EMBO REP, V8, P165, DOI 10.1038/sj.embor.7400889; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERAUD G, 1989, EXP CELL RES, V181, P27, DOI 10.1016/0014-4827(89)90179-1; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gordon D. J., NATURE REV IN PRESS; Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KATO H, 1967, J CELL BIOL, V34, P35, DOI 10.1083/jcb.34.1.35; Kline-Smith SL, 2004, MOL BIOL CELL, V15, P1146, DOI 10.1091/mbc.E03-08-0581; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Liu PF, 2011, CELL, V146, P888, DOI 10.1016/j.cell.2011.07.042; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Nakano M, 2008, DEV CELL, V14, P507, DOI 10.1016/j.devcel.2008.02.001; NICHOLS WW, 1965, HEREDITAS-GENETISK A, V54, P101; OBE G, 1975, MUTAT RES, V27, P89, DOI 10.1016/0027-5107(75)90276-6; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Orth J. D., 2011, MOL BIOL CELL; Peterson-Roth E, 2005, MOL CELL BIOL, V25, P3596, DOI 10.1128/MCB.25.9.3596-3607.2005; Prasanth SG, 2004, PHILOS T R SOC B, V359, P7, DOI 10.1098/rstb.2003.1360; Quignon F, 2007, ONCOGENE, V26, P165, DOI 10.1038/sj.onc.1209787; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; SEN S, 1989, CANCER RES, V49, P6731; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Smith L, 2001, P NATL ACAD SCI USA, V98, P13300, DOI 10.1073/pnas.241355098; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Terradas M, 2010, MUTAT RES-REV MUTAT, V705, P60, DOI 10.1016/j.mrrev.2010.03.004; Terradas M, 2009, DNA REPAIR, V8, P1225, DOI 10.1016/j.dnarep.2009.07.004; Thompson SL, 2011, P NATL ACAD SCI USA, V108, P17974, DOI 10.1073/pnas.1109720108; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003	50	778	798	6	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					53	U70		10.1038/nature10802	http://dx.doi.org/10.1038/nature10802			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22258507	Green Accepted			2022-12-28	WOS:000299726000033
J	Jenkins, A				Jenkins, Alice			LITERATURE Wonders and ologies	NATURE			English	Editorial Material									Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Jenkins, A (corresponding author), Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland.	alice.jenkins@glasgow.ac.uk							0	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					32	33		10.1038/482032a	http://dx.doi.org/10.1038/482032a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	884RN	22297955	Bronze			2022-12-28	WOS:000299726000017
J	Holbrook, JT; Wise, RA; Gold, BD; Blake, K; Brown, ED; Castro, M; Dozor, AJ; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG				Holbrook, Janet T.; Wise, Robert A.; Gold, Benjamin D.; Blake, Kathryn; Brown, Ellen D.; Castro, Mario; Dozor, Allen J.; Lima, John J.; Mastronarde, John G.; Sockrider, Marianna M.; Teague, W. Gerald		Amer Lung Assoc Asthma Clin Res Ct	Lansoprazole for Children With Poorly Controlled Asthma A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GASTROESOPHAGEAL-REFLUX DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; PROTON-PUMP INHIBITORS; QUALITY-OF-LIFE; RESPIRATORY SYMPTOMS; RISK; EXACERBATIONS; ASSOCIATIONS; VALIDATION; GUIDELINES	Context Asymptomatic gastroesophageal reflux (GER) is prevalent in children with asthma. Untreated GER has been postulated to be a cause of inadequate asthma control in children despite inhaled corticosteroid treatment, but it is not known whether treatment with proton pump inhibitors improves asthma control. Objective To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER. Design, Setting, and Participants The Study of Acid Reflux in Children With Asthma, a randomized, masked, placebo-controlled, parallel clinical trial that compared lansoprazole with placebo in children with poor asthma control who were receiving inhaled corticosteroid treatment. Three hundred six participants enrolled from April 2007 to September 2010 at 19 US academic clinical centers were followed up for 24 weeks. A subgroup had an esophageal pH study before randomization. Intervention Participating children were randomly assigned to receive either lansoprazole, 15 mg/d if weighing less than 30 kg or 30 mg/d if weighing 30 kg or more (n=149), or placebo (n=157). Main Outcome Measures The primary outcome measure was change in Asthma Control Questionnaire (ACQ) score (range, 0-6; a 0.5-unit change is considered clinically meaningful). Secondary outcome measures included lung function measures, asthma-related quality of life, and episodes of poor asthma control. Results The mean age was 11 years (SD, 3 years). The mean difference in change (lansoprazole minus placebo) in the ACQ score was 0.2 units (95% CI, 0.0-0.3 units). There were no statistically significant differences in the mean difference in change for the secondary outcomes of forced expiratory volume in the first second (0.0 L; 95% CI, -0.1 to 0.1 L), asthma-related quality of life (-0.1; 95% CI, -0.3 to 0.1), or rate of episodes of poor asthma control (relative risk, 1.2; 95% CI, 0.9-1.5). Among the 115 children with esophageal pH studies, the prevalence of GER was 43%. In the subgroup with a positive pH study, no treatment effect for lansoprazole vs placebo was observed for any asthma outcome. Children treated with lansoprazole reported more respiratory infections (relative risk, 1.3 [95% CI, 1.1-1.6]). Conclusion In this trial of children with poorly controlled asthma without symptoms of GER who were using inhaled corticosteroids, the addition of lansoprazole, compared with placebo, improved neither symptoms nor lung function but was associated with increased adverse events.	[Holbrook, Janet T.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Clin Trials, Baltimore, MD USA; [Wise, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; [Gold, Benjamin D.] Childrens Ctr Digest Healthcare, Atlanta, GA USA; [Blake, Kathryn; Lima, John J.] Nemours Childrens Clin, Jacksonville, FL USA; [Brown, Ellen D.] Johns Hopkins Sch Publ Hlth, Ctr Clin Trials, Baltimore, MD USA; [Castro, Mario] Washington Univ, Sch Med, St Louis, MO USA; [Dozor, Allen J.] Westchester Cty Med Ctr, Maria Fareri Childrens Hosp, Valhalla, NY 10595 USA; [Dozor, Allen J.] New York Med Coll, Valhalla, NY 10595 USA; [Mastronarde, John G.] Ohio State Univ, Med Ctr, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; [Sockrider, Marianna M.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; [Teague, W. Gerald] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Washington University (WUSTL); Westchester Medical Center; New York Medical College; University System of Ohio; Ohio State University; Baylor College of Medicine; University of Virginia	Holbrook, JT (corresponding author), Johns Hopkins Ctr Clin Trials, 911 S Ann St, Baltimore, MD 21231 USA.	jholbroo@jhsph.edu	Parsons, Jonathan/E-3824-2011	Wise, Robert/0000-0002-8353-2349	American Lung Association Asthma Clinical Research Centers; National Institutes of Health/National Heart, Lung, and Blood Institute [U01 HL080450, U01 HL080433]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL080433, U01HL080450] Funding Source: NIH RePORTER	American Lung Association Asthma Clinical Research Centers; National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by the American Lung Association Asthma Clinical Research Centers Infrastructure Award and National Institutes of Health/National Heart, Lung, and Blood Institute grants U01 HL080450 (Dr Holbrook) and U01 HL080433 (Dr Teague). Lansoprazole and placebo were provided by Takeda Pharmaceuticals; albuterol was provided by GlaxoSmithKline.	ANDZE GO, 1991, J PEDIATR SURG, V26, P295, DOI 10.1016/0022-3468(91)90505-N; Blondeau K, 2011, PEDIATR PULM, V46, P286, DOI 10.1002/ppul.21365; Canani RB, 2006, PEDIATRICS, V117, pE817, DOI 10.1542/peds.2005-1655; Cinquetti M, 2002, J ASTHMA, V39, P135, DOI 10.1081/JAS-120002194; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Deal L, 2005, J PEDIATR GASTR NUTR, V41, P178, DOI 10.1097/01.mpg.0000172885.77795.0f; DiMango E, 2009, AM J RESP CRIT CARE, V180, P809, DOI 10.1164/rccm.200904-0625OC; El-Serag HB, 2001, GASTROENTEROLOGY, V121, P1294, DOI 10.1053/gast.2001.29545; Eom CS, 2011, CAN MED ASSOC J, V183, P310, DOI 10.1503/cmaj.092129; Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290; Hancox RJ, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-142; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Harding SM, 1997, CHEST, V111, P1389, DOI 10.1378/chest.111.5.1389; Juniper EF, 2010, EUR RESPIR J, V36, P1410, DOI 10.1183/09031936.00117509; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Keene ON, 2007, PHARM STAT, V6, P89, DOI 10.1002/pst.250; Khoshoo V, 2009, PEDIATR PULM, V44, P1070, DOI 10.1002/ppul.21094; Khoshoo V, 2007, J PEDIATR GASTR NUTR, V44, P331, DOI 10.1097/MPG.0b013e31802fe89c; Kiljander TO, 2006, AM J RESP CRIT CARE, V173, P1091, DOI 10.1164/rccm.200507-1167OC; Kiljander TO, 2010, AM J RESP CRIT CARE, V181, P1042, DOI 10.1164/rccm.200910-1537OC; Laheij RJF, 2004, JAMA-J AM MED ASSOC, V292, P1955, DOI 10.1001/jama.292.16.1955; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Meijvis SCA, 2011, EUR RESPIR J, V38, P1165, DOI 10.1183/09031936.00020811; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Heart Lung and Blood Institute, 2007, NIH PUBL; Nelson S P, 2009, J Med Econ, V12, P348, DOI 10.3111/13696990903378680; Ohara T, 1999, DIGEST DIS SCI, V44, P1710, DOI 10.1023/A:1026604203237; Orenstein SR, 2009, J PEDIAT, V154, pe4; Orenstein SR, 2009, J PEDIATR-US, V154, P514, DOI 10.1016/j.jpeds.2008.09.054; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Sheikh S, 1999, PEDIATR PULM, V28, P181, DOI 10.1002/(SICI)1099-0496(199909)28:3<181::AID-PPUL4>3.0.CO;2-S; Sherman PM, 2009, AM J GASTROENTEROL, V104, P1278, DOI 10.1038/ajg.2009.129; Stordal K, 2005, ARCH DIS CHILD, V90, P956, DOI 10.1136/adc.2004.068890; Taylor AM, 2010, PEDIAT FOCUSED SAFET; Tolia V, 2009, ALIMENT PHARM THER, V29, P258, DOI 10.1111/j.1365-2036.2008.03879.x; Tolia V, 2002, J PEDIATR GASTR NUTR, V35, pS308, DOI 10.1097/00005176-200211004-00003; TUCCI F, 1993, J PEDIATR GASTR NUTR, V17, P265, DOI 10.1097/00005176-199310000-00006; US Food and Drug Administration, 2010, TRANSCR JUN 21 2010; US Food and Drug Administration, FDA DRUG SAF COMM PO; US Food and Drug Administration, 2010, TRANSCR NOV 5 2010 M; Vandenplas Y, 2009, J PEDIATR GASTR NUTR, V49, P498, DOI 10.1097/MPG.0b013e3181b7f563; Yoshida N, 2000, ALIMENT PHARM THERAP, V14, P74, DOI 10.1046/j.1365-2036.2000.014s1074.x; Zedtwitz-Liebenstein K, 2002, CRIT CARE MED, V30, P1118, DOI 10.1097/00003246-200205000-00026; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	48	169	171	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2012	307	4					373	381		10.1001/jama.2011.2035	http://dx.doi.org/10.1001/jama.2011.2035			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EP	22274684	Green Accepted, Bronze			2022-12-28	WOS:000299464000023
J	Beddington, JR; Asaduzzaman, M; Clark, ME; Bremauntz, AF; Guillou, MD; Howlett, DJB; Jahn, MM; Lin, E; Mamo, T; Negra, C; Nobre, CA; Scholes, RJ; Van Bo, N; Wakhungu, J				Beddington, J. R.; Asaduzzaman, M.; Clark, M. E.; Fernandez Bremauntz, A.; Guillou, M. D.; Howlett, D. J. B.; Jahn, M. M.; Lin, E.; Mamo, T.; Negra, C.; Nobre, C. A.; Scholes, R. J.; Van Bo, N.; Wakhungu, J.			What Next for Agriculture After Durban?	SCIENCE			English	Editorial Material									[Jahn, M. M.] Univ Wisconsin, Madison, WI 53706 USA; [Fernandez Bremauntz, A.] Univ Autonoma Metropolitana, Mexico City, DF, Mexico; [Howlett, D. J. B.] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England	University of Wisconsin System; University of Wisconsin Madison; Universidad Autonoma Metropolitana - Mexico; University of Leeds	Jahn, MM (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.	mjahn@wisc.edu	Jahn, Molly/G-6133-2015	Jahn, Molly/0000-0001-8319-3300; Scholes, Robert/0000-0001-5537-6935; Jahn, Molly/0000-0003-0181-0374	ESRC [ES/G021694/1] Funding Source: UKRI; Economic and Social Research Council [ES/G021694/1] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		[Anonymous], 2011, DECL DAN AGR GREENH; [Anonymous], CLIMATE SMART AGR MA; [Anonymous], GLOB SCI C CLIM SMAR; [Anonymous], 2011, UN CLIM CHANG C DURB; [Anonymous], AGR RURAL DEV DAY; Beddington J., 2011, Achieving food security in the face of climate change: summary for policy makers from the Commission on Sustainable Agriculture and Climate Change; Foresight, 2011, FUT FOOD FARM FIN PR; INRA and Agricultural Research for Development (CIRAD), 2011, AGR SCEN CHALL FEED; IPCC, 2011, SUMM POL MAK SPEC RE; Lobell DB, 2011, SCIENCE, V333, P616, DOI [10.1126/science.1204531, 10.1126/science.1206376]; Murray D., 2009, AGR CROSSROADS SYNTH; Pretty J, 2011, INT J AGR SUSTAIN, V9, P5, DOI 10.3763/ijas.2010.0583; Reij C., 2009, 911 IFPRI; Smith P, 2008, PHILOS T R SOC B, V363, P789, DOI 10.1098/rstb.2007.2184; The Johannesburg Communique, 2011, JOHANNESBURG COMMUNI	15	98	102	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					289	290		10.1126/science.1217941	http://dx.doi.org/10.1126/science.1217941			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	878RE	22267797				2022-12-28	WOS:000299273400030
J	Cannuscio, CC				Cannuscio, Carolyn C.			Lessons in Elder Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia VA Med Ctr,Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA	University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Cannuscio, CC (corresponding author), Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia VA Med Ctr,Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.	carolyncannu@gmail.com	Cannuscio, Carolyn/A-1123-2007						0	0	0	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2012	307	3					263	264		10.1001/jama.2011.2004	http://dx.doi.org/10.1001/jama.2011.2004			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877EY	22253392				2022-12-28	WOS:000299161200021
J	While, D; Bickley, H; Roscoe, A; Windfuhr, K; Rahman, S; Shaw, J; Appleby, L; Kapur, N				While, David; Bickley, Harriet; Roscoe, Alison; Windfuhr, Kirsten; Rahman, Shaiyan; Shaw, Jenny; Appleby, Louis; Kapur, Navneet			Implementation of mental health service recommendations in England and Wales and suicide rates, 1997-2006: a cross-sectional and before-and-after observational study	LANCET			English	Article							INPATIENT SUICIDE; PREVENTION; MORTALITY	Background Research investigating which aspects of mental health service provision are most effective in prevention of suicide is scarce. We aimed to examine the uptake of key mental health service recommendations over time and to investigate the association between their implementation and suicide rates. Methods We did a descriptive, cross-sectional, and before-and-after analysis of national suicide data in England and Wales. We collected data for individuals who died by suicide between 1997 and 2006 who were in contact with mental health services in the 12 months before death. Data were obtained as part of the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. When denominator data were missing, we used information from the Mental Health Minimum Data Set. We compared suicide rates for services implementing most of the recommendations with those implementing fewer recommendations and examined rates before and after implementation. We stratified results for level of socioeconomic deprivation and size of service provider. Findings The average number of recommendations implemented increased from 0.3 per service in 1998 to 7.2 in 2006. Implementation of recommendations was associated with lower suicide rates in both cross-sectional and before-and-after analyses. The provision of 24 h crisis care was associated with the biggest fall in suicide rates: from 11.44 per 10 000 patient contacts per year (95% CI 11.12-11.77) before to 9.32 (8.99-9.67) after (p<0.0001). Local policies on patients with dual diagnosis (10.55; 10.23-10.89 before vs 9.61; 9.18-10.05 after, p=0.0007) and multidisciplinary review after suicide (11.59; 11.31-11.88 before vs 10.48; 10.13-10.84 after, p<0.0001) were also associated with falling rates. Services that did not implement recommendations had little reduction in suicide. The biggest falls in suicide seemed to be in services with the most deprived catchment areas (incidence rate ratio 0.90; 95% CI 0.88-0.92) and the most patients (0.86; 0.84-0.88). Interpretation Our findings suggest that aspects of provision of mental health services can affect suicide rates in clinical populations. Investigation of the relation between new initiatives and suicide could help to inform future suicide prevention efforts and improve safety for patients receiving mental health care.	[While, David; Bickley, Harriet; Roscoe, Alison; Windfuhr, Kirsten; Rahman, Shaiyan; Shaw, Jenny; Appleby, Louis; Kapur, Navneet] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Mental Hlth & Risk, Ctr Suicide Prevent, Manchester M13 9PL, Lancs, England	University of Manchester	Kapur, N (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Mental Hlth & Risk, Ctr Suicide Prevent, Manchester M13 9PL, Lancs, England.	nav.kapur@manchester.ac.uk	windfuhr, kirsten/AAD-5326-2020	windfuhr, kirsten/0000-0002-2022-3442; Kapur, Nav/0000-0002-3100-3234; shaw, jennifer/0000-0003-2569-7687; Bickley, Harriet/0000-0002-3756-7137	National Patient Safety Agency, UK; NCI	National Patient Safety Agency, UK; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded by the National Patient Safety Agency, UK, and was done as part of the NCI into Suicide and Homicide by People with Mental Illness. We thank the district directors of public health, health authority, and mental health service contacts, and all respondents for completing the questionnaires. We thank Nicola Swinson and Hetal Mehta for assistance with data collection.	Appleby L, 1999, LANCET, V353, P1397, DOI 10.1016/S0140-6736(98)10014-4; Appleby L, 2001, SAFETY 1; BASSETT D, 1993, GEN HOSP PSYCHIAT, V15, P301, DOI 10.1016/0163-8343(93)90022-G; Bertolotte JM, 2002, WORLD PSYCHIAT, V1, P181; Currier GW, 2000, PSYCHIATR SERV, V51, P851, DOI 10.1176/appi.ps.51.7.851; De Leo D, 2002, BRIT J PSYCHIAT, V181, P226, DOI 10.1192/bjp.181.3.226; Dekker J, 2002, COMMUNITY MENT HLT J, V38, P425, DOI 10.1023/A:1019816613834; Glover G, 2006, BRIT J PSYCHIAT, V189, P441, DOI 10.1192/bjp.bp.105.020362; Goldney RD, 2005, CRISIS, V26, P128, DOI 10.1027/0227-5910.26.3.128; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Gunnell D, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6030; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; Hunt IM, 2009, PSYCHOL MED, V39, P443, DOI 10.1017/S0033291708003644; Iles V., 2001, ORGANISATIONAL CHANG; Johannessen HA, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-68; Kapur N, 2006, PSYCHOL MED, V36, P1485, DOI 10.1017/S0033291706008373; Kapur N, 2009, J MENT HEALTH, V18, P1, DOI 10.1080/09638230802370704; Khan MM, 2011, INTERNATIONAL HANDBOOK OF SUICIDE PREVENTION: RESEARCH, POLICY AND PRACTICE, P487; King EA, 2001, BRIT J PSYCHIAT, V178, P531, DOI 10.1192/bjp.178.6.531; Lieberman DZ, 2004, SUICIDE LIFE-THREAT, V34, P448, DOI 10.1521/suli.34.4.448.53740; Links PS, 2005, CAN J PSYCHIAT, V50, P490, DOI 10.1177/070674370505000809; Linsley KR, 2001, BRIT J PSYCHIAT, V178, P465, DOI 10.1192/bjp.178.5.465; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; Nordentoft M, 2011, PROG NEURO-PSYCHOPH, V35, P848, DOI 10.1016/j.pnpbp.2010.11.038; Office for National Statistics, REG TRENDS 41 UND PA; Pirkola S, 2009, LANCET, V373, P147, DOI 10.1016/S0140-6736(08)61848-6; Rehkopf DH, 2006, PSYCHOL MED, V36, P145, DOI 10.1017/S003329170500588X; Stack S, 2000, COMPREHENSIVE TEXTBOOK OF SUICIDOLOGY, P193; StataCorp, 2010, STAT STAT SOFTW REL; The Information Centre for Health and Social Care. The Mental Health Minimum Data Set (MHMDS), 2008, MENT HLTH MIN DAT SE; The Information Centre for Health and Social Care. The Mental Health Minimum Data Set (MHMDS), MENT HLTH MIN DAT SE; Windfuhr K, 2008, J CHILD PSYCHOL PSYC, V49, P1155, DOI 10.1111/j.1469-7610.2008.01938.x; World Health Organization, MENT HLTH SUIC PREV	34	197	200	1	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2012	379	9820					1005	1012		10.1016/S0140-6736(11)61712-1	http://dx.doi.org/10.1016/S0140-6736(11)61712-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22305767				2022-12-28	WOS:000301712300028
J	McManus, RJ; Mant, J				McManus, Richard J.; Mant, Jonathan			Do differences in blood pressure between arms matter?	LANCET			English	Editorial Material							HYPERTENSION		[McManus, Richard J.] Univ Oxford, Dept Primary Care Hlth Sci, Oxford OX1 2ET, England; [Mant, Jonathan] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England	University of Oxford; University of Cambridge	McManus, RJ (corresponding author), Univ Oxford, Dept Primary Care Hlth Sci, Oxford OX1 2ET, England.	richard.mcmanus@phc.ox.ac.uk		Mant, Jonathan/0000-0002-9531-0268	National Institute for Health Research [CDF/01/017] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		A'Court C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X593884; Aboyans V, 2007, J AM COLL CARDIOL, V49, P1540, DOI 10.1016/j.jacc.2006.09.055; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Clark CE, 2012, LANCET, V379, P905, DOI 10.1016/S0140-6736(11)61710-8; Heneghan C, 2007, BRIT J GEN PRACT, V57, P948, DOI 10.3399/096016407782604965; KRAUSE T, 2011, BRIT MED J, V343, DOI DOI 10.1136/BMJ.D4891; Mancia G, 2007, BLOOD PRESSURE, V16, P135, DOI 10.1080/08037050701461084; Martin U, 2009, BRIT HYP SOC ANN SCI, pS15; Verberk WJ, 2011, AM J HYPERTENS, V24, P1201, DOI 10.1038/ajh.2011.125	9	7	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 10	2012	379	9819					872	873		10.1016/S0140-6736(11)61926-0	http://dx.doi.org/10.1016/S0140-6736(11)61926-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	906NY	22293365				2022-12-28	WOS:000301353700008
J	Kratz, JR; He, JX; Van den Eeden, SK; Zhu, ZH; Gao, W; Pham, PT; Mulvihill, MS; Ziaei, F; Zhang, HR; Su, B; Zhi, XY; Quesenberry, CP; Habel, LA; Deng, QH; Wang, ZF; Zhou, JF; Li, HL; Huang, MC; Yeh, CC; Segal, MR; Ray, MR; Jones, KD; Raz, DJ; Xu, ZD; Jahan, TM; Berryman, D; He, B; Mann, MJ; Jablons, DM				Kratz, Johannes R.; He, Jianxing; Van den Eeden, Stephen K.; Zhu, Zhi-Hua; Gao, Wen; Pham, Patrick T.; Mulvihill, Michael S.; Ziaei, Fatemeh; Zhang, Huanrong; Su, Bo; Zhi, Xiuyi; Quesenberry, Charles P.; Habel, Laurel A.; Deng, Qiuhua; Wang, Zongfei; Zhou, Jiangfen; Li, Huiling; Huang, Mei-Chun; Yeh, Che-Chung; Segal, Mark R.; Ray, M. Roshni; Jones, Kirk D.; Raz, Dan J.; Xu, Zhidong; Jahan, Thierry M.; Berryman, David; He, Biao; Mann, Michael J.; Jablons, David M.			A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies	LANCET			English	Article							GENE-EXPRESSION SIGNATURES; VINORELBINE PLUS CISPLATIN; ADJUVANT CHEMOTHERAPY; RECURRENCE; PROGNOSIS; MORTALITY; MODEL	Background The frequent recurrence of early-stage non-small-cell lung cancer (NSCLC) is generally attributable to metastatic disease undetected at complete resection. Management of such patients depends on prognostic staging to identify the individuals most likely to have occult disease. We aimed to develop and validate a practical, reliable assay that improves risk stratification compared with conventional staging. Methods A 14-gene expression assay that uses quantitative PCR, runs on formalin-fixed paraffin-embedded tissue samples, and differentiates patients with heterogeneous statistical prognoses was developed in a cohort of 361 patients with non-squamous NSCLC resected at the University of California, San Francisco. The assay was then independently validated by the Kaiser Permanente Division of Research in a masked cohort of 433 patients with stage I non-squamous NSCLC resected at Kaiser Permanente Northern California hospitals, and on a cohort of 1006 patients with stage I-III non-squamous NSCLC resected in several leading Chinese cancer centres that are part of the China Clinical Trials Consortium (CCTC). Findings Kaplan-Meier analysis of the Kaiser validation cohort showed 5 year overall survival of 71.4% (95% CI 60.5-80.0) in low-risk, 58.3% (48.9-66.6) in intermediate-risk, and 49.2% (42.2-55.8) in high-risk patients (p(trend)=0.0003). Similar analysis of the CCTC cohort indicated 5 year overall survivals of 74.1% (66.0-80.6) in low-risk, 57.4% (48.3-65.5) in intermediate-risk, and 44.6% (40.2-48.9) in high-risk patients (p(trend)<0.0001). Multivariate analysis in both cohorts indicated that no standard clinical risk factors could account for, or provide, the prognostic information derived from tumour gene expression. The assay improved prognostic accuracy beyond National Comprehensive Cancer Network criteria for stage I high-risk tumours (p<0.0001), and differentiated low-risk, intermediate-risk, and high-risk patients within all disease stages. Interpretation Our practical, quantitative-PCR-based assay reliably identified patients with early-stage non-squamous NSCLC at high risk for mortality after surgical resection.	[Kratz, Johannes R.; Pham, Patrick T.; Mulvihill, Michael S.; Yeh, Che-Chung; Segal, Mark R.; Ray, M. Roshni; Jones, Kirk D.; Raz, Dan J.; Xu, Zhidong; Jahan, Thierry M.; He, Biao; Mann, Michael J.; Jablons, David M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [He, Jianxing; Zhang, Huanrong; Deng, Qiuhua; Wang, Zongfei; Zhou, Jiangfen; Li, Huiling] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Dept Cardiothorac Surg, Guangzhou, Guangdong, Peoples R China; [Van den Eeden, Stephen K.; Quesenberry, Charles P.; Habel, Laurel A.] Kaiser Permanente Dept Res, Oakland, CA USA; [Zhu, Zhi-Hua] Sun Yat Sen Univ, Ctr Canc, Dept Thorac Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Gao, Wen] Shanghai Pulm Hosp, Shanghai, Peoples R China; [Ziaei, Fatemeh; Huang, Mei-Chun; Berryman, David] Pinpoint Genom, Mountain View, CA USA; [Zhi, Xiuyi] Capital Med Univ, Beijing Lung Canc Ctr, Beijing, Peoples R China	University of California System; University of California San Francisco; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Kaiser Permanente; Sun Yat Sen University; Capital Medical University	Mann, MJ (corresponding author), UCSF Thorac Surg, 1600 Divisadero St,Room A-743, San Francisco, CA 94143 USA.	michael.mann@ucsfmedctr.org; david.jablons@ucsfmedctr.org		He, Jianxing/0000-0003-1737-8192; Ricchetti, Roshni/0000-0002-1969-1046; Kratz, Johannes R/0000-0003-0696-4073; Mulvihill, Michael/0000-0002-8122-1483; Habel, Laurel/0000-0002-7230-587X	UCSF Thoracic Oncology Laboratory; Pinpoint Genomics; NATIONAL CANCER INSTITUTE [R01CA132566] Funding Source: NIH RePORTER	UCSF Thoracic Oncology Laboratory; Pinpoint Genomics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	UCSF Thoracic Oncology Laboratory and Pinpoint Genomics.	Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066; [Anonymous], 2010, FIL SSDM; Arriagada R, 2010, J CLIN ONCOL, V28, P35, DOI 10.1200/JCO.2009.23.2272; Baty F, 2010, AM J RESP CRIT CARE, V181, P181, DOI 10.1164/rccm.200812-1807OC; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167; Boutros PC, 2009, P NATL ACAD SCI USA, V106, P2824, DOI 10.1073/pnas.0809444106; Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096; Cobo M, 2007, J CLIN ONCOL, V25, P2747, DOI 10.1200/JCO.2006.09.7915; Detterbeck FC, 2009, CHEST, V136, P260, DOI 10.1378/chest.08-0978; Douillard JY, 2006, LANCET ONCOL, V7, P719, DOI 10.1016/S1470-2045(06)70804-X; Dupuy A, 2007, JNCI-J NATL CANCER I, V99, P147, DOI 10.1093/jnci/djk018; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Guo L, 2006, CLIN CANCER RES, V12, P3344, DOI 10.1158/1078-0432.CCR-05-2336; Heagerty PJ, 2005, BIOMETRICS, V61, P92, DOI 10.1111/j.0006-341X.2005.030814.x; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kelsey CR, 2009, CANCER-AM CANCER SOC, V115, P5218, DOI 10.1002/cncr.24625; Kratz JR, 2009, CLIN LUNG CANCER, V10, P151, DOI 10.3816/CLC.2009.n.021; Larsen JE, 2007, CLIN CANCER RES, V13, P2946, DOI 10.1158/1078-0432.CCR-06-2525; Larsen JE, 2007, CARCINOGENESIS, V28, P760, DOI 10.1093/carcin/bgl207; Lau SK, 2007, J CLIN ONCOL, V25, P5562, DOI 10.1200/JCO.2007.12.0352; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; National Comprehensive Cancer Network, 2011, NCCN CLIN PRACT GUID; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; RADIANT, STUD TARC SURG ADJ C; Raponi M, 2006, CANCER RES, V66, P7466, DOI 10.1158/0008-5472.CAN-06-1191; Raz DJ, 2008, CLIN CANCER RES, V14, P5565, DOI 10.1158/1078-0432.CCR-08-0544; Roepman P, 2009, CLIN CANCER RES, V15, P284, DOI 10.1158/1078-0432.CCR-08-1258; Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Simon N, 2011, J STAT SOFTW, V39, P1; Skrzypski M, 2008, CLIN CANCER RES, V14, P4794, DOI 10.1158/1078-0432.CCR-08-0576; Strauss GM, 2008, J CLIN ONCOL, V26, P5043, DOI 10.1200/JCO.2008.16.4855; Subramanian J, 2010, JNCI-J NATL CANCER I, V102, P464, DOI 10.1093/jnci/djq025; Sun ZF, 2008, J CLIN ONCOL, V26, P877, DOI 10.1200/JCO.2007.13.1516; Team RDCR, 2011, LANG ENV STAT COMP; Tomida S, 2004, ONCOGENE, V23, P5360, DOI 10.1038/sj.onc.1207697; Vittinghoff E, 2005, STAT BIOL HEALTH, pVII; Waller D, 2004, EUR J CARDIO-THORAC, V26, P173, DOI 10.1016/j.ejcts.2004.03.041; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Zhu CQ, 2010, J CLIN ONCOL, V28, P4417, DOI 10.1200/JCO.2009.26.4325; Zhu CQ, 2009, CLIN LUNG CANCER, V10, P331, DOI 10.3816/CLC.2009.n.045	44	237	253	2	51	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 3	2012	379	9818					823	832		10.1016/S0140-6736(11)61941-7	http://dx.doi.org/10.1016/S0140-6736(11)61941-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901RB	22285053	Green Accepted			2022-12-28	WOS:000300983400032
J	Haga, K; Kruse, AC; Asada, H; Yurugi-Kobayashi, T; Shiroishi, M; Zhang, C; Weis, WI; Okada, T; Kobilka, BK; Haga, T; Kobayashi, T				Haga, Kazuko; Kruse, Andrew C.; Asada, Hidetsugu; Yurugi-Kobayashi, Takami; Shiroishi, Mitsunori; Zhang, Cheng; Weis, William I.; Okada, Tetsuji; Kobilka, Brian K.; Haga, Tatsuya; Kobayashi, Takuya			Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; TRANSMEMBRANE DOMAIN; SCANNING MUTAGENESIS; CRYSTAL-STRUCTURE; BINDING-PROTEIN; EXPRESSION; INSIGHTS; ACTIVATION; RHODOPSIN; COMPLEX	The parasympathetic branch of the autonomic nervous system regulates the activity of multiple organ systems. Muscarinic receptors are G-protein-coupled receptors that mediate the response to acetylcholine released from parasympathetic nerves(1-5). Their role in the unconscious regulation of organ and central nervous system function makes them potential therapeutic targets for a broad spectrum of diseases. The M2 muscarinic acetylcholine receptor (M2 receptor) is essential for the physiological control of cardiovascular function through activation of G-protein-coupled inwardly rectifying potassium channels, and is of particular interest because of its extensive pharmacological characterization with both orthosteric and allosteric ligands. Here we report the structure of the antagonist-bound human M2 receptor, the first human acetylcholine receptor to be characterized structurally, to our knowledge. The antagonist 3-quinuclidinyl-benzilate binds in the middle of a long aqueous channel extending approximately two-thirds through the membrane. The orthosteric binding pocket is formed by amino acids that are identical in all five muscarinic receptor subtypes, and shares structural homology with other functionally unrelated acetylcholine binding proteins from different species. A layer of tyrosine residues forms an aromatic cap restricting dissociation of the bound ligand. A binding site for allosteric ligands has been mapped to residues at the entrance to the binding pocket near this aromatic cap. The structure of the M2 receptor provides insights into the challenges of developing subtype-selective ligands for muscarinic receptors and their propensity for allosteric regulation.	[Kruse, Andrew C.; Zhang, Cheng; Weis, William I.; Kobilka, Brian K.] Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; [Haga, Kazuko; Okada, Tetsuji; Haga, Tatsuya] Gakushuin Univ, Dept Life Sci, Fac Sci, Tokyo 1718588, Japan; [Asada, Hidetsugu; Yurugi-Kobayashi, Takami; Kobayashi, Takuya] Kyoto Univ, Fac Med, Dept Med Chem & Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; [Asada, Hidetsugu; Yurugi-Kobayashi, Takami; Shiroishi, Mitsunori; Kobayashi, Takuya] Japan Sci & Technol Agcy, ERATO, Human Receptor Crystallog Project, Sakyo Ku, Kyoto 6068501, Japan; [Shiroishi, Mitsunori] Kyushu Univ, Grad Sch Pharmaceut Sci, Higashi Ku, Fukuoka 8128582, Japan; [Weis, William I.] Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; [Kobayashi, Takuya] Kyoto Univ, Fac Med, Japan Sci & Technol Agcy, Kyoto 6068501, Japan	Stanford University; Gakushuin University; Kyoto University; Japan Science & Technology Agency (JST); Kyushu University; Stanford University; Japan Science & Technology Agency (JST); Kyoto University	Kobilka, BK (corresponding author), Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, 279 Campus Dr, Stanford, CA 94305 USA.	kobilka@stanford.edu; tatsuya.haga@gakushuin.ac.jp; t-coba@mfour.med.kyoto-u.ac.jp	Zhang, Cheng/O-4372-2015; Okada, Tetsuji/U-8732-2019; Weis, William I/G-1437-2011	Zhang, Cheng/0000-0001-9042-4007; Okada, Tetsuji/0000-0003-1913-428X; Weis, William I/0000-0002-5583-6150; Kobilka, Brian/0000-0001-5958-3990; Shiroishi, Mitsunori/0000-0002-3133-157X; Asada, Hidetsugu/0000-0001-6255-4728	Japan Society for the Promotion of Science; Japan Science and Technology Corporation (CREST); Ministry of Education, Culture, Sports, Science and Technology of Japan [15083201]; Japan Science and Technology Corporation (ERATO); Toray Science Foundation; Takeda Science Foundation; Ichiro Kanehara Foundation; Sumitomo Foundation; National Institutes of Health [NS028471, GM083118]; Mathers Foundation; National Science Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471, R37NS028471] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23370049] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Science and Technology Corporation (CREST)(Japan Science & Technology Agency (JST)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Science and Technology Corporation (ERATO)(Japan Science & Technology Agency (JST)); Toray Science Foundation(Toray Industries, Inc.); Takeda Science Foundation(Takeda Science Foundation (TSF)); Ichiro Kanehara Foundation; Sumitomo Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mathers Foundation; National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank S. Iwata at Kyoto University for supporting the production of M2 receptor, and we acknowledge support from the Japan Society for the Promotion of Science (Research for Future Program) (T. H.), from the Japan Science and Technology Corporation (CREST) (T. H.), from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grants-in-Aid for Scientific Research on Priority Area 15083201 (T. H.), from the Japan Science and Technology Corporation (ERATO) (T. K.), from Toray Science Foundation (T. K.), from Takeda Science Foundation (T. K.), from Ichiro Kanehara Foundation (T. K.), from The Sumitomo Foundation (T. K.), from the National Institutes of Health Grants NS028471 and GM083118 (B. K. K.), from the Mathers Foundation (B. K. K. and W. I. W.), and from the National Science Foundation (A. C. K.). We thank T. S. Kobilka for organizing the GPCR Workshop 2010 that brought together the research groups, and for facilitating this collaboration	Afonine PV, 2005, ACTA CRYSTALLOGR D, V61, P850, DOI 10.1107/S0907444905007894; Asada H, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-24; BLUML K, 1994, J BIOL CHEM, V269, P18870; Brams M, 2011, J BIOL CHEM, V286, P4420, DOI 10.1074/jbc.M110.188730; Caffrey M, 2009, NAT PROTOC, V4, P706, DOI 10.1038/nprot.2009.31; Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410; Colletier JP, 2006, EMBO J, V25, P2746, DOI 10.1038/sj.emboj.7601175; Dale HH, 1914, J PHARMACOL EXP THER, V6, P147; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; Furukawa H, 2002, MOL PHARMACOL, V62, P778, DOI 10.1124/mol.62.4.778; Goodwin JA, 2007, MOL PHARMACOL, V72, P1484, DOI 10.1124/mol.107.038265; Gregory KJ, 2007, CURR NEUROPHARMACOL, V5, P157, DOI 10.2174/157015907781695946; HAGA K, 1985, NATURE, V316, P731, DOI 10.1038/316731a0; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAGA K, 1983, J BIOL CHEM, V258, P3575; Haga T., 1990, RECEPTOR BIOCH PRACT, P51; Heitz F, 1999, EUR J PHARMACOL, V380, P183, DOI 10.1016/S0014-2999(99)00439-2; Hulme EC, 2003, RECEPTOR CHANNEL, V9, P215, DOI 10.1080/10606820308261; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Ichlyama S, 2006, FEBS LETT, V580, P23, DOI 10.1016/j.febslet.2005.11.042; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McCoy AJ, 2007, ACTA CRYSTALLOGR D, V63, P32, DOI 10.1107/S0907444906045975; Oswald C, 2008, J BIOL CHEM, V283, P32848, DOI 10.1074/jbc.M806021200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648; Rosenbaum DM, 2007, SCIENCE, V318, P1266, DOI 10.1126/science.1150609; Shimamura T, 2011, NATURE, V475, P65, DOI 10.1038/nature10236; Ward SDC, 1999, MOL PHARMACOL, V56, P1031, DOI 10.1124/mol.56.5.1031; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Weber W, 2002, CYTOTECHNOLOGY, V38, P77, DOI 10.1023/A:1021102015070; WESS J, 1993, LIFE SCI, V53, P1447, DOI 10.1016/0024-3205(93)90618-D; Wess J, 2007, NAT REV DRUG DISCOV, V6, P721, DOI 10.1038/nrd2379; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; Zacharias N, 2002, TRENDS PHARMACOL SCI, V23, P281, DOI 10.1016/S0165-6147(02)02027-8	39	600	614	4	148	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2012	482	7386					547	U147		10.1038/nature10753	http://dx.doi.org/10.1038/nature10753			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	898VM	22278061	Green Accepted, Green Published			2022-12-28	WOS:000300770500055
J	Khajavikhan, M; Simic, A; Katz, M; Lee, JH; Slutsky, B; Mizrahi, A; Lomakin, V; Fainman, Y				Khajavikhan, M.; Simic, A.; Katz, M.; Lee, J. H.; Slutsky, B.; Mizrahi, A.; Lomakin, V.; Fainman, Y.			Thresholdless nanoscale coaxial lasers	NATURE			English	Article							OPTICAL MICROCAVITIES; SPONTANEOUS EMISSION; LINEWIDTH; NANOLASER; QUANTUM	The effects of cavity quantum electrodynamics (QED), caused by the interaction of matter and the electromagnetic field in subwavelength resonant structures, have been the subject of intense research in recent years(1). The generation of coherent radiation by subwavelength resonant structures has attracted considerable interest, not only as a means of exploring the QED effects that emerge at small volume, but also for its potential in applications ranging from on-chip optical communication to ultrahigh-resolution and high-throughput imaging, sensing and spectroscopy. One such strand of research is aimed at developing the 'ultimate' nanolaser: a scalable, low-threshold, efficient source of radiation that operates at room temperature and occupies a small volume on a chip(2). Different resonators have been proposed for the realization of such a nanolaser-microdisk(3) and photonic bandgap(4) resonators, and, more recently, metallic(5,6), metallodielectric(7-10) and plasmonic(11,12) resonators. But progress towards realizing the ultimate nanolaser has been hindered by the lack of a systematic approach to scaling down the size of the laser cavity without significantly increasing the threshold power required for lasing. Here we describe a family of coaxial nanostructured cavities that potentially solve the resonator scalability challenge by means of their geometry and metal composition. Using these coaxial nanocavities, we demonstrate the smallest room-temperature, continuous-wave telecommunications-frequency laser to date. In addition, by further modifying the design of these coaxial nanocavities, we achieve thresholdless lasing with a broadband gain medium. In addition to enabling laser applications, these nanoscale resonators should provide a powerful platform for the development of other QED devices and metamaterials in which atom-field interactions generate new functionalities(13,14).	[Khajavikhan, M.; Simic, A.; Katz, M.; Lee, J. H.; Slutsky, B.; Mizrahi, A.; Lomakin, V.; Fainman, Y.] Univ Calif San Diego, Dept Elect & Comp Engn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Khajavikhan, M (corresponding author), Univ Calif San Diego, Dept Elect & Comp Engn, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mercedeh@umn.edu		Khajavikhan, Mercedeh/0000-0002-7091-1470	Defense Advanced Research Projects Agency (DARPA); National Science Foundation (NSF); NSF Center for Integrated Access Networks (CIAN); Cymer Corporation; US Army Research Office; UCSD	Defense Advanced Research Projects Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); National Science Foundation (NSF)(National Science Foundation (NSF)); NSF Center for Integrated Access Networks (CIAN); Cymer Corporation; US Army Research Office; UCSD	We acknowledge support from the Defense Advanced Research Projects Agency (DARPA), the National Science Foundation (NSF), the NSF Center for Integrated Access Networks (CIAN), the Cymer Corporation and the US Army Research Office. M. Khajavikhan thanks the personnel of the UCSD Nano3 facilities for their help and support, T. Javidi and J. Leger for technical discussions regarding the analysis of the data and profile of the beam, and graduate student J. Shane for her help with editing the document.	Baida FI, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.205419; Bayer M, 2001, PHYS REV LETT, V86, P3168, DOI 10.1103/PhysRevLett.86.3168; BENZAQUEN R, 1994, J APPL PHYS, V75, P2633, DOI 10.1063/1.356239; Berman P., 1994, CAVITY QUANTUM ELECT; BJORK G, 1991, IEEE J QUANTUM ELECT, V27, P2386, DOI 10.1109/3.100877; BJORK G, 1992, APPL PHYS LETT, V60, P304, DOI 10.1063/1.106693; Burgos SP, 2010, NAT MATER, V9, P407, DOI [10.1038/nmat2747, 10.1038/NMAT2747]; Chang SW, 2009, IEEE J QUANTUM ELECT, V45, P1004, DOI 10.1109/JQE.2009.2017210; Ding Q, 2011, OPT LETT, V36, P1812, DOI 10.1364/OL.36.001812; Feigenbaum E, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.163902; HENRY CH, 1982, IEEE J QUANTUM ELECT, V18, P259, DOI 10.1109/JQE.1982.1071522; Hill MT, 2007, NAT PHOTONICS, V1, P589, DOI 10.1038/nphoton.2007.171; Jacob Z, 2011, SCIENCE, V334, P463, DOI 10.1126/science.1211736; MCCALL SL, 1992, APPL PHYS LETT, V60, P289, DOI 10.1063/1.106688; Mizrahi A, 2008, OPT LETT, V33, P1261, DOI 10.1364/OL.33.001261; Nezhad MP, 2010, NAT PHOTONICS, V4, P395, DOI 10.1038/NPHOTON.2010.88; Noda S, 2006, SCIENCE, V314, P260, DOI 10.1126/science.1131322; Noginov MA, 2009, NATURE, V460, P1110, DOI 10.1038/nature08318; Oulton RF, 2009, NATURE, V461, P629, DOI 10.1038/nature08364; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Pedrotti LM, 1999, PHYS REV A, V59, P2295, DOI 10.1103/PhysRevA.59.2295; RICE PR, 1994, PHYS REV A, V50, P4318, DOI 10.1103/PhysRevA.50.4318; Roy-Choudhury K, 2011, PHYS REV A, V83, DOI 10.1103/PhysRevA.83.043827; SCHAWLOW AL, 1958, PHYS REV, V112, P1940, DOI 10.1103/PhysRev.112.1940; Strauf S, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.127404; Vahala KJ, 2003, NATURE, V424, P839, DOI 10.1038/nature01939; Vuckovic J, 1999, IEEE J QUANTUM ELECT, V35, P1168, DOI 10.1109/3.777216; Walther C, 2010, SCIENCE, V327, P1495, DOI 10.1126/science.1183167; YOKOYAMA H, 1992, SCIENCE, V256, P66, DOI 10.1126/science.256.5053.66; Yu K, 2010, OPT EXPRESS, V18, P8790, DOI 10.1364/OE.18.008790	30	444	452	12	292	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					204	207		10.1038/nature10840	http://dx.doi.org/10.1038/nature10840			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22318604	Green Submitted			2022-12-28	WOS:000299994100035
J	Li, FZ; Harmer, P; Fitzgerald, K; Eckstrom, E; Stock, R; Galver, J; Maddalozzo, G; Batya, SS				Li, Fuzhong; Harmer, Peter; Fitzgerald, Kathleen; Eckstrom, Elizabeth; Stock, Ronald; Galver, Johnny; Maddalozzo, Gianni; Batya, Sara S.			Tai Chi and Postural Stability in Patients with Parkinson's Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OLDER-ADULTS; PHYSICAL-ACTIVITY; EXERCISE; BALANCE; FALLS; MOBILITY; QUALITY; PEOPLE; PREVENTION; STRENGTH	BACKGROUND Patients with Parkinson's disease have substantially impaired balance, leading to diminished functional ability and an increased risk of falling. Although exercise is routinely encouraged by health care providers, few programs have been proven effective. METHODS We conducted a randomized, controlled trial to determine whether a tailored tai chi program could improve postural control in patients with idiopathic Parkinson's disease. We randomly assigned 195 patients with stage 1 to 4 disease on the Hoehn and Yahr staging scale (which ranges from 1 to 5, with higher stages indicating more severe disease) to one of three groups: tai chi, resistance training, or stretching. The patients participated in 60-minute exercise sessions twice weekly for 24 weeks. The primary outcomes were changes from baseline in the limits-of-stability test (maximum excursion and directional control; range, 0 to 100%). Secondary outcomes included measures of gait and strength, scores on functional-reach and timed up-and-go tests, motor scores on the Unified Parkinson's Disease Rating Scale, and number of falls. RESULTS The tai chi group performed consistently better than the resistance-training and stretching groups in maximum excursion (between-group difference in the change from baseline, 5.55 percentage points; 95% confidence interval [CI], 1.12 to 9.97; and 11.98 percentage points; 95% CI, 7.21 to 16.74, respectively) and in directional control (10.45 percentage points; 95% CI, 3.89 to 17.00; and 11.38 percentage points; 95% CI, 5.50 to 17.27, respectively). The tai chi group also performed better than the stretching group in all secondary outcomes and outperformed the resistance-training group in stride length and functional reach. Tai chi lowered the incidence of falls as compared with stretching but not as compared with resistance training. The effects of tai chi training were maintained at 3 months after the intervention. No serious adverse events were observed. CONCLUSIONS Tai chi training appears to reduce balance impairments in patients with mild-to-moderate Parkinson's disease, with additional benefits of improved functional capacity and reduced falls. (Funded by the National Institute of Neurological Disorders and Stroke; ClinicalTrials.gov number, NCT00611481.)	[Li, Fuzhong] Oregon Res Inst, Eugene, OR 97403 USA; [Fitzgerald, Kathleen] Oregon Med Grp, Eugene, OR USA; [Stock, Ronald] PeaceHlth Med Grp Oregon, Eugene, OR USA; [Harmer, Peter] Willamette Univ, Salem, OR 97301 USA; [Galver, Johnny] BPM Phys Therapy Ctr, Salem, OR USA; [Eckstrom, Elizabeth] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Maddalozzo, Gianni] Oregon State Univ, Corvallis, OR 97331 USA	Oregon Research Institute; Willamette University; Oregon Health & Science University; Oregon State University	Li, FZ (corresponding author), Oregon Res Inst, 1715 Franklin Blvd, Eugene, OR 97403 USA.	fuzhongl@ori.org	Northcote, Matthew/L-1135-2019; Northcote, Matthew/B-8209-2019	Li, Fuzhong/0000-0001-6644-4702	National Institute of Neurological Disorders and Stroke [NS047130]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047130] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by a grant (NS047130) from the National Institute of Neurological Disorders and Stroke.	Ashburn A, 2001, AGE AGEING, V30, P47, DOI 10.1093/ageing/30.1.47; Cheng EM, 2010, NEUROLOGY, V75, P2021, DOI 10.1212/WNL.0b013e3181ff96dd; Deane K, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002815, DOI 10.1002/14651858.CD002815]; Dibble LE, 2006, ARCH PHYS MED REHAB, V87, P1280, DOI 10.1016/j.apmr.2006.05.016; Dibble LE, 2009, J NEUROL PHYS THER, V33, P14, DOI 10.1097/NPT.0b013e3181990fcc; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Fahn S., 2007, PRINCIPLES PRACTICE; Fahn S., 1987, RECENT DEV PARKINSON, P153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; GOETZ CG, 1995, MOVEMENT DISORD, V10, P263, DOI 10.1002/mds.870100305; Goodwin VA, 2008, MOVEMENT DISORD, V23, P631, DOI 10.1002/mds.21922; Greendale GA, 2000, J AM GERIATR SOC, V48, P305, DOI 10.1111/j.1532-5415.2000.tb02651.x; Hackney ME, 2008, GAIT POSTURE, V28, P456, DOI 10.1016/j.gaitpost.2008.02.005; Hirsch MA, 2003, ARCH PHYS MED REHAB, V84, P1109, DOI 10.1016/S0003-9993(03)00046-7; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Li FZ, 2008, AM J PUBLIC HEALTH, V98, P1195, DOI 10.2105/AJPH.2007.120402; Li FZ, 2007, J AGING PHYS ACTIV, V15, P139, DOI 10.1123/japa.15.2.139; Li FZ, 2005, J GERONTOL A-BIOL, V60, P187, DOI 10.1093/gerona/60.2.187; Li FZ, 2004, J AM GERIATR SOC, V52, P892, DOI 10.1111/j.1532-5415.2004.52255.x; Lugassy M, 2005, PRINCIPLES TREATMENT, P313; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI 10.1161/CIRCULATIONAHA.107.185650; Nirenberg MJ, 2005, PRINCIPLES TREATMENT, P3; Paterson C, 2004, J CLIN PHARM THER, V29, P339, DOI 10.1111/j.1365-2710.2004.00570.x; Pickering RM, 2007, MOVEMENT DISORD, V22, P1892, DOI 10.1002/mds.21598; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Rubenstein LZ, 2000, J GERONTOL A-BIOL, V55, pM317, DOI 10.1093/gerona/55.6.M317; Scandalis TA, 2001, AM J PHYS MED REHAB, V80, P38, DOI 10.1097/00002060-200101000-00011; Schapira AHV, 2005, PRINCIPLES TREATMENT, P119; Shaw JM, 1998, J GERONTOL A-BIOL, V53, pM53, DOI 10.1093/gerona/53A.1.M53; Voukelatos A, 2007, J AM GERIATR SOC, V55, P1185, DOI 10.1111/j.1532-5415.2007.01244.x; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x	33	479	524	16	355	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					511	519		10.1056/NEJMoa1107911	http://dx.doi.org/10.1056/NEJMoa1107911			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GH	22316445	Green Accepted			2022-12-28	WOS:000299991300007
J	Lin, YY; Kiihl, S; Suhail, Y; Liu, SY; Chou, YH; Kuang, Z; Lu, JY; Khor, CN; Lin, CL; Bader, JS; Irizarry, R; Boeke, JD				Lin, Yu-yi; Kiihl, Samara; Suhail, Yasir; Liu, Shang-Yun; Chou, Yi-hsuan; Kuang, Zheng; Lu, Jin-ying; Khor, Chin Ni; Lin, Chi-Long; Bader, Joel S.; Irizarry, Rafael; Boeke, Jef D.			RETRACTED: Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK (Retracted article. See vol. 503, 2013)	NATURE			English	Article; Retracted Publication							ACTIVATED PROTEIN-KINASE; HISTONE ACETYLATION; CELLULAR-METABOLISM; ESSENTIAL GENES; CANCER-CELLS; INHIBITORS; COMPLEXES; IDENTIFICATION; PANTHER; YEAST	First identified as histone-modifying proteins, lysine acetyltransferases (KATs) and deacetylases (KDACs) antagonize each other through modification of the side chains of lysine residues in histone proteins(1). Acetylation of many non-histone proteins involved in chromatin, metabolism or cytoskeleton regulation were further identified in eukaryotic organisms(2-6), but the corresponding enzymes and substrate-specific functions of the modifications are unclear. Moreover, mechanisms underlying functional specificity of individual KDACs(7) remain enigmatic, and the substrate spectra of each KDAC lack comprehensive definition. Here we dissect the functional specificity of 12 critical human KDACs using a genome-wide synthetic lethality screen(8-13) in cultured human cells. The genetic interaction profiles revealed enzyme-substrate relationships between individual KDACs and many important substrates governing a wide array of biological processes including metabolism, development and cell cycle progression. We further confirmed that acetylation and deacetylation of the catalytic subunit of the adenosine monophosphate-activated protein kinase (AMPK), a critical cellular energy-sensing protein kinase complex, is controlled by the opposing catalytic activities of HDAC1 and p300. Deacetylation of AMPK enhances physical interaction with the upstream kinase LKB1, leading to AMPK phosphorylation and activation, and resulting in lipid breakdown in human liver cells. These findings provide new insights into previously underappreciated metabolic regulatory roles of HDAC1 in coordinating nutrient availability and cellular responses upstream of AMPK, and demonstrate the importance of high-throughput genetic interaction profiling to elucidate functional specificity and critical substrates of individual human KDACs potentially valuable for therapeutic applications.	[Lin, Yu-yi; Liu, Shang-Yun; Chou, Yi-hsuan] Natl Taiwan Univ, Inst Biochem & Mol Biol, Coll Med, Taipei 100, Taiwan; [Lin, Yu-yi; Lu, Jin-ying] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Lin, Yu-yi] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan; [Kiihl, Samara; Irizarry, Rafael] Sch Publ Hlth, Dept Biostat, Baltimore, MD 21231 USA; [Suhail, Yasir; Bader, Joel S.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; [Kuang, Zheng; Boeke, Jef D.] Johns Hopkins Univ, Dept Mol Biol & Genet, Sch Med, Baltimore, MD 21205 USA; [Kuang, Zheng; Boeke, Jef D.] Johns Hopkins Univ, High Throughput Biol Ctr, Sch Med, Baltimore, MD 21205 USA; [Lu, Jin-ying] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan; [Khor, Chin Ni; Lin, Chi-Long] Acad Sinica, Inst Mol Biol, Natl RNAi Core Facil, Taipei 115, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Taiwan University; National Taiwan University Hospital; Academia Sinica - Taiwan	Lin, YY (corresponding author), Natl Taiwan Univ, Inst Biochem & Mol Biol, Coll Med, Taipei 100, Taiwan.	yuyilin@ntu.edu.tw; jboeke1@jhmi.edu	Bader, Joel/A-1818-2009	Bader, Joel/0000-0002-6020-4625; Boeke, Jef/0000-0001-5322-4946	National Science Council [NSC 98-2320-B-002-057-, NSC 99-2320-B-002-057-, NSC 100-2325-002-044]; National Taiwan University Frontier and Innovative Research [99R71424]; National Taiwan University College of Medicine; National Taiwan University Hospital Excellent Translational Medicine Research [99C101-603]; National Health Research Institutes [NHRI-EX100-10017BC]; Liver Disease Prevention and Treatment Research Foundation; NIH [U54 RR 020839]; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020839] Funding Source: NIH RePORTER	National Science Council(Ministry of Science and Technology, Taiwan); National Taiwan University Frontier and Innovative Research; National Taiwan University College of Medicine(National Taiwan University); National Taiwan University Hospital Excellent Translational Medicine Research; National Health Research Institutes(National Health Research Institutes, Japan); Liver Disease Prevention and Treatment Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank H. Zhu, S.-L. Yu and L.-P. Chow for gifts of reagents, J. Lu for IMR-90 cells, Department of Medical Science, National Taiwan University for technical help with sequencing, and the National RNAi Core Facility, Academia Sinica for reagents and technical support with RNAi screen. We are grateful to P. Meluh and members of the Lin and Boeke laboratories for discussions. We thank D. Root for discussions. This study was supported by National Science Council grants NSC 98-2320-B-002-057-, NSC 99-2320-B-002-057- and NSC 100-2325-002-044 (Y.-y.L.), National Taiwan University Frontier and Innovative Research 99R71424 (Y.-y.L.), National Taiwan University College of Medicine and National Taiwan University Hospital Excellent Translational Medicine Research Project 99C101-603 (Y.-y.L. and J.-y.L.), National Health Research Institutes Career Development grant NHRI-EX100-10017BC (Y.-y.L.), Liver Disease Prevention and Treatment Research Foundation (Y.-y.L. and J.-y.L.) and NIH Common Fund grant U54 RR 020839 (J.D.B.).	Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Berriz GF, 2009, BIOINFORMATICS, V25, P3043, DOI 10.1093/bioinformatics/btp498; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Costanzo M, 2010, SCIENCE, V327, P425, DOI 10.1126/science.1180823; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Haberland M, 2009, P NATL ACAD SCI USA, V106, P7751, DOI 10.1073/pnas.0903139106; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418; Hwang JT, 2005, BIOCHEM BIOPH RES CO, V338, P694, DOI 10.1016/j.bbrc.2005.09.195; Jayapandian M, 2007, NUCLEIC ACIDS RES, V35, pD566, DOI 10.1093/nar/gkl859; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Lin YY, 2008, GENE DEV, V22, P2062, DOI 10.1101/gad.1679508; Lin YY, 2009, CELL, V136, P1073, DOI 10.1016/j.cell.2009.01.033; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Mi HY, 2010, NUCLEIC ACIDS RES, V38, pD204, DOI 10.1093/nar/gkp1019; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schlabach MR, 2008, SCIENCE, V319, P620, DOI 10.1126/science.1149200; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Silva JM, 2008, SCIENCE, V319, P617, DOI 10.1126/science.1149185; Stark C, 2011, NUCLEIC ACIDS RES, V39, pD698, DOI 10.1093/nar/gkq1116; Suter M, 2006, J BIOL CHEM, V281, P32207, DOI 10.1074/jbc.M606357200; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	38	73	80	0	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					251	U149		10.1038/nature10804	http://dx.doi.org/10.1038/nature10804			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22318606	Green Accepted			2022-12-28	WOS:000299994100045
J	Baldwin, LM; Trivers, KF; Matthews, B; Andrilla, CHA; Miller, JW; Berry, DL; Lishner, DM; Goff, BA				Baldwin, Laura-Mae; Trivers, Katrina F.; Matthews, Barbara; Andrilla, C. Holly A.; Miller, Jacqueline W.; Berry, Donna L.; Lishner, Denise M.; Goff, Barbara A.			Vignette-Based Study of Ovarian Cancer Screening: Do US Physicians Report Adhering to Evidence-Based Recommendations?	ANNALS OF INTERNAL MEDICINE			English	Article							RISK WOMEN; TRANSVAGINAL ULTRASOUND; CARE; SUSCEPTIBILITY; SERVICES; PROSTATE; EFFICACY; QUALITY; POPULATION; CA125	Background: No professional society or group recommends routine ovarian cancer screening, yet physicians' enthusiasm for several cancer screening tests before benefit has been proven suggests that some women may be exposed to potential harms. Objective: To provide nationally representative estimates of physicians' reported nonadherence to recommendations against ovarian cancer screening. Design: Cross-sectional survey of physicians offering women's primary care. The 12-page questionnaire contained a woman's annual examination vignette and questions about offers or orders for transvaginal ultrasonography (TVU) and cancer antigen 125 (CA-125). Setting: United States. Participants: 3200 physicians randomly sampled equally from the 2008 American Medical Association Physician Masterfile lists of family physicians, general internists, and obstetrician-gynecologists; 61.7% responded. After exclusions, 1088 respondents were included; their responses were weighted to represent the specialty distribution of practicing U. S. physicians nationally. Measurements: Reported nonadherence to screening recommendations (defined as sometimes or almost always ordering screening TVU or CA-125 or both). Results: Twenty-eight percent (95% CI, 24.5% to 32.9%) of physicians reported nonadherence to screening recommendations for women at low risk for ovarian cancer; 65.4% (CI, 61.1% to 69.4%) did so for women at medium risk for ovarian cancer. Six percent (CI, 4.4% to 8.9%) reported routinely ordering or offering ovarian cancer screening for low-risk women, as did 24.0% (CI, 20.5% to 28.0%) for medium-risk women (P <= 0.001). Thirty-three percent believed TVU or CA-125 was an effective screening test. In adjusted analysis, actual and physician-perceived patient risk, patient request for ovarian cancer screening, and physician belief that TVU or CA-125 was an effective screening test were the strongest predictors of physician-reported nonadherence to published recommendations. Limitation: The results are limited by their reliance on survey methods; there may be respondent-nonrespondent bias. Conclusion: One in 3 physicians believed that ovarian cancer screening was effective, despite evidence to the contrary. Substantial proportions of physicians reported routinely offering or ordering ovarian cancer screening, thereby exposing women to the documented risks of these tests.	[Baldwin, Laura-Mae] Univ Washington, Dept Family Med, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Dana Farber Canc Inst, Boston, MA 02115 USA	University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA; Harvard University; Dana-Farber Cancer Institute	Baldwin, LM (corresponding author), Univ Washington, Dept Family Med, Box 354982, Seattle, WA 98195 USA.	lmb@uw.edu	Andrilla, Holly/AAC-6264-2019	Goff, Barbara/0000-0003-0153-5544	Centers for Disease Control and Prevention through the University of Washington Health Promotion Research Centers [U48DP001911]; Centers for Disease Control and Prevention through the Alliance for Reducing Cancer, Northwest; Centers for Disease Control and Prevention [U48DP001911]; National Cancer Institute; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U48DP001911] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention through the University of Washington Health Promotion Research Centers; Centers for Disease Control and Prevention through the Alliance for Reducing Cancer, Northwest; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Grant Support: By the Centers for Disease Control and Prevention through the University of Washington Health Promotion Research Centers Cooperative Agreement U48DP001911 and through the Alliance for Reducing Cancer, Northwest, funded by both the Centers for Disease Control and Prevention (grant U48DP001911; V. Taylor, primary investigator) and the National Cancer Institute.	ACOG Committee on Gynecologic Practice, 2006, Obstet Gynecol, V108, P1611; Ajzen I, 2002, J APPL SOC PSYCHOL, V32, P665, DOI 10.1111/j.1559-1816.2002.tb00236.x; Ajzen I., THEORY PLANNED BEHAV; American Cancer Society, OV CANC; American Cancer Society, 2010, OV CANC COMM QUEST S; American Cancer Society, 2011, AM CANC SOC GUID EAR; [Anonymous], 1994, Gynecol Oncol, V55, pS4; [Anonymous], 2009, Obstet Gynecol, V113, P957, DOI 10.1097/AOG.0b013e3181a106d4; [Anonymous], 2009, GYNECOL ONCOL, V113, P6, DOI 10.1016/j.ygyno.2009.02.017; Bell R, 1998, Health Technol Assess, V2, pi; Berg AO, 2005, ANN INTERN MED, V143, P355, DOI 10.7326/0003-4819-143-5-200509060-00011; Bieler GS, 2010, AM J EPIDEMIOL, V171, P618, DOI 10.1093/aje/kwp440; Buys SS, 2005, AM J OBSTET GYNECOL, V193, P1630, DOI 10.1016/j.ajog.2005.05.005; Centers for Disease Control and Prevention, NAT PROGR CANC REG N; Chan ECY, 2006, J GEN INTERN MED, V21, P257, DOI 10.1111/j.1525-1497.2006.00327.x; Dillman DA, 2014, INTERNET PHONE MAIL; Dresselhaus TR, 2004, J GEN INTERN MED, V19, P1013, DOI 10.1007/s11606-004-0003-2; Economic Research Service, 2010, MEAS RUR RUR URB COM; Eichorn J., 2011, ONCLIVE         0518; Fishbein M.A., 1975, PHILOS RHETORIC; Fishman DA, 2005, AM J OBSTET GYNECOL, V192, P1214, DOI 10.1016/j.ajog.2005.01.041; Fowler FJ, 1998, AM J MED, V104, P526, DOI 10.1016/S0002-9343(98)00124-7; Franks P, 2000, J GEN INTERN MED, V15, P163, DOI 10.1046/j.1525-1497.2000.04079.x; Gladstone CQ., 1994, CANADIAN TASK FORCE, P870; Goff BA, 2005, WOMENS HLTH PRIMARY, V8, P262; Goff BA, 2011, CANCER-AM CANCER SOC, V117, P4414, DOI 10.1002/cncr.26035; Green MJ, 2004, JAMA-J AM MED ASSOC, V292, P442, DOI 10.1001/jama.292.4.442; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; Jacobs IJ, 2004, MOL CELL PROTEOMICS, V3, P355, DOI 10.1074/mcp.R400006-MCP200; Katz DA, 2005, ANN EMERG MED, V46, P525, DOI 10.1016/j.annemergmed.2005.04.016; Keitz SA, 2007, ARCH INTERN MED, V167, P445, DOI 10.1001/archinte.167.5.445; Klein WMP, 2007, CA-CANCER J CLIN, V57, P147, DOI 10.3322/canjclin.57.3.147; Kravitz RL, 2003, ARCH INTERN MED, V163, P1673, DOI 10.1001/archinte.163.14.1673; Liede A, 2002, J CLIN ONCOL, V20, P1570, DOI 10.1200/JCO.20.6.1570; MacDonald Deborah J, 2006, Oncol Nurs Forum, V33, pE27, DOI 10.1188/06.ONF.E27-E35; Mehrotra A, 2007, ARCH INTERN MED, V167, P1876, DOI 10.1001/archinte.167.17.1876; Menon U, 2001, CURR OPIN OBSTET GYN, V13, P61, DOI 10.1097/00001703-200102000-00009; Morrill R, 1999, URBAN GEOGR, V20, P727, DOI 10.2747/0272-3638.20.8.727; Murray E, 2003, J AM BOARD FAM PRACT, V16, P513, DOI 10.3122/jabfm.16.6.513; Olivier RI, 2006, GYNECOL ONCOL, V100, P20, DOI 10.1016/j.ygyno.2005.08.038; Paley PJ, 2001, CURR OPIN ONCOL, V13, P399, DOI 10.1097/00001622-200109000-00015; Partridge E, 2009, OBSTET GYNECOL, V113, P775, DOI 10.1097/AOG.0b013e31819cda77; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Peabody JW, 2004, ANN INTERN MED, V141, P771, DOI 10.7326/0003-4819-141-10-200411160-00008; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Pham HH, 2005, JAMA-J AM MED ASSOC, V294, P473, DOI 10.1001/jama.294.4.473; Schorge JO, 2010, GYNECOL ONCOL, V119, P7, DOI 10.1016/j.ygyno.2010.06.003; Schwartz LM, 2004, JAMA-J AM MED ASSOC, V291, P71, DOI 10.1001/jama.291.1.71; Sifri R, 2003, CLIN GENET, V64, P355, DOI 10.1034/j.1399-0004.2003.00131.x; Skates SJ, 2004, J CLIN ONCOL, V22, P4059, DOI 10.1200/JCO.2004.03.091; Trivers KF, 2011, CANCER-AM CANCER SOC, V117, P5334, DOI 10.1002/cncr.26166; United States Census Bureau, 2012 STAT ABSTR POP; US Preventive Services Task Force Agency for Healthcare Research and Quality, 2004, SCREEN OV CANC TOP P; van der Velde NM, 2009, INT J CANCER, V124, P919, DOI 10.1002/ijc.24038; van Nagell JR, 2000, GYNECOL ONCOL, V77, P350, DOI 10.1006/gyno.2000.5816; White DB, 2008, CANCER EPIDEM BIOMAR, V17, P2980, DOI 10.1158/1055-9965.EPI-07-2879; Wideroff L, 2003, CANCER EPIDEM BIOMAR, V12, P295; Woodward ER, 2007, BJOG-INT J OBSTET GY, V114, P1500, DOI 10.1111/j.1471-0528.2007.01499.x	58	38	39	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2012	156	3					182	U46		10.7326/0003-4819-156-3-201202070-00006	http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00006			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XD	22312138				2022-12-28	WOS:000299964200002
J	Richardson, R				Richardson, Ruth			The art of medicine Charles Dickens, The Lancet, and Oliver Twist	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Richardson, R (corresponding author), The Lancet, London NW1 7BY, England.							Allen Michael, 2011, C DICKENS BLACKING F; Higginbotham P, 2011, LIFE VICTORIAN WORKH; RICHARDSON R, 1989, BRIT MED J, V299, P1507, DOI 10.1136/bmj.299.6714.1507; Richardson Ruth, 2012, DICKENS WORKHOUSE; Rogers J., 1889, REMINISCENCES WORKHO	5	2	2	3	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 4	2012	379	9814					404	405		10.1016/S0140-6736(12)60178-0	http://dx.doi.org/10.1016/S0140-6736(12)60178-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	891AF	22312643				2022-12-28	WOS:000300187800020
J	Donnez, J; Tomaszewski, J; Vazquez, F; Bouchard, P; Lemieszczuk, B; Baro, F; Nouri, K; Selvaggi, L; Sodowski, K; Bestel, E; Terrill, P; Osterloh, I; Loumaye, E				Donnez, Jacques; Tomaszewski, Janusz; Vazquez, Francisco; Bouchard, Philippe; Lemieszczuk, Boguslav; Baro, Francesco; Nouri, Kazem; Selvaggi, Luigi; Sodowski, Krzysztof; Bestel, Elke; Terrill, Paul; Osterloh, Ian; Loumaye, Ernest		PEARL II Study Grp	Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGESTERONE-RECEPTOR MODULATORS; QUALITY-OF-LIFE; LEIOMYOMA CELLS; MEDROXYPROGESTERONE ACETATE; DOUBLE-BLIND; CDB-2914; PROLIFERATION; CDB-4124; PLACEBO; MIFEPRISTONE	Background The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear. Methods In this double-blind noninferiority trial, we randomly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy with oral ulipristal acetate (at a dose of either 5 mg or 10 mg) or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg). The primary outcome was the proportion of patients with controlled bleeding at week 13, with a prespecified noninferiority margin of -20%. Results Uterine bleeding was controlled in 90% of patients receiving 5 mg of ulipristal acetate, in 98% of those receiving 10 mg of ulipristal acetate, and in 89% of those receiving leuprolide acetate, for differences (as compared with leuprolide acetate) of 1.2 percentage points (95% confidence interval [CI], -9.3 to 11.8) for 5 mg of ulipristal acetate and 8.8 percentage points (95% CI, 0.4 to 18.3) for 10 mg of ulipristal acetate. Median times to amenorrhea were 7 days for patients receiving 5 mg of ulipristal acetate, 5 days for those receiving 10 mg of ulipristal acetate, and 21 days for those receiving leuprolide acetate. Moderate-to-severe hot flashes were reported for 11% of patients receiving 5 mg of ulipristal acetate, for 10% of those receiving 10 mg of ulipristal acetate, and for 40% of those receiving leuprolide acetate (P<0.001 for each dose of ulipristal acetate vs. leuprolide acetate). Conclusions Both the 5-mg and 10-mg daily doses of ulipristal acetate were noninferior to once-monthly leuprolide acetate in controlling uterine bleeding and were significantly less likely to cause hot flashes. (Funded by PregLem; ClinicalTrials.gov number, NCT00740831.)	[Donnez, Jacques] Clin Univ St Luc Catholic Univ Louvain, Brussels, Belgium; [Tomaszewski, Janusz] Prywatna Klinika Polozniczo Ginekologiczna, Bialystok, Poland; [Lemieszczuk, Boguslav] Gabinet Lekarski Specjalistyczny Sonus, Warsaw, Poland; [Sodowski, Krzysztof] Ctr Med Krzysztof Sodowski, Katowice, Poland; [Vazquez, Francisco] Clin Ginecol Ctr Estudios Obstet & Ginecol Asocia, Lugo, Spain; [Bouchard, Philippe] Hop St Antoine, AP HP, F-75571 Paris, France; [Bouchard, Philippe] Univ Paris 06, Paris, France; [Baro, Francesco] Hosp Valle De Hebron, Dept Gynecol, Barcelona, Spain; [Nouri, Kazem] Med Univ Vienna, Vienna, Austria; [Selvaggi, Luigi] Univ Bari, Clin Ostetr & Ginecol 2, Bari, Italy; [Bestel, Elke; Loumaye, Ernest] PregLem, Geneva, Switzerland; [Terrill, Paul] MDSL Int, Maidenhead, Berks, England; [Osterloh, Ian] OsterMed, Birmingham, W Midlands, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Hospital Universitari Vall d'Hebron; Medical University of Vienna; Universita degli Studi di Bari Aldo Moro; Gedeon Richter Chemistry Works	Donnez, J (corresponding author), St Luc Cathol Univ Louvain, Av Hippocrate 10, B-1200 Brussels, Belgium.	jacques.donnez@uclouvain.be		PELLICER, ANTONIO/0000-0002-8254-863X; Barri Rague, Pedro N/0000-0002-1369-0675	PregLem; Gedeon Richter Group; Serono; Merck; Organon; Ferring; HRA Pharma; Theramex; Pierre Fabre; OsterMed; Darwin Healthcare Communications	PregLem; Gedeon Richter Group; Serono; Merck(Merck & Company); Organon; Ferring(Ferring Pharmaceuticals); HRA Pharma; Theramex; Pierre Fabre; OsterMed; Darwin Healthcare Communications	Supported by PregLem.; Dr. Donnez reports receiving payment for serving on a scientific advisory board from PregLem, payment from stocks sold in October 2010 from the company's full acquisition by Gedeon Richter Group, and lecture fees from Serono, Merck, Organon, and Ferring; Dr. Bouchard, receiving payment for serving on a scientific advisory board from PregLem, payment from stocks sold in October 2010 from the company's full acquisition by Gedeon Richter Group, and lecture fees from HRA Pharma, Theramex, Pierre Fabre, and PregLem; Dr. Bestel, being an employee of PregLem and receiving payment from stocks sold in October 2010 from the company's full acquisition by Gedeon Richter Group; Dr. Terrill, being an employee of MDSL International and receiving payment to his institution for consultancy and contracted data-management and statistical support; Dr. Osterloh, receiving payment to his institution for consultancy from OsterMed; and Dr. Loumaye, being an employee of PregLem and receiving payment from stocks sold in October 2010 from the company's full acquisition by Gedeon Richter Group. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.; We thank Venkat Ramanan of PregLem for assistance with the preparation of the manuscript with the support of Tove Anderson and Nigel Eastmond of Darwin Healthcare Communications.	Attardi BJ, 2004, J STEROID BIOCHEM, V88, P277, DOI 10.1016/j.jsbmb.2003.12.004; Attardi BJ, 2002, MOL CELL ENDOCRINOL, V188, P111, DOI 10.1016/S0303-7207(01)00743-2; CARR BR, 1993, J CLIN ENDOCR METAB, V76, P1217, DOI 10.1210/jc.76.5.1217; Chen W, 2006, J CLIN ENDOCR METAB, V91, P1296, DOI 10.1210/jc.2005-2379; CIRKEL U, 1992, CLIN THER, V14, P37; CODDINGTON CC, 1992, SURG GYNECOL OBSTET, V175, P57; Donnez J, 2002, HUM REPROD, V17, P1424, DOI 10.1093/humrep/17.6.1424; Fiscella K, 2006, OBSTET GYNECOL, V108, P1381, DOI 10.1097/01.AOG.0000243776.23391.7b; FRIEDMAN AJ, 1991, OBSTET GYNECOL, V77, P720; Gainer EE, 2003, STEROIDS, V68, P1005, DOI 10.1016/S0039-128X(03)00130-2; HIGHAM JM, 1990, BRIT J OBSTET GYNAEC, V97, P734, DOI 10.1111/j.1471-0528.1990.tb16249.x; Hoekstra AV, 2009, J CLIN ENDOCR METAB, V94, P1768, DOI 10.1210/jc.2008-2093; Ioffe OB, 2009, MODERN PATHOL, V22, P450, DOI 10.1038/modpathol.2008.204; JANSSEN CAH, 1995, OBSTET GYNECOL, V85, P977, DOI 10.1016/0029-7844(95)00062-V; Kim JJ, 2011, MOL CELL ENDOCR 0606; Lethaby A, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000547; Levens ED, 2008, OBSTET GYNECOL, V111, P1129, DOI 10.1097/AOG.0b013e3181705d0e; Luo X, 2010, FERTIL STERIL, V93, P2668, DOI 10.1016/j.fertnstert.2009.11.031; Maruo T, 2007, CONTRACEPTION, V75, pS99, DOI 10.1016/j.contraception.2007.01.025; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Mutter GL, 2008, MODERN PATHOL, V21, P591, DOI 10.1038/modpathol.2008.19; Nieman LK, 2011, FERTIL STERIL, V95, p767e1; Nisolle M, 1999, HUM REPROD, V14, P2844, DOI 10.1093/humrep/14.11.2844; Sasaki H, 2007, J CLIN ENDOCR METAB, V92, P616, DOI 10.1210/jc.2006-0898; Sayed GH, 2011, INT J GYNECOL OBSTET, V112, P126, DOI 10.1016/j.ijgo.2010.08.009; SCIALLI AR, 1995, FERTIL STERIL, V64, P313, DOI 10.1016/S0015-0282(16)57729-2; Spies JB, 2002, OBSTET GYNECOL, V99, P290, DOI 10.1016/S0029-7844(01)01702-1; Spitz IM, 2009, CURR OPIN OBSTET GYN, V21, P318, DOI 10.1097/GCO.0b013e32832e07e8; STOVALL TG, 1995, OBSTET GYNECOL, V86, P65, DOI 10.1016/0029-7844(95)00102-W; US Food and Drug Administration, GUID IND ESTR ESTR P; Viswanathan Meera, 2007, Evid Rep Technol Assess (Full Rep), P1; Wang JY, 2006, HUM REPROD, V21, P1869, DOI 10.1093/humrep/del035; WATANABE Y, 1992, FERTIL STERIL, V58, P66; Xu Q, 2005, J CLIN ENDOCR METAB, V90, P953, DOI 10.1210/jc.2004-1569; Xu Q, 2007, AM J PHYSIOL-ENDOC M, V293, pE1002, DOI 10.1152/ajpendo.00210.2007; Xu Q, 2006, HUM REPROD, V21, P2408, DOI 10.1093/humrep/del159; Yin P, 2010, CANCER RES, V70, P1722, DOI 10.1158/0008-5472.CAN-09-2612; Yoshida S, 2010, SEMIN REPROD MED, V28, P259, DOI 10.1055/s-0030-1251483	38	394	446	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					421	432		10.1056/NEJMoa1103180	http://dx.doi.org/10.1056/NEJMoa1103180			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QX	22296076				2022-12-28	WOS:000299724400007
J	Weedon-Fekjaer, H; Bakken, K; Vatten, LJ; Tretli, S				Weedon-Fekjaer, Harald; Bakken, Kjersti; Vatten, Lars J.; Tretli, Steinar			Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN PLUS PROGESTIN; MEAN SOJOURN TIME; REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; TEMPORAL VARIATION; NORDIC COUNTRIES; RATES; RISK; SENSITIVITY; OVERDIAGNOSIS	Objective To quantify the separate contributions of menopausal hormone treatment and mammography screening activities on trends in incidence of invasive breast cancer between 1987 and 2008. Design Population study using aggregated data analysed by an extended age-period-cohort model. Setting Norway. Population Norwegian women aged 30-90 between 1987 and 2008, including 50 102 newly diagnosed cases of invasive breast cancer. Main outcomes measures Attributable proportions of mammography screening and hormone treatment to recent incidence of invasive breast cancer, and the remaining variation in incidence after adjustment for mammography screening and hormone treatment. Results The incidence of invasive breast cancer in Norway increased steadily until 2002, levelled off, and then declined from 2006. All non-linear changes in incidence were explained by use of hormone treatment and mammography screening activities, with about similar contributions of each factor. In 2002, when the incidence among women aged 50-69 was highest, an estimated 23% of the cases in that age group could be attributed to mammography screening and 27% to use of hormone treatment. Conclusions Changes in incidence trends of invasive breast cancer since the early 1990s may be fully attributed to mammography screening and hormone treatment, with about similar contributions of each factor.	[Weedon-Fekjaer, Harald; Tretli, Steinar] Canc Registry Norway, Inst Populat Based Canc Res, Dept Etiol Res, N-0304 Oslo, Norway; [Bakken, Kjersti] Univ Tromso, Dept Community Med, N-9001 Tromso, Norway; [Bakken, Kjersti] Univ Bergen, N-5020 Bergen, Norway; [Vatten, Lars J.; Tretli, Steinar] Norwegian Univ Sci & Technol, Dept Publ Hlth, N-7034 Trondheim, Norway	University of Oslo; UiT The Arctic University of Tromso; University of Bergen; Norwegian University of Science & Technology (NTNU)	Weedon-Fekjaer, H (corresponding author), Canc Registry Norway, Inst Populat Based Canc Res, Dept Etiol Res, POB 5313 Majorstuen, N-0304 Oslo, Norway.	harald.weedon-fekjaer@kreftregisteret.no	Vatten, Lars/AFK-2073-2022; Weedon-Fekjær, Harald/B-6900-2008; Vatten, Lars/AAF-9380-2022	Weedon-Fekjær, Harald/0000-0002-9109-0034; 	Norwegian Cancer Society [PK01-2008-0080]	Norwegian Cancer Society(Norwegian Cancer Society)	This work was supported by the Norwegian Cancer Society through a postdoctoral scholarship to HW-F (PK01-2008-0080).	Bakken K, 2011, INT J CANCER, V128, P144, DOI 10.1002/ijc.25314; Bakken L, 2004, INT J CANCER, V112, P130, DOI 10.1002/ijc.20389; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Calle EE, 2009, CANCER-AM CANCER SOC, V115, P936, DOI 10.1002/cncr.24101; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; CLEMMESEN J, 1948, BRIT J RADIOL, V21, P583, DOI 10.1259/0007-1285-21-252-583; de Gelder R, 2011, EPIDEMIOL REV, V33, P111, DOI 10.1093/epirev/mxr009; Ernster V L, 1997, J Natl Cancer Inst Monogr, P151; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Glass AG, 2007, JNCI-J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; Hankinson S, 2002, TXB CANC EPIDEMIOLOG, P3001; Hemminki E, 2008, MATURITAS, V61, P299, DOI 10.1016/j.maturitas.2008.09.022; Hofvind S., 2005, NORWEGIAN BREAST CAN; Hofvind S, 2008, JNCI-J NATL CANCER I, V100, P1082, DOI 10.1093/jnci/djn224; Hofvind S, 2006, INT J CANCER, V118, P3112, DOI 10.1002/ijc.21742; HOLFORD TR, 1983, BIOMETRICS, V39, P311, DOI 10.2307/2531004; Jemal A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1672; Jorgensen KJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2587; Katalinic A, 2008, BREAST CANCER RES TR, V107, P427, DOI 10.1007/s10549-007-9566-z; Kerlikowske K, 2007, JNCI-J NATL CANCER I, V99, P1335, DOI 10.1093/jnci/djm111; Lambe M, 2010, BREAST CANCER RES TR, V121, P679, DOI 10.1007/s10549-009-0615-7; Larsen IK, 2009, EUR J CANCER, V45, P1218, DOI 10.1016/j.ejca.2008.10.037; Moller B, 2005, EUR J CANCER PREV, V14, P117, DOI 10.1097/00008469-200504000-00007; Moller B, 2002, EUR J CANCER PREV, V11, pS1; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; NORDCAN, 2010, NORDCAN; PACI E, 1991, INT J EPIDEMIOL, V20, P852, DOI 10.1093/ije/20.4.852; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Statistics Norway, 2010, STAT NORW; Tretli S, 1996, CANCER CAUSE CONTROL, V7, P507, DOI 10.1007/BF00051882; Virnig Beth A., 2010, Journal of the National Cancer Institute Monographs, P113, DOI 10.1093/jncimonographs/lgq024; Weedon-Fekjaer H, 2005, J MED SCREEN, V12, P172, DOI 10.1258/096914105775220732; Weedon-Fekjaer H, 2008, J MED SCREEN, V15, P83, DOI 10.1258/jms.2008.007071; Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014; Zackrisson S, 2006, BRIT MED J, V332, P689, DOI 10.1136/bmj.38764.572569.7C	38	32	33	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	2012	344								e299	10.1136/bmj.e299	http://dx.doi.org/10.1136/bmj.e299			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QD	22290099	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000300087400003
J	Li, GL; Ruan, XA; Auerbach, RK; Sandhu, KS; Zheng, MZ; Wang, P; Poh, HM; Goh, Y; Lim, J; Zhang, JY; Sim, HS; Peh, SQ; Mulawadi, FH; Ong, CT; Orlov, YL; Hong, SZ; Zhang, ZZ; Landt, S; Raha, D; Euskirchen, G; Wei, CL; Ge, WH; Wang, HE; Davis, C; Fisher-Aylor, KI; Mortazavi, A; Gerstein, M; Gingeras, T; Wold, B; Sun, Y; Fullwood, MJ; Cheung, E; Liu, E; Sung, WK; Snyder, M; Ruan, YJ				Li, Guoliang; Ruan, Xiaoan; Auerbach, Raymond K.; Sandhu, Kuljeet Singh; Zheng, Meizhen; Wang, Ping; Poh, Huay Mei; Goh, Yufen; Lim, Joanne; Zhang, Jingyao; Sim, Hui Shan; Peh, Su Qin; Mulawadi, Fabianus Hendriyan; Ong, Chin Thing; Orlov, Yuriy L.; Hong, Shuzhen; Zhang, Zhizhuo; Landt, Steve; Raha, Debasish; Euskirchen, Ghia; Wei, Chia-Lin; Ge, Weihong; Wang, Huaien; Davis, Carrie; Fisher-Aylor, Katherine I.; Mortazavi, Ali; Gerstein, Mark; Gingeras, Thomas; Wold, Barbara; Sun, Yi; Fullwood, Melissa J.; Cheung, Edwin; Liu, Edison; Sung, Wing-Kin; Snyder, Michael; Ruan, Yijun			Extensive Promoter-Centered Chromatin Interactions Provide a Topological Basis for Transcription Regulation	CELL			English	Article							ORGANIZATION; GENES; BIOLOGY; TOOLS; CTCF	Higher-order chromosomal organization for transcription regulation is poorly understood in eukaryotes. Using genome-wide Chromatin Interaction Analysis with Paired-End-Tag sequencing (ChIA-PET), we mapped long-range chromatin interactions associated with RNA polymerase II in human cells and uncovered widespread promoter-centered intragenic, extragenic, and intergenic interactions. These interactions further aggregated into higher-order clusters, wherein proximal and distal genes were engaged through promoter-promoter interactions. Most genes with promoter-promoter interactions were active and transcribed cooperatively, and some interacting promoters could influence each other implying combinatorial complexity of transcriptional controls. Comparative analyses of different cell lines showed that cell-specific chromatin interactions could provide structural frameworks for cell-specific transcription, and suggested significant enrichment of enhancer-promoter interactions for cell-specific functions. Furthermore, genetically-identified disease-associated noncoding elements were found to be spatially engaged with corresponding genes through long-range interactions. Overall, our study provides insights into transcription regulation by three-dimensional chromatin interactions for both housekeeping and cell-specific genes in human cells.	[Landt, Steve; Raha, Debasish; Euskirchen, Ghia; Snyder, Michael] Stanford Univ, Dept Genet, Ctr Genom & Personalized Med, Stanford, CA 94305 USA; [Li, Guoliang; Ruan, Xiaoan; Sandhu, Kuljeet Singh; Zheng, Meizhen; Wang, Ping; Poh, Huay Mei; Goh, Yufen; Lim, Joanne; Zhang, Jingyao; Sim, Hui Shan; Peh, Su Qin; Mulawadi, Fabianus Hendriyan; Ong, Chin Thing; Orlov, Yuriy L.; Hong, Shuzhen; Wei, Chia-Lin; Fullwood, Melissa J.; Cheung, Edwin; Liu, Edison; Sung, Wing-Kin; Ruan, Yijun] Genome Inst Singapore, Singapore 138672, Singapore; [Auerbach, Raymond K.; Gerstein, Mark] Yale Univ, Program Computat Biol, New Haven, CT 06520 USA; [Auerbach, Raymond K.; Gerstein, Mark] Yale Univ, Dept Mol Biol, New Haven, CT 06520 USA; [Auerbach, Raymond K.; Gerstein, Mark] Yale Univ, Dept Cellular Biol, New Haven, CT 06520 USA; [Auerbach, Raymond K.; Gerstein, Mark] Yale Univ, Dept Dev Biol, New Haven, CT 06520 USA; [Zhang, Zhizhuo; Sung, Wing-Kin] Natl Univ Singapore, Sch Comp, Dept Comp Sci, Singapore 117417, Singapore; [Ge, Weihong; Sun, Yi] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Wang, Huaien; Davis, Carrie; Gingeras, Thomas] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11797 USA; [Fisher-Aylor, Katherine I.; Mortazavi, Ali; Wold, Barbara] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Cheung, Edwin] Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; [Ruan, Yijun] Huazhong Agr Univ, Coll Life Sci & Technol, Wuhan 430070, Peoples R China	Stanford University; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Yale University; Yale University; Yale University; Yale University; National University of Singapore; University of California System; University of California Los Angeles; Cold Spring Harbor Laboratory; California Institute of Technology; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Huazhong Agricultural University	Snyder, M (corresponding author), Stanford Univ, Dept Genet, Ctr Genom & Personalized Med, Stanford, CA 94305 USA.	mpsnyder@stanford.edu; ruanyj@gis.a-star.edu.sg	Li, Guoliang/D-8014-2012; Orlov, Yuriy L/F-1520-2013; Sandhu, Kuljeet/C-3039-2011; Fullwood, Melissa/G-5713-2011	Li, Guoliang/0000-0003-1601-6640; Orlov, Yuriy L/0000-0003-0587-1609; Fullwood, Melissa/0000-0003-0321-7865; Gingeras, Thomas/0000-0001-9106-3573; Sandhu, Kuljeet/0000-0001-7632-6339; Sung, Wing-Kin/0000-0001-7806-7086; zheng, meizhen/0000-0001-5569-1812; Fisher-Aylor, Katherine/0000-0003-3371-2947; Snyder, Michael/0000-0003-0784-7987	Singapore A*STAR; NIH [HG004456]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004456] Funding Source: NIH RePORTER	Singapore A*STAR(Agency for Science Technology & Research (A*STAR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We acknowledge the Genome Technology and Biology Group at the Genome Institute of Singapore for technical support. This work was supported by Singapore A*STAR and an NIH grant (HG004456) to Y.R.	Amano T, 2009, DEV CELL, V16, P47, DOI 10.1016/j.devcel.2008.11.011; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bau D, 2011, NAT STRUCT MOL BIOL, V18, P107, DOI 10.1038/nsmb.1936; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cope NF, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-204; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Eisenberg E, 2003, TRENDS GENET, V19, P362, DOI 10.1016/S0168-9525(03)00140-9; Euskirchen GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002008; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042; Handoko L, 2011, NAT GENET, V43, P630, DOI 10.1038/ng.857; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Hou CH, 2010, P NATL ACAD SCI USA, V107, P3651, DOI 10.1073/pnas.0912087107; JACOB F, 1960, CR HEBD ACAD SCI, V250, P1727; Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109; Kilpelainen TO, 2011, NAT GENET, V43, P753, DOI 10.1038/ng.866; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Li G, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r22; Merkenschlager M, 2010, CURR OPIN GENET DEV, V20, P555, DOI 10.1016/j.gde.2010.05.007; Pan YF, 2008, J BIOL CHEM, V283, P32977, DOI 10.1074/jbc.M802024200; PAULI D, 1988, J MOL BIOL, V200, P47, DOI 10.1016/0022-2836(88)90332-4; Raha D., 2010, CURR PROTOC MOL BIOL, DOI [10.1002/0471142727.mb2119s91, DOI 10.1002/0471142727.MB2119S91]; Roussel MJS, 2001, ONCOGENE, V20, P7287, DOI 10.1038/sj.onc.1204863; Ruan YJ, 2007, GENOME RES, V17, P828, DOI 10.1101/gr.6018607; Schoenfelder S, 2010, NAT GENET, V42, P53, DOI 10.1038/ng.496; Singer GAC, 2005, MOL BIOL EVOL, V22, P767, DOI 10.1093/molbev/msi062; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Taylor J, 2005, TRENDS BIOTECHNOL, V23, P269, DOI 10.1016/j.tibtech.2005.04.003; van Steensel B, 2010, NAT BIOTECHNOL, V28, P1089, DOI 10.1038/nbt.1680; Versteeg R, 2003, GENOME RES, V13, P1998, DOI 10.1101/gr.1649303; Visel A, 2009, NATURE, V461, P199, DOI 10.1038/nature08451; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	33	826	858	2	144	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					84	98		10.1016/j.cell.2011.12.014	http://dx.doi.org/10.1016/j.cell.2011.12.014			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265404	Bronze, Green Accepted			2022-12-28	WOS:000299540700016
J	Robinton, DA; Daley, GQ				Robinton, Daisy A.; Daley, George Q.			The promise of induced pluripotent stem cells in research and therapy	NATURE			English	Review							HUMAN SOMATIC-CELLS; DYSKERATOSIS-CONGENITA; HUMAN FIBROBLASTS; IPS CELLS; CHROMOSOMAL-ABERRATIONS; EPIGENETIC MEMORY; GENE-EXPRESSION; COPY NUMBER; MOUSE; GENERATION	The field of stem-cell biology has been catapulted forward by the startling development of reprogramming technology. The ability to restore pluripotency to somatic cells through the ectopic co-expression of reprogramming factors has created powerful new opportunities for modelling human diseases and offers hope for personalized regenerative cell therapies. While the field is racing ahead, some researchers are pausing to evaluate whether induced pluripotent stem cells are indeed the true equivalents of embryonic stem cells and whether subtle differences between these types of cell might affect their research applications and therapeutic potential.	[Robinton, Daisy A.; Daley, George Q.] Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Div Pediat Hematol Oncol,Stem Cell Transplantat P, Boston, MA 02115 USA; [Robinton, Daisy A.; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Robinton, Daisy A.; Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; [Robinton, Daisy A.; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Robinton, Daisy A.; Daley, George Q.] Broad Inst, Cambridge, MA 02142 USA; [Robinton, Daisy A.; Daley, George Q.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Daley, GQ (corresponding author), Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Div Pediat Hematol Oncol,Stem Cell Transplantat P, 300 Longwood Ave, Boston, MA 02115 USA.	george.daley@childrens.harvard.edu			National Institutes of Health [RO1-DK70055, RO1-DK59279, UO1-HL100001]; American Recovery and Reinvestment Act [RC2-HL102815]; Roche Foundation for Anemia Research; Alex's Lemonade Stand Foundation; Harvard Stem Cell Institute; Burroughs Wellcome Fund; Leukemia and Lymphoma Society; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100001, RC2HL102815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070055, R01DK059279] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Recovery and Reinvestment Act; Roche Foundation for Anemia Research; Alex's Lemonade Stand Foundation; Harvard Stem Cell Institute; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	G.Q.D. is supported by grants from the National Institutes of Health (RO1-DK70055, RO1-DK59279 and UO1-HL100001, as well as special funds from the American Recovery and Reinvestment Act of 2009 (RC2-HL102815), the Roche Foundation for Anemia Research, Alex's Lemonade Stand Foundation and the Harvard Stem Cell Institute. G. Q. D. is an affiliate member of the Broad Institute, a recipient of Clinical Scientist Awards in Translational Research from the Burroughs Wellcome Fund and the Leukemia and Lymphoma Society, and an investigator of the Howard Hughes Medical Institute and the Manton Center for Orphan Disease Research. We gratefully acknowledge A. de Los Angeles for providing the images for Fig. 1a, d, f; T. Onder, for Fig. 1b; and A. Cherry, for Fig. 1c, e.	Agarwal S, 2011, CELL RES, V21, P1157, DOI 10.1038/cr.2011.120; Agarwal S, 2010, NATURE, V464, P292, DOI 10.1038/nature08792; Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001; Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884; Bar-Nur O, 2011, CELL STEM CELL, V9, P17, DOI 10.1016/j.stem.2011.06.007; Batista LFZ, 2011, NATURE, V474, P399, DOI 10.1038/nature10084; Ben-David U, 2011, CELL STEM CELL, V9, P97, DOI 10.1016/j.stem.2011.06.013; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bock C, 2011, CELL, V144, P439, DOI 10.1016/j.cell.2010.12.032; Boland MJ, 2009, NATURE, V461, P91, DOI 10.1038/nature08310; BRINSTER RL, 1974, J EXP MED, V140, P1049, DOI 10.1084/jem.140.4.1049; Buecker C, 2010, CELL STEM CELL, V6, P535, DOI 10.1016/j.stem.2010.05.003; Carey BW, 2011, CELL STEM CELL, V9, P588, DOI 10.1016/j.stem.2011.11.003; Chan EM, 2009, NAT BIOTECHNOL, V27, P1033, DOI 10.1038/nbt.1580; Daley GQ, 2009, CELL STEM CELL, V4, P200, DOI 10.1016/j.stem.2009.02.009; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; DEWEY MJ, 1977, P NATL ACAD SCI USA, V74, P5564, DOI 10.1073/pnas.74.12.5564; Driesch H, 1891, Z WISS ZOOL ABT A, V53, P160; Eakin GS, 2005, DEV BIOL, V288, P150, DOI 10.1016/j.ydbio.2005.09.028; Eggan K, 2003, METHOD ENZYMOL, V365, P25; Eminli S, 2008, STEM CELLS, V26, P2467, DOI 10.1634/stemcells.2008-0317; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Feng Q, 2010, STEM CELLS, V28, P704, DOI 10.1002/stem.321; Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348; GARDNER RL, 1968, NATURE, V220, P596, DOI 10.1038/220596a0; Ghosh Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008975; Hanna J, 2008, CELL, V133, P250, DOI 10.1016/j.cell.2008.03.028; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; Hanna J, 2010, P NATL ACAD SCI USA, V107, P9222, DOI 10.1073/pnas.1004584107; Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008; Harrison NJ, 2007, INT J ANDROL, V30, P275, DOI 10.1111/j.1365-2605.2007.00762.x; Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107; Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; Hussein SM, 2011, NATURE, V471, P58, DOI 10.1038/nature09871; Itzhaki I, 2011, NATURE, V471, P225, DOI 10.1038/nature09747; Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005; Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; Laurent LC, 2011, CELL STEM CELL, V8, P106, DOI 10.1016/j.stem.2010.12.003; Lee G, 2009, NATURE, V461, P402, DOI 10.1038/nature08320; Lensch MW, 2007, CELL STEM CELL, V1, P253, DOI 10.1016/j.stem.2007.07.019; Li WL, 2009, CELL STEM CELL, V4, P16, DOI 10.1016/j.stem.2008.11.014; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Maherali N, 2008, CELL STEM CELL, V3, P340, DOI 10.1016/j.stem.2008.08.003; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Maherali N, 2008, CELL STEM CELL, V3, P595, DOI 10.1016/j.stem.2008.11.008; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Martinez Y., J CELL MOL IN PRESS; Mayshar Y, 2010, CELL STEM CELL, V7, P521, DOI 10.1016/j.stem.2010.07.017; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Miura K, 2009, NAT BIOTECHNOL, V27, P743, DOI 10.1038/nbt.1554; Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001; Moretti A, 2010, NEW ENGL J MED, V363, P1397, DOI 10.1056/NEJMoa0908679; Mosher JT, 2010, NEW ENGL J MED, V362, P183, DOI 10.1056/NEJMc0910371; Muller FJ, 2011, NAT METHODS, V8, P315, DOI 10.1038/NMETH.1580; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Newman AM, 2010, CELL STEM CELL, V7, P258, DOI 10.1016/j.stem.2010.06.016; Nichols J, 2009, CELL STEM CELL, V4, P487, DOI 10.1016/j.stem.2009.05.015; Noggle S, 2011, NATURE, V478, P70, DOI 10.1038/nature10397; Ohi Y, 2011, NAT CELL BIOL, V13, P541, DOI 10.1038/ncb2239; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Osafune K, 2008, NAT BIOTECHNOL, V26, P313, DOI 10.1038/nbt1383; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Payer B, 2011, HUM GENET, V130, P265, DOI 10.1007/s00439-011-1024-7; Pick M, 2009, STEM CELLS, V27, P2686, DOI 10.1002/stem.205; Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667; Pomp O, 2011, CELL STEM CELL, V9, P156, DOI 10.1016/j.stem.2011.06.004; Shen Y, 2008, P NATL ACAD SCI USA, V105, P4709, DOI 10.1073/pnas.0712018105; Si-Tayeb K, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-81; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Somers A, 2010, STEM CELLS, V28, P1728, DOI 10.1002/stem.495; Sommer CA, 2009, STEM CELLS, V27, P543, DOI 10.1634/stemcells.2008-1075; Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Stadtfeld M, 2008, CURR BIOL, V18, P890, DOI 10.1016/j.cub.2008.05.010; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Sun N, 2009, P NATL ACAD SCI USA, V106, P15720, DOI 10.1073/pnas.0908450106; Tabar V, 2008, NAT MED, V14, P379, DOI 10.1038/nm1732; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tchieu J, 2010, CELL STEM CELL, V7, P329, DOI 10.1016/j.stem.2010.06.024; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Urbach A, 2010, CELL STEM CELL, V6, P407, DOI 10.1016/j.stem.2010.04.005; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Vogel G, 2008, SCIENCE, V321, P756, DOI 10.1126/science.321.5890.756b; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Wernig M, 2008, NAT BIOTECHNOL, V26, P916, DOI 10.1038/nbt1483; Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; Wray J, 2010, BIOCHEM SOC T, V38, P1027, DOI 10.1042/BST0381027; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135; Zhao XY, 2009, NATURE, V461, P86, DOI 10.1038/nature08267; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005; Zhou WB, 2009, STEM CELLS, V27, P2667, DOI 10.1002/stem.201	100	756	804	27	725	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					295	305		10.1038/nature10761	http://dx.doi.org/10.1038/nature10761			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258608	Green Accepted			2022-12-28	WOS:000299210600031
J	Kahan, S; Freedhoff, Y				Kahan, Scott; Freedhoff, Yoni			Review: Interventions to reduce dietary salt do not reduce mortality or morbidity	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							FAT; RISK		[Kahan, Scott] Johns Hopkins Weight Management Ctr, Baltimore, MD 21218 USA; [Freedhoff, Yoni] Univ Ottawa, Ottawa, ON, Canada	Johns Hopkins University; University of Ottawa	Kahan, S (corresponding author), Johns Hopkins Weight Management Ctr, Baltimore, MD 21218 USA.		Taylor, Rod/R-9581-2019	Taylor, Rod/0000-0002-3043-6011				He FJ, 2011, LANCET, V378, P380, DOI 10.1016/S0140-6736(11)61174-4; Hu FB, 2001, J AM COLL NUTR, V20, P5, DOI 10.1080/07315724.2001.10719008; Mozaffarian D, 2011, CIRCULATION, V123, P2870, DOI 10.1161/CIRCULATIONAHA.110.968735; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Wansink B, 2006, J MARKETING RES, V43, P605, DOI 10.1509/jmkr.43.4.605; World Health Organization, 2007, PREV CARD DIS GUID A	6	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-4	10.7326/0003-4819-156-2-201201170-02004	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02004			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31YU	22250166				2022-12-28	WOS:000208919700003
J	Rice, TW; Wheeler, AP; Thompson, BT; Steingrub, J; Hite, RD; Moss, M; Morris, A; Dong, N; Rock, P				Rice, Todd W.; Wheeler, Arthur P.; Thompson, B. Taylor; Steingrub, Jay; Hite, R. Duncan; Moss, Marc; Morris, Alan; Dong, Ning; Rock, Peter		National Heart Lung & Blood Inst A	ONLINE FIRST Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury The EDEN Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MECHANICALLY VENTILATED PATIENTS; CRITICALLY-ILL PATIENTS; CLINICAL-PRACTICE GUIDELINES; INTENSIVE-CARE-UNIT; NUTRITION SUPPORT; PARENTERAL-NUTRITION; CALORIC-INTAKE; ADULT PATIENTS; OUTCOMES; MORTALITY	Context The amount of enteral nutrition patients with acute lung injury need is unknown. Objective To determine if initial lower-volume trophic enteral feeding would increase ventilator-free days and decrease gastrointestinal intolerances compared with initial full enteral feeding. Design, Setting, and Participants The EDEN study, a randomized, open-label, multicenter trial conducted from January 2, 2008, through April 12, 2011. Participants were 1000 adults within 48 hours of developing acute lung injury requiring mechanical ventilation whose physicians intended to start enteral nutrition at 44 hospitals in the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Interventions Participants were randomized to receive either trophic or full enteral feeding for the first 6 days. After day 6, the care of all patients who were still receiving mechanical ventilation was managed according to the full feeding protocol. Main Outcome Measures Ventilator-free days to study day 28. Results Baseline characteristics were similar between the trophic-feeding (n=508) and full-feeding (n=492) groups. The full-feeding group received more enteral calories for the first 6 days, about 1300 kcal/d compared with 400 kcal/d (P<.001). Initial trophic feeding did not increase the number of ventilator-free days (14.9 [95% CI, 13.9 to 15.8] vs 15.0 [95% CI, 14.1 to 15.9]; difference, -0.1 [95% CI, -1.4 to 1.2]; P=.89) or reduce 60-day mortality (23.2% [95% CI, 19.6% to 26.9%] vs 22.2% [95% CI, 18.5% to 25.8%]; difference, 1.0% [95% CI, -4.1% to 6.3%]; P=.77) compared with full feeding. There were no differences in infectious complications between the groups. Despite receiving more prokinetic agents, the full-feeding group experienced more vomiting (2.2% vs 1.7% of patient feeding days; P=.05), elevated gastric residual volumes (4.9% vs 2.2% of feeding days; P<.001), and constipation (3.1% vs 2.1% of feeding days; P=.003). Mean plasma glucose values and average hourly insulin administration were both higher in the full-feeding group over the first 6 days. Conclusion In patients with acute lung injury, compared with full enteral feeding, a strategy of initial trophic enteral feeding for up to 6 days did not improve ventilator-free days, 60-day mortality, or infectious complications but was associated with less gastrointestinal intolerance.	[Rice, Todd W.; Wheeler, Arthur P.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Thompson, B. Taylor; Dong, Ning] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Steingrub, Jay] Baystate Med Ctr, Springfield, MA USA; [Hite, R. Duncan] Wake Forest Sch Med, Winston Salem, NC USA; [Moss, Marc] Univ Colorado, Sch Med, Denver, CO USA; [Morris, Alan] Univ Utah, Sch Med, Salt Lake City, UT USA; [Rock, Peter] Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Vanderbilt University; Harvard University; Massachusetts General Hospital; Baystate Medical Center; Wake Forest University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah; University System of Maryland; University of Maryland Baltimore	Rice, TW (corresponding author), Vanderbilt Univ Sch Med, T-1218 MCN, Nashville, TN 37232 USA.	todd.rice@vanderbilt.edu	Rice, Todd/X-7853-2019	Rice, Todd/0000-0002-7136-5408	National Heart, Lung, and Blood Institute (NHLBI) [HHSN268200536165C, HHSN268200536179C]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056169, R01HL056176] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268200536165C and HHSN268200536179C.	Arabi YM, 2010, JPEN-PARENTER ENTER, V34, P280, DOI 10.1177/0148607109353439; Artinian V, 2006, CHEST, V129, P960, DOI 10.1378/chest.129.4.960; Barr J, 2004, CHEST, V125, P1446, DOI 10.1378/chest.125.4.1446; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Burrin DG, 2000, AM J CLIN NUTR, V71, P1603; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Clermont G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022512; Dickerson RN, 2002, NUTRITION, V18, P241, DOI 10.1016/S0899-9007(01)00793-6; Doig GS, 2009, INTENS CARE MED, V35, P2018, DOI 10.1007/s00134-009-1664-4; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; HADFIELD RJ, 1995, AM J RESP CRIT CARE, V152, P1545, DOI 10.1164/ajrccm.152.5.7582291; Hernandez G, 1999, J CRIT CARE, V14, P73, DOI 10.1016/S0883-9441(99)90017-5; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P74, DOI 10.1177/014860710302700174; Heyland DK, 2004, CRIT CARE MED, V32, P2260, DOI 10.1097/01.CCM.0000145581.54571.32; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Ibrahim EH, 2002, JPEN-PARENTER ENTER, V26, P174, DOI 10.1177/0148607102026003174; Krishnan JA, 2003, CHEST, V124, P297, DOI 10.1378/chest.124.1.297; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; McClure RJ, 2000, ARCH DIS CHILD-FETAL, V82, pF29, DOI 10.1136/fn.82.1.F29; Omura K, 2000, ANN SURG, V231, P112, DOI 10.1097/00000658-200001000-00016; Owens L, 2002, J NUTR, V132, P2717, DOI 10.1093/jn/132.9.2717; Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435; Rice TW, 2011, CRIT CARE MED, V39, P967, DOI 10.1097/CCM.0b013e31820a905a; Rice TW, 2005, NUTRITION, V21, P786, DOI 10.1016/j.nut.2004.11.014; Rubinson L, 2004, CRIT CARE MED, V32, P350, DOI 10.1097/01.CCM.0000089641.06306.68; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564	29	573	606	2	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2012	307	8					795	803		10.1001/jama.2012.137	http://dx.doi.org/10.1001/jama.2012.137			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	896FQ	22307571	Green Accepted			2022-12-28	WOS:000300551300022
J	Oliveira, GD; Lieberman, J; Barillas-Mury, C				Oliveira, Giselle de Almeida; Lieberman, Joshua; Barillas-Mury, Carolina			Epithelial Nitration by a Peroxidase/NOX5 System Mediates Mosquito Antiplasmodial Immunity	SCIENCE			English	Article							ANOPHELES-GAMBIAE; MIDGUT CELLS; PLASMODIUM; COMPLEMENT; INVASION; DISEASE	Plasmodium ookinetes traverse midgut epithelial cells before they encounter the complement system in the mosquito hemolymph. We identified a heme peroxidase (HPX2) and NADPH oxidase 5 (NOX5) as critical mediators of midgut epithelial nitration and antiplasmodial immunity that enhance nitric oxide toxicity in Anopheles gambiae. We show that the two immune mechanisms that target ookinetes-epithelial nitration and thioester-containing protein 1 (TEP1)-mediated lysis-work sequentially, and we propose that epithelial nitration works as an opsonization-like system that promotes activation of the mosquito complement cascade.	[Oliveira, Giselle de Almeida; Lieberman, Joshua; Barillas-Mury, Carolina] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Barillas-Mury, C (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Rockville, MD 20892 USA.	cbarillas@niaid.nih.gov		Lieberman, Joshua/0000-0002-0376-1337; Oliveira, Giselle/0000-0002-5898-7843	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000947] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH. We thank A. Laughinghouse and K. Lee for insectary support; J. Ribeiro and J. Valenzuela for their comments and insight; and L. Garver and B. Marshall for editorial assistance.	Baxter RHG, 2007, P NATL ACAD SCI USA, V104, P11615, DOI 10.1073/pnas.0704967104; Blandin S, 2004, CELL, V116, P661, DOI 10.1016/S0092-8674(04)00173-4; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; Fraiture M, 2009, CELL HOST MICROBE, V5, P273, DOI 10.1016/j.chom.2009.01.005; Guzik TJ, 2008, J AM COLL CARDIOL, V52, P1803, DOI 10.1016/j.jacc.2008.07.063; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Jaramillo-Gutierrez G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011168; Kawahara T, 2007, BMC EVOL BIOL, V7, DOI 10.1186/147-2148-7-109; Kumar S, 2004, J BIOL CHEM, V279, P53475, DOI 10.1074/jbc.M409905200; Kumar S, 2010, SCIENCE, V327, P1644, DOI 10.1126/science.1184008; Molina-Cruz A, 2008, J BIOL CHEM, V283, P3217, DOI 10.1074/jbc.M705873200; Oliveira JHM, 2011, INSECT BIOCHEM MOLEC, V41, P349, DOI 10.1016/j.ibmb.2011.02.001; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Povelones M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002023; Povelones M, 2009, SCIENCE, V324, P258, DOI 10.1126/science.1171400; Shiao SH, 2006, PLOS PATHOG, V2, P1152, DOI 10.1371/journal.ppat.0020133	17	129	129	4	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	2012	335	6070					856	859		10.1126/science.1209678	http://dx.doi.org/10.1126/science.1209678			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893LC	22282475	Green Accepted			2022-12-28	WOS:000300356400044
J	DuPage, M; Mazumdar, C; Schmidt, LM; Cheung, AF; Jacks, T				DuPage, Michel; Mazumdar, Claire; Schmidt, Leah M.; Cheung, Ann F.; Jacks, Tyler			Expression of tumour-specific antigens underlies cancer immunoediting	NATURE			English	Article							MOUSE MODEL; IMMUNOSURVEILLANCE; IMMUNITY; REJECTION; VARIANTS; ESCAPE; CELLS	Cancer immunoediting is a process by which immune cells, particularly lymphocytes of the adaptive immune system, protect the host from the development of cancer and alter tumour progression by driving the outgrowth of tumour cells with decreased sensitivity to immune attack(1,2). Carcinogen-induced mouse models of cancer have shown that primary tumour susceptibility is thereby enhanced in immune-compromised mice, whereas the capacity for such tumours to grow after transplantation into wild-type mice is reduced(2,3). However, many questions about the process of cancer immunoediting remain unanswered, in part because of the known antigenic complexity and heterogeneity of carcinogen-induced tumours(4). Here we adapted a genetically engineered, autochthonous mouse model of sarcomagenesis to investigate the process of cancer immunoediting. This system allows us to monitor the onset and growth of immunogenic and non-immunogenic tumours induced in situ that harbour identical genetic and histopathological characteristics. By comparing the development of such tumours in immune-competent mice with their development in mice with broad immunodeficiency or specific antigenic tolerance, we show that recognition of tumour-specific antigens by lymphocytes is critical for immunoediting against sarcomas. Furthermore, primary sarcomas were edited to become less immunogenic through the selective outgrowth of cells that were able to escape T lymphocyte attack. Loss of tumour antigen expression or presentation on major histocompatibility complex I was necessary and sufficient for this immunoediting process to occur. These results highlight the importance of tumour-specific-antigen expression in immune surveillance, and potentially, immunotherapy.	[DuPage, Michel; Mazumdar, Claire; Schmidt, Leah M.; Cheung, Ann F.; Jacks, Tyler] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [DuPage, Michel; Mazumdar, Claire; Schmidt, Leah M.; Cheung, Ann F.; Jacks, Tyler] MIT, Dept Biol, Cambridge, MA 02139 USA; [Jacks, Tyler] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu			NIH [1 U54 CA126515-01]; Cancer Center from National Cancer Institute [P30-CA14051]; John D. Proctor Foundation; NATIONAL CANCER INSTITUTE [P30CA014051, U54CA126515] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center from National Cancer Institute; John D. Proctor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M. M. Winslow and A. G. DuPage for critical reading of this manuscript. This work was supported by grant 1 U54 CA126515-01 from the NIH, and partially by Cancer Center Support (core) grant P30-CA14051 from the National Cancer Institute and the Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship Award (M. D.) from the John D. Proctor Foundation. T.J. is a Howard Hughes Investigator and a Daniel K. Ludwig Scholar.	Cheung AF, 2008, CANCER RES, V68, P9459, DOI 10.1158/0008-5472.CAN-08-2634; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; DuPage M, 2011, CANCER CELL, V19, P72, DOI 10.1016/j.ccr.2010.11.011; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; EMBLETON MJ, 1972, INT J CANCER, V9, P8, DOI 10.1002/ijc.2910090103; Guerra N, 2008, IMMUNITY, V28, P723, DOI 10.1016/j.immuni.2008.04.001; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Guo ZS, 2006, CANCER RES, V66, P1105, DOI 10.1158/0008-5472.CAN-05-3020; Gure AO, 2002, INT J CANCER, V101, P448, DOI 10.1002/ijc.10634; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; MONACH PA, 1995, IMMUNITY, V2, P45, DOI 10.1016/1074-7613(95)90078-0; PREHN RT, 1957, J NATL CANCER I, V18, P769; Qin ZH, 2004, NAT IMMUNOL, V5, P3, DOI 10.1038/ni0104-3; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Schietinger A, 2006, SCIENCE, V314, P304, DOI 10.1126/science.1129200; SCOTT OCA, 1991, CANCER RES, V51, P757; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; STAUSS HJ, 1986, J EXP MED, V164, P1516, DOI 10.1084/jem.164.5.1516; Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105; UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; Zhou G, 2004, J EXP MED, V200, P1581, DOI 10.1084/jem.20041240; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	27	360	392	9	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	2012	482	7385					405	U1512		10.1038/nature10803	http://dx.doi.org/10.1038/nature10803			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	892LG	22318517	Green Accepted, Green Submitted			2022-12-28	WOS:000300287100047
J	Badri, T; Ishak, F				Badri, Talel; Ishak, Faten			Pyogenic Granuloma of the Finger	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Badri, Talel; Ishak, Faten] Univ Tunis El Manar, Habib Thameur Hosp, Tunis, Tunisia	Universite de Tunis-El-Manar; Hopital Habib Thameur	Badri, T (corresponding author), Univ Tunis El Manar, Habib Thameur Hosp, Tunis, Tunisia.	talel_badri@yahoo.fr							0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					E10	E10		10.1056/NEJMicm1107409	http://dx.doi.org/10.1056/NEJMicm1107409			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GH	22316469				2022-12-28	WOS:000299991300001
J	Bolan, GA; Sparling, PF; Wasserheit, JN				Bolan, Gail A.; Sparling, P. Frederick; Wasserheit, Judith N.			The Emerging Threat of Untreatable Gonococcal Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NEISSERIA-GONORRHOEAE; RESISTANCE		[Bolan, Gail A.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA; [Sparling, P. Frederick] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA; [Wasserheit, Judith N.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Wasserheit, Judith N.] Univ Washington, Dept Med, Seattle, WA USA; [Wasserheit, Judith N.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bolan, GA (corresponding author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA.							[Anonymous], 2010, MMWR RECOMM REP, V59, P1; [Anonymous], 2011, MMWR MORB MORTAL WKL, V60, P873; Katz AR, 2011, CLIN INFECT DIS 1219; Ohnishi M, 2011, ANTIMICROB AGENTS CH, V55, P3538, DOI 10.1128/AAC.00325-11; Workowski KA, 2008, ANN INTERN MED, V148, P888, DOI 10.7326/0003-4819-148-11-200806030-00024; Workowski KA, 2008, ANN INTERN MED, V148, P606, DOI 10.7326/0003-4819-148-8-200804150-00005	6	183	191	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					485	487		10.1056/NEJMp1112456	http://dx.doi.org/10.1056/NEJMp1112456			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888GH	22316442				2022-12-28	WOS:000299991300002
J	Lazarus, JH; Bestwick, JP; Channon, S; Paradice, R; Maina, A; Rees, R; Chiusano, E; John, R; Guaraldo, V; George, LM; Perona, M; Dall'Amico, D; Parkes, AB; Joomun, M; Wald, NJ				Lazarus, John H.; Bestwick, Jonathan P.; Channon, Sue; Paradice, Ruth; Maina, Aldo; Rees, Rhian; Chiusano, Elisabetta; John, Rhys; Guaraldo, Varvara; George, Lynne M.; Perona, Marco; Dall'Amico, Daniela; Parkes, Arthur B.; Joomun, Mohammed; Wald, Nicholas J.			Antenatal Thyroid Screening and Childhood Cognitive Function	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EARLY-PREGNANCY; NEUROPSYCHOLOGICAL DEVELOPMENT; MATERNAL HYPOTHYROXINEMIA; CHILDREN; DEFICIENCY; BRAIN	Background Children born to women with low thyroid hormone levels have been reported to have decreased cognitive function. Methods We conducted a randomized trial in which pregnant women at a gestation of 15 weeks 6 days or less provided blood samples for measurement of thyrotropin and free thyroxine (T-4). Women were assigned to a screening group (in which measurements were obtained immediately) or a control group (in which serum was stored and measurements were obtained shortly after delivery). Thyrotropin levels above the 97.5th percentile, free T-4 levels below the 2.5th percentile, or both were considered a positive screening result. Women with positive findings in the screening group were assigned to 150 mu g of levothyroxine per day. The primary outcome was IQ at 3 years of age in children of women with positive results, as measured by psychologists who were unaware of the group assignments. Results Of 21,846 women who provided blood samples (at a median gestational age of 12 weeks 3 days), 390 women in the screening group and 404 in the control group tested positive. The median gestational age at the start of levothyroxine treatment was 13 weeks 3 days; treatment was adjusted as needed to achieve a target thyrotropin level of 0.1 to 1.0 mIU per liter. Among the children of women with positive results, the mean IQ scores were 99.2 and 100.0 in the screening and control groups, respectively (difference, 0.8; 95% confidence interval [CI], -1.1 to 2.6; P = 0.40 by intention-to-treat analysis); the proportions of children with an IQ of less than 85 were 12.1% in the screening group and 14.1% in the control group (difference, 2.1 percentage points; 95% CI, -2.6 to 6.7; P = 0.39). An on-treatment analysis showed similar results. Conclusions Antenatal screening (at a median gestational age of 12 weeks 3 days) and maternal treatment for hypothyroidism did not result in improved cognitive function in children at 3 years of age. (Funded by the Wellcome Trust UK and Compagnia di San Paulo, Turin; Current Controlled Trials number, ISRCTN46178175.)	[Channon, Sue; Paradice, Ruth] St Davids Hosp, Dept Child Psychol, Cardiff, S Glam, Wales; [John, Rhys] Univ Wales Hosp, Dept Med Biochem, Cardiff CF4 4XW, S Glam, Wales; [Bestwick, Jonathan P.; George, Lynne M.; Joomun, Mohammed; Wald, Nicholas J.] Queen Mary Uni London, Wolfson Inst Prevent Med, Barts & London Sch Med & Dent, London, England; [Maina, Aldo; Chiusano, Elisabetta; Guaraldo, Varvara; Perona, Marco; Dall'Amico, Daniela] Azienda Osped Osped Infantile Regina Margherita S, Turin, Italy; [Lazarus, John H.; Rees, Rhian; Parkes, Arthur B.] Cardiff Sch Med, Ctr Endocrine & Diabet Sci, Cardiff, S Glam, Wales	Cardiff University; University of London; Queen Mary University London; A.O.U. Citta della Salute e della Scienza di Torino; Cardiff University	Lazarus, JH (corresponding author), Cardiff Univ, Ctr Endocrine & Diabet Sci, Sch Med, Cardiff CF14 4XN, S Glam, Wales.	lazarus@cf.ac.uk	Lazarus, John H/H-5108-2017; maina, aldo/HHC-0895-2022; maina, aldo/AAD-8530-2022; Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021	Lazarus, John H/0000-0001-8852-704X; Channon, Sue/0000-0002-5394-1483	Wellcome Trust; Compagnia di San Paulo, Turin; Abbott Diagnostics; Merck (Darmstadt); Wellcome Trust UK	Wellcome Trust(Wellcome TrustEuropean Commission); Compagnia di San Paulo, Turin(Compagnia di San Paolo); Abbott Diagnostics(Abbott Laboratories); Merck (Darmstadt)(Merck & Company); Wellcome Trust UK(Wellcome Trust)	Supported by the Wellcome Trust and Compagnia di San Paulo, Turin.; Dr. Lazarus reports receiving consulting fees from Abbott Diagnostics and lecture fees from Abbott Diagnostics and Merck (Darmstadt). No other potential conflict of interest relevant to this article was reported.; Antenatal screening (at a median gestational age of 12 weeks 3 days) and maternal treatment for hypothyroidism did not result in improved cognitive function in children at 3 years of age. (Funded by the Wellcome Trust UK and Compagnia di San Paulo, Turin; Current Controlled Trials number, ISRCTN46178175.)	Berbel P, 2009, THYROID, V19, P511, DOI 10.1089/thy.2008.0341; de Escobar GM, 2004, BEST PRACT RES CL EN, V18, P225, DOI 10.1016/j.beem.2004.03.012; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), THYR THER MILD THYR; Ghassabian A, 2011, PEDIATR RES, V69, P454, DOI 10.1203/PDR.0b013e3182125b0c; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Henrichs J, 2010, J CLIN ENDOCR METAB, V95, P4227, DOI 10.1210/jc.2010-0415; Kooistra L, 2006, PEDIATRICS, V117, P161, DOI 10.1542/peds.2005-0227; Li Y, 2010, CLIN ENDOCRINOL, V72, P825, DOI 10.1111/j.1365-2265.2009.03743.x; MAN EB, 1971, AM J OBSTET GYNECOL, V111, P905, DOI 10.1016/0002-9378(71)90945-8; Mirabella G, 2005, PEDIATR RES, V57, P902, DOI 10.1203/01.PDR.0000157681.38042.B4; PHAROAH POD, 1971, LANCET, V1, P308; Pop VJ, 2003, CLIN ENDOCRINOL, V59, P282, DOI 10.1046/j.1365-2265.2003.01822.x; Pop VJ, 1999, CLIN ENDOCRINOL, V50, P149, DOI 10.1046/j.1365-2265.1999.00639.x; Smit BJ, 2000, ACTA PAEDIATR, V89, P291; Stagnaro-Green A, 2011, THYROID, V21, P1081, DOI 10.1089/thy.2011.0087; Velasco I, 2009, J CLIN ENDOCR METAB, V94, P3234, DOI 10.1210/jc.2008-2652; Zoeller RT, 2004, J NEUROENDOCRINOL, V16, P809, DOI 10.1111/j.1365-2826.2004.01243.x	17	391	433	1	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					493	501		10.1056/NEJMoa1106104	http://dx.doi.org/10.1056/NEJMoa1106104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GH	22316443	Green Accepted			2022-12-28	WOS:000299991300005
J	Inagaki, HK; De-Leon, SBT; Wong, AM; Jagadish, S; Ishimoto, H; Barnea, G; Kitamoto, T; Axel, R; Anderson, DJ				Inagaki, Hidehiko K.; de-Leon, Shlomo Ben-Tabou; Wong, Allan M.; Jagadish, Smitha; Ishimoto, Hiroshi; Barnea, Gilad; Kitamoto, Toshihiro; Axel, Richard; Anderson, David J.			Visualizing Neuromodulation In Vivo: TANGO-Mapping of Dopamine Signaling Reveals Appetite Control of Sugar Sensing	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FEEDING-BEHAVIOR; NEURAL CIRCUIT; DROSOPHILA; TASTE; RECEPTOR; MODULATION; RESPONSES; EXPRESSION; HUNGER	Behavior cannot be predicted from a "connectome'' because the brain contains a chemical "map'' of neuromodulation superimposed upon its synaptic connectivity map. Neuromodulation changes how neural circuits process information in different states, such as hunger or arousal. Here we describe a genetically based method to map, in an unbiased and brain-wide manner, sites of neuromodulation under different conditions in the Drosophila brain. This method, and genetic perturbations, reveal that the well-known effect of hunger to enhance behavioral sensitivity to sugar is mediated, at least in part, by the release of dopamine onto primary gustatory sensory neurons, which enhances sugar-evoked calcium influx. These data reinforce the concept that sensory neurons constitute an important locus for state-dependent gain control of behavior and introduce a methodology that can be extended to other neuro-modulators and model organisms.	[Inagaki, Hidehiko K.; de-Leon, Shlomo Ben-Tabou; Wong, Allan M.; Axel, Richard; Anderson, David J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; [Inagaki, Hidehiko K.; de-Leon, Shlomo Ben-Tabou; Wong, Allan M.; Anderson, David J.] CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; [Ishimoto, Hiroshi; Kitamoto, Toshihiro] Univ Iowa, Dept Anesthesia, Iowa City, IA 52242 USA; [Ishimoto, Hiroshi; Kitamoto, Toshihiro] Univ Iowa, Interdisciplinary Program Genet, Iowa City, IA 52242 USA; [Ishimoto, Hiroshi; Kitamoto, Toshihiro] Univ Iowa, Interdisciplinary Program Neurosci, Iowa City, IA 52242 USA; [Jagadish, Smitha; Axel, Richard] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Barnea, Gilad] Brown Univ, Dept Neurosci, Providence, RI 02912 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of Iowa; University of Iowa; University of Iowa; Columbia University; Brown University	Anderson, DJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	wuwei@caltech.edu	Ishimoto, Hiroshi/AAV-1923-2021	Axel, Richard/0000-0002-3141-4076; Inagaki, Hidehiko/0000-0003-4580-2763; Kitamoto, Toshihiro/0000-0003-0863-8466; Ishimoto, Hiroshi/0000-0002-8859-6931	NIH [5R01MH086920, 1RO1 DA031389]; Nakajima Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH086920, R01MH085081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA031389] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nakajima Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank Dr. K.J. Lee for sharing Tango DNA constructs prior to publication. We also thank Drs. T. Lee, K. Deisseroth, A. Stathopoulos, and B. Pfeiffer for plasmids. Fly stocks were generously provided by the Bloomington Stock Center, the VDRC stock center, the Drosophila RNAi Screening Center, and Drs. G.M. Rubin, J. Simpson, L.L Looger, H. Keshishian, K. Scott, T. Lee, S. Birman, P. A. Garrity, C.Q. Doe, and K. Ito. We also thank Drs. H. Otsuna and Y. Wan for Fluorender and members of the Anderson lab for helpful discussion and sharing of flies. H.K.I. is supported by the Nakajima Foundation. G.B. is a Pew scholar and is supported in part by NIH grant 5R01MH086920. D.J.A. is an investigator of the Howard Hughes Medical Institute. This work was supported in part by NIH grant 1RO1 DA031389 to D.J.A.	Bainton RJ, 2000, CURR BIOL, V10, P187, DOI 10.1016/S0960-9822(00)00336-5; Barnea G, 2008, P NATL ACAD SCI USA, V105, P64, DOI 10.1073/pnas.0710487105; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; BERRIDGE KC, 1991, APPETITE, V16, P103, DOI 10.1016/0195-6663(91)90036-R; Bhattacharya A, 1999, J NEUROBIOL, V39, P491, DOI 10.1002/(SICI)1097-4695(19990615)39:4<491::AID-NEU3>3.0.CO;2-6; BICKER G, 1989, NATURE, V337, P33, DOI 10.1038/337033a0; Birmingham JT, 2003, J EXP BIOL, V206, P3541, DOI 10.1242/jeb.00601; BROOKHART GL, 1987, J NEUROCHEM, V48, P1307, DOI 10.1111/j.1471-4159.1987.tb05662.x; Chiappe ME, 2010, CURR BIOL, V20, P1470, DOI 10.1016/j.cub.2010.06.072; Crocker A, 2010, NEURON, V65, P670, DOI 10.1016/j.neuron.2010.01.032; Dahanukar A, 2007, NEURON, V56, P503, DOI 10.1016/j.neuron.2007.10.024; Dethier V. G., 1976, HUNGRY FLY PHYSL STU; DUBNER R, 1988, PROG BRAIN RES, V77, P213; Friggi-Grelin F, 2003, J NEUROBIOL, V54, P618, DOI 10.1002/neu.10185; Gillette R, 2000, P NATL ACAD SCI USA, V97, P3585, DOI 10.1073/pnas.97.7.3585; Gordon MD, 2009, NEURON, V61, P373, DOI 10.1016/j.neuron.2008.12.033; GOTZES F, 1994, RECEPTOR CHANNEL, V2, P131; Hamada FN, 2008, NATURE, V454, P217, DOI 10.1038/nature07001; Han KA, 1996, NEURON, V16, P1127, DOI 10.1016/S0896-6273(00)80139-7; HARRISWARRICK RM, 1991, ANNU REV NEUROSCI, V14, P39, DOI 10.1146/annurev.ne.14.030191.000351; Hearn MG, 2002, P NATL ACAD SCI USA, V99, P14554, DOI 10.1073/pnas.202498299; Hurley LM, 2004, CURR OPIN NEUROBIOL, V14, P488, DOI 10.1016/j.conb.2004.06.007; Kong EC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009954; Krashes MJ, 2009, CELL, V139, P416, DOI 10.1016/j.cell.2009.08.035; Lebestky T, 2009, NEURON, V64, P522, DOI 10.1016/j.neuron.2009.09.031; Lee GH, 2004, GENETICS, V167, P311, DOI 10.1534/genetics.167.1.311; LONG TF, 1986, COMP BIOCHEM PHYS C, V83, P201, DOI 10.1016/0742-8413(86)90037-X; Maimon G, 2010, NAT NEUROSCI, V13, P393, DOI 10.1038/nn.2492; Mao ZM, 2009, FRONT NEURAL CIRCUIT, V3, DOI 10.3389/neuro.04.005.2009; Marder E, 2007, ANNU REV PHYSIOL, V69, P291, DOI 10.1146/annurev.physiol.69.031905.161516; Marella S, 2006, NEURON, V49, P285, DOI 10.1016/j.neuron.2005.11.037; Meunier N, 2007, J EXP BIOL, V210, P1424, DOI 10.1242/jeb.02755; Miller MR, 2009, NAT METHODS, V6, P439, DOI [10.1038/nmeth.1329, 10.1038/NMETH.1329]; Monastirioti M, 1999, MICROSC RES TECHNIQ, V45, P106, DOI 10.1002/(SICI)1097-0029(19990415)45:2<106::AID-JEMT5>3.3.CO;2-V; Montell C, 2009, CURR OPIN NEUROBIOL, V19, P345, DOI 10.1016/j.conb.2009.07.001; MOSKOWITZ HR, 1976, PHYSIOL BEHAV, V16, P471, DOI 10.1016/0031-9384(76)90326-7; MOSS CF, 1983, BEHAV NEUROSCI, V97, P541, DOI 10.1037/0735-7044.97.4.541; Nassel DR, 2010, PROG NEUROBIOL, V92, P42, DOI 10.1016/j.pneurobio.2010.04.010; Niell CM, 2010, NEURON, V65, P472, DOI 10.1016/j.neuron.2010.01.033; Nusbaum MP, 2002, NATURE, V417, P343, DOI 10.1038/417343a; Osterwalder T, 2001, P NATL ACAD SCI USA, V98, P12596, DOI 10.1073/pnas.221303298; Page RE, 1998, J COMP PHYSIOL A, V182, P489, DOI 10.1007/s003590050196; Pauli A, 2008, DEV CELL, V14, P239, DOI 10.1016/j.devcel.2007.12.009; Pfaff DW, 2008, ANN NY ACAD SCI, V1129, P1, DOI 10.1196/annals.1417.031; Phillips PEM, 2003, METH MOLEC MED, V79, P443; Riemensperger T, 2011, P NATL ACAD SCI USA, V108, P834, DOI 10.1073/pnas.1010930108; Root CM, 2011, CELL, V145, P133, DOI 10.1016/j.cell.2011.02.008; Scheiner R, 2004, LEARN MEMORY, V11, P303, DOI 10.1101/lm.71604; Scheiner R, 2002, BEHAV BRAIN RES, V136, P545, DOI 10.1016/S0166-4328(02)00205-X; Scott K, 2001, CELL, V104, P661, DOI 10.1016/S0092-8674(01)00263-X; Shea SD, 2010, J CHEM NEUROANAT, V39, P132, DOI 10.1016/j.jchemneu.2009.10.002; Shiraiwa Takashi, 2007, J Vis Exp, P193, DOI 10.3791/193; Srivastava DP, 2005, J NEUROSCI, V25, P6145, DOI 10.1523/JNEUROSCI.1005-05.2005; SUGAMORI KS, 1995, FEBS LETT, V362, P131, DOI 10.1016/0014-5793(95)00224-W; Szymczak AL, 2005, EXPERT OPIN BIOL TH, V5, P627, DOI 10.1517/14712598.5.5.627; Thibault ST, 2004, NAT GENET, V36, P283, DOI 10.1038/ng1314; Thorne N, 2004, CURR BIOL, V14, P1065, DOI 10.1016/j.cub.2004.05.019; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; Tsuno Yusuke, 2009, Commun Integr Biol, V2, P362; Wang ZR, 2004, CELL, V117, P981, DOI 10.1016/j.cell.2004.06.011; Weiss LA, 2011, NEURON, V69, P258, DOI 10.1016/j.neuron.2011.01.001; Wu Q, 2005, NAT NEUROSCI, V8, P1350, DOI 10.1038/nn1540; Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936; Zhang W, 2007, EUR J NEUROSCI, V26, P2405, DOI 10.1111/j.1460-9568.2007.05862.x	64	200	201	1	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					583	595		10.1016/j.cell.2011.12.022	http://dx.doi.org/10.1016/j.cell.2011.12.022			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304923	Green Accepted, Bronze			2022-12-28	WOS:000300225000024
J	Venitt, S; Phillips, DH				Venitt, Stanley; Phillips, David H.			Philip D. Lawley (1927-2011) OBITUARY	NATURE			English	Biographical-Item									[Venitt, Stanley; Phillips, David H.] Kings Coll London, Analyt & Environm Sci Div, London SE1 9NH, England; [Venitt, Stanley; Phillips, David H.] Inst Canc Res, London, England	University of London; King's College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Venitt, S (corresponding author), Kings Coll London, Analyt & Environm Sci Div, London SE1 9NH, England.	stan.venitt@kcl.ac.uk		Phillips, David/0000-0001-8509-3485	Medical Research Council [G0801056B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		LAWLEY PD, PUBLICATION LIST	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					36	36		10.1038/482036a	http://dx.doi.org/10.1038/482036a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22297963	Bronze			2022-12-28	WOS:000299726000025
J	Brake, M				Brake, Mike			A Doctor's Kid	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												brakescribe@cox.net							0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					465	466		10.1001/jama.2012.38	http://dx.doi.org/10.1001/jama.2012.38			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22298677				2022-12-28	WOS:000299728000026
J	Shea, EK; Weiss, BP; Cassata, WS; Shuster, DL; Tikoo, SM; Gattacceca, J; Grove, TL; Fuller, MD				Shea, Erin K.; Weiss, Benjamin P.; Cassata, William S.; Shuster, David L.; Tikoo, Sonia M.; Gattacceca, Jerome; Grove, Timothy L.; Fuller, Michael D.			A Long-Lived Lunar Core Dynamo	SCIENCE			English	Article							DRIVEN; CONSTRAINTS; MANTLE; MOON; BODY	Paleomagnetic measurements indicate that a core dynamo probably existed on the Moon 4.2 billion years ago. However, the subsequent history of the lunar core dynamo is unknown. Here we report paleomagnetic, petrologic, and 40Ar/39Ar thermochronometry measurements on the 3.7-billion-year-old mare basalt sample 10020. This sample contains a high-coercivity magnetization acquired in a stable field of at least similar to 12 microteslas. These data extend the known lifetime of the lunar dynamo by 500 million years. Such a long-lived lunar dynamo probably required a power source other than thermochemical convection from secular cooling of the lunar interior. The inferred strong intensity of the lunar paleofield presents a challenge to current dynamo theory.	[Shea, Erin K.; Weiss, Benjamin P.; Tikoo, Sonia M.; Grove, Timothy L.] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; [Cassata, William S.; Shuster, David L.] Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; [Shuster, David L.] Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; [Gattacceca, Jerome] Univ Aix Marseille 3, Ctr Europeen Rech & Enseignement, CNRS, F-13628 Aix En Provence, France; [Fuller, Michael D.] Univ Hawaii Manoa, Honolulu, HI 96822 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California Berkeley; Berkeley Geochronolgy Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Hawaii System; University of Hawaii Manoa	Shea, EK (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	nuptse@mit.edu	Gattacceca, Jerome/AAG-5651-2019; Shuster, David/A-4838-2011; Grove, Timothy/M-9638-2013	Gattacceca, Jerome/0000-0002-1639-7140; Grove, Timothy/0000-0003-0628-1969	NASA; NASA Lunar Science Institute; MIT; CNRS; INSU/CNES; Ann and Gordon Getty Foundation; NSF [EAR-0618219, EAR-0838572]; Division Of Earth Sciences [0838572] Funding Source: National Science Foundation	NASA(National Aeronautics & Space Administration (NASA)); NASA Lunar Science Institute; MIT; CNRS(Centre National de la Recherche Scientifique (CNRS)); INSU/CNES(Centre National D'etudes Spatiales); Ann and Gordon Getty Foundation; NSF(National Science Foundation (NSF)); Division Of Earth Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	We thank the Johnson Space Center staff and the Curation and Analysis Planning Team for Extraterrestrial Materials for allocating 10020; N. Chatterjee for help with the microprobe analyses; C. Ross for use of her vibrating sample magnetometer; B. Carbone for administrative help; and C. Dwyer, F. Nimmo, M. Wieczorek, and J. Wisdom for helpful discussions. B. P. W., M. D. F., and D. L. S. thank the NASA Lunar Advanced Science and Exploration Research Program; B. P. W. thanks the NASA Lunar Science Institute; B. P. W. and J. G. thank the MIT-France Seed Funds Program, the PICS Program (CNRS), and the Programme National de Planetologie (INSU/CNES); E. K. S. and S. M. T. thank the NASA Graduate Student Researchers Program; and D. L. S. thanks the Ann and Gordon Getty Foundation for support. D. L. S acknowledges the support of NSF grants EAR-0618219 and EAR-0838572. W. S. C. was supported by an NSF Graduate Research Fellowship. Paleomagnetic data have been included in the SOM.	Beaty D., 1978, LUNAR PLANETARY SCI, P359; Beaty D. W., 1980, P LUNAR PLANET SCI C, P23; Chapman CR, 2007, ICARUS, V189, P233, DOI 10.1016/j.icarus.2006.12.020; Collinson D. W., 1972, P LUNAR PLANET SCI C, P2343; Crawford DA, 1999, INT J IMPACT ENG, V23, P169, DOI 10.1016/S0734-743X(99)00070-6; Dence M. R., 1970, P AP 11 LUN SCI C, P315; Dwyer CA, 2011, NATURE, V479, P212, DOI 10.1038/nature10564; Fechtig H., 1966, POTASSIUM ARGON DATI, P68, DOI DOI 10.1007/978-3-642-87895-4_4; Fuller M., 1987, GEOMAGN AERON, V2, P307; Garrick-Bethell I, 2009, SCIENCE, V323, P356, DOI 10.1126/science.1166804; GEISS J, 1977, PHILOS T R SOC A, V285, P151, DOI 10.1098/rsta.1977.0051; Grove T.L., 1977, P 8 LUNAR SCI C, P1501, DOI DOI 10.1130/0091-7613(1977)5%3C425:PFALCF%3E2.0.CO;2; Guggisberg S., 1979, P LUNAR PLANET SCI C, P1; Haggerty S. E., 1970, P AP 11 LUN SCI C, P513; Hood LL, 2008, ICARUS, V193, P485, DOI 10.1016/j.icarus.2007.08.023; Konrad W, 1997, ADV SPACE RES-SERIES, V19, P1511, DOI 10.1016/S0273-1177(97)00364-5; Lawrence K, 2008, PHYS EARTH PLANET IN, V168, P71, DOI 10.1016/j.pepi.2008.05.007; Le Bars M, 2011, NATURE, V479, P215, DOI 10.1038/nature10565; Pearce G. W., 1972, NASA, P7; Renne PR, 2011, GEOCHIM COSMOCHIM AC, V75, P5097, DOI 10.1016/j.gca.2011.06.021; Roedder E., 1970, P APOLLO 11 LUNAR SC, P801; SNYDER GA, 1994, GEOCHIM COSMOCHIM AC, V58, P4795, DOI 10.1016/0016-7037(94)90209-7; Stegman DR, 2003, NATURE, V421, P143, DOI 10.1038/nature01267; Stevenson DJ, 2010, SPACE SCI REV, V152, P651, DOI 10.1007/s11214-009-9572-z; TURNER G, 1971, EARTH PLANET SC LETT, V11, P169, DOI 10.1016/0012-821X(71)90161-0; Weber RC, 2011, SCIENCE, V331, P309, DOI 10.1126/science.1199375; Weiss BP, 2008, SCIENCE, V322, P713, DOI 10.1126/science.1162459; Williams JG, 2001, J GEOPHYS RES-PLANET, V106, P27933, DOI 10.1029/2000JE001396	28	65	65	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					453	456		10.1126/science.1215359	http://dx.doi.org/10.1126/science.1215359			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282809				2022-12-28	WOS:000299466800046
J	Chan, FKM; Baehrecke, EH				Chan, Francis Ka-Ming; Baehrecke, Eric H.			RIP3 Finds Partners in Crime	CELL			English	Editorial Material							CELL-DEATH; NECROSIS	Programmed necrosis has long been recognized as a crucial component of animal development; however, the signaling pathway beyond the protein kinases RIP1 and RIP3 remains largely unknown. Sun et al. and Wang et al. now identify critical factors downstream of RIP1 and RIP3 in programmed necrosis, extending our understanding of this form of cell death.	[Chan, Francis Ka-Ming] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01505 USA; [Baehrecke, Eric H.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01505 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Chan, FKM (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01505 USA.	francis.chan@umassmed.edu; eric.baehrecke@umassmed.edu	Chan, Francis Ka-Ming/E-9647-2014; Chan, Francis/ABB-1895-2021	Chan, Francis Ka-Ming/0000-0002-4803-8353; 	NCI NIH HHS [R01 CA159314] Funding Source: Medline; NIAID NIH HHS [R01 AI083497, R21 AI088502] Funding Source: Medline; NIGMS NIH HHS [R01 GM079431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA159314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI088502, R01AI083497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Imai Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001229; Moquin D, 2010, TRENDS BIOCHEM SCI, V35, P434, DOI 10.1016/j.tibs.2010.03.001; Oberst A, 2011, NAT REV MOL CELL BIO, V12, P757, DOI 10.1038/nrm3214; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308	9	30	31	3	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 20	2012	148	1-2					17	18		10.1016/j.cell.2011.12.020	http://dx.doi.org/10.1016/j.cell.2011.12.020			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265396	Bronze, Green Accepted			2022-12-28	WOS:000299540700007
J	Chiang, WC; Ching, TT; Lee, HC; Mousigian, C; Hsu, AL				Chiang, Wei-Chung; Ching, Tsui-Ting; Lee, Hee Chul; Mousigian, Carol; Hsu, Ao-Lin			HSF-1 Regulators DDL-1/2 Link Insulin-like Signaling to Heat-Shock Responses and Modulation of Longevity	CELL			English	Article							CAENORHABDITIS-ELEGANS; MOLECULAR CHAPERONES; LIFE-SPAN; C-ELEGANS; FACTOR-I; TRANSCRIPTIONAL RESPONSE; NEGATIVE REGULATION; GENE-TRANSCRIPTION; STRESS; PROTEIN	Extended longevity is often correlated with increased resistance against various stressors. Insulin/IGF-1-like signaling (IIS) is known to have a conserved role in aging and cellular mechanisms against stress. In C. elegans, genetic studies suggest that heat-shock transcription factor HSF-1 is required for IIS to modulate longevity. Here, we report that the activity of HSF-1 is regulated by IIS. This regulation occurs at an early step of HSF-1 activation via two HSF-1 regulators, DDL-1 and DDL-2. Inhibition of DDL-1/2 increases longevity and thermotolerance in an hsf-1-dependent manner. Furthermore, biochemical analyses suggest that DDL-1/2 negatively regulate HSF-1 activity by forming a protein complex with HSF-1. The formation of this complex (DHIC) is affected by the phosphorylation status of DDL-1. Both the formation of DHIC and the phosphorylation of DDL-1 are controlled by IIS. Our findings point to DDL-1/2 as a link between IIS and the HSF-1 pathway.	[Chiang, Wei-Chung; Hsu, Ao-Lin] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Ching, Tsui-Ting; Lee, Hee Chul; Mousigian, Carol; Hsu, Ao-Lin] Univ Michigan, Sch Med, Div Geriatr Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hsu, AL (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	aolinhsu@umich.edu	Hsu, Ao-Lin Allen/AAX-1856-2020; Chiang, Wei-Chung/AAZ-5494-2020	Chiang, Wei-Chung/0000-0003-3149-435X; Hsu, Ao-Lin/0000-0002-2864-3134; Ching, Tsui-Ting/0000-0001-7650-1766	NIH/NIA [AG028516]; Ellison Medical Foundation; NATIONAL INSTITUTE ON AGING [R01AG028516] Funding Source: NIH RePORTER	NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grant AG028516 from NIH/NIA and a grant from the Ellison Medical Foundation to A.-L.H. We thank the Caenorhabditis Genetic Center for providing the PS3551, CH116, VC2193, and RB2380 strains.	CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; Derivery E, 2009, DEV CELL, V17, P712, DOI 10.1016/j.devcel.2009.09.010; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Garigan D, 2002, GENETICS, V161, P1101; Guettouche Toumy, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-4; Hajdu-Cronin YM, 2004, GENETICS, V168, P1937, DOI 10.1534/genetics.104.028423; Hansen M, 2005, PLOS GENET, V1, P119, DOI 10.1371/journal.pgen.0010017; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hunt-Newbury R, 2007, PLOS BIOL, V5, P1981, DOI 10.1371/journal.pbio.0050237; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Khazaeli AA, 1997, J GERONTOL A-BIOL, V52, pB48, DOI 10.1093/gerona/52A.1.B48; Kim JH, 2004, BIOINFORMATICS, V20, P3179, DOI 10.1093/bioinformatics/bth382; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kurapati R, 2000, J GERONTOL A-BIOL, V55, pB552, DOI 10.1093/gerona/55.11.B552; Li J, 2008, PLOS BIOL, V6, P1870, DOI 10.1371/journal.pbio.0060233; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Lithgow GJ, 2002, MECH AGEING DEV, V123, P765, DOI 10.1016/S0047-6374(01)00422-5; McColl G, 2010, CELL METAB, V12, P260, DOI 10.1016/j.cmet.2010.08.004; Mercier PA, 1999, J CELL SCI, V112, P2765; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; Soti C, 2000, BIOGERONTOLOGY, V1, P225, DOI 10.1023/A:1010082129022; Voellmy R, 2004, CELL STRESS CHAPERON, V9, P122, DOI 10.1379/CSC-14R.1; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	37	148	162	3	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					322	334		10.1016/j.cell.2011.12.019	http://dx.doi.org/10.1016/j.cell.2011.12.019			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265419	Bronze, Green Accepted			2022-12-28	WOS:000299540700034
J	Cranch, GA; Foster, S				Cranch, Geoffrey A.; Foster, Scott			Comment on "Probing the Ultimate Limit of Fiber-Optic Strain Sensing"	SCIENCE			English	Editorial Material							FREQUENCY NOISE; THERMAL NOISE; LASER		[Cranch, Geoffrey A.] USN, Res Lab, Washington, DC 20375 USA; [Foster, Scott] Def Sci & Technol Org, Edinburgh, SA 5111, Australia	United States Department of Defense; United States Navy; Naval Research Laboratory; Defence Science & Technology	Cranch, GA (corresponding author), USN, Res Lab, 4555 Overlook Ave SW, Washington, DC 20375 USA.	geoff.cranch@nrl.navy.mil; scott.foster@dsto.defence.gov.au		Foster, Scott/0000-0002-5464-1036				Alnis J, 2011, PHYS REV A, V84, DOI 10.1103/PhysRevA.84.011804; Cranch GA, 2011, OPT LETT, V36, P906, DOI 10.1364/OL.36.000906; Cranch GA, 2008, IEEE SENS J, V8, P1161, DOI 10.1109/JSEN.2008.926876; Duan LZ, 2010, ELECTRON LETT, V46, P1515, DOI 10.1049/el.2010.1653; Foster S, 2007, IEEE J QUANTUM ELECT, V43, P378, DOI 10.1109/JQE.2007.894744; Foster S, 2009, PHYS REV A, V79, DOI 10.1103/PhysRevA.79.053802; Foster S, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.013820; Gagliardi G, 2010, SCIENCE, V330, P1081, DOI 10.1126/science.1195818; GLENN WH, 1989, IEEE J QUANTUM ELECT, V25, P1218, DOI 10.1109/3.29251; Jiang HF, 2010, OPT EXPRESS, V18, P3284, DOI 10.1364/OE.18.003284; Kirkendall CK, 2004, J PHYS D APPL PHYS, V37, pR197, DOI 10.1088/0022-3727/37/18/R01; KOO KP, 1995, ELECTRON LETT, V31, P1180, DOI 10.1049/el:19950811; Sheard BS, 2006, APPL OPTICS, V45, P8491, DOI 10.1364/AO.45.008491; Wanser K. H., 1993, OPT PHOTONICS NEWS, V4, P37; WANSER KH, 1992, ELECTRON LETT, V28, P53, DOI 10.1049/el:19920033	15	17	17	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2012	335	6066								10.1126/science.1205452	http://dx.doi.org/10.1126/science.1205452			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267794				2022-12-28	WOS:000299273400026
J	Selnes, OA; Gottesman, RF; Grega, MA; Baumgartner, WA; Zeger, SL; McKhann, GM				Selnes, Ola A.; Gottesman, Rebecca F.; Grega, Maura A.; Baumgartner, William A.; Zeger, Scott L.; McKhann, Guy M.			CURRENT CONCEPTS Cognitive and Neurologic Outcomes after Coronary-Artery Bypass Surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HIGH-RISK PATIENTS; OFF-PUMP; ON-PUMP; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; STROKE; DYSFUNCTION; DECLINE; ENCEPHALOPATHY; PREDICTORS		[Selnes, Ola A.; Gottesman, Rebecca F.; McKhann, Guy M.] Johns Hopkins Univ, Sch Med, Dept Neurol, Div Cardiac Surg, Baltimore, MD 21205 USA; [Grega, Maura A.; Baumgartner, William A.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD 21205 USA; [Zeger, Scott L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [McKhann, Guy M.] Johns Hopkins Univ, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Selnes, OA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Div Cognit Neurosci, Reed Hall E2,1620 McElderry St, Baltimore, MD 21205 USA.	oselnes@jhmi.edu	Gottesman, Rebecca/ABA-8468-2020	Zeger, Scott/0000-0001-8907-1603				Angelini GD, 2002, LANCET, V359, P1194, DOI 10.1016/S0140-6736(02)08216-8; Belcher PR, 2002, J HUM HYPERTENS, V16, P691, DOI 10.1038/sj.jhh.1001469; Bouchard D, 2011, ANN THORAC SURG, V91, P654, DOI 10.1016/j.athoracsur.2010.11.036; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Bucerius J, 2003, ANN THORAC SURG, V75, P472, DOI 10.1016/S0003-4975(02)04370-9; Bybee KA, 2005, CIRCULATION, V112, pI286, DOI 10.1161/CIRCULATIONAHA.104.522805; Caplan LR, 2009, ARCH NEUROL-CHICAGO, V66, P1062, DOI 10.1001/archneurol.2009.181; Caplan LR, 1998, ARCH NEUROL-CHICAGO, V55, P1475, DOI 10.1001/archneur.55.11.1475; Dijkstra JB, 2002, NEUROPSYCHOL REV, V12, P1, DOI 10.1023/A:1015404122161; Durand DJ, 2004, ANN THORAC SURG, V78, P159, DOI 10.1016/j.athoracsur.2004.02.024; Eagle KA, 2005, J AM COLL CARDIOL, V45, P1377; Eagle Kim A, 2004, J Am Coll Cardiol, V44, pe213; Fontes ML, 2008, ANESTH ANALG, V107, P1122, DOI 10.1213/ane.0b013e31816ba404; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; Gerriets T, 2010, AM J CARDIOL, V105, P1095, DOI 10.1016/j.amjcard.2009.12.009; GOLD JP, 1995, J THORAC CARDIOV SUR, V110, P1302, DOI 10.1016/S0022-5223(95)70053-6; Goto T, 2001, ANN THORAC SURG, V72, P137, DOI 10.1016/S0003-4975(01)02676-5; Gottesman RF, 2006, STROKE, V37, P2306, DOI 10.1161/01.STR.0000236024.68020.3a; Hedberg M, 2011, EUR J CARDIO-THORAC, V40, P379, DOI 10.1016/j.ejcts.2010.11.060; Hernandez F, 2007, ANN THORAC SURG, V84, P1897, DOI 10.1016/j.athoracsur.2007.07.036; Ho PM, 2004, ANN THORAC SURG, V77, P597, DOI 10.1016/S0003-4975(03)01358-4; Hogue CW, 1999, CIRCULATION, V100, P642, DOI 10.1161/01.CIR.100.6.642; Hueb W, 2010, CIRCULATION, V122, pS48, DOI 10.1161/CIRCULATIONAHA.109.924258; Jensen BO, 2006, CIRCULATION, V113, P2790, DOI 10.1161/CIRCULATIONAHA.105.587931; Kapetanakis EI, 2004, ANN THORAC SURG, V78, P1564, DOI 10.1016/j.athoracsur.2004.05.019; Karkouti K, 2005, ANN THORAC SURG, V80, P1381, DOI 10.1016/j.athoracsur.2005.03.137; Knopman DS, 2005, NEUROLOGY, V65, P986, DOI 10.1212/01.WNL.0000171954.92119.c7; Kozora E, 2010, ANN THORAC SURG, V90, P1134, DOI 10.1016/j.athoracsur.2010.05.076; Krenk L, 2010, ACTA ANAESTH SCAND, V54, P951, DOI 10.1111/j.1399-6576.2010.02268.x; Legare JF, 2004, CIRCULATION, V109, P887, DOI 10.1161/01.CIR.0000115943.41814.7D; Li YB, 2009, ARCH NEUROL-CHICAGO, V66, P1091, DOI 10.1001/archneurol.2009.114; Maekawa K, 2008, ANN THORAC SURG, V86, P1563, DOI 10.1016/j.athoracsur.2008.07.021; Maganti M, 2009, CAN J CARDIOL, V25, pE32, DOI 10.1016/S0828-282X(09)70481-7; Mangano DT, 2002, NEW ENGL J MED, V347, P1309, DOI 10.1056/NEJMoa020798; McKhann GM, 2006, STROKE, V37, P562, DOI 10.1161/01.STR.0000199032.78782.6c; Millar K, 2001, BRIT J ANAESTH, V86, P63, DOI 10.1093/bja/86.1.63; Moller CH, 2010, CIRCULATION, V121, P498, DOI 10.1161/CIRCULATIONAHA.109.880443; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Moritz S, 2010, EUR J ANAESTH, V27, P542, DOI 10.1097/EJA.0b013e3283343ef8; Mullges W, 2000, CRIT CARE MED, V28, P1808, DOI 10.1097/00003246-200006000-00020; Muneretto C, 2003, ANN THORAC SURG, V76, P778, DOI 10.1016/S0003-4975(03)00564-2; Mutch WAC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017457; Nakamura M, 2008, ANN THORAC SURG, V85, P513, DOI 10.1016/j.athoracsur.2007.08.056; Nakamura Yoshitsugu, 2004, Ann Thorac Cardiovasc Surg, V10, P81; Nathoe HM, 2003, NEW ENGL J MED, V348, P394, DOI 10.1056/NEJMoa021775; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Nishiyama K, 2009, ANN THORAC SURG, V87, P1839, DOI 10.1016/j.athoracsur.2009.02.061; Price CC, 2008, ANESTHESIOLOGY, V108, P8, DOI 10.1097/01.anes.0000296072.02527.18; Puskas JD, 2004, JAMA-J AM MED ASSOC, V291, P1841, DOI 10.1001/jama.291.15.1841; Raja SG, 2007, J CARDIAC SURG, V22, P445, DOI 10.1111/j.1540-8191.2007.00447.x; Rodriguez RA, 2010, STROKE, V41, P2229, DOI 10.1161/STROKEAHA.110.590513; Selnes OA, 2009, ANN THORAC SURG, V88, P445, DOI 10.1016/j.athoracsur.2009.04.061; Shahian DM, 2009, ANN THORAC SURG, V88, pS2, DOI 10.1016/j.athoracsur.2009.05.053; Shroyer AL, 2009, NEW ENGL J MED, V361, P1827, DOI 10.1056/NEJMoa0902905; Slater JP, 2009, ANN THORAC SURG, V87, P36, DOI 10.1016/j.athoracsur.2008.08.070; Stroobant N, 2008, EUR J CARDIO-THORAC, V34, P396, DOI 10.1016/j.ejcts.2008.05.001; Sweet JJ, 2008, ANN THORAC SURG, V85, P1571, DOI 10.1016/j.athoracsur.2008.01.090; Tarakji KG, 2011, JAMA-J AM MED ASSOC, V305, P381, DOI 10.1001/jama.2011.37; Westaby S, 2001, ANN THORAC SURG, V71, P667, DOI 10.1016/S0003-4975(00)02405-X	59	203	228	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					250	257		10.1056/NEJMra1100109	http://dx.doi.org/10.1056/NEJMra1100109			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877RZ	22256807				2022-12-28	WOS:000299201400011
J	Kamerow, D				Kamerow, Douglas			YANKEE DOODLING Does nicotine replacement really help smokers quit?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												dkamerow@rti.org		Kamerow, Douglas/0000-0001-7000-9957				Adhikari B., 2008, Morbidity and Mortality Weekly Report, V57, P1226; Alpert HR, TOB CONTROL, DOI [10.1136/tobaccocontrol-2011-050129, DOI 10.1136/TOBACCOCONTR0L-2011-050129]; Carey B., 2012, NEW YORK TIMES  0120, pA1; Maarcher Ann, 2011, Morbidity and Mortality Weekly Report, V60, P1513; Moore David, 2009, BMJ, V338, pb1024, DOI 10.1136/bmj.b1024; Shiffman S, 2008, AM J PREV MED, V34, P102, DOI 10.1016/j.amepre.2007.09.033; US Department of Health and Human Services, 2010, TOB SMOK CAUS DIS BI	7	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	2012	344								e450	10.1136/bmj.e450	http://dx.doi.org/10.1136/bmj.e450			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YZ	22257979				2022-12-28	WOS:000300041900008
J	Doshi, P; Jones, M; Jefferson, T				Doshi, Peter; Jones, Mark; Jefferson, Tom			Rethinking credible evidence synthesis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RESPIRATORY-TRACT COMPLICATIONS; INFLUENZA; OSELTAMIVIR		[Doshi, Peter] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; [Jones, Mark] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia; [Jefferson, Tom] Cochrane Collaborat, Rome, Italy	Johns Hopkins University; University of Queensland	Doshi, P (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.	pnd@jhu.edu	Jones, Mark/I-2720-2016	Jones, Mark/0000-0001-6858-9710	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS019488] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], CHANNEL 4 NEWS 0927; [Anonymous], DATA ANAL AGREEMENT; [Anonymous], OUTP EUR MED AG POL; [Anonymous], OS EFF RED RISK SOM; [Anonymous], PROD LAB TAM OS PHOS; [Anonymous], US ANT DRUGS INFL PA; [Anonymous], PAND INFL P IN PRESS; [Anonymous], 21087 NDA US FOOD DR; [Anonymous], COCHRANE DATABASE SY; [Anonymous], 2005, HHS PAND INFL PLAN; Del Mar C, 2011, CLIN INFECT DIS, V53, P1302, DOI 10.1093/cid/cir706; Dutkowski R, 2010, INT J ANTIMICROB AG, V35, P461, DOI 10.1016/j.ijantimicag.2009.12.023; Eyding D, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4737; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Gotzsche PC, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2686; Hernan MA, 2011, CLIN INFECT DIS, V53, P277, DOI 10.1093/cid/cir400; Jefferson T, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008965.pub4, 10.1002/14651858.CD008965.pub3]; Jefferson T, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7258; Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5106; Kaiser L, 2003, ARCH INTERN MED, V163, P1667, DOI 10.1001/archinte.163.14.1667; Krumholz HM, 2011, JAMA-J AM MED ASSOC, V306, P1593, DOI 10.1001/jama.2011.1459; Marshall E, 2011, SCIENCE, V333, P145, DOI 10.1126/science.333.6039.145; Pott A, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3838; Smith J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b5374	24	44	45	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	2012	344								d7898	10.1136/bmj.d7898	http://dx.doi.org/10.1136/bmj.d7898			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YY	22252039	Bronze			2022-12-28	WOS:000300041800014
J	Hall, WJ				Hall, William J.			An 11-item index predicted 5-year and 9-year mortality in community-dwelling elderly adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Hall, William J.] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Hall, WJ (corresponding author), Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA.							Hall WJ, 2008, ARCH INTERN MED, V168, P262, DOI 10.1001/archinte.168.3.262; Reis JP, 2011, ANN INTERN MED, V155, P292, DOI 10.7326/0003-4819-155-5-201109060-00006	2	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-13	10.7326/0003-4819-156-2-201201170-02013	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V41QD	22250175				2022-12-28	WOS:000209559800004
J	McKnight, RF; Adida, M; Budge, K; Stockton, S; Goodwin, GM; Geddes, JR				McKnight, Rebecca F.; Adida, Marc; Budge, Katie; Stockton, Sarah; Goodwin, Guy M.; Geddes, John R.			Lithium toxicity profile: a systematic review and meta-analysis	LANCET			English	Article							BIPOLAR-I DISORDER; CONTROLLED 18-MONTH TRIAL; CHRONIC KIDNEY-DISEASE; MAINTENANCE TREATMENT; RENAL-FUNCTION; POPULATION; LAMOTRIGINE; DIVALPROEX; PREVALENCE; EXPRESSION	Background Lithium is a widely used and effective treatment for mood disorders. There has been concern about its safety but no adequate synthesis of the evidence for adverse effects. We aimed to undertake a clinically informative, systematic toxicity profile of lithium. Methods We undertook a systematic review and meta-analysis of randomised controlled trials and observational studies. We searched electronic databases, specialist journals, reference lists, textbooks, and conference abstracts. We used a hierarchy of evidence which considered randomised controlled trials, cohort studies, case-control studies, and case reports that included patients with mood disorders given lithium. Outcome measures were renal, thyroid, and parathyroid function; weight change; skin disorders; hair disorders; and teratogenicity. Findings We screened 5988 abstracts for eligibility and included 385 studies in the analysis. On average, glomerular filtration rate was reduced by -6.22 mL/min (95% CI -14.65 to 2.20, p=0.148) and urinary concentrating ability by 15% of normal maximum (weighted mean difference -158.43 mOsm/kg, 95% CI -229.78 to -87.07, p<0.0001). Lithium might increase risk of renal failure, but the absolute risk was small (18 of 3369 [0.5%] patients received renal replacement therapy). The prevalence of clinical hypothyroidism was increased in patients taking lithium compared with those given placebo (odds ratio [OR] 5.78, 95% CI 2.00-16.67; p=0.001), and thyroid stimulating hormone was increased on average by 4.00 iU/mL (95% CI 3.90-4.10, p<0.0001). Lithium treatment was associated with increased blood calcium (+0.09 mmol/L, 95% CI 0.02-0.17, p=0.009), and parathyroid hormone (+7.32 pg/mL, 3.42-11.23, p<0.0001). Patients receiving lithium gained more weight than did those receiving placebo (OR 1.89, 1.27-2.82, p=0.002), but not those receiving olanzapine (0.32, 0.21-0.49, p<0.0001). We recorded no significant increased risk of congenital malformations, alopecia, or skin disorders. Interpretation Lithium is associated with increased risk of reduced urinary concentrating ability, hypothyroidism, hyperparathyroidism, and weight gain. There is little evidence for a clinically significant reduction in renal function in most patients, and the risk of end-stage renal failure is low. The risk of congenital malformations is uncertain; the balance of risks should be considered before lithium is withdrawn during pregnancy. Because of the consistent finding of a high prevalence of hyperparathyroidism, calcium concentrations should be checked before and during treatment.	[McKnight, Rebecca F.; Budge, Katie; Stockton, Sarah; Goodwin, Guy M.; Geddes, John R.] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; [Adida, Marc] Hop St Marguerite, Univ Dept Psychiat, Marseille, France	University of Oxford; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Geddes, JR (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	john.geddes@psych.ox.ac.uk	Geddes, John/B-8240-2011; Goodwin, Guy/ABE-6084-2020	Geddes, John/0000-0002-5281-5960; 	National Institute for Health Research [RP-PG-0108-10087]; National Institute for Health Research [NF-SI-0611-10150] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This Article presents independent research commissioned by the National Institute for Health Research (NIHR) under Research Programme Grant for Applied Research: RP-PG-0108-10087. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. The review was designed, conducted, analysed, and interpreted by the authors entirely independently of the funding sources.	AURELL M, 1981, KIDNEY INT, V20, P663, DOI 10.1038/ki.1981.191; BENDZ H, 1985, ACTA PSYCHIAT SCAND, V72, P451, DOI 10.1111/j.1600-0447.1985.tb02639.x; Bendz H, 2010, KIDNEY INT, V77, P219, DOI 10.1038/ki.2009.433; BERENS SC, 1970, J CLIN INVEST, V49, P1357, DOI 10.1172/JCI106352; Blount MA, 2010, AM J PHYSIOL-RENAL, V298, pF601, DOI 10.1152/ajprenal.00424.2009; Bowden CL, 2000, ARCH GEN PSYCHIAT, V57, P481, DOI 10.1001/archpsyc.57.5.481; Bowden CL, 2003, ARCH GEN PSYCHIAT, V60, P392, DOI 10.1001/archpsyc.60.4.392; BURROW GN, 1971, J CLIN ENDOCR METAB, V32, P647, DOI 10.1210/jcem-32-5-647; Calabrese JR, 2003, J CLIN PSYCHIAT, V64, P1013, DOI 10.4088/JCP.v64n0906; Calabrese JR, 2005, AM J PSYCHIAT, V162, P2152, DOI 10.1176/appi.ajp.162.11.2152; Cipriani A, 2005, AM J PSYCHIAT, V162, P1805, DOI 10.1176/appi.ajp.162.10.1805; COHEN LS, 1994, JAMA-J AM MED ASSOC, V271, P146, DOI 10.1001/jama.271.2.146; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; CZEIZEL A, 1990, TERATOLOGY, V42, P505, DOI 10.1002/tera.1420420507; Geddes JR, 2010, LANCET, V375, P385, DOI 10.1016/S0140-6736(09)61828-6; Geddes JR, 2004, AM J PSYCHIAT, V161, P217, DOI 10.1176/appi.ajp.161.2.217; HAGGERTY JJ, 1995, ANNU REV MED, V46, P37, DOI 10.1146/annurev.med.46.1.37; HESTBECH J, 1977, KIDNEY INT, V12, P205, DOI 10.1038/ki.1977.102; MARPLES D, 1995, J CLIN INVEST, V95, P1838, DOI 10.1172/JCI117863; National Science Foundation, 2006, BIP DIS MAN BIP DIS, P1, DOI [10.1016/0165-022X(93)90047-R, DOI 10.1016/0165-022X(93)90047-R]; NORA JJ, 1974, LANCET, V2, P594; OKUSA MD, 1994, AM J MED, V97, P383, DOI 10.1016/0002-9343(94)90308-5; PALMER M, 1987, LANCET, V1, P59; Paul R, 2010, J PSYCHOPHARMACOL, V24, P1425, DOI 10.1177/0269881109104930; Razvi S, 2010, J CLIN PATHOL, V63, P379, DOI 10.1136/jcp.2008.057414; SCHOU M, 1958, ACTA PHARMACOL TOX, V15, P70; SOUZA FGM, 1991, J AFFECT DISORDERS, V22, P165, DOI 10.1016/0165-0327(91)90050-3; Szalat A, 2009, EUR J ENDOCRINOL, V160, P317, DOI 10.1530/EJE-08-0620; Zhang QL, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-117	29	493	508	3	99	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 25	2012	379	9817					721	728		10.1016/S0140-6736(11)61516-X	http://dx.doi.org/10.1016/S0140-6736(11)61516-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899CU	22265699				2022-12-28	WOS:000300792600028
J	Donohue, JM; Morden, NE; Gellad, WF; Bynum, JP; Zhou, WP; Hanlon, JT; Skinner, J				Donohue, Julie M.; Morden, Nancy E.; Gellad, Walid F.; Bynum, Julie P.; Zhou, Weiping; Hanlon, Joseph T.; Skinner, Jonathan			Sources of Regional Variation in Medicare Part D Drug Spending	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; GEOGRAPHIC-VARIATION; POTENTIAL SAVINGS; GENERIC DRUGS; INHIBITORS; QUALITY; COST; RISK	Background Sources of regional variation in spending for prescription drugs under Medicare Part D are poorly understood, and such variation may reflect differences in health status, use of effective treatments, or selection of branded drugs over lower-cost generics. Methods We analyzed 2008 Medicare data for 4.7 million beneficiaries for prescription-drug use and expenditures overall and in three drug categories: angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), and selective serotonin-reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Differences in per capita expenditures across hospital-referral regions (HRRs) were decomposed into annual prescription volume and cost per prescription. The ratio of prescriptions filled as branded drugs to all prescriptions filled was calculated. We adjusted all measures for demographic, socioeconomic, and health-status differences. Results Mean adjusted per capita pharmaceutical spending ranged from $2,413 in the lowest to $3,008 in the highest quintile of HRRs. Most (75.9%) of that difference was attributable to the cost per prescription ($53 vs. $63). Regional differences in cost per prescription explained 87.5% of expenditure variation for ACE inhibitors and ARBs and 56.3% for statins but only 36.1% for SSRIs and SNRIs. The ratio of branded-drug to total prescriptions, which correlated highly with cost per prescription, ranged across HRRs from 0.24 to 0.45 overall and from 0.24 to 0.55 for ACE inhibitors and ARBs, 0.29 to 0.60 for statins, and 0.15 to 0.51 for SSRIs and SNRIs. Conclusions Regional variation in Medicare Part D spending results largely from differences in the cost of drugs selected rather than prescription volume. A reduction in branded-drug use in some regions through modification of Part D plan benefits might lower costs without reducing quality of care. (Funded by the National Institute on Aging and others.)	[Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA; [Gellad, Walid F.] Univ Pittsburgh, Dept Med Gen Internal Med, Pittsburgh, PA 15261 USA; [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med Geriatr Pharm & Therapeut & Biomed Infor, Pittsburgh, PA 15261 USA; [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA; [Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA; [Gellad, Walid F.] RAND, Pittsburgh, PA USA; [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA; [Morden, Nancy E.; Bynum, Julie P.; Zhou, Weiping; Skinner, Jonathan] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA; [Morden, Nancy E.; Skinner, Jonathan] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; [Skinner, Jonathan] Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; RAND Corporation; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Dartmouth College; Dartmouth College; Dartmouth College	Donohue, JM (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A613, Pittsburgh, PA 15261 USA.	jdonohue@pitt.edu		Donohue, Julie/0000-0003-2418-6017	National Institute on Aging [P01AG019783, AG-07-001, P30AG024827, T32 AG021885, K07AG033174, K23AG028947, R01AG034056, U01 AG012553, R56AG027017]; Agency for Healthcare Research and Quality [R01HS017695, R01HS018721, K12 HS019461]; National Institute of Nursing Research [R01 NR010135]; National Institute of Mental Health [R34 MH082682]; Robert Wood Johnson Foundation [059491]; Veterans Affairs Health Services Research and Development Service [IIR-06-062, CDA 09-207]; National Institute on Aging and others; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS017695, R01HS018721, K12HS019461] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000146, UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R34MH082682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG012553, R37AG007001, R01AG034056, R56AG027017, P01AG019783, P30AG024827, K23AG028947, T32AG021885, K23AG035030, K07AG033174] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Veterans Affairs Health Services Research and Development Service(US Department of Veterans Affairs); National Institute on Aging and others; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants from the National Institute on Aging (P01AG019783, AG-07-001, P30AG024827, T32 AG021885, K07AG033174, K23AG028947, R01AG034056, U01 AG012553, and R56AG027017), the Agency for Healthcare Research and Quality (R01HS017695, R01HS018721, and K12 HS019461), the National Institute of Nursing Research (R01 NR010135), the National Institute of Mental Health (R34 MH082682), the Robert Wood Johnson Foundation (059491), and the Veterans Affairs Health Services Research and Development Service (IIR-06-062 and CDA 09-207).; Funded by the National Institute on Aging and others.	Agency for Healthcare Research and Quality, CREAT NEW RAC ETHN C; [Anonymous], 2009, GENERIC DRUGS REVISI; [Anonymous], 2008, FACT SHEET MED PRESC; [Anonymous], LEX DAT BAS DAT LEX; [Anonymous], CENS 2000 SUMM FIL A; [Anonymous], 2007, GEN DRUG UT MED D; Anthony DL, 2009, HEALTH AFFAIR, V28, P864, DOI 10.1377/hlthaff.28.3.864; Anthony JDL, 2009, HLTH AFF MILLWOOD, V28, P1233; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Centers for Medicare and Medicaid Services, RXHCC MOD SOFTW; Dartmouth Medical School Center for the Evaluative Clinical Sciences, 1998, DARTM ATL HLTH CAR; Donohue JM, 2008, HEALTH SERV RES, V43, P1557, DOI 10.1111/j.1475-6773.2008.00858.x; Fischer MA, 2004, PHARMACOEPIDEM DR S, V13, P207, DOI 10.1002/pds.872; Fischer MA, 2004, JAMA-J AM MED ASSOC, V291, P1850, DOI 10.1001/jama.291.15.1850; Fischer MA, 2003, HEALTH SERV RES, V38, P1051, DOI 10.1111/1475-6773.00162; Fisher ES, 2009, NEW ENGL J MED, V360, P849, DOI 10.1056/NEJMp0809794; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Gellad WF, 2010, AM J MANAG CARE, V16, P741; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; Kaiser Family Foundation, 2007, MED PRESCR DRUG BEN; Kaiser Family Foundation, 2010, MED PRESCR DRUG PLAN; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Kunz R, 2008, ANN INTERN MED, V148, P30, DOI 10.7326/0003-4819-148-1-200801010-00190; MaCurdy T., 2009, GEOGRAPHIC VARIATION; Matchar DB, 2008, ANN INTERN MED, V148, P16, DOI 10.7326/0003-4819-148-1-200801010-00189; Matchar DB., COMPARATIVE EFFECTIV; Oaxaca R., 1973, INT ECON REV, V14, P693, DOI DOI 10.2307/2525981; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Robst J, 2007, HEALTH CARE FINANC R, V28, P15; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2007, J GEN INTERN MED, V22, P1298, DOI 10.1007/s11606-007-0284-3; Song YJ, 2010, NEW ENGL J MED, V363, P45, DOI 10.1056/NEJMsa0910881; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Sutherland JM, 2009, NEW ENGL J MED, V361, P1227, DOI 10.1056/NEJMp0907172; Welch HG, 2011, JAMA-J AM MED ASSOC, V305, P1113, DOI 10.1001/jama.2011.307; Yasaitis L, 2009, HEALTH AFFAIR, V28, pW566, DOI 10.1377/hlthaff.28.4.w566; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317; Zhang YT, 2010, NEW ENGL J MED, V363, P405, DOI 10.1056/NEJMp1004872	39	58	58	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					530	538		10.1056/NEJMsa1104816	http://dx.doi.org/10.1056/NEJMsa1104816			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888GH	22316446	Green Accepted, Bronze			2022-12-28	WOS:000299991300009
J	Rich, RM; Collins, MLM; Black, CM; Longstaff, FA; Koch, A; Benson, A; Reitzel, DB				Rich, R. M.; Collins, M. L. M.; Black, C. M.; Longstaff, F. A.; Koch, A.; Benson, A.; Reitzel, D. B.			A tidally distorted dwarf galaxy near NGC 4449	NATURE			English	Article							TAILS; EVOLUTION; CLUSTER	NGC 4449 is a nearby Magellanic irregular starburst galaxy(1) with a B-band absolute magnitude of -18 and a prominent, massive, intermediate-age nucleus(2) at a distance from Earth of 3.8 megaparsecs (ref. 3). It is wreathed in an extraordinary neutral hydrogen (H I) complex, which includes rings, shells and a counter-rotating core, spanning similar to 90 kiloparsecs (kpc; refs 1, 4). NGC 4449 is relatively isolated(5), although an interaction with its nearest known companion-the galaxy DDO 125, some 40 kpc to the south-has been proposed as being responsible for the complexity of its HI structure(6). Here we report the presence of a dwarf galaxy companion to NGC 4449, namely NGC 4449B. This companion has a V-band absolute magnitude of -13.4 and a half-light radius of 2.7 kpc, with a full extent of around 8 kpc. It is in a transient stage of tidal disruption, similar to that of the Sagittarius dwarf(7) near the Milky Way. NGC 4449B exhibits a striking S-shaped morphology that has been predicted for disrupting galaxies(7,8) but has hitherto been seen only in a dissolving globular cluster(9). We also detect an additional arc or disk ripple embedded in a two-component stellar halo, including a component extending twice as far as previously known, to about 20 kpc from the galaxy's centre.	[Rich, R. M.; Black, C. M.; Reitzel, D. B.] Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; [Rich, R. M.; Longstaff, F. A.] Polaris Observ Assoc, Frazier Pk, CA 93225 USA; [Collins, M. L. M.] Max Planck Inst Astron, D-69117 Heidelberg, Germany; [Longstaff, F. A.] Univ Calif Los Angeles, Anderson Sch Management, Los Angeles, CA 90095 USA; [Koch, A.] Heidelberg Univ, Zentrum Astronomieder, D-69117 Heidelberg, Germany; [Benson, A.] CALTECH, Dept Astron, Pasadena, CA 91125 USA; [Reitzel, D. B.] Griffith Observ, Los Angeles, CA 90027 USA	University of California System; University of California Los Angeles; Max Planck Society; University of California System; University of California Los Angeles; Ruprecht Karls University Heidelberg; California Institute of Technology	Rich, RM (corresponding author), Univ Calif Los Angeles, Dept Phys & Astron, 430 Portola Plaza,Box 951547, Los Angeles, CA 90095 USA.	rmr@astro.ucla.edu		Black, Christine/0000-0002-4471-9960; Koch, Andreas/0000-0002-9859-4956; Benson, Andrew/0000-0001-5501-6008	National Science Foundation	National Science Foundation(National Science Foundation (NSF))	R.M.R. acknowledges support from the National Science Foundation. The Saturn Lodge 0.7-m telescope was funded and implemented by R. M. R. and F. A. L. The authors acknowledge members of the Polaris Observatory Association, who maintain the observatory infrastructure and who assisted in the construction and implementation of the telescope and enclosure, and J. Riffle, who designed and built the Centurion 28-inch telescope. This research has made use of the NASA/IPAC Extragalactic Database (NED) and of the Sloan Digital Sky Survey.	Annibali F, 2008, ASTRON J, V135, P1900, DOI 10.1088/0004-6256/135/5/1900; Boker T, 2001, ASTRON J, V121, P1473, DOI 10.1086/319415; Brosch N, 2008, ASTROPHYS SPACE SCI, V314, P163, DOI 10.1007/s10509-008-9752-4; Dale DA, 2009, ASTROPHYS J, V703, P517, DOI 10.1088/0004-637X/703/1/517; DEVAUCOULEURS G, 1975, GALAXIES UNIVERSE, P557; Dolcetta RC, 2005, ASTRON J, V129, P1906, DOI 10.1086/426006; Hunter DA, 1998, ASTROPHYS J, V495, pL47, DOI 10.1086/311213; Hunter DA, 1999, ASTRON J, V118, P2184, DOI 10.1086/301096; Majewski SR, 2007, ASTROPHYS J, V670, pL9, DOI 10.1086/524033; Neff SG, 2005, ASTROPHYS J, V619, pL91, DOI 10.1086/426137; Odenkirchen M, 2003, ASTRON J, V126, P2385, DOI 10.1086/378601; Penarrubia J, 2009, ASTROPHYS J, V698, P222, DOI 10.1088/0004-637X/698/1/222; Purcell CW, 2011, NATURE, V477, P301, DOI 10.1038/nature10417; SCHOMBERT JM, 1987, ASTRON J, V94, P300, DOI 10.1086/114471; Theis C, 2001, ASTRON ASTROPHYS, V370, P365, DOI 10.1051/0004-6361:20010198; WALLIN JF, 1988, ASTRON J, V96, P1850, DOI 10.1086/114931; Wang JL, 2006, ASTROPHYS J, V649, P722, DOI 10.1086/506902	18	62	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					192	U78		10.1038/nature10837	http://dx.doi.org/10.1038/nature10837			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22318602	Green Submitted			2022-12-28	WOS:000299994100032
J	Chatterjee, P				Chatterjee, Patralekha			MEDICINE IN INDIA How free healthcare became mired in corruption and murder in a key Indian state	BRITISH MEDICAL JOURNAL			English	Editorial Material												patralekha.chatterjee@gmail.com							0	6	6	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 6	2012	344								e453	10.1136/bmj.e453	http://dx.doi.org/10.1136/bmj.e453			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IA	22310993				2022-12-28	WOS:000300278700001
J	Kirby, T				Kirby, Tony			Joseph Lau: mastering the meta-analysis Profile	LANCET			English	Biographical-Item																		LAU J, PUBLICATION LIST	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 4	2012	379	9814					403	403		10.1016/S0140-6736(12)60177-9	http://dx.doi.org/10.1016/S0140-6736(12)60177-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891AF	22305215				2022-12-28	WOS:000300187800019
J	Ghosh, R; Andersen, EC; Shapiro, JA; Gerke, JP; Kruglyak, L				Ghosh, Rajarshi; Andersen, Erik C.; Shapiro, Joshua A.; Gerke, Justin P.; Kruglyak, Leonid			Natural Variation in a Chloride Channel Subunit Confers Avermectin Resistance in C. elegans	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; COOPERIA-ONCOPHORA; ARABIDOPSIS-THALIANA; HAEMONCHUS-CONTORTUS; IVERMECTIN; POLYMORPHISM; SENSITIVITY; ACTIVATION; NEMATODES; GENETICS	Resistance of nematodes to anthelmintics such as avermectins has emerged as a major global health and agricultural problem, but genes conferring natural resistance to avermectins are unknown. We show that a naturally occurring four-amino-acid deletion in the ligand-binding domain of GLC-1, the alpha-subunit of a glutamate-gated chloride channel, confers resistance to avermectins in the model nematode Caenorhabditis elegans. We also find that the same variant confers resistance to the avermectin-producing bacterium Streptomyces avermitilis. Population-genetic analyses identified two highly divergent haplotypes at the glc-1 locus that have been maintained at intermediate frequencies by long-term balancing selection. These results implicate variation in glutamate-gated chloride channels in avermectin resistance and provide a mechanism by which such resistance can be maintained.	[Kruglyak, Leonid] Princeton Univ, Dept Ecol & Evolut Biol, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA	Princeton University; Howard Hughes Medical Institute; Princeton University	Kruglyak, L (corresponding author), Princeton Univ, Dept Ecol & Evolut Biol, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.	leonid@genomics.princeton.edu	Shapiro, Joshua/B-5948-2008	Shapiro, Joshua/0000-0002-6224-0347; Andersen, Erik/0000-0003-0229-9651	Life Science Research Foundation; NIH Ruth L. Kirschstein National Research Service; James S. McDonnell Foundation; Howard Hughes Medical Institute; NIH [R01-HG004321, R37- MH59520, P50-GM071508]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059520, R37MH059520] Funding Source: NIH RePORTER	Life Science Research Foundation; NIH Ruth L. Kirschstein National Research Service(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James S. McDonnell Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank F. Albert, I. Ehrenreich, M. Rockman, and H. Seidel for critical reading of the manuscript and members of the Kruglyak laboratory for suggestions, K. Chattopadhyay for advice regarding protein structure analysis, and P. McGrath for sharing unpublished sequence information of the MY14 strain. Supported by a Merck fellowship of the Life Science Research Foundation (J.P.G.), NIH Ruth L. Kirschstein National Research Service Award (E. C. A.), James S. McDonnell Foundation Centennial Fellowship, Howard Hughes Medical Institute, NIH grants R01-HG004321 and R37- MH59520 (L. K.), and NIH grant P50-GM071508 to the Center for Quantitative Biology at the Lewis-Sigler Institute of Princeton University. Some of the C. elegans strains used were obtained from the Caenorhabditis Genetics Center. GenBank sequence accession numbers for the sequences are JN983734 to JN983793.	ARENA JP, 1995, J PARASITOL, V81, P286, DOI 10.2307/3283936; BURG RW, 1979, ANTIMICROB AGENTS CH, V15, P361, DOI 10.1128/AAC.15.3.361; Cook A, 2006, MOL BIOCHEM PARASIT, V147, P118, DOI 10.1016/j.molbiopara.2006.02.003; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Dent JA, 2000, P NATL ACAD SCI USA, V97, P2674, DOI 10.1073/pnas.97.6.2674; Dent JA, 1997, EMBO J, V16, P5867, DOI 10.1093/emboj/16.19.5867; El-Abdellati A, 2011, INT J PARASITOL, V41, P951, DOI 10.1016/j.ijpara.2011.04.003; Etter A, 1996, J BIOL CHEM, V271, P16035, DOI 10.1074/jbc.271.27.16035; Gilleard JS, 2007, PARASITOLOGY, V134, P1133, DOI 10.1017/S0031182007000066; Hibbs RE, 2011, NATURE, V474, P54, DOI 10.1038/nature10139; Kaplan RM, 2007, INT J PARASITOL, V37, P795, DOI 10.1016/j.ijpara.2007.01.001; KRUGLYAK L, 1995, GENETICS, V139, P1421; Kwon DH, 2010, INSECT MOL BIOL, V19, P583, DOI 10.1111/j.1365-2583.2010.01017.x; McCavera S, 2007, PARASITOLOGY, V134, P1111, DOI 10.1017/S0031182007000042; McCavera S, 2009, MOL PHARMACOL, V75, P1347, DOI 10.1124/mol.108.053363; Njue AI, 2004, PARASITOL RES, V93, P419, DOI 10.1007/s00436-004-1149-x; Njue AI, 2004, J NEUROCHEM, V89, P1137, DOI 10.1111/j.1471-4159.2004.02379.x; Rockman MV, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000419; Seidel HS, 2008, SCIENCE, V319, P589, DOI 10.1126/science.1151107; Stahl EA, 1999, NATURE, V400, P667, DOI 10.1038/23260; TAJIMA F, 1989, GENETICS, V123, P585; Tian D, 2003, NATURE, V423, P74, DOI 10.1038/nature01588; Todesco M, 2010, NATURE, V465, P632, DOI 10.1038/nature09083; Vassilatis DK, 1997, J BIOL CHEM, V272, P33167, DOI 10.1074/jbc.272.52.33167; Wicks SR, 2001, NAT GENET, V28, P160, DOI 10.1038/88878; Wolstenholme AJ, 2005, PARASITOLOGY, V131, pS85, DOI 10.1017/S0031182005008218; Wolstenholme AJ, 2004, TRENDS PARASITOL, V20, P469, DOI 10.1016/j.pt.2004.07.010	27	106	108	3	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2012	335	6068					574	578		10.1126/science.1214318	http://dx.doi.org/10.1126/science.1214318			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301316	Green Accepted			2022-12-28	WOS:000299769200041
J	Sethi, AJ; Wikramanayake, RM; Angerer, RC; Range, RC; Angerer, LM				Sethi, Aditya J.; Wikramanayake, Radhika M.; Angerer, Robert C.; Range, Ryan C.; Angerer, Lynne M.			Sequential Signaling Crosstalk Regulates Endomesoderm Segregation in Sea Urchin Embryos	SCIENCE			English	Article							NUCLEAR BETA-CATENIN; GENE NETWORK; VEGETAL PLATE; SPECIFICATION; ENDODERM; NOTCH; INDUCTION; CELLS; MESENDODERM; ACTIVATION	The segregation of embryonic endomesoderm into separate endoderm and mesoderm fates is not well understood in deuterostomes. Using sea urchin embryos, we showed that Notch signaling initiates segregation of the endomesoderm precursor field by inhibiting expression of a key endoderm transcription factor in presumptive mesoderm. The regulatory circuit activated by this transcription factor subsequently maintains transcription of a canonical Wnt (cWnt) ligand only in endoderm precursors. This cWnt ligand reinforces the endoderm state, amplifying the distinction between emerging endoderm and mesoderm. Before gastrulation, Notch-dependent nuclear export of an essential beta-catenin transcriptional coactivator from mesoderm renders it refractory to cWnt signals, insulating it against an endoderm fate. Thus, we report that endomesoderm segregation is a progressive process, requiring a succession of regulatory interactions between cWnt and Notch signaling.	[Sethi, Aditya J.; Angerer, Robert C.; Range, Ryan C.; Angerer, Lynne M.] NIDCR, NIH, Bethesda, MD 20892 USA; [Wikramanayake, Radhika M.] Univ Oxford, Dept Publ Hlth, Oxford, England	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Oxford	Angerer, LM (corresponding author), NIDCR, NIH, Bethesda, MD 20892 USA.	langerer@mail.nih.gov			National Institute of Dental and Craniofacial Research, NIH; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000712] Funding Source: NIH RePORTER	National Institute of Dental and Craniofacial Research, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank D. Adams and R. Benabentos for their comments. Funding was provided by the Intramural Program at the National Institute of Dental and Craniofacial Research, NIH.	Croce J, 2011, DEVELOPMENT, V138, P3297, DOI 10.1242/dev.058792; Croce JC, 2010, DEVELOPMENT, V137, P83, DOI 10.1242/dev.044149; Davidson EH, 2002, DEV BIOL, V246, P162, DOI 10.1006/dbio.2002.0635; De-Leon SBT, 2010, P NATL ACAD SCI USA, V107, P10103, DOI 10.1073/pnas.1004824107; Hinman VF, 2007, P NATL ACAD SCI USA, V104, P19404, DOI 10.1073/pnas.0709994104; Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363; Kikuchi Y, 2004, DEV DYNAM, V229, P756, DOI 10.1002/dvdy.10483; Kimelman D, 2000, CURR OPIN GENET DEV, V10, P350, DOI 10.1016/S0959-437X(00)00095-2; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; Logan CY, 1999, DEVELOPMENT, V126, P345; Martin BL, 2008, DEV CELL, V15, P121, DOI 10.1016/j.devcel.2008.04.013; McClay DR, 2000, DEVELOPMENT, V127, P5113; Oliveri P, 2002, DEV BIOL, V246, P209, DOI 10.1006/dbio.2002.0627; Peter IS, 2011, NATURE, V474, P635, DOI 10.1038/nature10100; Peter IS, 2010, DEV BIOL, V340, P188, DOI 10.1016/j.ydbio.2009.10.037; Petersen CP, 2009, CELL, V139, P1056, DOI 10.1016/j.cell.2009.11.035; Revinski DR, 2010, DEV BIOL, V339, P477, DOI 10.1016/j.ydbio.2010.01.010; Rodaway A, 2001, CELL, V105, P169, DOI 10.1016/S0092-8674(01)00307-5; Rottinger E, 2006, DEVELOPMENT, V133, P4341, DOI 10.1242/dev.02603; Ruffins SW, 1996, DEVELOPMENT, V122, P253; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Sherwood DR, 1997, DEVELOPMENT, V124, P3363; Sherwood DR, 1999, DEVELOPMENT, V126, P1703; Sherwood DR, 2001, DEVELOPMENT, V128, P2221; Smith J, 2008, DEV BIOL, V313, P863, DOI 10.1016/j.ydbio.2007.10.042; Smith J, 2007, SCIENCE, V318, P794, DOI 10.1126/science.1146524; Sweet HC, 2002, DEVELOPMENT, V129, P1945; Sweet HC, 1999, DEVELOPMENT, V126, P5255; Wikramanayake AH, 1998, P NATL ACAD SCI USA, V95, P9343, DOI 10.1073/pnas.95.16.9343; Wikramanayake AH, 2004, GENESIS, V39, P194, DOI 10.1002/gene.20045	31	48	48	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2012	335	6068					590	593		10.1126/science.1212867	http://dx.doi.org/10.1126/science.1212867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301319	Green Accepted			2022-12-28	WOS:000299769200045
J	Villeval, MC				Villeval, Marie Claire			Ready, Steady, Compete	SCIENCE			English	Editorial Material							GENDER-DIFFERENCES; WOMEN		[Villeval, Marie Claire] Univ Lyon, F-69007 Lyon, France; [Villeval, Marie Claire] GATE Lyon St Etienne, CNRS, F-69130 Ecully, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; Universite Lyon 2	Villeval, MC (corresponding author), Univ Lyon, F-69007 Lyon, France.	villeval@gate.cnrs.fr	Villeval, Marie Claire/H-7773-2017	Villeval, Marie Claire/0000-0001-8578-5449				[Anonymous], 2010, GENDER DIFFERENCES C; Balafoutas L, 2012, SCIENCE, V335, P579, DOI 10.1126/science.1211180; Bertrand M, 2001, IND LABOR RELAT REV, V55, P3, DOI 10.2307/2696183; Bertrand M, 2011, HBK ECON, V4, P1543, DOI 10.1016/S0169-7218(11)02415-4; Booth Alison L., 2009, 4027 IZA; Croson R, 2009, J ECON LIT, V47, P448, DOI 10.1257/jel.47.2.448; Eckel CC., 2008, HDB EXPT EC RESULTS, DOI 10.1016/S1574-0722(07)00113-8; Gneezy U, 2004, AM ECON REV, V94, P377, DOI 10.1257/0002828041301821; Gneezy U, 2003, Q J ECON, V118, P1049, DOI 10.1162/00335530360698496; Gneezy U, 2009, ECONOMETRICA, V77, P1637, DOI 10.3982/ECTA6690; Gupta ND, 2013, ECON INQ, V51, P816, DOI 10.1111/j.1465-7295.2011.00378.x; Holzer H, 2000, J ECON LIT, V38, P483, DOI 10.1257/jel.38.3.483; Niederle M., COSTLY IS DIVERSITY; Niederle M, 2007, Q J ECON, V122, P1067, DOI 10.1162/qjec.122.3.1067; Organization for Economic Co-operation and Development, 2002, EMPL OUTL; Palmieri S., 2011, REPORTS DOCUMENTS IN; Wozniak D., MENSTRUAL CYCLE PERF	17	13	13	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2012	335	6068					544	545		10.1126/science.1218000	http://dx.doi.org/10.1126/science.1218000			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	885HI	22301308	Green Submitted			2022-12-28	WOS:000299769200029
J	Zwerger, W				Zwerger, Wilhelm			Seeing the Superfluid Transition of a Gas	SCIENCE			English	Editorial Material							BOSE-EINSTEIN CONDENSATION; INTERACTING FERMI GAS; NOBEL LECTURE		Tech Univ Munich, Dept Phys, D-85748 Garching, Germany	Technical University of Munich	Zwerger, W (corresponding author), Tech Univ Munich, Dept Phys, D-85748 Garching, Germany.	zwerger@ph.tum.de						BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; Bertsch G., 2000, P 10 INT C REC PROGR; Chin C, 2010, REV MOD PHYS, V82, P1225, DOI 10.1103/RevModPhys.82.1225; Cornell EA, 2002, REV MOD PHYS, V74, P875, DOI 10.1142/S0217979202014681; Gaebler JP, 2010, NAT PHYS, V6, P569, DOI 10.1038/NPHYS1709; Horikoshi M, 2010, SCIENCE, V327, P442, DOI 10.1126/science.1183012; Ketterle W, 2002, REV MOD PHYS, V74, P1131, DOI [10.1103/RevModPhys.74.1131, 10.1142/S0217979202014668]; Kinast J, 2005, SCIENCE, V307, P1296, DOI 10.1126/science.1109220; Ku MJH, 2012, SCIENCE, V335, P563, DOI 10.1126/science.1214987; Nascimbene S, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.215303; Nascimbene S, 2010, NATURE, V463, P1057, DOI 10.1038/nature08814; Randeria M., 1995, BOSE EINSTEIN CONDEN, P355; Schwenk A, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.160401; Zwerger W., 2012, LECT NOTES PHYS	14	0	0	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2012	335	6068					549	550		10.1126/science.1218074	http://dx.doi.org/10.1126/science.1218074			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301312				2022-12-28	WOS:000299769200033
J	Khalili, H; Huang, ES; Jacobson, BC; Camargo, CA; Feskanich, D; Chan, AT				Khalili, Hamed; Huang, Edward S.; Jacobson, Brian C.; Camargo, Carlos A., Jr.; Feskanich, Diane; Chan, Andrew T.			Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							INTESTINAL CALCIUM-ABSORPTION; FOOD FREQUENCY QUESTIONNAIRE; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; REPRODUCIBILITY; OMEPRAZOLE; MORTALITY; VALIDITY; SMOKING; METAANALYSIS	Objective To examine the association between chronic use of proton pump inhibitors (PPIs) and risk of hip fracture. Design Prospective cohort study. Setting Nurses' Health Study, which originally recruited from the 11 most populous states in the US. Participants 79 899 postmenopausal women enrolled in the Nurses' Health Study who provided data on the use of PPIs and other risk factors biennially since 2000 and were followed up to 1 June 2008. Main outcome measure Incident hip fracture Results During 565 786 person years of follow-up, we documented 893 incident hip fractures. The absolute risk of hip fracture among regular users of PPIs was 2.02 events per 1000 person years, compared with 1.51 events per 1000 person years among non-users. Compared with non-users, the risk of hip fracture among women who regularly used PPIs for at least two years was 35% higher (age adjusted hazard ratio 1.35 (95% confidence interval 1.13 to 1.62)), with longer use associated with increasing risk (P-trend<0.01). Adjustment for risk factors, including body mass index, physical activity, and intake of calcium did not materially alter this association (hazard ratio 1.36 (1.13 to 1.63)). These associations were also not changed after accounting for reasons for PPI use. The relation between PPI use and fracture differed by smoking history (P-interaction=0.03). Among current and former smokers, PPI use was associated with greater than 50% increase in risk of fracture, with a multivariate hazard ratio for fracture of 1.51 (1.20 to 1.91). In contrast, among women who never smoked there was no association (multivariate hazard ratio 1.06 (0.77 to 1.46)). In a meta-analysis of these results with 10 prior studies, the pooled odds ratio of hip fracture associated with PPI use was 1.30 (1.25 to 1.36). Conclusion Chronic use of PPIs is associated with increased risk of hip fracture, particularly among women with a history of smoking.	[Khalili, Hamed; Huang, Edward S.; Chan, Andrew T.] Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA; [Jacobson, Brian C.] Boston Univ, Med Ctr, Sect Gastroenterol, Boston, MA 02118 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Camargo, Carlos A., Jr.; Feskanich, Diane; Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Camargo, Carlos A., Jr.; Feskanich, Diane; Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Boston University; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Chan, AT (corresponding author), Massachusetts Gen Hosp, Gastroenterol Unit, 55 Fruit St,GRJ 728A, Boston, MA 02114 USA.	achan@partners.org	Camargo, Carlos A./C-2145-2008; Chan, Andrew T/P-8293-2014	Camargo, Carlos A./0000-0002-5071-7654; Chan, Andrew T/0000-0001-7284-6767; Jacobson, Brian/0000-0001-7064-2357	US National Institutes of Health [NIH R01 CA137178, P01 CA87969]; National Institutes of Health (NIH) [R01 DK088782]; IBD Working Group; American Gastroenterological Association; NATIONAL CANCER INSTITUTE [P01CA087969, R01CA137178] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088782] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); IBD Working Group; American Gastroenterological Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was funded by the US National Institutes of Health (grant No NIH R01 CA137178, P01 CA87969). ATC is a Damon Runyon Cancer Research Foundation clinical investigator. BCJ is supported by a grant from the National Institutes of Health (NIH R01 DK088782). HK is supported by a career development award from the IBD Working Group. ESH is supported by a career development award from the American Gastroenterological Association.	Bliuc D, 2009, JAMA-J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50; Brauer CA, 2009, JAMA-J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462; Chan AT, 2004, ANN INTERN MED, V140, P157, DOI 10.7326/0003-4819-140-3-200402030-00006; Chiu HF, 2010, PHARMACOEPIDEM DR S, V19, P1131, DOI 10.1002/pds.2026; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Corley DA, 2010, GASTROENTEROLOGY, V139, P93, DOI 10.1053/j.gastro.2010.03.055; Cornuz J, 1999, AM J MED, V106, P311, DOI 10.1016/S0002-9343(99)00022-4; de Vries F, 2009, OSTEOPOROSIS INT, V20, P1989, DOI 10.1007/s00198-009-0891-4; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FDA, 2010, DRUG SAF COMM POSS I; Feskanich D, 2002, JAMA-J AM MED ASSOC, V288, P2300, DOI 10.1001/jama.288.18.2300; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Feskanich D, 1997, OSTEOPOROSIS INT, V7, P79, DOI 10.1007/BF01623465; Feskanich D, 2003, AM J CLIN NUTR, V77, P504, DOI 10.1093/ajcn/77.2.504; Feskanich D, 2002, JAMA-J AM MED ASSOC, V287, P47, DOI 10.1001/jama.287.1.47; GagnemoPersson R, 1997, CALCIFIED TISSUE INT, V61, P210, DOI 10.1007/s002239900325; Gray SL, 2010, ARCH INTERN MED, V170, P765, DOI 10.1001/archinternmed.2010.94; Hansen KE, 2010, J BONE MINER RES, V25, P2510, DOI 10.1002/jbmr.166; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Jacobson BC, 2006, NEW ENGL J MED, V354, P2340, DOI 10.1056/NEJMoa054391; Kaye JA, 2008, PHARMACOTHERAPY, V28, P951, DOI 10.1592/phco.28.8.951; Krall EA, 1999, J BONE MINER RES, V14, P215, DOI 10.1359/jbmr.1999.14.2.215; Kwok CS, 2011, BONE, V48, P768, DOI 10.1016/j.bone.2010.12.015; Leibson CL, 2002, J AM GERIATR SOC, V50, P1644, DOI 10.1046/j.1532-5415.2002.50455.x; Liu XD, 2003, OSTEOPOROSIS INT, V14, P235, DOI 10.1007/s00198-002-1350-7; MIZUNASHI K, 1993, CALCIFIED TISSUE INT, V53, P21, DOI 10.1007/BF01352010; Ngamruengphong S, 2011, AM J GASTROENTEROL, V106, P1209, DOI 10.1038/ajg.2011.113; O'Connell MB, 2005, AM J MED, V118, P778, DOI 10.1016/j.amjmed.2005.02.007; Pouwels S, 2011, OSTEOPOROSIS INT, V22, P903, DOI 10.1007/s00198-010-1337-8; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1992, AM J EPIDEMIOL, V135, P1127, DOI [DOI 10.1093/OXFORDJOURNALS.AJE.A116211, DOI 10.1093/OXFORDJOUMALS.AJE.A116211]; Roux C, 2009, CALCIFIED TISSUE INT, V84, P13, DOI 10.1007/s00223-008-9188-4; Targownik LE, 2008, CAN MED ASSOC J, V179, P319, DOI 10.1503/cmaj.071330; Targownik LE, 2007, AM J GASTROENTEROL, V102, P942, DOI 10.1111/j.1572-0241.2007.01106.x; Targownik LE, 2010, GASTROENTEROLOGY, V138, P896, DOI 10.1053/j.gastro.2009.11.014; Vestergaard P, 2006, CALCIFIED TISSUE INT, V79, P76, DOI 10.1007/s00223-006-0021-7; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; WOLFE MM, 1988, NEW ENGL J MED, V319, P1707; Wright MJ, 2010, J BONE MINER RES, V25, P2205, DOI 10.1002/jbmr.108; Yang YX, 2008, CURR DRUG SAF, V3, P204, DOI 10.2174/157488608785699414; Yang YX, 2006, JAMA-J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947; Yu EW, 2008, CALCIFIED TISSUE INT, V83, P251, DOI 10.1007/s00223-008-9170-1	43	152	163	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2012	344								e372	10.1136/bmj.e372	http://dx.doi.org/10.1136/bmj.e372			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QI	22294756	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000300087900003
J	Evan, G				Evan, Gerard			Taking a Back Door to Target Myc	SCIENCE			English	Editorial Material							NEOPLASTIC PHENOTYPE; C-MYC; SUPPRESSION; APOPTOSIS; INDUCTION; THERAPY; CANCER		Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Evan, G (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	gie20@cam.ac.uk						Brough R, 2011, CURR OPIN GENET DEV, V21, P34, DOI 10.1016/j.gde.2010.10.009; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Zhang ZF, 2010, ONCOTARGET, V1, P497; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	13	27	30	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2012	335	6066					293	294		10.1126/science.1217819	http://dx.doi.org/10.1126/science.1217819			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267799				2022-12-28	WOS:000299273400032
J	Samaras, N; Rossi, C				Samaras, Nikolaos; Rossi, Cecile			Tophaceous Gout	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Samaras, Nikolaos; Rossi, Cecile] Hop Univ Geneva, Geneva, Switzerland	University of Geneva	Samaras, N (corresponding author), Hop Univ Geneva, Geneva, Switzerland.	nikolassamaras@hotmail.com							0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					E6	E6		10.1056/NEJMicm1110969	http://dx.doi.org/10.1056/NEJMicm1110969			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877RZ	22256825				2022-12-28	WOS:000299201400001
J	Angiolillo, DJ; Firstenberg, MS; Price, MJ; Tummala, PE; Hutyra, M; Welsby, IJ; Voeltz, MD; Chandna, H; Ramaiah, C; Brtko, M; Cannon, L; Dyke, C; Liu, T; Montalescot, G; Manoukian, SV; Prats, J; Topol, EJ				Angiolillo, Dominick J.; Firstenberg, Michael S.; Price, Matthew J.; Tummala, Pradyumna E.; Hutyra, Martin; Welsby, Ian J.; Voeltz, Michele D.; Chandna, Harish; Ramaiah, Chandrashekhar; Brtko, Miroslav; Cannon, Louis; Dyke, Cornelius; Liu, Tiepu; Montalescot, Gilles; Manoukian, Steven V.; Prats, Jayne; Topol, Eric J.		BRIDGE Investigators	Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CORONARY SYNDROMES; GLYCOPROTEIN IIB/IIIA INHIBITORS; ELEVATION MYOCARDIAL-INFARCTION; PLATELET INHIBITION; PREMATURE DISCONTINUATION; STOPPING CLOPIDOGREL; TASK-FORCE; PREDICTORS; MANAGEMENT; REVASCULARIZATION	Context Thienopyridines are among the most widely prescribed medications, but their use can be complicated by the unanticipated need for surgery. Despite increased risk of thrombosis, guidelines recommend discontinuing thienopyridines 5 to 7 days prior to surgery to minimize bleeding. Objective To evaluate the use of cangrelor, an intravenous, reversible P2Y(12) platelet inhibitor for bridging thienopyridine-treated patients to coronary artery bypass grafting (CABG) surgery. Design, Setting, and Patients Prospective, randomized, double-blind, placebo-controlled, multicenter trial, involving 210 patients with an acute coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopyridine awaiting CABG surgery to receive either cangrelor or placebo after an initial open-label, dose-finding phase (n=11) conducted between January 2009 and April 2011. Interventions Thienopyridines were stopped and patients were administered cangrelor or placebo for at least 48 hours, which was discontinued 1 to 6 hours before CABG surgery. Main Outcome Measures The primary efficacy end point was platelet reactivity (measured in P2Y(12) reaction units [PRUs]), assessed daily. The main safety end point was excessive CABG surgery-related bleeding. Results The dose of cangrelor determined in 10 patients in the open-label stage was 0.75 mu g/kg per minute. In the randomized phase, a greater proportion of patients treated with cangrelor had low levels of platelet reactivity throughout the entire treatment period compared with placebo (primary end point, PRU <240; 98.8% (83 of 84) vs 19.0% (16 of 84); relative risk [RR], 5.2 [95% CI, 3.3-8.1] P<.001). Excessive CABG surgery-related bleeding occurred in 11.8% (12 of 102) vs 10.4% (10 of 96) in the cangrelor and placebo groups, respectively (RR, 1.1 [95% CI, 0.5-2.5] P=.763). There were no significant differences in major bleeding prior to CABG surgery, although minor bleeding episodes were numerically higher with cangrelor. Conclusions Among patients who discontinue thienopyridine therapy prior to cardiac surgery, the use of cangrelor compared with placebo resulted in a higher rate of maintenance of platelet inhibition.	[Price, Matthew J.; Topol, Eric J.] Scripps Translat Sci Inst, La Jolla, CA 92037 USA; [Angiolillo, Dominick J.] Univ Florida, Dept Cardiol, Jacksonville, FL USA; [Firstenberg, Michael S.] Ohio State Univ, Med Ctr, Div Cardiothorac Surg, Columbus, OH 43210 USA; [Price, Matthew J.; Topol, Eric J.] Scripps Clin, Div Cardiovasc Dis, La Jolla, CA 92037 USA; [Tummala, Pradyumna E.] NE Georgia Heart Ctr, Dept Cardiol, Gainesville, FL USA; [Hutyra, Martin] Fac Hosp Olomouc, Internal Clin 1, Olomouc, Czech Republic; [Welsby, Ian J.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Voeltz, Michele D.] Henry Ford Hosp, Dept Cardiol, Detroit, MI 48202 USA; [Chandna, Harish] Detar Hosp, Dept Cardiol, Victoria, TX USA; [Ramaiah, Chandrashekhar] Univ Kentucky, Dept Surg, Lexington, KY USA; [Brtko, Miroslav] Univ Hosp, Deptartment Cardiac Surg, Hradec Kralove, Czech Republic; [Cannon, Louis] No Michigan Reg Hosp, Cardiac & Vasc Res Ctr No Michigan, Petoskey, MI USA; [Dyke, Cornelius] SE Texas Cardiovasc Surg Associates, Humble, TX USA; [Liu, Tiepu; Prats, Jayne] Med Co, Parsippany, NJ USA; [Montalescot, Gilles] Univ Paris 06, INSERM, CMR 937, Grp Hosp Pitie Salpetriere, Paris, France; [Manoukian, Steven V.] Sarah Cannon Res Inst, Nashville, TN USA; [Manoukian, Steven V.] Hosp Corp Amer, Nashville, TN USA	Scripps Research Institute; State University System of Florida; University of Florida; University System of Ohio; Ohio State University; Scripps Research Institute; University Hospital Olomouc; Duke University; Henry Ford Health System; Henry Ford Hospital; University of Kentucky; University Hospital Hradec Kralove; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Sarah Cannon Research Institute; Hospital Corporation of America	Topol, EJ (corresponding author), Scripps Translat Sci Inst, 3344 N Torrey Pines Ct,Ste 300, La Jolla, CA 92037 USA.	etopol@scripps.edu	Price, Matthew/AAJ-7679-2020; Brtko, Miroslav/ABE-3493-2020; Widimsky, Petr/P-8088-2016	Price, Matthew/0000-0002-7892-2430; Brtko, Miroslav/0000-0002-9577-9736; Widimsky, Petr/0000-0001-5686-7752; Topol, Eric/0000-0002-1478-4729; Welsby, Ian/0000-0002-2789-5612	Bristol-Myers Squibb-sanofi-aventis; Eli Lilly Co-Daiichi Sankyo; Medicines Company; Portola; Novartis; Medicure; Accumetrics; Arena Pharmaceuticals; AstraZeneca; Abbott Vascular; GlaxoSmithKline; Boston Scientific; Otsuka; Schering-Plough; Johnson Johnson; Eisai; sanofi-aventis; Quest Diagnostics; Medtronic; Cordis-Johnson Johnson; Bayer Healthcare; Bristol-Myers Squibb; CardioMems; Corindus; Eli Lilly; Foxhollow; Genentech; Regado Biosciences; Stereotaxis; IIT CSL Behring; CSL Behring; Bayer; Boehringer Ingelheim; Cardiovascular Research Foundation; Cleveland Clinic Research Foundation; Daiichi-Sankyo; Duke Institute; Europa; Lead-Up; Institut de Cardiologie de Montreal; Menarini; Nanosheres; Pfizer; TIMI Study Group; Abbott Vascular AstraZeneca; BMS; Cordis; Eli Lilly Federation Francaise de Cardiologie; Fondation de France; Guerbet Medical; INSERM; ITC Edison; Servier; Societe Francaise de Cardiologie; Stago; Guerbet Medical INSERM; ITC Edison Medronic; National Institutes of Health-National Center for Research Resources [UL1 RR025774]; Eli Lilly-Daiichi Sankyo; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER	Bristol-Myers Squibb-sanofi-aventis(Sanofi-AventisBristol-Myers Squibb); Eli Lilly Co-Daiichi Sankyo; Medicines Company; Portola; Novartis(Novartis); Medicure; Accumetrics; Arena Pharmaceuticals; AstraZeneca(AstraZeneca); Abbott Vascular(Abbott Laboratories); GlaxoSmithKline(GlaxoSmithKline); Boston Scientific(Boston Scientific); Otsuka(Otsuka Pharmaceutical); Schering-Plough(Merck & CompanySchering Plough Corporation); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Eisai(Eisai Co Ltd); sanofi-aventis(Sanofi-Aventis); Quest Diagnostics; Medtronic(Medtronic); Cordis-Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Bristol-Myers Squibb(Bristol-Myers Squibb); CardioMems; Corindus; Eli Lilly(Eli Lilly); Foxhollow; Genentech(Roche HoldingGenentech); Regado Biosciences; Stereotaxis; IIT CSL Behring; CSL Behring; Bayer(Bayer AG); Boehringer Ingelheim(Boehringer Ingelheim); Cardiovascular Research Foundation; Cleveland Clinic Research Foundation; Daiichi-Sankyo(Daiichi Sankyo Company Limited); Duke Institute; Europa; Lead-Up; Institut de Cardiologie de Montreal; Menarini(Menarini Group); Nanosheres; Pfizer(Pfizer); TIMI Study Group; Abbott Vascular AstraZeneca; BMS(Bristol-Myers Squibb); Cordis; Eli Lilly Federation Francaise de Cardiologie(Eli Lilly); Fondation de France(Fondation de France); Guerbet Medical; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ITC Edison; Servier(Servier); Societe Francaise de Cardiologie; Stago; Guerbet Medical INSERM; ITC Edison Medronic; National Institutes of Health-National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Eli Lilly-Daiichi Sankyo(Daiichi Sankyo Company LimitedEli Lilly); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Angiolillo reports receiving: honoraria for lectures from Bristol Myers Squibb-sanofi-aventis, and Eli Lilly-Daiichi Sankyo, serving on the advisory boards of Bristol Myers Squibb-sanofi-aventis, Eli Lilly-Daiichi Sankyo, Astra Zeneca, The Medicines Company, Portola, Novartis, Medicure, Accumetrics, Arena Pharmaceuticals, Merck, Evolva, and Abbott Vascular; receiving consulting fees from Bristol-Myers Squibb-sanofi-aventis, Eli Lilly Co-Daiichi Sankyo, The Medicines Company, Portola, Novartis, Medicure, Accumetrics, Arena Pharmaceuticals, AstraZeneca, and Abbott Vascular; and research grants from Bristol-Myers Squibb-sanofi-aventis, GlaxoSmithKline, Boston Scientific, Otsuka, Eli Lilly-Daiichi Sankyo, The Medicines Company, Portola, Accumetrics, Schering-Plough, Astra-Zeneca, Johnson & Johnson, and Eisai. Dr Firstenberg reports receiving speaking fees from sanofi-aventis. Dr Price reports serving on the advisory boards and receiving honoraria for research support from Bristol-Myers Squibb-sanofi-aventis, Quest Diagnostics, and Accumetrics; receiving consulting fees from Bristol-Myers Squibb-sanofi aventis, Accumetrics, AstraZeneca, Eli Lilly-Daiichi Sankyo, and Medicure; and receiving honoraria for lectures from Eli Lilly-Daiichi Sankyo, AstraZeneca, Medtronic, Boston Scientific, and St Jude. Dr Tummala reports receiving consultancy fees from Medtronic, Cordis-Johnson & Johnson and research grants from Abbott Vascular, Bayer Healthcare, Bristol-Myers Squibb, CardioMems, Cordis-Johnson & Johnson, Corindus, Eli Lilly, Foxhollow, Genentech, GlaxoSmithKline, The Medicines Company, Novartis, Regado Biosciences, sanofi aventis, Schering-Plough, and Stereotaxis. Dr Welsby reports receiving grant support from IIT CSL Behring and consultancy fees from CSL Behring. Dr Voeltz reports receiving consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cardiovascular Research Foundation, Cleveland Clinic Research Foundation, Daiichi-Sankyo, Duke Institute, Eli Lilly, Europa, Lead-Up, GlaxoSmithKline, Institut de Cardiologie de Montreal, Menarini, Nanosheres, Novartis, Pfizer, Portola, sanofi-aventis, The Medicines Company, and TIMI Study Group and receiving research grants from Abbott Vascular AstraZeneca, BMS, Boston Scientific, Cordis, Eli Lilly Federation Francaise de Cardiologie, Fondation de France, Guerbet Medical, INSERM, ITC Edison, Medtronic, Pfizer, sanofi-aventis, Servier, Societe Francaise de Cardiologie, and Stago. Dr Chandna reports receiving speaking fees from Bristol-Myers Squibb, sanofi-aventis, and Eli Lilly; consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cardiovascular Research Foundation, Daiichi-Sankyo, Duke Institute, Eli Lilly, Europa, Lead-Up, GlaxoSmithKline, Institut de Cardiologie de Montreal, Menarini, Nanospheres, Novartis, Pfizer, Portola, sanofi-aventis, The Medicines Company, and TIMI Study Group; and research support from Abbot Vascular AstraZeneca, BMS, Boston Scientific, Cordis, Eli Lilly, Federation Francaise de Cardiologie, Fondation de France, Guerbet Medical INSERM, ITC Edison Medronic, Pfizer, sanofi-aventis, Servier, Societe Francaise de Cardiologie, and Stago. Dr Dyke reports receiving consultancy fees from The Medicines Company (Non-paying for last 2 years); having equity ownership in The Medicines Company (<$5000), and receiving speaker fees from sanofi-aventis, Bristol-Myers Squibb. Dr Liu is an employee of The Medicines Company.; Dr Montalescot reports receiving grant supprt from Abbott Vascular, Boston Scientific, Cordis, Eli Lilly, Federation Francaise de Cardiologie, Fondation de France, Guerbet Medical, INSERM, ITC Edison, Medtronic, Pfizer, sanofi-aventis, Societe Francaise de Cardiologie, and Stago and receiving consulting, board, or lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cardiovascular Research Foundation, Cleveland Clinic Research Foundation, Daiichi-Sankyo, Duke Institute, Eli Lilly, Europa, Lead-Up, GlaxoSmithKline, Institut de Cardiologie de Montreal, Menarini, Nanospheres, Novartis, Pfizer, Portola, sanofi-aventis, The Medicines Company, and the TIMI Study Group. Dr Prats is an employee of The Medicines Company. Dr Topol reports serving as a consultant and receiving grant support from The Medicines Company and sanofi-aventis. The other authors did not report disclosures.; This study was sponsored by The Medicines Company and by grant UL1 RR025774 from the National Institutes of Health-National Center for Research Resources Clinical and Translational Science Award (PI Topol).	Akowuah E, 2005, ANN THORAC SURG, V80, P149, DOI 10.1016/j.athoracsur.2005.01.009; Anderson JL, 2011, CIRCULATION, V123, pE426, DOI 10.1161/CIR.0b013e318212bb8b; Angiolillo DJ, 2007, J AM COLL CARDIOL, V49, P1505, DOI 10.1016/j.jacc.2006.11.044; Bhatt DL, 2009, NEW ENGL J MED, V361, P2330, DOI 10.1056/NEJMoa0908629; Bhatt DL, 2000, JAMA-J AM MED ASSOC, V284, P1549, DOI 10.1001/jama.284.12.1549; Boggon R, 2011, EUR HEART J, V32, P2376, DOI 10.1093/eurheartj/ehr340; Bonello L, 2010, J AM COLL CARDIOL, V56, P919, DOI 10.1016/j.jacc.2010.04.047; Brilakis ES, 2007, J AM COLL CARDIOL, V49, P2145, DOI 10.1016/j.jacc.2007.02.046; Collet JP, 2004, CIRCULATION, V110, P2361, DOI 10.1161/01.CIR.0000145171.89690.B4; Ferreiro Jose Luis, 2009, Expert Rev Cardiovasc Ther, V7, P1195, DOI 10.1586/erc.09.101; Fox KAA, 2004, CIRCULATION, V110, P1202, DOI 10.1161/01.CIR.0000140675.85342.1B; Gurbel PA, 2009, CIRCULATION, V120, P2577, DOI 10.1161/CIRCULATIONAHA.109.912550; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Harrington RA, 2009, NEW ENGL J MED, V361, P2318, DOI 10.1056/NEJMoa0908628; Held C, 2011, J AM COLL CARDIOL, V57, P672, DOI 10.1016/j.jacc.2010.10.029; Ho PM, 2008, JAMA-J AM MED ASSOC, V299, P532, DOI 10.1001/jama.299.5.532; Ho PM, 2010, CIRC-CARDIOVASC QUAL, V3, P303, DOI 10.1161/CIRCOUTCOMES.109.890707; Iakovou I, 2005, JAMA-J AM MED ASSOC, V293, P2126, DOI 10.1001/jama.293.17.2126; Kushner FG, 2009, CIRCULATION, V120, P2271, DOI 10.1161/CIRCULATIONAHA.109.192663; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Malinin A, 2007, THROMB RES, V119, P277, DOI 10.1016/j.thromres.2006.01.019; Mascelli MA, 2000, AM HEART J, V139, P696, DOI 10.1016/S0002-8703(00)90050-4; Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449; Pfisterer M, 2006, J AM COLL CARDIOL, V48, P2584, DOI 10.1016/j.jacc.2006.10.026; Price MJ, 2006, AM J CARDIOL, V98, P681, DOI 10.1016/j.amjcard.2006.03.054; Price MJ, 2009, CIRCULATION, V119, P2625, DOI 10.1161/CIRCULATIONAHA.107.696732; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; Rossini R, 2011, AM J CARDIOL, V107, P186, DOI 10.1016/j.amjcard.2010.08.067; Sabatine MS, 2005, JAMA-J AM MED ASSOC, V294, P1224, DOI 10.1001/jama.294.10.1224; Smith PK, 2010, CIRCULATION, V122; Spertus JA, 2006, CIRCULATION, V113, P2803, DOI 10.1161/CIRCULATIONAHA.106.618066; Stone GW, 2006, NEW ENGL J MED, V355, P2203, DOI 10.1056/NEJMoa062437; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), 2010, Eur Heart J, V31, P2501, DOI 10.1093/eurheartj/ehq277; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Tricoci P, 2011, CIRC-CARDIOVASC QUAL, V4, P448, DOI 10.1161/CIRCOUTCOMES.110.960294; Yusuf S, 2001, NEW ENGL J MED, V345, P494	36	298	310	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2012	307	3					265	274		10.1001/jama.2011.2002	http://dx.doi.org/10.1001/jama.2011.2002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877EY	22253393	Bronze, Green Accepted			2022-12-28	WOS:000299161200022
J	Zipkin, DA				Zipkin, Daniella A.			Cytisine increased smoking cessation in adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Duke Univ Med Ctr, Durham, NC 27706 USA	Duke University	Zipkin, DA (corresponding author), Duke Univ Med Ctr, Durham, NC 27706 USA.							Cahill K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006103.pub5; Fiore MC, 2008, TREATING TOBACCO USE; Leung Lawrence K, 2011, BMC Clin Pharmacol, V11, P15, DOI 10.1186/1472-6904-11-15; Singh S, 2011, CAN MED ASSOC J, V183, P1359, DOI 10.1503/cmaj.110218; Wu P, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-300	5	0	0	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-6	10.7326/0003-4819-156-2-201201170-02006	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31YU	22250168				2022-12-28	WOS:000208919700007
J	Berden, A; Goceroglu, A; Jayne, D; Luqmani, R; Rasmussen, N; Bruijn, JA; Bajema, I				Berden, Annelies; Goceroglu, Arda; Jayne, David; Luqmani, Raashid; Rasmussen, Niels; Bruijn, Jan Anthonie; Bajema, Ingeborg			Diagnosis and management of ANCA associated vasculitis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; ANTIBODY-ASSOCIATED VASCULITIS; SMALL-VESSEL VASCULITIS; WEGENERS-GRANULOMATOSIS; RENAL VASCULITIS; RANDOMIZED-TRIAL; MICROSCOPIC POLYANGIITIS; SYSTEMIC VASCULITIS; PLASMA-EXCHANGE; GLOMERULONEPHRITIS		[Berden, Annelies; Goceroglu, Arda; Bruijn, Jan Anthonie; Bajema, Ingeborg] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; [Jayne, David] Addenbrookes Hosp, Renal Unit, Cambridge, England; [Luqmani, Raashid] Univ Oxford, Dept Rheumatol, Oxford, England; [Rasmussen, Niels] Statens Serum Inst, Dept Autoimmune Serol, DK-2300 Copenhagen, Denmark	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Oxford; Statens Serum Institut	Bajema, I (corresponding author), Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands.	i.bajema@lumc.nl		Jayne, David/0000-0002-1712-0637; Jayne, David/0000-0002-8725-3283; Luqmani, Raashid/0000-0002-4446-5841	Roche; Nordic	Roche(Roche Holding); Nordic	Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: DJ has received a grant and consulting fee/honorarium from Roche; RL does consultancy work for Chemocentryx and Nordic, reports for solicitors on individual cases (expert testimony), is in discussion with Nordic for administrative support to oversee data collection for a Nordic funded study in vasculitis (grants/grants pending), gets paid for lectures including service on speakers' bureaux for UCB, receives royalties from EPS research for software that he originally designed to manage use of biological therapy within NICE guidelines, and receives travel, accommodation, and registration fees to attend the annual American College of Rheumatology and European League Against Rheumatism meetings; NR is paid for lectures including service on speakers' bureaux for Phadia and EuroDiagnostica; IB does consultancy work for Roche on lupus nephritis; no other relationships or activities that could appear to have influenced the submitted work.	Abdou NI, 2002, J RHEUMATOL, V29, P309; Arnold DF, 2010, J CLIN PATHOL, V63, P678, DOI 10.1136/jcp.2009.072504; Bansal PJ, 2004, ANN ALLERG ASTHMA IM, V93, P398, DOI 10.1016/S1081-1206(10)61400-7; Basu N, 2010, RHEUMATOLOGY, V49, P1383, DOI 10.1093/rheumatology/keq098; Berden AE, 2009, ARTHRITIS RHEUM, V60, P1578, DOI 10.1002/art.24576; Booth AD, 2003, AM J KIDNEY DIS, V41, P776, DOI 10.1016/S0272-6386(03)00025-8; BUSSEL A, 1987, LIFE SUPPORT SYST, V5, P353; Cotch MF, 2000, CURR OPIN RHEUMATOL, V12, P20, DOI 10.1097/00002281-200001000-00004; de Groot K, 2005, ARTHRITIS RHEUM-US, V52, P2461, DOI 10.1002/art.21142; de Groot K, 2009, ANN INTERN MED, V150, P670, DOI 10.7326/0003-4819-150-10-200905190-00004; de Leeuw K, 2005, ANN RHEUM DIS, V64, P753, DOI 10.1136/ard.2004.029033; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; Faurschou M, 2009, ARTHRITIS RHEUM-US, V60, P1187, DOI 10.1002/art.24386; Flossmann O, 2011, ANN RHEUM DIS, V70, P488, DOI 10.1136/ard.2010.137778; Hagen EC, 1998, KIDNEY INT, V53, P743, DOI 10.1046/j.1523-1755.1998.00807.x; Harper L, 2011, ANN RHEUM DIS; Hauer HA, 2002, KIDNEY INT, V62, P1732, DOI 10.1046/j.1523-1755.2002.00605.x; Heijl C, 2011, ANN RHEUM DIS, V70, P1415, DOI 10.1136/ard.2010.145250; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hogan SL, 1996, J AM SOC NEPHROL, V7, P23; Hopkins J, 2003, ARTHRITIS RHEUM-US, V48, P2299, DOI 10.1002/art.11075; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; Jayne DRW, 2007, J AM SOC NEPHROL, V18, P2180, DOI 10.1681/ASN.2007010090; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; Jones RB, 2010, NEW ENGL J MED, V363, P211, DOI 10.1056/NEJMoa0909169; Knight A, 2008, ARTHRITIS RHEUM-US, V58, P302, DOI 10.1002/art.23157; Koldingsnes W, 2002, RHEUMATOLOGY, V41, P572, DOI 10.1093/rheumatology/41.5.572; Little MA, 2004, NEPHROL DIAL TRANSPL, V19, P356, DOI 10.1093/ndt/gfg551; Little MA, 2010, ANN RHEUM DIS, V69, P1036, DOI 10.1136/ard.2009.109389; LUQMANI RA, 1994, Q J MED, V87, P671; Luqmani RA, 1997, BAILLIERE CLIN RHEUM, V11, P423, DOI 10.1016/S0950-3579(97)80052-0; Mahr A, 2004, ARTHRIT RHEUM-ARTHR, V51, P92, DOI 10.1002/art.20077; McLaren JS, 2001, QJM-INT J MED, V94, P615, DOI 10.1093/qjmed/94.11.615; Merkel PA, 2005, ANN INTERN MED, V142, P620, DOI 10.7326/0003-4819-142-8-200505030-00011; Morgan MD, 2009, ARTHRITIS RHEUM-US, V60, P3493, DOI 10.1002/art.24957; Mukhtyar C, 2009, ANN RHEUM DIS, V68, P1827, DOI 10.1136/ard.2008.101279; Mukhtyar C, 2009, ANN RHEUM DIS, V68, P310, DOI 10.1136/ard.2008.088096; Pagnoux C, 2008, NEW ENGL J MED, V359, P2790, DOI 10.1056/NEJMoa0802311; PORGES AJ, 1994, J IMMUNOL, V153, P1271; Rasmussen N, 1990, APMIS Suppl, V19, P15; Reinhold-Keller E, 2000, ARTHRITIS RHEUM, V43, P1021, DOI 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J; Savige J, 1999, AM J CLIN PATHOL, V111, P507; Schlieben DJ, 2005, AM J KIDNEY DIS, V45, P758, DOI 10.1053/j.ajkd.2005.01.001; Silva F, 2009, AM J KIDNEY DIS, V54, P542, DOI 10.1053/j.ajkd.2009.02.016; Slot MC, 2003, KIDNEY INT, V63, P670, DOI 10.1046/j.1523-1755.2003.00769.x; Stassen PM, 2008, RHEUMATOLOGY, V47, P530, DOI 10.1093/rheumatology/ken035; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Stegeman CA, 1996, NEW ENGL J MED, V335, P16, DOI 10.1056/NEJM199607043350103; Stone JH, 2010, NEW ENGL J MED, V363, P221, DOI 10.1056/NEJMoa0909905; Suppiah R, 2011, ARTHRIT CARE RES, V63, P588, DOI 10.1002/acr.20433; van Wijngaarden RAFDL, 2008, CLIN J AM SOC NEPHRO, V3, P237, DOI 10.2215/CJN.03550807; Walsh M, 2011, AM J KIDNEY DIS, V57, P566, DOI 10.1053/j.ajkd.2010.10.049; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; Watts RA, 2001, ANN RHEUM DIS, V60, P1156; Watts RA, 2000, ARTHRITIS RHEUM, V43, P414, DOI 10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0; Watts RA, 2008, NEPHROL DIAL TRANSPL, V23, P3928, DOI 10.1093/ndt/gfn354; Weidner S, 2006, ARTHRIT RHEUM-ARTHR, V55, P146, DOI 10.1002/art.21704; Willcocks LC, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2928; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Xiao H, 2007, AM J PATHOL, V170, P52, DOI 10.2353/ajpath.2007.060573; Xing GQ, 2009, J CLIN IMMUNOL, V29, P282, DOI 10.1007/s10875-008-9268-2	61	72	76	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	2012	344								e26	10.1136/bmj.e26	http://dx.doi.org/10.1136/bmj.e26			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888YP	22250224				2022-12-28	WOS:000300040900010
J	Jacob, T; Wahr, J; Pfeffer, WT; Swenson, S				Jacob, Thomas; Wahr, John; Pfeffer, W. Tad; Swenson, Sean			Recent contributions of glaciers and ice caps to sea level rise	NATURE			English	Article							MASS CHANGES; GRACE; GRAVITY	Glaciers and ice caps (GICs) are important contributors to present-day global mean sea level rise(1-4). Most previous global mass balance estimates for GICs rely on extrapolation of sparse mass balance measurements(1,2,4) representing only a small fraction of the GIC area, leaving their overall contribution to sea level rise unclear. Here we show that GICs, excluding the Greenland and Antarctic peripheral GICs, lost mass at a rate of 148 +/- 30 Gt yr(-1) from January 2003 to December 2010, contributing 0.41 +/- 0.08 mm yr(-1) to sea level rise. Our results are based on a global, simultaneous inversion of monthly GRACE-derived satellite gravity fields, from which we calculate the mass change over all ice-covered regions greater in area than 100 km(2). The GIC rate for 2003-2010 is about 30 per cent smaller than the previous mass balance estimate that most closely matches our study period(2). The high mountains of Asia, in particular, show a mass loss of only 4 +/- 20 Gt yr(-1) for 2003-2010, compared with 47-55 Gt yr(-1) in previously published estimates(2,5). For completeness, we also estimate that the Greenland and Antarctic ice sheets, including their peripheral GICs, contributed 1.06 +/- 0.19 mm yr(-1) to sea level rise over the same time period. The total contribution to sea level rise from all ice-covered regions is thus 1.48 +/- 0.26 mm yr(-1), which agrees well with independent estimates of sea level rise originating from land ice loss and other terrestrial sources(6).	[Jacob, Thomas; Wahr, John] Univ Colorado, Dept Phys, Boulder, CO 80309 USA; [Jacob, Thomas; Wahr, John] Univ Colorado, Cooperat Inst Environm Studies, Boulder, CO 80309 USA; [Pfeffer, W. Tad] Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; [Pfeffer, W. Tad] Univ Colorado, Dept Civil Environm & Architectural Engn, Boulder, CO 80309 USA; [Swenson, Sean] Natl Ctr Atmospher Res, Boulder, CO 80305 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; National Center Atmospheric Research (NCAR) - USA	Wahr, J (corresponding author), Univ Colorado, Dept Phys, Boulder, CO 80309 USA.	john.wahr@gmail.com	Jacob, Thomas/AAJ-9417-2020	Jacob, Thomas/0000-0001-9819-5165	NASA [NNX08AF02G, NNXI0AR66G]	NASA(National Aeronautics & Space Administration (NASA))	We thank Geruo A for providing the glacial isostatic adjustment model, and G. Cogley, G. Kaser, I. Velicogna, T. Perron and M. Tamisiea for comments. This work was partially supported by NASA grants NNX08AF02G and NNXI0AR66G, and by NASA's 'Making Earth Science Data Records for Use in Research Environments (MEaSUREs) Program'.	Bettinelli P, 2006, J GEODESY, V80, P567, DOI 10.1007/s00190-006-0030-3; Brown J., 1998, CIRCUM ARCTIC MAP PE; Chen JL, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031871; Cheng MK, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2004JB003028; Cogley J. G., 2012, FUTURE CLIMATES WORL, P189; Cogley JG, 2009, ANN GLACIOL, V50, P96, DOI 10.3189/172756409787769744; Dyurgerov M B, 2010, DATA GLACIOLOGICAL S, V108, P1; Gardner AS, 2011, NATURE, V473, P357, DOI 10.1038/nature10089; Hirabayashi Y, 2010, J HYDROL, V390, P245, DOI 10.1016/j.jhydrol.2010.07.001; Hock R, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL037020; Ivins ER, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021500; JACKSON M, 1994, J GEOPHYS RES-SOL EA, V99, P13897, DOI 10.1029/94JB00714; Kaser G, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027511; Lemoine FG, 1998, DEV JOINT NASA GSFC; Luthcke SB, 2008, J GLACIOL, V54, P767, DOI 10.3189/002214308787779933; Matsuo K, 2010, EARTH PLANET SC LETT, V290, P30, DOI 10.1016/j.epsl.2009.11.053; Meier MF, 2007, SCIENCE, V317, P1064, DOI 10.1126/science.1143906; Raup BH, 2000, IEEE T GEOSCI REMOTE, V38, P1105, DOI 10.1109/36.841989; Rignot E, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL046583; Riva REM, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL044770; Rodell M, 2009, NATURE, V460, P999, DOI 10.1038/nature08238; Rowlands DD, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021908; Swenson S, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB005338; Tapley BD, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019920; Tiwari VM, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039401; Velicogna I, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040222; Wahr J, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019779; Willis JK, 2010, OCEANOGRAPHY, V23, P26, DOI 10.5670/oceanog.2010.03; Zhong SJ, 2000, GEOPHYS RES LETT, V27, P3009, DOI 10.1029/1999GL011242	29	711	765	20	369	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	2012	482	7386					514	518		10.1038/nature10847	http://dx.doi.org/10.1038/nature10847			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	898VM	22318519				2022-12-28	WOS:000300770500048
J	Berns, KI; Casadevall, A; Cohen, ML; Ehrlich, SA; Enquist, LW; Fitch, JP; Franz, DR; Fraser-Liggett, CM; Grant, CM; Imperiale, MJ; Kanabrocki, J; Keim, PS; Lemon, SM; Levy, SB; Lumpkin, JR; Miller, JF; Murch, R; Nance, ME; Osterholm, MT; Relman, DA; Roth, JA; Vidaver, AK				Berns, Kenneth I.; Casadevall, Arturo; Cohen, Murray L.; Ehrlich, Susan A.; Enquist, Lynn W.; Fitch, J. Patrick; Franz, David R.; Fraser-Liggett, Claire M.; Grant, Christine M.; Imperiale, Michael J.; Kanabrocki, Joseph; Keim, Paul S.; Lemon, Stanley M.; Levy, Stuart B.; Lumpkin, John R.; Miller, Jeffery F.; Murch, Randall; Nance, Mark E.; Osterholm, Michael T.; Relman, David A.; Roth, James A.; Vidaver, Anne K.			Adaptations of Avian Flu Virus Are a Cause for Concern	SCIENCE			English	Editorial Material							RECOMBINANT DNA; GUIDELINES; MOLECULES		[Keim, Paul S.] No Arizona Univ, Flagstaff, AZ 86011 USA; [Keim, Paul S.] Translat Genom Res Inst, Phoenix, AZ 85004 USA; [Berns, Kenneth I.] Univ Florida, Genet Inst, Gainesville, FL 32611 USA; [Casadevall, Arturo] Albert Einstein Coll Med, Bronx, NY 10461 USA; [Cohen, Murray L.] Frontline Healthcare Workers Safety Fdn Ltd, Atlanta, GA 30338 USA; [Ehrlich, Susan A.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Enquist, Lynn W.] Princeton Univ, Princeton, NJ 08544 USA; [Fitch, J. Patrick] Battelle Natl Biodef Inst LLC, Frederick, MD 21702 USA; [Franz, David R.] MRIGlobal, Frederick, MD 21702 USA; [Fraser-Liggett, Claire M.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Grant, Christine M.] InfecDetect Rapid Diagnost Tests LLC, Princeton, NJ 08540 USA; [Imperiale, Michael J.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA; [Kanabrocki, Joseph] Univ Chicago, Chicago, IL 60637 USA; [Lemon, Stanley M.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Levy, Stuart B.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Lumpkin, John R.] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; [Miller, Jeffery F.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA; [Murch, Randall] Virginia Polytech Inst & State Univ, Virginia Tech Resource Ctr, Arlington, VA 22203 USA; [Nance, Mark E.] GE Healthcare, Princeton, NJ 08540 USA; [Osterholm, Michael T.] Univ Minnesota, Minneapolis, MN 55455 USA; [Relman, David A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Roth, James A.] Iowa State Univ, Ctr Food Secur & Publ Hlth, Ames, IA 50011 USA; [Vidaver, Anne K.] Univ Nebraska, Lincoln, NE 68588 USA	Northern Arizona University; Translational Genomics Research Institute; State University System of Florida; University of Florida; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Princeton University; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan; University of Chicago; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Tufts University; Robert Wood Johnson Foundation (RWJF); University of California System; University of California Los Angeles; Virginia Polytechnic Institute & State University; General Electric; University of Minnesota System; University of Minnesota Twin Cities; Stanford University; Iowa State University; University of Nebraska System; University of Nebraska Lincoln	Keim, PS (corresponding author), No Arizona Univ, Flagstaff, AZ 86011 USA.	Paul.Keim@nau.edu	Roth, James A/A-7122-2009	Roth, James A/0000-0003-3562-668X; Relman, David A./0000-0001-8331-1354; Fraser, Claire/0000-0003-1462-2428				BERG P, 1975, P NATL ACAD SCI USA, V72, P1981, DOI 10.1073/pnas.72.6.1981; National Research Council, 2004, BIOT RES AG TERR; National Research Council, 2006, GLOB BIOS FUT LIF SC; National Science Advisory Board for Biosecurity (NSABB), 2008, STRAT PLAN OUTR ED D; Office of Biotechnology Activities, AB NSABB; SINGER M, 1973, SCIENCE, V181, P1114, DOI 10.1126/science.181.4105.1114; SINGER MF, 1976, SCIENCE, V193, P186, DOI 10.1126/science.11643320; World Health Organization, 2003, CONF HUM CAS H5N1 20	8	49	52	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2012	335	6069					660	661		10.1126/science.1217994	http://dx.doi.org/10.1126/science.1217994			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	889AY	22294736				2022-12-28	WOS:000300047100034
J	Colloca, L; Finniss, D				Colloca, Luana; Finniss, Damien			Nocebo Effects, Patient-Clinician Communication, and Therapeutic Outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Colloca, Luana] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA; [Colloca, Luana] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA; [Finniss, Damien] Univ Sydney, Royal N Shore Hosp, Pain Management & Res Inst, St Leonards, NSW 2065, Australia	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; Royal North Shore Hospital; University of Sydney	Colloca, L (corresponding author), NIH, Dept Bioeth, Ctr Clin, 10 Ctr Dr,10-1C118, Bethesda, MD 20892 USA.	luana.colloca@nih.gov	Colloca, Luana/S-1389-2018	Colloca, Luana/0000-0002-6503-4709	NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [ZIAAT000019] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 MH999999] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Brody H, 2011, JAMA-J AM MED ASSOC, V306, P2612, DOI 10.1001/jama.2011.1850; Colloca L, 2008, PAIN, V136, P211, DOI 10.1016/j.pain.2008.02.006; Colloca L, 2004, LANCET NEUROL, V3, P679, DOI 10.1016/S1474-4422(04)00908-1; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55; Mondaini N, 2007, J SEX MED, V4, P1708, DOI 10.1111/j.1743-6109.2007.00563.x; Rodriguez-Raecke R, 2010, J NEUROSCI, V30, P11363, DOI 10.1523/JNEUROSCI.2197-10.2010; Varelmann D, 2010, ANESTH ANALG, V110, P868, DOI 10.1213/ANE.0b013e3181cc5727	8	206	209	4	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					567	568		10.1001/jama.2012.115	http://dx.doi.org/10.1001/jama.2012.115			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318275	Green Accepted			2022-12-28	WOS:000299992500018
J	Jackson, DP; Laws, PW; Franklin, SV				Jackson, David P.; Laws, Priscilla W.; Franklin, Scott V.			An Inquiry-Based Curriculum for Nonmajors	SCIENCE			English	Editorial Material									[Jackson, David P.; Laws, Priscilla W.] Dickinson Coll, Dept Phys & Astron, Carlisle, PA 17013 USA; [Franklin, Scott V.] Rochester Inst Technol, Rochester, NY 14623 USA	Dickinson College; Rochester Institute of Technology	Jackson, DP (corresponding author), Dickinson Coll, Dept Phys & Astron, Carlisle, PA 17013 USA.	jacksond@dickinson.edu						Browne K. P., 2003, Physics Education, V38, P115, DOI 10.1088/0031-9120/38/2/302; DeHaan R. L., 2005, J SCI EDUC TECHNOL, V14, P253, DOI DOI 10.1007/S10956-005-4425-3; Jackson D.P., 2003, EXPLORATIONS PHYS AC; Jackson David P., 2007, PHYS TEACH, V45, P425, DOI DOI 10.1119/1.2783151; Jackson DP, 2006, AM J PHYS, V74, P94, DOI 10.1119/1.2162547; Jackson DP, 1997, AIP CONF PROC, P623; Miller J. D., 2007, ANN M AM ASS ADV SCI; Morrow  Rebecca, 1999, PHYS TEACH, V37, P412	8	0	0	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					418	419		10.1126/science.1213444	http://dx.doi.org/10.1126/science.1213444			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	881FG	22282801				2022-12-28	WOS:000299466800036
J	Nagata, T; Koyanagi, M; Tsukamoto, H; Saeki, S; Isono, K; Shichida, Y; Tokunaga, F; Kinoshita, M; Arikawa, K; Terakita, A				Nagata, Takashi; Koyanagi, Mitsumasa; Tsukamoto, Hisao; Saeki, Shinjiro; Isono, Kunio; Shichida, Yoshinori; Tokunaga, Fumio; Kinoshita, Michiyo; Arikawa, Kentaro; Terakita, Akihisa			Depth Perception from Image Defocus in a Jumping Spider	SCIENCE			English	Article							PRINCIPAL EYES; SPECTRAL SENSITIVITIES; USE ACCOMMODATION; SALTICIDAE; DENDRYPHANTINAE; MOVEMENTS; RECEPTORS; DISTANCE; BEHAVIOR; RETINAE	The principal eyes of jumping spiders have a unique retina with four tiered photoreceptor layers, on each of which light of different wavelengths is focused by a lens with appreciable chromatic aberration. We found that all photoreceptors in both the deepest and second-deepest layers contain a green-sensitive visual pigment, although green light is only focused on the deepest layer. This mismatch indicates that the second-deepest layer always receives defocused images, which contain depth information of the scene in optical theory. Behavioral experiments revealed that depth perception in the spider was affected by the wavelength of the illuminating light, which affects the amount of defocus in the images resulting from chromatic aberration. Therefore, we propose a depth perception mechanism based on how much the retinal image is defocused.	[Nagata, Takashi; Koyanagi, Mitsumasa; Tsukamoto, Hisao; Terakita, Akihisa] Osaka City Univ, Dept Biol & Geosci, Grad Sch Sci, Osaka 5588585, Japan; [Saeki, Shinjiro; Isono, Kunio] Tohoku Univ, Grad Sch Informat Sci, Sendai, Miyagi 9808579, Japan; [Shichida, Yoshinori] Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; [Tokunaga, Fumio] Osaka Univ, Grad Sch Sci, Dept Earth & Space Sci, Toyonaka, Osaka 5600043, Japan; [Kinoshita, Michiyo; Arikawa, Kentaro] Grad Univ Adv Studies Sokendai, Lab Neuroethol, Hayama 2400193, Japan	Osaka Metropolitan University; Tohoku University; Kyoto University; Osaka University; Graduate University for Advanced Studies - Japan	Koyanagi, M (corresponding author), Osaka City Univ, Dept Biol & Geosci, Grad Sch Sci, Osaka 5588585, Japan.	koyanagi@sci.osaka-cu.ac.jp; terakita@sci.osaka-cu.ac.jp	Nagata, Takashi/ABB-1780-2020	Nagata, Takashi/0000-0001-5379-2951; Kinoshita, Michiyo/0000-0002-5818-9622; Koyanagi, Mitsumasa/0000-0002-7741-918X; Terakita, Akihisa/0000-0002-8379-8913; Arikawa, Kentaro/0000-0002-4365-0762	Grants-in-Aid for Scientific Research [21770078, 22687005] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		BLEST AD, 1981, J COMP PHYSIOL, V145, P227, DOI 10.1007/BF00605035; Chaudhuri S., 1999, DEPTH DEFOCUS REAL A; DEVOE RD, 1975, J GEN PHYSIOL, V66, P193, DOI 10.1085/jgp.66.2.193; EAKIN RM, 1971, J ULTRA MOL STRUCT R, V37, P618, DOI 10.1016/S0022-5320(71)80029-1; FORSTER LM, 1979, NEW ZEAL J ZOOL, V6, P79, DOI 10.1080/03014223.1979.10428351; HARKNESS L, 1977, NATURE, V267, P346, DOI 10.1038/267346a0; Harris JM, 2004, PHILOS T R SOC A, V362, P2721, DOI 10.1098/rsta.2004.1464; Kral K, 2003, BEHAV PROCESS, V64, P1, DOI 10.1016/S0376-6357(03)00054-8; LAND MF, 1969, J EXP BIOL, V51, P443; LAND MF, 1969, J EXP BIOL, V51, P471; PENTLAND AP, 1987, IEEE T PATTERN ANAL, V9, P523, DOI 10.1109/TPAMI.1987.4767940; WAGNER H, 1991, J COMP PHYSIOL A, V169, P515; YAMASHITA S, 1976, J COMP PHYSIOL, V105, P29, DOI 10.1007/BF01380051; Zurek DB, 2010, J EXP BIOL, V213, P2372, DOI 10.1242/jeb.042382	14	82	86	0	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					469	471		10.1126/science.1211667	http://dx.doi.org/10.1126/science.1211667			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282813	Green Published			2022-12-28	WOS:000299466800051
J	Jia, YC; Mu, JC; Ackerman, SL				Jia, Yichang; Mu, John C.; Ackerman, Susan L.			Mutation of a U2 snRNA Gene Causes Global Disruption of Alternative Splicing and Neurodegeneration	CELL			English	Article							SMALL NUCLEAR-RNA; NONSENSE-MEDIATED DECAY; MESSENGER-RNA; DEVELOPMENTAL DISORDER; U4ATAC SNRNA; IN-SITU; EXPRESSION; MOUSE; U1; SPLICEOSOME	Although uridine-rich small nuclear RNAs (UsnRNAs) are essential for pre-mRNA splicing, little is known regarding their function in the regulation of alternative splicing or of the biological consequences of their dysfunction in mammals. Here, we demonstrate that mutation of Rnu2-8, one of the mouse multicopy U2 snRNA genes, causes ataxia and neurodegeneration. Coincident with the observed pathology, the level of mutant U2 RNAs was highest in the cerebellum and increased after granule neuron maturation. Furthermore, neuron loss was strongly dependent on the dosage of mutant and wild-type snRNA genes. Comprehensive transcriptome analysis identified a group of alternative splicing events, including the splicing of small introns, which were disrupted in the mutant cerebellum. Our results suggest that the expression of mammalian U2 snRNA genes, previously presumed to be ubiquitous, is spatially and temporally regulated, and dysfunction of a single U2 snRNA causes neuron degeneration through distortion of pre-mRNA splicing.	[Jia, Yichang; Ackerman, Susan L.] Howard Hughes Med Inst, Bar Harbor, ME 04609 USA; [Jia, Yichang; Ackerman, Susan L.] Jackson Lab, Bar Harbor, ME 04609 USA; [Mu, John C.] Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Jackson Laboratory; Stanford University	Ackerman, SL (corresponding author), Howard Hughes Med Inst, 600 Main St, Bar Harbor, ME 04609 USA.	susan.ackerman@jax.org	Mu, John/AAE-9853-2020	Mu, John/0000-0002-9666-8528	National Cancer Institute; NIH [R01HG004634, R01HG005717]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG005717, R01HG004634] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank The Jackson Laboratory sequencing, gene expression, histology, microinjection, and multimedia services for their assistance. We also thank W. H. Wong for discussions on RNA-Seq analysis, J. Blake and C. Bult for discussion on GO analysis, L. Beverly-Staggs and J. Cook for mouse husbandry assistance, P. de la Grange for exon array analysis, J. Hammer and L. Zhao for graphics assistance, J. McCarthy and M. Nasim for plasmids, and R. Burgess, G. Cox, and M. Hibbs for comments on the manuscript. This work was partially supported by an institutional National Cancer Institute core grant (JAX), and the work of J. C. M. was partially supported by NIH Grants R01HG004634 and R01HG005717. S. L. A. is an investigator of the Howard Hughes Medical Institute.	Au KF, 2010, NUCLEIC ACIDS RES, V38, P4570, DOI 10.1093/nar/gkq211; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Bult C, 2004, NAT NEUROSCI, V7, P484, DOI 10.1038/nn0504-484; Chacko E, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S1-S5; Clark TA, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r64; Cooper TA, 2009, CELL, V136, P777, DOI 10.1016/j.cell.2009.02.011; Corioni M, 2011, NUCLEIC ACIDS RES, V39, P1868, DOI 10.1093/nar/gkq1042; de la Grange P, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-180; de la Grange P, 2010, NUCLEIC ACIDS RES, V38, P2825, DOI 10.1093/nar/gkq008; Edery P, 2011, SCIENCE, V332, P240, DOI 10.1126/science.1202205; Egloff S, 2008, BIOCHEM SOC T, V36, P590, DOI 10.1042/BST0360590; FORBES DJ, 1984, CELL, V38, P681, DOI 10.1016/0092-8674(84)90263-0; Gardner LB, 2010, MOL CANCER RES, V8, P295, DOI 10.1158/1541-7786.MCR-09-0502; Giorgi C, 2007, CELL, V130, P179, DOI 10.1016/j.cell.2007.05.028; He HL, 2011, SCIENCE, V332, P238, DOI 10.1126/science.1200587; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kollmus H, 1996, NUCLEIC ACIDS RES, V24, P1195, DOI 10.1093/nar/24.7.1195; Lagier-Tourenne C, 2010, HUM MOL GENET, V19, pR46, DOI 10.1093/hmg/ddq137; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lemmens R, 2010, TRENDS NEUROSCI, V33, P249, DOI 10.1016/j.tins.2010.02.003; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Li LB, 2008, NATURE, V453, P1107, DOI 10.1038/nature06909; Licatalosi DD, 2006, NEURON, V52, P93, DOI 10.1016/j.neuron.2006.09.017; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; LUND E, 1985, SCIENCE, V229, P1271, DOI 10.1126/science.2412294; MANSER T, 1982, CELL, V29, P257, DOI 10.1016/0092-8674(82)90110-6; Marz M, 2008, J MOL EVOL, V67, P594, DOI 10.1007/s00239-008-9149-6; McGrail JC, 2006, EMBO J, V25, P3813, DOI 10.1038/sj.emboj.7601258; Mordes D, 2006, MOL VIS, V12, P1259; Munroe Robert, 2009, V530, P131, DOI 10.1007/978-1-59745-471-1_7; Nasim MT, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf108; Ni JZ, 2007, GENE DEV, V21, P708, DOI 10.1101/gad.1525507; Park JW, 2004, P NATL ACAD SCI USA, V101, P15974, DOI 10.1073/pnas.0407004101; PAVELITZ T, 1995, EMBO J, V14, P169, DOI 10.1002/j.1460-2075.1995.tb06987.x; Polymenidou M, 2011, NAT NEUROSCI, V14, P459, DOI 10.1038/nn.2779; Ryan DE, 2002, RNA, V8, P997, DOI 10.1017/S1355838202025013; Sakabe NJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-59; Saltzman AL, 2011, GENE DEV, V25, P373, DOI 10.1101/gad.2004811; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; Shaw SD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000854; Sierra-Montes JM, 2005, GENE, V352, P127, DOI 10.1016/j.gene.2005.02.013; Smith DJ, 2009, MOL CELL, V34, P333, DOI 10.1016/j.molcel.2009.03.012; STEFANOVIC B, 1991, DEV BIOL, V148, P284, DOI 10.1016/0012-1606(91)90337-3; Tollervey JR, 2011, NAT NEUROSCI, V14, P452, DOI 10.1038/nn.2778; VANARSDELL SW, 1984, MOL CELL BIOL, V4, P492, DOI 10.1128/MCB.4.3.492; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; WESTIN G, 1984, P NATL ACAD SCI-BIOL, V81, P3811, DOI 10.1073/pnas.81.12.3811; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Zahler AM, 2004, GENETICS, V167, P1689, DOI 10.1534/genetics.104.028746; Zhang Z, 2008, CELL, V133, P585, DOI 10.1016/j.cell.2008.03.031; Zhao LH, 2005, NAT GENET, V37, P974, DOI 10.1038/ng1620	54	68	71	2	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 20	2012	148	1-2					296	308		10.1016/j.cell.2011.11.057	http://dx.doi.org/10.1016/j.cell.2011.11.057			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265417	Green Accepted, Bronze			2022-12-28	WOS:000299540700032
J	Yoshida, H; Kuwauchi, Y; Jinschek, JR; Sun, KJ; Tanaka, S; Kohyama, M; Shimada, S; Haruta, M; Takeda, S				Yoshida, Hideto; Kuwauchi, Yasufumi; Jinschek, Joerg R.; Sun, Keju; Tanaka, Shingo; Kohyama, Masanori; Shimada, Satoshi; Haruta, Masatake; Takeda, Seiji			Visualizing Gas Molecules Interacting with Supported Nanoparticulate Catalysts at Reaction Conditions	SCIENCE			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; CO OXIDATION; GOLD; SURFACE; TEMPERATURE; AU/TIO2; PERFORMANCE; MECHANISM; BEHAVIOR; AU(111)	Understanding how molecules can restructure the surfaces of heterogeneous catalysts under reaction conditions requires methods that can visualize atoms in real space and time. We applied a newly developed aberration-corrected environmental transmission electron microscopy to show that adsorbed carbon monoxide (CO) molecules caused the {100} facets of a gold nanoparticle to reconstruct during CO oxidation at room temperature. The CO molecules adsorbed at the on-top sites of gold atoms in the reconstructed surface, and the energetic favorability of this reconstructed structure was confirmed by ab initio calculations and image simulations. This atomic-scale visualizing method can be applied to help elucidate reaction mechanisms in heterogeneous catalysis.	[Yoshida, Hideto; Takeda, Seiji] Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan; [Kuwauchi, Yasufumi] Osaka Univ, Grad Sch Sci, Dept Phys, Toyonaka, Osaka 5600043, Japan; [Jinschek, Joerg R.] FEI Co, NL-5651 GG Eindhoven, Netherlands; [Sun, Keju; Tanaka, Shingo; Kohyama, Masanori] Natl Inst Adv Ind Sci & Technol, Res Inst Ubiquitous Energy Devices, Ikeda, Osaka 5638577, Japan; [Shimada, Satoshi; Haruta, Masatake] Tokyo Metropolitan Univ, Grad Sch Urban Environm Sci, Dept Appl Chem, Tokyo 1920397, Japan	Osaka University; Osaka University; Thermo Fisher Scientific; FEI Company; National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Metropolitan University	Takeda, S (corresponding author), Osaka Univ, Inst Sci & Ind Res, 8-1 Mihogaoka, Osaka 5670047, Japan.	takeda@sanken.osaka-u.ac.jp	Yoshida, Hideto/AAG-3672-2021; Sun, Keju/F-2593-2013; Kohyama, Masanori/M-5459-2018; haruta, masatake/J-6561-2012; Takeda, Seiji/V-6386-2019; Jinschek, Joerg/AAS-3344-2020; Tanaka, Shingo/L-3325-2018	Yoshida, Hideto/0000-0002-4195-3225; Sun, Keju/0000-0001-8791-4646; Kohyama, Masanori/0000-0001-7167-7703; Jinschek, Joerg/0000-0003-1574-0899; Tanaka, Shingo/0000-0002-5381-2470	Ministry of Education, Culture, Sports, Science and Technology, Japan [19001005]	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by a Grant-in-Aid for Specially Promoted Research, grant 19001005, from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Allen JE, 2008, NAT NANOTECHNOL, V3, P168, DOI 10.1038/nnano.2008.5; BARTH JV, 1990, PHYS REV B, V42, P9307, DOI 10.1103/PhysRevB.42.9307; Boccuzzi F, 2001, J CATAL, V202, P256, DOI 10.1006/jcat.2001.3290; Boyes ED, 1997, ULTRAMICROSCOPY, V67, P219, DOI 10.1016/S0304-3991(96)00099-X; FEDAK DG, 1967, SURF SCI, V8, P77, DOI 10.1016/0039-6028(67)90074-X; Feng YJ, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.125401; FIORENTINI V, 1993, PHYS REV LETT, V71, P1051, DOI 10.1103/PhysRevLett.71.1051; Fujitani T, 2011, ANGEW CHEM INT EDIT, V50, P10144, DOI 10.1002/anie.201104694; Gai PL, 2009, MICROSC RES TECHNIQ, V72, P153, DOI 10.1002/jemt.20668; GARDNER SD, 1991, LANGMUIR, V7, P2135, DOI 10.1021/la00058a027; Green IX, 2011, SCIENCE, V333, P736, DOI 10.1126/science.1207272; Haider M, 1998, NATURE, V392, P768, DOI 10.1038/33823; Hansen PL, 2002, SCIENCE, V295, P2053, DOI 10.1126/science.1069325; Hansen TW, 2010, MATER SCI TECH-LOND, V26, P1338, DOI 10.1179/026708310X12756557336355; Haruta M, 2002, CATTECH, V6, P102, DOI 10.1023/A:1020181423055; Haruta M, 1997, CATAL TODAY, V36, P153, DOI 10.1016/S0920-5861(96)00208-8; HARUTA M, 1989, J CATAL, V115, P301, DOI 10.1016/0021-9517(89)90034-1; Jacob T, 2007, ELECTROCHIM ACTA, V52, P2229, DOI 10.1016/j.electacta.2006.03.114; Jia CL, 2003, SCIENCE, V299, P870, DOI 10.1126/science.1079121; Koshino M, 2007, SCIENCE, V316, P853, DOI 10.1126/science.1138690; Liu Z, 2007, NAT NANOTECHNOL, V2, P422, DOI 10.1038/nnano.2007.187; Mavrikakis M, 2000, CATAL LETT, V64, P101, DOI 10.1023/A:1019028229377; McKenna KP, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2722751; Meyer JC, 2008, NANO LETT, V8, P3582, DOI 10.1021/nl801386m; Molina LM, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.155424; Oshima Y, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.035317; Oshima Y, 2010, J ELECTRON MICROSC, V59, P457, DOI 10.1093/jmicro/dfq017; Sasaki T, 2010, J ELECTRON MICROSC, V59, pS7, DOI 10.1093/jmicro/dfq027; TAKAYANAGI K, 1988, SURF SCI, V205, P637, DOI 10.1016/0039-6028(88)90306-8; VANHOVE MA, 1981, SURF SCI, V103, P189, DOI 10.1016/0039-6028(81)90107-2; Wang R, 2008, NANO LETT, V8, P962, DOI 10.1021/nl073135c; Yoshida H, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.195428; Yoshida H, 2008, NANO LETT, V8, P2082, DOI 10.1021/nl080452q; Yoshida H, 2011, APPL PHYS EXPRESS, V4, DOI 10.1143/APEX.4.065001; Zandbergen HW, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.036103; Zolyomi V, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/9/095007	36	310	318	11	507	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2012	335	6066					317	319		10.1126/science.1213194	http://dx.doi.org/10.1126/science.1213194			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267808				2022-12-28	WOS:000299273400042
J	Adu, J; Nixon, M; Bass, A				Adu, John; Nixon, Matthew; Bass, Alfie			PICTURE QUIZ A child with knee pain	BRITISH MEDICAL JOURNAL			English	Editorial Material							CAPITAL FEMORAL EPIPHYSIS; TERM FOLLOW-UP; CUNEIFORM OSTEOTOMY; NECK		[Adu, John; Nixon, Matthew; Bass, Alfie] Alder Hey Hosp, Liverpool L12 2AP, Merseyside, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital	Adu, J (corresponding author), Alder Hey Hosp, Liverpool L12 2AP, Merseyside, England.	john.adu@doctors.org.uk						AADALEN RJ, 1974, J BONE JOINT SURG AM, VA 56, P1473, DOI 10.2106/00004623-197456070-00016; ARONSON DD, 1992, J BONE JOINT SURG AM, V74A, P810, DOI 10.2106/00004623-199274060-00002; Billing L, 2002, PEDIATR RADIOL, V32, P423, DOI 10.1007/s00247-002-0697-4; BOYER DW, 1981, J BONE JOINT SURG AM, V63, P85, DOI 10.2106/00004623-198163010-00011; Brenkel IJ, 1998, J PEDIATR ORTHOPED, V8, P22; CARNEY BT, 1991, J BONE JOINT SURG AM, V73A, P667, DOI 10.2106/00004623-199173050-00004; DeRosa GP, 1996, CLIN ORTHOP RELAT R, P48; EISENSTEIN A, 1976, J BONE JOINT SURG AM, V58, P459, DOI 10.2106/00004623-197658040-00005; EXNER GU, 1986, J PEDIATR ORTHOPED, V6, P403, DOI 10.1097/01241398-198607000-00003; FISH JB, 1994, J BONE JOINT SURG AM, V76A, P46, DOI 10.2106/00004623-199401000-00007; Jacobs B, 1972, INSTRUCTIONAL COURSE, V21, P167; Jerre R, 1996, J PEDIATR ORTHOP B, V5, P80, DOI 10.1097/01202412-199605020-00005; Kalogrianitis S, 2007, J PEDIATR ORTHOP B, V16, P6, DOI 10.1097/01.bpb.0000236224.14325.f1; KLEIN A, 1952, J BONE JOINT SURG AM, V34-A, P233, DOI 10.2106/00004623-195234010-00033; LODER RT, 1993, J BONE JOINT SURG AM, V75A, P1134, DOI 10.2106/00004623-199308000-00002; Loder RT, 2001, J PEDIATR ORTHOPED, V21, P488, DOI 10.1097/00004694-200107000-00014; Loder RT, 1996, CLIN ORTHOP RELAT R, P8; Loder RT, 2000, J BONE JOINT SURG AM, V82A, P1170, DOI 10.2106/00004623-200008000-00015; Lowdnes S, 2009, BR MED B, V90, P133; MANN DC, 1988, J PEDIATR ORTHOPED, V8, P543, DOI 10.1097/01241398-198809000-00009; Matava MJ, 1999, J PEDIATR ORTHOPED, V19, P455, DOI 10.1097/00004694-199907000-00007; Rab GT, 1999, J PEDIATR ORTHOPED, V19, P419, DOI 10.1097/00004694-199907000-00001; STEEL HH, 1986, J BONE JOINT SURG AM, V68A, P920, DOI 10.2106/00004623-198668060-00015; Tosounidis T, 2010, J PEDIATR-US, V157, P674, DOI 10.1016/j.jpeds.2010.04.018; Uglow MG, 2004, J BONE JOINT SURG BR, V86B, P631, DOI 10.1302/0301-620X.86B5.15058	25	1	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JAN 19	2012	344								e250	10.1136/bmj.e250	http://dx.doi.org/10.1136/bmj.e250			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888ZA	22262786				2022-12-28	WOS:000300042000008
J	Berrill, JW; Ahmed, H; Butt, S; Swift, G				Berrill, James W.; Ahmed, Haroon; Butt, Sohail; Swift, Gillian			10-MINUTE CONSULTATION Reviewing a patient with coeliac disease	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Berrill, James W.; Swift, Gillian] Univ Hosp Llandough, Cardiff CF64 2XX, S Glam, Wales; [Ahmed, Haroon] Foundry Town Clin, Aberdare, Wales; [Butt, Sohail] Studholme Med Ctr, Ashford, Kent, England		Berrill, JW (corresponding author), Univ Hosp Llandough, Cardiff CF64 2XX, S Glam, Wales.	jamesberrill1@doctors.org.uk		Ahmed, Haroon/0000-0002-0634-8548					0	1	1	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 17	2012	344								d8152	10.1136/bmj.d8152	http://dx.doi.org/10.1136/bmj.d8152			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888YY	22251863	Green Accepted			2022-12-28	WOS:000300041800008
J	Soofi, S; Cousens, S; Imdad, A; Bhutto, N; Ali, N; Bhutta, ZA				Soofi, Sajid; Cousens, Simon; Imdad, Aamer; Bhutto, Naveed; Ali, Nabeela; Bhutta, Zulfiqar A.			Topical application of chlorhexidine to neonatal umbilical cords for prevention of omphalitis and neonatal mortality in a rural district of Pakistan: a community-based, cluster-randomised trial	LANCET			English	Article							HEALTH; INTERVENTION; MORBIDITY	Background Umbilical cord infection (omphalitis) is a risk factor for neonatal sepsis and mortality in low-resource settings where home deliveries are common. We aimed to assess the effect of umbilical-cord cleansing with 4% chlorhexidine (CHX) solution, with or without handwashing with antiseptic soap, on the incidence of omphalitis and neonatal mortality. Methods We did a two-by-two factorial, cluster-randomised trial in Dadu, a rural area of Sindh province, Pakistan. Clusters were defined as the population covered by a functional traditional birth attendant (TBA), and were randomly allocated to one of four groups (groups A to D) with a computer-generated random number sequence. Implementation and data collection teams were masked to allocation. Liveborn infants delivered by participating TBAs who received birth kits were eligible for enrolment in the study. One intervention comprised birth kits containing 4% CHX solution for application to the cord at birth by TBAs and once daily by family members for up to 14 days along with soap and educational messages promoting hand washing. One intervention was CHX solution only and another was handwashing only. Standard dry cord care was promoted in the control group. The primary outcomes were incidence of neonatal omphalitis and neonatal mortality. The trial is registered with ClinicalTrials.gov, number NCT00682006. Findings 187 clusters were randomly allocated to one of the four study groups. Of 9741 newborn babies delivered by participating TBAs, factorial analysis indicated a reduction in risk of omphalitis with CHX application (risk ratio [RR]=0.58, 95% CI 0.41-0.82; p=0.002) but no evidence of an effect of handwashing (RR=0.83, 0.61-1.13; p=0.24). We recorded strong evidence of a reduction in neonatal mortality in neonates who received CHX cleansing (RR=0.62, 95 % CI 0.45-0.85; p=0.003) but no evidence of an effect of handwashing promotion on neonatal mortality (RR=1.08, 0.79-1.48; p=0.62). We recorded no serious adverse events. Interpretation Application of 4% CHX to the umbilical cord was effective in reducing the risk of omphalitis and neonatal mortality in rural Pakistan. Provision of CHX in birth kits might be a useful strategy for the prevention of neonatal mortality in high-mortality settings.	[Soofi, Sajid; Cousens, Simon; Imdad, Aamer; Bhutto, Naveed; Bhutta, Zulfiqar A.] Aga Khan Univ, Div Women & Child Hlth, Karachi 74800, Pakistan; [Cousens, Simon; Bhutta, Zulfiqar A.] London Sch Hyg & Trop Med, London WC1, England; [Ali, Nabeela] John Snow Int Res Inst, Islamabad, Pakistan	Aga Khan University; University of London; London School of Hygiene & Tropical Medicine	Bhutta, ZA (corresponding author), Aga Khan Univ, Div Women & Child Hlth, Karachi 74800, Pakistan.	zulfiqar.bhutta@aku.edu	Imdad, Aamer/AAJ-3842-2020	Imdad, Aamer/0000-0002-7026-0006	PAIMAN (Pakistan Initiative for Mothers and Newborns); John Snow Inc via US Agency for International Development (USAID) [36098-01, 391-A-00-05-01037-00]	PAIMAN (Pakistan Initiative for Mothers and Newborns); John Snow Inc via US Agency for International Development (USAID)(United States Agency for International Development (USAID))	This study was funded by PAIMAN (Pakistan Initiative for Mothers and Newborns) and John Snow Inc, via a grant from by the US Agency for International Development (USAID; Award Number: 36098-01, cooperative agreement number 391-A-00-05-01037-00). We would like to acknowledge the support provided by members of the data safety and monitoring board (Sajid Maqbool, Salma Sheikh, Iqbal Memon, and Yaseen Meenai). We are grateful for the support provided by Kamran Sadiq. We would like to thank all the staff of the this study for their hard work and support, and, notably, the excellent support provided by Asghar Ali, the manager of outreach and research in the Women and Child Health Division, Aga Khan University. We are also thankful to Shabina Ariff for her contribution in preparation of this paper.	ALHAZZAA SAF, 1995, INT OPHTHALMOL, V19, P83, DOI 10.1007/BF00133177; [Anonymous], 1970, Br Med J, V3, P235; Bhutta ZA, 2004, PERINATAL NEWBORN CA; Bhutta ZA, 2011, LANCET, V377, P403, DOI 10.1016/S0140-6736(10)62274-X; Cairncross S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000365; Cairncross S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/ije/dyq035; Darmstadt GL, 2009, INT J GYNECOL OBSTET, V107, pS89, DOI 10.1016/j.ijgo.2009.07.010; Denton GW, 2001, DISINFECTION STERILI, P321; District health profile-Dadu, 2005, DISTR HLTH PROF DAD; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; El Arifeen S, 2012, LANCET, V379, P1022, DOI 10.1016/S0140-6736(11)61848-5; Hafeez A, 2011, J PAK MED ASSOC, V61, P210; Hundley VA, 2012, MIDWIFERY, V28, P204, DOI 10.1016/j.midw.2011.03.004; Jokhio AH, 2005, NEW ENGL J MED, V352, P2091, DOI 10.1056/NEJMsa042830; KAPOOR S K, 1991, Indian Journal of Pediatrics, V58, P341, DOI 10.1007/BF02754963; KLEIN J O, 1970, Clinical Obstetrics and Gynecology, V13, P321, DOI 10.1097/00003081-197006000-00008; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Luby SP, 2005, LANCET, V366, P225, DOI 10.1016/S0140-6736(05)66912-7; McClure EM, 2007, INT J GYNECOL OBSTET, V97, P89, DOI 10.1016/j.ijgo.2007.01.014; Meegan ME, 2001, LANCET, V358, P640, DOI 10.1016/S0140-6736(01)05787-7; MORTIMER EA, 1966, BMJ-BRIT MED J, V1, P319, DOI 10.1136/bmj.1.5483.319; Mullany LC, 2006, LANCET, V367, P910, DOI 10.1016/S0140-6736(06)68381-5; Mullany LC, 2007, AM J EPIDEMIOL, V165, P203, DOI 10.1093/aje/kwj356; Mullany LC, 2006, PEDIATR INFECT DIS J, V25, P665, DOI 10.1097/01.inf.0000223489.02791.70; National Institute of Population Studies (NIPS) Pakistan and Macro International Inc, 2008, PAK DEM HLTH SURV 20; Oxford Policy Management Group, LAD HLTH WORK PROGR; Panyavudhikrai Sopapan, 2002, Journal of the Medical Association of Thailand, V85, P229; Parashar UD, 1998, INT J EPIDEMIOL, V27, P904, DOI 10.1093/ije/27.5.904; Patel A B, 2001, Int J Occup Environ Health, V7, P119; Patel AB, 2011, INT J OCCUP ENV HEAL, V17, P24, DOI 10.1179/107735211799031040; Qadir Maqbool, 2009, V13, P148; Rhee V, 2008, ARCH PEDIAT ADOL MED, V162, P603, DOI 10.1001/archpedi.162.7.603; Saleem S, 2010, OBSTET GYNECOL, V115, P1225, DOI 10.1097/AOG.0b013e3181e00ff0; SARKANY I, 1968, J PATHOL BACTERIOL, V95, P115, DOI 10.1002/path.1700950113; Thaver D, 2009, PEDIATR INFECT DIS J, V28, pS3, DOI 10.1097/INF.0b013e3181958755; WHO, 2011, ESS MED LIST 2011; Zupan J, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/1465-1858.CD001057	38	102	104	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2012	379	9820					1029	1036		10.1016/S0140-6736(11)61877-1	http://dx.doi.org/10.1016/S0140-6736(11)61877-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JE	22322126				2022-12-28	WOS:000301712300031
J	Atala, A				Atala, Anthony			Human embryonic stem cells: early hints on safety and efficacy	LANCET			English	Editorial Material							FIBROBLASTS		Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Atala, A (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Inst Regenerat Med, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	aatala@wakehealth.edu		Atala, Anthony/0000-0001-8186-2160				Frantz S, 2012, NAT BIOTECHNOL, V30, P12, DOI 10.1038/nbt0112-12; Lee AS, 2009, CELL CYCLE, V8, P2608, DOI 10.4161/cc.8.16.9353; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; THOMAS ED, 1957, NEW ENGL J MED, V257, P491, DOI 10.1056/NEJM195709122571102; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259	11	16	16	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2012	379	9817					689	690		10.1016/S0140-6736(12)60118-4	http://dx.doi.org/10.1016/S0140-6736(12)60118-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899CU	22281387				2022-12-28	WOS:000300792600005
J	Whyte, WA; Bilodeau, S; Orlando, DA; Hoke, HA; Frampton, GM; Foster, CT; Cowley, SM; Young, RA				Whyte, Warren A.; Bilodeau, Steve; Orlando, David A.; Hoke, Heather A.; Frampton, Garrett M.; Foster, Charles T.; Cowley, Shaun M.; Young, Richard A.			Enhancer decommissioning by LSD1 during embryonic stem cell differentiation	NATURE			English	Article							HISTONE DEMETHYLASE; INTERACTION NETWORK; GENE; TRANSCRIPTION; CHROMATIN; EXPRESSION; COMPLEXES; PROGRAMS; OCT-3/4; SOX2	Transcription factors and chromatin modifiers are important in the programming and reprogramming of cellular states during development(1,2). Transcription factors bind to enhancer elements and recruit coactivators and chromatin-modifying enzymes to facilitate transcription initiation(3,4). During differentiation a subset of these enhancers must be silenced, but the mechanisms underlying enhancer silencing are poorly understood. Here we show that the histone demethylase lysine-specific demethylase 1 (LSD1; ref. 5), which demethylates histone H3 on Lys 4 or Lys 9 (H3K4/K9), is essential in decommissioning enhancers during the differentiation of mouse embryonic stem cells (ESCs). LSD1 occupies enhancers of active genes that are critical for control of the state of ESCs. However, LSD1 is not essential for the maintenance of ESC identity. Instead, ESCs lacking LSD1 activity fail to differentiate fully, and ESC-specific enhancers fail to undergo the histone demethylation events associated with differentiation. At active enhancers, LSD1 is a component of the NuRD (nucleosome remodelling and histone deacetylase) complex, which contains additional subunits that are necessary for ESC differentiation. We propose that the LSD1-NuRD complex decommissions enhancers of the pluripotency program during differentiation, which is essential for the complete shutdown of the ESC gene expression program and the transition to new cell states.	[Whyte, Warren A.; Bilodeau, Steve; Orlando, David A.; Hoke, Heather A.; Frampton, Garrett M.; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Whyte, Warren A.; Hoke, Heather A.; Frampton, Garrett M.; Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Foster, Charles T.] Univ Munich, Adolf Butenandt Inst, Dept Mol Biol, D-80336 Munich, Germany; [Foster, Charles T.; Cowley, Shaun M.] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Munich; University of Leicester	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	young@wi.mit.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Bilodeau, Steve/0000-0002-9799-3832; Cowley, Shaun/0000-0002-2510-1305; Frampton, Garrett/0000-0002-2361-2750	Canadian Institutes of Health Research; Medical Research Council; National Institutes of Health [HG002668, NS055923]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS055923] Funding Source: NIH RePORTER; Medical Research Council [G0600135, MR/J009202/1] Funding Source: researchfish; MRC [G0600135, MR/J009202/1] Funding Source: UKRI	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank J. Loven, M. H. Kagey, J. Dowen, A. C. Mullen, A. Sigova, P. B. Rahl, T. Lee and members of Y. Shi's laboratory for experimental assistance, reagents and helpful discussions; and J.-A. Kwon, V. Dhanapal, J. Love, S. Gupta, T. Volkert, W. Salmon and N. Watson for assistance with ChIP-Seq, expression arrays and immunofluorescence imaging acquisition. This work was supported by a Canadian Institutes of Health Research Fellowship (S. B.), a Career Development Award from the Medical Research Council (S. M. C.), and by National Institutes of Health grants HG002668 and NS055923 (R.Y.).	Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Choi J, 2010, BIOCHEM BIOPH RES CO, V401, P327, DOI 10.1016/j.bbrc.2010.09.014; Dovey OM, 2010, P NATL ACAD SCI USA, V107, P8242, DOI 10.1073/pnas.1000478107; Forneris F, 2005, J BIOL CHEM, V280, P41360, DOI 10.1074/jbc.M509549200; Foster CT, 2010, MOL CELL BIOL, V30, P4851, DOI 10.1128/MCB.00521-10; Fuda NJ, 2009, NATURE, V461, P186, DOI 10.1038/nature08449; Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kaji K, 2006, NAT CELL BIOL, V8, P285, DOI 10.1038/ncb1372; Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Musri MM, 2010, J BIOL CHEM, V285, P30034, DOI 10.1074/jbc.M110.151209; Nakatake Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okumura-Nakanishi S, 2005, J BIOL CHEM, V280, P5307, DOI 10.1074/jbc.m410015200; Pardo M, 2010, CELL STEM CELL, V6, P382, DOI 10.1016/j.stem.2010.03.004; Ray S, 2009, J BIOL CHEM, V284, P4978, DOI 10.1074/jbc.M807329200; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; Scimone ML, 2010, DEVELOPMENT, V137, P1231, DOI 10.1242/dev.042051; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; van den Berg DLC, 2010, CELL STEM CELL, V6, P369, DOI 10.1016/j.stem.2010.02.014; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Yeom YI, 1996, DEVELOPMENT, V122, P881; Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032	30	411	431	6	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2012	482	7384					221	225		10.1038/nature10805	http://dx.doi.org/10.1038/nature10805			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22297846	Green Accepted			2022-12-28	WOS:000299994100039
J	Wang, CJ; Huang, AT				Wang, C. Jason; Huang, Andrew T.			Integrating Technology Into Health Care What Will It Take?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Wang, C. Jason] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Huang, Andrew T.] Duke Univ, Dept Med, Durham, NC USA; [Huang, Andrew T.] Sun Yat Sen Canc Ctr, Koo Fdn, Taipei, Taiwan	Stanford University; Duke University	Wang, CJ (corresponding author), CHP PCOR, 117 Encina Commons, Stanford, CA 94305 USA.	cjwang1@stanford.edu			OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD008647] Funding Source: NIH RePORTER; NIH HHS [DP2 OD008647] Funding Source: Medline	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Brown A., UPDATE GOOGLE HLTH G; Christensen C, 2009, INNOVATORS PRESCRIPT; DesRoches CM, 2008, NEW ENGL J MED, V359, P50, DOI 10.1056/NEJMsa0802005; Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3; Vlopp KG, 2009, NEW ENGL J MED, V361, P331, DOI 10.1056/NEJMp0903496	5	29	30	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					569	570		10.1001/jama.2012.102	http://dx.doi.org/10.1001/jama.2012.102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318276				2022-12-28	WOS:000299992500019
J	Sexton, T; Yaffe, E; Kenigsberg, E; Bantignies, F; Leblanc, B; Hoichman, M; Parrinello, H; Tanay, A; Cavalli, G				Sexton, Tom; Yaffe, Eitan; Kenigsberg, Ephraim; Bantignies, Frederic; Leblanc, Benjamin; Hoichman, Michael; Parrinello, Hugues; Tanay, Amos; Cavalli, Giacomo			Three-Dimensional Folding and Functional Organization Principles of the Drosophila Genome	CELL			English	Article							GENE-EXPRESSION; CHROMOSOME CONFORMATION; NUCLEAR-ORGANIZATION; INTERPHASE CHROMOSOMES; CHROMATIN INTERACTOME; CHROMODOMAIN PROTEIN; RESPONSE ELEMENTS; YEAST GENOME; POLYCOMB; TRANSCRIPTION	Chromosomes are the physical realization of genetic information and thus form the basis for its readout and propagation. Here we present a high-resolution chromosomal contact map derived from a modified genome-wide chromosome conformation capture approach applied to Drosophila embryonic nuclei. The data show that the entire genome is linearly partitioned into well-demarcated physical domains that overlap extensively with active and repressive epigenetic marks. Chromosomal contacts are hierarchically organized between domains. Global modeling of contact density and clustering of domains show that inactive domains are condensed and confined to their chromosomal territories, whereas active domains reach out of the territory to form remote intra-and interchromosomal contacts. Moreover, we systematically identify specific long-range intrachromosomal contacts between Polycomb-repressed domains. Together, these observations allow for quantitative prediction of the Drosophila chromosomal contact map, laying the foundation for detailed studies of chromosome structure and function in a genetically tractable system.	[Yaffe, Eitan; Kenigsberg, Ephraim; Hoichman, Michael; Tanay, Amos] Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel; [Sexton, Tom; Bantignies, Frederic; Leblanc, Benjamin; Cavalli, Giacomo] CNRS, Inst Genet Humaine, UPR 1142, F-34396 Montpellier 5, France; [Yaffe, Eitan; Kenigsberg, Ephraim; Hoichman, Michael; Tanay, Amos] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Parrinello, Hugues] Montpellier GenomiX IBiSA, F-34396 Montpellier 5, France	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Weizmann Institute of Science	Tanay, A (corresponding author), Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel.	amos.tanay@weizmann.ac.il; giacomo.cavalli@igh.cnrs.fr	Kenigsberg, Ephraim/AAM-5690-2020; Cavalli, Giacomo/A-7958-2008; cavalli, giacomo/Z-2754-2019	Cavalli, Giacomo/0000-0003-3709-3469; cavalli, giacomo/0000-0003-3709-3469; Sexton, Thomas/0000-0002-7824-1846; Yaffe, Eitan/0000-0002-2896-3349; Leblanc, Benjamin/0000-0002-8657-2821	European Research Council [ERC-2008-AdG, 232947]; CNRS; European Network of Excellence EpiGeneSys; Agence Nationale de la Recherche; Association pour la Recherche sur le Cancer; Fondation pour la Recherche Medicale; Israel Science Foundation; MODHEP	European Research Council(European Research Council (ERC)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); European Network of Excellence EpiGeneSys; Agence Nationale de la Recherche(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Israel Science Foundation(Israel Science Foundation); MODHEP	Research at the G.C. lab was supported by grants from the European Research Council (ERC-2008-AdG No 232947), the CNRS, the European Network of Excellence EpiGeneSys, and the Agence Nationale de la Recherche, by the Association pour la Recherche sur le Cancer, and by a fellowship to T.S. by the Fondation pour la Recherche Medicale. Research at the A.T. lab was supported by the Israel Science Foundation (Converging Technologies Program), European Network of Excellence EpiGeneSys, and the European Large Scale Collaborative Project MODHEP.	Apostolou E, 2008, CELL, V134, P85, DOI 10.1016/j.cell.2008.05.052; Artero RD, 2001, DEVELOPMENT, V128, P4251; Bantignies F, 2011, CELL, V144, P214, DOI 10.1016/j.cell.2010.12.026; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Comet I, 2011, P NATL ACAD SCI USA, V108, P2294, DOI 10.1073/pnas.1002059108; Cremer T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003889; de Wit E, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000045; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Duan Z, 2010, NATURE, V465, P363, DOI 10.1038/nature08973; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Filion GJ, 2010, CELL, V143, P212, DOI 10.1016/j.cell.2010.09.009; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Grimaud C, 2006, CELL, V124, P957, DOI 10.1016/j.cell.2006.01.036; Handoko L, 2011, NAT GENET, V43, P630, DOI 10.1038/ng.857; Heermann DW, 2011, CURR OPIN CELL BIOL, V23, P332, DOI 10.1016/j.ceb.2011.03.010; Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105; Kharchenko PV, 2011, NATURE, V471, P480, DOI 10.1038/nature09725; Lanctot C, 2007, NAT REV GENET, V8, P104, DOI 10.1038/nrg2041; Lanzuolo C, 2007, NAT CELL BIOL, V9, P1167, DOI 10.1038/ncb1637; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Lowenstein MG, 2004, MOL BIOL CELL, V15, P5678, DOI 10.1091/mbc.E04-04-0289; Mateos-Langerak J, 2009, P NATL ACAD SCI USA, V106, P3812, DOI 10.1073/pnas.0809501106; Munkel C, 1999, J MOL BIOL, V285, P1053, DOI 10.1006/jmbi.1998.2361; Noordermeer D, 2011, NAT CELL BIOL, V13, P944, DOI 10.1038/ncb2278; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; Rath U, 2004, J CELL BIOCHEM, V93, P1033, DOI 10.1002/jcb.20243; Rath U, 2006, J CELL SCI, V119, P2332, DOI 10.1242/jcs.02960; Robinson PJJ, 2006, CURR OPIN STRUC BIOL, V16, P336, DOI 10.1016/j.sbi.2006.05.007; SACHS RK, 1995, P NATL ACAD SCI USA, V92, P2710, DOI 10.1073/pnas.92.7.2710; Schoenfelder S, 2010, NAT GENET, V42, P53, DOI 10.1038/ng.496; Schuettengruber B, 2009, PLOS BIOL, V7, P146, DOI 10.1371/journal.pbio.1000013; Schwartz YB, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000805; Sexton T, 2007, NAT STRUCT MOL BIOL, V14, P1049, DOI 10.1038/nsmb1324; Sexton T, 2009, SEMIN CELL DEV BIOL, V20, P849, DOI 10.1016/j.semcdb.2009.06.004; Shelton C, 2009, DEVELOPMENT, V136, P1159, DOI 10.1242/dev.026302; Simonis M, 2006, NAT GENET, V38, P1348, DOI 10.1038/ng1896; Tanizawa H, 2010, NUCLEIC ACIDS RES, V38, P8164, DOI 10.1093/nar/gkq955; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Tolhuis B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001343; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; Wood AM, 2011, MOL CELL, V44, P29, DOI 10.1016/j.molcel.2011.07.035; Wurtele H, 2006, CHROMOSOME RES, V14, P477, DOI 10.1007/s10577-006-1075-0; Yaffe E, 2011, NAT GENET, V43, P1059, DOI 10.1038/ng.947; Zhao Z, 2006, NAT GENET, V38, P1341, DOI 10.1038/ng1891	44	1220	1255	3	111	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					458	472		10.1016/j.cell.2012.01.010	http://dx.doi.org/10.1016/j.cell.2012.01.010			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22265598	Bronze			2022-12-28	WOS:000300225000015
J	Nodine, MD; Bartel, DP				Nodine, Michael D.; Bartel, David P.			Maternal and paternal genomes contribute equally to the transcriptome of early plant embryos	NATURE			English	Article							TO-ZYGOTIC TRANSITION; SEED DEVELOPMENT; GENE-EXPRESSION; EARLY EMBRYOGENESIS; PATTERN-FORMATION; ARABIDOPSIS; CELLS; ACTIVATION; ENDOSPERM; CHROMATIN	In animals, maternal gene products deposited into eggs regulate embryonic development before activation of the zygotic genome(1). In plants, an analogous period of prolonged maternal control over embryogenesis is thought to occur based on some gene-expression studies(2-6). However, other gene-expression studies and genetic analyses show that some transcripts must derive from the early zygotic genome(7-14), implying that the prevailing model does not fully explain the nature of zygotic genome activation in plants. To determine the maternal, paternal and zygotic contributions to the early embryonic transcriptome, we sequenced the transcripts of hybrid embryos from crosses between two polymorphic inbred lines of Arabidopsis thaliana and used single-nucleotide polymorphisms diagnostic of each parental line to quantify parental contributions. Although some transcripts seemed to be either inherited from primarily one parent or transcribed from imprinted loci, the vast majority of transcripts were produced in near-equal amounts from both maternal and paternal alleles, even during the initial stages of embryogenesis. Results of reporter experiments and analyses of transcripts from genes that are not expressed in sperm and egg indicate early and widespread zygotic transcription. Thus, in contrast to early animal embryogenesis, early plant embryogenesis is mostly under zygotic control.	[Nodine, Michael D.; Bartel, David P.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Nodine, Michael D.; Bartel, David P.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Nodine, Michael D.; Bartel, David P.] MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Bartel, DP (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	dbartel@wi.mit.edu	Nodine, Michael/D-3897-2014	Nodine, Michael/0000-0002-6204-8857	NIH [GM067031, GM084656]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM084656, R01GM067031] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. Ecker and the 1001 Genomes Project for generating the list of Cvi-0 SNPs; the J. Harada and R. Goldberg laboratories for making the Arabidopsis seed development LCM microarray data sets publicly available; I. Moore for the transactivation vectors; J. Long for the UBI3 promoter fragment; the Whitehead Genome Technology Core for sequencing; and D. Meinke for providing a curated list of preglobular zygotic-recessive mutants before publication. This work used the W. M. Keck Biological Imaging Facility at the Whitehead Institute and was supported by NIH grant GM067031 (D. P. B.) and NIH Postdoctoral Fellowship GM084656 (M.D.N). D. P. B. is an Investigator of the Howard Hughes Medical Institute.	[Anonymous], 2010, R LANG ENV STAT COMP; Autran D, 2011, CELL, V145, P707, DOI 10.1016/j.cell.2011.04.014; Baroux C, 2008, COLD SH Q B, V73, P89, DOI 10.1101/sqb.2008.73.053; Baroux C, 2001, FEBS LETT, V509, P11, DOI 10.1016/S0014-5793(01)03097-6; Bayer M, 2009, SCIENCE, V323, P1485, DOI 10.1126/science.1167784; Borges F, 2008, PLANT PHYSIOL, V148, P1168, DOI 10.1104/pp.108.125229; Feil R, 2007, TRENDS GENET, V23, P192, DOI 10.1016/j.tig.2007.02.004; Gehring M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023687; Grimanelli D, 2005, PLANT CELL, V17, P1061, DOI 10.1105/tpc.104.029819; Hsieh TF, 2011, P NATL ACAD SCI USA, V108, P1755, DOI 10.1073/pnas.1019273108; Ingouff M, 2010, CURR BIOL, V20, P2137, DOI 10.1016/j.cub.2010.11.012; Jahnke S, 2009, CURR BIOL, V19, P1677, DOI 10.1016/j.cub.2009.08.053; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Laux T, 2004, PLANT CELL, V16, pS190, DOI 10.1105/tpc.016014; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; Meyer S, 2007, CURR BIOL, V17, P1686, DOI 10.1016/j.cub.2007.08.046; Moore I, 1998, P NATL ACAD SCI USA, V95, P376, DOI 10.1073/pnas.95.1.376; Muralla R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028398; Nodine MD, 2010, GENE DEV, V24, P2678, DOI 10.1101/gad.1986710; Pillot M, 2010, PLANT CELL, V22, P307, DOI 10.1105/tpc.109.071647; Ronceret A, 2008, PLANT J, V53, P776, DOI 10.1111/j.1365-313X.2007.03372.x; Scholten S, 2002, PLANT J, V32, P221, DOI 10.1046/j.1365-313X.2002.01418.x; Springer PS, 2000, DEVELOPMENT, V127, P1815; Sprunck S, 2005, PLANT J, V41, P660, DOI 10.1111/j.1365-313X.2005.02332.x; Tadros W, 2009, DEVELOPMENT, V136, P3033, DOI 10.1242/dev.033183; Vielle-Calzada JP, 2000, NATURE, V404, P91, DOI 10.1038/35003595; Weijers D, 2001, NATURE, V414, P709, DOI 10.1038/414709a; Wuest SE, 2010, CURR BIOL, V20, P506, DOI 10.1016/j.cub.2010.01.051; Xu J, 2005, PLANT J, V42, P743, DOI 10.1111/j.1365-313X.2005.02411.x; Zhao J, 2011, PLANT J, V65, P131, DOI 10.1111/j.1365-313X.2010.04403.x	30	141	146	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2012	482	7383					94	U120		10.1038/nature10756	http://dx.doi.org/10.1038/nature10756			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22266940	Green Accepted, Green Submitted			2022-12-28	WOS:000299726000042
J	Nair, RR; Wu, HA; Jayaram, PN; Grigorieva, IV; Geim, AK				Nair, R. R.; Wu, H. A.; Jayaram, P. N.; Grigorieva, I. V.; Geim, A. K.			Unimpeded Permeation of Water Through Helium-Leak-Tight Graphene-Based Membranes	SCIENCE			English	Article							CARBON NANOTUBES; GRAPHITE OXIDE; DYNAMICS; FLUID; FLOW	Permeation through nanometer pores is important in the design of materials for filtration and separation techniques and because of unusual fundamental behavior arising at the molecular scale. We found that submicrometer-thick membranes made from graphene oxide can be completely impermeable to liquids, vapors, and gases, including helium, but these membranes allow unimpeded permeation of water (H2O permeates through the membranes at least 10(10) times faster than He). We attribute these seemingly incompatible observations to a low-friction flow of a monolayer of water through two-dimensional capillaries formed by closely spaced graphene sheets. Diffusion of other molecules is blocked by reversible narrowing of the capillaries in low humidity and/or by their clogging with water.	[Nair, R. R.; Wu, H. A.; Grigorieva, I. V.; Geim, A. K.] Univ Manchester, Sch Phys & Astron, Manchester M13 9PL, Lancs, England; [Nair, R. R.; Jayaram, P. N.; Geim, A. K.] Univ Manchester, Ctr Mesosci & Nanotechnol, Manchester M13 9PL, Lancs, England; [Wu, H. A.] Univ Sci & Technol China, Dept Modern Mech, Chinese Acad Sci, Key Lab Mech Behav & Design Mat, Hefei 230027, Anhui, Peoples R China	University of Manchester; University of Manchester; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Geim, AK (corresponding author), Univ Manchester, Sch Phys & Astron, Manchester M13 9PL, Lancs, England.	geim@manchester.ac.uk	Nair, Rahul Raveendran/Z-1566-2019; Geim, Andre K/J-7888-2012; Raveendran Nair, Rahul/G-5839-2010; Wu, Hengan/A-3646-2009	Geim, Andre K/0000-0003-2861-8331; Wu, Hengan/0000-0003-0288-1617	Engineering and Physical Research Council (UK); U.S. Office of Naval Research; U.S. Air Force Office of Scientific Research; Royal Society; Korber Foundation; National Science Foundation of China; University of Science and Technology of China; EPSRC [EP/G035954/1, EP/K005014/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/K005014/1, EP/G035954/1] Funding Source: researchfish	Engineering and Physical Research Council (UK)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); U.S. Office of Naval Research(Office of Naval Research); U.S. Air Force Office of Scientific Research(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); Royal Society(Royal Society of London); Korber Foundation; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); University of Science and Technology of China; EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by the Engineering and Physical Research Council (UK), the U.S. Office of Naval Research, the U.S. Air Force Office of Scientific Research, the Royal Society, and the Korber Foundation. We thank K. S. Novoselov, E. Hill, P. Blake, S. Neubeck, and R. Joshi for their help. H. A. W. is grateful for support from the National Science Foundation of China and Oversea Academic Training Funds-University of Science and Technology of China.	Bunch JS, 2008, NANO LETT, V8, P2458, DOI 10.1021/nl801457b; Caupin F, 2008, EPL-EUROPHYS LETT, V82, DOI 10.1209/0295-5075/82/56004; Cerveny S, 2010, J PHYS CHEM C, V114, P2604, DOI 10.1021/jp907979v; Dikin DA, 2007, NATURE, V448, P457, DOI 10.1038/nature06016; Eda G, 2010, ADV MATER, V22, P2392, DOI 10.1002/adma.200903689; Geim AK, 2009, SCIENCE, V324, P1530, DOI 10.1126/science.1158877; Giovambattista N, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.050603; Goedecke N, 2002, LAB CHIP, V2, P219, DOI 10.1039/b208031c; Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298; Jeong HK, 2009, CHEM PHYS LETT, V470, P255, DOI 10.1016/j.cplett.2009.01.050; Kofinger J, 2008, P NATL ACAD SCI USA, V105, P13218, DOI 10.1073/pnas.0801448105; Leenaerts O, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3021413; Lerf A, 2006, J PHYS CHEM SOLIDS, V67, P1106, DOI 10.1016/j.jpcs.2006.01.031; Li YX, 2010, MICROFLUID NANOFLUID, V9, P1011, DOI 10.1007/s10404-010-0612-5; LIVSHITS AI, 1995, J NUCL MATER, V220, P259, DOI 10.1016/0022-3115(94)00424-2; Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a; McAllister MJ, 2007, CHEM MATER, V19, P4396, DOI 10.1021/cm0630800; NORTON FJ, 1953, J AM CERAM SOC, V36, P90, DOI 10.1111/j.1151-2916.1953.tb12843.x; Pacile D, 2011, CARBON, V49, P966, DOI 10.1016/j.carbon.2010.09.063; Peng XS, 2009, NAT NANOTECHNOL, V4, P353, DOI [10.1038/NNANO.2009.90, 10.1038/nnano.2009.90]; Qin XC, 2011, NANO LETT, V11, P2173, DOI 10.1021/nl200843g; Rasaiah JC, 2008, ANNU REV PHYS CHEM, V59, P713, DOI 10.1146/annurev.physchem.59.032607.093815; Robinson JT, 2008, NANO LETT, V8, P3441, DOI 10.1021/nl8023092; Thomas JA, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.184502; Whitby M, 2007, NAT NANOTECHNOL, V2, P87, DOI 10.1038/nnano.2006.175; Wilson NR, 2009, ACS NANO, V3, P2547, DOI 10.1021/nn900694t; Zangi R, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.025502	27	2126	2269	118	2279	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2012	335	6067					442	444		10.1126/science.1211694	http://dx.doi.org/10.1126/science.1211694			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282806	Green Submitted			2022-12-28	WOS:000299466800042
J	Nunes, VD; Sawyer, L; Neilson, J; Sarri, G; Cross, JH				Nunes, Vanessa Delgado; Sawyer, Laura; Neilson, Julie; Sarri, Grammati; Cross, J. Helen			Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Nunes, Vanessa Delgado; Sawyer, Laura; Neilson, Julie; Sarri, Grammati] Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England; [Cross, J. Helen] Great Ormond St Hosp Sick Children, UCL Inst Child Hlth, London, England; [Cross, J. Helen] Young Epilepsy, Lingfield RH7 6PW, England	Royal College of Physicians; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Nunes, VD (corresponding author), Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England.	vanessa.nunes@rcplondon.ac.uk	Cross, J. Helen/ACK-3032-2022	Cross, J. Helen/0000-0001-7345-4829				[Anonymous], NAT HLTH SERV DRUG T; Chowdhury FA, 2008, EUR J NEUROL, V15, P1034, DOI 10.1111/j.1468-1331.2008.02260.x; Clinical Standards Advisory Group (CSAG), 2000, SERV PAT EP; Medicines and Healthcare Products Regulatory Agency, 2011, ANT; National Institute for Health and Clinical Excellence: Guidance, 2012, EP DIAGN MAN EP AD C	5	73	80	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 26	2012	344								e281	10.1136/bmj.e281	http://dx.doi.org/10.1136/bmj.e281			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885LE	22282528	Green Submitted			2022-12-28	WOS:000299779700003
J	Kelley, LA; Endler, JA				Kelley, Laura A.; Endler, John A.			Illusions Promote Mating Success in Great Bowerbirds	SCIENCE			English	Article							FEMALE PREFERENCES; PIGEONS PERCEIVE; PERCEPTION; EVOLUTION	Sexual selection studies normally compare signal strengths, but signal components and sensory processing may interact to create misleading or attention-capturing illusions. Visual illusions can be produced by altering object and scene geometry in ways that trick the viewer when seen from a particular direction. Male great bowerbirds actively maintain size-distance gradients of objects on their bower courts that create forced-perspective illusions for females viewing their displays from within the bower avenue. We show a significant relationship between mating success and the female's view of the gradient; this view explains substantially more variance in mating success than the strength of the gradients. Illusions may be widespread in other animals because males of most species display to females with characteristic orientation and distance, providing excellent conditions for illusions.	[Kelley, Laura A.; Endler, John A.] Deakin Univ, Sch Life & Environm Sci, Ctr Integrat Ecol, Geelong, Vic 3216, Australia; [Endler, John A.] James Cook Univ, Sch Marine & Trop Ecol, Townsville, Qld 4811, Australia	Deakin University; James Cook University	Endler, JA (corresponding author), Deakin Univ, Sch Life & Environm Sci, Ctr Integrat Ecol, Geelong, Vic 3216, Australia.	john.endler@deakin.edu.au	Kelley, Laura/A-4268-2011; Endler, John A/B-6659-2009	Kelley, Laura/0000-0003-0700-1471; Endler, John A/0000-0002-7557-7627	Deakin University	Deakin University	We thank the Smith family for access and hospitality at Dreghorn Station; L. Endler for help in fieldwork and photograph analysis; Deakin University for financial support; and L. Barrett, B. Buttemer, J. Madden, S. Nakagawa, M. Richardson, J. Zeil, and two anonymous reviewers for excellent comments on the manuscript. The field research was done with an EPA-Queensland Parks and Wildlife Service permit (WISP01994004) and ethics approval from Deakin University (A22-2010) and James Cook University (A1318). Data are in the supporting online material.	Akre KL, 2011, SCIENCE, V333, P751, DOI 10.1126/science.1205623; Andersson Malte, 1994; Bateson M, 2005, TRENDS ECOL EVOL, V20, P659, DOI 10.1016/j.tree.2005.08.013; BORGIA G, 1985, ANIM BEHAV, V33, P266, DOI 10.1016/S0003-3472(85)80140-8; Coleman SW, 2007, BIOL LETTERS, V3, P463, DOI 10.1098/rsbl.2007.0234; Coren S., 1978, SEEING IS DECEIVING; Dakin SC, 2009, J VIS, V9; Endler JA, 2005, EVOLUTION, V59, P1795, DOI 10.1111/j.0014-3820.2005.tb01827.x; Endler JA, 1998, TRENDS ECOL EVOL, V13, P415, DOI 10.1016/S0169-5347(98)01471-2; Endler JA, 1996, AM NAT, V148, P421, DOI 10.1086/285934; Endler JA, 2010, CURR BIOL, V20, P1679, DOI 10.1016/j.cub.2010.08.033; Frith C, 2004, BOWERBIRDS PTILONORH; FUJITA K, 1991, ANIM LEARN BEHAV, V19, P283, DOI 10.3758/BF03197888; Madden JR, 2003, BEHAV ECOL SOCIOBIOL, V53, P263, DOI 10.1007/s00265-003-0582-7; Nakamura N, 2008, J EXP PSYCHOL ANIM B, V34, P375, DOI 10.1037/0097-7403.34.3.375; Nakamura N, 2006, J COMP PSYCHOL, V120, P252, DOI 10.1037/0735-7036.120.3.252; Patricelli GL, 2002, NATURE, V415, P279, DOI 10.1038/415279a; Pepperberg IM, 2008, PERCEPTION, V37, P765, DOI 10.1068/p5898; Pryke SR, 2008, BEHAV ECOL, V19, P1116, DOI 10.1093/beheco/arn100; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Rogers B, 2010, PERCEPTION, V39, P330, DOI 10.1068/p6583; Ross H. E., 1998, PERCEPTUAL CONSTANCY, P499; Watanabe S, 2011, COGNITION, V119, P137, DOI 10.1016/j.cognition.2010.10.020	23	43	44	1	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					335	338		10.1126/science.1212443	http://dx.doi.org/10.1126/science.1212443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267812				2022-12-28	WOS:000299273400047
J	Eccleston, A; Eggleston, A; Heemels, MT; Marte, B; Weiss, U				Eccleston, Alex; Eggleston, Angela; Heemels, Marie-Therese; Marte, Barbara; Weiss, Ursula			FRONTIERS IN BIOLOGY	NATURE			English	Editorial Material																			0	0	0	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2012	481	7381					277	277		10.1038/481277a	http://dx.doi.org/10.1038/481277a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258605	Bronze			2022-12-28	WOS:000299210600051
J	Misra, S; Froelich, PN				Misra, Sambuddha; Froelich, Philip N.			Lithium Isotope History of Cenozoic Seawater: Changes in Silicate Weathering and Reverse Weathering	SCIENCE			English	Article							CLAY MINERAL FORMATION; CHEMICAL-COMPOSITION; GEOCHEMISTRY; ELEMENT; RECORD; RIVERS; CYCLE; LI; FRACTIONATION; EXTINCTION	Weathering of uplifted continental rocks consumes carbon dioxide and transports cations to the oceans, thereby playing a critical role in controlling both seawater chemistry and climate. However, there are few archives of seawater chemical change that reveal shifts in global tectonic forces connecting Earth ocean-climate processes. We present a 68-million-year record of lithium isotopes in seawater (delta Li-7(SW)) reconstructed from planktonic foraminifera. From the Paleocene (60 million years ago) to the present, delta Li-7(SW) rose by 9 per mil (parts per thousand), requiring large changes in continental weathering and seafloor reverse weathering that are consistent with increased tectonic uplift, more rapid continental denudation, increasingly incongruent continental weathering (lower chemical weathering intensity), and more rapid CO2 drawdown. A 5 parts per thousand drop in delta Li-7(SW) across the Cretaceous-Paleogene boundary cannot be produced by an impactor or by Deccan trap volcanism, suggesting large-scale continental denudation.	[Misra, Sambuddha] Florida State Univ, Natl High Magnet Field Lab, Geochem Grp, Tallahassee, FL 32310 USA; [Misra, Sambuddha] Florida State Univ, Dept Earth Ocean & Atmospher Sci, Tallahassee, FL 32310 USA; [Froelich, Philip N.] Froelich Educ Serv, Tallahassee, FL 32309 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University	Misra, S (corresponding author), Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England.	sm929@cam.ac.uk			U.S. National Science Foundation (MGG); American Chemical Society; Francis Eppes Society of Florida State University	U.S. National Science Foundation (MGG); American Chemical Society(American Chemical Society); Francis Eppes Society of Florida State University	We thank the U.S. National Science Foundation (MG&G), American Chemical Society (Petroleum Research Fund), and The Francis Eppes Society of Florida State University for providing financial support. We sincerely thank S. Clemens, D. Hodell, E. Hathorne, E. Martin, E. Thomas, W. Landing, and H. Spero for providing samples. The manuscript greatly benefited from the constructive reviews of M. Bender, V. Salters, M. Humayun, A. Paytan, P. Pogge von Strandmann, and an anonymous reviewer. We are very thankful to B. Peucker-Ehrenrbrink and G. Ravizza for providing the osmium isotope data from GTS 2012 (in press). We also thank H. Elderfield, I. N. McCave, and A. Galy for helpful discussions. Tabulated data are provided on Science Online.	ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; BERNER RA, 1983, AM J SCI, V283, P641, DOI 10.2475/ajs.283.7.641; Broecker W.S., 1982, TRACERS SEA; CHAN LH, 1994, GEOCHIM COSMOCHIM AC, V58, P4443; Chan LH, 2002, EARTH PLANET SC LETT, V201, P187, DOI 10.1016/S0012-821X(02)00707-0; CHAN LH, 1992, EARTH PLANET SC LETT, V108, P151, DOI 10.1016/0012-821X(92)90067-6; Chan LH, 2006, GEOCHEM GEOPHY GEOSY, V7, DOI 10.1029/2005GC001202; Clementz MT, 2011, SCIENCE, V332, P455, DOI 10.1126/science.1201182; Courtillot V, 2003, CR GEOSCI, V335, P1, DOI 10.1016/S1631-0713(03)00002-6; EDMOND JM, 1995, GEOCHIM COSMOCHIM AC, V59, P3301, DOI 10.1016/0016-7037(95)00128-M; EDMOND JM, 1992, SCIENCE, V258, P1594, DOI 10.1126/science.258.5088.1594; Elderfield H, 1996, ANNU REV EARTH PL SC, V24, P191, DOI 10.1146/annurev.earth.24.1.191; FARRELL JW, 1995, GEOLOGY, V23, P403, DOI 10.1130/0091-7613(1995)023<0403:ICRCOL>2.3.CO;2; Gaillardet J., 2003, TREATISE GEOCHEMISTR, DOI DOI 10.1016/B0-08-043751-6/05165-3; Gislason SR, 2006, GEOLOGY, V34, P49, DOI 10.1130/G22045.1; Griffith EM, 2008, SCIENCE, V322, P1671, DOI 10.1126/science.1163614; Hall JM, 2005, MAR GEOL, V217, P255, DOI 10.1016/j.margeo.2004.11.015; Hathorne EC, 2006, EARTH PLANET SC LETT, V246, P393, DOI 10.1016/j.epsl.2006.04.020; HESS J, 1986, SCIENCE, V231, P979, DOI 10.1126/science.231.4741.979; HODELL DA, 1991, GEOLOGY, V19, P24, DOI 10.1130/0091-7613(1991)019<0024:VITSIC>2.3.CO;2; Hodell DA, 2007, GEOCHEM GEOPHY GEOSY, V8, DOI 10.1029/2007GC001607; Holland HD., 1984, CHEM EVOLUTION ATMOS; Huh Y, 1998, GEOCHIM COSMOCHIM AC, V62, P2039, DOI 10.1016/S0016-7037(98)00126-4; Huh Y, 2001, EARTH PLANET SC LETT, V194, P189, DOI 10.1016/S0012-821X(01)00523-4; James RH, 1999, EARTH PLANET SC LETT, V171, P157, DOI 10.1016/S0012-821X(99)00140-5; Jaramillo C, 2006, SCIENCE, V311, P1893, DOI 10.1126/science.1121380; Kent DV, 2008, P NATL ACAD SCI USA, V105, P16065, DOI 10.1073/pnas.0805382105; Kisakurek B, 2005, EARTH PLANET SC LETT, V237, P387, DOI 10.1016/j.epsl.2005.07.019; Lear CH, 2003, EARTH PLANET SC LETT, V208, P69, DOI 10.1016/S0012-821X(02)01156-1; Li Y.H., 2003, TREATISE GEOCHEMISTR, V7, P1, DOI DOI 10.1016/B0-08-043751-6/07088-2; MACKENZIE FT, 1966, AM J SCI, V264, P507, DOI 10.2475/ajs.264.7.507; MACKENZIE FT, 1995, SCIENCE, V270, P586, DOI 10.1126/science.270.5236.586; Martin EE, 2004, EARTH PLANET SC LETT, V220, P25, DOI 10.1016/S0012-821X(04)00030-5; Martin EE, 1999, PALEOCEANOGRAPHY, V14, P74, DOI 10.1029/1998PA900008; MICHALOPOULOS P, 1995, SCIENCE, V270, P614, DOI 10.1126/science.270.5236.614; Misra S, 2009, J ANAL ATOM SPECTROM, V24, P1524, DOI 10.1039/b907122a; PALMER MR, 1992, GEOCHIM COSMOCHIM AC, V56, P2099, DOI 10.1016/0016-7037(92)90332-D; Paytan A, 2004, SCIENCE, V304, P1663, DOI 10.1126/science.1095258; Peucker-Ehrenbrink B, 2000, TERRA NOVA, V12, P205, DOI 10.1046/j.1365-3121.2000.00295.x; Peucker-Ehrenbrink B, 2000, GEOLOGY, V28, P475, DOI 10.1130/0091-7613(2000)28<475:EOBSWO>2.0.CO;2; Peucker-Ehrenbrink B, 2012, GEOLOGIC TIME SCALE 2012, VOLS 1 & 2, P145, DOI 10.1016/B978-0-444-59425-9.00008-1; Plank T, 1998, CHEM GEOL, V145, P325, DOI 10.1016/S0009-2541(97)00150-2; RAYMO ME, 1988, GEOLOGY, V16, P649, DOI 10.1130/0091-7613(1988)016<0649:IOLCMB>2.3.CO;2; Rowley DB, 2002, GEOL SOC AM BULL, V114, P927, DOI 10.1130/0016-7606(2002)114<0927:ROPCAD>2.0.CO;2; Rudnick R.L., 2004, TREATISE GEOCHEMISTR, P1, DOI DOI 10.1016/B0-08-043751-6/03016-4; Schulte P, 2010, SCIENCE, V327, P1214, DOI 10.1126/science.1177265; Seyfried WE, 1998, GEOCHIM COSMOCHIM AC, V62, P949, DOI 10.1016/S0016-7037(98)00045-3; STALLARD RF, 1987, J GEOPHYS RES-OCEANS, V92, P8293, DOI 10.1029/JC092iC08p08293; Tomascak PB, 2008, GEOCHIM COSMOCHIM AC, V72, P1626, DOI 10.1016/j.gca.2007.12.021; Verney-Carron A, 2011, GEOCHIM COSMOCHIM AC, V75, P3452, DOI 10.1016/j.gca.2011.03.019; Vigier N, 2008, GEOCHIM COSMOCHIM AC, V72, P780, DOI 10.1016/j.gca.2007.11.011; Westerhold T, 2008, PALAEOGEOGR PALAEOCL, V257, P377, DOI 10.1016/j.palaeo.2007.09.016; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	53	307	323	27	320	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	2012	335	6070					818	823		10.1126/science.1214697	http://dx.doi.org/10.1126/science.1214697			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	893LC	22282473				2022-12-28	WOS:000300356400035
J	Gossger, N; Snape, MD; Yu, LM; Finn, A; Bona, G; Esposito, S; Principi, N; Diez-Domingo, J; Sokal, E; Becker, B; Kieninger, D; Prymula, R; Dull, P; Ypma, E; Toneatto, D; Kimura, A; Pollard, AJ				Gossger, Nicoletta; Snape, Matthew D.; Yu, Ly-Mee; Finn, Adam; Bona, Gianni; Esposito, Susanna; Principi, Nicola; Diez-Domingo, Javier; Sokal, Etienne; Becker, Birgitta; Kieninger, Dorothee; Prymula, Roman; Dull, Peter; Ypma, Ellen; Toneatto, Daniela; Kimura, Alan; Pollard, Andrew J.		European MenB Vaccine Study Grp	Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM BACTERICIDAL ACTIVITY; ANTIBODY PERSISTENCE; CONJUGATE VACCINE; CHILDREN; DISEASE	Context In the absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a major cause of invasive disease in early childhood in developed countries. Objective To determine the immunogenicity and reactogenicity of a multicomponent MenB vaccine (4CMenB) and routine infant vaccines when given either concomitantly or separately. Design, Setting, and Participants Phase 2b, multicenter, open-label, parallel-group, randomized controlled study of 1885 infants enrolled at age 2 months from August 2008 to July 2010 in Europe. Intervention Participants were randomized 2: 2: 1: 1 to receive (1) 4CMenB at 2, 4, and 6 months with routine vaccines (7-valent pneumococcal and combined diphtheria, tetanus, acellular pertussis, inactivated polio, hepatitis B, Haemophilus influenzae type b vaccines); (2) 4CMenB at 2, 4, and 6 months and routine vaccines at 3, 5, and 7 months; (3) 4CMenB with routine vaccines at 2, 3, and 4 months; or (4) routine vaccines alone at 2, 3, and 4 months. Main Outcome Measures Percentage of participants with human complement serum bactericidal activity (hSBA) titer of 1: 5 or greater against 3 MenB strains specific for vaccine antigens (NZ98/254, 44/76-SL, and 5/99). Results After three 4CMenB vaccinations, 99% or more of infants developed hSBA titers of 1: 5 or greater against strains 44/76-SL and 5/99. For NZ98/254, this proportion was 79% (95% CI, 75.2%-82.4%) for vaccination at 2, 4, and 6 months with routine vaccines, 86.1% (95% CI, 82.9%-89.0%) for vaccination at 2, 4, and 6 months without routine vaccines, and 81.7% (95% CI, 76.6%-86.2%) for vaccination at 2, 3, and 4 months with routine vaccines. Responses to routine vaccines given with 4CMenB were noninferior to routine vaccines alone for all antigens, except for the responses to pertactin and serotype 6B pneumococcal polysaccharide. Fever was seen following 26% (158/602) to 41% (247/607) of 4CMenB doses when administered alone, compared with 23% (69/304) to 36% (109/306) after routine vaccines given alone and 51% (306/605) to 61% (380/624) after 4CMenB and routine vaccines administered together. Conclusion A 4CMenB vaccine is immunogenic against reference strains when administered with routine vaccines at 2, 4, and 6 or at 2, 3, and 4 months of age, producing minimal interference with the response to routine infant vaccinations.	[Gossger, Nicoletta; Snape, Matthew D.; Pollard, Andrew J.] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford OX3 7LJ, England; [Yu, Ly-Mee] Ctr Stat Med, Oxford, England; [Finn, Adam] Univ Bristol, Bristol Childrens Vaccine Ctr, Bristol, Avon, England; [Finn, Adam] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England; [Bona, Gianni] Univ Piemonte Orientale, Azienda Osped Univ Maggiore Carita, Dept Med Sci, Div Pediat, Novara, Italy; [Esposito, Susanna; Principi, Nicola] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Maternal & Pediat Sci, Milan, Italy; [Diez-Domingo, Javier] CSISP, Valencia, Spain; [Sokal, Etienne] Catholic Univ Louvain, Clin St Luc, Dept Pediat, B-1200 Brussels, Belgium; [Becker, Birgitta] NETSTAP eV, Bochum, Germany; [Kieninger, Dorothee] Johannes Gutenberg Univ Mainz, Dept Paediat Immunol, Ctr Clin Studies, Mainz, Germany; [Prymula, Roman] Univ Hosp, Hradec Kralove, Czech Republic; [Dull, Peter; Ypma, Ellen; Toneatto, Daniela; Kimura, Alan] Novartis Vaccines & Diagnost, Cambridge, MA USA; [Dull, Peter; Ypma, Ellen; Toneatto, Daniela; Kimura, Alan] Novartis Vaccines & Diagnost, Siena, Italy	University of Oxford; University of Oxford; University of Bristol; University of Bristol; Azienda Ospedaliera Maggiore della Carita di Novara; University of Eastern Piedmont Amedeo Avogadro; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Universite Catholique Louvain; Johannes Gutenberg University of Mainz; University Hospital Hradec Kralove; Novartis; Novartis	Snape, MD (corresponding author), Univ Oxford, Churchill Hosp, CCVTM, Oxford Vaccine Grp, Old Rd, Oxford OX3 7LJ, England.	matthew.snape@paediatrics.ox.ac.uk	Martinon-Torres, Federico/E-4982-2016; Yu, LM/J-4284-2012; Prymula, Roman/AEG-7401-2022; Domingo, Javier Diez/B-7293-2015; Esposito, Susanna/K-3475-2016; Chlibek, Roman/P-9084-2016	Martinon-Torres, Federico/0000-0002-9023-581X; Domingo, Javier Diez/0000-0003-1008-3922; Esposito, Susanna/0000-0003-4103-2837; GIAQUINTO, CARLO/0000-0001-9365-0413; Yu, Ly-Mee/0000-0003-0331-7364; Prymula, Roman/0000-0003-1567-2259; Sokal, Etienne/0000-0001-5597-4708; Snape, Matthew/0000-0003-0531-5426; Finn, Adam/0000-0003-1756-5668	Novartis Vaccines; GlaxoSmithKline; sanofi-aventis; Sanofi Pasteur MSD; MedImmune; Pfizer Vaccines; NIHR Oxford Biomedical Research Centre; Pfizer/Wyeth Vaccines; GlaxoSmithKline Vaccines; Crucell; Tibotec; Pfizer/Wyeth; Sanofi Pasteur; Novartis; Pfizer; Novartis Vaccines and Diagnostics	Novartis Vaccines; GlaxoSmithKline(GlaxoSmithKline); sanofi-aventis(Sanofi-Aventis); Sanofi Pasteur MSD; MedImmune(AstraZenecaMedimmune); Pfizer Vaccines; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Pfizer/Wyeth Vaccines; GlaxoSmithKline Vaccines; Crucell; Tibotec; Pfizer/Wyeth(WyethPfizer); Sanofi Pasteur; Novartis(Novartis); Pfizer(Pfizer); Novartis Vaccines and Diagnostics	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Snape, Finn, Esposito, Principi, Diez-Domingo, Kieninger, Sokal, Prymula, and Pollard reported acting as chief and principal investigators for clinical studies and receiving funding from noncommercial funding bodies as well as commercial sponsors (ie, some or all of Novartis Vaccines, GlaxoSmithKline, sanofi-aventis, Sanofi Pasteur MSD, MedImmune, and Pfizer Vaccines) conducted on behalf of their institutions as listed in the affiliations. Dr Snape reported that his institution received payment from Novartis Vaccines for lectures and from Novartis Vaccines, GlaxoSmithKline, and Pfizer to support his travel and accomodation expenses for attendance at conferences; Dr Snape receives salary support from the NIHR Oxford Biomedical Research Centre. Dr Bona reported receiving grants or grants pending from Novartis Vaccines, Pfizer/Wyeth Vaccines, and GlaxoSmithKline Vaccines. Dr Esposito reported serving as a board member for GlaxoSmithKline, Medimmune, Johnson & Johnson, and Novartis Vaccines and receiving grants or grants pending from Crucell, GlaxoSmithKline, Novartis Vaccines, Tibotec, and Pfizer/Wyeth. Dr Principi reported serving as a board member for Pfizer/Wyeth and receiving grants or grants pending from Crucell, GlaxoSmithKline, Novartis Vaccines, and Pfizer/Wyeth. Dr Diez-Domingo reported providing expert testimony for Novartis and receiving payment for lectures from Novartis and Pfizer. Dr Kieninger reported receiving support for travel to meetings from Novartis Vaccines and Diagnostics; receiving grants or grants pending from Novartis Vaccines, Pfizer/Wyeth Vaccines, GlaxoSmithKline Vaccines, and Sanofi Pasteur; and receiving payment for lectures from Pfizer/Wyeth Vaccines and GlaxoSmithKline Vaccines. Dr Prymula reported receiving support for travel to meetings from Novartis and Pfizer; serving as a board member for Novartis and Pfizer; serving as a consultant for Novartis and Pfizer; receiving grants or grants pending from Novartis and Pfizer; receiving payment for lectures from Novartis and Pfizer; and receiving travel/accommodations/meeting expenses from Novartis, Pfizer, GlaxoSmithKline, Baxter, and Sanofi Pasteur. Dr Pollard reported receiving grants or grants pending from Novartis Vaccines, Pfizer/Wyeth Vaccines, GlaxoSmithKline Vaccines, and Sanofi Pasteur; and that his institution received payment for lectures or organization of educational activities, which he coordinated; and that he is a Jenner Investigator and James Martin Senior Fellow. Drs Finn and Pollard do not receive any personal financial support from vaccine manufacturers. Ms Yu, an employee of the Centre for Statistics in Medicine, Oxford, reported that she provides general and project-specific statistical support to the Oxford Vaccine Group.; This study was funded by Novartis Vaccines and Diagnostics.	Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; [Anonymous], 2009, SAF TOL IMM MEN B RE; [Anonymous], 2011, MEN MEN GROUPS A C Y; Biolchi A, 2010, 17 INT PATH NEISS C; Borrow R, 2005, CLIN DIAGN LAB IMMUN, V12, P970, DOI 10.1128/CDLI.12.8.970-976.2005; Brunelli B, 2011, VACCINE, V29, P1072, DOI 10.1016/j.vaccine.2010.11.064; Campbell H, 2009, VACCINE, V27, pB20, DOI 10.1016/j.vaccine.2009.04.067; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Donnelly J, 2011, MEN RES FDN C 2011 N; Donnelly J, 2010, P NATL ACAD SCI USA, V107, P19490, DOI 10.1073/pnas.1013758107; Findlow J, 2010, CLIN INFECT DIS, V51, P1127, DOI 10.1086/656741; Frasch CE, 2009, VACCINE, V27, pB112, DOI 10.1016/j.vaccine.2009.04.065; Galloway Y, 2009, INT J EPIDEMIOL, V38, P413, DOI 10.1093/ije/dyn228; Giuliani MM, 2006, P NATL ACAD SCI USA, V103, P10834, DOI 10.1073/pnas.0603940103; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063; Harrison LH, 2010, CLIN INFECT DIS, V50, pS37, DOI 10.1086/648963; Holst J, 2009, VACCINE, V27, pB3, DOI 10.1016/j.vaccine.2009.04.071; Jackson C, 2009, ARCH DIS CHILD, V94, P745, DOI 10.1136/adc.2007.132571; Jackson C, 2011, ARCH DIS CHILD, V96, P744, DOI 10.1136/adc.2009.180596; Kitchin N, 2006, VACCINE, V24, P3964, DOI 10.1016/j.vaccine.2006.02.018; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Nokleby H, 2007, VACCINE, V25, P3080, DOI 10.1016/j.vaccine.2007.01.022; Perrett KP, 2010, CLIN INFECT DIS, V50, P1601, DOI 10.1086/652765; Ramsay ME., 2011, MEN RES FDN C 2011 N; Rubin D, 1987, SEMIPARAMETRIC THEOR; Smith HNM, 2011, 7 WORLD C WORLD SOC; Snape MD, 2010, PEDIATR INFECT DIS J, V29, pE71, DOI 10.1097/INF.0b013e3181f59f6d; Snape MD, 2005, PEDIATR INFECT DIS J, V24, P128, DOI 10.1097/01.inf.0000151029.58752.27; Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2; Tappero JW, 1999, JAMA-J AM MED ASSOC, V281, P1520, DOI 10.1001/jama.281.16.1520; Vogel U, 2010, INT J MED MICROBIOL, V300, P415, DOI 10.1016/j.ijmm.2010.04.017; Waddington CS, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2649; Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2; Wong SH, 2009, PEDIATR INFECT DIS J, V28, P385, DOI 10.1097/INF.0b013e318195205e	35	200	206	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					573	582		10.1001/jama.2012.85	http://dx.doi.org/10.1001/jama.2012.85			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318278	Bronze			2022-12-28	WOS:000299992500021
J	Herrington, WG; Lewis, DA				Herrington, William G.; Lewis, David A.			PICTURE QUIZ Kidney failure with a diagnostic chest radiograph	BRITISH MEDICAL JOURNAL			English	Editorial Material							MULTIPLE-MYELOMA		[Herrington, William G.; Lewis, David A.] Churchill Hosp, Oxford Kidney Unit, Headington OX3 7LJ, England		Herrington, WG (corresponding author), Churchill Hosp, Oxford Kidney Unit, Headington OX3 7LJ, England.	w.herrington@doctors.org.uk		Herrington, William/0000-0003-1172-8243				Cockwell P, 2010, CURR OPIN NEPHROL HY, V19, P550, DOI 10.1097/MNH.0b013e32833ef72c; Davids MS, 2010, AM J HEMATOL, V85, P787, DOI 10.1002/ajh.21815; Hutchison CA, 2008, BMC NEPHROL, V9, DOI 10.1186/1471-2369-9-11; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Rajkumar SV, 2011, AM J HEMATOL, V86, P57, DOI 10.1002/ajh.21913	5	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 3	2012	344								e659	10.1136/bmj.e659	http://dx.doi.org/10.1136/bmj.e659			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QT	22306480				2022-12-28	WOS:000300089000003
J	Wolstenholme, AJ				Wolstenholme, Adrian J.			Surviving in a Toxic World	SCIENCE			English	Editorial Material							MACROCYCLIC LACTONE RESISTANCE; CHLORIDE CHANNEL SUBUNIT; HAEMONCHUS-CONTORTUS; COOPERIA-ONCOPHORA; IVERMECTIN; GLUTAMATE; PROSPECTS; ELEGANS; GENE		[Wolstenholme, Adrian J.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Wolstenholme, Adrian J.] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Wolstenholme, AJ (corresponding author), Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA.	adrianw@uga.edu	Wolstenholme, Adrian/AAY-1611-2020	Wolstenholme, Adrian/0000-0001-7989-3929				Amazigo U, 2008, ANN TROP MED PARASIT, V102, P19, DOI 10.1179/136485908X337436; Blackhall WJ, 1998, EXP PARASITOL, V90, P42, DOI 10.1006/expr.1998.4316; CAMPBELL WC, 1983, SCIENCE, V221, P823, DOI 10.1126/science.6308762; Dent JA, 2000, P NATL ACAD SCI USA, V97, P2674, DOI 10.1073/pnas.97.6.2674; El-Abdellati A, 2011, INT J PARASITOL, V41, P951, DOI 10.1016/j.ijpara.2011.04.003; Forrester SG, 2002, BIOCHEM PHARMACOL, V63, P1061, DOI 10.1016/S0006-2952(02)00852-3; Ghosh R, 2012, SCIENCE, V335, P574, DOI 10.1126/science.1214318; Hibbs RE, 2011, NATURE, V474, P54, DOI 10.1038/nature10139; McCavera S, 2007, PARASITOLOGY, V134, P1111, DOI 10.1017/S0031182007000042; Mitchell-Olds T, 2007, NAT REV GENET, V8, P845, DOI 10.1038/nrg2207; Njue AI, 2004, J NEUROCHEM, V89, P1137, DOI 10.1111/j.1471-4159.2004.02379.x; Prichard RK, 2007, PARASITOLOGY, V134, P1123, DOI 10.1017/S0031182007000091; Taly A, 2009, NAT REV DRUG DISCOV, V8, P733, DOI 10.1038/nrd2927; Wolstenholme AJ, 2005, PARASITOLOGY, V131, pS85, DOI 10.1017/S0031182005008218; Wolstenholme AJ, 2004, TRENDS PARASITOL, V20, P469, DOI 10.1016/j.pt.2004.07.010	15	5	6	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2012	335	6068					545	546		10.1126/science.1218166	http://dx.doi.org/10.1126/science.1218166			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301309				2022-12-28	WOS:000299769200030
J	Elsharkawy, AM; McPherson, S; Masson, S; Burt, AD; Dawson, RT; Hudson, M				Elsharkawy, Ahmed M.; McPherson, Stuart; Masson, Steven; Burt, Alastair D.; Dawson, Robert T.; Hudson, Mark			LESSON OF THE WEEK Cholestasis secondary to anabolic steroid use in young men	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONSEQUENCES		[Elsharkawy, Ahmed M.; McPherson, Stuart; Masson, Steven; Hudson, Mark] Freeman Rd Hosp, Liver Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; [McPherson, Stuart; Masson, Steven; Burt, Alastair D.; Hudson, Mark] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Dawson, Robert T.] Med Ctr, The Grove NE39 1PW, Rowlands Gill, England	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle University - UK	Elsharkawy, AM (corresponding author), Freeman Rd Hosp, Liver Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	ahmede@doctors.org.uk	Burt, Alastair D/D-3634-2013	Burt, Alastair D/0000-0002-3011-7774; Masson, Steven/0000-0003-1041-9844; Elsharkawy, Ahmed Mohamed/0000-0001-5369-3734; McPherson, Stuart/0000-0002-5638-2453				ACMD, 2010, CONS AN STER; Bispo M, 2009, WORLD J GASTROENTERO, V15, P2920, DOI 10.3748/wjg.15.2920; Bolding G, 2002, ADDICTION, V97, P195, DOI 10.1046/j.1360-0443.2002.00031.x; BUCKLEY W E, 1988, Journal of the American Medical Association, V260, P3441, DOI 10.1001/jama.260.23.3441; Cordaro FG, 2011, SCAND J MED SCI SPOR, V21, pE247, DOI 10.1111/j.1600-0838.2010.01263.x; Dawson RT, 2001, J ENDOCRINOL, V170, P55, DOI 10.1677/joe.0.1700055; Evans-Brown M, 2008, LANCET, V372, P1544, DOI 10.1016/S0140-6736(08)61651-7; Kanayama G, 2008, DRUG ALCOHOL DEPEN, V98, P1, DOI 10.1016/j.drugalcdep.2008.05.004; Lumia AR, 2010, PHYSIOL BEHAV, V100, P199, DOI 10.1016/j.physbeh.2010.01.007; Parr MK, 2007, BIOMED CHROMATOGR, V21, P164, DOI 10.1002/bmc.728; Rosenfeld Greg A, 2011, J Med Case Rep, V5, P138, DOI 10.1186/1752-1947-5-138	11	17	17	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	2012	344								e468	10.1136/bmj.e468	http://dx.doi.org/10.1136/bmj.e468			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QO	22302781				2022-12-28	WOS:000300088500003
J	Coombes, R				Coombes, Rebecca			NHS REFORMS Into the abyss? How the health bill affects the NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ, London WC1H 9JR, England		Coombes, R (corresponding author), BMJ, London WC1H 9JR, England.	rcoombes@bmjgroup.com							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2012	344								e767	10.1136/bmj.e767	http://dx.doi.org/10.1136/bmj.e767			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889QJ	22297796				2022-12-28	WOS:000300088000016
J	Herberstein, ME; Kemp, DJ				Herberstein, Marie E.; Kemp, Darrel J.			A Clearer View from Fuzzy Images	SCIENCE			English	Editorial Material							JUMPING SPIDERS; PRINCIPAL EYES; BEHAVIOR; VISION		[Herberstein, Marie E.; Kemp, Darrel J.] Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia	Macquarie University	Herberstein, ME (corresponding author), Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia.	marie.herberstein@mq.edu.au	Herberstein, Marie E./D-2042-2011; Kemp, Darrell/ABC-9638-2021	Herberstein, Marie E./0000-0001-5071-2952; Kemp, Darrell/0000-0002-5845-5513				BLEST AD, 1981, J COMP PHYSIOL, V145, P227, DOI 10.1007/BF00605035; Foelix R. F, 2011, BIOL SPIDERS; Jackson RR, 1996, ANNU REV ENTOMOL, V41, P287, DOI 10.1146/annurev.en.41.010196.001443; Kelber A, 2003, BIOL REV, V78, P81, DOI 10.1017/S1464793102005985; Kral K, 2003, BEHAV PROCESS, V64, P1, DOI 10.1016/S0376-6357(03)00054-8; LAND MF, 1969, J EXP BIOL, V51, P443; Nagata T, 2012, SCIENCE, V335, P469, DOI 10.1126/science.1211667; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Shichida Y, 2009, PHILOS T R SOC B, V364, P2881, DOI 10.1098/rstb.2009.0051; Zurek DB, 2010, J EXP BIOL, V213, P2372, DOI 10.1242/jeb.042382	10	1	2	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					409	410		10.1126/science.1216887	http://dx.doi.org/10.1126/science.1216887			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881FG	22282795				2022-12-28	WOS:000299466800030
J	Stiggelbout, AM; Van der Weijden, T; De Wit, MPT; Frosch, D; Legare, F; Montori, VM; Trevena, L; Elwyn, G				Stiggelbout, A. M.; Van der Weijden, T.; De Wit, M. P. T.; Frosch, D.; Legare, F.; Montori, V. M.; Trevena, L.; Elwyn, G.			Shared decision making: really putting patients at the centre of healthcare	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RISK COMMUNICATION; INVOLVEMENT; PHYSICIANS; OUTCOMES; IMPROVE; WOMEN	Although many clinicians feel they already use shared decision making, research shows a perception-reality gap. A M Stiggelbout and colleagues discuss why it is important and highlight some best practices	[Stiggelbout, A. M.] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands; [Van der Weijden, T.] Maastricht Univ, Dept Gen Practice, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands; [De Wit, M. P. T.] Dutch League Arthrit Patients, Zaltbommel, Netherlands; [Frosch, D.] Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA; [Legare, F.] Hop St Francois Assise, Knowledge Transfer & Hlth Technol Assessment Res, Quebec City, PQ, Canada; [Montori, V. M.] Mayo Clin, Ctr Sci Healthcare Delivery, Rochester, MN USA; [Trevena, L.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia; [Elwyn, G.] Cardiff Univ, Sch Med, Inst Primary Care & Publ Hlth, Cardiff, S Glam, Wales	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Maastricht University; Palo Alto Medical Foundation Research Institute; Laval University; Mayo Clinic; University of Sydney; Cardiff University	Stiggelbout, AM (corresponding author), Leiden Univ, Med Ctr, Dept Med Decis Making, POB 9600, NL-2300 RC Leiden, Netherlands.	a.m.stiggelbout@lumc.nl	Elwyn, G./L-4292-2015; Stiggelbout, Anne M/D-2293-2018; Elwyn, Glyn/B-4798-2009	Stiggelbout, Anne M/0000-0002-6293-4509; Legare, France/0000-0002-2296-6696; Trevena, Lyndal/0000-0003-1419-1832; Elwyn, Glyn/0000-0002-0917-6286; Montori, Victor/0000-0003-0595-2898; van der weijden, trudy/0000-0002-7469-3781				[Anonymous], 2009, UN CHRONICLE; Beauchamp T L, 2012, PRINCIPLES BIOMEDICA; Edwards A, 2001, Health Expect, V4, P151, DOI 10.1046/j.1369-6513.2001.00116.x; Elwyn G, 2000, BRIT J GEN PRACT, V50, P892; Elwyn G, 2004, FAM PRACT, V21, P337, DOI 10.1093/fampra/cmh401; Elwyn G, 2011, Z EVID FORTBILD QUAL, P227; Elwyn G, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5146; Ferguson T., 2007, E PATIENTS THEY CAN; Frosch DL, 2011, 6 INT SHAR DEC MAK C, P42; Frosch DL, 2011, Z EVIDENZ FORTBILD Q, V105, P305, DOI 10.1016/j.zefq.2011.04.004; Gagnon S, 2010, PRENATAL DIAG, V30, P115, DOI 10.1002/pd.2421; Hack TF, 2006, PSYCHO-ONCOL, V15, P9, DOI 10.1002/pon.907; Hibbard JH, 2009, AM J MANAG CARE, V15, P353; Legare F, 2011, Z EVIDENZ FORTBILD Q, V105, P245, DOI 10.1016/j.zefq.2011.04.011; Legare F, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006732.pub2; Molewijk AC, 2003, HEALTH CARE ANAL, V11, P69, DOI 10.1023/A:1025390030467; Montori VM, 2011, AM J MED, V124, P549, DOI 10.1016/j.amjmed.2011.01.013; Montori VM, 2008, JAMA-J AM MED ASSOC, V300, P814; O'Connor AM, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub2, 10.1002/14651858.CD001431.pub3, 10.1002/14651858.CD001431.pub4]; O'Connor AM, 2003, BMJ-BRIT MED J, V327, P736, DOI 10.1136/bmj.327.7417.736; Option grid, 2011, TONS WATCHF WAIT CHI; Salzburg Global Seminar, 2011, BMJ, V342, pd1745, DOI 10.1136/bmj.d1745; Shepherd HL, 2011, PATIENT EDUC COUNS, V84, P379, DOI 10.1016/j.pec.2011.07.022; Towle A, 2006, HEALTH EXPECT, V9, P321, DOI 10.1111/j.1369-7625.2006.00404.x; Van der Weijden T, J CLIN EPID IN PRESS; van Tol-Geerdink JJ, 2006, INT J RADIAT ONCOL, V66, P1105, DOI 10.1016/j.ijrobp.2006.07.001; World Health Organization, 2011, MHEALTHNEW HOR HLTH, V3	27	467	472	0	55	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2012	344								e256	10.1136/bmj.e256	http://dx.doi.org/10.1136/bmj.e256			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885LJ	22286508	Green Submitted, Green Accepted			2022-12-28	WOS:000299780200002
J	Kondrashov, A				Kondrashov, Alexey			James Crow (1916-2012) OBITUARY	NATURE			English	Biographical-Item									Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kondrashov, A (corresponding author), Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.	kondrash@umich.edu						CROW JF, PUBLICATION LIST	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2012	481	7382					444	444		10.1038/481444a	http://dx.doi.org/10.1038/481444a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881GY	22281585	Bronze			2022-12-28	WOS:000299471800020
J	Bass, H				Bass, Hannah			LOBBY WATCH Guttmacher Institute	BRITISH MEDICAL JOURNAL			English	Editorial Material									City Univ London, London, England	City University London	Bass, H (corresponding author), City Univ London, London, England.	mhd.bass@gmail.com						2011, BRIT MED J, V343, DOI DOI 10.1136/BMJ.D7313; 2010, BRIT MED J, V340, DOI DOI 10.1136/BMJ.C2527	2	0	0	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 25	2012	344								e623	10.1136/bmj.e623	http://dx.doi.org/10.1136/bmj.e623			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KV	22279095				2022-12-28	WOS:000299778800025
J	Schmidt, B; Anderson, PJ; Doyle, LW; Dewey, D; Grunau, RE; Asztalos, EV; Davis, PG; Tin, W; Moddemann, D; Solimano, A; Ohlsson, A; Barrington, KJ; Roberts, RS				Schmidt, Barbara; Anderson, Peter J.; Doyle, Lex W.; Dewey, Deborah; Grunau, Ruth E.; Asztalos, Elizabeth V.; Davis, Peter G.; Tin, Win; Moddemann, Diane; Solimano, Alfonso; Ohlsson, Arne; Barrington, Keith J.; Roberts, Robin S.		Caffeine Apnea Prematurity CAP Tri	Survival Without Disability to Age 5 Years After Neonatal Caffeine Therapy for Apnea of Prematurity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT CHILDREN; DEVELOPMENTAL-DISABILITY; COGNITIVE FUNCTION; PRETERM CHILDREN; CEREBRAL-PALSY; MICE LACKING; RECEPTOR; OUTCOMES; INFANTS	Context Very preterm infants are prone to apnea and have an increased risk of death or disability. Caffeine therapy for apnea of prematurity reduces the rates of cerebral palsy and cognitive delay at 18 months of age. Objective To determine whether neonatal caffeine therapy has lasting benefits or newly apparent risks at early school age. Design, Setting, and Participants Five-year follow-up from 2005 to 2011 in 31 of 35 academic hospitals in Canada, Australia, Europe, and Israel, where 1932 of 2006 participants (96.3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004. A total of 1640 children (84.9%) with birth weights of 500 to 1250 g had adequate data for the main outcome at 5 years. Main Outcome Measures Combined outcome of death or survival to 5 years with 1 or more of motor impairment (defined as a Gross Motor Function Classification System level of 3 to 5), cognitive impairment (defined as a Full Scale IQ<70), behavior problems, poor general health, deafness, and blindness. Results The combined outcome of death or disability was not significantly different for the 833 children assigned to caffeine from that for the 807 children assigned to placebo (21.1% vs 24.8%; odds ratio adjusted for center, 0.82; 95% CI, 0.65-1.03; P=.09). The rates of death, motor impairment, behavior problems, poor general health, deafness, and blindness did not differ significantly between the 2 groups. The incidence of cognitive impairment was lower at 5 years than at 18 months and similar in the 2 groups (4.9% vs 5.1%; odds ratio adjusted for center, 0.97; 95% CI, 0.61-1.55; P=.89). Conclusion Neonatal caffeine therapy was no longer associated with a significantly improved rate of survival without disability in children with very low birth weights who were assessed at 5 years. JAMA. 2012;307(3):275-282	[Schmidt, Barbara; Roberts, Robin S.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Schmidt, Barbara] Childrens Hosp Philadelphia, Div Neonatol, Philadelphia, PA 19104 USA; [Schmidt, Barbara] Univ Penn, Philadelphia, PA 19104 USA; [Anderson, Peter J.; Doyle, Lex W.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Peter J.; Doyle, Lex W.; Davis, Peter G.] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia; [Anderson, Peter J.; Doyle, Lex W.; Davis, Peter G.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Doyle, Lex W.; Davis, Peter G.] Royal Womens Hosp, Melbourne, Vic, Australia; [Dewey, Deborah] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Calgary, AB, Canada; [Dewey, Deborah] Univ Calgary, Dept Pediat, Calgary, AB T2N 1N4, Canada; [Dewey, Deborah] Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada; [Grunau, Ruth E.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 1M9, Canada; [Grunau, Ruth E.; Solimano, Alfonso] Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 1M9, Canada; [Asztalos, Elizabeth V.; Ohlsson, Arne] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Tin, Win] James Cook Univ Hosp, Dept Pediat, Middlesbrough, Cleveland, England; [Moddemann, Diane] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Barrington, Keith J.] McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; [Barrington, Keith J.] Univ Montreal, St Justine Univ Hosp, Montreal, PQ, Canada	McMaster University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; Alberta Childrens Hospital; University of Calgary; University of Calgary; University of Calgary; Child & Family Research Institute; University of British Columbia; University of British Columbia; University of Toronto; James Cook University Hospital; University of Manitoba; McGill University; Universite de Montreal	Schmidt, B (corresponding author), Hosp Univ Penn, Div Neonatol, Ravdin 8,3400 Spruce St, Philadelphia, PA 19104 USA.	barbara.schmidt@uphs.upenn.edu	Anderson, Peter J/B-6839-2015; Herlenius, Eric/B-7260-2008; van der Hoeven, Markus/M-8558-2015; Anderson, Peter John/O-5302-2019; Dewey, Deborah/AGK-7348-2022; Asztalos, Elizabeth/L-8834-2019; Doyle, Lex/AAJ-5205-2021	Anderson, Peter J/0000-0001-7430-868X; Herlenius, Eric/0000-0002-6859-0620; van der Hoeven, Markus/0000-0002-3978-256X; Anderson, Peter John/0000-0001-7430-868X; Asztalos, Elizabeth/0000-0002-9468-2860; Doyle, Lex/0000-0002-7667-7312; Ringstedt, Thomas/0000-0003-0294-9351; Grunau, Ruth/0000-0002-5428-9212; Hilgendorff, Anne/0000-0002-3725-996X; Barrington, Keith/0000-0001-9669-5094; Bairam, Aida/0000-0003-3475-6546; Halliday, Henry/0000-0001-7978-4992; Dewey, Deborah/0000-0002-1323-5832	Canadian Institutes of Health Research [MCT 13288]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This follow-up study was supported by the Canadian Institutes of Health Research (MCT 13288).	Abu-Shaweesh JM, 2008, PEDIATR PULM, V43, P937, DOI 10.1002/ppul.20832; ACHENBACH T, 2002, MANUAL CHILD BEHAV C; Aranda JV, 2010, J MATERN-FETAL NEO M, V23, P20, DOI 10.3109/14767058.2010.517704; Aylward GP, 2003, JAMA-J AM MED ASSOC, V289, P752, DOI 10.1001/jama.289.6.752; BEERY KE, 2004, BEERYBUKTENICA DEV T; Centers for Disease Control and Prevention, GROWTH CHARTS; Clark RH, 2006, PEDIATRICS, V117, P1979, DOI 10.1542/peds.2005-1707; de Kieviet JF, 2009, JAMA-J AM MED ASSOC, V302, P2235, DOI 10.1001/jama.2009.1708; Dukhovny D, 2011, PEDIATRICS, V127, pE146, DOI 10.1542/peds.2010-1014; Finer NN, 2006, PEDIATRICS, V117, pS47, DOI 10.1542/peds.2005-0620H; Hack M, 2005, PEDIATRICS, V116, P333, DOI 10.1542/peds.2005-0173; Henderson S., 1992, MOVEMENT ASSESSMENT; Henderson-Smart DJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000140.pub2; Hille ETM, 2001, LANCET, V357, P1641, DOI 10.1016/S0140-6736(00)04818-2; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; Millar David, 2004, Semin Neonatol, V9, P239, DOI 10.1016/j.siny.2003.11.008; Msall ME, 2009, JAMA-J AM MED ASSOC, V302, P2257, DOI 10.1001/jama.2009.1730; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Pesce AJ, 1998, CLIN CHEM, V44, P1124; Roberts G, 2010, ARCH DIS CHILD, V95, P786, DOI 10.1136/adc.2009.160283; Robertson CMT, 2009, PEDIATR NEUROL, V40, P189, DOI 10.1016/j.pediatrneurol.2008.09.017; Schmidt B, 2006, NEW ENGL J MED, V354, P2112, DOI 10.1056/NEJMoa054065; Schmidt B, 2005, BIOL NEONATE, V88, P208, DOI 10.1159/000087584; Schmidt B, 2007, NEW ENGL J MED, V357, P1893, DOI 10.1056/NEJMoa073679; The Psychological Corporation, 2002, WECHSL PRESCH PRIM S; Williams J, 2010, DEV MED CHILD NEUROL, V52, P232, DOI 10.1111/j.1469-8749.2009.03544.x; Yi S.H., 1993, MANUAL BAYLEY SCALES	30	224	239	2	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2012	307	3					275	282		10.1001/jama.2011.2024	http://dx.doi.org/10.1001/jama.2011.2024			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	877EY	22253394	Bronze			2022-12-28	WOS:000299161200023
J	Gaw, A				Gaw, Allan			Exposing Unethical Human Research: The Transatlantic Correspondence of Beecher and Pappworth	ANNALS OF INTERNAL MEDICINE			English	Article							IMPENDING HEPATIC COMA; LIVER DISEASE; CLINICAL RESEARCH; PREVENTION; DIAMOX	Henry K. Beecher and Maurice H. Pappworth were the 2 most prominent medical whistleblowers in research ethics of the 20th century. Independently, both wrote highly controversial and ultimately influential articles and books. Although their work is now well-known in clinical research circles, their collaboration is not. Pappworth's article "Human Guinea Pigs: A Warning" was published in 1962; in it, he discussed a series of published studies that he considered unethical. Beecher read it and wrote to Pappworth seeking help. The current article reconstructs, from Beecher and Pappworth's correspondence in 1965-1966, an important juncture in the genesis of modern clinical research ethics. Although they shared much in common, they differed radically in the strategies they adopted: Beecher chose to conceal the identities of individuals, whereas Pappworth believed that only by naming and shaming could any expose 'act as a deterrent. Their correspondence reveals how the 2 men shared their ideas and their material and provided each other with much-needed support. It also tracks the development of Beecher's shift from a position initially indistinguishable from Pappworth's toward the one he adopted when his seminal article of 1966 was published.	Royal Victoria Hosp, Clin Res Facil, Inst Clin Sci, Ctr Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland		Gaw, A (corresponding author), Royal Victoria Hosp, Clin Res Facil, Inst Clin Sci, Ctr Publ Hlth, 2nd Floor,Block B,Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.							BEARN AG, 1952, CLIN SCI, V11, P151; BEARN AG, 1951, LANCET, V261, P698; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; BEECHER HK, 1959, JAMA-J AM MED ASSOC, V169, P461, DOI 10.1001/jama.1959.73000220003010; Beecher HK, 1965, COMMUNICATION   0309; Beecher HK, 1966, COMMUNICATION   0711; Beecher HK, 1966, COMMUNICATION   0729; Beecher HK, 1966, COMMUNICATION   0328; Beecher HK, 1965, ETHICS EXPLOSI UNPUB; Beecher HK, 1966, COMMUNICATION   0727; Beecher HK, 1965, COMMUNICATION   0107; Beecher HK, 1965, COMMUNICATION   0125; BESTERMAN EMM, 1954, BRIT HEART J, V16, P8; BOOTH C, 1994, BRIT MED J, V309, P1577; Bunker JP, 2001, INFORM CONSENT MED R, P37; Campbell A, 1970, HOSP TIMES      0904, P4; DAWSON AM, 1957, CLIN SCI, V16, P413; DAWSON AM, 1957, LANCET, V1, P392; DERRICK JR, 1960, AM HEART J, V59, P442, DOI 10.1016/0002-8703(60)90307-0; Eastwood M, 2009, BMJ-BRIT MED J, V339, pb5113; Emanuel E, 2008, OXFORD TXB CLIN RES; Harkness J, 2001, B WORLD HEALTH ORGAN, V79, P365; Kopp VJ, 1999, ANESTHESIOLOGY, V90, P1756, DOI 10.1097/00000542-199906000-00034; Lasagna L, 1994, COMMUNICATION   1213; MACKIE JE, 1958, NEW ENGL J MED, V259, P1151, DOI 10.1056/NEJM195812112592402; MCHENRY LC, 1961, AM J MED SCI, V241, P173, DOI 10.1097/00000441-196102000-00004; NORDIN BEC, 1956, LANCET, V270, P823; Osmundsen JA, 1965, NY TIMES        0324, P35; Pappworth M. H., 1967, HUMAN GUINEA PIGS EX; Pappworth M. H., 1962, 20 CENTURY, P66; PAPPWORTH MH, 1990, BRIT MED J, V301, P1456, DOI 10.1136/bmj.301.6766.1456; Pappworth MH, 1965, COMMUNICATION   0220; Pappworth MH, 1966, COMMUNICATION   0325; Pappworth MH, 1965, COMMUNICATION   0119; PHEAR EA, 1955, LANCET, V1, P836; PHEAR EA, 1956, CLIN SCI, V15, P93; READ AE, 1959, CLIN SCI, V18, P409; REICHMAN S, 1958, J CLIN INVEST, V37, P1848, DOI 10.1172/JCI103777; Rothman David, 1991, STRANGERS BEDSIDE, P70; Rothman DJ, 1991, STRANGERS BEDSIDE LA; RUDOLPH A M, 1958, Pediatr Clin North Am, V5, P907; Schmidt U, 2006, JUSTICE NUREMBERG; WEBSTER LT, 1956, P SOC EXP BIOL MED, V91, P27; WHITE LP, 1955, J CLIN INVEST, V34, P158, DOI 10.1172/JCI103070; ZOLLINGER RM, 1964, NEW ENGL J MED, V270, P707, DOI 10.1056/NEJM196404022701404	45	9	9	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2					150	W32		10.7326/0003-4819-156-2-201201170-00012	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894IW	22250147				2022-12-28	WOS:000300421400007
J	Thapar, A; Collishaw, S; Pine, DS; Thapar, AK				Thapar, Anita; Collishaw, Stephan; Pine, Daniel S.; Thapar, Ajay K.			Depression in adolescence	LANCET			English	Article							COGNITIVE-BEHAVIORAL THERAPY; SEROTONIN TRANSPORTER GENE; RECENT LIFE EVENTS; MATERNAL DEPRESSION; MENTAL-HEALTH; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; INTERPERSONAL PSYCHOTHERAPY; LONGITUDINAL COURSE; GENDER-DIFFERENCES	Unipolar depressive disorder in adolescence is common worldwide but often unrecognised. The incidence, notably in girls, rises sharply after puberty and, by the end of adolescence, the 1 year prevalence rate exceeds 4%. The burden is highest in low-income and middle-income countries. Depression is associated with substantial present and future morbidity, and heightens suicide risk. The strongest risk factors for depression in adolescents are a family history of depression and exposure to psychosocial stress. Inherited risks, develop mental factors, sex hormones, and psychosocial adversity interact to increase risk through hormonal factors and associated perturbed neural pathways. Although many similarities between depression in adolescence and depression in adulthood exist, in adolescents the use of antidepressants is of concern and opinions about clinical management are divided. Effective treatments are available, but choices are dependent on depression severity and available resources. Prevention strategies targeted at high-risk groups are promising.	[Thapar, Anita; Collishaw, Stephan; Thapar, Ajay K.] Cardiff Univ, Sch Med, Dept Psychol Med & Neurol, Child & Adolescent Psychiat Sect, Heath Pk, Cardiff CF14 4XN, S Glam, Wales; [Thapar, Anita; Collishaw, Stephan] Cardiff Univ, Sch Med, MRC Ctr Neuropsychiat Genet & Genom, Cardiff CF14 4XN, S Glam, Wales; [Pine, Daniel S.] NIMH, Emot & Dev Branch, Intramural Res Program, Bethesda, MD 20892 USA; [Thapar, Ajay K.] Taff Riverside Practice, Cardiff, S Glam, Wales	Cardiff University; Cardiff University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Thapar, A (corresponding author), Cardiff Univ, Sch Med, Dept Psychol Med & Neurol, Child & Adolescent Psychiat Sect, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	thapar@Cardiff.ac.uk	Collishaw, Stephan/H-4593-2019; Thapar, Anita/AAH-5555-2020; Pine, Daniel/Z-1601-2019	Collishaw, Stephan/0000-0002-4296-820X; Thapar, Anita/0000-0002-3689-737X; 	Sir Jules Thorn Charitable Trust; Waterloo Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002781] Funding Source: NIH RePORTER; MRC [G9810900] Funding Source: UKRI; Medical Research Council [G9810900, G0801418B] Funding Source: researchfish; The Sir Jules Thorn Charitable Trust [06JTA] Funding Source: researchfish	Sir Jules Thorn Charitable Trust; Waterloo Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); The Sir Jules Thorn Charitable Trust	The authors' research on depression is funded by the Sir Jules Thorn Charitable Trust. SC is supported by the Waterloo Foundation. We thank Sir Michael Rutter, Antonio Munoz, Robert Potter, Gemma Lewis, and Miriam Cooper for comments on an earlier draft, Robert Goodman for advice, and Peter MacSorley (medical student) for assistance with the literature search.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Angold A, 1999, PSYCHOL MED, V29, P1043, DOI 10.1017/S0033291799008946; ANGOLD A, 1993, AM J PSYCHIAT, V150, P1779; Angold A, 1999, J CHILD PSYCHOL PSYC, V40, P57, DOI 10.1017/S0021963098003448; Angold A, 2006, CHILD ADOL PSYCH CL, V15, P919, DOI 10.1016/j.chc.2006.05.013; Asarnow JR, 2005, JAMA-J AM MED ASSOC, V293, P311, DOI 10.1001/jama.293.3.311; Bardone AM, 1998, J AM ACAD CHILD PSY, V37, P594, DOI 10.1097/00004583-199806000-00009; Birmaher B, 2004, J AM ACAD CHILD PSY, V43, P63, DOI 10.1097/00004583-200401000-00015; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bolton P, 2007, JAMA-J AM MED ASSOC, V298, P519, DOI 10.1001/jama.298.5.519; Borner I, 2010, CLIN PEDIATR, V49, P947, DOI 10.1177/0009922810370203; Brennan PA, 2003, J AM ACAD CHILD PSY, V42, P1469, DOI 10.1097/00004583-200312000-00014; Brent D, 2008, JAMA-J AM MED ASSOC, V299, P901, DOI 10.1001/jama.299.8.901; Bridge JA, 2007, JAMA-J AM MED ASSOC, V63, P332; Brody AL, 1999, PSYCHIAT RES-NEUROIM, V91, P127, DOI 10.1016/S0925-4927(99)00034-7; Brotman MA, 2006, BIOL PSYCHIAT, V60, P991, DOI 10.1016/j.biopsych.2006.08.042; Calear AL, 2010, J ADOLESCENCE, V33, P429, DOI 10.1016/j.adolescence.2009.07.004; Casey BJ, 2010, DEV PSYCHOBIOL, V52, P225, DOI 10.1002/dev.20447; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Clauss JA, 2011, COGN AFFECT BEHAV NE, V11, P13, DOI 10.3758/s13415-010-0007-9; Cluver L, 2007, J CHILD PSYCHOL PSYC, V48, P755, DOI 10.1111/j.1469-7610.2007.01757.x; Cole J, 2009, J AM ACAD CHILD PSY, V48, P1094, DOI 10.1097/CHI.0b013e3181b7666e; Collishaw S., 2009, DEPRESSION CHILDHOOD, P7; Collishaw S, 2007, CHILD ABUSE NEGLECT, V31, P211, DOI 10.1016/j.chiabu.2007.02.004; Conradi HJ, 2011, PSYCHOL MED, V41, P1165, DOI 10.1017/S0033291710001911; Copeland WE, 2009, ARCH GEN PSYCHIAT, V66, P764, DOI 10.1001/archgenpsychiatry.2009.85; Costello EJ, 2006, J CHILD PSYCHOL PSYC, V47, P1263, DOI 10.1111/j.1469-7610.2006.01682.x; Costello EJ, 2005, J AM ACAD CHILD PSY, V44, P972, DOI 10.1097/01.chi.0000172552.41596.6f; Costello EJ, 2006, J AM ACAD CHILD PSY, V45, P8, DOI 10.1097/01.chi.0000184929.41423.c0; Costello EJ, 2003, ARCH GEN PSYCHIAT, V60, P837, DOI 10.1001/archpsyc.60.8.837; Costello EJ, 1996, ARCH GEN PSYCHIAT, V53, P1137; Cyranowski JM, 2000, ARCH GEN PSYCHIAT, V57, P21, DOI 10.1001/archpsyc.57.1.21; Daviss WB, 2006, J CHILD PSYCHOL PSYC, V47, P927, DOI 10.1111/j.1469-7610.2006.01646.x; Dunn V, 2006, BRIT J PSYCHIAT, V188, P216, DOI 10.1192/bjp.188.3.216; Eaves L, 2003, J CHILD PSYCHOL PSYC, V44, P1006, DOI 10.1111/1469-7610.00185; Emslie GJ, 2009, J AM ACAD CHILD PSY, V48, P721, DOI 10.1097/CHI.0b013e3181a2b304; Engle PL, 2007, LANCET, V369, P229, DOI 10.1016/S0140-6736(07)60112-3; Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001; Fava GA, 2007, PSYCHOL MED, V37, P307, DOI 10.1017/S0033291706008981; Feder A, 2009, NAT REV NEUROSCI, V10, P446, DOI 10.1038/nrn2649; Fergusson DM, 2005, ARCH GEN PSYCHIAT, V62, P66, DOI 10.1001/archpsyc.62.1.66; Fleitlich-Bilyk B, 2004, J AM ACAD CHILD PSY, V43, P727, DOI 10.1097/01.chi.0000120021.14101.ca; Fletcher JM, 2008, HEALTH ECON, V17, P1215, DOI 10.1002/hec.1319; Forbes EE, 2005, DEV PSYCHOPATHOL, V17, P827, DOI 10.1017/S095457940505039X; Forbes EE, 2009, AM J PSYCHIAT, V166, P64, DOI 10.1176/appi.ajp.2008.07081336; Ford T, 2003, J AM ACAD CHILD PSY, V42, P1203, DOI 10.1097/00004583-200310000-00011; Foster CE, 2008, J CLIN CHILD ADOLESC, V37, P714, DOI 10.1080/15374410802359726; Fox CL, 2009, BRIT J GUID COUNS, V37, P95, DOI 10.1080/03069880902728598; Garber J, 2006, AM J PREV MED, V31, pS104, DOI 10.1016/j.amepre.2006.07.007; Garber J, 2009, JAMA-J AM MED ASSOC, V301, P2215, DOI 10.1001/jama.2009.788; Goodman R, 2000, J CHILD PSYCHOL PSYC, V41, P645, DOI 10.1017/S0021963099005909; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Goodman SH, 1999, PSYCHOL REV, V106, P458, DOI 10.1037/0033-295X.106.3.458; GOODYER I, 1990, BRIT J PSYCHIAT, V156, P689, DOI 10.1192/bjp.156.5.689; Goodyer IM, 2008, HEALTH TECHNOL ASSES, V12, P1; Goodyer I, 2007, BMJ-BRIT MED J, V335, P142, DOI 10.1136/bmj.39224.494340.55; Goodyer IM, 1996, PSYCHOL MED, V26, P245, DOI 10.1017/S0033291700034644; Goodyer IM, 2000, BRIT J PSYCHIAT, V177, P499, DOI 10.1192/bjp.177.6.499; Goodyer IM, 2008, HEALTH TECHNOL ASSES, V12, piii; Gotlib IH, 2010, ARCH GEN PSYCHIAT, V67, P380, DOI 10.1001/archgenpsychiatry.2010.13; Green H., 2005, J RES SPEC EDUC NEED; Guyer AE, 2009, CHILD DEV, V80, P1000, DOI 10.1111/j.1467-8624.2009.01313.x; Hammen C, 2003, ARCH GEN PSYCHIAT, V60, P253, DOI 10.1001/archpsyc.60.3.253; Hankin BL, 1998, J ABNORM PSYCHOL, V107, P128, DOI 10.1037/0021-843X.107.1.128; Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829; Hariri AR, 2005, ARCH GEN PSYCHIAT, V62, P146, DOI 10.1001/archpsyc.62.2.146; Harrington R, 2001, ARCH GEN PSYCHIAT, V58, P21, DOI 10.1001/archpsyc.58.1.21; Hasler G, 2005, MOL PSYCHIATR, V10, P842, DOI 10.1038/sj.mp.4001671; Hawker DSJ, 2000, J CHILD PSYCHOL PSYC, V41, P441, DOI 10.1017/S0021963099005545; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; Hay DF, 2008, J CHILD PSYCHOL PSYC, V49, P1079, DOI 10.1111/j.1469-7610.2008.01959.x; HAZELL P, 1995, BRIT MED J, V310, P897, DOI 10.1136/bmj.310.6984.897; Hetrick S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004851.pub2; Hollis C., 2008, RUTTERS CHILD ADOLES, P737; Hyde JS, 2008, PSYCHOL REV, V115, P291, DOI 10.1037/0033-295X.115.2.291; Institute of Medicine, 2009, PREV MENT EM BEH DIS; Jones L, 2008, INT REV PSYCHIATR, V20, P291, DOI 10.1080/09540260801996081; Karg K, 2011, ARCH GEN PSYCHIAT, V68, P444, DOI 10.1001/archgenpsychiatry.2010.189; Keenan-Miller D, 2007, J ADOLESCENT HEALTH, V41, P256, DOI 10.1016/j.jadohealth.2007.03.015; Kendler KS, 2008, PSYCHOL MED, V38, P1567, DOI 10.1017/S003329170800384X; Kessler R C, 1998, Depress Anxiety, V7, P3, DOI 10.1002/(SICI)1520-6394(1998)7:1<3::AID-DA2>3.0.CO;2-F; Kessler RC, 2001, BIOL PSYCHIAT, V49, P1002, DOI 10.1016/S0006-3223(01)01129-5; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; Kim-Cohen J, 2003, ARCH GEN PSYCHIAT, V60, P709, DOI 10.1001/archpsyc.60.7.709; Klein DN, 2009, J AM ACAD CHILD PSY, V48, P703, DOI 10.1097/CHI.0b013e3181a56606; Klein JB, 2007, J AM ACAD CHILD PSY, V46, P1403, DOI 10.1097/chi.0b013e3180592aaa; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Lau JYF, 2008, J CHILD PSYCHOL PSYC, V49, P142, DOI 10.1111/j.1469-7610.2007.01803.x; Leaf PJ, 1996, J AM ACAD CHILD PSY, V35, P889, DOI 10.1097/00004583-199607000-00014; Lewinsohn PM, 2000, AM J PSYCHIAT, V157, P1584, DOI 10.1176/appi.ajp.157.10.1584; LEWINSOHN PM, 1995, J AM ACAD CHILD PSY, V34, P454, DOI 10.1097/00004583-199504000-00012; Lewinsohn PM, 1998, CLIN PSYCHOL REV, V18, P765, DOI 10.1016/S0272-7358(98)00010-5; Lewinsohn PM, 1999, J ABNORM PSYCHOL, V108, P483, DOI 10.1037/0021-843X.108.3.483; Lewinsohn PM, 2003, J ABNORM PSYCHOL, V112, P244, DOI 10.1037/0021-843X.112.2.244; Lewinsohn PM, 1999, J AM ACAD CHILD PSY, V38, P56, DOI 10.1097/00004583-199901000-00020; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Lopez-Duran NL, 2009, PSYCHONEUROENDOCRINO, V34, P1272, DOI 10.1016/j.psyneuen.2009.03.016; Ma J, 2005, J ADOLESCENT HEALTH, V37, P434, DOI 10.1016/j.jadohealth.2005.07.012; March J, 2004, JAMA-J AM MED ASSOC, V292, P807; Masten A. S., 2006, HDB DEVE PSYCHOPATHO, V2, P710, DOI DOI 10.1016/J.S0CSCIMED.2011.12.026; Milne BJ, 2009, ARCH GEN PSYCHIAT, V66, P738, DOI 10.1001/archgenpsychiatry.2009.55; Moffitt TE, 2010, PSYCHOL MED, V40, P899, DOI 10.1017/S0033291709991036; Mufson L, 2004, ARCH GEN PSYCHIAT, V61, P577, DOI 10.1001/archpsyc.61.6.577; Mufson L, 1999, ARCH GEN PSYCHIAT, V56, P573, DOI 10.1001/archpsyc.56.6.573; National Institute for Health and Clinical Excellence, 2005, DEPR CHILDR YOUNG PE; Nelson EE, 2005, PSYCHOL MED, V35, P163, DOI 10.1017/S0033291704003915; Pargas RCM, 2010, DEV PSYCHOL, V46, P805, DOI 10.1037/a0019817; Parker G, 2010, INT REV PSYCHIATR, V22, P429, DOI 10.3109/09540261.2010.492391; Patel V, 2007, LANCET, V370, P991, DOI 10.1016/S0140-6736(07)61240-9; Patel V, 2007, LANCET, V369, P1302, DOI 10.1016/S0140-6736(07)60368-7; Patton GC, 2007, LANCET, V369, P1130, DOI 10.1016/S0140-6736(07)60366-3; Pickles A, 2001, BRIT J PSYCHIAT, V179, P230, DOI 10.1192/bjp.179.3.230; Pillai A, 2008, BRIT J PSYCHIAT, V192, P45, DOI 10.1192/bjp.bp.106.034223; Pine DS, 2010, J AM ACAD CHILD PSY, V49, P772, DOI 10.1016/j.jaac.2009.12.022; Pine DS, 2003, BIOL PSYCHIAT, V53, P796, DOI 10.1016/S0006-3223(03)00112-4; Pine DS, 2002, J AFFECT DISORDERS, V68, P49, DOI 10.1016/S0165-0327(00)00331-1; Ramchandani P, 2009, LANCET, V374, P646, DOI 10.1016/S0140-6736(09)60238-5; Restifo K, 2009, CLIN PSYCHOL REV, V29, P294, DOI 10.1016/j.cpr.2009.02.005; Rice F, 2010, PSYCHOL MED, V40, P335, DOI 10.1017/S0033291709005911; Rice F, 2002, J CHILD PSYCHOL PSYC, V43, P65, DOI 10.1111/1469-7610.00004; Richardson LP, 2010, PEDIATRICS, V125, pE1097, DOI 10.1542/peds.2009-2712; Risch N, 2009, JAMA-J AM MED ASSOC, V301, P2462, DOI 10.1001/jama.2009.878; Rossello J, 1999, J CONSULT CLIN PSYCH, V67, P734, DOI 10.1037/0022-006X.67.5.734; Rowe R, 2008, J CHILD PSYCHOL PSYC, V49, P526, DOI 10.1111/j.1469-7610.2008.01834.x; Rueter MA, 1999, ARCH GEN PSYCHIAT, V56, P726, DOI 10.1001/archpsyc.56.8.726; Rutter M, 2009, ARCH GEN PSYCHIAT, V66, P1287, DOI 10.1001/archgenpsychiatry.2009.167; Rutz EM, 2004, EUR CHILD ADOLES PSY, V13, P321, DOI 10.1007/s00787-004-0406-y; Saxena Shekhar, 2004, J Ment Health Policy Econ, V7, P127; Shansky RM, 2004, MOL PSYCHIATR, V9, P531, DOI 10.1038/sj.mp.4001435; Sharan P, 2009, BRIT J PSYCHIAT, V195, P354, DOI 10.1192/bjp.bp.108.050187; Shi J, 2011, MOL PSYCHIATR, V16, P193, DOI 10.1038/mp.2009.124; Shyn SI, 2011, MOL PSYCHIATR, V16, P202, DOI 10.1038/mp.2009.125; Silberg J, 1999, ARCH GEN PSYCHIAT, V56, P225, DOI 10.1001/archpsyc.56.3.225; Silberg J, 2001, BRIT J PSYCHIAT, V179, P116, DOI 10.1192/bjp.179.2.116; Silk JS, 2007, DEV PSYCHOPATHOL, V19, P841, DOI 10.1017/S0954579407000417; Soares CN, 2008, J PSYCHIATR NEUROSCI, V33, P331; Stice E, 2009, J CONSULT CLIN PSYCH, V77, P486, DOI 10.1037/a0015168; THAPAR A, 1994, BRIT J PSYCHIAT, V165, P259, DOI 10.1192/bjp.165.2.259; Thapar A, 2006, CHILD ADOL PSYCH CL, V15, P869, DOI 10.1016/j.chc.2006.05.007; Thapar A, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c209; TODD RD, 1993, J AM ACAD CHILD PSY, V32, P1164, DOI 10.1097/00004583-199311000-00008; Tully EC, 2008, AM J PSYCHIAT, V165, P1148, DOI 10.1176/appi.ajp.2008.07091438; Uher R, 2010, MOL PSYCHIATR, V15, P18, DOI 10.1038/mp.2009.123; van Noorden MS, 2010, J AFFECT DISORDERS, V125, P116, DOI 10.1016/j.jad.2009.12.007; Verhulst FC, 2008, RUTTERS CHILD ADOLES, P289; Weissman MM, 2006, JAMA-J AM MED ASSOC, V295, P1389, DOI 10.1001/jama.295.12.1389; Weisz JR, 2006, PSYCHOL BULL, V132, P132, DOI 10.1037/0033-2909.132.1.132; Windfuhr K, 2008, J CHILD PSYCHOL PSYC, V49, P1155, DOI 10.1111/j.1469-7610.2008.01938.x; World Health Organization, 2016, MHGAP INT GUID MENT; Young JF, 2006, J AM ACAD CHILD PSY, V45, P904, DOI 10.1097/01.chi.0000222791.23927.5f; Zuckerbrot RA, 2007, PEDIATRICS, V120, pE1299, DOI 10.1542/peds.2007-1144	152	1169	1208	36	491	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2012	379	9820					1056	1067		10.1016/S0140-6736(11)60871-4	http://dx.doi.org/10.1016/S0140-6736(11)60871-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22305766	Green Accepted			2022-12-28	WOS:000301712300034
J	Sedgh, G; Singh, S; Shah, IH; Ahman, E; Henshaw, SK; Bankole, A				Sedgh, Gilda; Singh, Susheela; Shah, Iqbal H.; Ahman, Elisabeth; Henshaw, Stanley K.; Bankole, Akinrinola			Induced abortion: incidence and trends worldwide from 1995 to 2008	LANCET			English	Article							UNITED-STATES; UNSAFE ABORTION; PREGNANCY; MORTALITY; WOMEN; TERMINATION; MISOPROSTOL; RATES; RISK	Background Data of abortion incidence and trends are needed to monitor progress toward improvement of maternal health and access to family planning. To date, estimates of safe and unsafe abortion worldwide have only been made for 1995 and 2003. Methods We used the standard WHO definition of unsafe abortions. Safe abortion estimates were based largely on official statistics and nationally representative surveys. Unsafe abortion estimates were based primarily on information from published studies, hospital records, and surveys of women. We used additional sources and systematic approaches to make corrections and projections as needed where data were misreported, incomplete, or from earlier years. We assessed trends in abortion incidence using rates developed for 1995, 2003, and 2008 with the same methodology. We used linear regression models to explore the association of the legal status of abortion with the abortion rate across subregions of the world in 2008. Findings The global abortion rate was stable between 2003 and 2008, with rates of 29 and 28 abortions per 1000 women aged 15-44 years, respectively, following a period of decline from 35 abortions per 1000 women in 1995. The average annual percent change in the rate was nearly 2.4% between 1995 and 2003 and 0.3% between 2003 and 2008. Worldwide, 49% of abortions were unsafe in 2008, compared to 44% in 1995. About one in five pregnancies ended in abortion in 2008. The abortion rate was lower in subregions where more women live under liberal abortion laws (p<0.05). Interpretation The substantial decline in the abortion rate observed earlier has stalled, and the proportion of all abortions that are unsafe has increased. Restrictive abortion laws are not associated with lower abortion rates. Measures to reduce the incidence of unintended pregnancy and unsafe abortion, including investments in family planning services and safe abortion care, are crucial steps toward achieving the Millennium Development Goals.	[Sedgh, Gilda; Singh, Susheela; Henshaw, Stanley K.; Bankole, Akinrinola] Alan Guttmacher Inst, New York, NY 10005 USA; [Shah, Iqbal H.; Ahman, Elisabeth] WHO, CH-1211 Geneva, Switzerland	World Health Organization	Sedgh, G (corresponding author), Alan Guttmacher Inst, 120 Wall St, New York, NY 10005 USA.	gsedgh@guttmacher.org			UK Department of International Development; Dutch Ministry of Foreign Affairs; John D and Catherine T MacArthur Foundation; WHO; Guttmacher Institute	UK Department of International Development; Dutch Ministry of Foreign Affairs; John D and Catherine T MacArthur Foundation; WHO(World Health Organization); Guttmacher Institute	This study was funded by the UK Department of International Development, the Dutch Ministry of Foreign Affairs, and the John D and Catherine T MacArthur Foundation. The estimation of unsafe abortion was developed and commissioned by WHO and some of these estimates have been published previously. 4 The estimation of safe abortion and the compilation of worldwide levels was led by the Guttmacher Institute. The authors alone are responsible for the views expressed in this paper and they do not necessarily represent the decisions, policy, or views of their institutions or those of funding agencies. We thank Alyssa Tartaglione, Rubina Hussain, and Michelle Eilers for their assistance with obtaining and managing data and preparing the manuscript.	[Anonymous], 2010, MILL DEV GOALS REP; Bankole A, 1999, INT FAM PLAN PERSPEC, V25, P68, DOI 10.2307/2991944; Bartlett LA, 2004, OBSTET GYNECOL, V103, P729, DOI 10.1097/01.AOG.0000116260.81570.60; Benson J, 2009, MONITORING SAFE ABOR; Boland R, 2008, INT FAM PLAN PERSPEC, V34, P110, DOI [10.1363/3411008, 10.1363/ifpp.34.110.08]; Bongaarts J, 1983, FERTILITY BIOL BEHAV, p[71, 85]; Centers for Disease Control and Prevention (CDC) and ORC Macro, 2003, REPR MAT CHILD HLTH; Clark S, 2002, INT J GYNECOL OBSTET, V76, P65, DOI 10.1016/S0020-7292(01)00567-7; Duggal R, 2004, SUMMARY KEY FINDINGS; Fetters T, 2009, 26 INT POP C IUSSP M; Gebrehiwot Y, 2009, J PUBLIC HEALTH-UK, V31, P81, DOI 10.1093/pubmed/fdn068; Grimes DA, 2006, AM J OBSTET GYNECOL, V194, P92, DOI 10.1016/j.ajog.2005.06.070; Grimes DA, 2006, LANCET, V368, P1908, DOI 10.1016/S0140-6736(06)69481-6; Grossman D, 2010, REPROD HEALTH MATTER, V18, P136, DOI 10.1016/S0968-8080(10)36534-7; Guttmacher Institute, 2000, READ IND AB, P165; Harlap S, 1980, HUMAN EMBRYONIC FETA, p[148, 157]; Harries J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-296; Henshaw SK, 1999, INT FAM PLAN PERSPEC, V25, pS30, DOI 10.2307/2991869; HENSHAW SK, 1993, C ST GYN OB, V5, P31; Jewkes R, 2005, SAMJ S AFR MED J, V95, P250; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; Jones RK, 2007, STUD FAMILY PLANN, V38, P187, DOI 10.1111/j.1728-4465.2007.00130.x; Jones RK, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.019; Juarez F, 2005, INT FAM PLAN PERSPEC, V31, P140, DOI 10.1363/3114005; Juarez F, 2008, INT FAM PLAN PERSPEC, V34, P158, DOI [10.1363/3415808, 10.1363/ifpp.34.158.08]; Lafaurie M. M., 2005, ABORTO CON MEDICAMEN; Marston C, 2003, INT FAM PLAN PERSPEC, V29, P6, DOI 10.2307/3180995; Miller S, 2005, BJOG-INT J OBSTET GY, V112, P1291, DOI 10.1111/j.1471-0528.2005.00704.x; Remez Alyssa., 2010, METHODOLOGIES ESTIMA, P71; Rossier C, 2003, STUD FAMILY PLANN, V34, P87, DOI 10.1111/j.1728-4465.2003.00087.x; Sedgh G, 2010, METHODOLOGIES ESTIMA, P23; Sedgh G, 2007, LANCET, V370, P1338, DOI 10.1016/S0140-6736(07)61575-X; Sedgh G, 2011, INT PERSPECT SEX R H, V37, P84, DOI 10.1363/3708411; Shah I, 2010, REPROD HEALTH MATTER, V18, P90, DOI 10.1016/S0968-8080(10)36537-2; Singh S, 2009, ADDING IT COSTS BENE; Singh S, 2010, METHODOLOGIES ESTIMA; Singh S, 2006, LANCET, V368, P1887, DOI 10.1016/S0140-6736(06)69778-X; Singh S, 2010, STUD FAMILY PLANN, V41, P241, DOI 10.1111/j.1728-4465.2010.00250.x; Singh S, 2010, WOMENS HEALTH, V6, P849, DOI [10.2217/whe.10.70, 10.2217/WHE.10.70]; Singh S, 2010, INT PERSPECT SEX R H, V36, P16, DOI 10.1363/ipsrh.36.016.10; SINGH Susheela, 2009, ABORTION WORLDWIDE D; Suvedi B. K., 2009, NEPAL MATERNAL MORTA; United Nations, 2009, WORLD POP PROSP 2008; United Nations Department of Economic and Social Affairs Population Division, 2011, WORLD CONTR US 2010; [United Nations Department of Economics and Social Affairs Population division], 2009, WORLD POP PROSP 2008; Westoff, 2005, DHS ANAL STUDIES, V8; Westoff CF, 2008, DHS ANAL STUDIES, V13; World Health Organization, 1992, WHOMSM925; World Health Organization, 2013, UNS AB GLOB REG EST; World Health Organization, 2007, US LIQ MED CULT DRUG, P1	50	377	395	3	104	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2012	379	9816					625	632		10.1016/S0140-6736(11)61786-8	http://dx.doi.org/10.1016/S0140-6736(11)61786-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	897ES	22264435				2022-12-28	WOS:000300629000033
J	Forget, AL; Kowalczykowski, SC				Forget, Anthony L.; Kowalczykowski, Stephen C.			Single-molecule imaging of DNA pairing by RecA reveals a three-dimensional homology search	NATURE			English	Article							DOUBLE-STRANDED DNA; ESCHERICHIA-COLI; PROTEIN; RECOMBINATION; MECHANISM; BINDING; EXCHANGE; TRANSLOCATION; BIOCHEMISTRY; FILAMENTS	DNA breaks can be repaired with high fidelity by homologous recombination. A ubiquitous protein that is essential for this DNA template-directed repair is RecA(1). After resection of broken DNA to produce single-stranded DNA (ssDNA), RecA assembles on this ssDNA into a filament with the unique capacity to search and find DNA sequences in double-stranded DNA (dsDNA) that are homologous to the ssDNA. This homology search is vital to recombinational DNA repair, and results in homologous pairing and exchange of DNA strands. Homologous pairing involves DNA sequence-specific target location by the RecA-ssDNA complex. Despite decades of study, the mechanism of this enigmatic search process remains unknown. RecA is a DNA-dependent ATPase, but ATP hydrolysis is not required for DNA pairing and strand exchange(2,3), eliminating active search processes. Using dual optical trapping to manipulate DNA, and single-molecule fluorescence microscopy to image DNA pairing, we demonstrate that both the three-dimensional conformational state of the dsDNA target and the length of the homologous RecA-ssDNA filament have important roles in the homology search. We discovered that as the end-to-end distance of the target dsDNA molecule is increased, constraining the available three-dimensional (3D) conformations of the molecule, the rate of homologous pairing decreases. Conversely, when the length of the ssDNA in the nucleoprotein filament is increased, homology is found faster. We propose a model for the DNA homology search process termed 'intersegmental contact sampling', in which the intrinsic multivalent nature of the RecA nucleoprotein filament is used to search DNA sequence space within 3D domains of DNA, exploiting multiple weak contacts to rapidly search for homology. Our findings highlight the importance of the 3D conformational dynamics of DNA, reveal a previously unknown facet of the homology search, and provide insight into the mechanism of DNA target location by this member of a universal family of proteins.	[Forget, Anthony L.; Kowalczykowski, Stephen C.] Univ Calif Davis, Dept Microbiol, Davis, CA 95616 USA; [Forget, Anthony L.; Kowalczykowski, Stephen C.] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Dept Microbiol, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			American Cancer Society [PF-08-046-01-GMC]; National Institutes of Health [GM-62653, GM-64745]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064745, R37GM062653, R01GM062653] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to members of the laboratory for their comments on this work. A.L.F. was funded by an American Cancer Society Postdoctoral Fellowship (PF-08-046-01-GMC) and S.C.K. was supported by the National Institutes of Health (GM-62653 and GM-64745).	Adzuma K, 1998, J BIOL CHEM, V273, P31565, DOI 10.1074/jbc.273.47.31565; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; Berg OG, 1990, BIOL NONSPECIFIC DNA, P71; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Forget AL, 2010, TRENDS CELL BIOL, V20, P269, DOI 10.1016/j.tcb.2010.02.004; Fulconis R, 2006, EMBO J, V25, P4293, DOI 10.1038/sj.emboj.7601260; Galletto R, 2006, NATURE, V443, P875, DOI 10.1038/nature05197; GONDA DK, 1983, CELL, V34, P647, DOI 10.1016/0092-8674(83)90397-5; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; JULIN DA, 1986, J BIOL CHEM, V261, P1025; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; Mirshad JK, 2003, BIOCHEMISTRY-US, V42, P5945, DOI 10.1021/bi027233i; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; van der Heijden T, 2008, MOL CELL, V30, P530, DOI 10.1016/j.molcel.2008.03.010; van Mameren J, 2009, NATURE, V457, P745, DOI 10.1038/nature07581	22	147	149	1	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2012	482	7385					423	U178		10.1038/nature10782	http://dx.doi.org/10.1038/nature10782			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	892LG	22318518	Green Accepted, Green Submitted			2022-12-28	WOS:000300287100051
J	Patel, DV; Scott, V; Pilcher, J				Patel, Dhruv V.; Scott, Victoria; Pilcher, James			RATIONAL IMAGING Investigating focal liver lesions	BRITISH MEDICAL JOURNAL			English	Editorial Material							CONTRAST-ENHANCED ULTRASONOGRAPHY; NODULAR HYPERPLASIA; MULTICENTER TRIAL; CT; HEMANGIOMAS; SONOGRAPHY; MANAGEMENT; BIOPSY; MRI		[Patel, Dhruv V.; Scott, Victoria; Pilcher, James] St Georges Healthcare NHS Trust, London SW17 0QT, England	St Georges University London	Patel, DV (corresponding author), St Georges Healthcare NHS Trust, London SW17 0QT, England.	dhruv_patel@hotmail.com						Brenner DJ, 2004, RADIOLOGY, V232, P735, DOI 10.1148/radiol.2323031095; Broome DR, 2007, AM J ROENTGENOL, V188, P586, DOI 10.2214/AJR.06.1094; Cherqui D, 1995, HEPATOLOGY, V22, P1674, DOI 10.1016/0270-9139(95)90190-6; Dickie B, 2009, J PEDIATR SURG, V44, P125, DOI 10.1016/j.jpedsurg.2008.10.021; Faccioli N, 2007, RADIOL MED, V112, P810, DOI 10.1007/s11547-007-0185-x; Halavaara J, 2006, J COMPUT ASSIST TOMO, V30, P345, DOI 10.1097/00004728-200605000-00001; Hamer OW, 2006, RADIOGRAPHICS, V26, P1637, DOI 10.1148/rg.266065004; Leen E, 2006, AM J ROENTGENOL, V186, P1551, DOI 10.2214/AJR.05.0138; Nguyen BN, 1999, AM J SURG PATHOL, V23, P1441, DOI 10.1097/00000478-199912000-00001; Padia SA, 2009, J CLIN ULTRASOUND, V37, P138, DOI 10.1002/jcu.20553; Piscaglia F, 2010, ULTRASOUND MED BIOL, V36, P531, DOI 10.1016/j.ultrasmedbio.2010.01.004; Quaia E, 2004, RADIOLOGY, V232, P420, DOI 10.1148/radiol.2322031401; Rockey DC, 2009, HEPATOLOGY, V49, P1017, DOI 10.1002/hep.22742; Romanini Laura, 2007, Eur Radiol, V17 Suppl 6, pF99; Rossai J, 1995, ACKERMANS SURG PATHO, V1, P898; Thomsen HS, 2006, CONTRAST MEDIA SAFET; Trillaud H, 2009, WORLD J GASTROENTERO, V15, P3748, DOI 10.3748/wjg.15.3748; Ungermann L, 2007, EUR J RADIOL, V63, P290, DOI 10.1016/j.ejrad.2007.01.026; Valls C, 2006, EUR RADIOL, V16, P2292, DOI 10.1007/s00330-006-0146-0; Vilgrain V, 2000, RADIOGRAPHICS, V20, P379, DOI 10.1148/radiographics.20.2.g00mc01379	20	3	3	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 8	2012	344								e657	10.1136/bmj.e657	http://dx.doi.org/10.1136/bmj.e657			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	892IE	22318436				2022-12-28	WOS:000300279100003
J	Paschal, D				Paschal, Dean			Launching Complex Medical Workups From an Urgent Care Platform	ANNALS OF INTERNAL MEDICINE			English	Article								The basic parameters for medical workups have scarcely changed in the past 30 years. That is, what the internal medicine community has deemed acceptable for outpatient, inpatient, emergency department, and urgent care evaluation has remained pretty much stable or stagnant during all that time. We are failing to take advantage of the phenomenal speed and accuracy of new laboratory and imaging technologies. Due to Hurricane Katrina, which destroyed the Veterans Administration Hospital in New Orleans, those of us who work in its urgent care clinic were forced to undertake complex medical workups from an 8-to-5, walk-in platform. We have been amazed at the efficiency of this. Workups that used to take weeks can often be done in a few hours or days. What we have discovered here serendipitously may be worth deliberately duplicating elsewhere.	Tulane Univ, New Orleans, LA 70115 USA	Tulane University	Paschal, D (corresponding author), Tulane Univ, 5721 Magazine St,132, New Orleans, LA 70115 USA.	ldpaschal@bellsouth.net							0	2	2	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2012	156	3					232	U95		10.7326/0003-4819-156-3-201202070-00012	http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XD	22312142				2022-12-28	WOS:000299964200007
J	Rodbell, DT				Rodbell, Donald T.			Marching in Near Lock-Step	SCIENCE			English	Editorial Material							CLIMATE; RECORD; OCEAN		Union Coll, Dept Geol, Schenectady, NY 12308 USA	Union College	Rodbell, DT (corresponding author), Union Coll, Dept Geol, Schenectady, NY 12308 USA.	rodbelld@union.edu						Baker PA, 2001, NATURE, V409, P698, DOI 10.1038/35055524; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Burns SJ, 2003, SCIENCE, V301, P1365, DOI 10.1126/science.1086227; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; DANSGAARD W, 1964, TELLUS, V16, P436; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; Kanner LC, 2012, SCIENCE, V335, P570, DOI 10.1126/science.1213397; Smith JA, 2010, J QUATERNARY SCI, V25, P243, DOI 10.1002/jqs.1393; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618	9	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2012	335	6068					548	549		10.1126/science.1218365	http://dx.doi.org/10.1126/science.1218365			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301311				2022-12-28	WOS:000299769200032
J	Tondreau, AM; Atienza, CCH; Weller, KJ; Nye, SA; Lewis, KM; Delis, JGP; Chirik, PJ				Tondreau, Aaron M.; Atienza, Crisita Carmen Hojilla; Weller, Keith J.; Nye, Susan A.; Lewis, Kenrick M.; Delis, Johannes G. P.; Chirik, Paul J.			Iron Catalysts for Selective Anti-Markovnikov Alkene Hydrosilylation Using Tertiary Silanes	SCIENCE			English	Article							TRANSITION-METAL-COMPLEXES; DINITROGEN	Alkene hydrosilylation, the addition of a silicon hydride (Si-H) across a carbon-carbon double bond, is one of the largest-scale industrial applications of homogeneous catalysis and is used in the commercial production of numerous consumer goods. For decades, precious metals, principally compounds of platinum and rhodium, have been used as catalysts for this reaction class. Despite their widespread application, limitations such as high and volatile catalyst costs and competing side reactions have persisted. Here, we report that well-characterized molecular iron coordination compounds promote the selective anti-Markovnikov addition of sterically hindered, tertiary silanes to alkenes under mild conditions. These Earth-abundant base-metal catalysts, coordinated by optimized bis(imino)pyridine ligands, show promise for industrial application.	[Tondreau, Aaron M.; Atienza, Crisita Carmen Hojilla; Chirik, Paul J.] Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; [Weller, Keith J.; Nye, Susan A.] Moment Performance Mat, Waterford, NY 12188 USA; [Lewis, Kenrick M.] Moment Performance Mat, Tarrytown, NY 10591 USA; [Delis, Johannes G. P.] Moment Performance Mat Bv, NL-4612 PX Bergen Op Zoom, Netherlands	Princeton University	Chirik, PJ (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	pchirik@princeton.edu		Tondreau, Aaron/0000-0003-0440-5497	Momentive Performance Materials	Momentive Performance Materials	We thank Momentive Performance Materials for financial support. Portions of this work have been published in the following patent applications: US2011/0009573 A1 and U. S. serial no. 13/325,250.	Bart SC, 2004, J AM CHEM SOC, V126, P13794, DOI 10.1021/ja046753t; Buisine O, 2005, CHEM COMMUN, P3856, DOI 10.1039/b506369h; Chirik P. J., 2010, CATALYSIS PRECIOUS M, P83, DOI DOI 10.1002/9783527631582.CH4; Chirik PJ, 2010, SCIENCE, V327, P794, DOI 10.1126/science.1183281; Corey JY, 1999, CHEM REV, V99, P175, DOI 10.1021/cr9701086; Czaplik WM, 2009, CHEMSUSCHEM, V2, P396, DOI 10.1002/cssc.200900055; Enthaler S., 2008, IRON CATALYSIS ORGAN, P125; Hill RM, 1999, SURF SCI SERIES, V86, P1; HITCHCOCK PB, 1991, ANGEW CHEM INT EDIT, V30, P438, DOI 10.1002/anie.199104381; Holwell A.J., 2008, PLATINUM MET REV, V52, P243, DOI [10.1595/147106708X366975, DOI 10.1595/147106708X366975]; KAKIUCHI F, 1993, J ORGANOMET CHEM, V456, P45, DOI 10.1016/0022-328X(93)83315-M; Marciniec B, 2005, COORDIN CHEM REV, V249, P2374, DOI 10.1016/j.ccr.2005.02.025; Marciniec B., 2002, SILICON CHEM, V1, P155, DOI [10.1023/A:1021235922742, DOI 10.1023/A:1021235922742]; Marciniec B., 2002, COMPREHENSIVE HDB HY, P3; Marko IE, 2002, SCIENCE, V298, P204, DOI 10.1126/science.1073338; MITCHENER JC, 1981, J AM CHEM SOC, V103, P975, DOI 10.1021/ja00394a060; Morris RH, 2009, CHEM SOC REV, V38, P2282, DOI 10.1039/b806837m; Noels A. F., 1985, IND APPL HOMOGENEOUS, P80; Ojima I., 1989, CHEM ORGANIC SILICON, P1479; Plueddemann E., 1991, SILANE COUPLING AGEN; Pukhnarevitch V. B., 1992, PERSPECTIVES HYDROSI; Roy AK, 2008, ADV ORGANOMET CHEM, V55, P1, DOI 10.1016/SO065-3055(07)55001-X; Russell SK, 2010, INORG CHEM, V49, P2782, DOI 10.1021/ic902162z; SANNER RD, 1979, INORG CHEM, V18, P928, DOI 10.1021/ic50194a007; SCHROEDER MA, 1977, J ORGANOMET CHEM, V128, P345; Sprengers JW, 2003, EUR J INORG CHEM, P3811, DOI 10.1002/ejic.200300088; STEVENS PJG, 1993, PESTIC SCI, V38, P103, DOI 10.1002/ps.2780380206; Trovitch RJ, 2008, J AM CHEM SOC, V130, P11631, DOI 10.1021/ja803296f; Wong M., 2004, U.S. Patent, Patent No. [6805856, 6,805,856]; Wu JY, 2010, J AM CHEM SOC, V132, P13214, DOI 10.1021/ja106853y; Yang CJ, 2009, ENERG POLICY, V37, P1805, DOI 10.1016/j.enpol.2009.01.019; Zhang M, 2010, APPL ORGANOMET CHEM, V24, P751, DOI 10.1002/aoc.1701	32	400	419	10	338	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2012	335	6068					567	570		10.1126/science.1214451	http://dx.doi.org/10.1126/science.1214451			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301315				2022-12-28	WOS:000299769200039
J	Cassenaer, S; Laurent, G				Cassenaer, Stijn; Laurent, Gilles			Conditional modulation of spike-timing-dependent plasticity for olfactory learning	NATURE			English	Article							DROSOPHILA MUSHROOM BODY; SYNAPTIC PLASTICITY; ODOR REPRESENTATIONS; NEURONS; MEMORY; DOPAMINE; LOCUST; BODIES; BRAIN; OSCILLATIONS	Mushroom bodies are a well-known site for associative learning in insects. Yet the precise mechanisms that underlie plasticity there and ensure their specificity remain elusive. In locusts, the synapses between the intrinsic mushroom body neurons and their postsynaptic targets obey a Hebbian spike-timing-dependent plasticity (STDP) rule. Although this property homeostatically regulates the timing of mushroom body output, its potential role in associative learning is unknown. Here we show in vivo that pre-post pairing causing STDP can, when followed by the local delivery of a reinforcement-mediating neuromodulator, specify the synapses that will undergo an associative change. At these synapses, and there only, the change is a transformation of the STDP rule itself. These results illustrate the multiple actions of STDP, including a role in associative learning, despite potential temporal dissociation between the pairings that specify synaptic modification and the delivery of reinforcement-mediating neuromodulator signals.	[Cassenaer, Stijn; Laurent, Gilles] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Cassenaer, Stijn] CALTECH, Broad Fellows Program Brain Circuitry, Pasadena, CA 91125 USA; [Laurent, Gilles] Max Planck Inst Brain Res, D-60528 Frankfurt, Germany	California Institute of Technology; California Institute of Technology; Max Planck Society	Laurent, G (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	stijn@caltech.edu; gilles.laurent@brain.mpg.de	Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X	Lawrence Hanson Chair at Caltech; National Institutes on Deafness and other Communication Disorders; Caltech; Office of Naval Research [N00014-07-1-0741, N00014-10-1-0735]; Max Planck Society	Lawrence Hanson Chair at Caltech; National Institutes on Deafness and other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Caltech; Office of Naval Research(Office of Naval Research); Max Planck Society(Max Planck Society)	This work was funded by the Lawrence Hanson Chair at Caltech, the National Institutes on Deafness and other Communication Disorders, Caltech's Broad Fellows Program, the Office of Naval Research (grants N00014-07-1-0741 and N00014-10-1-0735) and the Max Planck Society. We are grateful to L.-P. Mok for help with locust dissections and to E. Schuman, A. Siapas, E. Lubenov, M. Papadopoulou and members of the Laurent lab for comments on the manuscript.	Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; Akalal DBG, 2006, LEARN MEMORY, V13, P659, DOI 10.1101/lm.221206; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BRAUNIG P, 1991, PHILOS T ROY SOC B, V332, P221, DOI 10.1098/rstb.1991.0051; Cassenaer S, 2007, NATURE, V448, P709, DOI 10.1038/nature05973; Claridge-Chang A, 2009, CELL, V139, P405, DOI 10.1016/j.cell.2009.08.034; Davis RL, 2005, ANNU REV NEUROSCI, V28, P275, DOI 10.1146/annurev.neuro.28.061604.135651; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; Gerber B, 2004, CURR OPIN NEUROBIOL, V14, P737, DOI 10.1016/j.conb.2004.10.014; Gervasi N, 2010, NEURON, V65, P516, DOI 10.1016/j.neuron.2010.01.014; Gutig R, 2006, NAT NEUROSCI, V9, P420, DOI 10.1038/nn1643; Gutig R, 2003, J NEUROSCI, V23, P3697; HAMMER M, 1993, NATURE, V366, P59, DOI 10.1038/366059a0; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; Heisenberg M, 2003, NAT REV NEUROSCI, V4, P266, DOI 10.1038/nrn1074; Huerta R, 2004, NEURAL COMPUT, V16, P1601, DOI 10.1162/089976604774201613; Huerta R, 2009, NEURAL COMPUT, V21, P2123, DOI 10.1162/neco.2009.03-08-733; Isabel G, 2004, SCIENCE, V304, P1024, DOI 10.1126/science.1094932; Ito I, 2008, NAT NEUROSCI, V11, P1177, DOI 10.1038/nn.2192; Izhikevich EM, 2003, IEEE T NEURAL NETWOR, V14, P1569, DOI 10.1109/TNN.2003.820440; Izhikevich EM, 2007, CEREB CORTEX, V17, P2443, DOI 10.1093/cercor/bhl152; Kanerva P., 1988, SPARSE DISTRIBUTED M; Keene AC, 2007, NAT REV NEUROSCI, V8, P341, DOI 10.1038/nrn2098; Kim YC, 2007, J NEUROSCI, V27, P7640, DOI 10.1523/JNEUROSCI.1167-07.2007; LAURENT G, 1994, J NEUROSCI, V14, P2993; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Masquelier T, 2007, PLOS COMPUT BIOL, V3, P247, DOI 10.1371/journal.pcbi.0030031; Mazor O, 2005, NEURON, V48, P661, DOI 10.1016/j.neuron.2005.09.032; McGuire SE, 2001, SCIENCE, V293, P1330, DOI 10.1126/science.1062622; Meeks JP, 2008, NAT NEUROSCI, V11, P1126, DOI 10.1038/nn1008-1126; Mizunami M, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00172; Papadopoulou M, 2011, SCIENCE, V332, P721, DOI 10.1126/science.1201835; Pawlak V., 2010, FRONT SYNAPTIC NEURO, V2, P146, DOI DOI 10.3389/FNSYN.2010.00146; Perez-Orive J, 2002, SCIENCE, V297, P359, DOI 10.1126/science.1070502; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; Riemensperger T, 2005, CURR BIOL, V15, P1953, DOI 10.1016/j.cub.2005.09.042; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; Seol GH, 2007, NEURON, V55, P919, DOI 10.1016/j.neuron.2007.08.013; Shen WX, 2008, SCIENCE, V321, P848, DOI 10.1126/science.1160575; Tully J. B. C. T., 1998, DROSOPHILA PRACTICAL, P265; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; Turner GC, 2008, J NEUROPHYSIOL, V99, P734, DOI 10.1152/jn.01283.2007; Waddell S, 2001, SCIENCE, V293, P1271, DOI 10.1126/science.1064604; Wang YL, 2008, J NEUROSCI, V28, P4368, DOI 10.1523/JNEUROSCI.2958-07.2008; WENDT B, 1992, J COMP NEUROL, V321, P387, DOI 10.1002/cne.903210307	45	150	150	5	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					47	U62		10.1038/nature10776	http://dx.doi.org/10.1038/nature10776			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22278062				2022-12-28	WOS:000299726000032
J	Donnez, J; Tatarchuk, TF; Bouchard, P; Puscasiu, L; Zakharenko, NF; Ivanova, T; Ugocsai, G; Mara, M; Jilla, MP; Bestel, E; Terrill, P; Osterloh, I; Loumaye, E				Donnez, Jacques; Tatarchuk, Tetyana F.; Bouchard, Philippe; Puscasiu, Lucian; Zakharenko, Nataliya F.; Ivanova, Tatiana; Ugocsai, Gyula; Mara, Michal; Jilla, Manju P.; Bestel, Elke; Terrill, Paul; Osterloh, Ian; Loumaye, Ernest		PEARL I Study Grp	Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGESTERONE-RECEPTOR MODULATORS; LAPAROSCOPIC MYOMECTOMY; MEDROXYPROGESTERONE ACETATE; UTERINE FIBROIDS; HORMONE AGONIST; LEIOMYOMATA; MANAGEMENT; MYOMAS; PROLIFERATION; MENORRHAGIA	Background The efficacy and safety of oral ulipristal acetate for the treatment of symptomatic uterine fibroids before surgery are uncertain. Methods We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessment of blood loss, in which monthly scores range from 0 to >500, with higher numbers indicating more bleeding]) and anemia (hemoglobin level of <= 10.2 g per deci-liter) to receive treatment for up to 13 weeks with oral ulipristal acetate at a dose of 5 mg per day (96 women) or 10 mg per day (98 women) or to receive placebo (48 women). All patients received iron supplementation. The coprimary efficacy end points were control of uterine bleeding (PBAC score of <75) and reduction of fibroid volume at week 13, after which patients could undergo surgery. Results At 13 weeks, uterine bleeding was controlled in 91% of the women receiving 5 mg of ulipristal acetate, 92% of those receiving 10 mg of ulipristal acetate, and 19% of those receiving placebo (P<0.001 for the comparison of each dose of ulipristal acetate with placebo). The rates of amenorrhea were 73%, 82%, and 6%, respectively, with amenorrhea occurring within 10 days in the majority of patients receiving ulipristal acetate. The median changes in total fibroid volume were -21%, -12%, and +3% (P=0.002 for the comparison of 5 mg of ulipristal acetate with placebo, and P=0.006 for the comparison of 10 mg of ulipristal acetate with placebo). Ulipristal acetate induced benign histologic endometrial changes that had resolved by 6 months after the end of therapy. Serious adverse events occurred in one patient during treatment with 10 mg of ulipristal acetate (uterine hemorrhage) and in one patient during receipt of placebo (fibroid protruding through the cervix). Headache and breast tenderness were the most common adverse events associated with ulipristal acetate but did not occur significantly more frequently than with placebo. Conclusions Treatment with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids. (Funded by PregLem; ClinicalTrials.gov number, NCT00755755.)	[Donnez, Jacques] Clin Univ St Luc Catholic Univ Louvain, Brussels, Belgium; [Tatarchuk, Tetyana F.] Kiev City Clin Hosp 16, Dept Endocrine Gynecol, Kiev, Ukraine; [Zakharenko, Nataliya F.] Kiev City Clin Hosp 9, Dept Gynecol, Kiev, Ukraine; [Bouchard, Philippe] Hop St Antoine, AP HP, F-75571 Paris, France; [Bouchard, Philippe] Univ Paris 06, Paris, France; [Puscasiu, Lucian] Spitalul Clin Judetean Urgenta, Sectia Obstet Ginecol 1, Targu Mures, Romania; [Ivanova, Tatiana] Kursk State Med Univ, Kursk, Russia; [Ugocsai, Gyula] Dr Bugyi Istvan Hosp Szentes, Dept Obstet & Gynecol, Szentes, Hungary; [Mara, Michal] Charles Univ Prague, Fac Med 1, Dept Obstet & Gynecol, Prague, Czech Republic; [Jilla, Manju P.] Dr Jilla Hosp, Aurangabad, Maharashtra, India; [Bestel, Elke; Loumaye, Ernest] PregLem, Geneva, Switzerland; [Terrill, Paul] MDSL Int, Maidenhead, Berks, England; [Osterloh, Ian] OsterMed, Birmingham, W Midlands, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Kursk State Medical University; Charles University Prague; Gedeon Richter Chemistry Works	Donnez, J (corresponding author), St Luc Catholic Univ Louvain, Av Hippocrate 10, B-1200 Brussels, Belgium.	jacques.donnez@uclouvain.be	Tatarchuk, Tetiana/AAT-2603-2020; Mara, Michal/K-3489-2017; Bezhenar, Vitaly/R-7055-2017	Tatarchuk, Tetiana/0000-0002-5498-4143; Mara, Michal/0000-0001-8222-3141; Bezhenar, Vitaly/0000-0002-7807-4929; Hudecek, Robert/0000-0003-0617-0126	Darwin Healthcare Communications	Darwin Healthcare Communications	We thank Venkat Ramanan of PregLem for coordinating the manuscript writing with the support of Arthur Smyth Medina, Tove Anderson, and Nigel Eastmond of Darwin Healthcare Communications.	Amer Soc Reprod Med Collaboration, 2008, FERTIL STERIL, V90, pS125, DOI 10.1016/j.fertnstert.2008.09.012; Attardi BJ, 2002, MOL CELL ENDOCRINOL, V188, P111, DOI 10.1016/S0303-7207(01)00743-2; Campo S, 1999, HUM REPROD, V14, P44, DOI 10.1093/humrep/14.1.44; CARR BR, 1993, J CLIN ENDOCR METAB, V76, P1217, DOI 10.1210/jc.76.5.1217; Chabbert-Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002; Chabbert-Buffet N, 2007, J CLIN ENDOCR METAB, V92, P3582, DOI 10.1210/jc.2006-2816; Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, GUID IND ES IN PRESS; DONNEZ J, 1989, FERTIL STERIL, V51, P947; Donnez J, 2002, HUM REPROD, V17, P1424, DOI 10.1093/humrep/17.6.1424; Dubuisson JB, 2001, ANN NY ACAD SCI, V943, P269, DOI 10.1111/j.1749-6632.2001.tb03807.x; Dubuisson JB, 2001, HUM REPROD, V16, P1726, DOI 10.1093/humrep/16.8.1726; ESHRE Capri Workshop Grp, 2007, HUM REPROD UPDATE, V13, P421; Evans P, 2007, AM FAM PHYSICIAN, V75, P1503; HIGHAM JM, 1990, BRIT J OBSTET GYNAEC, V97, P734, DOI 10.1111/j.1471-0528.1990.tb16249.x; Hoffman R, 2008, HEMATOLOGY BASIC PRI, P453; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P75; Jacoby VL, 2010, AM J OBSTET GYNECOL, V202, P514, DOI 10.1016/j.ajog.2010.02.039; Kim JJ, 2011, MOL CELL ENDOCR 0606; Kolankaya A, 2006, OBSTET GYN CLIN N AM, V33, P145, DOI 10.1016/j.ogc.2005.12.008; Lethaby A, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000547; Levens ED, 2008, OBSTET GYNECOL, V111, P1129, DOI 10.1097/AOG.0b013e3181705d0e; Marret H, 2010, EUR J OBSTET GYN R B, V152, P133, DOI 10.1016/j.ejogrb.2010.07.016; MATTA WHM, 1989, BRIT J OBSTET GYNAEC, V96, P200, DOI 10.1111/j.1471-0528.1989.tb01663.x; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Mutter GL, 2008, MODERN PATHOL, V21, P591, DOI 10.1038/modpathol.2008.19; Newcombe RG, 1999, STAT MED, V18, P1293, DOI 10.1002/(SICI)1097-0258(19990530)18:10<1293::AID-SIM175>3.0.CO;2-7; Nieman LK, 2011, FERTIL STERIL, V95, p767e1; Nisolle M, 1999, HUM REPROD, V14, P2844, DOI 10.1093/humrep/14.11.2844; Rossetti A, 2001, HUM REPROD, V16, P770, DOI 10.1093/humrep/16.4.770; SCIALLI AR, 1995, FERTIL STERIL, V64, P313, DOI 10.1016/S0015-0282(16)57729-2; Somigliana E, 2007, HUM REPROD UPDATE, V13, P465, DOI 10.1093/humupd/dmm013; Spitz IM, 2003, STEROIDS, V68, P981, DOI 10.1016/j.steroids.2003.08.007; Spitz IM, 2005, FERTIL STERIL, V84, P1719, DOI 10.1016/j.fertnstert.2005.05.056; Van Voorhis B, 2009, JAMA-J AM MED ASSOC, V301, P82, DOI 10.1001/jama.2008.791; Viswanathan Meera, 2007, Evid Rep Technol Assess (Full Rep), P1; Wallach EE, 2004, OBSTET GYNECOL, V104, P393, DOI 10.1097/01.AOG.0000136079.62513.39; Yin P, 2010, CANCER RES, V70, P1722, DOI 10.1158/0008-5472.CAN-09-2612; Zapata LB, 2010, CONTRACEPTION, V82, P41, DOI 10.1016/j.contraception.2010.02.011	38	434	489	0	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					409	420		10.1056/NEJMoa1103182	http://dx.doi.org/10.1056/NEJMoa1103182			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QX	22296075				2022-12-28	WOS:000299724400006
J	Druitt, TH; Costa, F; Deloule, E; Dungan, M; Scaillet, B				Druitt, T. H.; Costa, F.; Deloule, E.; Dungan, M.; Scaillet, B.			Decadal to monthly timescales of magma transfer and reservoir growth at a caldera volcano	NATURE			English	Article							RESIDENCE TIMES; ION MICROPROBE; PLAGIOCLASE; DIFFUSION; SANTORINI; EVOLUTION; RECHARGE; TRACE; SR; EMPLACEMENT	Caldera-forming volcanic eruptions are low-frequency, high-impact events capable of discharging tens to thousands of cubic kilometres of magma explosively on timescales of hours to days, with devastating effects on local and global scales(1). Because no such eruption has been monitored during its long build-up phase, the precursor phenomena are not well understood. Geophysical signals obtained during recent episodes of unrest at calderas such as Yellowstone, USA, and Campi Flegrei, Italy, are difficult to interpret, and the conditions necessary for large eruptions are poorly constrained(2,3). Here we present a study of pre-eruptive magmatic processes and their timescales using chemically zoned crystals from the 'Minoan' caldera-forming eruption of Santorini volcano, Greece(4), which occurred in the late 1600s BC. The results provide insights into how rapidly large silicic systems may pass from a quiescent state to one on the edge of eruption(5,6). Despite the large volume of erupted magma(4) (40-60 cubic kilometres), and the 18,000-year gestation period between the Minoan eruption and the previous major eruption, most crystals in the Minoan magma record processes that occurred less than about 100 years before the eruption. Recharge of the magma reservoir by large volumes of silicic magma (and some mafic magma) occurred during the century before eruption, and mixing between different silicic magma batches was still taking place during the final months. Final assembly of large silicic magma reservoirs may occur on timescales that are geologically very short by comparison with the preceding repose period, with major growth phases immediately before eruption. These observations have implications for the monitoring of long-dormant, but potentially active, caldera systems.	[Druitt, T. H.] Univ Blaise Pascal, Clermont Univ, Lab Magmas & Volcans, F-63000 Clermont Ferrand, France; [Druitt, T. H.] CNRS, UMR 6524, LMV, F-63038 Clermont Ferrand, France; [Druitt, T. H.] IRD, LMV, F-63038 Clermont Ferrand, France; [Costa, F.] Nanyang Technol Univ, Earth Observ Singapore, Singapore 639798, Singapore; [Deloule, E.] CRPG CNRS, F-54501 Vandoeuvre Les Nancy, France; [Dungan, M.] Univ Geneva, Dept Mineral, CH-1205 Geneva, Switzerland; [Scaillet, B.] Univ Tours, Univ Orleans, CNRS, ISTO UMR 6113, F-45071 Orleans, France	Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Institut de Recherche pour le Developpement (IRD); Universite Clermont Auvergne (UCA); Universite Jean Monnet; Institut de Recherche pour le Developpement (IRD); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; University of Geneva; Centre National de la Recherche Scientifique (CNRS); Universite de Orleans; Universite de Tours	Druitt, TH (corresponding author), Univ Blaise Pascal, Clermont Univ, Lab Magmas & Volcans, BP 10448, F-63000 Clermont Ferrand, France.	t.druitt@opgc.univ-bpclermont.fr	Scaillet, Bruno/A-5846-2012; Costa, Fidel/B-7035-2011	Costa, Fidel/0000-0002-1409-5325; Druitt, Timothy/0000-0002-6594-1448; Deloule, Etienne/0000-0001-6955-1685; Scaillet, Bruno/0000-0003-1561-0226	French Agence National de Recherche (ANR STOMIXAN) [ANR-08CEA080]	French Agence National de Recherche (ANR STOMIXAN)(French National Research Agency (ANR))	This study was funded partly by the French Agence National de Recherche (ANR STOMIXAN, contract no. ANR-08CEA080, to B. S.). We are grateful to R. Armstrong, P. Crancon and R. Girardin for their contributions during the early stages of this study, and to J. Blundy and M. Reid for reviews. This is Laboratory of Excellence ClerVolc contribution no. 1.	Aizawa K, 2006, GEOL SOC SPEC PUBL, V269, P65, DOI 10.1144/GSL.SP.2006.269.01.05; Andersen D.J., 1985, NEW FINAL MODELS TI, V66, P416; Bachmann O, 2004, J PETROL, V45, P1565, DOI 10.1093/petrology/egh019; Bindeman IN, 1998, GEOCHIM COSMOCHIM AC, V62, P1175, DOI 10.1016/S0016-7037(98)00047-7; BLUNDY JD, 1991, GEOCHIM COSMOCHIM AC, V55, P193, DOI 10.1016/0016-7037(91)90411-W; Burgisser A, 2011, NATURE, V471, P212, DOI 10.1038/nature09799; Cherniak DJ, 2010, REV MINERAL GEOCHEM, V72, P691, DOI 10.2138/rmg.2010.72.15; Conticelli S., 1998, EUROPEAN LAB VOLCANO, P157; Costa F, 2003, GEOCHIM COSMOCHIM AC, V67, P2189, DOI 10.1016/S0016-7037(02)01345-5; Costa F., 2010, TIMESCALES MAGMATIC, DOI DOI 10.1002/9781444328509.CH7; Costa F, 2010, CONTRIB MINERAL PETR, V159, P371, DOI 10.1007/s00410-009-0432-3; Costa F, 2008, REV MINERAL GEOCHEM, V69, P545, DOI 10.2138/rmg.2008.69.14; Cottrell E, 1999, CONTRIB MINERAL PETR, V135, P315, DOI 10.1007/s004100050514; Cruden AR, 1998, J GEOL SOC LONDON, V155, P853, DOI 10.1144/gsjgs.155.5.0853; de Silva S, 2008, GEOLOGY, V36, P387, DOI 10.1130/G24380A.1; Dohmen R, 2002, EUR J MINERAL, V14, P1155, DOI 10.1127/0935-1221/2002/0014-1155; Druitt T. H., 1999, J GEOL SOC LOND MEM, V19; DZURISIN D, 1994, B VOLCANOL, V56, P261, DOI 10.1007/BF00302079; Dzurisin D., 1988, B US GEOL SURV, V1855; Francalanci L., 1998, EUROPEAN LAB VOLCANO, P175; Gertisser R, 2009, J VOLCANOL GEOTH RES, V186, P387, DOI 10.1016/j.jvolgeores.2009.07.015; GILETTI BJ, 1994, GEOCHIM COSMOCHIM AC, V58, P3785, DOI 10.1016/0016-7037(94)90363-8; Gottsmann J, 2008, DEV VOLCANO, V10, P1; Gottsmann J, 2008, DEV VOLCANO, V10, P417, DOI 10.1016/S1871-644X(07)00012-5; Grocott J, 2009, J GEOL SOC LONDON, V166, P295, DOI 10.1144/0016-76492007-165; Hill DP, 2006, GEOL SOC SPEC PUBL, V269, P1, DOI 10.1144/GSL.SP.2006.269.01.02; HINTON RW, 1990, CHEM GEOL, V83, P11, DOI 10.1016/0009-2541(90)90136-U; HUIJSMANS JPP, 1985, GEOLOGICA ULTRAIECTI, V41; Jellinek AM, 2003, B VOLCANOL, V65, P363, DOI 10.1007/s00445-003-0277-y; LASAGA AC, 1998, PR S GEOCH, P3; LaTourrette T, 1998, EARTH PLANET SC LETT, V158, P91, DOI 10.1016/S0012-821X(98)00048-X; Martin VM, 2010, GEOLOGY, V38, P539, DOI 10.1130/G30758.1; McLeod P, 1999, J VOLCANOL GEOTH RES, V92, P231, DOI 10.1016/S0377-0273(99)00053-0; Miller CF, 2008, ELEMENTS, V4, P11, DOI 10.2113/GSELEMENTS.4.1.11; Morgan DJ, 2006, GEOLOGY, V34, P845, DOI 10.1130/G22604.1; Santo AP, 2005, DEV VOLCANO, V7, P139, DOI 10.1016/S1871-644X(05)80036-1; Saunders KE, 2010, J PETROL, V51, P2465, DOI 10.1093/petrology/egq064; Sigurdsson H., 2006, EOS, V87, P337, DOI DOI 10.1029/2006E0340001; STORMER JC, 1983, AM MINERAL, V68, P586; Vaggelli G, 2009, J GEOPHYS RES-SOL EA, V114, DOI 10.1029/2008JB005936; Wark DA, 2007, GEOLOGY, V35, P235, DOI 10.1130/G23316A.1; Wiebe RA, 1998, J STRUCT GEOL, V20, P1273, DOI 10.1016/S0191-8141(98)00059-5; Zellmer GF, 1999, CONTRIB MINERAL PETR, V136, P345, DOI 10.1007/s004100050543; Zhang YX, 2010, REV MINERAL GEOCHEM, V72, P5, DOI 10.2138/rmg.2010.72.2	44	237	241	3	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2012	482	7383					77	U97		10.1038/nature10706	http://dx.doi.org/10.1038/nature10706			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884RN	22297973	Green Submitted, Green Accepted			2022-12-28	WOS:000299726000038
J	Spence, D				Spence, Des			FROM THE FRONTLINE Lessons from America: primary care	BRITISH MEDICAL JOURNAL			English	Editorial Material																		2011, BRIT MED J, V342, DOI DOI 10.1136/BMJ.D2684	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 1	2012	344								e760	10.1136/bmj.e760	http://dx.doi.org/10.1136/bmj.e760			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	889QJ	22298095				2022-12-28	WOS:000300088000015
J	Fleming, RE; Ponka, P				Fleming, Robert E.; Ponka, Prem			Iron Overload in Human Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HEREDITARY HEMOCHROMATOSIS PROTEIN; TRANSFERRIN RECEPTOR 2; HEPCIDIN EXPRESSION; RESPONSIVE ELEMENT; REGULATORY PROTEINS; BETA-THALASSEMIA; HFE; FERROPORTIN; METABOLISM; ABSORPTION	Iron-overload disorders are typically insidious, causing progressive and sometimes irreversible end-organ injury before clinical symptoms develop. With a high index of suspicion, however, the consequences of iron toxicity can be attenuated or prevented. Some iron-overload disorders are quite common (e.g., HFE-associated hereditary hemochromatosis and beta-thalassemia), whereas others are exceedingly rare. An understanding of the pathophysiology of these disorders is helpful in directing the workup and in identifying scenarios that merit consideration of the less common diagnoses. Since many of the molecular participants in iron metabolism have been characterized only in the past several years, we first review the current understanding of iron metabolism(1) and then discuss specific iron-overload diseases.	[Fleming, Robert E.] St Louis Univ, Sch Med, Dept Pediat, St Louis, MO 63103 USA; [Fleming, Robert E.] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63103 USA; [Ponka, Prem] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Ponka, Prem] McGill Univ, Dept Physiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Saint Louis University; Saint Louis University; Lady Davis Institute; McGill University; McGill University; McGill University	Ponka, P (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	prem.ponka@mcgill.ca	Ponka, Prem/A-4123-2011	Ponka, Prem/0000-0001-5835-1477	F. Hoffman-La Roche	F. Hoffman-La Roche	Dr. Ponka reports receiving consulting fees from F. Hoffman-La Roche. Dr. Fleming reports receiving support for meeting travel expenses and accommodations. No other potential conflict of interest relevant to this article was reported.	ALTSTATT LB, 1967, P SOC EXP BIOL MED, V124, P353, DOI 10.3181/00379727-124-31741; Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335; Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Babitt JL, 2007, J CLIN INVEST, V117, P1933, DOI 10.1172/JCI31342; Bacon BR, 1999, ANN INTERN MED, V130, P953, DOI 10.7326/0003-4819-130-12-199906150-00002; Barnham KJ, 2008, CURR OPIN CHEM BIOL, V12, P222, DOI 10.1016/j.cbpa.2008.02.019; Bartnikas TB, 2011, BLOOD, V117, P630, DOI 10.1182/blood-2010-05-287359; BARTON JC, 1994, J LAB CLIN MED, V124, P193; Becker E, 2001, INT J BIOCHEM CELL B, V33, P1, DOI 10.1016/S1357-2725(00)00067-4; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; Blanco E, 2009, BLOOD CELL MOL DIS, V43, P199, DOI 10.1016/j.bcmd.2009.05.003; Breda L, 2005, ANN NY ACAD SCI, V1054, P417, DOI 10.1196/annals.1345.069; Brissot P, 2011, BIOCH BIOPHYS A 0809; Brittenham GM, 2011, NEW ENGL J MED, V364, P146, DOI 10.1056/NEJMct1004810; Cabantchik ZI, 2005, BEST PRACT RES CL HA, V18, P277, DOI 10.1016/j.beha.2004.10.003; Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; Camaschella C, 2009, HAEMATOL-HEMATOL J, V94, P307, DOI 10.3324/haematol.2008.005405; Casanovas G, 2011, J MOL MED, V89, P811, DOI 10.1007/s00109-011-0751-5; Chen JX, 2007, J BIOL CHEM, V282, P36862, DOI 10.1074/jbc.M706720200; Corradini E, 2009, GASTROENTEROLOGY, V137, P1489, DOI 10.1053/j.gastro.2009.06.057; Curtis ARJ, 2001, NAT GENET, V28, P350, DOI 10.1038/ng571; De Domenico I, 2006, HAEMATOLOGICA, V91, P92; De Domenico I, 2011, CELL METAB, V13, P57, DOI 10.1016/j.cmet.2010.12.003; De Domenico I, 2009, P NATL ACAD SCI USA, V106, P3800, DOI 10.1073/pnas.0900453106; Dunn LL, 2007, TRENDS CELL BIOL, V17, P93, DOI 10.1016/j.tcb.2006.12.003; Fernandes A, 2009, BLOOD, V114, P437, DOI 10.1182/blood-2008-03-146134; Fleming MD, 2002, SEMIN HEMATOL, V39, P270, DOI 10.1053/shem.2002.35637; Galy B, 2008, CELL METAB, V7, P79, DOI 10.1016/j.cmet.2007.10.006; Gao JW, 2009, CELL METAB, V9, P217, DOI 10.1016/j.cmet.2009.01.010; Gardenghi S, 2010, J CLIN INVEST, V120, P4466, DOI 10.1172/JCI41717; Goldwurm S, 2000, Hematol J, V1, P390, DOI 10.1038/sj.thj.6200063; Goswami T, 2006, J BIOL CHEM, V281, P28494, DOI 10.1074/jbc.C600197200; Gurrin LC, 2009, HEPATOLOGY, V50, P94, DOI 10.1002/hep.22972; Hanchard NA, 2011, MOL GENET METAB, V103, P262, DOI 10.1016/j.ymgme.2011.03.006; Harris ZL, 1998, AM J CLIN NUTR, V67, p972S, DOI 10.1093/ajcn/67.5.972S; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hayflick SJ, 2003, NEW ENGL J MED, V348, P33, DOI 10.1056/NEJMoa020817; Herbert V, 1999, ANN INTERN MED, V131, P475, DOI 10.7326/0003-4819-131-6-199909210-00021; Hershko C, 2010, ANN NY ACAD SCI, V1202, P1, DOI 10.1111/j.1749-6632.2010.05544.x; Huang FW, 2005, J CLIN INVEST, V115, P2187, DOI 10.1172/JCI25049; Kato J, 2001, AM J HUM GENET, V69, P191, DOI 10.1086/321261; Kautz L, 2008, BLOOD, V112, P1503, DOI 10.1182/blood-2008-03-143354; Kautz L, 2009, BLOOD, V114, P2515, DOI 10.1182/blood-2009-02-206771; Knovich MA, 2009, BLOOD REV, V23, P95, DOI 10.1016/j.blre.2008.08.001; Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102; KONDO H, 1988, HEPATOLOGY, V8, P32, DOI 10.1002/hep.1840080108; Kroot JJC, 2011, CLIN CHEM, V57, P1650, DOI 10.1373/clinchem.2009.140053; Kurian MA, 2011, DEV MED CHILD NEUROL, V53, P394, DOI 10.1111/j.1469-8749.2011.03955.x; Lakhal S, 2011, J BIOL CHEM, V286, P4090, DOI 10.1074/jbc.M110.173096; Li HH, 2010, NAT MED, V16, P177, DOI 10.1038/nm.2073; Mahesh S, 2008, LEUKEMIA LYMPHOMA, V49, P427, DOI 10.1080/10428190701843221; Mainous AG, 2011, AM J HEMATOL, V86, P733, DOI 10.1002/ajh.22082; Mastrogiannaki M, 2009, J CLIN INVEST, V119, P1159, DOI 10.1172/JCI38499; McLaren CE, 2003, AM J MED SCI, V325, P53, DOI 10.1097/00000441-200302000-00001; Mcnamara L, 2005, J GASTROEN HEPATOL, V20, P1855, DOI 10.1111/j.1440-1746.2005.03930.x; Meynard D, 2009, NAT GENET, V41, P478, DOI 10.1038/ng.320; Mole DR, 2010, ANTIOXID REDOX SIGN, V12, P445, DOI 10.1089/ars.2009.2790; Murray KF, 2001, PEDIATRICS, V108, P960, DOI 10.1542/peds.108.4.960; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Nemeth E, 2006, HAEMATOLOGICA, V91, P727; Niederkofler V, 2005, J CLIN INVEST, V115, P2180, DOI 10.1172/JCI25683; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Papanikolaou G, 2005, BLOOD, V105, P4103, DOI 10.1182/blood-2004-12-4844; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Parrow NL, 2011, EXPERT REV HEMATOL, V4, P233, DOI [10.1586/ehm.11.22, 10.1586/EHM.11.22]; Pietrangelo A, 2005, GASTROENTEROLOGY, V128, P470, DOI 10.1053/j.gastro.2004.11.057; Pietrangelo A, 2011, J HEPATOL, V54, P173, DOI 10.1016/j.jhep.2010.08.004; Poll M, 2010, HAEMATOL-HEMATOL J, V95, P1832, DOI 10.3324/haematol.2010.027003; Ponka P, 1997, BLOOD, V89, P1; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Rand EB, 2009, J PEDIATR-US, V155, P566, DOI 10.1016/j.jpeds.2009.04.012; Renella R, 2009, HEMATOL ONCOL CLIN N, V23, P283, DOI 10.1016/j.hoc.2009.01.010; Richardson DR, 2010, P NATL ACAD SCI USA, V107, P10775, DOI 10.1073/pnas.0912925107; Rivera S, 2005, BLOOD, V106, P2196, DOI 10.1182/blood-2005-04-1766; Roetto A, 2001, BLOOD, V97, P2555, DOI 10.1182/blood.V97.9.2555; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; Rouault Tracey A, 2006, Semin Pediatr Neurol, V13, P142, DOI 10.1016/j.spen.2006.08.002; Sanchez M, 2007, NAT STRUCT MOL BIOL, V14, P420, DOI 10.1038/nsmb1222; Schmidt PJ, 2008, CELL METAB, V7, P205, DOI 10.1016/j.cmet.2007.11.016; Shah YM, 2009, CELL METAB, V9, P152, DOI 10.1016/j.cmet.2008.12.012; Silvestri L, 2008, BLOOD, V111, P924, DOI 10.1182/blood-2007-07-100677; Silvestri L, 2008, CELL METAB, V8, P502, DOI 10.1016/j.cmet.2008.09.012; Simpson RJ, 2009, CELL METAB, V10, P84, DOI 10.1016/j.cmet.2009.06.009; Taher AT, 2011, BRIT J HAEMATOL, V152, P512, DOI 10.1111/j.1365-2141.2010.08486.x; Taher Ali T, 2009, Hemoglobin, V33 Suppl 1, pS46, DOI 10.3109/03630260903346676; Tamary H, 2008, BLOOD, V112, P5241, DOI 10.1182/blood-2008-06-165738; Tanno T, 2007, NAT MED, V13, P1096, DOI 10.1038/nm1629; Tanno T, 2009, BLOOD, V114, P181, DOI 10.1182/blood-2008-12-195503; Thomas M, 2004, MOVEMENT DISORD, V19, P36, DOI 10.1002/mds.10650; Trombini P, 2007, HAEMATOLOGICA, V92, P1407, DOI 10.3324/haematol.11377; VALBERG LS, 1969, GASTROENTEROLOGY, V56, P241; van Bokhoven MA, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7251; Wallace DF, 2009, HEPATOLOGY, V50, P1992, DOI 10.1002/hep.23198; Wang RH, 2005, CELL METAB, V2, P399, DOI 10.1016/j.cmet.2005.10.010; Wang W, 2010, BBA-GEN SUBJECTS, V1800, P760, DOI 10.1016/j.bbagen.2010.03.011; Whitington PF, 2007, SEMIN LIVER DIS, V27, P243, DOI 10.1055/s-2007-985069; Whitington PF, 2004, LANCET, V364, P1690, DOI 10.1016/S0140-6736(04)17356-X; Xia Y, 2008, BLOOD, V111, P5195, DOI 10.1182/blood-2007-09-111567; Zhang DL, 2009, CELL METAB, V9, P461, DOI 10.1016/j.cmet.2009.03.006; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572; Zimmer M, 2008, MOL CELL, V32, P838, DOI 10.1016/j.molcel.2008.12.004	102	385	406	5	134	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					348	359		10.1056/NEJMra1004967	http://dx.doi.org/10.1056/NEJMra1004967			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EQ	22276824				2022-12-28	WOS:000299464100006
J	Morrison, N; Thomas, R; Smith, P				Morrison, Nicola; Thomas, Rhys; Smith, Phil			Juvenile myoclonic epilepsy	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Smith, Phil] Univ Wales Hosp, Dept Neurol, Alan Richens Epilepsy Unit, Cardiff CF14 4XW, S Glam, Wales; [Thomas, Rhys] Swansea Univ, Inst Life Sci, Swansea, W Glam, Wales	Cardiff University; Swansea University	Smith, P (corresponding author), Univ Wales Hosp, Dept Neurol, Alan Richens Epilepsy Unit, Heath Pk, Cardiff CF14 4XW, S Glam, Wales.	SmithPE@cardiff.ac.uk	Thomas, Rhys/I-3840-2019	Thomas, Rhys/0000-0003-2062-8623					0	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 26	2012	344								e360	10.1136/bmj.e360	http://dx.doi.org/10.1136/bmj.e360			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885LE	22282530	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000299779700005
J	Lord, CJ; Ashworth, A				Lord, Christopher J.; Ashworth, Alan			The DNA damage response and cancer therapy	NATURE			English	Review							POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; SYNTHETIC LETHALITY; PARP INHIBITORS; EXCISION-REPAIR; BREAST-CANCER; MUTANT-CELLS; TUMOR-CELLS; MUTATIONS; RESISTANCE	Genomic instability is one of the most pervasive characteristics of tumour cells and is probably the combined effect of DNA damage, tumour-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells. Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities. A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.	[Lord, Christopher J.; Ashworth, Alan] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Lord, CJ (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Fulham Rd, London SW3 6JB, England.	chris.lord@icr.ac.uk; alan.ashworth@icr.ac.uk	Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021	Lord, Christopher J/0000-0002-3226-0515; 	Cancer Research UK; Wellcome Trust; Breakthrough Breast Cancer; AACR; Komen Foundation; Breast Cancer Research Foundation; European Union; Breast Cancer Campaign; NHS	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Breakthrough Breast Cancer; AACR; Komen Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; European Union(European Commission); Breast Cancer Campaign; NHS	We thank Cancer Research UK, The Wellcome Trust, Breakthrough Breast Cancer, AACR, The Komen Foundation, The Breast Cancer Research Foundation, the European Union and The Breast Cancer Campaign for funding the work in our laboratory. We also acknowledge NHS funding to the Royal Marsden Hospital NIHR Biomedical Research Centre.	Akamatsu Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001160; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Balmana J, 2011, CANCER DISCOV, V1, P29, DOI 10.1158/2159-8274.CD-11-0048; Banerjee S, 2010, NAT REV CLIN ONCOL, V7, P508, DOI 10.1038/nrclinonc.2010.116; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barber LJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021639; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bell O, 2011, NAT REV GENET, V12, P554, DOI 10.1038/nrg3017; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cleaver JE, 2009, NAT REV GENET, V10, P756, DOI 10.1038/nrg2663; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; DOBZHANSKY T, 1946, GENETICS, V31, P269; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Friboulet L, 2011, CLIN CANCER RES, V17, P5562, DOI 10.1158/1078-0432.CCR-11-0790; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris H, 2008, J CELL SCI, V121, P3, DOI 10.1242/jcs.025742; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Issaeva N, 2010, CANCER RES, V70, P6268, DOI 10.1158/0008-5472.CAN-09-3416; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Kaelin WG, 2009, GENOME MED, V1, DOI 10.1186/gm99; Lansdorp PM, 2007, CELL, V129, P1244, DOI 10.1016/j.cell.2007.06.017; Lieber MR, 2010, NAT STRUCT MOL BIOL, V17, P393, DOI 10.1038/nsmb0410-393; Liu PF, 2011, CELL, V146, P888, DOI 10.1016/j.cell.2011.07.042; Liu X., 2011, CLIN CANC RES   1129; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; LUCCHESI JC, 1968, GENETICS, V59, P37; Mantoni TS, 2011, CANCER RES, V71, P3453, DOI 10.1158/0008-5472.CAN-10-1633; Martin SA, 2011, CANCER RES, V71, P1836, DOI 10.1158/0008-5472.CAN-10-2836; Martin SA, 2010, CANCER CELL, V17, P235, DOI 10.1016/j.ccr.2009.12.046; Martin SA, 2009, EMBO MOL MED, V1, P323, DOI 10.1002/emmm.200900040; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; MENDELEYEV J, 1995, BIOCHEM PHARMACOL, V50, P705, DOI 10.1016/0006-2952(95)00189-7; Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041; Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Murai J, 2011, MOL CELL BIOL, V31, P2462, DOI 10.1128/MCB.05058-11; Nakabeppu Y, 2006, BIOL CHEM, V387, P373, DOI 10.1515/BC.2006.050; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; Peasland A, 2011, BRIT J CANCER, V105, P372, DOI 10.1038/bjc.2011.243; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Warmerdam DO, 2010, MUTAT RES-REV MUTAT, V704, P2, DOI 10.1016/j.mrrev.2009.12.001; Weller M, 2010, NAT REV NEUROL, V6, P39, DOI 10.1038/nrneurol.2009.197; Zaremba T, 2007, ANTI-CANCER AGENT ME, V7, P515, DOI 10.2174/187152007781668715; Zhang M, 2010, P NATL ACAD SCI USA, V107, P3522, DOI 10.1073/pnas.0910179107	73	1110	1144	18	456	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					287	294		10.1038/nature10760	http://dx.doi.org/10.1038/nature10760			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22258607				2022-12-28	WOS:000299210600030
J	Cohen, D				Cohen, Deborah			FLU DRUGS Search for evidence goes on	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RESPIRATORY-TRACT COMPLICATIONS; OSELTAMIVIR TREATMENT; ACUTE INFLUENZA; EFFICACY; SAFETY		BMJ, London WC1H 9JR, England		Cohen, D (corresponding author), BMJ, London WC1H 9JR, England.	dcohen@bmj.com						[Anonymous], 2007, WHO GEN TECH REP; Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011, ANTIVIRAL AGENTS TRE; Brasseur D, 2006, LANCET, V367, P1572, DOI 10.1016/S0140-6736(06)68685-6; Chambers J, HLTH PLACE IN PRESS; Cohen D, 2009, BRIT MED J, V339, pb538; Cohen D, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2912; Epstein Helen, 2011, NEW YORK REV BO 0512; Godlee F, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5351; Hayden FG, 2004, J INFECT DIS, V189, P440, DOI 10.1086/381128; Health and Human Services, 2005, HHS PAND INFL PLAN; Hernan MA, 2011, CLIN INFECT DIS, V53, P277, DOI 10.1093/cid/cir400; Jack A, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3811; Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5106; Kaiser L, 2003, ARCH INTERN MED, V163, P1667, DOI 10.1001/archinte.163.14.1667; McNicoll A, 2011, PULSE           0923; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; Pott A, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3838; Roche, 2000, TAM OS PHOSPH NICE S; Roche, 2009, ROCH ANN REP 2009; Smith J, 2006, LANCET, V367, P1571, DOI 10.1016/S0140-6736(06)68683-2; Smith J, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5364; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; United Kingdom Clinical Pharmacy Association, 2011, ANT MAN INFL A H1N1; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748	24	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	2012	344								e458	10.1136/bmj.e458	http://dx.doi.org/10.1136/bmj.e458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888YY	22252041				2022-12-28	WOS:000300041800012
J	Stevens, SM				Stevens, Scott M.			Review: Gestalt or clinical decision rules have limited sensitivity and specificity for detecting acute PE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Stevens, Scott M.] Intermt Med Ctr, Murray, UT 84157 USA	Intermountain Healthcare; Intermountain Medical Center	Stevens, SM (corresponding author), Intermt Med Ctr, Murray, UT 84157 USA.							Fesmire FM, 2011, ANN EMERG MED, V57, P628, DOI 10.1016/j.annemergmed.2011.01.020; Torbicki A, 2008, EUR HEART J, V29, P2276, DOI 10.1093/eurheartj/ehn310	2	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-11	10.7326/0003-4819-156-2-201201170-02011	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V41QD	22250173				2022-12-28	WOS:000209559800002
J	Lipworth, W; Kerridge, I; Little, M; Day, R				Lipworth, Wendy; Kerridge, Ian; Little, Miles; Day, Richard			Evidence and desperation in off-label prescribing: recombinant factor VIIa	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ACTIVATED FACTOR-VII; HEMORRHAGE; SAFETY; RULE		[Lipworth, Wendy] Univ New S Wales, Australian Inst Hlth Innovat, Sydney, NSW 2052, Australia; [Lipworth, Wendy; Kerridge, Ian; Little, Miles] Univ Sydney, Ctr Values Eth & Law Med, Sydney, NSW 2006, Australia; [Day, Richard] St Vincents Hosp, Sydney, NSW 2010, Australia	University of New South Wales Sydney; University of Sydney; St Vincents Hospital Sydney	Lipworth, W (corresponding author), Univ New S Wales, Australian Inst Hlth Innovat, Sydney, NSW 2052, Australia.	w.lipworth@unsw.edu.au	Day, Richard/D-8699-2011	Day, Richard/0000-0002-6045-6937; Lipworth, Wendy/0000-0002-0234-657X; Kerridge, Ian/0000-0001-7445-4660	National Health and Medical Research Council (NHMRC) [568612]; Sydney Medical School Foundation, University of Sydney	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Sydney Medical School Foundation, University of Sydney	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. Empirical research related to this article has been funded by a National Health and Medical Research Council (NH&MRC) programme grant (568612) and by the Sydney Medical School Foundation, University of Sydney.	Avorn J, 2011, ANN INTERN MED, V154, P566, DOI 10.7326/0003-4819-154-8-201104190-00010; Bright JL, 2006, ARCH INTERN MED, V166, P2554, DOI 10.1001/archinte.166.22.2554-b; Dutton RP, 2011, J TRAUMA, V71, P12, DOI 10.1097/TA.0b013e31821a42cf; Gilovich T, 1998, PSYCHOL REV, V105, P602, DOI 10.1037/0033-295X.105.3.602; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; Jonsen A R, 1986, Law Med Health Care, V14, P172; Kalina Michael, 2011, Del Med J, V83, P109; Karkouti K, 2011, ANN INTERN MED, V155, P339, DOI 10.7326/0003-4819-155-5-201109060-00023; Kesselheim AS, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000431; Largent EA, 2009, ARCH INTERN MED, V169, P1745, DOI 10.1001/archinternmed.2009.314; Levi M, 2010, NEW ENGL J MED, V363, P1791, DOI 10.1056/NEJMoa1006221; Lin YL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005011.pub3; Logan AC, 2011, ANN INTERN MED, V154, P516, DOI 10.7326/0003-4819-154-8-201104190-00002; MARKS I, 1988, AM J PSYCHIAT, V145, P1207; McKie J, 2003, SOC SCI MED, V56, P2407, DOI 10.1016/S0277-9536(02)00244-7; Ray C., 2011, WALL STREET J   0610; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; Witmer CM, 2011, J PEDIAT, V158, P820; Yank V, 2011, ANN INTERN MED, V154, P529, DOI 10.7326/0003-4819-154-8-201104190-00004	19	11	11	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	2012	344								d7926	10.1136/bmj.d7926	http://dx.doi.org/10.1136/bmj.d7926			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888YP	22250217	Green Submitted			2022-12-28	WOS:000300040900012
J	Savas, JN; Toyama, BH; Xu, T; Yates, JR; Hetzer, MW				Savas, Jeffrey N.; Toyama, Brandon H.; Xu, Tao; Yates, John R., III; Hetzer, Martin W.			Extremely Long-Lived Nuclear Pore Proteins in the Rat Brain	SCIENCE			English	Article							MOUSE-BRAIN; TURNOVER; CELLS; MYELIN		[Toyama, Brandon H.; Hetzer, Martin W.] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; [Savas, Jeffrey N.; Xu, Tao; Yates, John R., III] Scripps Res Inst, Dept Biol Chem, La Jolla, CA 92037 USA	Salk Institute; Scripps Research Institute	Hetzer, MW (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hetzer@salk.edu		Toyama, Brandon/0000-0002-8355-9138	Hewitt Foundation; Ellison Medical foundation; Glenn foundation; National Institute of Aging [F32AG039127]; NIH [P41 RR011823, P01 AG031097, HHSN268201000035C, R01 MH067880, P30 CA014195]; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG031097, F32AG039127] Funding Source: NIH RePORTER	Hewitt Foundation; Ellison Medical foundation(Lawrence Ellison Foundation); Glenn foundation; National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are supported by the Hewitt Foundation (B.H.T.); the Ellison Medical and Glenn foundations (M.W.H.); National Institute of Aging fellowship F32AG039127 (J.N.S.); and NIH grants P41 RR011823, P01 AG031097, HHSN268201000035C, and R01 MH067880 (J.R.Y. and J.N.S.) and P30 CA014195 (M.W.H.). The RAW files and parameter files are publicly available at http://fields.scripps.edu/published/ellnpp2011/.	Cambridge SB, 2011, J PROTEOME RES, V10, P5275, DOI 10.1021/pr101183k; Capelson M, 2010, COLD SH Q B, V75, P585, DOI 10.1101/sqb.2010.75.059; COMMERFORD SL, 1982, P NATL ACAD SCI-BIOL, V79, P1163, DOI 10.1073/pnas.79.4.1163; D'Angelo MA, 2009, CELL, V136, P284, DOI 10.1016/j.cell.2008.11.037; FISCHER CA, 1974, BRAIN RES, V74, P51, DOI 10.1016/0006-8993(74)90111-5; Price JC, 2010, P NATL ACAD SCI USA, V107, P14508, DOI 10.1073/pnas.1006551107; SHAPIRA R, 1981, J NEUROCHEM, V36, P1427, DOI 10.1111/j.1471-4159.1981.tb00582.x; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028	8	203	203	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2012	335	6071					942	942		10.1126/science.1217421	http://dx.doi.org/10.1126/science.1217421			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900ZQ	22300851	Green Accepted			2022-12-28	WOS:000300931800038
J	Alsford, S; Eckert, S; Baker, N; Glover, L; Sanchez-Flores, A; Leung, KF; Turner, DJ; Field, MC; Berriman, M; Horn, D				Alsford, Sam; Eckert, Sabine; Baker, Nicola; Glover, Lucy; Sanchez-Flores, Alejandro; Leung, Ka Fai; Turner, Daniel J.; Field, Mark C.; Berriman, Matthew; Horn, David			High-throughput decoding of antitrypanosomal drug efficacy and resistance	NATURE			English	Article							BLOOD-STREAM FORMS; TRYPANOSOMA-BRUCEI; EXPRESSION; GLYCOPROTEIN; RNAI; DIAMIDINE; LYSOSOME; PROTEASE; SURAMIN; GENOME	The concept of disease-specific chemotherapy was developed a century ago. Dyes and arsenical compounds that displayed selectivity against trypanosomes were central to this work(1,2), and the drugs that emerged remain in use for treating human African trypanosomiasis (HAT)(3). The importance of understanding the mechanisms underlying selective drug action and resistance for the development of improved HAT therapies has been recognized, but these mechanisms have remained largely unknown. Here we use all five current HAT drugs for genome-scale RNA interference target sequencing (RIT-seq) screens in Trypanosoma brucei, revealing the transporters, organelles, enzymes and metabolic pathways that function to facilitate antitrypanosomal drug action. RIT-seq profiling identifies both known drug importers(4,5) and the only known prodrug activator(6), and links more than fifty additional genes to drug action. A bloodstream stage-specific invariant surface glycoprotein (ISG75) family mediates suramin uptake, and the AP1 adaptin complex, lysosomal proteases and major lysosomal transmembrane protein, as well as spermidine and N-acetylglucosamine biosynthesis, all contribute to suramin action. Further screens link ubiquinone availability to nitro-drug action, plasma membrane P-type H+-ATPases to pentamidine action, and trypanothione and several putative kinases to melarsoprol action. We also demonstrate a major role for aquaglyceroporins in pentamidine and melarsoprol cross-resistance. These advances in our understanding of mechanisms of antitrypanosomal drug efficacy and resistance will aid the rational design of new therapies and help to combat drug resistance, and provide unprecedented molecular insight into the mode of action of antitrypanosomal drugs.	[Alsford, Sam; Baker, Nicola; Glover, Lucy; Horn, David] London Sch Hyg & Trop Med, London WC1E 7HT, England; [Eckert, Sabine; Sanchez-Flores, Alejandro; Turner, Daniel J.; Berriman, Matthew] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; [Leung, Ka Fai; Field, Mark C.] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of London; London School of Hygiene & Tropical Medicine; Wellcome Trust Sanger Institute; University of Cambridge	Horn, D (corresponding author), London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	david.horn@lshtm.ac.uk	Sanchez-Flores, Alejandro/L-9454-2016; Field, Mark/AAD-6455-2021; Alsford, Sam/AGD-5139-2022; Berriman, Matthew/A-7618-2011	Sanchez-Flores, Alejandro/0000-0003-0476-3139; Alsford, Sam/0000-0001-8621-4920; Berriman, Matthew/0000-0002-9581-0377; Baker, Nicola/0000-0002-6193-9818; Field, Mark/0000-0002-4866-2885; Glover, Lucy/0000-0001-7191-6890; Horn, David/0000-0001-5173-9284	Wellcome Trust [093010/Z/10/Z, 085775/Z/08/Z, 090007/Z/09/Z]; Bloomsbury colleges PhD studentship	Wellcome Trust(Wellcome TrustEuropean Commission); Bloomsbury colleges PhD studentship	We thank J. Morris, Z. Wang, M. Drew and P. Englund for the RNAi plasmid library, V. Yardley for antitrypanosomal drugs, J. Bangs for anti-p67 and CatL sera, D. Russell for anti-GLP1 sera, A. Varghese for assistance with preliminary Sanger sequencing and J. Kelly, M. Taylor and B. Wren for comments on the draft manuscript. The work was funded by grants from The Wellcome Trust (093010/Z/10/Z at the London School of Hygiene & Tropical Medicine, 085775/Z/08/Z at The Wellcome Trust Sanger Institute and 090007/Z/09/Z at The University of Cambridge). N.B. was supported by a Bloomsbury colleges PhD studentship.	Allen CL, 2007, MOL BIOCHEM PARASIT, V156, P175, DOI 10.1016/j.molbiopara.2007.07.020; Alsford S, 2005, MOL BIOCHEM PARASIT, V144, P142, DOI 10.1016/j.molbiopara.2005.08.009; Alsford S, 2008, MOL BIOCHEM PARASIT, V161, P76, DOI 10.1016/j.molbiopara.2008.05.006; Alsford S, 2011, GENOME RES, V21, P915, DOI 10.1101/gr.115089.110; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Baker N, 2011, MOL BIOCHEM PARASIT, V176, P55, DOI 10.1016/j.molbiopara.2010.11.010; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Burkard GS, 2011, MOL BIOCHEM PARASIT, V175, P91, DOI 10.1016/j.molbiopara.2010.09.002; Buschini Annamaria, 2009, J Parasitol Res, V2009, P463575, DOI 10.1155/2009/463575; Caffrey CR, 2001, MOL BIOCHEM PARASIT, V118, P61, DOI 10.1016/S0166-6851(01)00368-1; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; Carver T, 2008, BIOINFORMATICS, V24, P2672, DOI 10.1093/bioinformatics/btn529; de Koning HP, 2008, TRENDS PARASITOL, V24, P345, DOI 10.1016/j.pt.2008.04.006; Ehrlich P, 1913, Br Med J, V2, P353; Fairlamb AH, 2003, TRENDS PARASITOL, V19, P488, DOI 10.1016/j.pt.2003.09.002; FAIRLAMB AH, 1980, MOL BIOCHEM PARASIT, V1, P315, DOI 10.1016/0166-6851(80)90050-X; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; Fevre EM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000333; Kelley RJ, 1995, MOL BIOCHEM PARASIT, V74, P167, DOI 10.1016/0166-6851(95)02493-X; Koumandou VL, 2011, J CELL SCI, V124, P1496, DOI 10.1242/jcs.081596; Kumar S, 2007, EUKARYOT CELL, V6, P2029, DOI 10.1128/EC.00213-07; Lanteri CA, 2008, ANTIMICROB AGENTS CH, V52, P875, DOI 10.1128/AAC.00642-07; Leung KF, 2008, TRAFFIC, V9, P1698, DOI 10.1111/j.1600-0854.2008.00797.x; Leung KF, 2011, EUKARYOT CELL, V10, P916, DOI 10.1128/EC.05012-11; Lingnau A, 1999, J CELL SCI, V112, P3061; Luo SH, 2006, J BIOL CHEM, V281, P21963, DOI 10.1074/jbc.M601057200; Mackey ZB, 2004, J BIOL CHEM, V279, P48426, DOI 10.1074/jbc.M402470200; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Matovu E, 2003, EUKARYOT CELL, V2, P1003, DOI 10.1128/EC.2.5.1003-1008.2003; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; OVERATH P, 1994, PARASITOL TODAY, V10, P53, DOI 10.1016/0169-4758(94)90393-X; Peck RF, 2008, MOL MICROBIOL, V68, P933, DOI 10.1111/j.1365-2958.2008.06195.x; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; Raz B, 1997, ACTA TROP, V68, P139, DOI 10.1016/S0001-706X(97)00079-X; Redmond S, 2003, MOL BIOCHEM PARASIT, V128, P115, DOI 10.1016/S0166-6851(03)00045-8; Scott AG, 1996, ACTA TROP, V60, P251, DOI 10.1016/0001-706X(96)00131-3; Singh PK, 2000, AM J PHYSIOL-LUNG C, V279, pL799, DOI 10.1152/ajplung.2000.279.5.L799; Steverding D, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-15; Uzcategui NL, 2004, J BIOL CHEM, V279, P42669, DOI 10.1074/jbc.M404518200; VANSTERKENBURG ELM, 1993, ACTA TROP, V54, P237, DOI 10.1016/0001-706X(93)90096-T; Vincent IM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001204; Wilkinson SR, 2008, P NATL ACAD SCI USA, V105, P5022, DOI 10.1073/pnas.0711014105; Williamson J., 1970, AFRICAN TRYPANOSOMIA; ZIEGELBAUER K, 1993, INFECT IMMUN, V61, P4540, DOI 10.1128/IAI.61.11.4540-4545.1993	45	225	226	1	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					232	U125		10.1038/nature10771	http://dx.doi.org/10.1038/nature10771			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22278056	Green Accepted			2022-12-28	WOS:000299994100041
J	van den Boogaard, M; Pickkers, P; Slooter, AJC; Kuiper, MA; Spronk, PE; van der Voort, PHJ; van der Hoeven, JG; Donders, R; van Achterberg, T; Schoonhoven, L				van den Boogaard, M.; Pickkers, P.; Slooter, A. J. C.; Kuiper, M. A.; Spronk, P. E.; van der Voort, P. H. J.; van der Hoeven, J. G.; Donders, R.; van Achterberg, T.; Schoonhoven, L.			Development and validation of PRE-DELIRIC (PREdiction of DELIRium in ICu patients) delirium prediction model for intensive care patients: observational multicentre study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONFUSION ASSESSMENT METHOD; MECHANICALLY VENTILATED PATIENTS; OLDER PATIENTS; ASSESSMENT TOOLS; RISK-FACTORS; UNIT	Objectives To develop and validate a delirium prediction model for adult intensive care patients and determine its additional value compared with prediction by caregivers. Design Observational multicentre study. Setting Five intensive care units in the Netherlands (two university hospitals and three university affiliated teaching hospitals). Participants 3056 intensive care patients aged 18 years or over. Main outcome measure Development of delirium (defined as at least one positive delirium screening) during patients' stay in intensive care. Results The model was developed using 1613 consecutive intensive care patients in one hospital and temporally validated using 549 patients from the same hospital. For external validation, data were collected from 894 patients in four other hospitals. The prediction (PRE-DELIRIC) model contains 10 risk factors-age, APACHE-II score, admission group, coma, infection, metabolic acidosis, use of sedatives and morphine, urea concentration, and urgent admission. The model had an area under the receiver operating characteristics curve of 0.87 (95% confidence interval 0.85 to 0.89) and 0.86 after bootstrapping. Temporal validation and external validation resulted in areas under the curve of 0.89 (0.86 to 0.92) and 0.84 (0.82 to 0.87). The pooled area under the receiver operating characteristics curve (n=3056) was 0.85 (0.84 to 0.87). The area under the curve for nurses' and physicians' predictions (n=124) was significantly lower at 0.59 (0.49 to 0.70) for both. Conclusion The PRE-DELIRIC model for intensive care patients consists of 10 risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. Clinical prediction by nurses and physicians performed significantly worse. The model allows for early prediction of delirium and initiation of preventive measures.	[van den Boogaard, M.; Pickkers, P.; van der Hoeven, J. G.] Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, NL-6500 HB Nijmegen, Netherlands; [Slooter, A. J. C.] Univ Med Ctr Utrecht, Dept Intens Care, Utrecht, Netherlands; [Kuiper, M. A.] Med Ctr Leeuwarden, Dept Intens Care, Leeuwarden, Netherlands; [Spronk, P. E.] Gelre Hosp, Dept Intens Care Med, Apeldoorn, Netherlands; [van der Voort, P. H. J.] Onze Lieve Vrouw Hosp, Dept Intens Care, Amsterdam, Netherlands; [Donders, R.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6500 HB Nijmegen, Netherlands; [van Achterberg, T.; Schoonhoven, L.] Radboud Univ Nijmegen, Med Ctr, Sci Inst Qual Healthcare, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Medical Center Leeuwarden; Gelre Hospitals; Onze Lieve Vrouwe Gasthuis Hospital; Radboud University Nijmegen; Radboud University Nijmegen	van den Boogaard, M (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, NL-6500 HB Nijmegen, Netherlands.	M.vandenboogaard@ic.umcn.nl	van den Boogaard, M./N-5857-2014; Donders, A.R.T./L-4277-2015; Kuiper, Michael/AAG-9878-2019; van der Hoeven, J.G./H-8048-2014; Pickkers, P./H-8080-2014; Schoonhoven, Lisette/O-3330-2013; Achterberg, M./H-8006-2014	van den Boogaard, M./0000-0003-4233-2903; Donders, A.R.T./0000-0002-0484-1419; Pickkers, P./0000-0002-1104-4303; Kuiper, Michael/0000-0001-6201-7332; van Achterberg, Theo/0000-0003-0111-6622				Aldemir M, 2001, CRIT CARE, V5, P265, DOI 10.1186/cc1044; Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Arts D, 2002, INTENS CARE MED, V28, P656, DOI 10.1007/s00134-002-1272-z; Devlin JW, 2011, HARVARD REV PSYCHIAT, V19, P59, DOI 10.3109/10673229.2011.565247; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Harrell F.E., 2009, HMISC PACKAGE; Inouye SK, 2007, ARCH INTERN MED, V167, P1406, DOI 10.1001/archinte.167.13.1406; Inouye SK, 2005, J AM GERIATR SOC, V53, P312, DOI 10.1111/j.1532-5415.2005.53120.x; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Kalisvaart KJ, 2005, J AM GERIATR SOC, V53, P1658, DOI 10.1111/j.1532-5415.2005.53503.x; Koster S, 2009, EUR J CARDIOVASC NUR, V8, P309, DOI 10.1016/j.ejcnurse.2009.02.006; Luetz A, 2010, CRIT CARE MED, V38, P409, DOI 10.1097/CCM.0b013e3181cabb42; McCaffrey Ruth, 2006, Holist Nurs Pract, V20, P218; McNicoll L, 2003, J AM GERIATR SOC, V51, P591, DOI 10.1034/j.1600-0579.2003.00201.x; Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92; Oldenbeuving AW, 2007, INT J STROKE, V2, P270, DOI 10.1111/j.1747-4949.2007.00163.x; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Pisani MA, 2007, ARCH INTERN MED, V167, P1629, DOI 10.1001/archinte.167.15.1629; R Core Team, 2020, R LANG ENV STAT COMP; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Spronk PE, 2009, INTENS CARE MED, V35, P1276, DOI 10.1007/s00134-009-1466-8; Steyerberg E., 2009, CLIN PREDICTION MODE; van den Boogaard M, 2009, CRIT CARE, V13, DOI 10.1186/cc7991; van Eijk MM, 2011, AM J RESP CRIT CARE, V184, P340, DOI 10.1164/rccm.201101-0065OC; van Eijk MMJ, 2009, CRIT CARE MED, V37, P1881, DOI 10.1097/CCM.0b013e3181a00118; Van Rompaey Bart, 2008, Intensive Crit Care Nurs, V24, P98; Vreeswijk R, 2009, NETH J CRIT CARE, V13, P73	32	227	230	1	42	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 9	2012	344								e420	10.1136/bmj.e420	http://dx.doi.org/10.1136/bmj.e420			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IH	22323509	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000300279400005
J	Reddy, M; Gill, SS; Wu, W; Kalkar, SR; Rochon, PA				Reddy, Madhuri; Gill, Sudeep S.; Wu, Wei; Kalkar, Sunila R.; Rochon, Paula A.			Does This Patient Have an Infection of a Chronic Wound?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETIC FOOT INFECTIONS; CHRONIC LEG ULCERS; PRESSURE ULCERS; DIAGNOSTIC-TEST; SWAB CULTURES; GUIDELINES; PROCALCITONIN; VALIDITY	Context Chronic wounds (those that have not undergone orderly healing) are commonly encountered, but determining whether wounds are infected is often difficult. The current reference standard for the diagnosis of infection of a chronic wound is a deep tissue biopsy culture, which is an invasive procedure. Objectives To determine the accuracy of clinical symptoms and signs to diagnose infection in chronic wounds and to determine whether there is a preferred noninvasive method for culturing chronic wounds. Data Sources We searched multiple databases from inception through November 18, 2011, to identify studies focusing on diagnosis of infection in a chronic wound. Study Selection Original studies were selected if they had extractable data describing historical features, symptoms, signs, or laboratory markers or were radiologic studies compared with a reference standard for diagnosing infection in patients with chronic wounds. Of 341 studies initially retrieved, 15 form the basis of this review. These studies include 985 participants with a total of 1056 chronic wounds. The summary prevalence of wound infection was 53%. Data Extraction Three authors independently assigned each study a quality grade, using previously published criteria. One author abstracted operating characteristic data. Data Synthesis An increase in the level of pain (likelihood ratio range, 11-20) made infection more likely, but its absence (negative likelihood ratio range, 0.64-0.88) did not rule out infection. Other items in the history and physical examination, in isolation or in combination, appeared to have limited utility when infection was diagnosed in chronic wounds. Routine laboratory studies had uncertain value in predicting infection of a chronic wound. Conclusions The presence of increasing pain may make infection of a chronic wound more likely. Further evidence is required to determine which, if any, type of quantitative swab culture is most diagnostic. JAMA. 2012;307(6):605-611	[Reddy, Madhuri] Hebrew Rehabil Ctr, Boston, MA 02131 USA; [Gill, Sudeep S.] Queens Univ, Dept Med, Div Geriatr Med, Kingston, ON K7L 3N6, Canada; [Wu, Wei; Kalkar, Sunila R.; Rochon, Paula A.] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON M5S 1B2, Canada; [Rochon, Paula A.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Rochon, Paula A.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada	Queens University - Canada; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University of Toronto	Reddy, M (corresponding author), Hebrew Rehabil Ctr, 1200 Ctr St, Boston, MA 02131 USA.	madhurireddy@hsl.harvard.edu	Rochon, Paula A/J-2918-2016; Hug, Balthasar L./G-1568-2010	Rochon, Paula A/0000-0002-5973-4151; Wu, Wei/0000-0002-9633-4122	Canadian Institutes of Health Research (CIHR) Institute of Gender and Health [HOA-80075]; CIHR Institute of Aging	Canadian Institutes of Health Research (CIHR) Institute of Gender and Health(Canadian Institutes of Health Research (CIHR)); CIHR Institute of Aging(Canadian Institutes of Health Research (CIHR))	This work was supported by an Interdisciplinary Capacity Enhancement grant (HOA-80075) from the Canadian Institutes of Health Research (CIHR) Institute of Gender and Health and the CIHR Institute of Aging.	Ambrosch A, 2008, INT WOUND J, V5, P99, DOI 10.1111/j.1742-481X.2007.00347.x; Anson CA, 1996, INT J REHABIL RES, V19, P55, DOI 10.1097/00004356-199603000-00006; Bamberg R, 2002, WOUNDS, V14, P314; Bill T J, 2001, Ostomy Wound Manage, V47, P34; Boyko EJ, 1995, Diabetes in America, V2, P485; Butalia S, 2008, JAMA-J AM MED ASSOC, V299, P806, DOI 10.1001/jama.299.7.806; EHRENKRANZ NJ, 1990, J CLIN MICROBIOL, V28, P2389, DOI 10.1128/JCM.28.11.2389-2393.1990; Eleftheriadou L, 2010, DRUGS, V70, P1785, DOI 10.2165/11538070-000000000-00000; Fierheller M, 2010, ADV SKIN WOUND CARE, V23, P369, DOI 10.1097/01.ASW.0000383197.28192.98; Gardner S E, 2001, Ostomy Wound Manage, V47, P40; Gardner SE, 2001, WOUND REPAIR REGEN, V9, P178, DOI 10.1046/j.1524-475x.2001.00178.x; Gardner SE, 2006, WOUND REPAIR REGEN, V14, P548, DOI 10.1111/j.1743-6109.2006.00162.x; Gardner SE, 2009, BIOL RES NURS, V11, P119, DOI 10.1177/1099800408326169; HEGGERS JP, 1991, QUANTITATIVE BACTERI, P15; Heym B, 2004, SPINAL CORD, V42, P230, DOI 10.1038/sj.sc.3101568; Hopf HW, 2006, WOUND REPAIR REGEN, V14, P693, DOI 10.1111/j.1524-475X.2006.00177.x; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; Jeandrot A, 2008, DIABETOLOGIA, V51, P347, DOI 10.1007/s00125-007-0840-8; Lavery LA, 2003, DIABETES CARE, V26, P1435, DOI 10.2337/diacare.26.5.1435; Lipsky BA, 2004, CLIN INFECT DIS, V39, P885, DOI 10.1086/383271; Mustoe TA, 2006, PLAST RECONSTR SURG, V117, p35S, DOI 10.1097/01.prs.0000225431.63010.1b; Ratliff CR, 2002, WOUNDS, V14, P329; Redelings Matthew D, 2005, Adv Skin Wound Care, V18, P367, DOI 10.1097/00129334-200509000-00010; Robson MC, 2006, WOUND REPAIR REGEN, V14, P649, DOI 10.1111/j.1524-475X.2006.00174.x; ROBSON MC, 1969, MIL MED, V134, P19, DOI 10.1093/milmed/134.1.19; S Boslaugh, 2008, ENCY EPIDEMIOLOGY, V2, P367; Schmidt K, 2000, VASA-J VASCULAR DIS, V29, P62, DOI 10.1024/0301-1526.29.1.62; SCHRAIBMAN IG, 1990, ANN ROY COLL SURG, V72, P123; Serena Thomas E, 2008, Int J Low Extrem Wounds, V7, P32, DOI 10.1177/1534734607313984; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Simel DL, 2009, RATIONAL CLIN EXAMIN; Slater RA, 2004, DIABETIC MED, V21, P705, DOI 10.1111/j.1464-5491.2004.01221.x; Smith PW, 1999, INFECT CONT HOSP EP, V20, P358, DOI 10.1086/501636; Steed DL, 2006, WOUND REPAIR REGEN, V14, P680, DOI 10.1111/j.1524-475X.2006.00176.x; Uzun G, 2007, TOHOKU J EXP MED, V213, P305, DOI 10.1620/tjem.213.305; Whitney J, 2006, WOUND REPAIR REGEN, V14, P663, DOI 10.1111/j.1524-475X.2006.00175.x; Woo KY, 2009, OSTOMY WOUND MANAG, V55, P40	37	61	62	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2012	307	6					605	611		10.1001/jama.2012.98	http://dx.doi.org/10.1001/jama.2012.98			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GT	22318282				2022-12-28	WOS:000299992500025
J	Reid, AWN; Shelley, OP				Reid, A. W. N.; Shelley, O. P.			PICTURE QUIZ A 79 year old man with a lesion on his cheek	BRITISH MEDICAL JOURNAL			English	Editorial Material							BASAL-CELL CARCINOMA		[Reid, A. W. N.] Lister Hosp, Dept Plast Surg, Stevenage SG1 4AB, Herts, England; [Reid, A. W. N.; Shelley, O. P.] Broomfield Hosp, St Andrews Ctr Plast Surg & Burns, Chelmsford, Essex, England	Lister Hospital; Mid Essex Hospital Services NHS Trust; Broomfield Hospital	Reid, AWN (corresponding author), Lister Hosp, Dept Plast Surg, Stevenage SG1 4AB, Herts, England.	awnr2@cam.ac.uk		shelley, odhran/0000-0001-7564-4175				Ceilley RI, 2006, INT J DERMATOL, V45, P489, DOI 10.1111/j.1365-4632.2006.02673.x; Giele H, 2008, PLASTIC RECONSTRUCTI; National Cancer Action Team, 2011, MAN CANC SERV SKIN M; National Institute for Health and Clinical Excellence, 2010, IMPR OUTC PEOPL SKIN; Netscher DT, 2004, PLAST RECONSTR SURG, V113, p74E, DOI 10.1097/01.PRS.0000113025.69154.D1; Nguyen TH, 2004, CLIN DERMATOL, V22, P209, DOI 10.1016/j.clindermatol.2003.12.007; Telfer NR, 2008, BRIT J DERMATOL, V159, P35, DOI 10.1111/j.1365-2133.2008.08666.x; Wong CSM, 2003, BMJ-BRIT MED J, V327, P794, DOI 10.1136/bmj.327.7418.794	8	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	2012	344								e482	10.1136/bmj.e482	http://dx.doi.org/10.1136/bmj.e482			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	892ID	22315244				2022-12-28	WOS:000300279000003
J	Longhurst, H; Cicardi, M				Longhurst, Hilary; Cicardi, Marco			Hereditary angio-oedema	LANCET			English	Article							C1 INHIBITOR DEFICIENCY; RECOMBINANT HUMAN C1-INHIBITOR; ACUTE ATTACKS; LARYNGEAL EDEMA; ECALLANTIDE TREATMENT; HELICOBACTER-PYLORI; ANGIONEUROTIC-EDEMA; CONCENTRATE; BRADYKININ; MANAGEMENT	Hereditary angio-oedema is caused by a heterozygous deficiency of C1 inhibitor. This inhibitor regulates several inflammatory pathways, and patients with hereditary angio-oedema have intermittent cutaneous or mucosal swellings because of a failure to control local production of bradykinin. Swellings typically evolve in several hours and persist for a few days. In addition to orofacial angio-oedema, painless swellings affect peripheries, which causes disfigurement or interference with work and other activities of daily living. Angio-oedema affecting the gastrointestinal tract or abdominal viscera causes severe pain often with vomiting due to oedematous bowel obstruction. About 2% of swellings involve the larynx and can be fatal if untreated. About 50% of patients have laryngeal swellings that are potentially fatal despite prophylaxis. In this Seminar we review the clinical features, diagnosis, and management of hereditary angio-oedema, with specific emphasis on the new treatments available for acute swellings.	[Longhurst, Hilary] Barts & London Natl Hlth Serv Trust, Dept Immunol, London E1 2ES, England; [Cicardi, Marco] Luigi Sacco Univ Milan, Osped Luigi Sacco Milano, Dept Clin Sci, Milan, Italy	Barts Health NHS Trust; University of London; Queen Mary University London; University of Milan; Luigi Sacco Hospital	Longhurst, H (corresponding author), Barts & London Natl Hlth Serv Trust, Dept Immunol, 80 Newark St, London E1 2ES, England.	hilary.longhurst@bartsandthelondon.nhs.uk	cicardi, marco/K-9219-2016	cicardi, marco/0000-0003-1251-225X	Shire; CSL; Pharming; Dyax	Shire; CSL; Pharming; Dyax	HL has received payment for advisory board membership from Shire, CSL Behring, Dyax and Pharming; consultancy fees from Shire, CSL and Pharming; payment for expert testimony from Pharming; payment for lectures from Shire, CLS Behring; payment for development of educational presentations from CSL Behring and Shire, and travel and accommodation support from CSL Behring, Shire, and Viropharma. MC has received payment for board membership from Shire, CSL Behring, Dyax, ViroPharma, and Pharming; consultancy fees from Shire, Dyax, and Pharming; payment for expert testimony from Pharming and Dyax; payment for lectures from Shire, Pharming, CLS Behring, and ViroPharma; payment for manuscript preparation from Shire and ViroPharma; and payment for development of educational presentations and travel and accommodation support from Shire. MC holds a patent from Dyax for methods for preservation of organs and tissues.	AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Blasko B, 2007, MOL IMMUNOL, V44, P2667, DOI 10.1016/j.molimm.2006.12.007; BLOHME G, 1972, ACTA MED SCAND, V192, P293; Bork K, 2003, AM J MED, V114, P294, DOI 10.1016/S0002-9343(02)01526-7; Bork K, 2008, ALLERGY, V63, P751, DOI 10.1111/j.1398-9995.2007.01577.x; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bork K, 2006, AM J GASTROENTEROL, V101, P619, DOI 10.1111/j.1572-0241.2006.00492.x; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 2003, J AM DENT ASSOC, V134, P1088, DOI 10.14219/jada.archive.2003.0323; Bork K, 2000, MAYO CLIN PROC, V75, P349, DOI 10.4065/75.4.349; Bork K, 2005, TRANSFUSION, V45, P1774, DOI 10.1111/j.1537-2995.2005.00602.x; Bork K, 2003, ARCH INTERN MED, V163, P1229, DOI 10.1001/archinte.163.10.1229; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Bork K, 2008, ANN ALLERG ASTHMA IM, V100, P153, DOI 10.1016/S1081-1206(10)60424-3; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Bossi F, 2009, J ALLERGY CLIN IMMUN, V124, P1303, DOI 10.1016/j.jaci.2009.08.007; Bouillet L, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.034; Bowen T, 2008, ANN ALLERG ASTHMA IM, V100, pS30, DOI 10.1016/S1081-1206(10)60584-4; Bowen Tom, 2010, Allergy Asthma Clin Immunol, V6, P24, DOI 10.1186/1710-1492-6-24; Bygum A, 2009, BRIT J DERMATOL, V161, P1153, DOI 10.1111/j.1365-2133.2009.09366.x; Bygum A, 2009, EUR J DERMATOL, V19, P147, DOI 10.1684/ejd.2008.0603; Cacoub P, 2001, ARTHRITIS RHEUM, V44, P1836, DOI 10.1002/1529-0131(200108)44:8<1836::AID-ART321>3.0.CO;2-Y; Caliezi C, 2000, PHARMACOL REV, V52, P91; Choi G, 2007, TRANSFUSION, V47, P1028, DOI 10.1111/j.1537-2995.2007.01239.x; Cicardi M, 2003, MEDICINE, V82, P274, DOI 10.1097/00005792-200307000-00006; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; Cicardi M, 2012, ALLERGY, V67, P147, DOI 10.1111/j.1398-9995.2011.02751.x; Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393; Cicardi M, 2010, INTERN EMERG MED, V5, P481, DOI 10.1007/s11739-010-0408-3; Cicardi M, 2010, NEW ENGL J MED, V363, P523, DOI 10.1056/NEJMoa0905079; Craig TJ, 2009, J ALLERGY CLIN IMMUN, V124, P801, DOI 10.1016/j.jaci.2009.07.017; Cugno M, 1997, BLOOD, V89, P3213, DOI 10.1182/blood.V89.9.3213; Cugno M, 2003, INT IMMUNOPHARMACOL, V3, P311, DOI 10.1016/S1567-5769(02)00162-5; Cugno M, 2009, ALLERGY, V64, P254, DOI 10.1111/j.1398-9995.2008.01859.x; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; Davis AE, 2007, IMMUNOBIOLOGY, V212, P313, DOI 10.1016/j.imbio.2006.10.003; European Medicines Agency, 2011, EUR PUBL ASS REP FIR; Farkas H, 2001, LANCET, V358, P1695, DOI 10.1016/S0140-6736(01)06720-4; Farkas H, 2001, EUR J GASTROEN HEPAT, V13, P1225, DOI 10.1097/00042737-200110000-00016; Farkas H, 2007, J ALLERGY CLIN IMMUN, V120, P941, DOI 10.1016/j.jaci.2007.06.026; Farkas H, 2007, PEDIATRICS, V120, pE713, DOI 10.1542/peds.2006-3303; FRANK MM, 1977, NEW ENGL J MED, V296, P1235; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Gompels MM, 2003, BRIT J DERMATOL, V148, P719, DOI 10.1046/j.1365-2133.2003.05231.x; Gompels MM, 2002, J CLIN PATHOL, V55, P145, DOI 10.1136/jcp.55.2.145; Grigoriadou S, 2009, CLIN EXP IMMUNOL, V155, P367, DOI 10.1111/j.1365-2249.2008.03845.x; Horn PT, 2010, J ALLERGY CLIN IMMUN, V125, pAB163, DOI 10.1016/j.jaci.2009.12.640; Kalmar L, 2005, HUM MUTAT, V25, P1, DOI 10.1002/humu.20112; Kaplan AP, 2010, ANN ALLERG ASTHMA IM, V104, P193, DOI 10.1016/j.anai.2010.01.007; Khan S, 2007, CLIN IMMUNOL, V123, P14, DOI 10.1016/j.clim.2006.09.015; Kreuz W, 2009, TRANSFUSION, V49, P1987, DOI 10.1111/j.1537-2995.2009.02230.x; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; Levi M, 2006, J ALLERGY CLIN IMMUN, V117, P904, DOI 10.1016/j.jaci.2006.01.002; Levy RJ, 2010, ANN ALLERG ASTHMA IM, V104, P523, DOI 10.1016/j.anai.2010.04.012; Lomas DA, 2005, CLIN MED, V5, P249, DOI 10.7861/clinmedicine.5-3-249; Longhurst HJ, 2007, CLIN EXP IMMUNOL, V147, P11, DOI 10.1111/j.1365-2249.2006.03256.x; Longhurst H, 2008, CURR OPIN INVEST DR, V9, P310; Longhurst Hilary J, 2010, Allergy Asthma Clin Immunol, V6, P22, DOI 10.1186/1710-1492-6-22; Martinez-Saguer I, 2010, TRANSFUSION, V50, P354, DOI 10.1111/j.1537-2995.2009.02394.x; Maurer M, 2011, 30 EUR AC ALL CLIN I, P1104; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; Pappalardo E, 2002, IMMUNOBIOLOGY, V205, P542, DOI 10.1078/0171-2985-00153; Pappalardo E, 2008, MOL IMMUNOL, V45, P3536, DOI 10.1016/j.molimm.2008.05.007; Prematta M, 2007, ANN ALLERG ASTHMA IM, V98, P383, DOI 10.1016/S1081-1206(10)60886-1; Prematta MJ, 2009, ALLERGY ASTHMA PROC, V30, P506, DOI 10.2500/aap.2009.30.3279; Roche O, 2005, ANN ALLERG ASTHMA IM, V94, P498, DOI 10.1016/S1081-1206(10)61121-0; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; Rusicke E, 2008, J ALLERGY CLIN IMMUN, V121, pS99, DOI 10.1016/j.jaci.2007.12.393; Schneider L, 2007, J ALLERGY CLIN IMMUN, V120, P416, DOI 10.1016/j.jaci.2007.04.028; SHEFFER AL, 1981, J ALLERGY CLIN IMMUN, V68, P181, DOI 10.1016/0091-6749(81)90181-0; Tarzi MD, 2007, CLIN EXP IMMUNOL, V149, P513, DOI 10.1111/j.1365-2249.2007.03438.x; US Food and Drug Administation, 2009, ADV COMM BRIEF DOC K; US Food and Drug Administration, 2008, SUMM BAS REG ACT CIN; van Doorn MBA, 2005, J ALLERGY CLIN IMMUN, V116, P876, DOI 10.1016/j.jaci.2005.05.019; Van Sickels NJ, 2010, ORAL SURG ORAL MED O, V109, P168, DOI 10.1016/j.tripleo.2009.09.031; Visy B, 2007, HELICOBACTER, V12, P251, DOI 10.1111/j.1523-5378.2007.00501.x; Wagenaar-Bos IGA, 2008, J IMMUNOL METHODS, V338, P14, DOI 10.1016/j.jim.2008.06.004; Wagenaar-Bos IGA, 2006, IMMUNOL ALLERGY CLIN, V26, P615, DOI 10.1016/j.iac.2006.08.004; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; Wilson DA, 2010, ANN ALLERG ASTHMA IM, V104, P314, DOI 10.1016/j.anai.2010.01.024; Zahedi R, 1997, J IMMUNOL, V159, P983; Zanichelli A, 2011, ALLERGY, V66, P192, DOI 10.1111/j.1398-9995.2010.02433.x; Zingale LC, 2006, CAN MED ASSOC J, V175, P1065, DOI 10.1503/cmaj.060535; Zuraw B, 2010, J ALLERGY CLIN IMMUN, V126, P821, DOI 10.1016/j.jaci.2010.07.021; Zuraw BL, 2010, NEW ENGL J MED, V363, P513, DOI 10.1056/NEJMoa0805538	89	233	241	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2012	379	9814					474	481		10.1016/S0140-6736(11)60935-5	http://dx.doi.org/10.1016/S0140-6736(11)60935-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891AF	22305226				2022-12-28	WOS:000300187800037
J	Berning, S; Willig, KI; Steffens, H; Dibaj, P; Hell, SW				Berning, Sebastian; Willig, Katrin I.; Steffens, Heinz; Dibaj, Payam; Hell, Stefan W.			Nanoscopy in a Living Mouse Brain	SCIENCE			English	Article							SPINES; GFP		[Berning, Sebastian; Willig, Katrin I.; Steffens, Heinz; Hell, Stefan W.] Max Planck Inst Biophys Chem, Dept NanoBiophoton, D-37077 Gottingen, Germany; [Dibaj, Payam] MPI Expt Med, D-37075 Gottingen, Germany	Max Planck Society	Willig, KI (corresponding author), Max Planck Inst Biophys Chem, Dept NanoBiophoton, Fassberg 11, D-37077 Gottingen, Germany.	kwillig@gwdg.de; shell@gwdg.de	Willig, Katrin/AAH-5418-2020; Dibaj, Payam/AAS-5479-2021; Dibaj, Payam/GQH-9423-2022	Willig, Katrin/0000-0002-1860-334X; Dibaj, Payam/0000-0003-1585-6330				Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Grotjohann T, 2011, NATURE, V478, P204, DOI 10.1038/nature10497; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; Kwon HB, 2011, NATURE, V474, P100, DOI 10.1038/nature09986; Misgeld T, 2007, NAT METHODS, V4, P559, DOI 10.1038/NMETH1055; Nagerl UV, 2008, P NATL ACAD SCI USA, V105, P18982, DOI 10.1073/pnas.0810028105; Urban NT, 2011, BIOPHYS J, V101, P1277, DOI 10.1016/j.bpj.2011.07.027	7	263	278	4	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2012	335	6068					551	551		10.1126/science.1215369	http://dx.doi.org/10.1126/science.1215369			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885HI	22301313	Green Submitted			2022-12-28	WOS:000299769200034
J	Lalvani, A; Behr, MA; Sridhar, S				Lalvani, Ajit; Behr, Marcel A.; Sridhar, Saranya			Innate Immunity to TB: A Druggable Balancing Act	CELL			English	Editorial Material							TUBERCULOSIS	Tobin and colleagues show that both inhibition and excessive production of the inflammatory mediator TNFa impact the pathogenesis of tuberculosis (TB) and the response to therapy. Identifying a critical role for the genetically determined balance between pro- and anti-inflammatory eicosanoids in regulating TNFa levels provides a roadmap to tailored TB treatment based on host genotype.	[Lalvani, Ajit; Sridhar, Saranya] Univ London Imperial Coll Sci Technol & Med, TB Res Unit, Natl Heart & Lung Inst, London W2 1PG, England; [Behr, Marcel A.] McGill Univ, Ctr Hlth, Montreal, PQ H3G 1A4, Canada	Imperial College London; McGill University	Lalvani, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, TB Res Unit, Natl Heart & Lung Inst, Norfolk Pl, London W2 1PG, England.	a.lalvani@imperial.ac.uk		Sridhar, Saranya/0000-0002-4267-3102; Lalvani, Ajit/0000-0002-2396-246X				Behar SM, 2011, MUCOSAL IMMUNOL, V4, P279, DOI 10.1038/mi.2011.3; Behr M, 2010, CELL, V140, P615, DOI 10.1016/j.cell.2010.02.030; Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767; Divangahi M, 2010, NAT IMMUNOL, V11, P751, DOI 10.1038/ni.1904; Prasad K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002244.pub3; Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573; Tobin DM, 2012, CELL, V148, P434, DOI 10.1016/j.cell.2011.12.023; Tobin DM, 2010, CELL, V140, P717, DOI 10.1016/j.cell.2010.02.013; WHO, 2011, WHO GLOBAL TUBERCULO	9	9	9	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 3	2012	148	3					389	391		10.1016/j.cell.2012.01.026	http://dx.doi.org/10.1016/j.cell.2012.01.026			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304907	Bronze			2022-12-28	WOS:000300225000006
J	Yu, XC; Breitman, M; Goldberg, J				Yu, Xinchao; Breitman, Marianna; Goldberg, Jonathan			A Structure-Based Mechanism for Arf1-Dependent Recruitment of Coatomer to Membranes	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; COATED VESICLES; PROTEIN COMPLEX; ARF; BINDING; CARGO; COPII; ACTIVATION; TRANSPORT	Budding of COPI-coated vesicles from Golgi membranes requires an Arf family G protein and the coatomer complex recruited from cytosol. Arf is also required with coatomer-related clathrin adaptor complexes to bud vesicles from the trans-Golgi network and endosomal compartments. To understand the structural basis for Arf-dependent recruitment of a vesicular coat to the membrane, we determined the structure of Arf1 bound to the gamma zeta-COP subcomplex of coatomer. Structure-guided biochemical analysis reveals that a second Arf1-GTP molecule binds to beta delta-COP at a site common to the gamma-and beta-COP subunits. The Arf1-binding sites on coatomer are spatially related to PtdIns4,5P(2)-binding sites on the endocytic AP2 complex, providing evidence that the orientation of membrane binding is general for this class of vesicular coat proteins. A bivalent GTP-dependent binding mode has implications for the dynamics of coatomer interaction with the Golgi and for the selection of cargo molecules.	[Yu, Xinchao; Breitman, Marianna; Goldberg, Jonathan] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA; [Yu, Xinchao; Breitman, Marianna; Goldberg, Jonathan] Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10065 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, 1275 York Ave, New York, NY 10065 USA.	jonathan@ximpact4.ski.mskcc.org			Howard Hughes Medical Institute Funding Source: Medline; NIBIB NIH HHS [P30 EB009998] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P30EB009998] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; Bi XP, 2007, DEV CELL, V13, P635, DOI 10.1016/j.devcel.2007.10.006; Boehm M, 2001, EMBO J, V20, P6265, DOI 10.1093/emboj/20.22.6265; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Eugster A, 2000, EMBO J, V19, P3905, DOI 10.1093/emboj/19.15.3905; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; Heldwein EE, 2004, P NATL ACAD SCI USA, V101, P14108, DOI 10.1073/pnas.0406102101; Ismail SA, 2010, CELL, V141, P812, DOI 10.1016/j.cell.2010.03.051; Jackson LP, 2010, CELL, V141, P1220, DOI 10.1016/j.cell.2010.05.006; Kliouchnikov L, 2009, MOL BIOL CELL, V20, P859, DOI 10.1091/mbc.E08-10-1010; Lee I, 2008, J CELL BIOL, V180, P467, DOI 10.1083/jcb.200709037; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Liu YZ, 2010, NAT STRUCT MOL BIOL, V17, P876, DOI 10.1038/nsmb.1853; Luo RB, 2008, J BIOL CHEM, V283, P21965, DOI 10.1074/jbc.M802268200; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Nickel W, 1998, J CELL SCI, V111, P3081; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Presley JF, 2002, NATURE, V417, P187, DOI 10.1038/417187a; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Sun Z, 2007, TRAFFIC, V8, P582, DOI 10.1111/j.1600-0854.2007.00554.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	36	77	80	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					530	542		10.1016/j.cell.2012.01.015	http://dx.doi.org/10.1016/j.cell.2012.01.015			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304919	Green Accepted, Bronze			2022-12-28	WOS:000300225000020
J	Garrett, L				Garrett, Laurie			Global health hits crisis point	NATURE			English	Editorial Material									Council Foreign Relat, New York, NY 10065 USA		Garrett, L (corresponding author), Council Foreign Relat, New York, NY 10065 USA.	lgarrett@cfr.org							0	9	9	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2012	482	7383					7	7		10.1038/482007a	http://dx.doi.org/10.1038/482007a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	884RN	22297931	Bronze			2022-12-28	WOS:000299726000004
J	Meyer, K				Meyer, Kaspar			Another Remembered Present	SCIENCE			English	Editorial Material							RAT VISUAL-CORTEX; FEEDBACK CONNECTIONS; CONSCIOUSNESS; INFORMATION		Univ So Calif, Brain & Creat Inst, Los Angeles, CA 90089 USA	University of Southern California	Meyer, K (corresponding author), Univ So Calif, Brain & Creat Inst, Los Angeles, CA 90089 USA.	kaspar.meyer@usc.edu						Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Bullier J, 2001, TRENDS COGN SCI, V5, P369, DOI 10.1016/S1364-6613(00)01730-7; Cauller L, 1995, BEHAV BRAIN RES, V71, P163, DOI 10.1016/0166-4328(95)00032-1; CHANGEUX JP, 1989, COGNITION, V33, P63, DOI 10.1016/0010-0277(89)90006-1; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; Dehaene S, 2004, COGNITIVE NEUROSCIEN; Edelman G, 2001, ANN NY ACAD SCI, V929, P111; Johnson RR, 1996, J COMP NEUROL, V368, P383, DOI 10.1002/(SICI)1096-9861(19960506)368:3<383::AID-CNE5>3.0.CO;2-1; Lamme V.A.F., 2000, BRAIN MIND, V1, P385, DOI [10.1023/A:1011569019782, DOI 10.1023/A:1011569019782]; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; Meyer K, 2011, CEREB CORTEX, V21, P2113, DOI 10.1093/cercor/bhq289; Meyer K, 2010, NAT NEUROSCI, V13, P667, DOI 10.1038/nn.2533; Pollen DA, 1999, CEREB CORTEX, V9, P4, DOI 10.1093/cercor/9.1.4; Ro T, 2003, CURR BIOL, V13, P1038, DOI 10.1016/S0960-9822(03)00337-3; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; Shao ZW, 1996, J NEUROSCI, V16, P7353; Smith FW, 2010, P NATL ACAD SCI USA, V107, P20099, DOI 10.1073/pnas.1000233107; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Williams MA, 2008, NAT NEUROSCI, V11, P1439, DOI 10.1038/nn.2218	20	11	12	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2012	335	6067					415	416		10.1126/science.1214652	http://dx.doi.org/10.1126/science.1214652			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	881FG	22282799				2022-12-28	WOS:000299466800034
J	Brodie, MJ; Kwan, P				Brodie, Martin J.; Kwan, Patrick			Newer drugs for focal epilepsy in adults	BRITISH MEDICAL JOURNAL			English	Editorial Material							ANTIEPILEPTIC DRUGS; ILAE-COMMISSION; THERAPEUTIC STRATEGIES; PREGNANCY-REGISTER; RESISTANT EPILEPSY; UK-EPILEPSY; EFFICACY; LEVETIRACETAM; CARBAMAZEPINE; METAANALYSIS		[Kwan, Patrick] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia; [Kwan, Patrick] Univ Melbourne, Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic 3050, Australia; [Brodie, Martin J.] Univ Glasgow, Western Infirm, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland; [Kwan, Patrick] Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; University of Glasgow; Chinese University of Hong Kong; Prince of Wales Hospital	Kwan, P (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia.	patrick.kwan@unimelb.edu.au		Kwan, Patrick/0000-0001-7310-276X				Andersohn F, 2010, NEUROLOGY, V75, P335, DOI 10.1212/WNL.0b013e3181ea157e; Arif H, 2007, NEUROLOGY, V68, P1701, DOI 10.1212/01.wnl.0000261917.83337.db; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Beyenburg S, 2010, EPILEPSIA, V51, P7, DOI 10.1111/j.1528-1167.2009.02299.x; Brodie MJ, 2007, NEUROLOGY, V68, P402, DOI 10.1212/01.wnl.0000252941.50833.4a; Brodie MJ, 2011, SEIZURE-EUR J EPILEP, V20, P369, DOI 10.1016/j.seizure.2011.01.004; Brodie MJ, 2010, SEIZURE-EUR J EPILEP, V19, P650, DOI 10.1016/j.seizure.2010.10.027; Costa J, 2011, EPILEPSIA, V52, P1280, DOI 10.1111/j.1528-1167.2011.03047.x; Dutton C, 2008, INT REV NEUROBIOL, V83, P113, DOI 10.1016/S0074-7742(08)00006-8; Food and Drug Administration, FDA DRUG SAF COMM RI; Food and Drug Administration, INF HEALTHC PROF SUI; French JA, 2004, EPILEPSIA, V45, P401, DOI 10.1111/j.0013-9580.2004.06204.x; Glauser T, 2006, EPILEPSIA, V47, P1094, DOI 10.1111/j.1528-1167.2006.00585.x; Harden CL, 2009, EPILEPSIA, V50, P1247, DOI 10.1111/j.1528-1167.2009.02130.x; Hunt S, 2006, NEUROLOGY, V67, P1876, DOI 10.1212/01.wnl.0000244491.48937.55; Kwan P, 2003, NEUROLOGY, V60, pS2, DOI 10.1212/WNL.60.11_suppl_4.S2; Kwan P, 2011, NEW ENGL J MED, V365, P919, DOI 10.1056/NEJMra1004418; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Loring DW, 2007, NEUROPSYCHOL REV, V17, P413, DOI 10.1007/s11065-007-9043-9; Marson AG, 2007, LANCET, V369, P1000, DOI 10.1016/S0140-6736(07)60460-7; Meador KJ, 2009, NEW ENGL J MED, V360, P1597, DOI 10.1056/NEJMoa0803531; Morrow J, 2006, J NEUROL NEUROSUR PS, V77, P193, DOI 10.1136/jnnp.2005.074203; National Institute for Health and Clinical Excellence, EP DIAGN MAN EP AD C; Patsalos PN, 2008, EPILEPSIA, V49, P1239, DOI 10.1111/j.1528-1167.2008.01561.x; Perucca E, 2011, LANCET NEUROL, V10, P446, DOI 10.1016/S1474-4422(11)70047-3; Porter RJ, 2010, EPILEPSY RES, V89, P163, DOI 10.1016/j.eplepsyres.2010.02.005; Tomson T, 2007, BRIT MED J, V335, P769, DOI 10.1136/bmj.39266.473113.BE; Tomson T, 2011, LANCET NEUROL, V10, P609, DOI 10.1016/S1474-4422(11)70107-7; Zaccara G, 2007, EPILEPSIA, V48, P1223, DOI 10.1111/j.1528-1167.2007.01041.x	29	24	25	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 26	2012	344								e345	10.1136/bmj.e345	http://dx.doi.org/10.1136/bmj.e345			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885LE	22282529	Green Accepted			2022-12-28	WOS:000299779700004
J	Korevaar, PA; George, SJ; Markvoort, AJ; Smulders, MMJ; Hilbers, PAJ; Schenning, APHJ; De Greef, TFA; Meijer, EW				Korevaar, Peter A.; George, Subi J.; Markvoort, Albert J.; Smulders, Maarten M. J.; Hilbers, Peter A. J.; Schenning, Albert P. H. J.; De Greef, Tom F. A.; Meijer, E. W.			Pathway complexity in supramolecular polymerization	NATURE			English	Article							SELF-ORGANIZATION; FIBRIL FORMATION; KINETICS; NUCLEATION; ASSEMBLIES; AMPLIFICATION; AGGREGATION; EVOLUTION	Self-assembly provides an attractive route to functional organic materials, with properties and hence performance depending sensitively on the organization of the molecular building blocks(1-5). Molecular organization is a direct consequence of the pathways involved in the supramolecular assembly process, which is more amenable to detailed study when using one-dimensional systems. In the case of protein fibrils, formation and growth have been attributed to complex aggregation pathways(6-8) that go beyond traditional concepts of homogeneous(9-11) and secondary (12-14) nucleation events. The self-assembly of synthetic supramolecular polymers has also been studied and even modulated(15-18), but our quantitative understanding of the processes involved remains limited. Here we report time-resolved observations of the formation of supramolecular polymers from pi-conjugated oligomers. Our kinetic experiments show the presence of a kinetically favoured metastable assembly that forms quickly but then transforms into the thermodynamically favoured form. Quantitative insight into the kinetic experiments was obtained from kinetic model calculations, which revealed two parallel and competing pathways leading to assemblies with opposite helicity. These insights prompt us to use a chiral tartaric acid as an auxiliary to change the thermodynamic preference of the assembly process(19). We find that we can force aggregation completely down the kinetically favoured pathway so that, on removal of the auxiliary, we obtain only metastable assemblies.	[Korevaar, Peter A.; Markvoort, Albert J.; Smulders, Maarten M. J.; Hilbers, Peter A. J.; De Greef, Tom F. A.; Meijer, E. W.] Eindhoven Univ Technol, Inst Complex Mol Syst, NL-5600 MB Eindhoven, Netherlands; [Korevaar, Peter A.; George, Subi J.; Smulders, Maarten M. J.; Schenning, Albert P. H. J.; De Greef, Tom F. A.; Meijer, E. W.] Eindhoven Univ Technol, Lab Macromol & Organ Chem, NL-5600 MB Eindhoven, Netherlands; [Markvoort, Albert J.; Hilbers, Peter A. J.; De Greef, Tom F. A.] Eindhoven Univ Technol, Biomodeling & Bioinformat Grp, NL-5600 MB Eindhoven, Netherlands	Eindhoven University of Technology; Eindhoven University of Technology; Eindhoven University of Technology	De Greef, TFA (corresponding author), Eindhoven Univ Technol, Inst Complex Mol Syst, POB 513, NL-5600 MB Eindhoven, Netherlands.	t.f.a.d.greef@tue.nl; e.w.meijer@tue.nl	Markvoort, Albert/AAI-4535-2021; Meijer, E.W./K-7632-2013; Markvoort, Albert J/A-9833-2013; Hilbers, Peter A.J./D-2468-2013; George, Subi/A-8328-2010; Smulders, Maarten/H-4162-2011; de Greef, Tom F. A./I-8124-2014	Meijer, E.W./0000-0003-4126-7492; Hilbers, Peter A.J./0000-0002-8805-5633; Smulders, Maarten/0000-0002-6855-0426; de Greef, Tom/0000-0002-9338-284X	European Research Council under the European Union [246829]; Netherlands Organization for Scientific Research	European Research Council under the European Union(European Research Council (ERC)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	We thank Z. Tomovic for providing the SOPV. We are grateful to R. M. Kellogg (Syncom, Groningen, The Netherlands) for providing the tartaric acid derivate. We also thank H. W. H. van Roekel and R. de Bruijn for discussions. Artwork was provided by K. Pieterse. The research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC grant agreement number 246829, and from the Netherlands Organization for Scientific Research.	Ajayaghosh A, 2006, ANGEW CHEM INT EDIT, V45, P3261, DOI 10.1002/anie.200600256; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; BISHOP MF, 1984, BIOPHYS J, V46, P631, DOI 10.1016/S0006-3495(84)84062-X; Capito RM, 2008, SCIENCE, V319, P1812, DOI 10.1126/science.1154586; Cui HG, 2007, SCIENCE, V317, P647, DOI 10.1126/science.1141768; Dankers PYW, 2005, NAT MATER, V4, P568, DOI 10.1038/nmat1418; De Greef TFA, 2009, CHEM REV, V109, P5687, DOI 10.1021/cr900181u; Ferrone F, 1999, METHOD ENZYMOL, V309, P256; George SJ, 2007, ANGEW CHEM INT EDIT, V46, P8206, DOI 10.1002/anie.200702730; Hoeben FJM, 2005, CHEM REV, V105, P1491, DOI 10.1021/cr030070z; Jonkheijm P, 2003, J AM CHEM SOC, V125, P15941, DOI 10.1021/ja0383118; Jonkheijm P, 2006, SCIENCE, V313, P80, DOI 10.1126/science.1127884; Knowles TPJ, 2009, SCIENCE, V326, P1533, DOI 10.1126/science.1178250; Lohr A, 2008, ANGEW CHEM INT EDIT, V47, P1232, DOI 10.1002/anie.200704550; Lund R, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.188301; Mulder AM, 2010, SCIENCE, V330, P673, DOI 10.1126/science.1193220; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Pashuck ET, 2010, J AM CHEM SOC, V132, P8819, DOI 10.1021/ja100613w; Pasternack RF, 1998, J AM CHEM SOC, V120, P5873, DOI 10.1021/ja980186q; Percec V, 2002, NATURE, V419, P384, DOI 10.1038/nature01072; Powers ET, 2008, BIOPHYS J, V94, P379, DOI 10.1529/biophysj.107.117168; Powers ET, 2006, BIOPHYS J, V91, P122, DOI 10.1529/biophysj.105.073767; van Gestel J, 2004, MACROMOLECULES, V37, P3894, DOI 10.1021/ma030480p; Wolffs M, 2008, CHEM COMMUN, P4613, DOI 10.1039/b809560d; Wurthner F, 2004, J AM CHEM SOC, V126, P10611, DOI 10.1021/ja0475353; Xue WF, 2008, P NATL ACAD SCI USA, V105, P8926, DOI 10.1073/pnas.0711664105; Yamamoto Y, 2006, SCIENCE, V314, P1761, DOI 10.1126/science.1134441	27	619	621	15	617	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2012	481	7382					492	U103		10.1038/nature10720	http://dx.doi.org/10.1038/nature10720			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881GY	22258506				2022-12-28	WOS:000299471800037
J	Allen, RM				Allen, Richard M.			Transforming Earthquake Detection?	SCIENCE			English	Editorial Material									[Allen, Richard M.] Univ Calif Berkeley, Seismol Lab, Berkeley, CA 94720 USA; [Allen, Richard M.] Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Allen, RM (corresponding author), Univ Calif Berkeley, Seismol Lab, Berkeley, CA 94720 USA.	rallen@berkeley.edu	Allen, Richard/H-8493-2016	Allen, Richard/0000-0003-4293-9772	Division Of Earth Sciences [1027974] Funding Source: National Science Foundation	Division Of Earth Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))		Atkinson GM, 2007, SEISMOL RES LETT, V78, P362, DOI 10.1785/gssrl.78.3.362; Bossu R., 2012, ANN GEOPHYS, V54, P6, DOI DOI 10.4401/AG-5265; Bossu R., 2011, COMP EMERGENCY MANAG, P235, DOI [10.1201/b10974-15, DOI 10.1201/B10974-15]; Chung AI, 2011, SEISMOL RES LETT, V82, P526, DOI 10.1785/gssrl.82.4.526; Clayton R. W., 2011, ANN GEOPHYS, V54, P6, DOI DOI 10.4401/AG-5269; Dashti S., 2011, G10AP00006 USGS; Earle P, 2010, NAT GEOSCI, V3, P221, DOI 10.1038/ngeo832; Earle PS, 2011, ANN GEOPHYS-ITALY, V54, P708, DOI 10.4401/ag-5364; Noam EM, 1996, SCIENCE, V274, P739, DOI 10.1126/science.274.5288.739; Wald DJ, 2011, ANN GEOPHYS-ITALY, V54, P688, DOI 10.4401/ag-5354	10	25	27	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					297	298		10.1126/science.1214650	http://dx.doi.org/10.1126/science.1214650			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267802				2022-12-28	WOS:000299273400035
J	Balaskas, N; Ribeiro, A; Panovska, J; Dessaud, E; Sasai, N; Page, KM; Briscoe, J; Ribes, V				Balaskas, Nikolaos; Ribeiro, Ana; Panovska, Jasmina; Dessaud, Eric; Sasai, Noriaki; Page, Karen M.; Briscoe, James; Ribes, Vanessa			Gene Regulatory Logic for Reading the Sonic Hedgehog Signaling Gradient in the Vertebrate Neural Tube	CELL			English	Article							PROGENITOR-CELL IDENTITY; MORPHOGEN GRADIENT; POSITIONAL INFORMATION; DROSOPHILA EMBRYO; NEURONAL FATE; BINDING-SITE; FLOOR PLATE; INDUCTION; SPECIFICATION; NOTOCHORD	Secreted signals, known as morphogens, provide the positional information that organizes gene expression and cellular differentiation in many developing tissues. In the vertebrate neural tube, Sonic Hedgehog (Shh) acts as a morphogen to control the pattern of neuronal subtype specification. Using an in vivo reporter of Shh signaling, mouse genetics, and systems modeling, we show that a spatially and temporally changing gradient of Shh signaling is interpreted by the regulatory logic of a downstream transcriptional network. The design of the network, which links three transcription factors to Shh signaling, is responsible for differential spatial and temporal gene expression. In addition, the network renders cells insensitive to fluctuations in signaling and confers hysteresis-memory of the signal. Our findings reveal that morphogen interpretation is an emergent property of the architecture of a transcriptional network that provides robustness and reliability to tissue patterning.	[Balaskas, Nikolaos; Ribeiro, Ana; Dessaud, Eric; Sasai, Noriaki; Briscoe, James; Ribes, Vanessa] Natl Inst Med Res, London NW7 1AA, England; [Panovska, Jasmina; Page, Karen M.] UCL, Dept Math, London WC1E 6BT, England	MRC National Institute for Medical Research; University of London; University College London	Briscoe, J (corresponding author), Natl Inst Med Res, Mill Hill, London NW7 1AA, England.	james.briscoe@nimr.mrc.ac.uk	RIBES, Vanessa/AAO-3488-2020	Sasai, Noriaki/0000-0003-0360-1138; Ribeiro, Ana/0000-0003-0132-9740; Panovska-Griffiths, Jasmina/0000-0002-7720-1121; RIBES, Vanessa/0000-0001-7016-9192; Briscoe, James/0000-0002-1020-5240; Dessaud, Eric/0000-0001-9723-6658; Page, Karen/0000-0003-4189-4664	MRC [U117560541]; Wellcome Trust [080630]; EMBO; Marie Curie Fellowships; FCT, Portugal; National Institute of Mathematical and Biological Synthesis (NSF) [EF-0832858]; University of Tennessee, Knoxville	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); EMBO(European Molecular Biology Organization (EMBO)); Marie Curie Fellowships(European Commission); FCT, Portugal(Portuguese Foundation for Science and TechnologyEuropean Commission); National Institute of Mathematical and Biological Synthesis (NSF); University of Tennessee, Knoxville	We are grateful to N. Bushati, A. Kicheva, T. M. Jessell, E. Kutejova, S. Tozer, and J.P. Vincent for discussions. We thank NIMR Biological Services staff for help with the mouse colonies. This work was supported by the MRC (U117560541) and Wellcome Trust (080630). E. D. was supported by EMBO and Marie Curie Fellowships, N. S. by a Marie Curie Fellowship, V. R. by an EMBO Fellowship, and A. R. by the FCT, Portugal. K. M. P. thanks the National Institute of Mathematical and Biological Synthesis for a sabbatical fellowship (NSF Grant EF-0832858 and University of Tennessee, Knoxville).	Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Alon U, 2007, NAT REV GENET, V8, P450, DOI 10.1038/nrg2102; Bergmann S, 2007, PLOS BIOL, V5, P232, DOI 10.1371/journal.pbio.0050046; Bollenbach T, 2008, DEVELOPMENT, V135, P1137, DOI 10.1242/dev.012062; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Chamberlain CE, 2008, DEVELOPMENT, V135, P1097, DOI 10.1242/dev.013086; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Cherry JL, 2000, J THEOR BIOL, V203, P117, DOI 10.1006/jtbi.2000.1068; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; Davidson EH, 2010, NATURE, V468, P911, DOI 10.1038/nature09645; Davidson EH, 2008, P NATL ACAD SCI USA, V105, P20063, DOI 10.1073/pnas.0806007105; Dessaud E, 2007, NATURE, V450, P717, DOI 10.1038/nature06347; Dessaud E, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000382; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Gregor T, 2007, CELL, V130, P153, DOI 10.1016/j.cell.2007.05.025; Grimm O, 2010, DEVELOPMENT, V137, P2253, DOI 10.1242/dev.032409; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Harvey SA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000101; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Ibanes M, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.14; Jaeger J, 2006, BIOESSAYS, V28, P1102, DOI 10.1002/bies.20494; Jeong JH, 2005, DEVELOPMENT, V132, P143, DOI 10.1242/dev.01566; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Kerszberg M, 2007, CELL, V130, P205, DOI 10.1016/j.cell.2007.06.038; Lander AD, 2007, CELL, V128, P245, DOI 10.1016/j.cell.2007.01.004; Lek M, 2010, DEVELOPMENT, V137, P4051, DOI 10.1242/dev.054288; Liberman LM, 2009, P NATL ACAD SCI USA, V106, P22317, DOI 10.1073/pnas.0906227106; Manu, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000303; Manu, 2009, PLOS BIOL, V7, P591, DOI 10.1371/journal.pbio.1000049; Marigo V, 1996, DEVELOPMENT, V122, P1225; Matise MP, 1998, DEVELOPMENT, V125, P2759; Nahmad M, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000202; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Ochoa-Espinosa A, 2005, P NATL ACAD SCI USA, V102, P4960, DOI 10.1073/pnas.0500373102; Ochoa-Espinosa A, 2009, P NATL ACAD SCI USA, V106, P3823, DOI 10.1073/pnas.0807878105; Pages F, 2000, TRENDS GENET, V16, P40, DOI 10.1016/S0168-9525(99)01880-6; Saka Y, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-47; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Stamataki D, 2005, GENE DEV, V19, P626, DOI 10.1101/gad.325905; Stathopoulos A, 2005, DEV CELL, V9, P449, DOI 10.1016/j.devcel.2005.09.005; Tyson J., 1978, PROG THEOR BIOL, V5, P1; Vokes SA, 2008, GENE DEV, V22, P2651, DOI 10.1101/gad.1693008; Vokes SA, 2007, DEVELOPMENT, V134, P1977, DOI 10.1242/dev.001966; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; Wartlick O, 2011, SCIENCE, V331, P1154, DOI 10.1126/science.1200037; Wolpert L., 1998, PRINCIPLES DEV, P340; Xu M, 2005, DEVELOPMENT, V132, P1637, DOI 10.1242/dev.01722; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	55	292	295	0	49	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					273	284		10.1016/j.cell.2011.10.047	http://dx.doi.org/10.1016/j.cell.2011.10.047			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265416	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000299540700030
J	Jansen, LET				Jansen, Lars E. T.			Sowing the Seeds of Centromeres	SCIENCE			English	Editorial Material							DE-NOVO KINETOCHORE; CENP-A CHROMATIN; HETEROCHROMATIN; CHROMOSOME; SUFFICIENT		Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal	Instituto Gulbenkian de Ciencia	Jansen, LET (corresponding author), Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal.	ljansen@igc.gulbenkian.pt		Jansen, Lars/0000-0002-2158-0345				Alonso A, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-6; Barnhart MC, 2011, J CELL BIOL, V194, P229, DOI 10.1083/jcb.201012017; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; Folco HD, 2008, SCIENCE, V319, P94, DOI 10.1126/science.1150944; Gascoigne KE, 2011, CELL, V145, P410, DOI 10.1016/j.cell.2011.03.031; Guse A, 2011, NATURE, V477, P354, DOI 10.1038/nature10379; Ishii K, 2008, SCIENCE, V321, P1088, DOI 10.1126/science.1158699; Jansen LET, 2007, J CELL BIOL, V176, P795, DOI 10.1083/jcb.200701066; Mendiburo MJ, 2011, SCIENCE, V334, P686, DOI 10.1126/science.1206880; Olszak AM, 2011, NAT CELL BIOL, V13, P799, DOI 10.1038/ncb2272; PALMER DK, 1990, CHROMOSOMA, V100, P32, DOI 10.1007/BF00337600; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Van Hooser AA, 2001, J CELL SCI, V114, P3529; Warburton PE, 2004, CHROMOSOME RES, V12, P617, DOI 10.1023/B:CHRO.0000036585.44138.4b; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4	15	1	2	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2012	335	6066					299	300		10.1126/science.1218162	http://dx.doi.org/10.1126/science.1218162			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267803	Green Submitted			2022-12-28	WOS:000299273400036
J	Mendoza, JL; Schmidt, A; Li, Q; Nuvaga, E; Barrett, T; Bridges, RJ; Feranchak, AP; Brautigam, CA; Thomas, PJ				Mendoza, Juan L.; Schmidt, Andre; Li, Qin; Nuvaga, Emmanuel; Barrett, Tyler; Bridges, Robert J.; Feranchak, Andrew P.; Brautigam, Chad A.; Thomas, Philip J.			Requirements for Efficient Correction of Delta F508 CFTR Revealed by Analyses of Evolved Sequences	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAIN; MULTIPLE PROTEIN-SEQUENCE; FIBROSIS-CAUSING MUTATION; CYSTIC-FIBROSIS; TRAFFICKING DEFECT; ATP-BINDING; IN-VIVO; CORRELATED MUTATIONS; STRUCTURE ALIGNMENTS	Misfolding of Delta F508 cystic fibrosis (CF) transmembrane conductance regulator (CFTR) underlies pathology in most CF patients. F508 resides in the first nucleotide-binding domain (NBD1) of CFTR near a predicted interface with the fourth intracellular loop (ICL4). Efforts to identify small molecules that restore function by correcting the folding defect have revealed an apparent efficacy ceiling. To understand the mechanistic basis of this obstacle, positions statistically coupled to 508, in evolved sequences, were identified and assessed for their impact on both NBD1 and CFTR folding. The results indicate that both NBD1 folding and interaction with ICL4 are altered by the Delta F508 mutation and that correction of either individual process is only partially effective. By contrast, combination of mutations that counteract both defects restores Delta F508 maturation and function to wild-type levels. These results provide a mechanistic rationale for the limited efficacy of extant corrector compounds and suggest approaches for identifying compounds that correct both defective steps.	[Mendoza, Juan L.; Thomas, Philip J.] Univ Texas SW Med Ctr Dallas, Mol Biophys Program, Dallas, TX 75390 USA; [Mendoza, Juan L.; Schmidt, Andre; Nuvaga, Emmanuel; Barrett, Tyler; Thomas, Philip J.] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; [Li, Qin; Feranchak, Andrew P.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Brautigam, Chad A.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Bridges, Robert J.] Rosalind Franklin Univ, Dept Physiol & Biophys, Abbott Pk, IL 60064 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Rosalind Franklin University Medical & Science	Thomas, PJ (corresponding author), Univ Texas SW Med Ctr Dallas, Mol Biophys Program, Dallas, TX 75390 USA.	philip.thomas@utsouthwestern.edu	Thomas, Philip J/F-7115-2012	Mendoza, Juan/0000-0001-6972-7476; Brautigam, Chad/0000-0001-6563-1338	CF Foundation; NIH [DK49835, DK76638, DE12309]; U.S. Department of Energy, Office of Biological and Environmental Research [DE-AC02-06CH11357]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049835, R01DK076638, R37DK049835] Funding Source: NIH RePORTER	CF Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Energy, Office of Biological and Environmental Research(United States Department of Energy (DOE)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors wish to thank Linda Millen, Bala Somalinga, and David Thompson for suggestions and technical assistance, the CFTR Folding Consortium for intellectual support, and the CF Foundation and NIH grants DK49835, DK76638, and DE12309 for support. P.J.T. is a cofounder of Reata Pharmaceuticals. Reata has licensed the beta-galatosidase folding assay from the University of Texas for commercial use. Results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. Argonne is operated by University of Chicago Argonne, LLC, for the U.S. Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357.	Accurso FJ, 2010, NEW ENGL J MED, V363, P1991, DOI 10.1056/NEJMoa0909825; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Atwell S, 2010, PROTEIN ENG DES SEL, V23, P375, DOI 10.1093/protein/gzq004; Berger AL, 2005, P NATL ACAD SCI USA, V102, P455, DOI 10.1073/pnas.0408575102; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Dawson RJP, 2007, FEBS LETT, V581, P935, DOI 10.1016/j.febslet.2007.01.073; Dean M, 2005, ANNU REV GENOM HUM G, V6, P123, DOI 10.1146/annurev.genom.6.080604.162122; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; deCarvalho ACV, 2002, J BIOL CHEM, V277, P35896, DOI 10.1074/jbc.M205644200; Dekker JP, 2004, BIOINFORMATICS, V20, P1565, DOI 10.1093/bioinformatics/bth128; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DORK T, 1991, HUM GENET, V87, P441; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; Fodor AA, 2004, PROTEINS, V56, P211, DOI 10.1002/prot.20098; GOBEL U, 1994, PROTEINS, V18, P309, DOI 10.1002/prot.340180402; Goh CS, 2000, J MOL BIOL, V299, P283, DOI 10.1006/jmbi.2000.3732; Hoelen H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015458; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Kass I, 2002, PROTEINS, V48, P611, DOI 10.1002/prot.10180; Krasnov KV, 2008, HUM MUTAT, V29, P1364, DOI 10.1002/humu.20866; Kunichika K, 2002, PROTEIN ENG, V15, P805, DOI 10.1093/protein/15.10.805; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Larson SM, 2000, J MOL BIOL, V303, P433, DOI 10.1006/jmbi.2000.4146; Lewis HA, 2010, J MOL BIOL, V396, P406, DOI 10.1016/j.jmb.2009.11.051; Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Madaoui H, 2008, P NATL ACAD SCI USA, V105, P7708, DOI 10.1073/pnas.0707032105; McCarty NA, 2000, J EXP BIOL, V203, P1947; Mendoza JL, 2007, J BIOENERG BIOMEMBR, V39, P499, DOI 10.1007/s10863-007-9117-7; Olmea O, 1999, J MOL BIOL, V293, P1221, DOI 10.1006/jmbi.1999.3208; Pazos F, 2008, EMBO J, V27, P2648, DOI 10.1038/emboj.2008.189; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Pei JM, 2008, NUCLEIC ACIDS RES, V36, pW30, DOI 10.1093/nar/gkn322; Pei JM, 2008, NUCLEIC ACIDS RES, V36, P2295, DOI 10.1093/nar/gkn072; Pei JM, 2001, BIOINFORMATICS, V17, P700, DOI 10.1093/bioinformatics/17.8.700; Pissarra LS, 2008, CHEM BIOL, V15, P62, DOI 10.1016/j.chembiol.2007.11.012; PJURA P, 1993, PROTEIN SCI, V2, P2217, DOI 10.1002/pro.5560021221; Protasevich I, 2010, PROTEIN SCI, V19, P1917, DOI 10.1002/pro.479; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Robert R, 2008, MOL PHARMACOL, V73, P478, DOI 10.1124/mol.107.040725; Robert R, 2010, MOL PHARMACOL, V77, P922, DOI 10.1124/mol.109.062679; Roxo-Rosa M, 2006, P NATL ACAD SCI USA, V103, P17891, DOI 10.1073/pnas.0608312103; Sampson HM, 2011, CHEM BIOL, V18, P231, DOI 10.1016/j.chembiol.2010.11.016; Schrodinger L., 2020, PYMOL MOL GRAPHICS S; Socolich M, 2005, NATURE, V437, P512, DOI 10.1038/nature03991; Stratford FLL, 2007, BIOCHEM J, V401, P581, DOI 10.1042/BJ20060968; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; Teem JL, 1996, RECEPTOR CHANNEL, V4, P63; Thibodeau PH, 2010, J BIOL CHEM, V285, P35825, DOI 10.1074/jbc.M110.131623; Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Van Goor F, 2011, P NATL ACAD SCI USA, V108, P18843, DOI 10.1073/pnas.1105787108; Van Goor F, 2009, P NATL ACAD SCI USA, V106, P18825, DOI 10.1073/pnas.0904709106; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang C, 2010, PROTEIN SCI, V19, P1932, DOI 10.1002/pro.480; Wang YX, 2006, EMBO J, V25, P5049, DOI 10.1038/sj.emboj.7601387; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Wigley WC, 2001, NAT BIOTECHNOL, V19, P131, DOI 10.1038/84389	66	205	207	0	31	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 20	2012	148	1-2					164	174		10.1016/j.cell.2011.11.023	http://dx.doi.org/10.1016/j.cell.2011.11.023			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265409	Green Accepted, Bronze			2022-12-28	WOS:000299540700022
J	Sun, LM; Wang, HY; Wang, ZG; He, SD; Chen, S; Liao, DH; Wang, L; Yan, JC; Liu, WL; Lei, XG; Wang, XD				Sun, Liming; Wang, Huayi; Wang, Zhigao; He, Sudan; Chen, She; Liao, Daohong; Wang, Lai; Yan, Jiacong; Liu, Weilong; Lei, Xiaoguang; Wang, Xiaodong			Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase	CELL			English	Article							CELL-DEATH; CYTOCHROME-C; APOPTOSIS; INHIBITION; IDENTIFICATION; CASPASES; CLEAVAGE; TARGET; SMAC	The receptor-interacting serine-threonine kinase 3 (RIP3) is a key signaling molecule in the programmed necrosis (necroptosis) pathway. This pathway plays important roles in a variety of physiological and pathological conditions, including development, tissue damage response, and antiviral immunity. Here, we report the identification of a small molecule called (E)-N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl) phenyl)-3-(5-nitrothiophene-2-yl)acrylamide-here-after referred to as necrosulfonamide-that specifically blocks necrosis downstream of RIP3 activation. An affinity probe derived from necrosulfonamide and coimmunoprecipitation using anti-RIP3 antibodies both identified the mixed lineage kinase domain-like protein (MLKL) as the interacting target. MLKL was phosphorylated by RIP3 at the threonine 357 and serine 358 residues, and these phosphorylation events were critical for necrosis. Treating cells with necrosulfonamide or knocking down MLKL expression arrested necrosis at a specific step at which RIP3 formed discrete punctae in cells. These findings implicate MLKL as a key mediator of necrosis signaling downstream of the kinase RIP3.	[Sun, Liming; Wang, Huayi; He, Sudan; Chen, She; Liao, Daohong; Yan, Jiacong; Liu, Weilong; Lei, Xiaoguang; Wang, Xiaodong] Natl Inst Biol Sci, Beijing 102206, Peoples R China; [Sun, Liming; Wang, Huayi; Wang, Zhigao; Wang, Lai; Wang, Xiaodong] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Liao, Daohong; Lei, Xiaoguang] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin 300072, Peoples R China; [Liu, Weilong] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Liu, Weilong] Peking Union Med Coll, Beijing 100730, Peoples R China	National Institute of Biological Sciences, Beijing; University of Texas System; University of Texas Southwestern Medical Center Dallas; Tianjin University; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Lei, XG (corresponding author), Natl Inst Biol Sci, 7 Sci Pk Rd,Zhongguancun Life Sci Pk, Beijing 102206, Peoples R China.	leixiaoguang@nibs.ac.cn; wangxiaodong@nibs.ac.cn	Wang, Zhigao/ABE-9411-2021	Wang, Zhigao/0000-0002-6544-4302; Yan, Jiacong/0000-0002-2429-036X; He, Sudan/0000-0002-0846-1210; Sun, Liming/0000-0002-0136-5605; Wang, Xiaodong/0000-0001-9885-356X	Howard Hughes Medical Institute; National Cancer Institute (NCI) [PO1 CA 95471]; Chinese Ministry of Science and Technology [2008AA022318, 2008AA022317, 2010CB835400]; NATIONAL CANCER INSTITUTE [P30CA142543, P01CA095471] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to express our gratitude to the High-throughput Screening Facility at the University of Texas Southwestern Medical Center for help with the chemical screening. We thank Dr. Agata Rybarska for critically reading the manuscript. This work was supported by the Howard Hughes Medical Institute and a grant from the National Cancer Institute (NCI) (PO1 CA 95471). The work in Beijing was supported by National High Technology Projects 863 (2008AA022318 [to X. W.] and 2008AA022317 [to X. L.]) and 973 (2010CB835400) from Chinese Ministry of Science and Technology.	Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Feng SS, 2007, CELL SIGNAL, V19, P2056, DOI 10.1016/j.cellsig.2007.05.016; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Sato S, 2007, J AM CHEM SOC, V129, P873, DOI 10.1021/ja0655643; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107; Upton JW, 2010, CELL HOST MICROBE, V7, P302, DOI 10.1016/j.chom.2010.03.006; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang Z., 2011, CELL, V148, P228; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308	29	1567	1658	24	373	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					213	227		10.1016/j.cell.2011.11.031	http://dx.doi.org/10.1016/j.cell.2011.11.031			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265413	Bronze			2022-12-28	WOS:000299540700026
J	Wargacki, AJ; Leonard, E; Win, MN; Regitsky, DD; Santos, CNS; Kim, PB; Cooper, SR; Raisner, RM; Herman, A; Sivitz, AB; Lakshmanaswamy, A; Kashiyama, Y; Baker, D; Yoshikuni, Y				Wargacki, Adam J.; Leonard, Effendi; Win, Maung Nyan; Regitsky, Drew D.; Santos, Christine Nicole S.; Kim, Peter B.; Cooper, Susan R.; Raisner, Ryan M.; Herman, Asael; Sivitz, Alicia B.; Lakshmanaswamy, Arun; Kashiyama, Yuki; Baker, David; Yoshikuni, Yasuo			An Engineered Microbial Platform for Direct Biofuel Production from Brown Macroalgae	SCIENCE			English	Article							TUMEFACIENS STRAIN C58; ESCHERICHIA-COLI; ALGINATE LYASE; ERWINIA-CHRYSANTHEMI; ETHANOL-PRODUCTION; MOLECULAR-IDENTIFICATION; METABOLISM; BIOSYNTHESIS; CONSTRUCTION; PURIFICATION	Prospecting macroalgae (seaweeds) as feedstocks for bioconversion into biofuels and commodity chemical compounds is limited primarily by the availability of tractable microorganisms that can metabolize alginate polysaccharides. Here, we present the discovery of a 36-kilo-base pair DNA fragment from Vibrio splendidus encoding enzymes for alginate transport and metabolism. The genomic integration of this ensemble, together with an engineered system for extracellular alginate depolymerization, generated a microbial platform that can simultaneously degrade, uptake, and metabolize alginate. When further engineered for ethanol synthesis, this platform enables bioethanol production directly from macroalgae via a consolidated process, achieving a titer of 4.7% volume/volume and a yield of 0.281 weight ethanol/weight dry macroalgae (equivalent to similar to 80% of the maximum theoretical yield from the sugar composition in macroalgae).	[Wargacki, Adam J.; Leonard, Effendi; Win, Maung Nyan; Regitsky, Drew D.; Santos, Christine Nicole S.; Kim, Peter B.; Cooper, Susan R.; Raisner, Ryan M.; Herman, Asael; Sivitz, Alicia B.; Lakshmanaswamy, Arun; Kashiyama, Yuki; Yoshikuni, Yasuo] Bio Architecture Lab, Berkeley, CA 94710 USA; [Kashiyama, Yuki] BAL Chile SA, Puerto Varas 5550658, Chile; [Kashiyama, Yuki] BAL Biofuels SA, Santiago 7550159, Chile; [Baker, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Yoshikuni, Y (corresponding author), Bio Architecture Lab, 604 Bancroft Way,Suite A, Berkeley, CA 94710 USA.	yoshikuni@ba-lab.com	Yoshikuni, Yasuo/A-8804-2019; Baker, David/K-8941-2012; Yoshikuni, Yasuo/K-7741-2019	Baker, David/0000-0001-7896-6217; Yoshikuni, Yasuo/0000-0002-8372-640X; Cooper, Susan/0000-0002-1608-6713	DOE under Advanced Research Projects Agency-Energy (ARPA-E) [DE-AR0000006]; CORFO INNOVA CHILE [09CTEI-6866]; agency of the U.S. government	DOE under Advanced Research Projects Agency-Energy (ARPA-E)(United States Department of Energy (DOE)); CORFO INNOVA CHILE; agency of the U.S. government	This work is supported by the DOE under Advanced Research Projects Agency-Energy (ARPA-E) award DE-AR0000006 and by the CORFO INNOVA CHILE (codigo 09CTEI-6866). We thank M. Polz (Department of Civil and Environmental Engineering, Massachussetts Institute of Technology) for the kind gift of the V. splendidus strain. We thank R. Bailey for important discussion on microbial engineering. We also thank A. Wahler for critical review and editing of the manuscript. The assistance of A. Gill for in vitro characterization of Oal enzymes is greatly appreciated. Patents describing components of this work can be found under U. S. patent application nos. 12/245537, 12/361293, 12/899419, 61/427077, and 61/436173. This report was prepared as an account of work sponsored by an agency of the U.S. government. Neither the U. S. government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the U. S. government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the U. S. government or any agency thereof.	Adams JM, 2009, J APPL PHYCOL, V21, P569, DOI 10.1007/s10811-008-9384-7; Ajikumar PK, 2010, SCIENCE, V330, P70, DOI 10.1126/science.1191652; Alper H, 2005, NAT BIOTECHNOL, V23, P612, DOI 10.1038/nbt1083; Alper H, 2009, NAT REV MICROBIOL, V7, P715, DOI 10.1038/nrmicro2186; Atsumi S, 2008, NATURE, V451, P86, DOI 10.1038/nature06450; Blot N, 2002, J BIOL CHEM, V277, P7936, DOI 10.1074/jbc.M109193200; Bond-Watts BB, 2011, NAT CHEM BIOL, V7, P222, DOI 10.1038/NCHEMBIO.537; Dellomonaco C, 2011, NATURE, V476, P355, DOI 10.1038/nature10333; Draget K. I., 2005, Polysaccharides and polyamides in the food industry: properties, production, and patents, P1; FUJIYAMA K, 1995, FEMS MICROBIOL LETT, V126, P19, DOI 10.1016/0378-1097(94)00519-W; Hashimoto W, 2000, J BACTERIOL, V182, P4572, DOI 10.1128/JB.182.16.4572-4577.2000; Hashimoto Wataru, 2010, Bioeng Bugs, V1, P97, DOI 10.4161/bbug.1.2.10322; HE SY, 1991, P NATL ACAD SCI USA, V88, P1079, DOI 10.1073/pnas.88.3.1079; Henderson IR, 1999, J BACTERIOL, V181, P2132, DOI 10.1128/JB.181.7.2132-2141.1999; Horn SJ, 2000, J IND MICROBIOL BIOT, V25, P249, DOI 10.1038/sj.jim.7000065; Horn SJ, 2000, J IND MICROBIOL BIOT, V24, P51, DOI 10.1038/sj.jim.2900771; Hugouvieux-Cotte-Pattat N, 2001, MOL MICROBIOL, V41, P1125, DOI 10.1046/j.1365-2958.2001.02565.x; Kazemi-Pour N, 2004, PROTEOMICS, V4, P3177, DOI 10.1002/pmic.200300814; Kjaergaard K, 2002, J BACTERIOL, V184, P4197, DOI 10.1128/JB.184.15.4197-4204.2002; Klemm P, 2004, MOL MICROBIOL, V51, P283, DOI 10.1046/j.1365-2958.2003.03833.x; Lau MW, 2009, P NATL ACAD SCI USA, V106, P1368, DOI 10.1073/pnas.0812364106; Lee HY, 2011, J ANTIBIOT, V64, P59, DOI 10.1038/ja.2010.129; Leonard E, 2008, MOL PHARM, V5, P257, DOI 10.1021/mp7001472; Li JW, 2011, MAR DRUGS, V9, P109, DOI 10.3390/md9010109; Lynd LR, 2005, CURR OPIN BIOTECH, V16, P577, DOI 10.1016/j.copbio.2005.08.009; Martin VJJ, 2003, NAT BIOTECHNOL, V21, P796, DOI 10.1038/nbt833; Ochiai A, 2006, ACTA CRYSTALLOGR F, V62, P486, DOI 10.1107/S1744309106014333; Ochiai A, 2006, RES MICROBIOL, V157, P642, DOI 10.1016/j.resmic.2006.02.006; OHTA K, 1991, APPL ENVIRON MICROB, V57, P893, DOI 10.1128/AEM.57.4.893-900.1991; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; PREISS J, 1962, J BIOL CHEM, V237, P317; Roesijadi G., 2010, MACROALGAE BIOMASS F; Schirmer A, 2010, SCIENCE, V329, P559, DOI 10.1126/science.1187936; Skraly FA, 1998, APPL ENVIRON MICROB, V64, P98; Somerville C, 2010, SCIENCE, V329, P790, DOI 10.1126/science.1189268; Steen EJ, 2010, NATURE, V463, P559, DOI 10.1038/nature08721; Stephanopoulos G, 2007, SCIENCE, V315, P801, DOI 10.1126/science.1139612; Takase R, 2010, BBA-PROTEINS PROTEOM, V1804, P1925, DOI 10.1016/j.bbapap.2010.05.010; Takeda H, 2011, ENERG ENVIRON SCI, V4, P2575, DOI 10.1039/c1ee01236c; van der Woude MW, 2008, ANNU REV MICROBIOL, V62, P153, DOI 10.1146/annurev.micro.62.081307.162938; Wong TY, 2000, ANNU REV MICROBIOL, V54, P289, DOI 10.1146/annurev.micro.54.1.289; Yim H, 2011, NAT CHEM BIOL, V7, P445, DOI [10.1038/NCHEMBIO.580, 10.1038/nchembio.580]; Yomano LP, 2009, BIOTECHNOL LETT, V31, P1389, DOI 10.1007/s10529-009-0011-8	43	498	527	12	551	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2012	335	6066					308	313		10.1126/science.1214547	http://dx.doi.org/10.1126/science.1214547			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878RE	22267807				2022-12-28	WOS:000299273400040
J	Lamas, D; Rosenbaum, L				Lamas, Daniela; Rosenbaum, Lisa			Painful Inequities - Palliative Care in Developing Countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Rajagopal MR, 2007, J PAIN SYMPTOM MANAG, V33, P615, DOI 10.1016/j.jpainsymman.2007.02.028; Statement of professor Sevil Atasoy, 2009, COMMUNICATION   0730; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	3	34	35	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					199	201		10.1056/NEJMp1113622	http://dx.doi.org/10.1056/NEJMp1113622			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	877RZ	22256803				2022-12-28	WOS:000299201400003
J	Saklayen, MG				Saklayen, Mohammad G.			Acetylcysteine did not reduce kidney injury in at-risk patients having vascular angiography	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Saklayen, Mohammad G.] VA Med Ctr, Dayton, OH USA; [Saklayen, Mohammad G.] Wright State Univ, Dayton, OH 45435 USA	Wright State University Dayton	Saklayen, MG (corresponding author), VA Med Ctr, Dayton, OH USA.							Aitio ML, 2006, BRIT J CLIN PHARMACO, V61, P5, DOI 10.1111/j.1365-2125.2005.02523.x; Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2; Kelly AM, 2008, ANN INTERN MED, V148, P284, DOI 10.7326/0003-4819-148-4-200802190-00007; Nallamothu BK, 2004, AM J MED, V117, P938, DOI 10.1016/j.amjmed.2004.06.046; Saklayen MG, 2010, J INVEST MED, V58, P28, DOI 10.2310/JIM.0b013e3181c5e9e9; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; Zagler A, 2006, AM HEART J, V151, P140, DOI 10.1016/j.ahj.2005.01.055	7	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2							JC1-8	10.7326/0003-4819-156-2-201201170-02008	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-02008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31YU	22250170				2022-12-28	WOS:000208919700009
J	Parks, T; Hill, AV; Chapman, SJ				Parks, Tom; Hill, Adrian V.; Chapman, Stephen J.			The Perpetual Challenge of Infectious Diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Parks, Tom; Hill, Adrian V.; Chapman, Stephen J.] Wellcome Trust Ctr Human Genet, Oxford, England	University of Oxford; Wellcome Centre for Human Genetics	Parks, T (corresponding author), Wellcome Trust Ctr Human Genet, Oxford, England.	schapman@well.ox.ac.uk	Parks, Tom/D-7741-2013	Parks, Tom/0000-0002-1163-8654	Medical Research Council [G1001712] Funding Source: researchfish; National Institute for Health Research [CL-2006-13-003] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))		Chapman SJ, 2006, NAT GENET, V38, P499, DOI 10.1038/ng0506-499; Chapman SJ, 2012, NAT REV GENET, V13, P175, DOI 10.1038/nrg3114; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; Zhang FR, 2009, NEW ENGL J MED, V361, P2609, DOI 10.1056/NEJMoa0903753	4	307	331	7	103	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					90	90		10.1056/NEJMc1202013	http://dx.doi.org/10.1056/NEJMc1202013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22296079				2022-12-28	WOS:000305979400032
J	Butler, CC; Simpson, SA; Dunstan, F; Rollnick, S; Cohen, D; Gillespie, D; Evans, MR; Alam, MF; Bekkers, MJ; Evans, J; Moore, L; Howe, R; Hayes, J; Hare, M; Hood, K				Butler, Christopher C.; Simpson, Sharon A.; Dunstan, Frank; Rollnick, Stephen; Cohen, David; Gillespie, David; Evans, Meirion R.; Alam, M. Fasihul; Bekkers, Marie-Jet; Evans, John; Moore, Laurence; Howe, Robin; Hayes, Jamie; Hare, Monika; Hood, Kerenza			Effectiveness of multifaceted educational programme to reduce antibiotic dispensing in primary care: practice based randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS; COMMUNICATION-SKILLS; SORE THROAT; RESISTANCE; INTERVENTIONS; STRATEGIES; COMMUNITY; OUTCOMES; QUALITY; CONSULTATIONS	Objective To evaluate the effectiveness and costs of a multifaceted flexible educational programme aimed at reducing antibiotic dispensing at the practice level in primary care. Design Randomised controlled trial with general practices as the unit of randomisation and analysis. Clinicians and researchers were blinded to group allocation until after randomisation. Setting 68 general practices with about 480 000 patients in Wales, United Kingdom. Participants 34 practices were randomised to receive the educational programme and 34 practices to be controls. 139 clinicians from the intervention practices and 124 from control practices had agreed to participate before randomisation. Practice level data covering all the clinicians in the 68 practices were analysed. Interventions Intervention practices followed the Stemming the Tide of Antibiotic Resistance (STAR) educational programme, which included a practice based seminar reflecting on the practices' own dispensing and resistance data, online educational elements, and practising consulting skills in routine care. Control practices provided usual care. Main outcome measures Total numbers of oral antibiotic items dispensed for all causes per 1000 practice patients in the year after the intervention, adjusted for the previous year's dispensing. Secondary outcomes included reconsultations, admissions to hospital for selected causes, and costs. Results The rate of oral antibiotic dispensing (items per 1000 registered patients) decreased by 14.1 in the intervention group but increased by 12.1 in the control group, a net difference of 26.1. After adjustment for baseline dispensing rate, this amounted to a 4.2% (95% confidence interval 0.6% to 7.7%) reduction in total oral antibiotic dispensing for the year in the intervention group relative to the control group (P=0.02). Reductions were found for all classes of antibiotics other than penicillinase-resistant penicillins but were largest and significant individually for phenoxymethylpenicillins (penicillin V) (7.3%, 0.4% to 13.7%) and macrolides (7.7%, 1.1% to 13.8%). There were no significant differences between intervention and control practices in the number of admissions to hospital or in reconsultations for a respiratory tract infection within seven days of an index consultation. The mean cost of the programme was 2923 pound ((sic)3491, $4572) per practice (SD 1187) pound. There was a 5.5% reduction in the cost of dispensed antibiotics in the intervention group compared with the control group (-0.4% to 11.4%), equivalent to a reduction of about 830 pound a year for an average intervention practice. Conclusion The STAR educational programme led to reductions in all cause oral antibiotic dispensing over the subsequent year with no significant change in admissions to hospital, reconsultations, or costs.	[Butler, Christopher C.; Simpson, Sharon A.; Dunstan, Frank; Rollnick, Stephen; Gillespie, David; Evans, Meirion R.; Bekkers, Marie-Jet; Evans, John; Hare, Monika; Hood, Kerenza] Cardiff Univ, Sch Med, Inst Primary Care & Publ Hlth, Cardiff CF14 4XN, S Glam, Wales; [Simpson, Sharon A.; Gillespie, David; Bekkers, Marie-Jet; Evans, John; Hare, Monika; Hood, Kerenza] Cardiff Univ, Sch Med, S E Wales Trials Unit, Cardiff CF14 4XN, S Glam, Wales; [Cohen, David; Alam, M. Fasihul] Univ Glamorgan, Hlth Econ & Policy Res Unit, Pontypridd CF37 1DL, M Glam, Wales; [Moore, Laurence] Cardiff Univ, Sch Social Sci, Cardiff Inst Soc & Hlth, Cardiff CF14 4XN, S Glam, Wales; [Howe, Robin] Univ Wales Hosp, Natl Publ Hlth Serv Microbiol Cardiff Velindre NH, Cardiff CF4 4XW, S Glam, Wales; [Hayes, Jamie] Univ Hosp Llandough, Acad Ctr, Welsh Med Resource Ctr WeMeReC, Penarth, S Glam, Wales	Cardiff University; Cardiff University; University of South Wales; Cardiff University; Cardiff University	Butler, CC (corresponding author), Cardiff Univ, Sch Med, Inst Primary Care & Publ Hlth, Cardiff CF14 4XN, S Glam, Wales.	butlercc@cf.ac.uk	Hood, Kerenza/C-2528-2008; Alam, M Fasihul/AAD-7268-2020; Evans, Meirion/C-2990-2008	Hood, Kerenza/0000-0002-5268-8631; Alam, M Fasihul/0000-0003-2590-851X; Gillespie, David/0000-0002-6934-2928; Simpson, Sharon Anne/0000-0002-6219-1768; Moore, Laurence/0000-0003-2182-823X; Evans, Meirion/0000-0003-3578-1866; Butler, Christopher/0000-0002-0102-3453	UK Medical Research Council [G0500956]; National Institute for Health and Social care Research; ESRC [ES/G007543/1] Funding Source: UKRI; MRC [G0500956] Funding Source: UKRI; Economic and Social Research Council [ES/G007543/1] Funding Source: researchfish; Medical Research Council [G0500956] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health and Social care Research; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by the UK Medical Research Council (G0500956). The South East Wales Trials Unit is funded by the National Institute for Health and Social care Research, which also provide service support costs.	Ahovuo-Saloranta A, 2008, COCHRANE DB SYST REV, V2; Alam MF, 2009, INT J ANTIMICROB AG, V33, P255, DOI 10.1016/j.ijantimicag.2008.08.027; Arnold SR, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003539.PUB2; Arroll B, 2006, BMJ-BRIT MED J, V333, P279, DOI 10.1136/bmj.38891.681215.AE; Ball P, 2002, J ANTIMICROB CHEMOTH, V49, P31, DOI 10.1093/jac/49.1.31; Bekkers MJ, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-34; [British Medical Association Royal Pharmaceutical Society of Great Britain], 2007, BRIT NAT FORM; Butler CC, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2242; Butler CC, 1998, BRIT J GEN PRACT, V48, P1865; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; Butler CC, 2001, J ANTIMICROB CHEMOTH, V48, P435, DOI 10.1093/jac/48.3.435; Butler CC, 2007, BRIT J GEN PRACT, V57, P785; Butler CC, 2006, BRIT J GEN PRACT, V56, P686; Cals JWL, 2007, PATIENT EDUC COUNS, V68, P270, DOI 10.1016/j.pec.2007.06.014; Cals JWL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1374; Carter BR, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-65; Coenen S, 2001, LANCET, V358, P1272, DOI 10.1016/S0140-6736(01)06364-4; Cosby JL, 2007, LANCET INFECT DIS, V7, P749, DOI 10.1016/S1473-3099(07)70263-3; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Curtis L., 2008, UNIT COSTS HLTH SOCI; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Del Mar CB, 2006, COCHRANE DB SYST REV, V4, DOI 10.1002/14651858.cd000023; Eccles M, 2005, J CLIN EPIDEMIOL, V58, P107, DOI 10.1016/j.jclinepi.2004.09.002; Eldridge S, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4006; Finch RG, 2004, LANCET INFECT DIS, V4, P44, DOI 10.1016/S1473-3099(03)00860-0; Foy R, 2002, J CLIN EPIDEMIOL, V55, P717, DOI 10.1016/S0895-4356(02)00403-1; Francis NA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2885; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Grijalva CG, 2009, JAMA-J AM MED ASSOC, V302, P758, DOI 10.1001/jama.2009.1163; Grol R, 2002, QUAL SAF HEALTH CARE, V11, P110, DOI 10.1136/qhc.11.2.110; Guillemot D, 2005, CLIN INFECT DIS, V41, P930, DOI 10.1086/432721; Huttner B, 2010, LANCET INFECT DIS, V10, P17, DOI 10.1016/S1473-3099(09)70305-6; Lambert MF, 2007, J ANTIMICROB CHEMOTH, V59, P537, DOI 10.1093/jac/dkl511; Little P, 1997, BRIT MED J, V315, P350; Malhotra-Kumar S, 2007, LANCET, V369, P482, DOI 10.1016/S0140-6736(07)60235-9; Martens JD, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-145; McIsaac WJ, 2000, CAN MED ASSOC J, V163, P811; McNulty CAM, 2010, J ANTIMICROB CHEMOTH, V65, P1526, DOI 10.1093/jac/dkq126; Meropol SB, 2009, BRIT J GEN PRACT, V59, P735, DOI 10.3399/bjgp09X472610; OBRIEN MAT, 2000, COCHRANE DB SYST REV, V2; Ostini R, 2009, ANN PHARMACOTHER, V43, P502, DOI 10.1345/aph.1L488; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Ranji SR, 2008, MED CARE, V46, P847, DOI 10.1097/MLR.0b013e318178eabd; Rollnick S, 2002, MED EDUC, V36, P678, DOI 10.1046/j.1365-2923.2002.01255.x; Rollnick S, 2002, MED EDUC, V36, P377, DOI 10.1046/j.1365-2923.2002.01174.x; Rollnick S., 2008, MOTIVATIONAL INTERVI; Rollnick S., 1999, HLTH BEHAV CHANGE GU, V1st; Schiff GD, 2009, JAMA-J AM MED ASSOC, V301, P865, DOI 10.1001/jama.2009.195; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Simpson SA, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-20; Smith SM, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000245.pub2, 10.1002/14651858.CD000245, DOI 10.1002/14651858.CD000245.PUB2]; Thompson PL, 2009, ARCH DIS CHILD, V94, P337, DOI 10.1136/adc.2008.147579; van Driel ML, 2007, QUAL SAF HEALTH CARE, V16, P197, DOI 10.1136/qshc.2006.018663; Venekamp RP, 2015, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000219.PUB4, 10.1002/14651858.CD000219.pub4]; Welschen I, 2004, BRIT MED J, V329, P431, DOI 10.1136/bmj.38182.591238.EB; Wood F, 2007, FAM PRACT, V24, P427, DOI 10.1093/fampra/cmm040; Xiao L, 2011, CLIN TRIALS, V8, P59, DOI 10.1177/1740774510391683	57	175	176	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	2012	344								d8173	10.1136/bmj.d8173	http://dx.doi.org/10.1136/bmj.d8173			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QO	22302780	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000300088500002
J	Schwartzentruber, J; Korshunov, A; Liu, XY; Jones, DTW; Pfaff, E; Jacob, K; Sturm, D; Fontebasso, AM; Quang, DAK; Tonjes, M; Hovestadt, V; Albrecht, S; Kool, M; Nantel, A; Konermann, C; Lindroth, A; Jager, N; Rausch, T; Ryzhova, M; Korbel, JO; Hielscher, T; Hauser, P; Garami, M; Klekner, A; Bognar, L; Ebinger, M; Schuhmann, MU; Scheurlen, W; Pekrun, A; Fruhwald, MC; Roggendorf, W; Kramm, C; Durken, M; Atkinson, J; Lepage, P; Montpetit, A; Zakrzewska, M; Zakrzewski, K; Liberski, PP; Dong, ZF; Siegel, P; Kulozik, AE; Zapatka, M; Guha, A; Malkin, D; Felsberg, J; Reifenberger, G; von Deimling, A; Ichimura, K; Collins, VP; Witt, H; Milde, T; Witt, O; Zhang, CD; Castelo-Branco, P; Lichter, P; Faury, D; Tabori, U; Plass, C; Majewski, J; Pfister, SM; Jabado, N				Schwartzentruber, Jeremy; Korshunov, Andrey; Liu, Xiao-Yang; Jones, David T. W.; Pfaff, Elke; Jacob, Karine; Sturm, Dominik; Fontebasso, Adam M.; Quang, Dong-Anh Khuong; Toenjes, Martje; Hovestadt, Volker; Albrecht, Steffen; Kool, Marcel; Nantel, Andre; Konermann, Carolin; Lindroth, Anders; Jaeger, Natalie; Rausch, Tobias; Ryzhova, Marina; Korbel, Jan O.; Hielscher, Thomas; Hauser, Peter; Garami, Miklos; Klekner, Almos; Bognar, Laszlo; Ebinger, Martin; Schuhmann, Martin U.; Scheurlen, Wolfram; Pekrun, Arnulf; Fruehwald, Michael C.; Roggendorf, Wolfgang; Kramm, Christoph; Duerken, Matthias; Atkinson, Jeffrey; Lepage, Pierre; Montpetit, Alexandre; Zakrzewska, Magdalena; Zakrzewski, Krzystof; Liberski, Pawel P.; Dong, Zhifeng; Siegel, Peter; Kulozik, Andreas E.; Zapatka, Marc; Guha, Abhijit; Malkin, David; Felsberg, Joerg; Reifenberger, Guido; von Deimling, Andreas; Ichimura, Koichi; Collins, V. Peter; Witt, Hendrik; Milde, Till; Witt, Olaf; Zhang, Cindy; Castelo-Branco, Pedro; Lichter, Peter; Faury, Damien; Tabori, Uri; Plass, Christoph; Majewski, Jacek; Pfister, Stefan M.; Jabado, Nada			Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma	NATURE			English	Article							INTEGRATED GENOMIC ANALYSIS; EMBRYONIC STEM-CELLS; HIGH-GRADE GLIOMAS; ATRX; TUMORS; METHYLATION; TELOMERES; ABERRATIONS; EXPRESSION; MULTIFORME	Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases(1-4). To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (alpha-thalassaemia/mental retardation syndrome X-linked)(5) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres(6,7), were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n = 784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.	[Liu, Xiao-Yang; Jacob, Karine; Fontebasso, Adam M.; Quang, Dong-Anh Khuong; Faury, Damien; Majewski, Jacek; Jabado, Nada] McGill Univ, Dept Human Genet, Montreal, PQ H3Z 2Z3, Canada; [Liu, Xiao-Yang; Jacob, Karine; Fontebasso, Adam M.; Quang, Dong-Anh Khuong; Faury, Damien; Majewski, Jacek; Jabado, Nada] McGill Univ, Dept Expt Med, Montreal, PQ H3Z 2Z3, Canada; [Schwartzentruber, Jeremy; Lepage, Pierre; Montpetit, Alexandre] McGill Univ, Montreal, PQ H3A 1A4, Canada; [Schwartzentruber, Jeremy; Lepage, Pierre; Montpetit, Alexandre] Genome Quebec Innovat Ctr, Montreal, PQ H3A 1A4, Canada; [Korshunov, Andrey; von Deimling, Andreas] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, D-69120 Heidelberg, Germany; [Jones, David T. W.; Pfaff, Elke; Sturm, Dominik; Kool, Marcel; Witt, Hendrik; Pfister, Stefan M.] German Canc Res Ctr, Divis Pediat Neurooncol, D-69120 Heidelberg, Germany; [Toenjes, Martje; Hovestadt, Volker; Zapatka, Marc; Lichter, Peter] German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany; [Albrecht, Steffen] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Dept Pathol, Montreal, PQ H3H 1P3, Canada; [Nantel, Andre] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; [Konermann, Carolin; Lindroth, Anders; Plass, Christoph] German Canc Res Ctr, Div Epigenom & Canc Risk Factors, D-69120 Heidelberg, Germany; [Jaeger, Natalie] German Canc Res Ctr, Div Theoret Bioinformat, D-69120 Heidelberg, Germany; [Rausch, Tobias; Korbel, Jan O.] European Mol Biol Lab, D-69117 Heidelberg, Germany; [Ryzhova, Marina] Burdenko Neurosurg Inst, Dept Neuropathol, Moscow 125047, Russia; [Hielscher, Thomas] German Canc Res Ctr, Div Biostat, D-69120 Heidelberg, Germany; [Hauser, Peter; Garami, Miklos] Semmelweis Univ, Dept Paediat 2, H-1094 Budapest, Hungary; [Klekner, Almos; Bognar, Laszlo] Univ Debrecen, Dept Neurosurg, Med & Hlth Sci Ctr, H-4032 Debrecen, Hungary; [Ebinger, Martin] Childrens Univ Hosp, Dept Hematol & Oncol, D-72076 Tubingen, Germany; [Schuhmann, Martin U.] Univ Hosp, Dept Neurosurg, D-72076 Tubingen, Germany; [Scheurlen, Wolfram] Nuremberg Childrens Hosp, Cnopfsche Kinderklin, D-90419 Nurnberg, Germany; [Pekrun, Arnulf] Prof Hess Childrens Hosp, D-28177 Bremen, Germany; [Fruehwald, Michael C.] Augsburg Childrens Hosp, Klinikum Augsburg, D-86156 Augsburg, Germany; [Roggendorf, Wolfgang] Univ Wurzburg, Inst Pathol, Dept Neuropathol, D-97080 Wurzburg, Germany; [Kramm, Christoph] Univ Childrens Hosp, D-06097 Halle, Germany; [Duerken, Matthias] Univ Childrens Hosp, D-68167 Mannheim, Germany; [Atkinson, Jeffrey] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Div Neurosurg,Dept Surg, Montreal, PQ H3H 1P3, Canada; [Zakrzewska, Magdalena; Liberski, Pawel P.] Med Univ Lodz, Dept Mol Pathol & Neuropathol, PL-92216 Lodz, Poland; [Zakrzewski, Krzystof] Polish Mothers Mem Hosp, Res Inst, Dept Neurosurg, PL-93338 Lodz, Poland; [Dong, Zhifeng; Siegel, Peter] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Kulozik, Andreas E.; Witt, Hendrik; Milde, Till; Witt, Olaf; Pfister, Stefan M.] Univ Heidelberg Hosp, Dept Paediat Oncol Hematol & Immunol, D-69120 Heidelberg, Germany; [Guha, Abhijit; Zhang, Cindy; Castelo-Branco, Pedro; Tabori, Uri] Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Res Inst, Toronto, ON M5G 1X8, Canada; [Malkin, David; Tabori, Uri] Univ Toronto, Hosp Sick Children, Div Hematol Oncol, Dept Paediat, Toronto, ON M5G 1X8, Canada; [Felsberg, Joerg; Reifenberger, Guido] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; [von Deimling, Andreas] Univ Heidelberg Hosp, Dept Neuropathol, D-69120 Heidelberg, Germany; [Ichimura, Koichi; Collins, V. Peter] Univ Cambridge, Dept Pathol, Div Mol Histopathol, Cambridge CB2 0QQ, England; [Milde, Till; Witt, Olaf] German Canc Res Ctr, Clin Cooperat Unit Paediat Oncol, D-69120 Heidelberg, Germany; [Jabado, Nada] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3Z 2Z3, Canada; [Jabado, Nada] McGill Univ, Dept Paediat, Montreal, PQ H3Z 2Z3, Canada	McGill University; McGill University; McGill University; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); McGill University; National Research Council Canada; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); Burnazyan Federal Medical Biophysical Center; Helmholtz Association; German Cancer Research Center (DKFZ); Semmelweis University; University of Debrecen; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Klinikum Augsburg; University of Wurzburg; Martin Luther University Halle Wittenberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; McGill University; Medical University Lodz; Polish Mother's Memorial Hospital - Research Institute; McGill University; Ruprecht Karls University Heidelberg; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg; University of Cambridge; Helmholtz Association; German Cancer Research Center (DKFZ); McGill University; McGill University	Majewski, J (corresponding author), McGill Univ, Dept Human Genet, Montreal, PQ H3Z 2Z3, Canada.	jacek.majewski@mcgill.ca; s.pfister@dkfz-heidelberg.de; nada.jabado@mcgill.ca	Korbel, Jan O/G-6470-2012; Zakrzewski, Krzysztof/M-5985-2014; Zakrzewska, Magdalena/S-9308-2016; Jones, David TW/G-9588-2013; Garami, Miklós/AAK-5680-2021; Milde, Till/L-7755-2015; Khuong Quang, Dong Anh/GPT-2523-2022; Ryzhova, Marina/G-4178-2014; Reifenberger, Guido/AAE-3599-2019; Ebinger, Martin/O-4936-2016; Milde, Till/AAR-4528-2021; Zapatka, Marc/G-9896-2013; Kool, Marcel/H-2541-2013; Lindroth, Anders M/C-7744-2015; Rausch, Tobias/H-6511-2019; Malkin, David/AAW-8715-2021; Witt, Hendrik/L-7810-2015; Kulozik, Andreas/AAO-2432-2020; Sturm, Dominik/AAL-3689-2020; Plass, Christoph/H-7192-2014; von Deimling, Andreas/F-7774-2013; Pfister, Stefan M/F-6860-2013; Jabado, Nada/AAN-4026-2020; Jones, David T. W./Z-1963-2019	Korbel, Jan O/0000-0002-2798-3794; Zakrzewska, Magdalena/0000-0001-5826-7726; Jones, David TW/0000-0002-2036-5141; Ryzhova, Marina/0000-0001-7206-6365; Ebinger, Martin/0000-0002-4229-8058; Milde, Till/0000-0002-7267-1052; Zapatka, Marc/0000-0001-8287-5967; Lindroth, Anders M/0000-0002-8291-2745; Rausch, Tobias/0000-0001-5773-5620; Sturm, Dominik/0000-0003-0250-1696; von Deimling, Andreas/0000-0002-5863-540X; Pfister, Stefan M/0000-0002-5447-5322; Schwartzentruber, Jeremy/0000-0002-6183-2092; Hovestadt, Volker/0000-0002-3480-6649; Zakrzewski, Krzysztof/0000-0001-5454-1783; Tabori, Uri/0000-0002-5019-2683; Liberski, Pawel P./0000-0001-6507-4682; Castelo-Branco, Pedro/0000-0002-3453-3978; Korshunov, Andrey/0000-0002-5257-3623; Jaeger, Natalie/0000-0002-9589-7580	Cole Foundation; Genome Canada; Canadian Institute for Health Research (CIHR); Genome BC; Genome Quebec; CIHR-ICR (Institute for Cancer Research); C17, through the Genome Canada/CIHR; Hungarian Scientific Research Fund(OTKA) [T-04639]; National Research and Development Fund (NKFP) [1A/002/2004]; German Cancer Aid [109252]; CNS tumour tissue bank [108456]; BMBF; Samantha Dickson Brain Tumour Trust; National Cancer Center Heidelberg; German Cancer Research Center; Foundation of Stars; Sybille Assmus Award for Neurooncology; Fonds de Recherche en Sante du Quebec; The Brain Tumour Charity [10/106] Funding Source: researchfish	Cole Foundation; Genome Canada(Genome Canada); Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Genome BC; Genome Quebec; CIHR-ICR (Institute for Cancer Research)(Canadian Institutes of Health Research (CIHR)); C17, through the Genome Canada/CIHR; Hungarian Scientific Research Fund(OTKA)(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); National Research and Development Fund (NKFP); German Cancer Aid(Deutsche Krebshilfe); CNS tumour tissue bank; BMBF(Federal Ministry of Education & Research (BMBF)); Samantha Dickson Brain Tumour Trust; National Cancer Center Heidelberg; German Cancer Research Center(Helmholtz Association); Foundation of Stars; Sybille Assmus Award for Neurooncology; Fonds de Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); The Brain Tumour Charity	The authors are indebted to J. Rak, N. Sonenberg and C. Polychronakos for critical reading of this manuscript. D. M. Pearson, A. Wittmann, L. Sieber and L. Senf are acknowledged for technical assistance. This work was supported by the Cole Foundation, and was funded in part by Genome Canada and the Canadian Institute for Health Research (CIHR) with co-funding from Genome BC, Genome Quebec, CIHR-ICR (Institute for Cancer Research) and C17, through the Genome Canada/CIHR joint ATID Competition (project title: The Canadian Paediatric Cancer Genome Consortium: Translating next generation sequencing technologies into improved therapies for high-risk childhood cancer (NJ)), the Hungarian Scientific Research Fund(OTKA) Contract No. T-04639, the National Research and Development Fund (NKFP) Contract No. 1A/002/2004 (P. H., M. G., L. B.), the PedBrain project contributing to the International Cancer Genome Consortium funded by the German Cancer Aid (109252) and the CNS tumour tissue bank within the priority program on tumour tissue banking of the German Cancer Aid (108456), the BMBF, the Samantha Dickson Brain Tumour Trust, a grant from the National Cancer Center Heidelberg ("Paediatric Brain Tumor Preclinical Testing"), and a guest scientist stipend to M. R. from the German Cancer Research Center. X.-Y.L. and A. M. F. are the recipients of studentship awards from CIHR. K. J. is the recipient of a studentship from the Foundation of Stars. S. M. P. is the recipient of the Sybille Assmus Award for Neurooncology in 2009 and N. J. is the recipient of a Chercheur Boursier Award from Fonds de Recherche en Sante du Quebec.	Bax DA, 2010, CLIN CANCER RES, V16, P3368, DOI 10.1158/1078-0432.CCR-10-0438; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Cervera AM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-89; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; De La Fuente R, 2004, DEV BIOL, V272, P1, DOI 10.1016/j.ydbio.2003.12.012; Dhayalan A, 2011, HUM MOL GENET, V20, P2195, DOI 10.1093/hmg/ddr107; Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967; Faury D, 2007, J CLIN ONCOL, V25, P1196, DOI 10.1200/JCO.2006.07.8626; Fullgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; Hakin-Smith V, 2003, LANCET, V361, P836, DOI 10.1016/S0140-6736(03)12681-5; Haque T, 2007, CLIN CANCER RES, V13, P6284, DOI 10.1158/1078-0432.CCR-07-0525; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; Iwase S, 2011, NAT STRUCT MOL BIOL, V18, P769, DOI 10.1038/nsmb.2062; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322; Lewis PW, 2010, P NATL ACAD SCI USA, V107, P14075, DOI 10.1073/pnas.1008850107; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Nakamura K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr344; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Paugh BS, 2010, J CLIN ONCOL, V28, P3061, DOI 10.1200/JCO.2009.26.7252; Peiffer DA, 2006, GENOME RES, V16, P1136, DOI 10.1101/gr.5402306; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Qu HQ, 2010, NEURO-ONCOLOGY, V12, P153, DOI 10.1093/neuonc/nop001; Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Villard L, 1996, NAT GENET, V12, P359, DOI 10.1038/ng0496-359; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wong LH, 2010, GENOME RES, V20, P351, DOI 10.1101/gr.101477.109; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	35	1625	1654	8	212	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2012	482	7384					226	U119		10.1038/nature10833	http://dx.doi.org/10.1038/nature10833			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888HI	22855408				2022-12-28	WOS:000299994100040
J	Fauci, AS; Morens, DM				Fauci, Anthony S.; Morens, David M.			200 NEJM ANNIVERSARY ARTICLE The Perpetual Challenge of Infectious Diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							UNITED-STATES; TRANSMISSION; EMERGENCE; ERADICATION; IDENTIFICATION; PLAGUES; ORIGIN; HEALTH; SPREAD	Among the many challenges to health, infectious diseases stand out for their ability to have a profound impact on the human species. Great pandemics and local epidemics alike have influenced the course of wars, determined the fates of nations and empires, and affected the progress of civilization, making infections compelling actors in the drama of human history.(1-11) For 200 years, the Journal has captured the backdrop to this human drama in thousands of articles about infectious diseases and about biomedical research and public health efforts to understand, treat, control, and prevent them.	[Fauci, Anthony S.; Morens, David M.] NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, NIH, Bldg 31,Rm 7A-03, Bethesda, MD 20892 USA.	afauci@niaid.nih.gov	Parks, Tom/D-7741-2013	Parks, Tom/0000-0002-1163-8654	Medical Research Council [G1001712] Funding Source: researchfish; National Institute for Health Research [CL-2006-13-003] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))		Agarwal AK, 2011, ANN NY ACAD SCI, V1228, P175; Agarwal AK, 2010, ANN NY ACAD SCI, V1213, P20, DOI 10.1111/j.1749-6632.2010.05859.x; AMPEL NM, 1991, REV INFECT DIS, V13, P658, DOI 10.1093/clinids/13.4.658; Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; Butler JC, 2001, EMERG INFECT DIS, V7, P554; Cartwright FF, 1972, DIS HIST, P113; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Davies J, 2010, MICROBIOL MOL BIOL R, V74, P417, DOI 10.1128/MMBR.00016-10; De Cock KM, 2011, EMERG INFECT DIS, V17, P1044, DOI [10.3201/eid/1706.100184, 10.3201/eid1706.100184]; DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239; Dheda K, 2010, INFECT DIS CLIN N AM, V24, P705, DOI 10.1016/j.idc.2010.05.001; Diamond J., 2010, RUZHYA MIKROBY STALI; DUFFY JOHN, 1951, BULL HIST MED, V25, P324; Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235; FELDMAN HA, 1972, J INFECT DIS, V125, pS22, DOI 10.1093/infdis/125.Supplement_1.S22; FENNER F, 1993, HIST PHIL LIFE SCI, V15, P397; Fredricks DN, 1998, CURR CLIN TOPICS INF, V18, P180; Garrett L., 1994, COMING PLAGUE NEWLY; Guerrant RL, 1999, CLIN INFECT DIS, V28, P966, DOI 10.1086/514765; Haynes BF, 2012, HARRISONS PRINCIPLES, V2, P2650; HECKER JFC, 1832, SCHWARZE TOD VIERZEH; HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994; Hopkins DR, 2008, AM J TROP MED HYG, V79, P474, DOI 10.4269/ajtmh.2008.79.474; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Jarcho Saul, 2000, CONCEPT CONTAGION ME; Jordan EO., 1927, EPIDEMIC INFLUENZA S; Kane M, 2011, SCIENCE, V334, P245, DOI 10.1126/science.1210718; Keesing F, 2010, NATURE, V468, P647, DOI 10.1038/nature09575; Kinross JM, 2011, GENOME MED, V3, DOI 10.1186/gm228; Koch R, 1876, BEITR BIOL PFLANZ, V2, P277; Krause RM, 1997, J INFECT DIS, V176, P549, DOI 10.1086/514074; KRAUSE RM, 1992, SCIENCE, V257, P1073, DOI 10.1126/science.257.5073.1073; Kuss SK, 2011, SCIENCE, V334, P249, DOI 10.1126/science.1211057; Lederberg J, 2000, SCIENCE, V288, P287, DOI 10.1126/science.288.5464.287; Lederberg J., 1992, I MED US COMMITTEE; Lee JH, 2003, APPL ENVIRON MICROB, V69, P6489, DOI 10.1128/AEM.69.11.6489-6494.2003; Lipkin WI, 2010, MICROBIOL MOL BIOL R, V74, P363, DOI 10.1128/MMBR.00007-10; Maurice JM., 2009, STATE WORLDS VACCINE, V3; MCDERMOTT W, 1969, J INFECT DIS, V119, P678, DOI 10.1093/infdis/119.6.678; McMichael AJ, 2001, HUMAN FRONTIERS ENV, DOI [10.1017/CBO9781139106924, DOI 10.1017/CBO9781139106924]; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Modlin JF, 2010, NEW ENGL J MED, V362, P2346, DOI 10.1056/NEJMp1005405; Morens DM, 2010, NATURE, V463, P122, DOI 10.1038/nature08554; Morens DM, 2008, LANCET INFECT DIS, V8, P710, DOI 10.1016/S1473-3099(08)70256-1; Morens DM, 2007, J INFECT DIS, V195, P1018, DOI 10.1086/511989; Morens DM, 2011, J INFECT DIS, V204, P502, DOI 10.1093/infdis/jir327; Morens DM, 2009, NEW ENGL J MED, V361, P225, DOI 10.1056/NEJMp0904819; Morens DM, 1999, NEW ENGL J MED, V341, P1845, DOI 10.1056/NEJM199912093412413; Morens DM, 2003, AM J PUBLIC HEALTH, V93, P886, DOI 10.2105/AJPH.93.6.886; Morens DM, 2002, EMERG INFECT DIS, V8, P1353, DOI 10.3201/eid0811.020549; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; Murray KO, 2011, EPIDEMIOL INFECT, V139, P807, DOI 10.1017/S0950268811000185; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Pallen MJ, 2010, CURR OPIN MICROBIOL, V13, P625, DOI 10.1016/j.mib.2010.08.003; Parascandola John, 2009, Pharm Hist, V51, P14; Parrish CR, 2008, MICROBIOL MOL BIOL R, V72, P457, DOI 10.1128/MMBR.00004-08; Parsonnet J, 1999, MICROBES MALIGNANCY; Powell JH, 2020, REC EC DEV CHALL AH; Prinzing F., 1916, EPIDEMICS RESULTING; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Relman DA, 2011, NEW ENGL J MED, V365, P347, DOI 10.1056/NEJMra1003071; Sanders Michael K, 2002, Curr Gastroenterol Rep, V4, P448, DOI 10.1007/s11894-002-0019-x; Schief WR, 2009, CURR OPIN HIV AIDS, V4, P431, DOI 10.1097/COH.0b013e32832e6184; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Spink W W, 1973, Minn Med, V56, P551; van Sighem A, 2010, AIDS, V24, P1527, DOI 10.1097/QAD.0b013e32833a3946; Vucic S, 2009, J CLIN NEUROSCI, V16, P733, DOI 10.1016/j.jocn.2008.08.033; Walter J, 2011, ANNU REV MICROBIOL, V65, P411, DOI 10.1146/annurev-micro-090110-102830; Winslow, 1943, CONQUEST EPIDEMIC DI; Woolhouse M, 2007, CRIT REV MICROBIOL, V33, P231, DOI 10.1080/10408410701647560; World Health Organization, 2011, WORLD HLTH STAT 2011; World Health Organization, 2008, GLOB BURD DIS 2004 U; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	75	307	331	7	103	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					454	461		10.1056/NEJMra1108296	http://dx.doi.org/10.1056/NEJMra1108296			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QX	22296079				2022-12-28	WOS:000299724400010
